Symbol	Gene	Protein_change	Disease	Drug	Drug_Type	Drug_Directions	Evidence_Level	Significance	Dt_Chrom	Dt_Start	Dt_Stop	Dt_Ref	Dt_Alt	Evidence_Statement	Citation	Variant_origin	Representative_Transcript	Functional_Region
WWTR1 WWTR1::CAMTA1	WWTR1	WWTR1::CAMTA1	Malignant Epithelioid Hemangioendothelioma		Diagnostic	Supports	B	Positive	chr1	7661726	7769706			"Performed a systematic molecular analysis of 17 epithelioid hemangioendothelioma (EHE) and compared to 13 epithelioid hemangiomas, five epithelioid angiosarcomas, and four epithelioid sarcoma-like EHE. A FISH positional cloning strategy, and RT-PCR analysis identified WWTR1-CAMTA1 in all EHE cases and none of the other benign or malignant epithelioid vascular tumors examined."	"Errani et al., 2011, Genes Chromosomes Cancer"	Somatic	ENST00000465804.1	transcript_fusion
ERRFI1 E384*	ERRFI1	E384*	Cholangiocarcinoma	Erlotinib	Predictive	Supports	C	Sensitivity/Response	chr1	8013449	8013449	C	A	"An ERRFI1 (E384X) was detected in a patient with metastatic, recurrent/refractory cholangiocarcinoma (allelic fraction 11%) without any mutations or amplifications in other EGFR signaling members such as EGFR and BRAF. The patient was treated with erlotinib 150 mg orally/daily. After 3 months, RECIST v1.1 partial response evidenced by a decrease of 58% in the sum of largest diameters was observed."	"Borad et al., 2014, PLoS Genet."	Somatic	ENST00000377482.5	"stop_gained,loss_of_function_variant"
MTOR Mutation	MTOR	Mutation	Bladder Carcinoma	"Everolimus,Pazopanib"	Predictive	Supports	C	Sensitivity/Response	chr1	11106535	11262507			A case-study of a patient with urothelial carcinoma reported exceptional response (14 months) in a phase 1 study of Everolimus and Pazopanib. Mutations E2014K and E2419K were shown to be activating in-vitro.	"Wagle et al., 2014, Cancer Discov"	Somatic	ENST00000361445.4	protein_altering_variant
MTOR Mutation	MTOR	Mutation	Melanoma		Prognostic	Supports	B	Poor Outcome	chr1	11106535	11262507			Median overall survival of patients with nonsynonymous mutations in mTOR was shorter.	"Kong et al., 2016, Clin. Cancer Res."	Somatic	ENST00000361445.4	protein_altering_variant
MTOR M2327I	MTOR	M2327I	Breast Cancer	MTOR Kinase Inhibitor AZD8055	Predictive	Supports	D	Resistance	chr1	11117039	11117039	C	A	MCF-7 breast cancer cell line was exposed to mTOR inhibitor AZD8055 until resistance developed. Deep sequencing revealed an MTOR M2327I mutation in the AZD8055-resistant clone. Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in MDA-MB-468 cells led to resistance. Tumor volume grew more rapidly in mice with xenografts of M2327I mTOR mutant MCF7 cells treated with AZD8055 than rapamycin or RapaLink-1 treatment.	"Rodrik-Outmezguine et al., 2016, Nature"	Somatic	ENST00000361445.4	missense_variant
MTOR M2327I	MTOR	M2327I	Breast Cancer	"Sirolimus,RapaLink-1"	Predictive	Does Not Support	D	Resistance	chr1	11117039	11117039	C	A	MCF-7 breast cancer cell line was exposed to mTOR inhibitor AZD8055 until resistance developed. Deep sequencing revealed an MTOR M2327I mutation in the AZD8055-resistant clone. These cells remained sensitive to rapamycin and RapaLink-1 in vitro and in mouse xenografts. Expression of the mutation in MDA-MB-468 cells led to AZD8055 resistance and these cells were also rapamycin and RapaLink-1 sensitive.	"Rodrik-Outmezguine et al., 2016, Nature"	Somatic	ENST00000361445.4	missense_variant
MTOR S2215Y	MTOR	S2215Y	Endometrial Adenocarcinoma	Sirolimus	Predictive	Supports	D	Sensitivity/Response	chr1	11124516	11124516	G	T	Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line JHUEM7 with the MTOR mutation S2215Y was hypersensitive to rapamycin treatment (IC50 of 0.23 nmol/L).	"Grabiner et al., 2014, Cancer Discov"	Somatic	ENST00000361445.4	missense_variant
MTOR P2213S	MTOR	P2213S	Melanoma	"PI3K/BET Inhibitor LY294002,Capivasertib"	Predictive	Supports	D	Sensitivity/Response	chr1	11124523	11124523	G	A	"In a cell line (HEK293T) with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth."	"Kong et al., 2016, Clin. Cancer Res."	Somatic	ENST00000361445.4	"missense_variant,gain_of_function_variant"
MTOR F2108L	MTOR	F2108L	Thyroid Gland Carcinoma	Everolimus	Predictive	Supports	C	Resistance	chr1	11127037	11127037	G	T	"The pretreatment tumor contained a somatic nonsense mutation (Q1178*) in the tumor-suppressor gene TSC2 that inactivates the gene, allowing for activation of the mTOR pathway and resulting in sensitivity to mTOR inhibition by everolimus. The patient received a sustained response to everolimus for 18 months, after which time resistance developed. The resistant tumor had a somatic mutation in MTOR (F2108L), that was not detected in the pretreatment tumor."	"Wagle et al., 2014, N. Engl. J. Med."	Somatic	ENST00000361445.4	missense_variant
MTOR F2108L	MTOR	F2108L	Breast Cancer	Sirolimus	Predictive	Supports	D	Resistance	chr1	11127037	11127037	G	T	MCF-7 breast cancer cell line was exposed to mTOR inhibitors AZD8055 or rapamycin until resistance developed. Deep sequencing revealed an MTOR F2108L mutation in rapamycin-resistant clones (RR2 cells). Downstream signalling was independent of inhibitor presence in these clones and expression of the mutations in MDA-MB-468 cells led to resistance.	"Rodrik-Outmezguine et al., 2016, Nature"	Somatic	ENST00000361445.4	missense_variant
MTOR A2034V	MTOR	A2034V	Breast Cancer	Sirolimus	Predictive	Supports	D	Resistance	chr1	11127739	11127739	G	A	MCF-7 breast cancer cell line was exposed to mTOR inhibitor rapamycin until resistance developed. Deep sequencing revealed an MTOR A2034V mutation in the resistant clone. Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in MDA-MB-468 cells led to resistance. Xenografts of these cells were more resistant to rapamycin than AZD8055 or RapaLink-1 treatment.	"Rodrik-Outmezguine et al., 2016, Nature"	Somatic	ENST00000361445.4	missense_variant
MTOR A2034V	MTOR	A2034V	Breast Cancer	"RapaLink-1,MTOR Kinase Inhibitor AZD8055"	Predictive	Does Not Support	D	Resistance	chr1	11127739	11127739	G	A	MCF-7 breast cancer cell line was exposed to mTOR inhibitor rapamycin until resistance developed. Deep sequencing revealed an MTOR A2034V mutation in the resistant clone (RR1). Downstream signalling was independent of inhibitor presence in these clones and expression of the mutation in MDA-MB-468 cells led to resistance to rapamycin but maintained sensistivity to AZD8055. A novel mTOR inhibitor RapaLink-1 was designed and showed efficacy in A2034V mTOR mutant cell lines in-vivo and in-vitro. AZD8055 also retained efficacy in these clones in xenograft.	"Rodrik-Outmezguine et al., 2016, Nature"	Somatic	ENST00000361445.4	missense_variant
MTOR H1968Y	MTOR	H1968Y	Melanoma	"PI3K/BET Inhibitor LY294002,Capivasertib"	Predictive	Supports	D	Sensitivity/Response	chr1	11128462	11128462	G	A	"In a cell line (HEK293T) with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth."	"Kong et al., 2016, Clin. Cancer Res."	Somatic	ENST00000361445.4	"missense_variant,gain_of_function_variant"
MTOR E1799K	MTOR	E1799K	Clear Cell Renal Cell Carcinoma	Sirolimus	Predictive	Supports	D	Sensitivity/Response	chr1	11130747	11130747	C	T	"Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line SNU349, with MTOR mutation E1799K was hypersensitive to rapamycin treatment (IC50 of 0.19 nmol/L)."	"Grabiner et al., 2014, Cancer Discov"	Somatic	ENST00000361445.4	missense_variant
MTOR C1483Y	MTOR	C1483Y	T-cell Acute Lymphoblastic Leukemia	Sirolimus	Predictive	Supports	D	Sensitivity/Response	chr1	11157173	11157173	C	T	"Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line MOLT16, with MTOR mutation C1483Y was hypersensitive to rapamycin treatment (IC50 of 0.75 nmol/L)."	"Grabiner et al., 2014, Cancer Discov"	Somatic	ENST00000361445.4	missense_variant
STMN1 EXPRESSION	STMN1	EXPRESSION	Endometrial Carcinoma	Paclitaxel	Predictive	Supports	B	Resistance	chr1	25885440	25906466			33 patients were retrospectively analyzed for Stathmin expression by IHC. High protein expression was correlated with poor response to paclitaxel but not other chemotherapy. The authors supported this conclusion with pre-clinical studies that showed that knock-down of stathmin improved sensitivity to paclitaxel in endometrial carcinoma cell lines with both naturally higher and lower sensitivity to paclitaxel.	"Werner et al., 2014, PLoS ONE"	N/A	ENST00000426559.2	N/A
ARID1A Loss-of-function	ARID1A	Loss-of-function	Ovarian Clear Cell Carcinoma	Dasatinib	Predictive	Supports	D	Sensitivity/Response	chr1	26696033	26782104			"High-throughput  drug screens in OCCC tumor cell model identified synthetic lethal (SL) interaction between the kinase inhibitor dasatinib and ARID1A mutation. Imposing ARID1A deficiency upon a variety of human or mouse cells induced dasatinib sensitivity, both in vitro and in vivo."	"Miller et al., 2016, Mol. Cancer Ther."	Somatic	ENST00000324856.7	
ARID1A Loss-of-function	ARID1A	Loss-of-function	Ovarian Clear Cell Carcinoma	GSK126	Predictive	Supports	D	Sensitivity/Response	chr1	26696033	26782104			"Inhibition of the EZH2 methyltransferase acts in a synthetic lethal manner in ARID1A mutated ovarian cancer cells. ARID1A mutational status correlates with response to the EZH2 inhibitor. Significantly, EZH2 inhibition causes regression of ARID1A mutated ovarian tumors in vivo."	"Bitler et al., 2015, Nat. Med."	Somatic	ENST00000324856.7	
ARID1A Underexpression	ARID1A	Underexpression	Stomach Cancer		Prognostic	Supports	D	Poor Outcome	chr1	26696033	26782104			"In this study, real-time quantitative RT-PCR assays were used in 66 pairs of cancerous and matched adjacent normal tissues. In 43 of those pairs, the expression level of ARID1A was significantly lower in the cancerous tissue than in the normal tissue (P=0.0029). This was then again tested using Western Blotting. Consistent with the real-time PCR results, there was a lower expression of ARID1A in 13 of the tumor tissue samples compared to the normal tissue samples (P=0.0015). In an immunohistochemical analysis of 224 tissue blocks, 115 of those had a decreased ARID1A expression. The data conveyed that lower ARID1A expression was correlated with depth of tumor infiltration (P=0.001). Lastly, cell proliferation in regards to ARID1A expression was tested in cell lines. The cells with silenced expression of ARID1A had a much greater growth than those with greater expression of the protein."	"Wang et al., 2012, PLoS ONE"	N/A	ENST00000324856.7	N/A
ARID1A Underexpression	ARID1A	Underexpression	Clear Cell Renal Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr1	26696033	26782104			"This study included 290 patients with Clear Cell Renal Cell Carcinoma whose tumor tissues were sampled and then analyzed. These samples were then divided according to ARID1A expression after immunohistochemical staining. Of the 290 patients, 213 had a low ARID1A expression and 77 patients had a high expression. Low ARID1A expression was associated with higher nuclear grade (P<0.001), advanced pTNM stage (P=0.013), shorter cancer-specific survival (p=0.001) and progression-free survival (P<0.001). After a multivariate analysis using Cox proportional hazards, it was found that ARID1A expression levels are an independent predictor of progression-free survival in patients with CCRCC, although no significant correlation was found between the expression levels and cancer-specific survival."	"Park et al., 2015, Hum. Pathol."	N/A	ENST00000324856.7	N/A
ARID1A Underexpression	ARID1A	Underexpression	Ovarian Clear Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr1	26696033	26782104			"In a study of 60 individuals with ovarian clear cell carcinoma, ARID1A expression was analyzed using immunohistochemistry. Of these 60 patients, 9 (15%) patients had a loss of ARID1A expression. Results showed that a low ARID1A expression was significantly related to advanced FIGO stages (P=0.02) and high CA125 levels (P=0.01). Patients with low expression experienced shorter progression free survival than those with no loss of expression (P<0.01). In a multivariate analysis it was found that a loss of ARID1A expression was significant for shorter disease free survival (P=0.03) and shorter overall survival for patients whose ovarian clear cell carcinoma was treated with platinum-based chemotherapy (P=0.015). Lastly, tumors with low expression were significantly more likely to be resistant to primary adjuvant chemotherapy than tumors with a higher expression (P=0.04)."	"Katagiri et al., 2012, Mod. Pathol."	N/A	ENST00000324856.7	N/A
ARID1A Q456*	ARID1A	Q456*	Ovarian Clear Cell Carcinoma	Dasatinib	Predictive	Supports	D	Sensitivity/Response	chr1	26731167	26731167	C	T	"In an in vitro study, a HCT116 cell line expressing ARID1A Q456* mutation demonstrated increased sensitivity to dasatinib treatment, compared to HCT116 cells expressing wild-type ARID1A. Sensitivity was determined by assessing cell survival."	"Miller et al., 2016, Mol. Cancer Ther."	Somatic	ENST00000324856.7	stop_gained
CSF3R Mutation	CSF3R	Mutation	Chronic Neutrophilic Leukemia		Diagnostic	Supports	B	Positive	chr1	36466495	36467843			"Study found that mutations in CSF3R are enriched in patients with Chronic Neutrophilic Leukemia (CNL) or Atypical Chronic Myeloid Leukemia (16/27, 59%) when compared to other blood disorders (AML=1/292, t-cell ALL=0/8, B-cell ALL=0/41)"	"Maxson et al., 2013, N. Engl. J. Med."	Somatic	ENST00000373106.1	protein_altering_variant
CSF3R Mutation	CSF3R	Mutation	"Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative"		Diagnostic	Supports	B	Positive	chr1	36466495	36467843			"Study found that mutations in CSF3R are enriched in patients with Chronic Neutrophilic Leukemia (CNL) or Atypical Chronic Myeloid Leukemia (16/27, 59%) when compared to other blood disorders (AML=1/292, t-cell ALL=0/8, B-cell ALL=0/41)"	"Maxson et al., 2013, N. Engl. J. Med."	Somatic	ENST00000373106.1	protein_altering_variant
CSF3R T618I	CSF3R	T618I	Chronic Neutrophilic Leukemia	Ruxolitinib	Predictive	Supports	D	Sensitivity/Response	chr1	36467833	36467833	G	A	Demonstrates that activating mutations in CSF3R are sufficient to drive a myeloproliferative disorder resembling aCML and CNL that is sensitive to pharmacologic JAK inhibition.	"Fleischman et al., 2013, Blood"	Somatic	ENST00000373103.1	missense_variant
CSF3R T618I	CSF3R	T618I	Chronic Neutrophilic Leukemia	Ruxolitinib	Predictive	Supports	C	Sensitivity/Response	chr1	36467833	36467833	G	A	"Case report of a patient treated with ruxolitinib, an FDA-approved JAK1/2 inhibitor, which resulted in dramatic improvement of his blood counts. He also had significant reduction of spleen volume and constitutional symptoms."	"Dao et al., 2014, Leuk Res Rep"	Somatic	ENST00000373103.1	missense_variant
MYCL EXPRESSION	MYCL	EXPRESSION	Multiple Myeloma	"I-BET151,JQ1"	Predictive	Supports	D	Sensitivity/Response	chr1	39895426	39902013			"Four myeloma cell lines were treated with two different BET inhibitors (I-BET151 or JQ1). Proliferation of three cell lines (KMS11, RPMI8226 and MM1S) but not U266 (only partial inhibition) was strongly inhibited by the BET inhibitors. Microarray analysis showed a downregulation of MYC-dependent genes after treatment. qRT-PCR showed that MYCL1 but not c-MYC and MYCN was expressed in U266 cells and I-BET151 induced downregulation of MYCL1. In contrast, c-MYC but not MYCL was expressed in the other cell lines and I-BET151 induced downregulation of c-MYC."	"Suzuki et al., 2016, Anticancer Drugs"	N/A	ENST00000397332.2	N/A
PRKAA2 T172 PHOSPHORYLATION	PRKAA2	T172 PHOSPHORYLATION	Cancer	ACLY SiRNA	Predictive	Supports	E	Sensitivity/Response	chr1	56693803	56693805			"Low levels of baseline p-AMPK (PRKAA2, measured at Thr172) were predictive of efficacy of ACLY inhibition by siRNA in cell lines of various cancer histologies."	"Migita et al., 2013, Am. J. Pathol."	N/A	ENST00000371244.4	N/A
JUN Overexpression	JUN	Overexpression	Colorectal Adenocarcinoma	Irbesartan	Predictive	Supports	C	Sensitivity/Response	chr1	58780793	58784113			"A 67-year-old female presents with recurrent metastatic colonic adenocarcinoma.  Immunohistochemical and genetic workup showed overexpression of c-JUN and FOS, which presumably signals through the RAAS pathway. The patient was treated with irbesartan and after 5 weeks of therapy, the CEA value decreased from 18 to 3.1 and there was radiological resolution of the disease.  Her 10 month CEA was 1.4."	"Jones et al., 2016, Ann. Oncol."	Somatic	ENST00000371222.2	N/A
JAK1 OVEREXPRESSION	JAK1	OVEREXPRESSION	Lung Non-small Cell Carcinoma	Enzastaurin	Predictive	Supports	D	Sensitivity/Response	chr1	64833229	64966504			Overexpression of JAK1 in 22 lung cancer cell lines was associated with sensitivity to PKC-inhibitor enzastaurin. Silencing of JAK1 (by small molecule JAK 1/2/3 inhibitor) led to resistance.  Overexpression of JAK1 (lentiviral mediated) led to sensitivity to enzastaurin.	"Shimokawa et al., 2012, Br. J. Cancer"	N/A	ENST00000342505.4	N/A
JAK1 OVEREXPRESSION	JAK1	OVEREXPRESSION	Sarcoma	Ruxolitinib	Predictive	Supports	C	Sensitivity/Response	chr1	64833229	64966504			"Sequencing of an 8-year old patient diagnosed with a left tentorial-based CNS sarcoma discovered an EWSR1-ATF fusion and IL6 and JAK1 overexpression. Patient was treated with ruxolitinib based on overexpression of JAK1. Stable disease per RECIST and improvement of Lansky score from 60 to 90-100 was observed for 5 months. After ruxolitinib discontinuation, the patient's symptoms worsened and lung lesions progressed. Ruxolitinib was started again per family request and patient again had stable disease and improvement in body weight and Lansky score. Dose reduction was required because of myelosuppression and patient death occurred 23 months after relapse."	"Newton et al., 2018, JCO Precis Oncol"	N/A	ENST00000342505.4	N/A
JAK1 S703I	JAK1	S703I	Hepatocellular Carcinoma	Ruxolitinib	Predictive	Supports	D	Sensitivity/Response	chr1	64845520	64845520	C	A	A JAK1 S703I mutation was found to activate the JAK-STAT signaling pathway in vitro and in vivo in hepatocellular carcinoma. Ruxolitinib causes the suppression of JAK-STAT signaling pathway in PDX models bearing JAK1 S703I mutation and delays tumor progression.	"Yang et al., 2016, Oncotarget"	Somatic	ENST00000342505.4	missense_variant
JAK1 Q503*	JAK1	Q503*	Skin Melanoma	Pembrolizumab	Predictive	Supports	C	Resistance	chr1	64855650	64855650	G	A	"Paired tumor samples were analyzed from four patients with metastatic melanoma and initial response with a subsequent relapse under pembrolizumab (PD-1 checkpoint inhibitor) therapy. Baseline biopsies were obtained before therapy initiation with pembrolizumab (before prior vemurafenib treatment in patient 1). A JAK1 Q503* mutation was observed at the time of relapse in patient 1. This mutation was one of 3 new homozygous mutations in this patient (53 new mutations total) and the tumor was described to be genetically similar to the pre-treatment tumor. CRIPR-Cas9 mediated modelling of the JAK1 mutation in a melanoma cell line led to a loss of response to interferon alpha, beta and gamma."	"Zaretsky et al., 2016, N. Engl. J. Med."	Somatic	ENST00000342505.4	stop_gained
LEPR UNDEREXPRESSION	LEPR	UNDEREXPRESSION	Meningioma		Prognostic	Supports	B	Poor Outcome	chr1	65420652	65641559			"144 cases (discovery set: N=62 discovery; Independent validation set: N = 82) of meningiomas were analyzed for transcriptional features defining aggressive clinical course (recurrent, malignantly progressing or WHO grade III). Meningiomas were categorized into non-recurrent (NR), recurrent (R), and tumors undergoing malignant progression (M). Unsupervised transcriptomic analysis in 62 meningiomas revealed a large set of differentially expressed genes in aggressive subgroups (R+M tumors and WHO grade III, n=332; p<0.01, FC>1.25). Multivariate analysis identified PTTG1 and LEPR mRNA expression independent of gender, WHO grade and extent of resection. The patient group with the longest PFS was characterized by co-occurrence of low PTTG1 and high LEPR mRNA expression. IHC in 36 tumors validated these results on protein level."	"Schmidt et al., 2016, Oncotarget"	N/A	ENST00000349533.6	N/A
DPYD EXON 11-19 DELETION	DPYD	EXON 11-19 DELETION	Head And Neck Squamous Cell Carcinoma	"Leucovorin,Fluorouracil"	Predictive	Supports	C	Sensitivity/Response	chr1	97234852	97573970			"A 69 year old patient diagnosed with HNSCC presented with an unresectable neck mass three months after surgery and adjuvant radiation therapy. A biopsy was taken for whole genome and transcriptome analysis and the patient was started on systemic therapy. After showing resistance to the systemic therapy treatment with 5-FU and leucovorin was initiated based on the discovery of a somatic exon 11-19 in frame deletion in DPYD, which was hypothesized to increase sensitivity to 5-FU in the tumour. A dramatic clinical and radiographic response was sustained for 17 weeks, but following a 3 week treatment break a new nodule appeared. This recurrence showed resistance to re-initiation of treatment with capecitabine (oral 5-FU), and analysis of an additional biopsy provided no evidence as to the mechanism of resistance."	"Majounie et al., 2019, Cold Spring Harb Mol Case Stud"	Somatic	ENST00000370192.3	inframe_deletion
FGFR2 FGFR2::AHCYL1	FGFR2	FGFR2::AHCYL1	Cholangiocarcinoma		Diagnostic	Supports	B	Positive	chr1	110012362	110023735			"Massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1. In RT-PCR screening, the FGFR2 fusion was detected in nine patients with cholangiocarcinoma (9/102), exclusively in the intrahepatic subtype (9/66, 13.6%)."	"Arai et al., 2014, Hepatology"	Somatic	ENST00000457416.2	transcript_fusion
FGFR2 FGFR2::AHCYL1	FGFR2	FGFR2::AHCYL1	Cholangiocarcinoma	"Infigratinib,PD173074"	Predictive	Supports	D	Sensitivity/Response	chr1	110012362	110023735			Expression of the FGFR2-AHCYL1 fusion kinase in NIH3T3 cells demonstrated transforming ability that was effectively suppressed with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074.	"Arai et al., 2014, Hepatology"	Somatic	ENST00000457416.2	transcript_fusion
NRAS Mutation	NRAS	Mutation	Colorectal Cancer		Prognostic	Supports	B	Poor Outcome	chr1	114704469	114716894			Patients with colorectal cancer harboring NRAS mutation have poorer survival outcome and worse prognosis than patients with wildtype NRAS.	"Therkildsen et al., 2014, Acta Oncol"	Somatic	ENST00000369535.4	"transcript_variant,gain_of_function_variant"
NRAS Mutation	NRAS	Mutation	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	N/A	chr1	114704469	114716894			"The presence of NRAS mutation in AML patients does not impact diease prognosis (resistant disease, disease-free survival, complete remission rate, relapse rate, induction death)."	"Bowen et al., 2005, Blood"	Somatic	ENST00000369535.4	"transcript_variant,gain_of_function_variant"
NRAS Mutation	NRAS	Mutation	Melanoma		Prognostic	Supports	B	Poor Outcome	chr1	114704469	114716894			"In patients with stage IV melanoma, NRAS mutation was associated with reduced median survival compared to patients with wildtype NRAS."	"Jakob et al., 2012, Cancer"	Somatic	ENST00000369535.4	"transcript_variant,gain_of_function_variant"
NRAS Mutation	NRAS	Mutation	Multiple Myeloma		Prognostic	Supports	B	N/A	chr1	114704469	114716894			"In patients with multiple myeloma, the presence of a mutation in NRAS was not significantly associated with progression-free or overall survival."	"Chng et al., 2008, Leukemia"	Somatic	ENST00000369535.4	"transcript_variant,gain_of_function_variant"
NRAS Mutation	NRAS	Mutation	Melanoma	MEK Inhibitor RO4987655	Predictive	Does Not Support	C	Resistance	chr1	114704469	114716894			"Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). Among 8 patients with NRAS mutated melanoma, 3 experienced clinical benefit: 2 stable disease and 1 partial response (1 Patient received study treatment for 323 days). Of 10 NRAS wt patients, 4 experienced clinical benefit. Authors note that RO4987655 demonstrates clinical efficacy in BRAF wildtype melanomas with NRAS mutations."	"Zimmer et al., 2014, Clin. Cancer Res."	Somatic	ENST00000369535.4	"transcript_variant,gain_of_function_variant"
NRAS Mutation	NRAS	Mutation	Skin Melanoma	"Docetaxel,Trametinib"	Predictive	Supports	B	Sensitivity/Response	chr1	114704469	114716894			"Phase 1 trial of trametinib and docetaxel in patients with advanced melanoma lacking BRAF V600 mutations. 15 patients were enrolled (14 BRAF wt). Six patients had a partial response, including four out of eight patients with NRAS mutations."	"Coupe et al., 2015, Eur. J. Cancer"	Somatic	ENST00000369535.4	"transcript_variant,gain_of_function_variant"
NRAS Mutation	NRAS	Mutation	Melanoma	Trametinib	Predictive	Does Not Support	B	Sensitivity/Response	chr1	114704469	114716894			"Phase 1 trial in 97 patients with melanoma (81 cutaneous or unknown, 16 uveal). Seven patients were found to harbor an NRAS mutation and two of them experienced stable disease (one 48 weeks on treatment). Patients with concurrent BRAFV600wt/NRASwt (n=20) had a trend of higher response rates (20%) than BRAFV600wt/NRAS-mutant patients (n=11; RR=0%; p=0.27), as well as a trend of higher percentage of patients on study at Week 24 or at 1 year (40% vs. 18% [p=0.26] and 30% vs. 0% [p=0.07], respectively)."	"Falchook et al., 2012, Lancet Oncol."	Somatic	ENST00000369535.4	"transcript_variant,gain_of_function_variant"
NRAS Mutation	NRAS	Mutation	Cancer	"Metformin,Trametinib"	Predictive	Supports	D	Sensitivity/Response	chr1	114704469	114716894			"Preclinical study in 16 NRAS mutant cell lines (melanoma, lung carcinoma, neuroblastoma with various Q61, G13, G12 mutations). The combination of metformin and trametinib shown synergistic effects in most tested cell lines (no antagonistic effects observed) and a melanoma xenograft model. Metformin-induced PI3K pathway suppression was identified as a potential mechanism."	"Vujic et al., 2015, Oncotarget"	Somatic	ENST00000369535.4	"transcript_variant,gain_of_function_variant"
NRAS Mutation	NRAS	Mutation	Melanoma	"Trametinib,Omipalisib"	Predictive	Supports	D	Sensitivity/Response	chr1	114704469	114716894			"In six NRAS mutant melanoma cell lines, concomitant use of MEK inhibitor and PI3K/mTOR inhibitor resulted in greater decrease in cell viability than either alone, with the synergistic effect being marked in 4/6 cell lines. MEK inhibitor JTP-74057 and PI3K/mTOR inhibitor GSK2126458 together induced synergistic increase in apoptotic Annexin V+/PI+ cells in these cell lines. Tumor xenografts in nude mice were established with 5 of the 6 cell lines. Effects of single agent treatment with JTP-74057 or GSK2126458 ranged from minor inhibition to tumor stasis, while dual inhibitor treatment showed synergistic effects in each case, with marked tumor reductions in 2/5 cases and the authors report one compete response in a MaMel301 cell line xenograft mouse."	"Posch et al., 2013, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000369535.4	"transcript_variant,gain_of_function_variant"
NRAS Mutation	NRAS	Mutation	Skin Melanoma	Binimetinib	Predictive	Supports	B	Sensitivity/Response	chr1	114704469	114716894			Phase II study in 71 patients with NRAS or BRAF V600 mutant melanoma treated with MEK162. Six (20%) of 30 patients with NRAS-mutated melanoma had a partial response (three confirmed).	"Ascierto et al., 2013, Lancet Oncol."	Somatic	ENST00000369535.4	"transcript_variant,gain_of_function_variant"
NRAS Mutation	NRAS	Mutation	Skin Melanoma	Amuvatinib	Predictive	Supports	D	Sensitivity/Response	chr1	114704469	114716894			"Preclinical study in melanoma cell lines. Cell lines (2-5/assay) with NRAS mutation were more sensitive to Amuvatinib (inhibitor targets multiple tyrosine kinases) than BRAF mutant cell lines in growth inhibition, tyrosine phosphorylation inhibition, cell cycle and apoptotic (Annexin V) assays."	"Fedorenko et al., 2014, Melanoma Res."	Somatic	ENST00000369535.4	"transcript_variant,gain_of_function_variant"
NRAS Mutation	NRAS	Mutation	Melanoma	Binimetinib	Predictive	Supports	D	Sensitivity/Response	chr1	114704469	114716894			"In a panel of 7 NRAS mutant melanoma cell lines, all 7 were found to be sensitive to the MEK inhibitor MEK162, whereas 3 of 5 melanoma cell lines that were wild type for BRAF and NRAS were not sensitive to MEK162. In further tests using two of the seven NRAS mutant cell lines (YUDOSO Q16K/wt and YUKIM Q16R), colony forming capacity was reduced with increased MEK162 treatment, and MEK162 induced apoptotic markers in these cells."	"Thumar et al., 2014, Mol. Cancer"	Somatic	ENST00000369535.4	"transcript_variant,gain_of_function_variant"
NRAS Mutation	NRAS	Mutation	Colorectal Cancer	Cetuximab	Predictive	Supports	D	Resistance	chr1	114704469	114716894			"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab."	"Bertotti et al., 2011, Cancer Discov"	Somatic	ENST00000369535.4	"transcript_variant,gain_of_function_variant"
NRAS Mutation	NRAS	Mutation	Colorectal Cancer	"Cetuximab,Chemotherapy"	Predictive	Supports	B	Resistance	chr1	114704469	114716894			"This was a retrospective study of 605 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy. Patients with KRAS wildtype, NRAS assessable tumors, and individual response data (n=301) were genotyped for NRAS mutations. Patients harboring NRAS mutant tumors (n=13) had a significantly lower response rate than did patients with wildtype NRAS (n=289; 1/13 [7.7%] vs 110/289 [77.9%]; p =.013). However, there was no significant difference between patients with mutant or wildtype NRAS in disease control rate, progression free survival, or overall survival. Authors note that their small sample size of patients with NRAS mutant tumors made it difficult to assess the effect of NRAS mutation on survival thus the large confidence intervals. Authors further note that the close relationship between KRAS and NRAS, and the lack of NRAS response to another EGFR inhibitor (panitumumab) support the inclusion of NRAS genotyping prior to cetuximab treatment. Authors suggest screening for mutations in the following gene order: KRAS, BRAF, NRAS, PIK3CA exon 21 (listed as PIK3CA exon 20 in the source)."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000369535.4	"transcript_variant,gain_of_function_variant"
NRAS Mutation	NRAS	Mutation	Skin Melanoma	"Binimetinib,Ribociclib"	Predictive	Supports	B	Sensitivity/Response	chr1	114704469	114716894			"Inhibition of CDK4 and 6, regulators of the G1/S cell cycle checkpoint, arrests the cell cycle in the G1 phase, suppresses DNA synthesis, and inhibits cancer cell growth. There is an ongoing phase 1/2 trial of binimetinib with the CDK4/6 inhibitor ribociclib (LEE011) in mutant NRAS melanoma patients (NCT01781572). Early results from the 21 evaluable patients were very promising, with 7 patients achieving a partial response (33%) and 11 patients with stable disease (52%)"	"Vu et al., 2016, Pharmacol. Res."	Somatic	ENST00000369535.4	"transcript_variant,gain_of_function_variant"
NRAS Mutation	NRAS	Mutation	Skin Melanoma	Binimetinib	Predictive	Supports	B	Sensitivity/Response	chr1	114704469	114716894			"NEMO is an ongoing, randomised, open-label phase 3 study of patients with advanced, unresectable, AJCC IIIC/IV NRAS-mutant melanoma. 402 patients that were previously untreated or progressed on or after previous immunotherapy were randomised to receive either binimetinib (269) or dacarbazine (133). The study's primary endpoint was progression free survival. Median follow-up was 1.7 months (IQR 1.4-4.1). Median progression-free survival was 2.8 months (95% CI 2.8-3.6) in the binimetinib group and 1.5 months (1.5-1.7) in the dacarbazine group, demonstrating improved progression-free survival of binimetinib compared with dacarbazine."	"Dummer et al., 2017, Lancet Oncol."	Somatic	ENST00000369535.4	"transcript_variant,gain_of_function_variant"
NRAS Mutation	NRAS	Mutation	Colorectal Cancer	"Cetuximab,Panitumumab"	Predictive	Supports	A	Resistance	chr1	114704469	114716894			NCCN guidelines indicate colorectal cancer patients with NRAS mutations should not be treated with EGFR inhibitors cetuximab or panitumumab.	"Benson et al., 2017, J Natl Compr Canc Netw"	Somatic	ENST00000369535.4	"transcript_variant,gain_of_function_variant"
NRAS Mutation	NRAS	Mutation	Melanoma	"Vemurafenib,Dabrafenib"	Predictive	Supports	B	Resistance	chr1	114704469	114716894			"In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired resistance to BRAF inhibitor (vemurafenib or dabrafenib) monotherapy. The following MAPK pathway variants were found in progressive tumors with patient matched baseline tumors (some patients donated samples from multiple geographically/temporally distinct progressive tumors): NRAS mutations (G12D, G12R, G13R, Q61K, Q61R, Q61L) in 13/71 (18%) of progressive tumors, KRAS mutations (G12C, G12R, Q61H) in 5/71 (7%) of progressive tumors, mutant BRAF amplification (2-15 fold or 4-75 copies) in 11/57 (19%) of progressive tumors, mutant BRAF alternative splice variants (novel exon boundaries between 1/9, 1/11, 3/9) in 6/48 (13%) of progressive tumor RNA."	"Shi et al., 2014, Cancer Discov"	Somatic	ENST00000369535.4	"transcript_variant,gain_of_function_variant"
NRAS Q61	NRAS	Q61	Melanoma		Diagnostic	Supports	B	Positive	chr1	114713907	114713909			Melanoma associated with NRAS Q61 mutation was more often associated with those at the extremity than those at the trunk.	"Tschandl et al., 2013, PLoS ONE"	Somatic	ENST00000369535.4	missense_variant
NRAS Q61	NRAS	Q61	Melanoma	Vemurafenib	Predictive	Supports	B	Resistance	chr1	114713907	114713909			Vemurafenib resistance is associated with gain of Q61 mutation in NRAS.	"Trunzer et al., 2013, J. Clin. Oncol."	Somatic	ENST00000369535.4	missense_variant
NRAS Q61	NRAS	Q61	Colorectal Cancer	"Chemotherapy,Cetuximab"	Predictive	Supports	B	Resistance	chr1	114713907	114713909			"Chemotherapy-refractory patients with KRAS wt metastatic colorectal cancer harboring NRAS mutation (primarily Q61, n=10) have a significantly lower response rate to cetuximab than patients wildtype for NRAS (7.1% [1/14] vs 38.1% [110/289])."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000369535.4	missense_variant
NRAS Q61	NRAS	Q61	Colorectal Cancer	Cetuximab	Predictive	Does Not Support	B	Resistance	chr1	114713907	114713909			"In chemotherapy-refractory patients with colorectal cancer, NRAS mutation status (primarily Q61, N=13) was not informative for disease control rate, progression free survival or overall survival following cetuximab plus chemotherapy (N=480)."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000369535.4	missense_variant
NRAS Q61	NRAS	Q61	Thyroid Gland Follicular Carcinoma		Prognostic	Supports	B	N/A	chr1	114713907	114713909			"In patients with follicular thyroid carcinoma, those with mutations in NRAS at codon 61 did not have significantly different overall survival than patients with wild-type NRAS (p=0.36)."	"Fukahori et al., 2012, Thyroid"	Somatic	ENST00000369535.4	missense_variant
NRAS Q61	NRAS	Q61	Skin Melanoma	Binimetinib	Predictive	Supports	B	Sensitivity/Response	chr1	114713907	114713909			"Phase 2 study of MEK162 in patients with advanced melanoma and NRAS or BRAF mutation. 71 patients were enrolled, 6/30 patients with NRAS mutation had a partial response (Gln61Leu 1 Patient, Gln61Lys 9 Patients, Gln61Arg 15 Patients). Another 13 patients had stable disease (63% disease control rate)."	"Ascierto et al., 2013, Lancet Oncol."	Somatic	ENST00000369535.4	missense_variant
NRAS Q61	NRAS	Q61	Skin Melanoma	Selumetinib	Predictive	Supports	C	Sensitivity/Response	chr1	114713907	114713909			Phase 1 trial in 57 patients with advanced cancers treated with selumetinib. 4 melanoma patients had NRAS Q61 mutations. One patient with NRAS mutation had 70% tumor shrinkage after three cycles of selumetinib (AZD6244) but developed symptomatic brain metastases before confirmatory scans could be performed.	"Adjei et al., 2008, J. Clin. Oncol."	Somatic	ENST00000369535.4	missense_variant
NRAS Q61H	NRAS	Q61H	Colorectal Cancer	"Irinotecan,Cetuximab"	Predictive	Supports	C	Resistance	chr1	114713907	114713907	T	G	"One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS Q61H was wildtype for KRAS, BRAF and PIK3CA. This patient was was a 73 year old male treated with cetuximab and irinotecan as 4th line therapy who experienced progressive disease and had PFS of 10 weeks and OS of 36 weeks."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000369535.4	missense_variant
NRAS Q61	NRAS	Q61	Thyroid Gland Follicular Carcinoma		Prognostic	Does Not Support	B	Poor Outcome	chr1	114713907	114713909			"Follicular thyroid cancers harboring RAS mutations have limited aggressiveness in the absence of TERT mutations. 2/2 follicular thyroid cancer patients with co-mutations in NRAS (10 Q61R and 1 Q61K) or HRAS (2 Q61R and 1 Q61K) and TERT promoter mutations had persistent or recurrent disease compared to 1/11 patients with only a RAS mutation (100% vs 8%, P=0.03)."	"Muzza et al., 2015, Mol. Cell. Endocrinol."	Somatic	ENST00000369535.4	missense_variant
NRAS Q61L	NRAS	Q61L	Melanoma	Temozolomide	Predictive	Supports	C	Sensitivity/Response	chr1	114713908	114713908	T	A	"In a melanoma patient with NRAS Q61L mutation, treatment with temozolomide resulted in disease free survival of 14 months."	"Soon et al., 2011, Arch Dermatol"	Somatic	ENST00000369535.4	missense_variant
NRAS Q61R	NRAS	Q61R	Melanoma	Temozolomide	Predictive	Supports	C	Sensitivity/Response	chr1	114713908	114713908	T	C	"In a melanoma patient with Q61R mutation, treatment with temozolomide resulted in overall survival of 16 months."	"Soon et al., 2011, Arch Dermatol"	Somatic	ENST00000369535.4	missense_variant
NRAS Q61L	NRAS	Q61L	Colorectal Cancer	"Cetuximab,Irinotecan"	Predictive	Supports	C	Resistance	chr1	114713908	114713908	T	A	"Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61L and were wildtype for KRAS, BRAF and PIK3CA. Both patients experienced stable disease, which the authors classified as non-response. The two patients whose tumors harbored NRAS Q61L included a 53 year old female treated with cetuximab and irinotecan as a 6th line treatment who had PFS of 12 weeks and OS of 25 weeks; and a 64 year old female treated with cetuximab and ironotecan as a 3rd line therapy who had PFS of 12 weeks and OS of 46 weeks."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000369535.4	missense_variant
NRAS Q61R	NRAS	Q61R	Colorectal Cancer	Cetuximab	Predictive	Supports	C	Resistance	chr1	114713908	114713908	T	C	"Five patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61R and were wildtype for KRAS, BRAF and PIK3CA. Overall, one patient experienced stable disease, and the other four experienced progressive disease.The five patients whose tumors harbored NRAS Q61R included a 65 year old male treated with cetuximab monotherapy as a 3rd line treatment who experienced progressive disease and had PFS of 6 weeks and OS of 41 weeks; a 47 year old female treated with cetuximab and ironotecan as a 5th line therapy who experienced progressive disease and had PFS of 4 weeks and OS of 10 weeks; a 60 year old female treated with cetuximab and ironotecan as a 3rd line therapy who experienced stable disease and had PFS of 24 weeks and OS of 38 weeks; a 47 year old female treated with cetuximab and ironotecan as a 3rd line therapy who experienced progressive disease and had PFS of 14 weeks and OS of 18 weeks; and a 77 year old male treated with cetuximab monotherapy as a 1st line therapy who experienced progressive disease and had PFS of 7 weeks and OS of 67 weeks."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000369535.4	missense_variant
NRAS Q61K	NRAS	Q61K	Neuroblastoma	"Binimetinib,Everolimus"	Predictive	Supports	D	Sensitivity/Response	chr1	114713909	114713909	G	T	"In-vitro study in 5 neuroblastoma cell lines (2 with NRAS Q61K mutation). The combination of mTOR and MEK Inhibitors synergistically blocked cell growth in NRAS mutant but not wild type cell lines. Single agent MEK inhibition (AZD6244/selumetinib, MEK162 or PD0325901) and single agent mTOR inhibition (Everolimus or AZD8055) also blocked cell growth in NRAS mutant cell lines, whereas single agent PI3K inhibitors or MEK Inhibitors in combination with PIK3CA/AKT inhibitors did not show synergistic effects."	"Kiessling et al., 2016, PLoS ONE"	Somatic	ENST00000369535.4	missense_variant
NRAS Q61K	NRAS	Q61K	Skin Melanoma	Vemurafenib	Predictive	Supports	D	Resistance	chr1	114713909	114713909	G	T	"Preclinical study in melanoma cell lines. NRAS Q61K, in addition to the BRAF V600E mutation was associated with resistance to vemurafenib but sensitivity to AZD6244 (selumetinib) in vitro in the acquired resistant cell line M249-AR4 and in the patient-derived acquired resistant cell line M376."	"Atefi et al., 2011, PLoS ONE"	Somatic	ENST00000369535.4	missense_variant
NRAS Q61K	NRAS	Q61K	Skin Melanoma	Selumetinib	Predictive	Supports	D	Sensitivity/Response	chr1	114713909	114713909	G	T	"Preclinical study in melanoma cell lines. NRAS Q61K, in addition to the BRAF V600E mutation was associated with resistance to vemurafenib but sensitivity to AZD6244 (selumetinib) in vitro in the acquired resistant cell line M249-AR4 and in the patient-derived acquired resistant cell line M376."	"Atefi et al., 2011, PLoS ONE"	Somatic	ENST00000369535.4	missense_variant
NRAS Q61K	NRAS	Q61K	Colorectal Cancer	"Cetuximab,Chemotherapy"	Predictive	Supports	C	Resistance	chr1	114713909	114713909	G	T	"Four patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61K and were wildtype for KRAS, BRAF and PIK3CA. One patient experienced partial response and three patients experienced progressive disease. The four patients whose tumors harbored NRAS Q61K included an 80 year old male treated with cetuximab and irinotecan as a 3rd line treatment who experienced progressive disease and had PFS of 6 weeks and OS of 43 weeks; a 51 year old male treated with cetuximab and ironotecan as a 3rd line therapy who experienced a partial response and had PFS of 24 weeks and OS of 54 weeks; a 64 year old male treated with cetuximab and ironotecan as a 5th line therapy who experienced progressive disease and had PFS of 8 weeks and OS of 33 weeks; and a 65 year old female treated with cetuximab, oxaliplatin and 5FU as a 2nd line therapy who experienced progressive disease and had PFS of 31 weeks and OS of 50 weeks."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000369535.4	missense_variant
NRAS Q61K	NRAS	Q61K	Colorectal Cancer	"Dactolisib,Selumetinib"	Predictive	Supports	D	Sensitivity/Response	chr1	114713909	114713909	G	T	"In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring mutations in KRAS, NRAS, BRAF, or PIK3CA and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. NRAS mutations were in 4/40 tumors (three Q61K, one G12D)."	"Migliardi et al., 2012, Clin. Cancer Res."	Somatic	ENST00000369535.4	missense_variant
NRAS Q61K	NRAS	Q61K	Lung Non-small Cell Carcinoma	"Selumetinib,Trametinib"	Predictive	Supports	D	Sensitivity/Response	chr1	114713909	114713909	G	T	"Of the 4,562 patients with lung cancers, 30 showed NRAS mutations, which corresponded to 9 different amino acid substitutions. Cell lines were developed for 6 of these mutations (one harboring Q61L, two Q61R, and three Q61K mutations) and 5/6 were sensitive to MEK inhibitors selumetinib and trametinib. One Q61K line was not sensitive to these inhibitors."	"Ohashi et al., 2013, Clin. Cancer Res."	Somatic	ENST00000369535.4	missense_variant
NRAS Q61K	NRAS	Q61K	Ovary Serous Adenocarcinoma	Trametinib	Predictive	Supports	C	Sensitivity/Response	chr1	114713909	114713909	G	T	"One 56 year old female with advanced recurrent low grade serous ovarian cancer with NRAS Q61K mutation had a partial response to trametinib, with short follow-up."	"Champer et al., 2019, Gynecol Oncol Rep"	Somatic	ENST00000369535.4	missense_variant
NRAS G13D	NRAS	G13D	Melanoma	Tanespimycin	Predictive	Supports	C	Sensitivity/Response	chr1	114716123	114716123	C	T	"Likely due to increased reliance of mutant NRAS on HSP90 for stabilization, inhibition of HSP90 by 17-AAG was shown to be effective in a patient with metastatic malignant melanoma with an NRAS G13D mutation."	"Banerji et al., 2008, Mol. Cancer Ther."	Somatic	ENST00000369535.4	missense_variant
NRAS G12/G13	NRAS	G12/G13	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr1	114716123	114716127			"Patients with a triple mutation of NPM1, DNMT3A, and NRAS (G12/13) (three-way interaction p=0.04) showed a relatively benign prognosis with an 8-year survival rate of 75% and a 10-year survival rate of 55%.  Conversely, patients with a concomitant NPM1/DNMT3A co-mutation, in the absence of an NRAS (G12/13) mutation, showed a clinically unfavorable 10-year survival rate of 30%."	"Papaemmanuil et al., 2016, N. Engl. J. Med."	Somatic	ENST00000369535.4	protein_altering_variant
NRAS G13R	NRAS	G13R	Colorectal Cancer	"Irinotecan,Cetuximab"	Predictive	Supports	C	Resistance	chr1	114716124	114716124	C	G	"One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G13R, was wildtype for KRAS, BRAF and PIK3CA, and had individual response data. This patient was was a 68 year old male treated with cetuximab + irinotecan as 3rd line therapy who experienced stable disease (PFS: 18 weeks; OS: 34 weeks). Authors considered stable disease as both clinical benefit and non response."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000369535.4	missense_variant
NRAS G13R	NRAS	G13R	Colorectal Cancer	Panitumumab	Predictive	Supports	C	Resistance	chr1	114716124	114716124	C	G	"One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G13R, was wildtype for KRAS, BRAF and PIK3CA, and had individual response data. This patient was was a 50 year old male treated with panitumumab monotherapy as 3rd line therapy (discontinued for toxic/biochemical reasons) who experienced stable disease (PFS: 22 weeks; OS: 74 weeks). Authors considered stable disease as both clinical benefit and non-response"	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000369535.4	missense_variant
NRAS G12	NRAS	G12	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	N/A	chr1	114716126	114716127			"NRAS mutation status does not impact overall, event-free or disease-free survival in patients with AML."	"Bacher et al., 2006, Blood"	Somatic	ENST00000369535.4	missense_variant
NRAS G12D	NRAS	G12D	Colorectal Cancer	"Cetuximab,Irinotecan"	Predictive	Supports	C	Resistance	chr1	114716126	114716126	C	T	"One patient participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G12D and was wild type for KRAS, PIK3CA, and BRAF. This patient was a 64 year old male treated with cetuximab and irinotecan as 5th line therapy who experienced stable disease and had PFS of 64 weeks and OS of 84 weeks."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000369535.4	missense_variant
NRAS G12D	NRAS	G12D	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Resistance	chr1	114716126	114716126	C	T	"In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild-type KRAS and NRAS."	"Kaczirek et al., 2015, Clin Colorectal Cancer"	Somatic	ENST00000369535.4	missense_variant
NRAS G12C	NRAS	G12C	Colorectal Cancer	"Chemotherapy,Cetuximab"	Predictive	Supports	C	Resistance	chr1	114716127	114716127	C	A	"Two patients participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS G12C and were wild type for KRAS, PIK3CA, and BRAF. Both experienced stable disease, which the authors classified as non-response. The two patients whose tumors harbored NRAS G12C included a 63 year old female treated with cetuximab and irinotecan as a 3rd line treatment who had PFS of 34 weeks and OS of 55 weeks; and a 38 year old female treated with cetuximab, oxaliplatin and 5FU as a 2nd line therapy who had PFS of 12 weeks."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000369535.4	missense_variant
RIT1 OVEREXPRESSION	RIT1	OVEREXPRESSION	Endometrial Cancer		Prognostic	Supports	B	Poor Outcome	chr1	155900274	155910915			"After preliminary studies in cell lines, GEO datasets and fresh frozen tissues, RIT1 expression was determined in 257 tumors and 31 normal tissues. Elevated expression of RIT1 was correlated with poorer overall survival, pathological type, clinical stage, grade and vascular invasion."	"Xu et al., 2015, Int J Clin Exp Pathol"	Somatic	ENST00000368322.3	N/A
RIT1 Mutation	RIT1	Mutation	Lung Adenocarcinoma	"Pictilisib,Selumetinib"	Predictive	Supports	D	Sensitivity/Response	chr1	155900274	155910915			"RIT1 mutations were identified in approx. 2% of lung adenocarcinomas (5/87 in the ""oncogene negative"" samples of TCGA - no RIT1 mutations were observed in 143 samples with a known driver mutation). GDC-0941 impaired tumor growth of NCI-H2110 (RIT1 M90I mutated) xenografts in nude mice. GDC-0941 and AZD-6244 (selumetinib) impaired colony formation in-vitro. Combined PI3K/MEK inhibition was more effective than single agent treatment in-vitro."	"Berger et al., 2014, Oncogene"	Somatic	ENST00000368322.3	transcript_variant
NTRK1 LMNA::NTRK1 e11-e10	NTRK1	LMNA::NTRK1 e11-e10	Colorectal Adenocarcinoma	Entrectinib	Predictive	Supports	C	Sensitivity/Response	chr1	156114707	156138757			"A gene fusion between exon 11 of LMNA and exon 10 of NTRK1 was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI/cetuximab, and third-line irinotecan. The patient treated in a clinical trial with pan-TRK kinase inhibitor entrectinib. Treatment was well tolerated and led to a partial response (PR) with 30% tumor shrinkage of multiple liver metastases. Clinical response lasted 4 months."	"Russo et al., 2016, Cancer Discov"	Somatic	ENST00000368300.4	transcript_fusion
NTRK1 LMNA::NTRK1	NTRK1	LMNA::NTRK1	Sarcoma	Larotrectinib	Predictive	Supports	C	Sensitivity/Response	chr1	156114707	156138757			"One Patient with soft tissue sarcoma and a NTRK1-LMNA fusion had a partial response with larotrectinib. Treatment was done within a multicentre, open-label, phase 1/2 study and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion Status. In total, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) were enrolled. Among the fusion-positive patients, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response."	"Laetsch et al., 2018, Lancet Oncol."	Somatic	ENST00000368300.4	transcript_fusion
NTRK1 LMNA::NTRK1	NTRK1	LMNA::NTRK1	Lipofibromatosis-like Neural Tumor		Diagnostic	Supports	C	Positive	chr1	156114707	156138757			"A 14-month-old boy presented with a slow-growing, asymptomatic back plaque, which was biopsied and found to have S100 positivity, sparse CD34 staining, and no significant mitotic activity, nuclear pleomorphism, or necrosis; genetic workup found LMNA-NTRK1 gene fusion, overall consistent with lipofibromatosis-like neural tumor (LPF-NT). LPF-NT is rare, with 14 cases previously reported, and this patient was the first report of this diagnosis in infancy. This case report and literature review includes comparison of similar diagnoses including lipofibromatosis, low-grade malignant peripheral nerve sheath tumor, infantile fibrosarcoma, and dermatofibrosarcoma protuberans and serves to aid detection of LPF-NT presenting in pediatric patients by highlighting similarities and differences that should prompt consideration. LPF-NT shows locally aggressive behavior only and should not be confused with conditions that have potential for distant spread. However, case reports of metastasizing LMNA-NTRK1 tumors draw into question whether growths with this gene fusion exist on a spectrum of disease severity. The patient was treated with wide local excision and has developed no complications or evidence of recurrence with 6 months of follow-up time."	"Bartenstein et al., 2018, JAAD Case Rep"	Somatic	ENST00000368300.4	transcript_fusion
NTRK1 LMNA::NTRK1 e11-e10	NTRK1	LMNA::NTRK1 e11-e10	Colorectal Cancer	Entrectinib	Predictive	Supports	C	Sensitivity/Response	chr1	156114707	156138757			"After disease progression with no objective response to therapy, a 75-year-old with metastatic colorectal cancer that spread to the liver displayed elevated NTRK1 expression in both primary tumor and liver metastasis as measured by immunohistochemistry. FISH of the tumor and patient derived xenograft indicated NTRK1 involvement. 5RACE PCR discovered a novel LMNA-NTRK1 fusion (exon 11 & exon 10), which resulted in the expression of two different fusion splice transcripts (exons 1-10 with exons 10-16 and exons 1-11 with exons 10-16). Fusion expression of both transcripts was confirmed by western blot, and Sanger sequencing revealed the fusion to be in-frame with the kinase domain intact. After 4 weeks of treatment with Entrectinib, CT scan revealed the patient showed a partial response with a 30% reduction of target lesions. This response was maintained for 5 months."	"Sartore-Bianchi et al., 2016, J Natl Cancer Inst"	Somatic	ENST00000368300.4	transcript_fusion
NTRK1 LMNA::NTRK1 e11-e10	NTRK1	LMNA::NTRK1 e11-e10	Colorectal Cancer		Oncogenic	Supports	D	Oncogenicity	chr1	156114707	156138757			"FISH of the tumor and patient derived xenograft of a 75-year-old with metastatic colorectal cancer that spread to the liver indicated NTRK1 involvement. 5RACE PCR discovered a novel LMNA-NTRK1 fusion (exon 10 & exon 10), which resulted in the expression of two different fusion splice transcripts (exons 1-10 with exons 10-16 and exons 1-11 with exons 10-16). Expression was confirmed by Western and Sanger sequencing revealed the fusion to be in-frame with the kinase domain intact. Western blot of the tumor also indicated constitutive activation of the fusion based on phosphorylation of the fusion. Additionally, downstream kinase targets (PLC1, AKT, and MAPK) were also phosphorylated in the tumor, similar to levels observed in the TPM3-NTRK1 containing KM12 colorectal cancer cell line."	"Sartore-Bianchi et al., 2016, J Natl Cancer Inst"	Somatic	ENST00000368300.4	transcript_fusion
NTRK1 LMNA::NTRK1	NTRK1	LMNA::NTRK1	Cancer	Entrectinib	Predictive	Supports	D	Sensitivity/Response	chr1	156114707	156138757			"BaF3 cells were transduced with a number of NTRK fusions. IC50 values were measured following treatment with entrectinib: TPM3-NTRK1 (2.5nM), LMNA-NTRK1 (1.4nM), ETV6-NTRK1 (2.5nM), VCL-NTRK2 (4.3nM), AFAP1-NTRK2 (2.7nM), ETV6-NTRK2 (4.5nM), ETV6-NTRK3 (3.8nM), and control (>1000nM)."	"Drilon et al., 2016, Ann. Oncol."	N/A	ENST00000368300.4	transcript_fusion
CSF1R MEF2D::CSF1R	CSF1R	MEF2D::CSF1R	Acute Lymphoblastic Leukemia	"GW-2580,Imatinib"	Predictive	Supports	D	Sensitivity/Response	chr1	156477012	156500828			Cell lines with MEF2D-CSF1R fusion show sensitivity to the tyrosine kinase inhibitors Imatinib and GW-2580.	"Lilljebjrn et al., 2014, Leukemia"	Somatic	ENST00000348159.4	transcript_fusion
CSF1R MEF2D::CSF1R	CSF1R	MEF2D::CSF1R	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	Imatinib	Predictive	Supports	C	Sensitivity/Response	chr1	156477012	156500828			"This study describes a cohort of 24 patients with BCR-ABL1-like B-ALL and ABL-class kinase rearrangement exposed to TKI frontline or at relapse, who showed favorable MRD response and outcome. Specifically, one 34-year-old man with MEF2D-CSF1R identified by RNAseq was prescribed an unspecified dose of imatinib as adjuvant to his frontline chemotherapy (protocol GRAALL-2014). His initial MRD analysis at 94 days remained positive for blasts (1 x 10^-4), but was consistent with continuous complete remission at day 147."	"Tanasi et al., 2019, Blood"	Somatic	ENST00000348159.4	transcript_fusion
NTRK1 Overexpression	NTRK1	Overexpression	Neuroblastoma		Prognostic	Supports	B	Better Outcome	chr1	156860894	156881642			A high level of expression of the TRK proto-oncogene in a neuroblastoma is strongly predictive of a favorable outcome. A tumor with a functional nerve growth factor receptor may be dependent on the neurotrophin nerve growth factor for survival and may regress in its absence.	"Nakagawara et al., 1993, N. Engl. J. Med."	N/A	ENST00000524377.1	N/A
NTRK1 Amplification	NTRK1	Amplification	Cancer	Entrectinib	Predictive	Does Not Support	B	Sensitivity/Response	chr1	156860894	156881642			"Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including CNS disease. Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. No objective responses (per RECIST v1.1) were observed in patients whose tumors did not harbor gene fusions involving NTRK1/2/3, ROS1, or ALK, with the exception of 1 patient with an ALKF1245V mutant neuroblastoma."	"Drilon et al., 2017, Cancer Discov"	Somatic	ENST00000524377.1	transcript_amplification
NTRK1 Amplification	NTRK1	Amplification	Solid Tumor	Larotrectinib	Predictive	Supports	C	Sensitivity/Response	chr1	156860894	156881642			"In a phase I study of larotrectinib in 67 patients with solid tumours, 8 patients were recorded as having objective response. 7 of these harboured NTRK fusions, and one had a NTRK1 amplification. This patient's tumour had a size reduction measured as 45% and a response duration of 3.7 months. It is not stated in the publication whether a survey of amplification status in other patients in the study was done."	"Hong et al., 2019, Ann. Oncol."	Somatic	ENST00000524377.1	transcript_amplification
NTRK1 Fusion	NTRK1	Fusion	Colorectal Cancer	Larotrectinib	Predictive	Supports	D	Sensitivity/Response	chr1	156874383	156881642			"NTRK1 fusions (one LMNA-NTRK1 and two TPM3-NTRK1) were identified in 2% of Korean colorectal cancer patients (147 patients). TrkA (NTRK1) protein expression was associated with presence of NTRK1 gene fusion. These fusions were mutually exclusive with other oncogenic drivers and showed in-vitro sensitivity to TrkA Inhibitor ARRY470  (Larotrectinib) (one cell line with fusion (KM12), one control cell line)."	"Park et al., 2016, Oncotarget"	Somatic	ENST00000524377.1	transcript_fusion
NTRK1 Fusion	NTRK1	Fusion	Lung Adenocarcinoma	"Lestaurtinib,Larotrectinib,Crizotinib"	Predictive	Supports	D	Sensitivity/Response	chr1	156874383	156881642			"Two patients were found to harbor gene fusions maintaining the kinase domain of NTRK1 (3' partner), specifically: MPRIP-NTRK1 and CD74-NTRK1.  Both of these fusions lead to constitutive kinase activity and were found to be oncogenic. Treatment of cells expressing NTRK1 fusions with inhibitors of TRKA kinase activity (ARRY-470, CEP-701 and, to a lesser extent, crizotinib) inhibited autophosphorylation of TRKA and cell growth."	"Vaishnavi et al., 2013, Nat. Med."	Somatic	ENST00000524377.1	transcript_fusion
NTRK1 Fusion	NTRK1	Fusion	Cancer	Entrectinib	Predictive	Supports	B	Sensitivity/Response	chr1	156874383	156881642			"in two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer."	"Drilon et al., 2017, Cancer Discov"	Somatic	ENST00000524377.1	transcript_fusion
NTRK1 Fusion	NTRK1	Fusion	Cancer	Larotrectinib	Predictive	Supports	C	Sensitivity/Response	chr1	156874383	156881642			"Results from a phase I study show that the TRK inhibitor LOXO-101 is well tolerated and effective, with patients whose tumors bear NTRK fusions responding well and durably to this targeted therapy. This publication reported results from an AACR meeting for an ongoing study that had enrolled six patients with NTRK fusions, three of whom could be evaluated at the time. Each had a different, heavily pretreated advanced disease: soft-tissue sarcoma; gastrointestinal stromal tumor (GIST); and MASC. All three patients experienced partial responses by 3-4 months with resolution of key tumour-related symptoms within two weeks. One of three patients experienced near-complete response by 8 months."	"2016, Cancer Discov"	Somatic	ENST00000524377.1	transcript_fusion
NTRK1 Fusion	NTRK1	Fusion	Solid Tumor	Larotrectinib	Predictive	Supports	A	Sensitivity/Response	chr1	156874383	156881642			This was a Phase 1/2 study of 55 patients from 4 months to 76 years old with TRK-fusion positive tumors given NTRK inhibitor Larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall response rate was 75% according to independent review and 80% according to investigator assessment. Authors state that Larotrectinib had durable anti tumor activity regardless of age or tumor type. 17/23 patients with NTRK1-fusion showed maximum percent change in tumor size between -30% and -100%.	"Drilon et al., 2018, N. Engl. J. Med."	Somatic	ENST00000524377.1	transcript_fusion
NTRK1 Fusion	NTRK1	Fusion	Sarcoma	Larotrectinib	Predictive	Supports	B	Sensitivity/Response	chr1	156874383	156881642			"In a Phase 1/2 study involving 15 pediatric patients with infantile fibrosarcoma or soft tissue sarcoma, 8 patients had NTRK1 fusions. The patients were administered Larotrectinib, and 7 out of 8 patients showed objective response, with 2 complete and 5 partial responses. The patient without objective response had soft tissue sarcoma, and showed stable disease."	"Laetsch et al., 2018, Lancet Oncol."	Somatic	ENST00000524377.1	transcript_fusion
NTRK1 Fusion	NTRK1	Fusion	Solid Tumor	Entrectinib	Predictive	Supports	A	Sensitivity/Response	chr1	156874383	156881642			"Describes a meta-analysis of three separate phase I or II trials: ALKA-372-001, STARTRK-1, and STARTRK-2. All of these evaluate entrectinib in NTRK fusion-positive solid tumours. 31/54 had objective response (57%; 95% CI 432?08), including 4 CR and 27 PR. 9 had SD. Response by NTRK gene type: 13/22 NTRK1 fusions [59%; 95% CI 364?93], 18/31 NTRK3 fusions [58%; 391?55], and 0/1 NTRK2 fusion. Most frequent tumour types were sarcoma, NSCLC, salivary, breast, thyroid, colorectal. Most common fusions were ETV6-NTRK3 (25), TPM3-NTRK1 (4) and TPR-NTRK1 (4)."	"Doebele et al., 2020, Lancet Oncol"	Somatic	ENST00000524377.1	transcript_fusion
NTRK1 LMNA::NTRK1 e11-e10	NTRK1	LMNA::NTRK1 e11-e10	Colorectal Adenocarcinoma	Entrectinib	Predictive	Supports	C	Sensitivity/Response	chr1	156874571	156881642			"A gene fusion between exon 11 of LMNA and exon 10 of NTRK1 was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI/cetuximab, and third-line irinotecan. The patient treated in a clinical trial with pan-TRK kinase inhibitor entrectinib. Treatment was well tolerated and led to a partial response (PR) with 30% tumor shrinkage of multiple liver metastases. Clinical response lasted 4 months."	"Russo et al., 2016, Cancer Discov"	Somatic	ENST00000368300.4	transcript_fusion
NTRK1 LMNA::NTRK1	NTRK1	LMNA::NTRK1	Sarcoma	Larotrectinib	Predictive	Supports	C	Sensitivity/Response	chr1	156874571	156881642			"One Patient with soft tissue sarcoma and a NTRK1-LMNA fusion had a partial response with larotrectinib. Treatment was done within a multicentre, open-label, phase 1/2 study and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion Status. In total, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) were enrolled. Among the fusion-positive patients, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response."	"Laetsch et al., 2018, Lancet Oncol."	Somatic	ENST00000368300.4	transcript_fusion
NTRK1 LMNA::NTRK1	NTRK1	LMNA::NTRK1	Lipofibromatosis-like Neural Tumor		Diagnostic	Supports	C	Positive	chr1	156874571	156881642			"A 14-month-old boy presented with a slow-growing, asymptomatic back plaque, which was biopsied and found to have S100 positivity, sparse CD34 staining, and no significant mitotic activity, nuclear pleomorphism, or necrosis; genetic workup found LMNA-NTRK1 gene fusion, overall consistent with lipofibromatosis-like neural tumor (LPF-NT). LPF-NT is rare, with 14 cases previously reported, and this patient was the first report of this diagnosis in infancy. This case report and literature review includes comparison of similar diagnoses including lipofibromatosis, low-grade malignant peripheral nerve sheath tumor, infantile fibrosarcoma, and dermatofibrosarcoma protuberans and serves to aid detection of LPF-NT presenting in pediatric patients by highlighting similarities and differences that should prompt consideration. LPF-NT shows locally aggressive behavior only and should not be confused with conditions that have potential for distant spread. However, case reports of metastasizing LMNA-NTRK1 tumors draw into question whether growths with this gene fusion exist on a spectrum of disease severity. The patient was treated with wide local excision and has developed no complications or evidence of recurrence with 6 months of follow-up time."	"Bartenstein et al., 2018, JAAD Case Rep"	Somatic	ENST00000368300.4	transcript_fusion
NTRK1 LMNA::NTRK1 e11-e10	NTRK1	LMNA::NTRK1 e11-e10	Colorectal Cancer	Entrectinib	Predictive	Supports	C	Sensitivity/Response	chr1	156874571	156881642			"After disease progression with no objective response to therapy, a 75-year-old with metastatic colorectal cancer that spread to the liver displayed elevated NTRK1 expression in both primary tumor and liver metastasis as measured by immunohistochemistry. FISH of the tumor and patient derived xenograft indicated NTRK1 involvement. 5RACE PCR discovered a novel LMNA-NTRK1 fusion (exon 11 & exon 10), which resulted in the expression of two different fusion splice transcripts (exons 1-10 with exons 10-16 and exons 1-11 with exons 10-16). Fusion expression of both transcripts was confirmed by western blot, and Sanger sequencing revealed the fusion to be in-frame with the kinase domain intact. After 4 weeks of treatment with Entrectinib, CT scan revealed the patient showed a partial response with a 30% reduction of target lesions. This response was maintained for 5 months."	"Sartore-Bianchi et al., 2016, J Natl Cancer Inst"	Somatic	ENST00000368300.4	transcript_fusion
NTRK1 LMNA::NTRK1 e11-e10	NTRK1	LMNA::NTRK1 e11-e10	Colorectal Cancer		Oncogenic	Supports	D	Oncogenicity	chr1	156874571	156881642			"FISH of the tumor and patient derived xenograft of a 75-year-old with metastatic colorectal cancer that spread to the liver indicated NTRK1 involvement. 5RACE PCR discovered a novel LMNA-NTRK1 fusion (exon 10 & exon 10), which resulted in the expression of two different fusion splice transcripts (exons 1-10 with exons 10-16 and exons 1-11 with exons 10-16). Expression was confirmed by Western and Sanger sequencing revealed the fusion to be in-frame with the kinase domain intact. Western blot of the tumor also indicated constitutive activation of the fusion based on phosphorylation of the fusion. Additionally, downstream kinase targets (PLC1, AKT, and MAPK) were also phosphorylated in the tumor, similar to levels observed in the TPM3-NTRK1 containing KM12 colorectal cancer cell line."	"Sartore-Bianchi et al., 2016, J Natl Cancer Inst"	Somatic	ENST00000368300.4	transcript_fusion
NTRK1 LMNA::NTRK1	NTRK1	LMNA::NTRK1	Cancer	Entrectinib	Predictive	Supports	D	Sensitivity/Response	chr1	156874571	156881642			"BaF3 cells were transduced with a number of NTRK fusions. IC50 values were measured following treatment with entrectinib: TPM3-NTRK1 (2.5nM), LMNA-NTRK1 (1.4nM), ETV6-NTRK1 (2.5nM), VCL-NTRK2 (4.3nM), AFAP1-NTRK2 (2.7nM), ETV6-NTRK2 (4.5nM), ETV6-NTRK3 (3.8nM), and control (>1000nM)."	"Drilon et al., 2016, Ann. Oncol."	N/A	ENST00000368300.4	transcript_fusion
NTRK1 LMNA::NTRK1 G595R and G667C	NTRK1	LMNA::NTRK1 G595R and G667C	Colorectal Adenocarcinoma	Entrectinib	Predictive	Supports	C	Resistance	chr1	156876550	156879315			"A gene fusion between exon 10 of NTRK1 and exon 11 of the LMNA genes was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI/cetuximab, and third-line irinotecan. The patient treated in a clinical trial with pan-TRK kinase inhibitor entrectinib. Treatment was well tolerated and led to a partial response (PR) with 30% tumor shrinkage of multiple liver metastases. Clinical response lasted 4 months. Longitudinal analysis of ctDNA in plasma samples revealed a p.G595R- and p.G667C mutation in NTRK1 that were absent before treatment initiation but  emerged 4 weeks upon initiation of treatment with entrectinib. These mutations were also validated using xenograft, in vitro and 3D-modeling."	"Russo et al., 2016, Cancer Discov"	Somatic	ENST00000524377.1	"missense_variant,transcript_fusion"
DDR2 L63V	DDR2	L63V	Lung Non-small Cell Carcinoma	Dasatinib	Predictive	Supports	D	Sensitivity/Response	chr1	162754625	162754625	C	G	In 3T3 fibroblasts expressing the L63V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	"Hammerman et al., 2011, Cancer Discov"	Somatic	ENST00000367922.3	missense_variant
DDR2 L239R	DDR2	L239R	Lung Non-small Cell Carcinoma	Dasatinib	Predictive	Supports	D	Sensitivity/Response	chr1	162759840	162759840	T	G	In 3T3 fibroblasts expressing the L239R mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	"Hammerman et al., 2011, Cancer Discov"	Somatic	ENST00000367922.3	missense_variant
DDR2 G253C	DDR2	G253C	Lung Non-small Cell Carcinoma	Dasatinib	Predictive	Supports	D	Sensitivity/Response	chr1	162759881	162759881	G	T	In 3T3 fibroblasts expressing the G253C mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	"Hammerman et al., 2011, Cancer Discov"	Somatic	ENST00000367922.3	missense_variant
DDR2 G505S	DDR2	G505S	Lung Non-small Cell Carcinoma	Dasatinib	Predictive	Supports	D	Sensitivity/Response	chr1	162772032	162772032	G	A	In 3T3 fibroblasts expressing the G505S mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	"Hammerman et al., 2011, Cancer Discov"	Somatic	ENST00000367922.3	missense_variant
DDR2 I638F	DDR2	I638F	Lung Non-small Cell Carcinoma	Dasatinib	Predictive	Supports	D	Sensitivity/Response	chr1	162775707	162775707	A	T	In 3T3 fibroblasts expressing the I638F mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	"Hammerman et al., 2011, Cancer Discov"	Somatic	ENST00000367922.3	missense_variant
DDR2 S768R	DDR2	S768R	Lung Non-small Cell Carcinoma	"Erlotinib,Dasatinib"	Predictive	Supports	C	Sensitivity/Response	chr1	162778600	162778600	T	A	"In a patient expressing a DDR2 S768R mutation, treatment with dasatinib plus erlotinib acheived a partial response."	"Hammerman et al., 2011, Cancer Discov"	Somatic	ENST00000367922.3	missense_variant
DDR2 G774V	DDR2	G774V	Lung Non-small Cell Carcinoma	Dasatinib	Predictive	Supports	D	Sensitivity/Response	chr1	162778617	162778617	G	T	In 3T3 fibroblasts expressing the G774V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	"Hammerman et al., 2011, Cancer Discov"	Somatic	ENST00000367922.3	missense_variant
H3-3A K28M	H3-3A	K28M	"Diffuse Midline Glioma, H3 K27M-mutant"		Diagnostic	Supports	B	Positive	chr1	225876734	225876734	A	T	"Wu et al analyzed 127 pediatric HGGs, including diffuse intrinsic pontine gliomas (DIPGs) and non-brainstem HGGs (NBS-HGGs) by whole genome, whole exome, and/or transcriptome sequencing. In addition to ACVR1, they identified 41 recurrent K27M mutations in H3F3A (H3.3, 41/112 = 36.6%), and in 14 HIST1H3B (H3.1, 14/112, 12.5%) in NBS-HGGs and DIPGs. The authors focus on ACVR1 mutations, as H3F3A and HIST1H3A mutations in pediatric gliomas have previously been reported. However, this evidence helps confirm potential diagnostic utility of H3F3A K27M mutations."	"Wu et al., 2014, Nat. Genet."	Somatic	ENST00000366813.1	non_conservative_missense_variant
H3-3A K28M	H3-3A	K28M	"Diffuse Midline Glioma, H3 K27M-mutant"		Diagnostic	Supports	B	Positive	chr1	225876734	225876734	A	T	"Whole genome sequencing (WGS) was performed on the diffuse intrinsic pontine gliomas (DIPGs) and matched germline DNA of 7 pediatric patients. Targeted sequencing was performed on an additional 43 DIPGs and 36 non-brainstem pediatric glioblastomas (non-BS-PGs). Authors identified K27M mutations in 30/50 (60%) of pediatric DIPGs (including 4/7 WGS samples) and 7/36 (19%) pediatric non-brainstem glioblastomas. The authors comment that the K27M mutation appeared exclusive to pediatric high grade gliomas, with H3F3A p.K27M mutation in one of 9 pediatric anaplastic astrocytomas (Grade III), but no histone H3 mutations found in any other pediatric brain tumors including 7 low-grade brainstem gliomas, 15 low-grade non-brainstem gliomas, 38 medulloblastomas, and 22 ependymomas. H3 K27M was not found in an additional 170 non-central nervous system pediatric tumors."	"Wu et al., 2012, Nat. Genet."	Somatic	ENST00000366813.1	non_conservative_missense_variant
H3-3A K28M	H3-3A	K28M	Glioma	Akt/ERK Inhibitor ONC201	Predictive	Supports	B	Sensitivity/Response	chr1	225876734	225876734	A	T	"In a phase 2 trial, patients with H3 K27M mutant glioma have been treated with DRD2 antagonist ONC201. Among 29 patients, 1 patient experienced complete clinical regression lasting >14 months, and 3 patients experienced durable partial response by RANO. 10 patients had a best response of stable disease by RANO, with a few of these patients showing substantial tumor regression in some lesions. Author concluded that ONC201 is well tolerated and has clinical activity against K27M-mutated glioma."	"Isabel Arrillaga, 2019, ASCO Annual Meeting, Abstract 3005"	Somatic	ENST00000366813.1	non_conservative_missense_variant
ACTA1 EXPRESSION	ACTA1	EXPRESSION	Lung Adenocarcinoma		Prognostic	Supports	B	Poor Outcome	chr1	229431245	229434094			"ActA level was measured in serum and plasma samples of 64/87 lung adenocarcinoma patients and 46/66 age- and gender-matched controls (ELISA). ActA Levels were higher in patients than in controls and were significantly correlated with disease stage and metastasis. Patients were stratified as having high or low ActA levels using the median expression level. LADC patients with high serum or plasma ActA levels had significantly shorter OS than those with low circulating ActA concentrations (p < 0.0001 in both) and were identified as an independent prognostic factor (p=0.004 and p=0.002, respectively)."	"Hoda et al., 2016, Oncotarget"	N/A	ENST00000366684.3	N/A
AKT3 E17K	AKT3	E17K	Melanoma	Vemurafenib	Predictive	Supports	D	Resistance	chr1	243695714	243695714	C	T	"An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype AKT3 and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express AKT3 E17K were significantly more resistant to BRAF inhibition via vemurafenib than cells transduced with empty vectors (40% vs 20% survival, p = .0033)."	"Shi et al., 2014, Cancer Discov"	Somatic	ENST00000366539.1	missense_variant
ZEB1 Expression	ZEB1	Expression	Mantle Cell Lymphoma	"Cytarabine,Gemcitabine,Doxorubicin"	Predictive	Supports	D	Resistance	chr10	31319172	31529813			"Downregulation of ZEB1 expression in mantle cell lymphoma cell lines and mouse xenografts led to enhanced sensitivity towards treatment with doxorubicin, cytarabin and gemcitabine."	"Snchez-Till et al., 2014, Cell Death Differ."	N/A	ENST00000361642.5	N/A
ZEB1 Expression	ZEB1	Expression	Mantle Cell Lymphoma	"Salinomycin,Doxorubicin"	Predictive	Supports	D	Sensitivity/Response	chr10	31319172	31529813			"Downregulation of ZEB1 expression in mantle cell lymphoma cell lines and mouse xenografts led to enhanced sensitivity towards treatment with doxorubicin, cytarabin and gemcitabine. the combination of salinomycin (downregulating ZEB1) and doxorubicin was syngergistic."	"Snchez-Till et al., 2014, Cell Death Differ."	Somatic	ENST00000361642.5	N/A
RET KIF5B::RET	RET	KIF5B::RET	Lung Adenocarcinoma	Vandetanib	Predictive	Supports	C	Sensitivity/Response	chr10	32017143	32056431			"A case study of a patient with EGFR, KRAS, BRAF, HER2, ALK, ROS1 and MET negative adenocarcinoma of the lung. FISH analysis revealed a KIF5B-RET fusion. The RET inhibitor Vandetanib led to remission in the patient."	"Gautschi et al., 2013, J Thorac Oncol"	Somatic	ENST00000302418.4	transcript_fusion
RET KIF5B::RET	RET	KIF5B::RET	Lung Adenocarcinoma	"Everolimus,Vandetanib"	Predictive	Supports	C	Sensitivity/Response	chr10	32017143	32056431			"Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion of KIF5B and RET. The patient was enrolled in a clinical trial with vandetanib and everolimus (NCT01582191) with everolimus used to enhance brain accumulation of vandetanib. After two cycles of therapy a repeat MRI brain showed a decrease in the intracranial disease burden and PET/CT showed systemic response as well."	"Subbiah et al., 2015, Lung Cancer"	Somatic	ENST00000302418.4	transcript_fusion
RET Overexpression	RET	Overexpression	Breast Cancer	Vandetanib	Predictive	Supports	D	Sensitivity/Response	chr10	43077027	43130351			"Vandetanib was tested in 4 murine models of patient-derived xenografts. In xenografts with high expression of EGFR or RET, vandetanib led to tumor regression, in those without high expression, vandetanib slowed tumor growth."	"Hatem et al., 2016, Int. J. Cancer"	Somatic	ENST00000355710.3	N/A
RET Overexpression	RET	Overexpression	Papillary Adenocarcinoma	Sunitinib	Predictive	Supports	C	Sensitivity/Response	chr10	43077027	43130351			"A 78-year-old man presented with oral papillary adenocarcinoma and lung metastases that were refractory to standard treatment.  Tumor sequencing showed increased MAPK activity due to RET over-expression and PTEN deletion, therefore sunitinib (RET inhibitor) was initiated.  After 28 days post-administration, the lung metastases decreased in size by 22% (28mm to 21mm) and no new metastatic lesions had appeared.  After 4 months, the patient grew resistant to treatment."	"Jones et al., 2010, Genome Biol."	Somatic	ENST00000355710.3	N/A
RET Overexpression	RET	Overexpression	Lung Adenocarcinoma		Prognostic	Supports	B	Poor Outcome	chr10	43077027	43130351			"ASCL1 and RET mRNA levels were examined by microarray analysis in lung cancer samples. High expression of RET (RET-high) correlated with shorter overall survival compared to the RET-low group in patients with ASCL1 expression in stage I (P=0.007, N=15 vs 38) and all adenocarcinoma (P=0.037, N=31 vs 58). However, expression of RET did not affect survival in the ASCL1- tumors."	"Kosari et al., 2014, Oncogene"	N/A	ENST00000355710.3	N/A
RET KIF5B::RET	RET	KIF5B::RET	Lung Adenocarcinoma	Vandetanib	Predictive	Supports	C	Sensitivity/Response	chr10	43114480	43130351			"A case study of a patient with EGFR, KRAS, BRAF, HER2, ALK, ROS1 and MET negative adenocarcinoma of the lung. FISH analysis revealed a KIF5B-RET fusion. The RET inhibitor Vandetanib led to remission in the patient."	"Gautschi et al., 2013, J Thorac Oncol"	Somatic	ENST00000302418.4	transcript_fusion
RET KIF5B::RET	RET	KIF5B::RET	Lung Adenocarcinoma	"Everolimus,Vandetanib"	Predictive	Supports	C	Sensitivity/Response	chr10	43114480	43130351			"Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion of KIF5B and RET. The patient was enrolled in a clinical trial with vandetanib and everolimus (NCT01582191) with everolimus used to enhance brain accumulation of vandetanib. After two cycles of therapy a repeat MRI brain showed a decrease in the intracranial disease burden and PET/CT showed systemic response as well."	"Subbiah et al., 2015, Lung Cancer"	Somatic	ENST00000302418.4	transcript_fusion
RET C634W	RET	C634W	Thyroid Gland Medullary Carcinoma	Motesanib	Predictive	Supports	D	Resistance	chr10	43114502	43114502	C	G	"Medullary thyroid cancer cells with RET C634W mutation are insensitive to motesanib, compared to wild-type RET."	"Coxon et al., 2012, J. Endocrinol. Invest."	Somatic	ENST00000355710.3	missense_variant
RET M918T	RET	M918T	Thyroid Gland Medullary Carcinoma		Diagnostic	Supports	B	Positive	chr10	43121968	43121968	T	C	"In patients with medullary carcinoma, the presence of RET M918T mutation is associated with increased probability of lymph node metastases."	"Elisei et al., 2008, J. Clin. Endocrinol. Metab."	Somatic	ENST00000355710.3	missense_variant
RET M918T	RET	M918T	Thyroid Gland Medullary Carcinoma	Motesanib	Predictive	Supports	D	Resistance	chr10	43121968	43121968	T	C	"Medullary thyroid cancer cells with RET M918T mutation are insensitive to motesanib, compared to wild-type RET."	"Coxon et al., 2012, J. Endocrinol. Invest."	Somatic	ENST00000355710.3	missense_variant
RET M918T	RET	M918T	Thyroid Gland Medullary Carcinoma	JAK2 Inhibitor AZD1480	Predictive	Supports	D	Sensitivity/Response	chr10	43121968	43121968	T	C	The use of AZD1480 on RET-mutated/rearranged cell lines in vitro led to strong repression of tyroid cancer cell growth.	"Couto et al., 2012, PLoS ONE"	Somatic	ENST00000355710.3	missense_variant
RET M918T	RET	M918T	Thyroid Gland Medullary Carcinoma		Prognostic	Supports	B	Poor Outcome	chr10	43121968	43121968	T	C	"Compared to those who harbor a wild type RET, patients with RET M918T mutation develop larger and more aggressive medullary thyroid cancer."	"Egawa et al., 1998, Jpn. J. Clin. Oncol."	Somatic	ENST00000355710.3	missense_variant
RET M918T	RET	M918T	Thyroid Gland Medullary Carcinoma	Sorafenib	Predictive	Supports	B	Sensitivity/Response	chr10	43121968	43121968	T	C	"In a phase 2 clinical trial of sorafenib in patients with hereditary or sporadic advanced medullary thyroid cancer, 10 out of 12 patients genotyped in arm B (sporadic MTC) tested positive for RET mutations. In response to sorafenib, 8 patients with RET M918T mutations had stable disease, 1 RET M918T mutant had partial response, and 1 patient with a RET C634R mutation had stable disease. Prior to study entry, all patients with RET M918T mutations had progressive disease or were newly diagnosed."	"Lam et al., 2010, J. Clin. Oncol."	Somatic	ENST00000355710.3	missense_variant
RET M918T	RET	M918T	Thyroid Gland Medullary Carcinoma	Cabozantinib	Predictive	Supports	B	Sensitivity/Response	chr10	43121968	43121968	T	C	"In this retrospective analysis of a phase 3 trial of cabozantinib or placebo in 330 patients. Among those, 51.2% were RET mutation-positive (38.2% with RET M918T), 34.8% were RET mutation-unknown, and 13.9% were RET mutation-negative. Sixteen patients were RAS mutation-positive. Cabozantinib appeared to prolong PFS versus the placebo in the RET mutation-positive subgroup (hazard ratio [HR], 0.23; 95% confidence interval [CI], 0.14-0.38; P??0001).  Patients in a RET mutation-negative population showed relatively smaller benefits from cabozantinib (HR 0.53). The RET M918T subgroup achieved the greatest observed PFS benefit from cabozantinib versus the placebo (HR 0.15)."	"Sherman et al., 2016, Cancer"	Somatic	ENST00000355710.3	missense_variant
DKK1 NUCLEAR EXPRESSION	DKK1	NUCLEAR EXPRESSION	Colorectal Cancer	"Irinotecan,Levoleucovorin,Oxaliplatin,Fluorouracil"	Predictive	Supports	B	Resistance	chr10	52314296	52317657			"Nuclear expression of DICKKOPF-1 was identified in 15% of 699 patients with colorectal cancer and was associated with decreased progression-free survival (PFS) and overall survival (OS) after chemotherapy (FOLFOX, FOLFIRI, or 5-FU) [adjusted HR, 1.65; 95% confidence interval (CI), 1.23-2.21; P = 0.002)]."	"Aguilera et al., 2015, Oncotarget"	N/A	ENST00000373970.3	N/A
FGFR2 FGFR2::BICC1	FGFR2	FGFR2::BICC1	Cholangiocarcinoma		Diagnostic	Supports	B	Positive	chr10	58702074	58831435			"Massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1. In RT-PCR screening, the FGFR2 fusion was detected in nine patients with cholangiocarcinoma (9/102), exclusively in the intrahepatic subtype (9/66, 13.6%)."	"Arai et al., 2014, Hepatology"	Somatic	ENST00000457416.2	transcript_fusion
FGFR2 FGFR2::BICC1	FGFR2	FGFR2::BICC1	Cholangiocarcinoma	"Infigratinib,PD173074"	Predictive	Supports	D	Sensitivity/Response	chr10	58702074	58831435			Expression of the FGFR2-BICC1 fusion kinase in NIH3T3 cells demonstrated transforming ability that was effectively suppressed with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074.	"Arai et al., 2014, Hepatology"	Somatic	ENST00000457416.2	transcript_fusion
FGFR2 FGFR2::BICC1	FGFR2	FGFR2::BICC1	Transitional Cell Carcinoma	Erdafitinib	Predictive	Supports	C	Sensitivity/Response	chr10	58702074	58831435			"Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without known FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 partial responses as well as 16 with stable disease were seen. In patients with FGFR2-BICC1 fusions, 1 patient with urothelial cancer harboring FGFR2-BICC1/FGFR2-CASP7 fusions had a PR."	"Tabernero et al., 2015, J. Clin. Oncol."	Somatic	ENST00000457416.2	transcript_fusion
FGFR2 FGFR2::BICC1	FGFR2	FGFR2::BICC1	Endometrial Cancer	Erdafitinib	Predictive	Supports	C	Sensitivity/Response	chr10	58702074	58831435			"Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 partial responses as well as 16 with stable disease were seen. A patient with endometrial cancer with synchronous FGFR3-TACC3 and FGFR2-BICC1/FGFR2-OFD1 fusions had a PR."	"Tabernero et al., 2015, J. Clin. Oncol."	Somatic	ENST00000457416.2	transcript_fusion
SIRT1 Overexpression	SIRT1	Overexpression	Pancreatic Ductal Carcinoma		Prognostic	Supports	B	Poor Outcome	chr10	67884669	67918390			"Nuclear Sirt1 expression was identified by IHC in 36 (27.9%) of 129 pancreatic ductal adenocarcinoma cases. SIRT1 expression was associated with poor survival in univariate (p??.002) and multivariate (HR 1.65, p??.045) analyses. Overexpression of Sirt1 in pancreas cancer cell lines MiaPaCa-2 and PANC-1 led to increased cell viability."	"Stenzinger et al., 2013, BMC Cancer"	N/A	ENST00000212015.6	N/A
SIRT1 Overexpression	SIRT1	Overexpression	Pancreatic Cancer	Niacinamide	Predictive	Supports	D	Resistance	chr10	67884669	67918390			"In-vitro study with MiaPaCa-2 and PANC-1 pancreatic cancer cell lines. Inhibition of Sirt1 by increasing concentrations of nicotinamide led to a decrease in viability. Gefitinib treatment with concentrations of 50 M showed similar effects as observed for the application of 25 mM nicotinamide. Combinatory treatment with gefitinib and nicotinamide showed a synergistic effect on cell viability. In cell lines overexpressing Sirt1, higher concentrations of nicotinamide were required to abrogate increased cell viability mediated by Sirt1 overexpression compared to controls."	"Stenzinger et al., 2013, BMC Cancer"	N/A	ENST00000212015.6	N/A
ABL1 ZMIZ1::ABL1	ABL1	ZMIZ1::ABL1	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"		Diagnostic	Supports	C	Positive	chr10	79069035	79302212			"This study included 1389 cases of high-risk pediatric B-ALL, of which 284 were identified by TaqMan Low Density Array to have a BCR-ABL1-like (Ph-like) gene expression signature. RT-PCR or RNAseq performed on Ph-like, CRLF2 negative patients revealed 17 cases with ABL1 fusions with 8 different partner genes. There were three cases with the ZMIZ1-ABL1 fusion. Considering the previously confirmed Ph-like expression signature in the tested cases, the results suggest that the presence of the ZMIZ1-ABL1 fusion in B-ALL indicates the BCR-ABL1-like (Ph-like) subtype of the disease."	"Reshmi et al., 2017, Blood"	Somatic	ENST00000334512.5	transcript_fusion
ABL1 ZMIZ1::ABL1	ABL1	ZMIZ1::ABL1	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"		Prognostic	Supports	B	Better Outcome	chr10	79069035	79302212			"A multicenter, retrospective, cohort study that included 122 paediatric patients (aged 1-18 years) with newly diagnosed ABL-class fusion B-cell acute lymphocytic leukemia who had not received tyrosine-kinase inhibitor treatment as a first-line therapy. ABL-class genes included ABL1, ABL2, CSF1R and PDGFRB. There were 33% of patients (40/122) that harbored an ABL1 fusion, including 16 with a ZMIZ1-ABL1 fusion. For patients that were ABL1 fusion positive the 5-year event-free survival was 68.6% (54.5-86.3), the 5-year overall survival was 82.9% (71.2-96.4) and the 5-year cumulative incidence of relapse was 29.6% (15.0-45.9). Additionally ABL1 fusion positive patients had the lowest levels of MRD at the end of induction therapy. Patients with ZMIZ1-ABL1 had a median MRD between 10^-3 and <10^4 at the end of induction, but between fusion parters, MRD did not differ significantly."	"den Boer et al., 2021, Lancet Haematol"	Somatic	ENST00000334512.5	transcript_fusion
ABL1 ZMIZ1::ABL1	ABL1	ZMIZ1::ABL1	B-lymphoblastic Leukemia/lymphoma		Oncogenic	Supports	C	Oncogenicity	chr10	79069035	79302212			"A 18-month-old female with B-cell acute lymphoblastic leukemia. Chromosome and FISH analysis using a BCR-ABL1 probe confirmed the involvement of ABL1 in a t(9;10)(q34;q22.3) translocation. Follow-up molecular analysis using RT-PCR confirmed the presence of a ZMIZ1-ABL1 fusion transcript (ZMIZ1 exon 14 and ABL1 exon 2). Patient was treated according to standard risk protocol without kinase inhibitors and is in first complete remission. Authors note that The ZMIZ1-ABL1 fusion transcript predicts the the synthesis of ZMIZ1-ABL fusion protein, which contains one of the proline-rich domains of ZMIZ1 and ABL tyrosine kinase domain. Similar to other oncogenic fusion proteins, the proline-rich domain of ZMIZ1 is involved in protein-protein interactions, and therefore the fusion may encode a constitutively activated tyrosine kinase that promotes cellular transformation. The authors further note that patients with t(9;10) would be eligible for imatinib treatment."	"Soler et al., 2008, Leukemia"	Somatic	ENST00000334512.5	transcript_fusion
ABL1 ZMIZ1::ABL1	ABL1	ZMIZ1::ABL1	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"		Diagnostic	Supports	C	Positive	chr10	79069035	79302212			"Study comprised 574 children with newly diagnosed B-cell precursor acute lymphoblastic leukemia (BCP-ALL) and focused on B-other/BCR-ABL-like which were identified by hierarchical clustering of gene expression data. RT-PCR followed by Sanger sequencing for detection of tyrosine kinase fusions was performed for 153 cases. There were 14 fusions found among the BCR-ABL-like cases (14/77=18%), which included one case with a ZMIZ1-ABL1 (exon 18 and exon 2). ZMIZ1-AML1 fusion was among a group of nine fusions found, and characterized by the authors as predictive for activated ABL signaling. The 8-year cumulative incidence of relapse for the fusion-positive BCR-ABL1-like group (35%) was comparable to the fusion-negative BCR-ABL1-like group (35%), and worse than non-BCR-ABL1-like B-other group (17%, p=0.07)."	"Boer et al., 2017, Oncotarget"	Somatic	ENST00000334512.5	transcript_fusion
PTEN Deletion	PTEN	Deletion	Prostate Adenocarcinoma		Prognostic	Supports	B	Poor Outcome	chr10	87863113	87971930			"In a study of 107 prostate adenocarcinomas, those with either hemi- or homozygous deletions of PTEN (as determined by interphase FISH) have shorter biochemical recurence-free survival than those without deletions."	"Yoshimoto et al., 2007, Br. J. Cancer"	Somatic	ENST00000371953.3	transcript_ablation
PTEN Loss	PTEN	Loss	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Resistance	chr10	87863113	87971930			"In 27 patients with chemotherapy-naive or chemotherapy-refractory metastatic colorectal cancer who were treated with cetuximab and chemotherapy, PTEN loss was associated with non-response."	"De Roock et al., 2011, Lancet Oncol."	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Prostate Cancer	Temsirolimus	Predictive	Supports	D	Sensitivity/Response	chr10	87863113	87971930			"In prostate cancer xenographs, PTEN null tumors had a significant decrease in cell size and proliferation when treated with Temsirolimus (CCI-779)."	"Neshat et al., 2001, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Bladder Carcinoma	Everolimus	Predictive	Supports	B	Resistance	chr10	87863113	87971930			PTEN loss is associated with reduced response to mTOR inhibitors in patients with bladder cancer.	"Seront et al., 2013, Br. J. Cancer"	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Breast Cancer	Trastuzumab	Predictive	Supports	B	Resistance	chr10	87863113	87971930			"PTEN loss is associated with loss of sensitivity to the HER2-antibody trastuzumab in breast cancer in smaller trials, a phase III trial (NCCTG N9831) did not show an effect of PTEN on disease-free survival."	"Dillon et al., 2014, Curr Drug Targets"	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Melanoma	Uprosertib	Predictive	Supports	D	Sensitivity/Response	chr10	87863113	87971930			Most BRAF mutant cell lines (mostly V600E) with PTEN mutation or loss of expression were among those sensitive to inhibition with AKT inhibitor GSK2141795B.	"Lassen et al., 2014, Mol. Cancer"	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Breast Cancer	PI3Kbeta Inhibitor AZD8186	Predictive	Supports	D	Sensitivity/Response	chr10	87863113	87971930			Breast and prostate cancer cell lines responsive to AZD8186 were enriched for PTEN deficiency.	"Hancox et al., 2015, Mol. Cancer Ther."	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Cancer	"Buparlisib,Carboplatin,Paclitaxel"	Predictive	Supports	B	Sensitivity/Response	chr10	87863113	87971930			All three patients with PTEN loss had benefit from adding Buparlisib to carboplatin+paclitaxel therapy in a phase I study in advanced solid cancers.	"Hyman et al., 2015, Cancer Chemother. Pharmacol."	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Breast Cancer	Alpelisib	Predictive	Supports	D	Resistance	chr10	87863113	87971930			"A case report described a responder to PI3K inhibitor BYL719 for a tumor with PIK3CA E542K mutation. After partial response for 9.5 months, resistance developed. Sequencing in this and other patients as well as preclinical models showed loss of PTEN as the probable mechanism of resistance."	"Juric et al., 2015, Nature"	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Expression	PTEN	Expression	Glioblastoma	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Predictive	Supports	B	Sensitivity/Response	chr10	87863113	87971930			49 patients (26 pretreatment tissues available for analysis) with recurrent glioblastomas who were treated with EGFR TKIs were analyzed in this study. Results were confirmed in an independent cohort of 33 patients. EGFRvIII and PTEN coexpression were associated with responsiveness to EGFR TKI.	"Mellinghoff et al., 2005, N. Engl. J. Med."	N/A	ENST00000371953.3	N/A
PTEN Expression	PTEN	Expression	Glioblastoma	Dacomitinib	Predictive	Supports	D	Sensitivity/Response	chr10	87863113	87971930			"In this preclinical study, the EGFR inhibitor dacomitinib had an effect on cell viability, self-renewal and proliferation in EGFR amplified GBM cells in-vitro and in-vivo (with or without the EGFRvIII mutation). It was less effective in one cell-line with PTEN deletion."	"Zahonero et al., 2015, Mol. Cancer Ther."	N/A	ENST00000371953.3	N/A
PTEN Loss	PTEN	Loss	Gastric Adenocarcinoma	"Trastuzumab,Lapatinib"	Predictive	Supports	B	Resistance	chr10	87863113	87971930			"In 48 patients with advanced gastric cancer, retrospectively analyzed for PTEN expression using IHC, PTEN loss was associated with a shorter duration of response (median 4.2 vs. 6.1 months, p = 0.04) to HER2-targeted therapy (trastuzumab, N=39; lapatinib, N=9). Response rates did not differ between groups."	"Zhang et al., 2015, Oncology"	N/A	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Endometrial Cancer	"Ridaforolimus,Temsirolimus"	Predictive	Does Not Support	B	Resistance	chr10	87863113	87971930			"94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed. No predictive biomarkers were identified, including PIK3CA mutations, KRAS mutations or PTEN loss."	"Mackay et al., 2014, Cancer"	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Pancreatic Carcinoma	Akt Inhibitor MK2206	Predictive	Supports	C	Sensitivity/Response	chr10	87863113	87971930			"Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss/KRAS G12D mutation experienced a decrease of approximately 60% in cancer antigen 19-9 levels and 23% shrinkage in tumor measurements."	"Yap et al., 2011, J. Clin. Oncol."	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Expression	PTEN	Expression	Breast Cancer	Trastuzumab	Predictive	Supports	B	Sensitivity/Response	chr10	87863113	87971930			Trastuzumab was more effective in cell lines (SKBR3 vs. drug-resistant SKBR3/R) and 17 patient samples that exhibit elevated PTEN expression (by IHC).	"Fujita et al., 2006, Br. J. Cancer"	N/A	ENST00000371953.3	N/A
PTEN Expression	PTEN	Expression	Glioblastoma	"Gefitinib,Erlotinib"	Predictive	Supports	B	Sensitivity/Response	chr10	87863113	87971930			Expression of EGFRvIII and PTEN was evaluated in 26 patients with glioblastomas treated with erlotinib or gefitinib and no EGFR or Her2/neu kinase domain mutations. 7 patients responded to treatment while 19 progressed rapidly. Coexpression of EGFRvIII and PTEN was associated with clinical response (defined as 25% tumor shrinkage). These results were confirmed using IHC in an independent cohort of 33 patients (8 responders) treated with erlotinib at another institution.	"Mellinghoff et al., 2005, N. Engl. J. Med."	N/A	ENST00000371953.3	N/A
PTEN Deletion	PTEN	Deletion	Prostate Cancer	Everolimus	Predictive	Supports	B	Sensitivity/Response	chr10	87863113	87971930			"In a phase II trial on castration-resistant prostate cancer patients, FISH detection of PTEN deletion was associated with increased progression free survival (p=0.07) and with improved PSA response (p=0.02) in response to everolimus, an mTOR pathway inhibitor."	"Templeton et al., 2013, Eur. Urol."	Somatic	ENST00000371953.3	transcript_ablation
PTEN Mutation	PTEN	Mutation	Endometrial Carcinoma	Everolimus	Predictive	Does Not Support	B	Sensitivity/Response	chr10	87863113	87971930			"Tumors from 35 patients (12 with partial response or stable disease) with advanced endometrial carcinoma were assessed for PTEN mutational status, revealing 12 tumors with non-identical PTEN gene mutations. No mutations found in PTEN were effective in predicting tumor response to everolimus treatment. The clinical trial associated with this study is NCT00870337."	"Trdan et al., 2013, Target Oncol"	Somatic	ENST00000371953.3	protein_altering_variant
PTEN Loss	PTEN	Loss	Her2-receptor Positive Breast Cancer	Everolimus	Predictive	Supports	B	Sensitivity/Response	chr10	87863113	87971930			"Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger sequencing. In the BOLERO trials, patients with HER2-overexpressing advanced breast cancer were treated with trastuzumab, chemotherapy and randomized to receive either everolimus or placebo. In the pooled analysis of both trials, patients with PTEN loss (as defined by IHC staining intensity and proportion of positive tumor cells) had a longer progression-free survival with everolimus compared to placebo (HR 0.54 (95%CI 0.31 to 0.96, P=0.04) whereas patients with PTEN normal status had a hazard ration of 1.00 (95%CI 0.8 to 1.26, P=0.97). The same was found when PI3K mutations, PTEN loss and AKT E17K mutations were combined and analyzed as hyperactive PI3K pathway. Patients with PI3K hyperactive pathway had a hazard ratio of 0.67 (95%CI 0.48 to 0.93, P=0.02) compared to HR 1.19 (95%CI 0.87 to 1.62, P=0.28) in patients with PI3K normal pathway. These trends were independently confirmed in both trials but only pooled results showed consistent statistical significance."	"Andr et al., 2016, J. Clin. Oncol."	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Mutation	PTEN	Mutation	Head And Neck Cancer	"Tanespimycin,Pictilisib"	Predictive	Does Not Support	D	Sensitivity/Response	chr10	87863113	87971930			Analysis of drug response data from the Sanger center cell line screen. Cell lines with either PI3K and/or PTEN mutations did not show a significant difference in response to the class I PI3K inhibitor GDC-0941(p =0.07 for combined PI3K/PTEN aberrations with a trend towards lower IC50 for mutated cell lines). IC50 values with HSP90 inhibitor 17-AAG were significantly lower in PI3K and/or PTEN mutated cell lines in the Sanger cell line screening but these results could not be reproduced in the Broad cancer cell line encyclopedia screening.	"Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg"	Somatic	ENST00000371953.3	protein_altering_variant
PTEN Loss	PTEN	Loss	Her2-receptor Positive Breast Cancer	Trastuzumab	Predictive	Supports	D	Resistance	chr10	87863113	87971930			"A large-scale RNAi genetic sereen in HER2 overexpressing breast cancer cell line BT-474 was performed to discover genes whose loss induced trastuzumab resistance. The most prominently enriched gene in trastuzumab resistant populations was PTEN. Subsequent knockdown of PTEN in BT-474 cells increased cell survival when treated with trastuzumab, and growth curves showed partial restoration of proliferation in PTEN knockdown BT-474 cells treated with trastuzumab."	"Berns et al., 2007, Cancer Cell"	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Her2-receptor Positive Breast Cancer	Trastuzumab	Predictive	Supports	B	Resistance	chr10	87863113	87971930			"A subgroup of HER2-positive breast cancer patients that received first-line trastuzumab treatment were assessed for PTEN loss via IHC of FFPE samples. 46 samples showed PTEN loss while 41 did not, and PTEN loss alone was found to be significantly associated with resistance to trastuzumab (p=0.028) and shorter overall survival (p=0.008)."	"Esteva et al., 2010, Am. J. Pathol."	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Her2-receptor Positive Breast Cancer	Trastuzumab	Predictive	Does Not Support	B	Resistance	chr10	87863113	87971930			"While some reports indicate PTEN loss is associated with resistance to trastuzumab, in a subgroup of HER2 breast cancer FFPE samples from patients receiving trastuzumab as later line therapy (second or greater line therapy), with 25 PTEN loss and and 25 normal samples, no association was seen between trastuzumab response and PTEN status (p=1.000) or overall survival and PTEN status (p=0.863)."	"Esteva et al., 2010, Am. J. Pathol."	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Her2-receptor Positive Breast Cancer	"PI3K/BET Inhibitor LY294002,Trastuzumab"	Predictive	Supports	D	Sensitivity/Response	chr10	87863113	87971930			"Knockdown of PTEN in trastuzumab sensitive HER2 breast cancer BT474 cells induced trastuzumab resistance. PTEN null cells treated with PI3K inhibitor LY294002 also did not show substantial inhibition, but co-treatment with trastuzumab and LY294002 induced growth inhibition comparable to trastuzumab alone in normal BT474 cells. BT474 mouse xenograft tumors were injected with PTEN antisense (AS) oligonucleotides and this resulted in trastuzumab resitance. Co-treatment of PTEN AS tumor mice with LY294002 and trastuzumab inhibited tumor growth in comparison to PTEN AS tumors treated with trastuzumab or LY294002 alone."	"Nagata et al., 2004, Cancer Cell"	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Mutation	PTEN	Mutation	Head And Neck Squamous Cell Carcinoma	Taselisib	Predictive	Supports	D	Resistance	chr10	87863113	87971930			"In a panel of 26 HNSCC cell lines tested for sensitivity to taselisib (an alpha, delta and gamma isoform-specific PI3K inhibitor) the UD-SCC-2 cell line with homozygous PTEN deletion had considerably higher antiproliferative IC50 than taselisib sensitized cell lines. Western blots of UD-SCC-3 cells with increasing taselisib concentration showed reduction of phospho-Akt only at micro-molar doses, in contrast to nano-molar range for sensitized cells. Slight induction of the apoptotic marker cleaved PARP was only apparent at 4 micro-molar dose. Similar results were reported with the PTEN mutant HNSCC cell line UPCI-SCC-90, and 4 of the 6 most taselisib resistant cell lines had PTEN mutation."	"Zumsteg et al., 2016, Clin. Cancer Res."	Somatic	ENST00000371953.3	protein_altering_variant
PTEN Mutation	PTEN	Mutation	Cancer	Ipatasertib	Predictive	Supports	D	Sensitivity/Response	chr10	87863113	87971930			"IC50 for the pan-Akt inhibitor ipatasertib (GDC-0068) was determined over a panel of 100 cancer cell lines. Loss or mutation of PTEN (e.g. PTEN deletion, T319fsX1/Y155C, etc.) was significantly associated with ipatasertib sensitivity (p=0.000071). Non-transformed human mammary epithelial MCF10A cells were compared to an isogenic line with PTEN knockout. With low or high EGF culture conditions, a 4x or 3.5x decrease in IC50 for ipatasertib was seen in PTEN knockout cells, respectively."	"Lin et al., 2013, Clin. Cancer Res."	Somatic	ENST00000371953.3	protein_altering_variant
PTEN Loss	PTEN	Loss	Ovarian Cancer	Cisplatin	Predictive	Supports	D	Resistance	chr10	87863113	87971930			"A cisplatin resistant derivative of ovarian cancer cell line OVCAR-3 was generated by long term passage with increasing cisplatin levels. Western blot showed decreased PTEN level in the resistant cell line, and siRNA against PTEN in parent OVCAR-3 cells induced cisplatin resistance."	"Lee et al., 2005, Gynecol. Oncol."	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Stomach Carcinoma	Chemotherapy	Predictive	Supports	B	Resistance	chr10	87863113	87971930			"Cancer and normal tissue samples were taken from 68 gastric cancer patients undergoing surgery without prior chemotherapy. Tissue samples were divided into high grade and low grade for phospho Akt (p-Akt) expression, and tested for PTEN LOH by sequencing. Patients with PTEN LOH were significantly more likely to have elevated p-Akt (p=0.0081), and high p-Akt samples were significantly less sensitive to chemotherapy agents 5-flourouracil, adriamycin, mitomycin and cis-platinum in MTT assay."	"Oki et al., 2005, Int. J. Cancer"	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Stomach Cancer	"Docetaxel,Capivasertib"	Predictive	Supports	D	Sensitivity/Response	chr10	87863113	87971930			"A patient derived mouse xenograft model was established with gastric cancer cells having PTEN loss. The xenograft was resistant to monotherapy with both the pan-Akt inhibitor AZD5363, and also to the commonly used gastric cancer chemotheraputic docetaxel. When used in combination, AZD5363 and docetaxel induced significant tumor growth inhibition in comparison to monotherapy and vehicle control."	"Li et al., 2013, J Transl Med"	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Cancer	Capivasertib	Predictive	Supports	D	Sensitivity/Response	chr10	87863113	87971930			"In a panel of 182 cell lines (162 with PIK3CA mutation status known) from solid and hematological tumors, significant correlation was found between AZD5363 (pan-Akt inhibitor) sensitivity and PIK3CA mutation status (N=33, p=0.0059). In the subpopulation free of RAS mutation (N=19) the correlation was increased."	"Davies et al., 2012, Mol. Cancer Ther."	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Mutation	PTEN	Mutation	Prostate Cancer	"Alpelisib,PI3Kbeta Inhibitor AZD8186,Enzalutamide"	Predictive	Supports	D	Sensitivity/Response	chr10	87863113	87971930			"Castrated mice bearing androgen-sensitive human prostate adenocarcinomas (LNCaP tumors) were treated with PI3K inhibitors (AZD8186, BYL719) and an androgen receptor inhibitor (MDV3100).  Mice treated with single therapy of either MDV3100, BYL719, or AZD8186 resulted in mild tumor growth inhibition of 90%, 36%, and 40% respectively (n=5 mice/group).  However, triple therapy of MDV300, BYL719, and AZD8186 resulted in tumor regression of 113% (n=5 mice)."	"Schwartz et al., 2015, Cancer Cell"	Somatic	ENST00000371953.3	protein_altering_variant
PTEN Loss	PTEN	Loss	Breast Cancer	"MTOR Kinase Inhibitor PP242,Everolimus"	Predictive	Does Not Support	D	Sensitivity/Response	chr10	87863113	87971930			"In a panel of 31 breast cancer cell lines, 11 had loss of PTEN function. Cells were tested for sensitivity to mTORC1 inhibitor everolimus and mTORC1/2 inhibitor PP242, and no significant correlation was found between PTEN status and sensitivity to mTORC inhibition."	"Weigelt et al., 2011, Oncogene"	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Endometrial Cancer	Temsirolimus	Predictive	Supports	D	Sensitivity/Response	chr10	87863113	87971930			"A panel of 24 endometroid endometrial cancer (EEC) cell lines was characterized for mutations and 18 cell lines were found to have mutations in PTEN or absence of expression. Cell lines were assessed for sensitivity to mTORC1 allosteric inhibitor temsirolimus, and it was reported that PTEN loss had significant association with temsirolimus sensitivity. ."	"Weigelt et al., 2013, Clin. Cancer Res."	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Expression	PTEN	Expression	Her2-receptor Positive Breast Cancer	"Everolimus,Fulvestrant"	Predictive	Supports	C	Resistance	chr10	87863113	87971930			"Case report of a 44-year-old patient with recurrent HER2-positive breast cancer. The primary tumor was HR positive; however, the metastatic tumor was HR negative. The patient was resistant to classical chemotherapeutic agents and anti-HER2 treatment. Thus, the combination of everolimus and fulvestrant was administered. The patient experienced stable disease and PFS of 10 months. Genetic testing of pleural effusion after disease progression revealed a PIK3CA H1047R gene mutation but was positive for PTEN expression (IHC)."	"Sun et al., 2016, Onco Targets Ther"	N/A	ENST00000371953.3	N/A
PTEN Deletion	PTEN	Deletion	Prostate Cancer		Prognostic	Supports	B	Poor Outcome	chr10	87863113	87971930			"A meta-analysis of 26 published studies including 8097 prostate cancer patients showed that, compared to patients with normal PTEN, patients with PTEN deletion exhibited a greater aggressive Gleason score (OR: 1.284, 95% CI = 1.145?.439), pathological stage (OR: 1.628, 95% CI = 1.270?.087), and risk for recurrence of prostate cancer (HR: 1.738, 95% CI = 1.264?.390)."	"Gao et al., 2016, Biomed. Pharmacother."	Somatic	ENST00000371953.3	transcript_ablation
PTEN Mutation	PTEN	Mutation	Glioblastoma		Diagnostic	Supports	C	Positive	chr10	87863113	87971930			"Rasheed et al. identified that PTEN mutations occur with significantly greater frequency in adults with high-grade gliomas (42 adult glioblastoma multiforme and 13 adult anaplastic astrocytoma) compared to low-grade and child gliomas (68 others, varied). Mutation analysis performed using SSCP. No further testing was done."	"Rasheed et al., 1997, Cancer Res."	Somatic	ENST00000371953.3	protein_altering_variant
PTEN Loss	PTEN	Loss	Her2-receptor Positive Breast Cancer	Trastuzumab	Predictive	Supports	B	Resistance	chr10	87863113	87971930			"In a retrospective study of 111 HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapy, PTEN loss (as measured by IHC) was associated with shorter survival as measured from initiation of trastuzumab (HR = 1.92, P = 0.017) and diagnosis of first metastasis (HR = 1.69, P = 0.047)."	"Razis et al., 2011, Breast Cancer Res. Treat."	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Breast Cancer	Trastuzumab	Predictive	Supports	B	Resistance	chr10	87863113	87971930			"In a retrospective study of 182 metastatic breast cancer patients of mixed HER2 status treated with trastuzumab-based therapy, PTEN loss (as measured by IHC) was associated with a higher risk of death measured from initiation of trastuzumab (HR = 1.64, P = 0.029) and diagnosis of first metastasis (HR = 1.85, P = 0.003)."	"Razis et al., 2011, Breast Cancer Res. Treat."	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Her2-receptor Positive Breast Cancer	Pictilisib	Predictive	Supports	D	Sensitivity/Response	chr10	87863113	87971930			"This preclinical study tested the efficacy of GDC-0941, a selective inhibitor of class I PI3K, on several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. HCC1569 is a PTEN null, HER2 amplified breast cancer cell line. It had an IC50 of 0.46. Authors note that HER2 amplified breast cancer cell lines are generally more sensitive to GDC-0941 than basal-type cell lines (p = 0.002)."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Breast Cancer	Pictilisib	Predictive	Does Not Support	D	Sensitivity/Response	chr10	87863113	87971930			"This preclinical study tested the efficacy of GDC-0941, a selective inhibitor of class I PI3K, on several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. The authors tested several basal and luminal cell lines harboring PTEN loss for sensitivity to GDC-0941. ZR-75-1, a luminal-type cell line, had an IC50 of 0.15uM and reduction in phosphorylated AKT was noted following administration of GDC-0941. EVSTA-T, a luminal-type cell line, had an IC50 of 0.36uM; treatment resulted in an relative increase of Sub-G and G phase cells from 49% to 78% of total cells evaluated; there was a 12fold increase in annexin V (an apoptotic marker), and a substantial reduction in phosphorylated AKT following GDC-0941 administration. Seven basal-like cell lines harbored PTEN loss and had IC50s ranging fom 0.30uM to 20.00uM (4/7 had IC50s greater than 1 uM). There was a varied reduction in phosphorylated AKT among basal-like cell lines. Authors note that PTEN status may have low predictive power for response, and suggested that other factors such as basal/luminal characteristics may be more informative for GDC-0941 response. Authors further note that luminal type cell lines are generally more sensitive to GDC-0941 than basal type cell lines (p=0.02)."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Cancer	Everolimus	Predictive	Does Not Support	B	Sensitivity/Response	chr10	87863113	87971930			"In a single-arm, open label phase 2 trial in PIK3CA amplified/mutated and/or PTEN loss encompassing 10 patients, no objective responses were observed but a stable disease response in 4 patients, resulting in a median PFS of 1.4 months. Everolimus failed to meet its enpoint."	"Kim et al., 2017, BMC Cancer"	N/A	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Solid Tumor	"Paclitaxel,Buparlisib,Carboplatin"	Predictive	Does Not Support	B	Sensitivity/Response	chr10	87863113	87971930			"In one arm of this phase 1b study, 7 patients with PTEN deficient tumors were treated with continuous buparlisib (100 mg/daily) orally plus standard dose carboplatin AUC 5 and paclitaxel 175 mg/m2. No objective responses were observed. 2 patients had stable disease for ?6 cycles. The authors recommended against the addition of buparlisib to carboplatin and paclitaxel, citing toxicity. Authors noted that combination therapy did not produce significant clinical activity amongst a small and heterogenous group of PTEN deficient tumors."	"Smyth et al., 2017, Invest New Drugs"	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Melanoma	Vemurafenib	Predictive	Supports	D	Resistance	chr10	87863113	87971930			"An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PTEN and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that PTEN knockdown cells (achieved via lentiviral transduction of shPTEN) were more resistant to vemurafenib (a BRAF inhibitor) than cells expressing wildtype PTEN. Lentiviral mediated reintroduction of PTEN restored vemurafenib sensitivity in WM2664, a vemurafenib resistant, PTEN non-expressing and BRAF V600D mutated human melanoma cell line."	"Shi et al., 2014, Cancer Discov"	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Colorectal Cancer	"Cetuximab,Panitumumab"	Predictive	Supports	B	Resistance	chr10	87863113	87971930			"In this study, 81 metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). Multivariate analysis demonstrated a significant association between PTEN protein expression loss and lack of response to panitumumab or cetuximab (P = 0.0012). Patients with PTEN non-expressing tumors (32/80) had shorter overall survival, compared to those with PTEN expressing tumors (P = 0.0048), though they had a nonsignificant difference in progression free survival (p = .0681).  PIK3CA, PTEN, and KRAS were evaluated for mutations; PTEN loss was the only variant noted in 17 of the patients who experienced either stable disease or disease progression, while the other patients experienced PTEN loss in combination with a KRAS or PIK3CA mutation."	"Sartore-Bianchi et al., 2009, Cancer Res."	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Her2-receptor Positive Breast Cancer	PI-103	Predictive	Supports	D	Sensitivity/Response	chr10	87863113	87971930			"As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. HCC-1569 is a HER2 receptor amplified breast cancer cell line harboring PTEN Loss, and it had an IC50 of 0.40uM."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Her2-receptor Positive Breast Cancer	PI3Ka/Di	Predictive	Supports	D	Resistance	chr10	87863113	87971930			"As part of a preclinical study, the efficacy of PI3KA/Dia selective inhibitor for the  and  subunits of class I PI3Kwas evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. HCC-1569 is a HER2 amplified breast cancer cell line harboring PTEN loss and it had an IC50 of 2.82uM."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Her2-receptor Positive Breast Cancer	Trastuzumab	Predictive	Supports	D	Resistance	chr10	87863113	87971930			"In a preclinical study, efficacy of trastuzumab monotherapy was evaluated in vitro against HER2 amplified human breast cancer cell line BT474 (heterozygous for PIK3CA K111N) with shRNA-induced PTEN expression loss. Authors found that loss of PTEN expression induced resistance to trastuzumab as assessed by colony formation assay compared to PTEN expressing control cells. Among trastuzumab treated cells, concentration of phosphorylated AKT (S473 and T308) was higher in PTEN knockdown cells compared to PTEN expression cells, by western blot."	"Eichhorn et al., 2008, Cancer Res."	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Her2-receptor Positive Breast Cancer	Lapatinib	Predictive	Supports	D	Resistance	chr10	87863113	87971930			"In a preclinical study, efficacy of trastuzumab monotherapy was evaluated in vitro against HER2 amplified human breast cancer cell line BT474 (heterozygous for PIK3CA K111N) with shRNA-induced PTEN expression loss. Authors found that loss of PTEN expression induced resistance to lapatinib as assessed by colony formation assay compared to PTEN expressing control cells. Among lapatinib treated cells, concentration of phosphorylated AKT and ERK was substantially higher in cells with PTEN loss compared to PTEN expressing cells, by western blot. Furthermore, athymic nude mice injected with PTEN non-expressing BT474 cells had significantly higher mean tumor volume following lapatinib monotherapy compared to mice injected with PTEN expressing BT474. Authors conclude that loss of PTEN expression confers resistance to lapatinib in HER2 positive breast cancer cells."	"Eichhorn et al., 2008, Cancer Res."	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Her2-receptor Positive Breast Cancer	Dactolisib	Predictive	Supports	D	Resistance	chr10	87863113	87971930			"In a preclinical study, efficacy of dactolisib monotherapy was evaluated in vitro against HER2 amplified human breast cancer cell line BT474 (heterozygous for PIK3CA K111N) with shRNA-induced PTEN expression loss. PTEN loss resulted in partial rescue from the strong dactolisib induced reduction of colony formation that was seen in BT474 cells with unperturbed PTEN. Among cells treated with dactolisib (100nmol/L), those lacking PTEN expression demonstrated higher concentrations of phosphorylated AKT (S473) and phosphorylated ERK compared to PTEN expressing cells."	"Eichhorn et al., 2008, Cancer Res."	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Her2-receptor Positive Breast Cancer	"Lapatinib,Dactolisib"	Predictive	Does Not Support	D	Resistance	chr10	87863113	87971930			"In a preclinical study, efficacy of NVP-BEZ235 (dactolisib; a dual PI3K/mTOR inhibitor) and lapatinib combination therapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 (heterozygous for PIK3CA K111N) with shRNA-induced PTEN expression loss. Authors found that while PTEN loss induced resistance to lapatinib, combination with dactolisib produced an additive anti-proliferation effect. Western blot analysis of lapatinib and dactolisib combination treated cells showed a decrease in phosphorylated AKT and S6 relative to untreated and lapatinib treated control cells. Authors concluded that addition of dactolisib to lapatinib overcame PTEN loss induced lapatinib resistance in HER-2 positive breast cancer cells."	"Eichhorn et al., 2008, Cancer Res."	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Her2-receptor Positive Breast Cancer	"Dactolisib,Trastuzumab"	Predictive	Does Not Support	D	Resistance	chr10	87863113	87971930			"In a preclinical study, efficacy of NVP-BEZ235 (dactolisib; a dual PI3K/mTOR inhibitor) and trastuzumab combination therapy was evaluated in vitro against HER2 amplified human breast cancer cell line BT474 (heterozygous for PIK3CA K111N) with shRNA-induced PTEN expression loss. Authors found that while PTEN loss induced resistance to trastuzumab, combination with dactolisib produced an additive anti-proliferation effect."	"Eichhorn et al., 2008, Cancer Res."	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN Loss	PTEN	Loss	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	Predictive	Does Not Support	B	Resistance	chr10	87863113	87971930			"In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors had decreased, slightly decreased, or absent PTEN expression (assessed by IHC) treated with ado-trastuzumab emtansine (T-DM1; n= 113) were associated with similar median progression free survival (PFS) compared to patients whose tumors expressed PTEN normally or greater (n=21; 8.4 vs. 9.9 months). In HER2 patients with decreased or absent PTEN expression, T-DM1 was a more effective treatment than standard of care capecitabine + lapatinib as measured by PFS, although no difference in OS was seen."	"Baselga et al., 2016, Clin. Cancer Res."	Somatic	ENST00000371953.3	loss_of_function_variant
PTEN R130*	PTEN	R130*	Thyroid Gland Cancer	"Perifosine,Temsirolimus"	Predictive	Supports	D	Sensitivity/Response	chr10	87933147	87933147	C	T	"Preclinical study in thyroid cancer cell lines. 6 cell lines with alterations of the PI3K/Akt pathway were more sensitive to Akt inhibitor perifosine or MTOR inhibitor temsirolimus than 5 cell lines without genetic alterations in the PI3K/Akt pathway. Among the alterations, one cell line harbored a PTEN allele deletion and R130* mutation. This cell line harbored the lowest IC50 values to both perifosine and temsirolimus and also showed increased apoptosis with perifosine in a xenograft model."	"Liu et al., 2009, Cancer Res."	N/A	ENST00000371953.3	stop_gained
PTEN R173C	PTEN	R173C	Cancer		Predisposing	Supports	D	Uncertain Significance	chr10	87952142	87952142	C	T	"Han et al functionally tested the R173C mutation in PTEN using an expression vector construct, assessing phosphatase activity of the mutant construct with two phosphoinositide substrates (""with[ PtdIns(3,4,5)P3] or without[ Ins(1,3,4,5)P4] a diacylglycerol chain""). R173C resides in the NH2-terminal phosphatase domain of PTEN. R173C was one of four mutations (out of 42 tested) that displayed no significant phosphatase activity against either substrate, indicating, by this assay, that the mutation negatively impacts the function of PTEN.   However this mutation did not affect the ability of PTEN to bind lipid membranes in-vivo.  This data justifies PS3 level evidence for pathogenicity according to ACMG guidelines."	"Han et al., 2000, Cancer Res."	N/A	ENST00000371953.3	missense_variant
PTEN R173C	PTEN	R173C	Endometrial Hyperplasia		Oncogenic	Supports	C	Oncogenicity	chr10	87952142	87952142	C	T	"Maxwell et al identified R173C in 1 subject (of 51 endometrial hyperplasias assayed for mutations in PTEN), and identified 10 mutations of 51 in PTEN overall (20%). No additional functional testing or clinical description was given."	"Maxwell et al., 1998, Cancer Res."	Somatic	ENST00000371953.3	missense_variant
PTEN R233*	PTEN	R233*	Breast Cancer	MTOR Inhibitor	Predictive	Supports	D	Sensitivity/Response	chr10	87957915	87957915	C	T	Cells with PTEN deficiency have been shown to exhibit slowed growth in reponse to PI3K-mTOR inhibitors.	"Courtney et al., 2010, J. Clin. Oncol."	Somatic	ENST00000371953.3	"stop_gained,loss_of_function_variant"
PTEN R233*	PTEN	R233*	Glioblastoma		Prognostic	Does Not Support	B	Poor Outcome	chr10	87957915	87957915	C	T	"PTEN nonsense mutations, including R233*, have been shown to be inactivating and loss-of-function, but do not have prognostic value in glioblastoma multiforme patients."	"Carico et al., 2012, PLoS ONE"	Somatic	ENST00000371953.3	"stop_gained,loss_of_function_variant"
PTEN V317FS	PTEN	V317FS	Skin Melanoma	"MEK Inhibitor CI-1040,Akt Inhibitor MK2206"	Predictive	Supports	D	Sensitivity/Response	chr10	87961042	87961045	TACT		"A 26-year old patient presented with vemurafenib resistant BRAF V600E-mutated cutaneous melanoma. Five metastases were evaluated using whole genome sequencing and a 4-bp deletion in PTEN (frameshift mutation at V317) was identified as unanimously present in all five tumors and a pre-treatment biopsy. The other copy of PTEN was lost with a chromosome-wide loss of chr 10. Subsequently, a patient-derived tumor cell line (designated 22 092) was suspended in a solution of PD184352/MK2206 combination therapy and cell growth inhibition confirmed tumor sensitivity to MEK/AKT inhibitors compared to the BRAF V600E-containing A375P cell line. ERK inhibitor resistance was demonstrated as a result of a GNAQ Q209P mutation also identified in the patient. This cell line showed overexpression of AKT and no expression of PTEN."	"Turajlic et al., 2014, Ann. Oncol."	Somatic	ENST00000371953.3	frameshift_variant
PDGFRA TNKS2::PDGFRA	PDGFRA	TNKS2::PDGFRA	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	Imatinib	Predictive	Supports	C	Sensitivity/Response	chr10	91798312	91859648			A patient harbouring a novel TNKS2PDGFRA fusion in a myeloid neoplasm with eosinophilia demonstrated a dramatic and durable response upon treatment with Imatinib mono therapy.	"Chalmers et al., 2015, Blood Cancer J"	Somatic	ENST00000371627.4	transcript_fusion
FGFR2 FGFR2::MGEA5	FGFR2	FGFR2::MGEA5	Cholangiocarcinoma	Ponatinib	Predictive	Supports	C	Sensitivity/Response	chr10	101784452	101792943			"In a single patient with this fusion in intrahepatic cholangiocarcinoma. Ponatinib treatment resulted in necrosis and shrinkage of the primary and metastatic sites and overall stable disease. However, this response did not meet criteria for RECIST partial response."	"Borad et al., 2014, PLoS Genet."	Somatic	ENST00000457416.2	transcript_fusion
NT5C2 S445F	NT5C2	S445F	Childhood Acute Lymphocytic Leukemia	"Thioguanine,Mercaptopurine"	Predictive	Supports	D	Resistance	chr10	103090726	103090726	G	A	"Lentiviral-mediated overexpression of NT5C2 S445F in Reh cells resulted in significant resistance against thiopurines (mercaptopurine and thioguanine) versus wildtype and GFP controls, as indicated by reduced apoptosis.  Compared to controls, overexpression cells also displayed reduced intercellular thioguanoside nucleotides after 24 hours of drug exposure, as measured by HPLC. Additionally, recombinant protein expression of S445F led to increased 5?nucleotidase activity."	"Meyer et al., 2013, Nat. Genet."	Somatic	ENST00000343289.5	"missense_variant,gain_of_function_variant"
NT5C2 S445F	NT5C2	S445F	Childhood Acute Lymphocytic Leukemia	"Cytarabine,Prednisolone,Doxorubicin,Gemcitabine"	Predictive	Does Not Support	D	Resistance	chr10	103090726	103090726	G	A	"Overexpression of NT5C2 S445F in Reh cells resulted in no change in response to cytarabine, gemcitabine, doxorubicin or prednisolone versus wildtype or GFP controls as indicated by similar apoptosis."	"Meyer et al., 2013, Nat. Genet."	Somatic	ENST00000343289.5	"missense_variant,gain_of_function_variant"
NT5C2 S445F	NT5C2	S445F	Childhood Acute Lymphocytic Leukemia		Prognostic	Supports	C	Poor Outcome	chr10	103090726	103090726	G	A	"71 Childhood B-cell acute lymphocytic leukemia relapse patients had their diagnosis and relapse samples sequenced for NT5C2 mutations. Sequencing revealed an early relapse case with NT5C2 S445F enriched to a variant allele frequency (VAF) of 25% at relapse and was undetected at diagnosis. S445F could drive clonal outgrowth through the promotion of drug resistance, specifically to thiopurines, which are a staple of ALL maintenance therapy that are administered daily."	"Meyer et al., 2013, Nat. Genet."	Somatic	ENST00000343289.5	"missense_variant,gain_of_function_variant"
NT5C2 D407A	NT5C2	D407A	T-cell Acute Lymphoblastic Leukemia	"Mercaptopurine,Thioguanine"	Predictive	Supports	D	Resistance	chr10	103090988	103090988	T	G	"CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 D407A mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C2. Consistent with this, isolated mutant proteins also showed increased enzyme activity compared to wildtype protein."	"Tzoneva et al., 2013, Nat. Med."	Somatic	ENST00000343289.5	missense_variant
NT5C2 D407A	NT5C2	D407A	T-cell Acute Lymphoblastic Leukemia	"Nelarabine,Arabinosylguanine"	Predictive	Does Not Support	D	Resistance	chr10	103090988	103090988	T	G	"CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (K359Q, R367Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine treatment when compared to cells expressing wildtype protein or vector alone."	"Tzoneva et al., 2013, Nat. Med."	Somatic	ENST00000343289.5	missense_variant
NT5C2 R367Q	NT5C2	R367Q	T-cell Acute Lymphoblastic Leukemia	"Thioguanine,Mercaptopurine"	Predictive	Supports	D	Resistance	chr10	103093198	103093198	C	T	"CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 R367Q mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C2. Consistent with this, isolated mutant proteins also showed increased enzyme activity compared to wildtype proteins."	"Tzoneva et al., 2013, Nat. Med."	Somatic	ENST00000343289.5	missense_variant
NT5C2 R367Q	NT5C2	R367Q	T-cell Acute Lymphoblastic Leukemia	"Nelarabine,Arabinosylguanine"	Predictive	Does Not Support	D	Resistance	chr10	103093198	103093198	C	T	"CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (K359Q, R367Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine treatment when compared to cells expressing wildtype protein or vector alone."	"Tzoneva et al., 2013, Nat. Med."	Somatic	ENST00000343289.5	missense_variant
NT5C2 R367Q	NT5C2	R367Q	Childhood Acute Lymphocytic Leukemia	"Thioguanine,Mercaptopurine"	Predictive	Supports	C	Resistance	chr10	103093198	103093198	C	T	"71 Childhood B-cell acute lymphocytic leukemia relapse patients had their diagnosis and relapse samples sequenced for NT5C2 mutations. Sequencing revealed an early relapse case with NT5C2 R367Q enriched to a variant allele frequency (VAF) of 25% at relapse and only a VAF of .02% at diagnosis. R367Q could drive clonal outgrowth through the promotion of drug resistance, specifically to thiopurines, which are a staple of ALL maintenance therapy that are administered daily."	"Meyer et al., 2013, Nat. Genet."	Somatic	ENST00000343289.5	missense_variant
NT5C2 R367Q	NT5C2	R367Q	Childhood Acute Lymphocytic Leukemia	"Cytarabine,Gemcitabine,Prednisolone,Doxorubicin"	Predictive	Does Not Support	D	Resistance	chr10	103093198	103093198	C	T	"Lentiviral mediated overexpression of NT5C2 R367Q in Reh cells resulted in no change in apoptosis after exposure to cytarabine, gemcitabine, doxorubicin, or prednisolone compared to wildtype NT5C2 overexpression and GFP control lines."	"Meyer et al., 2013, Nat. Genet."	Somatic	ENST00000343289.5	missense_variant
NT5C2 R367Q	NT5C2	R367Q	Childhood Acute Lymphocytic Leukemia	"Thioguanine,Mercaptopurine"	Predictive	Supports	D	Resistance	chr10	103093198	103093198	C	T	"Lentiviral-mediated overexpression of NT5C2 R367Q in Reh cells resulted in significant resistance against thiopurines (mercaptopurine and thioguanine) versus wildtype and GFP controls, as indicated by reduced apoptosis. Compared to controls, overexpression cells also displayed reduced intercellular thioguanoside nucleotides after 24 hours of drug exposure, as measured by HPLC. Additionally, recombinant protein expression of R367Q led to increased 5?nucleotidase activity."	"Meyer et al., 2013, Nat. Genet."	Somatic	ENST00000343289.5	missense_variant
NT5C2 K359Q	NT5C2	K359Q	T-cell Acute Lymphoblastic Leukemia	"Mercaptopurine,Thioguanine"	Predictive	Supports	D	Resistance	chr10	103093223	103093223	T	G	"CCRF-CEM and to a lesser extent CUTLL1 T-ALL cell lines expressing the NT5C2 K359Q mutation had increased resistance to 6-mercaptopurine and 6-thioguanine treatment than cells expressing wildtype NT5C2. Consistent with this, isolated mutant proteins also showed increased enzyme activity compared to wildtype proteins."	"Tzoneva et al., 2013, Nat. Med."	Somatic	ENST00000343289.5	missense_variant
NT5C2 K359Q	NT5C2	K359Q	T-cell Acute Lymphoblastic Leukemia	"Nelarabine,Arabinosylguanine"	Predictive	Does Not Support	D	Resistance	chr10	103093223	103093223	T	G	"CCRF-CEM and CUTLL1 T-ALL cell lines expressing NT5C2 mutant proteins (K359Q, R367Q or D407A) observed in relapsed T-ALL patients showed no difference in sensitivity to nelarabine or arabinosylguanine treatment when compared to cells expressing wildtype protein or vector alone."	"Tzoneva et al., 2013, Nat. Med."	Somatic	ENST00000343289.5	missense_variant
NT5C2 K359Q	NT5C2	K359Q	Acute Lymphoblastic Leukemia		Prognostic	Supports	B	Poor Outcome	chr10	103093223	103093223	T	G	The K359Q somatic mutation was significantly correlated with early disease recurrence and relapse in 103 T-cell ALL regardless of treatment course. The data was obtained from Berlin Frankfurt Mnster Clinical Trials.	"Tzoneva et al., 2013, Nat. Med."	Somatic	ENST00000343289.5	missense_variant
NT5C2 R238W	NT5C2	R238W	Childhood Acute Lymphocytic Leukemia	"Mercaptopurine,Thioguanine"	Predictive	Supports	D	Resistance	chr10	103097350	103097350	G	A	"Lentiviral-mediated overexpression of NT5C2 R238W in Reh cells resulted in significant resistance against thiopurines (mercaptopurine and thioguanine) versus wildtype and GFP controls, as indicated by reduced apoptosis. Compared to controls, overexpression cells also displayed reduced intercellular thioguanoside nucleotides after 24 hours of drug exposure, as measured by HPLC. Additionally, recombinant protein expression of R238W led to increased 5?nucleotidase activity."	"Meyer et al., 2013, Nat. Genet."	Somatic	ENST00000343289.5	
NT5C2 R238W	NT5C2	R238W	Childhood Acute Lymphocytic Leukemia	"Prednisolone,Cytarabine,Gemcitabine,Doxorubicin"	Predictive	Does Not Support	D	Resistance	chr10	103097350	103097350	G	A	"Overexpression of NT5C2 R238W in Reh cells resulted in no change in response to cytarabine, gemcitabine, doxorubicin or prednisolone versus wildtype or GFP controls as indicated by similar apoptosis."	"Meyer et al., 2013, Nat. Genet."	Somatic	ENST00000343289.5	
NT5C2 R238W	NT5C2	R238W	Childhood Acute Lymphocytic Leukemia		Prognostic	Supports	C	Poor Outcome	chr10	103097350	103097350	G	A	"71 Childhood B-cell acute lymphocytic leukemia relapse patients had their diagnosis and relapse samples sequenced for NT5C2 mutations. Sequencing revealed 3 early relapse cases with NT5C2 R238W enriched at relapse at variant allele frequencies (VAF) of 27%, 18%, and 31% and only a VAF of .01%, 0%, and 0% at diagnosis. R238W could drive clonal outgrowth through the promotion of drug resistance, specifically to thiopurines, which are a staple of ALL maintenance therapy that are administered daily."	"Meyer et al., 2013, Nat. Genet."	Somatic	ENST00000343289.5	
PDCD4 EXPRESSION	PDCD4	EXPRESSION	Lung Cancer	Paclitaxel	Predictive	Supports	B	Sensitivity/Response	chr10	110871838	110900005			PDCD4 expression was associated with response to paclitaxel in a retrospective analysis of 77 patients after preclinical validation and mechanistic analysis of the biomarker.	"Xu et al., 2015, J. Proteome Res."	N/A	ENST00000393104.2	N/A
FGFR2 Mutation	FGFR2	Mutation	Endometrial Cancer	Ponatinib	Predictive	Supports	D	Sensitivity/Response	chr10	121479857	121598403			"Preclinical study in endometrial cancer cell lines (MFE-296, AN3CA, MFE-280 and Ishikawa). In cell proliferation assays, the three FGFR2 mutant cell lines were more sensitive to the pan-FGFR inhibitor ponatinib (AP24534) than the FGFR2 wild type cell line (Ishikawa) and human embryonic kidney cell line (HEK293). Ponatinib also inhibited FGFR2 kinase activity and phosphorylation (MFE-296 and MFE-280) as well as cell migration and invasion (MFE-296 and AN3CA) of FGFR2 mutated cancer cell lines."	"Kim et al., 2016, Cancer Biol. Ther."	Somatic	ENST00000457416.2	"transcript_variant,gain_of_function_variant"
FGFR2 Amplification	FGFR2	Amplification	Breast Cancer	Dovitinib	Predictive	Supports	B	Sensitivity/Response	chr10	121479857	121598403			"Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study. Dovitinib inhibited proliferation in one FGFR1- and one FGFR2-amplified breast cancer cell lines at higher IC50 values than in 11 nonamplified cell lines. Dovitinib inhibited tumor growth and caused regression in both a FGFR1- and FGFR2-amplified xenograft model. 81 patients were enrolled in the trial and treated with dovitinib. 2 patients were reported to harbor FGFR2 amplifications and both had a reduction in tumor size of 18.5 and 28.2%, respectively. When FGFR1, FGF3 and FGFR2 amplifications were combined, a combined FGF-pathway amplified patient group had a higher mean reduction in target lesion size than patients with FGF-non-amplified tumors."	"Andr et al., 2013, Clin. Cancer Res."	N/A	ENST00000457416.2	transcript_amplification
FGFR2 FGFR2::BICC1	FGFR2	FGFR2::BICC1	Cholangiocarcinoma		Diagnostic	Supports	B	Positive	chr10	121479857	121598403			"Massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1. In RT-PCR screening, the FGFR2 fusion was detected in nine patients with cholangiocarcinoma (9/102), exclusively in the intrahepatic subtype (9/66, 13.6%)."	"Arai et al., 2014, Hepatology"	Somatic	ENST00000457416.2	transcript_fusion
FGFR2 FGFR2::AHCYL1	FGFR2	FGFR2::AHCYL1	Cholangiocarcinoma		Diagnostic	Supports	B	Positive	chr10	121479857	121598403			"Massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1. In RT-PCR screening, the FGFR2 fusion was detected in nine patients with cholangiocarcinoma (9/102), exclusively in the intrahepatic subtype (9/66, 13.6%)."	"Arai et al., 2014, Hepatology"	Somatic	ENST00000457416.2	transcript_fusion
FGFR2 FGFR2::BICC1	FGFR2	FGFR2::BICC1	Cholangiocarcinoma	"Infigratinib,PD173074"	Predictive	Supports	D	Sensitivity/Response	chr10	121479857	121598403			Expression of the FGFR2-BICC1 fusion kinase in NIH3T3 cells demonstrated transforming ability that was effectively suppressed with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074.	"Arai et al., 2014, Hepatology"	Somatic	ENST00000457416.2	transcript_fusion
FGFR2 FGFR2::AHCYL1	FGFR2	FGFR2::AHCYL1	Cholangiocarcinoma	"Infigratinib,PD173074"	Predictive	Supports	D	Sensitivity/Response	chr10	121479857	121598403			Expression of the FGFR2-AHCYL1 fusion kinase in NIH3T3 cells demonstrated transforming ability that was effectively suppressed with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074.	"Arai et al., 2014, Hepatology"	Somatic	ENST00000457416.2	transcript_fusion
FGFR2 Mutation	FGFR2	Mutation	Cholangiocarcinoma	Infigratinib	Predictive	Supports	C	Sensitivity/Response	chr10	121479857	121598403			"Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. Among three patients with cholangiocarcinoma and FGFR2 aberrations (2 fusions, 1 mutation), all three had stable disease with a reduced tumor burden."	"Nogova et al., 2017, J. Clin. Oncol."	Somatic	ENST00000457416.2	"transcript_variant,gain_of_function_variant"
FGFR2 FGFR2::BICC1	FGFR2	FGFR2::BICC1	Transitional Cell Carcinoma	Erdafitinib	Predictive	Supports	C	Sensitivity/Response	chr10	121479857	121598403			"Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without known FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 partial responses as well as 16 with stable disease were seen. In patients with FGFR2-BICC1 fusions, 1 patient with urothelial cancer harboring FGFR2-BICC1/FGFR2-CASP7 fusions had a PR."	"Tabernero et al., 2015, J. Clin. Oncol."	Somatic	ENST00000457416.2	transcript_fusion
FGFR2 FGFR2::BICC1	FGFR2	FGFR2::BICC1	Endometrial Cancer	Erdafitinib	Predictive	Supports	C	Sensitivity/Response	chr10	121479857	121598403			"Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 partial responses as well as 16 with stable disease were seen. A patient with endometrial cancer with synchronous FGFR3-TACC3 and FGFR2-BICC1/FGFR2-OFD1 fusions had a PR."	"Tabernero et al., 2015, J. Clin. Oncol."	Somatic	ENST00000457416.2	transcript_fusion
FGFR2 Amplification	FGFR2	Amplification	Stomach Carcinoma	FGFR Inhibitor AZD4547	Predictive	Supports	B	Sensitivity/Response	chr10	121479857	121598403			"Nine patients with FGFR2-amplified gastroesophageal cancer were treated with AZD4547.  Of these 9 patients, 3 showed confirmed responses to AZD4547. Median progression-free survival was 6.6 months (range=6.2-10.5). Two additional patients had a response in day 15 using FDG-PET but were not considered complete responders by RECIST criteria. High-level FGFR2-amplified (arbitrarily defined as FISH-ratio > 5) cancers had a higher likelihood of response and were associated with a substantially higher expression of both FGFR2 mRNA and FGFR2 protein (IHC). In vitro and in PDX models, FGFR2-amplified cell lines were sensitive to FGFR inhibition. Further preclinical analyses suggested, that FGFR2 amplification mainly signals via the PI3K pathway."	"Pearson et al., 2016, Cancer Discov"	N/A	ENST00000457416.2	transcript_amplification
FGFR2 Mutation	FGFR2	Mutation	Cholangiocarcinoma	Infigratinib	Predictive	Supports	B	Sensitivity/Response	chr10	121479857	121598403			"Eight patients with cholangiocarcinoma haboring FGFR2 mutations received BGJ398. No response was observed, but one tumor showed a 23% reduction in  size. Water fall plot of this article showed 5 patients with stable disease."	"Javle et al., 2018, J. Clin. Oncol."	Somatic	ENST00000457416.2	"transcript_variant,gain_of_function_variant"
FGFR2 FGFR2::MGEA5	FGFR2	FGFR2::MGEA5	Cholangiocarcinoma	Ponatinib	Predictive	Supports	C	Sensitivity/Response	chr10	121483698	121598403			"In a single patient with this fusion in intrahepatic cholangiocarcinoma. Ponatinib treatment resulted in necrosis and shrinkage of the primary and metastatic sites and overall stable disease. However, this response did not meet criteria for RECIST partial response."	"Borad et al., 2014, PLoS Genet."	Somatic	ENST00000457416.2	transcript_fusion
FGFR2 N550K	FGFR2	N550K	Endometrial Cancer	PD173074	Predictive	Supports	D	Sensitivity/Response	chr10	121498520	121498520	A	T	"The endometrial cancer cell lines, AN3CA and MFE296, which carry the N550K FGFR2 mutation, were found to be sensitive to FGFR inhibition with PD174074 (10 to 40x more sensitive than cell lines with wild type FGFR2.)."	"Byron et al., 2008, Cancer Res."	Somatic	ENST00000457416.2	"missense_variant,gain_of_function_variant"
MKI67 EXPRESSION	MKI67	EXPRESSION	Breast Cancer		Prognostic	Supports	B	Poor Outcome	chr10	128096659	128126385			"A quantitative meta-analysis was performed to assess optimal IHC-calculated cutoff values for the prognostic use of proliferative biomarker Ki67 in breast cancer. The studies included ER positive and negative cases, and the MIB-1 antibody was used in the large majority of studies. 25 studies that employed multivariate analysis were used, and a hazard ratio of 2.05 for overall survival was obtained when Ki67 cutoff value was set at greater or equal to 25%."	"Petrelli et al., 2015, Breast Cancer Res. Treat."	N/A	ENST00000368654.3	N/A
MKI67 EXPRESSION	MKI67	EXPRESSION	Prostate Cancer		Prognostic	Supports	B	Poor Outcome	chr10	128096659	128126385			"293 cases of clinically localized prostate cancer were analyzed on needle-biopsy FFPE tissue microarray, using the MIB-1 antibody against the Ki67 marker of proliferation. IHC staining was used to generate a Ki67 score, and cases were divided into 2 groups with Ki67 score greater or less than 10%. Primary endpoint was death due to prostate cancer. A hazard ratio for high Ki67 values of 3.42 was seen in univariate analysis, and  Ki67 score also added significant predictive value in multivariate analysis, with a hazard ratio of 2.78."	"Fisher et al., 2013, Br. J. Cancer"	N/A	ENST00000368654.3	N/A
MGMT Promoter Methylation	MGMT	Promoter Methylation	Glioblastoma		Prognostic	Supports	B	Better Outcome	chr10	129466231	129467392			MGMT promoter methylation was associated with increased overall and disease-free survival as well as tumor regression in patients with gliomas.	"Esteller et al., 2000, N. Engl. J. Med."	Somatic	ENST00000306010.7	N/A
MGMT Promoter Methylation	MGMT	Promoter Methylation	Glioblastoma	Temozolomide	Predictive	Supports	A	Sensitivity/Response	chr10	129466231	129467392			"In a randomized clinical trial, patients with MGMT promoter methylation benefitted from temozolomide. This benefit was also methylation status dependent, as those without methylation did not see increased survival."	"Hegi et al., 2005, N. Engl. J. Med."	Somatic	ENST00000306010.7	N/A
MGMT Promoter Methylation	MGMT	Promoter Methylation	Glioblastoma	Carmustine	Predictive	Supports	B	Sensitivity/Response	chr10	129466231	129467392			"MGMT promoter methylation has been shown to confer sensitivity to alkylating agents, such as carmustine, in glioblastoma cells."	"Esteller et al., 2000, N. Engl. J. Med."	Somatic	ENST00000306010.7	N/A
MGMT Promoter Methylation	MGMT	Promoter Methylation	Glioblastoma	O6-Benzylguanine	Predictive	Supports	E	Sensitivity/Response	chr10	129466231	129467392			"In patients lacking MGMT promoter methylation, the use of an MGMT inhibitor, such as O(6)-benzylguanine, in combination with alkylating agents (Carmustine) may be useful in treating patients with initial resistance to alkylating agents."	"Esteller et al., 2000, N. Engl. J. Med."	Somatic	ENST00000306010.7	N/A
MGMT Promoter Methylation	MGMT	Promoter Methylation	Oligodendroglioma		Prognostic	Supports	B	Better Outcome	chr10	129466231	129467392			"In a study of 152 anaplastic oligodendroglial tumors, 121 samples had MGMT promoter methylation. Those with promoter methylation had better progression-free and overall survival."	"van den Bent et al., 2009, J. Clin. Oncol."	Somatic	ENST00000306010.7	N/A
MGMT Promoter Methylation	MGMT	Promoter Methylation	Glioblastoma		Prognostic	Supports	B	Better Outcome	chr10	129466231	129467392			"In patients with glioblastoma, those with methylated MGMT promoters have better overall survival than those with unmethylated promoters."	"Hegi et al., 2005, N. Engl. J. Med."	Somatic	ENST00000306010.7	N/A
MGMT Underexpression	MGMT	Underexpression	Glioblastoma	Temozolomide	Predictive	Supports	B	Sensitivity/Response	chr10	129467184	129768007			"In this study, patients with low MGMT expression, compared with patients with high MGMT expression, had a significantly higher response rate (55% v 7%, respectively; P = .004) and improved PFS (median, 5.5 v 1.9 months, respectively; P = .009) and OS (median, 16 v 5 months, respectively; P = .003). Among patients with MGMT data available for analysis, radiotherapy was started and completed in 91% of patients with low MGMT expression. In contrast, among patients with high MGMT expression, only 64% started radiotherapy, and 43% completed it. These results suggest that neoadjuvant chemotherapy may be feasible for inoperable glioblastoma patients expressing low levels of MGMT without compromising subsequent treatment with radiotherapy, whereas patients with high MGMT expression are less likely to respond and more likely to experience progression before or during radiotherapy."	"Chinot et al., 2007, J. Clin. Oncol."	N/A	ENST00000306010.7	N/A
MGMT Underexpression	MGMT	Underexpression	High Grade Glioma	Temozolomide	Predictive	Supports	B	Sensitivity/Response	chr10	129467184	129768007			"This study showed that low MGMT mRNA expression was strongly predictive for prolonged time to progression, treatment response, and length of survival in univariate and multivariate models (p<0.0001). The degree of MGMT mRNA expression was highly correlated with the MGMT promoter methylation status (p<0.0001); however, discordant findings were seen in 12 glioblastoma patients. Patients with methylated tumors with high MGMT mRNA expression (N = 6) did significantly worse than those with low transcriptional activity (p<0.01). Conversely, unmethylated tumors with low MGMT mRNA expression (N = 6) did better than their counterparts."	"Kreth et al., 2011, PLoS ONE"	N/A	ENST00000306010.7	N/A
MGMT Underexpression	MGMT	Underexpression	Oligodendroglioma	Temozolomide	Predictive	Supports	B	Sensitivity/Response	chr10	129467184	129768007			"In this study, loss of chromosome 1p and low MGMT protein expression were associated with objective response (P < .003 and P < .04, respectively). However, only 54% of the study group had evaluation of 1p/19q status, and MGMT protein expression was studied in only 33%. Therefore, the association between 1p deletion and low MGMT protein expression was statistically significant when evaluated further and verified in the extended group of 31 patients with low-grade oligodendrogliomas."	"Levin et al., 2006, Cancer"	N/A	ENST00000306010.7	N/A
MGMT Underexpression	MGMT	Underexpression	Glioblastoma	Temozolomide	Predictive	Supports	B	Sensitivity/Response	chr10	129467184	129768007			"In 41 glioblastomas treated with temozolomide (TMZ) therapy (MGMT-immunopositive: n = 22, negative: n = 19), both progression free survival and overall survival were significantly better in MGMT-immunonegative glioblastomas. (PFS: P = 0.0015, OS: P = 0.0384)."	"Watanabe et al., 2011, Brain Tumor Pathol"	N/A	ENST00000306010.7	N/A
MGMT Underexpression	MGMT	Underexpression	Neuroendocrine Tumor	Temozolomide	Predictive	Supports	B	Sensitivity/Response	chr10	129467184	129768007			"Among those patients who received temozolomide-based therapy in this study, the median progression-free survival for patients whose tumors showed intact MGMT expression was 9.3 months compared with 19.2 months for patients with MGMT-deficient tumors (P = 0.11). The median overall survival for patients whose tumors showed intact MGMT expression was 19.1 months; the median overall survival for patients with MGMT deficient tumors was not reached."	"Kulke et al., 2009, Clin. Cancer Res."	N/A	ENST00000306010.7	N/A
HRAS Mutation	HRAS	Mutation	Cancer	"MTOR Kinase Inhibitor AZD8055,Everolimus,Mirdametinib,Binimetinib,Selumetinib"	Predictive	Supports	D	Sensitivity/Response	chr11	533873	534289			"A pre-clinical study in 10 solid cancer cell lines. HRAS mutations (Q61L, Q61R and G12V) sensitized cell lines toward MEK inhibitors (AZD6244/selumetinib, MEK162 and PD0325901) and mTOR inhibitors (Everolimus and AZD8055)."	"Kiessling et al., 2015, Oncotarget"	Somatic	ENST00000451590.1	coding_transcript_variant
HRAS Mutation	HRAS	Mutation	Bladder Urothelial Carcinoma	Tipifarnib	Predictive	Supports	B	Sensitivity/Response	chr11	533873	534289			4 of 16 patients with urothelial carcinoma harboring HRAS hotspot point mutations and 1 patient with an HRAS frameshift insertion had a partial response to the farnesyltransferase inhibitor tipifarnib while none of the 6 patients with wild-type HRAS responded.	"Lee et al., 2020, Clin Cancer Res"	Somatic	ENST00000451590.1	coding_transcript_variant
HRAS Mutation	HRAS	Mutation	Head And Neck Squamous Cell Carcinoma	Tipifarnib	Predictive	Supports	B	Sensitivity/Response	chr11	533873	534289			"In a phase II HNSCC trial, an objective response rate of 55% was seen in HRAS-mutant patients (11 of 20) treated with the farnesyltransferase inhibitor tipifarnib with a PFS of 5.6 months and an OS of 15.6 months (providing the allele fraction was at least 20%)."	"Ho et al., 2021, J Clin Oncol"	Somatic	ENST00000451590.1	coding_transcript_variant
HRAS G13D	HRAS	G13D	Colorectal Cancer	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Predictive	Supports	C	Resistance	chr11	534285	534285	C	T	Case report of a patient with metastatic colorectal carcinoma and a novel HRAS G13D mutation showed resistance to treatment with panitumumab. In vitro models of HRAS G13D confirmed resistance mechanism in the same study.	"Boidot et al., 2016, Int J Colorectal Dis"	Somatic	ENST00000451590.1	missense_variant
HRAS G13D	HRAS	G13D	Skin Squamous Cell Carcinoma	Vemurafenib	Predictive	Supports	C	Resistance	chr11	534285	534285	C	T	"In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy, a patient harboring HRAS G13D co-mutation (n=1) was reported to be resistant to vemurafenib treatment."	"Su et al., 2012, N. Engl. J. Med."	Somatic	ENST00000451590.1	missense_variant
HRAS G13D	HRAS	G13D	Colorectal Cancer	Cetuximab	Predictive	Supports	D	Resistance	chr11	534285	534285	C	T	"In an in vitro study, Colo-320, SW48, and CaCO2 cell lines expressing HRAS G13D mutation were associated with resistance to cetuximab treatment, as compared to Colo-320, SW48, and CaCO2 cells expressing wild-type HRAS."	"Boidot et al., 2016, Int J Colorectal Dis"	Somatic	ENST00000451590.1	missense_variant
IGF2 Overexpression	IGF2	Overexpression	Prostate Cancer	Linsitinib	Predictive	Does Not Support	D	Sensitivity/Response	chr11	2129118	2149603			"Increased IGF2 expression was shown to mediate chemotherapy resistance in several prostate cancer cell lines. The IGF1R/INSR inhibitor OSI-906 did not have a significant effect on chemotherapy resistant castration-resistant prostate cancer cell lines, as measured by colony formation assay. Similarly, in vivo experiments showed no difference between OSI-906 and control treatment in terms of tumor growth and survival."	"Vidal et al., 2015, Cancer Cell"	Somatic	ENST00000300632.5	N/A
IGF2 Overexpression	IGF2	Overexpression	Prostate Cancer	"Linsitinib,Cabazitaxel,Docetaxel"	Predictive	Supports	D	Sensitivity/Response	chr11	2129118	2149603			"OSI-906, an IGF1R/INSR inhibitor, sensitizes cell lines to docetaxel and cabazitaxel, resulting in better overall survival in mouse xenografts of patient derived chemotherapy resistant castration-resistant prostate cancer cell lines."	"Vidal et al., 2015, Cancer Cell"	Somatic	ENST00000300632.5	N/A
RRM1 Overexpression	RRM1	Overexpression	Pancreatic Cancer	Gemcitabine	Predictive	Supports	D	Resistance	chr11	4094809	4138876			The mRNA expression level of RRM1 was analyzed by RT-PCR in 3 human pancreatic cancer cell lines cultured in incrementally increased concentrations of gemcitabine. Expression levels of RRM1 progressively increased during the development of gemcitabine resistance.	"Nakano et al., 2007, Br. J. Cancer"	N/A	ENST00000300738.5	N/A
RRM1 Underexpression	RRM1	Underexpression	Lung Non-small Cell Carcinoma	"Cisplatin,Gemcitabine"	Predictive	Supports	B	Sensitivity/Response	chr11	4094809	4138876			"In the personalized therapy group of this study, patients received chemotherapy based on RRM-1 IHC expression levels, whereas the standard therapy group received non-customized chemotherapy. There were statistically significant improvements between the personalized therapy group versus the standard therapy group in disease control rate (82.9% vs 55.3%, P=0.004), and progression-free survival (median: 5.5 months vs 3.0 months, P=0.005). Besides, the overall survival had a tendency to become more prolonged (median: 16.0 months vs 12.4 months, P=0.286)."	"Nie et al., 2013, Cancer Biomark"	N/A	ENST00000300738.5	N/A
RRM1 Underexpression	RRM1	Underexpression	Pancreatic Cancer	Gemcitabine	Predictive	Supports	B	Sensitivity/Response	chr11	4094809	4138876			"There were 68 patients enrolled in this study, 28 of which were treated with gemcitabine.  Of those 28, 14 patients had a low RRM1 expression and 14 had a high RRM1 expression. Only the patients with low RRM1 expression received a significant benefit from gemcitabine (p=0.0010) whereas the benefit for those with a high RRM1 expression was not significantly better (p=0.3309).  The study also tested the role of ERCC1 expression and its correlation to RRM1 expression. It was found that patients with a combined high RRM1 and ERCC1 expression had good prognosis with the highest survival rate (P=0.0127)."	"Akita et al., 2009, Oncogene"	N/A	ENST00000300738.5	N/A
RRM1 Underexpression	RRM1	Underexpression	Pancreatic Cancer	Gemcitabine	Predictive	Supports	B	Sensitivity/Response	chr11	4094809	4138876			"In this study, human pancreatic carcinoma cell line MiaPaCa2, which is a gemcitabine-sensitive cell line, was used for the establishment of chemoresistant cells MiaPaCa2-RG. Analysis for identifying genetic alterations relating to gemcitabine resistance revealed that RRM1 was the most upregulated gene with a 4.5 fold expression. RRM1-specic RNAi transfection significantly reduced the gemcitabine chemoresistance of MiaPaCa2-RG to the same level as that of gemcitabine sensitive MiaPaCa2. Moreover, gemcitabine response of MiaPaCa2 also became more sensitive.  Next, patients with pancreatic cancer were recruited and 18 tissue samples were taken. The patients with a low RRM1 expression had a significantly better outcome after gemcitabine treatment than those patients with high RRM1 expression (P=0.016)."	"Nakahira et al., 2007, Int. J. Cancer"	N/A	ENST00000300738.5	N/A
RRM1 Underexpression	RRM1	Underexpression	Lung Non-small Cell Carcinoma	Gemcitabine	Predictive	Supports	B	Sensitivity/Response	chr11	4094809	4138876			"In this study, 229 tumors were analyzed for RRM1 expression. This resulted in 146 that were negative for RRM1 expression and 83 that were positive. These tumors were studied for a relationship between RRM1 expression and chemotherapy regimens, gemcitabine, docetaxel and carboplatin, and vinorelbine and carboplatin. In the patients receiving gemcitabine treatment, the progression-free survival of RRM1-negative patients was significantly higher than that of RRM1-positive patients (8.8 months vs. 7.6 months, P = 0.01). The patients that were positive for RRM1 expression, had a better response to docetaxel or vinorelbine treatment than gemcitabine (P=0.047 and P=0.047). However, there were no differences of response to docetaxel and vinorelbine in regards to RRM1 expression."	"Dong et al., 2014, PLoS ONE"	N/A	ENST00000300738.5	N/A
RRM1 Underexpression	RRM1	Underexpression	Lung Non-small Cell Carcinoma	"Vinorelbine,Paclitaxel,Gemcitabine"	Predictive	Supports	B	Sensitivity/Response	chr11	4094809	4138876			"The study began with a total of 443 patients that were randomly assigned to either regimen A (Paclitaxel and cisplatin with gemcitabine) or regimen B ( cisplatin and vinorelbine). Of those patients, 261 had tissue available for RRM1 evaluation. In regimen B, survival increased significantly in patients with low RRM1 expression as compared to those with a high expression (P=0.046). However, in regimen A, the increase in survival for patients with low RRM1 expression as opposed to those with a high RRM1 expression was not as significant (P=0.366)."	"Vilmar et al., 2013, Ann. Oncol."	N/A	ENST00000300738.5	N/A
RRM1 Underexpression	RRM1	Underexpression	Lung Non-small Cell Carcinoma	"Gemcitabine,Carboplatin"	Predictive	Supports	B	Sensitivity/Response	chr11	4094809	4138876			"As part of a randomized phase III trial (USO-03012) in advanced NSCLC of gemcitabine vs. combination gemcitabine and carboplatin, protein expression levels for RRM1 (n=69) and ERCC1 (n=65) were evaluated using fluorescence-based IHC. RRM1 levels were significantly inversely correlated with response (r = ?.41; P = .001, n=58), as were ERCC1 levels (r = ?.39; P = .003, n=55). RRM1 and ERCC1 levels were correlated with each other (r = 0.36; P = .003, n=65). There was no significant interaction with treatment arm (P = .64 for RRM1; P = .79 for ERCC1). The authors conclude that RRM1 and ERCC1 expression levels are predictive of response to gemcitabine, and gemcitabine and carboplatin."	"Reynolds et al., 2009, J Clin Oncol"	N/A	ENST00000300738.5	N/A
BRAF PPFIBP2::BRAF	BRAF	PPFIBP2::BRAF	Skin Melanoma	Trametinib	Predictive	Supports	C	Sensitivity/Response	chr11	7513770	7565767			"Case report of a 47year old female patient with metastatic melanoma (BRAF, NRAS, KIT negative). A PPFIBP2-BRAF fusion was identified from DNA from a brain metastasis (inton 3 of PPFIBP2 fused to intron 10 of BRAF). Trametinib was introduced and anemia and ECOG status improved. Imaging revealed a 90% decrease in extracranial and 19% decrease in intracranial metastases with no new metastases and no progressing sites at 6 weeks. Trametinib was stopped and pembrolizumab introduced at this time. Progressive disease was noted after 5 cycles of pembrolizumab but re-introduction of trametinib did not show an effect."	"Menzies et al., 2015, Pigment Cell Melanoma Res"	Somatic	ENST00000299492.4	transcript_fusion
MYOD1 L122R	MYOD1	L122R	Spindle Cell Rhabdomyosarcoma		Diagnostic	Supports	B	Positive	chr11	17720147	17720147	T	G	"This study evaluated forty-nine cases of rhabdomyosarcoma (RMS) (17 cases of alveolar RMS, 10 of embryonal RMS, 21 of spindle cell and sclerosing RMS, and a single case of a pleomorphic RMS) for MYOD1 (L122R), PIK3CA (H1047), and PIK3CA (E542/E545) variants. All 10 cases that were positive for the MYOD1 (L122R) variant were either the spindle cell (3/12) or the sclerosing (7/9) subtypes of RMS, while all 10 cases of the embryonal subtype of RMS were negative for the MYOD1 (L122R) variant. The study suggests that the MYOD1 L122R variant is specific for spindle cell and sclerosing subtype of RMS (where it was detected in 10/21 cases or 48%). The study also confirmed the positive relationship between the spindle cell and the sclerosing subtypes of RMS, which both can have the same molecular abnormality (MYOD1 L122R variant) and are now considered to be the same subtype. Finally, the study confirmed the negative correlation between the aforementioned subtypes with the embryonal subtype of rhabdomyosarcoma."	"Rekhi et al., 2016, Mod. Pathol."	Somatic	ENST00000250003.3	missense_variant
MYOD1 L122R	MYOD1	L122R	Spindle Cell Rhabdomyosarcoma		Prognostic	Supports	B	Poor Outcome	chr11	17720147	17720147	T	G	"This study evaluated forty-nine cases of rhabdomyosarcoma (RMS) (17 cases of alveolar RMS, 10 of embryonal RMS, 21 of spindle cell and sclerosing RMS, and a single case of a pleomorphic RMS) for MYOD1 (L122R), PIK3CA (H1047), and PIK3CA (E542/E545) mutations. 10/49 cases were positive for the MYOD1 (L122R) variant, and all the positive cases belonged to either spindle cell or sclerosing RMS subtype. None of the embryonal RMS cases was positive for the MYOD1 L122R variant. All cases were treated with surgical resection and either adjuvant chemotherapy, adjuvant radiotherapy, or both. On patient follow-up, the alive-with-disease ratio was higher in the adult than in the pediatric population. Furthermore, the patients positive for MYOD1 mutation showed a higher number of disease-positive states on follow-up, while the patients negative for MYOD1 mutation showed a higher number of disease-free states on follow-up. This suggests that the MYOD1 L122R variant is associated with a more aggressive clinical course, although the difference did not reach statistical significance (P=0.34)."	"Rekhi et al., 2016, Mod. Pathol."	Somatic	ENST00000250003.3	missense_variant
MYOD1 L122R	MYOD1	L122R	Spindle Cell Rhabdomyosarcoma		Prognostic	Supports	B	Poor Outcome	chr11	17720147	17720147	T	G	"This study examined 17 cases of spindle cell/sclerosing rhabdomyosarcoma (SC/SRMS) for the presence of MYOD1 variants. 12 cases harbored a MYOD-1 mutation, of which 8 cases were homozygous for p.L122R, 3 were heterozygous for p.L122R, and 1 was heterozygous for a novel p.E118K variant. There was one case of predominantly spindle cell rhabdomyosarcoma with the MYOD-1 mutation that also contained a PIK3CA mutation. The case with both MYOD-1 and PIK3CA mutations consisted histologically of lipoblasts within focally myxoid stroma, thus demonstrating that the PIK3CA mutation was a secondary aberration while MYOD-1 was the primary neomorphic mutation. On clinical follow-up, seven of the MYOD-1 variant cases experienced local recurrences and/or metastatic disease. In a median of a 13.5 month follow-up, there was 1 patient who passed away, 8 patients who were alive with the disease, and 3 patients who were alive without the disease; there was no correlation with the type of treatment that the patients had received. This supports aggressive clinical course for SC/SRMS positive for MYOD-1 variants, regardless of the presence of a concurrent PIK3CA mutation."	"Tsai et al., 2019, Histopathology"	Somatic	ENST00000250003.3	missense_variant
MYOD1 L122R	MYOD1	L122R	Rhabdomyosarcoma		Prognostic	Supports	B	Poor Outcome	chr11	17720147	17720147	T	G	"This study evaluated 641 cases of rhabdomyosarcoma (RMS), enrolled on Childrens Oncology Group trials (1998-2017) and UK malignant mesenchymal tumor and RMS2005 trials (1995-2016), for mutations in 39 genes previously implicated in RMS. The analysis was done using a custom-capture sequencing assay. MYOD1 L122R variant was identified in 17 cases (3%) and was not restricted to spindle-cell histology, but was also observed in association with other histologic patterns (including cases with densely packed cells that mimicked embryonal rhabdomyosarcoma (ERMS) or RMS not otherwise specified ). MYOD1 mutation showed association with older age, head and neck primary site, and a dismal survival. In both COG and UK patient cohorts, patients with the MYOD1 L122R mutation had rapid disease progression and significantly worse event free survival as compared to the patients with wild-type MYOD1."	"Shern et al., 2021, J Clin Oncol"	Somatic	ENST00000250003.3	missense_variant
WT1 Exon 9 Mutation	WT1	Exon 9 Mutation	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	N/A	chr11	32391972	32392064			"Rates of complete remission and refractory disease are not different in patients with WT1 mutations (69% exon 7, 15% exon 9) than those without in young (16-60) patients with cytogenetically normal AML."	"Gaidzik et al., 2009, Blood"	Somatic	ENST00000332351.3	exon_variant
WT1 Exon 9 Mutation	WT1	Exon 9 Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr11	32391972	32392064			"WT1 mutations were associated with shorter overall and disease free survival in a cohort of cytogenetically normal, young (<60) AML patients."	"Paschka et al., 2008, J. Clin. Oncol."	Somatic	ENST00000332351.3	exon_variant
WT1 Exon 7 Mutation	WT1	Exon 7 Mutation	Acute Myeloid Leukemia	"Cytarabine,Daunorubicin"	Predictive	Supports	B	Resistance	chr11	32396257	32396407			"WT1 mutations were associated with an inferior response to induction chemotherapy with a higher rate of resistant disease in young (15-60+, median 45) patients with cytogenetically normal AML."	"Virappane et al., 2008, J. Clin. Oncol."	Somatic	ENST00000332351.3	exon_variant
WT1 Exon 7 Mutation	WT1	Exon 7 Mutation	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	N/A	chr11	32396257	32396407			"No differences in relapse-free or overall survival were identified between young (16-60) patients with or without WT1 mutations (69% exon 7, 15% exon 9) in cytogenetically normal AML."	"Gaidzik et al., 2009, Blood"	Somatic	ENST00000332351.3	exon_variant
WT1 Exon 7 Mutation	WT1	Exon 7 Mutation	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	N/A	chr11	32396257	32396407			"Rates of complete remission and refractory disease are not different in patients with WT1 mutations (69% exon 7, 15% exon 9) than those without in young (16-60) patients with cytogenetically normal AML."	"Gaidzik et al., 2009, Blood"	Somatic	ENST00000332351.3	exon_variant
WT1 Exon 7 Mutation	WT1	Exon 7 Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr11	32396257	32396407			Mutations  in WT1 were associated with increased risk of recurrence in young patients (15-50) with cytogenetically normal AML.	"Renneville et al., 2009, Cancer"	Somatic	ENST00000332351.3	exon_variant
WT1 Exon 7 Mutation	WT1	Exon 7 Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr11	32396257	32396407			"Mutations in WT1 were associated with a worse overall prognosis than patients wildtype for WT1 in young patients (15-50), primarily because of increased risk of disease recurrence."	"Renneville et al., 2009, Cancer"	Somatic	ENST00000332351.3	exon_variant
WT1 Exon 7 Mutation	WT1	Exon 7 Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr11	32396257	32396407			"Patients with WT1 (69% exon 7, 15% exon 9) and FLT3-ITD mutations had significantly lower complete remission and higher refractory disease rates than those with wildtype WT1 and without FLT3-ITD following induction therapy in young (16-60) patients with cytogenetically normal AML."	"Gaidzik et al., 2009, Blood"	Somatic	ENST00000332351.3	exon_variant
WT1 Exon 7 Mutation	WT1	Exon 7 Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr11	32396257	32396407			"WT mutations were associated with shorter overall and disease free survival in a cohort of cytogenetically normal, young (<60) AML patients."	"Paschka et al., 2008, J. Clin. Oncol."	Somatic	ENST00000332351.3	exon_variant
WT1 Exon 7 Mutation	WT1	Exon 7 Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr11	32396257	32396407			"WT1 mutations were a negative prognostic factor for overall survival in young (15-60+, median 45) patients with cytogenetically normal AML."	"Virappane et al., 2008, J. Clin. Oncol."	Somatic	ENST00000332351.3	exon_variant
WT1 Exon 7 Mutation	WT1	Exon 7 Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr11	32396257	32396407			"WT1 mutations were associated with a higher cumulative incidence of relapse and shorter relapse free survival in young (15-60+, median 45) patients with cytogenetically normal AML."	"Virappane et al., 2008, J. Clin. Oncol."	Somatic	ENST00000332351.3	exon_variant
CD44 CD44s Expression	CD44	CD44s Expression	Cancer	RG7356	Predictive	Supports	D	Sensitivity/Response	chr11	35139181	35230027			"CD44 isoform expression (especially CD44s) was identified to predict response to CD44 antibody RG7356 preclinically. Retrospective evaluation of 13 patients from a phase 1 study, treated with RG7356, identified 3 patients with CD44s isoform. 2/3 patients with CD44s had SD as best response. Overall, 5 patients had an OR."	"Birzele et al., 2015, Clin. Cancer Res."	N/A	ENST00000428726.2	N/A
MEN1 FRAMESHIFT TRUNCATION	MEN1	FRAMESHIFT TRUNCATION	Thyroid Gland Hurthle Cell Carcinoma		Diagnostic	Supports	C	Positive	chr11	64804620	64804620	C		Two patients diagnosed with oncocytic thyroid carcinoma (hurthle cell thyroid carcinoma) were evaluated for MEN1 mutations.  One tumor showed 592-end deletion of MEN1 and the other showed a 521 frameshift mutation.  These mutations are similar to the ones seen in MEN1 syndrome inducing endocrine gland tumors.	"Kasaian et al., 2015, J. Clin. Endocrinol. Metab."	Somatic	ENST00000337652.1	frameshift_truncation
GSTP1 Deletion	GSTP1	Deletion	Ovarian Carcinoma	"Carboplatin,Paclitaxel,Cisplatin"	Predictive	Supports	D	Sensitivity/Response	chr11	67583595	67586660			"Stable GSTP1 knockdown in ovarian carcinoma A2780 cell lines showed increased sensitivity to platinum-based chemotherapy drugs carboplatin, cisplatinum, carboplatin, and paclitaxel. For each drug, 3 biological replicates were performed for this study, and effectiveness was evaluated using an MTT assay. There was not a significant difference in sensitivity to other chemotherapy drugs such as gemcitabine, topotecan, and doxorubicin."	"Sawers et al., 2014, Br. J. Cancer"	Somatic	ENST00000398606.3	transcript_ablation
CCND1 Overexpression	CCND1	Overexpression	Breast Cancer		Diagnostic	Supports	B	Positive	chr11	69641087	69654474			Cyclin D1 overexpression is associated with the ER-positive subtype of breast cancer.	"Arnold et al., 2005, J. Clin. Oncol."	N/A	ENST00000227507.2	N/A
CCND1 Expression	CCND1	Expression	Lung Non-small Cell Carcinoma		Prognostic	Does Not Support	B	Poor Outcome	chr11	69641087	69654474			Three studies have found no significant survival impact for CCND1 in lung cancer.	"Gautschi et al., 2007, Lung Cancer"	Somatic	ENST00000227507.2	N/A
CCND1 Amplification	CCND1	Amplification	Lung Non-small Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr11	69641087	69654474			Inceased copy number of CCND1 is associated with poorer overall survival.	"Gautschi et al., 2007, Lung Cancer"	Somatic	ENST00000227507.2	transcript_amplification
CCND1 Expression	CCND1	Expression	Lung Non-small Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr11	69641087	69654474			Three studies have associated CCND1 expression with poorer survival.	"Gautschi et al., 2007, Lung Cancer"	Somatic	ENST00000227507.2	N/A
CCND1 Overexpression	CCND1	Overexpression	Breast Cancer		Prognostic	Supports	B	Poor Outcome	chr11	69641087	69654474			"In ER-positive breast cancer patients, Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis."	"Arnold et al., 2005, J. Clin. Oncol."	N/A	ENST00000227507.2	N/A
CCND1 Overexpression	CCND1	Overexpression	Head And Neck Squamous Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr11	69641087	69654474			Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in head and neck squamous cell carcinoma.	"Thomas et al., 2005, Int J Exp Pathol"	N/A	ENST00000227507.2	N/A
CCND1 Overexpression	CCND1	Overexpression	Mantle Cell Lymphoma		Prognostic	Supports	B	Poor Outcome	chr11	69641087	69654474			Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in mantle cell lymphoma.	"Jares et al., 2007, Nat. Rev. Cancer"	N/A	ENST00000227507.2	N/A
CCND1 Overexpression	CCND1	Overexpression	Estrogen-receptor Positive Breast Cancer	Tamoxifen	Predictive	Supports	B	Resistance	chr11	69641087	69654474			The authors performed a tissue microarray analysis of 167 postmenopausal breast cancers that had been randomized to treatment with or without tamoxifen.  ER +ve patients with high CCND1 tumor expression did not show any difference in survival between tamoxifen and no treatment.	"Stendahl et al., 2004, Br. J. Cancer"	N/A	ENST00000227507.2	N/A
CCND1 Amplification	CCND1	Amplification	Breast Cancer	Tamoxifen	Predictive	Does Not Support	B	Resistance	chr11	69641087	69654474			"In this retrospective analysis, CCND1 amplification was analyzed in 442 patients. No interaction with treatment was observed."	"Keilty et al., 2013, PLoS ONE"	Somatic	ENST00000227507.2	transcript_amplification
CCND1 Amplification	CCND1	Amplification	Skin Melanoma	"Paclitaxel,Carboplatin,Sorafenib"	Predictive	Supports	B	Sensitivity/Response	chr11	69641087	69654474			"Retrospective analysis of somatic mutations and copy number changes in 119 patient treated with carboplatin, paclitaxel,  sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved progression-free survival (PFS) compared with CP in patients with tumors with CCND1 gene copy gains (HR, 0.45; P = 0.035)."	"Wilson et al., 2016, Clin. Cancer Res."	Somatic	ENST00000227507.2	transcript_amplification
CCND1 Overexpression	CCND1	Overexpression	Mantle Cell Lymphoma	Palbociclib	Predictive	Does Not Support	B	Sensitivity/Response	chr11	69641087	69654474			"A pharmacodynamic study (NCT00420056) of 17 mantle cell lymphoma MCL patients was performed using the CDK4/6 inhibitor palbociclib (PD0332991). Patients were verified by IHC, FISH or molecular testing for the t(11:14) rearrangement causing Cyclin D overexpression in MCL. 1 patient demonstrated complete response, and 2 showed partial response for an 18% overall response rate. 7 patients showed stable disease. Patient population was heavily pretreated."	"Leonard et al., 2012, Blood"	N/A	ENST00000227507.2	N/A
CCND1 Amplification	CCND1	Amplification	Renal Cell Carcinoma	Palbociclib	Predictive	Does Not Support	D	Sensitivity/Response	chr11	69641087	69654474			"28 renal cell carcinoma cell lines were tested for sensitivity to CDK4/6 inhibitor Palbociclib (PD0332991). 19 were reported sensitive, and 9 resistant. 15 of the 28 cell lines had high levels of Cyclin D1 (CCND1) expression which did not correlate significantly with palbociclib sensitivity (p=0.348)."	"Logan et al., 2013, Anticancer Res."	Somatic	ENST00000227507.2	transcript_amplification
CCND1 Amplification	CCND1	Amplification	Breast Cancer	Palbociclib	Predictive	Supports	D	Sensitivity/Response	chr11	69641087	69654474			"A panel of 47 breast cancer cell lines was tested for sensitivty/resistance to CDK4/6 inhibitor Palbociclib (PD0332991),  where IC50 below 150nM was sensitive, and above 1000nM resistant. Cyclin D1 had higher expression levels in sensitive cell lines."	"Finn et al., 2009, Breast Cancer Res."	Somatic	ENST00000227507.2	transcript_amplification
CCND1 Overexpression	CCND1	Overexpression	Mantle Cell Lymphoma	Palbociclib	Predictive	Supports	D	Sensitivity/Response	chr11	69641087	69654474			"In Mantle Cell Lymphoma (MCL), t(11:14)-induced overexpression of cyclin D1 was targeted by CDK4/6 inhibitor Palbociclib (PD0332991). Palbociclib caused Rb dephosphorylation in MCL cell lines and patient derived tumor cells. MCL cell lines overexpressing cyclin D1 showed growth inhibition with Palbociclib. The VAL DLBCL cell line was used as control to verify cyclin D1 overexpression but was not used as a control in Palbociclib inhibitor experiments. Instead, the investigators report that other publications report cell lines without cyclin D1 overexpression had higher IC50 values for palbociclib, suggesting overexpresssed cyclin D1 targetability in MCL."	"Marzec et al., 2006, Blood"	N/A	ENST00000227507.2	N/A
CCND1 Amplification	CCND1	Amplification	Ovarian Cancer	Palbociclib	Predictive	Does Not Support	D	Sensitivity/Response	chr11	69641087	69654474			A panel of 40 ovarian cancer cell lines with varied mutation profiles was assayed for sensitivity to the cdk4/6 inhibitor palbociclib (PD0332991) via measurement of IC50 values for inhibition of proliferation. Large variation in palbociclib sensitivity was observed and cell lines (N=40) were classified as above (resistant) or below (sensitive) the mean log of all IC50 values. 6/18 (33%) of the resistant lines and in only 1/22 (5%) of the sensitive lines (P = 0.017) had CCND1 copy number gain. Increased CCND1 expression was not correlated with sensitivity to palbociclib (p=0.671).	"Konecny et al., 2011, Clin. Cancer Res."	Somatic	ENST00000227507.2	transcript_amplification
CCND1 Overexpression	CCND1	Overexpression	Childhood B-cell Acute Lymphoblastic Leukemia		Prognostic	Supports	B	Poor Outcome	chr11	69641087	69654474			"Reverse phase protein array (RPPA) revealed upregulation of CCND1 at diagnosis in B-ALL relapse patients (n=27) versus patients that did not relapse (n=86, p>.01). 5-year cumulative incidence of relapse analysis showed B-ALL patients within this cohort with CCND1 expression at diagnosis above the 75th percentile had a higher incidence of relapse versus those below the 75th percentile. CCND1 upregulation appears to impact relapse 500 days post initial diagnosis."	"Bortolozzi et al., 2018, Biochem. Pharmacol."	N/A	ENST00000227507.2	N/A
FGF3 Amplification	FGF3	Amplification	Breast Cancer	Dovitinib	Predictive	Supports	B	Sensitivity/Response	chr11	69810224	69819024			"81 patients were enrolled in a clinical trial with the FGFR inhibitor dovitinib. Four of these patients had FGF3 amplifications (qPCR) and showed tumor reductions of 100%, 30.8%, 23.0%, and 7.5%, respectively. 3 of these 4 patients also had FGFR1 amplifications (? copies by qPCR) and the fourth presented with FGFR1-gene gain (3.4 copies of FGFR1 by qPCR and SISH negative)."	"Andr et al., 2013, Clin. Cancer Res."	N/A	ENST00000334134.2	transcript_amplification
RSF1 Amplification	RSF1	Amplification	Breast Cancer	Tamoxifen	Predictive	Supports	B	Resistance	chr11	77659996	77821017			"In retrospective study, 413 patients were assessed for RSF1 amplification. 28 patients with RSF1 amplification did not show a benefit from adjuvant tamoxifen compared to placebo (12 treated vs 16 placebo). 381 patients without amplification did show a benefit compared to placebo (187 treated vs 194 placebo)."	"Keilty et al., 2013, PLoS ONE"	Somatic	ENST00000308488.6	transcript_amplification
MRE11 Loss	MRE11	Loss	Endometrial Cancer	Talazoparib	Predictive	Supports	D	Sensitivity/Response	chr11	94419729	94493908			One endometrial cell line with decreased MRE11 expression caused by a homozygous poly(T) mutation exhibited increased sensitivity to the PARP inhibitor BMN-673. Loss of MRE11 was identified in 30.7% of endometrial tumors (N=521).	"Koppensteiner et al., 2014, PLoS ONE"	N/A	ENST00000323929.3	loss_of_function_variant
MRE11 Frameshift	MRE11	Frameshift	Prostate Cancer	Olaparib	Predictive	Supports	B	Sensitivity/Response	chr11	94419729	94493908			"One patient in a cohort of 50 patients with metastatic prostate cancer had a frameshift mutation in the MRE11, ATM, MLH3 and NBN genes and showed clinical response to PARP inhibitor olaparib (16 weeks on Treatment)."	"Mateo et al., 2015, N. Engl. J. Med."	Somatic	ENST00000323929.3	frameshift_variant
PGR Expression	PGR	Expression	Breast Cancer		Prognostic	Supports	B	Better Outcome	chr11	101029624	101130524			"In patients with breast cancer, those with expression of PgR (determined by immunohistochemical staining) had better relapse-free survival than those without expression."	"Dowsett et al., 2006, Ann. Oncol."	N/A	ENST00000325455.5	N/A
PGR Expression	PGR	Expression	Breast Cancer	Tamoxifen	Predictive	Does Not Support	B	Sensitivity/Response	chr11	101029624	101130524			"In patients with ER-Positive breast cancer, expression of PgR does not effect the outcome of treatment with tamoxifen."	"Patani et al., 2013, Int. J. Cancer"	N/A	ENST00000325455.5	N/A
PGR Expression	PGR	Expression	Breast Cancer	"Exemestane,Tamoxifen"	Predictive	Does Not Support	B	Sensitivity/Response	chr11	101029624	101130524			"Multivariate Cox regression analysis showed no disease free survival benefit for exemestane compared with tamoxifen in either PgR-low (n=984; HR, 0.85; 95% CI, 0.61 to 1.19) or PgR-high (n=3,341; HR, 0.83; 95% CI, 0.65 to 1.05) breast cancer patients (P=.88 for interaction)."	"Bartlett et al., 2011, J. Clin. Oncol."	N/A	ENST00000325455.5	N/A
PGR Expression	PGR	Expression	Breast Cancer		Prognostic	Supports	B	Poor Outcome	chr11	101029624	101130524			"In patients with breast cancer, those with low expression of PgR had worse disease-free survival than those with high expression."	"Bartlett et al., 2011, J. Clin. Oncol."	N/A	ENST00000325455.5	N/A
BIRC3 TRUNCATING MUTATION	BIRC3	TRUNCATING MUTATION	Chronic Lymphocytic Leukemia		Prognostic	Supports	B	Poor Outcome	chr11	102330999	102337102			"BIRC3 mutations were identified in 23 of 919 screened  CLLs. They are strongly linked to non-mutated IGHV genes (18/23, P = 0.0001), a widely recognized prognostic signature for poor outcome."	"Baliakas et al., 2015, Leukemia"	Somatic	ENST00000263464.3	frameshift_variant
ATM Mutation	ATM	Mutation	Glioblastoma	Temozolomide	Predictive	Supports	D	Sensitivity/Response	chr11	108222832	108369099			Glioblastoma cell lines were shown to have increased sensitivity to Temozolomide when siRNA-induced ATM knockdown was applied.	"Eich et al., 2013, Mol. Cancer Ther."	Somatic	ENST00000278616.4	"transcription_variant,loss_of_function_variant"
ATM Mutation	ATM	Mutation	Melanoma	Temozolomide	Predictive	Supports	D	Sensitivity/Response	chr11	108222832	108369099			Melanoma cell lines were shown to have increased sensitivity to Temozolomide when siRNA-induced ATM knockdown was applied.	"Eich et al., 2013, Mol. Cancer Ther."	Somatic	ENST00000278616.4	"transcription_variant,loss_of_function_variant"
ATM Underexpression	ATM	Underexpression	Cancer	"NU7441,KU-0060648"	Predictive	Supports	D	Sensitivity/Response	chr11	108222832	108369099			ATM-deficient H1395 and HT144 cancer cell lines showed growth inhibition when treated with DNA PKcs inhibitors KU-0060648 and NU7441. These agents also increased the lifespan of mice transfused with ATM-deficient lymphoma cells when compared with etoposide or control.	"Riabinska et al., 2013, Sci Transl Med"	Somatic	ENST00000278616.4	N/A
ATM Mutation	ATM	Mutation	Hematologic Cancer	Olaparib	Predictive	Supports	D	Sensitivity/Response	chr11	108222832	108369099			"Olaparib was found to inhibit cancer cell growth in ATM mutant cell lines of several blood cancers including Lymphoblastoid Leukemia, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, and in a murine xenograft model of Mantle Cell Lymphoma."	"Weston et al., 2010, Blood"	Somatic	ENST00000278616.4	"transcription_variant,loss_of_function_variant"
ATM Underexpression	ATM	Underexpression	Gastric Adenocarcinoma	Olaparib	Predictive	Supports	D	Sensitivity/Response	chr11	108222832	108369099			Low ATM protein expression led to sensitivity to PARP inhibitors in TP53 -ve gastric cancer cell lines (8 lines were used for various aspects of this study).	"Kubota et al., 2014, Cell Cycle"	N/A	ENST00000278616.4	N/A
ATM Underexpression	ATM	Underexpression	Pancreatic Cancer		Prognostic	Supports	B	Poor Outcome	chr11	108222832	108369099			"Absent expression of ATM, as assessed by IHC in 133 pancreatic ductal adenocarcinomas, was found to be associated with dismal prognosis (median survival, 9.6 months), whereas expression of ATM was associated with increased survival (17.7 months, P = 0.001). Furthermore loss of expression of nuclear phosphorylated Ser1981-ATM (IHC) was indicative of the worst prognosis (median survival, 10.8 vs 14.3 months [low expression] vs 31.1 months [high expression], P < 0.001)."	"Kamphues et al., 2015, Pancreas"	N/A	ENST00000278616.4	N/A
ATM Mutation	ATM	Mutation	Chronic Lymphocytic Leukemia		Prognostic	Supports	A	Poor Outcome	chr11	108222832	108369099			"In a study of 406 previously untreated CLL cases, a multivariate analysis indicated that aberrations (N=44; mixed pathogenic germline and somatic) in exons 2-63 of ATM were significantly associated with shorter time to first treatment (HR: 1.36; 95% CI: 1.05-1.76; P = 0.021). These mutations were not significantly associated with overall survival."	"Nadeu et al., 2016, Blood"	N/A	ENST00000278616.4	"transcription_variant,loss_of_function_variant"
ATM Underexpression	ATM	Underexpression	Chronic Lymphocytic Leukemia		Prognostic	Supports	B	Poor Outcome	chr11	108222832	108369099			"43 B-CLL patients with LoH or reduced protein levels (<50% normal expression, radioimmunoassay, western blot) of ATM were found to have significantly shorter overall survival (35.6 vs. 97.3 months; P=0.003) when compared to 108 patients with normal expression levels."	"Starostik et al., 1998, Cancer Res."	N/A	ENST00000278616.4	N/A
ATM Mutation	ATM	Mutation	Mantle Cell Lymphoma	Olaparib	Predictive	Supports	D	Sensitivity/Response	chr11	108222832	108369099			Two ATM deficient mantle cell lymphoma (MCL) cell lines were more sensitive to PARP-1 inhibition with olaparib or PJ-34 than 4 other MCL cell lines. shRNA mediated ATM knockdown in a cell line increased sensitivity to olaparib. These results were confirmed in a xenograft model.	"Williamson et al., 2010, Mol. Cancer Ther."	Somatic	ENST00000278616.4	"transcription_variant,loss_of_function_variant"
ATM Mutation	ATM	Mutation	Chronic Lymphocytic Leukemia	Doxorubicin	Predictive	Supports	D	Resistance	chr11	108222832	108369099			"Primary cells from chronic lymphocytic leukemia patients were treated with doxorubicin to induce double-strand (DSB). In this setting, cells harboring rare ATM variants (n=8) had significantly higher viability, measured by mitochondrial dehydrogenase activity, compared to wildtype cells (n=8, p < 0.001) suggesting resistance. A qPCR functional assay showed that samples with rare ATM variants (n= 20) had significantly less p21 expression after treatment with doxorubicin compared to treated wildtype controls (n=31, p < 0.001). Furthermore, there was significantly decreased expression of BBC3, BAX, and GADD45 genes which are downstream of ATM in the DNA damage response. In the above studies, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for p21 induction to confirm wildtype p53."	"Navrkalova et al., 2013, Haematologica"	Somatic	ENST00000278616.4	"transcription_variant,loss_of_function_variant"
ATM Mutation	ATM	Mutation	Chronic Lymphocytic Leukemia		Prognostic	Supports	B	Poor Outcome	chr11	108222832	108369099			"ATM point mutations were found in 8/57 patients with CLL and were associated with a shorter treatment-free interval, suggesting a more aggressive course."	"Guarini et al., 2012, Haematologica"	Somatic	ENST00000278616.4	"transcription_variant,loss_of_function_variant"
ATM Underexpression	ATM	Underexpression	Stomach Cancer	"Paclitaxel,Olaparib"	Predictive	Supports	B	Sensitivity/Response	chr11	108222832	108369099			"A randomized phase 2 trial investigating the efficiency of Olaparib plus Paclitaxel vs. Placebo plus Paclitaxel in recurrent or metastatic gastric cancer patients. 123 patients received treatment. Combination treatment did not significantly improve ORR (26,4% vs 19,1%) or PFS (3,91m vs 3,55 m) but OS (13,8 m vs. 8,3 m) in the overall cohort.  A subcohort of ATM low expressing tumours (14%) experienced a greater improvement of OS (not reached vs. 8,2 m) and a trend towards improved PFS (5,29 m vs 3,68 m)."	"Bang et al., 2015, J. Clin. Oncol."	N/A	ENST00000278616.4	N/A
ATM Mutation	ATM	Mutation	Prostate Carcinoma	Olaparib	Predictive	Supports	A	Sensitivity/Response	chr11	108222832	108369099			"This study (PMID 32343890) by de Bono et al, is a randomized, open-label, phase 3 trial evaluating the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone).The study found that in men with mCRPC who had disease progression while receiving enzalutamide or abiraterone and who had somatic or germline deleterious alterations (irrespective of zygosity) in any of the following HRR genes (BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L), olaparib was associated with longer progression-free survival and better measures of response and patient- reported end points than either enzalutamide or abiraterone (PFS HR 0.49 [0.38, 0.63]). For patients with ATM mutations specifically, PFS HR 1.04 [0.61-1.87]. Based on the results of this study, On May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA) for adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC, who have progressed following prior treatment with enzalutamide or abiraterone."	"de Bono et al., 2020, N. Engl. J. Med."	Unknown	ENST00000278616.4	"transcription_variant,loss_of_function_variant"
ATM K293*	ATM	K293*	Chronic Lymphocytic Leukemia	Doxorubicin	Predictive	Supports	D	Resistance	chr11	108245002	108245002	A	T	"Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the K293* variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the K293* variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 92% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance."	"Navrkalova et al., 2013, Haematologica"	Somatic	ENST00000278616.4	stop_gained
ATM K468FS	ATM	K468FS	Chronic Lymphocytic Leukemia	Doxorubicin	Predictive	Does Not Support	D	Resistance	chr11	108250867	108250868	AA		"Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the K468FS variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the K468FS variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 91% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in p21 expression greater than 300% that of untreated wild-type controls. This was considered by the authors to be similar to treated wild-type controls with a median expression level 815% that of untreated controls suggesting this variant does not support resistance."	"Navrkalova et al., 2013, Haematologica"	Somatic	ENST00000278616.4	frameshift_variant
ATM F1025L	ATM	F1025L	Chronic Lymphocytic Leukemia	Doxorubicin	Predictive	Supports	D	Resistance	chr11	108271404	108271404	T	G	"Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the F1025L variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the F1025L variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 93% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance."	"Navrkalova et al., 2013, Haematologica"	Somatic	ENST00000278616.4	missense_variant
ATM D1682H	ATM	D1682H	Chronic Lymphocytic Leukemia	Doxorubicin	Predictive	Supports	D	Resistance	chr11	108299752	108299752	G	C	"Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the D1682H variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the D1682H variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 93% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance."	"Navrkalova et al., 2013, Haematologica"	Somatic	ENST00000278616.4	missense_variant
ATM D1930V	ATM	D1930V	Chronic Lymphocytic Leukemia	Doxorubicin	Predictive	Supports	D	Resistance	chr11	108310186	108310186	A	T	"Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the D1930V variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the D1930V variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 88% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in p21 expression greater than 300% that of untreated wild-type controls. This was considered by the authors to be similar to treated wild-type controls with a median expression level 815% that of untreated controls suggesting this variant does not support resistance."	"Navrkalova et al., 2013, Haematologica"	Somatic	ENST00000278616.4	missense_variant
ATM A2062V	ATM	A2062V	Chronic Lymphocytic Leukemia	Doxorubicin	Predictive	Supports	D	Resistance	chr11	108316100	108316100	C	T	"Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the A2062V variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the A2062V variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 87% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance."	"Navrkalova et al., 2013, Haematologica"	Somatic	ENST00000278616.4	missense_variant
ATM E2187*	ATM	E2187*	Chronic Lymphocytic Leukemia	Doxorubicin	Predictive	Supports	D	Resistance	chr11	108321407	108321407	G	T	"Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the E2187* variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the E2187* variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 96% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance."	"Navrkalova et al., 2013, Haematologica"	Somatic	ENST00000278616.4	stop_gained
ATM S2289*	ATM	S2289*	Prostate Cancer	Olaparib	Predictive	Supports	C	Sensitivity/Response	chr11	108326113	108326114	TC		"Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. Overall, 4/6 patients (3/5 with no other identified aberrations in DNA repair genes) with several germline and somatic aberrations of ATM had a response. Responders included a single patient with a somatic frameshift mutation (ATM V2288fs*1) predicted to result in truncation prior to the PI3K catalytic domain and other domains for p53 recognition and response to DNA damage. No other alterations in ATM were observed; however, this patient also had frameshift mutations in MLH3, MRE11 and NBN."	"Mateo et al., 2015, N. Engl. J. Med."	Somatic	ENST00000278616.4	frameshift_truncation
ATM L2427P	ATM	L2427P	Chronic Lymphocytic Leukemia	Doxorubicin	Predictive	Supports	D	Resistance	chr11	108329211	108329211	T	C	"Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the L2427P variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the L2427P variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 94% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance."	"Navrkalova et al., 2013, Haematologica"	Unknown	ENST00000278616.4	missense_variant
ATM T2666A	ATM	T2666A	Chronic Lymphocytic Leukemia	Doxorubicin	Predictive	Supports	D	Resistance	chr11	108333954	108333954	A	G	"Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. Cells were treated with doxorubicin to induce double-strand (DSB) and p21 induction was monitored by qPCR. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the T2666A variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 91% of cells by FISH. Western blot showed null ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance."	"Navrkalova et al., 2013, Haematologica"	Somatic	ENST00000278616.4	missense_variant
ATM F2732V	ATM	F2732V	Chronic Lymphocytic Leukemia	Doxorubicin	Predictive	Supports	D	Resistance	chr11	108335887	108335887	T	G	"Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the F2732V variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. A patient sample had the F2732V variant of ATM, confirmed by sanger sequencing, in trans with a loss of function 11q deletion found in 98% of cells by FISH. Western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance."	"Navrkalova et al., 2013, Haematologica"	Somatic	ENST00000278616.4	missense_variant
ATM N2875H	ATM	N2875H	Prostate Cancer	Olaparib	Predictive	Supports	C	Sensitivity/Response	chr11	108347317	108347317	A	C	"Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. Overall, 4/6 patients (3/5 with no other identified aberrations in DNA repair genes) with several germline and somatic aberrations of ATM had a response. Responders included a single patient with a somatic missense mutation (ATM N2875H) and no other alterations in ATM or other DNA repair genes."	"Mateo et al., 2015, N. Engl. J. Med."	Somatic	ENST00000278616.4	missense_variant
ATM R3008C	ATM	R3008C	Chronic Lymphocytic Leukemia	Doxorubicin	Predictive	Supports	D	Resistance	chr11	108365359	108365359	C	T	"Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. The effect of the R3008C variant on ATM expression was tested by western blot, and the effect on ATM function was tested by treating with doxorubicin to induce double-strand breaks (DSB) and monitoring p21 induction. To confirm wild type p53, parallel cell cultures were treated with fludarabine generating single-strand breaks, in addition to DSB, and monitored for adequate p21 induction. In a patient sample with the R3008C variant of ATM in trans with a wild-type allele, confirmed by sanger sequencing, western blot showed stable ATM expression. Treatment with doxorubicin resulted in a p21 expression level of less than 300% that of untreated wild-type controls. This was much lower than the median expression level of treated controls which was 815% that of untreated controls, supporting resistance. The authors propose that this variant has a dominant-negative effect."	"Navrkalova et al., 2013, Haematologica"	Somatic	ENST00000278616.4	missense_variant
ROBO4 EXPRESSION	ROBO4	EXPRESSION	Cancer	Angiogenesis Inhibitor	Predictive	Does Not Support	B	Sensitivity/Response	chr11	124883691	124898281			"Biomarkers for Response to antiangiogenic treatment were screened for in hepatocellular cancer (n = 11), renal cell cancer (n = 7) and non-small cell lung cancer (n = 2). Increased expression of tumor endothelial markers: Robo4 and ECSCR, nonsignificantly correlated with prolonged antiangiogenic time to progression (ECSCR high = 275 days vs. ECSCR low = 92.5 days; p = 0.07 and for Robo4 high = 387 days vs. Robo4 low = 90.0 days; p = 0.08)."	"Pircher et al., 2016, Oncotarget"	N/A	ENST00000306534.3	N/A
EWSR1 EWSR1::FLI1	EWSR1	EWSR1::FLI1	Ewing Sarcoma		Diagnostic	Supports	B	Positive	chr11	128768118	128813267			"t(11;22) rearrangements of EWSR1-FLI1 are diagnostic of ewing sarcoma, and are observed in 90% of cytogenetic samples."	"Warren et al., 2013, Hum. Pathol."	Somatic	ENST00000414183.2	transcript_fusion
EWSR1 EWSR1::FLI1	EWSR1	EWSR1::FLI1	Ewing Sarcoma Of Bone		Diagnostic	Supports	B	Positive	chr11	128768118	128813267			A total of 85 unrelated cases of Ewing's sarcoma were examined and 83% we found to harbor the t(11;22)(q24;q12) chromosomal abnormality (EWS/FLI).	"Turc-Carel et al., 1988, Cancer Genet. Cytogenet."	Somatic	ENST00000414183.2	transcript_fusion
EWSR1 EWSR1::FLI1	EWSR1	EWSR1::FLI1	Ewing Sarcoma Of Bone		Diagnostic	Supports	B	Positive	chr11	128768118	128813267			"The authors propose RT-PCR as a diagnostic test for Ewing sarcoma using FFPE materials.  Starting with 40 cases, intact RNA could be isolated from 6, and of these the EWS-FLI event was detected in 2 by nested PCR. Alternative diagnostic assays for this event are also considered."	"Park et al., 1998, J. Korean Med. Sci."	Somatic	ENST00000414183.2	transcript_fusion
EWSR1 EWSR1::FLI1	EWSR1	EWSR1::FLI1	Ewing Sarcoma Of Bone		Diagnostic	Supports	B	Positive	chr11	128768118	128813267			"An evaluation of alternative strategies for detection of EWS-FLI (FISH break apart, FISH fusion, and RT-PCR).  Of the 22 informative EWS/PNETs, 20 cases (91%) were positive by FISH break apart, FISH fusion, or both."	"Bridge et al., 2006, Mod. Pathol."	Somatic	ENST00000414183.2	transcript_fusion
FLI1 EWSR1::FLI1 e7-e6	FLI1	EWSR1::FLI1 e7-e6	Ewing Sarcoma		Prognostic	Supports	B	Better Outcome	chr11	128805366	128813267			"In patients with Ewing's sarcoma, those with type 1 EWS-FLI1 fusions had longer overall survival than those with other types of EWS-FLI1 fusions."	"de Alava et al., 1998, J. Clin. Oncol."	Somatic	ENST00000397938.2	transcript_fusion
CCND2 PROMOTER DEMETHYLATION	CCND2	PROMOTER DEMETHYLATION	Stomach Cancer		Diagnostic	Supports	D	Negative	chr12	4272271	4273771			CCND2 hypomethylation is seen to be more common in stage III and IV gastric tumors than stage I and II.	"Oshimo et al., 2003, Int. J. Oncol."	Somatic	ENST00000261254.3	N/A
CCND2 OVEREXPRESSION	CCND2	OVEREXPRESSION	Stomach Cancer		Prognostic	Supports	D	Poor Outcome	chr12	4273772	4305350			Cyclin D2 overexpression is associated with poor prognosis in gastric cancers.	"Takano et al., 1999, J. Pathol."	Somatic	ENST00000261254.3	N/A
CCND2 OVEREXPRESSION	CCND2	OVEREXPRESSION	Stomach Cancer		Prognostic	Supports	D	Poor Outcome	chr12	4273772	4305350			Cyclin D2 overexpression is associated with the increased depth of cancer invasion in gastric cancers.	"Takano et al., 1999, J. Pathol."	Somatic	ENST00000261254.3	N/A
CCND2 OVEREXPRESSION	CCND2	OVEREXPRESSION	Stomach Cancer		Prognostic	Supports	D	Poor Outcome	chr12	4273772	4305350			Cyclin D2 overexpression is associated with the presence pf lymph node metastasis in gastric cancers.	"Takano et al., 1999, J. Pathol."	Somatic	ENST00000261254.3	N/A
CCND2 OVEREXPRESSION	CCND2	OVEREXPRESSION	Stomach Cancer		Prognostic	Supports	D	Poor Outcome	chr12	4273772	4305350			Cyclin D2 overexpression is associated with vascular invasion by cancer cells in gastric cancers.	"Takano et al., 1999, J. Pathol."	Somatic	ENST00000261254.3	N/A
NTRK3 ETV6::NTRK3	NTRK3	ETV6::NTRK3	Mammary Analogue Secretory Carcinoma	Entrectinib	Predictive	Supports	C	Sensitivity/Response	chr12	11649854	11869969			Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an ETV6-NTRK3 fusion. The patient was treated with entrectinib and exhibited a partial response for 7 months followed by disease progression.	"Drilon et al., 2016, Ann. Oncol."	Somatic	ENST00000396373.4	transcript_fusion
NTRK3 ETV6::NTRK3	NTRK3	ETV6::NTRK3	Mammary Analogue Secretory Carcinoma	Crizotinib	Predictive	Does Not Support	C	Sensitivity/Response	chr12	11649854	11869969			Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an ETV6-NTRK3 fusion. The patient was treated with crizotinib and had stable disease but disease progression after 18 weeks. The patient was subsequently treated with entrectinib and exhibited a partial response for 7 months followed by disease progression.	"Drilon et al., 2016, Ann. Oncol."	Somatic	ENST00000396373.4	transcript_fusion
NTRK3 ETV6::NTRK3	NTRK3	ETV6::NTRK3	Congenital Fibrosarcoma	Larotrectinib	Predictive	Supports	A	Sensitivity/Response	chr12	11649854	11869969			"Four out of six patients with infantile fibrosarcoma and a ETV6-NTRK3 fusion had a partial response, the remaining two had a complete response with larotrectinib. Treatment was done within a multicentre, open-label, phase 1/2 study and enrolled infants, children, and adolescents aged 1 month to 21 years with locally advanced or metastatic solid tumours or CNS tumours that had relapsed, progressed, or were non-responsive to available therapies regardless of TRK fusion Status. In total, 24 patients (n=17 with tumours harbouring TRK fusions, n=7 without a documented TRK fusion) were enrolled. Among the fusion-positive patients, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer. 14 (93%) of 15 patients with TRK fusion-positive cancers achieved an objective response; the remaining patient had tumour regression that did not meet the criteria for objective response. None of the seven patients with TRK fusion-negative cancers had an objective response."	"Laetsch et al., 2018, Lancet Oncol."	Somatic	ENST00000396373.4	transcript_fusion
NTRK3 ETV6::NTRK3	NTRK3	ETV6::NTRK3	Congenital Fibrosarcoma	Larotrectinib	Predictive	Supports	C	Sensitivity/Response	chr12	11649854	11869969			"Nagasubramanian et al reports on a case of refractory infantile fibrosarcoma (IFS) with constitutive activation of the tropomyosinrelated kinase (TRK) signaling pathway from an ETS variant gene 6neurotrophin 3 receptor gene (ETV6NTRK3) gene fusion. The patient was diagnosed with IFS at 6 months of age. At 16 months the patient enrolled in a pediatric Phase 1 trial of LOXO?01 (Larotrectinib, ARRY-470), an experimental, highly selective inhibitor of TRK. The patient experienced a rapid, radiographic response, demonstrating the potential for LOXO?01 to provide benefit for IFS harboring NTRK gene fusions."	"Nagasubramanian et al., 2016, Pediatr Blood Cancer"	Somatic	ENST00000396373.4	transcript_fusion
NTRK3 ETV6::NTRK3	NTRK3	ETV6::NTRK3	Thyroid Gland Papillary Carcinoma		Prognostic	Supports	B	Poor Outcome	chr12	11649854	11869969			"Prasad et al queried the histopathology of 28 Papillary Thyroid Carcinomas (PTCs) from patients ages 6-18 years (20 females, 8 males). None had significant exposure to radiation. 5 / 27 PTCs (18.5%) had NTRK3-ETV6 fusion oncogenes. The authors compare NTRK3-ETV6 (and include 2 other NTRK fusion samples) to PTCs with BRAF(V) (600E) and find they are associated with large size (mean, 2.2 cm vs 1.5 cm, respectively; P = .05), solid and diffuse variants (11 of 13 vs 0 of 13 tumors, respectively; P < .001), and lymphovascular invasion (12 of 13 vs 6 of 13 tumors, respectively; P = .02); The authors conclude that NTRK fusion oncogene PTC presents with more extensive disease and aggressive pathology than BRAF(V) (600E) PTC in the pediatric population."	"Prasad et al., 2016, Cancer"	Somatic	ENST00000396373.4	transcript_fusion
NTRK3 ETV6::NTRK3	NTRK3	ETV6::NTRK3	Breast Secretory Carcinoma	Larotrectinib	Predictive	Supports	C	Sensitivity/Response	chr12	11649854	11869969			"Shukla et al report on a remarkable case study of a 14 year old pediatric patient with refractory secretory breast carcinoma first presenting as a fibroadenoma at 8 yo. Over the next years, she experienced recurrence, multiple rounds of chemotherapy and metastasis -- until her case was presented at a virtual multidisciplinary tumor board organized by the Global Cancer Institute which recommended testing for ETV6-NTRK3 fusion. This fusion was confirmed by RNA-seq, targeted DNA and WGS sequencing as well as immunohistochemistry staining with a TRK antibody. The patient was treated with LOXO-101 (larotrectinib) in a single patient use protocol. Within two months, she experienced near complete resolution of a 10.4  8.5 cm fungating chest mass with multiple satellite lesions (See Figure 2). The authors note that TERT promoter mutation and a reciprocal inversion including CDKN2A were also identified, but given what is known about LOXO-101 and ETV6-NTRK3, they  infer ETV6-NTRK3 fusion as the primary mitogenic driver in this patient."	"Shukla et al., 2017, JCO Precis Oncol"	Somatic	ENST00000396373.4	transcript_fusion
NTRK3 ETV6::NTRK3	NTRK3	ETV6::NTRK3	B-lymphoblastic Leukemia/lymphoma	Larotrectinib	Predictive	Supports	D	Sensitivity/Response	chr12	11649854	11869969			"Both in vivo and in vitro models demonstrated Larotrectinib was an effective treatment against cells harboring ETV6-NTRK3. In YFP-luciferase PDX mice from a 16-year-old with Ph-like B-ALL, flow cytometry indicated the absence of leukemic cells in the bone marrow (p<.0001), peripheral blood (p=.0018), and spleen (p=.0001) after 6 weeks of Larotrectinib (n=10) compared to vehicle treated mice (n=10). Treated mice also had lower splenic weight (p<.001) and the absence of leukemia burden in the bone marrow and central nervous system as determined by histopathology. In 2 mice, leukemic burden increased while Larotrectinib was paused from weeks 6-25. Upon the reintroduction of treatment for 4 weeks, leukemic burden was lowered. Conditional knock-in Etv6-NTRK CD19-Cre cells isolated from bone marrow and cultured ex vivo were highly sensitive to serial dilutions of Larotrectinib. After 48 hours of Larotrectinib exposure, Ba/F3 cells stably expressing ETV6-NTRK3 demonstrated a response with an IC50 of 17.0nM (viability measured by CellTiter blue). Finally, Larotrectinib was 1000x more potent against 3 human cancer cell lines with an NTRK fusion versus the 76 with other alterations. The most sensitive was an AML cell line (M0-91) with an ETV6-NTRK3 fusion."	"Roberts et al., 2018, Blood"	Somatic	ENST00000396373.4	transcript_fusion
NTRK3 ETV6::NTRK3	NTRK3	ETV6::NTRK3	Congenital Fibrosarcoma	Larotrectinib	Predictive	Supports	C	Sensitivity/Response	chr12	11649854	11869969			"In a pediatric phase 1 trial (NCT02637687) after initial chemotherapy failure, two ETV6-NTRK3 positive children (2 year old and 5 month old) were treated with Larotrectinib, resulting in reduced tumor burden (4 cycles showed ~50% reduction). Treatment was followed up by surgical resection resulting in a disease-free status at the time of last follow-up (>1 year)."	"DuBois et al., 2018, Cancer"	Somatic	ENST00000396373.4	transcript_fusion
NTRK3 ETV6::NTRK3	NTRK3	ETV6::NTRK3	Solid Tumor	Larotrectinib	Predictive	Supports	A	Sensitivity/Response	chr12	11649854	11869969			"In this phase 1 dose-escalation study seventy patients with metastatic solid tumours were enrolled. Eight patient tumours were found to harbour NTRK gene fusions, six of which were ETV6-NTRK3. Treatment with larotrectinib resulted in reduced tumour burden for all patients with NTRK fusions. The average time on treatment was 28.4 months for patients with NTRK fusion cancer, compared to 1.8 months for those without an NTRK fusion."	"Hong et al., 2019, Ann. Oncol."	Somatic	ENST00000396373.4	transcript_fusion
NTRK3 ETV6::NTRK3	NTRK3	ETV6::NTRK3	B-lymphoblastic Leukemia/lymphoma	Larotrectinib	Predictive	Supports	C	Sensitivity/Response	chr12	11649854	11869969			"Case report of a 61-year-old man with B-ALL. An initial analysis detected the ETV6-NTRK3 fusion and a NRASGly12Asp mutation. Initial therapies included chemotherapy and CAR-T infusion. Relapse 6 weeks after initial complete response to these therapies found a large increase in fusion transcripts and NTRK3 rearrangements were detectable by FISH in 50/50 blast nuclei whereas NRAS mutations were no longer detectable. The patient was treated with oral monotherapy larotrectinib (100mg twice per day). After 4 days on treatment peripheral blood blasts became undetectable; after 6 days on treatment lymphadenopathy and leukemia cutis resolved and a biopsy revealed an ablated bone marrow with only a few scattered blasts. The patient experienced clinical benefit with no apparent side effects during 42 days of larotrectinib treatment, however, patient eventually succumbed to multifocal angioinvasive aspergillosis because of insufficient recovery of normal hematopoiesis. Later sequencing of the NTRK3 kinase domain did not detect any larotrectinib resistance mutations (p.G623R, p.G696A)."	"Nardi et al., 2020, Blood Adv"	Somatic	ENST00000396373.4	transcript_fusion
NTRK3 ETV6::NTRK3	NTRK3	ETV6::NTRK3	Acute Myeloid Leukemia	Entrectinib	Predictive	Supports	D	Sensitivity/Response	chr12	11649854	11869969			"Two AML cell lines, IMS-M2 and M0-91, with the ETV6-NTRK3 fusion were treated with entrectinib.  Sequencing of these cell lines found no other driver mutations in 265 other cancer genes suggesting the ETV6-NTRK3 fusion is the oncogenic driver.  The IC50 for the IMS-M2 and M0-91 cell lines was 0.47 and 0.65 nmol/L, respectively.  Mouse xenografts treated with entrectinib at 10 or 30 mg/kg had complete remission while treatment with 3 mg/kg caused significant reduction in tumor growth.  Testing of the bone marrow of IMS-M2 xenografts after 3 weeks of treatment found no human CD45-positive cells in the 3, 10, and 30 mg/kg treatment groups; all vehicle treated mice had some human CD45-positive cells in their bone marrow.  Zebrafish xenotransplantation of M0-91 cells were sensitive to entrectinib treatment."	"Smith et al., 2018, Mol. Cancer Ther."	Somatic	ENST00000396373.4	transcript_fusion
NTRK3 ETV6::NTRK3	NTRK3	ETV6::NTRK3	Congenital Fibrosarcoma		Diagnostic	Supports	A	Positive	chr12	11649854	11869969			"This is the first study showing the ETV6-NTRK3 gene fusion in congenital fibrosarcoma (CFS). Using cytogenetic and FISH analyses, a novel t(12;15)(p13;q25) rearrangement was identified in CFS cases (3 of 4, including 1 case likely presenting overgrowth of normal fibroblasts). Mapping of breakpoints and mRNA analysis revealed that the translocation gives rise to the ETV6-NTRK3 fusion transcript, consisting of the HLH dimerization domain of ETV6 fused to the kinase domain of NTRK3. This aberration was absent in adult-type fibrosarcoma (ATFS, 2 cases) and infantile fibromatosis (IFB, 15 cases). This is the first study describing the involvement of NTRK proteins in human oncogenesis and ETV6 gene fusion in solid tumors and proposing ETV6-NTRK3 as a diagnostic biomarker for CFS."	"Knezevich et al., 1998, Nat. Genet."	Somatic	ENST00000396373.4	transcript_fusion
NTRK3 ETV6::NTRK3	NTRK3	ETV6::NTRK3	B-lymphoblastic Leukemia/lymphoma	"Etoposide,Larotrectinib,Methotrexate"	Predictive	Supports	C	Sensitivity/Response	chr12	11649854	11869969			"All lines of conventional therapy (including allogeneic HSCT, blinatumomab, and CAR T cells) were inefficient for a 6-year-old boy with B-cell ALL and CNS infiltration (National Cancer Institute high risk). Conventional cytogenetics, FISH, and an Abbott break-apart probe of a peripheral blood sample collected at diagnosis revealed an unbalance translocation of the ETV6 locus. The patient relapsed twice and RNA sequencing of the initial diagnosis sample revealed a cytogenetically cryptic ETV6-NTRK3 fusion. Treatment with larotrectinib was initiated in combination with etoposide and methotrexate resulted in molecular remission in 66 days in bone marrow and CNS. A third relapse occurred 45 days after Larotrectinib was paused for CAR-T infusions. Larotrectinib was resumed with a dosage increase and again achieved sustained undetectable minimal residual disease after 66 days, and displayed molecular remission through 39 days. The authors suggest larotrectinib as a potential effective treatment for B-cell ALL patients harboring ETV6-NTRK3, including those with CNS infiltration."	"Schewe et al., 2019, Blood Adv"	Somatic	ENST00000396373.4	transcript_fusion
NTRK3 ETV6::NTRK3	NTRK3	ETV6::NTRK3	B-lymphoblastic Leukemia/lymphoma	Larotrectinib	Predictive	Supports	D	Sensitivity/Response	chr12	11649854	11869969			"Conventional cytogenetics, FISH, and an Abbott break-apart probe of a peripheral blood sample collected at diagnosis of a 6-year-old boy with B-cell ALL and CNS infiltration (National Cancer Institute high risk) revealed an unbalance translocation of the ETV6 locus. RNA sequencing of detected a cytogenetically cryptic ETV6-NTRK3 fusion. Larotrectinib therapy achieved remission of the patients two separate relapses. Patient derived xenografts injected into mice and treated with Larotrectinib demonstrated significant reductions in spleen volume, blasts in spleen, and blast in bone marrow (p < .0001) compared to controls 25 days after injection. Larotrectinib treatment was effective regardless of the day of initiation post xenograft injection (1 day or 8 days after)."	"Schewe et al., 2019, Blood Adv"	Somatic	ENST00000396373.4	transcript_fusion
NTRK3 ETV6::NTRK3	NTRK3	ETV6::NTRK3	B-lymphoblastic Leukemia/lymphoma		Oncogenic	Supports	D	Oncogenicity	chr12	11649854	11869969			"The tyrosine kinase domain of NTRK3 was inserted into exon 6 of Etv6 to create conditional knock-in Etv6-NTRK3 mice . Expression was induced in pre-b cells during lymphoid development by CD19-Cre. Fusion expression in the bone marrow was confirmed by RT-PCR. Etv6-NTRK3/+ CD19-Cre mice developed aggressive lymphoid leukemia. Compared to controls (Etv6-NTRK3/+; n=28), Etv6-NTRK3/+ CD19-Cre mice (n=27) displayed worse overall survival (p<.0001), decreased body weight (p<.0001), increased spleen weights (p<.05), and increased circulating CD19+/B220+ cells (p=.0008). Over 60% of Etv6-NTRK3 CD19-Cre mice demonstrated extramedullary tumors and over 50% presented with central nervous system infiltration. RNA-sequencing indicated upregulation of the AP1 complex in the Etv6-NTRK3 CD19-Cre mice. The authors conclude this ETV6-NTRK3 Cre-19 mouse model mimics human B-ALL."	"Roberts et al., 2018, Blood"	Somatic	ENST00000396373.4	transcript_fusion
NTRK3 ETV6::NTRK3	NTRK3	ETV6::NTRK3	Congenital Mesoblastic Nephroma		Diagnostic	Supports	B	Positive	chr12	11649854	11869969			"A frequent genetic alteration is the translocation t(12;15) resulting in a fusion of the ETV6 gene on 12p13 and the NTRK3 gene on 15p15 that occurs almost exclusively in cellular MN.  In a group of 111 mesoblastic nephroma (MN) samples, 79 were were evaluable by FISH, which consisted of 38 classical MN, 29 cellular MN, and 12 mixed MN samples. 16 of 29 cellular type MN had ETV6::NTRK3 via break apart FISH, while 0/38 classical and 0/12 mixed types were positive."	"Vokuhl et al., 2018, Pediatr Blood Cancer"	Somatic	ENST00000396373.4	transcript_fusion
NTRK3 ETV6::NTRK3	NTRK3	ETV6::NTRK3	Congenital Fibrosarcoma		Diagnostic	Supports	B	Positive	chr12	11649854	11869969			"In this study, a collection of pediatric spindle cell tumors were screened for the ETV6::NTRK3 fusion by RT-PCR.  10 of 11 (91%) cases diagnosed as congenital fibrosarcoma were found to harbor the ETV6::NTRK3 fusion while none of the 51 other malignant or benign spindle cell tumors (including adult-type fibrosarcoma, infantile fibromatosis, myofibromatosis, and more aggressive malignant spindle cell tumors) were positive for this fusion.  The authors conclude ETV6::NTRK3 RT-PCR analysis is a reliable and specific modality to aid in the diagnosis of this disease."	"Bourgeois et al., 2000, Am J Surg Pathol"	Somatic	ENST00000396373.4	transcript_fusion
NTRK3 ETV6::NTRK3	NTRK3	ETV6::NTRK3	Congenital Fibrosarcoma		Diagnostic	Supports	B	Positive	chr12	11649854	11869969			"In this study, the ETV6::NTRK3fusion was detected in 7 of 10 (70%) of congenital fibrosarcomas by RT-PCR but absent in 38 other control spindle cell tumors,  including adult-type fibrosarcomas, leiomyosarcomas, malignant fibrous histiocytomas,  synovial sarcomas, MPNST, dermatofibrosarcoma protuberans,  schwannomas, fibromatosis cases, and nodular fasciitis cases.  This demonstrates utility of ETV6::NTRK3 fusion  detection in diagnosis of this disease."	"Sheng et al., 2001, Am J Clin Pathol"	Somatic	ENST00000396373.4	transcript_fusion
NTRK3 ETV6::NTRK3	NTRK3	ETV6::NTRK3	Congenital Mesoblastic Nephroma		Diagnostic	Supports	B	Positive	chr12	11649854	11869969			"In an analysis of 19 cases of mesoblastic nephroma, the ETV6::NTRK3 fusion was detected in 0 of 5 of the classic mesoblastic nephroma, 8 of 8 (100%) of the cellular mesoblastic nephroma and 5 of 6 (83%) of the mixed mesoblastic nephroma cohorts."	"El Demellawy et al., 2016, Pathology"	Somatic	ENST00000396373.4	transcript_fusion
NTRK3 ETV6::NTRK3	NTRK3	ETV6::NTRK3	Congenital Mesoblastic Nephroma		Diagnostic	Supports	B	Positive	chr12	11649854	11869969			"In an analysis of 22 cases of mesoblastic nephroma, 4 of 5 (80%) cellular mesoblastic nephromas harbored ETV6::NTRK3, 1 of 5 cellular mesoblastic nephromas harbored a KLHL7::BRAF fusion, 12 of 12 (100%) classic mesoblastic nephromas harbored EGFR ITD, 4 of 5 of mixed histology had EGFR ITD, and 1 of 5 of mixed histology had the  ETV6::NTRK3 fusion."	"Zhao et al., 2020, Histopathology"	Somatic	ENST00000396373.4	transcript_fusion
CDKN1B CYTOPLASMIC MISLOCALIZATION	CDKN1B	CYTOPLASMIC MISLOCALIZATION	Breast Cancer	Lapatinib	Predictive	Supports	D	Resistance	chr12	12717124	12722371			Cytoplasmic localization of p27 (CDKN1B) leads to lapatinib resistance in HER2+ breast cancer cell lines. p27 knockout resensitiuzed cells to lapatinib.	"Zhao et al., 2014, Oncotarget"	Somatic	ENST00000228872.4	N/A
CDKN1B EXPRESSION	CDKN1B	EXPRESSION	Head And Neck Squamous Cell Carcinoma	"Cisplatin,Fluorouracil"	Predictive	Supports	B	Sensitivity/Response	chr12	12717124	12722371			"41 HNSSC were analyzed by IHC for expression of EGFR, p53, CCND1, p16, p21, p27 (CDKN2B), p-AKT, HIF-1a, Caspase 3 and BCL2. p27 was the only protein that served as a predictive biomarker of response after multivariate analysis (p=0.025; n=41 patients)."	"Moreno-Galindo et al., 2014, Oral Oncol."	N/A	ENST00000228872.4	N/A
KRAS Mutation	KRAS	Mutation	Ovarian Cancer	Decitabine	Predictive	Supports	D	Sensitivity/Response	chr12	25209431	25250803			"KRAS mutation or amplification predicted sensitivity to decitabine in ovarian cancer cell lines. The authors profiled the response of 45 ovarian, melanoma, and breast cancer cell lines over 9 days of treatment with decitabine. 4 ovarian lines with KRAS mutation were among the most sensitive to decitabine."	"Stewart et al., 2015, Cancer Res."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Endometrial Cancer	"Temsirolimus,Ridaforolimus"	Predictive	Does Not Support	B	Sensitivity/Response	chr12	25209431	25250803			"94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed. Mutations were found in 32 of 73 analyzed tumors, 10 of which were KRAS mutations. No predictive biomarkers were identified, including PIK3CA mutations, KRAS mutations or PTEN loss."	"Mackay et al., 2014, Cancer"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Cancer	Trametinib	Predictive	Supports	D	Sensitivity/Response	chr12	25209431	25250803			"In this screen of 218 solid cancer cell lines, KRAS and BRAF mutations were predictive of response to MEK inhibitor GSK1120212. 40 cell lines harbored a KRAS mutation. In RAF/RAS mutant colon cancer cell lines, co-occurring PIK3CA/PTEN mutations led to a cytostatic (9/10 cell lines) response rather than a cytotoxic response (1/10 cell lines)."	"Jing et al., 2012, Mol. Cancer Ther."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Colorectal Cancer	"Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,Immunomodulatory Oligonucleotide"	Predictive	Supports	D	Sensitivity/Response	chr12	25209431	25250803			TLR9 agonist immunomodulatory oligonucleotide (IMO) led to inhibited survival of LS174T colorectal cancer and AsPC1 pancreatic cancer cell lines with KRAS mutations.	"Rosa et al., 2011, Clin. Cancer Res."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Colorectal Cancer	"Cetuximab,Dasatinib"	Predictive	Supports	D	Sensitivity/Response	chr12	25209431	25250803			"Combined treatment with dasatinib and cetuximab, but not either agent in monotherapy, had an antitumor efficacy in-vitro and in xenografts. These results were based on three KRAS mutant cell lines (LS180, LoVo and HCT116) and two KRAS wild-type cell lines (SW48 and CaCo2)."	"Dunn et al., 2011, Oncogene"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Colorectal Cancer	"B-Raf/VEGFR-2 Inhibitor RAF265,Selumetinib"	Predictive	Supports	D	Sensitivity/Response	chr12	25209431	25250803			"SiRNA Screening in 37 KRAS Mutant colorectal cancer cell lines identified RAF1 and MEK Inhibition as synergistic, whereas MEK Inhibition alone led to quick resistance via upregulation of RAF-signalling. This finding could be reproduced in colorectal and lung cancer cell lines in a second, independent screen."	"Lamba et al., 2014, Cell Rep"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Lung Non-small Cell Carcinoma	"Selumetinib,B-Raf/VEGFR-2 Inhibitor RAF265"	Predictive	Supports	D	Sensitivity/Response	chr12	25209431	25250803			"SiRNA Screening in 37 KRAS Mutant colorectal cancer cell lines identified RAF1 and MEK Inhibition as synergistic, whereas MEK Inhibition alone led to quick resistance via upregulation of RAF-signalling. This finding was reproduced two NSCLC cell lines in a second, independent shRNA screen."	"Lamba et al., 2014, Cell Rep"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Colorectal Cancer	"Trametinib,Afatinib"	Predictive	Supports	D	Sensitivity/Response	chr12	25209431	25250803			An shDNA Screen identified synergy betwenn ERBB3 Inhibition and MEK Inhibition in KRAS mutated cell lines. Dual EGFR/ERBB2 Inhibitors afatinib and dacomitinib and MEK Inhibition was synergistic in colorectal and lung cancer cell lines. Induction of ERBB3 signalling was also identified in a patient with KRAS mutation after MEK inhibition with trametinib.	"Sun et al., 2014, Cell Rep"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Lung Non-small Cell Carcinoma	"Afatinib,Trametinib"	Predictive	Supports	D	Sensitivity/Response	chr12	25209431	25250803			An shDNA screen identified synergy between ERBB3 Inhibition and MEK Inhibition in KRAS mutated cell lines. Dual EGFR/ERBB2 Inhibitors afatinib and dacomitinib and MEK Inhibition was synergistic in colorectal and lung cancer cell lines. Induction of ERBB3 signalling was also identified in a patient with KRAS mutation after MEK inhibition with trametinib.	"Sun et al., 2014, Cell Rep"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Lung Non-small Cell Carcinoma	MEK Inhibitor RO4987655	Predictive	Does Not Support	B	Resistance	chr12	25209431	25250803			"This was a phase I expansion and pharmacodynamic study of oral MEK inhibitor RO4987655 on advanced cancer. Of 18 patients with KRAS mutant non-small cell lung cancer (NSCLC), 10 experienced clinical benefit: 2 partial responses and 8 patients experiencing stable disease for longer than 8 weeks. The median days on treatment was 58.5 (13-394) with one patient ongoing treatment at the end of the study period (56 weeks). The response rate of patients with KRAS mutant NSCLC was 11%, and 71% showed decrease in metabolic response (less FDG uptake in FDG-PET analysis). All responders showed decreases in FDG-uptake. There was not a significant decrease in Ki67 expression between day 1 and day 15 of treatment. Authors conclude that RO4987655 has some clinical activity in KRAS mutated NSCLC, though patients with KRAS wild-type NSCLC were excluded from this expansion study, so it is not possible to determine whether activity of RO4987655 in NSCLC is related to KRAS mutation status."	"Zimmer et al., 2014, Clin. Cancer Res."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Colorectal Cancer	MEK Inhibitor RO4987655	Predictive	Does Not Support	B	Sensitivity/Response	chr12	25209431	25250803			"Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). All 25 patients with KRAS mutant colorectal cancer experienced PD. Median days on treatment was 57 (5-269). Among the patients with KRAS mutant cancer, 52% showed decrease in metabolic response (less FDG uptake in FDG-PET analysis). There was not a significant decrease in Ki67 expression between day 1 and day 15 of treatment. The authors concluded that RO4987655 does not have clinical activity in patients with KRAS mutant advanced colorectal cancer."	"Zimmer et al., 2014, Clin. Cancer Res."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Lung Non-small Cell Carcinoma	"Selumetinib,Docetaxel"	Predictive	Supports	B	Sensitivity/Response	chr12	25209431	25250803			"87 patients with KRAS mutant stage IIB-IV NSCLC after first line therapy were randomly assigned (1:1) to oral selumetunib and docetaxel or docetaxel and Placebo. Median OS was 94 months (68-136) in selumetinib group and 52 months (95% CI 38-non-calculable) in placebo group (hazard ratio [HR] for death 080, 80% CI 056-114; one-sided p=021). Median PFS was 53 months (46-64) in selumetinib group and 21 months (95% CI 14-37) in placebo group (HR for progression 058, 80% CI 042-079; one-sided p=0014). An objective response was observed in 16 (37%) patients in the selumetinib group and none in the placebo group(p<00001)."	"Jnne et al., 2013, Lancet Oncol."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Colorectal Cancer	Refametinib	Predictive	Does Not Support	C	Sensitivity/Response	chr12	25209431	25250803			"Phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766. 4 patients with KRAS +/- PIK3CA mutant colorectal cancer. 3 with SD, 1 with PD."	"Weekes et al., 2013, Clin. Cancer Res."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Pancreatic Adenocarcinoma	"PI3Kbeta Inhibitor AZD8186,SCH772984"	Predictive	Supports	D	Sensitivity/Response	chr12	25209431	25250803			"Inhibition of ERK in 11 KRAS mutant pancreatic cancer cell lines with SCH772984 was more effective than MEK Inhibition. Combined Treatment with PI3K Inhibitor AZD8186 was more effective than either agent alone. Chemical library screen in two cell lines also identified mTOR, AKT Family Inhibitors (Temsirolimus, Everolimus) to act synergistically with ERK Inhibition."	"Hayes et al., 2016, Cancer Cell"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Colorectal Cancer	"Teprotumumab,Selumetinib"	Predictive	Supports	D	Sensitivity/Response	chr12	25209431	25250803			"Preclinial data from KRAS mutant colorectal cancer cell lines show syngergistic effect on cell viability and apoptosis in vitro and in vivo when MEK and IGF-IR are inhibited concomitantly. In other cell lines, activation of other RTKs (such as MET) were observed upon MEK Inhibition and combination of RTKi and METi also showed synergistic activity. A total of 16 cell lines were used in this study. 6 were KRAS wild type, and 10 harbored various KRAS mutations (G12C, G12D, G12V, G13D, and Q61L). Additional data was obtained from xenografts."	"Ebi et al., 2011, J. Clin. Invest."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Colorectal Cancer	"Chemotherapy,Bevacizumab"	Predictive	Supports	B	Resistance	chr12	25209431	25250803			"Meta-Analysis of 12 studies with 2,266 patients (54 % were KRAS wt). The pooled response rates (RR) for KRAS wild-type (wt) versus mutated (mut) patients were 54.8 and 48.3 %, respectively (OR 1.42, P = 0.02). Median PFS in KRAS wild-type patients was significantly longer than in KRAS mut patients (HR = 0.85; 95 % confidence interval (CI) 0.74-0.98; P = 0.02). Median OS in wild-type KRAS patients compared was significantly better than in KRAS mut patients (HR = 0.65; 95 % CI 0.46-0.92; P = 0.01)."	"Petrelli et al., 2013, Med. Oncol."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Cancer	"MEK Inhibitor GDC-0623,G-573"	Predictive	Supports	D	Sensitivity/Response	chr12	25209431	25250803			"Preclinical study analyzing the differential response to MEK Inhibitors in KRAS and BRAF mutant cancer cell lines and mouse xenografts. Efficacy of MEK inhibitors (GDC-0623 and G-573) in KRAS-driven tumours is mediated by a hydrogen-bond interaction with S212 in MEK that is critical for blocking MEK feedback phosphorylation by wild-type RAF. This mechanism was distinct from GDC-0973 which is less potent in KRAS mutant tumors. Overall, this work indicates that MEK inhibitors with this mechanism of action will be most effective in patients with both BRAF and KRAS mutations."	"Hatzivassiliou et al., 2013, Nature"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Colorectal Cancer	Ixazomib	Predictive	Supports	D	Resistance	chr12	25209431	25250803			"Preclinical study in colorectal cancer xenografts. KRAS-G13D or KRAS-G12V mutations were introduced into KRAS-WT SW48 cell line. KRAS wild-type, but not KRAS mutant tumors were sensitive to proteasome inhibitor ixazomib"	"Chattopadhyay et al., 2015, PLoS ONE"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Cancer	AZD5438	Predictive	Supports	D	Sensitivity/Response	chr12	25209431	25250803			"CDK1 was identified in a preclinical siRNA screen to identify targets in KRAS mutant tumors. Cell viability was evaluated following knockdown of 834 genes in isogenic LIM1215 colorectal cancer cell lines harboring wildtype (parental), G12S, G12D or G12V KRAS. 6 targets identified by this screen were evaluated in a second set of isogenic colorectal cancer cell lines (SW48) harboring wildtype (parental), G12S, G12D, G12V or G13D KRAS where only CDK1 knockdown more profoundly reduced survival in mutant cells compared to wildtype. Results were validated in 5 KRAS mutant (BRAF WT) and 10 KRAS WT colorectal cancer cell lines. Chemical inhibition of CDK1 by AZD5438 in KRAS mutant vs WT pancreatic and colorectal cancer cell lines showed increased efficacy in mutant cell lines. Finally, AZD5438 reduced tumor growth induced by SW620 (KRAS p.G12V) colorectal tumour cells xenografted into immunodeficient mice."	"Costa-Cabral et al., 2016, PLoS ONE"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Lung Adenocarcinoma	Salirasib	Predictive	Does Not Support	B	Sensitivity/Response	chr12	25209431	25250803			"In a study of 30 lung adenocarcinoma patients with documented KRAS mutations, farnesylthiosalicylic acid (Salirasib) mono-therapy resulted in no partial responses and did not improve overall survival rates compared to previously untreated patients."	"Riely et al., 2011, J Thorac Oncol"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Lung Non-small Cell Carcinoma	Trametinib	Predictive	Supports	B	Sensitivity/Response	chr12	25209431	25250803			"In a phase 1 clinical trial for the use of trametinib for various advanced solid tumors, 22 out of 30 NSCLC patients harbored KRAS mutations. Of those 22 patients with mutant KRAS, 8 saw reductions in tumor size ranging from 6-52% including 2 partial responses."	"Infante et al., 2012, Lancet Oncol."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Amplification	KRAS	Amplification	Skin Melanoma	"Sorafenib,Docetaxel,Carboplatin"	Predictive	Supports	B	Sensitivity/Response	chr12	25209431	25250803			"Retrospective analysis of somatic mutations and copy number changes in 119 patients treated with carboplatin, paclitaxel,  sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved overall survival compared with CP in patients with tumors positive for KRAS gene copy gains (HR = 0.25; P = 0.035)."	"Wilson et al., 2016, Clin. Cancer Res."	N/A	ENST00000256078.4	transcript_amplification
KRAS Mutation	KRAS	Mutation	Pseudomyxoma Peritonei		Prognostic	Supports	B	Poor Outcome	chr12	25209431	25250803			40 patients with pseudomyxoma peritonei underwent panel sequencing after cytoreductive surgery and hypertermic intraperitoneal chemotherapy (HIPEC). KRAS mutations were found in 72% of samples and KRAS mutations were independently associated with PFS (p=0.012) after multivariate analysis.	"Pietrantonio et al., 2016, Ann. Oncol."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Hepatocellular Carcinoma	"Refametinib,Sorafenib"	Predictive	Supports	B	Sensitivity/Response	chr12	25209431	25250803			"Phase 2 study in Asian patients with unresectable hepatocellular carcinoma. 70 patients received refametinib (BAY 86-9766) plus sorafenib as study treatment. A retrospective biomarker analysis was performed in 69 patients for KRAS, NRAS and BRAF mutations (BEAM technology). 4 patients were identified to harbor RAS mutations. 3 of whom still received study treatment at the cutoff date used for the final data analysis. These 3 patients had achieved confirmed PR, with duration responses ranging from 128 to 382 days. The fourth patient with a RAS mutation discontinued study treatment after 41 days on therapy due to PD. An overall of 4 (6 by modified RECIST) patients achieved PR."	"Lim et al., 2014, Clin. Cancer Res."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Lung Adenocarcinoma		Prognostic	Supports	B	Poor Outcome	chr12	25209431	25250803			"In a study of 1036 patients with lung adenocarcinoma, patients with KRAS mutations (n=241) showed worse prognosis (OS: 19 months versus 23 months; HR=1.21; P=0.048)."	"Johnson et al., 2013, Cancer"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Colorectal Cancer	Cetuximab	Predictive	Supports	D	Resistance	chr12	25209431	25250803			"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab."	"Bertotti et al., 2011, Cancer Discov"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	B	Resistance	chr12	25209431	25250803			"In advanced-stage (IIIB or IV) non-small cell lung cancer patients treated with erlotinib and placebo, patients whose tumors harbored KRAS mutations (n=8) had a lower 12-week progression-free survival rate (0% vs. 37%, P=0.0390) compared to wildtype KRAS patients (n=35). Authors concluded that KRAS mutation was associated with poor response to erlotinib monotherapy."	"Ramalingam et al., 2011, J. Clin. Oncol."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Lung Non-small Cell Carcinoma	"Gefitinib,Erlotinib"	Predictive	Supports	B	Resistance	chr12	25209431	25250803			"In a retrospective study, 166 non-small cell lung cancer (NSCLC) patients that tended to have selected characteristics known to be predictive for TKI sensitivity (i.e. women, never smokers, and patients with ADC) were treated with either gefitinib or erlotinib. KRAS mutations (n=11) were associated with lack of objective response to drug treatment (0.0% vs. 35.7%, p=0.03), no significant difference in overall survival (19.3 vs. 28.6 months, p=0.47), and shorter median time to progression (2.7 vs. 5.6 months, p=0.003) when compared to wild-type KRAS. Through multivariate analyses, it was shown that KRAS mutations were significant predictors of shorter time to progression (HR: 2.43, 95% CI: 1.23-4.79, p=0.01)."	"Ludovini et al., 2011, J Thorac Oncol"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Lung Non-small Cell Carcinoma	"Docetaxel,Selumetinib"	Predictive	Supports	A	Resistance	chr12	25209431	25250803			"A phase 3 study of selumetinib and docetaxel in KRAS mutant, previously treated NSCLC. 866 were enrolled and 510 randomized. Median progression-free survival was 3.9 months with selumetinib?docetaxel and 2.8 months with placebo?docetaxel. Median overall survival was 8.7 months with selumetinib?docetaxel and 7.9 months with placebo?docetaxel. Objective response rate was 20.1% with selumetinib?docetaxel and 13.7% with placebo?docetaxel."	"Jnne et al., 2017, JAMA"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Colorectal Cancer	"Cetuximab,Chemotherapy"	Predictive	Supports	B	Resistance	chr12	25209431	25250803			"This was a retrospective study of 605 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy. Patients with KRAS mutant tumors (total [n = 253], codon 12 [n=183], 13 [n=47], 59 [n=1], 61 [n=13], 146 [n=9]) had a significantly lower response rate (17/253; 6.7%) compared to patients with KRAS wt tumors (126/352; 35.8%; OR: .13; P < .0001). Patients with KRAS mutant tumors also experienced significant lower disease control rate, shorter median progression free survival and overall survival. Association between KRAS mutation status and outcome was confirmed in multivariate analysis. Authors note that these patients were treated with cetuximab prior to widespread adoption of regular KRAS mutational status screening. Patients treated with cetuximab or panitumumab monotherapy were not included."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Lung Non-small Cell Carcinoma	"Erlotinib,Teprotumumab"	Predictive	Supports	B	Sensitivity/Response	chr12	25209431	25250803			"In advanced-stage (IIIB or IV) non-small cell lung cancer patients treated with erlotinib daily and teprotumumab (R1507) weekly or every three weeks, patients whose tumors harbored KRAS mutations had similar progression free survival rates compared to patients with wt KRAS. Among patients given R1507 weekly, those whose tumors had KRAS mutations (n=16) had a 12-week progression free survival (PFS) rate of 25% compared to 30% for KRAS wt patients (n=27; p = 0.7436). For patients given R1507 (teprotumumab) every three weeks, 12-week PFS rate for patients with KRAS mt tumors (n=12) was 50% compared to 27% for patients with KRAS wt tumors (n=34; p=0.1350). Authors concluded that KRAS mutation was predictive of a favorable response to erlotinib + R1507 combination therapy."	"Ramalingam et al., 2011, J. Clin. Oncol."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Lung Non-small Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr12	25209431	25250803			"Analysis was performed on the placebo group (n=451) of the Phase III study SATURN using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherpy. The study was not powered for prognostic tests, but it was still found that KRAS Mutant status was a significant negative prognostic factor on progression free survival. (HR, 1.50; 95% CI, 1.06 to 2.12; P=0.20)"	"Brugger et al., 2011, J. Clin. Oncol."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	B	Resistance	chr12	25209431	25250803			"In the placebo-controlled Phase III study SATURN, using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherapy, KRAS mutation was assessed. In the KRAS wildtype group, erlotinib showed a significant benefit for progression free survival (PFS) over placebo (HR, 0.70; 95% CI, 0.57 to 0.87, P<0.001). No statistically significant improvement in PFS was seen with erlotinib in the KRAS mutant group over placebo. Significant difference in PFS between erlotinib treated KRAS WT and MUT patients was not seen.  Overall, in the intent to treat population erlotinib significantly improved PFS over placebo (HR, 0.71; 95% CI, 0.62 to 0.82; P<0.001)."	"Brugger et al., 2011, J. Clin. Oncol."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Lung Non-small Cell Carcinoma	Abemaciclib	Predictive	Supports	B	Sensitivity/Response	chr12	25209431	25250803			"In this multicenter phase I study of abemaciclib, a total of 225 patients were enrolled: 33 in dose escalation and 192 in tumor-specific cohorts. Radiographic responses were achieved in previously treated patients with breast cancer, NSCLC, and melanoma. The disease control rate for the KRAS-mutant population was 55% (16/29) compared to 39% (13/33)  in KRAS wildtype cohort. Stable disease lasting ?4 weeks was achieved for 31% (9/29) with KRAS-mutant disease vs 12% (4/33) with KRAS wild-type disease. Median PFS was 2.8 months and 1.9 months for the KRAS-mutant and KRAS wild-type populations, respectively."	"Patnaik et al., 2016, Cancer Discov"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Lung Non-small Cell Carcinoma	"Trametinib,Pemetrexed,Docetaxel"	Predictive	Supports	B	Sensitivity/Response	chr12	25209431	25250803			"This phase I/Ib two-part study evaluated trametinib in combination with anticancer agents docetaxel or pemetrexed in NSCLC with and without KRAS mutations. Confirmed partial response (PR) was observed in 21% (10/47) patients receiving trametinib/docetaxel. The ORR was 18% (4 PR in 22 patients) in KRAS wild-type versus 24% (six PR in 25 patients) in KRAS-mutant NSCLC. Of the 42 patients treated with trametinib/pemetrexed, 14% (6/42) had a PR; the ORR was 17% (4/23) in KRAS-mutated NSCLC versus 11% (2/19) in KRAS wild-type NSCLC."	"Gandara et al., 2017, J Thorac Oncol"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Lung Non-small Cell Carcinoma	"Nivolumab,Atezolizumab"	Predictive	Supports	B	Sensitivity/Response	chr12	25209431	25250803			"A meta-analysis of randomized trials to investigate if KRAS mutation status affects survival benefits of immune checkpoint inhibition (ICI) in patients with advanced NSCLC. Of 3 eligible studies using either nivolumab or atezolizumab, 138 patients with KRAS mutant NSCLC and 371 with KRAS wild-type were included. ICI improved overall survival over that with docetaxel in KRAS mutant, previously-treated advanced NSCLC (hazard ratio=0.64 [95% confidence interval, 0.43-0.96], P = 0.03) but not in those with KRAS wild-type tumor (HR = 0.88 [95% CI, 0.68-1.13], P = 0.30). These results suggest that KRAS mutation status may be a potential biomarker for survival benefits to ICIs."	"Kim et al., 2017, Oncotarget"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Lung Non-small Cell Carcinoma	Immune Checkpoint Inhibitor	Predictive	Supports	E	Sensitivity/Response	chr12	25209431	25250803			This meta-analysis of 5 studies with 752 non-small cell lung cancer patients examined the association between PD-L1 expression and KRAS mutation status. KRAS-mutant tumors were marginally more likely to be PD-L1 positive than KRAS-wild type tumors (51% vs 36%; odds ratio: 1.69; 95% CI 1.01-2.84; p = 0.045). Authors concluded that this result contributes to a theoretical basis for including PD-L1 inhibitors in combination with other molecularly targeted drugs in the treatment of patients with KRAS mutations.	"Li et al., 2017, Eur J Surg Oncol"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Colorectal Cancer	"Selumetinib,Cetuximab"	Predictive	Does Not Support	B	Sensitivity/Response	chr12	25209431	25250803			"A phase I study  to determine the tolerability and pharmacokinetics of Selumetinib and Cetuximab with an expanded cohort in KRAS-mutant CRC. In the KRAS-mutant CRC dose expansion cohort 14 patients were evaluable for response. Five patients experienced stable disease, nine had progressive disease.  Minimal anti-tumor activity was observed in KRAS-mutant refractory metastatic CRC."	"Deming et al., 2016, Invest New Drugs"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Lung Non-small Cell Carcinoma	Trametinib	Predictive	Does Not Support	B	Sensitivity/Response	chr12	25209431	25250803			"In this phase II trial, trametinib or docetaxel was given to patients with advanced KRAS-mutant NSCLC. Median PFS was 12 weeks in the trametinib arm and 11 weeks in the docetaxel arm (HR 1.14; p = 0.5197). Median OS, while the data are immature, was 8 months in the trametinib arm and was not reached in the docetaxel arm (HR 0.97; P = 0.934). There were 10 (12%) partial responses (PRs) in the trametinib arm and 5 (12%) PRs in the docetaxel arm (P = 1.0000). These data suggest that trametinib is associated with similar PFS and response rates as docetaxel."	"Blumenschein et al., 2015, Ann. Oncol."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Lung Non-small Cell Carcinoma	"Erlotinib,Selumetinib"	Predictive	Does Not Support	B	Sensitivity/Response	chr12	25209431	25250803			38 KRAS wild-type patients were randomized to erlotinib or combination of selumetinib with erlotinib. 41 KRAS mutant patients were randomized to selumetinib or the combination. The primary end points were progression-free survival (PFS) for the KRAS wild-type cohort and objective response rate (ORR) for the KRAS mutant cohort. Median PFS in the KRAS wild-type arm was 2.4 months for erlotinib alone and 2.1 months for the combination. The ORR in the KRAS mutant group was 0% for selumetinib alone and 10% for the combination. These data suggest no difference in ORR or PFS with combination therapy of over monotherapy in KRAS mutant and KRAS wild-type advanced NSCLC.	"Carter et al., 2016, Ann. Oncol."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Colorectal Cancer	"Palbociclib,Binimetinib"	Predictive	Supports	D	Sensitivity/Response	chr12	25209431	25250803			"A preclinical study to investigate the efficacy of Binimetinib, Palbociclib and the combination on KRAS mutant colorectal cancer cell lines, cell line-derived and patient-derived xenografts.   The combination of MEK and CDK4/6 inhibition inhibited cancer cell growth and caused cell regression in a synergistic manner Combination therapy markedly decreased levels of phosphorylated ribosomal protein S6 both in vitro and in vivo and decreased Ki67 staining in vivo."	"Lee et al., 2016, Oncotarget"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Lung Non-small Cell Carcinoma	"Docetaxel,Erlotinib"	Predictive	Does Not Support	B	Sensitivity/Response	chr12	25209431	25250803			"222 EGFR-wt patients with advanced NSCLC were randomized to receive docetaxel or erlotinib In this study (4 patients not eligible, leaving 109 in each arm). KRAS was mutated in 25 and 26 out of 109 patients in the erlotinib and docetaxel arm, respectively. KRAS was neither prognostic nor predictive of benefit for either docetaxel or erlotinib."	"Rulli et al., 2015, Ann. Oncol."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Lung Non-small Cell Carcinoma	Docetaxel	Predictive	Does Not Support	B	Sensitivity/Response	chr12	25209431	25250803			"Of the 275 patients assessable for KRAS mutation status, 49 (18%) were positive for KRAS mutation. There were no differences between treatments in OS, PFS, or response rates according to KRAS mutation status, and no evidence that KRAS mutation is a predictive factor for a differential survival effect between gefitinib and docetaxel."	"Douillard et al., 2010, J. Clin. Oncol."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Mutation	KRAS	Mutation	Colorectal Cancer	"Cetuximab,Panitumumab"	Predictive	Supports	A	Resistance	chr12	25209431	25250803			NCCN guidelines indicate colorectal cancer patients with KRAS mutations should not be treated with the anti-EGFR therapies cetuximab or panitumumab.	"Benson et al., 2017, J Natl Compr Canc Netw"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Amplification	KRAS	Amplification	Endometrial Cancer		Prognostic	Supports	B	Poor Outcome	chr12	25209431	25250803			"In this study, KRAS gain (KRAS/CEP12q ratio >1 and <2) or amplification (ratio >2) was detected in 3% (13 of 414) of the primary endometrial carcinomas investigated. Presence of KRAS gain or amplification were highly significantly associated with poor prognosis with a 46% 5-year survival compared with 87% for patients with unamplified status (P<0.001). Amplification of KRAS maintains its independent prognostic impact in Cox multivariate analysis when adjusted for age, histological subtype, grade and FIGO stage (HR=2.6, 95% CI: 1.2?.8, P=0.02). In contrast, presence of KRAS mutation did not influence prognosis (P=0.67)"	"Birkeland et al., 2012, Br. J. Cancer"	Somatic	ENST00000256078.4	transcript_amplification
KRAS Mutation	KRAS	Mutation	Melanoma	"Dabrafenib,Vemurafenib"	Predictive	Supports	B	Resistance	chr12	25209431	25250803			"In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired resistance to BRAF inhibitor (vemurafenib or dabrafenib) monotherapy. The following MAPK pathway variants were found in progressive tumors with patient matched baseline tumors (some patients donated samples from multiple geographically/temporally distinct progressive tumors): NRAS mutations (G12D, G12R, G13R, Q61K, Q61R, Q61L) in 13/71 (18%) of progressive tumors, KRAS mutations (G12C, G12R, Q61H) in 5/71 (7%) of progressive tumors, mutant BRAF amplification (2-15 fold or 4-75 copies) in 11/57 (19%) of progressive tumors, mutant BRAF alternative splice variants (novel exon boundaries between 1/9, 1/11, 3/9) in 6/48 (13%) of progressive tumor RNA."	"Shi et al., 2014, Cancer Discov"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Amplification	KRAS	Amplification	Melanoma	Vemurafenib	Predictive	Supports	D	Resistance	chr12	25209431	25250803			In vitro studies of M229 (a human melanoma cell line) endogenously expressing wildtype KRAS and BRAF V600E (a known BRAF sensitizing mutation) found that cells induced to stably over-express wildtype KRAS4a or KRAS4b (via viral transduction with additional copies of KRAS4a or KRAS4b) were more resistant to vemurafenib (a BRAFi) than cells transduced with empty vectors. Resistance was determined by assessing cell survival.	"Shi et al., 2014, Cancer Discov"	Somatic	ENST00000256078.4	transcript_amplification
KRAS Mutation	KRAS	Mutation	Ovary Serous Adenocarcinoma	Binimetinib	Predictive	Supports	B	Sensitivity/Response	chr12	25209431	25250803			"Post hoc analysis of a randomized phase 3 trial (MILO/ENGOT-ov11) suggests a possible association between KRAS mutation and response to binimetinib in patients with pretreated (1-3 lines of prior chemotherapy) recurrent or persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. Of 133 binimetinib-treated patients with individual response and molecular data, 46 harbored KRAS mutations. KRAS mutation status was significantly associated with local best response (P=0.004); 44% of patients with KRAS mutation versus 19% of patients with KRAS WT had CR or PR in the binimetinib arm. KRAS mutation was also associated with prolonged PFS in patients treated with binimetinib (median PFS: KRAS mutant: 17.7 months; KRAS wild-type (WT): 10.8 months; P = .006), but not in patients receiving standard chemotherapy (physicians' choice, median PFS: KRAS mutant: 14.6 months; KRAS WT: 11.5 months; P=.502)."	"Monk et al., 2020, J Clin Oncol"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Wildtype	KRAS	Wildtype	Colorectal Cancer	Regorafenib	Predictive	Does Not Support	D	Resistance	chr12	25209431	25250803			"In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS wildtype did not demonstrate resistance to regorafenib treatment (IC50: 114.28 nM) compared to SW48 cells expressing various common KRAS G12/G13 mutations. Resistance was determined by assessing cell viability. In vivo, SW48 cells were injected into NOD/SCID mice. Treatment with regorafenib did not lead to a significant delay of tumor growth, although KRAS wt mice trended toward better response than KRAS G12C expressing mice. IHC analysis of mouse tissue revealed more pronounced changes in markers of proliferation (Ki67), angiogenesis (CD31), and apoptosis (TUNEL) in KRAS wt mice treated with regorafenib compared to KRAS G12C mice whose tumors did not display changes in these markers. Authors concluded that KRAS wildtype was not resistant to regorafenib compared to other common KRAS G12/G13 mutations."	"Camaj et al., 2015, Future Oncol"	Somatic	ENST00000256078.4	wild_type
KRAS R164Q	KRAS	R164Q	Cancer		Oncogenic	Does Not Support	D	Oncogenicity	chr12	25215520	25215520	C	T	"NIH3T3 cells were transfected with control or KRAS R164Q plasmid and focus formation assays were performed. R164Q cells formed 0 foci > 5mm diameter per well, which was the same as wt cells. In contrast, known gain of function mutations KRAS G12V and G12D formed over 70 foci > 5mm diameter average per well. In conclusion, these data suggest that R164Q does not promote oncogenic transformation of NIH3T3 cells by loss of contact inhibition, and gives support for ClinGen/CGC/VICC Oncogenicity Code SBS2."	"Smith et al., 2010, Br. J. Cancer"	Somatic	ENST00000256078.4	missense_variant
KRAS A146V	KRAS	A146V	Lung Non-small Cell Carcinoma	Abemaciclib	Predictive	Supports	C	Sensitivity/Response	chr12	25225627	25225627	G	A	"Case report of a patient with metastatic lung adenocarcinoma. Whole exome sequencing of the metastatic tumor revealed KRAS A146V, STK11 frameshift deletion and ATM alteration. Preclinical evidence led to administration of CDK4 inhibitor LY2835219. Specifically, the PHIAL algorithm nominated this variant as actionable on the basis of a predicted synthetic lethal relationship between activated KRAS and CDK4. The patient achieved stable disease and was on treatment for 16 weeks which was the patients best and only clinical response to any cancer-directed therapy."	"Van Allen et al., 2014, Nat. Med."	Somatic	ENST00000256078.4	missense_variant
KRAS A146V	KRAS	A146V	Colorectal Cancer	"Dactolisib,Selumetinib"	Predictive	Supports	D	Sensitivity/Response	chr12	25225627	25225627	G	A	"In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring NRAS, KRAS, BRAF or PIK3CA mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors harbored KRAS mutations including 2 tumors with A146V mutations which achieved stable disease with combined therapy but progressive disease in either monotherapy."	"Migliardi et al., 2012, Clin. Cancer Res."	Somatic	ENST00000256078.4	missense_variant
KRAS A146T	KRAS	A146T	Colorectal Cancer	"Dactolisib,Selumetinib"	Predictive	Supports	D	Sensitivity/Response	chr12	25225628	25225628	C	T	"In 28 out of 40 (70%) metastatic colorectal cancer tumors implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors harbored KRAS mutations including 2 A146T tumors (1 also harboring PIK3CA E545K) which both showed disease stabilization during doublet therapy but progression on either single agent."	"Migliardi et al., 2012, Clin. Cancer Res."	Somatic	ENST00000256078.4	missense_variant
KRAS A146P	KRAS	A146P	Colorectal Cancer	"Cetuximab,Irinotecan"	Predictive	Supports	C	Resistance	chr12	25225628	25225628	C	G	"In a retrospective study of 68 irinotecan-refractory metastatic colorectal cancer patients, one patient's tumor harbored a KRAS codon 146 mutation but was wildtype for BRAF, and KRAS codons 12, 13, and 61. This patient did not respond to irinotecan and cetuximab combination therapy and experienced progression free survival (PFS) lasting less than 10 months and overall survival (OS) lasting less than 30 months. Median PFS for patients with BRAF, KRAS G12/G13 wildtype tumors harboring mutations in either KRAS codon 146 (n=1) or KRAS codon 61 (n=7) was lower than patients whose tumors were additionally wildtype for KRAS A146 and Q61 (PFS: 3.8 vs 5.3mo, p= 0.023), though there wasn't a significant difference in overall survival (OS: 9.7 vs 14.8 mo, p=0.320)."	"Loupakis et al., 2009, Br. J. Cancer"	Somatic	ENST00000256078.4	missense_variant
KRAS A146T	KRAS	A146T	Colorectal Cancer	Cetuximab	Predictive	Supports	D	Resistance	chr12	25225628	25225628	C	T	"Preclinical data supporting resistance of Exon 4 mutations, in particular A146T, to cetuximab and sensitivity to PD0325901. This study involved treatment of mice bearing A146T KRAS xenografts treated with PD0325901 or cetuximab."	"Janakiraman et al., 2010, Cancer Res."	Somatic	ENST00000256078.4	missense_variant
KRAS A146T	KRAS	A146T	Colorectal Cancer	"FOLFOX-4 Regimen,Cetuximab"	Predictive	Supports	B	Resistance	chr12	25225628	25225628	C	T	"In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations and wildtype BRAF (n=10), including A146T (N=3), G15D (N=1), and V152M/NRAS V160A, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild-type KRAS, NRAS and BRAF."	"Kaczirek et al., 2015, Clin Colorectal Cancer"	Somatic	ENST00000256078.4	missense_variant
KRAS Q61	KRAS	Q61	Multiple Myeloma		Prognostic	Supports	B	Poor Outcome	chr12	25227341	25227343			"In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutaions in KRAS. Those with mutations had worse overall and progression free survival than those without mutations."	"Chng et al., 2008, Leukemia"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Q61H	KRAS	Q61H	Colorectal Cancer	"Cetuximab,Chemotherapy"	Predictive	Supports	C	Resistance	chr12	25227341	25227341	T	G	"Seven patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS Q61H (either c.183A > C or >T) and were wildtype for BRAF and PIK3CA mutations. A 73 year old man who was treated with cetixumab and irinotecan as a fourth line therapy experienced stable disease, with a PFS of 36 weeks and OS of 57 weeks. A 65 year old man who was treated with cetuximab and irinotecan as a 3rd line therapy experienced stable disease with a PFS of 32 weeks and an OS of 51 weeks. A 70 year old female who was treated with cetuximab, oxaliplatin and 5FU as a second line therapy experienced progressive disease after 4 weeks of treatment. A 66 year old male who was treated with cetuximab and irinotecan as a 4th line therapy experienced progression after 6 week and had an OS of 21 weeks. A 71 year old female who was treated with cetuximab and folfiri as a 3rd line therapy experienced progression after 8 weeks and had an OS of 116 weeks. A 77 year old male who was treated with cetuximab and irinotecan as a 4th line therapy experienced progression after 8 weeks and had an overall survival of 17 weeks. A 66 year old male who was treated with cetuximab and irinotecan as a 3rd line therapy experienced stable disease (11 weeks) and an OS of 14 weeks. In this study, authors considered stable disease to be non-response to treatment."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000256078.4	missense_variant
KRAS Q61H	KRAS	Q61H	Colorectal Cancer	Cetuximab	Predictive	Supports	C	Resistance	chr12	25227341	25227341	T	G	"In a colorectal cancer patient with a KRAS Q61H mutation, KRAS Q61H was reported to be refractory to cetuximab treatment. The patient was treated with cetuximab and irinotecan for 18 months, had a partial response to therapy and then experienced progressive disease with a re-biopsy of the tumor identifying a KRAS Q61H mutation."	"Misale et al., 2012, Nature"	Somatic	ENST00000256078.4	missense_variant
KRAS Q61	KRAS	Q61	Colorectal Cancer	"Chemotherapy,Cetuximab"	Predictive	Supports	B	Resistance	chr12	25227341	25227343			"This was a retrospective study of 605 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy. Patients harboring KRAS codon 61 mutations (n=13) had a significantly lower response rate than did patients with KRAS wildtype tumors (0/13 vs 123/345; p= .0055). Authors consider KRAS codon 61 mutations as supporting resistance to cetuximab and suggest that it should be included in KRAS mutation screening. Authors note that these patients were treated with cetuximab prior to widespread adoption of regular KRAS mutational status screening. Patients treated with cetuximab monotherapy were not included."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS Q61H	KRAS	Q61H	Cancer		Oncogenic	Supports	D	Oncogenicity	chr12	25227341	25227341	T	G	"NIH3T3 cells were transfected with control or KRAS Q61H plasmid and focus formation assays were performed. Q61H cells formed approximately 50 foci > 5mm diameter per well, where wt cells formed none, demonstrating Q61H promotes loss of contact inhibition suggestive of oncogenic transformation of NIH3T3 cells. This evidence provides support for the OS2 ClinGen/CGC/VICC evidence code for in vitro functional assays suggesting variant oncogenicity."	"Smith et al., 2010, Br. J. Cancer"	Somatic	ENST00000256078.4	missense_variant
KRAS Q61L	KRAS	Q61L	Colorectal Cancer	"Chemotherapy,Cetuximab"	Predictive	Supports	C	Resistance	chr12	25227342	25227342	T	A	"Two patients participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS Q61L. One patient, a 67 year old male, whose tumor was wildtype for BRAF and PIK3CA, was treated with cetuximab and irinotecan as a fourth line therapy. Cetuximab was discontinued due to toxicity and the patient experienced stable disease for 17 weeks and an overall survival of 23 weeks following treatment. The other patient was a 44 year old female whose tumor was wildtype for PIK3CA, BRAF and NRAS. The patient was treated with cetuximab and irinotecan as a third line therapy, and experienced progressive disease 23 weeks following treatment; overall survival was 30 weeks. Both patients experienced progressive disease following treatment."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000256078.4	missense_variant
KRAS Q61R	KRAS	Q61R	Colorectal Cancer	"Irinotecan,Cetuximab"	Predictive	Supports	C	Resistance	chr12	25227342	25227342	T	C	"Two patients participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS Q61R and were wild type for PIK3CA, BRAF, and NRAS. Both were treated with cetuximab and irinotecan as 3rd line treatments. One patient was a 72 year old female who experienced progressive disease 12 weeks following treatment; OS was 20 weeks. The other patient was a 43 year old female who experienced stable disease for the duration of the study and did not progress."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000256078.4	missense_variant
KRAS Q61K	KRAS	Q61K	Colorectal Cancer	"Cetuximab,Chemotherapy"	Predictive	Supports	C	Resistance	chr12	25227343	25227343	G	T	"Two patients participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS Q61K. One patient was a 61 year old female whose tumor was wildtype for BRAF and PIK3CA. This patient was treated with cetuximab, oxaliplatin, and 5FU, as a second line therapy, and experienced progressive disease 6 weeks following cetuximab administration; overall survival was 90 weeks. The other patient was a 65 year old female whose tumor was wildtype for PIK3CA. The patient was treated with cetuximab and irinotecan as a third line therapy, and experienced progressive disease 10 week following cetuximab. Both patients experienced progressive disease following treatment."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000256078.4	missense_variant
KRAS Exon 2 Mutation	KRAS	Exon 2 Mutation	Colorectal Cancer	Regorafenib	Predictive	Does Not Support	B	Sensitivity/Response	chr12	25245274	25245395			"KRAS mutation status was not predictive of response to regorafenib treatment in patients that had received standard therapy and progressed within 3 months of their last treatment. KRAS exon 2 variants (G12A, C, D, R, S, V; G13D) were sequenced, among variants in other KRAS exons."	"Sartore-Bianchi et al., 2014, Expert Rev Anticancer Ther"	Somatic	ENST00000256078.4	missense_variant
KRAS Exon 2 Mutation	KRAS	Exon 2 Mutation	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Resistance	chr12	25245274	25245395			Patients with colorectal cancer who harbor KRAS mutation have low response rate to cetuximab.	"Livre et al., 2006, Cancer Res."	Somatic	ENST00000256078.4	missense_variant
KRAS Exon 2 Mutation	KRAS	Exon 2 Mutation	Pancreatic Carcinoma	Erlotinib	Predictive	Does Not Support	B	Resistance	chr12	25245274	25245395			KRAS exon 2 was mutated in 121 of 173 (70%) patients with advanced pancreatic cancer and did not show an association with response to erlotinib treatment.	"Boeck et al., 2013, J. Gastroenterol."	Somatic	ENST00000256078.4	missense_variant
KRAS Exon 2 Mutation	KRAS	Exon 2 Mutation	Pancreatic Carcinoma		Prognostic	Supports	B	Poor Outcome	chr12	25245274	25245395			"KRAS exon 2 was mutated in 121 of 173 patients with advanced pancreatic cancer. Patients with KRAS wildtype had an improved OS (HR 1.68, p = 0.005)."	"Boeck et al., 2013, J. Gastroenterol."	Somatic	ENST00000256078.4	missense_variant
KRAS Exon 2 Mutation	KRAS	Exon 2 Mutation	Colorectal Cancer	Cetuximab	Predictive	Supports	A	Resistance	chr12	25245274	25245395			"KRAS mutation status was assessed in 394 tumor samples from colorectal cancer patients who were randomly assigned to receive cetuximab plus best supportive care or best supportive care alone.   42% of the tumors evaluated had at least one mutation in exon 2. Patients with a colorectal tumor bearing mutated K-ras did not benefit from cetuximab, whereas patients with a tumor bearing wild-type K-ras did benefit from cetuximab. The effectiveness of cetuximab was significantly associated with K-ras mutation status (P=0.01 for overall survival and P<0.001 for progression-free survival). In patients with wild-type K-ras tumors, treatment with cetuximab as compared with supportive care alone significantly improved overall survival. The related clinical trial ID is NCT00079066."	"Karapetis et al., 2008, N. Engl. J. Med."	Somatic	ENST00000256078.4	missense_variant
KRAS Exon 2 Mutation	KRAS	Exon 2 Mutation	Colorectal Cancer	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Predictive	Supports	B	Resistance	chr12	25245274	25245395			"102 mCRC patients treated with anti-EGFR therapy were analyzed for 34 hotspot mutations in KRAS, NRAS and BRAF with nanofluidic digital PCR and quantitative PCR. dPCR and qPCR results were correlated to PFS and OS. Analysis of only KRAS exon 2 hotspot mutations showed that patients with more than 1% mutant allele fraction (n = 19/83) had a hazard ratio of 3.43 for PFS (95% CI, 1.67?.02; P=0.002) and 2.72 for OS (95% CI, 1.52?.88; P=0.002) compared to wild-type patients or patients with less than 1% mutant allele fraction. Considering all RAS and BRAF mutations, the patients with more than 1% mutant allele fraction (n = 37/65) had a hazard ratio of 4.52 for PFS (95% CI, 2.25?.07; P<0.001) and 2.5 for OS (95% CI, 1.57?.02; P<0.001). ROC analysis showed that a cut-off of 1% for any mutated allele offered the best predictive value."	"Azuara et al., 2016, Mol. Cancer Ther."	Somatic	ENST00000256078.4	missense_variant
KRAS Exon 2 Mutation	KRAS	Exon 2 Mutation	Pancreatic Cancer	"Gemcitabine,Erlotinib"	Predictive	Supports	B	Resistance	chr12	25245274	25245395			"In a retrospective study of 136 pancreatic cancer patients, point mutations in KRAS exon 2 were associated with worse overall survival compared to that of wild-type KRAS (5.8 vs 8.0 months; P = 0.001; multivariate analysis). This difference was largely driven by the subgroup of patients with reduced response to gemcitabine-erlotinib combination therapy (7.5% vs 23.3%) with overall survival of 5.2 vs 9.7 months (N=40 vs 30) compared to those that received other therapies with an overall survival of 7.0 months for both KRAS mutated (N=31) and KRAS wildtype (N=35) patients."	"Kim et al., 2011, Mol. Cancer Ther."	Somatic	ENST00000256078.4	missense_variant
KRAS Exon 2 Mutation	KRAS	Exon 2 Mutation	Colorectal Cancer	"Irinotecan,Selumetinib"	Predictive	Supports	B	Sensitivity/Response	chr12	25245274	25245395			"31 patients with KRAS exon 2 mutation (codons 12 and 13) were treated with selumetinib and irinotecan. All patients had ECOG status 0 or 1 and confirmed progression after first line therapy with oxaliplatin-based chemotherapy and bevacizumab. Patients with more than one line of therapy, MEK or B-RAF inhibitor treatment or prior irinotecan treatment were excluded. The study was terminated before full accrual due to non-protocol considerations. Three patients had a PR, 16 patients had SD >= 4 weeks. Median PFS for all patients was 105 days, median OS was 267 days."	"Hochster et al., 2015, Cancer Chemother. Pharmacol."	Somatic	ENST00000256078.4	missense_variant
KRAS Exon 2 Mutation	KRAS	Exon 2 Mutation	Colorectal Cancer		Prognostic	Does Not Support	B	Poor Outcome	chr12	25245274	25245395			"This retrospective study examines outcomes of 158 primary sporadic colorectal cancer patients who had undergone surgical resection and were treated with 5-fluorouracil based chemotherapy. KRAS exon 2 mutations (listed as KRAS exon 1 as it was common at the time of source publication to exclude non-coding exon 1) were not associated with differences in disease specific survival compared to wt KRAS (n = 50 mutant, n = 108 wt; p =0.6077) or in relapse free survival. Authors noted that the tumors of 6 patients harbored both PIK3CA and KRAS mutations, but stated that the presence of PIK3CA mutations did not correlate with the presence of KRAS mutations."	"Kato et al., 2007, Int. J. Cancer"	Somatic	ENST00000256078.4	missense_variant
KRAS Exon 2 Mutation	KRAS	Exon 2 Mutation	Rectum Cancer		Prognostic	Does Not Support	B	Poor Outcome	chr12	25245274	25245395			"This study examined outcomes of 240 rectum cancer patients treated with total mesorectal excision therapy. Tumor samples were obtained at the time of surgery and genotyped for KRAS exon 2 mutations (listed as exon 1 in the source, as it was common at the time of publication to exclude non-coding exon 1). KRAS exon 2 mutations were identified in 81 cases. The authors reported that no differences were found in overall survival between patients with and without KRAS exon 2 mutations (P > 0.1)."	"He et al., 2009, Clin. Cancer Res."	Somatic	ENST00000256078.4	missense_variant
KRAS Exon 2 Mutation	KRAS	Exon 2 Mutation	Colorectal Cancer	Vemurafenib	Predictive	Does Not Support	D	Sensitivity/Response	chr12	25245274	25245395			"This preclinical study examined vemurafenib efficacy on various colorectal cancer cell lines and in vivo via mouse xenograft experiments. Three cell lines harbored KRAS exon 2 mutations and wt BRAF: HCT 116 (KRAS G13D), SW620 (KRAS G12V), LOVO (KRAS G13D). Cell lines with KRAS exon 2 mutations were insensitive to vemurafenib compare those with wt KRAS and BRAF V600E (a known vemurafenib sensitizing mutation; HT29, Colo205, Colo471, LS411N; IC50s >10uM vs 0.025-0.35 uM). Nude, athymic mice with HCT116 or LoVo xenografts did not experience tumor inhibition when treated with vemurafenib."	"Yang et al., 2012, Cancer Res."	Somatic	ENST00000256078.4	missense_variant
KRAS Q22*	KRAS	Q22*	Colon Mucinous Adenocarcinoma	Panitumumab	Predictive	Supports	C	Resistance	chr12	25245321	25245321	G	A	"A 43-year-old female was diagnosed with an adenocarcinoma of the ascending colon and received 6-months of adjuvant chemotherapy. After 5 years of completion of adjuvant chemotherapy, the disease relapsed. EGFR was assessed by immunohistochemistry, and the patient was subsequently treated with the anti-EGFR monoclonal antibody panitumumab. However, there was a rapid clinical worsening, which may possibly be attributed to a somatic mutation in KRAS (Q22*)."	"Palmirotta et al., 2009, Anticancer Res."	Somatic	ENST00000256078.4	stop_gained
KRAS G12/G13	KRAS	G12/G13	Lung Non-small Cell Carcinoma	"Gefitinib,Erlotinib"	Predictive	Supports	B	Resistance	chr12	25245346	25245351			"In 60 patients with NSCLC, Exon 2 KRAS mutations were associated with resistance to the EGFR kinase inhibitors gefitinib or erlotinib (9/38 refractory vs 0/21 sensitive patients; P=0.0201)."	"Pao et al., 2005, PLoS Med."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS G12/G13	KRAS	G12/G13	Colorectal Cancer	"Cetuximab,Chemotherapy"	Predictive	Supports	B	Resistance	chr12	25245346	25245351			"Chemotherapy-refractory patients with metastatic colorectal cancer harboring KRAS mutations (primarily G12/G13; n=230 out of 253 total KRAS mutant patients) had lower response rates (17/253; 6.7% vs KRAS wt 126/352; 35.8%; P < .0001), disease control rates and shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype KRAS. Authors note that these patients were treated with cetuximab prior to widespead adoption of regular KRAS mutational status screening. Patients treated with cetuximab or panitumumab monotherapy were not included."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS G12/G13	KRAS	G12/G13	Colorectal Cancer	Cetuximab	Predictive	Supports	D	Resistance	chr12	25245346	25245351			KRAS mutations were significantly associated with lack of response to cetuximab in patients with advanced colorectal cancer.	"Livre et al., 2008, J. Clin. Oncol."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS G12/G13	KRAS	G12/G13	Colorectal Cancer		Prognostic	Supports	D	Poor Outcome	chr12	25245346	25245351			KRAS mutations were significantly associated with reduced progression-free and overall survival in patients with advanced colorectal cancer.	"Livre et al., 2008, J. Clin. Oncol."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS G12/G13	KRAS	G12/G13	Pancreatic Adenocarcinoma	"Trametinib,Gemcitabine"	Predictive	Supports	B	Resistance	chr12	25245346	25245351			"Adding trametinib to gemcitabine does not improve overall survival (OS), progression-free survival (PFS), overall response rate (ORR) or duration of response (DOR) in patients with untreated metastatic adenocarcinoma of the pancreas."	"Infante et al., 2014, Eur. J. Cancer"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS G12/G13	KRAS	G12/G13	Pancreatic Adenocarcinoma	Trametinib	Predictive	Does Not Support	B	Sensitivity/Response	chr12	25245346	25245351			"KRAS G12/G13 status was evaluated in cell-free DNA (cfDNA) of patients with untreated metastatic adenocarcinoma of the pancreas that were randomised (1:1) to receive gemcitabine plus trametinib or placebo. KRAS mutations were identified in 103 patients using cfDNA. There was no difference betweeen overall survival of KRAS Mutation-positive and -negative patients. Of note, evaluation of KRAS mutations from archival tissue from 71/143 patients identified 8 patients with mutant KRAS (wildtype by cfDNA) and 3 patients with wildtype KRAS (mutant by cfDNA)."	"Infante et al., 2014, Eur. J. Cancer"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS G12/G13	KRAS	G12/G13	Colorectal Cancer	Panitumumab	Predictive	Supports	B	Resistance	chr12	25245346	25245351			"In a retrospective study of 427 chemotherapy-refractory metastatic colorectal patients treated with either panitumumab monotherapy or best supportive care (BSC), KRAS codon 12 or 13 mutations were observed in 43% of the tumor samples. The effect of panitumumab on PFS in the KRAS wt group was significantly greater than in the KRAS mutant group (HR:0.45, 95% CI:0.34-0.59 vs HR:0.99, 95% CI:0.73-1.36; P<0.0001). None of the 84 panitumumab-treated patients with KRAS mutant tumors responded to treatment (100% positive predictive value for nonresponse in mutant group). In the KRAS wt group treated with panitumumab (n=124), 21 patients had partial response (17%), 42 experienced stable disease (34%). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and BSC alone (PFS: 7.4 wk vs 7.3 wk). The authors concluded that their findings support the hypothesis that KRAS mutations confer primary resistance to anti-EGFR antibodies and recommend that KRAS status be evaluated prior to panitumumab administration."	"Amado et al., 2008, J. Clin. Oncol."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS G12/G13	KRAS	G12/G13	Colorectal Cancer		Prognostic	Does Not Support	B	Poor Outcome	chr12	25245346	25245351			"In a retrospective study of 427 chemotherapy-refractory metastatic colorectal patients treated with either panitumumab monotherapy or best supportive care (BSC), KRAS codon 12 or 13 mutations were observed in 43% of the tumor samples. The effect of BSC on PFS was the same in the KRAS mutant group as in the KRAS wildtype group (7.3 vs 7.3 weeks), suggesting that the presence of KRAS mutations does not support worse outcome compared to wildtype KRAS."	"Amado et al., 2008, J. Clin. Oncol."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS G12/G13	KRAS	G12/G13	Colorectal Cancer		Prognostic	Does Not Support	B	Poor Outcome	chr12	25245346	25245351			"This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan) alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between KRAS mutation status in primary tumors and post treatment progression free survival (PFS) and overall survival (OS). Of the 168 patients, 106 had wildtype KRAS and 62 had mutations in KRASincluding G12A, G12C, G12D, G12R, G12S, G12V, and G13D. Regardless of first line chemotherapy regimen or use of monoclonal antibody treatment, patients with KRAS-mutated tumors did not have a significantly worse outcome than patients with wtKRAS tumors,  as evidenced by non-significant differences in PFS (12.3 vs 11.8 months, respectively) and OS (35.8 and 40.5 months, respectively)."	"Souglakos et al., 2009, Br. J. Cancer"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS G12/G13	KRAS	G12/G13	Colorectal Cancer	Oxaliplatin	Predictive	Does Not Support	B	Resistance	chr12	25245346	25245351			"This was a retrospective clinical study of 100 metastatic colorectal cancer patients who received FOLFOX (oxaliplatin + 5-fluorouracil + folinic acid) first-line therapy alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between KRAS mutation status in primary tumors and response to oxaliplatin-based first-line therapy, as measured by post treatment PFS. Of 100 patients, 61 had wildtype KRAS and 39 had mutations in KRASincluding G12A, G12C, G12D, G12R, G12S, G12V, and G13D. The study found that patients with KRAS-mutated tumors were not significantly more resistant to oxaliplatin-based first-line therapy than patients with wildtype KRAS, as evidenced by a nonsignificant difference in PFS (11.7 and 11.4 months, respectively)."	"Souglakos et al., 2009, Br. J. Cancer"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS G12/G13	KRAS	G12/G13	Colorectal Cancer	Irinotecan	Predictive	Does Not Support	B	Resistance	chr12	25245346	25245351			"This was a retrospective clinical study of 44 metastatic colorectal cancer patients who recieved FOLFIRI (5-Fluorouacil + Folinic acid + irinotecan) first-line therapy alone or with bevacizumab. It assessed the relationship between KRAS mutation status in primary tumors and response to irinotecan-based first line therapy, as measured by PFS. Of the 44 patients, 26 had wildtype KRAS and 18 had mutations in KRASincluding G12A, G12C, G12D, G12R, G12S, G12V, and G13D. The study found that patients harboring a KRAS mutation were not significantly more resistant to irinotecan-based first-line therapy than patients with wildtype KRAS. The difference in PFS between patients with KRAS-mutated tumors and the patients with wtKRAS tumors was nonsignificant (PFS: 13.7 and 12.0 months; p= 0.074)."	"Souglakos et al., 2009, Br. J. Cancer"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS G12/G13	KRAS	G12/G13	Colorectal Cancer	Bevacizumab	Predictive	Does Not Support	B	Resistance	chr12	25245346	25245351			"This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan). It assessed the relationship between KRAS mutation status in primary tumors and response to bevacizumab-containing first line chemotherapy, as measured by PFS. Of the 97 patients, 58 had wildtype KRAS and 39 had mutations in KRASincluding G12A, G12C, G12D, G12R, G12S, G12V, and G13D. The study found that patients with KRAS-mutated tumors were not significantly more resistant to bevacizumab-containing first-line chemotherapy than patients with wildtype KRAS, as evidenced by a non-significant difference in PFS between the two groups (12.1 and 11.7 months, respectively)."	"Souglakos et al., 2009, Br. J. Cancer"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS G12/G13	KRAS	G12/G13	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Resistance	chr12	25245346	25245351			"This was a retrospective clinical study of 92 metastatic colorectal cancer patients who received cetuximab in conjunction with salvage chemotherapy (refractory to at least one line of treatment). Salvage chemotherapy was composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan. The study assessed the relationship between KRAS mutation status in primary tumors and response to cetuximab-containing salvage chemotherapy, as measured by PFS. Of the 92 patients, 60 had wildtype KRAS and 32 had mutations in KRASincluding G12A, G12C, G12D, G12R, G12S, G12V, and G13D. The study found that patients harboring a KRAS mutation were trending toward resistance to cetuximab-containing salvage chemotherapy as compared to patients with wildtype KRAS (p=0.094). Note: while differences in PFS were nonsignificant between patients with wildtype or mutant KRAS, differences in objective response (defined as reduction by at least 30% in the sum of the longest diameters of target lesions compared to baseline) were significantly different. Of the 32 patients with mutant KRAS, none responded to cetuximab-containing salvage therapy, while 14/60 of the patients with wildtype KRAS (23%) responded (p=.002)."	"Souglakos et al., 2009, Br. J. Cancer"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS G13V	KRAS	G13V	Colorectal Cancer	"Cetuximab,Panitumumab"	Predictive	Supports	C	Resistance	chr12	25245346	25245347	GC	AA	"In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN were tested for mutation; KRAS G13V was the only variant noted in the primary colon tumor of one patient who experienced disease progression (Patient 4; Supplemental Table 1) following treatment. In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant."	"Sartore-Bianchi et al., 2009, Cancer Res."	Somatic	ENST00000256078.4	missense_variant
KRAS G12/G13	KRAS	G12/G13	Colorectal Cancer	"Cetuximab,Panitumumab"	Predictive	Supports	B	Resistance	chr12	25245346	25245351			"Mutational analysis of 109 metastatic colorectal cancer patients was used to examine objective tumor response, progression free survival (PFS), and overall survival (OS) following treatment with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). In univariate analysis, KRAS mutations (G12V, G12S, G12D, G12A, G13V, G13D) were significantly associated with lack of response to panitumumab or cetuximab (objective response rate: 2/32 vs 20/77 for patients harboring KRAS mutated or wildtype tumors, respectively; P = 0.019). Multivariate logistic regression of KRAS mutations, PIK3CA mutations and PTEN protein expression also confirmed an independent effect of KRAS mutations on objective response (p = 0.0029). Authors noted that patients with tumors harboring KRAS mutations (32/108) tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant."	"Sartore-Bianchi et al., 2009, Cancer Res."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS G13D	KRAS	G13D	Colorectal Cancer	Cetuximab	Predictive	Supports	D	Sensitivity/Response	chr12	25245347	25245347	C	T	Cells harboring KRAS G13D mutation were sensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model.	"De Roock et al., 2010, JAMA"	Somatic	ENST00000256078.4	missense_variant
KRAS G13D	KRAS	G13D	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Sensitivity/Response	chr12	25245347	25245347	C	T	KRAS G13D mutation is associated with better response to Cetuximab with longer progression-free and overall survival in colorectal patients compared to other KRAS.	"De Roock et al., 2010, JAMA"	Somatic	ENST00000256078.4	missense_variant
KRAS G13	KRAS	G13	Multiple Myeloma		Prognostic	Supports	B	Poor Outcome	chr12	25245347	25245348			"In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutations in KRAS (22/28 in G12/G13). Those with KRAS (but not NRAS) mutations had worse overall (median 19.9 vs 44.3 months, p=0.005) and progression free survival (median 14.7 vs 30.3 months, p<0.001) than those without mutations."	"Chng et al., 2008, Leukemia"	Somatic	ENST00000256078.4	"missense_variant,inframe_insertion"
KRAS G13D	KRAS	G13D	Colorectal Cancer	Cetuximab	Predictive	Does Not Support	B	Resistance	chr12	25245347	25245347	C	T	"This is a retrospective analysis of 98 patients with metastatic colorectal cancer and KRAS mutations. 23 (23.5%) had KRAS p.G13D-mutated tumors. Of the 98 patients, 31 patients received cetuximab, of these, 9 (29.0%) had KRAS p.G13D mutations. Univariate analysis did not show any differences between these groups. Multivariate analysis showed a trend towards better PFS among patients with a G13D mutation (PFS: HR=0.29; 95% CI: 0.08-1.10; P=0.07; OS: HR=0.23; 95% CI: 0.04-1.54; P=0.13)."	"Osumi et al., 2015, Mol Clin Oncol"	Somatic	ENST00000256078.4	missense_variant
KRAS G13D	KRAS	G13D	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Resistance	chr12	25245347	25245347	C	T	"12 patients with KRAS G13D mutant, metastatic colorectal cancer were treated with single agent cetuximab in a prospective phase II study. The primary endpoint of the trial was 4-month progression-free survival, with a benefit to treatment evaluated to be 50% of patients were progression free at this point. None of 12 patients achieved response by RECIST 1.1 criteria and three patients (25%) were progression-free at 4 months, with disease control rate at 6 months reaching 0%. Median PFS and OS were 1.9 (95% CI 1.7?.8) and 7.2 months (95% CI 5.7?.7)."	"Schirripa et al., 2015, Ann. Oncol."	Somatic	ENST00000256078.4	missense_variant
KRAS G13D	KRAS	G13D	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Resistance	chr12	25245347	25245347	C	T	"Meta-analysis encompassing eight randomized controlled trials (n = 5967) for assessment of both overall survival (OS) and progression-free survival (PFS) of patients with KRAS mutant metastatic colorectal cancer. For other KRAS MT the hazard ratio for OS benefit with addition of anti-EGFR mAb therapy was 1.06 (95% confidence interval [CI]; 0.96, 1.17), compared to 1.08 (95% CI; 0.73, 1.60) for KRAS G13D [test for interaction p=0.99]. In contrast, the hazard ratio for KRAS wild-type (WT) tumours was 0.85 (95% CI; 0.76, 0.95). Regarding PFS benefit with anti-EGFR mAbs, the hazard ratio was 1.07 (95% CI; 0.92, 1.26) for other KRAS MT, 0.96 (95% CI; 0.73, 1.27) for KRAS G13D, and 0.68 (95% CI; 0.54, 0.85) for KRAS wild-type. Again, the test for interaction (p=0.46) demonstrated no significant difference in PFS benefit for anti-EGFR mAb therapy between KRAS G13D and other KRAS MT."	"Rowland et al., 2016, Eur. J. Cancer"	Somatic	ENST00000256078.4	missense_variant
KRAS G13D	KRAS	G13D	Breast Cancer	Pictilisib	Predictive	Supports	D	Resistance	chr12	25245347	25245347	C	T	"This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases over a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. MDA-MB-231 is a basal-type breast cancer cell line which harbors KRAS G13D, and it had an ICD50 of 20uM. To evaluate in vivo efficacy, cells were injected in the mammary fat pad of SCID mice and allowed to grow. Mice injected with MDA-MB-231 and treated with pictilisib saw no reduction in tumor volume compared to untreated control. There was no effect on G1 arrest in pictilisib treated cells; however, phosphorylated AKT (S473) was substantially reduced following pictilisib. Authors note that basal breast cancer cell lines were generally more resistant to pictilisib than luminal lines (p=0.02), and concluded that this cell line was resistant to pictilisib."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000256078.4	missense_variant
KRAS G13D	KRAS	G13D	Colorectal Cancer	Panitumumab	Predictive	Supports	C	Resistance	chr12	25245347	25245347	C	T	"Three patients participating in a large retrospective study of EGFR monoclonal antibodies in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS G13D, were wildtype for NRAS, BRAF and PIK3CA, and had individual response data. All three patients were males treated with panitumumab monotherapy. Their characteristics are as follows: 51 year old who experienced progressive disease (PFS: 8 weeks; OS: 24 weeks) and had three prior lines of chemotherapy; 54 year old who experienced progressive disease (PFS: 8 weeks; OS: 17 weeks) and had two prior lines of chemotherapy; 52 year old who experienced stable disease (PFS: 12 weeks; OS: 46 weeks) and had two prior lines of chemotherapy. Per the authors criteria, the clinical benefit rate is 1/3 and the response rate is 0/3."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000256078.4	missense_variant
KRAS G13D	KRAS	G13D	Colorectal Cancer	"Dactolisib,Selumetinib"	Predictive	Supports	D	Sensitivity/Response	chr12	25245347	25245347	C	T	"In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring KRAS, NRAS, PIK3CA or BRAF mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 mice harbored KRAS mutations including 5 G13D mutations where disease stabilization was achieved in 2/5 mice treated with AZD6244 or combination therapy and 0/5 mice treated with BEZ235 alone."	"Migliardi et al., 2012, Clin. Cancer Res."	Somatic	ENST00000256078.4	missense_variant
KRAS G13D	KRAS	G13D	Colorectal Cancer	Cetuximab	Predictive	Supports	D	Resistance	chr12	25245347	25245347	C	T	"In an in vitro study, a Lim1215 colorectal cancer cell line endogenously expressing KRAS G13D mutation demonstrated resistance to cetuximab treatment, compared to Lim1215 parental cells expressing wild-type KRAS. Resistance was determined by assessing cell viability."	"Misale et al., 2012, Nature"	Somatic	ENST00000256078.4	missense_variant
KRAS G13D	KRAS	G13D	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Resistance	chr12	25245347	25245347	C	T	"This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 50 patients harbored KRAS G13D, were BRAF, NRAS and PIK3CA wt, and had individual response data. Nine patients had partial response, 19 had stable disease, and 22 progressed. Treatments included cetuximab + irinotecan (n=38), cetuximab + FOLFIRI (n=5), cetuximab monotherapy (n=4), cetuximab + oxaliplatin + 5FU (n=2), and cetuximab + irinotecan + oxaliplatin + 5FU (n=1). Median PFS was 16 weeks (3-101 weeks), median OS was 33 weeks (3-161 weeks), and median number of previous chemotherapy lines was 2 (0-4). Median age was 65 years old (34-78), and there were 29 males and 20 females. Authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000256078.4	missense_variant
KRAS G13D	KRAS	G13D	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Resistance	chr12	25245347	25245347	C	T	"In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFOX4 plus cetuximab were associated with decreased overall survival (16.3mo vs. 28.5mo, HR:0.43, 95% CI:0.20-0.89, P=0.020) and decreased progression free survival (7.2mo vs. 9.7mo, HR:0.56, 95% CI:0.27-1.16, P=0.11), as compared to patients with wild-type KRAS and NRAS."	"Kaczirek et al., 2015, Clin Colorectal Cancer"	Somatic	ENST00000256078.4	missense_variant
KRAS G13D	KRAS	G13D	Colorectal Cancer	Regorafenib	Predictive	Supports	D	Resistance	chr12	25245347	25245347	C	T	"In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G13D mutation demonstrated resistance to regorafenib treatment (IC50: 172.23 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G13D is more resistant to regorafenib than KRAS wt, but more sensitive than common KRAS G12 mutations."	"Camaj et al., 2015, Future Oncol"	Somatic	ENST00000256078.4	missense_variant
KRAS G13D	KRAS	G13D	Colorectal Cancer	"Cetuximab,Panitumumab"	Predictive	Does Not Support	C	Resistance	chr12	25245347	25245347	C	T	"In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN were tested for mutation; KRAS G13D was the only variant noted in the primary colon tumors of two patients who experienced partial response following treatment (Patients 37, 47; Supplemental Table 1). In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant."	"Sartore-Bianchi et al., 2009, Cancer Res."	Somatic	ENST00000256078.4	missense_variant
KRAS G13D	KRAS	G13D	Colorectal Cancer	"Panitumumab,Cetuximab"	Predictive	Supports	C	Resistance	chr12	25245347	25245347	C	T	"In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS G13D was the only variant noted in the primary rectal tumor of one patient who experienced disease progression following treatment (Patient 45; Supplemental Table 1). This is response is consistent with observations made of the larger cohort, where patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant. However, two other patients (37 and 47; Table S1) had G13D as their only noted variant, but experienced partial response."	"Sartore-Bianchi et al., 2009, Cancer Res."	Somatic	ENST00000256078.4	missense_variant
KRAS G12	KRAS	G12	Acute Leukemia		Diagnostic	Supports	B	Positive	chr12	25245350	25245351			Children with early age leukaemia who had second hand smoke exposure are more likely to harbor KRAS mutation.	"Andrade et al., 2014, BMC Cancer"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS G12V	KRAS	G12V	Colorectal Cancer	Cetuximab	Predictive	Supports	D	Resistance	chr12	25245350	25245350	C	A	Cells harboring KRAS G12V mutation were insensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model.	"De Roock et al., 2010, JAMA"	Somatic	ENST00000256078.4	missense_variant
KRAS G12	KRAS	G12	Lung Non-small Cell Carcinoma		Diagnostic	Does Not Support	B	Positive	chr12	25245350	25245351			"KRAS mutations in lung cancer patients are not associated with smoking history, age or gender."	"Riely et al., 2008, Clin. Cancer Res."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS G12D	KRAS	G12D	Lung Cancer		Diagnostic	Supports	B	Positive	chr12	25245350	25245350	C	T	KRAS G12D mutation occurs in never smokers significantly more often than in smokers.	"Dogan et al., 2012, Clin. Cancer Res."	Somatic	ENST00000256078.4	missense_variant
KRAS G12A	KRAS	G12A	Lung Adenocarcinoma	"Erlotinib,Gefitinib"	Predictive	Supports	B	Resistance	chr12	25245350	25245350	C	G	"KRAS mutations (N=29 G12, N=1 G13) were the primary predictor of EGFR TKI resistance in patients with lung adenocarcinoma (N=83). Overall survival (P=0.001) and progression-free survival (P=0.005) were significantly shorter in mutated patients."	"Marchetti et al., 2009, Neoplasia"	Somatic	ENST00000256078.4	missense_variant
KRAS G12D	KRAS	G12D	Lung Non-small Cell Carcinoma	"Dactolisib,Selumetinib"	Predictive	Supports	D	Sensitivity/Response	chr12	25245350	25245350	C	T	"The use of NVP-BEZ235 in conjunction with ARRY-142886, but not as monotherapy, in a lung cancer model with KRAS G12D mutation led to marked tumor regression."	"Engelman et al., 2008, Nat. Med."	Somatic	ENST00000256078.4	missense_variant
KRAS G12	KRAS	G12	Colorectal Cancer		Prognostic	Does Not Support	B	N/A	chr12	25245350	25245351			"In patients with stage III colorectal cancer undergoing chemotherapy, KRAS G12 mutation did not impact overall or disease free survival."	"Ogino et al., 2009, Clin. Cancer Res."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS G12	KRAS	G12	Lung Non-small Cell Carcinoma		Prognostic	Does Not Support	B	N/A	chr12	25245350	25245351			There is no strong association between KRAS mutation status and overall or progression free survival in patients with NSCLC.	"Schiller et al., 2001, J. Clin. Oncol."	Somatic	ENST00000256078.4	protein_altering_variant
KRAS G12	KRAS	G12	Multiple Myeloma		Prognostic	Supports	B	Poor Outcome	chr12	25245350	25245351			The presence of KRAS mutations in MM patients is prognostic for shorter overall and progression free survival.	"Chng et al., 2008, Leukemia"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS G12	KRAS	G12	Lung Non-small Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr12	25245350	25245351			A meta-analysis showed KRAS mutation is associated with worse outcome in patients with NSCLC.	"Mascaux et al., 2005, Br. J. Cancer"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS G12	KRAS	G12	Multiple Myeloma		Prognostic	Supports	B	Poor Outcome	chr12	25245350	25245351			"In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutations in KRAS (22/28 in G12/G13). Those with KRAS (but not NRAS) mutations had worse overall (median 19.9 vs 44.3 months, p=0.005) and progression free survival (median 14.7 vs 30.3 months, p<0.001) than those without mutations."	"Chng et al., 2008, Leukemia"	Somatic	ENST00000256078.4	protein_altering_variant
KRAS G12V	KRAS	G12V	Lung Non-small Cell Carcinoma	Palbociclib	Predictive	Supports	D	Sensitivity/Response	chr12	25245350	25245350	C	A	"In vivo studies confirmed the activity of PD0332991 (CDK4 inhibitor) on KRAS G12V mutant tumors. 17% (2/12) of mice treated with PD0332991 developed detectable lesions, whereas 75% of mice (3/4) treated with vehicle developed lesions at the end of the treatment."	"Puyol et al., 2010, Cancer Cell"	Somatic	ENST00000256078.4	missense_variant
KRAS G12D	KRAS	G12D	Pancreatic Carcinoma	Akt Inhibitor MK2206	Predictive	Supports	C	Sensitivity/Response	chr12	25245350	25245350	C	T	"Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss and a KRAS G12D mutation experienced a decrease of approximately 60% in cancer antigen 19-9 levels and 23% shrinkage in tumor measurements."	"Yap et al., 2011, J. Clin. Oncol."	Somatic	ENST00000256078.4	missense_variant
KRAS G12V	KRAS	G12V	Lung Non-small Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr12	25245350	25245350	C	A	"Retrospective analysis of data from 841 patients who underwent surgery and molecular testing for NSCLC.  Mutant KRAS was observed in 265 (31.5%) cases and 90 of these were G12V. Patients with KRAS G12V exhibited worse OS and TTR compared with the entire cohort. These results were confirmed using multivariate analyses (non-G12V status, hazard ratio (HR): 0.43 (confidence interval: 0.28?.65), P<0.0001 for OS. Risk of recurrence was significantly lower for non-KRAS G12V (HR: 0.01, (0.001?.08), P<0.0001)."	"Renaud et al., 2015, Br. J. Cancer"	Somatic	ENST00000256078.4	missense_variant
KRAS G12V	KRAS	G12V	Lung Non-small Cell Carcinoma	"Docetaxel,Selumetinib"	Predictive	Supports	B	Sensitivity/Response	chr12	25245350	25245350	C	A	"83 patients from a phase II trial (docetaxel + placebo or selumetinib) with KRAS mutant tumors were retrospectively assessed for differences in OS, PFS, ORR and change in tumor size at week 6 according to type of KRAS mutation. G12C, G12D and G12V were the most common mutations (46%, 22%, 11%, respectively). Patients with G12C or G12V mutations receiving combination selumetinib and docetaxel had a trend towards longer OS, PFS and ORR compared to other KRAS mutations. Changes in tumor size were similar between groups with the best responses in tumors with G12V mutations. Few differences were observed between groups when treated with docetaxel + placebo."	"Jnne et al., 2015, Br. J. Cancer"	Somatic	ENST00000256078.4	missense_variant
KRAS G12D	KRAS	G12D	Colorectal Cancer		Prognostic	Supports	B	Better Outcome	chr12	25245350	25245350	C	T	"In 119 metastatic colorectal cancer patients treated with cetuximab-based first-line chemotherapy, KRAS G12D mutations (N=44) were associated with longer overall patient survival when compared to other KRAS G12 mutations (23.3 vs 14-18 months; G12V, A, C, S, R)."	"Modest et al., 2012, Oncology"	Somatic	ENST00000256078.4	missense_variant
KRAS G12D	KRAS	G12D	Pancreatic Cancer		Prognostic	Supports	B	Poor Outcome	chr12	25245350	25245350	C	T	"In 219 patients with metastatic pancreatic ductal adenocarcinoma, a multivariate analysis identified KRAS G12D mutations as an independent predictor of poorer prognosis both in patients that have received chemotherapy (N=49/162), and the entire series (N=73/219). HR of 1.84 (P=0.02) and 1.44 (P=0.01), respectively."	"Bournet et al., 2016, Clin Transl Gastroenterol"	Somatic	ENST00000256078.4	missense_variant
KRAS G12D	KRAS	G12D	Malignant Exocrine Pancreas Neoplasm		Prognostic	Supports	B	Poor Outcome	chr12	25245350	25245350	C	T	"In 171 patients with tumors of the exocrine pancreas, a KRAS G12D mutation (N=60) was associated with shorter overall survival than being wild-type for KRAS (N=21; Hazard Ratio: 95% CI between 1.14 and 2.67). Additionally, KRAS mutations combined with CDKN2A alterations (N=26) showed an even worse OS than those wild-type for both (N=17; HR: 95%CI 1.33-7.10)."	"Rachakonda et al., 2013, PLoS ONE"	Somatic	ENST00000256078.4	missense_variant
KRAS G12D	KRAS	G12D	Hairy Cell Leukemia	Vemurafenib	Predictive	Supports	C	Resistance	chr12	25245350	25245350	C	T	"One patient enrolled in a clinical study to evaluate vemurafenib treatment of BRAF V600E mutant hairy-cell leukemia developed resistance to vemurafenib retreatment. 300-gene targeted sequencing of the patients genome revealed activating subclonal KRAS mutations (KRAS G12D, 15.2% allele frequency; KRAS K117N, 1.2%), as well as a RUNX1 A55E mutation (5.9%) that had not been seen prior to vemurafenib treatment or at remission. BRAF V600E allele frequency was detectable (2.4%) at the time of remission but dramatically increased at relapse (64.9%)."	"Tiacci et al., 2015, N. Engl. J. Med."	Somatic	ENST00000256078.4	missense_variant
KRAS G12V	KRAS	G12V	Cancer	Crizotinib	Predictive	Does Not Support	C	Resistance	chr12	25245350	25245350	C	A	"Case report of a 59-year-old white female patient (60 pack-years) with a CUP-syndrome. Molecular profiling identified both MET amplification (16 copies) and a KRAS G12V mutation. The patient was treated with crizotinib and experienced a complete normalization of tumor metabolic activity for more than 19 months. Other identified aberrations include CCND1 amplification (8 copies), MYC amplification (9 copies) as well as KRAS G12V, TP53 R273L and CARD11 N184S."	"Palma et al., 2014, Case Rep Oncol"	Somatic	ENST00000256078.4	missense_variant
KRAS G12D	KRAS	G12D	Pancreatic Ductal Carcinoma		Prognostic	Supports	B	Poor Outcome	chr12	25245350	25245350	C	T	"Exon-2 KRAS mutation status was analyzed in 219 patients with pancreatic ductal carcinoma, excluding those who had previously undergone chemotherapy, first-line pancreatic resection, or neoadjuvant treatment with chemotherapy or radiotherapy. 72 patients had wild-type KRAS, 147 had a codon-12 KRAS mutation (G12D, G12V, or G12R) and 73 had a G12D KRAS mutation, specifically. There was no significant difference in overall survival between wild-type patients and patients with any type of exon-12 mutation. However, patients with the G12D mutation exhibited significantly lower overall survival compared to wild-type patients in univariate and multivariate analyses. This difference in overall survival between wild-type and G12D patients persisted in the subset of patients who underwent chemotherapy at any point after enrollment."	"Bournet et al., 2016, Clin Transl Gastroenterol"	Somatic	ENST00000256078.4	missense_variant
KRAS G12D	KRAS	G12D	Colorectal Cancer	Therapeutic Tumor Infiltrating Lymphocytes	Predictive	Supports	C	Sensitivity/Response	chr12	25245350	25245350	C	T	"A patient with metastatic colorectal cancer was enrolled in a phase 2 clinical trial (NCT01174121). 24 cultures of tumor-infiltrating lymphocytes were expanded from 3 lung metastasis resections. After cultures were tested for reactivity, the patient was infused with 1.48 x 10^11 tumor-infiltrating lymphocytes (75% CD8+ T cells) that were specifically reactive to KRAS G12D. All 7 metastatic lung lesions regressed 40 days after therapy, and the patient had a 9-month partial response."	"Tran et al., 2016, N. Engl. J. Med."	Somatic	ENST00000256078.4	missense_variant
KRAS G12V	KRAS	G12V	Colorectal Cancer	"Selumetinib,Dactolisib"	Predictive	Supports	D	Sensitivity/Response	chr12	25245350	25245350	C	A	"In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring KRAS, NRAS, BRAF, or PIK3CA mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors harbored KRAS mutations including 8 G12V mutations (3 with PIK3CA mutations) where progressive disease occurred in only 1 tumor upon doublet treatment but 6 tumors in monotherapy."	"Migliardi et al., 2012, Clin. Cancer Res."	Somatic	ENST00000256078.4	missense_variant
KRAS G12A	KRAS	G12A	Lung Cancer	Gefitinib	Predictive	Supports	B	Resistance	chr12	25245350	25245350	C	G	"In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390)."	"Endoh et al., 2006, J Thorac Oncol"	Somatic	ENST00000256078.4	missense_variant
KRAS G12A	KRAS	G12A	Multiple Myeloma	Melphalan	Predictive	Supports	B	Resistance	chr12	25245350	25245350	C	G	"In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015)."	"Greco et al., 2009, J. Exp. Clin. Cancer Res."	Somatic	ENST00000256078.4	missense_variant
KRAS G12A	KRAS	G12A	Multiple Myeloma	Melphalan	Predictive	Supports	D	Resistance	chr12	25245350	25245350	C	G	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	"Rowley et al., 2000, Blood"	Somatic	ENST00000256078.4	missense_variant
KRAS G12A	KRAS	G12A	Multiple Myeloma	Melphalan	Predictive	Supports	D	Resistance	chr12	25245350	25245350	C	G	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	"Rowley et al., 2002, Oncogene"	Somatic	ENST00000256078.4	missense_variant
KRAS G12A	KRAS	G12A	Multiple Myeloma	Melphalan	Predictive	Supports	D	Resistance	chr12	25245350	25245350	C	G	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	"Hoang et al., 2006, Blood"	Somatic	ENST00000256078.4	missense_variant
KRAS G12D	KRAS	G12D	Colorectal Cancer	Panitumumab	Predictive	Supports	C	Resistance	chr12	25245350	25245350	C	T	"One patient participating in a large retrospective study of EGFR monoclonal antibodies in metastatic, treatment refractory colorectal cancer had a tumor which harbored KRAS G12D, was wildtype for NRAS, BRAF and PIK3CA, and had individual response data. This patient was was a 55 year old female treated with panitumumab monotherapy as 3rd line therapy who experienced progressive disease (PFS: 8 weeks; OS: 9 weeks)."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000256078.4	missense_variant
KRAS G12D	KRAS	G12D	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Resistance	chr12	25245350	25245350	C	T	"This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 76 patients harbored KRAS G12D, were BRAF, NRAS and PIK3CA wt, and had individual response data. Five patients had partial response, 34 had stable disease, and 37 progressed. Treatments included cetuximab + irinotecan (n=61), cetuximab + FOLFIRI (n=6), cetuximab monotherapy (n=5), cetuximab + oxaliplatin + 5FU (n=2), cetuximab + 5FU (n=1), cetuximab + oxaliplatin + bevacizumab (n=1). Median PFS was 12 weeks (3-169 weeks), median OS was 31 weeks (6-232 weeks), and median number of previous chemotherapy lines was 2 (0-5). Median age was 62 years old (32-86), and there were 43 males and 33 females. Using these data and data from the larger cohort, authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000256078.4	missense_variant
KRAS G12D	KRAS	G12D	Colorectal Cancer	"Selumetinib,Dactolisib"	Predictive	Supports	D	Sensitivity/Response	chr12	25245350	25245350	C	T	"In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring KRAS, NRAS, BRAF or PIK3CA mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors studied had KRAS mutations with 9 G12D (2 with PIK3CA H1047R) and 13 other G12 mutations."	"Migliardi et al., 2012, Clin. Cancer Res."	Somatic	ENST00000256078.4	missense_variant
KRAS G12V	KRAS	G12V	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Resistance	chr12	25245350	25245350	C	A	"This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 39 patients harbored KRAS G12V, were BRAF, NRAS and PIK3CA wt, and had individual response data. Three patients had partial response, 16 had stable disease, and 20 progressed. Treatments included cetuximab + irinotecan (n=30), cetuximab + FOLFIRI (n=2), cetuximab monotherapy (n=2), cetuximab + oxaliplatin + 5FU (n=2), cetuximab + 5FU (n=1), cetuximab + irinotecan + oxaliplatin + 5FU + bevacizumab (n=1), and cetuximab+irinotecan+oxaliplatin+5FU (n=1). Median PFS was 12 weeks (1-37 weeks), median OS was 32 weeks (4-77 weeks), and median number of previous chemotherapy lines was 2 (0-5). Median age was 63 years old (34-76), and there were 21 males and 18 females. Authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000256078.4	missense_variant
KRAS G12V	KRAS	G12V	Colorectal Cancer	Panitumumab	Predictive	Supports	C	Resistance	chr12	25245350	25245350	C	A	"In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk)."	"Amado et al., 2008, J. Clin. Oncol."	Somatic	ENST00000256078.4	missense_variant
KRAS G12D	KRAS	G12D	Colorectal Cancer	Panitumumab	Predictive	Supports	C	Resistance	chr12	25245350	25245350	C	T	"In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk)."	"Amado et al., 2008, J. Clin. Oncol."	Somatic	ENST00000256078.4	missense_variant
KRAS G12D	KRAS	G12D	Lung Cancer	Gefitinib	Predictive	Supports	B	Resistance	chr12	25245350	25245350	C	T	"In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390)."	"Endoh et al., 2006, J Thorac Oncol"	Somatic	ENST00000256078.4	missense_variant
KRAS G12D	KRAS	G12D	Multiple Myeloma	Melphalan	Predictive	Supports	B	Resistance	chr12	25245350	25245350	C	T	"In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015)."	"Greco et al., 2009, J. Exp. Clin. Cancer Res."	Somatic	ENST00000256078.4	missense_variant
KRAS G12D	KRAS	G12D	Multiple Myeloma	Melphalan	Predictive	Supports	D	Resistance	chr12	25245350	25245350	C	T	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	"Rowley et al., 2000, Blood"	Somatic	ENST00000256078.4	missense_variant
KRAS G12D	KRAS	G12D	Multiple Myeloma	Melphalan	Predictive	Supports	D	Resistance	chr12	25245350	25245350	C	T	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	"Rowley et al., 2002, Oncogene"	Somatic	ENST00000256078.4	missense_variant
KRAS G12D	KRAS	G12D	Multiple Myeloma	Melphalan	Predictive	Supports	D	Resistance	chr12	25245350	25245350	C	T	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	"Hoang et al., 2006, Blood"	Somatic	ENST00000256078.4	missense_variant
KRAS G12V	KRAS	G12V	Lung Cancer	Gefitinib	Predictive	Supports	C	Resistance	chr12	25245350	25245350	C	A	"In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390)."	"Endoh et al., 2006, J Thorac Oncol"	Somatic	ENST00000256078.4	missense_variant
KRAS G12A	KRAS	G12A	Colorectal Cancer	Regorafenib	Predictive	Supports	D	Resistance	chr12	25245350	25245350	C	G	"In an in vitro study, a human colon adenocarcinoma SW48 cell line virally transduced to express KRAS G12A demonstrated resistance to regorafenib treatment (IC50: 330.13 nM vs. 114.28 nM, P<0.01, reported errantly as 3301.13nM in the source) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G12A was more strongly resistant to regorafenib than KRAS wt and other KRAS G12/G13 mutations."	"Camaj et al., 2015, Future Oncol"	Somatic	ENST00000256078.4	missense_variant
KRAS G12V	KRAS	G12V	Colorectal Cancer	Panitumumab	Predictive	Supports	C	Resistance	chr12	25245350	25245350	C	A	"One patient participating in a large retrospective study of EGFR monoclonal antibodies in metastatic, treatment refractory colorectal cancer had a tumor which harbored KRAS G12V, was wildtype for NRAS, BRAF and PIK3CA, and had individual response data. This patient was was a 78 year old female treated with panitumumab monotherapy as 2nd line therapy who experienced progressive disease (PFS: 5 weeks)."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000256078.4	missense_variant
KRAS G12V	KRAS	G12V	Colorectal Cancer	Regorafenib	Predictive	Supports	D	Resistance	chr12	25245350	25245350	C	A	"In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12V mutation demonstrated resistance to regorafenib treatment (IC50: 241.90 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wildtype. Resistance was determined by assessing cell viability. Regorafenib significantly reduced BRAF, Erk1/2 and Elk phosphorylation compared to wildtype, as assessed by western blot. Authors concluded that KRAS G12A was more resistant to regorafenib than KRAS wt, and intermediately resistant compared to other common KRAS mutations."	"Camaj et al., 2015, Future Oncol"	Somatic	ENST00000256078.4	missense_variant
KRAS G12D	KRAS	G12D	Colorectal Cancer	Regorafenib	Predictive	Supports	D	Resistance	chr12	25245350	25245350	C	T	"In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12D mutation demonstrated resistance to regorafenib treatment (IC50: 195.01nM vs. 114.28 nM P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G12D was more resistant to regorafenib than KRAS wt, and intermediately resistant compared to other common KRAS G12/G13 mutations."	"Camaj et al., 2015, Future Oncol"	Somatic	ENST00000256078.4	missense_variant
KRAS G12D	KRAS	G12D	Melanoma	Vemurafenib	Predictive	Supports	D	Resistance	chr12	25245350	25245350	C	T	In vitro studies of M229 (a human melanoma cell line) endogenously expressing wildtype KRAS and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express KRAS4a G12D or KRAS4b G12D  were more resistant to vemurafenib (a BRAF inhibitor) than cells transduced with empty vectors (90% vs 10% survival).	"Shi et al., 2014, Cancer Discov"	Somatic	ENST00000256078.4	missense_variant
KRAS G12D	KRAS	G12D	Ovarian Cancer	Cetuximab	Predictive	Supports	D	Resistance	chr12	25245350	25245350	C	T	"In an in vitro study, a MCAS cell line expressing KRAS G12D mutation was associated with reduced sensitivity to cetuximab treatment as compared to RMUG-L and OMC-1 cells expressing wild-type KRAS. Resistance was determined by assessing cell growth. Further, in an in vivo experiment, KRAS G12D expressing MCAS xenografts in nude mice had reduced response to cetuximab, as compared to KRAS wild-type expressing RMUG-L xenografts. Resistance was determined by assessing tumor growth."	"Sato et al., 2012, Oncol. Rep."	Somatic	ENST00000256078.4	missense_variant
KRAS G12A	KRAS	G12A	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Resistance	chr12	25245350	25245350	C	G	"This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 22 patients harbored KRAS G12A, were BRAF, NRAS and PIK3CA wt, and had individual response data. Three patients had partial response, 12 had stable disease, and seven progressed. Treatments included cetuximab + irinotecan (n=18), cetuximab monotherapy (n=1), cetuximab + FOLFIRI (n=2), and cetuximab + oxaliplatin + 5FU (n=1). Median PFS was 18 weeks (1-34 weeks), median OS was 35 weeks (1-143 weeks), and median number of previous chemotherapy lines was 2 (0-5). Median age was 62 years old (22-77) and there were 11 males and 11 females. Using these data and data from the larger cohort, authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000256078.4	missense_variant
KRAS G12D	KRAS	G12D	Colorectal Cancer	"Panitumumab,Cetuximab"	Predictive	Supports	C	Resistance	chr12	25245350	25245350	C	T	"In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN were tested for mutation; KRAS G12D was the only variant noted in the primary tumor of two patients who experienced stable disease  following treatment (Patients 22 and 36; colon and rectum tumors; Supplemental Table 1). In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant."	"Sartore-Bianchi et al., 2009, Cancer Res."	Somatic	ENST00000256078.4	missense_variant
KRAS G12A	KRAS	G12A	Colorectal Cancer	"Panitumumab,Cetuximab"	Predictive	Supports	C	Resistance	chr12	25245350	25245350	C	G	"In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN were tested for mutation; KRAS G12A was the only variant noted in the both the primary and metastatic colon tumors of one patient (Patient 29; Supplemental table 1) , and the primary colon tumor of another patient (104; Table S1),  who both experienced stable disease following treatment. In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant."	"Sartore-Bianchi et al., 2009, Cancer Res."	Somatic	ENST00000256078.4	missense_variant
KRAS G12V	KRAS	G12V	Colorectal Cancer	"Panitumumab,Cetuximab"	Predictive	Supports	C	Resistance	chr12	25245350	25245350	C	A	"In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN were tested for mutation; KRAS G12V was the only variant noted in the primary rectal tumor of one patient who experienced disease progression (patient 56; Supplemental Table 1), and the primary colon tumors of two patients (9, 13; Supplemental Table 1) who experienced stable disease following treatment. In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant."	"Sartore-Bianchi et al., 2009, Cancer Res."	Somatic	ENST00000256078.4	missense_variant
KRAS G12C	KRAS	G12C	Lung Cancer		Diagnostic	Supports	B	Positive	chr12	25245351	25245351	C	A	KRAS G12C occur more frequently in women than men.	"Dogan et al., 2012, Clin. Cancer Res."	Somatic	ENST00000256078.4	missense_variant
KRAS G12C	KRAS	G12C	Lung Non-small Cell Carcinoma	"Selumetinib,Docetaxel"	Predictive	Supports	B	Sensitivity/Response	chr12	25245351	25245351	C	A	"83 patients from a phase II trial (docetaxel + placebo or MEK1/2 inhibitor selumetinib) with KRAS mutant tumors were retrospectively assessed for differences in OS, PFS, ORR and change in tumor size at week 6 according to type of KRAS mutation. G12C, G12D and G12V were the most common mutations (46%, 22%, 11%, respectively). Patients with G12C or G12V mutations receiving selumetinib and docetaxel combined treatment had a trend towards longer OS, PFS and ORR compared to other KRAS mutations, but the differences did not reach statistical significance. Changes in tumor size were similar between groups with the best responses in tumors with G12V mutations. Few differences were observed between groups when treated with docetaxel + placebo."	"Jnne et al., 2015, Br. J. Cancer"	Somatic	ENST00000256078.4	missense_variant
KRAS G12C	KRAS	G12C	Cancer	"Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,ARS-853"	Predictive	Supports	D	Sensitivity/Response	chr12	25245351	25245351	C	A	"Preclinical study to investigate mechanisms of KRAS G12C activity and inhibition with ARS-853, a covalent (irreversible) inhibitor which binds KRAS G12C in the GDP-bound state to prevent activation. Results from a mass spectrometry-based assay to evaluate KRAS activity suggests that G12C mutant KRAS is in a hyperexcitable?rather than a statically active?state. ARS-853 targets the inactive state and inhibited proliferation in a subset  (3/11) of KRAS G12C mutant cell lines in 2-D growth assays and 11/11 cell lines in soft-agar colony formation and 3-D assays. This effect was specific for KRAS G12C as 12/12 cell lines with other KRAS mutations (including other G12 mutations V, D and A) were not inhibited in either soft-agar assay.  Relative resistance to ARS-853 developed after epidermal growth factor (50 ng/mL) administration and the combination of erlotinib or afatinib (EGFR-inhibitors) with ARS-853 greatly potentiated growth arrest, apoptosis and decrease of PI3K and MAPK-signaling over single-agent ARS-853 treatment, even in the presence of added EGF."	"Patricelli et al., 2016, Cancer Discov"	Somatic	ENST00000256078.4	missense_variant
KRAS G12C	KRAS	G12C	Colorectal Cancer	"Gefitinib,Erlotinib"	Predictive	Supports	B	Resistance	chr12	25245351	25245351	C	A	"In a study of 448 metastatic colorectal cancer patients treated with EGFR-TKIs and tested for EGFR and KRAS mutations, 69 tested positive for KRAS mutations. In 38 EGFR wildtype patients treated with erlotinib or gefitinib, those with KRAS G12C mutations (n=24) had shorter progression free survival rates compared to patients with non-G12C KRAS mutations (n=14; 4.3 vs 9 weeks; P = 0.009; HR=2.7). This was true when restricted to patients with an adenocarcinoma subtype only (n=18 vs 12; 4.1 vs 9 weeks; P = 0.007; HR=3.1). Overall survival was not different between groups."	"Fiala et al., 2013, Cancer Genet"	Somatic	ENST00000256078.4	missense_variant
KRAS G12C	KRAS	G12C	Lung Non-small Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr12	25245351	25245351	C	A	"In a study of 48 NSCLC patients, those with G12C or G12V mutant KRAS were associated with decreased progression free survival (1.84 months) compared with other KRAS mutants or with wild-type KRAS (3.35 and 1.95 months)."	"Ihle et al., 2012, J. Natl. Cancer Inst."	Somatic	ENST00000256078.4	missense_variant
KRAS G12R	KRAS	G12R	Pancreatic Cancer		Prognostic	Supports	B	Poor Outcome	chr12	25245351	25245351	C	G	"In 242 patients with unresectable pancreatic cancer, the presence of KRAS G12R (N=17) or G12D (N=92) was associated with poorer prognosis (overall survival HR 1.6; 95% confidence interval 1.11-2.28)."	"Ogura et al., 2013, J. Gastroenterol."	Somatic	ENST00000256078.4	missense_variant
KRAS G12C	KRAS	G12C	Colorectal Cancer	"Selumetinib,Dactolisib"	Predictive	Supports	D	Sensitivity/Response	chr12	25245351	25245351	C	A	"In 28 out of 40 (70%) metastatic colorectal cancer tumors harboring BRAF, KRAS, NRAS or PIK3CA mutations and implanted into mice, the therapeutic combination of the MEK inhibitor AZD6244 and the PI3K/mTor inhibitor BEZ235 resulted in disease stabilization. Mean tumor growth was lower in the tumors treated with AZD6244+ BEZ235 (+77% vs. +267%, P=1E-6) compared to AZD6244 alone and (+77% vs. +222%, P=0.0014) BEZ235 alone. 32/40 tumors harbored KRAS mutations including 4 G12C mutations where disease stabilization occurred in 3/4 treated with BEZ235 or doublet therapy and 2/4 treated with AZD6244 only."	"Migliardi et al., 2012, Clin. Cancer Res."	Somatic	ENST00000256078.4	missense_variant
KRAS G12C	KRAS	G12C	Colorectal Cancer	Panitumumab	Predictive	Supports	C	Resistance	chr12	25245351	25245351	C	A	"In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk)."	"Amado et al., 2008, J. Clin. Oncol."	Somatic	ENST00000256078.4	missense_variant
KRAS G12C	KRAS	G12C	Lung Cancer	Gefitinib	Predictive	Supports	B	Resistance	chr12	25245351	25245351	C	A	"In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390)."	"Endoh et al., 2006, J Thorac Oncol"	Somatic	ENST00000256078.4	missense_variant
KRAS G12C	KRAS	G12C	Multiple Myeloma	Melphalan	Predictive	Supports	B	Resistance	chr12	25245351	25245351	C	A	"In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015)."	"Greco et al., 2009, J. Exp. Clin. Cancer Res."	Somatic	ENST00000256078.4	missense_variant
KRAS G12C	KRAS	G12C	Multiple Myeloma	Melphalan	Predictive	Supports	D	Resistance	chr12	25245351	25245351	C	A	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	"Rowley et al., 2000, Blood"	Somatic	ENST00000256078.4	missense_variant
KRAS G12C	KRAS	G12C	Multiple Myeloma	Melphalan	Predictive	Supports	D	Resistance	chr12	25245351	25245351	C	A	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	"Rowley et al., 2002, Oncogene"	Somatic	ENST00000256078.4	missense_variant
KRAS G12C	KRAS	G12C	Multiple Myeloma	Melphalan	Predictive	Supports	D	Resistance	chr12	25245351	25245351	C	A	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	"Hoang et al., 2006, Blood"	Somatic	ENST00000256078.4	missense_variant
KRAS G12R	KRAS	G12R	Colorectal Cancer	Panitumumab	Predictive	Supports	C	Resistance	chr12	25245351	25245351	C	G	"In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk)."	"Amado et al., 2008, J. Clin. Oncol."	Somatic	ENST00000256078.4	missense_variant
KRAS G12S	KRAS	G12S	Colorectal Cancer	Panitumumab	Predictive	Supports	C	Resistance	chr12	25245351	25245351	C	T	"In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced response to panitumumab compared to wildtype KRAS (HR:0.99, 95% CI:0.73-1.36 vs. HR:0.45, 95% CI:0.34-0.59; P<0.0001). Additionally, patients with KRAS mutations showed no significant improvement between treatment with panitumumab and best supportive care alone (PFS: 7.4 wk vs 7.3 wk)."	"Amado et al., 2008, J. Clin. Oncol."	Somatic	ENST00000256078.4	missense_variant
KRAS G12S	KRAS	G12S	Lung Cancer	Gefitinib	Predictive	Supports	B	Resistance	chr12	25245351	25245351	C	T	"In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and stable disease (SD) and a higher rate of progressive disease (PD) (PR:0, SD:1, PD:15 vs. PR:24, SD:8, PD:14; P=0.0274) compared to wildtype KRAS patients. Patients with KRAS mutations also had a shorter overall survival compared to wildtype KRAS patients (HR:2.542, 95% CI:1.048-6.168, P=0.0390)."	"Endoh et al., 2006, J Thorac Oncol"	Somatic	ENST00000256078.4	missense_variant
KRAS G12S	KRAS	G12S	Multiple Myeloma	Melphalan	Predictive	Supports	B	Resistance	chr12	25245351	25245351	C	T	"In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015)."	"Greco et al., 2009, J. Exp. Clin. Cancer Res."	Somatic	ENST00000256078.4	missense_variant
KRAS G12S	KRAS	G12S	Multiple Myeloma	Melphalan	Predictive	Supports	D	Resistance	chr12	25245351	25245351	C	T	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	"Rowley et al., 2000, Blood"	Somatic	ENST00000256078.4	missense_variant
KRAS G12S	KRAS	G12S	Multiple Myeloma	Melphalan	Predictive	Supports	D	Resistance	chr12	25245351	25245351	C	T	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	"Rowley et al., 2002, Oncogene"	Somatic	ENST00000256078.4	missense_variant
KRAS G12S	KRAS	G12S	Multiple Myeloma	Melphalan	Predictive	Supports	D	Resistance	chr12	25245351	25245351	C	T	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	"Hoang et al., 2006, Blood"	Somatic	ENST00000256078.4	missense_variant
KRAS G12C	KRAS	G12C	Colorectal Cancer	"Cetuximab,Chemotherapy"	Predictive	Supports	B	Resistance	chr12	25245351	25245351	C	A	"This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 16 patients harbored KRAS G12C, were BRAF, NRAS and PIK3CA wt, and had individual response data. One patient had a partial response, 6 had stable disease, and 9 progressed. Treatments included cetuximab + irinotecan (n=15) and cetuximab + FOLFIRI (n=1). Median PFS was 11 weeks (6-65 weeks), median OS was 24 weeks (14-91 weeks), and median number of previous chemotherapy lines was 2 (1-6). Median age was 62 years old (46-73), and there were 8 males and 8 females. Using these data and data from the larger cohort, authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000256078.4	missense_variant
KRAS G12C	KRAS	G12C	Colorectal Cancer	Regorafenib	Predictive	Supports	D	Resistance	chr12	25245351	25245351	C	A	"In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12C mutation demonstrated resistance to regorafenib treatment (IC50: 386.22 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. In vivo, KRAS G12C expressing SW48 cells were injected into NOD/SCID mice. Treatment with regorafenib did not lead to a significant delay of tumor growth. Mice injected with KRAS wt cells did not significantly respond to regorafenib, although a trend was seen toward better response. IHC analysis of mouse tissue revealed no significant change in markers of proliferation (Ki67), angiogenesis (CD31) and apoptosis (TUNEL) in KRAS G12C expressing mice treated with regorafenib compared to KRAS wt expressing mice whose tumors displayed more pronounced changes. Authors concluded that G12C was more resistant to regorafenib than KRAS wt and other common KRAS G12/G13 mutants."	"Camaj et al., 2015, Future Oncol"	Somatic	ENST00000256078.4	missense_variant
KRAS G12R	KRAS	G12R	Colorectal Cancer	"Cetuximab,Chemotherapy"	Predictive	Supports	C	Resistance	chr12	25245351	25245351	C	G	"Three patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS G12R, were wildtype for NRAS, BRAF and PIK3CA, and had individual response data. One patient experienced stable disease, and two patients experienced progressive disease. Patient characteristics were as follows: a 67 year old female treated with cetuximab + irinotecan as a 4th line treatment who experienced progressive disease and had PFS of 8 weeks and OS of 17 weeks; a 78 year old female treated with cetuximab + irinotecan as a 3rd line therapy who experienced progressive disease and had PFS of 3 weeks and OS of 10 weeks; and a 55 year old male treated with cetuximab + FOLFIRI as a 3rd line therapy who experienced stable disease and had PFS of 13 weeks and OS of 15 weeks."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000256078.4	missense_variant
KRAS G12R	KRAS	G12R	Colorectal Cancer	Cetuximab	Predictive	Supports	D	Resistance	chr12	25245351	25245351	C	G	"In an in vitro study to identify cetuximab-resistant clones following continuous drug treatment, a resistant clone of the Lim1215 colorectal cancer cell line was identified to have the KRAS G12R mutation. No G12R was detected in the parental line despite high-resolution evaluation. Additionally, endogenously expressing KRAS G12R (knock-in) mutation demonstrated resistance to cetuximab treatment, compared to Lim1215 parental cells expressing wild-type KRAS. Resistance was determined by assessing cell viability."	"Misale et al., 2012, Nature"	Somatic	ENST00000256078.4	missense_variant
KRAS G12R	KRAS	G12R	Colorectal Cancer	Regorafenib	Predictive	Supports	D	Resistance	chr12	25245351	25245351	C	G	"In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12R mutation demonstrated resistance to regorafenib treatment (IC50: 181.77 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G12R was resistant to regorafenib compared to wildtype but was less resistant than other common KRAS G12/G13 mutations."	"Camaj et al., 2015, Future Oncol"	Somatic	ENST00000256078.4	missense_variant
KRAS G12S	KRAS	G12S	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Resistance	chr12	25245351	25245351	C	T	"This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 16 patients harbored KRAS G12S, were BRAF, NRAS and PIK3CA wt, and had individual response data. Nine patients had stable disease and seven progressed. Treatments included cetuximab + irinotecan (n=13), cetuximab + FOLFIRI (n=1), cetuximab+5FU (n=1), cetuximab + irinotecan + oxaliplatin + bevacizumab (n=1). Median PFS was 12 weeks (2-50 weeks), median OS was 25 weeks (10-135 weeks), and median number of previous chemotherapy lines was 2 (1-6). Median age was 59 years old (31-69), and there were 9 males and 7 females. Using these data and data from the larger cohort, authors concluded that KRAS mutation was strongly associated with poor response to cetuximab and suggested that mutation status of KRAS is the most informative compared to BRAF, NRAS, and PIK3CA exon 20 for predicting cetuximab response."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000256078.4	missense_variant
KRAS G12S	KRAS	G12S	Colorectal Cancer	Regorafenib	Predictive	Supports	D	Resistance	chr12	25245351	25245351	C	T	"In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12S mutation demonstrated resistance to regorafenib treatment (IC50: 264.23 nM vs. 114.28 nM, P<0.01) compared to SW48 cells expressing KRAS wild-type. Resistance was determined by assessing cell viability. Authors concluded that KRAS G12S was more resistant to regorafenib than KRAS wt, and intermediately resistant compared to other common KRAS G12/G13 mutations."	"Camaj et al., 2015, Future Oncol"	Somatic	ENST00000256078.4	missense_variant
KRAS G12S	KRAS	G12S	Colorectal Cancer	"Cetuximab,Panitumumab"	Predictive	Supports	C	Resistance	chr12	25245351	25245351	C	T	"In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN were tested for mutation; KRAS G12S was the only variant noted in the primary tumor of one patient who experienced disease progression following treatment (colon tumor of patient 20; Supplemental Table 1). In the larger cohort, patients with tumors harboring any KRAS mutation had significantly decreased incidence of objective response than patients with wtKRAS tumors. Authors noted that patients with tumors harboring KRAS mutations tended to have decreased PFS and OS compared to those with wild-type tumors though the differences were not statistically significant."	"Sartore-Bianchi et al., 2009, Cancer Res."	Somatic	ENST00000256078.4	missense_variant
KRAS G12C	KRAS	G12C	Lung Non-small Cell Carcinoma	Sotorasib	Predictive	Supports	A	Sensitivity/Response	chr12	25245351	25245351	C	A	"The phase II cohort of the CodeBreaK 100 study (NCT03600883) investigated the activity of the KRAS G12C inhibitor sotorasib in previously treated patients with KRAS G12C-mutated non-small cell lung cancer. A total of 124 patients had measurable disease and were evaluated for response by independent central review. Complete response was seen in four patients and partial response in 42 patients, for an objective response rate of 37.1% (95% CI, 28.6 to 46.2). The median progression-free survival and overall survival were 6.8 (95% CI, 5.1 to 8.2) months and 12.5 months (95% CI, 10.0 to could not be evaluated), respectively."	"Skoulidis et al., 2021, N Engl J Med"	Somatic	ENST00000256078.4	missense_variant
KMT2D Loss-of-function	KMT2D	Loss-of-function	Follicular Lymphoma		Diagnostic	Supports	B	Positive	chr12	49018975	49055324			"MLL2 was found to be the most frequently mutated gene in a sample of 31/35 follicular lymphoma patients and was not mutated in normal centroblast samples. Furthermore, MLL2 mutations were as frequently observed as t(14;18) Igh-BCL2 translocations, which are the most common clinically significant genetic event observed in follicular lymphoma. Mutations were predicted to be loss-of-function."	"Morin et al., 2011, Nature"	Somatic	ENST00000301067.7	loss_of_function_variant
KRT18 UNDEREXPRESSION	KRT18	UNDEREXPRESSION	Prostate Cancer		Prognostic	Supports	D	Poor Outcome	chr12	52948871	52952900			"Comparison of nuclear matrix protein (NMP) patterns of paclitaxel-resistant PCa cells (DU145-TxR), with that of parental cell (DU145) using two-dimensional electrophoresis, identified cytokeratin 18 (CK18) as downregulated in DU145-TxR cells (validated at mRNA, NMP and total cellular protein levels). An in-vivo assay of xenograft transplantation showed higher tumorigenicity of DU145-TxR cells. Immunohistochemistry showed that CK18 expression in PCa tissues was statistically significant inversely correlated with tumor grade."	"Yin et al., 2016, Int. J. Oncol."	N/A	ENST00000388837.2	N/A
ERBB3 Overexpression	ERBB3	Overexpression	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Resistance	chr12	56079861	56103505			High expression of ERBB3 (her3) was associated with shorter overall survival (OS) from Cetuximab treatment in patients with metastatic colorectal cancer. Gene expression measures (qRT-PCR) were available for 103 patients.	"Cushman et al., 2015, Clin. Cancer Res."	N/A	ENST00000267101.3	N/A
ERBB3 EXPRESSION	ERBB3	EXPRESSION	Cancer	Anti-ErbB3 Monoclonal Antibody AV-203	Predictive	Does Not Support	D	Sensitivity/Response	chr12	56079861	56103505			"The authors conducted an in vivo efficacy study of AV-203 (ERBB3 inhibitory antibody) using a panel of 32 xenograft models representing 12 human cancer types. To identify biomarkers that can predict response to AV-203, the relationship between tumor growth inhibition (TGI) by AV-203 and the expression levels of ERBB3 and NRG1 were evaluated in these tumor models. ERBB3 expression was not predictive of response."	"Meetze et al., 2015, Clin. Cancer Res."	N/A	ENST00000267101.3	N/A
ERBB3 EXPRESSION	ERBB3	EXPRESSION	Pancreatic Ductal Adenocarcinoma	"Pertuzumab,9F7-F11"	Predictive	Supports	D	Sensitivity/Response	chr12	56079861	56103505			In mice xenografts expressing ERBB3 (HER3) the combination of ERBB2 (HER2) and ERBB3 inhibitors pertuzumab and 9F7-F11enhanced tumor inhibition and the median survival time. Sensitivity to single-agent pertuzumab might also be increased through ERBB3 expression.	"Thomas et al., 2014, Oncotarget"	N/A	ENST00000267101.3	N/A
ERBB3 Overexpression	ERBB3	Overexpression	Cancer	"Afatinib,Selumetinib"	Predictive	Supports	D	Sensitivity/Response	chr12	56079861	56103505			"Preclinical study in KRAS mutant lung and colon cancer models. A synthetic lethal screen using a total of 3,530 shRNAs to target 518 human kinases identified ERBB3 knockdown to confer sensitivity of selumetinib-resistant H358 cells (NSCLC cell line) to the MEK inhibitor selumetinib. The dual EGFR-ERBB2 inhibitors afatinib and dacomitinib each showed synergy with MEK Inhibition via selumetinib in 4 KRAS mutant cell lines. Western blot evaluation of 9 NSCLC and 12 CRC cell lines showed ERBB3 expression correlated with the synergy score for combination afatinib and trametinib treatment. I.e. the synergy score was low in cells having low basal levels of ERBB3 protein and high for cells having high basal ERBB3 expression. Using selumetinib in patient-derived CRC xenografts or trametinib in NSCLC xenografts, MEK inhibition by selumetinib or trametinib in combination with afatinib more effectively inhibited increases in tumor volume than either monotherapy."	"Sun et al., 2014, Cell Rep"	N/A	ENST00000267101.3	N/A
ERBB3 Overexpression	ERBB3	Overexpression	Cancer	"Selumetinib,HER2 Inhibitor CP-724,714,Gefitinib"	Predictive	Supports	D	Resistance	chr12	56079861	56103505			Preclinical study in KRAS mutant lung and colon cancer models. A synthetic lethal screen identified ERBB3 blockade to confer sensitivity to MEK inhibitors. The dual EGFR-ERBB2 (both forming heterodimers with ERBB3) inhibitors afatinib and dacomitinib each showed strong synergy with MEK Inhibition (trametinib or selumetinib) in several KRAS mutant cell lines. MEK Inhibitors alone or the combination with gefitinib (EGFRi) or CP724714 (ERBB2i) showed strong synergy. Results were validated in-vivo. Basal ERBB3 expression was associated with higher synergy scores.	"Sun et al., 2014, Cell Rep"	N/A	ENST00000267101.3	N/A
ERBB3 Overexpression	ERBB3	Overexpression	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	Predictive	Does Not Support	B	Resistance	chr12	56079861	56103505			"In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors harbored higher than median levels of ERBB3 mRNA treated with ado-trastuzumab emtansine (T-DM1; n=210) were associated with similar median progression free survival (PFS) compared to patients whose tumors harbored the median or lower levels of ERBB3 mRNA (n=214; PFS: 9.8 vs. 9.3 months)."	"Baselga et al., 2016, Clin. Cancer Res."	N/A	ENST00000267101.3	N/A
ERBB3 R103G	ERBB3	R103G	Transitional Cell Carcinoma	Afatinib	Predictive	Supports	B	Sensitivity/Response	chr12	56085067	56085067	C	G	"In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3."	"Choudhury et al., 2016, J. Clin. Oncol."	Somatic	ENST00000267101.3	missense_variant
ERBB3 V104M	ERBB3	V104M	Transitional Cell Carcinoma	Afatinib	Predictive	Supports	B	Sensitivity/Response	chr12	56085070	56085070	G	A	"In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3."	"Choudhury et al., 2016, J. Clin. Oncol."	Somatic	ENST00000267101.3	missense_variant
ERBB3 G284R	ERBB3	G284R	Transitional Cell Carcinoma	Afatinib	Predictive	Supports	B	Sensitivity/Response	chr12	56088138	56088138	G	A	"In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or ERBB3 alterations achieved 3-month progression-free survival (PFS3) versus none of 15 patients without alterations (P < .001). Three of three patients with ERBB3 somatic mutations (G284R, V104M, and R103G) achieved PFS3."	"Choudhury et al., 2016, J. Clin. Oncol."	Somatic	ENST00000267101.3	missense_variant
ERBB3 V855A	ERBB3	V855A	Lung Non-small Cell Carcinoma	"Afatinib,Pertuzumab"	Predictive	Supports	D	Sensitivity/Response	chr12	56097888	56097888	T	C	Case report on a novel V855A mutation located in exon 21 of the HER3 tyrosine kinase domain and found in the tumor specimen of an adolescent patient with a chemotherapy-resistant advanced NSCLC. Protein alignments indicated this mutation was analogous to EGFR-L858R and BRAF-L597V. Co-expression of wildtype HER2 and HER3-V855A in Ba/F3 cells led to sensitivity to afatinib and pertuzumab.	"Umelo et al., 2016, Oncotarget"	Somatic	ENST00000267101.3	missense_variant
DDIT3 EWSR1::DDIT3	DDIT3	EWSR1::DDIT3	Myxoid Liposarcoma		Diagnostic	Supports	C	Positive	chr12	57516593	57517753			Identified two cases of myxoid liposarcoma with translocations (between 12q13 and 22q12) giving rise to EWSR1-DDIT3 (EWS-CHOP) fusions instead of the more common FUS-DDIT3.	"Panagopoulos et al., 1996, Oncogene"	Somatic	ENST00000414183.2	transcript_fusion
CDK4 EXPRESSION	CDK4	EXPRESSION	Estrogen-receptor Positive Breast Cancer	Alpelisib	Predictive	Supports	D	Sensitivity/Response	chr12	57747727	57752521			"In mouse xenograft studies of PIK3CA mutant breast cancers, the combination of PI3K and CDK4/6 inhibitors overcomes intrinsic and adaptive resistance leading to tumor regressions."	"Vora et al., 2014, Cancer Cell"	Somatic	ENST00000257904.6	N/A
CDK4 Amplification	CDK4	Amplification	Liposarcoma	Palbociclib	Predictive	Supports	B	Sensitivity/Response	chr12	57747727	57752521			"In a phase 2 clinical trial, NCT01209598, 30 patients with CDK4-amplified and RB-expressing well differentiated and dedifferentiated liposarcomas (WDLS/DDLS) were treated with a selective CDK 4/6 inhibitor, PD0332991. Treatment with PD0332991 was associated with favorable progression free survival rates (66% PFS rate, primary end point being greater than 40%) suggesting that CDK4 amplification is predictive of sensitivity to CDK4 inhibitor therapy."	"Dickson et al., 2013, J. Clin. Oncol."	Somatic	ENST00000257904.6	transcript_amplification
CDK4 Amplification	CDK4	Amplification	Liposarcoma	Palbociclib	Predictive	Supports	B	Sensitivity/Response	chr12	57747727	57752521			"A total of 59 patients with well-differentiated or dedifferentiated liposarcomas were enrolled in a phase 2 study to evaluate palbociclib efficacy. Half of the patients had received prior treatment and half were treatment naive. Of the 59 patients, at least 34 conferred CDK4 amplification and the remaining were not tested for CDK4 amplification. In the initial cohort (n=28), where all patients had confirmed CDK4 amplification, at least 14 of the patients were progression free at 12 weeks. Overall progression-free survival at 12 weeks was 57.2% and overall median PFS was 17.9 weeks. There was 1 complete response. Toxic effects were primarily hematologic and included neutropenia (grade 3, n??0 [33%]; grade 4, n?? [3%]) but no neutropenic fever."	"Dickson et al., 2016, JAMA Oncol"	Somatic	ENST00000257904.6	transcript_amplification
CDK4 EXPRESSION	CDK4	EXPRESSION	Sarcoma	Palbociclib	Predictive	Supports	D	Sensitivity/Response	chr12	57747727	57752521			"A preclinical study to explore the efficacy of CDK4/6 inhibition with palbociclib, in a panel of sarcoma cell lines and sarcoma tumor xenografts (PDXs). The responsiveness of these cell lines correlated with their levels of CDK4 mRNA as well as in vivo PDX, but not against sarcomas displaying low levels of CDK4 and high levels of p16ink4a (CDKN2A)."	"Perez et al., 2015, Oncotarget"	N/A	ENST00000257904.6	N/A
CDK4 EXPRESSION	CDK4	EXPRESSION	Childhood B-cell Acute Lymphoblastic Leukemia	"Dexamethasone,Ribociclib"	Predictive	Supports	D	Sensitivity/Response	chr12	57747727	57752521			"CDK4 was found to be significantly overexpressed in the bone marrow of MLL-rearranged B-ALL patients (n=70) compared to normal bone marrow (n=74, p<.001). Combination treatment with dexamethasone (glucocorticoid) and Ribociclib (a highly selective CDK4 / CDK6 inhibitor) of both glucocorticoid sensitive (Rs4;11 & NALM6) and glucocorticoid resistant (RCH-ACV & SEM) B-ALL cell lines synergistically reduced cell viability of all four lines greater than individual drug exposures. Combination therapy also synergistically reduced the cell viability of 5 primary B-ALL lines derived from diagnosis bone marrow compared to individual treatment. (Note: Expression of CDK4 was not quantitatively measured in the derived and primary B-ALL lines used). Further investigation in RCH-ACV and SEM lines revealed dexamethasone and Ribociclib combined increased apoptosis (annexin-V) and increased G1 arrest along with increased p16 (a CDK4 & CDK6 inhibitor) and decreased phosphorylation of downstream G1 to S cell cycle progression markers compared to single treatments. Combination treatment also led to the increase of NR3C1 expression. Knockdown of CDK4 and CDK6 by siRNAs in RCH-ACV sensitized these cells to dexamethasone treatment and increased NR3C1 expression."	"Bortolozzi et al., 2018, Biochem. Pharmacol."	N/A	ENST00000257904.6	N/A
CDK4 R24C	CDK4	R24C	Skin Melanoma	Palbociclib	Predictive	Supports	D	Sensitivity/Response	chr12	57751648	57751648	G	A	"In a cohort of 143 patients with primary invasive melanoma, copy-number gain of CDK4 was observed (FISH) in 37% of cases. PD0332991 efficacy (proliferation assay) was assessed in a panel of 47 melanoma cell lines. Four cell lines had an R24C activating mutation in CDK4, three of these were sensitive to PD0332991 (palbociclib)."	"Young et al., 2014, Pigment Cell Melanoma Res"	Somatic	ENST00000257904.6	missense_variant
TBK1 Overexpression	TBK1	Overexpression	Melanoma	"Selumetinib,AZ909"	Predictive	Supports	D	Sensitivity/Response	chr12	64451880	64502108			"Preclinical study in melanoma cell lines. TBK1 depletion (siRNA) inhibited migration and invasion, whereas its constitutive overexpression led to an increase in invasion. In MEK-resistant NRAS mutant melanoma cell lines, TBK1 depletion or inhibition (AZ909) in combination with MEK inhibitors (selumetinib) promoted apoptosis in 3D culture."	"Vu et al., 2014, Mol. Cancer Res."	N/A	ENST00000331710.5	N/A
MDM2 EXPRESSION	MDM2	EXPRESSION	Malignant Pleural Mesothelioma	"Pemetrexed,Cisplatin"	Predictive	Supports	B	Resistance	chr12	68808176	68845434			"72 patients with malignant pleural mesothelioma were analyzed, MDM2 immunoexpression was assessed in 65 patients. MDM2 mRNA and protein expression correlated with poor OS and PFS for patients treated with cisplatin and pemetrexed (standard of care therapy)."	"Walter et al., 2015, Br. J. Cancer"	N/A	ENST00000462284.1	N/A
MDM2 EXPRESSION	MDM2	EXPRESSION	Malignant Pleural Mesothelioma		Prognostic	Supports	B	Poor Outcome	chr12	68808176	68845434			"72 patients with malignant pleural mesothelioma were analyzed, MDM2 immunoexpression was assessed in 65 patients. MDM2 mRNA and protein expression correlated with poor OS and PFS for patients treated with standard of care therapy (cisplatin and pemetrexed)."	"Walter et al., 2015, Br. J. Cancer"	Somatic	ENST00000462284.1	N/A
MDM2 RS34886328	MDM2	RS34886328	Esophagus Squamous Cell Carcinoma		Prognostic	Supports	B	Better Outcome	chr12	68841208	68841208	A		"124 esophageal squamous cell carcinoma patients with radical resection were genotyped using MassArray.  Patients with the DEL/A +AA genotype of MDM2 rs34886328 had a notably increased overall survival (HR = 0.27, 95% CI: 0.13?.56, P = 4.710?, Pc = 0.003) and increased disease free survival (HR = 0.22, 95% CI: 0.11?.43, P < .0001) when compared to patients without this mutation."	"Li et al., 2016, PLoS ONE"	Somatic	ENST00000462284.1	3_prime_UTR_truncation
PTPRB Loss-of-function	PTPRB	Loss-of-function	Angiosarcoma	"Vatalanib,Sunitinib"	Predictive	Supports	D	Sensitivity/Response	chr12	70516850	70637440			"The endothelial phosphatase PTPRB, a negative regulator of vascular growth factor tyrosine kinases, harbored truncating mutations in 10 of 39 angiosarcomas (26%) which correlated with MYC amplifications. In HUVEC cell line model, silencing of PTPRB induced features of angiogenesis which were abolished in the presence of sunitinib or vatalinib, inhibitors of VEGFR."	"Behjati et al., 2014, Nat. Genet."	Somatic	ENST00000334414.6	loss_of_function_variant
PTPRB Loss-of-function	PTPRB	Loss-of-function	Angiosarcoma		Diagnostic	Supports	B	Positive	chr12	70516850	70637440			A cohort of angiosarcomas (n=36) was sequenced and revealed to contain recurrent mutations in PTPRB (10/36) which were predominantly truncating or splice variants which impact the tyrosine phosphotase domain. Loss of function variants in PTPRB are rare in other cancer types suggesting this is specfic to angiosarcomas.	"Behjati et al., 2014, Nat. Genet."	Somatic	ENST00000334414.6	loss_of_function_variant
DUSP6 EXPRESSION	DUSP6	EXPRESSION	Cancer	Trametinib	Predictive	Supports	D	Sensitivity/Response	chr12	89347232	89353271			Expression of DUSP6 was associated with sensitivity to MEK inhibitor GSK1120212 (Sensitivity: 79%; specificity: 82%: P = 0.0027) in 218 solid cancer cell lines.	"Jing et al., 2012, Mol. Cancer Ther."	N/A	ENST00000279488.7	N/A
PTPN11 Overexpression	PTPN11	Overexpression	Laryngeal Carcinoma		Prognostic	Supports	B	Poor Outcome	chr12	112418914	112509913			Study explored the expression of the PTPN11 protein (SHP2) and found that expression was increased in a cohort of 112 laryngeal cancer samples. Expression was also associated with poor survival (p=.02) and in vitro models showed SHP2 expression promoted tumor growth.	"Gu et al., 2014, Int. J. Oncol."	Somatic	ENST00000351677.2	N/A
POLE Mutation	POLE	Mutation	Endometrial Cancer	Pembrolizumab	Predictive	Supports	C	Sensitivity/Response	chr12	132626314	132680037			Case report of a patient with endometrial cancer and exceptional response to pembrolizumab (maintained at 14 months). POLE mutations V411L (exonuclease domain) and R114* were identified in the primary tumor as well as a resected lymph node metastasis. The tumor harbored a high mutational load as assessed by panel sequencing. Analysis of TCGA RNA-seq data revealed an association between POLE mutations and high immune marker expression.	"Mehnert et al., 2016, J. Clin. Invest."	Somatic	ENST00000320574.5	gene_variant
CDX2 EXPRESSION	CDX2	EXPRESSION	Colorectal Cancer		Prognostic	Supports	B	Better Outcome	chr13	27962137	27971139			"Patients with stage II/III colorectal cancer were analyzed for expression of CDX2 (by microarray and IHC). In the discovery (466 patients) and validation sets (314 patients), 5-year DFS was lower among patients with CDX2 negative tumors (discovery set:hazard ratio for disease recurrence, 3.44; 95% confidence interval [CI], 1.60 to 7.38; P=0.002; validation set: hazard ratio, 2.42; 95% CI, 1.36 to 4.29; P=0.003)."	"Dalerba et al., 2016, N. Engl. J. Med."	N/A	ENST00000381020.7	N/A
FLT3 Mutation	FLT3	Mutation	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	N/A	chr13	28003274	28100592			"FLT3 mutations did not alter overall survival or remission duration in younger (16-60), cytogenetically normal AML patients with CEBPA mutations. 10/36 patients with CEBPA mutations also had FLT3 mutations (8 FLT3-ITD, 2 FLT3-D835)."	"Frhling et al., 2004, J. Clin. Oncol."	Somatic	ENST00000241453.7	"transcript_variant,gain_of_function_variant"
FLT3 Overexpression	FLT3	Overexpression	B-cell Adult Acute Lymphocytic Leukemia	Sunitinib	Predictive	Supports	C	Sensitivity/Response	chr13	28003274	28100592			"A 25-year-old Caucasian male presented with a second relapse of B-ALL. RNA sequencing revealed FLT3 overexpression (also confirmed by IHC). The patient was treated with 22 days of sunitinib, permitting the patient to undergo a bone marrow transplant. A bone marrow biopsy showed complete clearance by variant allele frequency and the patient remains in remission 4-years post matched-unrelated donor allograft."	"Griffith et al., 2016, Exp. Hematol."	Somatic	ENST00000241453.7	N/A
FLT3 Mutation	FLT3	Mutation	Acute Myeloid Leukemia	Midostaurin	Predictive	Supports	A	Sensitivity/Response	chr13	28003274	28100592			Midostaurin is FDA-approved for the treatment of newly-diagnosed acute myeloid leukemia patients harboring FLT3 mutations.	"Levis, 2017, Blood"	Somatic	ENST00000241453.7	"transcript_variant,gain_of_function_variant"
FLT3 Mutation	FLT3	Mutation	Acute Myeloid Leukemia	Gilteritinib	Predictive	Supports	B	Sensitivity/Response	chr13	28003274	28100592			"In a phase 1/2 trial, patients with refractory or relapsed AML with FLT3 mutation (n=191; ITD n=162, D835 n=13, ITD-D835 n=16) received gilteritinib. 49% (93/191) of patients achieved an overall response, 9% (n=18) complete remission, 5% (n=10) complete remission with incomplete platelet recovery, 22% (n=42) complete remission with incomplete hematological recovery, and 12% (n=23) reached partial remission. The refractory or relapsed AML FLT wildtype group treated with gilteritinib(n=58) had lower overall response rate (12%), complete remission (2%), complete remission with incomplete platelet recovery (0%), complete remission with incomplete hematological recovery (7%), and fewer reached partiral remission (3%). Also, bone marrow myeloblast reduction was greater in FLT3 mutant patients compared to FLT3 wildtype."	"Perl et al., 2017, Lancet Oncol."	Somatic	ENST00000241453.7	"transcript_variant,gain_of_function_variant"
FLT3 Mutation	FLT3	Mutation	Acute Myeloid Leukemia	Gilteritinib	Predictive	Supports	B	Sensitivity/Response	chr13	28003274	28100592			"In this phase 3 trial (ADMIRAL), 371 patients with relapsed or refractory FLT3-mutated AML (required to have FLT3 ITD or TKD D835 or I836 mutations) were randomly assigned in a 2:1 ratio to receive either gilteritinib (n=247, at a dose of 120 mg per day) or salvage chemotherapy (n=124). Median overall survival in the gilteritinib group was significantly longer than in the chemotherapy group (9.3 months vs. 5.6 months; hazard ratio for death, 0.64; 95% confidence interval [CI], 0.49 to 0.83; P<0.001). Median event-free survival was 2.8 months in the gilteritinib group and 0.7 months in the chemotherapy group (hazard ratio for treatment failure or death, 0.79; 95% CI, 0.58 to 1.09). The complete remission rate with full or partial hematologic recovery was 34.0% in the gilteritinib group and 15.3% in the chemotherapy group (risk difference, 18.6 percentage points; 95% CI, 9.8 to 27.4); the percentages with complete remission were 21.1% and 10.5%, respectively (risk difference, 10.6 percentage points; 95% CI, 2.8 to 18.4). Notably, gilteritinib treatment resulted in similar median overall survival (9.3 months vs. 8.0 months) and percentage of complete remission (20.5% vs. 19.0%) in patients with ITD mutations and patients with TKD mutations. The authors concluded gilteritinib therapy in relapsed or refractory FLT3-mutated AML patients resulted longer survival and improved response versus salvage chemotherapy."	"Perl et al., 2019, N. Engl. J. Med."	Somatic	ENST00000241453.7	"transcript_variant,gain_of_function_variant"
FLT3 D835V	FLT3	D835V	Acute Myeloid Leukemia	Tandutinib	Predictive	Supports	D	Resistance	chr13	28018504	28018504	T	A	Murine Ba/F3 cells with FLT3-D835V mutations were evaluated as non-responsive to MLN518 (Tandutinib). Cells with single FLT3 (D835V) mutants were resistant to MLN518(IC50 > 10uM) whereas cells with FLT3 (ITD) mutants were not resistant to MLN518 (IC50 0.55uM).	"Clark et al., 2004, Blood"	Somatic	ENST00000241453.7	missense_variant
FLT3 D835V	FLT3	D835V	Acute Myeloid Leukemia	Sunitinib	Predictive	Does Not Support	D	Sensitivity/Response	chr13	28018504	28018504	T	A	Murine Ba/F3 cells with FLT3 D835V mutation were assessed as not sensitive to SU11248 (Sunitinib) with dose required to inhibit proliferation of cells to 50% of untreated controls ED50 = 110nM.	"Yee et al., 2004, Blood"	Somatic	ENST00000241453.7	missense_variant
FLT3 D835V	FLT3	D835V	Acute Myeloid Leukemia	"Cytarabine,Sunitinib"	Predictive	Supports	D	Sensitivity/Response	chr13	28018504	28018504	T	A	"SU11248 + Cytarabin has a synergic effect on Murine Ba/F3 cells with FLT3 D835V mutation (Combination Index = 0.59 for ED50, Combination Index = 0.71 for ED75, Combination Index = 0.82 for ED90)"	"Yee et al., 2004, Blood"	Somatic	ENST00000241453.7	missense_variant
FLT3 D835V	FLT3	D835V	Acute Myeloid Leukemia	"Daunorubicin,Sunitinib"	Predictive	Supports	D	Sensitivity/Response	chr13	28018504	28018504	T	A	"SU11248 + Daunorubicin has a synergic effect on Murine Ba/F3 cells with FLT3 D835V mutation. (Combination Index = 0.82 for ED50, Combination Index = 0.72 for ED75, Combination Index = 0.64 for ED90)"	"Yee et al., 2004, Blood"	Somatic	ENST00000241453.7	missense_variant
FLT3 D835V	FLT3	D835V	Acute Myeloid Leukemia	Quizartinib	Predictive	Does Not Support	D	Sensitivity/Response	chr13	28018504	28018504	T	A	"Murine Ba/F3 cell line has a restrictive sensitivity to Quizartinib (AC220), a second generation class II tyrosine kinase inhibitor (IC50 for proliferation = 172nM, IC50 for induction of apoptosis = 888nM)."	"Kampa-Schittenhelm et al., 2013, Mol. Cancer"	Somatic	ENST00000241453.7	missense_variant
FLT3 D835V	FLT3	D835V	Acute Myeloid Leukemia	"Tyrphostin AG 1296,AS602868"	Predictive	Supports	D	Sensitivity/Response	chr13	28018504	28018504	T	A	"Murine Ba/F3 cells with FLT3 D835V mutation were assessed as sensitive to both AS602868 and AG1296.(IC50 = 1.85uM and IC50 = 4.55uM, respectively)"	"Griessinger et al., 2007, Leukemia"	Somatic	ENST00000241453.7	missense_variant
FLT3 D835V	FLT3	D835V	Acute Myeloid Leukemia	Sunitinib	Predictive	Supports	C	Sensitivity/Response	chr13	28018504	28018504	T	A	"In a retrospective study of 15 acute myeloid leukemia patients, the patients with FLT3 D835 mutation (n=2) were associated with improved response to sunitinib treatment (2/2 vs. 2/7) compared to FLT3 wild-type patients. The FLT3 D835 mutation positive patients were treated with sunitinib after failure of standard chemotherapy. After 4wk of sunitinib therapy, one patient showed morphological response and the other patient showed partial response to sunitinib therapy."	"Fiedler et al., 2005, Blood"	Somatic	ENST00000241453.7	missense_variant
FLT3 D835V	FLT3	D835V	Acute Myeloid Leukemia	Gilteritinib	Predictive	Supports	D	Sensitivity/Response	chr13	28018504	28018504	T	A	"Ba/F3 cells were transfected to express FLT3-ITD or FLT3 tyrosine kinase domain mutations. Immunoblots revealed gilteritinib IC50s of 0.7nM, 1.6nM, and 5nM for D835H, FLT3-ITD, and wildtype (cell line: SEMK2) cells, respectively."	"Lee et al., 2017, Blood"	Somatic	ENST00000241453.7	missense_variant
FLT3 TKD MUTATION	FLT3	TKD MUTATION	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr13	28018505	28018505	C	A	"Event-free survival was significantly improved in patients with both NPM1 and FLT3-TKD mutations compared to patients with 1) FLT3-TKD mutations alone 2) either NPM1 or FLT3-TKD when FLT3-ITD patients were excluded from the analysis 3) neither FLT3-TKD or NPM1 mutations or FLT3-TKD alone when only de novo, normal karyotype patients were analyzed."	"Bacher et al., 2008, Blood"	Somatic	ENST00000241453.7	nonsynonymous_variant
FLT3 TKD MUTATION	FLT3	TKD MUTATION	Acute Myeloid Leukemia		Diagnostic	Does Not Support	B	Positive	chr13	28018505	28018505	C	A	WBC counts were not significantly different in AML patients with FLT3 D835 mutations compared to wild type.	"Yamamoto et al., 2001, Blood"	Somatic	ENST00000241453.7	nonsynonymous_variant
FLT3 TKD MUTATION	FLT3	TKD MUTATION	Acute Myeloid Leukemia	Sorafenib	Predictive	Supports	B	Resistance	chr13	28018505	28018505	C	A	Emergence of D835 mutation in AML patients with FLT3 tandem repeat is associated with sorafenib resistance.	"Man et al., 2012, Blood"	Somatic	ENST00000241453.7	nonsynonymous_variant
FLT3 TKD MUTATION	FLT3	TKD MUTATION	Acute Myeloid Leukemia	Sorafenib	Predictive	Supports	B	Resistance	chr13	28018505	28018505	C	A	"Sorafenib is effective in patients with FLT3 internal tandem repeat mutations, but not in patients with wild type or D835 mutation."	"Zhang et al., 2008, J. Natl. Cancer Inst."	Somatic	ENST00000241453.7	nonsynonymous_variant
FLT3 TKD MUTATION	FLT3	TKD MUTATION	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	N/A	chr13	28018505	28018505	C	A	AML patients with D835 mutation of FLT3 did not have worse overall survival than patients with wild type FLT3.	"Yamamoto et al., 2001, Blood"	Somatic	ENST00000241453.7	nonsynonymous_variant
FLT3 TKD MUTATION	FLT3	TKD MUTATION	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr13	28018505	28018505	C	A	"In AML patients, FLT3-TKD mutation was associated with poorer disease free survival compared to patients with wild type FLT3."	"Whitman et al., 2008, Blood"	Somatic	ENST00000241453.7	nonsynonymous_variant
FLT3 D835	FLT3	D835	Acute Myeloid Leukemia	"Quizartinib,Ponatinib"	Predictive	Supports	D	Resistance	chr13	28018505	28018505	C	A	"An in-vitro saturation mutagenesis screen of 50 independently derived FLT3-ITD clones was performed to identify mutations that confer resistance to ponatinib. Mutations at 3 AL residues (D835 [n = 31], D839 [n = 3], and Y842 [n = 16]), with varying degrees of resistance to ponatinib were identified. FLT3 D835 mutations were shown to confer resistance to the tyrosine kinase inhibitor AC220 and ponatinib.  This was especially found for D835Y and D835V mutations, whereas D835H mutations were found to confer moderate resistance to ponatinib but relatively minimal resistance to AC220."	"Smith et al., 2013, Blood"	Somatic	ENST00000241453.7	protein_altering_variant
FLT3 D835	FLT3	D835	Acute Myeloid Leukemia	SU5614	Predictive	Supports	D	Resistance	chr13	28018505	28018505	C	A	"An in-vitro cell-based screening approach generated FLT3-ITD-expressing cell lines resistant to the FLT3 inhibitors SU5614, PKC412, and sorafenib. SU5614 resistance mutations were limited to exchanges in the second part of the kinase domain (TK2), with exchanges of D835 predominating (D835E were most common). In clones that emerged at 1,500 nmol/L SU5614 after ENU (mutagen) treatment, 127 of 179 clones (71%) displayed mutations, generating 9 different exchanges affecting 6 positions in the activation loop of FLT3."	"von Bubnoff et al., 2009, Cancer Res."	Somatic	ENST00000241453.7	protein_altering_variant
FLT3 D835	FLT3	D835	Acute Myeloid Leukemia	"Quizartinib,Sorafenib"	Predictive	Supports	B	Resistance	chr13	28018505	28018505	C	A	"In an in-vitro study using an in vitro saturation mutagenesis assay, 4 residues with AC220 (quizartinib) resistance-conferring mutations in the kinase domain of FLT3-ITD were identified. Mutations at three of these amino acid positions conferred high degrees of in vitro AC220 resistance (based on proliferation and cell-based biochemical assays). Among these residues, two within the activation loop were found (D835, Y842).  Pre-treatment and relapse samples of 8 patients (treated with AC220) with FLT3-ITD+ acute myeloid leukemia were analyzed. The activation loop mutation D835Y was detected in three cases, D835V in two, and D835F was identified in a single patient. Cross-resistance to sorafenib was identified in-vitro."	"Smith et al., 2012, Nature"	Somatic	ENST00000241453.7	protein_altering_variant
FLT3 D835	FLT3	D835	Acute Myeloid Leukemia	Sorafenib	Predictive	Supports	B	Resistance	chr13	28018505	28018505	C	A	"13 patients with relapsed or chemo-refractory FLT3-ITD+ AML were treated with sorafenib (200-400 mg twice daily). 12 patients responded, but sorafenib response was lost in most patients after 72 (range 54-287) days. Leukemia initiating cells bearing the D835 mutation expanded during sorafenib treatment and dominated during the subsequent clinical resistance. Results were recapitulated in-vivo."	"Man et al., 2012, Blood"	Somatic	ENST00000241453.7	protein_altering_variant
FLT3 TKD MUTATION	FLT3	TKD MUTATION	Acute Myeloid Leukemia	Midostaurin	Predictive	Supports	B	Sensitivity/Response	chr13	28018505	28018505	C	A	"In a phase 2 clinical study of 95 AML/high-risk MDS patients treated with either 50 or 100 mg midostaurin, 35 harbored FLT3 mutations (26 had FLT3 ITD, 9 had FLT3 D835Y mutations). A higher percentage of patients saw blast reductions in the FLT3 mutant group than in the FLT3 wild type group (71 vs 42%). Only one permanent response occurred in a FLT3 mutant patient receiving the 100 mg dose. No differences were observed in toxicity or response rate between the two doses of midostaurin."	"Fischer et al., 2010, J. Clin. Oncol."	Somatic	ENST00000241453.7	nonsynonymous_variant
FLT3 D835H	FLT3	D835H	Acute Myeloid Leukemia	Sorafenib	Predictive	Supports	C	Resistance	chr13	28018505	28018505	C	G	"Three children with relapsed or refractory FLT3-ITD-positive AML were treated with sorafenib. FLT3 mutations were assessed before treatment and at the time of resistance. During the initiation of the treatment, all three patients had undetectable levels of FLT3 (D835H) mutations, however, after resistance developed, the mutation frequency rose to 33.1%, 35.7%, and 11.0% in the three patients. Ba/F3 cells expressing FLT3 mutants were resistant to sorafenib-dependent inhibition of cell viability"	"Baker et al., 2013, Clin. Cancer Res."	Somatic	ENST00000241453.7	missense_variant
FLT3 D835H/Y	FLT3	D835H/Y	Acute Myeloid Leukemia	Sorafenib	Predictive	Supports	D	Resistance	chr13	28018505	28018505	C	G/A	Mouse Ba/F3 cells with FLT3 mutations were evaluated for sorafenib resistance.  Cells with single FLT3 (D835H/Y) mutants were resistant to sorafenib (IC50 81 nm/210 nM) whereas cells with FLT3 (ITD) mutants were not resistant to sorafenib (IC50 1.1 nM).  Cells with double mutants (ITD-D835H/Y or ITD F691L) were highly resistant to sorafenib (IC50 460-3300 nM).	"Baker et al., 2013, Clin. Cancer Res."	Somatic	ENST00000241453.7	missense_variant
FLT3 D835H	FLT3	D835H	Acute Myeloid Leukemia	Gilteritinib	Predictive	Supports	D	Sensitivity/Response	chr13	28018505	28018505	C	G	"Ba/F3 cells were transfected to express FLT3-ITD or FLT3 tyrosine kinase domain mutations. Immunoblots revealed gilteritinib IC50s of 2nM, 1.6nM, and 5nM for D835H, FLT3-ITD, and wildtype (cell line: SEMK2) cells, respectively."	"Lee et al., 2017, Blood"	Somatic	ENST00000241453.7	missense_variant
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	N/A	chr13	28034082	28034214			"In young AML patients (<60 years old), DNMT3A mutation status was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD."	"Ribeiro et al., 2012, Blood"	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr13	28034082	28034214			"In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations were associated with worse overall survival compared to those without DNMT3A mutation."	"Ley et al., 2010, N. Engl. J. Med."	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia	Tretinoin	Predictive	Supports	B	Resistance	chr13	28034082	28034214			ATRA treatment did not effect overall survival in patients <60 years old with FLT3-ITD mutation.	"Burnett et al., 2010, Blood"	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr13	28034082	28034214			FLT3-ITD mutation without NPM1 was associated with increased relapse risk and reduced overall survival in young adult AML patients (median age 43).	"Gale et al., 2008, Blood"	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr13	28034082	28034214			Increasing level of FLT3-ITD mutant correlated with reduced disease-free and overall survival as well as increased relapse rate.	"Gale et al., 2008, Blood"	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia	Daunorubicin	Predictive	Supports	D	Resistance	chr13	28034082	28034214			Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to daunorubicin than cells with FLT3-ITD alone.	"Bagrintseva et al., 2005, Blood"	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia	SU5614	Predictive	Supports	D	Resistance	chr13	28034082	28034214			Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to the protein tyrosine kinase (PTK) inhibitor SU5614 than cells with FLT3-ITD alone or FLT3 ITD and TKD mutations on opposing alleles.	"Bagrintseva et al., 2005, Blood"	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	N/A	chr13	28034082	28034214			FLT3-ITD duplication length did not effect prognosis in patients with an NPM1 mutation.	"Schnittger et al., 2011, Leukemia"	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	N/A	chr13	28034082	28034214			Size of the FLT3-ITD mutant duplication had no impact on overall survival or relapse rate.	"Gale et al., 2008, Blood"	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia		Prognostic	Supports	A	Poor Outcome	chr13	28034082	28034214			Meta-analysis of studies involving cytogentically normal younger (<60) patients showed reduced overall and relapse-free survival for patients with FLT3-ITD.	"Port et al., 2014, Ann. Hematol."	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr13	28034082	28034214			A ratio of >0.49 FLT3-ITD/FLT3 wildtype level was associated with reduced event-free and overall survival in old (>59) and younger patients (<60) with an NPM1 mutation.	"Schnittger et al., 2011, Leukemia"	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr13	28034082	28034214			Patients with NPM1 mutation and FLT3-ITD had reduced event-free survival compared to patients with wildtype FLT3.	"Schnittger et al., 2011, Leukemia"	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr13	28034082	28034214			"Using a ratio of FLT3-ITD/FLT3 wildtype levels as a continuous variable, a higher ratio was associated with reduced event-free survival in patients with an NPM1 mutation."	"Schnittger et al., 2011, Leukemia"	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr13	28034082	28034214			"Coocurrence of FLT3-ITD mutations significantly reduced overall (N=74 vs 95, P=0.003) and disease-free survival (N=43 vs 67, P=0.02) of normal karyotype AML patients (<60 years old) compared to patients with NPM1 mutations alone."	"Thiede et al., 2006, Blood"	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr13	28034082	28034214			"Patients with NPM1 mutations and low (<25%, N=63), intermediate (25-50%, N=156) or high (>50%, N=66) levels of FLT3-ITD have worse overall survival (P<0.0001 for trend) and cumulative incidence of relapse (P<0.001) than those with NPM1 mutations alone (N=387) in young adult, intermediate risk AML patients."	"Linch et al., 2014, Blood"	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia		Diagnostic	Supports	B	Positive	chr13	28034082	28034214			WBC counts were higher in AML patients with internal tandem repeat of Flt3 compared to wild type.	"Yamamoto et al., 2001, Blood"	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia	Lestaurtinib	Predictive	Supports	B	Sensitivity/Response	chr13	28034082	28034214			CEP701 was effective in reducing blast counts of 5/14 heavily pre-treated AML patients with FLT3 mutations.	"Smith et al., 2004, Blood"	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia	Sorafenib	Predictive	Supports	B	Sensitivity/Response	chr13	28034082	28034214			"Sorafenib is effective in patients with FLT3 internal tandem repeats, but not in wild type or D835 mutation."	"Zhang et al., 2008, J. Natl. Cancer Inst."	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia	Tyrphostin AG 1296	Predictive	Supports	D	Sensitivity/Response	chr13	28034082	28034214			AG1296 is effective in triggering apoptosis in Ba/F3 and primary AML cells with FLT3 internal tandem repeat.	"Tse et al., 2002, Leukemia"	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr13	28034082	28034214			AML patients with internal tandem repeat of FLT3 has worse overall survival than patients with wild type FLT3.	"Yamamoto et al., 2001, Blood"	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr13	28034082	28034214			Simultaneous tandem repeat of FLT3 with loss of wild type FLT3 leads to poor survival and inferior disease free survival in patients with AML.	"Whitman et al., 2001, Cancer Res."	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia	Sorafenib	Predictive	Supports	B	Sensitivity/Response	chr13	28034082	28034214			13 patients with relapsed or chemo-refractory FLT3-ITD+ AML were treated with sorafenib (200-400 mg twice daily). 12 patients showed clearance or near clearance of bone marrow myeloblasts after 27 (range 21-84) days with evidence of differentiation of leukemia cells. Sorafenib response was lost in most patients after 72 (range 54-287) days.	"Man et al., 2012, Blood"	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Promyelocytic Leukemia		Prognostic	Supports	B	Poor Outcome	chr13	28034082	28034214			"In a study of 53 APL patients treated with combination ATRA/anthracycline chemotherapy, patients with the FLT3 ITD mutation (n=10) had higher rates of relapse (30% vs. 2.5%), lower rates of remission (70% vs 87.5%), and lower 3-year Leukemia-Free Survival (44.4% vs. 84.4%)."	"Hong et al., 2011, Korean J Hematol"	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Promyelocytic Leukemia	"Anthracycline Antineoplastic Antibiotic,Tretinoin"	Predictive	Supports	B	Resistance	chr13	28034082	28034214			"In a study of 171 APL patients treated with combination ATRA/anthracycline chemotherapy, FLT3 ITD mutations (n=35) were associated with lower 3-year OS compared to the FLT3 ITD-negative group (62% vs. 82%), as well as higher CR achievement failure and early death."	"Lucena-Araujo et al., 2014, Ann. Hematol."	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia	Selumetinib	Predictive	Supports	B	Resistance	chr13	28034082	28034214			"Forty-seven patients with relapsed/refractory AML or 60+ years old with untreated AML were enrolled on a phase II study. In FLT3 wild-type patients, six out of 36 (17%) had a response (1 PR, 3 MR, 2 uMR) that lasted a median of 58 days (range, 33?73 days). No patient with FLT3-ITD (n = 10) responded. One patient with unknown FLT3 status also had no response. Of note, this study did not meet its primary endpoint of 6 responses (CR, CRi, PR or MR) in the first 35 patients enrolled."	"Jain et al., 2014, Clin. Cancer Res."	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr13	28034082	28034214			"In the absence of a FLT3 (ITD) mutation, a co-mutation of NPM1 and DNMT3A had a 50% 10-year survival rate, whereas triple-mutation of NPM1, DNMT3A, and FLT3 (ITD) had a 20% 10-year survival rate."	"Papaemmanuil et al., 2016, N. Engl. J. Med."	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia	Sorafenib	Predictive	Supports	C	Sensitivity/Response	chr13	28034082	28034214			"Six children with relapsed or refractory FLT3-ITD-positive AML received initial therapy with sorafenib (alone or in combination with clofarabine and cytarabine).  Four of the patients initially achieved morphological complete remission (bone marrow blasts <5%), however, 3 patients developed resistance within 14-37 weeks and and 1 required a bone marrow transplant.  Two patients did not have any clinical response to sorafenib upon initial treatment."	"Baker et al., 2013, Clin. Cancer Res."	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia	Ponatinib	Predictive	Supports	D	Sensitivity/Response	chr13	28034082	28034214			"In a preclinical trial, multiple experiments testing the effectiveness of ponatinib on the mutation FLT3-ITD in acute myeloid leukemia (AML) were conducted. Ponatinib was very effective in targeting the FLT3-ITD mutation in MV4-11 cell lines (growth inhibition: IC50=2 nmol/L) compared to native FLT3 in RS4;11 cell lines (IC50>100 nmol/L). Additionally, MV4-11 cell lines incubated for 1 hour were shown to have reduced phosphorylation of tyrosine kinases beginning at a ponatinib concentration of 0.3 nmol/L. Ponatinib was shown to induce apoptotic mechanisms measured by caspase-3/7 activity in MV4-cell lines. In mice with the MV4-11 xenograft, ponatinib was very effective in targeting the FLT3-ITD mutation, as dosages of 1-5 mg/kg led to tumor growth inhibition and regression, while dosages of 10 and 25 mg/kg led to complete tumor regression. In primary blast cells from AML patients, Ponatinib was selectively effective in growth inhibition of the FLT3-ITD patient cells (n=1, IC50=4nmol/L) when compared to the native FLT3 patient cells (n=3, IC50>100nmol/L)."	"Gozgit et al., 2011, Mol. Cancer Ther."	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Leukemia	"Sunitinib,Sorafenib"	Predictive	Supports	D	Sensitivity/Response	chr13	28034082	28034214			"In a preclinical trial, the leukemic cell line MV4-11 with the FLT3-ITD mutation and the leukemic cell line RS4;11 with the native FLT3 gene were treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was similarly effective in the growth inhibition of cells harboring the FLT3-ITD mutation (IC50=2 nmol/L) compared to sorafenib (IC50=4 nmol/L) and sunitinib (IC50=12 nmol/L). Conversely, all three TKIs each were not effective in the growth inhibition of cells with native FLT3 (IC50>100 nmol/L)."	"Gozgit et al., 2011, Mol. Cancer Ther."	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia	Gilteritinib	Predictive	Supports	D	Sensitivity/Response	chr13	28034082	28034214			"This study was designed to test the efficacy of FLT3 inhibitors in vitro against FLT3-ITD and other TKD variants clinically observed. IC50s were determined from immunoblots quantifying FLT3 phosphorylation in endogenous (Molm14) or ectopic expression FLT3-ITD cell lines (TF-1, Ba/F3) and the endogenous wildtype FLT3 SEMK2 cell line after gilteritinib treatment. IC50 values ranged from 1.4 to 1.8 nM in the three FLT3-ITD lines compared to 5nM in wildtype cells, suggesting increased sensitivity to the inhibitor. As measured by MTT assay, primary cultures from two AML patients with high allelic FLT3-ITD showed cytotoxic response to gilteritinib. Additionally, plasma taken from 3 patients receiving 120mg of gilteritinib daily was able to inhibit FLT3 phosphorylation in Molm14 cells."	"Lee et al., 2017, Blood"	Somatic	ENST00000241453.7	inframe_insertion
FLT3 ITD	FLT3	ITD	Acute Myeloid Leukemia	Gilteritinib	Predictive	Supports	D	Sensitivity/Response	chr13	28034082	28034214			"In vitro gilteritinib treatment of MV4-11 and MOLM-13 cells, which endogenously express FLT3-ITD, showed growth suppression based on CellTiter GLO cytotoxicity assays with IC50 values of 0.92 nM (95% CI: 0.23?.6 nM) and 2.9 nM (95% CI: 1.4?.8 nM), respectively. Phosphorylation of FLT3 and its downstream targets were rapidly inhibited in MV4-11 cells relative to control treatment (DMSO). In a mouse xenograft model using MV4-11 cells, increasing doses of gilteritinib further reduced tumor size and growth and inhibited phosphorylation of both FLT3 and STAT5 (N=6, p<0.05 at lowest dose). Gilteritinib inhibited growth in vitro of Ba/F3 cells expressing FLT3-ITD (IC50 1.8nM; 95% CI: 1.0-3.0 nM) and in vivo as tumor maintenance or shrinkage was also significant in mice xenografted with Ba/F3 FLT3-ITD cells (N=5, p<0.001). Mice receiving an intra-bone marrow injection of MV4-11 cells labelled with luciferase began gilteritinib treatment on day 15. Gilteritinib treated mice showed significantly less widespread disease at day 42 than control counterparts (N=10, p<0.001) and significantly improved survival (log-rank, p<0.001)."	"Mori et al., 2017, Invest New Drugs"	Somatic	ENST00000241453.7	inframe_insertion
HSPH1 NUCLEAR EXPRESSION	HSPH1	NUCLEAR EXPRESSION	Gastric Adenocarcinoma		Prognostic	Supports	B	Poor Outcome	chr13	31136628	31161927			"HSP110 (HSPH1) expression was immunohistochemically assessed using a tissue microarray in 210 gastric cancer patients. The overall survival rate was significantly lower in patients with high nuclear expression (N=121, 2+ moderate/3+ strong staining) than patients with low nuclear staining (N=89, 0 no/1+ weak staining)(P = 0.0169). Multivariate regression analysis identified expression of nuclear HSP110 as an independent prognostic factor for gastric cancer outcome (P = 0.0068). This was not found for cytoplasmic expression."	"Kimura et al., 2016, Oncotarget"	N/A	ENST00000320027.5	N/A
HSPH1 NUCLEAR EXPRESSION	HSPH1	NUCLEAR EXPRESSION	Gastric Adenocarcinoma	"Cisplatin,Fluorouracil"	Predictive	Supports	D	Sensitivity/Response	chr13	31136628	31161927			"49 patients gastric cancer patients treated with adjuvant chemotherapy were immunohistochemically assessed for nuclear HSPH1 (HSP110) expression. Overall survival rate in the high expression group (2+ moderate/3+ strong staining) was significantly lower compared with the low expression group (0 no/1+ weak staining) (P = 0.0364). In gastric cancer cell lines (MKN7, MKN45), siRNA mediated HSP110 knockdown led to a higher sensitivity to 5-FU and cisplatin compared with the parent and control cells (p < 0.05)."	"Kimura et al., 2016, Oncotarget"	N/A	ENST00000320027.5	N/A
HSPH1 T17 DELETION	HSPH1	T17 DELETION	Colorectal Cancer	"Oxaliplatin,Fluorouracil"	Predictive	Supports	B	Sensitivity/Response	chr13	31148484	31148500			"329 consecutive patients with stage IIIII colorectal tumors with MSI after surgical resection at tertiary medical centers were screened for HSP110 T(17) by PCR. Patients underwent adjuvant chemotherapy with 5-fluorouracil and oxaliplatin. Patients with large HSP110 T(17) deletions (? bp; 18 of 77 patients, 23.4%) had longer times of relapse-free survival than patients with small or no deletions (? bp; 59 of 77 patients, 76.6%) in multivariate analysis (hazard ratio, 0.16; 95% confidence interval, 0.012?.8; P = .03). A significant interaction between chemotherapy and T17 deletion was found (P =.009)."	"Collura et al., 2014, Gastroenterology"	Somatic	ENST00000320027.5	short_tandem_repeat_variation
BRCA2 Loss-of-function	BRCA2	Loss-of-function	Prostate Cancer	Olaparib	Predictive	Supports	B	Sensitivity/Response	chr13	32315474	32399210			"In a phase 2 trial of patients with metastatic, castration-resistant prostate cancer, treated with olaparib tablets at a dose of 400 mg twice a day, all 7 patients harbouring BRCA2 loss of function alleles (biallelic somatic loss or germline mutations in combination with somatic copy loss or copy neutral LOH) demonstrated a clinical response."	"Mateo et al., 2015, N. Engl. J. Med."	Somatic	ENST00000380152.3	loss_of_function_variant
BRCA2 Mutation	BRCA2	Mutation	Ovarian Carcinoma	Platinum Compound	Predictive	Supports	B	Sensitivity/Response	chr13	32315474	32399210			"In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.002). Sensitivity to platinum was defined by maintenance of complete response greater than 6 months post platinum therapy."	"Pennington et al., 2014, Clin. Cancer Res."	Somatic	ENST00000380152.3	"gene_variant,loss_of_function_variant"
BRCA2 Loss-of-function	BRCA2	Loss-of-function	Breast Cancer	"Pidnarulex,Quarfloxin"	Predictive	Supports	D	Sensitivity/Response	chr13	32315474	32399210			"The authors show that in the CX-5461 and CX-3543, G-quadruplex stabilizing agents, demonstrate specific toxicity against BRCA deficient breast cancer derived cells and polyclonal patient-derived xenograft models. The BRCA and NHE J pathways are required for the repair of CX-5461 and CX-3543-induced DNA damage and failure to do so leads to lethality."	"Xu et al., 2017, Nat Commun"	Unknown	ENST00000380152.3	loss_of_function_variant
BRCA2 Mutation	BRCA2	Mutation	Ovarian Cancer	Rucaparib	Predictive	Supports	B	Sensitivity/Response	chr13	32315474	32399210			"A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA (BRCA1 or BRCA2) mutant patients, 5 had somatic BRCA2 mutation, 4 of which were homozygous mutations and one had unknown zygosity. Confirmed objective response was seen in 80% (4/5) of the somatic BRCA2 mutant subgroup. Authors note that response rate was similar regardless of whether the BRCA mutation was somatic or germline, in BRCA 1 or BRCA 2. In a BRCA wild-type subgroup, with low levels of loss of heterozygosity (LOH), confirmed objective response was observed in 10% (7/70) of the patients. Patients with BRCA mutant tumors experienced significantly longer median progression free survival than patients with BRCA wildtype, LOH low tumors (12.8 vs 5.2 mo, HR: 0.27, P<0.0001)."	"Swisher et al., 2017, Lancet Oncol."	Somatic	ENST00000380152.3	"gene_variant,loss_of_function_variant"
BRCA2 Mutation	BRCA2	Mutation	Prostate Cancer	Olaparib	Predictive	Supports	A	Sensitivity/Response	chr13	32315474	32399210			"In phase 3 trial of 387 patients comparing olaparib and new hormonal agent (enzalutamide or abiraterone) therapy for patients with metastatic castration-resistant prostate cancer harboring homologous recombinant repair-related gene mutation detected from a tumor sample, olaparib showed significant PFS benefit in an ITT population (HR [95%CI] 0.49 [0.38, 0.63]). But in subgroup analysis, the treatment effect differed in each mutated genes. Among them, patients with BRCA2 mutations (olaparib: n=92, control: n=53) showed a prominent benefit of olaparib (PFS HR [95%CI] 0.21 [0.13, 0.32])."	"de Bono et al., 2020, N. Engl. J. Med."	Unknown	ENST00000380152.3	"gene_variant,loss_of_function_variant"
BRCA2 M1R	BRCA2	M1R	Ovarian Cancer	Rucaparib	Predictive	Supports	C	Sensitivity/Response	chr13	32316462	32316462	T	G	"In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)."	"Swisher et al., 2017, Lancet Oncol."	Somatic	ENST00000544455.1	missense_variant
BRCA2 M1I	BRCA2	M1I	Ovarian Cancer	Rucaparib	Predictive	Supports	C	Sensitivity/Response	chr13	32316463	32316463	G	T	"In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)."	"Swisher et al., 2017, Lancet Oncol."	Somatic	ENST00000544455.1	missense_variant
BRCA2 V159M	BRCA2	V159M	Ovarian Cancer	Rucaparib	Predictive	Supports	C	Sensitivity/Response	chr13	32326150	32326150	G	A	"In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)."	"Swisher et al., 2017, Lancet Oncol."	Somatic	ENST00000544455.1	missense_variant
BRCA2 V211L	BRCA2	V211L	Ovarian Cancer	Rucaparib	Predictive	Supports	C	Sensitivity/Response	chr13	32326614	32326614	G	C	"In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)."	"Swisher et al., 2017, Lancet Oncol."	Somatic		missense_variant
BRCA2 V211I	BRCA2	V211I	Ovarian Cancer	Rucaparib	Predictive	Supports	C	Sensitivity/Response	chr13	32326614	32326614	G	A	"In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)."	"Swisher et al., 2017, Lancet Oncol."	Somatic		missense_variant
BRCA2 R2336P	BRCA2	R2336P	Ovarian Cancer	Rucaparib	Predictive	Supports	C	Sensitivity/Response	chr13	32346896	32346896	G	C	"In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)."	"Swisher et al., 2017, Lancet Oncol."	Somatic	ENST00000544455.1	missense_variant
RB1 EXPRESSION	RB1	EXPRESSION	Lung Non-small Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr13	48303775	48481986			Positive RB1 expression (2+ by IHC) was associated with adverse outcomes in a cohort of 73 cases with stage I and II NSCLC (P<0.001) in this retrospective study. This finding was independent from other genomic and clinical factors explored by the authors.	"Zhao et al., 2012, J Oncol"	N/A	ENST00000267163.4	N/A
RB1 Overexpression	RB1	Overexpression	Pancreatic Adenocarcinoma	"Mitomycin,Gemcitabine,Fluorouracil,Doxorubicin"	Predictive	Supports	D	Resistance	chr13	48303775	48481986			"In Capan-1 cell lines engineered to reduce pRB expression (by transfection with p16), resensitization to chemotherapy-induced apoptosis was observed. The effect was asserted to be specific to pRB depletion because, in two separate cell lines, also transfected with p16, that retained high pRB expression, chemotherapy resistance was still observed."	"Plath et al., 2002, J. Natl. Cancer Inst."	Somatic	ENST00000267163.4	N/A
RB1 Loss-of-function	RB1	Loss-of-function	Breast Cancer	Palbociclib	Predictive	Supports	D	Resistance	chr13	48303775	48481986			"In 3 ER positive and 2 ER negative breast cancer cell lines with intact Rb, significant growth inhibition, as measured by BrdU incorporation, was seen with incubation in CDK4/6 inhibitor palbociclib (PD-0332991). In contrast, two ER negative cell lines lacking detectable Rb were fully resistant to palbociclib. Knockdown of Rb in 3 of the tested Rb positive cell lines led to moderate palbociclib resistance in short term incubation experiments.  In longer term (15 day) palbociclib incubations of ER negative MDA-MB-231 cells and ER positive MCF-7 cells, significant resistance to palbociclib was seen in Rb knockdown conditions while wild-type Rb cells maintained sensitivity."	"Dean et al., 2010, Oncogene"	Somatic	ENST00000267163.4	loss_of_function_variant
RB1 Loss-of-function	RB1	Loss-of-function	Glioblastoma	Palbociclib	Predictive	Supports	D	Resistance	chr13	48303775	48481986			"A panel of 21 glioblastoma cell lines harboring various mutations was treated with palbociclib. 16 of the cell lines with intact Rb showed decreased proliferation (bromodeoxyuridine incorporation, BrdU flow cytometry) and growth arrest characteristic of senescence, while the 5 cell lines that did not show a palbociclib response had homozygous deletion of Rb. Rb positive and palbociclib responsive GBM cell line U87MG was treated with shRNA against Rb. shRb treated cells showed restoration of cell proliferation (BrdU incorporation) under palbociclib treatment, indicating resistance."	"Michaud et al., 2010, Cancer Res."	Somatic	ENST00000267163.4	loss_of_function_variant
RB1 PHOSPHORYLATION	RB1	PHOSPHORYLATION	Breast Cancer	Alpelisib	Predictive	Supports	B	Resistance	chr13	48303775	48481986			"The p110alpha-specific PI3K inhibitor BYL719 (Alpelisib) was used on a panel of five PI3K inhibitor sensitive and five resistant breast cancer cell lines. Sensitive cells (IC50<400nM) showed reduced phospho-Rb (p-Rb) western blot levels in response to BYL719 treatment, while resistant cell lines (IC50>800nM) showed significantly less reduction in p-Rb after BYL719. Paired biopsies before and after treatment were taken from a set of eight patients classified as either responder or non-responder to BYL719. Responder samples showed significantly reduced p-Rb staining after treatment in comparison to non-responder biopsies. In biopsies taken from a group of three responders who progressed, p-Rb levels were increased after progression."	"Vora et al., 2014, Cancer Cell"	N/A	ENST00000267163.4	N/A
RB1 Mutation	RB1	Mutation	Lung Small Cell Carcinoma	Chemotherapy	Predictive	Supports	B	Sensitivity/Response	chr13	48303775	48481986			"Study evaluated a total of 50 small cell lung cancer patients with extensive stage disease. Multivariate analysis identified RB1 as a factor in predicting response to first-line chemotherapy (odds ratio 5.58 compared to WT, p=.038). Kaplan-Meier survival analysis revealed patients with RB1 mutations exhibited better overall survival (p = .04, 11.7 versus 9.1 months, CI = 1.1-28.2)."	"Dowlati et al., 2016, Ann. Oncol."	Somatic	ENST00000267163.4	gene_variant
RB1 M695FS*26	RB1	M695FS*26	Estrogen-receptor Positive Breast Cancer	Palbociclib	Predictive	Supports	D	Resistance	chr13	48459810	48459811		A	"Preclinical study in breast cancer cell lines treated with CDK4/6 inhibitor palbociclib. Palbociclib-resistant xenografts from one cell line (PDX244) were developed in-vivo. In resistant xenografts, western blot analysis showed a decrease of pRb protein levels in 4 of 7 CDK4/6-acquired resistant tumors and a sustained expression of the E2F target cyclin E2, in contrast to CDK4/6 inhibitor-sensitive PDX244. Genomic characterization of PDX244LR1 showed the acquisition of an RB1 frameshift mutation (RB1 p.M695fs*26)."	"Herrera-Abreu et al., 2016, Cancer Res."	Somatic	ENST00000267163.4	frameshift_truncation
GAS6 EXPRESSION	GAS6	EXPRESSION	Prostate Cancer	Docetaxel	Predictive	Supports	D	Resistance	chr13	113820551	113864073			"Prostate Cancer (PCa) cell lines were either cultured alone, co-cultured with osteoblasts expressing GAS6, or cultured in the presence of media with GAS6 to examine their response to therapy with docetaxel. Docetaxel efficiently induced apoptosis in the cells cultured without any GAS6, but it was not able to do so in the cells that were in media with GAS6 present or that were co-cultured with osteoblasts expressing GAS6. PCa cells in the presence of GAS6 were found to be in G1 phase for a greater duration which may help explain the increased resistance to docetaxel."	"Lee et al., 2016, J. Cell. Biochem."	N/A	ENST00000357389.3	N/A
GAS6 EXPRESSION	GAS6	EXPRESSION	Oral Squamous Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr13	113820551	113864073			"128 patients with oral squamous cell carcinoma (OSCC) and 145 normal control subjects were evaluated for the concentration of GAS6 in their plasma serum. OSCC patients were found to be associated with a significantly higher level of GAS6 in serum ( P = .05 ). Furthermore, within the OSCC patients, increased GAS6 serum concentration was associated with higher stage tumors ( P < .01) , poorly differentiated tumors ( P < .01 ), and increased lymph node metastasis ( OR = 2.79 ; CI = 1.72-4.48 )."	"Jiang et al., 2015, PLoS ONE"	N/A	ENST00000357389.3	N/A
HIF1A OVEREXPRESSION	HIF1A	OVEREXPRESSION	Colorectal Cancer		Prognostic	Supports	B	Poor Outcome	chr14	61695540	61748258			"HIF1A overexpression was assessed by IHC in 731 colorectal cancers from two prospective cohort studies. 142 (19%) tumors showed HIF1A overexpression. Overexpression of HIF1A was associated with higher colorectal cancer-specific mortality in Kaplan-Meier analysis (log-rank test, P < 0.0001), univariate Cox regression (hazard ratio = 1.84; 95% confidence interval, 1.37 to 2.47; P < 0.0001) and multivariate analysis (adjusted hazard ratio = 1.72; 95% confidence interval, 1.26 to 2.36; P = 0.0007, adjusted for clinical and tumoral features: microsatellite instability, TP53 (p53), PTGS2 (cyclooxygenase-2), CpG island methylator phenotype, and KRAS, BRAF, PIK3CA, and LINE-1 methylation)."	"Baba et al., 2010, Am. J. Pathol."	N/A	ENST00000394997.1	N/A
HIF1A OVEREXPRESSION	HIF1A	OVEREXPRESSION	Sarcoma		Prognostic	Supports	B	Poor Outcome	chr14	61695540	61748258			"Expression of HIF1A was analyzed by IHC in 49 soft-tissue sarcomas (29 malignant fibrous histiocytomas, 12 synovial sarcomas, 4 leiomyosarcomas and 4 malignant peripheral nerve sheath tumors). High (18.4%) or moderate (35.4%) expression of HIF-1alpha was significatnly associated with shorter overall survival rate in comparison with those with a weak or negative expression in univariate analysis (P = 0.029; log-rank test) and multivariate analysis (P = 0.018)."	"Shintani et al., 2006, Virchows Arch."	N/A	ENST00000394997.1	N/A
HIF1A EXPRESSION	HIF1A	EXPRESSION	Renal Cell Carcinoma	Pazopanib	Predictive	Does Not Support	B	Sensitivity/Response	chr14	61697622	61747771			"Immunohistochemical staining for HIF1A was performed on tumor samples from 65 patients that received pazopanib as part of VEG102616, of which 17 were classified as low expression and 48 were classified as high expression. The response rates of patients with low and high HIF1a expression to pazopanib were 52.9% and 29.1% (p=0.13), and there was no significant difference in PFS between the two groups (p=0.25). The authors concluded that HIF1a expression levels are not associated with clinical response to pazopanib."	"Choueiri et al., 2013, Clin. Cancer Res."	N/A	ENST00000539097.1	N/A
FOS Overexpression	FOS	Overexpression	Colon Adenocarcinoma	Irbesartan	Predictive	Supports	C	Sensitivity/Response	chr14	75278774	75282230			"A 67-year-old female presents with recurrent metastatic colonic adenocarcinoma.  Immunohistochemical and genetic workup showed overexpression of c-JUN and FOS, which presumably signals through the RAAS pathway. The patient was treated with Irbesartan and after 5 weeks of therapy, the CEA value decreased from 18 to 3.1 and there was radiological resolution of the disease.  Her 10 month CEA was 1.4."	"Jones et al., 2016, Ann. Oncol."	Somatic	ENST00000303562.4	N/A
FOS TRUNCATING FUSION	FOS	TRUNCATING FUSION	Bone Epithelioid Hemangioma		Diagnostic	Supports	C	Positive	chr14	75278774	75281424			"FOS was found fused  with 3 different genes in 3 cases of bone epithelioid hemangioma. The fusion partners were not recurrent, respectively MBNL1, VIM and a lincRNA. The truncation of the FOS gene would result in the loss of the transactivation domain (TAD) in all three cases. Extension of this analysis identified FOS rearrangements in 5/7 additional classic epithelioid hemangiomas of bone."	"van IJzendoorn et al., 2015, Genes Chromosomes Cancer"	Somatic	ENST00000303562.4	"stop_gained,transcript_fusion"
DICER1 E1813Q	DICER1	E1813Q	Sertoli-Leydig Cell Tumor		Diagnostic	Does Not Support	B	Positive	chr14	95091293	95091293	C	G	"In this exploratory study of Sertoli-Leydig cell tumors, DICER1 mutations were found in over half of the samples sequenced, but were not found to have any role in tumorigenesis, contrary to what was previously believed. "	"Conlon et al., 2015, Mod. Pathol."	Somatic	ENST00000526495.1	missense_variant
DICER1 E1705K	DICER1	E1705K	Sertoli-Leydig Cell Tumor		Diagnostic	Supports	B	Positive	chr14	95094139	95094139	C	T	"Sanger sequencing identified DICER1 hotspot mutations in 20 of 32 (63%) ovarian SertoliLeydig cell tumors. These mutations were unrelated to tumor differentiation and mostly (16/20, 80%) were E1705K. Additionally, DICER1 E1705K mutations were identified in 5/8 (63%) Sertoli cell tumors and 2/5 (40%) gynandroblastomas. However, no mutations were identified in 15 testicular sex cord-stromal tumors (8 classical Sertoli cell tumors, 3 Sertoli cell tumors-large cell calcifying variant, 4 sex cord-stromal tumors not otherwise specified)."	"Conlon et al., 2015, Mod. Pathol."	Somatic	ENST00000526495.1	missense_variant
AKT1 Q79K	AKT1	Q79K	Melanoma	Vemurafenib	Predictive	Supports	D	Resistance	chr14	104776711	104776711	G	T	The AKT1 Q79K mutation has been shown to confer resistance to BRAF inhibitors (vemurafenib) in melanoma cell line M229.	"Shi et al., 2014, Cancer Discov"	Somatic	ENST00000407796.2	missense_variant
AKT1 Q79K	AKT1	Q79K	Melanoma	Vemurafenib	Predictive	Supports	D	Resistance	chr14	104776711	104776711	G	T	"In an in vitro study, a M229 cell line endogenously expressing BRAF V600E mutation (a known vemurafenib sensitizing mutation) and overexpressing AKT1 Q79K mutation was associated with resistance to vemurafenib treatment, as compared to cells expressing BRAF V600E mutation and wildtype AKT1. Resistance was determined by assessing cell survival."	"Shi et al., 2014, Cancer Discov"	Somatic	ENST00000407796.2	missense_variant
AKT1 Q79K	AKT1	Q79K	Melanoma	Dabrafenib	Predictive	Supports	C	Resistance	chr14	104776711	104776711	G	T	"In a retrospective study of 44 relapsed melanoma patients with BRAF V600E/K (known BRAF inhibitor sensitizing mutations), AKT1 Q79K was associated with acquired resistance to BRAF inhibitor (dabrafenib) monotherapy in one patient. This patient was a 38 year old female with stage IV M1a melanoma who took dabrafenib (35 mg twice daily to 100 mg three times a day). The best overall response was a 100% reduction in the sum of target lesions, and progression free survival lasted 119 days. Prior to dabrafenib monotherapy, this patient's baseline tumor harbored BRAF V600Kno other somatic alterations were noted. Following relapse, the patient gained AKT1 Q79K in one of two disease progressive tumors. Whole exome sequencing and Sanger re-sequencing were used for all tumors. The authors hypothesized that disruptions in the PI3K-PTEN-AKT pathway represent a core mechanism of acquired resistance to BRAF inhibitor therapy."	"Shi et al., 2014, Cancer Discov"	Somatic	ENST00000407796.2	missense_variant
AKT1 E17K	AKT1	E17K	Breast Cancer	Akt Inhibitor MK2206	Predictive	Does Not Support	D	Sensitivity/Response	chr14	104780214	104780214	C	T	"Breast cancer cell lines with the AKT1 E17K mutation did not show sensitivity to AKT inhibitor MK-2206, unlike cell lines with PIK3CA mutations."	"Beaver et al., 2013, Clin. Cancer Res."	Somatic	ENST00000407796.2	missense_variant
AKT1 E17K	AKT1	E17K	Melanoma	Uprosertib	Predictive	Supports	D	Sensitivity/Response	chr14	104780214	104780214	C	T	A cell line with AKT E17K mutation was found to be sensitive to AKT inhibition with GSK2141795B  in this study.	"Lassen et al., 2014, Mol. Cancer"	Somatic	ENST00000407796.2	missense_variant
AKT1 E17K	AKT1	E17K	Breast Cancer	Capivasertib	Predictive	Supports	C	Sensitivity/Response	chr14	104780214	104780214	C	T	"In a phase-I study of AZD5363, partial response was observed in 2 patients with breast and ovarian carcinoma, respectively, and AKT1 E17K mutations. While full study results have not yet been published, this paper highlights in vitro results that further confirm the role of AKT E17K mutation."	"Davies et al., 2015, Mol. Cancer Ther."	Somatic	ENST00000407796.2	missense_variant
AKT1 E17K	AKT1	E17K	Cancer	Capivasertib	Predictive	Supports	B	Sensitivity/Response	chr14	104780214	104780214	C	T	"AKT1 E17K mutations are oncogenic and occur in many cancers at a low prevalence. We performed a multihistology basket study of AZD5363. 58 patients with advanced solid tumors were treated. In patients with AKT1 E17K-mutant tumors (n = 52) and a median of 5 lines of prior therapy, the median PFS was 5.5 months , 6.6 months and 4.2 months in patients with ER+ breast, gynecologic, and other solid tumors, respectively. In an exploratory biomarker analysis, imbalance of the AKT1 E17K-mutant allele, most frequently caused by copy-neutral loss-of-heterozygosity targeting the wild-type allele, was associated with longer PFS as was the presence of coincident PI3K pathway hotspot mutations. Persistent declines in AKT1 E17K in cfDNA were associated with improved PFS and response. Responses were not restricted to patients with detectable AKT1 E17K in pretreatment cfDNA."	"Hyman et al., 2017, J. Clin. Oncol."	Somatic	ENST00000407796.2	missense_variant
AKT1 E17K	AKT1	E17K	Melanoma	Vemurafenib	Predictive	Supports	D	Resistance	chr14	104780214	104780214	C	T	"In an in vitro study, a M229 cell line endogenously expressing BRAF V600E mutation (a known vemurafenib sensitizing mutation) and overexpressing AKT1 E17K mutation was associated with resistance to vemurafenib treatment, as compared to cells expressing BRAF V600E mutation and wildtype AKT1. Resistance was determined by assessing cell survival."	"Shi et al., 2014, Cancer Discov"	Somatic	ENST00000407796.2	missense_variant
BCL2 IGH::BCL2	BCL2	IGH::BCL2	Diffuse Large B-cell Lymphoma		Diagnostic	Supports	B	Positive	chr14	105566277	106879844			The t(14;18) transloaction of BCL2 is shown to be associated with germinal-center B-celllike diffuse large-B-cell lymphomas.	"Rosenwald et al., 2002, N. Engl. J. Med."	Somatic		"transcript_fusion,transcript_regulatory_region_fusion"
B2M S14FS	B2M	S14FS	Skin Melanoma	Pembrolizumab	Predictive	Supports	C	Resistance	chr15	44711588	44711591	TCTT		Paired tumor samples were analyzed from four patients with metastatic melanoma and initial response with a subsequent relapse under pembrolizumab (PD-1 checkpoint inhibitor) therapy. Baseline biopsies were obtained before therapy initiation with pembrolizumab. A B2M frame-shift deletion in exon 1 was identified as the only new homozygous mutation among 24 new relapse-specific mutations. Immunohistochemistry revealed loss of MHC1 outer-membrane localization.	"Zaretsky et al., 2016, N. Engl. J. Med."	Somatic	ENST00000558401.1	frameshift_truncation
ALDH1A2 Overexpression	ALDH1A2	Overexpression	Head And Neck Squamous Cell Carcinoma		Prognostic	Supports	B	Better Outcome	chr15	57953424	58066418			"IHC for expression of ALDH1A2 and CRABP2 was performed in 89 patients with squamous cell carcinoma of the head and neck. High expression of both, ALDH1A2 and CRABP2 (in comparison to ALDH1A2 low or ALDH1A2 high and CRABP2 low) was significantly associated with OS and PFS in multivariate Cox analysis (OS, HR: 0.303, 95%CI 0.14?.63, p-value 0.002 PFS, HR: 0.395, 95%CI 0.20?.77, p-value 0.007)."	"Seidensaal et al., 2015, Mol. Cancer"	N/A	ENST00000249750.4	N/A
ALDH1A2 Underexpression	ALDH1A2	Underexpression	Head And Neck Squamous Cell Carcinoma	Tretinoin	Predictive	Supports	D	Sensitivity/Response	chr15	57953424	58066418			"FaDu (a high ALDH1A2 expression cell line) and Cal27 (a low expression cell line) were treated with all-trans retinoic acid (ATRA), Adapalene or Fenretinide. This led to concentration dependent decrease in the survival fraction in both cell lines with higher efficacy in Cal27 (ED50 ?1 M) as compared to FaDu cells (ED ?44 M). Treatment with 3 M ATRA sensitized Cal27 cells to irradiation at a dose of 2 Gy, but had no or only a minor effect on ALDH1A2-postitive cells."	"Seidensaal et al., 2015, Mol. Cancer"	N/A	ENST00000249750.4	N/A
ALDH1A2 Overexpression	ALDH1A2	Overexpression	Head And Neck Squamous Cell Carcinoma		Prognostic	Supports	B	Better Outcome	chr15	57953424	58066418			"ALDH1A2 protein levels were determined (IHC) in 115 patients with oropharyngeal squamous cell carcinoma with known HPV status (n = 89 nonHPV-driven; n = 26 HPV-driven). Low to moderate ALDH1A2 protein levels (combined as ALDH1A2low) were identified in keratinocytes of healthy mucosa as well as 73 (63.5%) primary tumors, and high ALDH1A2 protein levels in 42 (36.5%) primary tumors. Significantly higher ALDH1A2 protein levels were identified in HPV-driven than non-HPV-driven tumors. Moreover, PFS and OS strongly correlated with the ALDH1A2 protein expression level (OS, P < 0.001; PFS, P = 0.001; log-rank/Mantel-Cox test. Previous analyses in the same study identify hypermethylation of ALDH1A2 as the underlying mechanism of differential protein expression."	"Kostareli et al., 2013, J. Clin. Invest."	N/A	ENST00000249750.4	N/A
MAP2K1 Q56_V60del	MAP2K1	Q56_V60del	Ovarian Serous Carcinoma	Selumetinib	Predictive	Supports	C	Sensitivity/Response	chr15	66435111	66435125	CCAGAAGCAGAAGGT		Case report of a 51-year old patient with recurrent low-grade serous ovarian cancer. Selumetinib treatment in a phase-II trial led to a complete and durable response > 5 years. Sequencing (MSK-IMPACT Panel) was performed on the patients tumor and germline and identified a 15-bp in-frame deletion of MAP2K1 (8.3% of tumor reads but 0% in germline). In-silico modelling suggested loss of negative feedback on kinase activity from this deletion.In-vitro expression of the MEK1 Q56_V60 deletion as well as the previously characterized MEK1 F53L mutation in 293H cells resulted in elevated levels of phosphorylated ERK and phosphorylated ribosomal protein S6 kinase as compared with wild-type MEK1 as well as increased colony formation and tumor growth in-vivo. Selumetinib treatment of MEK1-transfected cells confirmed retained sensitivity to MEK inhibition and inhibition of colony formation.	"Grisham et al., 2015, J. Clin. Oncol."	Somatic	ENST00000307102.5	inframe_deletion
MAP2K1 Q56P	MAP2K1	Q56P	Melanoma	Selumetinib	Predictive	Supports	D	Resistance	chr15	66435113	66435113	A	C	"A375 cells expressing MAP2K1 Q56P mutation conferred an approximately 100-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expressing wild-type MAP2K1, or cells expressing a constitutively active form. This mutation also attenuated pERK inhibition by selumetinib in these cells."	"Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000307102.5	missense_variant
MAP2K1 K57N	MAP2K1	K57N	Lung Adenocarcinoma		Prognostic	Supports	B	Poor Outcome	chr15	66435117	66435117	G	T	"In a study of 6,024 lung adenocarcinomas, 36 conferred MEK1 mutations whereby 64% (n=23) were K57N and 19% (n=7) were Q56P.  Median overall survival of MEK1-mutated tumors was not significantly different from KRAS-mutated tumors (14.9 vs 13.7 months) or BRAP-mutated tumors (14.9 vs. 20.9 months).  MEK1-mutated tumors were significantly inferior compared to EGFR-mutated tumors (14.9 vs. 35.9 months; HR=2.64, p=0.01), ALK-rearranged tumors (14.9 vs. 35.9 months; HR, 2.64; P = 0.01), ROS1-rearranged tumors (14.9 vs. 76 months; HR, 4.00; P = 0.02), and RET-rearranged tumors (14.9 months vs. not reached; HR, 3.25; P = 0.03)."	"Arcila et al., 2015, Clin. Cancer Res."	Somatic	ENST00000307102.5	missense_variant
MAP2K1 K57N	MAP2K1	K57N	Lung Adenocarcinoma	Selumetinib	Predictive	Supports	D	Sensitivity/Response	chr15	66435117	66435117	G	T	"Mutational profiling of 207 lung adenocarcinomas identified in 2 of with activating mutation in exon 2 of MEK1 (K57N) in the nonkinase portion of the kinase. Neither of these two tumors harbored known mutations in other genes encoding components of the EGFR signaling pathway (i.e., EGFR, HER2, KRAS, PIK3CA, and BRAF). Expression of mutant, but not wild-type, MEK1 leads to constitutive activity of extracellular signal-regulated kinase (ERK)-1/2 in human 293T cells and to growth factor-independent proliferation of murine Ba/F3 cells. A selective MEK inhibitor, AZD6244, inhibits mutant-induced ERK activity in 293T cells and growth of mutant-bearing Ba/F3 cells."	"Marks et al., 2008, Cancer Res."	Somatic	ENST00000307102.5	missense_variant
MAP2K1 C121S	MAP2K1	C121S	Melanoma	Vemurafenib	Predictive	Supports	C	Resistance	chr15	66436816	66436816	G	C	A patient with BRAF-mutant melanoma relapsed after treatment with PLX4032 (vemurafenib). The MAP2K1 C121S mutation was identified as a relapse-specific variant and was undetectable in the pre-treatment tumor. In vitro experiments showed that the C121S mutation increased kinase activity and conferred resistance to PLX4032.	"Wagle et al., 2011, J. Clin. Oncol."	Somatic	ENST00000307102.5	missense_variant
MAP2K1 P124S	MAP2K1	P124S	Melanoma	Selumetinib	Predictive	Supports	D	Resistance	chr15	66436824	66436824	C	T	"A375 cells expressing MAP2K1 P124S mutation conferred an approximately 5-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expressing wild-type MAP2K1 or cells expressing a constitutively active form. This mutation also attenuated pERK inhibition by selumetinib in these cells."	"Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000307102.5	missense_variant
KIF23 EXPRESSION	KIF23	EXPRESSION	Hepatocellular Carcinoma		Prognostic	Supports	B	Better Outcome	chr15	69414349	69448417			"KIF23 variant 1 was found to be expressed in the cDNA of tumor tissues from a large cohort of HCC patients of chinese descent via PCR. This expression was absent in the normal tissues of these patients for this isoform. Using IHC and custom generated antibody, the overall survival with respect to KIF23 V1 expression was evaluated using the kaplan-meier method with a log rank test. It was found that positive KIF23 V1 staining was correlated with longer overall survival over a period of 5 years (p=.0052). This pattern was seen to a lesser degree over a period of 3 years (p=.1604). KIF23 V1 expression was independent of gender, age, tumor size, or TNM stage (multivariate cox regression)."	"Sun et al., 2015, BMC Cancer"	Somatic	ENST00000260363.4	N/A
PML PML::RARA	PML	PML::RARA	Acute Promyelocytic Leukemia	Tretinoin	Predictive	Supports	B	Sensitivity/Response	chr15	73994717	74033414			Fusion protein degradation is accelerated upon ATRA treatment of acute promyelocytic cells at pharmalogical concentrations.	"Yoshida et al., 1996, Cancer Res."	Somatic	ENST00000268058.3	transcript_fusion
PML PML::RARA	PML	PML::RARA	Acute Promyelocytic Leukemia		Diagnostic	Supports	A	Positive	chr15	73994717	74033414			"The presence of the PML-RARa fusion protein is a diagnostic marker of Acute Promyelocytic Leukemia, or M3 AML."	"Diverio et al., 1995, Haematologica"	Somatic	ENST00000268058.3	transcript_fusion
PML PML::RARA	PML	PML::RARA	Acute Promyelocytic Leukemia	"Tretinoin,Arsenic Trioxide"	Predictive	Supports	A	Sensitivity/Response	chr15	73994717	74033414			ATRA/Arsenic combined with standard chemotherapy has been shown to induce a complete remission rate of greater than 75% of patients with acute promyelocytic leukemia harboring the PML-RARa fusion.	"Degos et al., 2001, Oncogene"	Somatic	ENST00000268058.3	transcript_fusion
PML PML::RARA	PML	PML::RARA	Acute Promyelocytic Leukemia	Tretinoin	Predictive	Supports	C	Sensitivity/Response	chr15	73994717	74033414			"A 39-year old woman who presented with acute myeloid leukemia revealed a complicated genetic profile using conventional metaphase cytogenetics and FISH analysis.  Whole genome sequencing elucidated a PML-RARA fusion, which can be successfully treated with ATRA. Uncovering this mutation prevented an unnecessary allogeneic transplant and the patient remained in remission 15 months post-treatment (date of publication)."	"Welch et al., 2011, JAMA"	Somatic	ENST00000268058.3	transcript_fusion
PML B2 DOMAIN MUTATION	PML	B2 DOMAIN MUTATION	Acute Promyelocytic Leukemia	Tretinoin	Predictive	Supports	B	Resistance	chr15	74022872	74022878			Mutations in the B2 domain of PML in the PML-RARa fusion have been shown to be associated with resistance to standard ATRA treatment in patients with acute promyelocytic leukemia.	"Tomita et al., 2013, Int. J. Hematol."	Somatic	ENST00000268058.3	missense_variant
PML PML::RARA A216V	PML	PML::RARA A216V	Acute Promyelocytic Leukemia	Tretinoin	Predictive	Supports	C	Resistance	chr15	74022872	74022872	C	T	The mutation A216V in the B2 domain of PML in the PML-RARa fusion was seen in a patient with ATRA-resistant acute promyelocytic leukemia.	"Goto et al., 2011, Blood"	Somatic	ENST00000268058.3	"missense_variant,transcript_fusion"
PML PML::RARA A216V	PML	PML::RARA A216V	Acute Promyelocytic Leukemia	Arsenic Trioxide	Predictive	Supports	B	Resistance	chr15	74022872	74022872	C	T	"Five point mutations were identified in the PML B2 domain of PML-RARA transcripts in 9 patients diagnosed with APL and resistant to arsenic. DNA from these 9 patients was cloned into flag-tagged pCag expression vectors. Immunoblotting analyses demonstrated that after the addition of arsenic, the A216V, S214L, and A216T mutants experienced no change in expression or degradation when compared to wild type cells, indicating that these mutants were not inhibited by arsenic and demonstrate resistance. Immunofluorescent measurements indicated arsenic treatment did not alter the nuclear localization pattern of mutants A216V, S214L, or A216T, but had an effect on the localization of other mutants as well as wild type cells."	"Liu et al., 2016, Blood"	Somatic	ENST00000268058.3	"missense_variant,transcript_fusion"
PML PML::RARA L218P	PML	PML::RARA L218P	Acute Promyelocytic Leukemia	Tretinoin	Predictive	Supports	C	Resistance	chr15	74022878	74022878	T	C	"The PML L218P mutation in the PML-RARa fusion was observed in a patient with previously ATRA-treated, relapsed acute promyelocytic leukemia refractory to arsenic trioxide."	"Goto et al., 2011, Blood"	Somatic	ENST00000268058.3	"missense_variant,transcript_fusion"
NTRK3 Amplification	NTRK3	Amplification	Cancer	Entrectinib	Predictive	Does Not Support	B	Sensitivity/Response	chr15	87874999	88256747			"Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including CNS disease. Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. No objective responses (per RECIST v1.1) were observed in patients whose tumors did not harbor gene fusions involving NTRK1/2/3, ROS1, or ALK, with the exception of 1 patient with an ALKF1245V mutant neuroblastoma. Only 9 of 119 patients had NTRK Amplifications."	"Drilon et al., 2017, Cancer Discov"	Somatic	ENST00000394480.2	transcript_amplification
NTRK3 ETV6::NTRK3 G623R	NTRK3	ETV6::NTRK3 G623R	Mammary Analogue Secretory Carcinoma	Entrectinib	Predictive	Supports	C	Resistance	chr15	87933034	87933034	C	T	Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an etv6-ntrk3 fusion. The patient was treated with entrectinib and exhibited a partial response for 7 months followed by disease progression. A NTRK3 exon 16 G623R (c.1867G>A) mutation was identified in the progressive tumor. Cell line and structural models revealed that this mutation conferred relative resistance to entrectinib.	"Drilon et al., 2016, Ann. Oncol."	Somatic	ENST00000394480.2	"missense_variant,transcript_fusion"
IDH2 Mutation	IDH2	Mutation	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	N/A	chr15	90083045	90102504			"In patients with IDH2 R140 and R172 mutation, the presence of mutation does not impact overall survival or disease free survival."	"Thol et al., 2010, Blood"	Somatic	ENST00000330062.3	protein_altering_variant
IDH2 Mutation	IDH2	Mutation	Brain Glioma		Prognostic	Supports	B	Better Outcome	chr15	90083045	90102504			Genomewide analysis of 250 low-grade adult gliomas revealed that patients with a wildtype IDH1/2 had significantly shorter overall survival than those with a mutated IDH gene (HR 7.4; 95%CI: 4.0-13.8). The median survival for patients with low grade gliomas was 1.7 years for patients with wild-type IDH (N=55); 6.3 years for patients with mutated IDH and no 1p/19q co-deletion (N=139); and 8.0 years for patients with IDH mutation and a 1p/19q co-deletion (N=84).	"2015, N. Engl. J. Med."	Somatic	ENST00000330062.3	protein_altering_variant
IDH2 Mutation	IDH2	Mutation	Acute Myeloid Leukemia	Enasidenib	Predictive	Supports	D	Sensitivity/Response	chr15	90083045	90102504			"Mutations in IDH1 or IDH2 are identified in approximately 20% of patients with AML.This study report the discovery and characterization of AG-221, orally available, selective, potent inhibitor of the mutant IDH2 enzyme. AG-221 suppressed oncometobolite 2HG production and induced cellular differentiation in primary human IDH2 mutated AML cells in vivo and in xenograft mouse models, providing a statistically significant benefit in an aggressive IDH2 R140Q-mutant AML xenograft mouse model. Clinical trials are ongoing."	"Yen et al., 2017, Cancer Discov"	Somatic	ENST00000330062.3	protein_altering_variant
IDH2 Mutation	IDH2	Mutation	Acute Myeloid Leukemia	Enasidenib	Predictive	Supports	A	Sensitivity/Response	chr15	90083045	90102504			"A first-in-human phase 1/2 trial assessing the pharmacology, safety and activity of Enasidenib in IDH2-mutant myeloid hematoblastosis patients. In the AML subgroup (n=176, (n=130 R140; n=45 R172; n=1 Other)) of included patients (n=239) the overall response rate was 40.3%, with median response duration of 5.8 months. Responses were associated with cellular differentiation and maturation, typically without evidence of aplasia. Median overall survival among relapsed/refractory patients was 9.3 months, and for the 34 patients (19.3%) with complete response was 19.7 months."	"Stein et al., 2017, Blood"	Somatic	ENST00000330062.3	protein_altering_variant
IDH2 Mutation	IDH2	Mutation	Chondrosarcoma		Prognostic	Supports	B	Better Outcome	chr15	90083045	90102504			"In a retrospective study, the authors evaluated the association between IDH1/IDH2 mutation and prognosis in patients with high-grade central chondrosarcoma. Although no association was discovered between IDH mutation status and the patient's overall survival, IDH1/IDH2 mutation was found to be associated with longer relapse free and metastasis free survival in high-grade chondrosarcomas."	"Zhu et al., 2020, Clin. Cancer Res."	Somatic	ENST00000330062.3	protein_altering_variant
IDH2 Mutation	IDH2	Mutation	Acute Myeloid Leukemia	Venetoclax	Predictive	Supports	C	Sensitivity/Response	chr15	90083045	90102504			"In this case series, 7 elderly patients with secondary AML (sAML) not eligible for intensive chemotherapy and refractory to HMA (including 1 patient with antecedent myeloproliferative neoplasm) were treated with venetoclax monotherapy. Three of 7 patients showed response. Of these: 2 patients achieved complete remission (1 of which was mutated for IDH2). One patient with IDH1 mutation showed PB blast clearance (derived anti-leukemic benefit) but BM was not performed to evaluate response. Venetoclax responders had high BCL? and/or BIM expression levels in myeloblasts, and the response was significantly associated with OS. BCL-2 and BIM expression levels can potentially identifer venetoclax responders."	"Huemer et al., 2019, Eur J Haematol"	Somatic	ENST00000330062.3	protein_altering_variant
IDH2 R172	IDH2	R172	Glioblastoma		Prognostic	Supports	B	Better Outcome	chr15	90088605	90088607			"In patients with a glioblastoma, those with mutations at R172 of IDH2 had better overall survival than wild-type patients."	"Yan et al., 2009, N. Engl. J. Med."	Somatic	ENST00000330062.3	protein_altering_variant
IDH2 R172	IDH2	R172	Malignant Astrocytoma		Prognostic	Supports	B	Better Outcome	chr15	90088605	90088607			"In patients with anaplastic astrocytoma, those with mutations at R172 of IDH2 had better overall survival than wild-type patients."	"Yan et al., 2009, N. Engl. J. Med."	Somatic	ENST00000330062.3	protein_altering_variant
IDH2 R172	IDH2	R172	Peripheral T-cell Lymphoma		Prognostic	Does Not Support	B	Better Outcome	chr15	90088605	90088607			"In patients with angioimmunoblastic T-cell lymphoma (a subtype of peripheral T-cell lymphoma), IDH2 R172 mutations (N=16) had no impact on overall survival when compared to patients with wildtype IDH2 (N=24)."	"Wang et al., 2015, Blood"	Somatic	ENST00000330062.3	protein_altering_variant
IDH2 R172	IDH2	R172	Peripheral T-cell Lymphoma		Diagnostic	Supports	B	Positive	chr15	90088605	90088607			IDH2 R172 mutations were frequently observed in patients with the angioimmunoblastic T-cell lymphoma subtype of peripheral T-cell lymphomas but not observed in other subtypes.	"Cairns et al., 2012, Blood"	Somatic	ENST00000330062.3	protein_altering_variant
IDH2 R172	IDH2	R172	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr15	90088605	90088607			"In a study of 1,540 patients with Acute Myeloid Leukemia, 18 patients had a mutation in IDH2(R172).  IDH2(R172) mutations rarely showed co-mutation with NPM1 (odds ratio= 0.06; P=4x10-5), whereas IDH2(R140) mutations showed strong co-mutation with NPM1 (odds ratio= 3.6; P=5x10-10).  In an absence of gene fusion products, patients with IDH2(R172) mutations showed higher survival rates when compared to mutations in NPM1, chromatin-spliceosome mutations and TP53aneuploidy.  Patients with IDH2(R172) mutations showed worse prognosis when compared to CEBPA(biallelic) mutations."	"Papaemmanuil et al., 2016, N. Engl. J. Med."	Somatic	ENST00000330062.3	protein_altering_variant
IDH2 R172K	IDH2	R172K	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	N/A	chr15	90088606	90088606	C	T	AML patients with IDH2 mutations such as R172K have event free survival and overall survival similar to those with wild-type IDH2.	"Zhou et al., 2012, Leuk. Lymphoma"	Somatic	ENST00000330062.3	missense_variant
IDH2 R172K	IDH2	R172K	Myelodysplastic Syndrome		Prognostic	Does Not Support	B	N/A	chr15	90088606	90088606	C	T	"In patients suffering from MDS, the presence of IDH2 mutations such as R172K do not confer prognostic value (overall survival)."	"Lin et al., 2012, Ann. Hematol."	Somatic	ENST00000330062.3	missense_variant
IDH2 R172K	IDH2	R172K	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr15	90088606	90088606	C	T	"In AML, patients with an IDH2 R172K mutation have worse overall survival compared to those with wild-type IDH2."	"Green et al., 2011, Blood"	Somatic	ENST00000330062.3	missense_variant
IDH2 R140	IDH2	R140	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	N/A	chr15	90088702	90088702			"In this meta-analysis of adult non-promyelocytic AML (11 studies), patients with IDH2 R140 or R172 mutations had event free survival and overall survival similar to those with wild-type IDH2."	"Zhou et al., 2012, Leuk. Lymphoma"	Somatic	ENST00000330062.3	protein_altering_variant
IDH2 R140	IDH2	R140	Myelodysplastic Syndrome		Prognostic	Does Not Support	B	N/A	chr15	90088702	90088702			"In patients with myelodysplastic syndrome, the presence of IDH2 R140Q (N=3) or IDH1 R132 (N=2) mutations did not confer prognostic value (overall survival) compared to wild-type IDH1/2 patients (N=61; P=0.794)."	"Lin et al., 2012, Ann. Hematol."	Somatic	ENST00000330062.3	protein_altering_variant
IDH2 R140	IDH2	R140	Myelodysplastic Syndrome		Prognostic	Does Not Support	B	N/A	chr15	90088702	90088702			R140Q mutation in IDH2 does not have prognostic value in patients with MDS.	"Patnaik et al., 2012, Leukemia"	Somatic	ENST00000330062.3	protein_altering_variant
IDH2 R140	IDH2	R140	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr15	90088702	90088702			"In AML, patients with IDH2 R140 mutation have improved overall survival compared to those with wild-type IDH2."	"Green et al., 2011, Blood"	Somatic	ENST00000330062.3	protein_altering_variant
IDH2 R140	IDH2	R140	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	N/A	chr15	90088702	90088702			"In patients with acute myeloid leukemia, the presence of IDH2 R140Q (n??), IDH2 R172K (n??) or IDH1 R132 (N=4) mutations did not confer prognostic value (overall survival) compared to wild-type IDH1/2 patients overall (N=102; P=0.177). IDH1/2 mutations were significantly more common in cytogenetically normal AML (P=0.004). IDH1/2 mutations did also not confer an overall survival benefit in patients with an intermediate risk karyotype (N=68, P=0.484)."	"Lin et al., 2012, Ann. Hematol."	Somatic	ENST00000330062.3	protein_altering_variant
IGF1R EXPRESSION	IGF1R	EXPRESSION	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	D	Resistance	chr15	98648971	98964530			"Expression of IGF1R in NSCLC cell lines (n=17) was associated with resistance to EGFR inhibitor gefitinib, however, knock-in or knock-out of IGF1R did not affect gefitinib sensitivity. IGF1R expression was also higher in patients with disease progression after gefitinib therapy in a clinical cohort (n=98)."	"Peled et al., 2013, Cell Oncol (Dordr)"	N/A	ENST00000268035.6	N/A
IGF1R NUCLEAR EXPRESSION	IGF1R	NUCLEAR EXPRESSION	Sarcoma	IGF1R Monoclonal Antibody	Predictive	Supports	B	Sensitivity/Response	chr15	98648971	98964530			"IGF-1R nuclear immunostaining (IHC) was observed in 9 out of 16 samples of patients with different sarcomas (osteosarcoma, ewing sarcoma, liposarcoma, synovialsarcoma, desmoplastic tumor, rhabdomyosarcoma). Exclusive nuclear immunostaining was associated with better progression free survival and overall survival after therapy with IGF1R antibodies (R1507, IMC-A12, SCH 717454 and CP-751.871)."	"Asmane et al., 2012, Eur. J. Cancer"	N/A	ENST00000268035.6	N/A
TSC2 Q1178*	TSC2	Q1178*	Thyroid Gland Carcinoma	Everolimus	Predictive	Supports	C	Sensitivity/Response	chr16	2080299	2080299	C	T	"The pretreatment tumor contained a somatic nonsense mutation (Q1178*) in the tumor-suppressor gene TSC2 that inactivates the gene, allowing for activation of the mTOR pathway and resulting in sensitivity to mTOR inhibition by everolimus. The patient received a sustained response to everolimus for 18 months."	"Wagle et al., 2014, N. Engl. J. Med."	Somatic	ENST00000219476.3	stop_gained
CBFB CBFB::MYH11	CBFB	CBFB::MYH11	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr16	15703172	15727054			The CBFB-MYH11 fusion has been shown to be associated with favorable prognosis in acute myeloid leukemia.	"Estey, 2012, Am. J. Hematol."	Somatic	ENST00000412916.2	transcript_fusion
PALB2 Biallelic Inactivation	PALB2	Biallelic Inactivation	Pancreatic Cancer	Mitomycin	Predictive	Supports	C	Sensitivity/Response	chr16	23603170	23641310			"In a patient with gemcitabine-refractory pancreatic cancer, a tumor-derived xenograft was found to be responsive to Mitomycin C. After disease progression, the patient was started on a regimen of mitomycin C, and the patient was shown to be asymptomatic after 3 years of follow-up."	"Villarroel et al., 2011, Mol. Cancer Ther."	Somatic	ENST00000261584.4	loss_of_function_variant
PALB2 Biallelic Inactivation	PALB2	Biallelic Inactivation	Prostate Cancer	Olaparib	Predictive	Supports	C	Sensitivity/Response	chr16	23603170	23641310			"From 14 prostate cancer patients (88%) who had a response to olaparib, 7 patients had BRCA2 loss (4 with biallelic somatic loss, and 3 with germline mutations), 4 of 5 with had ATM aberrations and one had a biallelic inactivation of PALB2 (frameshift mutation and deletion)."	"Mateo et al., 2015, N. Engl. J. Med."	Somatic	ENST00000261584.4	loss_of_function_variant
MMP2 SERUM LEVELS	MMP2	SERUM LEVELS	Inflammatory Breast Carcinoma	Bevacizumab	Predictive	Supports	B	Sensitivity/Response	chr16	55478971	55506691			"MMP2 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. High bMMP2 was correlated with better disease-free survival (DFS, p=0.001) and overall survival (OS, p=0.032). Correlation to DFS was also found after multivariate analysis (p=0.003, Hazard Ratio [HR]: 0.115). bMMP2 was associated with relapse (p=0.002) and death (p=0.049). During treatment, significant increase in MMP2 was observed in 100% of patients."	"Tabouret et al., 2016, Oncotarget"	N/A	ENST00000219070.4	N/A
MMP2 SERUM LEVELS	MMP2	SERUM LEVELS	Brain Glioma	Bevacizumab	Predictive	Supports	B	Sensitivity/Response	chr16	55478971	55506691			"Plasma levels of 11 potential biomarkers were tested at baseline and 2 weeks after bevacizumab initiation in a prospective cohort of 26 patients with recurrent high-grade gliomas. Results were validated in a separate retrospective cohort (n = 50) and also tested in patients treated with cytotoxic agents without bevacizumab (n = 34). MMP2 level was correlated with PFS (hazard ratio, 3.92; 95% confidence interval [CI]:1.46-10.52; P = .007) and OS (hazard ratio, 4.62; 95% CI: 1.58-13.53; P = .005) in the discovery and validation cohorts but not in patients treated without bevacizumab."	"Tabouret et al., 2014, Neuro-oncology"	N/A	ENST00000219070.4	N/A
CBFB CBFB::MYH11	CBFB	CBFB::MYH11	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr16	67029245	67082308			The CBFB-MYH11 fusion has been shown to be associated with favorable prognosis in acute myeloid leukemia.	"Estey, 2012, Am. J. Hematol."	Somatic	ENST00000412916.2	transcript_fusion
CDH1 MUTATION	CDH1	MUTATION	Stomach Carcinoma		Prognostic	Supports	E	Poor Outcome	chr16	68737225	68835548			"285 intestinal-type tumors and 183 diffuse-type tumors were evaluated for mutational profiles.  CDH1 mutations are associated with diffuse type mucinous gastric carcinoma, which indicate worse prognosis when compared to intestinal type (p<0.001)."	"Rokutan et al., 2016, J. Pathol."	Somatic	ENST00000261769.5	transcription_variant
NQO1 EXPRESSION	NQO1	EXPRESSION	Lung Cancer	Amrubicin	Predictive	Supports	D	Resistance	chr16	69709401	69726951			Higher expression of NQO1 was correlated with decreased cytotoxicity of amrubicin (amrubicinol is the active metabolite) in 27 NSCLC and SCLC cell lines.  siRNA knockdown of NQO1 (in two cell lines) increased amrubicinol cytotoxicity.	"Takakuwa et al., 2011, J Thorac Oncol"	N/A	ENST00000320623.5	N/A
TUBB3 EXPRESSION	TUBB3	EXPRESSION	Cancer	Paclitaxel	Predictive	Supports	D	Resistance	chr16	89923279	89936097			"High expression of class 3 beta-tubulin led to decreased effect of paclitaxel on cell motility in HeLa, MCF-7 and CHO cell lines."	"Ganguly et al., 2011, Oncotarget"	N/A	ENST00000315491.7	N/A
TUBB3 EXPRESSION	TUBB3	EXPRESSION	Breast Cancer	Taxane Compound	Predictive	Supports	B	Sensitivity/Response	chr16	89923279	89936097			"High expression of betaIII-tubulin, as assessed in 85 breast cancers by IHC, was associated with better pathological response."	"Wang et al., 2013, Clin. Breast Cancer"	N/A	ENST00000315491.7	N/A
TP53 Deleterious Mutation	TP53	Deleterious Mutation	Head And Neck Squamous Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr17	7668402	7687538			"In a study of 74 patients with head and neck squamous cell carcinoma, those with disruptive mutations in TP53 had shorter overall survival and a higher rate of locoregional recurrence than those without mutations or with nondisruptive mutations."	"Skinner et al., 2012, Clin. Cancer Res."	Somatic	ENST00000269305.4	N/A
TP53 Mutation	TP53	Mutation	Head And Neck Squamous Cell Carcinoma		Prognostic	Does Not Support	B	Poor Outcome	chr17	7668402	7687538			"Unlike other studies, in this study of 110 patients with head and neck squamous cell carcinoma, there was no significant difference in the overall survival of patients with and without any TP53 mutations."	"Koch et al., 1996, J. Natl. Cancer Inst."	Somatic	ENST00000269305.4	protein_altering_variant
TP53 Mutation	TP53	Mutation	Esophagus Squamous Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr17	7668402	7687538			"In a retrospective study of patients with esophageal carcinoma, those with mutations in TP53 had worse overall survival."	"Yamasaki et al., 2010, Ann. Surg. Oncol."	Somatic	ENST00000269305.4	protein_altering_variant
TP53 Mutation	TP53	Mutation	B-lymphoblastic Leukemia/lymphoma		Prognostic	Supports	B	Poor Outcome	chr17	7668402	7687538			"In children with bone marrow relapsed B-cell precursor acute lymphoblastic leukemia, in multivariate analysis those with mutations in TP53 had worse event-free survival than patients without mutations."	"Krentz et al., 2013, Leukemia"	Somatic	ENST00000269305.4	protein_altering_variant
TP53 Mutation	TP53	Mutation	Myelodysplastic Syndrome		Prognostic	Supports	B	Poor Outcome	chr17	7668402	7687538			"In patients with myelodysplastic syndrome, in a multivariate analysis those with mutations in TP53 had shorter overall survival than wild-type patients."	"Bally et al., 2014, Leuk. Res."	Somatic	ENST00000269305.4	protein_altering_variant
TP53 Mutation	TP53	Mutation	Myeloid Neoplasm		Prognostic	Supports	B	Poor Outcome	chr17	7668402	7687538			"In patients with myeloma, those with mutations in TP53 had worse overall survival than those without."	"Chng et al., 2007, Leukemia"	Somatic	ENST00000269305.4	protein_altering_variant
TP53 Mutation	TP53	Mutation	Head And Neck Squamous Cell Carcinoma		Prognostic	Does Not Support	B	Poor Outcome	chr17	7668402	7687538			"Tumors from 114 patients with head and neck squamous cell carcinoma were analyzed for TP53 mutations, 21 of which were treated with surgery. Unlike those treated with radiotherapy, those treated with surgery did not show a significant difference in rates of loco-regional control between those with and without mutations in TP53."	"Alsner et al., 2001, Radiother Oncol"	Somatic	ENST00000269305.4	protein_altering_variant
TP53 Mutation	TP53	Mutation	Head And Neck Squamous Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr17	7668402	7687538			"Tumors from 114 patients with head and neck squamous cell carcinoma were analyzed for TP53 mutations. Of the 93 patients treated with radiotherapy, patients with mutations in TP53 had lower rates of loco-regional control and shorter disease-free, disease-specific, and overall survival."	"Alsner et al., 2001, Radiother Oncol"	Somatic	ENST00000269305.4	protein_altering_variant
TP53 Mutation	TP53	Mutation	B-lymphoblastic Leukemia/lymphoma		Prognostic	Supports	B	Poor Outcome	chr17	7668402	7687538			"In relapsed B-ALL patients, TP53 mutations were associated with morphologic nonresponse to therapy (>5% blasts in the bone marrow after 9 weeks of treatment) as well as reduced event free and overall survival when compared to TP53 wildtype patients."	"Hof et al., 2011, J. Clin. Oncol."	Somatic	ENST00000269305.4	protein_altering_variant
TP53 Mutation	TP53	Mutation	Gastric Adenocarcinoma	Chemotherapy	Predictive	Supports	B	Sensitivity/Response	chr17	7668402	7687538			In this meta-analysis of 13 studies (564 patients) p53 positivity as defined by high protein expression and/or p53 mutation was associated with improved response to chemotherapy (risk ratio [RR] = 0.704; 95% confidence intervals [CI] = 0.550-0.903; P = 0.006).	"Xu et al., 2014, PLoS ONE"	Somatic	ENST00000269305.4	protein_altering_variant
TP53 Mutation	TP53	Mutation	Breast Cancer	Doxorubicin	Predictive	Supports	D	Sensitivity/Response	chr17	7668402	7687538			"In this preclinical study, MMTV-Wnt1 mammary tumors with mutant TP53 showed a better clinical response to chemotherapy (doxorubicin) than TP53 wild-type tumors. This was mediated by wild-type TP53-induced cell-arrest under chemotherapy even in the context of heterozygous TP53 point mutations or absence of p21. Thus the status of both TP53 alleles should be assessed because even one copy of wild-type TP53 may contribute to poor response to chemotherapy."	"Jackson et al., 2012, Cancer Cell"	Somatic	ENST00000269305.4	protein_altering_variant
TP53 Wildtype	TP53	Wildtype	Colorectal Cancer	"Oxaliplatin,Cetuximab,Capecitabine"	Predictive	Supports	B	Sensitivity/Response	chr17	7668402	7687538			"In this retrospective biomarker analysis of the EXPERT-C trial, patients with TP53 wild-type status had a statistically significant better progression free survival (PFS) (89.3% vs 65.0% at 5 years; hazard ratio [HR] = 0.23; 95% confidence interval [CI] = 0.07 to 0.78; two-sided P = .02 by Cox regression) and overall survival (OS) (92.7% vs 67.5% at 5 years; HR = 0.16; 95% CI = 0.04 to 0.70; two-sided P = .02 by Cox regression) when treated with Cetuximab + CAPOX (Capecitabine, Oxaliplatin) than in the control arm without Cetuximab."	"Sclafani et al., 2014, J. Natl. Cancer Inst."	N/A	ENST00000269305.4	wild_type
TP53 Wildtype	TP53	Wildtype	Esophageal Carcinoma	Chemotherapy	Predictive	Supports	B	Sensitivity/Response	chr17	7668402	7687538			"Patients with p53 wild type (as defined by low expression and/or wild-type tp53 gene) had a higher response rate to chemotherapy-based treatment (total major response [MR]: risk ratio [RR] = 1.09, 95 % CI = 1.03-1.16, P = .003; pathological MR: RR = 1.15, 95 % CI = 1.06-1.25, P = .001; total complete response [CR]: RR = 1.08, 95 % CI = 1.00-1.17, P = .040) in this meta-analysis (28 studies, 1497 cases)."	"Zhang et al., 2013, Ann. Surg. Oncol."	N/A	ENST00000269305.4	wild_type
TP53 Mutation	TP53	Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr17	7668402	7687538			"In a study of 97 patients with AML  treated with HSCT, 40 had TP53 mutations comprising a total of 44 mutations. Patients with a TP53 mutation had a reduced three year probability of overall survival and event-free survival compared to patients with the wild-type TP53."	"Middeke et al., 2016, Br. J. Haematol."	Somatic	ENST00000269305.4	protein_altering_variant
TP53 Mutation	TP53	Mutation	Adrenocortical Carcinoma		Prognostic	Supports	B	Poor Outcome	chr17	7668402	7687538			"TP53 mutation was shown to be associated with shorter overall survival in patients with adrenocortical tumors (log-rank test; P=0.098). Of 20 patients studied, 5 had coding mutation in TP53. Four of the 5 patients with a TP53 mutation had metastases at diagnosis or detected soon thereafter, and 3 of 4 died of disease within 12 months of surgical resection."	"Sidhu et al., 2005, Eur J Surg Oncol"	Somatic	ENST00000269305.4	protein_altering_variant
TP53 Mutation	TP53	Mutation	Lung Non-small Cell Carcinoma	"Docetaxel,Selumetinib"	Predictive	Supports	D	Sensitivity/Response	chr17	7668402	7687538			A clinical trial comparing selumetinib and docetaxel vs. docetaxel and placebo in KRAS mutant NSCLC was recapitulated in mice. Tumors were induced in lung epithelium by nasal instillation of CRE-bearing adenovirus in conditionally targeted mice. Kras(G12D) and Trp53 knockout mutant mice were resistant to docetaxel monotherapy but sensitive to combined treatment. In a small number of human NSCLC patients with these genotypes FDG-PET signal intensity changes and pERK IHC staining correlated with mouse data.	"Chen et al., 2012, Nature"	Somatic	ENST00000269305.4	protein_altering_variant
TP53 Deleterious Mutation	TP53	Deleterious Mutation	Lung Non-small Cell Carcinoma		Prognostic	Does Not Support	B	Poor Outcome	chr17	7668402	7687538			"Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA). Mutations (434; 36%) had no prognostic effect (OBS: HROS=0.99; [95%CI 0.77-1.28], p=0.95; HRDFS=0.99 [0.78-1.25], p=0.92) but were marginally predictive of benefit from ACT for OS (test for interaction: OS: p=0.06; DFS: p=0.11)."	"Ma et al., 2016, J Thorac Oncol"	Somatic	ENST00000269305.4	N/A
TP53 Deleterious Mutation	TP53	Deleterious Mutation	Lung Non-small Cell Carcinoma	Adjuvant Chemotherapy	Predictive	Does Not Support	B	Sensitivity/Response	chr17	7668402	7687538			"Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA) of platinum-based adjuvant chemotherapy (ACT) versus observation (OBS). Patients with TP53wt had significantly better PFS and OS with ACT vs. OBS (p=0.005, p=0.02, respectively) whereas patients with TP53 mutations did not show significant differences in PFS and OS between ACT and OBS (p=0.86, p=0.63)."	"Ma et al., 2016, J Thorac Oncol"	Somatic	ENST00000269305.4	N/A
TP53 Wildtype	TP53	Wildtype	Lung Non-small Cell Carcinoma	Adjuvant Chemotherapy	Predictive	Supports	B	Sensitivity/Response	chr17	7668402	7687538			"Pooled analysis of TP53 mutations (exons 5-8) from 4 randomized trials (IALT, JBR10, CALGB-9633 and ANITA, 1209 patients, median follow-up 5.5 years) of platinum-based adjuvant chemotherapy (ACT) versus observation (OBS). Patients with wild-type TP53 had better outcomes with ACT than OBS (HROS=0.77 [0.62-0.95], p=0.02; HRDFS=0.75 [0.62-0.92], p=0.005)."	"Ma et al., 2016, J Thorac Oncol"	N/A	ENST00000269305.4	wild_type
TP53 Deleterious Mutation	TP53	Deleterious Mutation	Sarcoma	Pazopanib	Predictive	Supports	B	Sensitivity/Response	chr17	7668402	7687538			"19 advanced sarcoma patients treated with pazopanib were retrospectively assessed for mutations associated with response using the Foundation one sarcoma/heme panel. Progression-free survival (PFS) of patients with TP53 mutations (all predicted to be loss of function) was significantly greater than TP53 wild-type tumors with the median PFS of 208 versus 136 days, respectively [P = 0.036, hazards ratio 0.38 (95% confidence interval 0.09-0.83)]."	"Koehler et al., 2016, Ann. Oncol."	Somatic	ENST00000269305.4	N/A
TP53 Mutation	TP53	Mutation	Chronic Lymphocytic Leukemia		Prognostic	Supports	B	Poor Outcome	chr17	7668402	7687538			A study of 53 patients with B-CLL found a significant resistance to chemotherapy and corresponding poor clinical outcomes among the 7 treated patients with p53 mutations compared to the 29 treated patients without.	"el Rouby et al., 1993, Blood"	Somatic	ENST00000269305.4	protein_altering_variant
TP53 Mutation	TP53	Mutation	Chronic Lymphocytic Leukemia		Prognostic	Supports	B	Poor Outcome	chr17	7668402	7687538			"In a study of 126 patients with long-term follow-up, TP53 mutations were significantly associated with shorter median survival in patients (P = 0.002) from time of diagnosis. The median survival from the time of first observation of a TP53 mutation was much more pronounced (P = <0.001). These findings were statistically independent of 17p deletions."	"Zenz et al., 2008, Blood"	Somatic	ENST00000269305.4	protein_altering_variant
TP53 Mutation	TP53	Mutation	Chronic Lymphocytic Leukemia		Prognostic	Supports	B	Poor Outcome	chr17	7668402	7687538			"The authors analyzed 328 patients with CLL, of which 28 were identified to have TP53 mutations. Patients with TP53 mutations were found to have significantly shorter progression-free (HR = 3.8; P < 0.001) and overall survival (HR = 7.2; P < 0.001)."	"Zenz et al., 2010, J. Clin. Oncol."	Somatic	ENST00000269305.4	protein_altering_variant
TP53 Mutation	TP53	Mutation	Chronic Lymphocytic Leukemia		Prognostic	Supports	B	Poor Outcome	chr17	7668402	7687538			"In the CLL4 trial assessing first line treatment with chlorambucil or fludarabine with or without cyclophosphamide, patients with TP53 mutations experienced poorer overall response rates (27% vs 83%), shorter progression free survival (5 year PFS 5% vs 17%), and overall survival (20% vs 59%) compared to patients without TP53 mutations."	"Gonzalez et al., 2011, J. Clin. Oncol."	Somatic	ENST00000269305.4	protein_altering_variant
TP53 Mutation	TP53	Mutation	Chronic Lymphocytic Leukemia	Alemtuzumab	Predictive	Supports	B	Sensitivity/Response	chr17	7668402	7687538			"Thirty-six patients with CLL were treated with alemtuzumab. Partial or complete response was achieved in 6 of 15 patients with p53 mutations, compared to 4 of 21 without. These findings are not statistically significant, but the authors suggest that alemtuzumab is an effective therapy for patients with p53 mutations or deletions."	"Lozanski et al., 2004, Blood"	Somatic	ENST00000269305.4	protein_altering_variant
TP53 Mutation	TP53	Mutation	Chronic Lymphocytic Leukemia		Prognostic	Supports	B	Poor Outcome	chr17	7668402	7687538			"In a multivariate analysis of 774 CLL patients, TP53 aberrations were significantly correlated with shorter time to first treatment (HR=2.081; 95% CI=1.431-3.021). This finding was independent of IGHV mutation status."	"Baliakas et al., 2015, Leukemia"	Somatic	ENST00000269305.4	protein_altering_variant
TP53 Mutation	TP53	Mutation	Chronic Lymphocytic Leukemia		Prognostic	Supports	A	Poor Outcome	chr17	7668402	7687538			"In a cohort of 406 patients with CLL, those patients with clonal or sub-clonal mutations in TP53 had significantly shorter overall survival (HR: 1.71; 95% CI: 1.28-2.26; P = .0001)."	"Nadeu et al., 2016, Blood"	Somatic	ENST00000269305.4	protein_altering_variant
TP53 Overexpression	TP53	Overexpression	Ovarian Cancer		Prognostic	Supports	B	Poor Outcome	chr17	7668402	7687538			p53 overexpression (>10% positive stained nuclei) was found in 110 cases from a 178 patient cohort with invasive ovarian carcinoma who had undergone surgery. Overexpression of p53 was correlated with poor differentiation (p<0.001) and high S-phase fraction (p<0.001).	"Reles et al., 2001, Clin. Cancer Res."	N/A	ENST00000269305.4	N/A
TP53 ALTERATION	TP53	ALTERATION	Ovarian Cancer	"Cisplatin,Carboplatin"	Predictive	Supports	B	Resistance	chr17	7668402	7687538			"In a group of patients with invasive ovarian carcinoma who had undergone surgery, a subset of 74 patients treated with platinum based chemotherapy were assessed for  p53 alteration (p53 mutation or p53 overexpression by immunostaining >10% positive). Significant decreased time to progression (p=0.037) was seen in the subset of  patients with p53 alteration (n=54) in comparison to the group with normatl p53 (n=20)"	"Reles et al., 2001, Clin. Cancer Res."	Somatic	ENST00000269305.4	
TP53 Mutation	TP53	Mutation	Breast Cancer	Tamoxifen	Predictive	Supports	C	Resistance	chr17	7668402	7687538			"In a study 202 breast cancer patients undergoing tamoxifen treatment, a higher frequency of wildtype TP53 patients responded to treatment compared to those with mutations in TP53 (66% wild-type vs. 31%, odds ratio (OR):0.22, 95CI:0.12-0.42, P<0.0001, univariate analysis; OR:0.29, 95% CI:0.12-0.42, P=0.0014, multivariate analysis). The median survival after start of therapy was shorter in patients with mutations in TP53 than for patients with wild-type TP53 (20mo vs. 29mo, HR:1.99,95% CI:1.43-2.75, P<0.001). Breast cancer patients with TP53 mutations also had a decrease in progression-free survival (HR:2.61, 95% CI:1.90-3.6, P<0.001)."	"Berns et al., 2000, Cancer Res."	Somatic	ENST00000269305.4	protein_altering_variant
TP53 Overexpression	TP53	Overexpression	Stomach Cancer	"Cisplatin,Etoposide,Mitomycin"	Predictive	Supports	B	Sensitivity/Response	chr17	7668402	7687538			"In a Phase II trial of 25 patients with metastaic gastric cancer, patients received preoperative high dose chemotherapy (HDCT) consisting of etoposide, cisplatin and mitomycin. Patients with greater than 50% regression in response to HDCT received surgery. TP53 overexpression was assayed by immunohistochemistry. 14 patients showed p53 overexpression, and 12 of these qualified for resection. Overall survival in patients with p53 overexpression was 17.3 months in contrast to patients with negative p53 immunohistochemistry, where it was 7.2 months (p=0.0003)."	"Bataille et al., 2003, MP, Mol. Pathol."	N/A	ENST00000269305.4	N/A
TP53 Mutation	TP53	Mutation	Stomach Carcinoma	"Doxorubicin,Cisplatin,Etoposide"	Predictive	Supports	C	Sensitivity/Response	chr17	7668402	7687538			"In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment of a modified EAP protocol (combination of doxorubicin, etoposide and cisplatin). Patients with mutations in TP53 had an increased median survival compared to patients with wildtype TP53 (18.5mo vs. 10.2mo, P=0.044)."	"Bataille et al., 2003, MP, Mol. Pathol."	Somatic	ENST00000269305.4	protein_altering_variant
TP53 Wildtype	TP53	Wildtype	Cancer	Rebemadlin	Predictive	Supports	D	Sensitivity/Response	chr17	7668402	7687538			"MDM2 Inhibitor Nutlin-3a induced senescence in presence of functional TP53 in murine primary fibroblasts, oncogenically transformed fibroblasts, and fibrosarcoma cell lines. Cells lacking functional TP53 were completely insensitive to the drug."	"Efeyan et al., 2007, Cancer Res."	N/A	ENST00000269305.4	wild_type
TP53 Wildtype	TP53	Wildtype	Cancer	MDM2 Inhibitor AMGMDS3	Predictive	Supports	D	Sensitivity/Response	chr17	7668402	7687538			MDM2 Inhibitor screen in a panel of 260 cancer cell lines with well characterized TP53 status shows that only cancer cell lines with unaltered TP53 may be sensitive to MDM2 Inhibitor.	"Saiki et al., 2015, Oncotarget"	N/A	ENST00000269305.4	wild_type
TP53 Wildtype	TP53	Wildtype	Leukemia	RG7112	Predictive	Supports	B	Sensitivity/Response	chr17	7668402	7687538			"Phase I Trial of RG7112 in 116 heavily pretreated patients with AML, ALL, CML, CLL, sCLL demonstrated sustained clinical improvement and induction of TP53 target genes in subset of patients with wild type TP53. 96 patients were tested for TP53 mutation and 19 cases of mutation were detected. No sustained clinical improvement or induction of TP53 target genes was observed in patients with mutant TP53."	"Andreeff et al., 2016, Clin. Cancer Res."	N/A	ENST00000269305.4	wild_type
TP53 Deleterious Mutation	TP53	Deleterious Mutation	Leukemia	RG7112	Predictive	Supports	B	Resistance	chr17	7668402	7687538			"Phase I Trial of MDM2 inhibitor RG7112 in 116 patients with AML, ALL, CML, CLL, sCLL demonstrated sustained clinical improvement and induction of TP53 target genes in subset of patients with wild type TP53. No sustained clinical improvement or induction of TP53 target genes was observed in patients with mutant TP53."	"Andreeff et al., 2016, Clin. Cancer Res."	Somatic	ENST00000269305.4	N/A
TP53 Deleterious Mutation	TP53	Deleterious Mutation	Cancer	MDM2 Inhibitor AMGMDS3	Predictive	Supports	D	Resistance	chr17	7668402	7687538			"MDM2 Inhibitor screen in a panel of 260 cancer cell lines with well characterized TP53 status shows that only cancer cell lines with unaltered TP53 may be sensitive to MDM2 Inhibitor AMGMDS3, while those with p53 mutations demonstrated resistance."	"Saiki et al., 2015, Oncotarget"	Somatic	ENST00000269305.4	N/A
TP53 Deleterious Mutation	TP53	Deleterious Mutation	Cancer	Rebemadlin	Predictive	Supports	D	Resistance	chr17	7668402	7687538			"MDM2 Inhibitor Nutlin-3a induced senescence in presence of functional TP53 in murine primary fibroblasts, oncogenically transformed fibroblasts, and fibrosarcoma cell lines. TP53 mutant cells lacking functional TP53 were completely insensitive to the drug."	"Efeyan et al., 2007, Cancer Res."	Somatic	ENST00000269305.4	N/A
TP53 Mutation	TP53	Mutation	Lung Non-small Cell Carcinoma		Prognostic	Supports	B	N/A	chr17	7668402	7687538			"A pooled analysis to investigate the prognostic and predictive roles of TP53/KRAS and TP53/EGFR comutations (cm) in randomized trials of adjuvant chemotherapy compared to observational therapy encompassing a total of 3,553 patients. TP53/KRAS cm showed no prognostic effects but a borderline predictive effect (p=0,04) for negative effect of chemotherapy as compared to tp53/KRAS wt/wt. TP53/EGFR cm in was neither prognostic ( P = .83), nor significantly predictive ( P = .86). Similar results were observed for both groups for disease-free survival."	"Shepherd et al., 2017, J. Clin. Oncol."	Somatic	ENST00000269305.4	protein_altering_variant
TP53 Overexpression	TP53	Overexpression	Ovarian Cancer	"Carboplatin,Cisplatin"	Predictive	Supports	B	Resistance	chr17	7668402	7687538			"In a study involving patients with invasive ovarian carcinoma who had undergone surgery, a subset of 73 patients were classified via response to platinum-based chemotherapy as sensitive or resistant/refractory and tested for p53 overexpression (>10% postive stained nuclei). 78% of p53 negative patients were classified as sensitive, in compariston to 39% of p53 positive patients (p=0.001)."	"Reles et al., 2001, Clin. Cancer Res."	N/A	ENST00000269305.4	N/A
TP53 ALTERATION	TP53	ALTERATION	Ovarian Cancer		Prognostic	Supports	B	Poor Outcome	chr17	7668402	7687538			"In a study of invasive ovarian carcinoma patients who had undergone surgery, the p53 alteration variant was defined as p53 mutation or p53 overexpression by immunostain (>10% positive). Patients with p53 alterations showed increase in poor tumor cell differentiation (p<0.001) and increase in tumor cellular S-phase fraction (p<0.001). Out of 178 patients, p53 alteration (n=132) was associated with decreased overall survival in comparison to normal p53 (n=46), p=0.007."	"Reles et al., 2001, Clin. Cancer Res."	Somatic	ENST00000269305.4	
TP53 Mutation	TP53	Mutation	Medulloblastoma SHH Activated		Prognostic	Supports	B	Poor Outcome	chr17	7668402	7687538			"In the childhood (?.3 years) SHH-MB subgroup, TP53 mutations (n=13) are associated with shorter progression-free survival (PFS) compared to the no mutation group (n=35) (HR, 3.47; 95% CI, 1.29 to 9.3; p<0.014)."	"Schwalbe et al., 2017, Lancet Oncol."	N/A	ENST00000269305.4	protein_altering_variant
TP53 Overexpression	TP53	Overexpression	Renal Wilms' Tumor		Prognostic	Supports	B	Poor Outcome	chr17	7668402	7687538			"44 archival FFPE samples from confirmed cases of Wilms tumor with mean age 3 years 2 months, and taken from the most histologically aggressive parts of each tumor, were stained with p53 monoclonal antibody and the corresponding patient clinical data was analyzed. 24 samples were p53 positive, and did not correlate with age or sex. All tumors with unfavorable histology were p53 positive, in contrast to 13 of 33 tumors with favorable histology, with weak-moderate p53 signal (p<0.001). 2 year overall survival rate was 89.2% in p53 negative, and 55.7% for p53 positive cases (P = .01), and mean survival was 46 months in p53 negative and 26 months in p53 positive cases (P = .02). Compared with p53 negative, tumors with week to moderate p53 signal had HR 3.75 (P = .05), and high signal had HR 8.61 (P = .01). No significant correlation was seen between tumor clinicopathological stage and p53 expression."	"Jadali et al., 2011, Iran J Kidney Dis"	N/A	ENST00000269305.4	N/A
TP53 ALTERATION	TP53	ALTERATION	Rhabdomyosarcoma		Prognostic	Supports	B	Poor Outcome	chr17	7668402	7687538			"This study evaluated 641 cases of rhabdomyosarcoma (RMS) that were enrolled in the Childrens Oncology Group (COG) trials from 1998 to 2017 and the UK malignant mesenchymal tumor and RMS2005 trails from 1995 to 2016. Molecular testing included 39 genes which had been implicated in the past with regards to RMS. The analysis was performed with a custom-capture sequencing assay. Altered TP53 was noted in 69 out of 515 FOXO1 fusion-negative RMS cases (13%), with the most frequent mutations at codons G245S (6 cases), R248Q or W (6 cases), R175H (4 cases), and P72A (4 cases). These cases displayed a worse event free survival. In FOXO1 fusion-positive RMS subtype, there was a small number of cases with altered TP53 (3 and 2 cases in the COG and UK patient cohorts, respectively), but they were universally fatal. Due to lack of a matched germline sample, it could not be determined whether the TP53 abnormalities were of somatic or germline origin. Nevertheless, both cohorts show that mutations in TP53 are associated with a poor prognosis in both fusion-negative and fusion-positive RMS, with a particularly bleak outcome in fusion-positive RMS."	"Shern et al., 2021, J Clin Oncol"	Somatic	ENST00000269305.4	
TP53 Truncating Mutation	TP53	Truncating Mutation	Head And Neck Squamous Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr17	7670680	7676396			"In patients with head and neck squamous cell carcinoma, in a multivariate analysis those with truncating mutations in TP53 had worse progression-free and overall survival than wild-type patients."	"Lindenbergh-van der Plas et al., 2011, Clin. Cancer Res."	Somatic	ENST00000269305.4	frameshift_truncation
TP53 Truncating Mutation	TP53	Truncating Mutation	Head And Neck Squamous Cell Carcinoma		Prognostic	Does Not Support	B	Poor Outcome	chr17	7670680	7676396			"In patients with head and neck squamous cell carcinoma, when comparing patients with any mutation in TP53 to wild-type, there was not a significant difference in overall survival in a multivariate analysis."	"Lindenbergh-van der Plas et al., 2011, Clin. Cancer Res."	Somatic	ENST00000269305.4	frameshift_truncation
TP53 CONSERVED DOMAIN MUT	TP53	CONSERVED DOMAIN MUT	Ovarian Cancer		Prognostic	Supports	B	Poor Outcome	chr17	7673744	7676080			"Patients with conserved domain p53 mutation (n=61) were compared with those with wild type or non-conserved domain p53 mutation (n=117) in a cohort of 178 invasive ovarian carcinoma patients who had undergone surgery. Overall survival was decreased in the cohort with conserved domian mutation (p=0.005).  Conserved domain mutation was an independent factor in univariate (but not multivariate) analysis of overall survival with relative risk 1.70 (1.17-2.47, p<0.007)."	"Reles et al., 2001, Clin. Cancer Res."	Somatic	ENST00000269305.4	
TP53 R282L	TP53	R282L	Stomach Carcinoma	EAP Protocol	Predictive	Supports	C	Sensitivity/Response	chr17	7673775	7673775	C	A	"In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment of a modified EAP protocol (combination of doxorubicin, etoposide and cisplatin). Patients with mutations in TP53 had an increased median survival compared to patients with wildtype TP53 (18.5mo vs. 10.2mo, P=0.044)."	"Bataille et al., 2003, MP, Mol. Pathol."	Somatic	ENST00000269305.4	missense_variant
TP53 A276V	TP53	A276V			Functional	Does Not Support	D	Dominant Negative	chr17	7673793	7673793	G	A	A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. The authors used the RGC sequence as a p53 binding site. TP53 variant A276V was classified as recessive for RGC and a hotspot for mutation (P < 0.01) by the authors.	"Monti et al., 2002, Oncogene"	Somatic	ENST00000269305.4	missense_variant
TP53 R273H	TP53	R273H	Breast Cancer		Prognostic	Supports	B	Poor Outcome	chr17	7673802	7673802	C	T	"Breast cancer patients who harbor R273H mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation."	"Olivier et al., 2006, Clin. Cancer Res."	Somatic	ENST00000269305.4	missense_variant
TP53 R273H	TP53	R273H	Breast Cancer		Prognostic	Supports	B	Poor Outcome	chr17	7673802	7673802	C	T	"In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R273 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53."	"Berns et al., 1998, Br. J. Cancer"	Somatic	ENST00000269305.4	missense_variant
TP53 R273L	TP53	R273L	Ovarian Cancer	"Cisplatin,Carboplatin"	Predictive	Supports	C	Resistance	chr17	7673802	7673802	C	A	"Ovarian cancer patients with TP53 missense mutations were refractory to platinum-based chemotherapy (66% vs. 34% in wildtype, P=0.008) and had a shorter time to disease progression (n=54, P=0.037). A study of ovarian carcinoma patients (n=178) reported a reduced overall survival (HR:1.59, 95% CI:1.09-2.33, P=0.014) for patients with mutations in TP53."	"Reles et al., 2001, Clin. Cancer Res."	Somatic	ENST00000269305.4	missense_variant
TP53 R273H	TP53	R273H	Cancer	MDM2 Inhibitor AMGMDS3	Predictive	Supports	D	Resistance	chr17	7673802	7673802	C	T	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R273H loss of function mutation is present in 7 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.	"Saiki et al., 2015, Oncotarget"	Somatic	ENST00000269305.4	missense_variant
TP53 R273H	TP53	R273H	Osteosarcoma	"Doxorubicin,Methotrexate"	Predictive	Supports	D	Resistance	chr17	7673802	7673802	C	T	"Several preclinical studies were testing drug resistance mechanisms of TP53-R273H variant. Saos-2 cells were transfected with TP53-R273H mutation and these cells were used in the study. Using a western blot, Saos-2/TP53-R273H cells were shown to have a 0.6-fold down-regulation (compared to the Control) for Procaspase-3 protein expression. In addition, Saos-2/TP53-R273H cells were shown to be more resistant to methotrexate and doxorubicin. Reduced levels of drug-induced apoptosis were seen in Saos-2/TP53-R273H cells treated with doxorubicin (0.05 uM and 0.10 uM) and methotrexate (25 nM and 50 nM) in DNA fragmentation assays. According to the results, TP53-R273H induces drug resistance when procaspase-3 is down-regulated."	"Wong et al., 2007, Mol. Cancer Ther."	Somatic	ENST00000269305.4	missense_variant
TP53 R273H	TP53	R273H			Functional	Does Not Support	D	Neomorphic	chr17	7673802	7673802	C	T	"The R273H mutation was used to create isogenic AML cell lines using MOLM13 and K526 lines. R273H/- cells showed resistance to chemotherapeutic agents and failure to induce p21, indicating disruption of p53 function. ChIP assays demonstrated reduced p53 occupation across the genome for most p53 variants tested, including R273H. RNAseq studies determined that a novel gene expression program was not induced in R273H cells at baseline or with DNA damage induced p53 signal activation, and that the signature of gene expression was most similar to that of p53 loss, indicating that R273H mutation does not induce a neomophic p53 function."	"Boettcher et al., 2019, Science"	Unknown	ENST00000269305.4	missense_variant
TP53 R273C	TP53	R273C	Breast Cancer		Prognostic	Supports	B	Poor Outcome	chr17	7673803	7673803	G	A	"Breast cancer patients who harbor R273C mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation."	"Olivier et al., 2006, Clin. Cancer Res."	Somatic	ENST00000269305.4	missense_variant
TP53 R273C	TP53	R273C	Breast Cancer		Prognostic	Supports	B	Poor Outcome	chr17	7673803	7673803	G	A	"In breast cancer patients  harboring TP53 mutation, mutations in DNA contact regions such as R273 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53."	"Berns et al., 1998, Br. J. Cancer"	Somatic	ENST00000269305.4	missense_variant
TP53 R273C	TP53	R273C	Stomach Carcinoma	"Cisplatin,Etoposide,Mitomycin"	Predictive	Does Not Support	C	Sensitivity/Response	chr17	7673803	7673803	G	A	"A female patient taking part in a 25 patient gastric cancer trial was diagnosed at age 46, and received preoperative high dose chemotherapy (HDCT). Japanese Society for Gastric Cancer Response Score was 0. Resection was performed on patients with greater than 50% size reduction of the lesion. This patient did not undergo resection, and had on overall survival of 7.4 months."	"Bataille et al., 2003, MP, Mol. Pathol."	Somatic	ENST00000269305.4	missense_variant
TP53 R273C	TP53	R273C	Cancer	MDM2 Inhibitor AMGMDS3	Predictive	Supports	D	Resistance	chr17	7673803	7673803	G	A	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R273C loss of function mutation is present in 2 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.	"Saiki et al., 2015, Oncotarget"	Somatic	ENST00000269305.4	missense_variant
TP53 R273C	TP53	R273C			Functional	Supports	D	Dominant Negative	chr17	7673803	7673803	G	A	"A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. The authors used the RGC, p21, bax, and PIG3 sequences as p53 binding sites. TP53 variant R273C was classified as dominant negative for RGC, p21, bax, and PIG3. In addition, R273C was classified as a hotspot for mutation (P < 0.001) by the authors. The authors proposed a hierarchy of dominance of p53 variants for p21, PIG3, and bax sequences. They observed p53 variants that are dominant negative for p21 are also dominant for PIG3 and bax, and p53 variants that are dominant negative for PIG3 are also dominant for bax. The authors suggested lack of transactivation ability is necessary but not sufficient to predict dominance."	"Monti et al., 2002, Oncogene"	Somatic	ENST00000269305.4	missense_variant
TP53 DNA Binding Domain Mutation	TP53	DNA Binding Domain Mutation	Oral Squamous Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr17	7673831	7675125			"Oral squamous cell carcinoma patients with TP53 mutations in the DNA binding domain (L2, L3 and the LSH motif) have significantly reduced cumulative survival when compared to patients with TP53 mutations outside of this DNA binding domain. These mutations were also significantly associated with locoregional failure, cervical lymph node metastasis and distant metastasis, likely contributing to this finding."	"Yamazaki et al., 2003, Oral Oncol."	Somatic	ENST00000269305.4	DNA_binding_site
TP53 DNA Binding Domain Mutation	TP53	DNA Binding Domain Mutation	Breast Cancer	Tamoxifen	Predictive	Supports	B	Resistance	chr17	7673831	7675125			"In a study 202 breast cancer patients undergoing first line tamoxifen treatment, 65 patients had mutations in TP53. Among the p53 wild type population a 66% response rate was reported, where response was considered as complete response, partial response or stable disease. In a patient subgroup with mutations in p53 amino acids that directly interact with DNA, 2 of 11 (18%) of patients responded to tamoxifen."	"Berns et al., 2000, Cancer Res."	Somatic	ENST00000269305.4	DNA_binding_site
TP53 R249	TP53	R249	Breast Cancer		Prognostic	Supports	B	Poor Outcome	chr17	7674217	7674217	C	G	"In breast cancer patients harboring TP53 mutation, mutations in conserved regions such as R249 are prognostic for a worse overall survival compared to those harboring wild-type TP53."	"Berns et al., 1998, Br. J. Cancer"	Somatic	ENST00000269305.4	protein_altering_variant
TP53 R249	TP53	R249	Breast Cancer	Doxorubicin	Predictive	Supports	B	Sensitivity/Response	chr17	7674217	7674217	C	G	Breast tumors with R175H or R249 mutations are more responsive to doxorubicin than breast tumors with wild type TP53.	"Berns et al., 1998, Br. J. Cancer"	Somatic	ENST00000269305.4	protein_altering_variant
TP53 R248Q	TP53	R248Q	Breast Cancer		Prognostic	Supports	B	Poor Outcome	chr17	7674220	7674220	C	T	"Breast cancer patients who harbor a R248Q mutation (N=18) have worse overall survival than those with wild type TP53 (N=1460), but have better prognosis than those with a R248W mutation (N=8)."	"Olivier et al., 2006, Clin. Cancer Res."	Somatic	ENST00000269305.4	missense_variant
TP53 R248Q	TP53	R248Q	Breast Cancer		Prognostic	Supports	B	Poor Outcome	chr17	7674220	7674220	C	T	"In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R248 (N=10, 6 at R248) are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53 (N=43)."	"Berns et al., 1998, Br. J. Cancer"	Somatic	ENST00000269305.4	missense_variant
TP53 R248Q	TP53	R248Q	Cancer	MDM2 Inhibitor AMGMDS3	Predictive	Supports	D	Resistance	chr17	7674220	7674220	C	T	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R248Q loss of function mutation is present in 5 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.	"Saiki et al., 2015, Oncotarget"	Somatic	ENST00000269305.4	missense_variant
TP53 R248Q	TP53	R248Q			Functional	Supports	D	Dominant Negative	chr17	7674220	7674220	C	T	"CRISPR-Cas9 editing was used to create five isogenic MOLM13-TP53 AML cell lines with combinations of wild-type, mutant, and null TP53 alleles at the endogenous locus: p53+/+, p53+/-, p53-/-, R248Q/+, and R248Q/-. Cells were treated with and without DNA damaging agent and p53 inducing agent Daunorubicin and western blot used to assess p21 induction. p21 was induced in +/+ and +/-, but not -/-, R248Q/+, and R248Q/- cells. Daunorubicin treatment caused less cell death in +/- than in +/+ cells, but induced significantly less death in -/-, R248Q/+, and R248Q/-, where these three conditions were not statistically different. A similar result was seen with p53 activating agent Nutlin-3a, where p53-/-, R248Q/+, and R248Q/- cells grouped together with equivalent resistance to the agent in comparison to +/+ and +/- cells. The grouping in results of  -/-, R248Q/+, and R248Q/- suggest that R248Q inactivates the wt p53 copy, which does not occur in the +/- condition."	"Boettcher et al., 2019, Science"	Unknown	ENST00000269305.4	missense_variant
TP53 R248Q	TP53	R248Q			Functional	Does Not Support	D	Neomorphic	chr17	7674220	7674220	C	T	"The R248Q mutation was used to create isogenic AML cell lines using MOLM13 and K526 lines. R248Q/- cells showed resistance to chemotherapeutic agents and failure to induce p21, indicating disruption of p53 function. ChIP assays demonstrated reduced p53 occupation across the genome for most p53 variants tested, including R248Q. RNAseq studies determined that a novel gene expression program was not induced in R248Q cells at baseline or with DNA damage induced p53 signal activation, and that the signature of gene expression was most similar to that of p53 loss, indicating that R248Q mutation does not induce a neomophic p53 function."	"Boettcher et al., 2019, Science"	Unknown	ENST00000269305.4	missense_variant
TP53 R248W	TP53	R248W	Breast Cancer		Prognostic	Supports	B	Poor Outcome	chr17	7674221	7674221	G	A	"In breast cancer patients harboring R248W mutation, the prognosis is worse than any other hotspot TP53 mutation, as well as worse than patients with wild type TP53."	"Olivier et al., 2006, Clin. Cancer Res."	Somatic	ENST00000269305.4	missense_variant
TP53 R248W	TP53	R248W	Cancer	MDM2 Inhibitor AMGMDS3	Predictive	Supports	D	Resistance	chr17	7674221	7674221	G	A	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R248W loss of function mutation is present in 4 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.	"Saiki et al., 2015, Oncotarget"	Somatic	ENST00000269305.4	missense_variant
TP53 R248W	TP53	R248W			Functional	Supports	D	Dominant Negative	chr17	7674221	7674221	G	A	"A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. The authors used the p21, bax, and PIG3 sequences as p53 binding sites. TP53 variant R248W was classified as dominant negative for p21, bax, and PIG3. In addition, R248W was classified as a hotspot for mutation (P < 0.001) by the authors. The authors proposed a hierarchy of dominance of p53 variants for p21, PIG3, and bax sequences. They observed p53 variants that are dominant negative for p21 are also dominant for PIG3 and bax, and p53 variants that are dominant negative for PIG3 are also dominant for bax. The authors suggested lack of transactivation ability is necessary but not sufficient to predict dominance."	"Monti et al., 2002, Oncogene"	Somatic	ENST00000269305.4	missense_variant
TP53 G245S	TP53	G245S	Cancer	MDM2 Inhibitor AMGMDS3	Predictive	Supports	D	Resistance	chr17	7674230	7674230	C	T	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 G245S loss of function mutation is present in 3 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.	"Saiki et al., 2015, Oncotarget"	Somatic	ENST00000269305.4	missense_variant
TP53 G245S	TP53	G245S			Functional	Supports	D	Dominant Negative	chr17	7674230	7674230	C	T	"A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. The authors used the RGC, p21, bax, and PIG3 sequences as p53 binding sites. TP53 variant G245S was classified as dominant negative for RGC, p21, bax, and PIG3. In addition, G245S was classified as a hotspot for mutation (P < 0.001) by the authors. The authors proposed a hierarchy of dominance of p53 variants for p21, PIG3, and bax sequences. They observed p53 variants that are dominant negative for p21 are also dominant for PIG3 and bax, and p53 variants that are dominant negative for PIG3 are also dominant for bax. The authors suggested lack of transactivation ability is necessary but not sufficient to predict dominance."	"Monti et al., 2002, Oncogene"	Somatic	ENST00000269305.4	missense_variant
TP53 G245S	TP53	G245S			Functional	Supports	D	Dominant Negative	chr17	7674230	7674230	C	T	"Yeast strain yIG397 was cultured to express both wild-type (WT) and mutant G245S originally identified in an oral lesion. Should the mutant be dominant-negative (DN), TP53 will not bind and transactivate the ADE2 protein, resulting in red/pink colonies. If the mutant is recessive, then WT function is not blocked and ADE2 protein is expressed through TP53 transactivation, resulting in white colonies. Western blot analysis showed that yeast lysates showed expression of both WT and mutant alleles. Yeast expressing p53 variant and WT p53 produced red/pink colonies, demonstrating that G245S displays transdominance. Authors reported that all of the DN mutants affected the amino acids essential to the upkeep of DNA binding surfaces according to crystallographic structure."	"Marutani et al., 1999, Cancer Res"	Somatic	ENST00000269305.4	missense_variant
TP53 C242Y	TP53	C242Y			Functional	Supports	D	Dominant Negative	chr17	7674238	7674238	C	T	"A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. The authors used the RGC, p21, bax, and PIG3 sequences as p53 binding sites. TP53 variant C242Y was classified as dominant negative for RGC, p21, bax, and PIG3. In addition, C242Y was classified as a hotspot for mutation (P < 0.001) by the authors. The authors proposed a hierarchy of dominance of p53 variants for p21, PIG3, and bax sequences. They observed p53 variants that are dominant negative for p21 are also dominant for PIG3 and bax, and p53 variants that are dominant negative for PIG3 are also dominant for bax. The authors suggested lack of transactivation ability is necessary but not sufficient to predict dominance."	"Monti et al., 2002, Oncogene"	Somatic	ENST00000269305.4	missense_variant
TP53 C238Y	TP53	C238Y	Breast Cancer		Prognostic	Supports	E	Poor Outcome	chr17	7674250	7674250	C	T	Cys-238 was directly bound to zinc molecule. Patients with missense mutations affecting amino acids directly involved in DNA or zinc binding displayed a very aggressive clinical phenotype.	"Alsner et al., 2000, Clin. Cancer Res."	Somatic	ENST00000269305.4	missense_variant
TP53 M237I	TP53	M237I	Glioblastoma	MDM2 Inhibitor AMGMDS3	Predictive	Supports	D	Resistance	chr17	7674252	7674252	C	A	"Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 M237I loss of function mutation is present in 1 cell line (T98G, glioblastoma) and it is insensitive to MDM2 Inhibitor AMGMDS3 (IC50: 49.97uM)."	"Saiki et al., 2015, Oncotarget"	Somatic	ENST00000269305.4	missense_variant
TP53 M237I	TP53	M237I			Functional	Does Not Support	D	Neomorphic	chr17	7674252	7674252	C	A	"The M237I mutation was used to create isogenic AML cell lines using MOLM13 and K526 lines. M237I/- cells showed resistance to chemotherapeutic agents and failure to induce p21, indicating disruption of p53 function. ChIP assays demonstrated reduced p53 occupation across the genome for most p53 variants tested, including M237I. RNAseq studies determined that a novel gene expression program was not induced in M237I cells at baseline or with DNA damage induced p53 signal activation, and that the signature of gene expression was most similar to that of p53 loss, indicating that M237I mutation does not induce a neomophic p53 function."	"Boettcher et al., 2019, Science"	Unknown	ENST00000269305.4	missense_variant
TP53 Y234C	TP53	Y234C	Ovarian Cancer	"Cisplatin,Carboplatin"	Predictive	Supports	C	Resistance	chr17	7674262	7674262	T	C	"Ovarian cancer patients with TP53 missense mutations were refractory to platinum-based chemotherapy (66% vs. 34% in wildtype, P=0.008) and had a shorter time to disease progression (n=54, P=0.037). A study of ovarian carcinoma patients (n=178) reported a reduced overall survival (HR:1.59, 95% CI:1.09-2.33, P=0.014) for patients with mutations in TP53."	"Reles et al., 2001, Clin. Cancer Res."	Somatic	ENST00000269305.4	missense_variant
TP53 Y220C	TP53	Y220C	Stomach Carcinoma	"Etoposide,Cisplatin,Mitomycin"	Predictive	Supports	C	Sensitivity/Response	chr17	7674872	7674872	T	C	"A male patient taking part in a 25 patient gastric cancer trial was diagnosed at age 50, harbored a TP53 mutation and received preoperative high dose chemotherapy (HDCT). Japanese Society for Gastric Cancer Response Score was 2. Resection was performed on patients with >50% size reduction of the lesion. Consistent with response to preoperative chemotherapy, this patient did undergo resection, and had an overall survival of 12.6 months."	"Bataille et al., 2003, MP, Mol. Pathol."	Somatic	ENST00000269305.4	missense_variant
TP53 Y220C	TP53	Y220C	Cancer	MDM2 Inhibitor AMGMDS3	Predictive	Supports	D	Resistance	chr17	7674872	7674872	T	C	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 Y220C loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3.	"Saiki et al., 2015, Oncotarget"	Somatic	ENST00000269305.4	missense_variant
TP53 Y220C	TP53	Y220C			Functional	Does Not Support	D	Neomorphic	chr17	7674872	7674872	T	C	"The Y220C mutation was used to create isogenic AML cell lines using MOLM13 and K526 lines. Y220C/- cells showed resistance to chemotherapeutic agents and failure to induce p21, indicating disruption of p53 function. ChIP assays demonstrated reduced p53 occupation across the genome for most p53 variants tested, including Y220C. RNAseq studies determined that a novel gene expression program was not induced in Y220C cells at baseline or with DNA damage induced p53 signal activation, and that the signature of gene expression was most similar to that of p53 loss, indicating that Y220C mutation does not induce a neomophic p53 function."	"Boettcher et al., 2019, Science"	Unknown	ENST00000269305.4	missense_variant
TP53 R213P	TP53	R213P	Stomach Carcinoma	EAP Protocol	Predictive	Supports	C	Sensitivity/Response	chr17	7674893	7674893	C	G	"In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment of a modified EAP protocol (combination of doxorubicin, etoposide and cisplatin). Patients with mutations in TP53 had an increased median survival compared to patients with wildtype TP53 (18.5mo vs. 10.2mo, P=0.044)."	"Bataille et al., 2003, MP, Mol. Pathol."	Somatic	ENST00000269305.4	missense_variant
TP53 R175H	TP53	R175H	Breast Cancer	Doxorubicin	Predictive	Supports	D	Sensitivity/Response	chr17	7675088	7675088	C	T	Breast tumors in a mouse model with R172H mutation (homologous to human R175H) are more responsive to doxorubicin than breast tumors with wild type TP53.	"Jackson et al., 2012, Cancer Cell"	Somatic	ENST00000269305.4	missense_variant
TP53 R175H	TP53	R175H	Breast Cancer		Prognostic	Supports	B	Poor Outcome	chr17	7675088	7675088	C	T	"Breast cancer patients who harbor R175H mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation."	"Olivier et al., 2006, Clin. Cancer Res."	Somatic	ENST00000269305.4	missense_variant
TP53 R175H	TP53	R175H	Stomach Carcinoma	EAP Protocol	Predictive	Supports	C	Sensitivity/Response	chr17	7675088	7675088	C	T	"In a study of 25 patients with advanced gastric cancer, mutations in TP53 were identified in 32% of primary tumors. TP53 mutations were associated with an improved response to preoperative treatment of a modified EAP protocol (combination of doxorubicin, etoposide and cisplatin). Patients with mutations in TP53 had an increased median survival compared to patients with wildtype TP53 (18.5mo vs. 10.2mo, P=0.044)."	"Bataille et al., 2003, MP, Mol. Pathol."	Somatic	ENST00000269305.4	missense_variant
TP53 R175H	TP53	R175H	Cancer	MDM2 Inhibitor AMGMDS3	Predictive	Supports	D	Resistance	chr17	7675088	7675088	C	T	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R175H loss of function mutation is present in 4 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.	"Saiki et al., 2015, Oncotarget"	Somatic	ENST00000269305.4	missense_variant
TP53 R175H	TP53	R175H			Functional	Supports	D	Dominant Negative	chr17	7675088	7675088	C	T	"Yeast strain yIG397 was cultured to express both wild-type (WT) and mutant R175H originally identified in anaplastic astrocytoma. Should the mutant be dominant-negative (DN), TP53 will not bind and transactivate the ADE2 protein, resulting in red/pink colonies. If the mutant is recessive, then WT function is not blocked and ADE2 protein is expressed through TP53 transactivation, resulting in white colonies. Western blot analysis showed that yeast lysates showed expression of both WT and mutant alleles. Yeast expressing p53 variant and WT p53 produced red/pink colonies, demonstrating that R175H displays transdominance. Authors reported that all of the DN mutants affected the amino acids essential to the upkeep of DNA binding surfaces according to crystallographic structure."	"Marutani et al., 1999, Cancer Res"	Somatic	ENST00000269305.4	missense_variant
TP53 A161T	TP53	A161T			Functional	Supports	D	Loss of Function	chr17	7675131	7675131	C	T	"The TP53 A161T variant was identified in a chronic lymphocytic leukemia (CLL) cohort. In vitro work identified the A161T mutation as temperature sensitive, displaying the mutant loss-of-function phenotype (red yeast colonies) at 35 C and the wild type phenotype (white yeast colonies) at 25 . Protein activity was assessed via FASAY (functional analysis of separated alleles in yeast)."	"Pekova et al., 2011, Leuk Res"	Somatic		missense_variant
TP53 R158H	TP53	R158H	Vulva Squamous Cell Carcinoma	MDM2 Inhibitor AMGMDS3	Predictive	Supports	D	Resistance	chr17	7675139	7675139	C	T	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R158H loss of function mutation is present in 1 cell line (SW954) and it is insensitive to MDM2 Inhibitor AMGMDS3.	"Saiki et al., 2015, Oncotarget"	Somatic	ENST00000269305.4	missense_variant
TP53 R158L	TP53	R158L	Cancer	MDM2 Inhibitor AMGMDS3	Predictive	Supports	D	Resistance	chr17	7675139	7675139	C	A	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 R158L loss of function mutation is present in 2 cell lines and all are insensitive to MDM2 Inhibitor AMGMDS3.	"Saiki et al., 2015, Oncotarget"	Somatic	ENST00000269305.4	missense_variant
TP53 R158H	TP53	R158H			Functional	Does Not Support	D	Dominant Negative	chr17	7675139	7675139	C	T	"A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. The authors used the p21, bax, and PIG3 sequences as p53 binding sites. TP53 variant R158H was classified as recessive for p21, bax, and PIG3. In addition, R158H was classified as a hotspot for mutation (P < 0.001) by the authors."	"Monti et al., 2002, Oncogene"	Somatic	ENST00000269305.4	missense_variant
TP53 R158H	TP53	R158H			Functional	Does Not Support	D	Dominant Negative	chr17	7675139	7675139	C	T	"Yeast strain yIG397 was cultured to express both wild-type (WT) and mutant R158H originally identified in glioblastoma. Should the mutant be dominant-negative (DN), TP53 will not bind and transactivate the ADE2 protein, resulting in red/pink colonies. If the mutant is recessive, then WT function is not blocked and ADE2 protein is expressed through TP53 transactivation, resulting in white colonies. Western blot analysis showed that yeast lysates showed expression of both WT and mutant alleles. Yeast expressing R158H and WT p53 produced white colonies, indicating that R158H is not DN."	"Marutani et al., 1999, Cancer Res"	Somatic	ENST00000269305.4	missense_variant
TP53 V157F	TP53	V157F	Cancer	MDM2 Inhibitor AMGMDS3	Predictive	Supports	D	Resistance	chr17	7675143	7675143	C	A	Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP53 V157F loss of function mutation is present in 1 cell line and it is insensitive to MDM2 Inhibitor AMGMDS3.	"Saiki et al., 2015, Oncotarget"	Somatic	ENST00000269305.4	missense_variant
TP53 C135W	TP53	C135W			Functional	Does Not Support	D	Dominant Negative	chr17	7675207	7675207	G	C	"Yeast strain yIG397 was cultured to express both wild-type (WT) and mutant C135W originally identified in glioblastoma. Should the mutant be dominant-negative (DN), TP53 will not bind and transactivate the ADE2 protein, resulting in red/pink colonies. If the mutant is recessive, then WT function is not blocked and ADE2 protein is expressed through TP53 transactivation, resulting in white colonies. Western blot analysis showed that yeast lysates showed expression of both WT and mutant alleles. Yeast expressing C135W and WT p53 produced white colonies, indicating that C135W is not DN."	"Marutani et al., 1999, Cancer Res"	Somatic	ENST00000269305.4	missense_variant
NF1 Mutation	NF1	Mutation	Skin Melanoma	Vemurafenib	Predictive	Supports	D	Resistance	chr17	31094927	31377677			"Preclinical study of mouse melanoma in-vitro and in-vivo. In-vitro treament of Braf-mutant melanomas were 10-fold more sensitive to vermurafenib (PLX4032) treatment than Braf/Nf1-mutant melanomas. In vivo treatment of mice with Braf/Nf1-mutant allografts showed less sensitivity to vemurafenib (PLX4032) than the MEK inhibitor, PD0325901."	"Maertens et al., 2013, Cancer Discov"	Somatic	ENST00000358273.4	"protein_altering_variant,loss_of_function_variant"
NF1 Mutation	NF1	Mutation	Skin Melanoma	"Mirdametinib,Sirolimus"	Predictive	Supports	D	Sensitivity/Response	chr17	31094927	31377677			"Preclinical study of mouse melanoma both in-vitro and in-vivo. Braf/Nf1-mutant melanomas were less sensitive to vemurafenib than the MEK inhibitor PD0325901. mTOR inhibition with rapamycin had a more pronounced effect than GDC-0941 on mouse melanoma, but synergized with PD0325901(but not vemurafenib) to promote tumor regression."	"Maertens et al., 2013, Cancer Discov"	Somatic	ENST00000358273.4	"protein_altering_variant,loss_of_function_variant"
NF1 Mutation	NF1	Mutation	Skin Melanoma	Vemurafenib	Predictive	Supports	C	Resistance	chr17	31094927	31377677			"NF1 was identified in an unbiased RNAi screen as mediator of resistance to BRAF inhibition in BRAF mutant melanoma. Knockdown of NF1 led to PLX4720 resistance in-vitro. MEK inhibition with AZD6244 (selumetinib) had some efficacy but was also less active than in NF1 proficient cells.  4 patients with mutant alleles of NF1 were identified among patients relapsed after vemurafenib. Of these, one was a nonsense mutation (p.R2450*) present in both pretreatment and postrelapse biopsies. The patient had a progression-free survival (PFS) of about 10 weeks. The other NF1 mutations were silent events (patient 15, c.135T>C, patient 45 c.4023G>A, and patient 50 c3018C>T) located within candidate splicing motifs. Patients 15 and 50 exhibited response rates of relatively short duration (10 and 12 weeks, respectively) and the mutations were observed in both the pretreatment and postrelapse biopsies. Patient 45 experienced a PFS of 5 months, and the NF1 mutation was only present in the postrelapse biopsy indicative of acquired resistance."	"Whittaker et al., 2013, Cancer Discov"	Somatic	ENST00000358273.4	"protein_altering_variant,loss_of_function_variant"
NF1 Mutation	NF1	Mutation	Skin Melanoma	"VTX-11e,AZ628"	Predictive	Supports	D	Sensitivity/Response	chr17	31094927	31377677			"NF1 was identified in an unbiased RNAi screen as mediator of resistance to BRAF inhibition in BRAF mutant melanoma. BRAF V600E/NF1 mutant cell lines were sensitive to ERK inhibition with VTX-11e, modest resistance was observed against RAF inhibitor AZ628. Combined PLX4720 and AZD6244 (selumetinib) achieved greater efficacy than either agent alone but NF1 knockdown was still associated with residual resistance to combined RAF/MEK inhibition in vitro."	"Whittaker et al., 2013, Cancer Discov"	Somatic	ENST00000358273.4	"protein_altering_variant,loss_of_function_variant"
NF1 Loss	NF1	Loss	Malignant Peripheral Nerve Sheath Tumor	JQ1 Compound	Predictive	Supports	D	Sensitivity/Response	chr17	31094927	31377677			"BRD4 inhibition supressess growth and tumorigenesis of NF1-/-, TP53-/- MPNST cells in mouse xenografts"	"Patel et al., 2014, Cell Rep"	Somatic	ENST00000358273.4	loss_of_function_variant
SLFN11 EXPRESSION	SLFN11	EXPRESSION	Colorectal Cancer	7-Ethyl-10-Hydroxycamptothecin	Predictive	Supports	D	Sensitivity/Response	chr17	35350305	35373620			"In this study, SLFN11 expression was associated with sensitivity to SN-38 (an active metabolite of topoisomerase inhibitor irinotecan)."	"Tian et al., 2014, Anticancer Drugs"	Somatic	ENST00000394566.1	N/A
CDK12 Loss-of-function	CDK12	Loss-of-function	Ovarian Serous Carcinoma	Olaparib	Predictive	Supports	D	Sensitivity/Response	chr17	39462039	39535146			"In models of high-grade serous ovarian cancer (HGS-OVCa), CDK12 attenuation was sufficient to confer sensitivity to PARP1/2 inhibition, suppression of DNA repair via homologous recombination, and reduced expression of BRCA1."	"Bajrami et al., 2014, Cancer Res."	Somatic	ENST00000447079.4	loss_of_function_variant
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	Trastuzumab	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"A randomized clinical trial of 469 patients with previously untreated, HER2-positive, metastatic breast cancer demonstrated improved time to disease progression, objective response rate, and duration of response for patients who received trastuzumab in addition to chemotherapy compared to chemotherapy alone."	"Slamon et al., 2001, N. Engl. J. Med."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	Trastuzumab	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"A randomized clinical trial of 186 patients with previously untreated, HER2-positive, metastatic breast cancer demonstrated improved overall survival, response rate, response duration, time to progression, and time to treatment failure for patients who received trastuzumab in addition to chemotherapy (docetaxel) compared to chemotherapy alone."	"Marty et al., 2005, J. Clin. Oncol."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Breast Cancer	AKTi-1/2	Predictive	Supports	D	Sensitivity/Response	chr17	39700080	39728662			Xenografts established from breast cancer cell lines with ERBB2 amplification and PIK3CA mutation (BT474) or PIK3CA mutation alone (MCF7) were effectively inhibited in-vivo with an AKT1/2-inhibitor (AKTi-1/2; naphthyridinone).	"She et al., 2008, PLoS ONE"	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	Neratinib	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"Oral neratinib showed objective response rates of 24 and 56% respectively in prior-trastuzumab (n=63) and trastuzumab-naive (n=64) cohorts in a Phase II trial. As for the primary endpoint, the 16-week progression free survival was 59% in the prior-trastuzumab + neratibin patients and 78% in the trastuzumab-naive + neratinib patients. Overall, neratinib treatment results in substantial clinical activity and is well tolerated by patients."	"Burstein et al., 2010, J. Clin. Oncol."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Uterine Corpus Endometrial Carcinoma	Afatinib	Predictive	Supports	D	Sensitivity/Response	chr17	39700080	39728662			Eight uterine cancer cell lines (four with ERBB2 amplification and four without) were treated with scalar concentrations of afatinib. Primary chemotherapy-resistant USC cell lines harbouring ERBB2 gene amplification were sensitive to afatinib exposure and significantly more sensitive than non-amplified cell lines.	"Schwab et al., 2014, Br. J. Cancer"	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	"Trastuzumab,Afatinib,Lapatinib"	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"In this phase 2 trial, treatment-naive, ERBB2-positive (by IHC) breast cancer patients with stage IIIA, B, C or inflammatory disease were randomized 1:1:1 to afatinib (n = 10), lapatinib (n = 8), or trastuzumab (n = 11). The primary end point was objective response rate. Objective response was seen in 8 afatinib-, 6 lapatinib-, and 4 trastuzumab-treated patients. Afatinib demonstrated clinical activity that compared favorably to trastuzumab and lapatinib for neoadjuvant treatment of HER2-positive breast cancer."	"Rimawi et al., 2015, Clin. Breast Cancer"	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Colorectal Cancer	"Capecitabine,Cetuximab,Oxaliplatin"	Predictive	Does Not Support	B	Resistance	chr17	39700080	39728662			"141 patients were analyzed for ERBB2 (HER2) positivity by FISH and/or IHC. Only 6 (4.3%) were ERBB2 positive. These patients did not show a difference in outcome after capecitabine, oxaliplatin and chemoradiotherapy, with or without cetuximab."	"Sclafani et al., 2013, Ann. Oncol."	N/A	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	Afatinib	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"A phase II study involving adult female patients, >=18 years, with stage IIIB or IV HER2-positive (by IHC and/or in situ fluorescence) metastatic breast cancer. All patients were previously treated with trastuzumab and a median of three chemotherapy lines. 41 patients received 50 mg afatinib once-daily until disease progression and the primary endpoint was objective response rate. 4 patients (10% of 41 treated; 11% of evaluable patients) had partial response and 15 patients (37% of 41) had stable disease as best response. Thus a total of 19 (46% of 41) achieved clinical benefit. Median progression-free survival was 15.1 weeks."	"Lin et al., 2012, Breast Cancer Res. Treat."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Pancreatic Adenocarcinoma	Afatinib	Predictive	Supports	D	Sensitivity/Response	chr17	39700080	39728662			"Afatinib was growth-inhibitory for three pancreatic cancer cell lines but cytotoxic only toward BxPC3 (KRAS wt) and Capan-2 (KRAS mut) cells, both of which express high levels of EGFR, ERBB2, and ERBB3 receptors. Afatinib increased the radiosensitivity of BxPC3 and Capan-2 cells. In comparison, Panc-1 cells (KRAS mut) expressing low levels of EGFR family receptors were resistant to afatinib-induced radiosensitization."	"Huguet et al., 2016, Target Oncol"	N/A	ENST00000269571.5	transcript_amplification
ERBB2 SERUM LEVELS	ERBB2	SERUM LEVELS	Breast Cancer	Lapatinib	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"Serum and tissue levels of HER2 (ERBB2) were analyzed in 1,902 breast cancer patients treated with lapatinib or control. Serum HER2 (sHER2) levels measured by ELISA were higher in patients with HER2 amplification (median sHER2 levels were 25.1 ng/mL in patients with HER2-positive tumors). Serum HER2 levels were Independent predictors of lapatinib progression free survival benefit (HR per 10-ng/mL increase in serum HER2: lapatinib-containing therapies, 1.009 v nonlapatinib-containing therapies, 1.044; P interaction < .001). Tissue HER2 levels were also predictive, but within this subgroup, serum HER2 still independently predicted lapatinib PFS benefit."	"Lee et al., 2016, J. Clin. Oncol."	N/A	ENST00000269571.5	N/A
ERBB2 SERUM LEVELS	ERBB2	SERUM LEVELS	Breast Cancer		Prognostic	Supports	B	Poor Outcome	chr17	39700080	39728662			"Serum and tissue levels of HER2 (ERBB2) were analyzed in 1,902 breast cancer patients treated with lapatinib or control. In the control group (n = 936), higher serum HER2 (sHER2) was associated with worse prognosis in multivariable analyses (progression free survival hazard ratio per 10 ng/mL: PFS, 1.024; P < .001; and OS, 1.018; P < .001)."	"Lee et al., 2016, J. Clin. Oncol."	N/A	ENST00000269571.5	N/A
ERBB2 Amplification	ERBB2	Amplification	Breast Cancer	"Trastuzumab,Lapatinib"	Predictive	Supports	D	Sensitivity/Response	chr17	39700080	39728662			"In-vitro studies using ERBB2 over-expressing breast cancer cell lines BT474 and SKBR3 (with ERBB2 amplification) showed apoptosis under either labatinib or trastuzumab treatment.  A marked synergistic apoptotic effect under lapatinib and trastuzumab co-treatment was observed in BT474 cells, and a milder synergistic effect was observed in SKBR3 cells."	"Xia et al., 2005, Oncogene"	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	"Trastuzumab,Lapatinib"	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"In light of results showing increased PFS using mAB plus TKI in heavily pretreated patients, the efficacy of trastuzumab plus lapatinib in a neoadjuvant setting with untreated stage II or IIIA HER2 positive breast cancer was assessed.  In this randomized 3 arm phase II study (CHER-LOB), patients received (A) chemotherapy plus trastuzumab, (B) chemotherapy plus lapatinib, or (C) chemotherapy plus trastuzumab and lapatinib, with pathologic complete response (pCR) as endpoint.  From 121 patients, pCR rates were 25% in arm A, 26.3% in arm B, and 46.7% in arm C.  The authors conclude these results support the superiority of dual-HER2 inhibition in the neoadjuvant context of HER2 positive BC."	"Guarneri et al., 2012, J. Clin. Oncol."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	"Trastuzumab,Lapatinib"	Predictive	Does Not Support	B	Sensitivity/Response	chr17	39700080	39728662			"This Phase III trial compared the activity of lapatinib vs. trastuzumab vs. sequential trastuzumab followed by lapatinib vs. lapatinib plus trastuzumab in an adjuvant treatment setting.  8381 women were randomized to one of four treatment arms. Patients had HER2 positive non-metastatic operable BC. The primary endpoint was disease free survival.  First results report that after median 4.5 year follow up, a non significant 16% improvement in DFS was seen in trastuzumab + lapatinib vs. trastuzumab alone.  The results are interpreted as showing no added benefit for labatinib addition to trastuzumab in the adjuvant treatment context.  This trial is ongoing but not recruiting patients (NCT00490139)."	"Zardavas et al., 2015, Breast"	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	"Trastuzumab,Lapatinib"	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"This Phase III study (EGF104900) was motivated by preclinical and other data demonstrating synergistic activity between lapatinib and trastuzumab against HER2 positive breast cancer (BC) cells.  In this study of HER2 positive metastatic BC which had progressed on trastuzumab, two arms were compared: lapatinib vs. lapatinib + trastuzumab. Progression free survival (PFS) was the primary endpoint. For 296 patients, 148 in each arm, median PFS of 8.1 weeks for lapatinib and 12.0 for combination therapy was observed (P=0.008).  The authors conclude that in the context of metastatic trastuzumab-progressed HER2 positive BC, trastuzumab with lapatinib TKI addition is a favorable treatment."	"Blackwell et al., 2010, J. Clin. Oncol."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	Afatinib	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"This Phase II trial (LUX-Breast 3 - NCT01441596) compared afatinib, afatinib plus vinorelbine, or investigator's choice of treatment.  121 patients with HER2 overexpressing breast cancer with CNS recurrence or regression who had previously progressed on trastuzumab or lapatinib were assigned to 3 arms, with endpoint in the intention-to-treat population being patient benefit at 12 weeks defined as absence of CNS or extra CNS progression, no tumor related worsening of neurological symptoms and no increase in corticosteroid dose. Benefit was seen in 30% of 40 patients assigned to afatinib alone, 34.2% of 38 assigned to afatinib plus vinorelbine, and 41.9% of 43 assigned to investigator's treatment choice.  Differences were not statistically significant, and afatanib patients experienced more adverse effects.  While Afatanib did show response in HER2 breast cancer patients, it was not better than investigator's treatment choice and the investigators state that no further development of afatinib for HER2 breast cancer will be planned."	"Corts et al., 2015, Lancet Oncol."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	Afatinib	Predictive	Does Not Support	B	Sensitivity/Response	chr17	39700080	39728662			"LUX-Breast 1 is a phase 3 trial (NCT01125566) which enrolled 508 patients with metastatic HER2 positive BC who had progressed after adjuvant or first-line trastuzumab. It was thought that the wider range of ErbB family blocking and irreversible properties of afatinib could be beneficial in trastuzumab resistant cancer cells, since ErbB family members are thought to play a role in trastuzumab resistance. Primary endpoint was intention-to-treat group PFS. 339 patients were assigned to afatanib + vinorelbine and 169  to trastuzumab + vinorelbine.  Recruitment was stopped prematurely when it was deemed unlikely that the increased PFS would be seen in the afatinib group. Median PFS was 5.5 months in the afatinib group and 5.6 months in the trastuzumab group.  Afatanib plus vinorelbine was less well tolerated than trastuzumab plus vinorelbine, and the authors conclude that trastuzumab remains the best choice for treatment of trastuzumab-progressed HER2 positive metastatic BC."	"Harbeck et al., 2016, Lancet Oncol."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	"Trastuzumab,Afatinib"	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"Trastuzumab resistance is thought to consist of multiple compensatory mechanisms involving ErbB family members such as increased signaling through ErbB family heterodimers.  The irreversible TKI afatinib blocks EGFR, HER2, ErbB3 and ErbB4.  Thus afatinib was studied in this Phase I trial of trastuzumab-progressed HER2 positive metastatic BC (MBC) in combination with continued trastuzumab treatment, where trastuzumab is still the perferred treatment for trastuzumab-progressed MBC.  Objective response and disease control rates were 11% and 39%.  The authors conclude that the clinical activity observed in this trial warrants further work with afatinib and trastuzumab combination therapy."	"Ring et al., 2015, Clin. Cancer Res."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Gastric Adenocarcinoma	Trastuzumab	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and platinum-based combinations had been common practice.  Patients were given a chemotherapy regime containing capecitabine, flourouracil and cisplatin with (n=298) or without (n=296) trastuzumab, and had not been previously treated for metastatic cancer.  Study endpoint was overall survival, which was significantly different in the two populations (13.8 months with chemotherapy + trastuzumab and 11.1 months for chemotherapy alone).  The authors conclude that trastuzumab should be a standard option for HER2 positive advanced gastric cancer."	"Bang et al., 2010, Lancet"	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Gastric Adenocarcinoma	Lapatinib	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"TyTAN, a Phase III study in Asian patients, looked at addition of tyrosine kinase inhibitor lapatinib to chemptherapy in advanced HER2 positive gastric cancer.  Primary endpoint was Overall Survival (OS).  Participants had progressed under previous treatment and only a small percentage had seen first line trastuzumab.  Patients were a mix of those having undergone gastrectomy and not.  OS was not significantly  different in the ITT population, but certain subpopulations showed significant differences.  In the subset of patients showing a stronger immunohistochemistry result for HER2 (IHC3+), progression free survival was significantly different at 5.6 months for lapatinib + pacitaxel vs. 4.2 months for pacitaxel alone.  The authors conclude that proof of concept for lapatanib addition to chemotherapy for certain subgroups is provided in this study."	"Satoh et al., 2014, J. Clin. Oncol."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Lung Non-small Cell Carcinoma	Trastuzumab	Predictive	Does Not Support	B	Sensitivity/Response	chr17	39700080	39728662			"In this phase II trial with 2 arms, 103 patients with untreated stage IIIB/IV HER2 positive NSCLC were given gemcitabine-cisplatin with or without trastuzumab.  HER2 positivity was broadly defined as IHC2+/3+, positive by FISH, or increased circulating HER2 extracellular domain.  Significant differences between the treatment arms were not observed, but in a small subset of IHC3+/FISH positive patients, 5 of 6 responded to trastuzumab and had increased PFS of 8.5 months in comparison to 6.1 months in the IHC2+ group.  Although from 2004, this study remains cited in 2016 literature when discussing the unclear efficacy of trastuzumab in wild-type HER2 overexpressing NSCLC. The authors conclude that future studies of trastuzumab in HER2 positive NSCLC should focus on high expressing subjects."	"Gatzemeier et al., 2004, Ann. Oncol."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Lung Non-small Cell Carcinoma	Trastuzumab	Predictive	Does Not Support	B	Sensitivity/Response	chr17	39700080	39728662			"In this phase II trial a small group of patients with IHC2+ or IHC3+ HER2 NSCLC, in which primary platinum-based therapy had failed, were given either docetaxel or trastuzumab after which both groups were given docetaxel and trastuzumab together.  there was one partial response in the docetaxel group and none in the trastuzumab group.  The authors report that due to the limited clinical activity of trastuzumab-based therapy in this cohort, as well as similar results in other trastuzumab studies, that targets other than HER2 in NSCLC should be considered for future study.  This 2004 study remains cited in 2016 literature in discussing the unclear efficacy of trastuzumab in wild-type HER2 overexpressing NSCLC, but mutant HER2 in NSCLC has been further studied and a picture of different HER2 mutations being potentially responsive to specific targeted therapies is emerging."	"Lara et al., 2004, Clin Lung Cancer"	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Lung Small Cell Carcinoma	"Trastuzumab,Irinotecan"	Predictive	Supports	C	Sensitivity/Response	chr17	39700080	39728662			"This report details 2 case studies in relapsed HER2 positive SCLC.  In the first case, a 50 pack-year patient showed intense non-mutant HER2 expression by IHC without DNA amplification, and had undergone multiple prior lines of treatment.  With induction of trastuzumab and irinotecan treatment, tumor regression was observed with progression free survival of 4.5 months.  Case 2 involved a 68 year old never-smoker with relapsed SCLC.  Tumor showed HER2 positive SCLC cells with no amplification or mutation.  Third line trastuzumab plus irinotecan brought about some symptom improvement and PFS of 3.5 months.  While the efficacy of trastuzumab against NSCLC with elevated levels of wild-type HER2 expression remains unclear, the authors conclude that trastuzumab based therapy is a promising strategy for chemo-resistant SCLC."	"Kinehara et al., 2015, Lung Cancer"	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Lung Non-small Cell Carcinoma	Trastuzumab Emtansine	Predictive	Supports	D	Sensitivity/Response	chr17	39700080	39728662			"Efficacy of trastuzumab in HER2 overexpressing NSCLC remains unclear.  In this study using a panel of NSCLC HER2 overexpressing cell lines, antiproliferative effects of trastuzumab emtansine (T-DM1) were observed in a HER2-expression dependant manner, with strongest effects in Calu-3 (high expressing) and no effects in Calu-6 (low expressing).  Trastuzumab did not show notable effects on cell growth in any tested cells.  HER2 positivity in NSCLC is fairly common at 2-20%.  A clinical trial (NCT02289833) is currently underway to asses TDM-1 in HER2 overexpressing lung cancer."	"Cretella et al., 2014, Mol. Cancer"	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	"Docetaxel,Pertuzumab,Trastuzumab"	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"CLEOPATRA (NCT00567190) was a Phase III, randomized and double-blind, placebo-controlled study of 808 patients with HER2-positive metastatic breast cancer.  Patients were HER2-positive by IHC3+ or FISH, and patients who had received prior hormonal treatment or adjuvant/neo-adjuvant therapy with or without trastuzumab for longer than 12 months before randomization were also eligible.  The two arms of the study were trastuzumab and docetaxel with either placebo or pertuzumab.  Median PFS in the placebo arm was 12.4 months while in the petuzumab arm 18.5 months was achieved.  Median OS in the control arm was 40.8 months and 56.5 months with pertuzumab.  These strong results make a case for dual antibody blockade in first line treatments of HER2-positive metastatic breast cancer."	"Swain et al., 2015, N. Engl. J. Med."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Endometrial Serous Adenocarcinoma		Prognostic	Supports	B	Poor Outcome	chr17	39700080	39728662			"In a study of 27 African American and caucasian patients, endometrial adenocarcinoma samples were assessed for HER2 via IHC staining, and association studies were performed using corresponding patient information.  Earlier deaths were seen with heavier HER2 expression.  Multivariate Cox regression indicated that shorter survival was associated with higher HER2 expression, and not with age or ethnicity, and that observed differences in survival rates between ethnicities can be ascribed to higher rates of HER2 overexpression in African American patients.  The authors conclude that high HER2 expression in USPC is associated with poor outcome and explains observed differences in outcome between ethnicities."	"Santin et al., 2005, Am. J. Obstet. Gynecol."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Endometrial Serous Adenocarcinoma	Trastuzumab	Predictive	Supports	C	Sensitivity/Response	chr17	39700080	39728662			"HER2 expression in uterine serous papillary carcinoma (USPC) is thought to be associated with poor prognosis and may act as a targetable driver mutation in this cancer.  HER2 overexpression in USPC is more common in African American women.  This report covered 2 African American patients, the first of which presented high-grade endometrial adenocarcinoma with IHC3+ HER2-positivity as well as positivity by FISH.  Prior treatment involved surgery and chemotherapy.  Treatment with pacitaxel/carboplatin with trastuzumab showed clear clinical improvement assessed by CT scan and drop in CA-125 levels from 988 to 7.9 U/mL.  The second patient had USPC, and was treated with surgery and radiation.  Trastuzumab monotheraby was then administered.  After 7 months of treatment, the patient showed no sign of disease progression and CA-125 had dropped from 144 to 41 U/mL.  The investigators conclude there is promise in trastuzumab-based therapies in advanced endometrial cancers, including USPC."	"Santin et al., 2008, Int J Gynaecol Obstet"	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Endometrial Cancer	Trastuzumab	Predictive	Does Not Support	B	Sensitivity/Response	chr17	39700080	39728662			"This phase II single arm study assessed trastuzumab monotherapy in HER2 positive endometrial cancers with tumor response as primary endpoint.  Participants had stage III, IV or recurrent HER2 positive endometrial cancer.  During the trial's initial phase, 23 of 132 patients screened met the criteria of IHC2+ or 3+ or FISH positivity for HER2 status.  In the absence of results, the trial entered phase B, where only patients with HER2 amplification by FISH were admitted.  The trial ended early due to poor accrual with 11 of 154 screened meeting the phase B criteria. No major objective tumor responses were observed in the study.  28% of the cancers were of the serous type that had shown trastuzumab response in case studies.  The investigators note that in other HER2 cancers, such as breast and gastrointestinal, trastuzumab in combination with chemotherapy has been found most effective, and could warrant more study.  Currently a clinical trial (NCT01367002) is evaluating carboplatin/paclitaxel with or without trastuzumab in uterine serous cancer."	"Fleming et al., 2010, Gynecol. Oncol."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	"Trastuzumab,Neratinib"	Predictive	Supports	A	Sensitivity/Response	chr17	39700080	39728662			"In this two arm, Phase III study (NCT00878709) of the efficacy of a 12 month course of the TKI neratinib after trastuzumab-based adjuvant therapy of early stage HER2-positive breast cancer was assessed using invasive disease-free survival as primary endpoint. HER2 positivity was assessed via FISH. At 2 year follow-up, 70 vs. 109 disease-free survival events had occurred and disease-free survival rates were 93.9% vs. 91.6% (significant) in neratinib vs. placebo groups respectively. Distant disease-free survival and time to distant recurrence were similar in both groups. These results are an interesting contrast to results of long-term adjuvant therapy with trastuzumab (HERA) which did not show significant benefit."	"Chan et al., 2016, Lancet Oncol."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	Trastuzumab	Predictive	Supports	A	Sensitivity/Response	chr17	39700080	39728662			"HERA was a Phase III trial assessing application of trastuzumab in an extended adjuvant setting.  Patients were HER2 positive with completely excised invasive BC, node positive or negative, and having undergone prior adjuvant or neo-adjuvant chemotherapy.  In the 3 arm study patients were given trastuzumab courses of 1 year, 2 years, or untreated.  At the first planned interim analysis, trastuzumab treatment for one year was compared with observation alone.  A significant difference in disease-free survival was seen with 220 DFS events out of 1693 in the observation arm versus 127 DFS events out of 1694 in the 1 year trastuzumab arm.  1 year adjuvant trastuzumab is currently the standard of care."	"Piccart-Gebhart et al., 2005, N. Engl. J. Med."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	"Capecitabine,Lapatinib"	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"This Phase III trial took patients with locally advanced or metastatic HER2 (ERBB2) positive breast cancer that had progressed on prior trastuzumab treatment.  Patients were given capecitabine (n=161) or lapatinib plus capecitabine (n=163). The primary endpoint of the study was time to progression. Median time to progression was 4.4 months in the capecitabine group and 8.4 months in capecitabine plus lapatinib group (hazard ratio was 0.49 ; 95% confidence interval, 0.34 to 0.71; P<0.001).  The results indicated that lapatinib may be useful in addressing the problem of trastuzumab progression in HER2 breast cancer."	"Geyer et al., 2006, N. Engl. J. Med."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	"Capecitabine,Trastuzumab"	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"In this Phase III trial, trastuzumab-based treatment was assessed in women with locally advanced or metastatic HER2 positive breast cancer who had progressed on trastuzumab.  Patients had 12 weeks or greater previous trastuzumab treatment with time since end of last cycle less than 6 weeks.  Primary endpoint was time to progression.  78 patients were assigned to each group, with median time to progression of 5.6 months in capecitabine group and 8.2 months in trastuzumab plus capecitabine group.  The results are in contrast to the principle of change of treatment on disease progression, and authors suggest that chemotherapy-sensitizing mechanisms of trastuzumab remain intact in HER2 breast cancer cells with trastuzumab progression."	"von Minckwitz et al., 2009, J. Clin. Oncol."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"The Phase III trial, TH3RESA (NCT01419197), was performed in patients with advanced HER2 breast cancer that was heavily pretreated.  Patients were required to have prior exposure to trastuzumab and lapatinib as well as a taxane.  This patient population has not seen many studies, responds poorly to late-line treatment with trastuzumab, and in this study was treated with trastuzumab emtansine (T-DM1, n=404) vs. physician's choice (usually trastuzumab plus chemotherapy, n=198).  Results showed progression free survival was 6.2 months in T-DM1 treatment vs. 3.3 months under physician's choice, along with lower incidence of grade 3 or worse events with T-DM1.  The authors conclude that their findings in this heavily pretreated population, along with findings in the EMILIA trial, indicate promise for antibody-drug conjugates.  The NCI-MATCH trial with further study T-DM1 in the context of HER2 amplification."	"Krop et al., 2014, Lancet Oncol."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"The EMILIA study (NCT00829166) was a Phase II trial to assess the efficacy of trastuzumab emtansine (T-DM1, n=495) in comparison to lapatinib plus capecitabine (n=496), in treatment of advanced HER2 positive breast cancer.  Patients were required to have progressed on or after treatments involving trastuzumab and a taxane, and no prior exposure to lapatinib or T-DM1.   Primary endpoints included independently assessed progression free survival (PFS) and safety. PFS was 9.6 months in T-DM1 group vs. 6.4 months in lapatinib plus capecitabine.  Rates of adverse events of grade 3 or higher were greater with lapatinib plus capecitabine.  These results, together with other trials such as TH3RESA indicate promise for T-DM1 therapy in HER2 amplification, and this will be further studied in an arm of the NCI-MATCH trial."	"Verma et al., 2012, N. Engl. J. Med."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	Pictilisib	Predictive	Supports	D	Sensitivity/Response	chr17	39700080	39728662			"The HER2/Neu mammary tumor mouse model MMTV-NeuT was employed to demonstrate dependence of HER2 tumor formation on PIK3 p110alpha isoform. MMTV-NeuT mice were crossed with floxed p110alpha mice. Diassacociated tumors cells from these mice were treated with Cre adenovirus to delete p110alpha, or GFP adenovirus, and cells were transplanted into athymic mice. GFP treated cells formed new tumors, while p110alpha deletion blocked tumor formation indicating tumor dependence on PI3KA. Next, MMTV-NeuT tumors were dissociated and treated with pan-PI3K inhibitor GDC-0941. Reduced lipid kinase activity and reduced phospho-Akt levels were seen in these cells. Administration of 125 mg/kg GDC-0941 to athymic mice with transplantation of tumor cells caused marked reduction of tumor cell volume in comparison to control treatment."	"Utermark et al., 2012, Genes Dev."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	A66	Predictive	Supports	D	Sensitivity/Response	chr17	39700080	39728662			"Pharmacologic (A66; p110alpha specific inhibitor) or genetic (cre-mediated knockout) ablation of the p110alpha PI3K isoform reduced tumor growth and tumor formation, respectively, in athymic mice transplanted with cells transduced by MMTV-NeuT (mammary specific overexpression of HER2 that effectively induces tumors). A66 treatment of cells from MMTV-NeuT mouse tumors resulted in decreased lipid kinase activity and phospho Akt levels."	"Utermark et al., 2012, Genes Dev."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	Tgx 221	Predictive	Does Not Support	D	Sensitivity/Response	chr17	39700080	39728662			"Treatment of cells obtained from MMTV-NeuT mouse mammary tumors with the p110beta selective inhibitor TGX-221 showed significant but minimal reductions in lipid kinase activity and negligible reductions in phospho Akt levels. In simmilar cells subjected to p110alpha isoform knockout, TGX-221 treatment fully blocked Akt activation, indicating that TGX-221 was fully inhibiting the p110beta isoform. Athymic mice recieved MMTV-NeuT tumor cell transplants and were treated with TGX-221, which resulted in significant but minimal reduction in tumor growth compared to controls."	"Utermark et al., 2012, Genes Dev."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Lung Adenocarcinoma	"Erlotinib,Gefitinib"	Predictive	Supports	C	Resistance	chr17	39700080	39728662			"155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib). 2 of 24 patients tested were found to have HER2 amplification (but no baseline samples available for analysis). One patient of which had a metastasis sample which was reported to have only HER2 amplification whereas another autopsy specimen from the same patient was HER2 negative but EGFR T790M positive."	"Yu et al., 2013, Clin. Cancer Res."	N/A	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"In a randomized phase II study, first line treatment of HER2-positive metastatic breast cancer with trastuzumab emtansine (T-DM1) resulted in improved progression free survival and fewer serious adverse effects when compared to treatment with combination trastuzumab plus docetaxel (HT) (median follow up 14 months, median PFS with T-DM1 14.2 vs 9.2 with HT)."	"Hurvitz et al., 2013, J. Clin. Oncol."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	"Trastuzumab,Docetaxel,Pertuzumab"	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"In a randomized phase 3 trial, HER2 positive metastatic breast cancer patients given first-line treatment of pertuzumab plus trastuzumb plus docetaxel experienced improved progression free survival (18.5 vs 12.4 months,  P<0.001) and increased objective response rate (80.2% vs 69.3%, P=0.001) than the control group given placebo plus trastuzumab plus docetaxel."	"Baselga et al., 2012, N. Engl. J. Med."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	"Trastuzumab,Lapatinib"	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"In a randomized open label phase 3 study (NCT00553358), women with HER2 positive primary breast cancer treated with lapatinib plus trasuzumab had higher rates of pathological complete responses than seen in control groups receiving either IV trastuzumab or oral lapatinib alone (combination treatment pCR rate of 51% vs 29.5% and 24.7% for trastuzumab and lapatinib alone, respectively)."	"Baselga et al., 2012, Lancet"	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	"Pilaralisib,Trastuzumab"	Predictive	Supports	D	Sensitivity/Response	chr17	39700080	39728662			"In 5 trastuzumab resistant HER2 overexpressing breast cancer cell lines, combination of the pan-PI3K inhibitor XL147 (pilaralisib) and trastuzumab treatment induced cell death to similar or greater levels than XL147 alone. In three trastuzumab resistant cell lines tested, colony formation in matrigel was markedly inhibited by combination treatment. Apoptotic markers were apparent with combination treatment. In athymic mice, trastuzumab resistant cell line HR6 was used in tumor xenografts and tumors were allowed to form. Mice subsequently treated with trastuzumab or XL147 showed continued tumor growth without marked difference from control, while combination treatment essentially halted tumor growth rate."	"Chakrabarty et al., 2013, Cancer Res."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Gastric Adenocarcinoma	Trastuzumab	Predictive	Supports	A	Sensitivity/Response	chr17	39700080	39728662			"ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive (overexpression or amplification) advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and platinum-based combinations had been common practice.  Patients were given a chemotherapy regime containing capecitabine, flourouracil and cisplatin with (n=298) or without (n=296) trastuzumab, and had not been previously treated for metastatic cancer.  Study endpoint was overall survival, which was significantly different in the two populations (13.8 months with chemotherapy + trastuzumab and 11.1 months for chemotherapy alone).  The authors conclude that trastuzumab should be a standard option for HER2 positive advanced gastric cancer."	"Bang et al., 2010, Lancet"	N/A	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	"Palbociclib,Trastuzumab"	Predictive	Supports	D	Sensitivity/Response	chr17	39700080	39728662			"In a panel of 47 breast cancer cell lines, HER2 overexpressing cells were among those more sensitive to CDK4/6 inhibitor Palbociclib (PD0332991). In the trastuzumab sensitive cell line Bt474, palbociclib synergized with trastuzumab in growth inhibition, while in 2 trastuzumab resistant cell lines, addition of trastuzumab to palbociclib treatment resulted in increased growth inhibition over palbociclib alone."	"Finn et al., 2009, Breast Cancer Res."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Breast Cancer	MTOR Kinase Inhibitor PP242	Predictive	Supports	D	Sensitivity/Response	chr17	39700080	39728662			"In a panel of 31 breast cancer cell lines with varied mutation backgrounds, 10 cell lines harbored HER2 (ERBB2) amplification. Sensitivity to the mTORC1/2 inhibitor PP242 was assessed, and 8/10 HER2 positive cell lines were reported to be sensitive (IC50 < 1 micro molar PP242).  8/21 without HER2 amplification were reported as resistant (IC50 > 1 micro molar PP242). This pattern of HER2 positive cell sensitivity was not reported with the rapamycin analog  mTORC1 inhibitor everolimus."	"Weigelt et al., 2011, Oncogene"	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Resistance	chr17	39700080	39728662			"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab. Among 11 quadruple-negative samples with resistance to cetuximab, HER2 overexpression and amplification (N=3) and amplification (N=1) were identified. In an independent second retrospective patient cohort, 3 out of 17 patients with KRAS wt, cetuximab resitant CRC were found to harbor HER2 overexpression and amplification. In this cohort no HER2 overexpression or amplification was identified in 14 KRAS wt patients with response to cetuximab."	"Bertotti et al., 2011, Cancer Discov"	N/A	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Resistance	chr17	39700080	39728662			"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed resistance whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab. Among 11 quadruple-negative samples with resistance to cetuximab, HER2 overexpression and amplification (N=3) and amplification (N=1) were identified. In an independent second retrospective cohort, 3 out of 17 patients with KRAS wt, cetuximab resitant CRC were found to harbor HER2 overexpression and amplification. In this cohort no HER2 overexpression or amplification was identified in 14 KRAS wt patients with response to cetuximab."	"Bertotti et al., 2011, Cancer Discov"	N/A	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Colorectal Cancer	"Cetuximab,Panitumumab"	Predictive	Supports	B	Resistance	chr17	39700080	39728662			"HER2 amplification (FISH) was assessed in 170 KRAS wt mCRC patients treated with cetuximab or panitumumab. HER2 copy number status was significantly correlated with response rate, PFS and OS. Patients with amplification in all neoplastic cells (4%) had worse outcome compared to patients without amplification (35%, intermediate outcome) or amplification in minor clones (61%, highest survival probability)."	"Martin et al., 2013, Br. J. Cancer"	N/A	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Colorectal Cancer	"Lapatinib,Trastuzumab"	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"Phase 2 study in 27 patients with HER2 positive (IHC, FISH), KRAS wt metastatic colorectal cancer refractory to standard of care received trastuzumab and lapatinib. After a median follow-up of 94 weeks, eight (30%, 95% CI 14-50) of 27 patients had achieved an objective response, with one patient (4%, 95% CI -3 to 11) achieving a complete response, and seven (26%, 95% CI 9-43) achieving partial responses; 12 (44%, 95% CI 25-63) patients had stable disease. A total of 914 patients with KRAS wt were screened for this study, 48 patients (5%) were identified to have HER2-positive tumors."	"Sartore-Bianchi et al., 2016, Lancet Oncol."	N/A	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Scrotum Paget's Disease	Trastuzumab	Predictive	Supports	C	Sensitivity/Response	chr17	39700080	39728662			"A 71-year old male with metastatic extramammary Pagets disease of the scrotum overexpressing Her2/neu was treated with trastuzumab, achieving a complete response. At 12 months, he maintains stable disease."	"Barth et al., 2015, Case Rep Oncol Med"	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"In the single arm Phase II study (TDM4258g) breast cancer patients who had progressed on previous anti-HER2 therapy were given transtuzumab emtansine (T-DM1), a HER2 monoclonal antibody and antimicrotubule drug conjugate. 95 trial participants with archival primary tumor were reassessed for HER2 status (positivity defined by FISH or IHC 3+), and 74 patients were confirmed for HER2 positivity and 21 were normal. Overall response rate was 33.8% (95% CI, 23.2% to 44.9%) in patients with confirmed HER2-positive tumors and 4.8% (95% CI, 1.0% to 21.8%) in HER2 normal patients. Median PFS was 8.2 months (95% CI, 4.4 months to not estimable) in patients with confirmed HER2-positive tumors and 2.6 months (95% CI, 1.4 to 3.9 months) in HER2 normal patients."	"Burris et al., 2011, J. Clin. Oncol."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Lung Non-small Cell Carcinoma	Dacomitinib	Predictive	Does Not Support	B	Sensitivity/Response	chr17	39700080	39728662			"Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification. 4 patients with HER2 amplified NSCLC were enrolled in the trial, no one among them had a response."	"Kris et al., 2015, Ann. Oncol."	N/A	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Resistance	chr17	39700080	39728662			"We identified 142 patients with metastatic colorectal cancer whose tumors harbored both wild-type exons 2, 3, and 4 in KRAS and NRAS, and wild-type exon 15 in BRAF. All patients received cetuximab after oxaliplatin, irinotecan, and fluoropyrimidine failure. HER2 status was determined using immunohistochemistry and silver in situ hybridization and correlated with cetuximab efficacy. Of 142 RAS and BRAF wild-type tumors, we observed 7 cases (4.9%) of HER2 amplification by SISH. After a median follow-up of 13.2 months (range, 1.4-78.1 months), median progression-free survival (PFS) was significantly different according to HER2 status: 3.1 months in patients with HER2 amplification compared with 5.6 months in those with non-amplified HER2 (HR = 2.73; 95% CI = 1.18-6.31; P = 0.019). Overall survival (OS) was not significantly different between groups, although there was a tendency towards shorter OS in patients with HER2-amplified tumors (HR = 0.31; 95% CI = 0.61-2.82; 10.1 vs. 13.5 months; P = 0.488)."	"Jeong et al., 2017, Clin Colorectal Cancer"	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Breast Cancer	Pictilisib	Predictive	Supports	D	Sensitivity/Response	chr17	39700080	39728662			"This preclinical study tested the efficacy of GDC-0941, a selective inhibitor of class I PI3K, on several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. Authors tested six HER2 amplified breast cancer cell lines for sensitivity to GDC-0941. Their IC50s ranged from 0.19uM to 1.29uM (5/6 cell lines had IC50s below 1umol/L). Authors further note that HER2 amplified breast cancer cell lines are generally more sensitive to GDC-0941 than basal-type cell lines (p = 0.002)."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Colorectal Cancer	"Trastuzumab,Pertuzumab"	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively.  Thirty of 114 patients (26%; 95% CI, 19% to 35%) with HER2 amplification/overexpression had objective responses to treatment with trastuzumab plus pertuzumab (two CR, 28 PR).  Patients with HER2-amplified/overexpressing metastatic colorectal cancer composed the largest tumor-pathway cohort. In this group of 37 patients with refractory disease (median, four previous lines of therapy), treatment with trastuzumab plus pertuzumab produced PRs in 14 patients (38%; 95% CI, 23% to 55%; Fig 2A). An additional four patients had SD > 120 days. The median DOR was 11 months (range, < 1 to 16+ months; 95% CI, 2.8 months to not estimable)."	"Hainsworth et al., 2018, J. Clin. Oncol."	N/A	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Bladder Carcinoma	"Trastuzumab,Pertuzumab"	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Three of nine patients (33%; 95% CI, 8% to 70%) with advanced bladder cancer and HER2 amplification/overexpression had responses (one CR ongoing at 15 months; two PR lasting 1 and 6 months), and two patients had SD > 120 days."	"Hainsworth et al., 2018, J. Clin. Oncol."	N/A	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Biliary Tract Cancer	"Pertuzumab,Trastuzumab"	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Two of seven patients (29%; 95% CI, 4% to 71%) with biliary cancer and HER2 amplification/overexpression had PR, and three had SD > 120 days"	"Hainsworth et al., 2018, J. Clin. Oncol."	N/A	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Salivary Gland Carcinoma	"Pertuzumab,Trastuzumab"	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Four of five patients with HER2 amplified/overexpressing salivary gland carcinoma (80%; 95% CI, 28% to > 99%) had responses (all PR)."	"Hainsworth et al., 2018, J. Clin. Oncol."	N/A	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Pancreatic Cancer	"Trastuzumab,Pertuzumab"	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Two of nine patients (22%) with HER2 amplified/overexpressing pancreatic cancer had a PR with trastuzumab/pertuzumab combination. Another patient had SD > 120days."	"Hainsworth et al., 2018, J. Clin. Oncol."	N/A	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Uterine Cancer	"Trastuzumab,Pertuzumab"	Predictive	Does Not Support	B	Sensitivity/Response	chr17	39700080	39728662			"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. None of the 7 patients with HER2 amplified/overexpressing uterus cancer responded to pertuzumab/trastuzumab."	"Hainsworth et al., 2018, J. Clin. Oncol."	N/A	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Colorectal Cancer	"Pertuzumab,Trastuzumab"	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"In an updated report of a part of the phase 2a MyPathway trial, 57 patients with treatment-refractory, metastatic colorectal cancer with HER2 amplification received pertuzumab and trastuzumab. Objective response rate was 32% (n=18/57). One patient had a complete response, and 17 experienced a partial response. Patients were determined to have HER2 amplification by NGS and/or FISH/CISH. In addition, the authors note that 27/35 patients had HER2 overexpression as determined by IHC, 3 of 47 tested had HER2 mutations, 8 had PIK3CA mutations, and 13 had mutated KRAS. Exploratory analysis found that KRAS wild-type patients had better ORR as compared to KRAS mutated patients (40% vs 8%)."	"Meric-Bernstam et al., 2019, Lancet Oncol."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Cholangiocarcinoma	"Pertuzumab,Trastuzumab"	Predictive	Supports	C	Sensitivity/Response	chr17	39700080	39728662			A patient with cholangiocarcinoma harboring with ERBB2 amplification (3+) detected by circulating tumor DNA testing and confirmed by tissue-based testing was treated with trastuzumab and pertuzumab. This treatment showed a tumor response and continued over 12 months.	"Yarlagadda et al., 2019, NPJ Precis Oncol"	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Stomach Cancer	Trastuzumab Deruxtecan	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"In a phase 1 trial, 44 patients with HER2-positive gastric or gastroesophageal junction cancer previously treated with trastuzumab were treated with Trastuzumab Deruxtecan (DS-8201a). The response rate was 43.2% (19/44). All patients had at least one treatment-emergent adverse event (AE). A serious AE was recorded in 11 patients but without a drug-related death."	"Shitara et al., 2019, Lancet Oncol."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Colorectal Cancer	Afatinib	Predictive	Supports	D	Sensitivity/Response	chr17	39700080	39728662			Afatinib monotherapy was tested in patient-derived colorectal cancer (M051) mouse xenografts and gastric cancer cell-line (NCI-N87) mouse xenografts.  Tumor shrinkage was observed and tumor volume was significantly decreased compared to treatment with vehicle or lapatinib monotherapy (p<0.0001 (M051 Afatinib vs. Lapatinib) and p=0.0003 (NCI-N87 Afatinib vs. Lapatinib).	"Leto et al., 2015, Clin. Cancer Res."	Somatic	ENST00000269571.5	transcript_amplification
ERBB2 Amplification	ERBB2	Amplification	Childhood Ependymoma	Lapatinib	Predictive	Supports	B	Sensitivity/Response	chr17	39700080	39728662			"From a phase one clinical trial, pediatric patients with refractory CNS malignancies were administered 300-1150 mg/m2 twice daily of ERBB2 and EGFR inhibitor lapatinib. The maximum-tolerated dose was established at 900 mg/m2 twice daily, regardless of steroid use. From the 59 patients, 12 patients, including 5 diagnosed with ependymoma, demonstrated a prolonged stable disease in response to lapatinib. In comparison to other CNS tumors, pretrial samples from patients with ependymoma tumors displayed high expression of ERBB2 and activation of ERBB2 signaling. Due to the high expression of ERBB2 receptors, targeting ERBB2 may be a viable treatment for patients with ependymoma tumors and other high expressing ERBB2 brain tumors."	"Fouladi et al., 2010, J Clin Oncol"	N/A	ENST00000269571.5	transcript_amplification
ERBB2 Mutation	ERBB2	Mutation	Bladder Carcinoma	Platinum Compound	Predictive	Supports	C	Sensitivity/Response	chr17	39711943	39725079			"In patients with muscle-invasive bladder chancer, a cohort of complete responders to platinum chemotherapy (n=38) and non-responders to platinum chemotherapy (n=33) were evaluated for 178 cancer-associated genes. Of the complete responders, 24% had an ERBB2 missense mutations and no non-responders had ERBB2 mutations (p=0.003)."	"Groenendijk et al., 2016, Eur. Urol."	Somatic	ENST00000269571.5	missense_variant
ERBB2 Mutation	ERBB2	Mutation	Breast Cancer	Neratinib	Predictive	Supports	B	Sensitivity/Response	chr17	39711943	39725079			"16 patients with HER2-mutated metastatic breast cancer were treated with neratinib monotherapy. Of these 16 patients, 14 had known-activating mutations and 2 had mutations of unknown significance. Five of the 16 patients achieved clinical benefit including 1 complete response (6%), 1 partial response (6%) and 3 with stable disease >24 weeks (19%). Clinical benefit was observed across different HER2 mutations including L755S, V777_G778 insGSP, P780_Y781 insGSP, V842I, S310F, and L869R."	"Ma et al., 2017, Clin. Cancer Res."	Somatic	ENST00000269571.5	missense_variant
ERBB2 Mutation	ERBB2	Mutation	Lung Non-small Cell Carcinoma	"Trastuzumab,Pertuzumab"	Predictive	Supports	B	Sensitivity/Response	chr17	39711943	39725079			"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among thirty-six patients that received treatment with trastuzumab plus pertuzumab because of a HER2 mutation (without amplification/overexpression) four patients (11%; 95% CI, 3% to 26%) had objective responses.  Fourteen of the 36 patients with HER2-mutated tumors had NSCLC (adenocarcinoma, n = 13; adenosquamous, n = 1); in this group, three patients (21%; 95% CI, 5% to 51%) had PR and three had SD > 120 days. Only one of the other 22 patients with HER2-mutated tumors responded to treatment with pertuzumab plus trastuzumab (biliary cancer)."	"Hainsworth et al., 2018, J. Clin. Oncol."	Somatic	ENST00000269571.5	missense_variant
ERBB2 G309A	ERBB2	G309A	Breast Cancer	Neratinib	Predictive	Supports	D	Sensitivity/Response	chr17	39711952	39711952	G	C	"In MCF10A cell lines, the G309A mutation was shown to be sensitive to neratinib."	"Bose et al., 2013, Cancer Discov"	Somatic	ENST00000269571.5	missense_variant
ERBB2 S310F/Y	ERBB2	S310F/Y	Colon Cancer	"Lapatinib,Trastuzumab,Neratinib"	Predictive	Supports	D	Sensitivity/Response	chr17	39711955	39711955			Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.	"Kavuri et al., 2015, Cancer Discov"	Somatic	ENST00000269571.5	missense_variant
ERBB2 R678Q	ERBB2	R678Q	Breast Cancer	"Lapatinib,Neratinib"	Predictive	Supports	D	Sensitivity/Response	chr17	39723405	39723405	G	A	MCF10A cells transduced with ERBB2 harboring an R678Q mutation were sensitive to lapatinib and the irreversible kinase inhibitor neratinib in an matrigel colony forming assay.	"Bose et al., 2013, Cancer Discov"	Somatic	ENST00000269571.5	missense_variant
ERBB2 Kinase Domain Mutation	ERBB2	Kinase Domain Mutation	Lung Adenocarcinoma	Afatinib	Predictive	Supports	C	Sensitivity/Response	chr17	39723610	39726617			"A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup). Objective response was observed in all three of these patients."	"De Grve et al., 2012, Lung Cancer"	Somatic	ENST00000269571.5	protein_altering_variant
ERBB2 Kinase Domain Mutation	ERBB2	Kinase Domain Mutation	Lung Adenocarcinoma	Trastuzumab	Predictive	Supports	C	Sensitivity/Response	chr17	39723610	39726617			"This was a retrospective study of patients with advanced HER2-mutant NSCLC who had undergone varied courses of treatment.  All tumors were adenocarcinoma with in-frame HER2 exon 20 insertions.  In patients (n=57) that had been treated with trastuzumab plus chemotherapy, an overall response rate of 75% and progression free survival of 5.1 months were observed.  No standard of care currently exists for HER2-mutant NSCLC.  While trastuzumab has not shown clear benefit yet in wild-type HER2 overexpressed NSCLC, the authors conclude that further prospective studies should be done with trastuzumab plus chemotherapy in advanced HER2 mutant NSCLC, and that trastuzumab plus chemotherapy should be considered in current treatment courses of this cancer type."	"Mazires et al., 2016, Ann. Oncol."	Somatic	ENST00000269571.5	protein_altering_variant
ERBB2 L755_T759del	ERBB2	L755_T759del	Breast Cancer	Neratinib	Predictive	Supports	D	Sensitivity/Response	chr17	39723966	39723980	TTGAGGGAAAACACA		"In MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2, cells expressing the in-frame deletion of amino acids 755-759 were shown to be sensitive to neratinib."	"Bose et al., 2013, Cancer Discov"	Somatic	ENST00000269571.5	inframe_deletion
ERBB2 L755S	ERBB2	L755S	Breast Cancer	Lapatinib	Predictive	Supports	D	Resistance	chr17	39723967	39723967	T	C	The L755S mutation was shown to confer resistance to lapatinib in MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2.	"Bose et al., 2013, Cancer Discov"	Somatic	ENST00000269571.5	missense_variant
ERBB2 L755S	ERBB2	L755S	Breast Cancer	Neratinib	Predictive	Supports	D	Sensitivity/Response	chr17	39723967	39723967	T	C	The L755S mutation showed mild response to neratinib in MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2.	"Bose et al., 2013, Cancer Discov"	Somatic	ENST00000269571.5	missense_variant
ERBB2 L755W	ERBB2	L755W	Breast Cancer	Neratinib	Predictive	Supports	D	Sensitivity/Response	chr17	39723967	39723967	T	G	MCF10A cells transduced with ERBB2 harboring an L755W mutation were sensitive to the irreversible kinase inhibitor neratinib in an matrigel colony forming assay.	"Bose et al., 2013, Cancer Discov"	Somatic	ENST00000269571.5	missense_variant
ERBB2 L755S	ERBB2	L755S	Colon Cancer	"Lapatinib,Trastuzumab,Neratinib"	Predictive	Supports	D	Sensitivity/Response	chr17	39723967	39723967	T	C	Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.	"Kavuri et al., 2015, Cancer Discov"	Somatic	ENST00000269571.5	missense_variant
ERBB2 L755S	ERBB2	L755S	Colorectal Adenocarcinoma	"Leucovorin,Fluorouracil,Trastuzumab"	Predictive	Does Not Support	C	Sensitivity/Response	chr17	39723967	39723967	T	C	Patient was a 35 year old male who was treated with pseudoadjuvant FOLFOX chemotherapy. Patient relapsed and was found to have an ERBB2 L755S kinase domain mutation along with mutations in APC and BRAF. He was then treated with trastuzumab combined with infusional 5-Fu and leucovorin but exhibited no response.	"Aung et al., 2016, Cold Spring Harb Mol Case Stud"	Somatic	ENST00000269571.5	missense_variant
ERBB2 D769H	ERBB2	D769H	Breast Cancer	"Neratinib,Lapatinib"	Predictive	Supports	D	Sensitivity/Response	chr17	39724008	39724008	G	C	"In MCF10A cell lines, the D769H mutation was shown to be sensitive to neratinib."	"Bose et al., 2013, Cancer Discov"	Somatic	ENST00000269571.5	missense_variant
ERBB2 D769Y	ERBB2	D769Y	Breast Cancer	Neratinib	Predictive	Supports	D	Sensitivity/Response	chr17	39724008	39724008	G	T	"In MCF10A cell lines, the D769Y mutation was shown to be sensitive to neratinib."	"Bose et al., 2013, Cancer Discov"	Somatic	ENST00000269571.5	missense_variant
ERBB2 V773A	ERBB2	V773A	Breast Cancer	Lapatinib	Predictive	Supports	D	Sensitivity/Response	chr17	39724736	39724736	T	C	"The IC90 of ERBB2-V773A cell lines was approximately 0.5 M and was considered as lapatinib-sensitive. Since levels of up to 1 M of lapatinib may be achieved in patients, ERBB2-T773A might respond to higher doses of lapatinib."	"Kancha et al., 2011, PLoS ONE"	Somatic	ENST00000269571.5	missense_variant
ERBB2 M774DELINSWLV	ERBB2	M774DELINSWLV	Lung Non-small Cell Carcinoma	Dacomitinib	Predictive	Supports	C	Sensitivity/Response	chr17	39724738	39724738	A	TGGCTGG	"Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification (N=30). One patient was found to harbor a unique Exon 20 indel (p. M774delinsWLV, c.2320A>TGGCT GG; p. M774delinsWLV, c.2320delins TGGCTGG) and was among the three patients that had a partial response."	"Kris et al., 2015, Ann. Oncol."	Somatic	ENST00000269571.5	inframe_indel
ERBB2 Y772_A775DUP	ERBB2	Y772_A775DUP	Lung Non-small Cell Carcinoma	"Sirolimus,Afatinib"	Predictive	Supports	D	Sensitivity/Response	chr17	39724743	39724744		TACGTGATGGCT	"In preclinical studies of transgenic mice and xenografts, continuous expression of mutant ERBB2 (M774insAYVM or the equivalent A775insYVMA) was found to be essential for tumor maintenance. Furthermore, preclinical in vivo studies assessing erlotinib, trastuzumab, afatinib (aka BIBW2992), and/or sirolimus (aka rapamycin) revealed that the combination of afatinib and sirolimus was most effective in shrinking tumors harboring this insertion."	"Perera et al., 2009, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000269571.5	inframe_insertion
ERBB2 Y772_A775DUP	ERBB2	Y772_A775DUP	Lung Adenocarcinoma	Afatinib	Predictive	Supports	C	Sensitivity/Response	chr17	39724743	39724744		TACGTGATGGCT	"A 55 year old heavily pretreated patient with equivocal HER2 overexpression (IHC2+ and no amplification in FISH) was found to have the HER2 YMVA kinase domain insertion.  Afatinib monotherapy resulted in resolution of symptoms and 10 months before progressive disease.  The patient was subsequently given trastuzumab with no response.  The observed efficacy of afatinib against M774insAYVM, and studies reporting afatinib activity against other variants in the HER2 kinase domain, are cited by the authors as motivation for the arm of NCI-MATCH focusing on afatinib and activating HER2 mutations."	"Li et al., 2015, Lung Cancer"	Somatic	ENST00000269571.5	inframe_insertion
ERBB2 Y772_A775DUP	ERBB2	Y772_A775DUP	Lung Carcinoma	Afatinib	Predictive	Supports	D	Sensitivity/Response	chr17	39724743	39724744		TACGTGATGGCT	"Human HER2 with YVMA insertion was put under a clara cell specific, rtTA promoter system inducible via doxycycline.  Induction of mutant HER2 in these mice drove rapid development of adenosquamous lung tumors, where tumor maintenance was dependent on continued YMVA HER2 induction by doxycycline.  Administration of afatinib had a stronger effect than erlotinib or trastuzumab, as measured by histology and tumor volume regression.  Authors state that in the case of afatinib vs. trastuzumab, intracellular HER2 signaling may be blocked by afatanib but remain unaltered by trastuzumab."	"Perera et al., 2009, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000269571.5	inframe_insertion
ERBB2 Y772_A775DUP	ERBB2	Y772_A775DUP	Lung Adenocarcinoma	Trastuzumab Emtansine	Predictive	Supports	C	Sensitivity/Response	chr17	39724743	39724744		TACGTGATGGCT	"A 51-year old female never smoker with stage IV lung adenocarcinoma carrying a HER2 insertion in exon 20 (p.A775_G776insYVMA) by sequencing archived material, HER2 overexpression by IHC (2+) and HER2 amplification by in situ hybridization was treated with T-DM1 (trastuzumab emtansine). Patient received two cycles off-label at 3.6mg/kg and was found to have morphologic response of lung and bone lesions by PET and CT. TDM-1 therapy was ongoing as of publication April 2015."	"Weiler et al., 2015, J Thorac Oncol"	Somatic	ENST00000269571.5	inframe_insertion
ERBB2 Y772_A775DUP	ERBB2	Y772_A775DUP	Lung Adenocarcinoma	Afatinib	Predictive	Supports	C	Sensitivity/Response	chr17	39724743	39724744		TACGTGATGGCT	"A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup). Objective response was observed in all three of these patients. The patient with Y772_A775dup (Case 1 in the paper), maintained a metabolic complete response for 3 months, ultimately received a total of 9 months of Afatinib, and survived one year from study entry."	"De Grve et al., 2012, Lung Cancer"	Somatic	ENST00000269571.5	inframe_insertion
ERBB2 Y772_A775DUP	ERBB2	Y772_A775DUP	Lung Non-small Cell Carcinoma	Dacomitinib	Predictive	Does Not Support	B	Sensitivity/Response	chr17	39724743	39724744		TACGTGATGGCT	"Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification (N=30). Thirteen tumors harbored identical 12 base pair exon 20 insertions [A775_G776insYVMA, alternative nomenclature p.Y772_A775dup(c.2313_2324dup)]. No partial responses were found in this subgroup even though some were on study treatment for >2 years and 3 patients with other HER2 mutations achieved PRs."	"Kris et al., 2015, Ann. Oncol."	Somatic	ENST00000269571.5	inframe_insertion
ERBB2 G776L	ERBB2	G776L	Lung Adenocarcinoma	Afatinib	Predictive	Supports	C	Sensitivity/Response	chr17	39724744	39724745	GG	CT	"A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup). Objective response was observed in all three of these patients. The patient with G776L (Case 2 in the paper) achieved a partial response after two months of afatinib (50 mg/day). The time to progression of this single agent was four months. The patient was also noted to have a EGFR kinase domain (exon 21: p.Ala859Thr) mutation."	"De Grve et al., 2012, Lung Cancer"	Somatic	ENST00000269571.5	missense_variant
ERBB2 V777L	ERBB2	V777L	Breast Cancer	Neratinib	Predictive	Supports	D	Sensitivity/Response	chr17	39724747	39724747	G	T	"In MCF10A cell lines, the V777L mutation was shown to be sensitive to neratinib."	"Bose et al., 2013, Cancer Discov"	Somatic	ENST00000269571.5	missense_variant
ERBB2 V777L	ERBB2	V777L	Colon Cancer	"Neratinib,Lapatinib,Trastuzumab"	Predictive	Supports	D	Sensitivity/Response	chr17	39724747	39724747	G	T	Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.	"Kavuri et al., 2015, Cancer Discov"	Somatic	ENST00000269571.5	missense_variant
ERBB2 P780INS	ERBB2	P780INS	Breast Cancer	Neratinib	Predictive	Supports	D	Sensitivity/Response	chr17	39724758	39724759		GGCTCCCCA	"In MCF10A cell lines, the in-frame insertion of a single amino acid at position 780 was shown to be sensitive to neratinib."	"Bose et al., 2013, Cancer Discov"	Somatic	ENST00000269571.5	inframe_insertion
ERBB2 P780INS	ERBB2	P780INS	Lung Adenocarcinoma	Dacomitinib	Predictive	Supports	C	Sensitivity/Response	chr17	39724758	39724759		GGCTCCCCA	"In this phase II study (NCT00818441) of dacomitinib in HER2 amplified or mutant NSCLC tumors, three of 26 patients with HER2 p.P780_Y781insGSP or p.M774delinsWLV showed partial responses of duration between 3 and 14 months, while 13 patients with the more common HER2 p. A775_G776insYVMA showed no partial responses.  The authors conclude that in the set of activating HER2 mutations, benefits of an individual agent may be specific to certain mutations, and that ""HER2-positive lung cancers"" is not an adequate term to describe this group of distinguishable illnesses."	"Kris et al., 2015, Ann. Oncol."	Somatic	ENST00000269571.5	inframe_insertion
ERBB2 G778_P780DUP	ERBB2	G778_P780DUP	Lung Adenocarcinoma	Afatinib	Predictive	Supports	C	Sensitivity/Response	chr17	39724758	39724759		GGCTCCCCA	"A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were identified (Y772_A775dup, G776L, and G778_P780dup). Objective response was observed in all three of these patients. The patient with G778_P780dup (Case 3 in the paper), had a rapid clinical and symptomatic response to Afatinib and stable disease which lasted for 3 months. Progressive disease at 4 months led to the addition of paclitaxel, resulting in partial response. Total Afatinib treatment was 15 months (11 in combination) at which time the patient developed a brain metastasis but no other progressive disease."	"De Grve et al., 2012, Lung Cancer"	Somatic	ENST00000269571.5	inframe_insertion
ERBB2 G778_P780DUP	ERBB2	G778_P780DUP	Lung Non-small Cell Carcinoma	Dacomitinib	Predictive	Supports	C	Sensitivity/Response	chr17	39724758	39724759		GGCTCCCCA	"Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification. Two patients were identified with identical HER2 p.G778_P780dup mutations (p. P780_Y781insGSP, c. 2339_2340ins GGCTCCCCA) and no amplification. Both had a confirmed partial response lasting 11 and 14 months. Only 3/30 patients on this trial had a partial response (no complete responses)."	"Kris et al., 2015, Ann. Oncol."	Somatic	ENST00000269571.5	inframe_insertion
ERBB2 T798I	ERBB2	T798I	Breast Cancer	Osimertinib	Predictive	Does Not Support	D	Sensitivity/Response	chr17	39724811	39724811	C	T	"Efficacy of osimertinib and its metabolite, AZ5104, at reducing phosphorylation of key proteins was evaluated by western blot. Osimertinib failed to induce substantial reductions in phosphorylated ERBB2 in NR6 mouse fibroblast cells transduced to co-express ERBB2 L869R and T798I or ERBB2 wt. AZ5104 blocked phosphorylation to a greater extent in the mutant and wildtype cells. MCF10A cells transduced with ERBB2 wt, ERBB2 T798I alone or ERBB2 L869R and T798I co-expressed did not show substantial reductions in phosphorylated ERBB2, AKT, ERK or S6. AZ5104 induced greater reductions. Authors note that AZ5104 is not being developed independently of osimertinib and only 10% of osimertinib is metabolized into AZ5104 in humans. Authors concluded that ERBB2 T798I is not sensitive to osimertinib."	"Hanker et al., 2017, Cancer Discov"	Somatic	ENST00000269571.5	missense_variant
ERBB2 V842I	ERBB2	V842I	Breast Cancer	Neratinib	Predictive	Supports	D	Sensitivity/Response	chr17	39725079	39725079	G	A	"In MCF10A cell lines, the V842I mutation was shown to be sensitive to neratinib."	"Bose et al., 2013, Cancer Discov"	Somatic	ENST00000269571.5	missense_variant
ERBB2 V842I	ERBB2	V842I	Colon Cancer	"Lapatinib,Neratinib,Trastuzumab"	Predictive	Supports	D	Sensitivity/Response	chr17	39725079	39725079	G	A	Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.	"Kavuri et al., 2015, Cancer Discov"	Somatic	ENST00000269571.5	missense_variant
ERBB2 N857S	ERBB2	N857S	Breast Cancer	Lapatinib	Predictive	Supports	D	Sensitivity/Response	chr17	39725125	39725125	A	G	"The IC90 of ERBB2-N857S cell lines was approximately 0.5 M and was considered as lapatinib-sensitive. Since levels of up to 1 M of lapatinib may be achieved in patients, ERBB2-N857S might respond to higher doses of lapatinib."	"Kancha et al., 2011, PLoS ONE"	Somatic	ENST00000269571.5	missense_variant
ERBB2 T862A	ERBB2	T862A	Stomach Carcinoma	Lapatinib	Predictive	Supports	D	Sensitivity/Response	chr17	39725139	39725139	A	G	"Cell proliferation analysis showed that the ERBB2-H878Y mutant had the highest sensitivity against lapatinib among all mutations tested. Another mutation, ERBB2-V777L also remained sensitive to lapatinib with a cellular IC50 value similar to that of wild type ERBB2. Remaining mutations showed a shift towards significant higher cellular IC50 values compared to the wild type receptor. Since levels of up to 1 M of lapatinib may be achieved in patients, ERBB2-V773A, ERBB2-T862A and ERBB2-N857S mutations might respond to higher doses of lapatinib. In contrast, ERBB2-L755S, ERBB2-L755P and ERBB2-T798M caused strong lapatinib resistance."	"Kancha et al., 2011, PLoS ONE"	Somatic	ENST00000269571.5	missense_variant
ERBB2 L866M	ERBB2	L866M	Colon Cancer	"Lapatinib,Neratinib,Trastuzumab"	Predictive	Supports	D	Sensitivity/Response	chr17	39725151	39725151	C	A	Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.	"Kavuri et al., 2015, Cancer Discov"	Somatic	ENST00000269571.5	missense_variant
ERBB2 H878Y	ERBB2	H878Y	Hepatocellular Carcinoma	Lapatinib	Predictive	Supports	D	Sensitivity/Response	chr17	39725187	39725187	C	T	"Cell proliferation analysis of ERBB2 mutant expressing cell lines showed that the ERBB2-H878Y mutant, which is observed in 11% of hepatocellular carcinoma patients, had the highest sensitivity against lapatinib among all mutations tested (IC50<30nM)."	"Kancha et al., 2011, PLoS ONE"	Somatic	ENST00000269571.5	missense_variant
ERBB2 R896C	ERBB2	R896C	Breast Cancer	Neratinib	Predictive	Supports	D	Sensitivity/Response	chr17	39725363	39725363	C	T	"In MCF10A cell lines, the R896C mutation was shown to be sensitive to neratinib."	"Bose et al., 2013, Cancer Discov"	Somatic	ENST00000269571.5	missense_variant
PML PML::RARA	PML	PML::RARA	Acute Promyelocytic Leukemia	Tretinoin	Predictive	Supports	B	Sensitivity/Response	chr17	40348316	40356796			Fusion protein degradation is accelerated upon ATRA treatment of acute promyelocytic cells at pharmalogical concentrations.	"Yoshida et al., 1996, Cancer Res."	Somatic	ENST00000268058.3	transcript_fusion
PML PML::RARA	PML	PML::RARA	Acute Promyelocytic Leukemia		Diagnostic	Supports	A	Positive	chr17	40348316	40356796			"The presence of the PML-RARa fusion protein is a diagnostic marker of Acute Promyelocytic Leukemia, or M3 AML."	"Diverio et al., 1995, Haematologica"	Somatic	ENST00000268058.3	transcript_fusion
PML PML::RARA	PML	PML::RARA	Acute Promyelocytic Leukemia	"Tretinoin,Arsenic Trioxide"	Predictive	Supports	A	Sensitivity/Response	chr17	40348316	40356796			ATRA/Arsenic combined with standard chemotherapy has been shown to induce a complete remission rate of greater than 75% of patients with acute promyelocytic leukemia harboring the PML-RARa fusion.	"Degos et al., 2001, Oncogene"	Somatic	ENST00000268058.3	transcript_fusion
PML PML::RARA	PML	PML::RARA	Acute Promyelocytic Leukemia	Tretinoin	Predictive	Supports	C	Sensitivity/Response	chr17	40348316	40356796			"A 39-year old woman who presented with acute myeloid leukemia revealed a complicated genetic profile using conventional metaphase cytogenetics and FISH analysis.  Whole genome sequencing elucidated a PML-RARA fusion, which can be successfully treated with ATRA. Uncovering this mutation prevented an unnecessary allogeneic transplant and the patient remained in remission 15 months post-treatment (date of publication)."	"Welch et al., 2011, JAMA"	Somatic	ENST00000268058.3	transcript_fusion
TOP2A EXPRESSION	TOP2A	EXPRESSION	Breast Cancer	Doxorubicin	Predictive	Supports	B	Sensitivity/Response	chr17	40388516	40417950			"In a retrospective study, TOP2A expression was assessed by IHC for 108 breast cancer patients (from TAX 303 trial). TOP2A expression was associated with a higher probability of response in doxorubicin treated but not in docetaxel treated breast cancer patients."	"Durbecq et al., 2004, Mol. Cancer Ther."	N/A	ENST00000423485.1	N/A
STAT3 SH2 DOMAIN MUTATION	STAT3	SH2 DOMAIN MUTATION	T-cell Large Granular Lymphocyte Leukemia		Diagnostic	Supports	B	Positive	chr17	42313324	42323354			"Mutations in the Src homology 2 (SH2) domain (exon 21) of STAT3 were found in 31 of 77 patients (40%) with large granular lymphocytic leukemia. Recurrent mutational hot spots included Y640F, D661V, D661Y, and N647I. Patients with these mutations presented more often with neutropenia and rheumatoid arthritis than did patients without."	"Koskela et al., 2012, N. Engl. J. Med."	Somatic	ENST00000264657.5	protein_altering_variant
BRCA1 Loss-of-function	BRCA1	Loss-of-function	Prostate Cancer	Olaparib	Predictive	Supports	C	Sensitivity/Response	chr17	43045629	43125483			1/1 patients with BRCA1 homozygous deletion had a response to olaparib in this phase 2 study.	"Mateo et al., 2015, N. Engl. J. Med."	Somatic	ENST00000471181.2	"loss_of_heterozygosity,loss_of_function_variant"
BRCA1 Expression	BRCA1	Expression	Malignant Mesothelioma	Vinorelbine	Predictive	Supports	D	Sensitivity/Response	chr17	43045629	43125483			Expression of BRCA1 in 6 mesothelioma cell lines was associated with sensitivity to vinorelbine in functional studies.	"Busacca et al., 2012, J. Pathol."	N/A	ENST00000471181.2	N/A
BRCA1 Underexpression	BRCA1	Underexpression	Ovarian Cancer	"Platinum Compound,Taxane Compound"	Predictive	Supports	B	Sensitivity/Response	chr17	43045629	43125483			"Absent/low expression of BRCA1 (IHC) was associated with improved response to chemotherapy in 292 patients with sporadic ovarian cancer compared to patients with high expression (odds ratio 2.47: 95%CI 1.10-5.55, p=0.029)."	"Carser et al., 2011, Gynecol. Oncol."	N/A	ENST00000471181.2	N/A
BRCA1 Mutation	BRCA1	Mutation	Ovarian Carcinoma	Platinum Compound	Predictive	Supports	B	Sensitivity/Response	chr17	43045629	43125483			"In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.002). Sensitivity to platinum was defined by maintenance of complete response greater than 6 months post platinum-based therapy."	"Pennington et al., 2014, Clin. Cancer Res."	Somatic	ENST00000471181.2	"gene_variant,loss_of_function_variant"
BRCA1 Mutation	BRCA1	Mutation	Ovarian Cancer	Rucaparib	Predictive	Supports	B	Sensitivity/Response	chr17	43045629	43125483			"A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA mutant (BRCA1 or BRCA2) patients, 14 had homozygous somatic BRCA1 mutation or deletion. Confirmed objective response was seen in 71% (10/14) of the somatic BRCA1 mutant subgroup. Authors note that response rate was similar regardless of whether the BRCA mutation was somatic or germline, in BRCA 1 or BRCA 2. In a BRCA wild-type subgroup, with low levels of loss of heterozygosity (LOH), confirmed objective response was observed in 10% (7/70) of the patients. Patients with BRCA mutant tumors experienced significantly longer median progression free survival than patients with BRCA wildtype, LOH low tumors (12.8 vs 5.2 mo, HR: 0.27, P<0.0001)."	"Swisher et al., 2017, Lancet Oncol."	Somatic	ENST00000471181.2	"gene_variant,loss_of_function_variant"
BRCA1 Loss-of-function	BRCA1	Loss-of-function	Breast Cancer	"Quarfloxin,Pidnarulex"	Predictive	Supports	D	Sensitivity/Response	chr17	43045629	43125483			"The authors show that in the CX-5461 and CX-3543, G-quadruplex stabilizing agents, demonstrate specific toxicity against BRCA deficient breast cancer derived cells and polyclonal patient-derived xenograft models. Xenografts harbored both a germline BRCA and a somatic BRCA mutation leading to disruption of both. The BRCA and NHEJ pathways are required for the repair of CX-5461 and CX-3543-induced DNA damage and failure to do so leads to lethality."	"Xu et al., 2017, Nat Commun"	Unknown	ENST00000471181.2	"loss_of_heterozygosity,loss_of_function_variant"
BRCA1 Mutation	BRCA1	Mutation	Ovarian Cancer	Olaparib	Predictive	Supports	A	Sensitivity/Response	chr17	43045629	43125483			"In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were randomized 2:1 to receive olaparib or placebo. Two patients were found to have somatic BRCA1/2 mutations. Analysis of PFS by blinded independent review found freedom from disease progression or death at 3 years was 69% in the olaparib arm compared with 35% in the placebo arm (hazard ratio for disease progression or death, 0.28; 95% CI, 0.20 to 0.39; P<0.001)."	"Moore et al., 2018, N. Engl. J. Med."	Somatic	ENST00000471181.2	"gene_variant,loss_of_function_variant"
BRCA1 Mutation	BRCA1	Mutation	Prostate Carcinoma	Olaparib	Predictive	Supports	A	Sensitivity/Response	chr17	43045629	43125483			"This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a new hormonal agent (e.g., enzalutamide or abiraterone). The study found that in men with mCRPC who had somatic or germline deleterious alterations (irrespective of zygosity) in any of the following HRR genes (BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L), olaparib was associated with longer progression-free survival and better measures of response and patient-reported end points than either enzalutamide or abiraterone (PFS HR 0.49 [0.38, 0.63]). For 15 patients with BRCA1 mutations specifically, PFS HR 0.41 [0.13-1.39]. . Based on the results of this study, on May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA) for adult patients with deleterious or suspected deleterious germline or somatic HRR gene-mutated mCRPC, who have progressed following prior treatment with enzalutamide or abiraterone."	"de Bono et al., 2020, N. Engl. J. Med."	Unknown	ENST00000471181.2	"gene_variant,loss_of_function_variant"
BRCA1 W1815X	BRCA1	W1815X	Endometrioid Ovary Carcinoma	Olaparib	Predictive	Supports	D	Sensitivity/Response	chr17	43047665	43047665	C	T	"In an in vitro study, a SNU-251 cell line expressing BRCA1 W1815X truncating mutation demonstrated increased sensitivity to olaparib treatment with long-term exposure, compared to ovarian cell lines expressing BRCA1 wild-type. Sensitivity was determined by assessing cytotoxicity and doubling time. The authors note that the slow doubling time of SNU-251 cells was compensated for with a 2 week cytotoxicity assay as compared to the 1 week assay used for all other cell lines."	"Stordal et al., 2013, Mol Oncol"	Somatic		stop_gained
BRCA1 Q1467*	BRCA1	Q1467*	Ovarian Cancer	Rucaparib	Predictive	Supports	C	Sensitivity/Response	chr17	43076573	43076573	G	A	"In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression free survival (HR 0.27, 95% CI: 0.16-0.44, p<0.0001)  as compared to BRCA1/2 wild-type, loss of heterozygosity low patients (n=71) treated with rucaparib monotherapy; further, BRCA1/2 mutation patients achieved a longer median duration of response (9.2 months, 95% CI: 6.4-12.9, p=0.013 vs. 5.6 months, 95% CI: 4.6-8.5)."	"Swisher et al., 2017, Lancet Oncol."	Somatic	ENST00000357654.3	stop_gained
ETV4 Overexpression	ETV4	Overexpression	Prostate Cancer		Prognostic	Supports	B	Poor Outcome	chr17	43527844	43546432			"Immunohistochemical methods were used to evaluate the expression levels of ETV4 in prostate cancer (PCa) tumor samples. Increased expression of ETV4 was associated with greater Gleason score (P = 0.045) , pathological tumor stage (P = 0.041),  and an unfavorable prognosis (P = 0.040)."	"Qi et al., 2015, Tumour Biol."	N/A	ENST00000319349.5	N/A
ABCC3 Amplification	ABCC3	Amplification	Breast Cancer	"Monomethyl Auristatin E,Paclitaxel"	Predictive	Supports	D	Resistance	chr17	50634857	50692252			44 cell lines and 145 patient samples were utilized in various aspects of this study. 31 breast cancer cell lines for in vitro sensitivity to paclitaxel and Monomethyl Auristatin E (MMAE). Genome wide amplification was assessed by Affymetrix SNP arrays and expression was assessed by Affymetrix gene expression arrays. ABCC3 amplification (and expression) in ERBB2 (HER2) amplified breast cancer cell lines was associated with resistance to paclitaxel and  MMAE. Three independently derived EVSA-T cell lines overexpressing ABCC3 were at least 20-fold less sensitive to paclitaxel and MMAE based on EC50 values.	"O'Brien et al., 2008, Cancer Res."	Somatic	ENST00000285238.8	transcript_amplification
ALK CLTC::ALK	ALK	CLTC::ALK	Diffuse Large B-cell Lymphoma	TAE684	Predictive	Supports	D	Sensitivity/Response	chr17	59619858	59690711			"A cell line called LM1 was established from the bone marrow of a 13 year old female patient with relapsed CLTC-ALK positive diffuse large B-cell lymphoma (DLBCL). The patient had been heavily treated with chemotherapy before establishment of the cell line. The cell line maintained the tumor immunophenotype.  SNP analysis of patient bone marrow mononuclear cells and LM1 showed chromosomal changes associated with the cell line but 94.7% of SNPs were identically called.  ALK kinase inhibitor TAE684 induced cell death in LM1 cells at low nanomolar concentrations, while it did not significantly effect the ALK-rearrangement negative DLBCL cell line Karpas422.  LM1 cells formed tumors in 3/10 SCID and 9/10 NOD-SCID mice.  CD30 and CD138 immmunostaining were maintained between original tumor and LM1 xenografts. In mice, LM1 but not Karpas422 xenografts regressed with TAE684 administration, and complete remission for 13 weeks was observed before experiment was terminated."	"Cerchietti et al., 2011, PLoS ONE"	Somatic	ENST00000269122.3	transcript_fusion
ALK CLTC::ALK	ALK	CLTC::ALK	Diffuse Large B-cell Lymphoma		Prognostic	Supports	C	Poor Outcome	chr17	59619858	59690711			"CLTC-ALK is one of the most common ALK fusions found in diffuse large B cell lymphoma (DLBCL). In a retrospective study of 38 patients with ALK-rearranged DLBCL, 3 were CD20 positive. Only one showed cytoplasmic, nuclear and nucleolar staining associated with NPM-ALK, while the others showed granular cytoplasmic ALK stain characteristic for CLTC-ALK.  Seven molecularly characterized cases were positive for CLTC-ALK.  6/7 patients were treated with CHOP chemotherapy with survival of 5, 10, 26 and 27 months, and two alive at end of study, and one CD20 positive patient was treated with CHOP chemotherapy supplemented with CD20-targeted rituximab, with survival of 8 months, resulting in median survival of 26 months for this group.  Although these numbers are not sufficient for statistical comparison, they compare unfavorably to 3.1 year overall survival and 45% 5 year survival of CHOP treated DLBCL patients, and even less favorably to R-CHOP standard of care for CD20 positive DLBCL, suggesting poor prognosis for CLTC-ALK DLBCL and need for updated treatment in this cohort."	"Laurent et al., 2009, J. Clin. Oncol."	Somatic	ENST00000269122.3	transcript_fusion
ALK CLTC::ALK	ALK	CLTC::ALK	Diffuse Large B-cell Lymphoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr17	59619858	59690711			"A 21 year old male presented with lymphadenopathy and a low density mass in pancreas. Histopathological analysis showed diffuse tumor cell infiltrate (CD20/EMA negative) with cytoplasmic ALK. RT-PCR indicated CLTC-ALK fusion. The patient was diagnosed with splenic ALK + diffuse large B cell lymphoma (DLBCL), Stage III, Group A with an IPI of 3. CHOP-21 chemotherapy regimen was administered with improvement in abdominal lymph nodes but worsening in retroperitoneal lymph nodes assessed via standardized uptake values. Subsequent ICE chemotherapy regiment relieved some symptoms prompting the patient to refuse further treatment despite other indications of disease progression. Therapy was reinstated after worsening of disease. GEMOX chemotherapy was administered with dexamethasone and 250mg crizotinib twice daily resulting in symptom relief, decreased lymphadenopathy and LDH decline. The disease then progressed and the patient died 2 months after crizotinib initiation. The authors conclude that partial response to crizotinib was observed and that in future trials ALK rearranged DLBCL patients might see increased benefit with earlier application of targeted therapy during the treatment course."	"Li et al., 2015, Int J Clin Exp Med"	Somatic	ENST00000269122.3	transcript_fusion
SPHK1 OVEREXPRESSION	SPHK1	OVEREXPRESSION	Cervical Cancer		Prognostic	Supports	B	Poor Outcome	chr17	76384650	76387855			"SPHK1 protein expression was assessed in 287 cervical cancer and 5 normal cervical tissue samples using IHC. Univariate analysis for OS showed SPHK1 expression (p = 0.033; Figure 1C), tumor size (p = 0.033), and lymph node metastasis (p = 0.008) as associated with OS. SPHK1 expression did not directly predict OS. High SPHK1 expression was also associated with larger tumor size (p < 0.001), deeper invasion depth (p < 0.001), presence of lymph node metastasis (p = 0.029), higher FIGO stage (p = 0.029), presence of lymphovascular invasion (p = 0.045), and higher preoperative squamous cell carcinoma (SCC) antigen level (p = 0.009)."	"Kim et al., 2015, Oncotarget"	Somatic	ENST00000323374.4	N/A
SRSF2 MUTATION	SRSF2	MUTATION	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr17	76736320	76737031			"Patients with Acute Myeloid Leukemia showed an synergistic mortality rate with ASXL1 and SRSF2 co-mutations such that individual mutations of either ASXL1 or SRSF2 resulted in ~20% probability of survival after 10 years, whereas co-mutations resulted in a 100% mortality rate after 4 years."	"Papaemmanuil et al., 2016, N. Engl. J. Med."	Somatic	ENST00000392485.2	gene_variant
SRSF2 P95L	SRSF2	P95L	Myeloid Neoplasm	CTX-712	Predictive	Supports	D	Sensitivity/Response	chr17	76736877	76736877	G	A	"Several splicing factors known to drive myeloid neoplasms (including SRSF2) require phosphorylation by CLK family kinases for nuclear translocation.  The authors describe development of an inhibiter of a CLK family kinase called CTX-712 and evaluate its efficacy in cell line and murine models. CTX-712 efficacy was confirmed in MDS/AML-derived xenografts (PDX).  One PDX model with an SRSF2 P95L variant exhibited significant reduction in tumor volume 2 weeks after CTX-712 high dose treatment compared to vehicle (P=0.0162, N=6). CTX-712 treatment also improved survival in the SRSF2 P95L-mutated model (P=0.0030, N=6 mice)."	"Yoda et al., 2021, Blood"	Somatic	ENST00000359995.10:c.284C>T	missense_variant
SRSF2 P95H	SRSF2	P95H	Myeloid Neoplasm	CTX-712	Predictive	Supports	D	Sensitivity/Response	chr17	76736877	76736877	G	T	Several splicing factors known to drive myeloid neoplasms (including SRSF2) require phosphorylation by CLK family kinases for nuclear translocation. The authors describe development of an inhibiter of a CLK family kinase called CTX-712 and evaluate its efficacy in cell line and murine models. CTX-712 efficacy was confirmed in MDS/AML-derived xenografts (PDX). One PDX model with an SRSF2 P95H variant showed a significant response to CTX-712 in a dose-dependent manner. 4 out of 5 mice receiving a high dose protocol achieved complete remission. CLK inhibition also induced aberrant splicing events including skipped exons and this effect was more prevalent in the SRSF2-mutated model.	"Yoda et al., 2021, Blood"	Somatic	ENST00000359995.10	missense_variant
BIRC5 NUCLEAR EXPRESSION	BIRC5	NUCLEAR EXPRESSION	Lung Non-small Cell Carcinoma	"Taxane Compound,Platinum Compound"	Predictive	Supports	B	Sensitivity/Response	chr17	78214186	78225636			Patients with nuclear survivin (BIRC5) expression had significantly better responses to taxane-platinum chemotherapy than those with low tumor N-survivin expression (P < 0.001) in a retrospective analysis of 48 patients with non-small cell lung cancer.	"Wu et al., 2014, Med. Oncol."	N/A	ENST00000301633.4	N/A
BIRC5 Overexpression	BIRC5	Overexpression	Her2-receptor Positive Breast Cancer	Trastuzumab	Predictive	Supports	B	Resistance	chr17	78214186	78225636			"13 HER2 breast cancer patients were treated with trastuzumab and then trastuzumab + docetaxel prior to surgery. Pretreatment biopsies and post-treatment surgical samples were obtained, and microarray performed. 5 of 13 patients responded to treatment, and pretreatment biopsies from non-responders showed significantly higher survivin (BIRC5) mRNA (p=0.026) levels than responders. In HER2 positive, trastuzumab-sensitive BT474 cells, overexpression of survivin blunted sensitivity to trastuzumab. In HER2 positive trastuzumab-resistant breast cancer cell lines, knockdown of survivin with RNAi or with YM155 induced growth inhibition and apoptosis."	"Chakrabarty et al., 2013, Cancer Res."	N/A	ENST00000301633.4	N/A
TYMS Overexpression	TYMS	Overexpression	Lung Non-small Cell Carcinoma	Pemetrexed	Predictive	Supports	B	Resistance	chr18	657604	673578			"mRNA expression of thymidylate synthase (TYMS) in 62 NSCLC patients correlated with response rate to pemetrexed mono- or combination therapy. Response rate with low TYMS expression was 0.29 compared with 0.03 in patients with overexpression (P = 0.025). Patients with low expression exhibited a benefit in time to progression (average TTP = 56 vs. 23 months, P = 0.001) and in overall survival (average OS = 60 vs. 25 months, P = 0.002)."	"Chamizo et al., 2015, BMC Pulm Med"	N/A	ENST00000323274.10	N/A
TYMS Amplification	TYMS	Amplification	Lung Adenocarcinoma	Pemetrexed	Predictive	Supports	B	Resistance	chr18	657604	673578			TYMS copy number was lower in clinical samples responding to pemetrexed in combination with platinum (n=25). The same was found in 17 cell lines.	"Kasai et al., 2013, Anticancer Res."	Somatic	ENST00000323274.10	transcript_amplification
TYMS Underexpression	TYMS	Underexpression	Lung Non-small Cell Carcinoma	Pemetrexed	Predictive	Supports	B	Sensitivity/Response	chr18	657604	673578			49 tumor specimens from 268 NSCLC patients treated with pemetrexed were evaluated for expression of TYMS and DHFR by IHC and compared to treatment outcomes. Patients with low TS (?50) expression had a longer median progression-free survival (PFS) than those with high TS (>150) expression (4.8 vs. 3.4 months; p=0.01).	"Chen et al., 2011, Lung Cancer"	N/A	ENST00000323274.10	N/A
TYMS Underexpression	TYMS	Underexpression	Prostate Cancer	Pemetrexed	Predictive	Supports	C	Sensitivity/Response	chr18	657604	673578			Case report of a patient with metastatic prostate cancer and underexpression of TYMS who showed a nonspecified response to pemetrexed for at least 4 months.	"Russell et al., 2014, Front Pharmacol"	N/A	ENST00000323274.10	N/A
TYMS Overexpression	TYMS	Overexpression	Lung Non-small Cell Carcinoma	Pemetrexed	Predictive	Supports	B	Resistance	chr18	657604	673578			"mRNA levels of TYMS, DHFR and GARFT were assessed (rt-PCR) in 50 patient samples of NSCLC. TYMS mRNA levels were lower in responders compared to non-responders to pemetrexed (1.671  0.844 versus 5.978  1.895, p=0.0142)."	"Shimizu et al., 2012, Anticancer Res."	N/A	ENST00000323274.10	N/A
TYMS Overexpression	TYMS	Overexpression	Gastric Adenocarcinoma	Raltitrexed	Predictive	Supports	B	Resistance	chr18	657604	673578			"In 125 gastric tumors, plasma and tissue mRNA levels of TYMS were lower in the raltitrexed sensitive group compared to the resistant group (p = 0.007 and 0.013, respectively)."	"Shen et al., 2012, Int. J. Cancer"	N/A	ENST00000323274.10	N/A
SSX4 SS18::SSX4	SSX4	SS18::SSX4	Synovial Sarcoma		Diagnostic	Supports	C	Positive	chr18	26032399	26090625			"Three synovial sarcomas were assayed for SYT-SSX fusion messenger RNA by nested RT-PCR. In a single case an SYT-SSX4 (SS18-SSX4) fusion was detected. The majority of synovial sarcomas are characterized by SS18-SSX1 or SS18-SSX2, but other rare events such as this SS18-SSX4 may explain some or all of the synovial sarcomas that are negative for the most common fusions."	"Skytting et al., 1999, J. Natl. Cancer Inst."	Somatic	ENST00000415083.2	transcript_fusion
SETBP1 Exon 4 Mutation	SETBP1	Exon 4 Mutation	"Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative"		Prognostic	Supports	B	Poor Outcome	chr18	44951912	44951953			"Atypical Chronic Myeloid Leukemia has the same symptoms as CML, but it lacks the BCR-ABL1 fusion. Targeted sequencing of 70 aCML patients identified SETBP1 mutations between codons 858 and 871 in 24.3% of the patients. Patients with this mutation had a 22 month median survival compared to 77 months in aCML patients without the mutation (P=.01)."	"Piazza et al., 2013, Nat. Genet."	Somatic	ENST00000282030.5	exon_variant
SETBP1 G870S	SETBP1	G870S	Chronic Myeloid Leukemia		Prognostic	Supports	D	Poor Outcome	chr18	44951948	44951948	G	A	"Atypical Chronic Myeloid Leukemia has the same symptoms as CML, but it lacks the BCR-ABL1 fusion. The researchers transfected 293T cells with SETBP1 G870S, a variant found to be associated with poor prognosis in aCML, and found those cells had higher proliferation and higher expression of SET and SETBP1 proteins. This may be linked to the mutation abrogating a ubiquitination site."	"Piazza et al., 2013, Nat. Genet."	Somatic	ENST00000282030.5	missense_variant
SMAD4 Mutation	SMAD4	Mutation	Pancreatic Adenocarcinoma		Prognostic	Supports	B	Poor Outcome	chr18	51030213	51085039			"In a study of 89 patients with adenocarcinoma of the pancreas who underwent a pancreaticoduodenectomy, those with mutations in SMAD4 had shorter overall survival than wild-type patients."	"Blackford et al., 2009, Clin. Cancer Res."	Somatic	ENST00000342988.3	"transcript_variant,loss_of_function_variant"
SMAD4 Mutation	SMAD4	Mutation	Colorectal Cancer	"Panitumumab,Cetuximab"	Predictive	Supports	B	Resistance	chr18	51030213	51085039			"In a retrospective analysis of 65 patients with metastatic colorectal cancer, SMAD4 mutations were more common among patients with no benefit from EGFR-inhibition (cetuximab or panitumumab) (4 patients) than with patients with response to EGFR directed treatment (1 patient)."	"Lupini et al., 2015, BMC Cancer"	Somatic	ENST00000342988.3	"transcript_variant,loss_of_function_variant"
SMAD4 Underexpression	SMAD4	Underexpression	Head And Neck Squamous Cell Carcinoma	Cetuximab	Predictive	Supports	D	Resistance	chr18	51030213	51085039			"In this study, SMAD4 underexpression was associated with an epithelial-to-mesenchymal transition and resistance to EGFR-directed treatment with Cetuximab."	"Cheng et al., 2015, Cancer Biol. Ther."	Somatic	ENST00000342988.3	N/A
SMAD4 Expression	SMAD4	Expression	Pancreatic Ductal Adenocarcinoma		Prognostic	Supports	B	Better Outcome	chr18	51030213	51085039			"In 249 patients that have undergone a pancreaticoduodenectomy (Whipple) for the resection of pancreatic ductal adenocarcinoma, expression of SMAD4 is associated with favorable prognosis. SMAD4 was assessed by IHC in 56 of 249 (22%).  Relative hazard of mortality for cancers lacking SMAD4 after adjusting for other prognostic factors was 1.36 (95% confidence interval, 1.01-1.83; P = 0.04)."	"Tascilar et al., 2001, Clin. Cancer Res."	N/A	ENST00000342988.3	N/A
SMAD4 LOSS	SMAD4	LOSS	Pancreatic Cancer		Prognostic	Supports	B	Poor Outcome	chr18	51030213	51085039			"Study employed a rapid autopsy technique on a cohort of 76 patients with pancreatic cancer and explored the status of several genes. 63% (41/65) of carcinomas analyzed showed inactivation of SMAD4 (DPC4) via immunolabeling. Among the patterns of failure ""metastatic and locally destructive"", It was discovered that DPC4 loss was significantly associated with metastatic disease (p=.007)."	"Iacobuzio-Donahue et al., 2009, J. Clin. Oncol."	Somatic	ENST00000342988.3	loss_of_function_variant
SMAD4 Deletion	SMAD4	Deletion	Colorectal Cancer	Fluorouracil	Predictive	Supports	B	Resistance	chr18	51030213	51085039			"A retrospective study with 202 colorectal cancer patients found that SMAD4 deletion was associated with worse outcomes during 5-fluorouracil treatment. The hazard ratio for disease-free survival was 2.89 times greater for patients with SMAD4 deletion as compared to those  with normal SMAD4 diploidy (P = .045).  For overall survival, the hazard ratio was 3.23 times greater for SMAD4 deletion (P = .056)."	"Boulay et al., 2002, Br. J. Cancer"	N/A	ENST00000342988.3	transcript_ablation
BCL2 Overexpression	BCL2	Overexpression	Diffuse Large B-cell Lymphoma		Prognostic	Supports	B	Poor Outcome	chr18	63123346	63320128			"In patients with Diffuse Large B-Cell Lymphoma, those with increased levels of BCL2 were shown to have decreased overall, disease-free, and relapse-free survival."	"Gascoyne et al., 1997, Blood"	N/A	ENST00000398117.1	N/A
BCL2 Mutation	BCL2	Mutation	Follicular Lymphoma		Prognostic	Supports	B	Poor Outcome	chr18	63123346	63320128			"In a multivariate analysis, BCL2 mutations and high FL international prognostic index were independent risk factors for transformation and death due to lymphoma. Some mutant Bcl-2 proteins exhibited enhanced antiapoptotic capacity in vitro."	"Correia et al., 2015, Blood"	Somatic	ENST00000398117.1	
BCL2 IGH::BCL2	BCL2	IGH::BCL2	Diffuse Large B-cell Lymphoma		Diagnostic	Supports	B	Positive	chr18	63127035	63319786			The t(14;18) transloaction of BCL2 is shown to be associated with germinal-center B-celllike diffuse large-B-cell lymphomas.	"Rosenwald et al., 2002, N. Engl. J. Med."	Somatic		"transcript_fusion,transcript_regulatory_region_fusion"
BCL2 F104I	BCL2	F104I	Follicular Lymphoma	Venetoclax	Predictive	Supports	C	Resistance	chr18	63318357	63318357	A	T	This study identified BCL2 F104I mutation in one Follicular Lymphoma patient who developed resistance to venetoclax. Codon 104 is located at the venetoclax binding site of BCL2.	"Blombery et al., 2019, Br. J. Haematol."	Somatic	ENST00000398117.1	missense_variant
BCL2 F104I	BCL2	F104I	Follicular Lymphoma	Venetoclax	Predictive	Supports	D	Resistance	chr18	63318357	63318357	A	T	Rs4;11 cells overexpressing BCL2 F104I exhibited >40-fold greater resistance to venetoclax after 24-hour treatment (IC50 not reached) than Rs4;11 overexpressing BCL2 WT cells as determined by cell titer glo measured cytotoxicity assays. Plasmon resonance protein binding assays demonstrated marked impairment (300 fold) of venetoclax binding to F104I (Ki=5.9 nM) veresus WT (Ki=.018nM). The authors pointed out reduction in binding was a similar magnitude as that observed previously with the BCL2 G101V and F104L.	"Blombery et al., 2019, Br. J. Haematol."	Somatic	ENST00000398117.1	missense_variant
BCL2 G101V	BCL2	G101V	Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma	Venetoclax	Predictive	Supports	C	Resistance	chr18	63318365	63318365	C	A	The effective cohort in this study was 11 CLL patients who were first treated with ibrutinib and then on progression treated with venetoclax until progression. Patient samples were sequenced before and after progression on venetoclax. The previously described BCL2 G101V mutation was observed in 1 patient at progression	"Lucas et al., 2020, Blood"	Somatic	ENST00000398117.1	missense_variant
BCL2 G101V	BCL2	G101V	Chronic Lymphocytic Leukemia	Venetoclax	Predictive	Supports	D	Resistance	chr18	63318365	63318365	C	A	"This study described the similar crystal structures of BCL-2 wild-type and G101V when bound to venetoclax. Steady state competition surface plasmon resonance experiments demonstrated a ~177 fold decrease in venetoclax affinity for G101V (Ki=3.2nM) versus WT (Ki=.018nM). Resistance is acquired by a knock-on effect in the P2 pocket of V101 on an adjacent residue, E152 as affinity for venetoclax was restored in BCL2 G101V through the introduction of an E152A mutation (Ki =.002nM). Additionally, BCL2 G101V maintains similar affinity for apoptotic BH3 peptides, which assists in the prevention of apoptosis."	"Birkinshaw et al., 2019, Nat Commun"	Somatic	ENST00000398117.1	missense_variant
STK11 EXON 1-2 MUTATION	STK11	EXON 1-2 MUTATION	Lung Non-small Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr19	1205741	1218500			"In a retrospective analysis of 567 non-squamous, non-small cell lung cancer patients, Exon 1-2 mutations in STK11 were significantly associated with shorter OS (24 vs. 69 months) also after multivariate analysis. Results were validated in public datasets."	"Pcuchet et al., 2015, Oncotarget"	Somatic	ENST00000326873.7	exon_variant
STK11 Underexpression	STK11	Underexpression	Prostate Cancer	SB202190	Predictive	Supports	D	Sensitivity/Response	chr19	1205741	1228429			STK11-deficient cells were sensitive to treatment with MAPK11 inhibitor SB202190.	"Grossi et al., 2015, Autophagy"	Somatic	ENST00000326873.7	N/A
STK11 Loss	STK11	Loss	Lung Non-small Cell Carcinoma	"Docetaxel,Selumetinib"	Predictive	Supports	D	Resistance	chr19	1205741	1228429			A clinical trial comparing selumetinib and docetaxel vs. docetaxel and placebo in KRAS mutant NSCLC was recapitulated in mice. Tumors were induced in lung epithelium by nasal instillation of CRE-bearing adenovirus in conditionally targeted mice. Kras(G12D) and Lkb1 (STK11) knockout mutant mice showed only mild response to combined treatment and very low response rates to docetaxel monotherapy compared to mice with Kras(G12D) alone or Kras(G12D) and Trp53 knockout. In a small number of human NSCLC patients with these genotypes FDG-PET signal intensity changes and pERK IHC staining correlated with mouse data.	"Chen et al., 2012, Nature"	Somatic	ENST00000326873.7	loss_of_function_variant
STK11 Loss	STK11	Loss	Lung Non-small Cell Carcinoma	"Everolimus,Sirolimus"	Predictive	Does Not Support	D	Sensitivity/Response	chr19	1205741	1228429			Preclinical study in 5 NSCLC cell lines. Two LKB1 (STK11) mutant cell lines had higher basal levels of mTOR activity (pS6K and p4EBP1 levels) but were not more sensitive to mTOR inhibitors (everolimus or rapamycin) than two wild type cell lines. Knockdown of LKB1 in one additional cell line did not lead to an increase in sensitivity to mTOR inhibitors.	"Xiao et al., 2015, Acta Pharmacol. Sin."	Somatic	ENST00000326873.7	loss_of_function_variant
STK11 Mutation	STK11	Mutation	Lung Adenocarcinoma	"Pembrolizumab,Atezolizumab,Nivolumab"	Predictive	Supports	B	Resistance	chr19	1205741	1223075			"In a retrospective analysis in two separate datasets (Stand Up To Cancer 2 Cohort and Checkmate-057), patients with concomitant KRAS and STK11 mutations had significantly worse response rates, PFS and OS compares to KRAS only and KRAS-TP53 Mutant Patients. This work identifies STK11/LKB1 alterations as the most prevalent genomic driver of primary resistance to PD-1 axis inhibitors in KRAS-mutant lung adenocarcinoma. Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets."	"Skoulidis et al., 2018, Cancer Discov"	Somatic	ENST00000326873.7	gene_variant
GNA11 Mutation	GNA11	Mutation	Uveal Melanoma	JQ1	Predictive	Supports	D	Sensitivity/Response	chr19	3094410	3124004			"Preclinical study in uveal melanoma cell lines. Cell lines (n=5) with GNAQ (92.1, Omm1.3, Mel270, Mel202) or GNA11 (Omm1) mutation were more sensitive to BRD4 inhibition with JQ1 than GNAQ/11 wild type (n=3) cell line."	"Ambrosini et al., 2015, Oncotarget"	Somatic	ENST00000078429.4	
GNA11 Mutation	GNA11	Mutation	Uveal Melanoma	Trametinib	Predictive	Supports	C	Sensitivity/Response	chr19	3094410	3124004			"Phase 1 study of trametinib in 97 patients with melanoma (16 with uveal melanoma). Analysis in patients with uveal melanoma identified GNAQ and GNA11 mutations in six patients, in which three SD and three PD were the best responses. One patient with a GNA11 mutation identified by Illumina genotyping stayed on study treatment for >40 weeks."	"Falchook et al., 2012, Lancet Oncol."	Somatic	ENST00000078429.4	
GNA11 Mutation	GNA11	Mutation	Uveal Melanoma	"Mirdametinib,Sotrastaurin Acetate"	Predictive	Supports	D	Sensitivity/Response	chr19	3094410	3124004			Preclinical study in uveal melanoma. Increased PKC activity was found in uveal melanoma cell lines with GNA11 or GNAQ mutations (n=6) compared to GNA wt cell lines (n=4) and could be induced by introducing these mutations into wt cell lines. Cell lines carrying GNA mutations were more sensitive to PKC inhibition with AEB071 and AHT956 in vitro and in vivo. Combined inhibition of MEK and PKC with AEB071 and PD0325901led to sustained MAPK-signalling blockade and induced apoptosis.	"Chen et al., 2014, Oncogene"	Somatic	ENST00000078429.4	
GNA11 Mutation	GNA11	Mutation	Uveal Melanoma	Cabozantinib	Predictive	Supports	B	Sensitivity/Response	chr19	3094410	3124004			"In total, 77 patients with metastatic melanoma (62% cutaneous, 30% uveal, 8% mucosal) were admitted into a randomized phase II trial assessing the efficacy of Cabozantinib. Patients received cabozantinib 100mg/d during a 12-week lead-in. Patients with stable disease (SD; RECIST) at week 12 were randomized to cabozantinib or placebo. During lead-in phase, 55% of evaluable patients showed reduction in target lesion size (59% uveal melanoma). Uveal melanoma cohort included 23 patients, 9 with GNAQ (n=5) and GNA11 (n=4) mutations. Responses were reported in mutational patients. In the uveal melanoma cohort, 61% of patients (14/23) had SD at week 12, and no patient had a PR, resulting in an overall disease control rate of 61%. The median PFS for the 23 patients with uveal melanoma was 4.8 months."	"Daud et al., 2017, Br. J. Cancer"	Somatic	ENST00000078429.4	
GNA11 Q209	GNA11	Q209	Uveal Melanoma	Selumetinib	Predictive	Does Not Support	B	Sensitivity/Response	chr19	3118944	3118944			"101 patients with metastatic uveal melanoma were randomized 1:1 to receive selumetinib or chemotherapy. Median PFS among patients randomized to chemotherapy was 7 weeks (95% CI, 4.3-8.4 weeks; median treatment duration, 8 weeks; interquartile range [IQR], 4.3-16 weeks) vs. 15.9 weeks with selumetinib (95% CI, 8.4-21.1 weeks; median treatment duration, 16.1 weeks; IQR, 8.1-25.3 weeks) (hazard ratio, 0.46; 95% CI, 0.30-0.71; P??.001). Most patients (80/96 evaluable harbored a mutation in exon 5 of GNAQ or GNA11) but PFS benefit from Selumetinib compared to chemotherapy was greater in the GNAQ and GNA11 wild-type population (25.9 weeks [range, 3.7-40.4 weeks] vs 15.4 weeks [range, 8.1-16.9 weeks]). However, PFS was still better with Selumetinib than chemotherapy in the GNA mutant population (hazard ratio 0.55, 95% CI, 0.34-0.87; P??.01). The difference was explained by potential GNAQ or GNA11 mutations outside of exon 5 in the GNA wild-type population. Another three mutations in exon 4 were retrospectively identified in the wild-type population and one had a major response."	"Carvajal et al., 2014, JAMA"	Somatic	ENST00000078429.4	missense_variant
DNMT1 EXPRESSION	DNMT1	EXPRESSION	Ovarian Cancer	Decitabine	Predictive	Supports	D	Sensitivity/Response	chr19	10133346	10195135			"DNMT1 expression (mRNA expression from an independent study) correlated with sensitivity to decitabine (, ?.443, Pearson regression analysis) in this preclinical study of 45 solid tumor cell lines. DNMT1 protein expression was also evaluated in two KRAS-mutant ovarian cancer cell lines pre and post-decitabine treatment showing downregulation following treatment."	"Stewart et al., 2015, Cancer Res."	N/A	ENST00000340748.4	N/A
DNMT1 EXPRESSION	DNMT1	EXPRESSION	Gastric Adenocarcinoma	Cisplatin	Predictive	Supports	B	Resistance	chr19	10133346	10195135			"High DNMT1 expression was found in 105/127 (83%) or patients (by qPCR assay). Low DNMT1 expression was associated with improved histopathological and clinical response and OS in patients with gastric cancer  (P=0.03/P=0.008, P(log-rank)=0.001, respectively). In one cisplatin resistant cell line, DAC treatment and cisplatin had a synergistic effect."	"Mutze et al., 2011, Eur. J. Cancer"	N/A	ENST00000340748.4	N/A
SMARCA4 MUTATION	SMARCA4	MUTATION	Small-cell Carcinoma Of The Ovary Of Hypercalcemic Type		Diagnostic	Supports	B	Positive	chr19	10960922	11062282			"Nonsense mutations in SMARCA4 were associated with small cell carcinoma of the ovary, hypercalcemic type in 10/10 tumor samples, and were rarely found in other solid tumor types catalogued by TCGA."	"Jelinic et al., 2014, Nat. Genet."	Somatic	ENST00000358026.2	"gene_variant,loss_of_function_variant"
SMARCA4 INACTIVATING MUTATION	SMARCA4	INACTIVATING MUTATION	Lung Adenocarcinoma		Prognostic	Supports	B	Poor Outcome	chr19	10960922	11062282			"In patients with lung adenocarcinoma, those with loss-of-function mutations in SMARCA4 had worse overall survival than those with only missense or no mutations."	"Jelinic et al., 2014, Nat. Genet."	Somatic	ENST00000358026.2	loss_of_function_variant
SMARCA4 Underexpression	SMARCA4	Underexpression	Lung Non-small Cell Carcinoma	"Vinorelbine,Cisplatin"	Predictive	Supports	B	Sensitivity/Response	chr19	10960922	11062282			"SMARCA4 expression was determined with gene expression microarray in 133 patients. Improved five-year disease-specific survival (DSS) was noted only in patients with low SMARCA4 expression when treated with adjuvant cisplatin/vinorelbine (n=36) (HR=0.1, 95% CI: 0.0-0.5, P=0.002 [low]; HR 1.0, 95% CI: 0.5-2.3, P=0.92 [high]) compared to patients in the observation arm (N=30)."	"Bell et al., 2016, Clin. Cancer Res."	N/A	ENST00000358026.2	N/A
SMARCA4 Underexpression	SMARCA4	Underexpression	Lung Non-small Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr19	10960922	11062282			"SMARCA4 expression was determined with gene expression microarray in 133 patients. Reduced overall survival was observed in patients with low SMARCA4 expression compared to intermediate (P<0 .001) or high expression (P=0.009). In multivariate analysis, compared to low, high SMARCA4 expression predicted a decrease in risk of death (HR=0.6, 95% CI: 0.4-0.8, P=0.002)."	"Bell et al., 2016, Clin. Cancer Res."	Somatic	ENST00000358026.2	N/A
CALR EXON 9 FRAMESHIFT	CALR	EXON 9 FRAMESHIFT	Myelofibrosis		Prognostic	Supports	A	Better Outcome	chr19	12943713	12943913			"Study of 428 patients with primary Myelofibrosis found that those patients harboring CALR exon 9 mutations displayed significantly longer survival than those with JAK2 mutations (HR: 2.5, median survival yrs: CALR 15.9, JAK2 5.9)"	"Tefferi et al., 2014, Blood"	Somatic	ENST00000316448.5	exon_variant
CALR EXON 9 FRAMESHIFT	CALR	EXON 9 FRAMESHIFT	Essential Thrombocythemia	Peginterferon Alfa-2a	Predictive	Supports	B	Sensitivity/Response	chr19	12943713	12943913			"Study explored the hematologic and molecular responses in a cohort of 31 patients presenting with thrombocythemia and CALR exon 9 frameshift mutations. All 31 patients exhibited a hematologic response at the time of followup (European LeukemiaNet criteria). In regards to molecular response, before treatment the CALR mutant allele displayed a median frequency of 41% across the cohort, during treatment a significant decrease was observed in comparison to controls treated with hydroxyurea and aspirin."	"Verger et al., 2015, Blood"	Somatic	ENST00000316448.5	exon_variant
CALR EXON 9 FRAMESHIFT	CALR	EXON 9 FRAMESHIFT	Myelofibrosis		Prognostic	Supports	B	Better Outcome	chr19	12943713	12943913			"In patients with primary myelofibrosis CALR mutations were associated with improved median survival. For 277 patients, CALR mutated, ASXL1 wildtype patients (median survival, 10.4 years, N=46); CALR wildtype, ASXL1 mutant patients (2.3 years; HR, 5.9; 95% CI, 3.5?0.0, N=62); and either CALR/ASXL1wildtype or CALR/ASXL1 mutant patients (5.8 years; HR, 2.5; 95% CI, 1.5?.0, N=169). These results were independent of DIPSS-plus risk but added prognostic information to this risk categorization. These results were also validated in an independent cohort of 293 patients."	"Tefferi et al., 2014, Leukemia"	Somatic	ENST00000316448.5	exon_variant
PRKACA DNAJB1::PRKACA	PRKACA	DNAJB1::PRKACA	Fibrolamellar Carcinoma		Diagnostic	Supports	B	Positive	chr19	14091688	14107409			"A head-to-tail in-frame fusion between exon1 of DNAJB1 and exon2 of PRKACA resulting from a ~400kb deletion was observed in 100% (15/15) fibrolamellar hepatocellular carcinomas examined. The fusion was confirmed at both RNA and DNA level in all primary and metastatic tumor samples but not in adjacent normal tissue. Immunoprecipitation and Western blot analyses confirmed that the chimeric protein is expressed in tumor tissue, and a cell culture assay indicated that it retains kinase activity."	"Honeyman et al., 2014, Science"	Somatic	ENST00000254322.2	transcript_fusion
PRKACA DNAJB1::PRKACA	PRKACA	DNAJB1::PRKACA	Fibrolamellar Carcinoma		Diagnostic	Supports	B	Positive	chr19	14091688	14107409			"RT-PCR and FISH assays were developed for the detection of rearrangements of the PRKACA locus. A total of 106 primary liver tumors were studied by RT-PCR (26 fibrolamellar carcinomas, 25 conventional hepatocellular carcinomas, 25 cholangiocarcinomas, 25 hepatic adenomas, and 5 hepatoblastomas). FISH was tested in 19 fibrolamellar carcinomas and in 6 scirrhous hepatocellular carcinomas. Evidence of the DNAJB1-PRKACA fusion was found in all fibrolamellar cases but not in other tumor types for both methods indicating that detection of DNAJB1-PRKACA is a very sensitive and specific finding in support of the diagnosis of fibrolamellar carcinoma."	"Graham et al., 2015, Mod. Pathol."	Somatic	ENST00000254322.2	transcript_fusion
PRKACA DNAJB1::PRKACA	PRKACA	DNAJB1::PRKACA	Fibrolamellar Carcinoma		Diagnostic	Supports	B	Positive	chr19	14091688	14107409			The DNAJB1-PRKACA fusion was detected in 79% (58/73) of fibrolamellar hepatocellular carcinomas assayed.	"Cornella et al., 2015, Gastroenterology"	Somatic	ENST00000254322.2	transcript_fusion
PRKACA DNAJB1::PRKACA	PRKACA	DNAJB1::PRKACA	Mixed Fibrolamellar Hepatocellular Carcinoma		Diagnostic	Supports	C	Positive	chr19	14091688	14107409			"A DNAJB1:PRKACA fusion transcript was detected at very high expression levels by RNA-Seq in a case of mixed fibrolamellar hepatocellular carcinoma. Subsequent analysis revealed the presence of this fusion in all primary and metastatic samples, including those with mixed or conventional HCC pathology. A second case of mFL-HCC confirmed that the fusion was detectable in conventional components. An expanded screen of 112 additional HCC samples and 44 adjacent non-tumor liver samples was positive for a third case of HCC with both conventional and fibrolamellar features but negative for all conventional HCC and adjacent non-tumor liver samples."	"Griffith et al., 2016, Ann. Oncol."	Somatic	ENST00000254322.2	transcript_fusion
PRKACA DNAJB1::PRKACA	PRKACA	DNAJB1::PRKACA	Fibrolamellar Carcinoma		Diagnostic	Supports	B	Positive	chr19	14518139	14518420			"A head-to-tail in-frame fusion between exon1 of DNAJB1 and exon2 of PRKACA resulting from a ~400kb deletion was observed in 100% (15/15) fibrolamellar hepatocellular carcinomas examined. The fusion was confirmed at both RNA and DNA level in all primary and metastatic tumor samples but not in adjacent normal tissue. Immunoprecipitation and Western blot analyses confirmed that the chimeric protein is expressed in tumor tissue, and a cell culture assay indicated that it retains kinase activity."	"Honeyman et al., 2014, Science"	Somatic	ENST00000254322.2	transcript_fusion
PRKACA DNAJB1::PRKACA	PRKACA	DNAJB1::PRKACA	Fibrolamellar Carcinoma		Diagnostic	Supports	B	Positive	chr19	14518139	14518420			"RT-PCR and FISH assays were developed for the detection of rearrangements of the PRKACA locus. A total of 106 primary liver tumors were studied by RT-PCR (26 fibrolamellar carcinomas, 25 conventional hepatocellular carcinomas, 25 cholangiocarcinomas, 25 hepatic adenomas, and 5 hepatoblastomas). FISH was tested in 19 fibrolamellar carcinomas and in 6 scirrhous hepatocellular carcinomas. Evidence of the DNAJB1-PRKACA fusion was found in all fibrolamellar cases but not in other tumor types for both methods indicating that detection of DNAJB1-PRKACA is a very sensitive and specific finding in support of the diagnosis of fibrolamellar carcinoma."	"Graham et al., 2015, Mod. Pathol."	Somatic	ENST00000254322.2	transcript_fusion
PRKACA DNAJB1::PRKACA	PRKACA	DNAJB1::PRKACA	Fibrolamellar Carcinoma		Diagnostic	Supports	B	Positive	chr19	14518139	14518420			The DNAJB1-PRKACA fusion was detected in 79% (58/73) of fibrolamellar hepatocellular carcinomas assayed.	"Cornella et al., 2015, Gastroenterology"	Somatic	ENST00000254322.2	transcript_fusion
PRKACA DNAJB1::PRKACA	PRKACA	DNAJB1::PRKACA	Mixed Fibrolamellar Hepatocellular Carcinoma		Diagnostic	Supports	C	Positive	chr19	14518139	14518420			"A DNAJB1:PRKACA fusion transcript was detected at very high expression levels by RNA-Seq in a case of mixed fibrolamellar hepatocellular carcinoma. Subsequent analysis revealed the presence of this fusion in all primary and metastatic samples, including those with mixed or conventional HCC pathology. A second case of mFL-HCC confirmed that the fusion was detectable in conventional components. An expanded screen of 112 additional HCC samples and 44 adjacent non-tumor liver samples was positive for a third case of HCC with both conventional and fibrolamellar features but negative for all conventional HCC and adjacent non-tumor liver samples."	"Griffith et al., 2016, Ann. Oncol."	Somatic	ENST00000254322.2	transcript_fusion
CCNE1 Overexpression	CCNE1	Overexpression	Breast Cancer		Prognostic	Supports	B	Poor Outcome	chr19	29811898	29824308			"Patients with high expression of total cyclin E and low-molecular weight cyclin E is strongly associated with poor prognosis in breast cancer, and the hazard ratio for these patients in 13.3 times higher than those with normal cyclin E levels."	"Keyomarsi et al., 2002, N. Engl. J. Med."	N/A	ENST00000262643.3	N/A
CCNE1 Overexpression	CCNE1	Overexpression	Gastric Adenosquamous Carcinoma		Prognostic	Supports	B	Poor Outcome	chr19	29811898	29824308			Elevated levels of CCNE1 mRNA has been shown to be correlated with advanced stage gastric carcinoma.	"Donnellan et al., 1999, FASEB J."	N/A	ENST00000262643.3	N/A
CCNE1 Overexpression	CCNE1	Overexpression	Gastric Adenosquamous Carcinoma		Prognostic	Supports	B	Poor Outcome	chr19	29811898	29824308			Elevated levels of CCNE1 mRNA has been shown to be correlated with increased depth of tumor invasion in gastic carcinoma.	"Donnellan et al., 1999, FASEB J."	N/A	ENST00000262643.3	N/A
CCNE1 Amplification	CCNE1	Amplification	Ovarian Carcinoma		Prognostic	Supports	B	Poor Outcome	chr19	29811898	29824308			"In a retrospective study of 88 ovarian carcinomas, 18 had amplification of CCNE1. Those with amplification had worse overall and disease-free survival."	"Nakayama et al., 2010, Cancer"	Somatic	ENST00000262643.3	transcript_amplification
CCNE1 Amplification	CCNE1	Amplification	Estrogen-receptor Positive Breast Cancer	Palbociclib	Predictive	Supports	D	Resistance	chr19	29811898	29824308			"Preclinical study in breast cancer cell lines treated with CDK4/6 inhibitor palbociclib. Cell lines with acquired resistance to palbociclib were developed. Two palbociclib-resistant cell lines were derived through chronic exposure to 1 mol/L palbociclib during 3 to 4 months. Copy number profiling from exome sequencing of MCF-7 and MCF-7pR, confirmed relative amplification of CCNE1. Silencing of CCNE1 or CDK2 alone in MCF-7pR cells had no effect on cell-cycle arrest, but resulted in substantially increased cell-cycle arrest and reduction in cell growth in combination with palbociclib."	"Herrera-Abreu et al., 2016, Cancer Res."	N/A	ENST00000262643.3	transcript_amplification
CCNE1 Overexpression	CCNE1	Overexpression	Ovarian Cancer	CDK Inhibitor SNS-032	Predictive	Supports	D	Sensitivity/Response	chr19	29811898	29824308			Four ovarian cancer cell lines with elevated CCNE1 expression were 40x more sensitive to Cdk2 inhibitor SNS-032 than four cell lines without CCNE1 overexpression. SNS-032 greatly prolonged the survival of mice with CCNE1 overexpressing xenografts.	"Yang et al., 2015, Oncotarget"	N/A	ENST00000262643.3	N/A
CCNE1 Amplification	CCNE1	Amplification	Ovarian Serous Cystadenocarcinoma	"Dinaciclib,Akt Inhibitor MK2206"	Predictive	Supports	D	Sensitivity/Response	chr19	29811898	29824308			"A high throughput compound screen identified synergistic combinations in CCNE1 amplified high grade serous ovarian carcinoma, including dinaciclib and AKT inhibitors"	"Au-Yeung et al., 2016, Clin. Cancer Res."	Somatic	ENST00000262643.3	transcript_amplification
CEBPA Mutation	CEBPA	Mutation	Acute Myeloid Leukemia	Tretinoin	Predictive	Does Not Support	B	Sensitivity/Response	chr19	33299934	33302564			In a randomized trial of previously untreated younger (<60) patients with acute myeloid leukemia (excluding acute promyelocytic leukemia) and high-risk myelodysplastic syndrome CEBPA mutation status had no significant impact on patient response to ATRA (N=20) compared to randomized control (N=15).	"Burnett et al., 2010, Blood"	Somatic	ENST00000498907.2	"transcript_variant,loss_of_function_variant"
CEBPA Mutation	CEBPA	Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr19	33299934	33302564			"In a group of young (<60 years old) acute myeloid leukemia (exclude acute promyelocytic leukemia) and high-risk MDS patients, those with CEBPA mutations (35/423) showed marginally improved overall survival (36% vs 31%; P = .04) than those with wildtype CEBPA."	"Burnett et al., 2010, Blood"	Somatic	ENST00000498907.2	"transcript_variant,loss_of_function_variant"
CEBPA Mutation	CEBPA	Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr19	33299934	33302564			"In young patients (age 16-60) with previously untreated, cytogenetically normal acute myeloid leukemia, CEBPA mutation was significantly associated with complete remission in multivariate analysis (odds ratio, 1.33; 95% confidence interval [CI], 1.01 to 1.74). Multivariate analysis was performed on all patients  that were evaluated for a mutation in at least 1 gene (CEBPA, FLT3-ITD or NPM1) totaling 693/872 patients in the study. Only 509 patients in the study were evaluated for CEBPA, 67 of which had a mutation."	"Schlenk et al., 2008, N. Engl. J. Med."	Somatic	ENST00000498907.2	"transcript_variant,loss_of_function_variant"
CEBPA Mutation	CEBPA	Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr19	33299934	33302564			"Overall survival and remission duration were significantly longer (p=0.01 and p=0.05, respectively) in younger (16-60), cytogenetically normal acute myeloid leukemia patients with CEBPA mutations (21/236 patients)."	"Frhling et al., 2004, J. Clin. Oncol."	Somatic	ENST00000498907.2	"transcript_variant,loss_of_function_variant"
CEBPA Mutation	CEBPA	Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr19	33299934	33302564			"In children with acute myeloid leukemia, those with mutations in CEBPA had better overall and event-free survival and decreased cummulative incidence of relapse."	"Ho et al., 2009, Blood"	Somatic	ENST00000498907.2	"transcript_variant,loss_of_function_variant"
CEBPA Mutation	CEBPA	Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr19	33299934	33302564			"In a set of 315 pediatric patients with acute myeloid leukemia, 47 had mutations in CEBPA. Those with mutations had better overall survival than wild-type patients."	"Matsuo et al., 2014, Blood Cancer J"	Somatic	ENST00000498907.2	"transcript_variant,loss_of_function_variant"
CEBPA BIALLELIC INACTIVATION	CEBPA	BIALLELIC INACTIVATION	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr19	33299934	33302564			"In a study of 1,540 patients with Acute Myeloid Leukemia, 66 patients (4%) had a CEBPA (biallelic) mutation.  In the absence of gene fusion products, patients with biallelic CEBPA mutations showed the highest rate of survival (~78%) when compared to IDH2 (R172) mutations, NPM1(W288fs) mutations, chromatin-spliceosome mutations and TP53aneuploidy."	"Papaemmanuil et al., 2016, N. Engl. J. Med."	Somatic	ENST00000498907.2	loss_of_function_variant
CEBPA N-TERMINAL FRAME SHIFT	CEBPA	N-TERMINAL FRAME SHIFT	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr19	33302055	33302564			"Remission duration was significantly longer in younger (16-60), cytogenetically normal AML patients with CEBPA"	"Frhling et al., 2004, J. Clin. Oncol."	Somatic	ENST00000498907.2	"frameshift_truncation,dominant_negative_variant"
CEBPA N-TERMINAL FRAME SHIFT	CEBPA	N-TERMINAL FRAME SHIFT	Acute Myeloid Leukemia	OICR-9429	Predictive	Supports	D	Sensitivity/Response	chr19	33302055	33302564			"This preclinical study establishes that the p30 isoform of CEBPA expressed as a result of N-terminal truncating mutations preferentially interacts with WRD5, a component of the SET/MLL complex. Knockdown of WRD5 in 32D cells (mouse hematopoietic cell line) or transplanted primary mouse bone marrow expressing the p30 isoform restored myeloid differentiation in these cells. OICR-9429, a small molecule inhibitor of WRD5, and anti-WRD5 siRNAs selectively inhibited colony formation of mouse fetal liver cells homozygous for N-terminal CEBPA mutations but not wildtype colony formation. Finally, OICR-9429 reduced viability of primary human AML blasts harboring N-terminal domain CEBPA mutations in culture but not AML blasts with other mutations. Taken together, WRD5 inhibition is a potential therapeutic method for patients harboring N-terminal CEBPA mutations."	"Grebien et al., 2015, Nat. Chem. Biol."	Somatic	ENST00000498907.2	"frameshift_truncation,dominant_negative_variant"
AKT2 EXPRESSION	AKT2	EXPRESSION	Breast Cancer	Trastuzumab	Predictive	Supports	B	Sensitivity/Response	chr19	40230317	40285395			"In HER2+ metastatic breast cancer treated with trastuzumab (n = 74 patients), the expression of AKT2 and pAkt-Thr308 and/or pAkt-Ser473 localized in nucleus+cytoplasm was associated with an improved time to progression (TTP) and overall survival (OS) compared to AKT2 negative tumors as measured by immunohistochemistry."	"Grell et al., 2012, Int. J. Oncol."	N/A	ENST00000392038.2	N/A
AKT2 Amplification	AKT2	Amplification	Lung Adenocarcinoma	"Everolimus,Vandetanib"	Predictive	Supports	C	Sensitivity/Response	chr19	40230317	40285395			"Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion of KIF5B and RET, as well as an AKT2 gene amplification. The patient was enrolled in a clinical trial with vandetanib and everolimus (NCT01582191) with everolimus used to enhance brain accumulation of vandetanib. After two cycles of therapy a repeat MRI brain showed a decrease in the intracranial disease burden and PET/CT showed systemic response as well."	"Subbiah et al., 2015, Lung Cancer"	N/A	ENST00000392038.2	transcript_amplification
AXL EXPRESSION	AXL	EXPRESSION	Esophagus Squamous Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr19	41219203	41261766			"Immunohistochemical analysis of tumors from 116 esophageal squamous cell carcinoma found that expression of AXL was associated with increased progression of the tumor (P < 0.0001), increased risk of death (HR = 2.09 ; P = 0.028), and increased risk of distant metastasis (OR = 3.96 ; P = 0.029)."	"Hsieh et al., 2016, Oncotarget"	N/A	ENST00000301178.4	N/A
CBLC EXPRESSION	CBLC	EXPRESSION	Cancer	Olaparib	Predictive	Supports	D	Resistance	chr19	44777869	44800634			"The E3 ubiquitin ligase, CBLC, was identified as a candidate biomarker for olaparib sensitivity in a siRNA screen and further validated in-vitro. In other words, expression of CBLC is predicted to confer resistance to olaparib."	"Frankum et al., 2015, Oncotarget"	N/A	ENST00000270279.3	N/A
ERCC1 Expression	ERCC1	Expression	Bladder Carcinoma	Cisplatin	Predictive	Does Not Support	B	Sensitivity/Response	chr19	45413434	45423566			Immunhistochemistry of ERCC1 expression in 432 patients revealed no correlation to response to cisplatin based chemotherapy. In-vitro studies also did not show any effects.	"Klatte et al., 2015, J. Urol."	N/A	ENST00000013807.5	N/A
ERCC1 Expression	ERCC1	Expression	Bladder Carcinoma		Prognostic	Supports	B	Better Outcome	chr19	45413434	45423566			"ERCC1 expression as evaluated by IHC in 432 patients was associated with better disease-free survival (HR 0.70, p = 0.028) and cancer specific survival (HR 0.70, p = 0.032) on multivariable analysis."	"Klatte et al., 2015, J. Urol."	N/A	ENST00000013807.5	N/A
ERCC1 Underexpression	ERCC1	Underexpression	Lung Non-small Cell Carcinoma	"Gemcitabine,Carboplatin"	Predictive	Supports	B	Sensitivity/Response	chr19	45413434	45423566			"As part of a randomized phase III trial (USO-03012) in advanced NSCLC of gemcitabine vs. combination gemcitabine and carboplatin, protein expression levels for RRM1 (n=69) and ERCC1 (n=65) were evaluated using fluorescence-based IHC. RRM1 levels were significantly inversely correlated with response (r = ?.41; P = .001, n=58), as were ERCC1 levels (r = ?.39; P = .003, n=55). RRM1 and ERCC1 levels were correlated with each other (r = 0.36; P = .003, n=65). There was no significant interaction with treatment arm (P = .64 for RRM1; P = .79 for ERCC1). The authors conclude that RRM1 and ERCC1 expression levels are predictive of response to gemcitabine, and gemcitabine and carboplatin."	"Reynolds et al., 2009, J Clin Oncol"	N/A	ENST00000013807.5	N/A
ERCC1 Underexpression	ERCC1	Underexpression	Ovary Epithelial Cancer	Platinum Compound	Predictive	Supports	B	Sensitivity/Response	chr19	45413434	45423566			"Ovarian epithelial tumours (n=235) were used to create TMAs and IHC results were scored for ERCC1 (n=114 low, n=121 high). For platinum sensitive patients (n=250 in supplementary table, but not all have ERCC1 levels available), low ERCC1 was associated with better PFS (p = 0.034, HR 1.9, 95% CI 1.1-3.6). For platinum resistant patients (n=26 in supplementary table, but not all have ERCC1 levels available), there was no significant association (p = 0.550, HR 0.5, 95% CI 0.1-4.3)."	"Mesquita et al., 2019, Gynecol Oncol"	N/A	ENST00000013807.5	N/A
RRM2 OVEREXPRESSION	RRM2	OVEREXPRESSION	Pancreatic Cancer	Gemcitabine	Predictive	Supports	D	Resistance	chr2	10122328	10131418			The mRNA expression level of RRM2 was analyzed by RT-PCR in 3 human pancreatic cancer cell lines  cultured in incrementally increased concentrations of gemcitabine. Expression levels of RRM2 progressively increased during the development of gemcitabine resistance.	"Nakano et al., 2007, Br. J. Cancer"	N/A	ENST00000360566.2	N/A
MYCN Amplification	MYCN	Amplification	Neuroblastoma	FACT Complex-targeting Curaxin CBL0137	Predictive	Supports	D	Sensitivity/Response	chr2	15940564	15947007			"The drug CBL0137 (a drug that interacts with SSRP1 aka FACT) exhibited a synergistic effect with standard chemotherapy (cyclophosphamide, etoposide, cisplatin, vincristine, etc.) by blocking repair of DNA damage caused by genotoxic drugs, thus creating a synthetic lethal environment in MYCN-amplified neuroblastoma cells. High MYCN expression was found to sensitize neuroblastoma cells to CBL0137."	"Carter et al., 2015, Sci Transl Med"	Somatic	ENST00000281043.3	transcript_amplification
MYCN Amplification	MYCN	Amplification	Neuroblastoma		Prognostic	Supports	A	Poor Outcome	chr2	15940564	15947007			"In a cohort of 1596 diagnostic tumor samples taken from patients enrolled in the Children's oncology group (COG) neuroblastoma biology protocol ANBL00B1, 1579 samples were annotated with MYCN amplification status. 1239 (78%) were not MYCN amplified, and 349 (22%) were MYCN amplified. Five year event free survival was 74 +/- 1.6 months in non MYCN amplified cases and 39 +/- 4.1 months in amplified cases. Differences were significant with p<0.0001. Five year overall survival was 83 +/- 1.4 months and non MYCN amplified cases and 46 +/- 4.2 months in amplified cases, with p<0.0001, indicating poor prognosis for MYCN amplified cases."	"Bresler et al., 2014, Cancer Cell"	Somatic	ENST00000281043.3	transcript_amplification
MYCN Amplification	MYCN	Amplification	Neuroblastoma	"JQ1,Panobinostat"	Predictive	Supports	D	Sensitivity/Response	chr2	15940564	15947007			"JQ1 and panobinostat synergistically reduced LIN28B gene and N-Myc protein expression, and synergistically induced growth inhibition and apoptosis in neuroblastoma cells, but not normal nonmalignant cells in vitro In neuroblastoma-bearing mice, JQ1 and panobinostat synergistically and considerably reduced N-Myc protein expression in tumor tissues and blocked tumor progression."	"Shahbazi et al., 2016, Clin. Cancer Res."	Somatic	ENST00000281043.3	transcript_amplification
DNMT3A Mutation	DNMT3A	Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr2	25232976	25342590			Young AML patients (415 patients; <60 years old) with any DNMT3A mutation (n=96) have shorter overall survival and relapse-free survival than patients with wildtype DNMT3A.	"Ribeiro et al., 2012, Blood"	Somatic	ENST00000264709.3	transcript_variant
DNMT3A Mutation	DNMT3A	Mutation	T-cell Acute Lymphoblastic Leukemia		Prognostic	Supports	B	Poor Outcome	chr2	25232976	25342590			"In adult patients with early (n = 30), cortical (n = 30), mature (n = 3) or unknown (n = 8) T-cell acute lymphoblastic leukemia, those with mutations in DNMT3A (n=12) had shorter overall survival than wild-type patients (n=59; p=0.011). This was also true for the subset of patients with early T-ALL DNMT3A-mutated (n = 8) compared to wild-type patients (n = 22; p=0.005)."	"Grossmann et al., 2013, Genes Chromosomes Cancer"	Somatic	ENST00000264709.3	transcript_variant
DNMT3A Mutation	DNMT3A	Mutation	Myelodysplastic Syndrome		Prognostic	Supports	B	Poor Outcome	chr2	25232976	25342590			"12/150 patients with de novo myelodysplastic syndrome screened for DNMT3A mutations (bone marrow and paired normal skin) had heterozygous mutations with predicted translational consequences. 1 patient was identified with 2 nonsynonymous coding mutations. R882 mutations accounted for 4/13 reported mutations, P904L for 2/13 mutations and the remaining had not been previously reported at the time of this report. Overall and event-free survival were worse for DNMT3A mutant patients although transplantation status was not considered (log-rank p=0.005 and p=0.009). Transformation to AML was increased for mutant 7/12 (58%) versus wildtype 39/138 (28%) patients (p=0.007). The authors note larger cohorts will be required to confirm these results."	"Walter et al., 2011, Leukemia"	Somatic	ENST00000264709.3	transcript_variant
DNMT3A Mutation	DNMT3A	Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr2	25232976	25342590			"In AML patients aged <60years, presence of a DNMT3A mutation associated with inferior CR rate (HR, 0.54; P=.05) and shorter OS (HR, 1.84; P<.001) in multivariate analyses. Mutated DNMT3A associated with shorter RFS (HR 1.38; P=.034) irrespective of patient age."	"Metzeler et al., 2016, Blood"	Somatic	ENST00000264709.3	transcript_variant
DNMT3A Mutation	DNMT3A	Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr2	25232976	25342590			"DNMT3A mutations associate with adverse overall survival in acute myeloid leukemia patients if they occur in the context of mutated NPM1 and  FLT3-ITD (NPM1-FLT3ITD-DNMT3A phenotype), and in the context of IDH2 codon R140 mutations."	"Papaemmanuil et al., 2016, N. Engl. J. Med."	Somatic	ENST00000264709.3	transcript_variant
DNMT3A Mutation	DNMT3A	Mutation	Acute Myeloid Leukemia	Decitabine	Predictive	Supports	B	Sensitivity/Response	chr2	25232976	25342590			"Among 46 AML patients treated with decitabine, the response rate was 75% (6/8) among DNMT3A mutated and 34% (13/38) among DNMT3A wild-type patients (P=.008)"	"Metzeler et al., 2012, Leukemia"	Somatic	ENST00000264709.3	transcript_variant
DNMT3A Mutation	DNMT3A	Mutation	Cancer	"Nivolumab,Pembrolizumab,Atezolizumab"	Predictive	Supports	B	Resistance	chr2	25232976	25342590			"A subset of patients receiving PD1/PD-L1 inhibition appear to be ""hyper-progressors,"" with a greatly accelerated rate of tumor growth and clinical deterioration compared to pre-therapy. The current study investigated potential genomic markers associated with ""hyper-progression"". Consecutive stage IV cancer patients who received immunotherapies (CTLA-4, PD-1/PD-L1 inhibitors or other [investigational] agents) and had their tumor evaluated by next-generation sequencing Amongst 155 patients, TTF (time to treatment failure) <2 months was seen in 4/5 individuals harbouring DNMT3A alteration."	"Kato et al., 2017, Clin. Cancer Res."	Somatic	ENST00000264709.3	transcript_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Diagnostic	Supports	B	Positive	chr2	25234372	25234374			DNMT3A R882 mutations occur most often in de novo AML patients with intermediate risk cytogenetics (39/194 intermediate risk patients vs 0/89 low and high risk).	"LaRochelle et al., 2011, Oncotarget"	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Diagnostic	Supports	B	Positive	chr2	25234372	25234374			"Young AML patients (<60 years old) with DNMT3A mutations (60% of which were R882) were older in age, had higher white blood cell counts and had higher platelet counts than patients wildtype for DNMT3A."	"Ribeiro et al., 2012, Blood"	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia	Daunorubicin	Predictive	Does Not Support	B	Resistance	chr2	25234372	25234374			Daunorubicin treatment resulted in similar overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation.	"LaRochelle et al., 2011, Oncotarget"	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia	Idarubicin	Predictive	Supports	B	Sensitivity/Response	chr2	25234372	25234374			Idarubicin increases the overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation.	"LaRochelle et al., 2011, Oncotarget"	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	N/A	chr2	25234372	25234374			There is no difference in the complete remission rate of de novo AML patients with DNMT3A mutation compared to those who are wild type for DNMT3A.	"LaRochelle et al., 2011, Oncotarget"	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr2	25234372	25234374			De novo AML patients with DNMT3A D882 mutation showed worse survival (event-free and overall) outcome than those without DNMT3A mutation.	"Ley et al., 2010, N. Engl. J. Med."	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Diagnostic	Supports	B	Positive	chr2	25234372	25234374			"DNMT3A R882 mutations were associated with older age, higher white blood cell count, and FAB M4 and M5 subtypes compared to wildtype DNMT3A in a cohort of cytogenetically normal AML patients."	"El Ghannam et al., 2014, Blood Cells Mol Dis"	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	N/A	chr2	25234372	25234374			"In a large cohort of AML patients (mean = 48 years), DNMT3A mutation (64.5% of which were R882) had no prognostic value on overall, relapse free and event free survival."	"Gaidzik et al., 2013, Blood"	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	Poor Outcome	chr2	25234372	25234374			"In a large cohort (n=1770) of AML patients (18-60 years old), DNMT3A mutation status (65.4% of which were R882) had no prognostic value for overall, relapse free and event free survival. This was true for cytogenetically normal AML and the entire cohort."	"Gaidzik et al., 2013, Blood"	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	N/A	chr2	25234372	25234374			"In young AML patients (<60 years old), DNMT3A mutation status (60% of which were R882) was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD."	"Ribeiro et al., 2012, Blood"	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr2	25234372	25234374			"In a large cohort of young AML patients (18-60 years old), DNMT3A R882 mutations were associated with reduced relapse free survival in the entire cohort as well as the subset of patients with cytogenetically normal AML."	"Gaidzik et al., 2013, Blood"	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr2	25234372	25234374			AML patients with DNMT3A mutations (59% of which were R882) showed worse survival (event-free and overall) outcome than those without DNMT3A mutation.	"Ley et al., 2010, N. Engl. J. Med."	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr2	25234372	25234374			"DNMT3A R882 mutation was associated with reduced relapse free and overall survival in ELN-unfavorable, cytogenetically normal AMLs."	"Gaidzik et al., 2013, Blood"	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr2	25234372	25234374			"In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations (including R882) were associated with worse overall survival compared to those without DNMT3A mutation."	"Ley et al., 2010, N. Engl. J. Med."	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr2	25234372	25234374			"In cytogenetically normal AML patients, DNMT3A R882 mutations are associated with lower overall and disease free survival as compared to patients with wild type DNMT3A."	"El Ghannam et al., 2014, Blood Cells Mol Dis"	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr2	25234372	25234374			"In older cytogenetically normal AML patients (>59 years), DNMT3A R882 mutation is prognostic for shorter disease free survival and overall survival compared to patients without the mutation."	"Marcucci et al., 2012, J. Clin. Oncol."	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr2	25234372	25234374			"In young AML patients (<60 years old), DNMT3A mutations were associated with significantly reduced overall survival and relapse free survival in patients wildtype for NPM1 and FLT3."	"Ribeiro et al., 2012, Blood"	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr2	25234372	25234374			"In younger cytogenetically normal AML patients (<60 years), DNMT3A mutations other than R882 are prognostic for shorter disease free survival and overall survival compared to patients without the mutation."	"Marcucci et al., 2012, J. Clin. Oncol."	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Diagnostic	Supports	B	Negative	chr2	25234372	25234374			Therapy-related AML was less common in patients with DNMT3A mutations (64.5% of which were R882) than patients wildtype for DNMT3A in a large cohort of younger (18-60) AML patients.	"Gaidzik et al., 2013, Blood"	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Diagnostic	Supports	B	Positive	chr2	25234372	25234374			"DNMT3A mutations (59% of which were R882) were associated with an intermediate risk cytogenetic profile, normal cytogenetic profile, and M4 and M5 FAB subtypes."	"Ley et al., 2010, N. Engl. J. Med."	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Diagnostic	Supports	B	Positive	chr2	25234372	25234374			DNMT3A mutations (59% of which were R882) were associated with intermediate risk cytogenetics (including normal karyotype).	"Ley et al., 2010, N. Engl. J. Med."	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Diagnostic	Supports	B	Positive	chr2	25234372	25234374			"DNMT3A mutations (64.5% R882) were associated with older age, higher white blood cell count and cytogenetically normal AML in a large cohort of younger (18-60) AML patients."	"Gaidzik et al., 2013, Blood"	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Diagnostic	Supports	B	Positive	chr2	25234372	25234374			DNMT3A R882 mutations were associated with cytogenetically normal AML in a large cohort of younger (18-60) AML patients.	"Gaidzik et al., 2013, Blood"	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	N/A	chr2	25234372	25234374			Complete remission rates did not differ between patients with wildtype or mutant DNMT3A (62% of which affected R882) and cytogenetically normal AML.	"Marcucci et al., 2012, J. Clin. Oncol."	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr2	25234372	25234374			DNMT3A mutations were associated with achievement of complete remission in a large cohort of younger (18-60) AML patients.	"Gaidzik et al., 2013, Blood"	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr2	25234372	25234374			Complete remission rate was not different between young AML patients (<60 years old) with or without DNMT3A mutations (60% of which were R882).	"Ribeiro et al., 2012, Blood"	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr2	25234372	25234374			DNMT3A mutations (62% of which were R882) were associated with reduced disease-free survival in patients with cytogenetically normal AML.	"Marcucci et al., 2012, J. Clin. Oncol."	Somatic	ENST00000264709.3	missense_variant
DNMT3A R882	DNMT3A	R882	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr2	25234372	25234374			Young AML patients (415 patients; <60 years old) with DNMT3A R882 mutations (n=58) have shorter overall and relapse-free survival than patients with wildtype DNMT3A.	"Ribeiro et al., 2012, Blood"	Somatic	ENST00000264709.3	missense_variant
ALK EML4::ALK	ALK	EML4::ALK	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr2	29192774	29223528			A 28 year-old patient with non-small cell lung cancer that failed conventional therapy was found to harbor the EML4-ALK (E13;A20) fusion using reverse transcription PCR. Treatment with 250mg crizotinib twice daily resulted in rapid improvement of symptoms and disease control for 5 months.	"Choi et al., 2010, N. Engl. J. Med."	Somatic	ENST00000318522.5	transcript_fusion
ALK Fusion	ALK	Fusion	Lung Non-small Cell Carcinoma	Pemetrexed	Predictive	Supports	B	Sensitivity/Response	chr2	29192774	29223528			"Among 95 patients with NSCLC in this study, 15 had an ALK translocation. ORR of these patients compared to EGFR mutated or wild-type tumors was superior (46.7 versus 4.7 versus 16.2%, p = 0.001). TYMS expression was lower in ALK-positive cells."	"Lee et al., 2011, J Thorac Oncol"	Somatic	ENST00000389048.3	transcript_fusion
ALK EML4::ALK	ALK	EML4::ALK	Lung Acinar Adenocarcinoma	Erlotinib	Predictive	Supports	C	Resistance	chr2	29192774	29223528			"A 39-year-old man presented was observed to have lung acinar adenocarcinoma. Treatment with chemotherapy produced no remarkable response. A EGFR L858R point mutation was observed; the patient was therefore treated with erlotinib, but the disease progressed after 30 days. A second biopsy identified a EML4-ALK fusion, which may explain the therapeutic resistance."	"Tanaka et al., 2012, BMC Cancer"	Somatic	ENST00000318522.5	transcript_fusion
ALK Fusion	ALK	Fusion	Lung Non-small Cell Carcinoma	Ceritinib	Predictive	Supports	B	Sensitivity/Response	chr2	29192774	29223528			"Updated results from ASCEND-1 trial assessing safety and activity of ceritinib in ALK rearranged locally advanced or metastatic NSCLC. 255 patients were enrolled and received at least one dose of ceritinib 750 mg/day, of whom 246 had ALK-rearranged NSCLC (Median follow-up: 11.1 months). Overall response rate was 72% [95% CI 61-82] of 83 ALK inhibitor-naive patients and 56% [49-64] of 163 ALK inhibitor-pretreated patients. Median duration of response was 170 months (95% CI 11.3-non-estimable [NE]) in ALK inhibitor-naive patients and 8.3 months (6.8-9.7) in ALK inhibitor-pretreated patients. Median progression-free survival was 18.4 months (95% CI 11.1-NE) in ALK inhibitor-naive patients and 6.9 months (5.6-8.7) in ALK inhibitor-pretreated patients. Brain metastases control was reported in 79% [95% CI 54-94] of 19 ALK inhibitor-naive patients and in 65% [54-76] of 75 ALK inhibitor-pretreated patients."	"Kim et al., 2016, Lancet Oncol."	Somatic	ENST00000389048.3	transcript_fusion
ALK Fusion	ALK	Fusion	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	A	Sensitivity/Response	chr2	29192774	29223528			"In the Phase I study PROFILE 1001 (NCT00585195), a recommended crizotinib dose of 250 mg twice daily for 28 day cycles was established. Among 1,500 advanced NSCLC patients who were screened for ALK-rearrangement using a break-apart FISH assay, 82 patients were eligible for crizotinib treatment. Overall response rate was 57%, with 46 partial responses and one complete response. Since crizotinib inhibits MET, 33 patients with available tissue were screened for MET amplification and were found negative, further indicating that patient response was due to ALK inhibition. 31 patients were tested via RT-PCR for known EML4-ALK fusions, and 13 were shown to have EML4-ALK variant 1, four cases had variant 3, and one instance of variants 2, 3b and 5 were seen. 9 were unidentified, suggesting other fusion partners in these instances."	"Kwak et al., 2010, N. Engl. J. Med."	Somatic	ENST00000389048.3	transcript_fusion
ALK EML4::ALK	ALK	EML4::ALK	Lung Non-small Cell Carcinoma	WHI-P154	Predictive	Supports	D	Sensitivity/Response	chr2	29192774	29223528			"A retroviral cDNA expression library was constructed using a lung adenocarcinoma specimen from a 67 year old NSCLC patient, and transfected into mouse 3T3 fibroblasts which were assessed for transformed foci.  Analysis of clones from one transformed focus yielded a novel fusion. This fusion generated a protein with N-terminal consisting of EML4 exons 1-13 and C-terminal consisting of ALK exons 20-29, which comprise the intracellular kinase domain of ALK. In subsequent experiments using EML4-ALK or altered versions, the transforming potential of EML4-ALK was found to be dependent on a functional ALK kinase activity as well as the EML4 basic domain, which was shown to have an important role in EML4-ALK dimer formation.  BA/F3 cells expressing EML4-ALK were able to grow independently of IL3 addition, but addition of ALK inhibitor WHI-P154 induced cell death and inhibited tyrosine phosphorylation of EML4-ALK. These results indicated that EML4-ALK may be a driver mutation in NSCLC,  and a target for ALK inhibitor treatment."	"Soda et al., 2007, Nature"	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK e20-e20	ALK	EML4::ALK e20-e20	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr2	29192774	29223528			"In the PROFILE 1001 study, from 31 NSCLC tumors positive for ALK fusions with sufficient material for RT-PCR aided exon breakpoint identification, 1 case of EML4-ALK variant 2 (EML4 exon 20 fused to ALK exon 20) was found. This patient had adenocarcinoma and a 9 pack year smoking history. Crizotinib treatment duration was over 16 weeks. The patient had multiple lines of prior treatment and showed a partial response to first-time crizotinib treatment. Overall, in the 82 ALK positive patients treated in the study, 46 had partial responses (including this patient) and 1 had a complete response for an overall response rate of 57%."	"Kwak et al., 2010, N. Engl. J. Med."	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK e2-e20	ALK	EML4::ALK e2-e20	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	E	Sensitivity/Response	chr2	29192774	29223528			"Multiplex RT-PCR to detect in-frame fusions of EML4 to ALK was performed on total RNA from 253 lung adenocarcinomas, and 9 samples were found to contain such fusions, one of which was a novel fusion containing EML4 exon 2 and exon 20 of ALK. This was called variant 5. Two versions of this variant were seen: 5a consisted of EML4 exon 2 fused to ALK exon 20 while 5b contained a 117bp intronic ALK region between the two exons. Genomic PCR showed that EML4-ALK variant 5 tumor cells contained a single EML4-ALK fusion, suggesting 5a and 5b arise from alternate splicing.  5a and 5b showed in-vitro kinase activity and transformed 3T3 cells in cell culture. 5a and 5b transformed 3T3 cells formed tumors when injected in 8/8 nude mice, but 3T3 transformed with ALK alone did not.  These results suggest that EML4-ALK variant 5 is a driver mutation in lung adenocarcinoma targetable by ALK inhibitors like crizotinib."	"Takeuchi et al., 2008, Clin. Cancer Res."	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK e6-e20	ALK	EML4::ALK e6-e20	Lung Non-small Cell Carcinoma	"2,4-pyrimidinediamine"	Predictive	Supports	D	Sensitivity/Response	chr2	29192774	29223528			"In a cohort of 75 NSCLC patients that had tested positive for 3 EML4-ALK rearrangements, two individuals were identified via RT-PCR with a novel EML4-ALK translocation involving the first 6 exons of EML4 fused to the kinase domain of ALK. Genomic PCR resolved a single breakpoint, but 2 variants of the fusion were observed in cells. Variant 3a consisted of fusion at EML4 exon 6 and ALK exon 20, while variant 3b fused a 33 bp intronic EML4 region between EML4 exon 6 and ALK exon 20.  3a and 3b showed strong in-vitro kinase activity, transformed mouse 3T3 cells, and 3b-transformed 3T3 cells formed tumors in 8/8 nude mice.  The ALK inhibitor 2,4-pyrimidinediamine inhibited growth of the 3a/b containing NCI-H2228 NSCLC cell line.  The results indicate that 3a/b is a targetable driver-mutation as other EML4-ALK variants."	"Choi et al., 2008, Cancer Res."	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK e6-e20	ALK	EML4::ALK e6-e20	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr2	29192774	29223528			"In a set of 31 patients with NSCLC, RT-PCR was performed to test for known EML4-ALK variants.  Five patients tested positive for the 3a/3b EML4-ALK variant.  Of these, 4 had partial response (PR), and one had disease progression (DP), and this was the only DP in the group of 31.  In contrast, of the 13 testing positive for EML4-ALK variant 1, 12 showed PR, and 1 showed stable disease.  These results potentially mirror findings in the H2228 3a/3b containing NSCLC cell line where some literature indicates it does respond as strongly to ALK inhibition as other EML4-ALK NSCLC cell lines."	"Kwak et al., 2010, N. Engl. J. Med."	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK e6-e20	ALK	EML4::ALK e6-e20	Lung Non-small Cell Carcinoma	TAE684	Predictive	Supports	D	Sensitivity/Response	chr2	29192774	29223528			"In a panel of 602 cancer cell lines, 3/134 NSCLC cell lines showed <0.5% cell viability following treatment with the ALK inhibitor TAE684. Of these, NCI-H2228 harbored EML4-ALK variant 3a/b (EML4 exon 6 and ALK exon 20). TAE684 inhibited Akt and Erk1/2 phosphorylation in H2228 cells and appeared to induce a cytostatic response."	"McDermott et al., 2008, Cancer Res."	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK e6-e20	ALK	EML4::ALK e6-e20	Lung Non-small Cell Carcinoma	TAE684	Predictive	Does Not Support	D	Sensitivity/Response	chr2	29192774	29223528			"Exon-array and RT-PCR was used to screen a panel of 83 NSCLC cell lines for EML4-ALK variants. The cell lines NCI-H3122 (containing EML4-ALK variant 1) and NCI-H2228 (containing the EML4 exon 6 and ALK exon 20 fusion-variant 3a/3b) were identified. TAE684 (0.1uM) appreciably inhibited growth as well as Akt and Erk1/2 phosphorylation in variant 1 containing H3122 cells. However, incomplete inhibition in 3a/3b containing H2228 cells was observed. H2228 growth inhibition by TAE684 was more similar to NSCLC cell lines harboring KRAS and EGFR mutations."	"Koivunen et al., 2008, Clin. Cancer Res."	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK e20-e20	ALK	EML4::ALK e20-e20	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	D	Sensitivity/Response	chr2	29192774	29223528			"EML4-ALK variants v1 (E13;A20), v2 (E20;A20), v3a (E6;A20) and v3b (E6ins33;A20) were expressed in Ba/F3 cells using retrovirus.  While all constructs rendered Ba/F3 cells IL3-independant, marked differences in sensitivity to ALK inhibitors TAE684 and crizotinib were observed, where v2 was most sensitized to growth inhibition and v3a the least, with v1 and v3b intermediate.  While phospho-ALK western blots indicated that the ALK inhibitors acted similarly on both v2 and v3a EML4-ALK variants, blots of cyclohexamide-treated cells showed that v2 had a shorter half-life than 3a in the transduced cells, potentially explaining increased v2 sensitivity.  Assays with a panel of mutated EML4-ALK variants of varied length suggested that longer EML4-ALK variants are less stable in cells, although this tendency was not observed across other types of ALK fusion."	"Heuckmann et al., 2012, Clin. Cancer Res."	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK e6-e20	ALK	EML4::ALK e6-e20	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Does Not Support	D	Sensitivity/Response	chr2	29192774	29223528			"Ba/F3 cells transduced with EML4-ALK variants v1 (E13;A20), v2 (E20;A20), v3a (E6;A20) and v3b (E6ins33;A20) showed differential sensitivity to both crizotinib and TAE684, with variant 3a (E6;A20) being the least sensitive. The authors suggest that the type/structure of ALK fusion may have some impact on patient outcome in targeted therapy."	"Heuckmann et al., 2012, Clin. Cancer Res."	Somatic	ENST00000318522.5	transcript_fusion
ALK Fusion	ALK	Fusion	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	A	Sensitivity/Response	chr2	29192774	29223528			"This two arm Phase III study named PROFILE 1007 (NCT00932893) was performed to assess crizotinib vs. established chemotherapy in non-small cell lung cancer patients positive for ALK rearrangement (assessed by break-apart FISH) with locally advanced or metastatic disease. 347 patients with disease progression after one round of platinum-based chemotherapy were randomized to receive crizotinib (N=173) or chemotherapy (N=174) consisting of pemetrexed in pemetrexed-naive patients and docetaxel for patients previously treated with pemetrexed. The primary endpoint - progression free survival (PFS) - was found to be significantly better for patients treated with crizotinib (median 7.7 months) than with chemotherapy (median 3.0 months) (hazard ratio for disease progression or death with crizotinib, 0.49; 95% CI, 0.37 to 0.64; P<0.001). Response rates were 65% for crizotinib treatment and 20% for chemotherapy (P<0.001). Improvements in quality of life were also reported."	"Shaw et al., 2013, N. Engl. J. Med."	Somatic	ENST00000389048.3	transcript_fusion
ALK Fusion	ALK	Fusion	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	A	Sensitivity/Response	chr2	29192774	29223528			"This phase 3 trial named PROFILE 1014 (NCT01154140) compared crizotinib to established chemotherapy in first-line treatment for this disease. The study consisted of 343 patients with advanced or metastatic NSCLC that tested positive for ALK rearrangement via break-apart FISH assay, and had no prior systemic treatment. Patients were assigned in a 1:1 ratio to crizotinib (N=172) or pemetrexed with cisplatin or carboplatin (N=171). Progression free survival was significantly longer with crizotinib treatment than chemotherapy (10.9 vs. 7.0 months; hazard ratio for progression or death with crizotinib, 0.45; 95% CI, 0.35 to 0.60;P<0.001), and objective response rate was higher with crizotinib treatment than chemotherapy (75% vs. 45%, P<0.001). Improvement in quality of life was also reported."	"Solomon et al., 2014, N. Engl. J. Med."	Somatic	ENST00000389048.3	transcript_fusion
ALK Fusion	ALK	Fusion	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	B	Sensitivity/Response	chr2	29192774	29223528			"This retrospective study of patients from the PROFILE 1001 and 1005 studies of crizotinib in advanced ALK-rearranged NSCLC assessed the potential benefit of crizotinib beyond progressive disease (CBPD), defined as continuation of crizotinib for 3 or more weeks after disease progression on crizotinib. 194 patients who had developed PD by data cutoff were studied, where 120 received crizotinib for a median duration of 19.4 weeks and 74 discontinued crizotinib after PD. No gross imbalances in clinicopathologic features of the two groups were evident.  Significantly longer overall survival was observed in the crizotinib continuing group from time of PD (16.4 vs. 3.9 months; hazard ratio 0.27, 95% CI: 0.17?.42; P < 0.0001), and from the time of initial crizotinib (29.6 vs. 10.8 months; HR 0.30, 95% CI: 0.19?.46; P < 0.0001)."	"Ou et al., 2014, Ann. Oncol."	Somatic	ENST00000389048.3	transcript_fusion
ALK Fusion	ALK	Fusion	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	B	Sensitivity/Response	chr2	29192774	29223528			"This prospective Phase III study named Profile 1014 on NSCLC ALK-rearranged patients assessed intracranial disease control rate (IC-DCR) in the subset of patients entering the study with preexisting treated brain metastasis (tBM). IC-DCR was significantly improved in the tBM group given crizotinib (N=39) over chemotherapy (pemetrexed + cisplatin or carboplatin; N=40) at 12 weeks (85% vs. 45%, P<0.001), and at 24 weeks (56% vs. 25%, P=0.006). Progression free survival was also significantly improved with crizotinib over chemotherapy in the tBM subgroup (9.0 vs. 4.0 months; HR 0.40; P<0.001), where in the intent to treat population it was 10.9 vs. 7.0 months (HR 0.45; P<0.001), indicating that the difficult to treat BM population obtained benefit from crizotinib at both the brain and systemic level."	"Solomon et al., 2016, J. Clin. Oncol."	Somatic	ENST00000389048.3	transcript_fusion
ALK Fusion	ALK	Fusion	Lung Non-small Cell Carcinoma	Retaspimycin Hydrochloride	Predictive	Supports	C	Sensitivity/Response	chr2	29192774	29223528			"In this study, heavily pretreated advanced NSCLC patients with various molecular tumor makeup were treated with Hsp90 inhibitor IPI-504 to assess overall response rate. The study did not reach the targeted endpoint of 20% ORR. However, of 3/12 patients found to be ALK-rearranged via break apart FISH assay, 2 showed a partial response and the third stable disease, which was durable for 7.2 months. The authors note that the break apart FISH assay used to determine ALK-rearrangement status does not determine the identity of the ALK fusion partner and the promising results shown here may be dependent on the nature of the ALK fusion partner."	"Sequist et al., 2010, J. Clin. Oncol."	Somatic	ENST00000389048.3	transcript_fusion
ALK EML4::ALK	ALK	EML4::ALK	Lung Non-small Cell Carcinoma	"Crizotinib,Retaspimycin Hydrochloride"	Predictive	Supports	D	Sensitivity/Response	chr2	29192774	29223528			"In preclinical work using H3122 NSCLC cells which contain the EML4-ALK variant 1, administration of the Hsp90 inhibitor IPI-504 caused marked decrease of EML4-ALK protein levels at concentrations lower than those used to knock down protein levels of drivers such as HER2 or EGFR in other cell lines, making it the most sensitive Hsp90 client protein the authors had encountered.  IPI-504 treatment caused regression of H3122 tumors in nude mice, whereas Hsp90 inhibitors usually only cause growth inhibition in these models.  Combined treatment of these mice with IPI-504 and crizotinib caused an even stronger tumor regression."	"Normant et al., 2011, Oncogene"	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK e20-e20	ALK	EML4::ALK e20-e20	Lung Non-small Cell Carcinoma	"Alvespimycin,Crizotinib"	Predictive	Supports	D	Sensitivity/Response	chr2	29192774	29223528			"EML4-ALK fusions occur in 2-7% of lung adenocarcinomas. Transduction of Ba/F3 cells with EML4-ALK variant 2 (EML4 exon 20 fused to ALK exon 20) caused the cells to grow independently of IL3 addition.  EML4-ALK may be a client protein of Hsp90. Addition of Hsp90 inhibitor 17-DMAG to the EML4-ALK variant 2 cells induced cell death which was rescued at lower 17-DMAG concentrations by IL3 addition. This result suggests that 17-DMAG specifically  targeted the EML4-ALK driver in these cells. Finally, 17-DMAG and crizotinib showed a synergistic effect in killing EML4-ALK variant 2 cells."	"Heuckmann et al., 2012, Clin. Cancer Res."	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK e6-e20	ALK	EML4::ALK e6-e20	Lung Non-small Cell Carcinoma	Alvespimycin	Predictive	Does Not Support	D	Sensitivity/Response	chr2	29192774	29223528			"Transduction of Ba/F3 cells with EML4-ALK variant 3a caused the cells to grow independently of IL3 addition.  While incubation of Ba/F3 cells transduced with EML4-ALK variants 1 and 2 with Hsp90 inhibitor 17-DMAG caused cell death that was reversible with IL3 addition, Ba/F3 cells with variant 3a were not sensitized to 17-DMAG induced death, suggesting that 17-DMAG was effecting the EML4-ALK driver of IL3-independant proliferation. This in turn suggests that variant 3a may not rely on Hsp90 for stability in cancer cells to the extent of other variants."	"Heuckmann et al., 2012, Clin. Cancer Res."	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK	ALK	EML4::ALK	Lung Non-small Cell Carcinoma	"Alvespimycin,Crizotinib"	Predictive	Supports	D	Sensitivity/Response	chr2	29192774	29223528			"Transduction of Ba/F3 cells with EML4-ALK variant 1 causes IL3 independent growth. Incubation of EML4-ALK variant 1 transduced Ba/F3 cells with Hsp90 inhibitor 17-DMAG caused cell death that was reversible with IL3 addition, suggesting that 17-DMAG was effecting the EML4-ALK driver of IL3-independant proliferation, and that EML4-ALK variant 1 is a client protein of Hsp90. The degree of Hsp90 dependence, and targetability of EML4-ALK for Hsp90 inhibition, may vary among ALK fusion variants.  Addition of crizotinib to 17-DMAG caused synergistic death effects, suggesting potential clinical benefit for this inhibitor combination in targeting EML4-ALK variant 1."	"Heuckmann et al., 2012, Clin. Cancer Res."	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK	ALK	EML4::ALK	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr2	29192774	29223528			"In the PROFILE 1001 study of crizotinib in 82 patients with ALK-rearranged NSCLC, 31 patients with sufficient tumor material were tested using RT-PCR for the presence of certain EML4-ALK variants.  13/31 tested patients had the EML4-ALK variant 1. Of these, 12/13 had a partial response, and 1 had stable disease. This response rate of 92% is in contrast to the 57% response rate in the overall patient population, but the numbers of patients with specific EML4-ALK breakpoints were insufficient to correlate with patient response rate."	"Kwak et al., 2010, N. Engl. J. Med."	Somatic	ENST00000318522.5	transcript_fusion
ALK Mutation	ALK	Mutation	Lung Non-small Cell Carcinoma	Ceritinib	Predictive	Supports	B	Sensitivity/Response	chr2	29192774	29921566			"In a phase 1 clinical trial (NCT01283516) 130 patients with advanced cancers all harboring ALK alterations were treated with ceritinib.  Of 114 NSCLC patients treated with at least 400 mg/daily ceritinib, 1 had a complete response, 65 had a partial response, 25 had stable disease, 12 had progressive disease, and 11 withdrew from the study early. Ceritinib dosed at 400 mg or higher had similar results in patients who had or had not received prior crizotinib treatment. Overall response rate for patients with prior crizotinib treatment (83 out of 122) was 56% with median progression free survival of 6.9 months. For patients who had no prior crizotinib treatment, median progression free survival was 10.4 months."	"Shaw et al., 2014, N. Engl. J. Med."	Somatic	ENST00000389048.3	"gene_variant,gain_of_function_variant"
ALK NPM::ALK	ALK	NPM::ALK	Anaplastic Large Cell Lymphoma	Crizotinib	Predictive	Supports	D	Sensitivity/Response	chr2	29192774	29223528			"NPM-ALK in anaplastic large cell lymphoma (ALCL) was the first ALK-fusion to be discovered and characterized.  In this study, targeted activity against NPM-ALK by the ALK and MET inhibitor crizotinib was assessed in cell lines and tumor xenograft models. Treatment of NPM-ALK positive ALCL cell lines Karpas299 and SU-DHL-1 potently inhibited growth, and this was seen to occur at concentrations which also inhibited NPM-ALK phosphorylation in these cells. Administration of 100mg/kg/d crizotinib resulted in complete regression of all tumors, indicating that NPM-ALK could be an effective target for crizotinib in ALCL."	"Christensen et al., 2007, Mol. Cancer Ther."	Somatic	ENST00000517671.1	transcript_fusion
ALK Fusion	ALK	Fusion	Anaplastic Large Cell Lymphoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr2	29192774	29223528			"Crizotinib at 250mg daily was given to two patients with relapsed ALK-rearranged anaplastic large cell lymphoma (ALCL). Patient one, 26 yrs old, had been treated with the CHOP-15 chemotherapy regimen, then salvage chemotherapy to prepare for autologous bone marrow transplant but ultimately relapsed. After initiation of crizotinib, PET, CT and bone marrow aspirates showed complete remission of previous lesions at 28 days. At time of publication the patient continued to show persistent response at 6 months. A 20 year old patient relapsed after one month of CHOP, and was treated with further chemotherapy and autologous bone marrow transplantation resulting in partial response of 1 month. Crizotinib was initialized, and after 12 days PET scan showed complete regression of all lesions. On day 60 bone marrow aspirates were ALK-negative (pretreatment evaluation showed 8% ALK-positive). The authors conclude these two cases indicate sensitivity to crizotinib of relapsed ALK-rearranged ALCL."	"Gambacorti-Passerini et al., 2011, N. Engl. J. Med."	Somatic	ENST00000389048.3	transcript_fusion
ALK NPM::ALK	ALK	NPM::ALK	Anaplastic Large Cell Lymphoma	Crizotinib	Predictive	Supports	B	Sensitivity/Response	chr2	29192774	29223528			"In the second part of this Phase I study NCT00939770, nine patients between the ages of 12 months and 22 years with anaplastic large cell lymphoma (ALCL), who were refractory to treatment and for whom no further known treatments were available, were treated with crizotinib. Six patients with detectable NPM-ALK transcript levels responded with partial response, 1 with complete response, and 1 with stable disease.  Crizotinib was well tolerated in these children."	"Moss et al., 2013, Lancet Oncol."	Somatic	ENST00000517671.1	transcript_fusion
ALK Fusion	ALK	Fusion	Inflammatory Myofibroblastic Tumor	Crizotinib	Predictive	Supports	B	Sensitivity/Response	chr2	29192774	29223528			"As part of a phase 1 dose-escalation trial (NCT00939770), seven patients between ages 12 months and 22 years with relapsed or refractory inflammatory myofibroblastic tumors with ALK-rearrangement were given crizotinib. In six patients with measurable disease, responses included 3 with partial response and 3 with stable disease. One patient with evaluable disease had stable disease with treatment ongoing at the time of publication. Crizotinib was well tolerated in this group of pediatric patients."	"Moss et al., 2013, Lancet Oncol."	Somatic	ENST00000389048.3	transcript_fusion
ALK RANBP2::ALK	ALK	RANBP2::ALK	Inflammatory Myofibroblastic Tumor	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr2	29192774	29223528			"ALK-rearrangements are seen in 50% of inflammatory myofibroblastic tumor (IMT) cases. A 44 year old man was diagnosed with IMT.  He was treated with surgery and catheter placement for administration of cisplatin, doxyrubicin and mitomycin C.  Break-apart FISH showed ALK rearrangement, and immunohistochemical staining was characteristic of RANBP2 rearrangement. After further chemotherapy along with maintenance imatinib, crizotinib was started at 200mg twice daily, and a maximal partial response was achieved 5 months later, with regrowth occurring 2 months later. After further surgery, crizotinib was restarted at 250mg twice daily and almost 2 years later the patient was in complete radiographic remission. Another patient with non-ALK rearranged IMT was administered crizotinib in this study but did not respond."	"Butrynski et al., 2010, N. Engl. J. Med."	Somatic	ENST00000283195.6	transcript_fusion
ALK EML4::ALK e20-e20	ALK	EML4::ALK e20-e20	Cancer	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr2	29192774	29223528			"This case study presented a 53-year-old never-smoker with a poorly differentiated malignant neoplasm. Morphology and immunohistochemistry were unable to establish the primary tumor site. Right upper extremity (RUE), scalp, and multiple lung lesions were apparent. A lung lesion sample with sufficient material for molecular profiling was not attainable but sufficient material was present from the RUE for hybrid capture genomic profiling  (FoundationOne kit was used). EML4-ALK variant 2 was found, and the patient was started on crizotinib. Rapid symptom improvement was seen. After 1 month, a CT scan showed significant size reduction in lung tumors, and after 5 months the patient was asymptomatic with an entirely negative examination."	"Chung et al., 2014, Case Rep Oncol"	Somatic	ENST00000318522.5	transcript_fusion
ALK CLTC::ALK	ALK	CLTC::ALK	Diffuse Large B-cell Lymphoma	TAE684	Predictive	Supports	D	Sensitivity/Response	chr2	29192774	29223528			"A cell line called LM1 was established from the bone marrow of a 13 year old female patient with relapsed CLTC-ALK positive diffuse large B-cell lymphoma (DLBCL). The patient had been heavily treated with chemotherapy before establishment of the cell line. The cell line maintained the tumor immunophenotype.  SNP analysis of patient bone marrow mononuclear cells and LM1 showed chromosomal changes associated with the cell line but 94.7% of SNPs were identically called.  ALK kinase inhibitor TAE684 induced cell death in LM1 cells at low nanomolar concentrations, while it did not significantly effect the ALK-rearrangement negative DLBCL cell line Karpas422.  LM1 cells formed tumors in 3/10 SCID and 9/10 NOD-SCID mice.  CD30 and CD138 immmunostaining were maintained between original tumor and LM1 xenografts. In mice, LM1 but not Karpas422 xenografts regressed with TAE684 administration, and complete remission for 13 weeks was observed before experiment was terminated."	"Cerchietti et al., 2011, PLoS ONE"	Somatic	ENST00000269122.3	transcript_fusion
ALK CLTC::ALK	ALK	CLTC::ALK	Diffuse Large B-cell Lymphoma		Prognostic	Supports	C	Poor Outcome	chr2	29192774	29223528			"CLTC-ALK is one of the most common ALK fusions found in diffuse large B cell lymphoma (DLBCL). In a retrospective study of 38 patients with ALK-rearranged DLBCL, 3 were CD20 positive. Only one showed cytoplasmic, nuclear and nucleolar staining associated with NPM-ALK, while the others showed granular cytoplasmic ALK stain characteristic for CLTC-ALK.  Seven molecularly characterized cases were positive for CLTC-ALK.  6/7 patients were treated with CHOP chemotherapy with survival of 5, 10, 26 and 27 months, and two alive at end of study, and one CD20 positive patient was treated with CHOP chemotherapy supplemented with CD20-targeted rituximab, with survival of 8 months, resulting in median survival of 26 months for this group.  Although these numbers are not sufficient for statistical comparison, they compare unfavorably to 3.1 year overall survival and 45% 5 year survival of CHOP treated DLBCL patients, and even less favorably to R-CHOP standard of care for CD20 positive DLBCL, suggesting poor prognosis for CLTC-ALK DLBCL and need for updated treatment in this cohort."	"Laurent et al., 2009, J. Clin. Oncol."	Somatic	ENST00000269122.3	transcript_fusion
ALK Fusion	ALK	Fusion	Diffuse Large B-cell Lymphoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr2	29192774	29223528			"A 27 year old female patient with advanced-stage IV, CD20 negative diffuse large B cell lymphoma (DLBCL). ALK rearrangement was determined by FISH, but the ALK fusion partner was not determined due to limited tissue. The patient underwent treatment with CHOP chemotherapy regimen and radiation but did not respond. The patient progressed following salvage chemotherapy and autologous stem cell transplant. Crizotinib was then administered at 250 mg twice daily, and LDH levels rapidly dropped along with disappearance of palpable lymphadenopathy, but progression ensued after 21 days and the patient died soon after. The authors attribute the short response to crizotinib to the possibility of this tumor having an ALK fusion variant less responsive to ALK inhibition and to a high Ki-67 index in the patient, and deem that despite the brief response, crizotinib shows promise in ALK rearranged DLBCL."	"Wass et al., 2014, Eur. J. Haematol."	Somatic	ENST00000389048.3	transcript_fusion
ALK CLTC::ALK	ALK	CLTC::ALK	Diffuse Large B-cell Lymphoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr2	29192774	29223528			"A 21 year old male presented with lymphadenopathy and a low density mass in pancreas. Histopathological analysis showed diffuse tumor cell infiltrate (CD20/EMA negative) with cytoplasmic ALK. RT-PCR indicated CLTC-ALK fusion. The patient was diagnosed with splenic ALK + diffuse large B cell lymphoma (DLBCL), Stage III, Group A with an IPI of 3. CHOP-21 chemotherapy regimen was administered with improvement in abdominal lymph nodes but worsening in retroperitoneal lymph nodes assessed via standardized uptake values. Subsequent ICE chemotherapy regiment relieved some symptoms prompting the patient to refuse further treatment despite other indications of disease progression. Therapy was reinstated after worsening of disease. GEMOX chemotherapy was administered with dexamethasone and 250mg crizotinib twice daily resulting in symptom relief, decreased lymphadenopathy and LDH decline. The disease then progressed and the patient died 2 months after crizotinib initiation. The authors conclude that partial response to crizotinib was observed and that in future trials ALK rearranged DLBCL patients might see increased benefit with earlier application of targeted therapy during the treatment course."	"Li et al., 2015, Int J Clin Exp Med"	Somatic	ENST00000269122.3	transcript_fusion
ALK EML4::ALK e2-e20	ALK	EML4::ALK e2-e20	Renal Cell Carcinoma		Predictive	Supports	E	Sensitivity/Response	chr2	29192774	29223528			"Adenocarcinoma cells were detected via urinary cytology in a 53 year old woman. Cancer morphology suggested papillary renal cell carcinoma (RCC), type 2A.  EML4-ALK variant 5 was discovered in tumor tissue using PCR with EML4 and ALK specific primers. The authors conclude that their findings confirm the potential for ALK targeting therapy in select cases of RCC."	"Sugawara et al., 2012, Cancer"	Somatic	ENST00000318522.5	transcript_fusion
ALK Fusion	ALK	Fusion	Lung Non-small Cell Carcinoma	Alectinib	Predictive	Supports	B	Sensitivity/Response	chr2	29192774	29223528			"In this initial report of a single-arm Phase I and II study (JapicCTI-101264) of alectinib (CH5424802), 46 patients with advanced or metastatic ALK-rearranged non small cell lung cancer (NSCLC) were assessed for objective response during phase II. ALK positivity was assessed via IHC and verified with FISH or RT-PCR. Patients had received one or more rounds of previous chemotherapy, but no prior targeted therapy towards ALK. From the 46 patients, 41 showed partial response, and 2 showed complete response. CNS metastases in three patients which had not received prior brain irradiation showed response to alectinib. Alectinib was generally well tolerated, and the authors conclude that alectinib compared favorably to crizotinib and could be an effective and safe option in ALK-rearranged NSCLC."	"Seto et al., 2013, Lancet Oncol."	Somatic	ENST00000389048.3	transcript_fusion
ALK Fusion	ALK	Fusion	Lung Non-small Cell Carcinoma	Alectinib	Predictive	Supports	C	Sensitivity/Response	chr2	29192774	29223528			"In this case study of a critically ill 29 year old male nonsmoker with advanced metastatic ALK-positive NSCLC, alectinib (CH5424802), was administered as first line treatment. Where most clinical trials only admit patients with Eastern Cooperative Oncology Performance status (PS) of 0 or 1, this patient had PS 4 due to respiratory failure, multiple bone metastases and complications from disseminated intravascular coagulation (DIC). Administration of alectinib at 300 mg twice daily was followed by marked improvement seen in tests associated with DIC, pulmonary metastasis and change in PS from 4 to 0. Further improvements after a couple of months suggested a rapid complete response. Alectinib was well tolerated in this first line treatment of a critically ill ALK-positive NSCLC patient."	"Yoshida et al., 2016, Anticancer Drugs"	Somatic	ENST00000389048.3	transcript_fusion
ALK Fusion	ALK	Fusion	Lung Non-small Cell Carcinoma	Alectinib	Predictive	Supports	B	Sensitivity/Response	chr2	29192774	29223528			"In this Phase I trial (NCT01588028) in 47 patients, alectinib was assessed for its effectiveness in treating locally advanced or metastatic ALK-positive NSCLC that had progressed or been resistant to crizotinib treatment. ALK rearrangement was assessed via approved break apart FISH kit, and patients with asymptomatic CNS metastases were also included. Patients were divided into different cohorts receiving different doses of alectinib. In the 600 mg cohort (N=13), ten were assessable, and there were 4 confirmed partial responses, 3 unconfirmed partial responses and 3 instances of stable disease. Also, five of nine patients throughout the cohorts with measurable baseline CNS lesions showed partial response to alectinib. Cerebrospinal fluid levels of alectinib increased linearly with blood alectinib levels, indicating it effectively crossed the blood-brain barrier."	"Gadgeel et al., 2014, Lancet Oncol."	Somatic	ENST00000389048.3	transcript_fusion
ALK Fusion	ALK	Fusion	Lung Non-small Cell Carcinoma	Alectinib	Predictive	Supports	A	Sensitivity/Response	chr2	29192774	29223528			"In this Phase II trial of 87 patients (NCT01871805), alectinib was assayed for safety and efficacy in ALK positive NSCLC that had progressed on crizotinib. Of 69 patients with measurable disease, 35 achieved objective response, with median duration of response 13.5 months. Of 16 patients with measurable CNS disease, four achieved CNS complete response and 8 showed CNS partial response. median duration of CNS response was 11.1 months. 2 deaths were observed, and 1 was judged related to study treatment."	"Shaw et al., 2016, Lancet Oncol."	Somatic	ENST00000389048.3	transcript_fusion
ALK EML4::ALK	ALK	EML4::ALK	Lung Non-small Cell Carcinoma	Lorlatinib	Predictive	Supports	D	Sensitivity/Response	chr2	29192774	29223528			"EML4-ALK variant 1 containing H-3122 NSCLC cells were treated with second generation ALK inhibitor PF-06463922. PF-06463922 was 125x more potent at reducing cell viability than crizotinib. Control neuroblastoma cell lines with wild-type ALK did not show inhibition below 3800 nM with either drug. At values of 10 and 100 nM, PF-06463922 showed increased ability to inhibit ALK 1278 tyrosine phosphorylation in H3122 cells."	"Infarinato et al., 2016, Cancer Discov"	Somatic	ENST00000318522.5	transcript_fusion
ALK Fusion	ALK	Fusion	Colorectal Adenocarcinoma	Crizotinib	Predictive	Supports	E	Sensitivity/Response	chr2	29192774	29223528			"26 colorectal adenocarcinoma samples were run on Affymetrix human Exon 1.0 arrays and a computational method that assessed differential 5' and 3' gene expression for each gene was used to find potential rearrangements.  One sample showed potential rearrangement and RT-PCR demonstrated an EML4-ALK fusion where EML4 exon 21 was fused to ALK exon 13. This EML4-ALK variant is different from those commonly found in NSCLC. Genomic PCR verified the existence of the fusion breakpoint in intronic space, indicating that some colorectal adenocarcinoma may have targetable ALK-fusion driver mutations."	"Lin et al., 2009, Mol. Cancer Res."	Somatic	ENST00000389048.3	transcript_fusion
ALK Fusion	ALK	Fusion	Breast Cancer	Crizotinib	Predictive	Supports	E	Sensitivity/Response	chr2	29192774	29223528			"84 breast cancer samples acquired from commercial sources were assayed on Affymetrix human exon 1.0 arrays. A computational method was used to find potential gene fusions which assessed differential exon expression between the 3' and 5' ends of each gene. Two potential fusions were found and assessed using RNA ligase mediated rapid amplifiation of cDNA ends and RT-PCR. The fusions were EML4-ALK variants 1 and 2. Genomic PCR identified fusion breakpoints, and these differed from breakpoints for these EML4-ALK variants reported in NSCLC."	"Lin et al., 2009, Mol. Cancer Res."	Somatic	ENST00000389048.3	transcript_fusion
ALK EML4::ALK e6-e20	ALK	EML4::ALK e6-e20	Lung Non-small Cell Carcinoma	Ceritinib	Predictive	Supports	D	Sensitivity/Response	chr2	29192774	29223528			"Ceritinib was 28x more potent (GI50 3.8nM) than crizotinib (GI50 107nM) at inhibiting growth of  H2228, an NSCLC cell line which harbors the EML4-ALK variant 3a/3b. SCID mice xenografted with H2228 were treated for 14 days with crizotinib (100 mg/kg) or ceritinib (25 or 50 mg/kg). All treatments caused tumor regression, but tumors recurred within 11 days after crizotinib treatment withdrawal. 4/8 mice treated with 25 mg/kg ceritinib showed regrowth after 1 month treatment withdrawal. The remaining 4/8 mice treated at 25 mg/kg ceritinib, and all mice treated at 50 mg/kg ceritinib maintained complete remission for four months. While 100 mg/kg crizotinib in mice approximates levels 3-5 times the maximal tolerated dose in humans, the authors state 25 to 50 mg/kg ceritinib in mice is predicted to approximate tolerable doses in humans."	"Friboulet et al., 2014, Cancer Discov"	Somatic	ENST00000318522.5	transcript_fusion
ALK NPM::ALK	ALK	NPM::ALK	Cancer	Crizotinib	Predictive	Supports	D	Sensitivity/Response	chr2	29192774	29223528			"In Ba/F3 cells, crizotinib sensitivty of the NPM-ALK variant was compared to crizotinib sensitivity of EML4-ALK variant 3. 50% of maximal inhibitory concentration for NPM-ALK was 42 nM, which was approximately 4x greater than IC50 of 11 nM obtained for EML4-ALK. The IC50 for parental Ba/F3 supplemented with IL3 was 2299 nM, resulting in a fold difference of 209.2 for EML4-ALK and 55.1 for NPM-ALK, indicating some reduced sensitivity for NPM-ALK in direct comparison to EML4-ALK, but substantial sensitization to crizotinib for NPM-ALK in Ba/F3 cells."	"Fontana et al., 2015, Cancer Med"	Somatic	ENST00000517671.1	transcript_fusion
ALK Fusion	ALK	Fusion	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	B	Sensitivity/Response	chr2	29192774	29223528			"In a retrospective study comparing survival outcomes in a subgroup of 82 ALK-positive crizotinib-treated patients enrolled in a phase 1 clinical trial (NCT00585195), crizotinib therapy was associated with improved survival. For the crizotinib-treated, ALK-positive patient group, 1 year survival was 74% and 2 year overall survival was 54%, compared with 72% and 36% for the control group (ALK-positive crizotinib naive patients)."	"Shaw et al., 2011, Lancet Oncol."	Somatic	ENST00000389048.3	transcript_fusion
ALK Fusion	ALK	Fusion	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	B	Sensitivity/Response	chr2	29192774	29223528			"A phase-3 clinical trial evaluated 347 patients with ALK-positive lung cancer.  The study compared crizotinib treatment (n=173) with chemotherapy treatment of either pemetrexed or docetaxel (n=174).  In the crizotinib arm, the response rate was significantly higher (65% vs 20%; P<0.001), the progression-free survival was increased (7.7 months vs. 3.0 months; HR=0.49, 95%CI:14 months-26 months; p<0.001), however, there was no significant improvement in overall survival (HR=1.02; 95%CI:0.68-1.54; P=0.54).  Of the patients on crizotinib treatment, global quality of life was improved relative to baseline when compared to chemotherapy patients (+5 mean change, -5 mean change; P<0.001)."	"2015, N Engl J Med"	Somatic	ENST00000389048.3	transcript_fusion
ALK Fusion	ALK	Fusion	Lung Adenocarcinoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr2	29192774	29223528			"In an evaluation of a patient with crizotinib-sensitive lung adenocarcinoma, an EML4-ALK-E13;A20 rearrangement was identified using CGP.  The patient attained a reduction in the target lesions by 14.2%, however, the patient relapsed 17 months later."	"Le et al., 2015, Clin Lung Cancer"	Somatic	ENST00000389048.3	transcript_fusion
ALK Fusion	ALK	Fusion	Inflammatory Myofibroblastic Tumor		Diagnostic	Supports	C	Positive	chr2	29192774	29223528			"Fluorescence in situ hybridization with a probe flanking the ALK gene at 2p23 and immunohistochemistry revealed ALK expression, suggesting ALK fusions in three cases of IMT."	"Griffin et al., 1999, Cancer Res."	Somatic	ENST00000389048.3	transcript_fusion
ALK Fusion	ALK	Fusion	Cancer	Entrectinib	Predictive	Supports	B	Sensitivity/Response	chr2	29192774	29223528			"Two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the antitumor activity of entrectinib in a cohort of patients with tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. Notably, a complete CNS response was achieved in a patient with SQSTM1-NTRK1-rearranged lung cancer."	"Drilon et al., 2017, Cancer Discov"	Somatic	ENST00000389048.3	transcript_fusion
ALK Fusion	ALK	Fusion	Lung Non-small Cell Carcinoma	Brigatinib	Predictive	Supports	B	Sensitivity/Response	chr2	29192774	29223528			"In a phase II randomized trial we evaluated two regimens of Brigatinib in Crizotinib-refractory ALK-pos. NSCLC. They were randomly assigned (1:1) to oral Brigatinib 90 mg once daily (arm A) or 180 mg once daily with a 7-day lead-in at 90 mg. Of 222 patients enrolled (arm A: n = 112, arm B: n = 110), 154 (69%) had baseline brain metastases and 164 of 222 (74%) had received prior chemotherapy. ORR was 45 (arm A) and 54% (B). Investigator-assessed median PFS was 9.2 months (A) and 12.9 months (B). Independent review committee-assessed intracranial ORR in patients with measurable brain metastases at baseline was 42% (11/26, A) and 67% (12/18, B). Brigatinib yielded substantial whole-body and intracranial responses as well as robust PFS; 180 mg (with lead-in) showed consistently better efficacy than 90 mg, with acceptable safety."	"Kim et al., 2017, J. Clin. Oncol."	Somatic	ENST00000389048.3	transcript_fusion
ALK Fusion	ALK	Fusion	Lung Non-small Cell Carcinoma	"Crizotinib,Alectinib"	Predictive	Supports	B	Sensitivity/Response	chr2	29192774	29223528			"In a randomized, open-label phase 3 trial 303 patients with ALK-positive, previously untreated NSCLC (including asympt. CNS disease) were randomized to reiceive either Alectinib or Crizotinib. During a median follow-up of 17.6 months (crizotinib) and 18.6 months (alectinib), an event of disease progression/death occurred in 41% (62/152  pt) in the alectinib group and 68% (102/151 patients) in the crizotinib group. 12-month event-free survival rate 68.4% with alectinib vs. 48.7% with crizotinib. A total of 18 patients (12%) in the alectinib group had an event of CNS progression, compared to 68 patients (45%) in the crizotinib group. Response rates were 82.9% (Alectinib) and 75.5% (crizotinib)."	"Peters et al., 2017, N. Engl. J. Med."	Somatic	ENST00000389048.3	transcript_fusion
ALK Fusion	ALK	Fusion	Thyroid Gland Anaplastic Carcinoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr2	29192774	29223528			"A patient with anaplastic thyroid carcinoma harboring ALK rearrangement received crizotinib after chemotherapy for pulmonary recurrence. Crizotinib showed confirmed response of more than 90% by tumor volume, and her response has been stable on follow-up."	"Godbert et al., 2015, J. Clin. Oncol."	Somatic	ENST00000389048.3	transcript_fusion
ALK Fusion	ALK	Fusion	Vagina Sarcoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr2	29192774	29223528			"Patient was 34-year-old woman with vaginal sarcoma, which was excised with positive surgical margins. Fluorescence in situ hybridization testing of her tumor revealed  anaplastic lymphoma kinase gene rearrangements. A 3-cm mass recurred 1 month later. Treatment with crizotinib resulted in complete regression of all visible or palpable tumor within 3 weeks."	"Forde et al., 2016, Obstet Gynecol"	Somatic	ENST00000389048.3	transcript_fusion
ALK Fusion	ALK	Fusion	Epithelioid Inflammatory Myofibroblastic Sarcoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr2	29192774	29223528			"This is a case report of a  22-year-old Japanese man with a pelvic mesenchymal neoplasm. Tumor analysis include IHC and RT-PCR led to diagnosis of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion. Despite two surgical excision procedures, local recurrence rapidly occurred, and the tumor developed resistance to conventional chemotherapy with doxorubicin. Subsequent administration of crizotinib resulted in relief of severe pain and durable tumor shrinkage at least 10 months."	"Kimbara et al., 2014, Jpn. J. Clin. Oncol."	Somatic	ENST00000389048.3	transcript_fusion
ALK Fusion	ALK	Fusion	Lung Non-small Cell Carcinoma	Alectinib	Predictive	Supports	A	Sensitivity/Response	chr2	29192774	29223528			"In a phase 3 trial, 303 patients with NSCLC with ALK fusion were randomly assigned to alectinib arm (N=152) or crizotinib arm (N=151). PFS was significantly longer with alectinib than with crizotinib (HR for disease progression or death 0.47, 95% CI: 0.34-0.65, p<0.001). Investigator-assessed RR was 82.9% in alectinib arm and 75.5% in crizotinib arm. CNS RR in patients with measurable CNS lesions was 81% and 50% for alectinib and crizotinib, respectively. Eight patients in the alectinib group, in comparison to one patient with crizotinib, had a complete CNS response. Despite longer treatment duration for alectinib, there were fewer grade 3-5 adverse events compared with crizotinib treatment."	"Peters et al., 2017, N. Engl. J. Med."	Somatic	ENST00000389048.3	transcript_fusion
ALK Fusion	ALK	Fusion	Lung Non-small Cell Carcinoma	Ceritinib	Predictive	Supports	A	Sensitivity/Response	chr2	29192774	29223528			"In a phase 3 trial, patients with previously treatmented NSCLC with ALK fusion were randomly assigned to ceritinib or chemotherapy. Ceritinib showed a significant improvement in median  PFS compared with chemotherapy (54 months [95% CI 41-69] for ceritinib vs 16 months [14-28] for chemotherapy; hazard ratio 049 [036-067]; p<00001)."	"Shaw et al., 2017, Lancet Oncol."	Somatic	ENST00000389048.3	transcript_fusion
ALK Fusion	ALK	Fusion	Lung Non-small Cell Carcinoma	Lorlatinib	Predictive	Supports	B	Sensitivity/Response	chr2	29192774	29223528			"In a phase 2 trial, patients with NSCLC with ALK fusion received lorlatinib. In treatment-naive patients, ORR was 90.0% In patients with at least one previous ALK tyrosine kinase inhibitor, ORR were achieved in 47.0%.In patients who had only received crizotinib ORR was achieved in 69.5%."	"Solomon et al., 2018, Lancet Oncol."	Somatic	ENST00000389048.3	transcript_fusion
ALK Fusion	ALK	Fusion	Lung Non-small Cell Carcinoma	Alectinib	Predictive	Supports	A	Sensitivity/Response	chr2	29192774	29223528			"A randomized phase 3 trial (J-ALEX) of 207 Japanese ALK-positive NSCLC patients compared the efficacy and safety of alectinib (300mg twice daily) and crizotinib (250mg twice daily) in the first-line setting. When used as a first line treatment the median progression-free survival of the alectinib group was unreached (95% CI 17.5not estimated) versus 10.2 months (95% CI 8.3?3.9) in the crizotinib group (HR 0.31; 95% CI 0.17?57). In the overall intent to treat population, Alectinib showed improved median PFS (HR 0.34; 99.7% CI 0.17-0.71; stratified log-rank p<00001) with an unreached PFS (95% CI 20.3-not estimated) compared to 10.2 months (95% CI 8.2-12.0) for crizotinib. The safety profile of alectinib was favorable relative to crizotinib with fewer dose interruptions (29% vs 74%) and fewer grade 3-4 adverse events (26% vs 52%)."	"Hida et al., 2017, Lancet"	Somatic	ENST00000389048.3	transcript_fusion
ALK EML4::ALK	ALK	EML4::ALK	Malignant Pleural Mesothelioma	Alectinib	Predictive	Supports	C	Sensitivity/Response	chr2	29192774	29223528			"A 33 year old M non-smoker with no cancer family history and no known exposure to asbestos showed weakness, chest pain, and plural effusion (PE) accumulation. Mass in right lung was seen under enhanced CT. Patient was diagnosed with stage IIIB (cT4N2M0) malignant pleural mesothelioma (MPM) using National Comprehensive Cancer Network (NCCN) guidelines on MPM staging (v.1.2018).   Patient was given palliative chemotherapy for two cycles, which reduced the PE and improved physical mobility. Targeted NGS panel with 520 genes of PE showed EML4::ALK variant 3 (allelic fraction 24.21%). After 1 month symptoms were alleviated and NGS showed reduced EML4::ALK abundance (allelic fraction 8.22%). After 2 months CT showed tumor shrinkage. This was evaluated as partial response."	"Hu et al., 2020, Ther Adv Respir Dis"	Somatic	ENST00000318522.5	transcript_fusion
ALK Fusion	ALK	Fusion	Lung Non-small Cell Carcinoma	Brigatinib	Predictive	Supports	A	Sensitivity/Response	chr2	29192774	29223528			"The phase III ALTA-1L open-label randomized trial examined 275 NSCLC patients given brigatinib (137 patients) vs crizotinib (138 patients).  Patients were ALK fusion positive by an FDA-approved diagnostic test and had not previously received ALK inhibitors. Brigatinib showed superior PFS compared to crizotinib (HR 0.49 [95% CI, 0.35 to 0.68]; log-rank P < .0001; median, 24.0 v 11.0 months). Initial results from this trial were previously reported in 2018 (PMID: 30280657)."	"Camidge et al., 2020, J. Clin. Oncol."	Somatic	ENST00000389048.3	transcript_fusion
ALK R1275Q	ALK	R1275Q	Neuroblastoma	TAE684	Predictive	Supports	D	Sensitivity/Response	chr2	29209798	29209798	C	T	"TAE684 inhibits growth of Ba/F3 cells expressing ALK mutations; however, cells with the R1275Q mutation were inhibited at a higher IC50 than those expressing F1174L."	"George et al., 2008, Nature"	Somatic	ENST00000389048.3	missense_variant
ALK R1275Q	ALK	R1275Q	Neuroblastoma	TAE684	Predictive	Supports	D	Resistance	chr2	29209798	29209798	C	T	The SMS-KCNR cell line harboring the R1275Q mutation was resistant to TAE684.	"George et al., 2008, Nature"	Somatic	ENST00000389048.3	missense_variant
ALK R1275Q	ALK	R1275Q	Neuroblastoma	Crizotinib	Predictive	Supports	D	Sensitivity/Response	chr2	29209798	29209798	C	T	Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation.	"Bresler et al., 2011, Sci Transl Med"	Somatic	ENST00000389048.3	missense_variant
ALK R1275Q	ALK	R1275Q	Neuroblastoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr2	29209798	29209798	C	T	"A cohort of pediatric neuroblastoma patients ages 12 months to 22 years were assessed for response to crizotinib in a Phase I study.  11 patients in this cohort had characterized ALK mutations, 4 of which were R1275Q mutation. Two of these R1275Q mutations were germline and two were somatic. Of these 2 somatic R1275Q patients, 1 showed progressive disease (PD) and 1 showed stable disease (SD). In contrast, of the 7 characterized patients with ALK mutations that were not R1275Q, 6 showed PD and 1 SD. The stable disease patient had an R1275L mutation in ALK. In general, patients with germline or somatic R1275Q mutations or R1275L mutations had 1 complete response, 3 SD and one PD, while patients with other ALK mutations had 6 PD."	"Moss et al., 2013, Lancet Oncol."	Somatic	ENST00000389048.3	missense_variant
ALK R1275Q	ALK	R1275Q	Neuroblastoma	Lorlatinib	Predictive	Supports	D	Sensitivity/Response	chr2	29209798	29209798	C	T	"In NB-1643 and LAN-5 neuroblastoma cell lines containing R1275Q mutation, PF-06463922 showed 51 and 19 fold greater effect on cell viability over crizotinib treatment respectively. ALK wild-type neuroblastoma cell lines did not show differential sensitivity to the treatments within the sensitivity range of R1275Q cells, and had IC50 values above 3800 nM to the inhibitors. NB-1653 cells induced tumors in CB17 SCID mice and crizotinib treatment inhibited tumor growth over vehicle treatment, but PF-06463922 induced complete tumor regression."	"Infarinato et al., 2016, Cancer Discov"	Somatic	ENST00000389048.3	missense_variant
ALK F1245C	ALK	F1245C	Neuroblastoma	Lorlatinib	Predictive	Supports	D	Sensitivity/Response	chr2	29213993	29213993	A	C	"Patient derived xenografts of neuroblastoma Felix cells with F1245C ALK mutation in CB17 SCID mice showed growth inhibition with crizotinib treatment over control, and mice had improved duration of event-free survival (EFS) with crizotinib treatment over vehicle, but EFS with crizotinib went down to 0% by six weeks.  In contrast, PF-06463922 treatment induced complete tumor regression and EFS rate of 100% at six weeks.  PF-06463922 inhibited viability in Felix cells at 37x efficacy over crizotinib, with IC50 values of 21.8 +/- 0.4 and 814.0 +/- 119 respectively.  PF-06463922 was well tolerated in the animal models."	"Infarinato et al., 2016, Cancer Discov"	Somatic	ENST00000389048.3	missense_variant
ALK F1245C	ALK	F1245C	Neuroblastoma	Crizotinib	Predictive	Supports	C	Resistance	chr2	29213993	29213993	A	C	A participant in Children's Oncology Group (COG) study AVDL0912 with measurable neuroblastoma mutated at ALK F1245C was administered crizotinib at 100mg twice daily.  The patient showed progressive disease as best response after two 28-day cycles on crizotinib.	"Moss et al., 2013, Lancet Oncol."	Somatic	ENST00000389048.3	missense_variant
ALK F1245V	ALK	F1245V	Neuroblastoma	Entrectinib	Predictive	Supports	C	Sensitivity/Response	chr2	29213994	29213994	A	C	"Clinical trial of entrectinib in patients with ALK/ROS/TRK altered tumors. One patient with an ALK F1245V-mutant neuroblastoma achieved a durable, confirmed partial response (PR) lasting 8.3 months. The patient remained on study treatment for more than 3.5 years because of clinical benefit."	"Drilon et al., 2017, Cancer Discov"	Somatic	ENST00000389048.3	missense_variant
ALK F1174L	ALK	F1174L	Inflammatory Myofibroblastic Tumor	Crizotinib	Predictive	Supports	D	Resistance	chr2	29220829	29220829	G	T	Ba/F3 cells expressing the RANBP2-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing RANBP2-ALK without this mutation.	"Sasaki et al., 2010, Cancer Res."	Somatic	ENST00000389048.3	missense_variant
ALK F1174L	ALK	F1174L	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	D	Resistance	chr2	29220829	29220829	G	T	Ba/F3 cells expressing the EML4-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing EML4-ALK without this mutation.	"Sasaki et al., 2010, Cancer Res."	Somatic	ENST00000389048.3	missense_variant
ALK F1174L	ALK	F1174L	Neuroblastoma	Alectinib	Predictive	Supports	D	Sensitivity/Response	chr2	29220829	29220829	G	T	CH5424802 (Alectinib) is effective in inhibiting the activity of the F1174L ALK mutant in a kinase activity assay and proliferation assay using neuroblastoma KELLY cells.	"Sakamoto et al., 2011, Cancer Cell"	Somatic	ENST00000389048.3	missense_variant
ALK F1174L	ALK	F1174L	Neuroblastoma	Crizotinib	Predictive	Supports	D	Sensitivity/Response	chr2	29220829	29220829	G	T	High levels of crizotinib can overcome drug resistance of Ba/F3 cells expressing the EML4-ALK fusion containing the F1174L mutation.	"Heuckmann et al., 2011, Clin. Cancer Res."	Somatic	ENST00000389048.3	missense_variant
ALK F1174L	ALK	F1174L	Neuroblastoma	Crizotinib	Predictive	Supports	D	Resistance	chr2	29220829	29220829	G	T	Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation. The authors conclude that this effect should be surmountable with higher doses of crizotinib and/or with higher-affinity inhibitors.	"Bresler et al., 2011, Sci Transl Med"	Somatic	ENST00000389048.3	missense_variant
ALK F1174L	ALK	F1174L	Neuroblastoma	TAE684	Predictive	Supports	D	Sensitivity/Response	chr2	29220829	29220829	G	T	SH-SY5Y and Kelly cells with mutant ALK (F1174L) and Ba/F3 cells overexpressing ALK harboring the F1174L mutation are sensitive to TAE684-mediated growth inhibition.	"George et al., 2008, Nature"	Somatic	ENST00000389048.3	missense_variant
ALK F1174L	ALK	F1174L	Neuroblastoma	Crizotinib	Predictive	Does Not Support	C	Sensitivity/Response	chr2	29220829	29220829	G	T	"In a Phase I trial (NCT00939770) of the drug crizotinib in pediatric patients, a subset of 11 neuroblastoma patients were characterized for mutations in ALK. Of these 11 patients, 4 had the F1174L mutation. Among these 4 patients, stable disease (SD) was observed in one, and progressive disease (PD) was observed in 3 others after administration of crizotinib. In contrast, in the remaining 7 patients with mutations different than F1174L, 4 had PD, 2 had SD and one had complete response as best response after initiation of crizotinib."	"Moss et al., 2013, Lancet Oncol."	Somatic	ENST00000389048.3	missense_variant
ALK F1174L	ALK	F1174L	Neuroblastoma	AZD3463	Predictive	Supports	D	Sensitivity/Response	chr2	29220829	29220829	G	T	"The SH-SY5Y neuroblastoma cell line containing the F1174L ALK mutation was found to undergo cell death when treated with the ALK/IGF1R inhibitor AZD3463. These cells were more sensitive than other neuroblastoma cell lines containing wild-type ALK. Marked inhibition of soft agar colony formation of SH-SY5Y cells was also observed with drug treatment. AZD3463 inhibited Akt signaling in these cells within two hours of treatment, and activated apoptosis and autophagy pathways. Treatment of SH-SY5Y cells implanted into left kidneys of nude mice resulted in almost complete tumor regression."	"Wang et al., 2016, Sci Rep"	Somatic	ENST00000389048.3	missense_variant
ALK F1174L	ALK	F1174L	Neuroblastoma	Lorlatinib	Predictive	Supports	D	Sensitivity/Response	chr2	29220829	29220829	G	T	"Efficacy of the second generation ALK inhibitor PF-06463922 was tested on ALK mutation F1174L containing neuroblastoma-derived cells.  COG-N-453x and SH-SY5Y xenografts showed some inhibition when treated with crizotinib, but showed complete growth inhibition with PF-06463922 treatment.  This corresponded to 0% event free survival (EFS) in these mice by 6 weeks with crizotinib treatment, but 100% EFS with PF-06463922 treatment. Comparison of crizotinib and PF-06463922 growth inhibition in F1174L cells SH-SY5Y, NBSD 415-IMDM and KELLY showed increased sensitivity to PF-06463922, as compared to crizotinib. Inhibition effects were not seen on neuroblastoma cells with wild type ALK (NB-EBc1, SK-N-BE(2)C). Decreased phosphorylation on ALK tyrosine 1278 was seen with PF-06463922 over crizotinib at 10 and 100 nM concentrations in SH-SY5Y cells. PF-06463922 was well tolerated in the in-vivo models."	"Infarinato et al., 2016, Cancer Discov"	Somatic	ENST00000389048.3	missense_variant
ALK I1171	ALK	I1171	Lung Non-small Cell Carcinoma	Alectinib	Predictive	Supports	C	Resistance	chr2	29222347	29222347	A	G	"The I1171T mutation in ALK fusions was found in a NSCLC patient shown positive for ALK rearrangement via break apart FISH assay, who progressed after 8 months of crizotinib, and then progressed again after 4 months of alectinib. The MGH056-1 cell line was derived from this patient, and this cell line was resistant to alectinib. Sequencing of MGH056-1 cells revealed the I1171T mutation in ALK. In cell culture studies Ba/F3 cells with EML4-ALK I1171T required more that 10x the concentration of alectinib to significantly reduce viability that was required for EML4-ALK wild-type expressing cells. Computer simulation studies indicated that the I1171T mutation interfered with alectinib binding at the ALK active site."	"Katayama et al., 2014, Clin. Cancer Res."	Somatic	ENST00000389048.3	missense_variant
ALK I1171	ALK	I1171	Lung Non-small Cell Carcinoma	Ceritinib	Predictive	Supports	C	Sensitivity/Response	chr2	29222347	29222347	A	G	"The MGH056-1 cell line was derived from an NSCLC patient with ALK-rearrangement who had progressed on crizotinib and then on alectinib. the cell line was also resistant to crizotinib and alectinib, and sequencing of ALK from the cell line revealed the I1171T mutation. Further testing of this mutation in BaF3 cells revealed that cells expressing EML4-ALk with I1171T mutation required 10x higher concentration to induce cell death than BaF3 cells with wild-type EML4-ALK. In contrast, ceritinib caused loss of viability in EML4-ALK wild-type and I1171T BaF3 cells at comparable concentrations. Ceritinib was also effective at killing MGH056-1 cells that were resistant to alectinib, and reduced Akt and ERK phosphorylation in these cells. Finally, administration of ceritinib to the crizotinib and alectinib resistant patient let to tumor regression and partial response lasting 7 months."	"Katayama et al., 2014, Clin. Cancer Res."	Somatic	ENST00000389048.3	missense_variant
ALK I1171	ALK	I1171	Lung Non-small Cell Carcinoma	TAE684	Predictive	Supports	D	Sensitivity/Response	chr2	29222347	29222347	A	G	"The I1171T ALK kinase domain mutaion was found in the MGH056-1 cell line which was derived from an ALK rearranged NSCLC patient who had progressed on crizotinib and then on alectinib given at lower dose (300mg twice daily).  Ectopic expression of EML4-ALK I1171T in Ba/F3 cells made these cells moderately resistant to crizotinib and resistant to alectinib. In contrast, the frequently used tool compound TAE684 was equally effective against EML4-ALK wild-type and I1171T, causing cell death at 1000x lower concentration then in unaltered Ba/F3 cells supplemented with IL3."	"Katayama et al., 2014, Clin. Cancer Res."	Somatic	ENST00000389048.3	missense_variant
ALK I1171	ALK	I1171	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	D	Resistance	chr2	29222347	29222347	A	G	The MGH056-1 cell line was derived from a patient with ALK rearranged NSCLC who had progressed on crizotinib and then on lower dose alectinib (300 mg twice daily). The I1171T ALK kinase domain mutation was found in this cell line (established after alectinib resistance). MGH056-1 cells were resistant to crizotinib (IC50 236nmol/L; aproximately 50x higher than for ceritinib). About 50 fold higher concentration of crizotinib was required to inhibit Ba/F3 cells expressing EML4 ALK I1171T than was required for EML4 ALK wild-type.	"Katayama et al., 2014, Clin. Cancer Res."	Somatic	ENST00000389048.3	missense_variant
ALK I1171	ALK	I1171	Lung Non-small Cell Carcinoma	Ceritinib	Predictive	Supports	D	Sensitivity/Response	chr2	29222347	29222347	A	G	"Ba/F3 cells expressing EML4-ALK variant 3 with ALK I1171T mutation were treated with ceritinib, and survival IC50 of 2.6 nM was observed, which compares favorably with highly ceritinib sensitive EML4-ALK wild-type variant 1 survival IC50 of 1.7 nM reported from parallel experiments. Tumors from mice with EML4-ALK variant 3 H2228 NSCLC cell xenografts which had progressed after approximately 40 days of crizotinib treatment were sequenced for ALK mutations. I1171T was found as one of 6 ALK resistance mutations from 80 sequenced tumors. Treatment of these mouse xenograft models with ceritinib reduced tumor volume to zero, while in contrast tumor size increased with crizotinib treatment."	"Friboulet et al., 2014, Cancer Discov"	Somatic	ENST00000389048.3	missense_variant
ALK I1171	ALK	I1171	Lung Non-small Cell Carcinoma	Alectinib	Predictive	Supports	C	Resistance	chr2	29222347	29222347	A	G	"A 51 year old female never-smoker was diagnosed with stage IV NSCLC with liver metastases. ALK rearrangement was verified via FISH. She was treated with crizotinib at 250 mg twice daily but discontinued due to adverse response. She then started alectinib at 600 mg twice daily with partial response, but new liver metastases then formed at 5 months. Liver tumor biopsy was performed and was estimated to be 15% tumor tissue. Next-generation sequencing discovered an ALK I1171N mutation. The tumor was not sequenced prior to alectinib resistance."	"Ou et al., 2015, Lung Cancer"	Somatic	ENST00000389048.3	missense_variant
ALK I1171	ALK	I1171	Lung Non-small Cell Carcinoma	Ceritinib	Predictive	Supports	C	Sensitivity/Response	chr2	29222347	29222347	A	G	"A 51 year old female never smoker was diagnosed with stage IV NSCLC with liver metastases, and had adverse response to crizotinib treatment, after which she responded to alectinib until disease progressed after 5 months with new liver metastases. Liver tumor biopsy was taken and estimated to be 15% tumor. Hybrid capture next generation sequencing was performed and an I1171N mutation was found in rearranged ALK, and estimated to be in 33% of the tumor cells. Ceritinib was given at 750 mg once daily but dose reduction to 600 mg once daily was required due to persistent nausea. CT showed regression of liver lesions and primary lung lesion and ongoing response was seen at 3 months."	"Ou et al., 2015, Lung Cancer"	Somatic	ENST00000389048.3	missense_variant
ALK Exon 4-11 Deletion	ALK	Exon 4-11 Deletion	Neuroblastoma	Brigatinib	Predictive	Supports	D	Sensitivity/Response	chr2	29251662	29630790			"The MYCN amplification positive relapsed neuroblastoma-derived cell line CLB-BAR contains the driver ALK DEL 11-14 mutation, which removes extracellular domain exons 4 through 11. Brigatinib treatment of CLB-BAR cells reduced MYCN protein levels and ALK phosphorylation (Y1604) similar to crizotnib. Brigatinib reduced CLB-BAR cellular proliferation more effectively than crizotinib (IC50 75.2 vs 186.4nM). CLB-BAR xenografts in BalbC/NUDE mice responded to brigatinib with reduced tumor volume and weight (N=8/group) as well as reduced ALK phosphorylation and MYCN levels compared to untreated controls. Release of brigatinib administration at day 15 resulted in tumor growth (N=2)."	"Siaw et al., 2016, Oncotarget"	Somatic	ENST00000389048.3	inframe_deletion
ALK EML4::ALK	ALK	EML4::ALK	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr2	42169350	42295516			A 28 year-old patient with non-small cell lung cancer that failed conventional therapy was found to harbor the EML4-ALK (E13;A20) fusion using reverse transcription PCR. Treatment with 250mg crizotinib twice daily resulted in rapid improvement of symptoms and disease control for 5 months.	"Choi et al., 2010, N. Engl. J. Med."	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK	ALK	EML4::ALK	Lung Acinar Adenocarcinoma	Erlotinib	Predictive	Supports	C	Resistance	chr2	42169350	42295516			"A 39-year-old man presented was observed to have lung acinar adenocarcinoma. Treatment with chemotherapy produced no remarkable response. A EGFR L858R point mutation was observed; the patient was therefore treated with erlotinib, but the disease progressed after 30 days. A second biopsy identified a EML4-ALK fusion, which may explain the therapeutic resistance."	"Tanaka et al., 2012, BMC Cancer"	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK	ALK	EML4::ALK	Lung Non-small Cell Carcinoma	WHI-P154	Predictive	Supports	D	Sensitivity/Response	chr2	42169350	42295516			"A retroviral cDNA expression library was constructed using a lung adenocarcinoma specimen from a 67 year old NSCLC patient, and transfected into mouse 3T3 fibroblasts which were assessed for transformed foci.  Analysis of clones from one transformed focus yielded a novel fusion. This fusion generated a protein with N-terminal consisting of EML4 exons 1-13 and C-terminal consisting of ALK exons 20-29, which comprise the intracellular kinase domain of ALK. In subsequent experiments using EML4-ALK or altered versions, the transforming potential of EML4-ALK was found to be dependent on a functional ALK kinase activity as well as the EML4 basic domain, which was shown to have an important role in EML4-ALK dimer formation.  BA/F3 cells expressing EML4-ALK were able to grow independently of IL3 addition, but addition of ALK inhibitor WHI-P154 induced cell death and inhibited tyrosine phosphorylation of EML4-ALK. These results indicated that EML4-ALK may be a driver mutation in NSCLC,  and a target for ALK inhibitor treatment."	"Soda et al., 2007, Nature"	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK e20-e20	ALK	EML4::ALK e20-e20	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr2	42169350	42325554			"In the PROFILE 1001 study, from 31 NSCLC tumors positive for ALK fusions with sufficient material for RT-PCR aided exon breakpoint identification, 1 case of EML4-ALK variant 2 (EML4 exon 20 fused to ALK exon 20) was found. This patient had adenocarcinoma and a 9 pack year smoking history. Crizotinib treatment duration was over 16 weeks. The patient had multiple lines of prior treatment and showed a partial response to first-time crizotinib treatment. Overall, in the 82 ALK positive patients treated in the study, 46 had partial responses (including this patient) and 1 had a complete response for an overall response rate of 57%."	"Kwak et al., 2010, N. Engl. J. Med."	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK e2-e20	ALK	EML4::ALK e2-e20	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	E	Sensitivity/Response	chr2	42169350	42245687			"Multiplex RT-PCR to detect in-frame fusions of EML4 to ALK was performed on total RNA from 253 lung adenocarcinomas, and 9 samples were found to contain such fusions, one of which was a novel fusion containing EML4 exon 2 and exon 20 of ALK. This was called variant 5. Two versions of this variant were seen: 5a consisted of EML4 exon 2 fused to ALK exon 20 while 5b contained a 117bp intronic ALK region between the two exons. Genomic PCR showed that EML4-ALK variant 5 tumor cells contained a single EML4-ALK fusion, suggesting 5a and 5b arise from alternate splicing.  5a and 5b showed in-vitro kinase activity and transformed 3T3 cells in cell culture. 5a and 5b transformed 3T3 cells formed tumors when injected in 8/8 nude mice, but 3T3 transformed with ALK alone did not.  These results suggest that EML4-ALK variant 5 is a driver mutation in lung adenocarcinoma targetable by ALK inhibitors like crizotinib."	"Takeuchi et al., 2008, Clin. Cancer Res."	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK e6-e20	ALK	EML4::ALK e6-e20	Lung Non-small Cell Carcinoma	"2,4-pyrimidinediamine"	Predictive	Supports	D	Sensitivity/Response	chr2	42169350	42264731			"In a cohort of 75 NSCLC patients that had tested positive for 3 EML4-ALK rearrangements, two individuals were identified via RT-PCR with a novel EML4-ALK translocation involving the first 6 exons of EML4 fused to the kinase domain of ALK. Genomic PCR resolved a single breakpoint, but 2 variants of the fusion were observed in cells. Variant 3a consisted of fusion at EML4 exon 6 and ALK exon 20, while variant 3b fused a 33 bp intronic EML4 region between EML4 exon 6 and ALK exon 20.  3a and 3b showed strong in-vitro kinase activity, transformed mouse 3T3 cells, and 3b-transformed 3T3 cells formed tumors in 8/8 nude mice.  The ALK inhibitor 2,4-pyrimidinediamine inhibited growth of the 3a/b containing NCI-H2228 NSCLC cell line.  The results indicate that 3a/b is a targetable driver-mutation as other EML4-ALK variants."	"Choi et al., 2008, Cancer Res."	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK e6-e20	ALK	EML4::ALK e6-e20	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr2	42169350	42264731			"In a set of 31 patients with NSCLC, RT-PCR was performed to test for known EML4-ALK variants.  Five patients tested positive for the 3a/3b EML4-ALK variant.  Of these, 4 had partial response (PR), and one had disease progression (DP), and this was the only DP in the group of 31.  In contrast, of the 13 testing positive for EML4-ALK variant 1, 12 showed PR, and 1 showed stable disease.  These results potentially mirror findings in the H2228 3a/3b containing NSCLC cell line where some literature indicates it does respond as strongly to ALK inhibition as other EML4-ALK NSCLC cell lines."	"Kwak et al., 2010, N. Engl. J. Med."	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK e6-e20	ALK	EML4::ALK e6-e20	Lung Non-small Cell Carcinoma	TAE684	Predictive	Supports	D	Sensitivity/Response	chr2	42169350	42264731			"In a panel of 602 cancer cell lines, 3/134 NSCLC cell lines showed <0.5% cell viability following treatment with the ALK inhibitor TAE684. Of these, NCI-H2228 harbored EML4-ALK variant 3a/b (EML4 exon 6 and ALK exon 20). TAE684 inhibited Akt and Erk1/2 phosphorylation in H2228 cells and appeared to induce a cytostatic response."	"McDermott et al., 2008, Cancer Res."	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK e6-e20	ALK	EML4::ALK e6-e20	Lung Non-small Cell Carcinoma	TAE684	Predictive	Does Not Support	D	Sensitivity/Response	chr2	42169350	42264731			"Exon-array and RT-PCR was used to screen a panel of 83 NSCLC cell lines for EML4-ALK variants. The cell lines NCI-H3122 (containing EML4-ALK variant 1) and NCI-H2228 (containing the EML4 exon 6 and ALK exon 20 fusion-variant 3a/3b) were identified. TAE684 (0.1uM) appreciably inhibited growth as well as Akt and Erk1/2 phosphorylation in variant 1 containing H3122 cells. However, incomplete inhibition in 3a/3b containing H2228 cells was observed. H2228 growth inhibition by TAE684 was more similar to NSCLC cell lines harboring KRAS and EGFR mutations."	"Koivunen et al., 2008, Clin. Cancer Res."	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK e20-e20	ALK	EML4::ALK e20-e20	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	D	Sensitivity/Response	chr2	42169350	42325554			"EML4-ALK variants v1 (E13;A20), v2 (E20;A20), v3a (E6;A20) and v3b (E6ins33;A20) were expressed in Ba/F3 cells using retrovirus.  While all constructs rendered Ba/F3 cells IL3-independant, marked differences in sensitivity to ALK inhibitors TAE684 and crizotinib were observed, where v2 was most sensitized to growth inhibition and v3a the least, with v1 and v3b intermediate.  While phospho-ALK western blots indicated that the ALK inhibitors acted similarly on both v2 and v3a EML4-ALK variants, blots of cyclohexamide-treated cells showed that v2 had a shorter half-life than 3a in the transduced cells, potentially explaining increased v2 sensitivity.  Assays with a panel of mutated EML4-ALK variants of varied length suggested that longer EML4-ALK variants are less stable in cells, although this tendency was not observed across other types of ALK fusion."	"Heuckmann et al., 2012, Clin. Cancer Res."	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK e6-e20	ALK	EML4::ALK e6-e20	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Does Not Support	D	Sensitivity/Response	chr2	42169350	42264731			"Ba/F3 cells transduced with EML4-ALK variants v1 (E13;A20), v2 (E20;A20), v3a (E6;A20) and v3b (E6ins33;A20) showed differential sensitivity to both crizotinib and TAE684, with variant 3a (E6;A20) being the least sensitive. The authors suggest that the type/structure of ALK fusion may have some impact on patient outcome in targeted therapy."	"Heuckmann et al., 2012, Clin. Cancer Res."	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK	ALK	EML4::ALK	Lung Non-small Cell Carcinoma	"Crizotinib,Retaspimycin Hydrochloride"	Predictive	Supports	D	Sensitivity/Response	chr2	42169350	42295516			"In preclinical work using H3122 NSCLC cells which contain the EML4-ALK variant 1, administration of the Hsp90 inhibitor IPI-504 caused marked decrease of EML4-ALK protein levels at concentrations lower than those used to knock down protein levels of drivers such as HER2 or EGFR in other cell lines, making it the most sensitive Hsp90 client protein the authors had encountered.  IPI-504 treatment caused regression of H3122 tumors in nude mice, whereas Hsp90 inhibitors usually only cause growth inhibition in these models.  Combined treatment of these mice with IPI-504 and crizotinib caused an even stronger tumor regression."	"Normant et al., 2011, Oncogene"	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK e20-e20	ALK	EML4::ALK e20-e20	Lung Non-small Cell Carcinoma	"Alvespimycin,Crizotinib"	Predictive	Supports	D	Sensitivity/Response	chr2	42169350	42325554			"EML4-ALK fusions occur in 2-7% of lung adenocarcinomas. Transduction of Ba/F3 cells with EML4-ALK variant 2 (EML4 exon 20 fused to ALK exon 20) caused the cells to grow independently of IL3 addition.  EML4-ALK may be a client protein of Hsp90. Addition of Hsp90 inhibitor 17-DMAG to the EML4-ALK variant 2 cells induced cell death which was rescued at lower 17-DMAG concentrations by IL3 addition. This result suggests that 17-DMAG specifically  targeted the EML4-ALK driver in these cells. Finally, 17-DMAG and crizotinib showed a synergistic effect in killing EML4-ALK variant 2 cells."	"Heuckmann et al., 2012, Clin. Cancer Res."	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK e6-e20	ALK	EML4::ALK e6-e20	Lung Non-small Cell Carcinoma	Alvespimycin	Predictive	Does Not Support	D	Sensitivity/Response	chr2	42169350	42264731			"Transduction of Ba/F3 cells with EML4-ALK variant 3a caused the cells to grow independently of IL3 addition.  While incubation of Ba/F3 cells transduced with EML4-ALK variants 1 and 2 with Hsp90 inhibitor 17-DMAG caused cell death that was reversible with IL3 addition, Ba/F3 cells with variant 3a were not sensitized to 17-DMAG induced death, suggesting that 17-DMAG was effecting the EML4-ALK driver of IL3-independant proliferation. This in turn suggests that variant 3a may not rely on Hsp90 for stability in cancer cells to the extent of other variants."	"Heuckmann et al., 2012, Clin. Cancer Res."	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK	ALK	EML4::ALK	Lung Non-small Cell Carcinoma	"Alvespimycin,Crizotinib"	Predictive	Supports	D	Sensitivity/Response	chr2	42169350	42295516			"Transduction of Ba/F3 cells with EML4-ALK variant 1 causes IL3 independent growth. Incubation of EML4-ALK variant 1 transduced Ba/F3 cells with Hsp90 inhibitor 17-DMAG caused cell death that was reversible with IL3 addition, suggesting that 17-DMAG was effecting the EML4-ALK driver of IL3-independant proliferation, and that EML4-ALK variant 1 is a client protein of Hsp90. The degree of Hsp90 dependence, and targetability of EML4-ALK for Hsp90 inhibition, may vary among ALK fusion variants.  Addition of crizotinib to 17-DMAG caused synergistic death effects, suggesting potential clinical benefit for this inhibitor combination in targeting EML4-ALK variant 1."	"Heuckmann et al., 2012, Clin. Cancer Res."	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK	ALK	EML4::ALK	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr2	42169350	42295516			"In the PROFILE 1001 study of crizotinib in 82 patients with ALK-rearranged NSCLC, 31 patients with sufficient tumor material were tested using RT-PCR for the presence of certain EML4-ALK variants.  13/31 tested patients had the EML4-ALK variant 1. Of these, 12/13 had a partial response, and 1 had stable disease. This response rate of 92% is in contrast to the 57% response rate in the overall patient population, but the numbers of patients with specific EML4-ALK breakpoints were insufficient to correlate with patient response rate."	"Kwak et al., 2010, N. Engl. J. Med."	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK e20-e20	ALK	EML4::ALK e20-e20	Cancer	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr2	42169350	42325554			"This case study presented a 53-year-old never-smoker with a poorly differentiated malignant neoplasm. Morphology and immunohistochemistry were unable to establish the primary tumor site. Right upper extremity (RUE), scalp, and multiple lung lesions were apparent. A lung lesion sample with sufficient material for molecular profiling was not attainable but sufficient material was present from the RUE for hybrid capture genomic profiling  (FoundationOne kit was used). EML4-ALK variant 2 was found, and the patient was started on crizotinib. Rapid symptom improvement was seen. After 1 month, a CT scan showed significant size reduction in lung tumors, and after 5 months the patient was asymptomatic with an entirely negative examination."	"Chung et al., 2014, Case Rep Oncol"	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK e2-e20	ALK	EML4::ALK e2-e20	Renal Cell Carcinoma		Predictive	Supports	E	Sensitivity/Response	chr2	42169350	42245687			"Adenocarcinoma cells were detected via urinary cytology in a 53 year old woman. Cancer morphology suggested papillary renal cell carcinoma (RCC), type 2A.  EML4-ALK variant 5 was discovered in tumor tissue using PCR with EML4 and ALK specific primers. The authors conclude that their findings confirm the potential for ALK targeting therapy in select cases of RCC."	"Sugawara et al., 2012, Cancer"	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK	ALK	EML4::ALK	Lung Non-small Cell Carcinoma	Lorlatinib	Predictive	Supports	D	Sensitivity/Response	chr2	42169350	42295516			"EML4-ALK variant 1 containing H-3122 NSCLC cells were treated with second generation ALK inhibitor PF-06463922. PF-06463922 was 125x more potent at reducing cell viability than crizotinib. Control neuroblastoma cell lines with wild-type ALK did not show inhibition below 3800 nM with either drug. At values of 10 and 100 nM, PF-06463922 showed increased ability to inhibit ALK 1278 tyrosine phosphorylation in H3122 cells."	"Infarinato et al., 2016, Cancer Discov"	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK e6-e20	ALK	EML4::ALK e6-e20	Lung Non-small Cell Carcinoma	Ceritinib	Predictive	Supports	D	Sensitivity/Response	chr2	42169350	42264731			"Ceritinib was 28x more potent (GI50 3.8nM) than crizotinib (GI50 107nM) at inhibiting growth of  H2228, an NSCLC cell line which harbors the EML4-ALK variant 3a/3b. SCID mice xenografted with H2228 were treated for 14 days with crizotinib (100 mg/kg) or ceritinib (25 or 50 mg/kg). All treatments caused tumor regression, but tumors recurred within 11 days after crizotinib treatment withdrawal. 4/8 mice treated with 25 mg/kg ceritinib showed regrowth after 1 month treatment withdrawal. The remaining 4/8 mice treated at 25 mg/kg ceritinib, and all mice treated at 50 mg/kg ceritinib maintained complete remission for four months. While 100 mg/kg crizotinib in mice approximates levels 3-5 times the maximal tolerated dose in humans, the authors state 25 to 50 mg/kg ceritinib in mice is predicted to approximate tolerable doses in humans."	"Friboulet et al., 2014, Cancer Discov"	Somatic	ENST00000318522.5	transcript_fusion
ALK EML4::ALK	ALK	EML4::ALK	Malignant Pleural Mesothelioma	Alectinib	Predictive	Supports	C	Sensitivity/Response	chr2	42169350	42295516			"A 33 year old M non-smoker with no cancer family history and no known exposure to asbestos showed weakness, chest pain, and plural effusion (PE) accumulation. Mass in right lung was seen under enhanced CT. Patient was diagnosed with stage IIIB (cT4N2M0) malignant pleural mesothelioma (MPM) using National Comprehensive Cancer Network (NCCN) guidelines on MPM staging (v.1.2018).   Patient was given palliative chemotherapy for two cycles, which reduced the PE and improved physical mobility. Targeted NGS panel with 520 genes of PE showed EML4::ALK variant 3 (allelic fraction 24.21%). After 1 month symptoms were alleviated and NGS showed reduced EML4::ALK abundance (allelic fraction 8.22%). After 2 months CT showed tumor shrinkage. This was evaluated as partial response."	"Hu et al., 2020, Ther Adv Respir Dis"	Somatic	ENST00000318522.5	transcript_fusion
EPAS1 Overexpression	EPAS1	Overexpression	Colorectal Cancer		Prognostic	Does Not Support	B	Poor Outcome	chr2	46297402	46386697			Expression of EPAS1 (HIF-2alpha) was assessed in 731 colorectal cancers from two prospective cohort studies. EPAS1 overexpression was found in 322 (46%) cancers by immunohistochemistry and not significantly associated with patient survival.	"Baba et al., 2010, Am. J. Pathol."	N/A	ENST00000263734.3	N/A
EPAS1 Overexpression	EPAS1	Overexpression	Renal Cell Carcinoma	Pazopanib	Predictive	Does Not Support	B	Sensitivity/Response	chr2	46297402	46386697			"HIF2A (EPAS1) staining was conducted on tumors from 66 patients, of which 27 were classified as low expression and 39 were classified as high expression. The response rates of patients with low and high HIF2A expression to pazopanib were 44% and 33% (p=0.36) respectively and no significant difference in PFS between the two groups (p=0.76) was observed. The authors concluded that HIF2A expression levels are not associated with clinical response to pazopanib."	"Choueiri et al., 2013, Clin. Cancer Res."	N/A	ENST00000263734.3	N/A
MSH2 Loss	MSH2	Loss	Transitional Cell Carcinoma	"Durvalumab,Anti-PD-1 Monoclonal Antibody MEDI0680"	Predictive	Supports	C	Sensitivity/Response	chr2	47402969	47483228			"Case report of a 45-year old woman of Japanese descent with recurrent urothelial carcinoma. The patient was identified to harbor mutations in MSH2 (A913fs*2, E226*, E580*) and in MSH6 (R361H) by panel sequencing as well as loss of expression of these genes as confirmed by IHC. Testing also revealed a high mutational load as well as 2+ PD-L1 expression in 80% of the cells.  The patient was treated with anti-PD-L1 inhibitor MEDI4736 and MEDI0680 in a phase 1 trial and had a complete remission within 2 months of treatment that was ongoing after 11 months."	"Castro et al., 2015, J Immunother Cancer"	Somatic	ENST00000233146.2	loss_of_function_variant
MSH2 E28FS	MSH2	E28FS	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr2	47403274	47403275		G	"This variant (E28fs), identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a 66 year-old male patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which by definition is a germline condition.. This patient had two somatic mutations in MSH2 (E28fs, K172*)."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000233146.2	frameshift_elongation
MSH2 K172*	MSH2	K172*	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr2	47410241	47410241	A	T	"MSH2 K172*, identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 66 year old male patient (id: sLS-32) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. This patient had two somatic mutations in MSH2 (E28fs, K172*)."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000233146.2	stop_gained
MSH2 V273FS	MSH2	V273FS	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr2	47414294	47414294	T		"This variant (V273fs), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be a somatic mutation in a 61 year-old male patient (sLS-27) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition. LOH of the WT allele was demonstrated."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000233146.2	frameshift_variant
MSH2 R383*	MSH2	R383*	Endometrial Cancer		Oncogenic	Supports	C	Oncogenicity	chr2	47429812	47429812	C	T	"This variant (R383*), identified in two patients, was confirmed to be a somatic mutation in both patients' microsatellite-unstable tumors (39 year-old female with endometrial cancer & 34 year-old female with ovarian cancer) with suspected Lynch Syndrome (LS). These patients were therefore negative for LS, which is by definition a germline condition. LOH of the WT allele was confirmed in the case of ovarian cancer."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000233146.2	stop_gained
MSH2 E483G	MSH2	E483G	Endometrial Cancer		Oncogenic	Supports	C	Oncogenicity	chr2	47463092	47463092	A	G	"MSH2 E483G (c.1448A > G), identified in a case of microsatellite-unstable endometrial cancer was confirmed to be somatic in a 69 year old female patient (sLS-39) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, as LS is a germline condition by definition. This patient also harbored PMS2 p.R315*, MLH1 p.M490T and MSH6 p.V352I mutations. Authors note that this patient's tumor harbored wildtype BRAF."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000233146.2	missense_variant
MSH6 LOSS	MSH6	LOSS	Transitional Cell Carcinoma	"Anti-PD-1 Monoclonal Antibody MEDI0680,Durvalumab"	Predictive	Supports	C	Sensitivity/Response	chr2	47783082	47810101			"Case report of a 45-year old woman of Japanese descent with recurrent urothelial carcinoma. The patient was identified to harbor mutations in MSH2 (A913fs*2, E226*, E580*) and in MSH6 (R361H) by panel sequencing as well as loss of expression of these genes as confirmed by IHC. Testing also revealed a high mutational load as well as 2+ PD-L1 expression in 80% of the cells. The patient was treated with anti-PD-L1 inhibitor MEDI4736 and MEDI0680 in a phase 1 trial and had a complete remission within 2 months of treatment that was ongoing after 11 months."	"Castro et al., 2015, J Immunother Cancer"	Somatic	ENST00000234420.5	loss_of_function_variant
MSH6 P138T	MSH6	P138T	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr2	47791078	47791078	C	A	"This variant, identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000234420.5	missense_variant
MSH6 V352I	MSH6	V352I	Endometrial Cancer		Oncogenic	Supports	C	Oncogenicity	chr2	47799037	47799037	G	A	"This variant (V352I), identified in a case of microsatellite-unstable endometrial cancer, was confirmed to be somatic in a 69 year-old female patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition. This patient also harbored PMS2 p.R315*, MLH1 p.M490T and MSH2 p.E483G mutations."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000234420.5	missense_variant
MSH6 I891FS	MSH6	I891FS	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr2	47800655	47800656	TC		"This variant (I891fs), identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a 79 year-old male patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000234420.5	frameshift_truncation
MSH6 R1242C	MSH6	R1242C	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr2	47806281	47806281	C	T	"MSH6 R1242C (c.3724C > T), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 53 year old male patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, as LS is a germline condition by definition. The authors note that this patient's tumor was not deficient in mismatch repair (MMR) protein and retained heterozygosity in MSH6."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000234420.5	missense_variant
MSH6 R1242H	MSH6	R1242H	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr2	47806282	47806282	G	A	"This variant (R1242H), identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a 79 year-old male patient (sLS-37) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000234420.5	missense_variant
REL AMPLIFICATION	REL	AMPLIFICATION	Diffuse Large B-cell Lymphoma		Diagnostic	Supports	B	Positive	chr2	60881574	60922665			Amplification of REL is shown to be associated with germinal-center B-celllike diffuse large-B-cell lymphomas.	"Rosenwald et al., 2002, N. Engl. J. Med."	Somatic	ENST00000295025.8	transcript_amplification
TGFA EXPRESSION	TGFA	EXPRESSION	Head And Neck Squamous Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr2	70447280	70554015			Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced disease-free and cause-specific survival.	"Rubin Grandis et al., 1998, J. Natl. Cancer Inst."	Somatic	ENST00000295400.6	N/A
ALK RANBP2::ALK	ALK	RANBP2::ALK	Inflammatory Myofibroblastic Tumor	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr2	108719481	108758548			"ALK-rearrangements are seen in 50% of inflammatory myofibroblastic tumor (IMT) cases. A 44 year old man was diagnosed with IMT.  He was treated with surgery and catheter placement for administration of cisplatin, doxyrubicin and mitomycin C.  Break-apart FISH showed ALK rearrangement, and immunohistochemical staining was characteristic of RANBP2 rearrangement. After further chemotherapy along with maintenance imatinib, crizotinib was started at 200mg twice daily, and a maximal partial response was achieved 5 months later, with regrowth occurring 2 months later. After further surgery, crizotinib was restarted at 250mg twice daily and almost 2 years later the patient was in complete radiographic remission. Another patient with non-ALK rearranged IMT was administered crizotinib in this study but did not respond."	"Butrynski et al., 2010, N. Engl. J. Med."	Somatic	ENST00000283195.6	transcript_fusion
ABL1 RANBP2::ABL1	ABL1	RANBP2::ABL1	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"		Diagnostic	Supports	C	Positive	chr2	108719607	108758548			"This study included 1389 cases of high-risk pediatric B-ALL, of which 284 were identified by TaqMan Low Density Array to have a Ph-like gene expression signature. RT-PCR or RNAseq performed on Ph-like, CRLF2 negative patients revealed 17 cases with ABL1 fusions with 8 different partner genes. There were three cases with the RANBP2-ABL1 fusion. Considering the previously confirmed Ph-like expression signature in the tested cases, the results suggest that the presence of the RANBP2-ABL1 fusion in B-ALL indicates the BCR-ABL1-like (Ph-like) subtype of the disease."	"Reshmi et al., 2017, Blood"	Somatic	ENST00000283195	transcript_fusion
ABL1 RANBP2::ABL1	ABL1	RANBP2::ABL1	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	Dasatinib	Predictive	Supports	C	Sensitivity/Response	chr2	108719607	108758548			"This retrospective study reported the outcome of 24 patients with Ph-like acute lymphoblastic leukemia (Ph-like ALL) harboring ABL-class fusions, who were treated with a combination of tyrosine kinase inhibitors (TKIs) and chemotherapy. Of the 24 patients reported, 12 had fusions involving ABL1; in 7/12 patients the ABL1 fusion was detected at diagnosis, and in 5/12 it was identified at relapse. One relapse patient was found to have a RANBP2-ABL1 fusion. This patient was a 20 year old female. An IKZF1 intragenic deletion was detected in her leukemia in addition to the RANBP2-ABL1 fusion. She had good initial prednisone response and reached complete remission (CR) after treatment on the GRAALL2005R trial. However, she relapsed with refractory disease. The RANBP2-ABL1 fusion was detected at relapse, and dasatinib (140 mg daily) was added to chemotherapy; this resulted in a brief response even though her leukemia was previously refractory to several lines of salvage treatment (best MRD level 8x10-3). However, the patient experienced another relapse and died of progressive disease. The case illustrates partial response to TKIs in combination with chemotherapy in a relapsed Ph-like B-ALL with RANBP2-ABL1 fusion."	"Tanasi et al., 2019, Blood"	Somatic	ENST00000283195	transcript_fusion
MERTK OVEREXPRESSION	MERTK	OVEREXPRESSION	Melanoma	UNC1062	Predictive	Supports	D	Sensitivity/Response	chr2	111898479	112029561			"Highest MERTK expression was observed in metastatic melanomas, followed by primary melanomas, and lowest in benign nevi. Over half of melanoma cell lines overexpressed MERTK compared with normal human melanocytes; however, overexpression did not correlate with mutations in BRAF or RAS. MERTK inhibition via shRNA reduced MERTK-mediated downstream signaling, reduced colony formation by up to 59%, and diminished tumor volume by 60% in a human melanoma murine xenograft model. Treatment of melanoma cells with UNC1062, a novel MERTK-selective small-molecule tyrosine kinase inhibitor, reduced activation of MERTK-mediated downstream signaling, induced apoptosis in culture, reduced colony formation in soft agar, and inhibited invasion of melanoma cells."	"Schlegel et al., 2013, J. Clin. Invest."	Somatic	ENST00000295408.4	N/A
PAX8 Expression	PAX8	Expression	Female Reproductive Organ Cancer		Diagnostic	Supports	A	Positive	chr2	113215997	113278950			The authors explored the viability of PAX8 expression as a biomarker for differentiating mullerian from non-mullerian tumors. 74 tumors (37 Mullerian/37 non-Mullerian) were examined for PAX8 expression via IHC. Of these 29/37 Mullerian and 1/37 non-Mullerian tumors exhibited PAX8 expression. The sensitivity and specificity of using this as a biomarker to differentiate between the two tumor types was 78.4% and 97.3% respectively.	"Heidarpour et al., 2014, Adv Biomed Res"	N/A	ENST00000429538.3	N/A
PAX8 PAX8::PPARG	PAX8	PAX8::PPARG	Thyroid Gland Follicular Carcinoma		Diagnostic	Supports	B	Positive	chr2	113235394	113278944			"PAX8PPARG gene fusions were found in 12/33 follicular thyroid carcinoma tumor samples, but were rarely found in thyroid Hrthle cell tumors."	"Nikiforova et al., 2003, J. Clin. Endocrinol. Metab."	Somatic	ENST00000429538.3	transcript_fusion
CXCR4 EXPRESSION	CXCR4	EXPRESSION	Gastric Adenocarcinoma	Docetaxel	Predictive	Supports	B	Resistance	chr2	136114349	136116243			"CXCR4 expression as assessed by microarray analysis, was associated with resistance to docetaxel in 11 cancer cell lines (R^2 = 0.23, p = 0.019). Expression levels (by qtPCR) were also higher in resistant tumors among 25 patient samples."	"Xie et al., 2010, Anticancer Res."	N/A	ENST00000409817.1	N/A
LRP1B DELETION	LRP1B	DELETION	Glioblastoma		Prognostic	Supports	B	Poor Outcome	chr2	140231423	142131701			"A retrospective study of 178 glioblastoma patients found that LRP1B deletion (complete transcript, N=4 or focal transcript deletion of >150kb, N=13) was associated with a lower progress free survival (6.4 months vs. 10.1 months; P = 0.004) and overall free survival (13.4 months vs. 17.8 months; P = 0.001). Multivariate analysis adjusting for age and type of surgery also supported LRP1B deletion being associated with a higher hazard ratio."	"Tabouret et al., 2015, J. Neurol. Sci."	N/A	ENST00000389484.3	transcript_ablation
LRP1B EXON 12-22 DELETION	LRP1B	EXON 12-22 DELETION	Ovarian Cancer	Doxorubicin	Predictive	Supports	D	Resistance	chr2	140907877	141020102			"A minimum common region of deletion of 0.19Mb, encompassing exons 12?2 of LRP1B4 was observed in 4 patients exhibiting acquired treatment resistance. Transfection of mLRP1B4, a fully functional minigene of LRP1B, in IGROV1 and OVCAR4 ovarian cell lines with low expression of LRP1B4 increased sensitivity to liposomal doxorubicin but not doxorubicin. siRNA knockdown of LRP1B4 in JHOS3 and Kuramochi ovarian cancer cell lines decreased sensitivity to liposomal doxorubicin but not doxorubicin."	"Cowin et al., 2012, Cancer Res."	Somatic	ENST00000389484.3	exon_loss_variant
ACVR1 G328V	ACVR1	G328V	"Diffuse Midline Glioma, H3 K27M-mutant"		Diagnostic	Supports	B	Positive	chr2	157766004	157766004	C	A	"Sequencing of 39 pediatric midline high-grade astrocytomas identified 5 patients with ACVR1 mutations. The authors identified an increase in endogenous phospho-SMAD1/5/8 signal in diffuse intrinsic pontine glioma (DIPG) cells harboring ACVR1 G328V, with corresponding increase in phospho-SMAD1/5/8 staining as well. By PCR, the authors show strong increase in fold change of mRNA expression in downstream proteins of the ACVR1/BMP pathway, ID, ID2, ID3 and SNAI1 in ACVR1-mutant DIPG cell line compared to glioblastoma cells (KNS42 cells). These activating ACVR1 mutations were exclusively in midline high grade astrocytomas (P = 0.0040, Fisher's exact test)."	"Fontebasso et al., 2014, Nat. Genet."	Somatic	ENST00000434821.1	missense_variant
ACVR1 G328V	ACVR1	G328V	"Diffuse Midline Glioma, H3 K27M-mutant"		Diagnostic	Supports	B	Positive	chr2	157766004	157766004	C	A	"In a study sequencing 61 patients (median age 6.3) with diffuse intrinsic pontine glioma (DIPG), 12 variants affecting ACVR1 were observed. Five patients had G328V within the kinase domain. The ACVR1 G328V mutation was expressed using the pCDH511b vector in immortalized normal human astrocytes (iNHAs) where it activated downstream BMP signaling and enhanced cell growth. Activating ACVR1 mutations are recurrent and support diagnosis of high grade glioma. PEDIATRIC"	"Buczkowicz et al., 2014, Nat. Genet."	Somatic	ENST00000434821.1	missense_variant
ACVR1 G328V	ACVR1	G328V	"Diffuse Midline Glioma, H3 K27M-mutant"		Diagnostic	Supports	C	Positive	chr2	157766004	157766004	C	A	"It has been reported that recurrent activating somatic mutations (R206H, R258G, G328E/V/W, G356D) in the ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase, are in 21% (11/52) of DIPG samples. The mutations were highly specific to DIPG, with an overall frequency of 0.3% in other tumors present in the Catalogue of Somatic Mutations in Cancer database. Data was collected from whole genome sequencing on 20 pre-treated biopsy samples of DIPG as well as whole exome sequencing from 1 biopsy sample and five samples obtained at autopsy. An additional 26 DIPG biopsy samples were screened via Sanger sequencing and identified the variant (G328W). DIPG cases with somatic mutations of ACVR1 (R206H, R258G, G328E/V/W, G356D) had longer overall survival (n=11 versus 41; median of 14.9 versus 10.9 months; p=0.05, log-rank test)."	"Taylor et al., 2014, Nat. Genet."	Somatic	ENST00000434821.1	missense_variant
ACVR1 G328W	ACVR1	G328W	"Diffuse Midline Glioma, H3 K27M-mutant"		Diagnostic	Supports	C	Positive	chr2	157766005	157766005	C	A	"It has been reported that recurrent activating somatic mutations (R206H, R258G, G328E/V/W, G356D) in the ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase, are in 21% (11/52) of DIPG samples. The mutations were highly specific to DIPG, with an overall frequency of 0.3% in other tumors present in the Catalogue of Somatic Mutations in Cancer database. Data was collected from whole genome sequencing on 20 pre-treated biopsy samples of DIPG as well as whole exome sequencing from 1 biopsy sample and five samples obtained at autopsy. An additional 26 DIPG biopsy samples were screened via Sanger sequencing and identified the variant (G328W). DIPG cases with somatic mutations of ACVR1 (R206H, R258G, G328E/V/W, G356D) had longer overall survival (n=11 versus 41; median of 14.9 versus 10.9 months; p=0.05, log-rank test)."	"Taylor et al., 2014, Nat. Genet."	Somatic	ENST00000263640.3	missense_variant
SF3B1 Mutation	SF3B1	Mutation	Myelodysplastic Syndrome		Prognostic	Supports	B	Better Outcome	chr2	197389784	197435091			"Patients with SF3B1 mutations had a statistically significant longer overall survival as well as event free-survival. Both before and after adjustment for age, karyotype and sex."	"Papaemmanuil et al., 2011, N. Engl. J. Med."	Somatic	ENST00000335508.6	protein_altering_variant
SF3B1 Mutation	SF3B1	Mutation	Chronic Lymphocytic Leukemia		Prognostic	Supports	B	Poor Outcome	chr2	197389784	197435091			"In patients with chronic lymphocytic leukemia, those with mutations in SF3B1 had shorter time to treatment, progression-free survival, and overall survival. A majority of the mutations are in the C-terminal domain with the most frequent location being K700E (50% of reported cases)."	"Wan et al., 2013, Blood"	Somatic	ENST00000335508.6	protein_altering_variant
SF3B1 Mutation	SF3B1	Mutation	Chronic Lymphocytic Leukemia		Prognostic	Supports	B	Poor Outcome	chr2	197389784	197435091			"In the randomized phase 3 UK LRF CCL4 trial comparing first-line treatment with chlorambucil, fludarabine, or fludarabine plus cyclophosphamide, SF3B1 mutations (73/437 patients) were associated with poorer overall survival (median 54.3 vs 79 months, P <0.001), independent of treatment. Additionally, controlling for cases with TP53 deletions/mutations, SF3B1 mutations were associated with reduced progression free survival for patients in the fludarabine plus cyclophosphamide treatment arm when compared to wildtype SF3B1 (29.4 vs 46 months, P=0.002)."	"Oscier et al., 2013, Blood"	Somatic	ENST00000335508.6	protein_altering_variant
SF3B1 Mutation	SF3B1	Mutation	Chronic Lymphocytic Leukemia		Prognostic	Supports	B	Poor Outcome	chr2	197389784	197435091			"In a multivariate analysis of 774 CLL patients, SF3B1 mutations were significantly correlated with shorter time to first treatment (HR=1.644; 95% CI=1.134-2.383). This finding was independent of IGHV mutation status."	"Baliakas et al., 2015, Leukemia"	Somatic	ENST00000335508.6	protein_altering_variant
SF3B1 Mutation	SF3B1	Mutation	Chronic Lymphocytic Leukemia		Prognostic	Supports	A	Poor Outcome	chr2	197389784	197435091			"In a study of 406 previously untreated CLL cases, a multivariate analysis indicated SF3B1 mutations (N=51) were significantly associated with reduced time to first treatment (HR: 1.73; 95%CI: 1.05-2.86; P = 0.031). While clonal mutations (VAF >= 12%) were associated with reduced time to first treatment by univariate analysis (N=28, P<0.0001), subclonal mutations were not (N=21, P=0.22)."	"Nadeu et al., 2016, Blood"	Somatic	ENST00000335508.6	protein_altering_variant
SF3B1 K700E	SF3B1	K700E	Breast Cancer	Spliceostatin A	Predictive	Supports	D	Sensitivity/Response	chr2	197402110	197402110	T	C	"Mutations in SF3B1 were identified in 21/936 ER positive vs. 1/289 ER negative breast cancers. Mutation was recurrent (K700E in 74% or K666Q or K666E in another 9% of tumors). Treatment of two SF3B1 mutant cell lines (pancreatic and endometrial with K700 and K666 mutation, respectively) and six wild-type controls showed that mutant cell lines were significantly more sensitive to spliceostatin A (SF3b complex inhibitor)."	"Maguire et al., 2015, J. Pathol."	Somatic	ENST00000335508.6	missense_variant
SF3B1 K700E	SF3B1	K700E	Leukemia	"Olaparib,Etoposide"	Predictive	Supports	D	Sensitivity/Response	chr2	197402110	197402110	T	C	"The cancer-associated SF3B1-K700E mutation compromises homologous recombination repair and increases the sensitivity to ionising radiation and DNA damaging agents, such as etoposide or small molecule inhibitors including olaparib in isogenic K562 cell line. The SF3B1-WT and SF3B1-K700E cell lines were also engrafted subcutaneously into immunocompromised mice, and the mice were treated with etoposide, olaparib or a vehicle control and monitored tumour growth for 28 days. Treatment with either etoposide or olaparib significantly reduced the volume of the SF3B1-K700E mutant tumours, but had little effect on the volume of SF3B1-WT tumours."	"Lappin et al., 2022, Cancer Res"	Somatic	ENST00000335508.6	missense_variant
SF3B1 K666N	SF3B1	K666N	Breast Cancer	Spliceostatin A	Predictive	Supports	D	Sensitivity/Response	chr2	197402635	197402635	C	A	"Mutations in SF3B1 were identified in 21/936 ER positive vs. 1/289 ER negative breast cancers. Mutation was recurrent (K700E in 74% or K666Q or K666E in another 9% of tumors). Treatment of two SF3B1 mutant cell lines (pancreatic and endometrial with K700 and K666 mutation, respectively) and six wild-type controls showed that mutant cell lines were significantly more sensitive to spliceostatin A (SF3b complex inhibitor)."	"Maguire et al., 2015, J. Pathol."	Somatic	ENST00000335508.6	missense_variant
CFLAR EXPRESSION	CFLAR	EXPRESSION	Prostate Cancer	Bicalutamide	Predictive	Supports	D	Resistance	chr2	201116104	201176687			"Expression of c-FLIP (CFLAR) in 50 prostate specimens (assessed by IHC) was increased in castrate-resistant prostate cancer. In-vitro, silencing of CFLAR led to sensitization of two cell lines to bicalutamide."	"McCourt et al., 2012, Clin. Cancer Res."	N/A	ENST00000309955.3	N/A
CASP8 Overexpression	CASP8	Overexpression	Ewing Sarcoma Of Bone	Conatumumab	Predictive	Supports	D	Sensitivity/Response	chr2	201258036	201287711			In-vitro and in-vivo sensitivity to DR5 antibody conatumumab was correlated with expression of caspase-8.	"Kang et al., 2015, Br. J. Cancer"	N/A	ENST00000358485.4	N/A
CTLA4 CTLA4::CD28	CTLA4	CTLA4::CD28	Sezary's Disease	Ipilimumab	Predictive	Supports	C	Sensitivity/Response	chr2	203734784	203738912			"A 67-year-old Caucasian female with stage IVA Sezary syndrome presented refractory to traditional therapy and was enrolled in a whole genome study trial. Sequencing revealed a CTLA4-CD28 fusion protein such that the inhibitory CTLA4 receptor activated a stimulatory CD28 intracellular domain that promoted proliferation. The patient was treated with iplimumab, a CTLA4 receptor inhibitor, and after 10 days, there was a reduction in erythema and ulceration by 50%, a reduction in tumor size by 75%, and overall improved quality of life. However, during the sixth week of therapy, the patient rapidly developed skin tumors and died 3 months later."	"Sekulic et al., 2015, Mol Genet Genomic Med"	Somatic	ENST00000302823.3	transcript_fusion
CTLA4 CTLA4::CD28	CTLA4	CTLA4::CD28	Sezary's Disease	Ipilimumab	Predictive	Supports	C	Sensitivity/Response	chr2	203867786	203871487			"A 67-year-old Caucasian female with stage IVA Sezary syndrome presented refractory to traditional therapy and was enrolled in a whole genome study trial. Sequencing revealed a CTLA4-CD28 fusion protein such that the inhibitory CTLA4 receptor activated a stimulatory CD28 intracellular domain that promoted proliferation. The patient was treated with iplimumab, a CTLA4 receptor inhibitor, and after 10 days, there was a reduction in erythema and ulceration by 50%, a reduction in tumor size by 75%, and overall improved quality of life. However, during the sixth week of therapy, the patient rapidly developed skin tumors and died 3 months later."	"Sekulic et al., 2015, Mol Genet Genomic Med"	Somatic	ENST00000302823.3	transcript_fusion
IDH1 Mutation	IDH1	Mutation	Brain Glioma		Prognostic	Supports	B	Better Outcome	chr2	208237079	208251551			Genomewide analysis of 250 low-grade adult gliomas revealed that patients with a wildtype IDH1/2 had significantly shorter overall survival than those with a mutated IDH gene (HR 7.4; 95%CI: 4.0-13.8). The median survival for patients with low grade gliomas was 1.7 years for patients with wild-type IDH (N=55); 6.3 years for patients with mutated IDH and no 1p/19q co-deletion (N=139); and 8.0 years for patients with IDH mutation and a 1p/19q co-deletion (N=84).	"2015, N. Engl. J. Med."	Somatic	ENST00000415913.1	transcript_variant
IDH1 Mutation	IDH1	Mutation	Brain Glioma	Olaparib	Predictive	Supports	D	Sensitivity/Response	chr2	208237079	208251551			"Mutations in isocitrate dehydrogenase 1 and 2, which result in overproduction of 2-hydroxyglutarate (2HG). 2HG is considered to be an oncometabolite, or a metabolite that promotes carcinogenesis, and inhibitors of mutant isocitrate dehydrogenase are in development to target this process. The authors discovered that 2HG overproduction impairs homologous recombination used in DNA repair and sensitizes cancer cells to treatment with PARP inhibitors, another class of cancer drugs that are already in clinical use."	"Sulkowski et al., 2017, Sci Transl Med"	Somatic	ENST00000415913.1	transcript_variant
IDH1 Mutation	IDH1	Mutation	Acute Myeloid Leukemia	Ivosidenib	Predictive	Supports	A	Sensitivity/Response	chr2	208237079	208251551			"I phase 1 trial for patients with IDH1-mutated AML, patients who received ivosidenib (AG-120). The rate of complete remission was 21.6%, the over all response rate was 30.4%."	"DiNardo et al., 2018, N. Engl. J. Med."	Somatic	ENST00000415913.1	transcript_variant
IDH1 Mutation	IDH1	Mutation	Cholangiocarcinoma	Ivosidenib	Predictive	Supports	B	Sensitivity/Response	chr2	208237079	208251551			"In a phase1 trial, 73 patients with cholangiocarcinoma harboring IDH1 mutations were treated with mutant IDH1 inhibitor ivosidenib. The response rate was 5%, median progression free survival was 3.8 months, and median overall survival was 13.8 months."	"Lowery et al., 2019, Lancet Gastroenterol Hepatol"	Somatic	ENST00000415913.1	transcript_variant
IDH1 Mutation	IDH1	Mutation	Chondrosarcoma		Prognostic	Supports	B	Better Outcome	chr2	208237079	208251551			"In a retrospective study, the authors evaluated the association between IDH1/IDH2 mutation and prognosis in patients with high-grade central chondrosarcoma. Although no association was discovered between IDH mutation status and the patient's overall survival, IDH1/IDH2 mutation was found to be associated with longer relapse free and metastasis free survival in high-grade chondrosarcomas."	"Zhu et al., 2020, Clin. Cancer Res."	Somatic	ENST00000415913.1	transcript_variant
IDH1 Mutation	IDH1	Mutation	Acute Myeloid Leukemia	Venetoclax	Predictive	Supports	C	Sensitivity/Response	chr2	208237079	208251551			"In this case series, 7 elderly patients with secondary AML (sAML) not eligible for intensive chemotherapy and refractory to HMA (including 1 patient with antecedent myeloproliferative neoplasm) were treated with venetoclax monotherapy. Three of 7 patients showed response. Of these: 2 patients achieved complete remission (1 of which was mutated for IDH2). One patient with IDH1 mutation showed PB blast clearance (derived anti-leukemic benefit) but BM was not performed to evaluate response. Venetoclax responders had high BCL? and/or BIM expression levels in myeloblasts, and the response was significantly associated with OS. BCL-2 and BIM expression levels can potentially identifer venetoclax responders."	"Huemer et al., 2019, Eur J Haematol"	Somatic	ENST00000415913.1	transcript_variant
IDH1 R132	IDH1	R132	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	N/A	chr2	208248387	208248389			Mutation status of IDH1 did not change event-free survival of patients with an NPM1 mutation.	"Schnittger et al., 2010, Blood"	Somatic	ENST00000415913.1	protein_altering_variant
IDH1 R132	IDH1	R132	Acute Myeloid Leukemia		Diagnostic	Supports	B	Positive	chr2	208248387	208248389			"In leukemia patients, IDH1 R132 mutation is associated with adults and normal karyotype."	"Ho et al., 2010, Leukemia"	Somatic	ENST00000415913.1	protein_altering_variant
IDH1 R132	IDH1	R132	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	N/A	chr2	208248387	208248389			The complete remission and overall survival rates in patients with IDH1 R132 mutation is not significantly different from those who do not have this mutation.	"Wagner et al., 2010, J. Clin. Oncol."	Somatic	ENST00000415913.1	protein_altering_variant
IDH1 R132	IDH1	R132	Malignant Astrocytoma		Prognostic	Supports	B	Better Outcome	chr2	208248387	208248389			"In patients with astrocytoma, the presence of IDH1 R132 mutation is prognostic for better survival compared to patients who harbor wild type mutation."	"Dubbink et al., 2009, Neurology"	Somatic	ENST00000415913.1	protein_altering_variant
IDH1 R132	IDH1	R132	Glioblastoma		Prognostic	Supports	B	Better Outcome	chr2	208248387	208248389			"In patients with glioblastoma, those harboring IDH1 R132 mutation has higher overall survival compared to those who do not have IDH1 mutation."	"Bleeker et al., 2010, Acta Neuropathol."	Somatic	ENST00000415913.1	protein_altering_variant
IDH1 R132	IDH1	R132	Myelodysplastic Syndrome		Prognostic	Supports	B	Poor Outcome	chr2	208248387	208248389			IDH1 R132 mutation in patients suffering from myelodysplastic syndromes is associated with worse overall survival.	"Thol et al., 2010, Haematologica"	Somatic	ENST00000415913.1	protein_altering_variant
IDH1 R132	IDH1	R132	Glioblastoma		Prognostic	Supports	B	Better Outcome	chr2	208248387	208248389			"In patients with a glioblastoma, those with mutations at R132 of IDH1 had better overall survival than wild-type patients."	"Yan et al., 2009, N. Engl. J. Med."	Somatic	ENST00000415913.1	protein_altering_variant
IDH1 R132	IDH1	R132	Malignant Astrocytoma		Prognostic	Supports	B	Better Outcome	chr2	208248387	208248389			"In patients with anaplastic astrocytoma, those with mutations at R132 of IDH1 had better overall survival than wild-type patients."	"Yan et al., 2009, N. Engl. J. Med."	Somatic	ENST00000415913.1	protein_altering_variant
IDH1 R132	IDH1	R132	High Grade Glioma	"Sunitinib,Bevacizumab"	Predictive	Supports	B	Sensitivity/Response	chr2	208248387	208248389			"In a clinical study of 63 recurrent glioma patients, the combined cohort of patients treated with either bevacizumab or sunitinib showed that those harboring IDH1 codon 132 mutation were associated with improved overall survival (OS 7.53 vs. 4.83 months; P=0.04), as compared to patients with wild-type IDH1."	"Lv et al., 2011, Anticancer Res."	Somatic	ENST00000415913.1	protein_altering_variant
IDH1 R132	IDH1	R132	Intrahepatic Cholangiocarcinoma	Dasatinib	Predictive	Supports	D	Sensitivity/Response	chr2	208248387	208248389			"Through a high-throughput drug screen of a large panel of cancer cell lines, including 17 biliary tract cancers, this work found that IDH mutant (IDHm) ICC cells demonstrate a striking response to the multikinase inhibitor dasatinib,  identifying SRC as a critical dasatinib target in IDHm ICC. Dasatinib-treated IDHm xenografts exhibited pronounced apoptosis and tumor regression."	"Saha et al., 2016, Cancer Discov"	Somatic	ENST00000415913.1	protein_altering_variant
IDH1 R132	IDH1	R132	Cholangiocarcinoma	Ivosidenib	Predictive	Supports	A	Sensitivity/Response	chr2	208248387	208248389			"The multicenter randomized double-blind phase 3 study included patients with IDH1-mutant cholangiocarcinoma who had progressed on previous therapy. Patients were randomly assigned to Ivosidenib or placebo. Placebo to Ivosidenib crossover was permitted on radiological progression. The primary endpoint was progression-free survival by independent central review. Progression-free survival was significantly improved with Ivosidenib compared with the placebo (median 2.7, vs 1.4 months; hazard ratio 0.37; 95% CI 0.25-0.54; one-side p<0.0001). Median overall survival was 10.8 months for the Ivosidenib group versus 9.7 months for the placebo group (HR 0.69 [95% CI 0.44-1.10]; p=0.060) in which 35 patients were crossover from the placebo group. In a prespecified exploratory analysis, the rank-preserving structural failure time (RPSFT) method was used to reconstruct the survival curve for patients receiving a placebo as if crossover had never occurred. RPSFT assumes that the treatment effect is the same for all patients, regardless of when the treatment is given. The RPSFT-adjusted median overall survival was 6.0 months for the placebo group (HR 0.46 [95% CI 0.28-0.75]; p=0.0008)."	"Abou-Alfa et al., 2020, Lancet Oncol."	Somatic	ENST00000415913.1	protein_altering_variant
IDH1 R132H	IDH1	R132H	Oligodendroglioma	AGI-5198	Predictive	Supports	D	Sensitivity/Response	chr2	208248388	208248388	C	T	"In pre-clinical studies, an IDH1 inhibitor (AG-5198) impaired growth of glioma / anaplastic oligodendroglioma cell lines with IDH1 R132H mutations.  A phase I clinical trial of the AG-120 IDH1 inhibitor in IDH1 mutant positive solid tumors, including glioma is currently underway."	"Rohle et al., 2013, Science"	Somatic	ENST00000415913.1	missense_variant
IDH1 R132H	IDH1	R132H	Pancreatic Ductal Adenocarcinoma	Ivosidenib	Predictive	Does Not Support	C	Sensitivity/Response	chr2	208248388	208248388	C	T	"A 48-year-old female was diagnosed with metastatic pancreatic ductal adenocarcinoma and subsequently started on standard of care chemotherapy, during which her hepatic lesions progressed. Detailed molecular profiling was performed on a biopsy from a liver lesion that demonstrated an IDH1 mutation, R132H. The patient subsequently received a mutant IDH1 inhibitor (AG-120), but with no response."	"Brody et al., 2016, Cancer Biol. Ther."	Somatic	ENST00000415913.1	missense_variant
IDH1 R132C	IDH1	R132C	Acute Myeloid Leukemia		Diagnostic	Supports	B	Positive	chr2	208248389	208248389	G	A	"IDH1 R132 mutation is associated with patients of older age, high platelet count during diagnosis, cytogenic normalcy and NPM1 mutation."	"Abbas et al., 2010, Blood"	Somatic	ENST00000415913.1	missense_variant
IDH1 R132C	IDH1	R132C	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	N/A	chr2	208248389	208248389	G	A	IDH1 R132 mutation in patients with AML is not associated with any prognostic value compared to patients with wild-type IDH1.	"Abbas et al., 2010, Blood"	Somatic	ENST00000415913.1	missense_variant
IDH1 R132C	IDH1	R132C	Acute Myeloid Leukemia	GSK321	Predictive	Supports	D	Sensitivity/Response	chr2	208248389	208248389	G	A	Newly developed allosteric inhibitors (GSK321) of IDH1 led to granulocytic differentiation in-vitro and in-vivo.	"Okoye-Okafor et al., 2015, Nat. Chem. Biol."	Somatic	ENST00000415913.1	missense_variant
IDH1 R132C	IDH1	R132C	Brain Glioma	Temozolomide	Predictive	Supports	B	Sensitivity/Response	chr2	208248389	208248389	G	A	"In a study of 189 low-grade gliomas, IDH (IDH1 or IDH2) mutations were found in 132 patients (70%). IDH mutations were associated with improved rate of response to temozolomide as compared to patients with wildtype IDH (61%  vs. 17% , P=0.01)."	"Houillier et al., 2010, Neurology"	Somatic	ENST00000415913.1	missense_variant
IDH1 R132C	IDH1	R132C	High Grade Glioma	AGI-5198	Predictive	Supports	D	Sensitivity/Response	chr2	208248389	208248389	G	A	"In an experimental in vitro study, glioma cells expressing IDH1 R132C were associated with sensitivity to AGI-5198 (IC50: 0.16M vs. IC50 > 100.00M), as compared to cells expressing wild-type IDH1. Sensitivity was determined by assessing cell growth."	"Rohle et al., 2013, Science"	Somatic	ENST00000415913.1	missense_variant
IDH1 R132C	IDH1	R132C	Acute Myeloid Leukemia	Ivosidenib	Predictive	Supports	B	Sensitivity/Response	chr2	208248389	208248389	G	A	"In a clinical study of 17 relapsed or refractory AML patients harboring IDH1 mutations, these patients were associated with response to AG-120 monotherapy; 4/7 patients who achieved a response experienced complete remission."	"2015, Cancer Discov"	Somatic	ENST00000415913.1	missense_variant
IDH1 R132C	IDH1	R132C	Acute Myeloid Leukemia	BPTES	Predictive	Supports	D	Sensitivity/Response	chr2	208248389	208248389	G	A	"In an experimental study of acute myeloid leukemia (AML) cell lines expressing IDH1 R132C, IDH1 R132G, or IDH1 R132H mutations were associated with increased sensitivity to small molecule glutaminase inhibitor, bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) as compared to AML cell lines expressing wild-type IDH1. Sensitivity was determined by assessing cell growth."	"Emadi et al., 2014, Exp. Hematol."	Somatic	ENST00000415913.1	missense_variant
IDH1 R132C	IDH1	R132C	Cancer	Olaparib	Predictive	Supports	D	Sensitivity/Response	chr2	208248389	208248389	G	A	"IDH1 R132C mutation confers a switch of function mutation where the mutated protein produces 2-hydroxyglutarate (2HG), rather than -ketoglutarate (KG). The novel metabolite induces a homologous recombination (HR) defect that sensitizes the tumor cells to poly (ADP-ribose) polymerase (PARP) inhibitors. PARP inhibitor sensititivity was tested in vivo in HeLa cells where the R132C mutation was create with CRISPR, the HCT116 colon cancer cell line where R132C mutation was created with recombinant adeno-associated virus (rAAV), and the HT1080 human sarcoma cell line which already has R132C. The results were then duplicated in non-commercial glioma cell lines: 6 IDH1 R132 mutant; 4 IDH1 wt."	"Sulkowski et al., 2017, Sci Transl Med"	Somatic	ENST00000415913.1	missense_variant
ERBB4 NUCLEAR TRANSLOCATION	ERBB4	NUCLEAR TRANSLOCATION	Breast Cancer	Trastuzumab	Predictive	Supports	D	Resistance	chr2	211375721	212538841			HER4 nuclear translocation was identified as a mediator of trastuzumab resistance in HER2 positive breast cancer cell lines. Increased nuclear staining was also identified in xenograft and patient samples after trastuzumab treatment.	"Mohd Nafi et al., 2014, Oncotarget"	N/A	ENST00000342788.4	N/A
ERBB4 EXPRESSION	ERBB4	EXPRESSION	Breast Cancer	Trastuzumab	Predictive	Supports	D	Resistance	chr2	211375721	212538841			siRNA knockdown of HER4 or inhibition with neratinib enhanced trastuzumab response in breast cancer cell lines.	"Mohd Nafi et al., 2014, Oncotarget"	N/A	ENST00000342788.4	N/A
ERBB4 EXPRESSION	ERBB4	EXPRESSION	Breast Cancer	Lapatinib	Predictive	Supports	D	Resistance	chr2	211375721	212538841			"ERBB4 protein expression was identified in breast cancer cell lines with acquired lapatinib resistance. Genetic ablation of ERBB4 (not ERBB1-3) led to apoptosis in trastuzumab- and lapatinib resistant cells, probably through a decrease in the PI3K/Akt pathway."	"Canfield et al., 2015, Cell Cycle"	N/A	ENST00000342788.4	N/A
ERBB4 Mutation	ERBB4	Mutation	Melanoma	Lapatinib	Predictive	Supports	D	Sensitivity/Response	chr2	211430972	211713583			"ERBB4 was the most commonly mutated protein tyrosine kinase in this study in melanoma (19% in 79 patients). Seven of the identified mutations in ERBB4 (E317K, E452K, E542K, R544W, E563K, E836K and E872K) were transforming and activating in-vitro. ERBB4 inhibition with shRNA or lapatinib led to reduced cell growth."	"Prickett et al., 2009, Nat. Genet."	Somatic	ENST00000342788.4	"transcript_variant,gain_of_function_variant"
UGT1A EXPRESSION	UGT1A	EXPRESSION	Colorectal Cancer	Ganetespib	Predictive	Supports	D	Resistance	chr2	233617645	233773310			Colorectal cancer cell lines were evaluated for response to the HSP90 inhibitor ganetespib.  Correlating cell line-specific IC50s with the corresponding gene expression patterns revealed a possible relationship to UGT1A expression. High UGT1A expression was correlated with ganetespib resistance. Knockdown of UGT1A sensitized HT29 cells to HSP90 inhibition. HCT116 and SW480 cell lines became resistant through UGT1A overexpression.	"Landmann et al., 2014, Cell Death Dis"	N/A	ENST00000373450.4	N/A
ASXL1 Mutation	ASXL1	Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr20	32358352	32439319			"In patients with acute myeloid leukemia, in a univariate analysis those with mutations in ASXL1 had worse overall survival than wild-type."	"Ohgami et al., 2015, Mod. Pathol."	Somatic	ENST00000375687.4	protein_altering_variant
ASXL1 Mutation	ASXL1	Mutation	Acute Myeloid Leukemia		Diagnostic	Supports	B	Positive	chr20	32358352	32439319			"Among patients with AML, those with mutations in ASXL1 were more likely to have the AML with myelodysplasia-related changes (AML-MRC) subtype."	"Ohgami et al., 2015, Mod. Pathol."	Somatic	ENST00000375687.4	protein_altering_variant
ASXL1 Mutation	ASXL1	Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr20	32358352	32439319			"In a meta-analysis of six studies totalling 3311 patients with non-M3 acute myeloid leukemia, those with mutations in ASXL1 had worse overall survival than wild-type patients (Hazard ratio 1.86, 95% CI 1.49-2.33)."	"Shivarov et al., 2015, Leuk. Lymphoma"	Somatic	ENST00000375687.4	protein_altering_variant
ASXL1 Mutation	ASXL1	Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr20	32358352	32439319			"In older patients (>59 years) with cytogenetically normal acute myeloid leukemia classified as ELN favorable, multivariate analysis identified ASXL1 mutations (12/99 patients) were associated with lower complete remission rates (P = 0.03), disease-free survival (P < 0.001), overall survival (P < 0.001), and event-free survival (P < 0.001). This confirmed results from univariate analysis of patients not stratified by ELN category, but cytogenetically normal and older (38/220 patients)."	"Metzeler et al., 2011, Blood"	Somatic	ENST00000375687.4	protein_altering_variant
ASXL1 Mutation	ASXL1	Mutation	Myelofibrosis		Prognostic	Supports	B	Poor Outcome	chr20	32358352	32439319			"An ASXL1 mutation, especially in conjunction with DNMT3A and EZH2 mutations, results in a fourfold increase in resistance to treatment with ruxolitinib and a reduced time to treatment discontinuation (TTD) for patients with myelofibrosis."	"Patel et al., 2015, Blood"	Somatic	ENST00000375687.4	protein_altering_variant
ASXL1 Mutation	ASXL1	Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr20	32358352	32439319			"Patients with Acute Myeloid Leukemia showed an synergistic mortality rate with ASXL1 and SRSF2 co-mutations such that individual mutations of either ASXL1 or SRSF2 resulted in ~20% probability of survival after 10 years, whereas co-mutations resulted in a 100% mortality rate after 4 years."	"Papaemmanuil et al., 2016, N. Engl. J. Med."	Somatic	ENST00000375687.4	protein_altering_variant
ASXL1 EXON 12 MUTATION	ASXL1	EXON 12 MUTATION	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr20	32433284	32433917			"In patients with de novo AML who received intensive chemotherapy, ASXL1 mutations (N=51) were associated with shorter overall (P<0.001) and event free survival (P=0.012) compared to ASXL1 wild-type (N=430). Multivariate analysis identified ASXL1 mutations as an independent factor for adverse overall survival (P=0.032, relative risk: 1.70)."	"Schnittger et al., 2013, Leukemia"	Somatic	ENST00000375687.4	exon_variant
TOP1 Amplification	TOP1	Amplification	Colorectal Cancer	Irinotecan	Predictive	Supports	B	Sensitivity/Response	chr20	41028818	41124487			"FFPE tumor samples from 78 patients with colorectal cancer, who had received irinotecan monotherapy were analyzed with a FISH dual-probe. TOP1 gain was nonsignificantly associated with objective response to irinotecan Odds ratio (OR): 1.62; p = 0.07."	"Nygrd et al., 2014, Scand. J. Gastroenterol."	Somatic	ENST00000361337.2	transcript_amplification
TOP1 EXPRESSION	TOP1	EXPRESSION	Ovarian Cancer	"Topotecan,Carboplatin,Cyclophosphamide"	Predictive	Supports	B	Sensitivity/Response	chr20	41028818	41124487			"Shorter progression free survival was observed in patients with low expression (IHC) of topoisomerase 1 in 16 patients with relapsed or persistent ovarian or peritoneal carcinoma after treatment with topotecan, cyclophosphamide and carboplatin followed by an autologous hematopoietic stem cell transplant."	"Litzow et al., 2010, Bone Marrow Transplant."	N/A	ENST00000361337.2	N/A
TOP1 EXPRESSION	TOP1	EXPRESSION	Colorectal Cancer	Irinotecan	Predictive	Supports	B	Sensitivity/Response	chr20	41028818	41124487			"498 patients were retrospectively analyzed for topoisomerase 1 expression (IHC). In the subgroup of patients treated with irinotecan (38% of the 498), those patients expressing Topoisomerase I had a better overall survival according to multivariate analysis (HR = 0.47, 95% CI 0.23-0.94, p = 0.033)."	"Kostopoulos et al., 2009, BMC Cancer"	N/A	ENST00000361337.2	N/A
MMP9 SERUM LEVELS	MMP9	SERUM LEVELS	Inflammatory Breast Carcinoma	Bevacizumab	Predictive	Supports	B	Resistance	chr20	46008908	46016561			"MMP9 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. Low bMMP9 was correlated with better OS (p=0.022) and non-significantly associated with longer DFS (p=0.071). Correlation to DFS was also found after multivariate analysis (p=0.041, HR: 3.511). bMMP9 was associated with death (p=0.035). During treatment, a significant decrease in MMP9 levels (p<0.001) was observed in 87% of patients."	"Tabouret et al., 2016, Oncotarget"	N/A	ENST00000372330.3	N/A
NCOA3 AMPLIFICATION	NCOA3	AMPLIFICATION	Breast Cancer		Prognostic	Supports	B	Poor Outcome	chr20	47501902	47656877			"In patients with breast cancer, those with amplification of NCOA3 had shorter disease-specific survival."	"Burandt et al., 2013, Breast Cancer Res. Treat."	Somatic	ENST00000372004.3	transcript_amplification
NCOA3 OVEREXPRESSION	NCOA3	OVEREXPRESSION	Breast Cancer		Prognostic	Supports	B	Poor Outcome	chr20	47501902	47656877			"High expression determined by immunohistochemistry of NCOA3 was found in 571 out of 1,836 breast cancer samples. Those with high expression had worse overall and disease-specific survival."	"Burandt et al., 2013, Breast Cancer Res. Treat."	Somatic	ENST00000372004.3	N/A
AURKA EXPRESSION	AURKA	EXPRESSION	Ovarian Carcinoma		Prognostic	Supports	B	Better Outcome	chr20	56369390	56392337			"In patients with ovarian carcinomas, those with Aurora kinase A expression (as measured by immunohistochemistry) had increased progression-free and overall survival compared to those without expression."	"Mendiola et al., 2009, Hum. Pathol."	Somatic	ENST00000395913.3	N/A
AURKA Amplification	AURKA	Amplification	Esophagus Adenocarcinoma	"Cisplatin,Alisertib"	Predictive	Supports	E	Sensitivity/Response	chr20	56369390	56392337			Antitumour effect of alisertib treatment in esophageal adenocarcinomas can be intensified in combination with cisplatin.	"Sehdev et al., 2012, Mol. Cancer Ther."	Somatic	ENST00000395913.3	transcript_amplification
AURKA Overexpression	AURKA	Overexpression	Cervical Adenocarcinoma	Paclitaxel	Predictive	Supports	D	Resistance	chr20	56369390	56392337			"In the cervial andenocarcinoma cell line HeLa, when AURK-A was overexpressed, the cells were resistant to the apoptotic effects of Taxol."	"Anand et al., 2003, Cancer Cell"	Somatic	ENST00000395913.3	N/A
AURKA Overexpression	AURKA	Overexpression	Lung Non-small Cell Carcinoma	Cisplatin	Predictive	Supports	B	Resistance	chr20	56369390	56392337			High levels of Aurora-A expression (retrospectively assessed by IHC in 102 NSCLC patients) predicted poorer overall survival and progression free survival in a population treated with surgery and cisplatin-based chemotherapy. In-vitro data confirmed these results and overexpression or knockdown of AURKA decreased or increased in-vitro sensitivity to cisplatin.	"Xu et al., 2014, J Transl Med"	N/A	ENST00000395913.3	N/A
AURKA Overexpression	AURKA	Overexpression	Ovarian Serous Carcinoma	Platinum Compound	Predictive	Supports	B	Resistance	chr20	56369390	56392337			A study of 41 patients with high-grade ovarian serous carcinoma found that high expression levels of AURKA correlated with poorer overall survival (P??.001; HR 0.14) and platinum therapy resistance (P < 0.001). Expression of AURKA was measured using immunohistochemical techniques on tumor samples.	"Mignogna et al., 2016, J Ovarian Res"	N/A	ENST00000395913.3	N/A
AURKA EXPRESSION	AURKA	EXPRESSION	Esophagus Squamous Cell Carcinoma	"Radiation Therapy,Cisplatin,Fluorouracil"	Predictive	Supports	B	Sensitivity/Response	chr20	56369390	56392337			"A retrospective study examining the expression of AURKA in tumor samples of 78 esophageal squamous cell carcinoma patients found that positive expression of AURKA (>10% of cells by IHC) was correlated with increased clinical response to chemoradiation therapy consisting of cisplatin, 5-fluorouracil, and 40 gy radiation (P = 0.0003)."	"Tamotsu et al., 2015, BMC Cancer"	N/A	ENST00000395913.3	N/A
GNAS R201C	GNAS	R201C	Colorectal Cancer	"Cetuximab,Irinotecan,Vemurafenib"	Predictive	Supports	C	Resistance	chr20	58909365	58909365	C	T	"Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient acquired a novel GNAS1 R201C mutation at disease progression."	"Hong et al., 2016, Cancer Discov"	Somatic	ENST00000371085.3	missense_variant
BIRC7 Amplification	BIRC7	Amplification	Colon Cancer	Cisplatin	Predictive	Supports	D	Resistance	chr20	63235883	63240507			"Livin (BIRC7) overexpression in two colon cancer cell lines (RKO and SW620) increased resistance of these cells to cisplatin. siRNA knockdown of Livin rendered the cells more sensitive to cisplatin. The study also further showed that cytoplasmic Livin levels increased in four colon cancer cell lines (RKO, SW620, HCT116, and KM12C) after cisplatin treatment in a dose-dependent manner. This study highlighted Livin as a potential player in colon cancer therapy."	"Ding et al., 2013, Tumour Biol."	Somatic	ENST00000217169.3	transcript_amplification
RUNX1 Mutation	RUNX1	Mutation	Acute Myeloid Leukemia	Cytarabine	Predictive	Supports	B	Resistance	chr21	34787801	35049344			"In non-APL patients with AML (age 18-60), those who had mutations in RUNX1 had significantly shorter relapse-free survival following conventional post-remission treatment (repetitive cycles of high-dose cytarabine) than those treated with an allogeneic hematopoietic stem-cell transplantation (N=32) at first remission (4-year RFS; 0% vs 52%; P<0.0001)."	"Gaidzik et al., 2011, J. Clin. Oncol."	Somatic	ENST00000300305.3	"transcript_variant,loss_of_function_variant"
RUNX1 Mutation	RUNX1	Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr21	34787801	35049344			"In 878 non-APL patients with AML, those who had mutations in RUNX1 (N=53) had higher rates of refractory disease than those without (30% versus 19%; P = 0.047)."	"Gaidzik et al., 2011, J. Clin. Oncol."	Somatic	ENST00000300305.3	"transcript_variant,loss_of_function_variant"
RUNX1 Mutation	RUNX1	Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr21	34787801	35049344			"In 878 non-APL patients with AML (18-60 years), those who had mutations in RUNX1 (N=53) had shorter event-free survival (8% vs 30%, P<0.0001) and relapse-free survival (26% vs 44%, P=0.022) relative to wild-type. EFS was also shorter for the cytogenetically normal (CN) subgroup with RUNX1 mutations (N=34; 10% vs 34%; P<0.0001) compared to wild-type (N=499), but only trending for relapse-free survival (29% vs 43%; P=0.21). For multivariate analysis, RUNX1 was a significant marker of inferior EFS in the entire cohort (P=0.011) and the intermediate-risk (P=0.005) subgroup but not the CN subgroup."	"Gaidzik et al., 2011, J. Clin. Oncol."	Somatic	ENST00000300305.3	"transcript_variant,loss_of_function_variant"
RUNX1 Mutation	RUNX1	Mutation	Acute Lymphoblastic Leukemia		Prognostic	Supports	B	Poor Outcome	chr21	34787801	35049344			"In univariate analysis, mutations in RUNX1 were significantly associated with shorter overall survival compared to wildtype RUNX1 in adult (18-87 years old) T-cell acute lymphoblastic leukemia (N=9 mutated, 62 wild type patients; P=0.014) and the early subtype (N=7 mutated, 23 wild type patients; P=0.027). RUNX1 mutations were associated with other poor-risk parameters, early subtype and older age."	"Grossmann et al., 2013, Genes Chromosomes Cancer"	Somatic	ENST00000300305.3	"transcript_variant,loss_of_function_variant"
RUNX1 Mutation	RUNX1	Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr21	34787801	35049344			"In a study of patients with cytogenically normal acute myeloid leukemia, RUNX1 mutations were more frequent in patients 60 years old or older. Patients with RUNX1 mutations had shorter disease-free (younger, P = 0.058; older, P < 0.001), event-free (both, P < 0.001), and overall survival (younger, P = 0.003; older, P < 0.001) as well as lower complete remission rates (younger, P = 0.005; older, P = 0.006)."	"Mendler et al., 2012, J. Clin. Oncol."	Somatic	ENST00000300305.3	"transcript_variant,loss_of_function_variant"
RUNX1 Mutation	RUNX1	Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr21	34787801	35049344			"In patients with acute myeloid leukemia, those with RUNX1 mutations (n=245) had significantly worse outcomes when compared to those with RUNX1 wild-type alleles (n=2,194).  The complete remission rate for patients with RUNX1 mutations was significantly lower (48.4% vs. 68.1%; p <0.0001), the refractory disease rate was significantly higher (40.6% 23.4%; p=0.03), the 5-year event free survival rate was significantly lower (9%, 24%; p<0.0001), the 5-year relapse free survival rate was significantly lower (22%, 36%; p=0.0007), and the 5-year overall survival rate was significantly lower (22%, 37%; p=0.0001)."	"Gaidzik et al., 2016, Leukemia"	Somatic	ENST00000300305.3	"transcript_variant,loss_of_function_variant"
ERG EWSR1::ERG	ERG	EWSR1::ERG	Ewing Sarcoma		Diagnostic	Supports	B	Positive	chr21	38380027	38383923			t(21;22) rearrangements of EWSR1-ERG are associated with a diagnosis of Ewing sarcoma and are the second most common gene fusion reported in this disease.	"Warren et al., 2013, Hum. Pathol."	Somatic	ENST00000397938.2	transcript_fusion
ERG TMPRSS2::ERG	ERG	TMPRSS2::ERG	Prostate Carcinoma		Diagnostic	Supports	B	Positive	chr21	38380027	38445621			"TMPRSS2/ERG gene fusion was observed in 23 of 29 (79%) of prostate carcinoma samples, and 90% of ERG expression positive prostate carcinoma samples."	"Tomlins et al., 2005, Science"	Somatic	ENST00000398585.3	transcript_fusion
ERG TMPRSS2::ERG	ERG	TMPRSS2::ERG	Prostate Carcinoma		Diagnostic	Supports	B	Positive	chr21	41507950	41508065			"TMPRSS2/ERG gene fusion was observed in 23 of 29 (79%) of prostate carcinoma samples, and 90% of ERG expression positive prostate carcinoma samples."	"Tomlins et al., 2005, Science"	Somatic	ENST00000398585.3	transcript_fusion
TFF3 EXPRESSION	TFF3	EXPRESSION	Breast Cancer	"Aminoglutethimide,Tamoxifen"	Predictive	Supports	B	Sensitivity/Response	chr21	42311667	42315651			"TFF3 expression was assessed by IHC in 75 patients, 187 patients were identified for the validation cohort. TFF3 expression was associated with response to endocrine therapy (tamoxifen, aminoglutethimide or oophorectomy) and outperformed ER, PR and TFF1 as biomarkers."	"May et al., 2015, Endocr. Relat. Cancer"	N/A	ENST00000518498.1	N/A
U2AF1 MUTATION	U2AF1	MUTATION	Myelofibrosis		Prognostic	Supports	B	Poor Outcome	chr21	43092956	43107587			"In a large study of patients with primary myelofibrosis evaluating mutations associated with anemia, 457 patients were evaluated for U2AF1 mutations. U2AF1 mutations were significantly associated with anemia in univariate and multivariate analysis (72 mutated vs 385 wildtype; P<0.0001). U2AF1 mutations were significantly associated with shorter overall survival in univariate analysis (P < 0.0001) but not in multivariate analysis with adjustment for age and anemia (P=0.24)."	"Barraco et al., 2016, Blood Cancer J"	Somatic	ENST00000291552.4	protein_altering_variant
U2AF1 Q157P/R	U2AF1	Q157P/R	Acute Myeloid Leukemia		Diagnostic	Does Not Support	B	Positive	chr21	43094667	43094667	T	G	"Age, sex, FAB subtype and karyotypes were not statistically significant between AML patients with U2AF Q157P/R mutations and those who harbor wild type U2AF."	"Qian et al., 2012, PLoS ONE"	Somatic	ENST00000291552.4	missense_variant
U2AF1 Q157P/R	U2AF1	Q157P/R	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	N/A	chr21	43094667	43094667	T	G	"In patients with AML, those who harbor Q157P/R mutation of U2AF1 do not show a statistically significant difference in complete remission rate compared to those who harbor wild type U2AF1."	"Qian et al., 2012, PLoS ONE"	Somatic	ENST00000291552.4	missense_variant
U2AF1 Q157P/R	U2AF1	Q157P/R	Myelodysplastic Syndrome		Prognostic	Does Not Support	B	N/A	chr21	43094667	43094667	T	G	"In patients with MDS, those who harbor Q157P/R mutation of U2AF do not show statistical significance in complete remission rate compared to those who harbor wild type U2AF."	"Qian et al., 2012, PLoS ONE"	Somatic	ENST00000291552.4	missense_variant
U2AF1 Q157P/R	U2AF1	Q157P/R	Myelodysplastic Syndrome		Prognostic	Supports	B	Poor Outcome	chr21	43094667	43094667	T	G	"After adjusting for age and cancer stage, presence of U2AF mutation such as Q157P/R is prognostic for poorer survival outcomes in patients with MDS."	"Wu et al., 2013, Am. J. Hematol."	Somatic	ENST00000291552.4	missense_variant
U2AF1 S34Y/F	U2AF1	S34Y/F	Acute Myeloid Leukemia		Diagnostic	Does Not Support	B	Positive	chr21	43104346	43104346	G	A	"Age, sex, FAB subtype and karyotypes were not statistically significant between AML patients with U2AF S34Y/F mutations and those who harbor wild type U2AF."	"Qian et al., 2012, PLoS ONE"	Somatic	ENST00000291552.4	missense_variant
U2AF1 S34Y/F	U2AF1	S34Y/F	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	N/A	chr21	43104346	43104346	G	A	"In patients with AML, complete remission rates are not different between patients who harbor the U2AF1 S34Y/F mutation and those with wild type U2AF1."	"Qian et al., 2012, PLoS ONE"	Somatic	ENST00000291552.4	missense_variant
U2AF1 S34Y/F	U2AF1	S34Y/F	Myelodysplastic Syndrome		Prognostic	Supports	B	Poor Outcome	chr21	43104346	43104346	G	A	"After adjusting for age and cancer stage, the presence of U2AF mutations such as S34Y/F are prognostic for poorer survival outcomes in patients with MDS."	"Wu et al., 2013, Am. J. Hematol."	Somatic	ENST00000291552.4	missense_variant
MAPK1 Amplification	MAPK1	Amplification	Lung Non-small Cell Carcinoma	WZ4002	Predictive	Supports	D	Resistance	chr22	21754500	21867629			"Resistance to WZ4002 was induced in cell lines. Amplification of MAPK1 or downregulation of ERK-pathway inhibitors led to resistance to EGFR inhibition with WZ4002. Chemical inhibition (MEK inhibition with either CI-1040 or GSK1120212) or shRNA knockdown of MAPK1 resensitized cells to EGFR inhibition with WZ4002 in-vitro. Additionally, MAPK1 amplification was identified in 1/21 erlotinib-resistant NSCLC patients. MAPK1 amplification was not observed in the pretreatment tumor, only the post-treatment resistant tumor which lacked other more common drug-resistance mechanisms EGFR T790M or MET amplification."	"Ercan et al., 2012, Cancer Discov"	Somatic	ENST00000215832.6	transcript_amplification
MAPK1 E322K	MAPK1	E322K	Head And Neck Squamous Cell Carcinoma	Erlotinib	Predictive	Supports	C	Sensitivity/Response	chr22	21772875	21772875	C	T	Case report of a patient with stage IVA HNSCC with near-complete histologic response after 13 days of neoadjuvant erlotinib. Whole-exome sequencing of the pre-treatment tumor revealed a MAPK1 E322K mutation (allelic fraction 0.13). In-vitro studies in two HNSCC cell lines showed enhanced EGFR phosphorylation and erlotinib sensitivity in the mutant line compared with the wild-type line.	"Van Allen et al., 2015, JAMA Oncol"	Somatic	ENST00000215832.6	"missense_variant,gain_of_function_variant"
ABL1 BCR::ABL	ABL1	BCR::ABL	Chronic Myeloid Leukemia		Diagnostic	Does Not Support	C	Positive	chr22	23180210	23290413			"Data from deep sequencing of a Ph-negative clone of a Ph-positive CML patient has found a driving mutation in DNMT3A that preceeded the BCR-ABL fusion, and may imply the possibility that BCR-ABL is not universally the initiating event in CML."	"Schmidt et al., 2014, Leukemia"	Somatic	ENST00000305877.8	transcript_fusion
ABL1 BCR::ABL	ABL1	BCR::ABL	Chronic Myeloid Leukemia		Diagnostic	Supports	A	Positive	chr22	23180210	23290413			"The presence of BCR-ABL fusion is considered the characterizing feature of chronic myeloid leukemia, and has been widely thought of as the initiating event in the disease."	"An et al., 2010, Leuk. Res."	Somatic	ENST00000305877.8	transcript_fusion
ABL1 BCR::ABL	ABL1	BCR::ABL	Acute Myeloid Leukemia	Imatinib	Predictive	Supports	D	Resistance	chr22	23180210	23290413			BCR-ABL fusions have been found to contribute to imatinib resistance in AML cell lines.	"Nimmanapalli et al., 2002, Oncogene"	Somatic	ENST00000305877.8	transcript_fusion
ABL1 BCR::ABL	ABL1	BCR::ABL	Acute Myeloid Leukemia	Imatinib	Predictive	Supports	A	Sensitivity/Response	chr22	23180210	23290413			Treatment of Philadelphia chromosome positive leukemias with imatinib results in high rates of complete remission in patients with CML.	"Nimmanapalli et al., 2002, Oncogene"	Somatic	ENST00000305877.8	transcript_fusion
ABL1 BCR::ABL	ABL1	BCR::ABL	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	A	Sensitivity/Response	chr22	23180210	23290413			The clinical use of imatinib in patients with BCR-ABL fusion has resulted in drastic prognostic improvements in patients with CML.	"An et al., 2010, Leuk. Res."	Somatic	ENST00000305877.8	transcript_fusion
ABL1 BCR::ABL	ABL1	BCR::ABL	Chronic Myeloid Leukemia	"Dasatinib,Nilotinib"	Predictive	Supports	A	Sensitivity/Response	chr22	23180210	23290413			"The use of nilotinib and dasatinib, second-generation BCR-ABL targeted therapies, has been effective in patients resistant to imatinib, leading to their FDA-approval."	"An et al., 2010, Leuk. Res."	Somatic	ENST00000305877.8	transcript_fusion
ABL1 BCR::ABL	ABL1	BCR::ABL	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	A	Sensitivity/Response	chr22	23180210	23290413			"BCR-ABL inhibitors such as imatinib have lead to significantly improved prognosis, response rate, overall survival, and patient outcome in CML patients compared to previous therapeutic regimens."	"An et al., 2010, Leuk. Res."	Somatic	ENST00000305877.8	transcript_fusion
ABL1 BCR::ABL	ABL1	BCR::ABL	Acute Lymphoblastic Leukemia	Dasatinib	Predictive	Supports	C	Sensitivity/Response	chr22	23180210	23290413			"Prior to dasatinib treatment, one imatinib-resistant patient with acute lymphoblastic leukemia had the BCR-ABL1 fusion with no secondary variants in at least ten bacterial clones generated using peripheral blood RNA. They had NEL (no evidence of leukemia) best hematologic and minor best cytogenetic responses to dasatinib."	"Talpaz et al., 2006, N. Engl. J. Med."	Somatic	ENST00000305877.8	transcript_fusion
ABL1 BCR::ABL	ABL1	BCR::ABL	Chronic Myeloid Leukemia	Dasatinib	Predictive	Supports	C	Sensitivity/Response	chr22	23180210	23290413			"Prior to dasatanib treatment, fifteen imatinib-resistant patients with chronic myeloid leukemia in various phases had the BCR-ABL1 fusion with no secondary variants in at least ten clones generated using peripheral blood RNA. They had no evidence of leukemia (n = 3), complete (9), minor (2), and no (1) best hematologic responses to dasatinib and complete (3), partial (3), minor (2), minimal (2), and no (5) best cytogenetic responses to dasatinib."	"Talpaz et al., 2006, N. Engl. J. Med."	Somatic	ENST00000305877.8	transcript_fusion
ABL1 BCR::ABL	ABL1	BCR::ABL	Chronic Myeloid Leukemia	"Dasatinib,Bafetinib,Nilotinib"	Predictive	Supports	D	Sensitivity/Response	chr22	23180210	23290413			"In an in vitro study, six CML cell lines expressing the BCR-ABL1 fusion protein showed sensitivity to nilotinib (IC50: 24.3-84.5 nM), dasatinib (IC50: 1.5-10.9 nM), and bafetinib (IC50: 11.8-87.7 nM). When comparing potency of these treatments against the 6 CML cell lines, dasatinib, nilotinib and bafetinib were on average 98.6, 9.85 and 16.4 times more potent than imatinib. Sensitivity was determined by assessing cell proliferation using the MTT assay."	"Deguchi et al., 2008, Leuk. Res."	Somatic	ENST00000305877.8	transcript_fusion
SMARCB1 Underexpression	SMARCB1	Underexpression	Synovial Sarcoma	Tazemetostat	Predictive	Supports	D	Sensitivity/Response	chr22	23786963	23834516			"Treatment with tazemetostat , a small-molecule inhibitor of EZH2, results in concentration-dependent cell growth inhibition and cell death specifically in SS18-SSX-positive, SMARCB1-deficient synovial sarcomas."	"Kawano et al., 2016, PLoS ONE"	N/A	ENST00000344921.6	N/A
SMARCB1 Deletion	SMARCB1	Deletion	Rhabdoid Cancer	Tazemetostat	Predictive	Supports	D	Sensitivity/Response	chr22	23786963	23834516			EPZ-6438 (Tazemetostat) induces apoptosis and differentiation specifically in SMARCB1-deleted malignant rhabdoid tumors (MRT) cells. This study compared in vitro EPZ-6438 treatment of four SMARCB1-deleted MRT cell lines to three control (wild-type) cell lines. These data demonstrate the dependency of SMARCB1 mutant MRTs on EZH2 enzymatic activity and suggest treatment of these genetically defined cancers with EZH2 inhibitors.	"Knutson et al., 2013, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000344921.6	transcript_ablation
SMARCB1 Loss	SMARCB1	Loss	Atypical Teratoid Rhabdoid Tumor		Diagnostic	Supports	B	Positive	chr22	23786963	23834516			"53 pediatric tumors consisting of 20 AT/RT, 10 PNET, and 23 other central nervous system tumors were classified using microscopic diagnosis, and then tested for expression of the SMARCB1 gene product INI1. In the 20 cases of AT/RT, expression of INI1 was not detected in tumor cells using the BAF47/SNF5 monoclonal INI1 antibody. Expression of INI1 was detected in 31 out of the 33 remaining tumors, with one Oligodendroglioma showing no expression, and one pituitary adenoma showing weak expression. The authors conclude that immunohistochemical staining with an INI1 antibody may be useful in confirming histologic diagnosis of AT/RT."	"Judkins et al., 2004, Am J Surg Pathol"	Somatic	ENST00000344921.6	loss_of_function_variant
FLI1 EWSR1::FLI1 e7-e6	FLI1	EWSR1::FLI1 e7-e6	Ewing Sarcoma		Prognostic	Supports	B	Better Outcome	chr22	29268018	29287134			"In patients with Ewing's sarcoma, those with type 1 EWS-FLI1 fusions had longer overall survival than those with other types of EWS-FLI1 fusions."	"de Alava et al., 1998, J. Clin. Oncol."	Somatic	ENST00000397938.2	transcript_fusion
ERG EWSR1::ERG	ERG	EWSR1::ERG	Ewing Sarcoma		Diagnostic	Supports	B	Positive	chr22	29268018	29287134			t(21;22) rearrangements of EWSR1-ERG are associated with a diagnosis of Ewing sarcoma and are the second most common gene fusion reported in this disease.	"Warren et al., 2013, Hum. Pathol."	Somatic	ENST00000397938.2	transcript_fusion
EWSR1 EWSR1::FLI1	EWSR1	EWSR1::FLI1	Ewing Sarcoma		Diagnostic	Supports	B	Positive	chr22	29268318	29292169			"t(11;22) rearrangements of EWSR1-FLI1 are diagnostic of ewing sarcoma, and are observed in 90% of cytogenetic samples."	"Warren et al., 2013, Hum. Pathol."	Somatic	ENST00000414183.2	transcript_fusion
EWSR1 EWSR1::FLI1	EWSR1	EWSR1::FLI1	Ewing Sarcoma Of Bone		Diagnostic	Supports	B	Positive	chr22	29268318	29292169			A total of 85 unrelated cases of Ewing's sarcoma were examined and 83% we found to harbor the t(11;22)(q24;q12) chromosomal abnormality (EWS/FLI).	"Turc-Carel et al., 1988, Cancer Genet. Cytogenet."	Somatic	ENST00000414183.2	transcript_fusion
EWSR1 EWSR1::FLI1	EWSR1	EWSR1::FLI1	Ewing Sarcoma Of Bone		Diagnostic	Supports	B	Positive	chr22	29268318	29292169			"The authors propose RT-PCR as a diagnostic test for Ewing sarcoma using FFPE materials.  Starting with 40 cases, intact RNA could be isolated from 6, and of these the EWS-FLI event was detected in 2 by nested PCR. Alternative diagnostic assays for this event are also considered."	"Park et al., 1998, J. Korean Med. Sci."	Somatic	ENST00000414183.2	transcript_fusion
EWSR1 EWSR1::FLI1	EWSR1	EWSR1::FLI1	Ewing Sarcoma Of Bone		Diagnostic	Supports	B	Positive	chr22	29268318	29292169			"An evaluation of alternative strategies for detection of EWS-FLI (FISH break apart, FISH fusion, and RT-PCR).  Of the 22 informative EWS/PNETs, 20 cases (91%) were positive by FISH break apart, FISH fusion, or both."	"Bridge et al., 2006, Mod. Pathol."	Somatic	ENST00000414183.2	transcript_fusion
DDIT3 EWSR1::DDIT3	DDIT3	EWSR1::DDIT3	Myxoid Liposarcoma		Diagnostic	Supports	C	Positive	chr22	29268318	29291599			Identified two cases of myxoid liposarcoma with translocations (between 12q13 and 22q12) giving rise to EWSR1-DDIT3 (EWS-CHOP) fusions instead of the more common FUS-DDIT3.	"Panagopoulos et al., 1996, Oncogene"	Somatic	ENST00000414183.2	transcript_fusion
NF2 Loss	NF2	Loss	Thyroid Gland Carcinoma	Selumetinib	Predictive	Supports	D	Sensitivity/Response	chr22	29603558	29698598			"NF2 loss promotes oncogenic RAS-signaling via YAP-dependent transactivation of RAS and sensitizes to MEK inhibition. The authors demonstrate this in (A) isogenic lines derived from C643 cells (HRASG13R, NF2-WT) modified to stably express shNF2, (B) in set of 7 RAS-mutant thyroid cancer cell lines that differ in their NF2 expression levels, and (C) in a Hras-G12V/Nf2-null mouse model."	"Garcia-Rendueles et al., 2015, Cancer Discov"	Somatic	ENST00000338641.4	loss_of_function_variant
NF2 K159fs	NF2	K159fs	Breast Cancer	Temsirolimus	Predictive	Supports	C	Sensitivity/Response	chr22	29654685	29654685	A		23 patients were treated with temsirolimus containing regimens. 1 patient with a complete response >3 years had a K159fs*16 mutation in NF2. 2 patients were tested for NF2 mutations.	"Moulder et al., 2015, Ann. Oncol."	Somatic	ENST00000338641.4	frameshift_truncation
NF2 Y177fs	NF2	Y177fs	Peritoneal Mesothelioma	"Cisplatin,Carboplatin"	Predictive	Supports	C	Resistance	chr22	29655604	29655605		T	"A frameshift mutation in NF2 at position Y177 was found in a patient who responded poorly to therapy and died within 8 months of diagnosis. Initially treated with 3 cycles of systemic chemotherapy with cisplatin and pemetrexed with modest response, 2 months after cytoreductive surgery the patient had no response to platinum doublet chemotherapy."	"Sheffield et al., 2015, PLoS ONE"	Somatic	ENST00000338641.4	frameshift_elongation
HMOX1 EXPRESSION	HMOX1	EXPRESSION	Renal Cell Carcinoma	"Sunitinib,Sorafenib"	Predictive	Supports	B	Resistance	chr22	35380835	35394214			"In 66 patients with advanced renal cell carcinoma, high expression of heme oxygenase-1 (HO-1) was associated with poor overall response rate (2.6% versus 53.6%, P<0.01), clinical benefit rate (47.4% versus 92.9%, P<0.01), shorter progression-free survival (4.4 versus 42 months, P=0.022) and poor overall survival ( (2)=4.775, P=0.029) in patients receiving sorafenib or sunitinib."	"Zheng et al., 2015, Onco Targets Ther"	N/A	ENST00000216117.8	N/A
SOX10 Loss	SOX10	Loss	Melanoma	Vemurafenib	Predictive	Supports	D	Resistance	chr22	37972300	37984537			FACS-assisted shRNA genetic screen identified SOX10 as a determinant of vemurafenib resistance. Suppression of SOX10 in melanoma cells confers resistance to BRAF and MEK inhibitors through activation of TGF- signalling and upregulation of EGFR and PDGFRB. EGFR expression or exposure to TGF- becomes beneficial for proliferation of melanoma cells in the presence of BRAF or MEK inhibitors. Melanoma cells with low SOX10 and consequently high EGFR expression are enriched in the presence of vemurafenib. This study finds evidence for SOX10 loss (N=2) and/or activation of TGF- signalling (N=2) in 4 of the 6 EGFR-positive drug-resistant melanoma patient samples.	"Sun et al., 2014, Nature"	N/A	ENST00000396884.2	loss_of_function_variant
CRBN Mutation	CRBN	Mutation	Multiple Myeloma	"Lenalidomide,Pomalidomide"	Predictive	Supports	C	Resistance	chr3	3150011	3179710			"A 37 year old, heavily pretreated (including thalidomide and lenalidomide) patient with IgG-kappa multiple myeloma was sequenced following extramedullary relapse. A high number of alterations were observed including 38 rearrangements, 35 translocations, 4 indels, and 271 nonsynonymous point mutations. Two mutations altering CRBN (Q99* and R283K), a gene previously described as being necessary for immunomodulatory drug response, were observed and thought to be responsible for resistance to the pomalidomide and dexamethasone treatment she received but failed to respond to following sequencing."	"Egan et al., 2013, Br. J. Haematol."	Somatic	ENST00000231948.4	
VHL Mutation	VHL	Mutation	Clear Cell Renal Cell Carcinoma		Prognostic	Supports	B	Better Outcome	chr3	10141008	10152220			"In patients with renal clear cell carcinoma, patients with VHL mutations had longer cancer-specific survival."	"Patard et al., 2008, Int. J. Cancer"	Somatic	ENST00000256474.2	"gene_variant,loss_of_function_variant"
VHL Mutation	VHL	Mutation	Clear Cell Renal Cell Carcinoma		Prognostic	Supports	B	N/A	chr3	10141008	10152220			"In renal clear cell carcinoma, patients with VHL mutations did not have a significant impact on cancer specific survival."	"Hakimi et al., 2013, Clin. Cancer Res."	Somatic	ENST00000256474.2	"gene_variant,loss_of_function_variant"
VHL Loss-of-function	VHL	Loss-of-function	Clear Cell Renal Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr3	10141008	10152220			"In patients with renal clear cell carcinoma, patients with loss of function VHL mutations had shorter tumor-specific survival."	"Schraml et al., 2002, J. Pathol."	Somatic	ENST00000256474.2	loss_of_function_variant
VHL Loss	VHL	Loss	Renal Carcinoma	Temsirolimus	Predictive	Supports	D	Sensitivity/Response	chr3	10141008	10152220			Preclinical studies linking the efficacy of mTOR inhibitor CCI-779 to VHL loss in vitro and in mouse models of kidney cancer. VHL-deficient tumors were more sensitive to mTOR inhibition than VHL-proficient tumors. Growth arrest caused by CCI-779 correlated with a block in translation of HIF1A mRNA. Expression of a VHL-resistant HIF1A cDNA lacking the 5' untranslated region rescued tumor growth.	"Thomas et al., 2006, Nat. Med."	Somatic	ENST00000256474.2	loss_of_function_variant
VHL Mutation	VHL	Mutation	Renal Cell Carcinoma	Pazopanib	Predictive	Does Not Support	B	Sensitivity/Response	chr3	10141008	10152220			"VHL mutations were evaluated in 78 tumors samples of patients with metastatic RCC treated with pazopanib as part of a clinical trial. Overall, 87% had one VHL mutation, 12% showed promoter hypermethylation, and 6 patients had both. 8 patients exhibited neither mutation nor methylation of VHL. There was no correlation between VHL status and overall response rate or progression free survival under pazopanib therapy."	"Choueiri et al., 2013, Clin. Cancer Res."	Somatic	ENST00000256474.2	"gene_variant,loss_of_function_variant"
VHL Mutation	VHL	Mutation	Renal Cell Carcinoma	Anti-VEGF Monoclonal Antibody	Predictive	Does Not Support	B	Sensitivity/Response	chr3	10141008	10152220			"A meta-analysis to evaluate the association between the VHL alteration and clinical outcomes in patients with RCC. There were six studies including a total of 633 patients: 244 patients who received anti-VEGF therapy in the predictive value analysis and 419 in the prognostic value analysis. 410 (61.8%) had VHL alteration. The meta-analysis showed no association between the VHL gene alteration and ORR or PFS, as well as no correlation to OS. VEGFR inhibition included: Sunitinib, Sorafenib, Axitinib, Pazopanib, Bevacizumab."	"Kim et al., 2017, Oncotarget"	Somatic	ENST00000256474.2	"gene_variant,loss_of_function_variant"
VHL Mutation	VHL	Mutation	Renal Cell Carcinoma	Everolimus	Predictive	Supports	B	Sensitivity/Response	chr3	10141008	10152220			"A randomized, open-label phase 2 study, encompassing 85 patients, to compare the efficacy of dual PIK3/mTOR Inhibitor Apitolisib and mTORC1 inhibitor Everolimus in patients who progressed on or after antiangiogenetic therapy (VEGFR). There was a trend towards association between deleterious VHL alterations and progression-free-survival in the Everolimus arm only."	"Powles et al., 2016, J. Clin. Oncol."	Somatic	ENST00000256474.2	"gene_variant,loss_of_function_variant"
VHL M1? (c.1-1_20del21)	VHL	M1? (c.1-1_20del21)	Clear Cell Renal Cell Carcinoma		Oncogenic	Supports	C	Oncogenicity	chr3	10141847	10141867	AATGCCCCGGAGGGCGGAGAA		"This variant was detected in a single case with clear-cell renal cell carcinoma. The tumor had two somatic variants (c.1-1_20del21 and c.291_310del20). Either of these variants is predicted to be quite deleterious. While they were observed in a somatic context in an RCC, we can infer that they could be predisposing for VHL in a germline context."	"van Houwelingen et al., 2005, BMC Cancer"	Somatic	ENST00000256474.2	start_lost
VHL M1FS (c.1_17del17)	VHL	M1FS (c.1_17del17)	Chromophobe Renal Cell Carcinoma		Oncogenic	Supports	C	Oncogenicity	chr3	10141848	10141864	ATGCCCCGGAGGGCGGA		This somatic mutation was detected in two samples from a single patient with chromophobe renal cell carcinoma (a 74 year old male). The tumor also harbored a silent T157= (c.471T>A) somatic variant.	"van Houwelingen et al., 2005, BMC Cancer"	Somatic	ENST00000256474.2	start_lost
VHL M1? (c.3G>A)	VHL	M1? (c.3G>A)	Clear Cell Renal Cell Carcinoma		Oncogenic	Supports	C	Oncogenicity	chr3	10141850	10141850	G	A	Mutation detected in one case. Case shows clear-cell renal cell carcinoma. This case also harbored a second somatic variant in VHL: 209-210delAG (Stop130).	"Gallou et al., 2001, Pharmacogenetics"	Somatic	ENST00000256474.2	start_lost
VHL N7D (c.19A>G)	VHL	N7D (c.19A>G)	Renal Cell Carcinoma		Oncogenic	Supports	C	Oncogenicity	chr3	10141866	10141866	A	G	"A somatic mutation (N7D) detected in one case, a 79ya patient with renal cell carcinoma (case '1VT'). The patient had a second in-frame deletion of 5 amino acids (41-45), but the author speculate that it could be an inherited polymorphism."	"Ma et al., 2001, Oncogene"	Somatic	ENST00000256474.2	missense_variant
VHL W8* (c.24G>A)	VHL	W8* (c.24G>A)	Renal Cell Carcinoma		Oncogenic	Supports	C	Oncogenicity	chr3	10141871	10141871	G	A	"A single case (70 year-old named ""3GT"" in this study) with sporadic grade 3 renal cell carcinoma was observed with both W8* and G44D somatic variants."	"Ma et al., 2001, Oncogene"	Somatic	ENST00000256474.2	stop_gained
VHL M54IFS (c.162_166delGGAGG)	VHL	M54IFS (c.162_166delGGAGG)	Clear Cell Renal Cell Carcinoma		Oncogenic	Supports	C	Oncogenicity	chr3	10142009	10142013	GGAGG		A study of sporadic renal cell carcinoma identified this frameshift confirmed somatic variant along with LOH of the VHL gene in a case with clear cell renal carcinoma (case #152 in the study).	"Shuin et al., 1994, Cancer Res."	Somatic	ENST00000256474.2	frameshift_truncation
VHL E55FS (c.163_164delGA)	VHL	E55FS (c.163_164delGA)	Renal Cell Carcinoma		Oncogenic	Supports	C	Oncogenicity	chr3	10142010	10142011	GA		"In a 54 year old male patient with sporadic renal cell carcinoma, VHL c.163_164delGA causing a p.Glu55 Stop at 130 frameshift mutation was observed. Loss of heterozygosity analysis was non-informative. This result suggests a potential oncogenic role for VHL c.163_164delGA in Renal Cell Carcinoma."	"Gallou et al., 1999, Hum. Mutat."	Somatic	ENST00000256474.2	frameshift_truncation
VHL S65L (c.194C>T)	VHL	S65L (c.194C>T)	Clear Cell Renal Cell Carcinoma		Oncogenic	Supports	C	Oncogenicity	chr3	10142041	10142041	C	T	This study analyzed tumor and non-tumor kidney tissue from 195 unrelated patients with sporadic clear cell renal cell carcinoma (CCRCC) for a relationship between VHL variants in sporadic CCRCC and 'genotypes for genes encoding several carcinogen-metabolizing enzymes.' This missense variant was found in a 68 year-old male (tumour 311).	"Gallou et al., 2001, Pharmacogenetics"	Somatic	ENST00000256474.2	missense_variant
VHL S65L (c.194C>T)	VHL	S65L (c.194C>T)	Von Hippel-Lindau Disease		Predisposing	N/A	C	N/A	chr3	10142041	10142041	C	T	"Thirty-two surgically resected HB specimens from 28 patients treated at the University of Tokyo Hospital between 1995 and 2012 were analyzed retrospectively. Of the 32 specimens, 11 were VHL-related HBs from 7 patients, and 21 were sporadic HBs from 21 patients. One of the 7 VHL patients was a female patient with a c.194C>T (p.Ser65Leu) mutation in the VHL gene. She developed a CNS hemangioblastoma in the cerebellum at 19Y. It is unclear whether she had germline testing. However, the patient met clinical criteria for VHL (Losner et al., 2003). Interestingly, the HB from this patient was noted to have LOH of chromosome 3p. No other phenotypic information was available."	"Takayanagi et al., 2017, Neuro-oncology"	Unknown	ENST00000256474.2	missense_variant
VHL S65L (c.194C>T)	VHL	S65L (c.194C>T)	Renal Carcinoma		Oncogenic	Supports	C	Oncogenicity	chr3	10142041	10142041	C	T	"Tumors from 110 patients with sporadic renal carcinoma were analyzed for VHL mutations and loss of heterozygosity. 56 of the 98 samples from sporadic, clear cell renal carcinoma patients were identified with VHL somatic mutations; Loss of heterozygosity was observed in 97% of those samples. This missense mutation was found in one of the clear cell renal carcinoma cell lines (sample UOK164). No phenotype described."	"Gnarra et al., 1994, Nat. Genet."	Somatic	ENST00000256474.2	missense_variant
VHL E70* (c.208G>T)	VHL	E70* (c.208G>T)	Von Hippel-Lindau Disease		Predisposing	Supports	C	Uncertain Significance	chr3	10142055	10142055	G	T	"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This nonsense variant was found in a VHL type 1 patient  with CNS hemangioblastomas (family ID 4479)."	"Chen et al., 1995, Hum. Mutat."	N/A	ENST00000256474.2	stop_gained
VHL R82_V84del (c.244_252del)	VHL	R82_V84del (c.244_252del)	Von Hippel-Lindau Disease		Predisposing	Supports	C	Uncertain Significance	chr3	10142091	10142099	CGCGTCGTG		"In a study of 114 unrelated VHL families, 85 germline mutations were found. VHL mutations were detected in affected family members, but not in unaffected family members or 96 normal individuals. This in-frame deletion was  found in a VHL type 1 family of 6 individuals (family ID 3177). Four of 6 individuals were identified with angiomas and 3 had CNS hemangioblastomas."	"Chen et al., 1995, Hum. Mutat."	N/A	ENST00000256474.2	inframe_deletion
VHL Y98FS (c.291_310del20)	VHL	Y98FS (c.291_310del20)	Clear Cell Renal Cell Carcinoma		Oncogenic	Supports	C	Oncogenicity	chr3	10142138	10142157	CTACCCAACGCTGCCGCCTG		This variant was detected in a single case with clear-cell renal cell carcinoma. The tumor had two somatic variants (c.1-1_20del21 and c.291_310del20). Either of these variants is predicted to be quite deleterious.	"van Houwelingen et al., 2005, BMC Cancer"	Somatic	ENST00000256474.2	frameshift_truncation
VHL L118P (c.353T>C)	VHL	L118P (c.353T>C)	Clear Cell Renal Cell Carcinoma		Oncogenic	Supports	C	Oncogenicity	chr3	10146526	10146526	T	C	"Tumors from 98 patients with sporadic clear cell renal carcinoma (ccRC) were analyzed for VHL mutations and loss of heterozygosity (LOH). Somatic VHL variants were observed in 56 patients, and VHL LOH was observed in 98% of samples with VHL variants. VHL L118P (c.353T>C) was found in a granular ccRC (sample T36, variant location indicated at c.566 because of differences in reference transcript). Authors noted that VHL variants were highly specific to ccRC and not found in the 12 other tumor types examined."	"Gnarra et al., 1994, Nat. Genet."	Somatic	ENST00000256474.2	missense_variant
VHL P138R (c.413C>G)	VHL	P138R (c.413C>G)	Clear Cell Renal Cell Carcinoma		Oncogenic	Supports	C	Oncogenicity	chr3	10146586	10146586	C	G	"Tumors from 98 patients with sporadic clear cell renal carcinoma (ccRC) were analyzed for VHL mutations and loss of heterozygosity (LOH). Somatic VHL variants were observed in 56 patients, and VHL LOH was observed in 98% of samples with VHL variants. P138R (c.413C>G) was found in a granular ccRC (sample UOK102, variant location indicated at NT 626 because of differences in reference transcript). Authors noted that VHL variants were highly specific to ccRC and not found in the 12 other tumor types examined."	"Gnarra et al., 1994, Nat. Genet."	Somatic	ENST00000256474.2	missense_variant
VHL N150fs (c.447del)	VHL	N150fs (c.447del)	Renal Carcinoma		Oncogenic	Supports	C	Oncogenicity	chr3	10146619	10146619	C		"Tumors from 98 patients with sporadic clear cell renal carcinoma (ccRC) were analyzed for VHL mutations and loss of heterozygosity (LOH). Somatic VHL variants were observed in 56 patients, and VHL LOH was observed in 98% of samples with VHL variants. VHL N150fs (c.447del) was found in a ccRC (sample T683, variant noted as c.659del because of differences in reference transcript). Authors noted that VHL variants were highly specific to ccRC and not found in the 12 other tumor types examined."	"Gnarra et al., 1994, Nat. Genet."	Somatic	ENST00000256474.2	"minus_1_frameshift_variant,frameshift_truncation"
VHL Q164* (c.490C>T)	VHL	Q164* (c.490C>T)	Clear Cell Renal Cell Carcinoma		Oncogenic	Supports	C	Oncogenicity	chr3	10149813	10149813	C	T	"Tumors from 98 patients with sporadic clear cell renal cell carcinoma (ccRCC) were analyzed for VHL mutations and loss of heterozygosity (LOH). Somatic VHL variants were observed in 56 patients, and VHL LOH was observed in 98% of samples with VHL variants. VHL Q164* (c.490C>T) was found in a granular ccRC (sample UOK161, variant location indicated as c.703 because of differences in reference transcript). Authors noted that VHL variants were highly specific to ccRC and not found in the 12 other tumor types examined."	"Gnarra et al., 1994, Nat. Genet."	Somatic	ENST00000256474.2	stop_gained
VHL L184P (c.551T>C)	VHL	L184P (c.551T>C)	Renal Cell Carcinoma		Diagnostic	Supports	C	Positive	chr3	10149874	10149874	T	C	"In a study of 31 kidney tumors from France, 14 somatic VHL mutations were found. Most tumors were found to have heterozygous pattern of mutation likely due to contamination of renal cancer tissues with non-tumor cells. Genomic DNA was extracted from tumors, lymphocytes and cell lines using standard phenol/chloroform extraction or salt extraction protocols. Three sets of primers were designed to amplify the entire exons 2 and 3 and the last one third 3'-region of exon 1, the genotyping method used was PCR-SSCP (polymerase chain reaction-single-strand conformation polymorphism). A metastatic clear cell renal cell carcinoma sample (sample 3087) was obtained from a 68 year old male who was known to smoke one pack of cigarettes per day and had intense alcohol drinking habits. In this patient's tumor (sample 3087), a c.551T>C variant (noted in the paper as nucleotide 764) was identified as a somatic mutation, found only in the tumor. The second mutation, a C>G transversion, c.183C>G (p.P61=) (noted in the paper at nucleotide 396) was present in the non-tumor DNA, a germline synonymous mutation. The patient had no metastasis after nephrectomy and patients survival was >4 months. ACMG codes: none."	"Bailly et al., 1995, Int. J. Cancer"	Somatic	ENST00000256474.2	missense_variant
VHL L184P (c.551T>C)	VHL	L184P (c.551T>C)	Clear Cell Renal Cell Carcinoma		Diagnostic	Supports	C	Positive	chr3	10149874	10149874	T	C	"195 patients with sporadic clear cell renal cell carcinoma (sporadic CCRCC) were investigated for variants in the VHL gene, in order to determine the possible relationship between VHL mutations in CCRCC patients and polymorphisms in genes encoding enzymes involved in carcinogen metabolism. For each patient, fragments of tumor and non-tumoral kidney tissue were sampled, and DNA was extracted for analysis. PCR, SSCP (single strand conformation polymorphism,) and direct sequencing were used to investigate VHL variants. Tumor number 347 (a cytological grade 1 stage I tumor) was taken from a 60 year old female, and found to have the c.551T>C (p.L184P) somatic mutation in exon 3 of the VHL gene. No other phenotypic information was available for any of the patients included in this study. Relevant ACMG evidence codes: none."	"Gallou et al., 2001, Pharmacogenetics"	Somatic	ENST00000256474.2	missense_variant
PAX8 PAX8::PPARG	PAX8	PAX8::PPARG	Thyroid Gland Follicular Carcinoma		Diagnostic	Supports	B	Positive	chr3	12287901	12434311			"PAX8PPARG gene fusions were found in 12/33 follicular thyroid carcinoma tumor samples, but were rarely found in thyroid Hrthle cell tumors."	"Nikiforova et al., 2003, J. Clin. Endocrinol. Metab."	Somatic	ENST00000429538.3	transcript_fusion
RAF1 Amplification	RAF1	Amplification	Skin Melanoma	"Carboplatin,Paclitaxel,Sorafenib"	Predictive	Supports	B	Sensitivity/Response	chr3	12583601	12664226			"Retrospective analysis of somatic mutations and copy number changes in 119 patients treated with carboplatin, paclitaxel,  sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved progression-free survival (PFS) compared with CP in patients with tumors that were positive for RAF1 gene copy gains (HR = 0.372; P = 0.025)."	"Wilson et al., 2016, Clin. Cancer Res."	Somatic	ENST00000251849.4	transcript_amplification
RAF1 R391W	RAF1	R391W			Functional	Supports	D	Gain of Function	chr3	12591730	12591730	T	A	"RAF1 (CRAF) R391W was observed in a melanoma patient from which cell line M375 was derived (wild-type for BRAF and NRAS). RAF1 R391W expressed in 293T cells showed increased phosphorylation of MEK and ERK compared to wild-type, including when treated with vemurafenib. Measuring cleaved PARP also indicated that exogenous expression of CRAF R391W prevented induction of apoptosis by vemurafenib in M238 cells. A soft-agar transformation assay showed an increase in colonies in R391W compared to wild-type indicating increased anchorage-independent growth."	"Atefi et al., 2016, Sci Rep"	Somatic	ENST00000251849.4	missense_variant
MLH1 EXPRESSION	MLH1	EXPRESSION	Stomach Carcinoma		Prognostic	Supports	B	Poor Outcome	chr3	36993332	37050918			"46 patients with poorly cohesive, signet-cell ring, gastric carcinoma were evaluated for genetic mutations and MLH1 expression (immunohistochemistry). Overall survival rate of MLH1 negative cases were significantly better than MLH1 positive cases (p=0.020)."	"Rokutan et al., 2016, J. Pathol."	Somatic	ENST00000231790.2	N/A
MLH1 M1L	MLH1	M1L	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr3	36993548	36993548	A	T	"MLH1 M1L (c.1A>T), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 73 year old female patient (patient id: sLS-8) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition. Loss of heterozygosity resulting in overrepresentation of the M1L allele was observed. Additionally, this patient's tumor harbored a heterozygous MLH1 p.K618del mutation and was wildtype for BRAF."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	missense_variant
MLH1 E13fs	MLH1	E13fs	Endometrial Cancer		Oncogenic	Supports	C	Oncogenicity	chr3	36993584	36993584	G		"MLH1 E13fs (c.37del), identified in a case of microsatellite-unstable endometrial cancer, was confirmed to be somatic in a 46 year old female patient (sLS-1) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS. This patient also harbored MLH1 p.G606fs."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	"minus_1_frameshift_variant,frameshift_truncation"
MLH1 V49A	MLH1	V49A	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr3	36996648	36996648	T	C	"MLH1 V49A (c.146 T > C), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 68 year old female patient (id: sLS-7) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS as the disease is germline by definition. The patient also harbored a second MLH1 mutation (p.D667fs) which demonstrated loss of heterozygosity and BRAF wildtype."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	missense_variant
MLH1 G65D	MLH1	G65D	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr3	36996696	36996696	G	A	"This variant (G65D), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 71 year-old male patient (sLS-21) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition. This patient also had loss of heterozygosity."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	missense_variant
MLH1 G67R	MLH1	G67R	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr3	36996701	36996701	G	A	"This variant (G67R), identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a 61 year-old male patient (sLS-18) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition. Loss of heterozygosity of the wildtype allele was demonstrated."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	missense_variant
MLH1 I68S	MLH1	I68S	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr3	36996705	36996705	T	G	"MLH1 I68S (c.203 T > G), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 65 year old male patient (id: sLS-20) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, as the disease is germline by definition. Loss of heterozygosity leading to p.I68S at 77% variant allele frequency was demonstrated. The patient also harbored a heterozygous MLH1 p.T117M mutation (38% VAF)."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	missense_variant
MLH1 R100*	MLH1	R100*	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr3	37001045	37001045	C	T	"R100* (c.298C > T), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 46 year old female patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition. Loss of heterozygosity of the wildtype allele was confirmed."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	stop_gained
MLH1 T117M	MLH1	T117M	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr3	37004444	37004444	C	T	"MLH1 T117M (c.350C > T), identified in three cases of microsatellite-unstable colorectal cancer, was confirmed to be somatic in patients with suspected Lynch Syndrome (LS). The patients were therefore negative for LS, as the disease is germline by definition. Patient sLS-6 was a 59 year old female whose tumor harbored BRAF V600E and had loss of heterozygosity of MLH1. Patient sLS-19 was a 62 year old female whose tumor harbored loss of heterozygosity at MLH1 and wildtype BRAF. Patient sLS-20 was a 65 year old male whose tumor harbored concomitant MLH1 I68S and BRAF wildtype."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	missense_variant
MLH1 Q149*	MLH1	Q149*	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr3	37007055	37007055	C	T	"MLH1 Q149* (c.445C > T), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 65 year old female patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is a germline disease by definition. This patient also harbored MLH1 p.R226* and MSH6 p.I972F mutations at similar variant allele frequencies. Authors note that the tumor retained MLH1 heterozygosity, was wildtype for BRAF, and harbored two pathogenic variants in MMR."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	stop_gained
MLH1 V213FS	MLH1	V213FS	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr3	37012060	37012060	T		"This variant (V213fs), identified in two cases of microsatellite-unstable colorectal cancer, was confirmed to be somatic in both patients (40 year-old female & 70 year-old male) with suspected Lynch Syndrome (LS). The patients were therefore negative for LS, which is by definition a germline disorder."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	frameshift_truncation
MLH1 R226*	MLH1	R226*	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr3	37012098	37012098	C	T	"MLH1 R226* (c.676C > T), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 65 year old female patient (sLS-14) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition. This patient also harbored MLH1 p.Q149* and MSH6 p.I972F mutations as similar variant allele frequencies. Authors note that the tumor of this patient was wildtype for BRAF."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	stop_gained
MLH1 c.790+1G>A	MLH1	c.790+1G>A	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr3	37014545	37014545	G	A	"MLH1 c.790+1G > A, identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 61 year old male patient (sLS-2) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, as the disease is germline by definition. This patient's tumor also harbored a p.K618del mutation and was wildtype for BRAF."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	splice_donor_variant
MLH1 R265G	MLH1	R265G	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr3	37017508	37017508	C	G	"MLH1 R265G (c.793C > G), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 65 year old female patient (id: sLS-10) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, as the disease is germline by definition. Loss of heterozygosity of the wildtype allele and BRAF wildtype was observed."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	missense_variant
MLH1 A424T	MLH1	A424T	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr3	37025868	37025868	G	A	"MLH1 A424T (c.1270G>A), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 45 year old male patient (id: sLS-13) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS which is germline by definition. Patient also harbored a BRAF V600E mutation."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	missense_variant
MLH1 Q426FS	MLH1	Q426FS	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr3	37025874	37025874	C		"MLH1 Q426fs (c.1276del), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be a somatic mutation in a 46 year old male patient (patient id: sLS-5) with suspected Lynch syndrome (LS). The patient was therefore negative for LS as it is a germline disease, by definition. Loss of heterozygosity of the wildtype allele and wildtype BRAF was observed."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	frameshift_truncation
MLH1 M490T	MLH1	M490T	Endometrial Cancer		Oncogenic	Supports	C	Oncogenicity	chr3	37028843	37028843	T	C	"This variant (M490T), identified in a case of microsatellite-unstable endometrial cancer was confirmed to be somatic in a 69 year-old female patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which by definition is a germline condition. The patient also harbored PMS2 R315*, MSH2 p.E483G and MSH6 p.V352I mutations."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	missense_variant
MLH1 V534R	MLH1	V534R	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr3	37040227	37040228	GT	AG	"MLH1 V534R (c.1600_1601delinsAG), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be a somatic variant in a 27 year old male patient (id: sLS-24) with suspected Lynch syndrome (LS). The patient was therefore negative for LS which is germline by definition. Authors note that this patient's tumor retained MLH1 heterozygosity and wildtype BRAF."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	missense_variant
MLH1 P536FS	MLH1	P536FS	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr3	37040235	37040235	T		"This variant (P536fs), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 59 year-old female patient (sLS-17) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition. Loss of heterozygosity of the wildtype allele was demonstrated resulting in higher mutated allele representation (80% variant allele frequency)."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	frameshift_truncation
MLH1 N551T	MLH1	N551T	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr3	37040279	37040279	A	C	MLH1 N551T (c.1652A > C) identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a 51 year old female patient (id: sLS-12) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS as the disease is germline by definition.	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	missense_variant
MLH1 G606FS*2	MLH1	G606FS*2	Endometrial Cancer		Oncogenic	Supports	C	Oncogenicity	chr3	37047603	37047604	GG		"MLH1 G606fs*2 (c.1816_1817del), identified in a case of microsatellite-unstable endometrial cancer, was confirmed to be somatic in a 46 year old female patient (sLS-1) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition. This patient also harbored a MLH1 p.E13fs*3 mutation."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	frameshift_truncation
MLH1 K618DEL	MLH1	K618DEL	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr3	37047639	37047641	AAG		"MLH1 K618del (c.1852_1854del), identified in two cases of microsatellite-unstable colorectal cancer, was confirmed to be somatic in both patients with suspected Lynch Syndrome (LS). Both patients were therefore negative for LS, as it is germline by definition. sLS-2 was a 61 year old male whose tumor harbored MLH1 c.790 + 1G>A concomitantly, retained MLH1 heterozygosity and was wildtype for BRAF. sLS-8 was a 73 year old female whose tumor harbored MLH1 M1L and was wildtype for BRAF."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	inframe_deletion
MLH1 D667FS	MLH1	D667FS	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr3	37048915	37048915	C		"This variant (D667fs), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 68 year old female patient (id: sLS-7) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition. Loss of heterozygosity leading to primarily the D667fs allele detected (90% VAF). This patient also harbored a heterozygous p.V49A variant."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	frameshift_truncation
MLH1 A681V	MLH1	A681V	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr3	37048956	37048956	C	T	"This variant (A681V), identified in a case of microsatellite-unstable colorectal cancer was confirmed to be somatic in a 52 year-old male patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition. Loss of heterozygosity (wildtype allele loss) was also demonstrated."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	missense_variant
MLH1 R687FS	MLH1	R687FS	Colorectal Cancer		Oncogenic	Supports	C	Oncogenicity	chr3	37048973	37048973	C		"MLH1 R687fs (c.2059del), identified in a case of microsatellite-unstable colorectal cancer, was confirmed to be somatic in a 33 year old male patient (patient id: sLS-3) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS which is germline by definition. Loss of heterozygosity of the wildtype allele was demonstrated. Patient also had a BRAF p.D594G mutation."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	frameshift_variant
MLH1 *757L	MLH1	*757L	Villous Adenoma		Oncogenic	Supports	C	Oncogenicity	chr3	37050652	37050652	A	T	"MLH1 *757 L (c.2270A > T), identified in a case of microsatellite-unstable villous adenoma, was confirmed to be somatic in a 39 year old male patient (id: sLS-9) with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, as the disease is germline by definition. The patient also harbored an MLH1 c.453+1G > A mutation."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000231790.2	stop_lost
MYD88 Overexpression	MYD88	Overexpression	Breast Cancer	Paclitaxel	Predictive	Supports	D	Resistance	chr3	38138478	38143019			"In this retrospective analysis of 211 breast cancer tissues, MYD88 overexpression was correlated  with poor survival. In-vitro experiments showed a decrease in sensitivity towards paclitaxel in cell-lines with high MYD88 expression."	"Xiang et al., 2016, Tumour Biol."	Somatic	ENST00000417037.2	N/A
MYD88 L265P	MYD88	L265P	Lymphoplasmacytic Lymphoma	Ibrutinib	Predictive	Supports	B	Sensitivity/Response	chr3	38141150	38141150	T	C	A prospective study of ibrutinib in 63 symptomatic patients with Waldenstrm's macroglobulinemia who had received at least one previous treatment. The response rates were highest among patients with MYD88(L265P) and CXCR4(WT). The MYD88 L265P mutation was present in 56 patients (89%).	"Treon et al., 2015, N. Engl. J. Med."	Somatic	ENST00000396334.3	"missense_variant,gain_of_function_variant"
MYD88 L265P	MYD88	L265P	Chronic Lymphocytic Leukemia		Prognostic	Supports	B	Better Outcome	chr3	38141150	38141150	T	C	"MYD88 mutations were identified in 24 of 1080 screened  CLLs. They were exclusively seen in instances of mutated IGHV genes (18/23, P = 0.0001), a widely recognized prognostic signature for better outcome in CLL."	"Baliakas et al., 2015, Leukemia"	Somatic	ENST00000396334.3	"missense_variant,gain_of_function_variant"
MYD88 L265P	MYD88	L265P	Lymphoplasmacytic Lymphoma	"IRAK-1/4 Inhibitor,IMG-2005-5"	Predictive	Supports	D	Sensitivity/Response	chr3	38141150	38141150	T	C	"In a study of 30 patients with Waldenstrms macroglobulinemia, 87% had MYD88(L265P) mutations.  Waldenstrom macroglobulinemia cells expressing MYD88(L265P) were treated with an MYD88 homodimerization inhibitor or an IRAK 1/4 kinase inhibitor.  The cells showed a decrease in staining of NF-kappa-B p65 phosphorylation."	"Treon et al., 2012, N. Engl. J. Med."	Somatic	ENST00000396334.3	"missense_variant,gain_of_function_variant"
CTNNB1 Activating Mutation	CTNNB1	Activating Mutation	Melanoma	"Anti-CTLA-4 Monoclonal Antibody,Anti-PD-L1 Monoclonal Antibody"	Predictive	Supports	D	Resistance	chr3	41199439	41240445			Activation of melanoma-cell-intrinsic WNT/-catenin signalling pathway contributes to a lack of T-cell infiltration in melanoma. Molecular analysis of human metastatic melanoma samples revealed a correlation between activation of the WNT/-catenin signalling pathway and absence of a T-cell gene expression signature. In autochthonous mouse melanoma models active -catenin signalling results in T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy.	"Spranger et al., 2015, Nature"	Somatic	ENST00000349496.5	"transcript_variant,gain_of_function_variant"
CTNNB1 Exon 3 Mutation	CTNNB1	Exon 3 Mutation	Desmoid Tumor		Prognostic	Does Not Support	B	Poor Outcome	chr3	41224526	41224753			"This study illustrates the prevalence of CTNNB1 mutations in sporadic desmoid tumors, and examines whether the presence of CTNNB1 mutations correlates with the disease outcome. CTNNB1 mutations (including specific exon 3 mutations T41A, S45F, S45P, and S45C) were found in 106 out of 145 desmoid tumor specimens, and in 86 out of 115 specimens from patients who had undergone complete surgical resection. At a median follow-up of 31 months, the 5-year recurrence free survival rate of patients with the beta-catenin mutated tumors was worse than that of the patients with wild-type tumors (58% vs 74%), however, the difference was not statistically significant (p = 0.285). Thus, the study shows that there is no statistically significant correlation between the CTNNB1 mutation and the recurrence risk of sporadic desmoid tumors, even though specific exon 3 CTNNB1 mutations are commonly identified in these tumors."	"Mullen et al., 2013, Oncologist"	Somatic	ENST00000349496.5	
CTNNB1 Exon 3 Mutation	CTNNB1	Exon 3 Mutation	Childhood Medulloblastoma		Diagnostic	Supports	B	Positive	chr3	41224526	41224753			"A series of 72 pediatric medulloblastomas were evaluated for CTNNB1 mutations (by direct sequencing), copy number alterations (by array-comparative genomic hybridization), and beta-catenin protein expression (by immunohistochemistry). CTNNB1 mutations were detected in all six cases with extensive (>50% of the tumor cells) nuclear staining of beta-catenin. Remarkably, five out of these six tumors demonstrated a loss of chromosome 6, a cytogenetic event that is absent in CTNNB1-wildtype tumors (p <0.0001, Fishers exact test)."	"Fattet et al., 2009, J. Pathol."	Somatic	ENST00000349496.5	
CTNNB1 Exon 3 Mutation	CTNNB1	Exon 3 Mutation	Childhood Medulloblastoma		Diagnostic	Supports	B	Positive	chr3	41224526	41224753			"A total of 51 medulloblastomas from two independent cohorts (19 and 32 cases) were assessed for evidence of Wnt/Wg pathway activation, alongside a genome-wide analysis of associated copy-number aberrations. Cases displaying evidence of Wnt/Wg activation (CTNNB1 mutation and/or beta-catenin nuclear stabilization) were exclusively associated with a distinct genomic signature involving loss of an entire copy of chromosome 6 but few other aberrations. Loss of chromosome 6 was exclusively observed in Wnt/Wg-activated medulloblastoma, as evidenced by 3 of 3 cases with nuclear immune-positivity for b-catenin in the first cohort (19 cases). In the second cohort (32 cases), loss of chromosome 6 is observed in Wnt/Wg-active tumors and absence in Wnt/Wg-negative cases (8/13 vs. 0/19; p=0.0001)."	"Clifford et al., 2006, Cell Cycle"	Somatic	ENST00000349496.5	
CTNNB1 T41A	CTNNB1	T41A	Desmoid Tumor		Diagnostic	Supports	B	Positive	chr3	41224633	41224633	A	G	"Desmoid fibromatosis is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence. Beta-Catenin deregulation has been commonly identified in sporadic desmoids. CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%). Five-year recurrence-free survival was significantly poorer in S45F-mutated desmoids (23%, P < 0.0001) versus either T41A (57%) or nonmutated tumors (65%). In conclusion, CTNNB1 mutations are highly common in desmoid tumors. Furthermore, patients harboring CTNNB1 (45F) mutations are at particular risk for recurrence and therefore may especially benefit from adjuvant therapeutic approaches."	"Lazar et al., 2008, Am. J. Pathol."	Somatic	ENST00000349496.5	missense_variant
CTNNB1 T41A	CTNNB1	T41A	Desmoid Tumor		Prognostic	Supports	B	Better Outcome	chr3	41224633	41224633	A	G	"In an analysis of 138 desmoid fibromatosis tumors, which is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence, 117 tumors (85%) had CTNNB1 mutations. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%). Five-year recurrence-free survival was significantly poorer in S45F-mutated desmoids (23%, P < 0.0001) versus either T41A (57%) or nonmutated tumors."	"Lazar et al., 2008, Am. J. Pathol."	Somatic	ENST00000349496.5	missense_variant
CTNNB1 T41A	CTNNB1	T41A	Desmoid Tumor		Diagnostic	Supports	B	Positive	chr3	41224633	41224633	A	G	In this study a collection of 254 sporadic desmoid tumors were analysed for presence of mutations in CTNNB1. A mutation in exon 3 of the CTNNB1 gene was identified in 223 (88%) of the 254 cases. The CTNNB1 mutation spectra concerned mainly three point mutations in two codons (41 and 45): T41A was identified in 132 cases (59%); S45F was identified in 49 samples (22%); and S45P was identified in 27 samples (12%). None of the 175 lesions mimicking desmoid tumors analyzed harbored any CTNNB1 mutations.	"Le Guellec et al., 2012, Mod. Pathol."	Somatic	ENST00000349496.5	missense_variant
CTNNB1 S45P	CTNNB1	S45P	Desmoid Tumor		Diagnostic	Supports	B	Positive	chr3	41224645	41224645	T	C	"Desmoid fibromatosis is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence. Beta-Catenin deregulation has been commonly identified in sporadic desmoids. CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%). In conclusion, CTNNB1 mutations are highly common in desmoid tumors."	"Lazar et al., 2008, Am. J. Pathol."	Somatic	ENST00000349496.5	missense_variant
CTNNB1 S45P	CTNNB1	S45P	Desmoid Tumor		Prognostic	Supports	B	Better Outcome	chr3	41224645	41224645	T	C	"Desmoid fibromatosis is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence. Beta-Catenin deregulation has been commonly identified in sporadic desmoids. CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%). Five-year recurrence-free survival was significantly poorer in S45F-mutated desmoids (23%, P < 0.0001) versus either T41A (57%) or nonmutated tumors (65%). Because of their low frequency, patients with S45P mutations were excluded from these analyses but showed a recurrence course similar to T41A or wild type patients."	"Lazar et al., 2008, Am. J. Pathol."	Somatic	ENST00000349496.5	missense_variant
CTNNB1 S45P	CTNNB1	S45P	Desmoid Tumor		Diagnostic	Supports	B	Positive	chr3	41224645	41224645	T	C	In this study a collection of 254 sporadic desmoid tumors were analysed for presence of mutations in CTNNB1. A mutation in exon 3 of the CTNNB1 gene was identified in 223 (88%) of the 254 cases. The CTNNB1 mutation spectra concerned mainly three point mutations in two codons (41 and 45): T41A was identified in 132 cases (59%); S45F was identified in 49 samples (22%); and S45P was identified in 27 samples (12%). None of the 175 lesions mimicking desmoid tumors analyzed harbored any CTNNB1 mutations.	"Le Guellec et al., 2012, Mod. Pathol."	Somatic	ENST00000349496.5	missense_variant
CTNNB1 S45F	CTNNB1	S45F	Desmoid Tumor		Diagnostic	Supports	B	Positive	chr3	41224646	41224646	C	T	"Desmoid fibromatosis is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence. Beta-Catenin deregulation has been commonly identified in sporadic desmoids. CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%). Five-year recurrence-free survival was significantly poorer in S45F-mutated desmoids (23%, P < 0.0001) versus either T41A (57%) or nonmutated tumors (65%). In conclusion, CTNNB1 mutations are highly common in desmoid tumors. Furthermore, patients harboring CTNNB1 (S45F) mutations are at particular risk for recurrence and therefore may especially benefit from adjuvant therapeutic approaches."	"Lazar et al., 2008, Am. J. Pathol."	Somatic	ENST00000349496.5	missense_variant
CTNNB1 S45F	CTNNB1	S45F	Desmoid Tumor		Prognostic	Supports	B	Poor Outcome	chr3	41224646	41224646	C	T	"Desmoid fibromatosis is a rare, nonmetastatic neoplasm marked by local invasiveness and relentless recurrence. Beta-Catenin deregulation has been commonly identified in sporadic desmoids. CTNNB1 mutations were observed in 117 of 138 (85%) of desmoids. Three discrete mutations in two codons of CTNNB1 exon 3 were identified: T41A (59%), S45F (33%), and S45P (8%). Five-year recurrence-free survival was significantly poorer in S45F-mutated desmoids (23%, P < 0.0001) versus either T41A (57%) or nonmutated tumors (65%). In conclusion, CTNNB1 mutations are highly common in desmoid tumors. Furthermore, patients harboring CTNNB1 (S45F) mutations are at particular risk for recurrence and therefore may especially benefit from adjuvant therapeutic approaches."	"Lazar et al., 2008, Am. J. Pathol."	Somatic	ENST00000349496.5	missense_variant
CTNNB1 S45F	CTNNB1	S45F	Desmoid Tumor		Diagnostic	Supports	B	Positive	chr3	41224646	41224646	C	T	In this study a collection of 254 sporadic desmoid tumors were analysed for presence of mutations in CTNNB1. A mutation in exon 3 of the CTNNB1 gene was identified in 223 (88%) of the 254 cases. The CTNNB1 mutation spectra concerned mainly three point mutations in two codons (41 and 45): T41A was identified in 132 cases (59%); S45F was identified in 49 samples (22%); and S45P was identified in 27 samples (12%). None of the 175 lesions mimicking desmoid tumors analyzed harbored any CTNNB1 mutations.	"Le Guellec et al., 2012, Mod. Pathol."	Somatic	ENST00000349496.5	missense_variant
CTNNB1 S45F	CTNNB1	S45F	Desmoid Tumor	Meloxicam	Predictive	Does Not Support	C	Sensitivity/Response	chr3	41224646	41224646	C	T	"Of the 33 patients with desmoid fibromatosis treated with meloxicam, a COX-2 selective inhibitor, one showed complete remission (CR), 7 partial remission (PR), 12 stable disease (SD), and 13 progressive disease (PD). The following 3 point mutations were identified in 21 of the 33 cases (64%): T41A (16 cases), S45F (4 cases) and S45P (one case). All four cases with S45F mutation exhibited strong nuclear expression of -catenin. S45F mutation was significantly associated with a poor response (all cases; PD) (p = 0.017)"	"Hamada et al., 2014, PLoS ONE"	Somatic	ENST00000349496.5	missense_variant
CTNNB1 S45F	CTNNB1	S45F	Desmoid Tumor		Prognostic	Supports	B	Poor Outcome	chr3	41224646	41224646	C	T	"This was a multi-institutional retrospective cohort study which looked at the prognostic value of CTNNB1 gene mutations in aggressive fibromatosis (also known as desmoid tumor). The study analyzed 101 patients who had undergone surgical resection of confirmed primary extra-abdominal or abdominal wall aggressive fibromatosis. Specimens were reviewed for the presence of T41A, S45F, and 45P mutations on the CTNNB1 gene. Mutations were found in 76 patients, with T41A being most common (n = 49), followed by S45F (n = 18), and 45P (n = 3). The 5-year cumulative risk of recurrence was 22.8%. Further analysis revealed that patients with an S45F mutation had a 5-year recurrence risk of 63.8% and an 8.5-fold higher risk of recurrence compared to patients with wild type tumors (P=0.006)."	"van Broekhoven et al., 2015, Ann Surg Oncol"	Somatic	ENST00000349496.5	missense_variant
RHOA MUTATION	RHOA	MUTATION	Stomach Carcinoma		Prognostic	Supports	E	Poor Outcome	chr3	49359145	49412202			"285 intestinal-type tumors and 183 diffuse-type tumors were evaluated for mutational profiles.  RHOA mutations are associated with diffuse type mucinous gastric carcinoma, which indicate worse prognosis when compared to intestinal type (p<0.001)."	"Rokutan et al., 2016, J. Pathol."	Somatic	ENST00000418115.1	"transcription_variant,gain_of_function_variant"
BAP1 EXPRESSION	BAP1	EXPRESSION	Uveal Melanoma		Prognostic	Supports	B	Better Outcome	chr3	52401013	52410350			"In patients with uveal melanoma, those with BAP1 expression (determined by immunohistochemical staining) had better survival."	"van Essen et al., 2014, Br J Ophthalmol"	N/A	ENST00000460680.1	N/A
BAP1 Mutation	BAP1	Mutation	Clear Cell Renal Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr3	52401013	52410350			"In patients with clear cell renal cell carcinoma, in a multivariate analysis those with mutations in BAP1 had worse overall survival than wild-type."	"Sato et al., 2013, Nat. Genet."	Somatic	ENST00000460680.1	"protein_altering_variant,loss_of_function_variant"
BAP1 Mutation	BAP1	Mutation	Renal Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr3	52401013	52410350			"In patients with clear cell renal cell carcinoma, in a multivariate analysis those with mutations in BAP1 had worse overall survival than wild-type."	"Sato et al., 2013, Nat. Genet."	Somatic	ENST00000460680.1	"protein_altering_variant,loss_of_function_variant"
BAP1 Mutation	BAP1	Mutation	Clear Cell Renal Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr3	52401013	52410350			"In patients with clear cell renal cell carcinoma, those with nonsilent mutations of BAP1 had worse overall survival than wild-type."	"2013, Nature"	Somatic	ENST00000460680.1	"protein_altering_variant,loss_of_function_variant"
BAP1 Mutation	BAP1	Mutation	Uveal Melanoma	"Valproic Acid,Panobinostat,Vorinostat,Trichostatin A"	Predictive	Supports	D	Sensitivity/Response	chr3	52401013	52410350			"Somatic and germline BAP1 mutations are associated with uveal melanoma. In this preclinical study, gene set enrichment analysis revealed HDAC inhibitors as potential drugs in BAP1 mutant uveal melanomas. HDAC inhibitors VPA, TSA, LBH-589, and SAHA (vorinostat) were tested in-vitro and led to decreased proliferation (all inhibitors) decreased viability and cytotoxicity (TSA, SAHA, LBH-589) in-vitro and in-vivo (VPA). RNAi mediated BAP1 knockdown increased sensitivity to HDAC inhibition (VPA)."	"Landreville et al., 2012, Clin. Cancer Res."	Somatic	ENST00000460680.1	"protein_altering_variant,loss_of_function_variant"
BAP1 Mutation	BAP1	Mutation	Malignant Mesothelioma	"Vorinostat,MC1568,Mocetinostat"	Predictive	Supports	E	Sensitivity/Response	chr3	52401013	52410350			"A siRNA screen identified BAP1 associated with HDAC1 and HDAC2 expression. HDAC2 or BAP1 depletion sensitized a mesothelioma cell line (MSTO-211H) to HDAC inhibitors MC1568, vorinostat or mocetinostat. The paper indicates however, that temporary BAP knockdown might not adequately reflect long-term BAP1 mutation."	"Sacco et al., 2015, Oncotarget"	Somatic	ENST00000460680.1	"protein_altering_variant,loss_of_function_variant"
BAP1 Mutation	BAP1	Mutation	Renal Cell Carcinoma	"Sunitinib,Everolimus"	Predictive	Supports	B	Resistance	chr3	52401013	52410350			"This study evaluated the effects of everolimus and sunitinib on patients with metastatic renal cell carcinoma. A total of 220 patients with RCC were evaluated for 341 genes at 540x coverage. Of all 220 patients, 19% of had BAP1 mutations. Patients with BAP1 mutations treated with first line everolimus followed by sunitinib (N=87 wildtype, 22 mutant) were associated with shorter progression free survival (median [95% CI] 4.9 [2.9 - 8.1] vs 10.5 [7.3 - 12.9] mo; HR 1.84 [1.1-3.2]; P=0.02). For patients treated with sunitinib followed by everolimus (N=91 wildtype, 20 mutant) were associated with a trend towards shorter progression free survival (median [95% CI] 8.1 [3.1-11.3] vs 11.0 [8.3-13.8] mo; HR 1.69 [0.9-3.2]; P=0.06)."	"Hsieh et al., 2017, Eur. Urol."	Somatic	ENST00000460680.1	"protein_altering_variant,loss_of_function_variant"
PBRM1 Mutation	PBRM1	Mutation	Clear Cell Renal Cell Carcinoma		Prognostic	Supports	B	N/A	chr3	52547841	52685836			"In renal clear cell carcinoma, patients with PBRM1 mutations did not have a significantly different cancer specific survival."	"Hakimi et al., 2013, Clin. Cancer Res."	Somatic	ENST00000394830.3	"transcription_variant,loss_of_function_variant"
PBRM1 Mutation	PBRM1	Mutation	Renal Cell Carcinoma		Prognostic	Supports	B	Better Outcome	chr3	52547841	52685836			"In patients with sporatic clear cell renal cell carcinoma, those with mutations in PBRM1 had better overall survival than patients with BAP1 mutations."	"Kapur et al., 2013, Lancet Oncol."	Somatic	ENST00000394830.3	"transcription_variant,loss_of_function_variant"
FOXP1 AMPLIFICATION	FOXP1	AMPLIFICATION	Diffuse Large B-cell Lymphoma		Diagnostic	Supports	B	Positive	chr3	70954693	71583989			Amplification of FOXP1 is shown to be associated with ABC DLBCL.	"Lenz et al., 2008, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000318789.4	transcript_amplification
ROS1 TFG::ROS1	ROS1	TFG::ROS1	Inflammatory Myofibroblastic Tumor	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr3	100709425	100728858			Case report of a pediatric patient with treatment-refactory inflammatory myofibroblastic tumor negative for ALK expression and rearrangement. Next generation sequencing of the patient revealed a TFG-ROS1 fusion. CT scans after 3 cycles of crizotinib treatment showed a reduction of the tumor mass which continued to decrease at the time of publication after 4 months of crizonitib treatment.	"Lovly et al., 2014, Cancer Discov"	Somatic	ENST00000240851.4	transcript_fusion
ALCAM EXPRESSION	ALCAM	EXPRESSION	Colorectal Cancer	Fluorouracil	Predictive	Supports	B	Resistance	chr3	105366909	105576900			"112 patients with rectal cancer who received 5-FU based chemotherapy and surgery were retrospectively analyzed for expression of Ki67, TS, BAX, EpCAM, p53, p21, EGFR, CD44, CD133, CD166, HIF1 and ALDH1. Pretreatment CD166 (ALCAM) expression level was associated with poor disease free survival (p??.003; HR 5.61; 95% CI 1.81, 17.35)."	"Sim et al., 2014, BMC Cancer"	N/A	ENST00000306107.5	N/A
CIP2A EXPRESSION	CIP2A	EXPRESSION	Pancreatic Ductal Adenocarcinoma		Prognostic	Supports	B	Poor Outcome	chr3	108549869	108589452			"Expression of the protein CIP2A was investigated in 72 cases of pancreatic ductal adenocarcinoma and 27 cases of adjacent tissues. Immunohistochemistry revealed a significant difference in expression between tumor and adjacent normal samples. Furthermore, a statistically significant decrease in overall survival was discovered between positive and negative CIP2A expression."	"Xu et al., 2016, Oncotarget"	Somatic	ENST00000295746.8	N/A
CIP2A Underexpression	CIP2A	Underexpression	Pancreatic Ductal Adenocarcinoma	Gemcitabine	Predictive	Supports	D	Sensitivity/Response	chr3	108549869	108589452			"Researchers studied the effect of CIP2A expression in relation to  gemcitabine sensitivity via SW1990 cell lines. SW1990 cells with CIP2A expression knocked-down displayed lower IC50 (p=.024), indicating a sensitivity to gemcitabine."	"Xu et al., 2016, Oncotarget"	Somatic	ENST00000295746.8	N/A
GATA2 EXPRESSION	GATA2	EXPRESSION	Lung Adenocarcinoma	"Bortezomib,Fasudil"	Predictive	Supports	D	Sensitivity/Response	chr3	128479427	128493185			Targeting overactive GATA2-mediated pathways with inhibitors bortezomib and fasudil led to dramatic tumor regression.	"Kumar et al., 2012, Cell"	Somatic	ENST00000341105.2	N/A
FOXL2 C134W	FOXL2	C134W	Ovarian Granulosa Cell Tumor		Diagnostic	Supports	B	Positive	chr3	138946321	138946321	G	C	"FOXL2 C134W mutation was found in 52 / 56 adult granulosa cell tumors, and is absent in other types of sex-cord stromal tumors, and juvenile granulosa tumors."	"Jamieson et al., 2010, Mod. Pathol."	Somatic	ENST00000330315.3	missense_variant
FOXL2 C134W	FOXL2	C134W	Ovarian Sex-cord Stromal Tumor		Diagnostic	Supports	A	Positive	chr3	138946321	138946321	G	C	"FOXL2 mutations were found in 94% of pathologically confirmed A-GCTs (95/101), in one of eight juvenile granulosa cell tumours (J-GCTs), and in two of 19 SLCTs."	"Goulvent et al., 2016, Histopathology"	Somatic	ENST00000330315.3	missense_variant
ATR I774FS	ATR	I774FS	Endometrial Cancer		Prognostic	Supports	B	Poor Outcome	chr3	142555898	142555898			"Extension and reduction of the ATR exon 10 A10 repeat (alters codon I774) was associated with poorer overall and disease-free survival in patients with endometrioid endometrial cancer when compared to patients with wildtype ATR and with or without microsatellite instability. These ATR mutations were observed in 12 of 248 patients (4.8%, 3 insertions, 9 deletions)."	"Zighelboim et al., 2009, J. Clin. Oncol."	Somatic	ENST00000350721.4	frameshift_truncation
WWTR1 WWTR1::CAMTA1	WWTR1	WWTR1::CAMTA1	Malignant Epithelioid Hemangioendothelioma		Diagnostic	Supports	B	Positive	chr3	149517235	149573000			"Performed a systematic molecular analysis of 17 epithelioid hemangioendothelioma (EHE) and compared to 13 epithelioid hemangiomas, five epithelioid angiosarcomas, and four epithelioid sarcoma-like EHE. A FISH positional cloning strategy, and RT-PCR analysis identified WWTR1-CAMTA1 in all EHE cases and none of the other benign or malignant epithelioid vascular tumors examined."	"Errani et al., 2011, Genes Chromosomes Cancer"	Somatic	ENST00000465804.1	transcript_fusion
PIK3CA Amplification	PIK3CA	Amplification	Gastric Adenocarcinoma		Prognostic	Supports	B	Poor Outcome	chr3	179148523	179240093			"In patients with gastric cancer, those with amplification of PIK3CA had shorter overall survival than those without amplification."	"Shi et al., 2012, BMC Cancer"	Somatic	ENST00000263967.3	transcript_amplification
PIK3CA Amplification	PIK3CA	Amplification	Epithelial Ovarian Cancer	Pictilisib	Predictive	Supports	C	Sensitivity/Response	chr3	179148523	179240093			One platinum-refractory epithelial ovarian cancer patient with PTEN loss and PIK3CA amplification had a partial response on treatment with PI3K inhibitor pictilisib (GDC-0941) in this phase 1 study. A total of 60 patients with advanced solid tumors were enrolled in this study.	"Sarker et al., 2015, Clin. Cancer Res."	Somatic	ENST00000263967.3	transcript_amplification
PIK3CA Mutation	PIK3CA	Mutation	Colorectal Cancer	Cabozantinib	Predictive	Supports	D	Sensitivity/Response	chr3	179148523	179240093			"20 patient-derived colorectal cancer xenografts were treated with cabozantinib, a c-MET and VEGFR2 inhibitor. 16 xenografts showed sensitivity (as defined by TGII: tumor growth of treated compared to control?0%). Among the genes tested for mutations (KRAS, TP53, PIK3CA, MET, VEGFR2, RET and AXL), PIK3CA mutations (4 PDTX) showed a significant enrichment in sensitive xenografts. PIK3CA mutations were observed in 4/5 of the most responsive tumors. Treating xenografts derived from isogenic PIK3CA wildtype or mutant cell lines corroborated this finding with PIK3CA mutant xenografts showing greater sensitivity to cabozantinib."	"Song et al., 2015, Int. J. Cancer"	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Endometrial Cancer	"Ridaforolimus,Temsirolimus"	Predictive	Does Not Support	B	Sensitivity/Response	chr3	179148523	179240093			"94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed. No predictive biomarkers were identified, including PIK3CA mutations (N=21/73), KRAS mutations (10/73) or PTEN loss."	"Mackay et al., 2014, Cancer"	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Colorectal Cancer	Anti-EGFR Monoclonal Antibody	Predictive	Supports	B	Resistance	chr3	179148523	179240093			"A meta-analysis of 8 metastatic colorectal cancer studies (839 patients) was performed. PIK3CA mutations were significantly associated with shorter PFS and OS following therapy with anti-EGFR monoclonal antibodies (PFS: 8 studies, 839 patients; HR = 1.53; 95 % confidence interval (CI) 1.28-1.84; P < 0.001; OS: 5 studies; 587 patients; HR = 1.28; 95 % CI 1.05-1.56; P = 0.015)."	"Wu et al., 2013, J. Cancer Res. Clin. Oncol."	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Her2-receptor Positive Breast Cancer	Everolimus	Predictive	Supports	B	Sensitivity/Response	chr3	179148523	179240093			"Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger sequencing. In the BOLERO trials, patients with HER2-overexpressing advanced breast cancer were treated with trastuzumab, chemotherapy and randomized to receive either everolimus or placebo. In the pooled analysis of both trials, patients with PI3K mutations had longer progression-free survival with everolimus compared to placebo (HR 0.67 95%CI 0.45 to 1.00, P=0.05) whereas patients with PI3K wild type status did not benefit significantly (HR 1.1, 95%CI 0.83 to 1.46, P=0.5). The same was found when PI3K mutations, PTEN loss and AKT E17K mutations were combinedly analyzed as hyperactive PI3K pathway. Patients with PI3K hyperactive pathway had a hazard ratio of 0.67 (95%CI 0.48 to 0.93, P=0.02) compared to HR 1.19 (95%CI 0.87 to 1.62, P=0.28) in patients with PI3K normal pathway. These trends were independently confirmed in both trials but only pooled results showed consistent statistical significance."	"Andr et al., 2016, J. Clin. Oncol."	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Cancer	"Pictilisib,Tanespimycin"	Predictive	Does Not Support	D	Sensitivity/Response	chr3	179148523	179240093			Analysis of drug response data from the Sanger center cell line screen. Cell lines with either PI3K and/or PTEN mutations did not show a significant difference in response to class I PI3K inhibitor GDC-0941 (p =0.07 for combined PI3K/PTEN aberrations with a trend towards lower IC50 for mutated cell lines). IC50 values with HSP90 inhibitor 17-AAG were significantly lower in PI3K and/or PTEN mutated cell lines in the sanger cell line screening but these results could not be reproduced in the cancer cell line encyclopedia screening.	"Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg"	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Head And Neck Cancer	Dactolisib	Predictive	Supports	D	Sensitivity/Response	chr3	179148523	179240093			"Preclinical analysis of the predicitive value of PIK3CA mutations for mTOR/PI3K Inhibition with BEZ-235. Two cell lines with PIK3CA Mutation (H1047R) were more sensitive to BEZ-235 than two cell lines with wild-type PIK3CA (in-vitro, results from one cell line also confirmed in-vivo). Two patient-derived xenografts with PIK3CA mutations (E110K, E542K) showed sensitivity to BEZ-235."	"Lui et al., 2013, Cancer Discov"	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Head And Neck Cancer	"Pictilisib,Trametinib,Tanespimycin"	Predictive	Does Not Support	D	Sensitivity/Response	chr3	179148523	179240093			"6 head and neck cancer cell lines were tested for Response to 17-AAG, GDC-0941. Two of the cell lines did not carry PIK3CA mutations. No clear difference was shown between PIK3CA-mutant and wild-type cell lines and there was a trend towards increased resistance. SCC25 cell line was lentivirally transduced with PIK3CA E545K or H1047R mutation. Engineered cells, compared to the parental cell line, showed decreased sensitivity to 17-AAG, GDC-0941 or trametinib."	"Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg"	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Her2-receptor Positive Breast Cancer	Trastuzumab	Predictive	Supports	B	Resistance	chr3	179148523	179240093			"The HER2 overexpressing breast cancer cell line BT-474 transduced with mutant PIK3CA H1047R demonstrated essentially normal proliferation under trastuzumab, while control cells showed negligible proliferation with trastuzumab. Sequencing of 55 HER2 breast cancer samples revealed 25% PIK3CA mutation rate and Kaplan Meier curves showed decreased time to progression for mutant PIK3CA at borderline statistical significance (p=0.052). This was potentially explained by presence of PTEN loss in wild-type PIK3CA sample and combining PTEN loss with PIK3CA mutation resulted in significant differences in time to progression (p=0.007)."	"Berns et al., 2007, Cancer Cell"	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Cancer	Alpelisib	Predictive	Supports	D	Sensitivity/Response	chr3	179148523	179240093			"A set of 474 cell lines from the Cancer Cell Line Encyclopedia was tested for responsiveness to the PI3Kalpha specific inhibitor BYL719 (Alpelisib). In the PIK3CA wild type subroup of cell lines, 22% were assessed as responsive, while in the subgroup of cell lines with PIK3CA mutations, 64% were labeled as responders. 7 patient derived xenografts with PIK3CA mutations (H1047R, E545K, M1043I, C420R, Q546K) were transplanted into mice and treated with BYL719. 6/7 mice responded with strong tumor growth inhibition or regression, while one (H1047R) responded with weak growth inhibition."	"Fritsch et al., 2014, Mol. Cancer Ther."	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Amplification	PIK3CA	Amplification	Stomach Carcinoma	Alpelisib	Predictive	Supports	D	Sensitivity/Response	chr3	179148523	179240093			474 cancer cell lines from the cancer cell line encyclopedia were assessed for response to the PI3Kalpha inhibitor BYL719 (Alpelisib). PIK3CA amplification was significanly associated with BYL719 response. A gastric cancer patient derived xenograft (PDX) was transplanted into two athymic mice and one was treated with BYL719. The untreated PDX grew by over 100 percent while the BYL719 tumor was reduced by 86 percent.	"Fritsch et al., 2014, Mol. Cancer Ther."	Somatic	ENST00000263967.3	transcript_amplification
PIK3CA Amplification	PIK3CA	Amplification	Head And Neck Squamous Cell Carcinoma	Taselisib	Predictive	Supports	D	Sensitivity/Response	chr3	179148523	179240093			"The HNSCC cell line LB771 with PIK3CA amplification was shown to have low antiproliferative IC50 for the p110beta-sparing PI3K inhibitor taselisib. Under increasing taselisib concentrations, reduction in phospho-Akt pro-survival signal was apparent, along with increased levels of pro-apoptotic marker cleaved PARP. A general tendency for taselisib sensitivity to PI3K activation (mutation/amplification) was also seen in a panel of 26 HNSCC cell lines"	"Zumsteg et al., 2016, Clin. Cancer Res."	Somatic	ENST00000263967.3	transcript_amplification
PIK3CA Mutation	PIK3CA	Mutation	Head And Neck Squamous Cell Carcinoma	"Taselisib,Radiation Therapy"	Predictive	Supports	D	Sensitivity/Response	chr3	179148523	179240093			"A panel of 26 HNSCC cell lines was tested for efficacy of the p110 alpha, delta and gamma isoform inhibitor taselisib (GDC-0032). Cell lines with PIK3CA mutation or amplification were the most sensitive. Four HNSCC cell lines with activating PIK3CA alterations showed synergistic cell death response to the combination of drug with radiation treatment. This synergism was not apparent in 4 tested HNSCC cell lines with wild-type PIK3CA or PTEN mutation. Nude mouse xenografts were established with Cal-33 PIK3CA H1047R cells. Radiation and taselisib treatments alone showed some growth inhibition in comparison to control, but only the combined treatment led durable tumor regressions."	"Zumsteg et al., 2016, Clin. Cancer Res."	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Stomach Cancer	Capivasertib	Predictive	Supports	D	Sensitivity/Response	chr3	179148523	179240093			"In a panel of 22 gastric cancer cell lines, 4 of 6 cell lines having the highest sensitivity to AZD5363 contained a PIK3CA mutation (E542K, E453K, E545K). A patient derived gastric cancer xenograft mouse model was established with PIK3CA H1047R mutant cells, and treatment with AZD5363 induced significant tumor growth inhibition in comparison to vehicle control."	"Li et al., 2013, J Transl Med"	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Cancer	Capivasertib	Predictive	Supports	D	Sensitivity/Response	chr3	179148523	179240093			"Sensitivity to pan-Akt inhibitor AZD5363 was assessed in a panel of 182 cell lines (160 with PTEN evaluated) derived from solid and hematological tumors. PTEN loss of function due to loss or mutation (N=32) was found to be significantly correlated with AZD5363 sensitivity (p=0.0099), and correlation improved in the subpopulation free of RAS mutation. Mouse xenografts with 786-0 (PTEN-null renal cancer) cells were established. 75 mg/kg twice daily AZD5363 caused tumor growth inhibition while 150 mg/kg twice daily induced moderate tumor regression."	"Davies et al., 2012, Mol. Cancer Ther."	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Her2-receptor Positive Breast Cancer	Capivasertib	Predictive	Supports	D	Sensitivity/Response	chr3	179148523	179240093			"HER2 overexpressing breast cancer cell lines with PIK3CA mutation BT474c (K111N) and HCC-1954 (H1047R) were used to establish mouse tumor xenografts. In BT474c xenografts, three dosing schedules of AZD5363 caused significant tumor inhibition (200 mg/kg twice daily > 200 mg/kg once daily > 100 mg/kg once daily). In HCC-1954 xenografts two doses of AZD5363 induced significant tumor inhibition (150 mg/kg twice daily > 75 mg/kg twice daily) while 30 mg/kg twice weekly trastuzumab was inactive."	"Davies et al., 2012, Mol. Cancer Ther."	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Breast Cancer	"Ribociclib,Phosphatidylinositide 3-Kinase Inhibitor"	Predictive	Supports	D	Sensitivity/Response	chr3	179148523	179240093			"Three PI3K mutant breast cancer cell lines were rendered resistant to PI3K inhibitors (BYL719 or GDC-0941), and a panel of 42 inhibitor compounds was tested on the cells for ability to resensitize the cells to PI3K inhibition. The CDK4/6 inhibitor ribociclib (LEE011) acted synergistically with PI3K inhibitor to reduce viability in all three resistant cell lines. In a panel of 12 PIK3CA mutant and 10 wild type cell lines, synergistic effects between P110alpha inhibitor BYL719 and ribociclib were significantly stronger (weighted synergy score calculation, ANOVA, p=0.012) in PIK3CA mutant cells, indicating variant specific sensitization. Mouse xenografts of 4 different PIK3CA mutant breast cancer cells resistant to PI3K inhibitor showed stronger regression under dual PI3K inhibitor and ribociclib treatment than with either treatment alone."	"Vora et al., 2014, Cancer Cell"	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Breast Cancer	"Phosphatidylinositide 3-Kinase Inhibitor,Palbociclib"	Predictive	Supports	D	Sensitivity/Response	chr3	179148523	179240093			"Three PIK3CA mutant breast cancer cell lines were rendered resistant to PI3K inhibitors (BYL719 or GDC-0941) by chronic exposure. Co-treatment of all three cell lines with PI3K inhibitor and CDK4/6 inhibitor palbociclib resulted in synergistic reductions in cell viability which were not seen with treatment of either compound alone, and resulted in similar suppression to viability as seen in the respective PI3K inhibitor sensitive parental cell lines."	"Vora et al., 2014, Cancer Cell"	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Breast Cancer	"Everolimus,MTOR Kinase Inhibitor PP242"	Predictive	Supports	D	Sensitivity/Response	chr3	179148523	179240093			A panel of 31 breast cancer cell lines was tested for sensitivity to mTORC1 inhibitor everolimus and mTORC1/mTORC2 inhibitor PP242. Inhibitor concentrations for 50% survival fraction (SF50) were measured and SF50 less than one micro molar was considered sensitive. PIK3CA mutant cell lines were significantly more sensitive to both everolimus and PP242 than PIK3CA wild type cell lines. Apoptotic indicators and cell cycle analysis indicated that the mTOR inhibitors induced G1 arrest instead of apoptosis in the cell lines.	"Weigelt et al., 2011, Oncogene"	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Endometrial Cancer	Pictilisib	Predictive	Supports	D	Sensitivity/Response	chr3	179148523	179240093			"A panel of 24 endometrioid endometrial cancer (EEC) cell lines was characterized for a set of mutations and sensitivity to pan PI3K class I inhibitor GDC-0941 (pictilisib) was assessed. EEC cell lines with PIK3CA mutations were significantly more sensitive to GDC-0941 (Fishers exact test, two-tailed, P=0.038). Some of the PIK3CA mutant cells contained PTEN and KRAS mutations, but in these cells, these mutations did not effect sensitivity."	"Weigelt et al., 2013, Clin. Cancer Res."	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Colorectal Cancer	Cetuximab	Predictive	Supports	D	Resistance	chr3	179148523	179240093			"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab and only 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab."	"Bertotti et al., 2011, Cancer Discov"	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Breast Cancer		Prognostic	Supports	B	Better Outcome	chr3	179148523	179240093			"Prognostic significance of PIK3CA mutations was evaluated in a retrospective study of 590 patients with surgically resected invasive breast cancer. Patients with tumors harboring PIK3CA mutations (n=192, 32.5%; 14.9% with H1047R; 4.2% with E542K; 4.9% with E545K; 8.5% across all other variants) experienced longer PFS, OS, and breast cancer specific survival than patients with PIK3CA wt tumors (p=0.06; p=0.03; p=0.004). PIK3CA mutations were positively associated with lymph node negativity, lower tumor stage, hormone receptor positivity, and HER2 negativity. Patients with PIK3CA mutated tumors experienced a 2 fold decrease in death due to breast cancer at 5 and 10 years. Tumors with hot spot mutations (E542K, E545K, H10447), were strongly correlated with lower grade (2), ER-positive, PR-positive, HR-positive, HER2-negative compared to PIK3CA wt tumors."	"Kalinsky et al., 2009, Clin. Cancer Res."	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Wildtype	PIK3CA	Wildtype	Colorectal Cancer	Aspirin	Predictive	Does Not Support	B	Sensitivity/Response	chr3	179148523	179240093			"This was a retrospective study of 964 colorectal cancer patients who participated in the Nurses' Health Study and the Health Professionals Follow-up Study. Of 964 patients, 803 patients had wildtype PIK3CA (aspirin use: 337/803, no aspirin use: 466/803) and 161 had mutated PIK3CA (aspirin use: 66/161, no aspirin use: 95/161). Among patients with wild-type PIK3CA, regular use of aspirin after diagnosis was not significantly associated with increased survival. The 5-year cumulative colorectal cancer specific mortality was the same (15%) for users and nonusers of aspirin after diagnosis (P = 0.92)."	"Liao et al., 2012, N. Engl. J. Med."	Somatic	ENST00000263967.3	wild_type
PIK3CA Rare Mutation	PIK3CA	Rare Mutation	Breast Cancer		Prognostic	Supports	B	Better Outcome	chr3	179148523	179240093			"Prognostic significance of PIK3CA mutations was evaluated in a retrospective study of 590 patients with surgically resected invasive breast cancer. Tumors harboring rare PIK3CA mutations (N345K: 2.4%, C420R: 1.2%, E545A: 1.2%, E545Q: 0.3%, E545G: 0.3%, Q546R: 0.7%, Q546P: 0.2%, H1047L: 2.2%) were significantly associated with lower grade, HER2 negativity, and lymph-node negative status compared with WT."	"Kalinsky et al., 2009, Clin. Cancer Res."	Somatic	ENST00000263967.3	
PIK3CA Mutation	PIK3CA	Mutation	Breast Cancer	Trastuzumab	Predictive	Supports	B	Resistance	chr3	179148523	179240093			"In retrospective study of 175 metastatic breast cancer patients treated with trastuzumab-based therapy, the presence of a PIK3CA mutation (E542K, E545K, or H1047R) was associated with a greater risk of progression (HR = 1.86, P = 0.014, multivariate analysis ) compared to wildtype PIK3CA."	"Razis et al., 2011, Breast Cancer Res. Treat."	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Her2-receptor Positive Breast Cancer	Trastuzumab	Predictive	Supports	B	Resistance	chr3	179148523	179240093			"In a retrospective study of 105 HER2-positive metastic breast cancer patients treated with trastuzumab-based therapy, the presence of a PIK3CA mutation (E542K, E545K, or H1047R) was associated with a greater risk of progression (HR = 2.50, P = 0.003, multivariate analysis) compared to wildtype PIK3CA."	"Razis et al., 2011, Breast Cancer Res. Treat."	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Colorectal Cancer		Prognostic	Supports	B	Poor Outcome	chr3	179148523	179240093			"This retrospective study examines outcomes of 158 primary sporadic colorectal cancer patients who had undergone surgical resection and were treated with 5-fluorouracil based chemotherapy. PIK3CA mutations were associated with reduced relapse-free survival in stage II/III patients (HR:2.587, 95% CI:1.108-6.039, P=0.0280, univariate analysis; HR:2.478, 95% CI:1.028-5.973, P=0.0433, multivariate analysis) and reduced disease-specific survival in patients of any stage (n=18 vs. n=140, P=0.0357) compared to wildtype PIK3CA. Authors noted that the tumors of 6 patients harbored both PIK3CA and KRAS mutations, but stated that the presence of PIK3CA mutations did not correlate with the presence of KRAS mutations."	"Kato et al., 2007, Int. J. Cancer"	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Lung Non-small Cell Carcinoma	"Gefitinib,Erlotinib"	Predictive	Supports	B	Resistance	chr3	179148523	179240093			"In a retrospective study, 166 non-small cell lung cancer (NSCLC) patients that tended to have selected characteristics known to be predictive for TKI sensitivity (i.e. women, never smokers, and patients with ADC) were treated with either gefitinib or erlotinib. PIK3CA mutations (n=6) were associated with no difference in objective response to drug treatment (16.6% vs. 35.2%, p=0.61), shorter overall survival (9.9 vs. 30.2 months, p<0.001), and shorter median time to progression (2.3 vs. 6.0 months, p=0.01) when compared to wild-type PIK3CA. Through multivariate analyses, it was shown that PIK3CA mutations are significant predictors of worse overall survival (HR: 5.81, 95% CI: 2.43-13.91, p=0.0001) and shorter time to progression (HR: 2.71 95% CI: 1.23-4.79, p=0.03)."	"Ludovini et al., 2011, J Thorac Oncol"	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Cancer	Capivasertib	Predictive	Supports	B	Sensitivity/Response	chr3	179148523	179240093			"In a study of 37 patients with AKT1 (E13K) mutations, 5 patients harbored a concurrent PI3K/mTOR pathway alteration. The PFS of patients with a concurrent PI3K/mTOR pathway alteration was significantly longer than those without when treated with AZD-5363 (median PFS, not reached v 4.3 months, respectively; HR, 0.21; P = 0.045)."	"Hyman et al., 2017, J. Clin. Oncol."	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Colorectal Cancer	"Chemotherapy,Cetuximab"	Predictive	Does Not Support	B	Resistance	chr3	179148523	179240093			"This was a retrospective study of 605 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy. Patients with KRAS wildtype, PIK3CA assessable tumors, and individual response data (n=339) were genotyped for PIK3CA mutations. Patients harboring PIK3CA mutant tumors (n=34) had a significantly lower response rate than did patients with wildtype PIK3CA (6/34 [17.7%] vs 115/305 [37.7%]; p =.015). Patients with mutant PIK3CA also experienced lower disease control rate in response to cetuximab treatment. However, there was no significant difference between patients with mutant or wildtype PIK3CA in progression free or overall survival (median PFS: 18 vs 24 weeks; median OS: 39 vs 51 weeks). Authors suggest that PIK3CA exon 21 mutations are more relevant to cetuximab response than PIK3CA mutations as a whole, as PIK3CA exon 10 mutations do not appear to effect cetuximab response (exons are listed as exon 20 and exon 9 in the source)."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Breast Cancer		Prognostic	Supports	B	Better Outcome	chr3	179148523	179240093			"This was a Swedish study of 270 breast tumors removed from patients with unilateral operable breast cancer, and either lymph node metastases or a tumor diameter >30mm. PIK3CA missense mutations were found in 66/270 (24%) tumors. Of these, 36 tumors (55%) harbored mutations in exon 20?33 H1047R, 1 Y1021C, 1 G1049R, and 1 H1047P. The other 30 were missense mutations in exon 9?11 E542K, 18 E545K, 1 Q546P. The study found that the risk of relapse with a local recurrence was significantly lower among patients with a PIK3CA mutation in comparison with those who carried wild-type PIK3CA (p= 0.023). When adjusting for other factors, including ER status, node status, tumor size, and treatment (tamoxifen vs no tamoxifen or radiotherapy vs chemotherapy), mutations in the PIK3CA gene were associated with approximately half the risk for local recurrence in comparison with wtPIK3CA (p = .07)."	"Prez-Tenorio et al., 2007, Clin. Cancer Res."	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Estrogen-receptor Positive Breast Cancer	Tamoxifen	Predictive	Does Not Support	B	Sensitivity/Response	chr3	179148523	179240093			"This was a Swedish study of 270 breast tumors removed from patients with unilateral operable breast cancer, and either lymph node metastases or a tumor diameter >30mm. PIK3CA missense mutations were found in 65/270 (24%) tumors. Of these, 36 (55%) were in exon 20?33 H1047R, 1 Y10121C, 1 G1049R, and 1 H1047P. The other 30 were missense mutations in exon 9?11 E542K, 18 E545K, 1 Q546P. Within the group of 188 patients with ER+ tumors, PIK3CA mutation status did not predict response to tamoxifen."	"Prez-Tenorio et al., 2007, Clin. Cancer Res."	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Breast Cancer	"Paclitaxel,Fluorouracil,Cyclophosphamide,Epirubicin,Doxorubicin"	Predictive	Does Not Support	B	Resistance	chr3	179148523	179240093			"This study of 140 patients with stage II-III breast cancer assessed the response of patients with PIK3CA mutations to 6 months of preoperative chemotherapy. 23/170 patients had PIK3CA mutations. Of those patients, 12 received six courses of chemotherapy composed of 5-fluorouracil, doxorubicin (or epirubicin), and cyclophosphamide. This treatment group represented patients with the following mutations (number of patients in parentheses): E545K (7), E542K (1), and H1047R (4). The other 11 patients received 12 weekly courses of paclitaxel followed by four courses of the chemotherapy described above. This treatment group represented patients with the following mutations: E545K (1), Q546R (1), E542K (1), E542V (1), H1047R (5), G1049R (1), H1047T (1). The study did not find evidence that PIK3CA mutations are associated with resistance to preoperative chemotherapy in breast cancer, regardless of whether paclitaxel was also administered. The lack of association was true of estrogen receptor (ER)-positive and ER-negative tumors."	"Liedtke et al., 2008, Breast Cancer Res."	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Amplification	PIK3CA	Amplification	Melanoma	Vemurafenib	Predictive	Supports	D	Resistance	chr3	179148523	179240093			"An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells induced to stably over-express PIK3CA (via viral transduction with additional copies of wild type PIK3CA) were significantly more resistant to vemurafenib (a BRAFi) than cells transduced with an empty vector (30% vs 20% survival, p < .0001). Though statistics were not provided, it appears that amplification of wildtype PIK3CA confers less resistance than the positive control variant, PIK3CA E545K."	"Shi et al., 2014, Cancer Discov"	Somatic	ENST00000263967.3	transcript_amplification
PIK3CA Mutation	PIK3CA	Mutation	Colorectal Cancer		Prognostic	Does Not Support	B	Poor Outcome	chr3	179148523	179240093			"This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (made up of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan) alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between PIK3CA mutation status in primary tumors and post treatment PFS. Of 168 patients, 142 had wildtype PIK3CA and 26 had mutations in PIK3CA on either exon 9 or 20 (exon 9 mutations: E542K, E545K, E545G, E545D, Q546K, D549N. Exon 20 mutations: R1023Q, H1047R, H1047L, G1049A). The study found that patients harboring a PIK3CA mutation did not have a significantly worse outcome than patients expressing wildtype PIK3CA, regardless of first line chemotherapy regimen or use of monoclonal antibody treatment."	"Souglakos et al., 2009, Br. J. Cancer"	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Colorectal Cancer	Oxaliplatin	Predictive	Does Not Support	B	Resistance	chr3	179148523	179240093			"This was a retrospective clinical study of 100 metastatic colorectal cancer patients who received FOLFOX (oxaliplatin + 5-fluorouracil + folinic acid) first-line therapy alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between PIK3CA mutation status in primary tumors and response to oxaliplatin-based first-line therapy, as measured by post treatment PFS. Of 100 patients, 81 had wildtype PIK3CA and 19 had mutations in PIK3CA on either exon 9 or 20 (exon 9 mutations: E542K, E545K, E545G, E545D, Q546K, D549N. Exon 20 mutations: R1023Q, H1047R, H1047L, G1049A). The study found that patients harboring a PIK3CA mutation were not significantly more resistant to oxaliplatin-based first-line therapy than patients with wildtype PIK3CA, as evidenced by a nonsignificant difference in PFS between the two groups (10.7 and 11.7 months, respectively)."	"Souglakos et al., 2009, Br. J. Cancer"	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Colorectal Cancer	Irinotecan	Predictive	Does Not Support	B	Resistance	chr3	179148523	179240093			"This was a retrospective clinical study of 44 metastatic colorectal cancer patients who received FOLFIRI (5-Fluorouacil + Folinic acid + irinotecan) first-line therapy alone or with bevacizumab. It assessed the relationship between PIK3CA mutation status in primary tumors and response to irinotecan-based first line therapy, as measured by PFS. Of the 44 patients, 40 had wildtype PIK3CA and 4 had mutations in PIK3CA on either exon 9 or 20 (exon 9 mutations: E542K, E545K, E545G, E545D, Q546K, D549N. Exon 20 mutations: R1023Q, H1047R, H1047L, G1049A). The study found that patients harboring a PIK3CA mutation were not significantly more resistant to irinotecan-based first-line therapy than patients with wildtype PIK3CA, as evidenced by a nonsignificant difference in PFS between the two groups."	"Souglakos et al., 2009, Br. J. Cancer"	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Colorectal Cancer	Bevacizumab	Predictive	Does Not Support	B	Resistance	chr3	179148523	179240093			"This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan). It assessed the relationship between PIK3CA mutation status in primary tumors and response to bevacizumab-containing first line chemotherapy, as measured by PFS. Of the 97 patients, 83 had wildtype PIK3CA and 14 had mutations in PIK3CA on either exon 9 or 20 (exon 9 mutations: E542K, E545K, E545G, E545D, Q546K, D549N. Exon 20 mutations: R1023Q, H1047R, H1047L, G1049A). The study found that patients harboring a PIK3CA mutation were not significantly more resistant to bevacizumab-containing first-line chemotherapy than patients with wildtype PIK3CA, as evidenced by a nonsignificant difference in PFS between the two groups."	"Souglakos et al., 2009, Br. J. Cancer"	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Resistance	chr3	179148523	179240093			"This was a retrospective clinical study of 92 metastatic colorectal cancer patients who received cetuximab in conjunction with salvage chemotherapy (refractory to at least one line of treatment). Salvage chemotherapy was composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan. The study assessed the relationship between PIK3CA mutation status in primary tumors and response to cetuximab-containing salvage chemotherapy, as measured by PFS. Of the 92 patients, 79 had wildtype PIK3CA and 19 had mutations in PIK3CA on either exon 9 or 20 (exon 9 mutations: E542K, E545K, E545G, E545D, Q546K, D549N. Exon 20 mutations: R1023Q, H1047R, H1047L, G1049A). The study found that patients harboring a PIK3CA mutation were significantly more resistant to cetuximab-containing salvage chemotherapy than patients with wildtype PIK3CA (Median PFS: 2.5 and 3.9 months, respectively; p = .014)."	"Souglakos et al., 2009, Br. J. Cancer"	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Colorectal Cancer	"Cetuximab,Panitumumab"	Predictive	Supports	B	Resistance	chr3	179148523	179240093			"Mutational analysis of 110 metastatic colorectal cancer patients was used to examine objective tumor response, progression free survival (PFS), and overall survival (OS) following treatment with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). In univariate analysis, PIK3CA mutations (H1047R or E545K) were significantly associated with lack of response to panitumumab or cetuximab (objective response rate: 0/15 vs 22/95 for patients harboring PIK3CA mutated or wildtype tumors, respectively; P = 0.038). Multivariate logistic regression of KRAS mutations, PIK3CA mutations and PTEN protein expression also confirmed an independent effect of PIK3CA mutation on objective response (P = 0.0337; OR = 0.1153; CI for OR: 0.000?.865). Patients with tumors harboring either PIK3CA H1047R or E545K mutations (15/109) had decreased PFS, compared to those with wild-type tumors (P = 0.0035), though they had a nonsignificant difference in OS. Authors note a trend in decreasing OS in patients with PIK3CA mutated tumors."	"Sartore-Bianchi et al., 2009, Cancer Res."	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Colorectal Cancer	Aspirin	Predictive	Supports	B	Sensitivity/Response	chr3	179148523	179240093			"This was a retrospective study of 964 colorectal cancer patients who participated in the Nurses' Health Study and the Health Professionals Follow-up Study. Of 964 patients, 803 patients had wildtype PIK3CA (aspirin use: 337/803, no aspirin use: 466/803)  and 161 had mutated PIK3CA (aspirin use: 66/161, no aspirin use: 95/161). This study found thatamong patients with mutated PIK3CA cancer?regular use of aspirin following diagnosis was correlated with superior colorectal cancer specific survival (multivariate hazard ratio, 0.18; 95% CI, 0.06-0.61; P<0.001) and overall survival (multivariate hazard ratio, 0.54; 95% CI, 0.31-0.94; P = 0.01). Conversely, among patients with wild-type PIK3CA, regular use of aspirin after diagnosis was not significantly associated with colorectal cancerspecific survival or overall survival. Among patients with mutated-PIK3CA tumors, 23 of 90 patients who did not use aspirin after diagnosis (26%) died within 5 years after diagnosis, whereas only 2 of 62 regular users of aspirin after diagnosis (3%) died within 5 years after diagnosis (P<0.001). In contrast, among patients with wild-type PIK3CA tumors, the 5-year cumulative colorectal cancerspecific mortality was the same (15%) for users and nonusers of aspirin after diagnosis (P = 0.92). The authors conclude that PIK3CA mutation may predict response to aspirin therapy in patients with newly diagnosed colorectal cancer."	"Liao et al., 2012, N. Engl. J. Med."	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Head And Neck Squamous Cell Carcinoma	"Celecoxib,Sulindac,Aspirin"	Predictive	Supports	B	Sensitivity/Response	chr3	179148523	179240093			"In this retrospective study, the impact of nonsteroidal anti-inflammatory drugs (NSAID) on survival in PIK3CA-altered HNSCC patients (N=266) was assessed. 37 of 266 (14%) patients harbored a mutation, 29 of 266 (11%) had only amplification, and 9 patients had both. Among patients with a PIK3CA mutation or amplification, regular NSAID use was significantly associated with disease-specific (HR 0.23, p=0.0032) and overall survival (HR 0.31, p=0.0043). These findings were recreated in a panel of six patient-derived xenograft models, where treatment with NSAIDs (sulindac, Celecoxib or Aspirin) significantly reduced growth rates in PIK3CA mutant, but not wild-type models."	"Hedberg et al., 2019, J. Exp. Med."	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Amplification	PIK3CA	Amplification	Head And Neck Squamous Cell Carcinoma	"Aspirin,Sulindac,Ibuprofen"	Predictive	Supports	B	Sensitivity/Response	chr3	179148523	179240093			"In this retrospective study, the impact of nonsteroidal anti-inflammatory drugs (NSAID) on survival in PIK3CA-altered HNSCC patients (N=266) was assessed. 37 of 266 (14%) patients harbored a mutation, 29 of 266 (11%) had only amplification, and 9 patients had both. Among patients with a PIK3CA mutation or amplification, regular NSAID use was significantly associated with disease-specific (HR 0.23, p=0.0032) and overall survival (HR 0.31, p=0.0043). These findings were recreated in a panel of six patient-derived xenograft models, where treatment with NSAIDs (sulindac, Celecoxib or Aspirin) significantly reduced growth rates in PIK3CA mutant, but not wild-type models."	"Hedberg et al., 2019, J. Exp. Med."	N/A	ENST00000263967.3	transcript_amplification
PIK3CA Mutation	PIK3CA	Mutation	Breast Cancer	"Fulvestrant,Alpelisib"	Predictive	Supports	A	Sensitivity/Response	chr3	179148523	179240093			"In a phase 3 trial, patients with hormone receptor positive, HER2 receptor negative breast were allocated to alpelisib plus fulvestrant or placebo plus fulvestrant. Patients were enrolled into two cohorts on the basis of tumor-tissue PIK3CA mutation status. In the cohort of patients with PIK3CA-mutated cancer (defined by the presence of any PIK3CA mutation in mutation hot spots in the C2, helical, and kinase domains of PI3K corresponding to exons 7, 9, and 20, respectively), PFS was 11 months in the alpelisib-fulvestrant group, as compared with 5.7 months in the placebo-fulvestrant group (HR 0.65, 95% CI, 0.50 to 0.85, p<0.001). In the cohort without PIK3CA-mutated cancer, the HR was 0.85 (95% CI, 0.58 to 1.25). Overall response rate was also greater in the PIK3CA-mutant group (26.6% vs. 12.8%)."	"Andr et al., 2019, N. Engl. J. Med."	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Amplification	PIK3CA	Amplification	Her2-receptor Positive Breast Cancer	Trastuzumab	Predictive	Supports	D	Resistance	chr3	179148523	179240093			HER2-positive breast cancer cell line BT-474 (heterozygous for PIK3CA K111N) was retrovirally transduced with wildtype PIK3CA and treated with trastuzumab. PIK3CA amplification diminished the growth inhibitory effects of trastuzumab monotherapy in comparison to the inhibition of controls without PIK3CA overexpression.	"Eichhorn et al., 2008, Cancer Res."	Somatic	ENST00000263967.3	transcript_amplification
PIK3CA Amplification	PIK3CA	Amplification	Her2-receptor Positive Breast Cancer	"Lapatinib,Dactolisib"	Predictive	Supports	D	Sensitivity/Response	chr3	179148523	179240093			"This preclinical study tested the sensitivity of HER2-positive breast cancer cell line BT-474 (heterozygous for PIK3CA K111N) retrovirally transduced with wildtype PIK3CA to NVP-BEZ235 (dactolisib; a dual PI3K/mTOR inhibitor), lapatinib and trastuzumab. The study found that dactolisib and lapatinib were effective in inhibiting outgrowth of PIK3CA amplified cells as monotherapies. Combination therapy produced similar abrogation of growth for PIK3CA amplified cells. Additionally, growth of untransduced BT-474 control cells was prevented by treatment with any monotherapy or combination of lapatinib or dactolisib."	"Eichhorn et al., 2008, Cancer Res."	Somatic	ENST00000263967.3	transcript_amplification
PIK3CA Mutation	PIK3CA	Mutation	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	Predictive	Does Not Support	B	Resistance	chr3	179148523	179240093			"In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors harbored PIK3CA mutations treated with ado-trastuzumab emtansine (T-DM1; n=40) were associated with similar median progression free survival (PFS), overall response rate (ORR), and overall survival (OS) compared to patients whose tumors harbored wild-type PIK3CA (n=93; PFS: 10.9 vs. 9.8 months, ORR: 50% vs 47.4%, OS not reached for either group). Of PIK3CA mutant HER2 patients, those treated with T-DM1 experienced a greater decrease in disease progression than those treated with standard of care capecitabine + lapatinib. In vitro, HER2 amplified cell lines with various PIK3CA mutations were associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3. In mouse xenograft models of various PIK3CA mutations (H1047R, E545K, or K111N), tumor regression or complete tumor suppression >20 days was seen following a single dose >10mg/kg for all models."	"Baselga et al., 2016, Clin. Cancer Res."	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA Mutation	PIK3CA	Mutation	Her2-receptor Positive Breast Cancer	"Lapatinib,Capecitabine"	Predictive	Supports	B	Resistance	chr3	179148523	179240093			"In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors harbored PIK3CA mutations treated with standard of care capecitabine and lapatinib combination chemotherapy (n=39) were associated with lower median progression free survival (PFS), overall response rate (ORR), and overall survival (OS) compared to patients whose tumors harbored wild-type PIK3CA (n=87; PFS: 4.3 vs. 6.4 months, ORR: 17.1% vs 39.7%, OS 17.3 vs 27.8 mo)."	"Baselga et al., 2016, Clin. Cancer Res."	Somatic	ENST00000263967.3	"transcript_variant,gain_of_function_variant"
PIK3CA E81K	PIK3CA	E81K	Colorectal Cancer	"Fluorouracil,Cetuximab,Oxaliplatin"	Predictive	Does Not Support	C	Resistance	chr3	179199066	179199066	G	A	"Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA E81K, were wildtype for NRAS, BRAF and PIK3CA, and had individual response data. Both were treated with cetuximab + oxaliplatin + 5FU as 2nd line therapy and experienced stable disease, resulting in a response rate of 0/2 and a clinical benefit rate of 2/2 according to author criteria. One patient was a 57 year old female with a PFS of 24 weeks and an OS of 100 weeks. The other patient was a 60 year old male with a PFS of 23 weeks."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000263967.3	missense_variant
PIK3CA R88Q	PIK3CA	R88Q	Colorectal Cancer	"Irinotecan,Cetuximab"	Predictive	Does Not Support	C	Resistance	chr3	179199088	179199088	G	A	"One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA R88Q, was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 56 year old female treated with cetuximab and irinotecan as 2nd line therapy who experienced a partial response (PFS: 32 weeks, OS: 32 weeks)."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000263967.3	missense_variant
PIK3CA R93W	PIK3CA	R93W	Colorectal Cancer	"Oxaliplatin,Cetuximab,Fluorouracil"	Predictive	Supports	C	Resistance	chr3	179199102	179199102	C	T	"One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA R93W, was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 56 year old male treated with cetuximab + oxaliplatin + 5FU as 2nd line therapy who experienced progressive disease (PFS: 8 weeks)."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000263967.3	missense_variant
PIK3CA K111N	PIK3CA	K111N	Her2-receptor Positive Breast Cancer	Pictilisib	Predictive	Supports	D	Sensitivity/Response	chr3	179199158	179199158	G	C	"This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. BT-474 is a HER2 amplified breast cancer cell line harboring PIK3CA K111N, and it had an IC50 of 0.23uM. To evaluate in vivo efficacy, cells were injected in the mammary fat pad of SCID mice and allowed to grow. Mice subsequently treated with 100mg/kg pictilisib experienced a 69% tumor reduction, and those treated with 150mg/kg experienced an 82% tumor reduction, with respect to untreated control. Authors note that pictilisib was well tolerated and observed no toxicities or significant weight loss. Authors further note that HER2 amplified cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like cell lines (p=0.002)."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA K111N	PIK3CA	K111N	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	Predictive	Does Not Support	D	Resistance	chr3	179199158	179199158	G	C	"As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was evaluated against various HER2 positive cell lines. BT-474 cell line expressing PIK3CA K111N was associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; reduced cell viability was observed at concentrations > 0.01 ug/mL in both cell lines. Conversely, when treated with trastuzumab, the cell line harboring PIK3CA K111N experienced a smaller reduction in cell viability. Further, treatment with T-DM1 on SCID mice xenografted with PIK3CA K111N cells resulted in inhibition of tumor growth. A single dose of T-DM1 >5mg/kg was sufficient to induce tumor regression >20 days after administration."	"Baselga et al., 2016, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA K111N	PIK3CA	K111N	Her2-receptor Positive Breast Cancer	PI-103	Predictive	Supports	D	Sensitivity/Response	chr3	179199158	179199158	G	C	"As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. BT-474 is a HER2 receptor amplified breast cancer cell line harboring PIK3CA K111N, and it had an IC50 of 0.60uM."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA K111N	PIK3CA	K111N	Her2-receptor Positive Breast Cancer	PI3Ka/Di	Predictive	Supports	D	Sensitivity/Response	chr3	179199158	179199158	G	C	"As part of a preclinical study, the efficacy of PI3KA/Dia selective inhibitor for the  and  subunits of class I PI3Kwas evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. BT-474 is a HER2 amplified breast cancer cell line harboring PIK3CA K111N and it had an IC50 of 0.52uM."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA K111N	PIK3CA	K111N	Her2-receptor Positive Breast Cancer	"Trastuzumab,Lapatinib,Dactolisib"	Predictive	Does Not Support	D	Resistance	chr3	179199158	179199158	G	C	"The BT-474 HER2 positive human breast cancer cell line, which is heterozygous for the PIK3CA K111N mutation, demonstrated strongly reduced colony formation when treated with lapatinib, trastuzumab or dactolisib alone or in combination, suggesting that K111N does not induce resistance to these drugs."	"Eichhorn et al., 2008, Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA K111N	PIK3CA	K111N	Her2-receptor Positive Breast Cancer	Trastuzumab	Predictive	Does Not Support	D	Resistance	chr3	179199158	179199158	G	C	"As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines in cell viability assays. BT-474 cell line expressing PIK3CA K111N was associated with similar sensitivity to trastuzumab as PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL)."	"Baselga et al., 2016, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA S158L	PIK3CA	S158L	Colorectal Cancer	"Cetuximab,Irinotecan"	Predictive	Supports	C	Resistance	chr3	179199810	179199810	C	T	"One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA S158L, was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 53 year old male treated with cetuximab + irinotecan as 3rd line therapy who experienced progressive disease (PFS: 1 week; OS: 3 weeks)."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000263967.3	missense_variant
PIK3CA N345K	PIK3CA	N345K	Colorectal Cancer	Cetuximab	Predictive	Supports	C	Resistance	chr3	179203765	179203765	T	A	"Three patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA N345K, were wildtype for KRAS, BRAF and NRAS, and had individual response data. Patient characteristics are as follows: a 48 year old female treated with cetuximab + irinotecan as 3rd line therapy who experienced stable disease (PFS: 72 weeks, OS: 105 weeks); a 46 year old male treated with cetuximab monotherapy as 5th line therapy who experienced stable disease (PFS: 24 weeks, OS: 57 weeks); a 61 year old female treated with cetuximab + irinotecan as 3rd line therapy who experienced progressive disease (PFS: 12 weeks, OS: 45 weeks). The response rate was 0/3 and the clinical benefit rate was 2/3 according to author criteria."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000263967.3	missense_variant
PIK3CA D350G	PIK3CA	D350G	Melanoma	Vemurafenib	Predictive	Supports	D	Resistance	chr3	179203779	179203779	A	G	"An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express PIK3CA D350G were significantly more resistant to BRAF inhibition by vemurafenib  than cells transduced with empty vectors (40% vs 20% survival at the highest concentration, p=.0148). Though statistics were not provided, D350G appears to confer less resistance to vemurafenib than the positive control variant, PIK3CA E545K."	"Shi et al., 2014, Cancer Discov"	Somatic	ENST00000263967.3	missense_variant
PIK3CA I391M	PIK3CA	I391M	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	Predictive	Does Not Support	D	Resistance	chr3	179209622	179209622	A	G	"As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was evaluated against various HER2 positive cell lines. ZR-75-30 cell line expressing PIK3CA I391M was associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; reduced cell viability was observed at concentrations > 0.01 ug/mL in both cell lines. When treated with trastuzumab, the cell line harboring PIK3CA I391M experienced similar reduction in cell viability."	"Baselga et al., 2016, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA I391M	PIK3CA	I391M	Her2-receptor Positive Breast Cancer	Trastuzumab	Predictive	Does Not Support	D	Resistance	chr3	179209622	179209622	A	G	"As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines using cell viability assays. ZR-75-30 cell line expressing PIK3CA I391M was associated with similar sensitivity to trastuzumab compared to PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL)."	"Baselga et al., 2016, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA C420R	PIK3CA	C420R	Colorectal Cancer	Cetuximab	Predictive	Does Not Support	C	Resistance	chr3	179210192	179210192	T	C	"One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA C420R and was wildtype for KRAS, BRAF and NRAS. This patient was was a 60 year old female treated with cetuximab monotherapy as 5th line therapy who experienced partial response and had PFS of 31 weeks and OS of 59 weeks."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000263967.3	missense_variant
PIK3CA C420R	PIK3CA	C420R	Her2-receptor Positive Breast Cancer	Pictilisib	Predictive	Supports	D	Sensitivity/Response	chr3	179210192	179210192	T	C	"This preclinical study tested the efficacy on several HER2 amplified breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. Two HER2 amplified breast cancer cell lines harboring PIK3CA C420R were tested for sensitivity to pictilisib. EFM-192A had an IC50 of 0.32uM and JIMT-1 had an IC50 of 0.86uM. Authors note that HER2 amplified cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like cell lines (p=0.002)."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA C420R	PIK3CA	C420R	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	Predictive	Does Not Support	D	Resistance	chr3	179210192	179210192	T	C	"As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was compared to that of trastuzumab against various HER2 positive cell lines. EFM-192A cell line expressing PIK3CA C420R was associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; substantially reduced cell viability was observed at concentrations > 0.01 ug/mL in both cell lines. Conversely, when treated with trastuzumab, the cell line harboring PIK3CA C420R experienced a smaller reduction in cell viability."	"Baselga et al., 2016, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA C420R	PIK3CA	C420R	Her2-receptor Positive Breast Cancer	Trastuzumab	Predictive	Supports	D	Resistance	chr3	179210192	179210192	T	C	"As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines. EFM-192A cell line expressing PIK3CA C420R was associated with resistance to trastuzumab compared to PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL)."	"Baselga et al., 2016, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA P471L	PIK3CA	P471L	Merkel Cell Carcinoma	Idelalisib	Predictive	Supports	C	Sensitivity/Response	chr3	179210438	179210438	C	T	A case report of an 86-year old patient with metastasized Merkel cell carcinoma who achieved a complete clinical response under therapy with the PI3K-inhibitor Idelalisib.	"Shiver et al., 2015, N. Engl. J. Med."	Somatic	ENST00000263967.3	missense_variant
PIK3CA Exon 10 Mutation	PIK3CA	Exon 10 Mutation	Colorectal Cancer	"Cetuximab,Chemotherapy"	Predictive	Does Not Support	B	Resistance	chr3	179218210	179218334			"In chemotherapy-refractory patients with metastatic colorectal cancer and KRAS wt tumors, Exon 10 PIK3CA mutations (listed as Exon 9 in the source) had no significant impact on response rate (6/21 [28.6%] vs 115/317 [36.3%]; OR: 0.70; p = 0.47), disease control rate, median progression free survival or median overall survival (46 vs 51 weeks, HR: 1.30, p=0.28) following cetuximab + chemotherapy than wildtype PIK3CA. In multivariate analysis of KRAS wildtype patients, PIK3CA was not significantly associated with patient outcome. Authors conclude that PIK3CA exon 10 mutation status does not appear relevant to treatment response."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000263967.3	exon_variant
PIK3CA Exon 10 Mutation	PIK3CA	Exon 10 Mutation	Colorectal Cancer		Prognostic	Does Not Support	B	Poor Outcome	chr3	179218210	179218334			"This study analyzed tumor and patient characteristics from 1,170 colorectal cancer patients derived from the prospective cohort studies: Nurses' Health Study and Health Professionals Follow Up Study. PIK3CA mutations were found in 16% (189/1170) of patients via pyrosequencing of FFPE samples. Of patients with PIK3CA mutated tumors, 58% (109/189) had mutations in exon 10 (listed as exon 9 in the publication, as it was common at the time of its publication to exclude non-coding exon 1). The presence of an exon 10 mutation was not significantly associated with differences in colorectal cancer-specific or overall survival when compared to patients with wt PIK3CA (multivariate, stage-stratified HR = 1.15 vs 1). Authors note that they had limited data on cancer treatment data, but assume that treatment regimens did not differ substantially based on PIK3CA mutation status given that patients were diagnosed prior to clinical availability of PIK3CA genotype data. They further note that treatment decisions were typically based on cancer stage, for which their analyses adjusted."	"Liao et al., 2012, Clin. Cancer Res."	Somatic	ENST00000263967.3	exon_variant
PIK3CA Exon 10 Mutation	PIK3CA	Exon 10 Mutation	Breast Cancer		Prognostic	Supports	B	Poor Outcome	chr3	179218210	179218334			"An Italian study of 163 malignant breast tumors assessed the association between PIK3CA mutations and clinical outcome. Of the 163 tumors sequenced, 118 had wild-type (wt) PIK3CA, 24 had exon 9 (helical domain) missense mutations, and 21 had exon 20 (kinase domain) missense mutations. The study found that patients with exon 9 mutations showed significantly worse 5-year overall survival (OS) and 5-year disease free survival (DFS) compared to patients with wt PIK3CA (P=.018 and P = .04, respectively). Furthermore, patients with exon 9 mut showed especially worse OS and DFS than patients with exon 20 mutations (P=.0018 and P=.0017, respectively). The 21 cases with exon 20 mutations had excellent prognosis with no recurrences or deaths, whereas there were 10 recurrences and 9 deaths among the 24 cases of exon 9 mutations, in observed period. Note these exons are now referred to as exons 10 and 21 rather than as exons 9 and 20, as it was common at the time of publication to exclude non-coding exon 1."	"Barbareschi et al., 2007, Clin. Cancer Res."	Somatic	ENST00000263967.3	exon_variant
PIK3CA E542K	PIK3CA	E542K	Colorectal Cancer	Regorafenib	Predictive	Does Not Support	B	Resistance	chr3	179218294	179218294	G	A	"This was a retrospective analysis of genetic markers in 503 metastatic colorectal cancer patients who participated in the CORRECT phase III trial of regorafenib. PIK3CA mutations were identified in the tumors of 84 patients, including 27 with PIK3CA E542K. Authors found a clinical benefit of regorafenib across PIK3CA mutated and wildtype subgroups (progression free survival with regorafenib vs placebo: mutant HR: 0.54, wildtype HR: 0.50, P=0.85). Authors do not provide direct comparison between patients with wildtype and PIK3CA E542K patients. Note that it's unclear how many PIK3CA wildtype patients harbor KRAS mutations, though authors' suggest that regorafenib induces clinical benefit regardless of KRAS or PIK3CA mutation status."	"Tabernero et al., 2015, Lancet Oncol"	Somatic	ENST00000263967.3	missense_variant
PIK3CA E542K	PIK3CA	E542K	Breast Cancer	PI3K-alpha Inhibitor MEN1611	Predictive	Supports	D	Sensitivity/Response	chr3	179218294	179218294	G	A	Breast cancer cell lines with E542K/E545K mutations showed increased sensitivity to CH5132799 than cells with wild-type PIK3CA gene.	"Tanaka et al., 2011, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E542K	PIK3CA	E542K	Breast Cancer	Sirolimus	Predictive	Supports	D	Sensitivity/Response	chr3	179218294	179218294	G	A	Rapamycin inhibits transformation induced by mutation in PIK3CA.	"Kang et al., 2005, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E542K	PIK3CA	E542K	Head And Neck Squamous Cell Carcinoma	Apitolisib	Predictive	Supports	C	Sensitivity/Response	chr3	179218294	179218294	G	A	"Phase 1 study with the dual PI3K/mTOR inhibitor apitolisib. 120 patients were treated at doses between 2 and 70mg. Of the 14 evaluable patients with PIK3CA mutations total, there were 3 PRs (1 confirmed), 8 SD, and 3 PD as best radiological responses. One of the partial responses harbored a PIK3CA E542K mutation."	"Dolly et al., 2016, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E542K	PIK3CA	E542K	Thyroid Gland Cancer	"Perifosine,Temsirolimus"	Predictive	Supports	D	Sensitivity/Response	chr3	179218294	179218294	G	A	"Preclinical study in thyroid cancer cell lines. 6 cell lines with alterations of the PI3K/Akt pathway were more sensitive to Akt inhibitor perifosine or MTOR inhibitor temsirolimus than 5 cell lines without genetic alterations in the PI3K/Akt pathway. Among the alterations, One cell line harbored a PIK3CA E542K mutation. Transfection of another cell line with this mutation led to lower IC50 values to perifosine and temsirolimus than in a cell line transfected with a control vector"	"Liu et al., 2009, Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E542K	PIK3CA	E542K	Her2-receptor Positive Breast Cancer	Pictilisib	Predictive	Supports	D	Sensitivity/Response	chr3	179218294	179218294	G	A	"This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. HCC202 is a HER2 positive, ER/PR negative breast cancer cell line harboring PIK3CA E542K, and it had an IC50 of 0.80uM. Authors further note that HER2 amplified cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like cell lines (p=0.002)."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E542K	PIK3CA	E542K	Breast Cancer	Pictilisib	Predictive	Supports	D	Sensitivity/Response	chr3	179218294	179218294	G	A	"This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), which is a selective inhibitor of all four isoforms of class I PI3-kinases over a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. KPL-1 is a luminal-like breast cancer cell line harboring PIK3CA E542K, and it had an IC50 of 0.72uM. Authors note that luminal-like cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like cell lines (p=0.02)."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E542K	PIK3CA	E542K	Her2-receptor Positive Breast Cancer	PI-103	Predictive	Supports	D	Sensitivity/Response	chr3	179218294	179218294	G	A	"As part of a preclinical study, the efficacy of PI-103 (a dual inhibitor of MTOR and Class IA PI3Ks) was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. HCC202 is a HER2 receptor amplified breast cancer cell line harboring PIK3CA E542K, and it had an IC50 of 0.43uM."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E542K	PIK3CA	E542K	Colorectal Cancer	Cetuximab	Predictive	Does Not Support	C	Resistance	chr3	179218294	179218294	G	A	"This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 7 patients harbored PIK3CA E542K (exon 10), were wt for BRAF, NRAS and PIK3CA, and had individual response data. Two patients had partial response, three had stable disease, and two progressed, resulting in a response rate of 2/7 and a clinical benefit rate of 5/7 according to author criteria. Treatments included cetuximab + irinotecan (n=5), cetuximab + FOLFIRI (n=1), and cetuximab monotherapy (n=1). Median PFS was 34 weeks (17-48 weeks), median OS was 46 weeks (27-91 weeks), and median number of previous chemotherapy lines was 2 (0-4). Median age was 59 years old (53-74), and there were 6 females and one male. Using these and data from the larger cohort, authors concluded that PIK3CA exon 10 (listed as exon 9 in source) mutations are associated with weak or no resistance to cetuximab."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E542K	PIK3CA	E542K	Breast Cancer	"Fulvestrant,Alpelisib"	Predictive	Supports	A	Sensitivity/Response	chr3	179218294	179218294	G	A	"In a phase 3 trial, 572 patients with hormone receptor positive, HER2 receptor negative advanced breast cancer who previously received endocrine therapy were allocated to alpelisib plus fulvestrant or placebo plus fulvestrant. Patients were enrolled into two cohorts on the basis of tumor-tissue PIK3CA mutation status (N=341). PIK3CA mutation was determined according to the presence or absence of any hot spot mutation in the C2, helical, and kinase domains of PI3K (corresponding to exon 7, 9, and 20, respectively). In the cohort of patients with PIK3CA-mutated cancer, PFS was 11 months in the alpelisib-fulvestrant group, as compared with 5.7 months in the placebo-fulvestrant group (HR 0.65, p<0.001). In the cohort without PIK3CA-mutated cancer, the HR was 0.85. Analyses of PFS according to mutation types showed consistent benefit of treatment with alpelisibfulvestrant across prespecified subgroups, including E542K (N=60, HR 0.60, 95% CI 0.29-1.23), E545X, and H1047X."	"Andr et al., 2019, N. Engl. J. Med."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E542K	PIK3CA	E542K	Breast Cancer	PI-103	Predictive	Supports	D	Resistance	chr3	179218294	179218294	G	A	"As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. KPL1 is a luminal-like breast cancer cell line harboring PIK3CA E542K, and it had an IC50 of 7.62uM."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E542K	PIK3CA	E542K	Her2-receptor Positive Breast Cancer	PI3Ka/Di	Predictive	Supports	D	Sensitivity/Response	chr3	179218294	179218294	G	A	"As part of a preclinical study, the efficacy of PI3KA/Dia selective inhibitor for the  and  subunits of class I PI3Kwas evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. HCC-202 is a HER2 receptor amplified breast cancer cell line harboring PIK3CA E542K and it had an IC50 of 0.62uM."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E542K	PIK3CA	E542K	Breast Cancer	PI3Ka/Di	Predictive	Supports	D	Sensitivity/Response	chr3	179218294	179218294	G	A	"As part of a preclinical study, the efficacy of PI3KA/Dia selective inhibitor for the  (IC50 for p100: 3nM) and  (IC50 for p100: 20nM) subunits of class I PI3Kwas evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. KPL-1 is a luminal-type breast cancer cell line harboring PIK3CA E542K and it had an IC50 of 0.55uM."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545K	PIK3CA	E545K	Colorectal Cancer	"Panitumumab,Cetuximab"	Predictive	Supports	C	Resistance	chr3	179218303	179218303	G	A	"In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN were tested for mutation, and 1 patient (patient 95, see supplemental table 1) had PIK3CA E545K in the primary tumor without co-occurring mutations in the other tested genes. This response was consistent with observations made of the larger cohort, where patients with tumors harboring any PIK3CA mutation had significantly shorter progression free survival and decreased incidence of objective response than patients with wtPIK3CA tumors. However, there was one patient (Patient 55, Table S1) who had E545K as the only noted variant, but experienced partial response."	"Sartore-Bianchi et al., 2009, Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545K	PIK3CA	E545K	Breast Cancer	"Pictilisib,Akt Inhibitor MK2206"	Predictive	Supports	D	Sensitivity/Response	chr3	179218303	179218303	G	A	PIK3CA E545K mutation increased sensitivity to AKT inhibitor MK-2206 and PI3K inhibitor GDC-0941 in a breast cancer cell line model.	"Beaver et al., 2013, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545K	PIK3CA	E545K	Lung Adenocarcinoma	Gefitinib	Predictive	Supports	D	Resistance	chr3	179218303	179218303	G	A	"HCC827 cell lines harboring activated PI3K (HCC827 p110 E545K cells) were more resistant to gefitinib in vitro (IC50, 1 M) compared with those harboring GFP alone (IC50, 0.01 M). The presence of p110 E545K also protected HCC827 cells from gefitinib-mediated apoptosis."	"Engelman et al., 2006, J. Clin. Invest."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545K	PIK3CA	E545K	Her2-receptor Positive Breast Cancer	Trastuzumab	Predictive	Supports	D	Resistance	chr3	179218303	179218303	G	A	"PI3K mutant E545K was overexpressed in the trastuzumab sensitive HER2 BT474 breast cancer cell line, and significant resistance to trastuzumab was induced in comparison to control cells."	"Serra et al., 2008, Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545K	PIK3CA	E545K	Cancer	Apitolisib	Predictive	Supports	C	Sensitivity/Response	chr3	179218303	179218303	G	A	"Phase 1 study with the dual PI3K/mTOR inhibitor apitolisib. 120 patients were treated at doses between 2 and 70mg. Of 45 evaluable patients receiving 40mg, two patients with E545K PIK3CA mutation (one head and neck squamous cell carcinoma patient and a patient with ovarian cancer) had unconfirmed partial responses. Of the 14 evaluable patients with PIK3CA mutations total, there were 3 PRs (1 confirmed), 8 SD, and 3 PD as best radiological responses."	"Dolly et al., 2016, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545K	PIK3CA	E545K	Lung Adenocarcinoma	"Gefitinib,Erlotinib"	Predictive	Supports	C	Resistance	chr3	179218303	179218303	G	A	"48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosine kinase inhibition underwent next generation sequencing (AmpliSeq Cancer Hotspot Panel (v2) failed in 5 samples leading to a remaining 43 specimens from 39 patients). The prevalence of various mutations post-treatment was analyzed. 2 out of the 39 patients had the E545K PIK3CA mutation in the absence of EGFR T790M, indicating that E545K may be an alternative mutation contributing to resistance."	"Belchis et al., 2016, Oncotarget"	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545K	PIK3CA	E545K	Breast Cancer	Pictilisib	Predictive	Supports	D	Sensitivity/Response	chr3	179218303	179218303	G	A	"This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases over a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. MCF7 is a luminal type breast cancer cell line harboring PIK3CA E545K, and it had an IC50 of 0.34uM. To evaluate in vivo efficacy, MCF7 cells were injected in the mammary fat pad of SCID mice and allowed to grow. Mice treated with 100mg/kg pictilisib experienced a 62% tumor reduction, and those treated with 150mg/kg experienced a 70% tumor reduction, with respect to untreated control. Authors note that pictilisib was well tolerated and observed no toxicities or significant weight loss. Authors further note that luminal-like cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like (p=0.02)."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545K	PIK3CA	E545K	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	Predictive	Does Not Support	D	Resistance	chr3	179218303	179218303	G	A	"As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was compared to that of trastuzumab against various HER2 positive cell lines. MCF7-neo/HER2 cell line harboring PIK3CA E545K was associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; reduced cell viability was observed at concentrations >0.01 ug/mL in both cell lines. Conversely, the cell line harboring PIK3CA E545K was resistant to trastuzumab in vitro at all concentrations tested (0-10 ug/mL). Further, treatment with T-DM1 on nude mice xenografted with PIK3CA E545K-harboring cells resulted in inhibition of tumor growth. A single dose of T-DM1 >3mg/kg was sufficient to induce tumor suppression lasting >20 days after administration."	"Baselga et al., 2016, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545K	PIK3CA	E545K	Colorectal Cancer	"Cetuximab,Panitumumab"	Predictive	Does Not Support	C	Resistance	chr3	179218303	179218303	G	A	"In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). PIK3CA E545K was the only variant noted in the primary tumor (found in the sigma-rectum junction) of one patient who experienced partial response following treatment. In the larger cohort, patients with tumors harboring any PIK3CA mutation had significantly shorter progression free survival and decreased incidence of objective response than patients with wtPIK3CA tumors. See Patient 55 from Supplemental Table 1 for more information on this patient."	"Sartore-Bianchi et al., 2009, Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545K	PIK3CA	E545K	Lung Non-small Cell Carcinoma	PI103	Predictive	Supports	D	Sensitivity/Response	chr3	179218303	179218303	G	A	"H460, a gefitinib-resistant NSCLC cell line harboring PIK3CA E545K (a PIK3CA activating mutation), was used to test the anti-tumor effects of PI103. Without treatment, H460 cells expressed high levels of phosphorylated AKT. Following treatment, p-AKT decreased which correlated with cell senescence. PI103 treatment resulted in greater cell senescence in the PIK3CA E545K cell line than in A549, a wildtype PIK3CA gefinitib-resistant NSCLC cell line."	"Zou et al., 2009, Int. J. Mol. Med."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545K	PIK3CA	E545K	Her2-receptor Positive Breast Cancer	Pictilisib	Predictive	Supports	D	Sensitivity/Response	chr3	179218303	179218303	G	A	"This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. MDA-MB-361 is a HER2 amplified breast cancer cell line harboring PIK3CA E545K, and it had an IC50 of 0.14uM. To asses the effect of pictilisib on cell cycle progression and apoptosis, fluorescence based cell cycle and flow cytometry were used to measure the proportion of cells in various phases and the relative presence of Annexin V, a marker of apoptosis. Untreated, 68% of cells were in G1 or sub-G1. Following treatment with 1.0uM pictilisib, the proportion of cells in G1 or sub-G1 rose to 78%, and the amount of Annexin V detected rose 3 fold. A substantial reduction in phosphorylated AKT (S473) was also noted. Authors concluded that pictilisib had a modest effect on cell cycle progression and encouraged apoptosis in this cell line, and that this cell line is sensitive to pictilisib. Authors further noted that HER2 amplified cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like breast cancer cell lines (p=0.002)."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545K	PIK3CA	E545K	Rectum Cancer		Prognostic	Supports	B	Poor Outcome	chr3	179218303	179218303	G	A	"This study examined outcomes of 240 rectum cancer patients treated with total mesorectal excision therapy. Tumor samples were obtained at the time of surgery and genotyped for PIK3CA exon 10 and 21 mutations (listed as exon 9 and 20 in the publication, as it was common at the time of its publication to exclude non-coding exon 1). Of the 19 patients whose tumors harbored PIK3CA mutations, nine harbored PIK3CA E545K. PIK3CA E545K was associated with poor outcome compared to other PIK3CA mutations for local and distant recurrences (HR: 11.6, P < 0.001; HR 3.7, P = 0.006). Additionally, 89% of patients whose tumors harbored PIK3CA E545K experienced a relapse."	"He et al., 2009, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545Q	PIK3CA	E545Q	Colorectal Cancer	"Irinotecan,Cetuximab"	Predictive	Does Not Support	C	Resistance	chr3	179218303	179218303	G	C	"Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA E545Q (exon 10), were wildtype for NRAS, BRAF and PIK3CA, and had individual response data. Both were treated with cetuximab and irinotecan and experienced partial responses. One patient was a 44 year old female, on 5th line therapy, with a PFS of 67 weeks and an OS of 209 weeks. The other patient was a 46 year old male, on 2nd line therapy, with a PFS of 22 weeks and an OS of 105 weeks. Using these and data from the larger cohort, authors concluded that PIK3CA exon 10 (listed as exon 9 in source) mutations are associated with weak or no resistance to cetuximab."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545K	PIK3CA	E545K	Colorectal Cancer	Cetuximab	Predictive	Does Not Support	C	Resistance	chr3	179218303	179218303	G	A	"This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 16 patients harbored PIK3CA E545K (exon 10), were wt for BRAF, NRAS and PIK3CA, and had individual response data. Five patients had partial response, six had stable disease, and five progressed, resulting in a response rate of 5/16 and a clinical benefit rate of 11/16 according to author criteria. Treatments included cetuximab + irinotecan (n=13), cetuximab monotherapy (n=1), cetuximab + bevacizumab (n=1), and cetuximab + oxaliplatin + 5FU (n=1). Median PFS was 24 weeks (2-60 weeks), median OS was 43 weeks (9-107 weeks), and median number of previous chemotherapy lines was 2 (1-5). Median age was 58 years old (43-79), and there were 10 males and 6 females. Using these and data from the larger cohort, authors concluded that PIK3CA exon 10 (listed as exon 9 in source) mutations are associated with weak or no resistance to cetuximab."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545K	PIK3CA	E545K	Cervix Carcinoma	"Pictilisib,Cisplatin"	Predictive	Supports	D	Sensitivity/Response	chr3	179218303	179218303	G	A	"CaSki cells that are heterozygous for the PIK3CA-E545K mutation are more resistant to cisplatin or cisplatin plus radiation than either HeLa or SiHa cells that express only wild-type PIK3CA. Similarly, HeLa cells engineered to stably express PIK3CA-E545K were more resistant to cisplatin or cisplatin plus radiation than cells expressing only wild-type PIK3CA or with PIK3CA depleted. Cells expressing the PIK3CA-E545K mutation also had constitutive PI3K pathway activation and increased cellular migration and each of these phenotypes was reversed by treatment with the PI3K inhibitor GDC-0941/Pictilisib. In addition, GDC-0941 restored sensitivity of E545K mutant cell lines to cisplatin as combination treatment had a larger impact on cell survival than either drug alone."	"Arjumand et al., 2016, Oncotarget"	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545K	PIK3CA	E545K	Cervical Cancer	Cisplatin	Predictive	Supports	D	Resistance	chr3	179218303	179218303	G	A	"Authors tested various cervical cancer cell lines (CaSki, SiHa and HeLa) for their responses to cisplatin, radiation therapy, and GDC-0941. CaSki cells that are heterozygous for the PIK3CA-E545K mutation were significantly more resistant to cisplatin or cisplatin plus radiation than either HeLa or SiHa cells that express only wild-type PIK3CA. Similarly, HeLa cells engineered to stably express PIK3CA E545K were more resistant to cisplatin or cisplatin plus radiation than cells expressing only wild-type PIK3CA or with PIK3CA depleted. Cells expressing the PIK3CA-E545K mutation also had constitutive PI3K pathway activation and increased cellular migration and each of these phenotypes was reversed by treatment with the PI3K inhibitor GDC-0941 (pictilisib)."	"Arjumand et al., 2016, Oncotarget"	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545K	PIK3CA	E545K	Melanoma	Vemurafenib	Predictive	Supports	D	Resistance	chr3	179218303	179218303	G	A	"An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) used PIK3CA E545K as a positive control for testing resistance to BRAF inhibition by vemurafenib. M229 cells virally transduced with PIK3CA E545K were significantly more resistant to vemurafenib-mediated growth suppression than cells transduced with empty vectors (50% vs 20% survival at the highest concentration, p <.0001). Furthermore, E545K appears to confer more resistance to vemurafenib than PIK3CA D350G and similar levels of resistance as E545G. Resistance was determined by assessing cell survival."	"Shi et al., 2014, Cancer Discov"	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545K	PIK3CA	E545K	Her2-receptor Positive Breast Cancer	"Trastuzumab,Lapatinib"	Predictive	Supports	D	Resistance	chr3	179218303	179218303	G	A	"In a preclinical study, efficacy of lapatinib and trastuzumab was evaluated in vitro against HER2 amplified breast cancer cell line BT474 (heterozygous for PIK3CA K111N) retrovirally transduced with PIK3CA E45K. The study found that E545K abrogated the growth inhibitory effects of lapatinib and trastuzumab, either in isolation or in combination, though increased cell death was observed with combination therapy relative to monotherapy. The authors concluded that the PIK3CA E545K induces resistance to lapatinib and trastuzumab in HER2-positive breast cancer cells."	"Eichhorn et al., 2008, Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545K	PIK3CA	E545K	Her2-receptor Positive Breast Cancer	Dactolisib	Predictive	Does Not Support	D	Resistance	chr3	179218303	179218303	G	A	"This preclinical study tested the sensitivity of HER2-positive breast cancer cell line BT-474 (heterozygous for PIK3CA K111N) retrovirally transduced with PIK3CA E545K to NVP-BEZ235 (dactolisib; a dual PI3K/mTOR inhibitor). The study found that dactolisib was effective in inhibiting outgrowth of E545K mutant-containing cells. Dactolisib was also combined with trastuzumab and/or lapatinib with similar abrogation of growth for PIK3CA E545K expressing cells. Growth of untransduced BT-474 control cells was prevented by treatment with any monotherapy or combination of trastuzumab, lapatinib, or dactolisib."	"Eichhorn et al., 2008, Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545K	PIK3CA	E545K	Breast Cancer	PI-103	Predictive	Supports	D	Resistance	chr3	179218303	179218303	G	A	"As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. MCF7 is a luminal-like breast cancer cell line harboring PIK3CA E545K, and it had an IC50 of 1.53uM."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545K	PIK3CA	E545K	Her2-receptor Positive Breast Cancer	PI3Ka/Di	Predictive	Supports	D	Sensitivity/Response	chr3	179218303	179218303	G	A	"As part of a preclinical study, the efficacy of PI3KA/Dia selective inhibitor for the  (IC50 for p100: 3nM) and  (IC50 for p100: 20nM) subunits of class I PI3Kwas evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. MDA-MB-361 is a HER2 amplified breast cancer cell line harboring PIK3CA E545K and it had an IC50 of 0.16uM."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545K	PIK3CA	E545K	Breast Cancer	PI3Ka/Di	Predictive	Supports	D	Sensitivity/Response	chr3	179218303	179218303	G	A	"As part of a preclinical study, the efficacy of PI3KA/Dia selective inhibitor for the  (IC50 for p100: 3nM) and  (IC50 for p100: 20nM) subunits of class I PI3Kwas evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. MCF7 is a luminal-type breast cancer cell line harboring PIK3CA E545K and it had an IC50 of 0.84uM."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545K	PIK3CA	E545K	Cervical Cancer	"Cisplatin,Radiation Ionizing Radiotherapy"	Predictive	Supports	D	Resistance	chr3	179218303	179218303	G	A	Cervical cancer cell lines were treated with 1uM cisplatin followed by 1-6Gy ionizing radiation (IR). CaSki cells with PIK3CA E545K mutation show resistance to cisplatin plus IR when compared with HeLa or SiHa cells that express only wild-type PIK3CA. Transfection of HeLa cells with PIK3CA E545K resulted in resistance to cisplatin plus IR compared to cells expressing only wild-type PIK3CA or with PIK3CA depleted.	"Arjumand et al., 2016, Oncotarget"	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545K	PIK3CA	E545K	Her2-receptor Positive Breast Cancer	Trastuzumab	Predictive	Supports	D	Resistance	chr3	179218303	179218303	G	A	"As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines. MCF7-neo/HER2 cell line harboring PIK3CA E545K was associated with resistance to trastuzumab compared to PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL)."	"Baselga et al., 2016, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA E545G	PIK3CA	E545G	Melanoma	Vemurafenib	Predictive	Supports	D	Resistance	chr3	179218304	179218304	A	G	"An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype PIK3CA and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over-express PIK3CA E545G were significantly more resistant to BRAF inhibition by vemurafenib than cells transduced with an empty vector (50% vs 20% survival at the highest concentration, p < .0001). Though statistics were not provided, E545G appears to confer similar levels of resistance to vemurafenib as the positive control variant, PIK3CA E545K."	"Shi et al., 2014, Cancer Discov"	Somatic	ENST00000263967.3	missense_variant
PIK3CA Q546K	PIK3CA	Q546K	Colorectal Cancer	"Cetuximab,Irinotecan"	Predictive	Does Not Support	C	Resistance	chr3	179218306	179218306	C	A	"One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA Q546K (exon 10), was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 75 year old female treated with cetuximab and irinotecan as 2nd line therapy (discontinued for toxic/biochemical reasons) who experienced a partial response (PFS: 43 weeks, OS: 57 weeks). Using clinical data compiled from the larger cohort, authors concluded that PIK3CA exon 10 (listed as exon 9 in the source) mutations predict weak or no resistance to cetuximab."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000263967.3	missense_variant
PIK3CA V955I	PIK3CA	V955I	Colorectal Cancer	Cetuximab	Predictive	Supports	C	Resistance	chr3	179230303	179230303	G	A	"Among 32 colorectal cancer patients with acquired resistance (PFS > 12 weeks) to cetuximab, one was determined to have V955I mutation. V995I allelic fractions low at start of treatment but increased in frequency during treatment. PolyPhen-2 and SIFT functional predict folding changes to activation-loop domain. DiFi cells transfected with PIK3CA V955I plasmid assayed with western blot for pAKT (phosphorylated AKT) and pERK showed increased phosphorylation, which was not affected by the addition of cetuximab. PIK3CA V955I transfected cells also promoted cell viability in the presence of cetuximab."	"Xu et al., 2017, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA Exon 21 Mutation	PIK3CA	Exon 21 Mutation	Colorectal Cancer	"Chemotherapy,Cetuximab"	Predictive	Supports	B	Resistance	chr3	179234094	179234707			"Chemotherapy-refractory patients with metastatic colorectal cancer harboring wildtype KRAS and Exon 21 (listed as exon 20 in the source) PIK3CA mutations had lower response rates (0/9 vs 121/329; OR: 0.00; p=0.029) and disease control rates as well as shorter progression free and overall survival (median 34 vs 51 weeks; HR: 3.29, p=0.0057) following cetuximab plus chemotherapy than those with wildtype PIK3CA. In multivariate analysis of the KRAS wildtype population, significant associations between PIK3CA exon 21 mutations and poor response to cetuximab were retained. The authors concluded that PIK3CA exon 21 mutation status is more predictive of poor response to cetuximab than PIK3CA mutation status as a whole. They also recommended screening for mutations in the following gene order: KRAS, BRAF, NRAS, PIK3CA exon 21."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000263967.3	exon_variant
PIK3CA Exon 21 Mutation	PIK3CA	Exon 21 Mutation	Colorectal Cancer		Prognostic	Does Not Support	B	Poor Outcome	chr3	179234094	179234707			"This study analyzed tumor and patient characteristics from 1,170 colorectal cancer patients derived from the prospective cohort studies: Nurses' Health Study and Health Professionals Follow Up Study. PIK3CA mutations were found in 16% (189/1170) of patients via pyrosequencing of FFPE samples. Of patients with PIK3CA mutations, 39% (73/189) had mutations in exon 21 (listed as exon 20 in the publication, as it was common at the time of its publication to exclude non-coding exon 1). The presence of an exon 21 mutation was not significantly associated with colorectal cancer-specific or overall survival when compared to patients with wt PIK3CA (multivariate, stage-stratified HR = 1.11 vs 1). Authors note that they had limited data on cancer treatment data, but assume that treatment regimens did not differ substantially based on PIK3CA mutation status given that patients were diagnosed prior to clinical availability of PIK3CA genotype data. They further note that treatment decisions were typically based on cancer stage, for which their analyses adjusted."	"Liao et al., 2012, Clin. Cancer Res."	Somatic	ENST00000263967.3	exon_variant
PIK3CA Exon 21 Mutation	PIK3CA	Exon 21 Mutation	Breast Cancer		Prognostic	Supports	B	Better Outcome	chr3	179234094	179234707			"An Italian study of 163 malignant breast tumors assessed the association between PIK3CA mutations and clinical outcome. Of the 163 tumors sequenced, 118 had wild-type (wt) PIK3CA, 24 had exon 9 (helical domain) missense mutations, and 21 had exon 20 (kinase domain) missense mutations. The study found that patients with exon 20 mutations showed significantly better 5-year overall survival (OS) and 5-year disease free survival (DFS) compared to patients with wt PIK3CA (P=.011 and P = .01, respectively). Furthermore, patients with exon 20 mut showed especially better OS and DFS than patients with exon 9 mutations (P=.0018 and P=.0017, respectively). The 21 cases with exon 20 mutations had excellent prognosis with no recurrences or deaths, whereas there were 10 recurrences and 9 deaths among the 24 cases of exon 9 mutations, in observed period. Note these exons are now referred to as exons 10 and 21 rather than as exons 9 and 20, as it was common at the time of publication to exclude non-coding exon 1."	"Barbareschi et al., 2007, Clin. Cancer Res."	Somatic	ENST00000263967.3	exon_variant
PIK3CA H1047R	PIK3CA	H1047R	Colorectal Cancer	"Panitumumab,Cetuximab"	Predictive	Does Not Support	B	Resistance	chr3	179234297	179234297	A	G	"In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN were tested for mutation; PIK3CA H1047R was the only variant noted in the primary tumor (located in rectum) of one patient who experienced partial response (patient 38; Supplemental Table 1), following treatment. In the larger cohort, patients with tumors harboring any PIK3CA mutation had significantly shorter progression free survival and decreased incidence of objective response than patients with wtPIK3CA tumors."	"Sartore-Bianchi et al., 2009, Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047R	PIK3CA	H1047R	Breast Cancer	PI3K-alpha Inhibitor MEN1611	Predictive	Supports	D	Sensitivity/Response	chr3	179234297	179234297	A	G	Breast cancer cell lines with H1047R mutation showed increased sensitivity to CH5132799 than cells with wild-type PIK3CA gene.	"Tanaka et al., 2011, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047R	PIK3CA	H1047R	Colorectal Cancer	"Panitumumab,Cetuximab"	Predictive	Supports	C	Resistance	chr3	179234297	179234297	A	G	"In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS PIK3CA and PTEN were tested for mutation; PIK3CA H1047R was the only variant noted in the primary tumors of four patients (Patient Ids: 7, 42, 52, 64; Table S1) and the metastatic tumor of one patient (11; Table S1), who experienced disease progression following treatment. It was also noted in the primary tumors of 3 patients (25, 48, 88; Table S1) who experienced stable disease following treatment.This response was consistent with observations made of the larger cohort, where patients with tumors harboring any PIK3CA mutation had significantly shorter progression free survival and decreased incidence of objective response than patients with wtPIK3CA tumors. However, one patient (38, Table S1) had PIK3CA H1047R as the only noted variant, but experienced partial response."	"Sartore-Bianchi et al., 2009, Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047R	PIK3CA	H1047R	Head And Neck Cancer	Dactolisib	Predictive	Supports	D	Sensitivity/Response	chr3	179234297	179234297	A	G	Lentiviral transduction of PIK3CA H1047R mutation into head and neck cancer cell line SCC25 led to increased sensitivity to PI3K/mTOR inhibition with BEZ235 compared to unmanipulated cells (IC50 values 6 nM and 31 nM).	"Wirtz et al., 2015, JAMA Otolaryngol Head Neck Surg"	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047R	PIK3CA	H1047R	Head And Neck Cancer	Dactolisib	Predictive	Supports	D	Sensitivity/Response	chr3	179234297	179234297	A	G	"Two head and neck cancer cell lines with PIK3CA H1047R mutation were more sensitive to PI3K/mTOR inhibition with BEZ-235 (NVP-BEZ235, Dactolisib) than two wild type cell lines in vitro. One cell line with H1047R mutation was also found to be sensitive to BEZ-235 in vivo. PIK3CA (H1047R) mutation positive cell lines used were ""CAL-33"" and ""Detroit 562"". Wild type cell lines used here were ""SCC-9"" and ""PE/CA-PJ34(clone C12)""."	"Lui et al., 2013, Cancer Discov"	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047R	PIK3CA	H1047R	Head And Neck Cancer	"Cetuximab,Dactolisib"	Predictive	Supports	D	Sensitivity/Response	chr3	179234297	179234297	A	G	"Xenografts from one head and neck cancer cell line (CAL-33) with a PIK3CA H1047R mutation were more sensitive to the combined inhibition of PI3K/mTOR and EGFR with BEZ-235 and cetuximab (N=9) than cetuximab (N=9, P=0.0039) or BEZ-235 alone (N=9, P=0.0002) in-vivo."	"Lui et al., 2013, Cancer Discov"	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047R	PIK3CA	H1047R	Head And Neck Cancer	Alpelisib	Predictive	Supports	D	Sensitivity/Response	chr3	179234297	179234297	A	G	"In a panel of head and neck cancer cell lines, 2 lines containing the PIK3CA mutation H1047R (Detroit562 and SNU-1076) were more sensitive to growth inhibition (IC50 1.10 and 6.82) by the PI3Kalpha specific inhibitor BYL719 (Alepelisib) than 3 of 4 lines with wild type PI3K (SNU-1066 IC50 1.13 M; SNU-1041, 20.65 M; FaDu, 19.67 M; SCC25, 49.30 M). In the H1047R mutant cell lines and the wildtype cell line tested, phospho-Akt and phospho-S6 levels were diminished with increasing BYL719 levels."	"Keam et al., 2015, Anticancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047R	PIK3CA	H1047R	Lung Adenocarcinoma	Dactolisib	Predictive	Supports	D	Sensitivity/Response	chr3	179234297	179234297	A	G	"Doxycycline dependent expression of the PIK3CA H1047R mutation in mouse type II alveolar epithelial cells drove lung cancer in a reversible fashion, indicating the driver properties of this p110alpha catalytic domain mutation. Administration of pan-p110 isoform and mTOR inhibitor BEZ235 to H1047R mice with established tumors resulted in reduced tumor phospho-Akt and phosoho-S6 levels, and significant regression of tumor volume."	"Engelman et al., 2008, Nat. Med."	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047R	PIK3CA	H1047R	Head And Neck Squamous Cell Carcinoma	Taselisib	Predictive	Supports	D	Sensitivity/Response	chr3	179234297	179234297	A	G	"The Cal-33 HNSCC cell line with H1047R mutation was found to have a low antiproliferative IC50 value for the alpha, gamma and delta isoform-specific PI3K inhibitor taselisib. Increasing taselisib concentration induced reduction of phospho-Akt levels in Call-33 cells, while upregulating the cleaved PARP apoptotic marker. Among a panel of 26 HNSCC cell lines, activating PI3K mutations were associated with taselisib sensitivity in comparison to wild-type PI3K or PTEN mutant cell lines."	"Zumsteg et al., 2016, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047R	PIK3CA	H1047R	Her2-receptor Positive Breast Cancer	"Capivasertib,Trastuzumab"	Predictive	Supports	D	Sensitivity/Response	chr3	179234297	179234297	A	G	"Tumor xenografts in mice were established with the KPL4 HER2 positive breast cancer cell line with PIK3CA H1047R mutation. KPL4 has suboptimal responses to trastuzumab and lapatinib. Xengraft treatment with trastuzumab and AZD5363 monotherapy induced moderate growth inhibition which was significant for AZD5363, but co-treatment with trastuzumab and AZD5363 induced significant tumor regression and enhanced growth delay upon removal of treatment."	"Davies et al., 2012, Mol. Cancer Ther."	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047R	PIK3CA	H1047R	Her2-receptor Positive Breast Cancer	"Capivasertib,Lapatinib"	Predictive	Supports	D	Sensitivity/Response	chr3	179234297	179234297	A	G	"The HER2 breast cancer cell line KPL4 with PIK3CA H1047R shows sub-optimal responses to trastuzumab and lapatinib, and was used to establish mouse xenografts. Treatment of mice with monotherapy of AZD5363 or lapatinib alone induced growth inhibition (37%, not significant; 65%, P = 0.004), but treatment with AZD5363 and lapatinib together induced significant tumor regression (109%, P < 0.0001) as well as delayed tumor regrowth after removal of therapy."	"Davies et al., 2012, Mol. Cancer Ther."	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047R	PIK3CA	H1047R	Her2-receptor Positive Breast Cancer	"Fulvestrant,Everolimus"	Predictive	Supports	C	Sensitivity/Response	chr3	179234297	179234297	A	G	"Case report of a 44-year-old patient with recurrent HER2-positive breast cancer. The primary tumor was HR positive; however, the metastatic tumor was HR negative. The patient was resistant to classical chemotherapeutic agents and anti-HER2 treatment. Thus, the combination of everolimus and fulvestrant was administered. The patient experienced stable disease and PFS of 10 months. Genetic testing of pleural effusion after disease progression revealed a PIK3CA H1047R gene mutation but was positive for PTEN expression (IHC)."	"Sun et al., 2016, Onco Targets Ther"	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047R	PIK3CA	H1047R	Thyroid Gland Cancer	"Temsirolimus,Perifosine"	Predictive	Supports	D	Sensitivity/Response	chr3	179234297	179234297	A	G	"Preclinical study in thyroid cancer cell lines. 6 cell lines with alterations of the PI3K/Akt pathway were more sensitive to Akt inhibitor perifosine or MTOR inhibitor temsirolimus than 5 cell lines without genetic alterations in the PI3K/Akt pathway. Among the alterations, One cell line harbored a PIK3CA H1047R mutation. Transfection of another cell line with this mutation led to lower IC50 values to perifosine and temsirolimus than in a cell line transfected with a control vector. Perifosine treatment also increased apoptosis of a thyroid tumor xenograft with PIK3CA H1047R mutation."	"Liu et al., 2009, Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047L	PIK3CA	H1047L	Breast Cancer	Pictilisib	Predictive	Supports	D	Sensitivity/Response	chr3	179234297	179234297	A	T	"This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1 umol/L, respectively, with a maximum tested concentration of 20 umol/L. EFM-19 is a luminal type breast cancer cell line harboring PIK3CA H1047L, and it had an IC50 of 0.09uM, suggesting sensitivity. Authors note that luminal-like cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like (p=.02)"	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047R	PIK3CA	H1047R	Her2-receptor Positive Breast Cancer	Pictilisib	Predictive	Supports	D	Sensitivity/Response	chr3	179234297	179234297	A	G	"This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of IC50 values. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. KPL4 is a HER2 amplified breast cancer cell line harboring PIK3CA H1047R, and it had an IC50 of 0.28uM. To evaluate in vivo efficacy, cells were injected in the mammary fat pad of SCID mice, and allowed to grow. Subsequently, pictilisib was administered orally daily for 14 days. Mice treated with 100mg/kg experienced a 76% tumor reduction, and those treated with 150mg/kg experienced a 90% tumor reduction, with respect to untreated control. Phosphorylated AKT (S473) was substantially reduced with pictilisib administration. Three other HER2 amplified breast cancer cell lines harbored PIK3CA H1047R: UACC-893, HCC1954, MDA-MB-453, which had IC50s of 0.41uM, 0.49uM, and 0.64uM, suggesting that PIK3CA H1047R induces sensitivity to pictilisib in HER2 amplified breast cancer. Authors note that pictilisib was well tolerated in vivo and further note that HER2 amplified cell lines were generally more sensitive, regardless of mutation, to pictilisib than basal-like cell lines (p=0.002)."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047R	PIK3CA	H1047R	Breast Cancer		Prognostic	Supports	B	Better Outcome	chr3	179234297	179234297	A	G	"Prognostic significance of PIK3CA mutations was evaluated in a retrospective study of 590 patients with surgically resected invasive breast cancer. Patients whose tumors harbored PIK3CA H1047R (n=88, 14.9%) experienced significantly higher 10-year overall survival rate (76% vs 62%) and lower 10-year probability of breast cancer specific death (11% vs 23%) compared to those with wildtype PIK3CA. They also experienced a 2.8 and 2 fold reduction in probability of death due to breast cancer at 5 and 10 years. Authors found that PIK3CA H1047R was specifically associated with lymph node-negative status: 64% of H1047R patients were lymph-node negative compared to 48% of patients with PIK3CA WT and helical domain mutated tumors (P=0.007). PIK3CA H1047R was positively associated with lymph node negative status, lower nodal stage, lower overall stage, and smaller tumor size compared to WT PIK3CA"	"Kalinsky et al., 2009, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047R	PIK3CA	H1047R	Breast Cancer		Prognostic	Supports	B	Better Outcome	chr3	179234297	179234297	A	G	"In Japanese invasive breast cancer patients, PIK3CA mutation was associated with improved relapse-free survival (p < .05)."	"Maruyama et al., 2007, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047R	PIK3CA	H1047R	Breast Cancer	Pictilisib	Predictive	Supports	D	Sensitivity/Response	chr3	179234297	179234297	A	G	"This preclinical study tested the efficacy of GDC-0941, a selective inhibitor of class I PI3K, on several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. Three cell lines harbored PIK3CA H1047R. T-47D is a luminal type breast cancer cell line, and it had an IC50 of 0.22uM. Treatment with GDC-0941 resulted in a substantial reduction of phosphorylated AKT. BT-20 is a basal breast cancer cell line which had an ICD50 of 0.62uM. MFM-223 is basal cell line that had an ICD50 of 2.10uM, and experienced some reduction in pAKT. Authors note that luminal-like cell lines were generally more sensitive to GDC-0941 than basal-like (p=0.02)."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047R	PIK3CA	H1047R	Her2-receptor Positive Breast Cancer	Trastuzumab Emtansine	Predictive	Does Not Support	D	Resistance	chr3	179234297	179234297	A	G	"As part of a pre-clinical experiment, the efficacy of ado-trastuzumab emtansine (T-DM1) was compared to that of trastuzumab against various HER2 positive cell lines. HCC1954 and KPL-4 cell lines expressing PIK3CA H1047R were associated with similar sensitivity to T-DM1 as PIK3CA wild-type cell line SK-BR-3; reduced cell viability was observed at concentrations > 0.01 ug/mL in all three cell lines. Conversely, the cell lines harboring PIK3CA H1047R were resistant to trastuzumab in vitro at all concentrations tested (0-10 ug/mL). Further, treatment with T-DM1 on SCID mice xenografted with KPL-4 (PIK3CA H1047R cells) resulted in inhibition of tumor growth. A single dose of T-DM1 >5mg/kg was sufficient to induce tumor regression >20 days after administration."	"Baselga et al., 2016, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047R	PIK3CA	H1047R	Colorectal Cancer	Vemurafenib	Predictive	Supports	D	Resistance	chr3	179234297	179234297	A	G	"In an in vitro study, a RKO cell line expressing BRAF V600E (a known vemurafenib sensitizing mutation) and PIK3CA H1047R co-mutation demonstrated reduced sensitivity to vemurafenib treatment. Resistance was determined by assessing cellular proliferation and AKT phosphorylation."	"Yang et al., 2012, Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047R	PIK3CA	H1047R	Colorectal Cancer	"Irinotecan,Cetuximab"	Predictive	Supports	C	Resistance	chr3	179234297	179234297	A	G	"Five patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA H1047R (exon 21), were wildtype for KRAS, BRAF and NRAS, and had individual response data. All patients were treated with cetuximab and irinotecan, four as 3rd line therapy, one as 4th line. Patient characteristics are as follows: a 65 year old female who experienced stable disease (PFS: 33 weeks, OS: 37 weeks); a 56 year old female who experienced stable disease (PFS: 28 weeks, OS: 43 weeks); a 69 year old female who experienced progressive disease (PFS: 10 weeks, OS: 28 weeks); a 63 year old male who experienced progressive disease (PFS:11 weeks, OS: 18 weeks); a 60 year old female who experienced progressive disease (PFS: 12 weeks, OS: 34 weeks). Based off this information and clinical data compiled from the larger cohort, authors concluded that PIK3CA exon 21 (listed as exon 20 in source) mutations predict poor response to cetuximab."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047L	PIK3CA	H1047L	Colorectal Cancer	"Cetuximab,Irinotecan"	Predictive	Supports	C	Resistance	chr3	179234297	179234297	A	T	"Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA H1047L (exon 21), were wildtype for NRAS, BRAF and PIK3CA, and had individual response data. Both were males treated with cetuximab + irinotecan as 3rd line therapy and experienced progressive disease. One patient was 73 years old with a PFS of 11 weeks and an OS of 31 weeks. The other patient was 61 years old with a PFS and OS of 4 weeks. Authors concluded from this information and data from larger cohort that PIK3CA exon 21 (listed as exon 20 in source) mutations predict poor response to cetuximab."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047R	PIK3CA	H1047R	Her2-receptor Positive Breast Cancer	"Trastuzumab,Lapatinib"	Predictive	Supports	D	Resistance	chr3	179234297	179234297	A	G	"In a preclinical study, efficacy of lapatinib and trastuzumab was evaluated in vitro against HER2 amplified breast cancer cell line BT474 (heterozygous for PIK3CA K111N) retrovirally transduced with PIK3CA H1047R. The study found that H1047R abrogated the growth inhibitory effects of lapatinib and trastuzumab, either in isolation or in combination, though somewhat increased cell death was observed with combination therapy relative to monotherapy. The authors concluded that the PIK3CA H1047R induces resistance to lapatinib and trastuzumab in HER2-positive breast cancer cells."	"Eichhorn et al., 2008, Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047R	PIK3CA	H1047R	Her2-receptor Positive Breast Cancer	Dactolisib	Predictive	Does Not Support	D	Resistance	chr3	179234297	179234297	A	G	"This preclinical study tested the sensitivity of HER2-positive breast cancer cell line BT-474 (heterozygous for PIK3CA K111N) retrovirally transduced with PIK3CA H1047R to NVP-BEZ235 (dactolisib; a dual PI3K/mTOR inhibitor). The study found that dactolisib was effective in inhibiting outgrowth of H1047R mutant-containing cells. Dactolisib was also combined with trastuzumab and/or lapatinib with similar abrogation of growth for PIK3CA H1047R expressing cells. Additionally, growth of untransduced BT-474 control cells was prevented by treatment with any monotherapy or combination of trastuzumab, lapatinib, or dactolisib. Authors concluded that PIK3CA H1047R induces resistance to lapatinib and trastuzumab in HER2 positive breast cancer cells, but resistance can be reversed by dactolisib."	"Eichhorn et al., 2008, Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047L	PIK3CA	H1047L	Breast Cancer	PI-103	Predictive	Supports	D	Sensitivity/Response	chr3	179234297	179234297	A	T	"As part of a preclinical study, the efficacy of PI-103 was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. EFM-19 is a luminal-like breast cancer cell line harboring PIK3CA H1047L, and it had an IC50 of 0.16uM."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047L	PIK3CA	H1047L	Breast Cancer	PI3Ka/Di	Predictive	Supports	D	Sensitivity/Response	chr3	179234297	179234297	A	T	"As part of a preclinical study, the efficacy of PI3KA/Dia selective inhibitor for the  and  subunits of class I PI3Kwas evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized as less than and more than an IC50 of 1umol/L, respectively, with a maximum tested concentration of 20 umol/L. EFM-19 is a luminal-type breast cancer cell line harboring PIK3CA H1047L and it had an IC50 of 0.17uM."	"O'Brien et al., 2010, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047R	PIK3CA	H1047R	Colorectal Cancer	"Akt Inhibitor MK2206,Vemurafenib"	Predictive	Supports	D	Sensitivity/Response	chr3	179234297	179234297	A	G	"Resistance of RKO cells, which harbor BRAF V600E (a known vemurafenib sensitizing mutation) and PIK3CA H1047R, to vemurafenib monotherapy was abrogated by the addition of pan-AKT inhibitor MK-2206 in vitro and in vivo. In vitro, vemurafenib and MK-2206 combination treatment of RKO cells resulted in substantially greater proliferation inhibition than either agent in isolation or untreated control cells (combination index score = 0.691 at EC50). Synergistic effects of vemurafenib and MK-2206 on RKO cells was confirmed in vivo via xenografts on an athymic mouse model, where mice treated with vemurafenib monotherapy experienced minimal tumor growth inhibition (25%), mice treated with MK-2206 monotherapy experienced modest tumor growth inhibition (37%), and mice treated with both achieved 87% tumor growth inhibition compared to vehicle treated control mice (P <0.001)."	"Yang et al., 2012, Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA H1047R	PIK3CA	H1047R	Her2-receptor Positive Breast Cancer	Trastuzumab	Predictive	Supports	D	Resistance	chr3	179234297	179234297	A	G	"As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines. CC1954 and KPL-4 cell lines expressing PIK3CA H1047R were associated with resistance to trastuzumab compared to PIK3CA wild-type cell line SK-BR-3, at all concentrations tested (0-10 ug/mL)."	"Baselga et al., 2016, Clin. Cancer Res."	Somatic	ENST00000263967.3	missense_variant
PIK3CA G1049R	PIK3CA	G1049R	Colorectal Cancer	Cetuximab	Predictive	Supports	C	Resistance	chr3	179234302	179234302	G	C	"One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA G1049R (exon 20), was wildtype for KRAS, BRAF and NRAS, and had individual response data. This patient was was a 69 year old male treated with cetuximab + FOLFIRI as 3rd line therapy who experienced progressive disease and had PFS of 13 weeks and OS of 36 weeks. Using this information and data from the larger cohort, authors concluded that PIK3CA exon 21 (listed as exon 20 in source) mutations predict poor response to cetuximab."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000263967.3	missense_variant
FGFR2 FGFR2::TACC3	FGFR2	FGFR2::TACC3	Cholangiocarcinoma	"Pazopanib,Ponatinib"	Predictive	Supports	C	Sensitivity/Response	chr4	1721539	1739778			In a 43 year old female patient with this fusion in intrahepatic cholangiocarcinoma. Both pazopanib and ponatinib separately resulted in minor tumor shrinkage. This fusion is also shown to be recurrent in multiple other cancer types.	"Borad et al., 2014, PLoS Genet."	Somatic	ENST00000358487.5	transcript_fusion
FGFR3 FGFR3::TACC3	FGFR3	FGFR3::TACC3	Cancer	Erdafitinib	Predictive	Supports	B	Sensitivity/Response	chr4	1739702	1745171			"Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 5 partial responses (PR) and 16 with stable disease were seen. In patients harboring FGFR3-TACC3, there were 2 urothelial cancer patients with PRs, 1 endometrial cancer patient with PR (also had FGFR2-BICC1/FGFR2-OFD1 fusions), and tumor shrinkage in a patient with adrenal carcinoma (also had FGFR2-CCDC6 fusion)."	"Tabernero et al., 2015, J. Clin. Oncol."	Somatic	ENST00000340107.4	transcript_fusion
FGFR3 FGFR3::TACC3	FGFR3	FGFR3::TACC3	Transitional Cell Carcinoma	Infigratinib	Predictive	Supports	C	Sensitivity/Response	chr4	1739702	1745171			"In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or more prior antineoplastic therapies. An overall response rate of 25.4% was observed and an additional 38.8% of patients had disease stabilization. No clear differences between type of FGFR3 aberration and response could be seen. Four of five patients with FGFR3-TACC3 fusions had response data, with three achieving stable disease and one having a complete response. The authors conclude that BGJ398 appears to have moderate anticancer activity in patients with metastatic urothelial carcinoma, that response rates and disease control rate exceed outcomes with most agents in this setting, and that enriching for patients with activating FGFR3 mutations together with the high specificity of BGJ398 for FGFR3 likely explains this improved response."	"Pal et al., 2018, Cancer Discov"	Somatic	ENST00000340107.4	transcript_fusion
FGFR3 FGFR3::BAIAP2L1	FGFR3	FGFR3::BAIAP2L1	Bladder Carcinoma	PD173074	Predictive	Supports	D	Sensitivity/Response	chr4	1793312	1808872			"Following identification of this fusion in a patient, this fusion was expressed in HEK 293T cells leading to oligomerization in the absence of ligand, induced morphologic changes in the cell and increased cellular proliferation consistent with FGFR activation. Mouse xenografts using the bladder cell line SW780 which harbors an FGFR3-BAIAP2L1 fusion showed reduced tumor burden when treated with the FGFR inhibitor PD173074."	"Wu et al., 2013, Cancer Discov"	Somatic	ENST00000340107.4	transcript_fusion
FGFR3 Overexpression	FGFR3	Overexpression	Bladder Carcinoma	"PD173074,Tyrosine Kinase Inhibitor SU5402,Dovitinib"	Predictive	Supports	D	Sensitivity/Response	chr4	1793312	1808872			"The effects of FGFR inhibitors (PD173074, TKI-258 and SU5402) in bladder carcinoma cell lines were related to FGFR3 (and/or FGFR1) expression."	"Lamont et al., 2011, Br. J. Cancer"	N/A	ENST00000440486.2	N/A
FGFR3 Mutation	FGFR3	Mutation	Bladder Carcinoma	Infigratinib	Predictive	Supports	B	Sensitivity/Response	chr4	1793312	1808872			"Phase 1 study evaluated 132 patients who had advanced cancer with FGFR-aberrations treated with FGFR-inhibitor BGJ398. In the subgroup of eight patients with FGFR3-mutated bladder/urothelial cancer treated at doses ?100 mg, the disease control rate (SD + PR) was 75%. Three patients achieved partial response and 3 patients had stable disease. Of the six patients with disease control, the time on treatment ranged from 15.1 to ?101 weeks, with one ongoing at data cutoff."	"Nogova et al., 2017, J. Clin. Oncol."	Somatic	ENST00000340107.4	
FGFR3 FGFR3::TACC3	FGFR3	FGFR3::TACC3	Cancer	Erdafitinib	Predictive	Supports	B	Sensitivity/Response	chr4	1793312	1806934			"Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 5 partial responses (PR) and 16 with stable disease were seen. In patients harboring FGFR3-TACC3, there were 2 urothelial cancer patients with PRs, 1 endometrial cancer patient with PR (also had FGFR2-BICC1/FGFR2-OFD1 fusions), and tumor shrinkage in a patient with adrenal carcinoma (also had FGFR2-CCDC6 fusion)."	"Tabernero et al., 2015, J. Clin. Oncol."	Somatic	ENST00000340107.4	transcript_fusion
FGFR3 FGFR3::TACC3	FGFR3	FGFR3::TACC3	Transitional Cell Carcinoma	Infigratinib	Predictive	Supports	C	Sensitivity/Response	chr4	1793312	1806934			"In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or more prior antineoplastic therapies. An overall response rate of 25.4% was observed and an additional 38.8% of patients had disease stabilization. No clear differences between type of FGFR3 aberration and response could be seen. Four of five patients with FGFR3-TACC3 fusions had response data, with three achieving stable disease and one having a complete response. The authors conclude that BGJ398 appears to have moderate anticancer activity in patients with metastatic urothelial carcinoma, that response rates and disease control rate exceed outcomes with most agents in this setting, and that enriching for patients with activating FGFR3 mutations together with the high specificity of BGJ398 for FGFR3 likely explains this improved response."	"Pal et al., 2018, Cancer Discov"	Somatic	ENST00000340107.4	transcript_fusion
FGFR3 Mutation	FGFR3	Mutation	Transitional Cell Carcinoma	Erdafitinib	Predictive	Supports	A	Sensitivity/Response	chr4	1793312	1808872			"In a phase 2 trial, patients with locally advanced and unresectable or metastatic urothelial carcinoma harboring FGFR3 mutation or FGFR2/3 fusion were treated with Erdafitinib. All the patients had a history of disease progression during or after at least one course of chemotherapy. The response rate in patients receiving continuous daily 8 or 9mg Erdafitinib treatment was 40% (40/99). Within this treatment group, the response rate of patients with FGFR3 mutation was 49% (36/74). FGFR3 mutations included G370C, R248C, S249C, and Y373C."	"Loriot et al., 2019, N. Engl. J. Med."	Somatic	ENST00000340107.4	
FGFR3 Mutation	FGFR3	Mutation	Urinary Bladder Cancer	"Cisplatin,Gemcitabine"	Predictive	Supports	B	Sensitivity/Response	chr4	1793312	1808872			"In this study, 52 patients with Muscle Invasive Bladder Cancer (MIBC) were randomly selected and administered neoadjuvant cisplatin and gemcitabine chemotherapy. 39 out of 52 patients showed pathological response (partial & complete) and 13 patients were resistant to neoadjuvant chemotherapy.35.9% (14/39) patients that responded to neoadjuvant chemotherapy had the following FGFR3 somatic mutations - p.S249C,p.V372C, p.G299S, p.V411M. FGFR3 somatic mutations exclusively occurred in the responder group.The somatic FGFR3 mutation frequency in the responder group was also compared with three unselected bladder cancer populations from TCGA, Kim et al.study and Guo et al. studies.This analysis revealed that FGFR3 somatic mutations were significantly enriched in the responder cohort compared with the unselected bladder cancer cohorts."	"Yang et al., 2018, EBioMedicine"	Somatic	ENST00000340107.4	
FGFR3 Overexpression	FGFR3	Overexpression	Cancer	R3Mab	Predictive	Supports	D	Sensitivity/Response	chr4	1793312	1808872			Pro-B Ba/F3 cells transfected with wild type FGFR3 resulted in Il-3 independence with FGF1 dependence for growth.  Monoclonal antibody R3Mab treatment in addition to FGF1 resulted in suppression of proliferation of Ba/F3 cells with wild type FGFR3.	"Qing et al., 2009, J. Clin. Invest."	Somatic	ENST00000440486.2	N/A
FGFR3 R248C	FGFR3	R248C	Cancer	R3Mab	Predictive	Does Not Support	D	Resistance	chr4	1801837	1801837	C	T	"In this preclinical study, R3Mab (a monoclonal antibody specific to FGFR3) inhibited ligand-independent proliferation in Ba/F3 cells expressing common bladder carcinoma variant: FGFR3 R248C. Authors note that R3Mab similarly inhibited proliferation of FGF1 stimulated Ba/F3 cells expressing wildtype FGFR3 and bladder carcinoma cell lines expressing wildtype FGFR3 (RT112 and RT4). They conclude that R3Mab inhibits wildtype and mutant FGFR3 by inhibiting receptor dimerization."	"Qing et al., 2009, J. Clin. Invest."	Somatic	ENST00000340107.4	missense_variant
FGFR3 S249C	FGFR3	S249C	Transitional Cell Carcinoma	Pazopanib	Predictive	Supports	C	Sensitivity/Response	chr4	1801841	1801841	C	G	"Case report of a 67 year old woman with high-grade papillary urothelial carcinoma. The patient underwent chemotherapy and palliative cystectomy followed by tumor progression and pulmonary lesion enlargement. Genomic profiling of the cystectomy specimen identified FGFR3, CCND1 and FGF19 amplification as well as an FGFR3 S249C mutation (allele frequency 58%). Pazopanib was initiated on the basis of these findings and a partial response was achieved for >6 months."	"Palma et al., 2015, Eur. Urol."	Somatic	ENST00000340107.4	missense_variant
FGFR3 S249C	FGFR3	S249C	Lung Squamous Cell Carcinoma		Oncogenic	Supports	D	Oncogenicity	chr4	1801841	1801841	C	G	"NIH-3T3 cells with the FGFR3 S249C extracellular domain mutation demonstrated an increase in colony formation compared to wild-type in an anchorage-independence assay, which was counteracted by the treatment with AP24534 or BGJ398. Xenograft assays showed similar results with all transforming FGFR3 mutations leading to increased tumor growth compared to wild-type."	"Liao et al., 2013, Cancer Res."	Somatic	ENST00000340107.4	missense_variant
FGFR3 S249C	FGFR3	S249C	Transitional Cell Carcinoma	Cisplatin	Predictive	Supports	D	Resistance	chr4	1801841	1801841	C	G	"Bladder cancer cell line 97-7 expressing endogenous FGFR3 S249C (IC50 44.6ug/ml) was resistant to cisplatin compared to two FGFR3 wild-type cell lines, 5637 (IC50 2.07ug/ml) and T24 (IC50 1.58ug/ml) as shown by a CCK-8 colorimetric cytotoxicity. Western blot revealed the ratio of phosphorylated-Akt/total Akt was higher in the 97-7 cells than in the wild-type cells, which was reversed by siRNA knockdown of FGFR3. Inhibition of Akt signaling by treatment with GDC0068 or LY294002 increased the cisplatin sensitivity of 97-7 cells (IC50 4.17ug/ml & 8.91ug/ml respectively)."	"Xie et al., 2019, Exp Ther Med"	Somatic	ENST00000340107.4	missense_variant
FGFR3 S249C	FGFR3	S249C	Bladder Urothelial Carcinoma		Oncogenic	Supports	D	Oncogenicity	chr4	1801841	1801841	C	G	"In contrast to controls (empty vector and FGFR3 wildtype overexpression NIH-3T3 cell lines), the stable transfection of NIH-3T3 cells with FGFR3b-S249C led to ligand-independent phosphorylation of FGFR3 and the acquisition of elongated, refractile spindle-shaped morphology like transformed cells. Using a thymidine incorporation assay, S249C expressing cells were shown to lose contact inhibition and grew 3x to 4x more rapidly than controls. Soft agar assays demonstrated increased colony formation and anchorage independent growth in S249C expressing cells versus controls. All nude mice subcutaneously injected with S249C cells rapidly formed tumors, but no tumors were observed in empty vector injected mice. The authors conclude mutated FGFR3b-S249C has transforming properties attributed to oncogenes."	"Bernard-Pierrot et al., 2006, Carcinogenesis"	Somatic	ENST00000340107.4	missense_variant
FGFR3 S249C	FGFR3	S249C			Functional	Supports	D	Gain of Function	chr4	1801841	1801841	C	G	"Forster Resonance Energy Transfer (FRET)-based technique acquired quantitative measurement of the effect of S249C on unliganded mutant FGFR3 dimer stability and structure in plasma membrane vesicles from CHO cells. Dimer stability was modestly increased by S249C (-3.7 kcal/mol) versus wildtype FGFR3 (-3.4 kcal/mol). Intrinsic FRET demonstrated S249C dimers were significantly closer together (45 A) than the wildtype dimer (53 A). The substitution of cysteine was expected to lead to strong covalent bonds, but the authors conclude their data demonstrates S249C does not induce constitutive FGFR3 dimerization, but induces dimer structural modifications."	"Del Piccolo et al., 2015, Biophys J"	N/A	ENST00000340107.4	missense_variant
FGFR3 G370C	FGFR3	G370C	Cancer	R3Mab	Predictive	Does Not Support	D	Resistance	chr4	1804362	1804362	G	T	"Ba/F3 cells transfected with wild type FGFR3 or common bladder carcinoma variant FGFR3 G372C both resulted in IL-3 independence with FGF1 dependence for growth. Monoclonal antibody R3Mab treatment with FGF1 suppressed proliferation of Ba/F3 FGFR3 G372C cells. Wildtype FGFR3 overexpression in Ba/F3 cells as well as bladder cancer cell lines RT112 and RT4 (who both have normal levels of endogenously expressed wildtype FGFR3), were similarly sensitive to R3Mab treatment, therefore mutation G372C did not change that responsiveness."	"Qing et al., 2009, J. Clin. Invest."	Somatic	ENST00000440486.8	missense_variant
FGFR3 Y373C	FGFR3	Y373C	Bladder Carcinoma		Diagnostic	Supports	B	Positive	chr4	1804372	1804372	A	G	Y375C mutation results in activation of FGFR3 and is associated with bladder carcinoma. Patients with low-grade tumors were more likely to have FGFR3 mutations than those with high-grade tumors.	"Bodoor et al., 2010, Cancer Epidemiol"	Somatic	ENST00000440486.2	missense_variant
FGFR3 Y373C	FGFR3	Y373C	Urinary Bladder Cancer		Oncogenic	Supports	D	Oncogenicity	chr4	1804372	1804372	A	G	"The authors identified a bladder cancer cell line (MGH-U3) with a homozygous Y373C mutation. With immunoprecipitation (IP), and immunoblotting (IB) experiments, they demonstrated constitutional phosphorylation of FGFR3 Y373C protein. Then with SU5492 (an FGFR3 TKI) and FGFR3 siRNA, they also demonstrate that constitutional phosphorylation of the FGFR3 Y373C can be inhibited. Furthermore, cells treated with SU5492 (for inhibition) and FGFR3 siRNA (for depletion) of the mutant FGFR3 Y373C protein show inhibition of cell proliferation and anchorage independent growth. These studies suggest potentially oncogenic properties for the Y373C mutation."	"Bernard-Pierrot et al., 2006, Carcinogenesis"	Somatic	ENST00000440486.2	missense_variant
FGFR3 Y373C	FGFR3	Y373C	Cancer	R3Mab	Predictive	Does Not Support	D	Resistance	chr4	1804372	1804372	A	G	"Pro-B Ba/F3 cells transfected with wild type FGFR3 resulted in IL-3 independence with FGF1 dependence for growth. Cell transfected FGFR3 with mutation Y375C also resulted in IL-3 independence and FGF1 dependence. Monoclonal antibody R3Mab treatment along with FGF1 resulted in suppression of proliferation of Ba/F3 cells with FGFR3 Y375C. Wild type FGFR3 overexpression in Ba/F3 cells with FGF1 was sensitive to monoclonal antibody R3Mab treatment, and mutation Y375C did not change that responsiveness."	"Qing et al., 2009, J. Clin. Invest."	Somatic	ENST00000440486.2	missense_variant
FGFR3 G380R	FGFR3	G380R			Functional	Supports	D	Gain of Function	chr4	1804392	1804392	G	C	"Achondroplasia  associated FGFR3 mutant G380R (ACH), K650E (TDII), and wildtype (WT) FGFR3 constructs were cloned and transfected into NIH3T3 cells, and immunopercipitated with anti-FGFR3. In vitro kinase assays were performed and G380R was found to have activity between WT and K650E, which had approximately 100 fold increase over WT."	"Webster et al., 1996, Mol Cell Biol"	Unknown	ENST00000340107.4	missense_variant
FGFR3 A391E	FGFR3	A391E			Functional	Supports	D	Gain of Function	chr4	1804426	1804426	C	A	"FRET was used to compare the structural changes in FGFR dimers when FGF1 and FGF2 bind, and found that FGF2 bound dimers were much closer to each other than FGF1. The authors also looked at FGFR3 phosphorylation using western blot analysis and found that FGF2-bound dimers had increased FGFR3 phosphorylation. Therefore it was concluded that the FGF1 bound dimer is the inactive state, while the FGF2 bound dimer is the active state. Common bladder cancer and Crouzon syndrome with acanthosis nigricans variant FGFR3 A391E dimerization and phosphorylation were measured via FRET and western blot assays respectively. The A391E substitution was shown to activate FGFR3 through ligand-independent dimerization similar to the FGF2 bound state. Thus the authors concluded that the A391E mutation traps FGF3R in its most active state."	"Sarabipour et al., 2016, Nat Commun"	Somatic	ENST00000440486.8	missense_variant
FGFR3 V555M	FGFR3	V555M	Myeloid Neoplasm	"FGFR Inhibitor AZD4547,PD173074,AZ12908010"	Predictive	Supports	D	Resistance	chr4	1805767	1805767	G	A	"Preclinical study of FGFR Inhibitors AZ12908010, PD173074 and AZD4547 in cancer cell lines. Cell lines with aberrant FGFR signalling were more sensitive to FGFR Inhibition. Sequencing of a myeloma cell line KMS-11R with acquired resistance to FGFR inhibition revealed a FGFR3 V555M Mutation. These cells were cross-resistant to AZD4547 and PD173074."	"Chell et al., 2013, Oncogene"	Somatic	ENST00000440486.8	missense_variant
FGFR3 K650E	FGFR3	K650E	Cancer	R3Mab	Predictive	Does Not Support	D	Resistance	chr4	1806162	1806162	A	G	"Ba/F3 cells transfected with wildtype FGFR3 resulted in IL-3 independence with FGF1 dependence for growth, whereas cells transfected with common bladder carcinoma variant FGFR3 K652E resulted in IL-3 independence, weak ligand-independent proliferation and a strong growth response to FGF1. Monoclonal antibody R3Mab treatment with FGF1 suppressed proliferation of Ba/F3 FGFR3 K652E cells. Wildtype FGFR3 overexpression in Ba/F3 cells as well as bladder cancer cell lines RT112 and RT4 (who both have normal levels of endogenously expressed wildtype FGFR3), were similarly sensitive to R3Mab treatment, therefore mutation K652E did not change that responsiveness."	"Qing et al., 2009, J. Clin. Invest."	Somatic	ENST00000340107.4	missense_variant
FGFR3 K650Q	FGFR3	K650Q			Functional	Supports	D	Gain of Function	chr4	1806162	1806162	A	C	"A patient suffering from skeletal dysplasia was found to harbor a novel heterozygous K650Q variant in FGFR3. NIH3T3 cells were transfected with the variant construct followed by kinase activity assay that showed increased activity by 5 folds compared to the wild type. The authors suggest that this variant, although showed lower activation levels than other known variants responsible for severe skeletal dysplasia forms, is responsible for the milder skeletal dysplasia form seen in those patients (mild hypochondroplasia phenotype), and they further highlight the significance of Lys650 site in the active domain loop of the receptor."	"Bellus et al., 2000, Am J Hum Genet"	Somatic	ENST00000440486.8	missense_variant
FGFR3 K650D	FGFR3	K650D			Functional	Supports	D	Gain of Function	chr4	1806162	1806164	GAC	AAG	"NIH 3T3 cells were transfected with wild-type and mutant FGFR3 K650D. Immunoprecipitation measuring kinase activity showed FGFR3 K650D had similar autophosphorylation through constitutive action to FGFR3 K650E, which had 100-fold greater autophosphorylation than wildtype. The authors concluded that for constitutive FGFR3 activation, an acidic residue at position 650 is beneficial but not required."	"Webster et al., 1996, Mol Cell Biol"	Somatic	ENST00000440486.8	delins
FGFR3 K650Q	FGFR3	K650Q			Functional	Supports	D	Gain of Function	chr4	1806162	1806162	A	C	"NIH 3T3 cells were transfected with wild-type and mutant FGFR3 K650Q. Immunoprecipitation measuring kinase activity showed FGFR3 K650Q had much lower autophosphorylation to FGFR3 K650E, which had 100-fold greater autophosphorylation than wildtype, but that FGFR K650Q still had higher autophosphorylation driven by constitutive action than wildtype. The authors concluded that for constitutive FGFR3 activation, an acidic residue at position 650 is beneficial but not required."	"Webster et al., 1996, Mol Cell Biol"	Somatic	ENST00000440486.8	missense_variant
FGFR3 K650L	FGFR3	K650L			Functional	Supports	D	Gain of Function	chr4	1806162	1806163	AA	CT	"NIH 3T3 cells were transfected with wild-type and mutant FGFR3 K650L. Immunoprecipitation measuring kinase activity showed FGFR3 K650L had much lower autophosphorylation than FGFR3 K650E, which had 100-fold greater autophosphorylation than wildtype but had higher autophosphorylation driven by constitutive action than wildtype. The authors concluded that for constitutive FGFR3 activation, an acidic residue at position 650 is beneficial but not required."	"Webster et al., 1996, Mol Cell Biol"	Somatic	ENST00000440486.8	
FGFR3 K650E	FGFR3	K650E			Functional	Supports	D	Gain of Function	chr4	1806162	1806162	A	G	"A construct of PDGF and FGFR3 was created as a chimeric receptor to study the effect of the K650E variant on downstream signaling pathways. Transfecting PC12 cells showed continuous ligand-independent activity of the chimeric mutant receptor with the presence of an inducer alone (zinc) but not the ligand; PDFG. Upon addition of PDGF, further activation was also observed. Conversely, control cells showed activity only with the addition of both ligand and zinc. Gene expression profiling showed P21 gene was expressed at a higher level (1.7 folds) in mutant receptor cells, providing evidence of ERK1/2 and STAT1/3 activation. The mutant receptor produced a highly sustained ERK1/2 activation even after 1 hour of PDGF treatment, whereas wild-type expressing cells showed a decrease in ERK1/2 activity. Lastly, cells only expressing the variant K650E receptor were able to phosphorylate tyrosine in STAT1, and tyrosine, along with serine, in a ligand-independent manner in STAT3. Authors confirm that mutant FGFR3 activates ERK1/2 and STAT1/3 in a ligand-independent manner and maintains this activation over longer periods of time when treated with ligand than does the wild-type receptor."	"Nowroozi et al., 2005, Hum Mol Genet"	N/A	ENST00000340107.4	missense_variant
FGFR3 K650M	FGFR3	K650M			Functional	Supports	D	Gain of Function	chr4	1806163	1806163	A	T	The K650M variant in FGFR3 is known to be responsible for the severe skeletal dysplasia forms seen in TDI/SADDAN. The mutant receptor was tested for comparison between other variants discussed in this paper. FGFR3 cDNA construct with the K650M variant was synthesized and transfected into NIH3T3 cells. The K650M variant receptor had 18- fold greater kinase activity compared to the wild type receptor.	"Bellus et al., 2000, Am J Hum Genet"	N/A	ENST00000440486.8	missense_variant
FGFR3 K650N	FGFR3	K650N			Functional	Supports	D	Gain of Function	chr4	1806164	1806164	G	C	"Five patients from four families suffering from skeletal dysplasia were found to harbor a novel heterozygous K650N variant in FGFR3. The variant cosegregated in two patients from one family (a father and his daughter), whereas it occurred sporadically in the others. NIH3T3 cells were transfected with the variant construct followed by kinase activity assay that showed increased activity by ~ 4 folds compared to the wild type. The authors suggest that this variant, although showing lower activation levels than other known variants responsible for severe skeletal dysplasia forms, is responsible for the milder skeletal dysplasia form seen in those patients (mild hypochondroplasia phenotype), and they further highlight the significance of Lys650 site in the active domain loop of the receptor."	"Bellus et al., 2000, Am J Hum Genet"	N/A	ENST00000440486.8	missense_variant
PROM1 EXPRESSION	PROM1	EXPRESSION	Hepatocellular Carcinoma	Sorafenib	Predictive	Supports	B	Resistance	chr4	15968234	16083701			"CD133 (PROM1) expression in 39 samples of hepatocellular carcinomas was correlated with JNK activity. Both were more highly expressed in patients not responding to sorafenib. CD133+ cells (sorted) were xenografted into mice, producing larger, more JNK inhibitor responsive tumors than CD133- xenografts."	"Hagiwara et al., 2012, Br. J. Cancer"	N/A	ENST00000510224.1	N/A
MIR218-1 EXPRESSION	MIR218-1	EXPRESSION	Colorectal Cancer		Prognostic	Supports	B	Better Outcome	chr4	20528275	20528384			"Researchers examined the prognostic role of miR-218 expression in CRC tumor samples when receiving 5-FU based treatment. CRC samples from patients who received first-line 5-FU-based adjuvant chemotherapy were stratified into two groups (complete/partial response and stable/progressive disease) based on RECIST criteria. miR-218 expression levels were found to be significantly higher in the complete/partial response group.  Further Kaplan-Meier survival analysis revealed that in groups with higher miR-218 expression, overall survival was significantly greater."	"Li et al., 2015, Carcinogenesis"	N/A	ENST00000384999.1	N/A
MIR218-1 EXPRESSION	MIR218-1	EXPRESSION	Colorectal Cancer		Prognostic	Supports	B	Better Outcome	chr4	20528275	20528384			"Researchers examined the overall and progression free survival of CRC patients receiving first line 5-Fluorouracil therapy.  Samples were stratified into two groups (low/high expressing miR-218). Kaplan-Meier survival analysis revealed that in groups with higher miR-218 expression, overall survival was significantly greater."	"Li et al., 2015, Carcinogenesis"	N/A	ENST00000384999.1	N/A
MIR218-1 UNDEREXPRESSION	MIR218-1	UNDEREXPRESSION	Pancreatic Cancer		Prognostic	Supports	D	Poor Outcome	chr4	20528275	20528384			"The study found mir-218 was significantly under-expressed when compared to matched adjacent normal tissue in 107 samples via qPCR. Further, low expression of mir-218 was revealed to be associated with lower overall survival (p < .001), and multivariate analysis revealed that low expression of mir-218 as an independent predictor of poor prognosis (p < .007)."	"Li et al., 2015, Genet. Mol. Res."	Somatic	ENST00000384999.1	N/A
PDGFRA FIP1L1::PDGFRA	PDGFRA	FIP1L1::PDGFRA	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	Imatinib	Predictive	Supports	B	Sensitivity/Response	chr4	53377645	53428183			A cohort of seven male patients with myeloproliferative hypereosinophilic syndrome and elevated serum tryptase levels were enrolled in a study of imatinib mesylate therapy. All seven patients demonstrated improvement in clinical symptoms and resolution of laboratory abnormalities and bone marrow pathology in response to treatment. Complete molecular remission of FIP1L1-PDGFRA was observed in 5 of 6 patients tested post-therapy.	"Klion et al., 2004, Blood"	Somatic	ENST00000337488.6	transcript_fusion
PDGFRA FIP1L1::PDGFRA	PDGFRA	FIP1L1::PDGFRA	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	Imatinib	Predictive	Supports	A	Sensitivity/Response	chr4	53377645	53428183			"Of eleven patients prospectively accrued with hypereosinophilic syndrome, nine had favorable responses to imatinib that lasted >3 months post-treatment. Of these nine patients, five were found to have a FIP1L1-PDGFRA fusion."	"Cools et al., 2003, N. Engl. J. Med."	Somatic	ENST00000337488.6	transcript_fusion
PDGFRA FIP1L1::PDGFRA	PDGFRA	FIP1L1::PDGFRA	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	Imatinib	Predictive	Supports	C	Sensitivity/Response	chr4	53377645	53428183			"A patient with monoblastic myeloid sarcoma harbouring a PCR confirmed FIP1L1-PDGFRA rearrangement was treated with imatinib monotherapy. The patient demonstrated a durable response (10 wks) while on therapy which was reversed when the patient discontinued treatment. Imatinib therapy was subsequently restarted, with peripheral blood and BM analyses returning to normal after 4 weeks."	"Srinivas et al., 2014, Br. J. Haematol."	Somatic	ENST00000337488.6	transcript_fusion
PDGFRA FIP1L1::PDGFRA	PDGFRA	FIP1L1::PDGFRA	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	Ponatinib	Predictive	Supports	D	Sensitivity/Response	chr4	53377645	53428183			"In a FIP1L1-PDGFRA positive eosinophil cell line growth-inhibitory effects were seen with all PDGFR-blocking agents, (ponatinib, sorafenib, masitinib, nilotinib, dasatinib, sunitinib, midostaurin) with ponatinib found to be the most potent compound."	"Sadovnik et al., 2014, Exp. Hematol."	Somatic	ENST00000337488.6	transcript_fusion
PDGFRA FIP1L1::PDGFRA	PDGFRA	FIP1L1::PDGFRA	Acute Myeloid Leukemia	"Sorafenib,Sunitinib"	Predictive	Supports	D	Sensitivity/Response	chr4	53377645	53428183			"In a preclinical trial, the AML cell line EOL1with the FIP1L1-PDGFRa fusion mutation was treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was similarly effective in the growth inhibition of cells harboring the fusion mutation (IC50=0.5 nmol/L) compared to sorafenib (IC50=0.5 nmol/L) and sunitinib (IC50=3 nmol/L)."	"Gozgit et al., 2011, Mol. Cancer Ther."	Somatic	ENST00000337488.6	transcript_fusion
PDGFRA Amplification	PDGFRA	Amplification	Lung Non-small Cell Carcinoma	Sunitinib	Predictive	Supports	D	Sensitivity/Response	chr4	54229097	54298247			"In a high-throughput cell line screen of 637 cell lines, only 2 sunitinib sensitive cell lines were identified. In the sunitinib-sensitive adenosquamous NSCLC cell line (NCI-H1703), PDGFRA expression was associated with focal PDGFRA gene amplification. This alteration was detected in a small fraction of primary squamous cell NSCLC tumor specimens. Focal amplification of PDGFC, the gene encoding the PDGFR ligand, was also detected."	"McDermott et al., 2009, Cancer Res."	Somatic	ENST00000257290.5	transcript_amplification
PDGFRA FIP1L1::PDGFRA	PDGFRA	FIP1L1::PDGFRA	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	Imatinib	Predictive	Supports	B	Sensitivity/Response	chr4	54274841	54298247			A cohort of seven male patients with myeloproliferative hypereosinophilic syndrome and elevated serum tryptase levels were enrolled in a study of imatinib mesylate therapy. All seven patients demonstrated improvement in clinical symptoms and resolution of laboratory abnormalities and bone marrow pathology in response to treatment. Complete molecular remission of FIP1L1-PDGFRA was observed in 5 of 6 patients tested post-therapy.	"Klion et al., 2004, Blood"	Somatic	ENST00000337488.6	transcript_fusion
PDGFRA FIP1L1::PDGFRA	PDGFRA	FIP1L1::PDGFRA	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	Imatinib	Predictive	Supports	A	Sensitivity/Response	chr4	54274841	54298247			"Of eleven patients prospectively accrued with hypereosinophilic syndrome, nine had favorable responses to imatinib that lasted >3 months post-treatment. Of these nine patients, five were found to have a FIP1L1-PDGFRA fusion."	"Cools et al., 2003, N. Engl. J. Med."	Somatic	ENST00000337488.6	transcript_fusion
PDGFRA FIP1L1::PDGFRA	PDGFRA	FIP1L1::PDGFRA	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	Imatinib	Predictive	Supports	C	Sensitivity/Response	chr4	54274841	54298247			"A patient with monoblastic myeloid sarcoma harbouring a PCR confirmed FIP1L1-PDGFRA rearrangement was treated with imatinib monotherapy. The patient demonstrated a durable response (10 wks) while on therapy which was reversed when the patient discontinued treatment. Imatinib therapy was subsequently restarted, with peripheral blood and BM analyses returning to normal after 4 weeks."	"Srinivas et al., 2014, Br. J. Haematol."	Somatic	ENST00000337488.6	transcript_fusion
PDGFRA FIP1L1::PDGFRA	PDGFRA	FIP1L1::PDGFRA	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	Ponatinib	Predictive	Supports	D	Sensitivity/Response	chr4	54274841	54298247			"In a FIP1L1-PDGFRA positive eosinophil cell line growth-inhibitory effects were seen with all PDGFR-blocking agents, (ponatinib, sorafenib, masitinib, nilotinib, dasatinib, sunitinib, midostaurin) with ponatinib found to be the most potent compound."	"Sadovnik et al., 2014, Exp. Hematol."	Somatic	ENST00000337488.6	transcript_fusion
PDGFRA TNKS2::PDGFRA	PDGFRA	TNKS2::PDGFRA	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	Imatinib	Predictive	Supports	C	Sensitivity/Response	chr4	54274841	54298247			A patient harbouring a novel TNKS2PDGFRA fusion in a myeloid neoplasm with eosinophilia demonstrated a dramatic and durable response upon treatment with Imatinib mono therapy.	"Chalmers et al., 2015, Blood Cancer J"	Somatic	ENST00000371627.4	transcript_fusion
PDGFRA FIP1L1::PDGFRA	PDGFRA	FIP1L1::PDGFRA	Acute Myeloid Leukemia	"Sorafenib,Sunitinib"	Predictive	Supports	D	Sensitivity/Response	chr4	54274841	54298247			"In a preclinical trial, the AML cell line EOL1with the FIP1L1-PDGFRa fusion mutation was treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was similarly effective in the growth inhibition of cells harboring the fusion mutation (IC50=0.5 nmol/L) compared to sorafenib (IC50=0.5 nmol/L) and sunitinib (IC50=3 nmol/L)."	"Gozgit et al., 2011, Mol. Cancer Ther."	Somatic	ENST00000337488.6	transcript_fusion
PDGFRA V561A	PDGFRA	V561A	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	D	Sensitivity/Response	chr4	54274869	54274869	T	C	"293T cells stably transduced with PDGFRA V561A showed constitutive tyrosine phosphorylation in the absense of ligand; however, when treated with imatinib, this phosphorylation was inhibited similarly to that of wildtype PDGFRA, consistent with sensitivity to this inhibitor."	"Hirota et al., 2003, Gastroenterology"	Somatic	ENST00000257290.5	missense_variant
PDGFRA V561D	PDGFRA	V561D	Cancer	Imatinib	Predictive	Does Not Support	D	Resistance	chr4	54274869	54274869	T	A	"In an in vitro study of imatinib sensitivity, PDGFRA V561D was cloned into a plasmid by site-directed mutagenesis of PDGFRA WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. The cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of PDGFRA activation. Cells expressing PDGFRA V561D were as sensitive to imatinib as ligand activated wildtype PDGFRA (IC50: 100-200 nmol/L)."	"Heinrich et al., 2003, J. Clin. Oncol."	Somatic	ENST00000257290.5	missense_variant
PDGFRA V561D	PDGFRA	V561D	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	C	Sensitivity/Response	chr4	54274869	54274869	T	A	"This case study examines one patient from a larger cohort of 397 patients with incurable (i.e. metastatic or unresectable) CD117-positive Gastrointestinal stromal tumors (GISTs) enrolled in the North American phase III study SWOG S0033/CALGB 150105. Patients in this cohort were treated with either 400mg or 800mg of imatinib per day. This patient's GIST harbored PDGFRA exon 12 V561D. The patient was treated with 800mg of imatinib per day, and had not progressed or died as of 31 months of follow up (vs median TTP of 12.8 months for WT)."	"Heinrich et al., 2008, J. Clin. Oncol."	Somatic	ENST00000257290.5	missense_variant
PDGFRA V561D	PDGFRA	V561D	Cancer	Sunitinib	Predictive	Does Not Support	D	Resistance	chr4	54274869	54274869	T	A	"In an in vitro study, Chinese hamster ovary cells expressing PDGFRA V561D mutation demonstrated sensitivity to sunitinib treatment (IC50<100), though this sensitivity was indistinguishable from Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation."	"Heinrich et al., 2008, J. Clin. Oncol."	Somatic	ENST00000257290.5	missense_variant
PDGFRA V561D	PDGFRA	V561D	Cancer	Imatinib Mesylate	Predictive	Does Not Support	D	Resistance	chr4	54274869	54274869	T	A	"In an in vitro study, Chinese hamster ovary cells expressing PDGFRA V561D mutation demonstrated sensitivity to imatinib treatment (IC50<100), though this sensitivity was indistinguishable from Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation."	"Heinrich et al., 2008, J. Clin. Oncol."	Somatic	ENST00000257290.5	missense_variant
PDGFRA P577S	PDGFRA	P577S	Melanoma	"Imatinib,Crenolanib"	Predictive	Supports	D	Sensitivity/Response	chr4	54274916	54274916	C	T	"PDGFRA mutations (exon 12, 14, 18) were assessed in 351 melanoma patient samples. 18 different mutations were detected in 4,6% of samples (all without chronic sun-induced damage and mainly in acral and mucosal melanoma, mutually exclusive with KIT). 12 novel missense mutations were tested for functional significance (western blot of autophosphorylation in transduced 293T cell line). Five PDGFRA Mutations (P577S, V658A, R841K, H845Y, and G853D)  resulted in strong autophosphorylation of PDGFRA. Crenolanib showed higher potency than imatinib in inhibiting the kinase activity of PDGFRA. Except for the  imatinib-resistant V658A mutation, all the other mutations were sensitive to both imatinib and crenolanib."	"Dai et al., 2013, Clin. Cancer Res."	Somatic	ENST00000257290.5	missense_variant
PDGFRA FIP1L1::PDGFRA T674I	PDGFRA	FIP1L1::PDGFRA T674I	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	Imatinib	Predictive	Supports	C	Resistance	chr4	54278380	54278380	C	T	"A patient treated with imatinib for a FIP1L1-PDGFRA mutation relapsed during treatment. A T674I mutation in the PDGFRA split kinase domain was hypothesized to confer resistance, due to the strong evidence of this fusion in driving myeloproliferative hypereosinophilic syndrome and the contextual similarity to T315I mutations in BCR-ABL."	"Cools et al., 2003, N. Engl. J. Med."	Somatic	ENST00000257290.5	"missense_variant,transcript_fusion"
PDGFRA FIP1L1::PDGFRA T674I	PDGFRA	FIP1L1::PDGFRA T674I	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	Ponatinib	Predictive	Supports	D	Sensitivity/Response	chr4	54278380	54278380	C	T	"Ba/F3 cells expressing two clinically relevant, imatinib-resistant, mutant forms of FIP1L1-PDGFRA, namely T674I and D842V were tested for growth inhibition by 8 PDGFR-blocking TKIs. Strong inhibitory effects on both mutants were seen only with ponatinib."	"Sadovnik et al., 2014, Exp. Hematol."	Somatic	ENST00000257290.5	"missense_variant,transcript_fusion"
PDGFRA FIP1L1::PDGFRA T674I	PDGFRA	FIP1L1::PDGFRA T674I	"Myeloid And Lymphoid Neoplasms With Eosinophilia And Abnormalities Of PDGFRA, PDGFRB, And FGFR1"	Imatinib	Predictive	Supports	C	Resistance	chr4	54278380	54278380	C	T	"One patient with FIP1L1/PDGFRA-positive CEL was identified as developing secondary resistance to imatinib. A PDGFRA T674I mutation was identified in the tyrosine kinase domain. Salvage therapy with nilotinib and sorafenib each failed in this patient, who was eventually transplanted with an HLA-matched sibling donor."	"Metzgeroth et al., 2012, Leukemia"	Somatic	ENST00000257290.5	"missense_variant,transcript_fusion"
PDGFRA R841K	PDGFRA	R841K	Melanoma	"Imatinib,Crenolanib"	Predictive	Supports	D	Sensitivity/Response	chr4	54285923	54285923	G	A	"PDGFRA mutations (exon 12, 14, 18) were assessed in 351 melanoma patient samples. 18 different mutations were detected in 4.6% of samples (all without chronic sun-induced damage and mainly in acral and mucosal melanoma, mutually exclusive with KIT). 12 novel missense mutations were tested for functional significance (western blot of autophosphorylation in transduced 293T cell line). PDGFRA R841K was detected in one sample of mucosal melanoma. In vitro, PDGFRA R841K expressed in IL-3 dependent Ba/F3 cells resulted in strong auto-phosphorylation and cell growth of PDGFRA independent of the presence of IL-3, suggesting oncogenicity. Crenolanib showed higher potency than imatinib in inhibiting the kinase activity of PDGFRA and cell proliferation. The authors concluded that PDGFRA R841K is sensitive to imatinib and crenolanib."	"Dai et al., 2013, Clin. Cancer Res."	Somatic	ENST00000257290.5	missense_variant
PDGFRA D842I	PDGFRA	D842I	Gastrointestinal Stromal Tumor	Crenolanib	Predictive	Supports	D	Sensitivity/Response	chr4	54285925	54285926	GA	AT	"In CHO cells with PDGFRA D842I mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib."	"Heinrich et al., 2012, Clin. Cancer Res."	Somatic	ENST00000257290.5	missense_variant
PDGFRA D842Y	PDGFRA	D842Y	Gastrointestinal Stromal Tumor	Crenolanib	Predictive	Supports	D	Sensitivity/Response	chr4	54285925	54285925	G	T	"In CHO cells with PDGFRA D842Y mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib."	"Heinrich et al., 2012, Clin. Cancer Res."	Somatic	ENST00000257290.5	missense_variant
PDGFRA D842V	PDGFRA	D842V	Gastrointestinal Stromal Tumor		Diagnostic	Supports	B	Negative	chr4	54285926	54285926	A	T	GIST tumors harboring PDGFRA D842V mutation are more likely to be benign than malignant.	"Lasota et al., 2004, Lab. Invest."	Somatic	ENST00000257290.5	missense_variant
PDGFRA D842V	PDGFRA	D842V	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	B	Resistance	chr4	54285926	54285926	A	T	GIST cancer with D842V mutation is resistant to imatinib.	"Corless et al., 2005, J. Clin. Oncol."	Somatic	ENST00000257290.5	missense_variant
PDGFRA D842V	PDGFRA	D842V	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	B	Resistance	chr4	54285926	54285926	A	T	"While cancer with PDGFRA V561D mutation is known to be sensitive to Imatinib, double mutation of V561D and D842V mutants are resistant to imatinib."	"Heinrich et al., 2006, J. Clin. Oncol."	Somatic	ENST00000257290.5	missense_variant
PDGFRA D842V	PDGFRA	D842V	Gastrointestinal Stromal Tumor	Crenolanib	Predictive	Supports	D	Sensitivity/Response	chr4	54285926	54285926	A	T	"In CHO cells with PDGFRA D842V mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib."	"Heinrich et al., 2012, Clin. Cancer Res."	Somatic	ENST00000257290.5	missense_variant
PDGFRA D842_I843delinsVM	PDGFRA	D842_I843delinsVM	Gastrointestinal Stromal Tumor	Crenolanib	Predictive	Supports	D	Sensitivity/Response	chr4	54285926	54285930	ACATC	TCATG	"In CHO cells with PDGFRA DI842-843VM mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib."	"Heinrich et al., 2012, Clin. Cancer Res."	Somatic	ENST00000257290.5	missense_variant
PDGFRA D842V	PDGFRA	D842V	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	D	Resistance	chr4	54285926	54285926	A	T	"When 293T cells stably transduced with PDGFRA A842V were treated with imatinib, tyrosine phosphorylation was maintained at 1 and 10umol/L concentrations that inhibited phosphorylation of wildtype PDGFRA, consistent with resistance to this inhibitor."	"Hirota et al., 2003, Gastroenterology"	Somatic	ENST00000257290.5	missense_variant
PDGFRA D842V	PDGFRA	D842V	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	B	Resistance	chr4	54285926	54285926	A	T	"823 patients with GIST under therapy with imatinib were genotyped for this study. 18 patients (2%) with PDGFRA mutations were identified. In D842V-mutant GISTs, PFS (median 3.8 months) and OS (median 25.2 months) were significantly poorer than Non-D842V mutated (PFS median 29.5 months OS median 59.8 months)."	"Yoo et al., 2016, Cancer Res Treat"	Somatic	ENST00000257290.5	missense_variant
PDGFRA D842V	PDGFRA	D842V	Cancer	Imatinib	Predictive	Supports	D	Resistance	chr4	54285926	54285926	A	T	"In an in vitro study of imatinib sensitivity, PDGFRA D842V was cloned into a plasmid by site-directed mutagenesis of PDGFRA WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. The cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of PDGFRA activation. Cells expressing PDGFRA D842V required 10-20 fold higher concentrations of imatinib as ligand activated wildtype PDGFRA (IC50: 1-2 umol/L)."	"Heinrich et al., 2003, J. Clin. Oncol."	Somatic	ENST00000257290.5	missense_variant
PDGFRA D842V	PDGFRA	D842V	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	C	Resistance	chr4	54285926	54285926	A	T	This prospective study of 127 patients with metastatic gastrointestinal stromal tumors (GISTs) examined the relationship between kinase (KIT and PDGFRA) genotype and treatment outcome for patients enrolled in a randomized phase II trial of imatinib (CSTI571B 2222). Three patients' GISTs harbored PDGFRA D842V. Two of these patients experienced progressive disease and one was unassessable. The authors conclude that this finding is consistent with the work of others suggesting that PDGFRA D842V is an imatinib resistant variant in GIST.	"Heinrich et al., 2003, J. Clin. Oncol."	Somatic	ENST00000257290.5	missense_variant
PDGFRA D842V	PDGFRA	D842V	Cancer	Sunitinib	Predictive	Supports	D	Resistance	chr4	54285926	54285926	A	T	"In an in vitro study, Chinese hamster ovary cells expressing PDGFRA D842V mutation demonstrated reduced sensitivity to sunitinib treatment (IC50>1000 vs. IC50<100), compared to Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation."	"Heinrich et al., 2008, J. Clin. Oncol."	Somatic	ENST00000257290.5	missense_variant
PDGFRA D842V	PDGFRA	D842V	Gastrointestinal Stromal Tumor	Sunitinib	Predictive	Supports	C	Resistance	chr4	54285926	54285926	A	T	"Patients 29 and 66 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) PDGFRA D842V mutation. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. Patients took 50 mg sunitib per day. Patient 29 was on a treatment schedule of two weeks on/two weeks off, and patient 66 was scheduled for four weeks on/two weeks off.  Patient 29 experienced stable disease for less than 6 months and patient 66 experienced disease progression. Time to progression was censored at 0.1 weeks for patient 29 and was 10 weeks for patient 66. Overall survival was 99 and censored at 129 weeks for patients 29 and 66."	"Heinrich et al., 2008, J. Clin. Oncol."	Somatic	ENST00000257290.5	missense_variant
PDGFRA D842V	PDGFRA	D842V	Cancer	Imatinib Mesylate	Predictive	Supports	D	Resistance	chr4	54285926	54285926	A	T	"In an in vitro study, Chinese hamster ovary cells expressing PDGFRA D842V mutation demonstrated reduced sensitivity to imatinib treatment (IC50=2,500 vs. IC50<100), compared to Chinese hamster ovary cells expressing wild-type PDGFRA. Sensitivity was determined by assessing PDGFRA auto-phosphorylation."	"Heinrich et al., 2008, J. Clin. Oncol."	Somatic	ENST00000257290.5	missense_variant
PDGFRA I843DEL	PDGFRA	I843DEL	Gastrointestinal Stromal Tumor	Crenolanib	Predictive	Supports	D	Sensitivity/Response	chr4	54285928	54285930	ATC		"In CHO cells with the PDGFRA deletion I843 mutation that have shown imatinib sensitivity, crenolanib showed no significant difference from imatinib in kinase activity inhibition."	"Heinrich et al., 2012, Clin. Cancer Res."	Somatic	ENST00000257290.5	inframe_deletion
PDGFRA I843DEL	PDGFRA	I843DEL	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	D	Sensitivity/Response	chr4	54285928	54285930	ATC		15/127 patients with KIT-WT metastatic gastrointestinal stromal tumors were tested for PDGFRA mutations. 6 GISTs harbored PDGFRA mutations. 1 patient had a deletion of I843. CHO cells expressing this variant showed similar sensitivity to imatinib as cells expressing wildtype PDGFRA. 2/3 patients with a mutation determined to be sensitive in vitro achieved partial response on imatinib treatment. It is not noted whether the patient whose GISTs harbored I843del had partial response or progressive disease.	"Heinrich et al., 2003, J. Clin. Oncol."	Somatic	ENST00000257290.5	inframe_deletion
PDGFRA H845Y	PDGFRA	H845Y	Melanoma	"Imatinib,Crenolanib"	Predictive	Supports	D	Sensitivity/Response	chr4	54285934	54285934	C	T	"PDGFRA mutations (exon 12, 14, 18) were assessed in 351 melanoma patient samples. 18 different mutations were detected in 4,6% of samples (all without chronic sun-induced damage and mainly in acral and mucosal melanoma, mutually exclusive with KIT). 12 novel missense mutations were tested for functional significance (western blot of autophosphorylation in transduced 293T cell line). Five PDGFRA Mutations (P577S, V658A, R841K, H845Y, and G853D) resulted in strong autophosphorylation of PDGFRA. Crenolanib showed higher potency than imatinib in inhibiting the kinase activity of PDGFRA. Except for the imatinib-resistant V658A mutation, all the other mutations were sensitive to both imatinib and crenolanib."	"Dai et al., 2013, Clin. Cancer Res."	Somatic	ENST00000257290.5	missense_variant
PDGFRA G853D	PDGFRA	G853D	Melanoma	"Crenolanib,Imatinib"	Predictive	Supports	D	Sensitivity/Response	chr4	54285959	54285959	G	A	"PDGFRA mutations (exon 12, 14, 18) were assessed in 351 melanoma patient samples. 18 different mutations were detected in 4,6% of samples (all without chronic sun-induced damage and mainly in acral and mucosal melanoma, mutually exclusive with KIT). 12 novel missense mutations were tested for functional significance (western blot of autophosphorylation in transduced 293T cell line). Five PDGFRA Mutations (P577S, V658A, R841K, H845Y, and G853D) resulted in strong autophosphorylation of PDGFRA. Crenolanib showed higher potency than imatinib in inhibiting the kinase activity of PDGFRA. Except for the imatinib-resistant V658A mutation, all the other mutations were sensitive to both imatinib and crenolanib."	"Dai et al., 2013, Clin. Cancer Res."	Somatic	ENST00000257290.5	missense_variant
KIT Mutation	KIT	Mutation	Gastrointestinal Stromal Tumor	"Imatinib,Pictilisib"	Predictive	Supports	D	Sensitivity/Response	chr4	54657918	54740715			"Human GISTs with different KIT mutations were grafted in 136 nude muce. Mice were then treated with control, imatinib, GDC-0941, or GDC-0941 + imatinib. The combination showed superior antitumor efficacy that was sustained after treatment withdrawal."	"Floris et al., 2013, Clin. Cancer Res."	Somatic	ENST00000288135.5	transcript_variant
KIT EXPRESSION	KIT	EXPRESSION	Endometrial Cancer	Imatinib	Predictive	Supports	C	Sensitivity/Response	chr4	54657918	54740715			Case Report of a 42-year old patient with low-grade endometrial stromal sarcoma. IHC was focally positive for CD117. Imatinib mesylate led to complete metabolic response (PET-CT).	"Kalender et al., 2009, Cancer Chemother. Pharmacol."	N/A	ENST00000288135.5	N/A
KIT EXPRESSION	KIT	EXPRESSION	Endometrial Cancer	Imatinib	Predictive	Supports	C	Sensitivity/Response	chr4	54657918	54740715			Case Report of a 41-year old patient with high-grade stromal endometrial sarcoma and a large abdominal and retroperitoneal mass progressing after chemotherapy. IHC for c-Kit was positive and treatment with imatinib led to an objective Response. Surgery was performed and the patient was free of disease two years later.	"Salvatierra et al., 2006, Gynecol. Oncol."	N/A	ENST00000288135.5	N/A
KIT Mutation	KIT	Mutation	Melanoma	Imatinib	Predictive	Supports	B	Sensitivity/Response	chr4	54657918	54740715			"In a phase II clinical trial of 43 melanoma patients harboring KIT mutations or amplifications, imatinib treatment exhibited significant anti-tumor activity with a median progression free survival of 3.5 months, tumor regression in 41.9% of patients, and a 1-year overall survival rate of 51%. 9/10 partial responses were in patients with exon 11 or 13 KIT mutations."	"Guo et al., 2011, J. Clin. Oncol."	Somatic	ENST00000288135.5	transcript_variant
KIT Amplification	KIT	Amplification	Mucosal Melanoma	Imatinib	Predictive	Supports	B	Resistance	chr4	54657918	54740715			"Phase 2 trial in metastatic mucosal, acral or chronically sun-damaged melanoma. Twenty-five patients were enrolled (24 evaluable). Eight patients (33%) had tumors with KIT mutations, 11 (46%) with KIT amplifications, and five (21%) with both. Median follow-up was 10.6 months. Best overall response rate was statistically significantly different by mutation status: 7 of 13 or 54% KIT mutated v 0% KIT amplified only."	"Hodi et al., 2013, J. Clin. Oncol."	N/A	ENST00000288135.5	transcript_amplification
KIT EXPRESSION	KIT	EXPRESSION	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	B	Sensitivity/Response	chr4	54657918	54740715			"In a prospective phase III study (SWOG S0033/CALGB 150105) of 407 patients with gastrointestinal stromal tumors (GISTs), 397 patients were observed to be CD117-positive (i.e. KIT-positive) and 10 patients were CD117-negative. Patients were treated with either 400mg or 800mg of imatinib per day. When compared to CD117-positive, GISTs, CD117-negative GISTs did not show significant difference in median time to progression (18.3 months vs. 20.5 months; P = 0.46), however, CD-117-negative GISTs showed reduced overall survival relative to CD-117-positive GISTs (25.8 months vs. 57.1 months; P= 0.01)."	"Heinrich et al., 2008, J. Clin. Oncol."	Somatic	ENST00000288135.5	N/A
KIT WILDTYPE	KIT	WILDTYPE	Gastrointestinal Stromal Tumor	Regorafenib	Predictive	Supports	B	Sensitivity/Response	chr4	54657918	54740715			"This phase II clinical trial of regorafenib (NCT01068769) examined the long term safety and efficacy of regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) who failed previous treatments with imatinib. Patients whose GISTs were wildtype for KIT and PDGFR and who were succinate dehydrogenase (SDH) deficient (n=6) experienced higher rates of clinical benefit (defined as complete response, partial response, or stable disease lasting >16 weeks) than patients whose GISTs were wildtype for KIT and PDGFR but were not SDH deficient (n=2). 6/6 patients with SDH deficient GISTs had clinical benefit (including 2 PRs), and their median PFS was 10 months vs 1.6 months for patients with non-SDH deficient GISTs."	"Ben-Ami et al., 2016, Ann. Oncol."	Somatic	ENST00000288135.5	wild_type
KIT EXPRESSION	KIT	EXPRESSION	Glioblastoma	Sunitinib	Predictive	Supports	B	Sensitivity/Response	chr4	54657918	54740715			"Phase II trial of sunitinib in 40 patients with first recurrence of primary glioblastoma. Median PFS 2.2 mo, median OS 9.2 mo, 5 stable disease >=6 months, no objective responses, so primary study endpoint was not met. However, IHC of multiple receptor kinases was performed, and protein expression of KIT in vascular endothelial cells was associated with longer PFS (P = .017; HR, 2.564; 95% CI, 1.180?.570). All 5 with stable disease were KIT+ in vascular endothelial cells. Note KIT staining was not observed in tumour cells. No association with OS."	"Hutterer et al., 2014, Neuro Oncol"	Somatic	ENST00000288135.5	N/A
KIT Exon 9 Mutation	KIT	Exon 9 Mutation	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	A	Sensitivity/Response	chr4	54725857	54726050			"In a phase III clinical trial comparing different doses of imatinib in GIST patients, KIT exon 9 mutations were associated with significantly improved progression free survival (P=0.0013) and a 61% relative risk reduction in response to the higher dose regimen (N=31; 800mg/daily) when compared to the lower dose regimen (N=27; 400 mg/daily; HR 0.329; 95% CI 0.218?.706). The same dose dependent responses were not observed with KIT exon 11 mutations (N=130 vs 118; P=0.25; HR 0.821; 95% CI 0.585?.151) or with wild-type KIT (N=25 vs 27; P=0.07; HR 1.823; 95% CI 0.938?.543)."	"Debiec-Rychter et al., 2006, Eur. J. Cancer"	Somatic	ENST00000288135.5	exon_variant
KIT Exon 9 Mutation	KIT	Exon 9 Mutation	Gastrointestinal Stromal Tumor	Sunitinib	Predictive	Supports	B	Sensitivity/Response	chr4	54725857	54726050			"Primary tumor genotyping of 89 patients with metastatic GIST given 2nd-line sunitinib treatment after prior imatinib therapy failure, revealed an improved response to sunitinib in patients with KIT exon 9 mutations or with wild-type KIT compared those with KIT exon 11 or PDGFRA mutations. 1-year progression free survival rates for exon 9 mutants and wild type were 68% and 57%, compared with 34% and 15% for exon 11 and PDGFRA mutants."	"Rutkowski et al., 2012, BMC Cancer"	Somatic	ENST00000288135.5	exon_variant
KIT Exon 9 Mutation	KIT	Exon 9 Mutation	Gastrointestinal Stromal Tumor	Sunitinib	Predictive	Supports	B	Sensitivity/Response	chr4	54725857	54726050			"In a study of 78 patients with gastrointestinal stromal tumors treated with sunitinib, patients with Kit exon 9 mutations or wildtype (lacking KIT or PDGFRA mutations) showed increased progression free survival and overall survival compared to patients with Kit exon 11 mutations."	"Heinrich et al., 2008, J. Clin. Oncol."	Somatic	ENST00000288135.5	exon_variant
KIT Exon 9 Mutation	KIT	Exon 9 Mutation	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	B	Sensitivity/Response	chr4	54725857	54726050			"This prospective study of 127 patients with metastatic gastrointestinal stromal tumors (GISTs) examined the relationship between KIT genotype and treatment outcome for patients enrolled in a randomized phase II trial of imatinib (CSTI571B 2222). 23 patients harbored KIT exon 9 mutated GISTs: 22 harbored A502_503Ydup and 1 harbored F506_F508dup. Of patients harboring KIT exon 9 mutated GISTs, 11 (47.8%) had a partial response, 6 had stable disease, 4 had progressive disease and 2 were nonassessable. Patients with KIT exon 9 mutant GISTs were significantly more likely to have a partial response than those with WT KIT (P = .013), though significantly less likely than those with KIT exon 11 mutated GISTs (P = .0006). Patients harboring KIT exon 9 mutant GISTs experienced longer event free survival (median: 200 days) than those with WT KIT GISTs (82 days). Furthermore, there was a signficant difference in overall survival between patients with KIT exon 9 mutant and double WT kinase GISTs (P = .0067). There was no significant difference in the rate of treatment failure for patients with exon 9 mutation compared with those with no KIT or PDGFRA mutation (P = .14)."	"Heinrich et al., 2003, J. Clin. Oncol."	Somatic	ENST00000288135.5	exon_variant
KIT Exon 9 Mutation	KIT	Exon 9 Mutation	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	B	Reduced Sensitivity	chr4	54725857	54726050			"This prospective study of 397 patients with incurable (i.e. metastatic or unresectable) CD117-positive Gastrointestinal stromal tumors (GISTs) examined the relationship between KIT genotype and treatment outcome for patients enrolled in the North American phase III study SWOG S0033/CALGB 150105 who were treated with either 400mg or 800mg of imatinib per day. Of 33 patients with KIT exon-9 mutant GISTs, 31 harbored KIT A502_Y503 internal tandom duplication, one harbored K484_G487del (KHNG).  Of the KIT exon 9 mutant patients, 14 were treated with 400mg daily and 19 were treated with 800mg daily. Patients with KIT exon-9 mutant GISTs had a significantly higher response rate when treated with 800mg compared with 400mg (CR/PR 17% vs 67% for 400mg and 800mg, respectively; OR, 9.05; p = .02). However, the authors report that there was not a significant difference in time to progression or overall survival between the two dose groups for patients harboring KIT exon-9 mutant GISTs."	"Heinrich et al., 2008, J. Clin. Oncol."	Somatic	ENST00000288135.5	exon_variant
KIT Exon 9 Mutation	KIT	Exon 9 Mutation	Gastrointestinal Stromal Tumor	Regorafenib	Predictive	Supports	C	Reduced Sensitivity	chr4	54725857	54726050			"This phase II clinical trial of regorafenib (NCT01068769) examined the long term safety and efficacy of regorafenib monotherapy in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) who failed previous treatments with imatinib. In response to regorafenib monotherapy, patients whose GISTs harbored KIT exon 9 mutations experienced lower rates of clinical benefit (defined as complete response, partial response, or stable disease lasting >16 weeks) than patients whose GISTs harbored KIT exon 11 mutations or KIT/PDGFR wildtype SDH-deficient patients. Of 3 patients with KIT exon 9 mutant GISTs, 2 experienced clinical benefit (including one PR), and the median progression free survival was 5.7 months."	"Ben-Ami et al., 2016, Ann. Oncol."	Somatic	ENST00000288135.5	exon_variant
KIT Exon 9 Mutation	KIT	Exon 9 Mutation	Gastrointestinal Stromal Tumor	Regorafenib	Predictive	Supports	B	Reduced Sensitivity	chr4	54725857	54726050			"This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients who failed previous treatments with at least imatinib and sunitinib. Of 30 genotyped patients treated with regorafenib, those with KIT exon 9 mutant GISTs (n=3) experienced decreased progression free survival as compared to patients with KIT exon 11 mutated GISTs (n=19) or wildtype (lacking KIT or PDGFRA mutations) GISTs (n= 8). The difference in PFS was significant between Exon 9 and 11 mutant GISTs (P = .01). Median PFS for the whole cohort was 10.0 months. Regorafenib treatment induced clinical benefit (defined as complete response, partial response, stable disease <16 weeks) in 2/3 patients with KIT exon 9 mutant GISTs."	"George et al., 2012, J. Clin. Oncol."	Somatic	ENST00000288135.5	exon_variant
KIT Exon 9 Mutation	KIT	Exon 9 Mutation	Gastrointestinal Stromal Tumor	Regorafenib	Predictive	Supports	B	Sensitivity/Response	chr4	54725857	54726050			"This international, placebo controlled prospective phase 3 clinical trial (NCT01271712) examined safety and efficacy of regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) who failed previous treatments with at least imatinib or sunitinib. Progression free survival was measured for 199 patients treated with either daily 160mg regorafenib (n=133) or a matching placebo (n= 66).  Overall, median PFS was 7.4 months in the regorafenib group and 1.7 months in the placebo group (HR= .22, P <.001). Patients with KIT exon 9 mutations (n=15) treated with regorafenib were associated with a similarly favorable progression free survival (HR: 0.239), as compared to patients with treated with placebo."	"Demetri et al., 2013, Lancet"	Somatic	ENST00000288135.5	exon_variant
KIT A502_Y503insAY	KIT	A502_Y503insAY	Cancer	Sunitinib	Predictive	Does Not Support	D	Resistance	chr4	54726016	54726017		GCCTAT	"In an in vitro study, Chinese hamster ovary cells expressing KIT A502_Y503INSAY demonstrated comparable sensitivity to sunitinib treatment compared to CHO cells expressing ligand activated wild-type KIT (IC50<100 nmol/L). Sensitivity was determined by assessing KIT auto-phosphorylation."	"Heinrich et al., 2008, J. Clin. Oncol."	Somatic		inframe_insertion
KIT A502_Y503insAY	KIT	A502_Y503insAY	Gastrointestinal Stromal Tumor	"Ponatinib,Regorafenib,Imatinib"	Predictive	Does Not Support	D	Sensitivity/Response	chr4	54726016	54726017		GCCTAT	"In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT A502_Y503insAY primary activating mutation demonstrated insensitivity to regorafenib (IC50: 138nmol/L), imatinib (IC50: 143nmol/L), and ponatinib (IC50: 56nmol/L) treatments. In comparison, sensitizing KIT mutation del550-557 showed IC50 22, 13 and 3 nmol/L for these drugs respectively. IC50 was determined by assessing cell viability."	"Garner et al., 2014, Clin. Cancer Res."	Somatic		inframe_insertion
KIT A502_Y503insAY	KIT	A502_Y503insAY	Gastrointestinal Stromal Tumor	Sunitinib	Predictive	Supports	D	Sensitivity/Response	chr4	54726016	54726017		GCCTAT	"In an in vitro study, an IL3 independant Ba/F3 cell line expressing KIT V560D primary activating mutation demonstrated sensitivity to sunitinib treatment (IC50: 5nmol/L). IC50 was determined by assessing cell viability."	"Garner et al., 2014, Clin. Cancer Res."	Somatic		inframe_insertion
KIT Y503_F504insAY	KIT	Y503_F504insAY	Cancer	Imatinib	Predictive	Does Not Support	D	Resistance	chr4	54726019	54726020		GCCTAT	"In an in vitro study of imatinib sensitivity, KIT Y503_F504insAY was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Then, protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT Y503_F504insAY were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L)."	"Heinrich et al., 2003, J. Clin. Oncol."	Somatic	ENST00000288135.5	inframe_insertion
KIT F506_F508DUP	KIT	F506_F508DUP	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Does Not Support	C	Sensitivity/Response	chr4	54726026	54726034		TTTGCATTT	This patient was part of a larger cohort of 397 patients with incurable (i.e. metastatic or unresectable) CD117-positive Gastrointestinal stromal tumors (GISTs) enrolled in the North American phase III study SWOG S0033/CALGB 150105. Patients in the study were treated with either 400mg or 800mg of imatinib per day. This patient's GIST harbored a tandem reduplication of KIT codons 506 to 508 (FAF) after F508 (F506_F508dup). The patient's response to imatinib was not assessed but the TTP was 10.6 months.	"Heinrich et al., 2008, J. Clin. Oncol."	Somatic	ENST00000288135.5	
KIT M541L	KIT	M541L	Chronic Leukemia	Imatinib	Predictive	Supports	C	Sensitivity/Response	chr4	54727298	54727298	A	C	"In 5 patients with KIT M541L mutation-positive chronic eosinophilic leukemia (4 somatic and 1 germline mutation), treatment with low dose imatinib resulted in complete and lasting remission with a median follow up of 74 months and 1 patient relapse at 50 months."	"Iurlo et al., 2014, Oncotarget"	Somatic	ENST00000288135.5	missense_variant
KIT Exon 11 Mutation	KIT	Exon 11 Mutation	Gastrointestinal Stromal Tumor		Prognostic	Does Not Support	B	N/A	chr4	54727416	54727542			There is no significant association between wildtype KIT or KIT mutations in exon 9 or 11 in survival among GIST patients.	"Wardelmann et al., 2006, Clin. Cancer Res."	Somatic	ENST00000288135.5	coding_sequence_variant
KIT Exon 11 Mutation	KIT	Exon 11 Mutation	Melanoma	Imatinib	Predictive	Supports	B	Sensitivity/Response	chr4	54727416	54727542			Melanoma patients with KIT mutation but not KIT amplification showed response to imatinib treatment in a small cohort of patients.	"Hodi et al., 2013, J. Clin. Oncol."	Somatic	ENST00000288135.5	coding_sequence_variant
KIT Exon 11 Mutation	KIT	Exon 11 Mutation	Gastrointestinal Stromal Tumor		Diagnostic	Supports	B	Positive	chr4	54727416	54727542			"KIT mutation is associated with larger, more invasive tumors, greater pathologic histology and older patients compared to tumors with wildtype KIT."	"Taniguchi et al., 1999, Cancer Res."	Somatic	ENST00000288135.5	coding_sequence_variant
KIT Internal Duplication	KIT	Internal Duplication	Malignant Anus Melanoma	Imatinib	Predictive	Supports	C	Sensitivity/Response	chr4	54727416	54727542			"In a case study, a patient with anal melanoma harboring a 7 codon duplication in the juxtamambrane region (exon 11) of KIT showed marked response 4 months after imatinib treatment."	"Hodi et al., 2008, J. Clin. Oncol."	Somatic	ENST00000288135.5	inframe_insertion
KIT Exon 11 Mutation	KIT	Exon 11 Mutation	Gastrointestinal Stromal Tumor		Prognostic	Does Not Support	B	N/A	chr4	54727416	54727542			"KIT mutations were identified in morphologically benign, incidentally discovered GISTs at a rate similar to that seen in advanced, metastatic GIST patients indicating is not a prognostic marker for GIST."	"Corless et al., 2002, Am. J. Pathol."	Somatic	ENST00000288135.5	coding_sequence_variant
KIT Exon 11 Mutation	KIT	Exon 11 Mutation	Lung Cancer		Prognostic	Does Not Support	B	N/A	chr4	54727416	54727542			KIT mutations detected in 5/60 patients showed no prognostic significance in patients with small cell lung cancer.	"Boldrini et al., 2004, Clin. Cancer Res."	Somatic	ENST00000288135.5	coding_sequence_variant
KIT Exon 11 Mutation	KIT	Exon 11 Mutation	Gastrointestinal Stromal Tumor		Prognostic	Supports	B	Poor Outcome	chr4	54727416	54727542			KIT mutation is associated with worse overall and cause-specific prognosis in patients with GIST compared to patients with wildtype KIT.	"Taniguchi et al., 1999, Cancer Res."	Somatic	ENST00000288135.5	coding_sequence_variant
KIT Exon 11 Mutation	KIT	Exon 11 Mutation	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	A	Sensitivity/Response	chr4	54727416	54727542			"This prospective study of 127 pretreatment patients with metastatic gastrointestinal stromal tumors (GISTs) examined the relationship between kinase (KIT and PDGFRA) genotype and treatment outcome for patients enrolled in a randomized phase II trial of imatinib (CSTI571B 2222). 85 patients harbored KIT exon 11 mutated GISTs: 71 had an in-frame deletion and 15 had unspecified point mutations (3 codon 557 cases, 3 codon 559 cases, 6 codon 560 cases and 2 codon 576 cases). Of patients harboring KIT exon 11 mutated GISTs, 71 (83.5%) had a partial response, 7 had stable disease, 4 had progressive disease and 3 were nonassessable.  Patients with KIT exon 11 mutations were significantly more likely to have a partial response than those with KIT exon 9 mutations (P=.0006)  or double WT kinases (WT KIT and WT PDGFRA; P < .0001). The presence of a KIT exon 11 mutation was the strongest predictor of response (Hazard ratio= 7.85). Patients harboring KIT exon 11 mutant GISTs experienced longer event free survival (median: 687 days) than those with  KIT exon 9 mutant or double WT kinase GISTs (200 days and 82 days, respectively). Furthermore, patients whose tumors expressed an exon 11 mutant KIT had improved overall survival compared to patients whose tumor expressed an exon 9 mutant KIT (P = .0034)  or double WT kinases (P <.0001)."	"Heinrich et al., 2003, J. Clin. Oncol."	Somatic	ENST00000288135.5	coding_sequence_variant
KIT Exon 11 Mutation	KIT	Exon 11 Mutation	Melanoma	Sunitinib	Predictive	Supports	C	Sensitivity/Response	chr4	54727416	54727542			"10 melanoma patients were evaluated after sunitinib treatment, among which 3 out of the 4 patients with KIT exon 11 mutations showed either complete or partial response."	"Minor et al., 2012, Clin. Cancer Res."	Somatic	ENST00000288135.5	coding_sequence_variant
KIT Exon 11 Mutation	KIT	Exon 11 Mutation	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	B	Sensitivity/Response	chr4	54727416	54727542			"This prospective study of 397 patients with incurable (i.e. metastatic or unresectable) CD117-positive Gastrointestinal stromal tumors (GISTs) examined the relationship between KIT genotype and treatment outcome for patients enrolled in the North American phase III study SWOG S0033/CALGB 150105 who were treated with either 400mg or 800mg of imatinib per day. The study found that patients whose tumors harbored mutations in KIT exon 11 had signficantly superior responses to imatinib, regardless of dose,  than those whose tumors harbored wildtype KIT or KIT exon 9 mutations. This is evidenced by the findings that imatinib-treated patients whose tumors contained KIT exon 11 mutations had longer overall survival compared to those with exon 9 mutations (60.0mo vs.38.4mo, P=0.011) or wildtype KIT (60mo vs. 49.0mo, P=0.049). Patients with exon 11 mutations had improved progression-free survival in comparison to those with exon 9 mutations (24.7mo vs. 16.7mo, P=0.0013) or wildtype KIT (24.7mo vs. 12.8mo, P=0.005)."	"Heinrich et al., 2008, J. Clin. Oncol."	Somatic	ENST00000288135.5	coding_sequence_variant
KIT K550_K558del	KIT	K550_K558del	Gastrointestinal Stromal Tumor	Sunitinib	Predictive	Supports	C	Resistance	chr4	54727416	54727442	AAACCCATGTATGAAGTACAGTGGAAG		"Patient 3 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT K550_K558 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient started on 50mg sunitinib on a schedule of two weeks on/two weeks off. This patient experienced stable disease less than 6 months; time to progresssion of 14 weeks and overall survival of 17 weeks (Table A1)."	"Heinrich et al., 2008, J. Clin. Oncol."	Somatic	ENST00000288135.5	inframe_deletion
KIT Exon 11 Mutation	KIT	Exon 11 Mutation	Gastrointestinal Stromal Tumor	Sunitinib	Predictive	Supports	B	Resistance	chr4	54727416	54727542			"In a phase I/II trial of sunitinib efficacy on imatinib resistant or intolerant gastrointestinal stromal tumor (GIST) patients (n=77), patients harboring primary (pre-imatinib treatment) KIT exon 11 mutant GISTs (n=44) treated with sunitinib experienced shorter progression free survival (5.1 vs 19.0 months, P = .0356) and overall survival (12.3 vs 30.5 months, P=0.0132) as compared to patients with wild-type KIT (n=9)."	"Heinrich et al., 2008, J. Clin. Oncol."	Somatic	ENST00000288135.5	coding_sequence_variant
KIT K550_W557del	KIT	K550_W557del	Gastrointestinal Stromal Tumor	"Sunitinib,Ponatinib,Regorafenib,Imatinib"	Predictive	Supports	D	Sensitivity/Response	chr4	54727416	54727439	AAACCCATGTATGAAGTACAGTGG		"In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT K550_W557del primary activating mutation demonstrated sensitivity to imatinib (IC50: 13nmol/L), sunitinib (IC50: 5nmol/L), regorafenib (IC50: 22nmol/L), and ponatinib (IC50: 3nmol/L) treatments. IC50 was determined by assessing cell viability."	"Garner et al., 2014, Clin. Cancer Res."	Somatic	ENST00000288135.5	inframe_deletion
KIT Exon 11 Mutation	KIT	Exon 11 Mutation	Gastrointestinal Stromal Tumor	Regorafenib	Predictive	Supports	B	Sensitivity/Response	chr4	54727416	54727542			"This international, placebo controlled prospective phase 3 clinical trial (NCT01271712) examined safety and efficacy of regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) who failed previous treatments with at least imatinib or sunitinib. Progression free survival was measured for 199 patients treated with either daily 160mg regorafenib (n=133) or a matching placebo (n= 66). Overall, median PFS was 7.4 months in the regorafenib group and 1.7 months in the placebo group (HR= .22, P <.001). Patients with KIT exon 11 mutations (n=51) treated with regorafenib were associated with similarly favorable progression free survival (HR: 0.212), as compared to patients with treated with placebo."	"Demetri et al., 2013, Lancet"	Somatic	ENST00000288135.5	coding_sequence_variant
KIT Exon 11 Mutation	KIT	Exon 11 Mutation	Gastrointestinal Stromal Tumor	Regorafenib	Predictive	Supports	B	Sensitivity/Response	chr4	54727416	54727542			"This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients who failed previous treatments with imatinib and sunitinib. Of 30 genotyped patients treated with regorafenib, those with KIT exon 11 mutant GISTs (n=19) experienced significantly increased progression free survival (P=0.01), as compared to patients with KIT exon 9 mutant GISTs (n=3). Median PFS for the entire cohort was 10.0 months. Regorafenib treatment induced clinical benefit (defined as complete response, partial response, stable disease > 16 weeks) in 16/19 patients with KIT exon 11 mutant GISTs."	"George et al., 2012, J. Clin. Oncol."	Somatic	ENST00000288135.5	coding_sequence_variant
KIT Exon 11 Mutation	KIT	Exon 11 Mutation	Gastrointestinal Stromal Tumor	Regorafenib	Predictive	Supports	B	Sensitivity/Response	chr4	54727416	54727542			"This phase II clinical trial of regorafenib (NCT01068769) examined the long term safety and efficacy of regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) who failed previous treatments with imatinib. Patients whose GISTs harbored KIT exon 11 mutations (n=19) experienced higher rates of clinical benefit (defined as complete response, partial response, or stable disease lasting >16 weeks) than patients whose GISTs harbored KIT exon 9 mutations.  15/19 patients with exon 11 mutant GISTs experienced clinical benefit (including 2 PRs). KIT exon 11 mutant GISTs treated with regorafenib monotherapy were associated with improved median progression free survival (13.4 months vs. 5.7 and 1.6 months, P<0.0001), as compared to patients with KIT exon 9 mutation (n=2) and patients with KIT wildtype, non-succinate dehydrogenase-deficient tumors (n=2)."	"Ben-Ami et al., 2016, Ann. Oncol."	Somatic	ENST00000288135.5	coding_sequence_variant
KIT K550_K559DEL	KIT	K550_K559DEL	Gastrointestinal Stromal Tumor	Sunitinib	Predictive	Does Not Support	C	Resistance	chr4	54727416	54727445	AAACCCATGTATGAAGTACAGTGGAAGGTT		"Patient 78 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT K550_V559 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient started on 50mg sunitinib on a schedule of two weeks on/one weeks off. This patient experienced partial response; time to progression and overall survival were censored at 54 weeks and 84 weeks (Table A1)."	"Heinrich et al., 2008, J. Clin. Oncol."	Somatic	ENST00000288135.5	
KIT P551_E554delPMYE	KIT	P551_E554delPMYE	Gastrointestinal Stromal Tumor	Ponatinib	Predictive	Supports	D	Sensitivity/Response	chr4	54727419	54727430			"In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT P551_E554delPMYE primary activating mutation demonstrated sensitivity to ponatinib treatment (IC50: 15nM). IC50 was determined by assessing cell viability."	"Garner et al., 2014, Clin. Cancer Res."	Somatic		inframe_deletion
KIT P551_E554delPMYE	KIT	P551_E554delPMYE	Gastrointestinal Stromal Tumor	"Regorafenib,Sunitinib,Imatinib"	Predictive	Does Not Support	D	Sensitivity/Response	chr4	54727419	54727430			"In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT P551_E554delPMYE primary activating mutation demonstrated insensitivity to regorafenib (IC50: 141nmol/L), imatinib (IC50: 90nmol/L), and sunitinib (IC50: 42nmol/L) treatments. In comparison, sensitizing KIT mutation del550-557 showed IC50 22, 13 and 5 nmol/L for these drugs respectively. IC50 was determined by assessing cell viability."	"Garner et al., 2014, Clin. Cancer Res."	Somatic		inframe_deletion
KIT W557_K558del	KIT	W557_K558del	Cancer	Imatinib	Predictive	Does Not Support	D	Resistance	chr4	54727437	54727442	TGGAAG		"In an in vitro study of imatinib sensitivity, KIT W557_K558del was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT W557_K558del were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L)."	"Heinrich et al., 2003, J. Clin. Oncol."	Somatic	ENST00000288135.5	conservative_inframe_deletion
KIT W557_K558del	KIT	W557_K558del	Gastrointestinal Stromal Tumor	Sunitinib	Predictive	Supports	C	Resistance	chr4	54727437	54727442	TGGAAG		"Patients 11, 69, and 73 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT W557_K558 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. Patient 11 started on 25 mg sunitinib daily, for a two week on/two week off schedule. Patients 69 and 73 were on a 50 mg sunitib per day for four weeks on/ two weeks off. All three patients experienced stable disease for less than 6 months. Time to progression for patients 11, 69, and 73: 8, 22, and 10 weeks. Overall survival for patients 11, 69, and 73: 10, 38, and 19 weeks (Table A1)."	"Heinrich et al., 2008, J. Clin. Oncol."	Somatic	ENST00000288135.5	conservative_inframe_deletion
KIT W557_K558del	KIT	W557_K558del	Gastrointestinal Stromal Tumor	"Ponatinib,Imatinib"	Predictive	Supports	D	Sensitivity/Response	chr4	54727437	54727442	TGGAAG		"In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT W557_K558del primary activating mutation demonstrated sensitivity to imatinib (IC50: 27nmol/L) and ponatinib (IC50: 3nmol/L) treatments. IC50 was determined by assessing cell viability. In mice treated in vivo with Ba/F3 cells expressing KIT W557_K558 mutation, tumor volume was significantly reduced in response to both ponatinib and imatinib treatments."	"Garner et al., 2014, Clin. Cancer Res."	Somatic	ENST00000288135.5	conservative_inframe_deletion
KIT W557_K558del	KIT	W557_K558del	Gastrointestinal Stromal Tumor	"Regorafenib,Sunitinib"	Predictive	Supports	D	Sensitivity/Response	chr4	54727437	54727442	TGGAAG		"In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT W557_K558del primary activating mutation demonstrated sensitivity to sunitinib (IC50: 7 +/-  2nmol/L) and regorafenib (IC50: 30 +/- 14nmol/L) treatments. IC50 was determined by assessing cell viability."	"Garner et al., 2014, Clin. Cancer Res."	Somatic	ENST00000288135.5	conservative_inframe_deletion
KIT K558_V559del	KIT	K558_V559del	Gastrointestinal Stromal Tumor	Sunitinib	Predictive	Supports	C	Resistance	chr4	54727440	54727445	AAGGTT		"Patient 47 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT K558_V559 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of two weeks on/one week off.  The patient experienced progressive disease. Time to progression was censored at 5 weeks, and overall survival was 60 weeks."	"Heinrich et al., 2008, J. Clin. Oncol."	Somatic	ENST00000288135.5	
KIT K558delinsNP	KIT	K558delinsNP	Gastrointestinal Stromal Tumor	"Imatinib,Regorafenib,Ponatinib,Sunitinib"	Predictive	Supports	D	Sensitivity/Response	chr4	54727442	54727442	G	TCCT	"In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT K558NP primary activating mutation demonstrated sensitivity to imatinib (IC50: 2nmol/L), sunitinib (IC50: 2nmol/L ), regorafenib (IC50: 4nmol/L), and ponatinib (IC50: 1nmol/L) treatments. IC50 was determined by assessing cell viability."	"Garner et al., 2014, Clin. Cancer Res."	Somatic		delins
KIT V559D	KIT	V559D	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	C	Sensitivity/Response	chr4	54727444	54727444	T	A	A patient with an uncontrolled relapse of c-kit-positive mesenchymal tumor in descending part of the duodenum had received 400mg Imatinib daily for more than 10 years at the time of publication. He responded well to therapy (Karnofsky index 90%). KIT V559D (Exon 11) was identified in the diagnostic biopsy and indicated as a positive predictor of imatinib response with long term usage.	"Cameron et al., 2011, Case Rep Oncol"	Somatic	ENST00000288135.5	missense_variant
KIT V559D	KIT	V559D	Cancer	"Dasatinib,Imatinib,Tandutinib,Sunitinib,PD-180970"	Predictive	Supports	D	Sensitivity/Response	chr4	54727444	54727444	T	A	"KIT(V559D) were expressed in HEK-293 cells (in vitro). Imatinib, BMS-354825 (dasatinib), PD-180970, MLN-518 (tandutinib), and SU-11248 bind variant V559D with high affinity (Kd =< 20 nM), and inhibit KIT autophosphorylation. Despite similar binding affinities, the cellular activity of BMS-354825 was >10-fold greater than that of SU-11248 or PD-180970, and the authors hypothesize that additional pharmaceutical properties may contribute to the greater cellular potency."	"Carter et al., 2005, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000288135.5	missense_variant
KIT V559D	KIT	V559D	Gastrointestinal Stromal Tumor	"Regorafenib,Ponatinib,Imatinib"	Predictive	Supports	D	Sensitivity/Response	chr4	54727444	54727444	T	A	"In an in vitro kinase study, a KIT V559D primary activating mutant kinase demonstrated sensitivity to imatinib (IC50: 36nmol/L vs. 640nmol/L), regorafenib (IC50: 57nmol/L vs. 533nmol/L), and ponatinib (IC50: 0.8nmol/L vs. 6nmol/L) treatments compared to the wild-type KIT. IC50 was determined by assessing kinase activity."	"Garner et al., 2014, Clin. Cancer Res."	Somatic	ENST00000288135.5	missense_variant
KIT V560DEL	KIT	V560DEL	Thymic Carcinoma	Imatinib	Predictive	Supports	C	Sensitivity/Response	chr4	54727446	54727448	GTT		"In a patient with thymic carcinoma, the tumor expressing an activating mutation in exon 11 of KIT (V560del) was sensitive to imatinib."	"Strbel et al., 2004, N. Engl. J. Med."	Somatic	ENST00000288135.5	"amino_acid_deletion,inframe_deletion"
KIT V560_L576DEL	KIT	V560_L576DEL	Gastrointestinal Stromal Tumor	Regorafenib	Predictive	Supports	D	Sensitivity/Response	chr4	54727446	54727496			A GIST430 patient derived cell line expressing KIT V560_L576del primary activating mutation demonstrated insensitivity to regorafenib (IC50: 191nmol/L) treatment. IC50 was determined by assessing cell viability.	"Garner et al., 2014, Clin. Cancer Res."	Somatic		inframe_deletion
KIT V560_L576DEL	KIT	V560_L576DEL	Gastrointestinal Stromal Tumor	"Ponatinib,Imatinib"	Predictive	Does Not Support	D	Sensitivity/Response	chr4	54727446	54727496			"In the patient-derived cell line GIST430 harboring KIT V560_L576del primary activating mutation implanted in mice, imatinib and ponatinib were shown to reduce KIT phosphorylation compared to the vehicle. In GIST430 cell lines, ponatinib and imatinib reduced phospho-AKT and phospho-ERK levels. A cell line derived from GIST430 patients expressing KIT V560_L576del primary mutation demonstrated sensitivity to imatinib (IC50: 61nmol/L) and ponatinib (IC50: 12nmol/L) treatments. In comparison, the insensitve KIT-independent GIST226 cell line showed IC50 >5000nmol/L and 2807nmol/L for these drugs respectively. IC50 was determined by assessing cell viability."	"Garner et al., 2014, Clin. Cancer Res."	Somatic		inframe_deletion
KIT V560G	KIT	V560G	Cancer	Imatinib	Predictive	Does Not Support	D	Resistance	chr4	54727447	54727447	T	G	"In an in vitro study of imatinib sensitivity, KIT V560G was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. The cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for the presence of phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT V560G were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L)."	"Heinrich et al., 2003, J. Clin. Oncol."	Somatic	ENST00000288135.5	missense_variant
KIT V560D	KIT	V560D	Cancer	Sunitinib	Predictive	Does Not Support	D	Resistance	chr4	54727447	54727447	T	A	"In an in vitro study, Chinese hamster ovary cells expressing KIT V560D demonstrated comparable sensitivity to sunitinib treatment compared to cells expressing ligand activated wild-type KIT (IC50<100 nmol/L). Sensitivity was determined by assessing KIT auto-phosphorylation."	"Heinrich et al., 2008, J. Clin. Oncol."	Somatic	ENST00000288135.5	missense_variant
KIT V560D	KIT	V560D	Gastrointestinal Stromal Tumor	Sunitinib	Predictive	Supports	C	Resistance	chr4	54727447	54727447	T	A	"Patient 72 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT V560D mutation. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of four weeks on/two weeks off. The patient experienced progressive disease. Time to progression and overall survival were 9 and 33 weeks."	"Heinrich et al., 2008, J. Clin. Oncol."	Somatic	ENST00000288135.5	missense_variant
KIT V560D	KIT	V560D	Gastrointestinal Stromal Tumor	"Sunitinib,Ponatinib,Regorafenib,Imatinib"	Predictive	Supports	D	Sensitivity/Response	chr4	54727447	54727447	T	A	"In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT V560D primary activating mutation demonstrated sensitivity to imatinib (IC50: 3nmol/L), sunitinib (IC50: 2nmol/L), regorafenib (IC50: 3nmol/L), and ponatinib (IC50: 2nmol/L) treatments. IC50 was determined by assessing cell viability."	"Garner et al., 2014, Clin. Cancer Res."	Somatic	ENST00000288135.5	missense_variant
KIT V560D	KIT	V560D	Cancer	Imatinib Mesylate	Predictive	Supports	D	Sensitivity/Response	chr4	54727447	54727447	T	A	"In an in vitro study, Chinese hamster ovary cells expressing KIT V560D mutation demonstrated sensitivity to imatinib treatment (IC50 = 100 vs IC50 = 1000) when compared to Chinese hamster ovary cells expressing ligand-activated wild-type KIT. Sensitivity was determined by assessing KIT auto-phosphorylation."	"Heinrich et al., 2008, J. Clin. Oncol."	Somatic	ENST00000288135.5	missense_variant
KIT V560G	KIT	V560G	Gastrointestinal Stromal Tumor	"Ponatinib,Imatinib,Regorafenib"	Predictive	Supports	D	Sensitivity/Response	chr4	54727447	54727447	T	G	"In an in vitro kinase study, a KIT V560G primary activating mutant kinase demonstrated sensitivity to imatinib (IC50: 38nmol/L vs. 640nmol/L), regorafenib (IC50: 27nmol/L vs. 533nmol/L), and ponatinib (IC50: 0.3nmol/L vs. 6nmol/L) treatments compared to the wildtype KIT. IC50 was determined by assessing kinase activity."	"Garner et al., 2014, Clin. Cancer Res."	Somatic	ENST00000288135.5	missense_variant
KIT L576P	KIT	L576P	Melanoma	"Imatinib,Sorafenib,Nilotinib"	Predictive	Supports	D	Resistance	chr4	54727495	54727495	T	C	"The melanoma cell line WM3211, which harbors the L576P mutation, is not sensitive to imatinib, nilotinib, and sorafenib. Molecular modeling indicated the L576P mutation alters the conformation of KIT and reduces the binding affinity of imatinib."	"Woodman et al., 2009, Mol. Cancer Ther."	Somatic	ENST00000288135.5	missense_variant
KIT L576P	KIT	L576P	Melanoma	Dasatinib	Predictive	Supports	D	Sensitivity/Response	chr4	54727495	54727495	T	C	"The melanoma cell line WM3211, which harbors the L576P mutation, is sensitive to dasatinib. Molecular modeling indicated the L576P mutation alters the conformation of KIT but did not alter the binding affinity of dasatinib."	"Woodman et al., 2009, Mol. Cancer Ther."	Somatic	ENST00000288135.5	missense_variant
KIT L576P	KIT	L576P	Lung Non-small Cell Carcinoma	"Dasatinib,Imatinib,Nilotinib"	Predictive	Supports	D	Sensitivity/Response	chr4	54727495	54727495	T	C	"Ba/F3 cells harboring the KIT L576P mutation are sensitive to nilotinib, imatinib and lower concentrations of dasatinib."	"Antonescu et al., 2007, Int. J. Cancer"	Somatic	ENST00000288135.5	missense_variant
KIT L576P	KIT	L576P	Gastrointestinal Stromal Tumor	Sunitinib	Predictive	Supports	C	Resistance	chr4	54727495	54727495	T	C	"Patient 29 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT L576P mutation. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of two weeks on/two weeks off.  The patient experienced stable disease for less than 6 months. Time to progression and overall survival were 31 and 29 weeks."	"Heinrich et al., 2008, J. Clin. Oncol."	Somatic	ENST00000288135.5	missense_variant
KIT L576P	KIT	L576P	Cancer	"Dasatinib,Imatinib"	Predictive	Supports	D	Sensitivity/Response	chr4	54727495	54727495	T	C	"In an in vitro study, COS-7 cells expressing KIT L576P activating mutation demonstrated sensitivity to imatinib and dasatinib treatments. Sensitivity was determined by assessing reduced mutant KIT auto-phosphorylation via western blotting with addition of inhibitors."	"Vita et al., 2014, JAMA Dermatol"	Somatic	ENST00000288135.5	missense_variant
KIT D579del	KIT	D579del	Gastrointestinal Stromal Tumor	Sunitinib	Predictive	Supports	C	Resistance	chr4	54727503	54727505	GAT		"Patient 74 from a larger cohort of genotyped patients (n= 78) with imatinib resistant or intolerant gastrointestinal stromal tumors (GISTs) harbored a primary (pre-imatinib treatment) KIT D579 deletion. Following failure of imatinib, the GIST was again genotyped, but no secondary mutations were found. The patient took 50 mg sunitinib per day on a treatment schedule of four weeks on/two weeks off. The patient experienced stable disease for less than six months. Time to progression was censored at 10 weeks and overall survival was 85 weeks."	"Heinrich et al., 2008, J. Clin. Oncol."	Somatic	ENST00000288135.5	conservative_inframe_deletion
KIT Exon 13 Mutation	KIT	Exon 13 Mutation	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	C	Sensitivity/Response	chr4	54728011	54728121			"This prospective study of 127 patients with metastatic gastrointestinal stromal tumors (GISTs) examined the relationship between kinase (KIT and PDGFRA) genotype and treatment outcome for patients enrolled in a randomized phase II trial of imatinib (CSTI571B 2222). Two patients' GISTs harbored KIT exon 13 mutations, and both experienced partial responses to imatinib. The authors conclude that this uncommon variant is sensitive to imatinib."	"Heinrich et al., 2003, J. Clin. Oncol."	Somatic	ENST00000288135.5	
KIT S628N	KIT	S628N	Cancer	"Dasatinib,Imatinib"	Predictive	Supports	D	Sensitivity/Response	chr4	54728014	54728014	G	A	"In an in vitro study, COS-7 cells expressing KIT S628N activating mutation demonstrated sensitivity to imatinib and dasatinib treatments when compared to the KIT L576P, which was used as an imatinib-sensitive control. Sensitivity was determined by assessing reduced mutant KIT auto-phosphorylation via western blotting with addition of inhibitors."	"Vita et al., 2014, JAMA Dermatol"	Somatic		missense_variant
KIT S628N	KIT	S628N	Melanoma	Imatinib	Predictive	Does Not Support	C	Sensitivity/Response	chr4	54728014	54728014	G	A	"A melanoma patient harboring the KIT S628N activating mutation underwent second-line imatinib therapy following lung metastatic progression that appeared after an eighth cycle of chemotherapy. The S628N mutation was not present in the blood, which confirmed that it was a somatic mutation. After 3 months of imatinib treatment (300 mg/d for first three weeks, then 400 mg/d), the patient exhibited disease progression and increased tumor size, and after an additional three months of imatinib treatment (400 mg/d), the patient developed multiple supratentorial brain metastases in addition to increased lung metastases and died 5 days later. The authors reported preclinical data which indicated variant sensitivity to imatinib. although this outcome did not coroberate the preclinical result, the authors still concluded the variant may be sensitive."	"Vita et al., 2014, JAMA Dermatol"	Somatic		missense_variant
KIT K642E	KIT	K642E	Cancer	Imatinib	Predictive	Does Not Support	D	Resistance	chr4	54728055	54728055	A	G	"In an in vitro study of imatinib sensitivity, KIT K642E was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Then, protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT K642E were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L)."	"Heinrich et al., 2003, J. Clin. Oncol."	Somatic	ENST00000288135.5	missense_variant
KIT K642E	KIT	K642E	Mucosal Melanoma	Imatinib	Predictive	Supports	C	Sensitivity/Response	chr4	54728055	54728055	A	G	"A 69 y.o. woman presented with metastatic mucosal melanoma of the anus. KIT was amplified in the tumor and harbored the K642E mutation. Post surgery with extensive margins, she was given a dose of anti-CTLA-4 antibody and adjuvant radiation therapy for 2.5 weeks.  Two weeks post radiation she developed nodules in the same region and testing indicated they were malignant melanoma with high KIT expression. She enrolled in a clinical trial with a dose of 400mg imatinib per day (Nov 2006). Less than 4 weeks later, all nodules had disappeared. Upon a lowered dosage to 200mg of imatinib, the nodules returned and subsequently the dosage was increased to 600mg/day. The patient remained melanoma-free on 600mg imatinib until a follow up in Jan 2008. The authors do not provide further details on patient outcome."	"Lutzky et al., 2008, Pigment Cell Melanoma Res"	Somatic	ENST00000288135.5	missense_variant
KIT K642E	KIT	K642E	Melanoma	Dasatinib	Predictive	Supports	C	Sensitivity/Response	chr4	54728055	54728055	A	G	"In a phase 2 clinical trial of 39 stage 3/4 chemotherapy-naive unresectable melanoma patients, a subungual melanoma patient harboring the KIT K642E mutation was reported to have a partial response to dasatinib monotherapy of 24 weeks with a 56% tumor reduction."	"Kluger et al., 2011, Cancer"	Somatic	ENST00000288135.5	missense_variant
KIT K642E	KIT	K642E	Gastrointestinal Stromal Tumor	"Sunitinib,Ponatinib"	Predictive	Supports	D	Sensitivity/Response	chr4	54728055	54728055	A	G	"The GIST882 patient derived cell line expressing KIT K642E mutation demonstrated sensitivity to ponatinib (IC50: 31nmol/L) and sunitinib (IC50: 54nmol/L) treatments. In comparison, the insensitve KIT-independent GIST226 cell line showed IC50 >2807nmol/L and >5000nmol/L for these drugs respectively. IC50 was determined by assessing cell viability. The GIST882 cell line only showed reduced levels of phospho-KIT and phospho-ERK at high concentrations for ponatinib and sunitinib, while phospho-AKT levels were reduced at all concentrations for ponatinib and sunitinib."	"Garner et al., 2014, Clin. Cancer Res."	Somatic	ENST00000288135.5	missense_variant
KIT V654A	KIT	V654A	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	D	Resistance	chr4	54728092	54728092	T	C	KIT V654A results in imatinib resistance in GIST patient-derived cell lines.	"Heinrich et al., 2006, J. Clin. Oncol."	Somatic	ENST00000288135.5	missense_variant
KIT V654A	KIT	V654A	Gastrointestinal Stromal Tumor	Sunitinib	Predictive	Supports	B	Sensitivity/Response	chr4	54728092	54728092	T	C	"In GIST tumor cells and patients harboring KIT V654A mutation, SU11248 is effective for those that are refractory to imatinib."	"Prenen et al., 2006, Clin. Cancer Res."	Somatic	ENST00000288135.5	missense_variant
KIT Exon 14 Mutation	KIT	Exon 14 Mutation	Gastrointestinal Stromal Tumor		Prognostic	Supports	B	Poor Outcome	chr4	54729335	54729485			GIST patients with exon 14 KIT mutations had reduced overall survival compared to patients wiltype for KIT.	"Wardelmann et al., 2006, Clin. Cancer Res."	Somatic	ENST00000288135.5	exon_variant
KIT T670I	KIT	T670I	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	C	Resistance	chr4	54729353	54729353	C	T	"147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. T670I was observed as a secondary KIT mutation in one patient with secondary imatinib resistance. The mutation was shown to occur at a hotspot (T670) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro T670I showed ""extreme"" imatinib resistance. It also showed resistance in isolation."	"Heinrich et al., 2006, J. Clin. Oncol."	Somatic	ENST00000288135.5	missense_variant
KIT T670I	KIT	T670I	Gastrointestinal Stromal Tumor	Regorafenib	Predictive	Supports	D	Resistance	chr4	54729353	54729353	C	T	"A preclinical study tested the effects of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with representative primary regorafenib-sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation T670I. The cells were tested for Regorafenib resistance. Ba/F3 cells with del 557-558/T670I mutations (IC50 = 132 +- 25 nM) did show resistance towards  Regorafenib  compared to Ba/F3 cells with del 557-558 alone (IC50 = 30 +- 14 nM). In addition, Ba/F3 cells were mutagenized with N-ethyl-N-nitrosourea and incubated with varying concentrations of Regorafenib. In Regorafenib incubated cells, T670I mutations were seen in approximately 10% of the resistant cell populations. The results suggest that T670I does induce regorafenib resistance in del 557-558/T670I cells."	"Garner et al., 2014, Clin. Cancer Res."	Somatic	ENST00000288135.5	missense_variant
KIT T670I	KIT	T670I	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	D	Resistance	chr4	54729353	54729353	C	T	"A preclinical study tested the effects of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with representative primary imatinib-sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation T670I. The cells were tested for Imatinib resistance. Ba/F3 cells with del 557-558/T670I mutations (IC50 = >10000 nM) showed resistance towards Imatinib compared to Ba/F3 cells with del 557-558 alone (IC50 = 27 +- 8 nM). Similarly, patient-derived GIST-T1/670 cells with 560-578 deletion/T670I mutations (IC50 > 5000 nM) did show resistance towards Imatinib compared to GIST-T1 cells with 560-578 deletion (IC50 = 30 nM). Del 557-558/T670I cells were implanted into mice and treated with Imatinib. Imatinib was not effective in treating the del 557-558/T670I cells in mice as tumor volume progressively increased. In addition, Ba/F3 cells were mutagenized with N-ethyl-N-nitrosourea and incubated with varying concentrations of Imatinib. In Imatinib incubated cells, T670I mutations were seen in approximately 80% of the resistant cell populations."	"Garner et al., 2014, Clin. Cancer Res."	Somatic	ENST00000288135.5	missense_variant
KIT T670I	KIT	T670I	Gastrointestinal Stromal Tumor	"Ponatinib,Sunitinib"	Predictive	Does Not Support	D	Resistance	chr4	54729353	54729353	C	T	"Several preclinical studies tested the effects of various tyrosine kinase inhibitors (TKIs) on Ba/F3 cell lines with representative primary ponatinib and sunitinib sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation T670I. The cells were tested for Ponatinib and Sunitinib resistances. Ba/F3 cells with del 557-558/T670I mutations (Ponatinib IC50 = 15 +/- 1 nM, Sunitinib IC50 = 12 +/- 2 nM) did not show resistance towards Ponatinib and Sunitinib compared to Ba/F3 cells with del 557-558 alone (Ponatinib IC50 = 3 +/- 0, Sunitinib IC50 = 7  +/- 2 nM). Similarly, patient-derived GIST-T1/670 cells with 560-578 deletion/T670I mutations (Ponatinib IC50 = 8 nM, Sunitinib IC50 = 15 nM) showed no resistance towards Ponatinib and Sunitinib compared to GIST-T1 cells with 560-578 deletion (Ponatinib IC50 = 5 nM, Sunitinib IC50 = 48 nM). Additionally, del 557-558/T670I cells was implanted into mice and treated with Ponatinib or Sunitinib. Ponatinib or Sunitinib were shown to be effective in treating the Ba/F3 mutant cells as tumor volume progressively decreased to zero at around 14 days."	"Garner et al., 2014, Clin. Cancer Res."	Somatic	ENST00000288135.5	missense_variant
KIT C809G	KIT	C809G	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	C	Resistance	chr4	54733133	54733133	T	G	"147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. C809G was observed as a secondary KIT mutation in one patient with secondary imatinib resistance. In vitro, C809G showed imatinib resistance both in isolation and when coexpressed with K642E + N822H (the primary KIT mutations, found on the same allele, for this patient)."	"Heinrich et al., 2006, J. Clin. Oncol."	Somatic	ENST00000288135.5	missense_variant
KIT D816H	KIT	D816H	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	C	Resistance	chr4	54733154	54733154	G	C	"147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. D816H was observed as a secondary KIT mutation in two patients with secondary imatinib resistance. The mutation was shown to occur at a hotspot (D816) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro D816H showed ""extreme"" imatinib resistance. It was also highly resistant in isolation."	"Heinrich et al., 2006, J. Clin. Oncol."	Somatic	ENST00000288135.5	missense_variant
KIT D816V	KIT	D816V	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr4	54733155	54733155	A	T	"In acute myloid leukemia patients, D816 mutation is associated with earlier relapse and poorer prognosis than wildtype KIT."	"Cairoli et al., 2006, Blood"	Somatic	ENST00000288135.5	missense_variant
KIT D816V	KIT	D816V	Systemic Mastocytosis	Midostaurin	Predictive	Supports	B	Sensitivity/Response	chr4	54733155	54733155	A	T	"In a phase II clinical trial, 60% of patients (N=89) with advanced systemic mastocytosis responded to treatment with midostaurin."	"Gotlib et al., 2016, N. Engl. J. Med."	Somatic	ENST00000288135.5	missense_variant
KIT D816V	KIT	D816V	Systemic Mastocytosis		Prognostic	Supports	B	Poor Outcome	chr4	54733155	54733155	A	T	"The D816V+ advanced systemic mastocytosis patients with additional mutations in SRSF2 (N=30), ASLX1 (N=20), or RUNX1 (N=16) exhibited lower overall survival over 14 years as compared to D816V+ patients with wildtype SRSF2 (N=40), ASXL1(N=50), or RUNX1 (N=54)."	"Jawhar et al., 2016, Leukemia"	Somatic	ENST00000288135.5	missense_variant
KIT D816V	KIT	D816V	Cancer	Imatinib	Predictive	Supports	D	Resistance	chr4	54733155	54733155	A	T	"In an in vitro study of imatinib sensitivity, KIT D816V was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT D816V were resistant to imatinib up to 10 umol/L."	"Heinrich et al., 2003, J. Clin. Oncol."	Somatic	ENST00000288135.5	missense_variant
KIT D816V	KIT	D816V	Cancer	"Dasatinib,Imatinib"	Predictive	Supports	C	Resistance	chr4	54733155	54733155	A	T	"In an in vitro study, COS-7 cells expressing KIT D816V activating mutation demonstrated resistance to 1uM dasatinib treatment. In a separate in vitro study, TF-1 cells expressing KIT D816V activating mutation demonstrated resistance to 1 and 10 uM imatinib treatment. Sensitivity was determined by assessing reduced mutant KIT auto-phosphorylation with addition of inhibitors. No reduction in D816V autophosphorylation was observed with inhibitor treatment."	"Vita et al., 2014, JAMA Dermatol"	Somatic	ENST00000288135.5	missense_variant
KIT D816E	KIT	D816E	Gastrointestinal Stromal Tumor	"Sunitinib,Imatinib"	Predictive	Supports	D	Resistance	chr4	54733156	54733156	C	G	"Several preclinical studies were done in order to test the effects of various tyrosine kinase inhibitors (TKIs) on KIT-mutant cell lines derived from Gastrointestinal Stromal Tumor (GIST) patients with primary mutation 560-578 deletion and secondary mutation D816E. The cells were tested for Imatinib and Sunitinib resistances. GIST-T1/816 cells with 560-578 deletion and D816E mutations were resistant towards Imatinib and Sunitinib (Imatinib IC50: 604 nM and Sunitinib IC50: 3111 nM) compared to GIST-T1 cells with the 560-578 deletion mutation alone (Imatinib IC50: 30 nM and Sunitinib IC50: 15 nM). Imatinib inhibited phosphorylation in KIT and ERK at high concentrations. Sunitinib did not inhibit phosphorylation in KIT, ERK, or AKT at all. Additionally, Ba/F3 cells were mutagenized with N-ethyl-N-nitrosourea and incubated with varying concentrations of Sunitinib and Imatinib separately. In Imatinib incubated cells, D816E mutations were seen in less than 5% of resistant Ba/F3 cell clones only in the lowest concentration. In Imatinib incubated cells, D816E mutations were seen in approximately 10% of resistant Ba/F3 cell clones."	"Garner et al., 2014, Clin. Cancer Res."	Somatic	ENST00000288135.5	missense_variant
KIT D816E	KIT	D816E	Gastrointestinal Stromal Tumor	Ponatinib	Predictive	Does Not Support	D	Resistance	chr4	54733156	54733156	C	G	"A preclinical study was done in order to test the effects of a tyrosine kinase inhibitor (TKI) on the ponatinib-sensitive KIT-mutant cell line GIST-T1 derived from Gastrointestinal Stromal Tumor (GIST) patients with primary mutation 560-578 deletion and additional secondary mutation D816E. The cells were tested for Ponatinib resistance. GIST-T1/816 cells containing del 560-578 and D816E mutations (IC50: 23 nM) did not show resistance towards Ponatinib compared to GIST-T1 cells with only del 560-578 mutation (IC50: 5 nM). Ponatinib reduced phosphorylation in KIT, AKT, and ERK at higher concentrations. According to the results, the authors suggest that Ponatinib remained highly active in GIST cell lines with secondary mutation D816E."	"Garner et al., 2014, Clin. Cancer Res."	Somatic	ENST00000288135.5	missense_variant
KIT D820Y	KIT	D820Y	Melanoma	Imatinib	Predictive	Supports	C	Resistance	chr4	54733166	54733166	G	T	"FFPE tumor specimens from 295 melanoma patients were screened for KIT amplification and mutation. Of these, 51 patients had variants in KIT and 28 of these were treated with imatinib mesylate at 400 mg orally, twice daily with 25 patients eligible for response evaluation. None of the patients had mutations in BRAF, NRAS, or GNAQ. Two patients achieved a durable complete response, two achieved a durable partial response, and 5 achieved stable disease >12 weeks with a median survival of 46.3 weeks. One patient harboring a somatic D820Y mutation at roughly 50% variant allele frequency (1:1 with wild type) displayed Imatinib mesylateresistance and disease progression, which is consistent with resistant mechanisms described in Gastro-Intestinal Stromal Tumors."	"Carvajal et al., 2011, JAMA"	Somatic	ENST00000288135.5	missense_variant
KIT D820Y	KIT	D820Y	Melanoma	Sunitinib	Predictive	Supports	D	Sensitivity/Response	chr4	54733166	54733166	G	T	"28 acral or mucosal melanomas were examined for KIT expression and mutations (exons 11, 13, 17, and 18). Two of 19 melanomas examined harbored KIT mutations, with one subject harboring a D820Y mutation. Western blotting showed KIT phosphorylation (Y219) in this case and the SM3 cell line harboring the D820Y mutation. The SM3 cell line showed significant growth inhibition with sunitinib exposures of 1uM and 10uM while imatinib showed no activity. The authors comment that this indicates a potential role for sunitinib in growth inhibition of acral melanomas."	"Ashida et al., 2009, Int. J. Cancer"	Somatic	ENST00000288135.5	missense_variant
KIT D820Y	KIT	D820Y	Gastrointestinal Stromal Tumor	Regorafenib	Predictive	Supports	C	Sensitivity/Response	chr4	54733166	54733166	G	T	"This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients refractory to at least imatinib and sunitinib. Three patients whose GIST harbored KIT D820Y experienced clinical benefit (defined as complete response, partial response, stable disease >16 weeks) in response to regorafenib. One patient remained on study without disease progression for >11 months, one patient developed disease progression at 5.7 months, and the other patient underwent surgical removal of all residual disease after 7 months, but continued on regorafenib. Immunoblotting of matched pre- and post- treatment GIST biopsies from these patients demonstrated decreased levels of KIT phosphorylation in response to regorafenib."	"George et al., 2012, J. Clin. Oncol."	Somatic	ENST00000288135.5	missense_variant
KIT D820A	KIT	D820A	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	C	Resistance	chr4	54733167	54733167	A	C	"147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. D820A was observed as a secondary KIT mutation in one patient with secondary imatinib resistance. The mutation was shown to occur at a hotspot (D820) of previously reported secondary KIT mutations in imatinib resistant GISTs. A cell line derived from a separate patient with the same primary (V560D) and secondary (D820A) mutations showed moderately increased resistance to imatinib compared to reports for GIST lines with primary exon 11 KIT mutations alone."	"Heinrich et al., 2006, J. Clin. Oncol."	Somatic	ENST00000288135.5	missense_variant
KIT D820G	KIT	D820G	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	C	Resistance	chr4	54733167	54733167	A	G	"147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. D820G was observed as a secondary KIT mutation in two patients with secondary imatinib resistance. The mutation was shown to occur at a hotspot (D820) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro D820G showed ""extreme"" imatinib resistance."	"Heinrich et al., 2006, J. Clin. Oncol."	Somatic	ENST00000288135.5	missense_variant
KIT N822H	KIT	N822H	Cancer	Imatinib	Predictive	Does Not Support	D	Resistance	chr4	54733172	54733172	A	C	"In an in vitro study of imatinib sensitivity, KIT N822H was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT N822H were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L)."	"Heinrich et al., 2003, J. Clin. Oncol."	Somatic		missense_variant
KIT N822K	KIT	N822K	Cancer	Imatinib	Predictive	Does Not Support	D	Sensitivity/Response	chr4	54733174	54733174	T	A	"In an in vitro study of imatinib sensitivity, KIT N822K was cloned into a plasmid by site-directed mutagenesis of KIT WT cDNA. Chinese hamster ovary cells were transiently transfected with the plasmid. Cells were treated with control media or media containing various concentrations of imatinib for 90 minutes. Protein lysates from the transfected cells were examined for phosphorylated tyrosine, a measure of KIT activation. Cells expressing KIT N822K were as sensitive to imatinib as ligand activated wildtype KIT (IC50: 100-200 nmol/L)."	"Heinrich et al., 2003, J. Clin. Oncol."	Somatic	ENST00000288135.5	missense_variant
KIT N822K	KIT	N822K	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	C	Resistance	chr4	54733174	54733174	T	A	"147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. N822K was observed as a secondary KIT mutation in two patients with secondary imatinib resistance and one patient with primary resistance, and also as a primary mutation in a patient with primary resistance. The mutation was shown to occur at a hotspot (N822) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro N822K showed moderate imatinib resistance."	"Heinrich et al., 2006, J. Clin. Oncol."	Somatic	ENST00000288135.5	missense_variant
KIT N822K	KIT	N822K	Gastrointestinal Stromal Tumor	Ponatinib	Predictive	Does Not Support	D	Resistance	chr4	54733174	54733174	T	A	"A preclinical study tested the effect of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with primary ponatinib-sensitizing del 557-558 mutation, which induced IL-3 independent growth, and secondary mutation N822K. The cells were tested for Ponatinib resistance. Ba/F3 cells with del 557-558 and N822K mutations did not show resistance towards Ponatinib (IC50 for growth inhibition: 3 nM) compared to Ba/F3 cells with del 557-558  alone (IC50: 3 nM). Ponatinib inhibited KIT phosphorylation at moderate concentrations. The results suggest that N822K does not induce Ponatinib resistance."	"Garner et al., 2014, Clin. Cancer Res."	Somatic	ENST00000288135.5	missense_variant
KIT N822K	KIT	N822K	Gastrointestinal Stromal Tumor	Regorafenib	Predictive	Supports	D	Resistance	chr4	54733174	54733174	T	A	"A preclinical study tested the effects of tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with primary regorafenib-sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation N822K. The cells were tested for Regorafenib resistance. Ba/F3 cells with del 557-558 and N822K mutations did show resistance towards Regorafenib (IC50 for growth inhibition: 131 +- 9 nM) compared to Ba/F3 cells with the del 557-558 mutation (IC50 for growth inhibition: 30 +- 14 nM). Regorafenib inhibited KIT phosphorylation only at high concentrations. The results suggest that N822K does induce Regorafenib resistance."	"Garner et al., 2014, Clin. Cancer Res."	Somatic	ENST00000288135.5	missense_variant
KIT N822K	KIT	N822K	Gastrointestinal Stromal Tumor	Regorafenib	Predictive	Supports	C	Sensitivity/Response	chr4	54733174	54733174	T	A	This retrospective study of a phase 2 clinical trial (NCT01068769) examined regorafenib safety and efficacy in advanced gastrointestinal stromal tumor (GIST) patients refractory to at least imatinib and sunitinib. One patient whose GIST harbored KIT N882K did not experienced disease progression for >7 months following treatment by regorafenib. Immunoblotting of matched pre- and post- treatment GIST biopsies from this patient demonstrated decreased levels of KIT phosphorylation in response to regorafenib.	"George et al., 2012, J. Clin. Oncol."	Somatic	ENST00000288135.5	missense_variant
KIT N822K	KIT	N822K	Acute Myeloid Leukemia	"Sorafenib,Sunitinib"	Predictive	Does Not Support	D	Sensitivity/Response	chr4	54733174	54733174	T	A	"In a preclinical trial, the AML cell line Kasumi-1 with the KIT mutation N822K was treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was much more effective in the growth inhibition of cells harboring the KIT mutation (IC50=8 nmol/L) compared to sorafenib (IC50=59 nmol/L) and sunitinib (IC50=56 nmol/L)."	"Gozgit et al., 2011, Mol. Cancer Ther."	Somatic	ENST00000288135.5	missense_variant
KIT N822K	KIT	N822K	Acute Myeloid Leukemia	Ponatinib	Predictive	Supports	D	Sensitivity/Response	chr4	54733174	54733174	T	A	"In this preclinial trial, the AML cell line Kasumi-1 with c-KIT N822K mutation was treated with Ponatinib. This drug effectively inhibits both KIT phosphorylation and viability for Kasumi-1 cells at IC50 values 20 nmol/L and 8 nmol/L respectively."	"Gozgit et al., 2011, Mol. Cancer Ther."	Somatic	ENST00000288135.5	missense_variant
KIT N822K	KIT	N822K	Gastrointestinal Stromal Tumor	"Imatinib,Sunitinib"	Predictive	Supports	D	Resistance	chr4	54733174	54733174	T	A	"Several preclinical studies tested the effects of various tyrosine kinase inhibitors (TKIs) on Ba/F3 cell lines with primary TKI-sensitizing del 557-558 mutation, which induced IL-3 independent growth, and secondary mutation N822K. The cells were tested for Sunitinib and Imatinib resistances. Ba/F3 cells with del 557-558 and N822K mutations (Sunitinib IC50 for growth inhibition: 225 +- 19 nM, Imatinib IC50: 483 +- 24 nM) did show resistance towards Sunitinib and Imatinib compared to Ba/F3 cells with the del 557-558 alone (Sunitinib IC50: 7 +- 2 nM, Imatinib IC50: 27 +- 8 nM).  Sunitinib and Imatinib did not completely inhibit KIT phosphorylation at 1000 nM, which was the highest concentration tested. Additionally, Ba/F3 cells were mutagenized with N-ethyl-N-nitrosourea and incubated with varying concentrations of Sunitinib and Imatinib separately. From these results, N822K mutations were the most frequent KIT mutation observed in resistant Ba/F3 cell populations incubated in Sunitinib. In Imatinib incubated cells, N822K mutations were seen in approximately 10% of resistant Ba/F3 cell clones."	"Garner et al., 2014, Clin. Cancer Res."	Somatic	ENST00000288135.5	missense_variant
KIT Y823D	KIT	Y823D	Gastrointestinal Stromal Tumor	Imatinib	Predictive	Supports	C	Resistance	chr4	54733175	54733175	T	G	"147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors were analyzed to identify molecular correlates of imatinib resistance. Y823D was observed as a secondary KIT mutation in five patients with secondary imatinib resistance. The mutation was shown to occur at a hotspot (Y823) of previously reported secondary KIT mutations in imatinib resistant GISTs. When co-expressed with V560D (imatinib sensitive) in vitro Y823D showed ""extreme"" imatinib resistance."	"Heinrich et al., 2006, J. Clin. Oncol."	Somatic	ENST00000288135.5	missense_variant
KIT A829P	KIT	A829P	Gastrointestinal Stromal Tumor	Ponatinib	Predictive	Does Not Support	D	Resistance	chr4	54736498	54736498	G	C	"Ponatinib possesses potent activity against A829P KIT mutant cells in preclinical experiments. A preclinical study tested the effect of a tyrosine kinase inhibitor (TKI) on Ba/F3 cell lines with representative primary ponatinib-sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation A829P. The cells were tested for Ponatinib resistance. Ba/F3 cells with del 557-558 and A829P mutations (IC50 for growth inhibition: 2 nM) did not show resistance towards Ponatinib compared to Ba/F3 cells with the del 557-558 mutation alone (IC50: 3 nM).  Ponatinib was shown to inhibit KIT phosphorylation in moderate concentrations. Similarly, GIST-T1/829 cells with 560-578 deletion/A829P mutations (IC50 = 16 nM) were not resistant to Ponatinib compared to GIST T1 cells with 560-578 deletion alone (IC50 = 5 nM). Ponatinib inhibited phosphorylation in KIT, ERK, and AKT at moderate to high concentrations in GIST-T1/829 cells."	"Garner et al., 2014, Clin. Cancer Res."	Somatic		missense_variant
KIT A829P	KIT	A829P	Gastrointestinal Stromal Tumor	"Imatinib,Sunitinib"	Predictive	Supports	D	Resistance	chr4	54736498	54736498	G	C	"Several preclinical studies tested the effects of various tyrosine kinase inhibitors (TKIs) on Ba/F3 cell lines with representative primary sunitinib and imatinib sensitizing mutation del 557-558, which induced IL-3 independent growth, and secondary mutation A829P. The cells were tested for Sunitinib and Imatinib resistances. Ba/F3 cells with del 557-558 and A829P mutations did show resistance towards Sunitinib and Imatinib (Sunitinib IC50 for growth inhibition: 319 +- 88 nM and Imatinib IC50: 179 +- 27 nM) compared to Ba/F3 cells with the del 557-558 mutation (Sunitinib IC50: 7 +- 2 nM and Imatinib IC50:  27 +- 8 nM). Imatinib and Sunitinib were shown to not reduce p-KIT at all in Ba/F3 cells with del 557-558/ A829P mutations.  Patient-derived GIST-T1/829 cells with 560-578 deletion/A829P mutations (Sunitinib IC50: 1168 nM and Imatinib IC50:1201 nM) did show resistance towards Sunitinib and Imatinib compared to GIST-T1 cells with 560-578 deletion alone (Sunitinib IC50: 15 nM and Imatinib IC50: 30 nM). Sunitinib and Imatinib did not inhibit p-KIT, p-ERK, and p-AKT in GIST-T1/829 cells."	"Garner et al., 2014, Clin. Cancer Res."	Somatic		missense_variant
KDR A1065T	KDR	A1065T	Angiosarcoma	"Sorafenib,Sunitinib"	Predictive	Supports	D	Sensitivity/Response	chr4	55089802	55089802	C	T	"COS-7 cells were transiently transfected with expression constructs encoding cDNAs for wild-type or A1065T-mutant KDR. Autophosphorylation was observed on tyrosine of mutant cells, but not wild-type cells, which were starved from serum for 6 hours without rhVEGF stimulation. Decreased phosphorylation in mutant cells was noted after treatment with either sunitinib or sorafenib."	"Antonescu et al., 2009, Cancer Res."	Somatic	ENST00000263923.4	missense_variant
KDR R961W	KDR	R961W	Colorectal Adenocarcinoma	Regorafenib	Predictive	Supports	C	Sensitivity/Response	chr4	55094892	55094892	G	A	"Case Report of a 84-year-old woman with stage IVb CRC after progression under 5-fluorouracil and bevacizumab. NGS revealed a frameshift mutation in APC, a missense mutation in KRAS. Variants of uncertain significance were: a missense variant in ERBB2 and a missense variant in KDR at amino acid 961 converting the wild type residue, Arginine, to Tryptophan (frequency 28.25%). Because of the high frequency of the KDR (VEGFR2) mutation, the patient was considered a suitable candidate for a VEGFR inhibitor and received regorafenib monotherapy, which is approved for this situation, at 80mg daily which was later reduced to 40mg daily and had CEA normalization as well as partial metabolic and radiologic response. The patient remained almost asymptomatic and without disease progression after 39 weeks."	"Loaiza-Bonilla et al., 2016, Cureus"	Somatic	ENST00000263923.4	missense_variant
KDR D717V	KDR	D717V	Angiosarcoma	"Sorafenib,Sunitinib"	Predictive	Supports	D	Sensitivity/Response	chr4	55102013	55102013	T	A	"COS-7 cells were transiently transfected with expression constructs encoding cDNAs for wild-type or D717V-mutant KDR. Autophosphorylation was observed on tyrosine of mutant cells, but not wild-type cells, which were starved from serum for 6 hours without rhVEGF stimulation. Decreased phosphorylation in mutant cells was noted after treatment with either sunitinib or sorafenib."	"Antonescu et al., 2009, Cancer Res."	Somatic	ENST00000263923.4	missense_variant
EREG EXPRESSION	EREG	EXPRESSION	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Sensitivity/Response	chr4	74365143	74388751			"226 cetuximab-treated patients with CRC were analyzed for mRNA expression of EGFR and its ligands. Favorable predictors in a multivariate analysis were high AREG mRNA in KRAS wild type tumours, high EREG mRNA and low Ephrin A2 receptor mRNA."	"Pentheroudakis et al., 2013, BMC Cancer"	N/A	ENST00000244869.2	N/A
EREG EXPRESSION	EREG	EXPRESSION	Colorectal Cancer	Panitumumab	Predictive	Supports	B	Sensitivity/Response	chr4	74365143	74388751			"Prospectively planned retrospective biomarker study in archived tumor tissue from 323 patients from the PICCOLO trial (panitumumab plus irinotecan in CRC patients with KRAS wt). Tumors were classified as ""high expressor"" (either EREG or AREG mRNA level) or ""low expressor"" (neither EREG nor AREG in top tertile). For RAS wild-type patients with high ligand expression, median PFS was 8.3 [4.0-11.0] months (irinotecan with panitumumab) vs 4.4 [2.8-6.7] months (irinotecan alone); HR, 0.38 [95% CI, 0.24-0.61]; P??001. In RAS wild-type patients with low ligand expression, median PFS was 3.2 [2.7-8.1] months (irinotecan with panitumumab) vs 4.0 [2.7-7.5] months (irinotecan); HR, 0.93 [95% CI, 0.64-1.37]; P??73; interaction test results were significant [P??01]). Results were less clear for response rate (interaction P??17) and OS (interaction P??11)."	"Seligmann et al., 2016, JAMA Oncol"	N/A	ENST00000244869.2	N/A
EREG EXPRESSION	EREG	EXPRESSION	Lung Adenocarcinoma		Prognostic	Supports	E	Poor Outcome	chr4	74365143	74388751			"Study reporting an in-vivo two-stage initiation/promotion model, testing the hypothesis that Ereg deficiency would reduce lung tumor promotion in mice. Cancerogenesis with chemical initiators/promoters (3-methylcholanthrene or control, butylated hydroxytoluene) was assessed in mice lacking Ereg (Ereg-/-) and wildtype controls (BALB/ByJ; Ereg+/+) at multiple time points and endpoints (bronchoalveolar lavage analysis, tumor analysis, mRNA expression, ELISA, wound assay). Initially a significantly reduced amount of inflammation (macrophages, PMNs) was observed in the Ereg-/- mice. At 20wk, tumor multiplicity was also significantly decreased in the Ereg-/- mice."	"Bauer et al., 2016, Mol. Carcinog."	N/A	ENST00000244869.2	N/A
AREG Expression	AREG	Expression	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	D	Resistance	chr4	74445134	74455009			A cell line (DFCI076) with EML1-ALK fusion and resistance mutation L1152R showed no response to ALK inhibition with crizotinib or TAE684. There was co-dependancy on AKT and EGFR-signaling and inhibition of both pathways led to decreased cell-growth. Amphiregulin (AREG) production was identified as a potential mediator of EGFR-activation (no other alterations detectable). The same mechanism could be reproduced in a cell line (H3122) without EML1-ALK mutation and resistance to crizotinib that was acquired in-vitro.	"Sasaki et al., 2011, Cancer Res."	N/A	ENST00000395748.3	N/A
AREG Expression	AREG	Expression	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	B	Resistance	chr4	74445134	74455009			Five patients with acquired resistance to crizotinib showed high concentration of amphiregulin in malignant pleural effusions.	"Kim et al., 2013, J Thorac Oncol"	N/A	ENST00000395748.3	N/A
AREG Expression	AREG	Expression	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Sensitivity/Response	chr4	74445134	74455009			"226 cetuximab-treated patients with colorectal cancer (CRC) were analyzed for mRNA expression (by qPCR) of EGFR and its ligands (EGF, TGFA, AREG and EREG). High AREG mRNA expression in KRAS wild type tumours was a favorable predictor in a multivariate analysis (median survival 33 vs. 15months, p=0.0005).   Cetuximab-treated patients with AREG-low KRAS wild type CRC had poor survival, similar to KRAS mutated CRC."	"Pentheroudakis et al., 2013, BMC Cancer"	N/A	ENST00000395748.3	N/A
AREG Expression	AREG	Expression	Head And Neck Squamous Cell Carcinoma	"Cetuximab,Docetaxel"	Predictive	Supports	B	Resistance	chr4	74445134	74455009			"47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 45% of cases expressed high level of AREG. High AREG expression in tumor cells was associated with reduced overall survival  (hazard ratio: 2.2, P = 0.002) and progression free survival (hazard ratio: 2.2, P = 0.016) compared to patients with low AREG expression score. AREG was an independent prognosticator of OS in multivariate Cox analysis. High EGFRvIII and AREG expression levels identified SCCHN (squamous cell carcinoma, head and neck) patients that were less likely to benefit from combination treatment with cetuximab and docetaxel."	"Tinhofer et al., 2011, Clin. Cancer Res."	N/A	ENST00000395748.3	N/A
AREG Expression	AREG	Expression	Colorectal Cancer	Panitumumab	Predictive	Supports	B	Sensitivity/Response	chr4	74445134	74455009			"Prospectively planned retrospective biomarker study in archived tumor tissue from 323 patients from the PICCOLO trial (panitumumab plus irinotecan in CRC patients with KRAS wt). Tumors were classified as ""high expressor"" (either EREG or AREG mRNA level) or ""low expressor"" (neither EREG nor AREG in top tertile).  For RAS wild-type patients with high ligand expression, median PFS was 8.3 [4.0-11.0] months (irinotecan with panitumumab) vs 4.4 [2.8-6.7] months (irinotecan alone); HR, 0.38 [95% CI, 0.24-0.61]; P??001. In RAS wild-type patients with low ligand expression, median PFS was 3.2 [2.7-8.1] months (irinotecan with panitumumab) vs 4.0 [2.7-7.5] months (irinotecan); HR, 0.93 [95% CI, 0.64-1.37]; P??73; interaction test results were significant [P??01]). Results were less clear for response rate (interaction P??17) and OS (interaction P??11)."	"Seligmann et al., 2016, JAMA Oncol"	N/A	ENST00000395748.3	N/A
TET2 Mutation	TET2	Mutation	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	N/A	chr4	105146293	105279816			"In a cohort of 783 young adult patients with acute myeloid leukemia, those with TET2 mutations did not have significantly different rates of complete recovery, refractory disease, or hypoplastic death."	"Gaidzik et al., 2012, J. Clin. Oncol."	Somatic	ENST00000513237.1	"gene_variant,loss_of_function_variant"
TET2 Mutation	TET2	Mutation	Myelodysplastic Syndrome		Prognostic	Supports	B	Better Outcome	chr4	105146293	105279816			"In patients with myelodysplastic syndromes, those with TET2 mutations have been shown to have better overall survival than patients without TET2 mutations."	"Kosmider et al., 2009, Blood"	Somatic	ENST00000513237.1	"gene_variant,loss_of_function_variant"
TET2 Mutation	TET2	Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr4	105146293	105279816			"In patients with cytogenetically normal acute myeloid leukemia, those in the intermediate-I risk group with TET2 mutations had higher rates of complete remission."	"Gaidzik et al., 2012, J. Clin. Oncol."	Somatic	ENST00000513237.1	"gene_variant,loss_of_function_variant"
TET2 Mutation	TET2	Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	N/A	chr4	105146293	105279816			"In patients with cytogenetically normal acute myeloid leukemia, those in the intermediate-I risk group with TET2 mutations did not have significantly different rates of event-free survival, complete remission, disease-free survival, or overall survival."	"Metzeler et al., 2011, J. Clin. Oncol."	Somatic	ENST00000513237.1	"gene_variant,loss_of_function_variant"
TET2 Mutation	TET2	Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr4	105146293	105279816			"In patients classified as intermediate-risk via cytogenetics, TET2 mutations have been shown to be correlated with poor prognosis."	"Chou et al., 2011, Blood"	Somatic	ENST00000513237.1	"gene_variant,loss_of_function_variant"
TET2 Mutation	TET2	Mutation	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr4	105146293	105279816			"In patients with cytogenetically normal acute myeloid leukemia, those in the ELN favorable-risk group with TET2 mutations had shorter event-free survival, lower rates of complete remission, and shorter disease-free survival."	"Metzeler et al., 2011, J. Clin. Oncol."	Somatic	ENST00000513237.1	"gene_variant,loss_of_function_variant"
BRAF PAPSS1::BRAF	BRAF	PAPSS1::BRAF	Melanoma	Vemurafenib	Predictive	Supports	D	Resistance	chr4	107682015	107720452			"BRAF-fusion in ""pan-negative"" melanomas were identified in TCGA data. Cell-lines with PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib."	"Hutchinson et al., 2013, Clin. Cancer Res."	Somatic	ENST00000265174.4	"gene_fusion,transcript_fusion"
BRAF PAPSS1::BRAF	BRAF	PAPSS1::BRAF	Melanoma	Trametinib	Predictive	Supports	D	Sensitivity/Response	chr4	107682015	107720452			"BRAF-fusion in ""pan-negative"" melanomas were identified in TCGA data. Cell-lines with a PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib but sensitive to treatment with Trametinib. This fusion is believed to activate MAPK pathway signaling."	"Hutchinson et al., 2013, Clin. Cancer Res."	Somatic	ENST00000265174.4	"gene_fusion,transcript_fusion"
EGF EXPRESSION	EGF	EXPRESSION	Head And Neck Squamous Cell Carcinoma	Cetuximab	Predictive	Supports	D	Resistance	chr4	109912891	110012266			3 tongue cancer cell lines were used for this study. Addition of recombinant human EGF led to increased cetuximab resistance. EGF downregulation suppressed proliferation of cell lines. Results for amphiregulin and epiregulin were inconclusive.	"Ansell et al., 2016, J. Oral Pathol. Med."	N/A	ENST00000265171.5	N/A
FGFR2 FGFR2::TACC3	FGFR2	FGFR2::TACC3	Cholangiocarcinoma	"Pazopanib,Ponatinib"	Predictive	Supports	C	Sensitivity/Response	chr4	122322057	122436443			In a 43 year old female patient with this fusion in intrahepatic cholangiocarcinoma. Both pazopanib and ponatinib separately resulted in minor tumor shrinkage. This fusion is also shown to be recurrent in multiple other cancer types.	"Borad et al., 2014, PLoS Genet."	Somatic	ENST00000358487.5	transcript_fusion
FGF2 EXPRESSION	FGF2	EXPRESSION	Acute Myeloid Leukemia	Quizartinib	Predictive	Supports	D	Resistance	chr4	122826708	122898236			"AML MOLM14 cells were cocultured with FLT3 inhibitor AC220 (10 nM) and selected proteins expressed in the bone marrow microenvironment. FL and FGF2 were the only proteins that increased viability >2 standard deviations. FGFR inhibitor PD173074 (and FGFR1 siRNA) was able to attenuate the protective effect of FGF2.  Removing FL or FGF2 from ligand-dependent resistant cultures transiently restored sensitivity to AC220, but accelerated acquisition of secondary resistance mutations. 10 FLT3-ITD AML patients treated with AC220 developed increased FGF2 expression (IHC) in marrow stromal cells, which peaked prior to overt clinical relapse and detection of resistance mutations"	"Traer et al., 2016, Cancer Res."	N/A	ENST00000264498.3	N/A
FBXW7 Loss-of-function	FBXW7	Loss-of-function	Renal Cell Carcinoma	Everolimus	Predictive	Supports	E	Sensitivity/Response	chr4	152321258	152536101			mTOR protein levels were found to underly a circadian 24-hour rhythm regulated by time-dependent Fbxw7-mediated ubiquitination. Survival rates of tumor-bearing mice with everolimus showed time-dependency consistent with mTOR protein levels. It could be hypothesized that FBXW7 loss leads to an increase in mTOR protein levels independent of circadian regulation and higher sensitivity to mTOR inhibitors.	"Okazaki et al., 2014, Cancer Res."	N/A	ENST00000281708.4	loss_of_function_variant
FBXW7 Loss-of-function	FBXW7	Loss-of-function	Cancer	Sirolimus	Predictive	Supports	D	Sensitivity/Response	chr4	152321258	152536101			"FBXW7 was shown to target mTOR for ubiquitination and degradation.  A reciprocal relationship between FBXW7 or PTEN loss was identified in breast cancer tumors and cell lines (mutual exclusivity of these two events).  In total only 4 out of 450 tumor and cell line samples had concomitant loss of both genes (p=4.9x10^-7). Cell lines (n=5) with FBXW7 mutations or deletions were significantly sensitive to rapamycin and downregulation of FBXW7 (shRNA) increased the sensitivity to rapamycin. In summary, this evidence suggests that FBXW7 may be a biomarker for cancers sensitivity to inhibitors of the mTOR pathway."	"Mao et al., 2008, Science"	Somatic	ENST00000281708.4	loss_of_function_variant
FBXW7 Mutation	FBXW7	Mutation	Colorectal Cancer	"Cetuximab,Panitumumab"	Predictive	Supports	B	Resistance	chr4	152324294	152411562			65 patients were retrospectively analyzed for mutational profiles predictive of response to EGFR-inhibitors (cetuximab or panitumumab). FBXW7 mutation was found to be more prevalent in non-responders (5 mutations) than responders (1 mutation).	"Lupini et al., 2015, BMC Cancer"	Somatic	ENST00000281708.4	"protein_altering_variant,loss_of_function_variant"
FBXW7 Mutation	FBXW7	Mutation	Cancer	MTOR Inhibitor	Predictive	Supports	B	Sensitivity/Response	chr4	152324294	152411562			"418 patients with advanced cancer were screened for FBXW7 mutations using a multiplex gene panel. 17 FBXW7 mutations were detected (isolated mutation in 2 patients). Ten patients were treated with an mTOR inhibitor with 7 patients having stable disease as best responses and a median time to treatment failure of 2.8 months, two patients had prolonged stable disease of >16 weeks."	"Jardim et al., 2014, PLoS ONE"	Somatic	ENST00000281708.4	"protein_altering_variant,loss_of_function_variant"
TERT Amplification	TERT	Amplification	Acral Lentiginous Melanoma		Prognostic	Supports	B	Poor Outcome	chr5	1253167	1295047			"In patients with acral lentiginous melanoma, those with amplification of TERT had shorter overall survival."	"Diaz et al., 2014, J. Am. Acad. Dermatol."	Somatic	ENST00000310581.5	transcript_amplification
TERT Promoter Mutation	TERT	Promoter Mutation	Skin Melanoma		Prognostic	Supports	B	Poor Outcome	chr5	1295046	1295258			"In patients with nonacral cutaneous melanoma, those with mutations in the TERT promoter had shorter overall survival than wild-type patients."	"Griewank et al., 2014, J. Natl. Cancer Inst."	Somatic	ENST00000310581.5	regulatory_region_variant
TERT Promoter Mutation	TERT	Promoter Mutation	Glioblastoma		Prognostic	Supports	B	Poor Outcome	chr5	1295046	1295258			"In 187 patients with glioblastoma, those with TERT promoter mutations had worse cummulative survival than wild-type patients. The most common mutation was C228T (73% of mutants) followed by C250T (27% of mutants). However, most of the Prognostic value of TERT mutations is thought to be derived from their inverse coorelation with IDH1 mutations."	"Nonoguchi et al., 2013, Acta Neuropathol."	Somatic	ENST00000310581.5	regulatory_region_variant
TERT Promoter Mutation	TERT	Promoter Mutation	Thyroid Gland Cancer		Diagnostic	Supports	B	Positive	chr5	1295046	1295258			TERT promoter mutations are prevalent in aggressive sub-types of thyroid cancers. This work showed that TERT promoter mutations were significantly more prevalent in the tall cell papillary thyroid carcinoma (PTC) samples than in the conventional PTC and follicular variant PTC samples.	"Liu et al., 2013, Endocr. Relat. Cancer"	Somatic	ENST00000310581.5	regulatory_region_variant
TERT Promoter Mutation	TERT	Promoter Mutation	Thyroid Gland Cancer		Prognostic	Supports	B	Poor Outcome	chr5	1295046	1295258			"TERT promoter mutation C228T is significantly associated with BRAF V600E mutation, a marker of more aggressive tumors, in papillary thyroid cancer (PTC). Conversely, the BRAF V600E mutation is significantly more common in PTC cases with the TERT C228T mutation than in cases with the wild-type allele of TERT. TERT promoter mutations were also enriched in the more aggressive tall cell PTC compared to follicular or conventional PTC (30.8% vs 10.3%, P=0.046) and in the worse outcome anaplastic thyroid cancer than differentiated thyroid cancers (46.3% vs 12.2%, P=310?)."	"Liu et al., 2013, Endocr. Relat. Cancer"	Somatic	ENST00000310581.5	regulatory_region_variant
TERT Promoter Mutation	TERT	Promoter Mutation	Brain Glioma		Diagnostic	Supports	B	Positive	chr5	1295046	1295258			"In this meta-analysis of 16 Trials, TERT mutations were more common in glioblastomas (69%), oligodendrogliomas (72%) in comparison to astrocytomas (24%) and oligoastrocytomas (38%)."	"Yuan et al., 2016, J Clin Neurosci"	Somatic	ENST00000310581.5	regulatory_region_variant
TERT Promoter Mutation	TERT	Promoter Mutation	Glioblastoma		Prognostic	Supports	B	Poor Outcome	chr5	1295046	1295258			"In 50 patients with primary glioblastomas, patients without TERT promoter mutations (N=13, median 27 mo) survived longer than those harboring mutations (N=37, 14 mo; P = 0.01 by the log rank test; HR 0.38, 95% CI [0.18, 0.81])."	"Killela et al., 2013, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000310581.5	regulatory_region_variant
TERT Promoter Mutation	TERT	Promoter Mutation	Childhood Low-grade Glioma		Prognostic	Supports	C	Poor Outcome	chr5	1295046	1295258			"The aim of this Chinese study was to identify prognostic biomarkers for pediatric low-grade gliomas (PLGG). Approximately 300 patients were included. Using Sanger sequencing, mutations at TERT promoter (TERTp) regions were identified (C228T: 3/278; C250T: 4/278). The median age of patients with TERTp mutations was 15 years. There were 5 males and 2 females. Six patients had diffuse astrocytoma and one had pilocytic astrocytoma. Tumors were found in the midline of four patients, the hemisphere of two, and the cerebellum of one. Kaplan-Meier survival analysis showed that TERTp mutations were associated with shorter progression-free survival and overall survival [mt (n=6) vs wt (n=205); p<0.0001 for both OS and PFS]. However, the association of TERTp mutations with OS and PFS was no longer statistically significant after adjusting for age, grade, histology, tumor location, and extent of resection in multivariate analysis."	"Yang et al., 2018, Acta Neuropathol."	Somatic	ENST00000310581.5	regulatory_region_variant
TERT C228T	TERT	C228T	Thyroid Gland Papillary Carcinoma		Prognostic	Supports	B	Poor Outcome	chr5	1295113	1295113	G	A	"In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T, recurrence-free survival is worse than in patients harboring one of these mutations or no mutations in either gene."	"Xing et al., 2014, J. Clin. Oncol."	Somatic	ENST00000310581.5	regulatory_region_variant
TERT C228T	TERT	C228T	Thyroid Gland Cancer		Diagnostic	Supports	B	Positive	chr5	1295113	1295113	G	A	"In 308 thyroid fine-needle aspiration biopsies, 0 of the 179 benign tumors displayed either the C228T or the C250T TERT promoter mutation; however, 9 of the 129 differentiated thyroid cancers had either of these mutations. The biomarker displayed 100% diagnostic specificity and 7% sensitivity."	"Liu et al., 2014, Endocr. Relat. Cancer"	Somatic	ENST00000310581.5	regulatory_region_variant
RICTOR Amplification	RICTOR	Amplification	Lung Adenocarcinoma	"Sapanisertib,Onatasertib"	Predictive	Supports	C	Sensitivity/Response	chr5	38937919	39074408			Study describes an 18 year old never smoker patient presenting with lung adenocarcinoma. A genomic profiling assay (FoundationOne) revealed a 7-copy amplification of RICTOR as the only somatic alteration. RICTOR amplification was confirmed via FISH and IHC. On two separate treatments with dual mTOR1/2 inhibitors patient exhibited stable disease for more than 18 months.	"Cheng et al., 2015, Cancer Discov"	Somatic	ENST00000357387.3	transcript_amplification
RICTOR Amplification	RICTOR	Amplification	Lung Small Cell Carcinoma	Vistusertib	Predictive	Does Not Support	C	Sensitivity/Response	chr5	38937919	39074408			"In a phase 2 basket trial, patients with small-cell lung carcinoma (SLC) who failed platinum-based chemotherapy and harbored RICTOR amplification were treated with mTOR 1/2 inhibitor vistusertib (AZD2014). Among 4 patients enrolled in this study, no patients showed tumor response or disease control. Progression free survival was 1.25 months, and three patients experienced adverse effects grade 3 or greater. Authors conclude that further development of the tested AZD2014 regimen is not warranted."	"Sehhoon Park, 2019, ASCO Annual Meeting, Abstract 8514"	Somatic	ENST00000357387.3	transcript_amplification
PIK3R1 Mutation	PIK3R1	Mutation	Breast Cancer	MTOR Kinase Inhibitor PP242	Predictive	Supports	D	Sensitivity/Response	chr5	68215720	68301821			"Sensitivity to mTORC1/2 inhibitor PP242 was assessed in a panel of breast cancer cell lines with various mutation backgrounds. PTEN and PIK3CA mutations were heavily represented in the panel. However, a PTEN and PIK3CA wild type cell line 'HS578T' was found to harbor a mutation in the PI3K regulatory protein PIK3R1. Like PIK3CA mutant cell lines, the PIK3R1 mutant HS578T line was also determined to be sensitive to PP242. Approximately 70% of PIK3CA wild type lines were not sensitive to PP242. This suggests that mutations in the PI3K holoenzyme may be targetable by mTORC1/2 inhibition."	"Weigelt et al., 2011, Oncogene"	Somatic	ENST00000521381.1	"missense_variant,gain_of_function_variant"
APC Mutation	APC	Mutation	Colon Carcinoma	JW55	Predictive	Supports	D	Sensitivity/Response	chr5	112707521	112846239			Canonical Wnt signaling in colon carcinoma cells with APC mutation was inhibited by JW55 treatment.	"Waaler et al., 2012, Cancer Res."	Somatic	ENST00000457016.1	
APC Mutation	APC	Mutation	Colorectal Cancer	G007-LK	Predictive	Supports	D	Sensitivity/Response	chr5	112707521	112846239			G007-LK inhibits in vivo tumor growth in a subset of APC-mutant colorectal cancers xenograft models but may be limited by intestinal toxicity.	"Lau et al., 2013, Cancer Res."	Somatic	ENST00000457016.1	
ABL1 SNX2::ABL1	ABL1	SNX2::ABL1	B-lymphoblastic Leukemia/lymphoma	Dasatinib	Predictive	Supports	C	Resistance	chr5	122774996	122799855			"A 7-yr-old boy with B-cell precursor acute lymphoblastic leukemia was found to harbor the SNX2-ABL1 fusion gene. Gene expression analysis showed enrichment for BCR-ABL1+ ALL using GSEA. After first relapse (15 months after diagnosis) the patient was given imatinib at a dose of 240 mg/m2/d once daily and his disease stabilized for 2 months. The patient received dasatinib (80 mg/m2/d once daily) after an umbilical cord blood transplant and did not respond to treatment. Patient was put back on imatinib at a dose of 600 mg/m2/d once daily which rapidly decreased the number of blast cells. However, 6 months after transplant he had bone marrow relapse and did not again achieve remission by the time of reporting."	"Masuzawa et al., 2014, Eur. J. Haematol."	Somatic	ENST00000379516.2	transcript_fusion
ABL1 SNX2::ABL1	ABL1	SNX2::ABL1	B-lymphoblastic Leukemia/lymphoma	Imatinib	Predictive	Supports	C	Reduced Sensitivity	chr5	122774996	122799855			"In a 29-year-old man with pre B-cell ALL, the t(5;9)(q23;q34) [SNX2-ABL1] was identified. The SNX2-ABL1 fusion, which joins the N-terminal domain of SNX2 without the PX domain to ABL1 exon 4, was detected by RACE PCR and confirmed by RT-PCR and Sanger sequencing. The patient responded to initial chemotherapy, but relapsed early. He then demonstrated a response to hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-C-VAD), but relapsed again. The patient next received imatinib and supportive measures, including hydroxycarbamide, but unfortunately succumbed to his disease approximately one year after diagnosis."	"Ernst et al., 2011, Br. J. Haematol."	Somatic	ENST00000379516.2	transcript_fusion
ABL1 SNX2::ABL1	ABL1	SNX2::ABL1	B-lymphoblastic Leukemia/lymphoma	"Imatinib,Dasatinib"	Predictive	Supports	D	Resistance	chr5	122774996	122799855			"SNX2-ABL1 protein (SNX2 exon 3 to ABL1 exon 4) was transfected in murine Ba/F3 cells and proliferation rates in the presence of IL-3, and tyrosine kinase inhibitors, imatinib and dasatinib was compared to BCR-ABL1 p190 and p210 transfected Ba/F3 cells. Cell proliferation assays showed that SNX2-ABL1 transfected cells had over 20% and 50% of cell survival after 24-hr incubation with imatinib (2M) and dasatinib (10nM). SNX2-ABL1 transfected cells continued to proliferate again 48 hr after treatment with dasatinib (10nM). This data was further supported by apoptosis (annexin V-propidium iodide) studies. In addition, newer tyrosine kinase inhibitors including nilotinib (500nM), bafetinib (500nM), rebastinib (500nM), and ponatinib (100nM), were examined and SNX2-ABL1 cells showed a better response, but still some resistance to these compounds. Further examination of downstream phosphorylation of SNX2-ABL1 cells showed only partial inhibition with imatinib and dasatinib."	"Tomita et al., 2014, Leuk. Res."	Somatic	ENST00000379516.2	transcript_fusion
ABL1 SNX2::ABL1	ABL1	SNX2::ABL1	B-lymphoblastic Leukemia/lymphoma		Prognostic	Supports	C	Poor Outcome	chr5	122774996	122799855			"A 16 yr-old male with precursor B-ALL was found to have the t(5;9)(q23;q34) in his peripheral blasts. Fluorescence in situ hybridization (FISH), RT-PCR, and sequencing of the product confirmed a SNX2-ABL1 fusion gene (SNX2 exon 3 fused in frame to ABL1 exon 4) was present. The patient also was found to carry an IKZF1 deletion (exons 2-8) and amplification of PAX5. The patient was treated with vindesine, idarubicin, and dexamethasone (VDP) and VDCP (plus cyclophosphamide) regimens. He received two bone marrow transplants, but eventually died of disease. The patient did not receive tyrosine-kinase inhibitors."	"Mu et al., 2017, Leuk. Lymphoma"	Somatic	ENST00000379516.2	transcript_fusion
ABL1 SNX2::ABL1	ABL1	SNX2::ABL1	B-lymphoblastic Leukemia/lymphoma		Prognostic	Supports	C	Poor Outcome	chr5	122774996	122799855			"This case report describes a 7-year old boy with B-ALL who presented with high white blood count (115.4x109 /L). Karyotype analysis showed a t(5;9)(q22;q34), resulting in a SNX2-ABL1 fusion. The patient was treated based on the ALL-BFM95 regimen; although he received remission, he relapsed during maintenance, 15 months after the initial diagnosis. He could not achieve the second remission using chemotherapy, but was treated at this time with imatinib (dose of 240 mg/m2 /d once daily); this allowed to achieve disease control and proceed with an umbilical cord blood transplant. However, at 6 months from transplantation, the patient developed bone marrow relapse again. He never achieved a remission after the second relapse (despite salvage chemotherapies and therapy with both imatinib and dasatinib). The patient died of progressive disease."	"Masuzawa et al., 2014, Eur. J. Haematol."	Somatic	ENST00000379516.2	transcript_fusion
ABL1 SNX2::ABL1	ABL1	SNX2::ABL1	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"		Diagnostic	Supports	C	Positive	chr5	122774996	122799855			"This retrospective study intended to clarify clinical characteristics of patients with B-lymphoblastic leukemia/lymphoma (B-ALL) and kinase fusions that are not well described (excluding ETV6-RUNX1, E2A-PBX1, MLL rearrangements and BCR-ABL). The SNX2-ABL1 fusion is rare; in this study investigating 373 high risk pediatric B-ALL patients of which 29 demonstrated uncommon kinase gene fusions, only one case with SNX2-ABL1 (exon 3-exon 4) was observed. Gene expression profiles were compared to Ph-positive B-ALL and reportedly all fusion-containing samples (except P2RY8-CRLF2) were similar to BCR-ABL1-positive patients. This patient did not respond to tyrosine kinase inhibitors administered in combination with chemotherapy at the first or second relapses."	"Imamura et al., 2016, Blood Cancer J"	Somatic	ENST00000379516.2	transcript_fusion
ABL1 SNX2::ABL1	ABL1	SNX2::ABL1	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"		Diagnostic	Supports	C	Positive	chr5	122774996	122799855			"In the study involving 1725 B-ALL patients, 264 were identified by microarray-based algorithm to have a Ph-like expression signature. Next generation sequencing (RNAseq, WGS, and/or WES) performed on 154 Ph-like patients revealed 91% possessed genomic alterations activating kinase signaling with 96 (62%) involving rearrangements. In one adolescent male, an in-frame SNX2-ABL1 fusion (exon 3 and exon 4) with the ABL1 tyrosine kinase domain intact was identified and confirmed by RT-PCR and Sanger. This patient, evaluated by WES and RNA-seq, also harbored IKZF1, EBF1, and VPREB deletions, and was designated Ph-like non CRLF2."	"Roberts et al., 2014, N. Engl. J. Med."	Somatic	ENST00000379516.2	transcript_fusion
CSF1R MEF2D::CSF1R	CSF1R	MEF2D::CSF1R	Acute Lymphoblastic Leukemia	"GW-2580,Imatinib"	Predictive	Supports	D	Sensitivity/Response	chr5	150054224	150061849			Cell lines with MEF2D-CSF1R fusion show sensitivity to the tyrosine kinase inhibitors Imatinib and GW-2580.	"Lilljebjrn et al., 2014, Leukemia"	Somatic	ENST00000348159.4	transcript_fusion
CSF1R MEF2D::CSF1R	CSF1R	MEF2D::CSF1R	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	Imatinib	Predictive	Supports	C	Sensitivity/Response	chr5	150054224	150061849			"This study describes a cohort of 24 patients with BCR-ABL1-like B-ALL and ABL-class kinase rearrangement exposed to TKI frontline or at relapse, who showed favorable MRD response and outcome. Specifically, one 34-year-old man with MEF2D-CSF1R identified by RNAseq was prescribed an unspecified dose of imatinib as adjuvant to his frontline chemotherapy (protocol GRAALL-2014). His initial MRD analysis at 94 days remained positive for blasts (1 x 10^-4), but was consistent with continuous complete remission at day 147."	"Tanasi et al., 2019, Blood"	Somatic	ENST00000348159.4	transcript_fusion
PDGFRB EBF1::PDGFRB	PDGFRB	EBF1::PDGFRB	Childhood B-cell Acute Lymphoblastic Leukemia	Imatinib	Predictive	Supports	C	Sensitivity/Response	chr5	150113837	150125577			"A 10-year-old boy with B-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and harboring an EBF1-PDGFRB fusion responded to imatinib plus induction chemotherapy (vincristine, daunorubicin, prednisone, and intrathecal methotrexate). Complete remission was achieved with bone marrow MRD of 0.059% by flow cytometry and normal PDGFRB by FISH. Consolidation therapy with cyclophosphamide, cytarabine, mercaptopurine, and imatinib followed and the patient was still in remission 10 months after beginning imatinib."	"Weston et al., 2013, J. Clin. Oncol."	Somatic	ENST00000517373.1	transcript_fusion
PDGFRB EBF1::PDGFRB	PDGFRB	EBF1::PDGFRB	Childhood B-cell Acute Lymphoblastic Leukemia	Imatinib	Predictive	Supports	C	Sensitivity/Response	chr5	150113837	150125577			"A 16-year-old boy with B-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and harboring an IKZF1 deletion (delta 2-7) and a 5q33 microdeletion resulting in an EBF1-PDGFRB fusion responded to continuous imatinib (400 mg/d) during consolidation. Following consolidation therapy that included dexamethasone, vincristine, etoposide, cytarabine, and high-dose methotrexate, MRD declined to 10^-5 and the patient underwent bone marrow transplant. MRD performed at 105 days post-BMT found no detectable blasts with a sensitivity of 10^-5."	"Lengline et al., 2013, Haematologica"	Somatic	ENST00000517373.1	transcript_fusion
PDGFRB EBF1::PDGFRB	PDGFRB	EBF1::PDGFRB	Childhood B-cell Acute Lymphoblastic Leukemia	Imatinib	Predictive	Supports	C	Sensitivity/Response	chr5	150113837	150125577			Two patients with EBF1-PDGFRB positive pediatric B-ALL were treated with induction/post-induction therapy and Imatinib. Neither patient experienced disease relapse. One patient died of an undefined encephalopathy at 6 mos post-transplant and the other patient was alive in clinical remission at 10 months after diagnosis.	"Schwab et al., 2016, Blood"	Somatic	ENST00000517373.1	transcript_fusion
PDGFRB EBF1::PDGFRB	PDGFRB	EBF1::PDGFRB	Childhood B-cell Acute Lymphoblastic Leukemia	"Imatinib,Dasatinib"	Predictive	Supports	C	Sensitivity/Response	chr5	150113837	150125577			"The EBF1-PDGFRB fusion was detected in leukemia cells of a 7 year old Latino boy who presented with B-ALL and initial WBC of 600,000. He failed to enter remission with 4 drug induction (90% blasts at day 23), and showed testicular involvement. SNP array showed deletion of IKZF1 deletion and gains in 5q32 and 5q33.3 that interrupted the PDGFRB and EBF1 loci, respectively. FISH studies demonstrated an extra PDGFRB signal with suspect EBF1-PDGFRB that needs molecular confirmation. Imatinib, cyclophosphamide and etoposide were commenced with MRD 4.3% after 1 month. Imatinib dose was increased with MRD 0.44% after additional month of treatment. MRD was 0.0226% after two months of dasatinib treatment, and the patient proceeded to matched unrelated donor hematopoietic stem cell transplantation."	"Roberts et al., 2014, N. Engl. J. Med."	Somatic	ENST00000517373.1	transcript_fusion
PDGFRB EBF1::PDGFRB	PDGFRB	EBF1::PDGFRB	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	"Imatinib,Chemotherapy"	Predictive	Supports	C	Sensitivity/Response	chr5	150113837	150125577			"A 9 year old girl with B-lymphoblastic leukemia/ lymphoma (2016 WHO) relapsed 15 months post-maintenance chemotherapy. FISH and genomic analysis detected the EBF1-PDGFRB fusion (exon 11 with Exon14). The patient was treated with induction [fludarabine, idarubicin and cytarabine] therapy followed by additional chemotherapy (cyclophosphamide, adriamycin, vincristine, and dexamethasone followed by high-dose methotrexate and cytarabine) plus tyrosine kinase inhibitor (TKI, imatinib). Imatinib was stopped 10 days before cord blood transplant (CBT) with reduced intensity conditional and re-initiated on day 47 until 12 months post-transplant. The EBF1-PDGFRB transcript level measured using reverse-transcriptase polymerase chain reaction remained below detection limit (<2.5x102 copies/ microgram RNA) for 36 months post CBT. Furthermore, the patient maintained molecular remission during the 24 months post-CBT and the 12 months following completion of TKI administration, based on minimal residual disease (MRD) testing conducted every 6 months."	"Sakurai et al., 2020, J. Pediatr. Hematol. Oncol."	Somatic	ENST00000517373.1	transcript_fusion
HAVCR2 Overexpression	HAVCR2	Overexpression	Lung Non-small Cell Carcinoma	PD1 Inhibitor	Predictive	Supports	C	Resistance	chr5	157085832	157109714			"In a preclinical study in an immunocompetent mouse model of lung adenocarcinoma, upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3, aka HAVCR2) was observed after progression under PD-1 antibody. A survival advantage was observed with the addition of a TIM-3 blocking antibody. Two patients who developed adaptive resistance to anti-PD-1 treatment also showed TIM-3 upregulation in blocking antibody-bound T cells at treatment failure."	"Koyama et al., 2016, Nat Commun"	N/A	ENST00000307851.4	N/A
HAVCR2 Overexpression	HAVCR2	Overexpression	Lung Non-small Cell Carcinoma	"PD1 Inhibitor,Anti-TIM-3 Monoclonal Antibody"	Predictive	Supports	D	Sensitivity/Response	chr5	157085832	157109714			"In a preclinical study in an immunocompetent mouse model of lung adenocarcinoma, upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3, aka HAVCR2) was observed after progression under PD-1 antibody. A survival advantage was observed with the addition of a TIM-3 blocking antibody."	"Koyama et al., 2016, Nat Commun"	N/A	ENST00000307851.4	N/A
PDGFRB EBF1::PDGFRB	PDGFRB	EBF1::PDGFRB	Childhood B-cell Acute Lymphoblastic Leukemia	Imatinib	Predictive	Supports	C	Sensitivity/Response	chr5	158707979	159099761			"A 10-year-old boy with B-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and harboring an EBF1-PDGFRB fusion responded to imatinib plus induction chemotherapy (vincristine, daunorubicin, prednisone, and intrathecal methotrexate). Complete remission was achieved with bone marrow MRD of 0.059% by flow cytometry and normal PDGFRB by FISH. Consolidation therapy with cyclophosphamide, cytarabine, mercaptopurine, and imatinib followed and the patient was still in remission 10 months after beginning imatinib."	"Weston et al., 2013, J. Clin. Oncol."	Somatic	ENST00000517373.1	transcript_fusion
PDGFRB EBF1::PDGFRB	PDGFRB	EBF1::PDGFRB	Childhood B-cell Acute Lymphoblastic Leukemia	Imatinib	Predictive	Supports	C	Sensitivity/Response	chr5	158707979	159099761			"A 16-year-old boy with B-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and harboring an IKZF1 deletion (delta 2-7) and a 5q33 microdeletion resulting in an EBF1-PDGFRB fusion responded to continuous imatinib (400 mg/d) during consolidation. Following consolidation therapy that included dexamethasone, vincristine, etoposide, cytarabine, and high-dose methotrexate, MRD declined to 10^-5 and the patient underwent bone marrow transplant. MRD performed at 105 days post-BMT found no detectable blasts with a sensitivity of 10^-5."	"Lengline et al., 2013, Haematologica"	Somatic	ENST00000517373.1	transcript_fusion
PDGFRB EBF1::PDGFRB	PDGFRB	EBF1::PDGFRB	Childhood B-cell Acute Lymphoblastic Leukemia	Imatinib	Predictive	Supports	C	Sensitivity/Response	chr5	158707979	159099761			Two patients with EBF1-PDGFRB positive pediatric B-ALL were treated with induction/post-induction therapy and Imatinib. Neither patient experienced disease relapse. One patient died of an undefined encephalopathy at 6 mos post-transplant and the other patient was alive in clinical remission at 10 months after diagnosis.	"Schwab et al., 2016, Blood"	Somatic	ENST00000517373.1	transcript_fusion
PDGFRB EBF1::PDGFRB	PDGFRB	EBF1::PDGFRB	Childhood B-cell Acute Lymphoblastic Leukemia	"Imatinib,Dasatinib"	Predictive	Supports	C	Sensitivity/Response	chr5	158707979	159099761			"The EBF1-PDGFRB fusion was detected in leukemia cells of a 7 year old Latino boy who presented with B-ALL and initial WBC of 600,000. He failed to enter remission with 4 drug induction (90% blasts at day 23), and showed testicular involvement. SNP array showed deletion of IKZF1 deletion and gains in 5q32 and 5q33.3 that interrupted the PDGFRB and EBF1 loci, respectively. FISH studies demonstrated an extra PDGFRB signal with suspect EBF1-PDGFRB that needs molecular confirmation. Imatinib, cyclophosphamide and etoposide were commenced with MRD 4.3% after 1 month. Imatinib dose was increased with MRD 0.44% after additional month of treatment. MRD was 0.0226% after two months of dasatinib treatment, and the patient proceeded to matched unrelated donor hematopoietic stem cell transplantation."	"Roberts et al., 2014, N. Engl. J. Med."	Somatic	ENST00000517373.1	transcript_fusion
PDGFRB EBF1::PDGFRB	PDGFRB	EBF1::PDGFRB	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	"Imatinib,Chemotherapy"	Predictive	Supports	C	Sensitivity/Response	chr5	158707979	159099761			"A 9 year old girl with B-lymphoblastic leukemia/ lymphoma (2016 WHO) relapsed 15 months post-maintenance chemotherapy. FISH and genomic analysis detected the EBF1-PDGFRB fusion (exon 11 with Exon14). The patient was treated with induction [fludarabine, idarubicin and cytarabine] therapy followed by additional chemotherapy (cyclophosphamide, adriamycin, vincristine, and dexamethasone followed by high-dose methotrexate and cytarabine) plus tyrosine kinase inhibitor (TKI, imatinib). Imatinib was stopped 10 days before cord blood transplant (CBT) with reduced intensity conditional and re-initiated on day 47 until 12 months post-transplant. The EBF1-PDGFRB transcript level measured using reverse-transcriptase polymerase chain reaction remained below detection limit (<2.5x102 copies/ microgram RNA) for 36 months post CBT. Furthermore, the patient maintained molecular remission during the 24 months post-CBT and the 12 months following completion of TKI administration, based on minimal residual disease (MRD) testing conducted every 6 months."	"Sakurai et al., 2020, J. Pediatr. Hematol. Oncol."	Somatic	ENST00000517373.1	transcript_fusion
PTTG1 OVEREXPRESSION	PTTG1	OVEREXPRESSION	Meningioma		Prognostic	Supports	B	Poor Outcome	chr5	160421822	160428741			"144 cases (discovery set: N=62 discovery; independent validation set: N = 82) of meningiomas were analyzed for transcriptional features defining aggressive clinical course (recurrent, malignantly progressing, or WHO grade III). Meningiomas were categorized into non-recurrent (NR), recurrent (R), and tumors undergoing malignant progression (M). Unsupervised transcriptomic analysis in 62 meningiomas revealed a large set of differentially expressed genes in aggressive subgroups (R+M tumors and WHO grade III, n=332; p<0.01, FC>1.25). Multivariate analysis identified PTTG1 and LEPR mRNA expression independent of gender, WHO grade and extent of resection. The patient group with the longest progression free survival was characterized by co-occurrence of low PTTG1 and high LEPR mRNA expression. IHC in 36 tumors validated these results at the protein level."	"Schmidt et al., 2016, Oncotarget"	N/A	ENST00000352433.5	N/A
ALK NPM::ALK	ALK	NPM::ALK	Anaplastic Large Cell Lymphoma	Crizotinib	Predictive	Supports	D	Sensitivity/Response	chr5	171387116	171391799			"NPM-ALK in anaplastic large cell lymphoma (ALCL) was the first ALK-fusion to be discovered and characterized.  In this study, targeted activity against NPM-ALK by the ALK and MET inhibitor crizotinib was assessed in cell lines and tumor xenograft models. Treatment of NPM-ALK positive ALCL cell lines Karpas299 and SU-DHL-1 potently inhibited growth, and this was seen to occur at concentrations which also inhibited NPM-ALK phosphorylation in these cells. Administration of 100mg/kg/d crizotinib resulted in complete regression of all tumors, indicating that NPM-ALK could be an effective target for crizotinib in ALCL."	"Christensen et al., 2007, Mol. Cancer Ther."	Somatic	ENST00000517671.1	transcript_fusion
ALK NPM::ALK	ALK	NPM::ALK	Anaplastic Large Cell Lymphoma	Crizotinib	Predictive	Supports	B	Sensitivity/Response	chr5	171387116	171391799			"In the second part of this Phase I study NCT00939770, nine patients between the ages of 12 months and 22 years with anaplastic large cell lymphoma (ALCL), who were refractory to treatment and for whom no further known treatments were available, were treated with crizotinib. Six patients with detectable NPM-ALK transcript levels responded with partial response, 1 with complete response, and 1 with stable disease.  Crizotinib was well tolerated in these children."	"Moss et al., 2013, Lancet Oncol."	Somatic	ENST00000517671.1	transcript_fusion
ALK NPM::ALK	ALK	NPM::ALK	Cancer	Crizotinib	Predictive	Supports	D	Sensitivity/Response	chr5	171387116	171391799			"In Ba/F3 cells, crizotinib sensitivty of the NPM-ALK variant was compared to crizotinib sensitivity of EML4-ALK variant 3. 50% of maximal inhibitory concentration for NPM-ALK was 42 nM, which was approximately 4x greater than IC50 of 11 nM obtained for EML4-ALK. The IC50 for parental Ba/F3 supplemented with IL3 was 2299 nM, resulting in a fold difference of 209.2 for EML4-ALK and 55.1 for NPM-ALK, indicating some reduced sensitivity for NPM-ALK in direct comparison to EML4-ALK, but substantial sensitization to crizotinib for NPM-ALK in Ba/F3 cells."	"Fontana et al., 2015, Cancer Med"	Somatic	ENST00000517671.1	transcript_fusion
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia		Diagnostic	Does Not Support	B	Positive	chr5	171410527	171410565			NPM1 mutations were not associated with the M3 acute myeloid leukemia FAB subtype (0/55).	"Thiede et al., 2006, Blood"	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia		Diagnostic	Supports	B	Negative	chr5	171410527	171410565			NPM1 mutations were not associated with the M2 FAB subtype of acute myeloid leukemia.	"Schnittger et al., 2005, Blood"	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia		Diagnostic	Supports	A	Positive	chr5	171410527	171410565			AML with mutated NPM1 is a provisional entity in the World Health Organization (WHO) classification of acute myeloid leukemia (AML). This mutation should be tested for in clinical trials and is recommended for testing in patients with cytogentically normal AML.	"Vardiman et al., 2009, Blood"	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia		Diagnostic	Supports	B	Positive	chr5	171410527	171410565			NPM1 mutations were associated with de novo AML as well as M4 and M5 FAB subtypes.	"Gale et al., 2008, Blood"	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia		Diagnostic	Supports	B	Positive	chr5	171410527	171410565			"NPM1 mutations were associated with M4, M5a and M5b FAB subtypes of acute myeloid leukemia."	"Schnittger et al., 2005, Blood"	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia		Diagnostic	Supports	B	Positive	chr5	171410527	171410565			NPM1 mutations were associated with M5a and M5b FAB subtypes of acute myeloid leukemia.	"Thiede et al., 2006, Blood"	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia		Diagnostic	Supports	B	Positive	chr5	171410527	171410565			NPM1 mutations were associated with normal karyotype in older (>60) patients.	"Schlenk et al., 2009, Haematologica"	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia	Tretinoin	Predictive	Does Not Support	B	Sensitivity/Response	chr5	171410527	171410565			"ATRA treatment plus chemotherapy (daunorubicin, Ara-C, and thioguanine, N=113) did not effect overall survival in patients <60 years old with NPM1 mutation regardless of FLT3-ITD status compared to chemotherapy alone (N=94)."	"Burnett et al., 2010, Blood"	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia	Tretinoin	Predictive	Supports	B	Sensitivity/Response	chr5	171410527	171410565			ATRA treatment improved overall and relapse-free survival in older (>60) patients with mutant NPM1 and without FLT3-ITD.	"Schlenk et al., 2009, Haematologica"	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia	Daunorubicin	Predictive	Supports	B	Sensitivity/Response	chr5	171410527	171410565			"Young patients (18-60) with NPM1 mutations had improved overall survival following high-dose versus standard dose daunorubicin (p=0.01) in univariate analysis. However, the adjusted p-value for multiple testing is 0.11."	"Patel et al., 2012, N. Engl. J. Med."	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia	Valproic Acid	Predictive	Supports	B	Sensitivity/Response	chr5	171410527	171410565			"For patients with NPM1 mutation that achieved CR following induction therapy, relapse-free survival was improved following treatment with valproic acid."	"Tassara et al., 2014, Blood"	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia	"NSC348884,Tretinoin"	Predictive	Supports	D	Sensitivity/Response	chr5	171410527	171410565			NSC348884 combined with ATRA treatment induces apoptosis in primary AML cells harboring mutant NPM1 but not in cells with wildtype NPM1 or both mutant NPM1 and FLT3-ITD.	"Balusu et al., 2011, Blood"	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia	"Anti-CD123,Anti-CD33"	Predictive	Supports	E	Sensitivity/Response	chr5	171410527	171410565			"CD33 and CD123 expression was significantly increased in patients with NPM1 mutation with FLT3-ITD, indicating these patients may respond to combined anti-CD33 and anti-CD123 therapy."	"Ehninger et al., 2014, Blood Cancer J"	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia	Anti-CD33	Predictive	Supports	E	Sensitivity/Response	chr5	171410527	171410565			"CD33 expression was significantly increased in patients with NPM1 mutation with or without FLT3-ITD, indicating these patients may respond to anti-CD33 therapy."	"Ehninger et al., 2014, Blood Cancer J"	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr5	171410527	171410565			NPM1 mutation without FLT3-ITD was associated with reduced relapse risk and increased overall survival in young adult acute myeloid leukemia patients (median age 43).	"Gale et al., 2008, Blood"	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr5	171410527	171410565			"Patients with NPM1 mutations were associated with improved complete remission rates as well as overall and disease free survival when all ages and karyotype were analyzed; however, when only normal karyotype patients were analyzed, only complete remission rates were improved."	"Schlenk et al., 2009, Haematologica"	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr5	171410527	171410565			"Complete remission rates were higher (P<0.001) and both disease-free survival (N=205 vs 352, P=0.041) and overall survival (N=372 vs 956, P=0.022) were longer for AML patients with Exon 12 NPM1 mutations (irrespective of FLT3 status) than those with wildtype NPM1. Improved CR rates were also higher for those with NPM1 exon 12 mutations and normal karyotype. In multivariate analysis, NPM1 mutation alone (FLT3 wildtype) was associated with improved overall survival (but not DFS) in the entire cohort and in normal karyotype patients <60 years old."	"Thiede et al., 2006, Blood"	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr5	171410527	171410565			"Complete remission rates were higher (70.5% vs 54.7%, P = 0.003) and event-free survival was longer (median, 428 vs 336 days; P = 0.012) for normal karyotype AML patients (median age 60.3 years) with Exon 12 NPM1 mutations (N=212) compared to those with wildtype NPM1 (N=189)."	"Schnittger et al., 2005, Blood"	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr5	171410527	171410565			Cytoplasmic localization of NPM in AML patients was an independent prognositic factor associated with complete remission in response to induction therapy in a multivariate analysis (p=0.019) but not in a univariate analysis (p=0.07).	"Falini et al., 2005, N. Engl. J. Med."	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr5	171410527	171410565			Intermediate risk patients with mutant NPM1 had improved overall survival with the presence of either IDH1 or IDH2 mutations than those wildtype for both IDH1 and IDH2.	"Patel et al., 2012, N. Engl. J. Med."	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr5	171410527	171410565			"Normal karyotype patients with NPM1 mutation and without FLT3-ITD had improved overall and relapse-free survival, complete remission rates and remission duration compared to all other combinations of mutants."	"Bchner et al., 2009, J. Clin. Oncol."	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr5	171410527	171410565			"NPM1 mutation (N=724) was associated with higher complete remission rates (92% vs 82%; P < 0.0001), lower cumulative incidence of relapse (42% vs 58%; P < 0.0001) and higher overall survival (48% vs 27%; P < .0001) than NPM1 wildtype status (N=885) in intermediate risk, young adult AML patients (median age 46 years)."	"Linch et al., 2014, Blood"	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr5	171410527	171410565			"NPM1 mutation was associated with increased overall, event-free and relapse-free survival and remission after induction therapy in the entire cohort and in the cytogenetically normal subset of patients."	"Gaidzik et al., 2012, J. Clin. Oncol."	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr5	171410527	171410565			"In young patients (age 16-60) with previously untreated, cytogenetically normal acute myeloid leukemia, NPM1 mutation without FLT3-ITD was significantly associated with complete remission in multivariate analysis (odds ratio, 1.48; 95% CI, 1.21 to 1.80). Multivariate analysis was performed on all patients that were evaluated for a mutation in at least 1 gene (CEBPA, FLT3-ITD or NPM1) totaling 693/872 patients in the study. 130 patients had NPM1 mutations without FLT3-ITD. NPM1 mutations were evaluated in 570 patients (310 mutated).  FLT3-ITD was evaluated in 531 patients (164 mutated)."	"Schlenk et al., 2008, N. Engl. J. Med."	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr5	171410527	171410565			"NPM1 mutations were associated with increased complete remission rates as well as longer overall disease free survival in normal karyotype AML patients >59 years old, particularly in those >69 years old."	"Becker et al., 2010, J. Clin. Oncol."	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia		Prognostic	Supports	B	Better Outcome	chr5	171410527	171410565			"Younger (16-60), normal karyotype AML patients with Exon 12 NPM1 mutation and without FLT3-ITD have increased overall survival (N=74, P = .001), relapse-free survival (N=86, P < .001) and response to induction chemotherapy. Multivariate analysis identified NPM1 mutation in the absence of FLT3-ITD as a prognostic marker for the achievement of CR (P=0.004)."	"Dhner et al., 2005, Blood"	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr5	171410527	171410565			Monitoring NPM1 mutation by cDNA-based RT-PCR effectively predicted relapse in 62/93 patients by >1 log increase in NPM1 levels (N=57) or lack of reduction in NPM1 levels following first line therapy (N=15).	"Schnittger et al., 2009, Blood"	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr5	171410527	171410565			TET2 mutation reduces overall survival of normal karyotype patients with either an NPM1 mutation or NPM1 mutation without FLT3-ITD.	"Tian et al., 2014, Int. J. Hematol."	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia		Prognostic	Supports	B	Poor Outcome	chr5	171410527	171410565			"Peripheral blood from NPM1 mutated AMLs was assessed for NPM1 mutation status at multiple time points using RT-qPCR with primers designed to amplify different mutant NPM1 transcripts. The test development cohort consisted of 194 cases and an independent validation cohort consisted of 91 cases. Persistence of NPM1-mutated transcripts in blood was present in 15% of the patients after the second chemotherapy cycle. This persistence was associated with a greater risk of relapse after 3 years of follow-up than was an absence of such transcripts (82% vs. 30%; hazard ratio, 4.80; 95% confidence interval [CI], 2.95 to 7.80; P<0.001) and a lower rate of survival (24% vs. 75%; hazard ratio for death, 4.38; 95% CI, 2.57 to 7.47; P<0.001). The presence of minimal residual disease was the only independent prognostic factor for death in multivariate analysis (hazard ratio, 4.84; 95% CI, 2.57 to 9.15; P<0.001). On sequential monitoring of minimal residual disease, relapse was reliably predicted by a rising level of NPM1-mutated transcripts."	"Ivey et al., 2016, N. Engl. J. Med."	Somatic	ENST00000517671.1	exon_variant
NPM1 EXON 12 MUTATION	NPM1	EXON 12 MUTATION	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	Better Outcome	chr5	171410527	171410565			"In normal karyotype patients with AML (15-65 years old), complete remission rates and overall, event-free and relapse-free survival were not different for patients harboring NPM1 exon 12 mutations (N=50) than those wildtype for NPM1 (N=56)."	"Boissel et al., 2005, Blood"	Somatic	ENST00000517671.1	exon_variant
NPM1 W288FS	NPM1	W288FS	Acute Myeloid Leukemia		Diagnostic	Does Not Support	B	Positive	chr5	171410543	171410544		TCTG	No NPM1 mutations were identified in patients with favorable risk cytogenetics (79/215 patients).	"Ley et al., 2010, N. Engl. J. Med."	Somatic	ENST00000517671.1	frameshift_elongation
NPM1 W288FS	NPM1	W288FS	Acute Myeloid Leukemia		Diagnostic	Supports	B	Positive	chr5	171410543	171410544		TCTG	NPM1 mutations were associated with intermediate risk cytogenetics (including normal karyotype).	"Ley et al., 2010, N. Engl. J. Med."	Somatic	ENST00000517671.1	frameshift_elongation
NPM1 W288FS	NPM1	W288FS	Acute Myeloid Leukemia	NSC348884	Predictive	Supports	D	Sensitivity/Response	chr5	171410543	171410544		TCTG	NSC348884 induced apoptosis in OPI-AML3 cells harboring an NPM1 mutation.	"Balusu et al., 2011, Blood"	Somatic	ENST00000517671.1	frameshift_elongation
NPM1 W288FS	NPM1	W288FS	Acute Myeloid Leukemia	"Daunorubicin,Etoposide,Cytarabine"	Predictive	Supports	E	Sensitivity/Response	chr5	171410543	171410544		TCTG	"NPM1 mutation (Type A, W288fs) causes cytoplasmic localization of NPM when transfected into a non-hematopoietic cell line (293T cells). Cytoplasmic localization of NPM in AML patients was associated with good response to induction therapy."	"Falini et al., 2005, N. Engl. J. Med."	Somatic	ENST00000517671.1	frameshift_elongation
NEDD9 EXPRESSION	NEDD9	EXPRESSION	Hepatocellular Carcinoma		Prognostic	Supports	B	Poor Outcome	chr6	11184818	11382348			"IHC was performed in 123 hepatocellular carcinoma tissues and their adjacent normal liver tissues for protein expression of HEF1 (NEDD9). Overexpression of HEF1 protein was observed in HCC tissue when compared with their adjacent non-malignant liver tissue. High expression of HEF1 correlated with higher advanced tumor, node, metastasis (TNM) stage and vascular invasion (P<0.05). In univariate and multivariate analysis, the expression of HEF1 was identified as an independent prognostic factor (Spearman's rank correlation, Kaplan-Meier plots and Cox regression model). In subgroup analysis, high expression of HEF1 correlated with a poorer prognosis in advanced (TNM III+IV) stages (P<0.05)."	"Li et al., 2016, Mol Clin Oncol"	N/A	ENST00000504387.1	N/A
POU5F1 EXPRESSION	POU5F1	EXPRESSION	Colon Cancer	Oxaliplatin	Predictive	Supports	D	Resistance	chr6	31164343	31170693			OCT4B1 (POU5F1 splice variant) expression reduced sensitivity to oxaliplatin (via P-gp and ABCG2 differential expression) in vitro.	"Wen et al., 2015, Oncol. Rep."	N/A	ENST00000259915.8	N/A
HLA-DRA EXPRESSION	HLA-DRA	EXPRESSION	Skin Melanoma	"Pembrolizumab,Nivolumab,Atezolizumab"	Predictive	Supports	B	Sensitivity/Response	chr6	32439842	32445046			"Melanoma patients treated with Anti-PD1 or anti-PD-L1(nivolumab, pembrolizumab, MPDL3280A) therapy were analyzed for expression of HLA-DRA (the primary antigen-presenting molecule of the MHC-II pathway). In a discovery cohort, 30 patients underwent IHC for HLA-DRA. 11/14 (79%) patients with positive HLA-DR staining, had complete (n=3) or partial (n=8) response. 6/16 (38%) HLA-DR non-expressing melanomas responded to therapy (overall response rate 79 versus 38%, Fishers exact test P=0.033). This finding was confirmed in a second independent data set of 23 melanoma patients with 6/8 (75%) of HLA-DR(+) tumours in comparison to 4/15 (27%) HLA-DR(? responding (Fishers exact test P=0.025). Preclinical models confirmed the result."	"Johnson et al., 2016, Nat Commun"	N/A	ENST00000395388.2	N/A
PSMB8 NUCLEAR EXPRESSION	PSMB8	NUCLEAR EXPRESSION	Gastric Adenocarcinoma		Prognostic	Supports	B	Poor Outcome	chr6	32840717	32844703			"Microarray expression data from 48 patients with gastric adenocarcinoma were analyzed for genes differentially expressed with regard to overall survival. Expression of 294 and 116 genes was enriched in good and poor prognosis subtypes, respectively. Of these genes, upregulation of proteasome subunit beta type 8 PSMB8 and PDZ binding kinase PBK was confirmed by real-time reverse transcription-PCR Analysis. IHC in 385 gastric cancer patients showed that increased nuclear expression of PSMB8 and PBK was correlated with depth of invasion, lymph node metastasis, and lower survival rates (survival durations of the (-), (+), and (++) groups, classified according to nuclear PSMB8 expression, were 77.2, 70.6, and 62.2 months, respectively; P = 0.004). Cytoplasmic staining of PSMB8 and PBK were not statistically significant. In multivariate Analysis, nuclear expression of PSMB8 and PBK were not significant predictors of overall survival (P = 0.085, P = 0.083, respectively)."	"Kwon et al., 2016, Oncotarget"	N/A	ENST00000374881.2	N/A
CDKN1A EXPRESSION	CDKN1A	EXPRESSION	Colorectal Cancer	Fluorouracil	Predictive	Supports	B	Resistance	chr6	36678710	36687331			"112 patients with rectal cancer who received 5-FU based chemotherapy and surgery were retrospectively analyzed for expression of Ki67, TS, BAX, EpCAM, p53, p21, EGFR, CD44, CD133, CD166, HIF1 and ALDH1. High pretreatment p21 (CDKN1A) expression was significantly associated with non-pCR (p??.022) and poor disease free survival (median DFS - low vs high p21: 75.8 vs 58.1 months, p??.002). Multivariate analysis was also significant (p??.001, HR 6.14; 95% CI 2.03, 18.55)."	"Sim et al., 2014, BMC Cancer"	N/A	ENST00000405375.1	N/A
PIM1 NUCLEAR EXPRESSION	PIM1	NUCLEAR EXPRESSION	Lung Non-small Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr6	37170203	37175426			"The expression of PIM1, p-STAT3, and c-MYC was tested (IHC) in 194 NSCLC archival tumor samples. High nuclear expression of PIM1 was detected in 43.3% of cases and was significantly correlated with advanced clinical stage (p<0.001) and poor pathologic differentiation (P = 0.004) and was an independent unfavorable prognostic factors for overall and disease-free survival (OS, P=0.009; DFS, P=0.034)."	"Jiang et al., 2016, J Cancer"	N/A	ENST00000373509.5	N/A
CCND3 Loss	CCND3	Loss	T-cell Lymphoblastic Leukemia/lymphoma	Palbociclib	Predictive	Supports	D	Sensitivity/Response	chr6	41934933	41941848			Treatment of Notch-driven T-cell leukemia in Ccnd3 knockout mice with Palbociclib (PD-0332991) significantly increased median survival.	"Sawai et al., 2012, Cancer Cell"	Somatic	ENST00000372991.4	loss_of_function_variant
ABCC10 Overexpression	ABCC10	Overexpression	Lung Non-small Cell Carcinoma	Paclitaxel	Predictive	Supports	D	Resistance	chr6	43427554	43450430			Increased expression of ABCC10 in 17 NSCLC cell lines was inversely correlated with paclitaxel sensitivity (r = 0.574; P < 0.05).	"Oguri et al., 2008, Mol. Cancer Ther."	N/A	ENST00000372530.4	N/A
VEGFA Decreased Peri-therapeutic Expression	VEGFA	Decreased Peri-therapeutic Expression	Colorectal Cancer	"Bevacizumab,Levoleucovorin,Irinotecan,Fluorouracil"	Predictive	Supports	B	Sensitivity/Response	chr6	43770707	43784609			Decreased peri- and post-therapeutic expression of VEGFA were significantly associated with response to FOLFIRI plus bevacizumab in 57 patients with metastatic CRC.	"Tsai et al., 2015, Int J Clin Exp Pathol"	N/A	ENST00000372055.4	N/A
DDX43 Overexpression	DDX43	Overexpression	Uveal Melanoma	"Selumetinib,Mirdametinib,Trametinib"	Predictive	Supports	D	Resistance	chr6	73394748	73417569			"MEK inhibitor-resistant (selumetinib, PD0325901, GSK1129212) uveal melanoma cell lines were created from two GNAQ Q209L mutant cell lines. Overexpression of DDX43 mediated RAS-induced selumetinib resistance as demonstrated by depletion of DDX43 decreasing RAS proteins and ectopic expression of DDX43 induced RAS protein levels. These results were confirmed using biopsies from liver metastases in 14 patients with uveal melanoma harboring GNAQ or GNA11 mutations who were treated on a phase II study of selumetinib. 6 patients with partial response or stable disease for ?6 weeks, were defined as responders?(R), 8 patients who had disease progression before 16 weeks were defined as nonresponders?(NR). DDX43 Expression (qPCR) was higher in nonresponders (P = 0.045). Liver metastasis biopsy samples (3 R and 3 NR) were immunoblotted for DDX43, pERK and RAS proteins with consistent results."	"Ambrosini et al., 2014, Mol. Cancer Ther."	Somatic	ENST00000370336.4	N/A
NT5E Overexpression	NT5E	Overexpression	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Sensitivity/Response	chr6	85450091	85495778			CD73 high expression was identified as a potential marker of improved PFS from cetuximab treatment in patients with metastatic CRC.	"Cushman et al., 2015, Clin. Cancer Res."	N/A	ENST00000257770.3	N/A
PRDM1 MUTATION	PRDM1	MUTATION	Diffuse Large B-cell Lymphoma		Prognostic	Supports	B	Poor Outcome	chr6	106086320	106109938			"Biopsies from 520 DLBCL patients treated with R-CHOP were evaluated for PRDM1 mutations or protein (BLIMP-1) expression. Patients with a homozygous deletion of PRDM1 (7%, N=19) had a significantly shorter overall survival and poorer progression free survival compared to heterozygous or wildtype PRDM1."	"Xia et al., 2016, Leukemia"	Somatic	ENST00000369096.4	"transcript_variant,loss_of_function_variant"
PRDM1 MUTATION	PRDM1	MUTATION	Diffuse Large B-cell Lymphoma		Prognostic	Supports	B	Poor Outcome	chr6	106086320	106109938			"In 177 patients with activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL), PRDM1 mutations (N=46) were associated with worse overall (P=0.016) and progression-free (P=0.023) survival compared to wildtype patients. This may have been driven by patients with exon1-2 mutations (N=15; P=0.021 for OS; P=0.024 for PFS) versus those with exon 3-7 mutations (N=31; P=0.16 for OS; P=0.24 for PFS) when compared to wildtype patients. Multivariate analysis did not identify PRDM1 mutations as an independent prognostic factor."	"Xia et al., 2016, Leukemia"	Somatic	ENST00000369096.4	"transcript_variant,loss_of_function_variant"
ROS1 Rearrangement	ROS1	Rearrangement	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	B	Sensitivity/Response	chr6	117288300	117425855			"An expansion cohort of a phase-1 Crizotinib study found a 72% objective response rate among 50 patients with ROS1 rearrangement. The study did not compare to patients without rearrangement that were treated with Crizotinib.  Several different ROS1 fusion partners were identified, but no clinical differences in outcome were associated with the identity of the 5' partner."	"Shaw et al., 2014, N. Engl. J. Med."	Somatic	ENST00000368508.3	transcript_fusion
ROS1 Rearrangement	ROS1	Rearrangement	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	B	Sensitivity/Response	chr6	117288300	117425855			"In a retrospective study, 30 patients were evaluated after crizotinib treatment for stage IV NSCLC confirmed for ROS1 rearrangement. On crizotinib, 24 of the patients achieved objective responses including 5 complete responses. Median progression free survival was 9.1 months and all patients had  been pretreated with 1 or more lines of chemotherapy."	"Mazires et al., 2015, J. Clin. Oncol."	Somatic	ENST00000368508.3	transcript_fusion
ROS1 Rearrangement	ROS1	Rearrangement	Lung Adenocarcinoma	Ceritinib	Predictive	Supports	C	Sensitivity/Response	chr6	117288300	117425855			"Case report of a 77-year old male patient with lung adenocarcinoma (T2aN1M0, stage IIA) without EGFR, KRAS, or BRAF mutations, and no ALK gene rearrangement. CD72-ROS1 was identified in sequencing after progression on chemotherapy. Crizotinib at 250 mg orally twice daily led to resolution of metastatic disease. The patient remained disease-free for 13 months when a CT-scan showed a relapse with two nodules in the right lower lobe. Stereotactic radiation therapy, gamma knife radiosurgery, and ipilimumab did not lead to a relevant response (new pleural nodules, new intracranial metastases). The patient next received ceritinib on a Signature Trial"" for tumors with aberrations in ALK or ROS1 that are treated with oral ceritinib (LDK378) at 750 mg daily (NCT02186821). Restaging scans after two cycles showed a partial response confirmed after four cycles (56% decrease) per RECIST1.1. MRI showed that his brain metastases decreased as well."	"Subbiah et al., 2016, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000368508.3	transcript_fusion
ROS1 Rearrangement	ROS1	Rearrangement	Colorectal Adenocarcinoma	Crizotinib	Predictive	Supports	E	Sensitivity/Response	chr6	117288300	117425855			"A tissue microarray of 268 patients with histologically confirmed colorectal adenocarcinoma was performed to search for ROS1 gene fusion events to guide potential targeted therapy in future cases. Break apart FISH assay, which does not distinguish ROS1-fusion partner, was used on the tissue microarray to determine ROS1 fusion status. 2 cases of ROS1 fusions were found. 1 case was verified by RT-PCR to be a SLC34A2-ROS1 fusion, but this case was also positive for BRAF V600E.  The second case of ROS1 fusion was of undetermined fusion partner, where known ROS1 fusion parters SLC34A2, CD74 and SDC4 were tested. This case did not have KRAS or BRAF mutations, indicating that ROS1 fusion may act in a small subset of colorectal cancer as a driver targetable by crizotinib or other inhibitors."	"Aisner et al., 2014, Mol. Cancer Res."	Somatic	ENST00000368508.3	transcript_fusion
ROS1 Rearrangement	ROS1	Rearrangement	Bronchiolo-alveolar Adenocarcinoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr6	117288300	117425855			"Study describes a 31-year old male, never-smoker patient with advanced NSCLC with a ROS1 rearrangement. The patient was treated with crizotinib with marked response at 1 week and resolution of the tumor confirmed at 8 and 12 weeks via CT-scans. It was also demonstrated that crizotinib inhibits ROS1 phosphorylation in HEK 293 cells transfected with a CD14-ROS1 fusion gene, and crizotinib inhibited growth in the HCC78 cell line containing a ROS1 rearrangement to a similar degree as ALK-fusion positive cell lines."	"Bergethon et al., 2012, J. Clin. Oncol."	Somatic	ENST00000368508.3	transcript_fusion
ROS1 TFG::ROS1	ROS1	TFG::ROS1	Inflammatory Myofibroblastic Tumor	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr6	117288300	117321394			Case report of a pediatric patient with treatment-refactory inflammatory myofibroblastic tumor negative for ALK expression and rearrangement. Next generation sequencing of the patient revealed a TFG-ROS1 fusion. CT scans after 3 cycles of crizotinib treatment showed a reduction of the tumor mass which continued to decrease at the time of publication after 4 months of crizonitib treatment.	"Lovly et al., 2014, Cancer Discov"	Somatic	ENST00000240851.4	transcript_fusion
ROS1 Rearrangement	ROS1	Rearrangement	Lung Adenocarcinoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr6	117288300	117425855			"In an evaluation of a patient and never smoker with crizotinib-sensitive lung adenocarcinoma, an SDC4-ROS1 rearrangement was identified using comprehensive genomic profiling. The patient attained a decrease in RESIST target lesions by 26.8% (stable disease); however, the patient relapsed 4 months later. This patient also harbored a TP53 mutation, MCL1 amplification and CDKN2A deletion."	"Le et al., 2015, Clin Lung Cancer"	Somatic	ENST00000368508.3	transcript_fusion
ROS1 Rearrangement	ROS1	Rearrangement	Cancer	Entrectinib	Predictive	Supports	B	Sensitivity/Response	chr6	117288300	117425855			"Two phase I studies included 119 patients with advanced or metastatic solid tumors, which included 28 patients with ROS1 rearrangements (n=28) where the overall safety and antitumor activity of entrectinib was examined. Entrectinib was shown to be safe and well tolerated. For phase 2, 14 ROS1-rearranged solid tumors were eligible and demonstrated an overall objective response rate of 86% (95% CI: 60?6) to entrectinib. Of the 14, 13 were Non-small cell lung cancer cases, 12 of which showed response with 2 of these patients demonstrated a complete response. A single melanoma case with a ROS1 rearrangement also showed a response to treatment."	"Drilon et al., 2017, Cancer Discov"	Somatic	ENST00000368508.3	transcript_fusion
ROS1 Rearrangement	ROS1	Rearrangement	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	A	Sensitivity/Response	chr6	117288300	117425855			"A phase 2 clinical trial studied the efficacy of Crizotinib in East Asian NSCLC patients positive for ROS1 rearrangements (detected by RT-PCR AmoyDx assay) and negative for ALK1 rearrangements. Of the 127 patients enrolled, 17 achieved complete response and 74 achieved partial response. Overall response rate by independent radiology review was 71.7% (95% CI 63-79.3%) Time to response was rapid (median 1.9 months) and durable (Duration of response median 19.7 months). Median progression free survival was 15.9 months. Crizotinib was clinically beneficial regardless of demographics and prior therapy. Based on these results, Crizotinib was approved for the treatment of ROS1 positive NSCLC in 2017 in Japan, Taiwan, China, and Korea."	"Wu et al., 2018, J. Clin. Oncol."	Somatic	ENST00000368508.3	transcript_fusion
ROS1 CD74::ROS1 L2155S	ROS1	CD74::ROS1 L2155S	Lung Non-small Cell Carcinoma	"TAE684,Crizotinib,Foretinib"	Predictive	Supports	D	Resistance	chr6	117308899	117308899	A	G	"The L2155S mutation in ROS1 was identified in the HCC78CR1, -2 and -3 cell lines which harbor the SLC34A2ROS1 rearrangement and in 2 patients with NSCLC with progressive disease following crizotinib treatment and CD74ROS1 rearrangment. Crystal structure predicted ROS1 L2155S mutation to be highly destabilizating and cause protein structural modification. HCC78CR1, 2, and 3 cells and Ba/F3 cells transfected with CD74ROS1 L2155S, showed resistance to crizotinib compared with parental HCC78 and Ba/F3 cells. In addition, these cell lines showed resistance to foretinib, a potent ROS1 inhibitor that is effective against ROS1 G2032R-mutant cells (16), and TAE684, a potent ALK inhibitor"	"Song et al., 2015, Clin. Cancer Res."	Somatic	ENST00000368508.3	"missense_variant,transcript_fusion"
ROS1 CD74::ROS1 G2101A	ROS1	CD74::ROS1 G2101A	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	D	Resistance	chr6	117310213	117310213	C	G	"Ba/F3 cells expressing CD74ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74ROS1, and were sensitive to foretinib."	"Song et al., 2015, Clin. Cancer Res."	Somatic	ENST00000368508.3	"missense_variant,transcript_fusion"
ROS1 CD74::ROS1 G2101A	ROS1	CD74::ROS1 G2101A	Lung Non-small Cell Carcinoma	Foretinib	Predictive	Supports	D	Sensitivity/Response	chr6	117310213	117310213	C	G	"Ba/F3 cells expressing CD74ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74ROS1, and were sensitive to foretinib."	"Song et al., 2015, Clin. Cancer Res."	Somatic	ENST00000368508.3	"missense_variant,transcript_fusion"
ROS1 CD74::ROS1 G2032R	ROS1	CD74::ROS1 G2032R	Lung Adenocarcinoma	Crizotinib	Predictive	Supports	C	Resistance	chr6	117317184	117317184	C	T	"Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment. An acquired G2032R mutation in the ROS1 kinase domain was observed in the resistant tumor, and was found to confer resistance to ROS1 kinase inhibition through steric interference with drug binding."	"Awad et al., 2013, N. Engl. J. Med."	Somatic	ENST00000368508.3	"missense_variant,transcript_fusion"
ROS1 CD74::ROS1 G2032R	ROS1	CD74::ROS1 G2032R	Lung Non-small Cell Carcinoma	Cabozantinib	Predictive	Supports	D	Sensitivity/Response	chr6	117317184	117317184	C	T	"Cabozantinib was assessed in the CD74-ROS1-mutant Ba/F3 cells and crizotinib-resistant patient-derived cancer cells (MGH047) harboring G2032R-mutated CD74-ROS1. It effectively inhibited the survival of CD74-ROS1 wild-type (WT) and resistant mutants harboring Ba/F3 and MGH047 cells. Furthermore, cabozantinib could overcome all the resistance by all newly identified secondary mutations."	"Katayama et al., 2015, Clin. Cancer Res."	Somatic	ENST00000368508.3	"missense_variant,transcript_fusion"
ROS1 CD74::ROS1 G2032R	ROS1	CD74::ROS1 G2032R	Lung Non-small Cell Carcinoma	"Cabozantinib,Foretinib"	Predictive	Supports	D	Sensitivity/Response	chr6	117317184	117317184	C	T	"Preclinical study analyzing the efficacy of dual ROS1/ALK and more specific ROS1 inhibitors on cell lines (Ba/F3) expressing CD74-ROS1 with and without the G2032R mutation. Selective ROS1 inhibitors retained activity against the G2032R mutation (cabozatinib, foretinib), whereas dual ALK/ROS inhibitors (crizotinib, brigatinib, ceritinib, AZD3463) or ALK-selective inhibitors (alectinib) were ineffective."	"Davare et al., 2015, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000368508.3	"missense_variant,transcript_fusion"
ROS1 CD74::ROS1 G2032R	ROS1	CD74::ROS1 G2032R	Lung Non-small Cell Carcinoma	"Crizotinib,AZD3463,Ceritinib,Brigatinib"	Predictive	Supports	D	Resistance	chr6	117317184	117317184	C	T	"Preclinical study analyzing the efficacy of dual ROS1/ALK and more specific ROS1 inhibitors on cell lines (Ba/F3) expressing CD74-ROS1 with and without the G2032R mutation. Selective ROS1 inhibitors retained activity against the G2032R mutation (cabozatinib, foretinib), whereas dual ALK/ROS inhibitors (crizotinib, brigatinib, ceritinib, AZD3463) or ALK-selective inhibitors (alectinib) were ineffective."	"Davare et al., 2015, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000368508.3	"missense_variant,transcript_fusion"
ROS1 CD74::ROS1 G2032R	ROS1	CD74::ROS1 G2032R	Lung Non-small Cell Carcinoma	Lorlatinib	Predictive	Supports	D	Sensitivity/Response	chr6	117317184	117317184	C	T	"Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays. PF-06463922 showed inhibition of kinase activity, cell viability and tumor growth in wild-type, G2032R and L2026M mutations in ROS1."	"Zou et al., 2015, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000368508.3	"missense_variant,transcript_fusion"
ROS1 CD74::ROS1 G2032R	ROS1	CD74::ROS1 G2032R	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	C	Resistance	chr6	117317184	117317184	C	T	ROS1 kinase domain mutations were assessed in two patients with stage IIIa/IV pulmonary adenocarcinoma and a cell line. The ROS1 G2032R mutation was identified in a crizotinib-resistant tumor from one of the patients harboring the CD74ROS1 fusion. Expression of CD74ROS1 G2032R in Ba/F3 cells conferred resistance to crizotinib combared to CD74ROS1 (IC50=353.62+/-20.15 vs. 2.76+/-0.82).	"Song et al., 2015, Clin. Cancer Res."	Somatic	ENST00000368508.3	"missense_variant,transcript_fusion"
ROS1 CD74::ROS1 G2032R	ROS1	CD74::ROS1 G2032R	Lung Non-small Cell Carcinoma	Foretinib	Predictive	Supports	D	Sensitivity/Response	chr6	117317184	117317184	C	T	"Ba/F3 cells expressing CD74ROS1 G2032R showed resistance to crizotinib, compared with those expressing wild-type CD74ROS1 (~128 fold higher IC50); however, showed relative sensitivity to foretinib (only ~6 fold higher IC50 than WT)."	"Song et al., 2015, Clin. Cancer Res."	Somatic	ENST00000368508.3	"missense_variant,transcript_fusion"
ROS1 G2032R	ROS1	G2032R	Lung Adenocarcinoma	Crizotinib	Predictive	Supports	C	Resistance	chr6	117317184	117317184	C	T	"Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment. A biopsy of a resistant tumor showed an acquired G2032R mutation in the ROS1 kinase domain. Although this mutation does not lie at the gatekeeper residue, it confers resistance to ROS1 kinase inhibition through steric interference with drug binding. The same resistance mutation was observed at all the metastatic sites that were examined at autopsy, suggesting that this mutation was an early event in the clonal evolution of resistance."	"Awad et al., 2013, N. Engl. J. Med."	Somatic	ENST00000368508.3	missense_variant
ROS1 CD74::ROS1 L2026M	ROS1	CD74::ROS1 L2026M	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	D	Resistance	chr6	117317202	117317202	G	T	"Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays. BaF3 cells expressing CD74-ROS1 L2026M were more resistant to crizotinib treatment than wildtype CD74-ROS1 in both cell viability and ROS1 phosphorylation. Crizotinib was also less effective at inhibiting kinase activity in ROS1 with L2026M mutation than wildtype. In contrast, PF-06463922 was effectively inhibited the fusion harboring this mutation in these assays."	"Zou et al., 2015, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000368508.3	"missense_variant,transcript_fusion"
ROS1 CD74::ROS1 L2026M	ROS1	CD74::ROS1 L2026M	Lung Non-small Cell Carcinoma	Lorlatinib	Predictive	Supports	D	Sensitivity/Response	chr6	117317202	117317202	G	T	"Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo, and in enzyme assays. After establishing that the CD74-ROS1 L2026M mutation confers crizotinib resistance in kinase activity and cell viability assays (in transduced BaF3 cells), response to PF-06463922 was tested.  Wild-type CD74-ROS1, CD74-ROS1 G2032R, and CD74-ROS1 L2026M all showed sensitivity to PF-06463922 in these assays."	"Zou et al., 2015, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000368508.3	"missense_variant,transcript_fusion"
ROS1 CD74::ROS1 L2026M	ROS1	CD74::ROS1 L2026M	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	D	Resistance	chr6	117317202	117317202	G	T	"Ba/F3 cells expressing CD74ROS1 L2026M mutation showed resistance to crizotinib (~10 fold higher IC50 value), compared with those expressing wild-type CD74ROS1; however, showed similar sensitivity to foretinib."	"Song et al., 2015, Clin. Cancer Res."	Somatic	ENST00000368508.3	"missense_variant,transcript_fusion"
ROS1 CD74::ROS1 L2026M	ROS1	CD74::ROS1 L2026M	Lung Non-small Cell Carcinoma	Foretinib	Predictive	Supports	D	Sensitivity/Response	chr6	117317202	117317202	G	T	Ba/F3 cells expressing CD74ROS1 L2026M mutation showed similar sensitivity to foretinib compared with those expressing wild-type CD74ROS1. This is in contrast to the increased resistance to crizotinib associated with this mutation in the same assay.	"Song et al., 2015, Clin. Cancer Res."	Somatic	ENST00000368508.3	"missense_variant,transcript_fusion"
SGK1 Overexpression	SGK1	Overexpression	Breast Cancer	Alpelisib	Predictive	Supports	D	Resistance	chr6	134169246	134318058			SGK1 mRNA expression was elevated in five breast cancer cell lines which were resistant to PI3Kalpha inhibitor alpelisib (NVP-BYL719) in comparison to five sensitive cell lines. Western blots showed clear elevation of protein levels in 3/5 resistant cell lines. Ectopic SGK1 expression in sensitive MDA-MB-361 cells resulted in alpelisib resistance and preservation of phopho-S6K and phospho-4EBP with alpelisib treatment. Knockdown of SGK1 in resistant HCC1954 cells increased alpelisib sensitivity and reduced p-S6K and p-4EBP levels with alpelisib treatment. Promoter methylation at SGK1 was increased in sensitive cells compared to alpelisib resistant cell lines.	"Castel et al., 2016, Cancer Cell"	Somatic	ENST00000367858.5	N/A
SGK1 Overexpression	SGK1	Overexpression	Breast Cancer	Alpelisib	Predictive	Supports	B	Resistance	chr6	134169246	134318058			"A group of 18 breast cancer patients were treated with PI3Kalpha inhibitor alpelisib (NVP-BYL719) plus an aromatase inhbitor (NCT01870505). 3 out of 3 patients expressing high tumor SGK1 mRNA had disease progression as best response with median progression free survival (PFS) of 56 days, while 15 patients classified with low to medium SGK1 mRNA had median PFS 111 days with 4/15 having disease progression as best response."	"Castel et al., 2016, Cancer Cell"	N/A	ENST00000367858.5	N/A
SGK1 Overexpression	SGK1	Overexpression	Breast Cancer	"Alpelisib,SGK1-Inh"	Predictive	Supports	D	Sensitivity/Response	chr6	134169246	134318058			"The alpelisib (PI3Kalpha inhibitor) resistant breast cancer cell line HCC1954 was treated with alpelsisb alone or in combination with the SGK1 kinase inhibitor SGK1-Inh. Addition of SGK1 reduced viability over alpelisib alone, and phospho-S6K as well as phospho-4EBP1 levels decreased with combination treatment. HCC1954 xenografts showed increased tumor volume with treatment of alpelisib or SGK1-Inh alone, but only combination treatment resulted in lack of volume increase and decreased phospho-S6K levels in tumors by IHC."	"Castel et al., 2016, Cancer Cell"	Somatic	ENST00000367858.5	N/A
ESR1 Overexpression	ESR1	Overexpression	Breast Cancer	"Letrozole,Palbociclib"	Predictive	Supports	B	Sensitivity/Response	chr6	151807551	152103271			"A phase 2 clinical trial evaluated 165 patients with oestrogen receptor positive and HER2-negative breast cancer such that 84 patients received combination therapy of palbociclib plus letrozole and 81 patients received letrozole alone. The combination therapy arm had higher median duration of progression-free survival when compared to the letrozole only group (20.2 months vs. 10.2 months; p<0.0004). A subcategory of patients taking combination therapy, who lacked mutations in p16 or CCND1 (n=34), had an even higher median free survival of 26.1 months. Noticeable side effects in the combination therapy group included neutropenia (54%) leucopenia (19%), fatigue (4%) back pain (2%), diarrhea (2%) and pulmonary embolism (4%)."	"Finn et al., 2015, Lancet Oncol."	N/A	ENST00000206249.3	N/A
ESR1 S463P	ESR1	S463P	Estrogen-receptor Positive Breast Cancer	Aromatase Inhibitor	Predictive	Supports	D	Resistance	chr6	152094402	152094402	T	C	ESR1 S463P variants were observed after extensive treatment with hormonal therapy (aromatase inhibition). Expression of the S463P mutant was found to induce modest activity in the absence of hormone. This mutation displayed elevated levels of Ser118 phosphorylation compared to wild-type ER and appeared to possess estrogen-independent activity.	"Toy et al., 2013, Nat. Genet."	Somatic	ENST00000440973.1	missense_variant
ESR1 L536Q	ESR1	L536Q	Breast Cancer	Hormone Therapy	Predictive	Supports	D	Resistance	chr6	152098785	152098786	TC	AG	MCF7 cell lines harboring the L536Q mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	"Toy et al., 2013, Nat. Genet."	Somatic	ENST00000440973.1	missense_variant
ESR1 L536Q	ESR1	L536Q	Breast Cancer	"Tamoxifen,Fulvestrant"	Predictive	Supports	D	Sensitivity/Response	chr6	152098785	152098786	TC	AG	"Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the L536Q ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines."	"Robinson et al., 2013, Nat. Genet."	Somatic	ENST00000440973.1	missense_variant
ESR1 Y537N	ESR1	Y537N	Breast Cancer	Hormone Therapy	Predictive	Supports	D	Resistance	chr6	152098787	152098787	T	A	MCF7 cell lines harboring the Y537N mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	"Toy et al., 2013, Nat. Genet."	Somatic	ENST00000206249.3	missense_variant
ESR1 Y537N	ESR1	Y537N	Breast Cancer	"Tamoxifen,Fulvestrant"	Predictive	Supports	D	Sensitivity/Response	chr6	152098787	152098787	T	A	"Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the Y537N ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines."	"Robinson et al., 2013, Nat. Genet."	Somatic	ENST00000206249.3	missense_variant
ESR1 Y537C	ESR1	Y537C	Breast Cancer	Hormone Therapy	Predictive	Supports	D	Resistance	chr6	152098788	152098788	A	G	MCF7 cell lines harboring the Y537C mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	"Toy et al., 2013, Nat. Genet."	Somatic	ENST00000206249.3	missense_variant
ESR1 Y537S	ESR1	Y537S	Breast Cancer	Hormone Therapy	Predictive	Supports	D	Resistance	chr6	152098788	152098788	A	C	MCF7 cell lines harboring the L537S mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	"Toy et al., 2013, Nat. Genet."	Somatic	ENST00000206249.3	missense_variant
ESR1 Y537C	ESR1	Y537C	Breast Cancer	"Fulvestrant,Tamoxifen"	Predictive	Supports	D	Sensitivity/Response	chr6	152098788	152098788	A	G	"Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the Y537C ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines."	"Robinson et al., 2013, Nat. Genet."	Somatic	ENST00000206249.3	missense_variant
ESR1 Y537S	ESR1	Y537S	Breast Cancer	"Tamoxifen,Fulvestrant"	Predictive	Supports	D	Sensitivity/Response	chr6	152098788	152098788	A	C	"Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the Y537S ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines."	"Robinson et al., 2013, Nat. Genet."	Somatic	ENST00000206249.3	missense_variant
ESR1 D538G	ESR1	D538G	Breast Cancer	Hormone Therapy	Predictive	Supports	D	Resistance	chr6	152098791	152098791	A	G	MCF7 cell lines harboring the D538G mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	"Toy et al., 2013, Nat. Genet."	Somatic	ENST00000206249.3	missense_variant
ESR1 D538G	ESR1	D538G	Breast Cancer	"Tamoxifen,Fulvestrant"	Predictive	Supports	D	Sensitivity/Response	chr6	152098791	152098791	A	G	"Using an estrogen response element (ERE)-luciferase reporter system co-transfected with one of five ESR1 mutants, the N538G ligand binding domain mutation was shown to result in constitutive activity (response in the absence of beta-estradiol ligand) and continued responsiveness (inhibition of downstream target activation) to anti-estrogen therapies (tamoxifen or fulvestrant) in HEK293T cell lines."	"Robinson et al., 2013, Nat. Genet."	Somatic	ENST00000206249.3	missense_variant
ESR1 D538G	ESR1	D538G	Breast Cancer	"Palbociclib,Letrozole"	Predictive	Does Not Support	B	Sensitivity/Response	chr6	152098791	152098791	A	G	"In a study of 16 patients with metastatic breast cancer (NCT02142868) treated with palbociclib in combination with letrozole, patients with ESR1 mutations (5/16), including ESR1 D538G (n=2), detected at any time or at initial blood draw, were associated with reduced progression free survival (HR=0.31, 95% CI: 0.05-0.95, P=0.047), as compared with patients with wildtype ESR1 (n=11). There was no significant difference in overall survival (median; 14.1 versus 12.8 months, HR=0.40; 95% CI: 0.06-2.0, P-value=0.24)."	"Gyanchandani et al., 2016, Oncotarget"	Somatic	ENST00000206249.3	missense_variant
THBS2 UNDEREXPRESSION	THBS2	UNDEREXPRESSION	Colorectal Cancer		Prognostic	Supports	B	Poor Outcome	chr6	169215780	169254044			"172 patients treated with neoadjuvant concurrent chemoradiotherapy (CCRT) were retrospectively analyzed for expression of thrombospondin 2 (THBS2) using IHC (discovery set with 46 rectal cancer patients, GSE35452). Low expression was associated with advanced pretreatment tumor, nodal status, post-treatment tumor, vascular invasion and inferior regression grade. In multivariate analysis, low expression served as negative prognostic factor for disease-free survival (Hazard ratio=3.057, P=0.002)."	"Lin et al., 2015, Am J Transl Res"	N/A	ENST00000366787.3	N/A
PMS2 R315*	PMS2	R315*	Endometrial Cancer		Oncogenic	Supports	C	Oncogenicity	chr7	5992018	5992018	G	A	"This variant (R315*), identified in a case of microsatellite-unstable endometrial cancer, was confirmed to be somatic in a 69 year-old female patient with suspected Lynch Syndrome (LS). The patient was therefore negative for LS, which is by definition a germline condition. This patient also harbored MLH1 M490T, MSH2 E483G, and MSH6 V352I mutations."	"Geurts-Giele et al., 2014, J. Pathol."	Somatic	ENST00000265849.7	stop_gained
RAC1 P29S	RAC1	P29S	Melanoma	"Vemurafenib,Dabrafenib"	Predictive	Supports	D	Resistance	chr7	6387261	6387261	C	T	Melanoma cell lines harboring the RAC1 P29S hotspot mutation were shown to be resistant to BRAF inhibition with vemurafenib or dabrafenib and knock-in or knock-out of this mutation decreased and increased sensitivity to these drugs.	"Watson et al., 2014, Cancer Res."	Somatic	ENST00000356142.4	missense_variant
AGR2 EXPRESSION	AGR2	EXPRESSION	Breast Cancer	Tamoxifen	Predictive	Supports	B	Resistance	chr7	16791811	16805080			"mRNA expression of AGR2 in 61 patients with tamoxifen treated postmenopausal breast cancer was determined by qRT-PCR and was inversely associated with treatment response and progression free survival (p= 0.0011, p = 0.0366 respectively). AGR2 protein expression as assessed by IHC was not significantly associated with treatment outcome."	"Hrstka et al., 2013, Dis. Markers"	N/A	ENST00000419304.2	N/A
EGFR Amplification	EGFR	Amplification	Barrett's Adenocarcinoma		Prognostic	Supports	B	Poor Outcome	chr7	55019101	55211628			"In patients with Barrett's adenocarcinoma, those with amplification of EGFR had shorter disease-specific survial."	"Marx et al., 2010, Histopathology"	Somatic	ENST00000275493.2	transcript_amplification
EGFR Amplification	EGFR	Amplification	Cervical Squamous Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr7	55019101	55211628			"In patients with cervical squamous cell carcinoma, those with gene amplification of EGFR had worse overall survival."	"Iida et al., 2011, Br. J. Cancer"	Somatic	ENST00000275493.2	transcript_amplification
EGFR Copy Number Variation	EGFR	Copy Number Variation	Head And Neck Squamous Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr7	55019101	55211628			"In 134 patients with head and neck squamous cancer 32 had copy number variations. Tumors with variation (either increase or decrease) in copy number of EGFR had worse overall, cancer-specific, and disease-free survival."	"Temam et al., 2007, J. Clin. Oncol."	Somatic	ENST00000275493.2	copy_number_change
EGFR Amplification	EGFR	Amplification	Head And Neck Squamous Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr7	55019101	55211628			The group of 43 out of 75 tumor samples with increased copy number or amplification of EGFR as determined by FISH (FISH-positive) had worse progression-free and overall survival than FISH-negative tumors.	"Chung et al., 2006, J. Clin. Oncol."	Somatic	ENST00000275493.2	transcript_amplification
EGFR Overexpression	EGFR	Overexpression	Brain Glioblastoma Multiforme		Prognostic	Supports	B	Poor Outcome	chr7	55019101	55211628			"In patients with glioblastoma multiforme, those with overespression of wild-type EGFR had shorter overall survival."	"Shinojima et al., 2003, Cancer Res."	N/A	ENST00000275493.2	N/A
EGFR Amplification	EGFR	Amplification	Head And Neck Squamous Cell Carcinoma	"Fluorouracil,Platinum Compound,Cetuximab"	Predictive	Does Not Support	B	Sensitivity/Response	chr7	55019101	55211628			EGFR amplification was not a predictor of response to cetuximab/5-FU/platinum in patients with recurrent or metastatic HNSSC from the EXTREME study.	"Licitra et al., 2011, Ann. Oncol."	Somatic	ENST00000275493.2	transcript_amplification
EGFR Overexpression	EGFR	Overexpression	Head And Neck Squamous Cell Carcinoma	Cetuximab	Predictive	Does Not Support	B	Sensitivity/Response	chr7	55019101	55211628			EGFR expression level was not predicitive of response to cetuximab-containing first line regimens in recurrent or metastatic head and neck squamous cell carcinoma and KRAS-wild type colorectal carcinoma.	"Licitra et al., 2013, Eur. J. Cancer"	N/A	ENST00000275493.2	N/A
EGFR Overexpression	EGFR	Overexpression	Lung Non-small Cell Carcinoma	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			EGFR overexpression was correlated with longer overall survival in patients with advanced NSCLC treated with first line chemotherapy and cetuximab than those treated with first line chemotherapy alone.	"Pirker et al., 2012, Lancet Oncol."	N/A	ENST00000275493.2	N/A
EGFR Overexpression	EGFR	Overexpression	Lung Non-small Cell Carcinoma	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"In this prospective study in 37 patients of whom 34 were treated with different EGFR inhibitors (gefitinib, erlotinib, afatinib), EGFR mutations and a higher relative expression of EGFR in comparison to MET expression were correlated with longer PFS."	"Park et al., 2015, Oncotarget"	N/A	ENST00000275493.2	N/A
EGFR Overexpression	EGFR	Overexpression	Head And Neck Squamous Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr7	55019101	55211628			Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced disease-free and cause-specific survival.	"Rubin Grandis et al., 1998, J. Natl. Cancer Inst."	N/A	ENST00000275493.2	N/A
EGFR Overexpression	EGFR	Overexpression	Esophagus Squamous Cell Carcinoma	Nimotuzumab	Predictive	Does Not Support	B	Sensitivity/Response	chr7	55019101	55211628			55 tumor samples were analyzed for EGFR expression using IHC. The objective response rate to anti-EGFR antibody nimotuzumab did not differ significantly between EGFR high- (18 pts) and EGFR low to moderate groups (37 pts).	"Jia et al., 2016, Clin Transl Oncol"	N/A	ENST00000275493.2	N/A
EGFR Overexpression	EGFR	Overexpression	Esophagus Squamous Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr7	55019101	55211628			"55 tumor samples were analyzed for EGFR expression using IHC. PFS and OS was shorter for the EGFR high expressing group (18 pts) than for the low to moderate expression group (37 pts). PFS: 5.8  0.5 vs. 11.0  2.8 months, P = 0.007; OS: 9.7  0.5 vs. 21.5  1.5 months, P = 0.03."	"Jia et al., 2016, Clin Transl Oncol"	N/A	ENST00000275493.2	N/A
EGFR Overexpression	EGFR	Overexpression	Head And Neck Squamous Cell Carcinoma	"Cetuximab,Docetaxel"	Predictive	Does Not Support	B	Sensitivity/Response	chr7	55019101	55211628			"47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 73 % of cases expressed high level of EGFR. EGFR expression had no impact on PFS (P=0.73) or OS (P=0.75)."	"Tinhofer et al., 2011, Clin. Cancer Res."	N/A	ENST00000275493.2	N/A
EGFR Amplification	EGFR	Amplification	Colorectal Cancer	"Cetuximab,Panitumumab"	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"In this meta-analysis (14 studies, 1021 patients), EGFR gene copy number (GCN) was predictive of improved progression free survival (PFS) and overall survival (OS) with cetuximab or panitumumab regardless of KRAS status. For the pooled analysis, the objective response rate (ORR) was 65.2% (167/256) in patients with high EFGR GCN, while in patients with low EFGR GCN, the pooled ORR was 12.2% (44/361). The odds ratio (OR) was 6.905 (95% CI: 4.489-10.620; Z=8.79, P=0.000). In wild type KRAS patients, the pooled OR was 8.133 (95% CI: 4.316-15.326; Z=6.48, P=0.000)."	"Shen et al., 2014, Chin. J. Cancer Res."	Somatic	ENST00000275493.2	transcript_amplification
EGFR Amplification	EGFR	Amplification	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"87 patients with metastatic colorectal cancer treated with cetuximab were retrospectively analyzed for EGFR amplifications by FISH. In multivariate analysis, EGFR amplification predicted response and overall survival independent of KRAS status."	"Personeni et al., 2008, Clin. Cancer Res."	Somatic	ENST00000275493.2	transcript_amplification
EGFR Amplification	EGFR	Amplification	Lung Non-small Cell Carcinoma	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"A meta-analysis of EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment was performed. In total, 20 (1689 patients, 594 with increased gene copy number), 10 (822 patients, 290 with increased gene copy number) and 5 studies (294 patients, 129 with increased gene copy number) were analyzed for overall survival (OS), progression-free survival (PFS) and time-to-progression (TTP) meta-analyses respectively. EGFR amplification was associated with increased OS (HR = 0.77; 95% CI 0.66-0.89; P = 0.001), PFS (HR = 0.60; 95% CI 0.46-0.79; P<0.001) and TTP (HR = 0.50; 95% CI 0.28-0.91; P = 0.02). This effect was shown to influence survival in predominantly white patient populations but not patients of Asian descent."	"Dahabreh et al., 2011, Ann. Oncol."	Somatic	ENST00000275493.2	transcript_amplification
EGFR Overexpression	EGFR	Overexpression	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"82 patients treated with gefitinib were retrospectively analyzed for EGFR mRNA expression (rt-PCR in 64 patients). Patients with high EGFR mRNA expression (>5.01) had 43% response probability, whereas patients with low EGFR mRNA expression had 8% response probability (P = 0.006). PFS but not OS was also longer in patients with high EGFR mRNA expression."	"Dziadziuszko et al., 2006, Clin. Cancer Res."	N/A	ENST00000275493.2	N/A
EGFR Amplification	EGFR	Amplification	Lung Non-small Cell Carcinoma	"Erlotinib,Gefitinib"	Predictive	Does Not Support	B	Sensitivity/Response	chr7	55019101	55211628			"In 290 patients with advanced NSCLC, 177 of which were treated with EGFR TKI (erlotinib or gefitinib). EGFR amplification (Multiplex ligation-dependent probe amplification; MLPA) and Mutation (PCR) were analzed. EGFR amplification was associated with EGFR mutation but not independently with patient benefit from EGFR TKI (overall and progression-free survival)."	"Fiala et al., 2016, Anticancer Res."	Somatic	ENST00000275493.2	transcript_amplification
EGFR Expression	EGFR	Expression	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"Patients with refractory colorectal cancer expressing immunohistochemically detectable EGFR were randomly assigned to receive treatment with cetuximab (n=287) or receive supportive care alone (n=285). Patients receiving cetuximab had increased overall survival (HR=0.77, 95%CI 0.64-0.92; p=0.005), increased progression-free survival (HR=0.68, 95%CI 0.57-0.80; p<0.001), and improved quality of life at 4 months measured by survey on physical deterioration (-5.9 vs -12.5; p=0.03) and global health status (-3.6 vs. -15.2; p<0.001)."	"Jonker et al., 2007, N. Engl. J. Med."	N/A	ENST00000275493.2	N/A
EGFR Mutation	EGFR	Mutation	Lung Adenocarcinoma		Prognostic	Supports	B	Better Outcome	chr7	55019101	55211628			"In a study of 1036 patients with lung adenocarcinomas, patients with EGFR mutations (n=275) showed better prognosis (OS: 34 months versus 23 months; HR=0.6; P<0.001)."	"Johnson et al., 2013, Cancer"	Somatic	ENST00000275493.2	inframe_variant
EGFR Expression	EGFR	Expression	Colorectal Cancer	Panitumumab	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"463 patients with 1% or more EGFR tumor cell membrane staining, with metastatic CRC progressive after standard chemotherapy were randomized to panitumumab plus best supportive care (BSC, n = 231) or BSC alone (n = 232). Panitumumab significantly prolonged PFS (hazard ratio [HR], 0.54; 95% CI, 0.44 to 0.66, [P < .0001]). Objective response rates favored panitumumab over BSC; after a 12-month minimum follow-up, response rates were 10% for panitumumab and 0% for BSC (P < .0001). No difference was observed in OS (HR, 1.00; 95% CI, 0.82 to 1.22), but 76% of BSC patients entered the cross-over study."	"Van Cutsem et al., 2007, J. Clin. Oncol."	N/A	ENST00000275493.2	N/A
EGFR Expression	EGFR	Expression	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"57 patients with chemorefractory colorectal cancer expressing EGFR (IHC staining) were treated with single-agent cetuximab in this phase 2 study. Five patients (9%; 95% CI, 3% to 19%) achieved a partial response. Twenty-one additional patients had stable disease or minor responses. The median survival in these previously treated patients with chemotherapy-refractory colorectal cancer was 6.4 months."	"Saltz et al., 2004, J. Clin. Oncol."	N/A	ENST00000275493.2	N/A
EGFR Mutation	EGFR	Mutation	Lung Non-small Cell Carcinoma	Afatinib	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"In the LUX-LUNG 7 trial, (NCT01466660) stage IIIB or IV NSCLC patients with EGFR exon 19 deletion, (n=186) Leu858Arg mutation, (n=132) or both (n=1) were divided into equal groups and treated with first line reversible EGFR inhibitor gefitinib or irreversible pan-ErbB family inhibitor afatinib in order to obtain a direct comparison of these two approved first line treatments. Significant difference was seen in objective response with 70%  of cases with afatinib vs. 56% of cases with gefitinib. Median progression free survival was 11.0 months (10.6-12.9) with afatinib and 10.9 months (9.1-11.5) with gefitinib, HR 0.73 [0.57-0.95] p=0.017."	"Park et al., 2016, Lancet Oncol."	Somatic	ENST00000275493.2	inframe_variant
EGFR Mutation	EGFR	Mutation	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"This open label Phase 3 Trial performed across 36 centers in Japan (WJTOG3405) assessed patients with postoperative recurrent or stage IIIB/IV NSCLC and activating EGFR mutations (Exon 19 deletion and L858R).  88 patients were treated with EGFR inhibitor gefitinib, while 89 were treated with cisplatin/docetaxel. Progression free survival was significantly longer with gefitinib treatment with a median of 9.2 months vs. 6.3 with cisplatin/docetaxel (HR 0.48; 95% CI 0.336-0.710; p<0.0001). Difference in response to gefitinib between the two EGFR mutation types was not observed."	"Mitsudomi et al., 2010, Lancet Oncol."	Somatic	ENST00000275493.2	inframe_variant
EGFR Expression	EGFR	Expression	Chordoma	Lapatinib	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"18 advanced progressing chordoma patients that were positive for EGFR by at least one technique (immunohistochemistry and/or phospho-arrays, real-time polymerase chain reaction for EGFR ligands, FISH) entered this phase 2 study investigating the efficacy of lapatinib (median age: 61 years; disease extent: metastatic 72% and locally advanced 28%). Of the 25 patients screened, three tested negative for EGFR. Six (33.3%) patients had PR and 7 (38.9%) SD, as their best Choi responses, corresponding to RECIST SD in all cases. Median PFS by Choi was 6 [interquartile (IQ) range 3-8] months. Median PFS by RECIST was 8 (IQ range 4-12) months, with a 22% CBR. This phase II study showed a modest antitumor activity of lapatinib in chordoma"	"Stacchiotti et al., 2013, Ann. Oncol."	N/A	ENST00000275493.2	N/A
EGFR Mutation	EGFR	Mutation	Lung Non-small Cell Carcinoma	"Gefitinib,Erlotinib"	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"In a retrospective study, 166 non-small cell lung cancer (NSCLC) patients that tended to have selected characteristics known to be predictive for TKI sensitivity (i.e. women, never smokers, and patients with ADC) were treated with either gefitinib or erlotinib. EGFR mutations (n=42) were associated with improved objective response to drug treatment (71.4% vs. 20.1%, p<0.0001), improved but not significant overall survival (36.9 vs. 24.8 months, p=0.09), and longer median time to progression (not reached vs. 3.7 months, p<0.0001) when compared to wild-type EGFR. Through multivariate analyses, it was shown that EGFR mutations are independent predictive favorable factors of response to drug treatment (p<0.0001) and are significant predictors of longer time to progression (HR: 0.27, 95% CI: 0.14-0.52, p=0.0001)"	"Ludovini et al., 2011, J Thorac Oncol"	Somatic	ENST00000275493.2	inframe_variant
EGFR Mutation	EGFR	Mutation	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"In a phase 3 clinical trial of East Asian advanced pulmonary adenocarcinoma patients, a subset of patients with EGFR mutations (n=261) treated with gefitinib were associated with improved response (HR:0.48, 95% CI:0.36-0.64, P<0.001), compared to carboplatin plus paclitaxel treatment. The frequency of mutation in exon 19 deletion and L858R was 53.6% (140/261) and 42.5% (111/261), respectively."	"Mok et al., 2009, N. Engl. J. Med."	Somatic	ENST00000275493.2	inframe_variant
EGFR Mutation	EGFR	Mutation	Lung Non-small Cell Carcinoma	Afatinib	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"In a phase 2b/3 study of 585 stage IIIB-IV lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revealed that 96 tumors had an EGFR mutation, of which 76 (79%) were positive for either L858R or a deletion in exon 19. These mutations were associated with improved progression-free survival (median 3.3 months  vs 1.0 month ; HR:0.51, 95% CI:0.31-0.85, P<0.009) compared to placebo control. No difference was reported between the treatment groups for EGFR mutation negative subgroup."	"Miller et al., 2012, Lancet Oncol."	Somatic	ENST00000275493.2	inframe_variant
EGFR Wildtype	EGFR	Wildtype	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	B	Resistance	chr7	55019101	55211628			"In a phase 3 clinical trial of East Asian pulmonary adenocarcinoma patients, a subset of patients with EGFR mutations (n=261) treated with gefitinib were associated with improved response compared to carboplatin plus paclitaxel treatment, but in patients shown to be negative for EGFR mutation (n=176), patients given gefitinib fared worse than those given carboplatin and paclitaxel: Hazard ratio 2.85 (85% CI 2.05-3.98) p<0.001"	"Mok et al., 2009, N. Engl. J. Med."	Somatic	ENST00000275493.2	wild_type
EGFR Mutation	EGFR	Mutation	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical imporvement in response to gefitinib, and in 8 patients who had not shown gefitinib response. 7 of 10 sensitive patients had mutations in EGFR, while none of the 8 gefitinib refractory patients showed EGFR mutation in these exons (p=0.004)"	"Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000275493.2	inframe_variant
EGFR Mutation	EGFR	Mutation	Lung Cancer	Gefitinib	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"In a study of 52 patients with recurrent lung cancer, 27 individuals had EGFR mutation including 2 point mutations in exon 18 (G719A and G1719C), 23 deletions in exon 19, two insertions in exon 19 (I744KIPVAI), on mutation in exon 20 (S768I), and 16 point mutations in exon 21 (L858R and E709H). Patients were treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, and tumors harboring an EGFR mutation had an increased frequency of partial response (PR) and a lower rate of progressive disease (PD) (PR:22, PD:2 vs. PR:2, PD:17; P<0.0001) compared to wildtype EGFR patients. Patients with KRAS mutations also had a longer overall survival compared to wildtype EGFR patients (HR:2.526, 95% CI:1.314-4.858, P=0.0055)."	"Endoh et al., 2006, J Thorac Oncol"	Somatic	ENST00000275493.2	inframe_variant
EGFR Amplification	EGFR	Amplification	Lung Non-small Cell Carcinoma	"Osimertinib,Rociletinib"	Predictive	Supports	D	Resistance	chr7	55019101	55211628			"Evidence of wild-type allele-mediated resistance, a novel concept of acquired resistance in response to mutation-selective inhibitor therapy in cancer treatment. This study reports that the Src-AKT pathway contributes to acquired resistance to third generation EGFR TKIs. In addition, amplification of EGFR wild-type alleles but not mutant alleles was sufficient to confer acquired resistance."	"Nukaga et al., 2017, Cancer Res."	Somatic	ENST00000275493.2	transcript_amplification
EGFR Mutation	EGFR	Mutation	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"In a phase 3 clinical trial of non-small cell lung cancer (NSCLC) patients, a subset of patients with EGFR mutations (n=44) treated with gefitinib were associated with improved progression free survival (HR: 0.16, 95% CI: 0.05-0.49, P=0.001), and a higher objective response rate (ORR: 42.1% vs 21.1%, p=0.04) compared to patients treated with docetaxel. Of the 44 patients, 22 had an exon 19 deletion, 16 had an L858R mutation, one patient had an exon 20 T790M mutation, two had an exon G719A mutation and four had other mutations."	"Douillard et al., 2010, J. Clin. Oncol."	Somatic	ENST00000275493.2	inframe_variant
EGFR Mutation	EGFR	Mutation	Lung Adenocarcinoma		Prognostic	Supports	B	Better Outcome	chr7	55019101	55211628			"Analysis was performed on the placebo group (n=451) of the Phase III study SATURN using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherapy. It was found that EGFR Mutant status was a significant positive prognostic factor for overall survival. (HR, 0.33; 95% CI, 0.19 to 0.59; P<0.01)"	"Brugger et al., 2011, J. Clin. Oncol."	Somatic	ENST00000275493.2	inframe_variant
EGFR Mutation	EGFR	Mutation	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"In a phase II trial for Bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma), EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to Erlotinib, and 10 patients who did not.  EGFR mutations were seen in 5/7 responders but not in any of the non-responders, which was a significant result (p=0.003)."	"Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000275493.2	inframe_variant
EGFR Mutation	EGFR	Mutation	Lung Cancer	Erlotinib	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"In advanced-stage (IIIB or IV) non-small cell lung cancer patients treated with erlotinib, patients whose tumors harbored EGFR mutations (n=3) had a higher 12-week progression-free survival rate compared to wildtype EGFR patients (n=54; 100% vs. 25%, P=0.0064)."	"Ramalingam et al., 2011, J. Clin. Oncol."	Somatic	ENST00000275493.2	inframe_variant
EGFR Mutation	EGFR	Mutation	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	C	Sensitivity/Response	chr7	55019101	55211628			"In the placebo-controlled Phase III study SATURN, using erlotinib maintenance therapy for patients with advanced NSCLC who were selected for response or stable disease after first line chemotherapy, EGFR mutation was assessed. In patients with EGFR mutation, erlotinib maintenance reduced progression and death significantly with median progression free survival (PFS) of 44.6 vs. 13 weeks over placebo. Erlotinib also significantly improved PFS in EGFR wildtype patients, but EGFR mutant tumors treated with erlotinib had significant better PFS than EGFR wildtype. Overall, in the intent to treat population erlotinib significantly improved PFS over placebo (HR, 0.71; 95% CI, 0.62 to 0.82; P<0.001)."	"Brugger et al., 2011, J. Clin. Oncol."	Somatic	ENST00000275493.2	inframe_variant
EGFR Expression	EGFR	Expression	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"Double blind Phase II clinical trial evaluated 208 patients for efficacy of gefitinib against non-small cell lung cancer. For individuals taking 250mg/day, they observed an objective response rate of 18.4%, a PFS of 2.7 months and a median overall survival of 7.6 months. For individuals taking 500mg/day objective response rate was 19%, PFS was 2.8 months, and median overall survival was 8.0 months. For those who responded, median duration of the response was 3 months (ranges=1-5.5 months). The disease control rate was found to be 54.4% and 51.4% for the two groups."	"Fukuoka et al., 2003, J. Clin. Oncol."	N/A	ENST00000275493.2	N/A
EGFR Mutation	EGFR	Mutation	Peritoneal Mesothelioma	"Cytoreductive Surgery,Hyperthermic Intraperitoneal Chemotherapy"	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"25 patients with metastatic peritoneal mesothelioma were treated with surgical cytoreduction consolidated with intraperitoneal hyperthermic chemotherapy (CRS/IPHC). 8 of the patients carried EGFR mutations in the tyrosine kinase domain. Each mutation was not found in 100 unrelated controls. At study end 10/18 wildtype patients had died with median survival of 14 months, while 2/7 EGFR mutant patients had died and median survival was not yet reached. Median time to progression (TTP) was 12 months in the wildtype group and in the mutant group median TTP was not yet reached. 3 year progression free survival was 71% in the mutant group and 28% in the wildtype group."	"Foster et al., 2010, World J Surg Oncol"	Somatic	ENST00000275493.2	inframe_variant
EGFR Amplification	EGFR	Amplification	Lung Non-small Cell Carcinoma	"Erlotinib,Gefitinib"	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"The result of the analysis found that EGFR gene copy number was associated with increased OS and PFS, supporting the idea that EGFR gene copy number is a biomarker for response to EGFR-TKI therapy in patients with advanced NSCLC."	"Dahabreh et al., 2011, Ann. Oncol."	Somatic	ENST00000275493.2	transcript_amplification
EGFR Amplification	EGFR	Amplification	Lung Non-small Cell Carcinoma	"Gefitinib,Erlotinib"	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"Among TKI-treated patients, increased EGFR gene copy number appears to be associated with improved survival outcomes."	"Zhang et al., 2017, J. Investig. Med."	Somatic	ENST00000275493.2	transcript_amplification
EGFR Rare Mutation	EGFR	Rare Mutation	Lung Adenocarcinoma	Gefitinib	Predictive	Supports	C	Sensitivity/Response	chr7	55019101	55211628			"A Japanese Phase III clinical study assessed the noninferiority of gefitinib as compared to erlotinib in 561 advanced stage (IIIB and IV) postoperative lung adenocarcinoma patients. All patients had prior chemotherapy but no treatment with TKIs. 19 patients had unspecified uncommon EGFR mutations, including single mutations other than ex19del and L858R and double mutations. Of those 19 patients, 7 were treated with erlotinib and 12 were treated with gefitinib. Objective response (42.9% for erlotinib and 25% for gefitinib) and disease control rate (71.4% with eflotinib and 66.7% with gefitinib) between were not significantly different between the treatments. The study failed to satisfy the primary endpoint of demonstrating statistical noninferiority in PFS of gefitinib."	"Urata et al., 2016, J. Clin. Oncol."	Somatic	ENST00000275493.2	
EGFR Mutation	EGFR	Mutation	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"In this open-label, randomised, phase 3 trial at 22 centres in China, patients with stage IIIB or IV NSCLC who had exon 19 deletion or exon 21 L858R point mutation, and who had not received previous systemic anticancer therapy, were administered tyrosine kinase inhibitor erlotinib (83 patients) or gemcitabine plus carboplatin (82 patients). Median progression-free survival was found to be significantly longer with erlotinib than in patients on chemotherapy (13.1 [95% CI 10.58?6.53] vs 4.6 [4.21?.42] months; hazard ratio 0.16, 95% CI 0.10?.26; p<0.0001). Chemotherapy was also associated with more grade 3 or 4 toxic effects. Authors conclude that in patients with advanced EGFR mutant NSCLC, erlotinib offers an improved first line treatment option."	"Zhou et al., 2011, Lancet Oncol."	Somatic	ENST00000275493.2	inframe_variant
EGFR Mutation	EGFR	Mutation	Lung Non-small Cell Carcinoma	Dacomitinib	Predictive	Supports	B	Sensitivity/Response	chr7	55019101	55211628			"In the ARCHER 1050 Phase 3 Trial (NCT01774721), 452 patients with newly diagnosed stage IIIB/IV or recurrent NSCLC exon 19 deletion or the Leu858Arg mutation, (with or without the T790M) were treated with second generation tyrosine kinase inhibitor (TKI) dacomitinib (227 patients) or first generation TKI gefitinib (225 patients).  Primary endpoint was progression free survival (PFS), and median PFS according to masked independent review was 14.7 months (95% CI 11.1?6.6) with dacomitinib group 9.2 months (9.1?1.0) with gefitinib (HR 059, 95% CI 047?74; p<00001).  Benefit of dacomitinib over gefitinib was lower in non-Asian patient subgroup (n=106) than in Asian group (n=346) although authors note smaller sample size may explain this. Authors state that PFS was significantly improved with first line dacomitinib treatment, and that dacomitinib should be considered for EGFR mutant NSCLC treatment."	"Wu et al., 2017, Lancet Oncol."	Somatic	ENST00000275493.2	inframe_variant
EGFR VIII	EGFR	VIII	Glioblastoma	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Predictive	Supports	B	Sensitivity/Response	chr7	55019365	55155830			49 patients (26 pretreatment tissues available for analysis) with recurrent glioblastomas who were treated with EGFR TKIs were analyzed in this study. Results were confirmed in an independent cohort of 33 patients. EGFRvIII and PTEN coexpression were associated with responsiveness to EGFR TKI.	"Mellinghoff et al., 2005, N. Engl. J. Med."	Somatic	ENST00000275493.2	disruptive_inframe_deletion
EGFR VIII	EGFR	VIII	Glioblastoma	Afatinib	Predictive	Supports	C	Sensitivity/Response	chr7	55019365	55155830			"Case report of a 58-year old patient with disease progression after radiotherapy and three temozolomide cycles. Afatinib and temozolomide led to disease regression. At last assessment 63 treatment cycles had been completed and the patient had survived for about 5 years since recurrence. Identified EGFR aberrations included EGFRvIII positivity, EGFR gene amplification and three somatic EGFR mutations."	"Alshami et al., 2015, Oncotarget"	Somatic	ENST00000275493.2	disruptive_inframe_deletion
EGFR VIII	EGFR	VIII	Head And Neck Squamous Cell Carcinoma	"Cetuximab,Docetaxel"	Predictive	Supports	B	Resistance	chr7	55019365	55155830			"47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR, and AREG expression by IHC. 17% of cases expressed high levels of EGFRvIII. High vIII expression was associated with reduced disease control rate (DCR) and shortened progression free survival (PFS) (HR: 3.3, P = 0.005) but not with OS."	"Tinhofer et al., 2011, Clin. Cancer Res."	Somatic	ENST00000275493.2	disruptive_inframe_deletion
EGFR VIII	EGFR	VIII	Glioblastoma	Rindopepimut	Predictive	Supports	B	Sensitivity/Response	chr7	55019365	55155830			"In a Phase II clinical trial, patients with Glioblastoma Multiforme (GBM), positive for EGFR VIII deletion mutation (N=65), were treated with the Rindopepimut cancer vaccine,  and standard adjuvant temozolomide chemotherapy.  Median progression free survival (PFS) was 9.2 months, and median overall survival (OS) was 21.8 months.  A pivotal, randomized Phase III trial is currently underway."	"Schuster et al., 2015, Neuro-oncology"	Somatic	ENST00000275493.2	disruptive_inframe_deletion
EGFR VIII	EGFR	VIII	Brain Glioma	Nimotuzumab	Predictive	Supports	D	Sensitivity/Response	chr7	55019365	55155830			"Two human glioma cell lines (U87MG or LNZ308) overexpressing either wild-type (wt) EGFR or EGFRvIII were treated with nimotuzumab, temozolomide, or both in vitro. Anti-tumor effects of nimotuzumab were greater in EGFRvIII in comparison to EGFRwt (as measured by antitumor effects, growth suppression, survival elongation and EGFR and Akt phosphorylation). Combination of nimotuzumab and temozolomide further increased efficacy."	"Nitta et al., 2016, Cancer Med"	Somatic	ENST00000275493.2	disruptive_inframe_deletion
EGFR VIII	EGFR	VIII	Glioblastoma	"Erlotinib,Gefitinib"	Predictive	Supports	B	Sensitivity/Response	chr7	55019365	55155830			Expression of EGFRvIII and PTEN was evaluated in 26 patients with glioblastomas treated with erlotinib or gefitinib and no EGFR or Her2/neu kinase domain mutations. 7 patients responded to treatment while 19 progressed rapidly. Coexpression of EGFRvIII and PTEN was associated with clinical response (defined as 25% tumor shrinkage). These results were confirmed using IHC in an independent cohort of 33 patients (8 responders) treated with erlotinib at another institution.	"Mellinghoff et al., 2005, N. Engl. J. Med."	Somatic	ENST00000275493.2	disruptive_inframe_deletion
EGFR VIII	EGFR	VIII	High Grade Glioma	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55019365	55155830			"In an in vitro study, a Ba/F3 cell line expressing EGFR vIII demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0?0 uM)."	"Lee et al., 2006, PLoS Med."	Somatic	ENST00000275493.2	disruptive_inframe_deletion
EGFR R108K	EGFR	R108K	High Grade Glioma	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55143387	55143387	G	A	"In an in vitro study, a Ba/F3 cell line expressing EGFR R108K demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0?0 uM)."	"Lee et al., 2006, PLoS Med."	Somatic	ENST00000275493.2	missense_variant
EGFR Exon 4 Deletion	EGFR	Exon 4 Deletion	Epithelial Ovarian Cancer	Cisplatin	Predictive	Supports	D	Resistance	chr7	55146606	55146740			"A variant of EGFR with exon 4 deletion (de4 EGFR) enhanced the invasiveness and cisplatin resistance of epithelial ovarian cancer cell lines (SKOV3, CAOV3, ES2) in vitro when compared with wild-type EGFR. The three cell lines were infected with lentivirus for either EGFR or de4 EGFR, and lentivirus-infected cells were used to perform transwell migration assays, invasion assays, and cisplatin sensitivity assays."	"Zhang et al., 2013, Carcinogenesis"	Somatic	ENST00000275493.2	exon_loss_variant
EGFR R222C	EGFR	R222C			Functional	Supports	D	Gain of Function	chr7	55152581	55152581	C	T	"A moderate throughput platform was used to functionally characterize 1000 somatic cancer variants. The platform found EGFR R222C to be an activating mutation based on in vitro screening in two growth-factordependent cell models using reverse-phase protein arrays for assessment. This was also the consensus from 5 other tools as well: HotSpot3D, HotMAPS, VEST, CanDrA, and Mutation Assessor (supplemental figure S5)."	"Ng et al., 2018, Cancer Cell"	Somatic	ENST00000275493.2	missense_variant
EGFR T263P	EGFR	T263P	High Grade Glioma	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55154050	55154050	A	C	"In an in vitro study, a Ba/F3 cell line expressing EGFR T263P demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0?0 uM)."	"Lee et al., 2006, PLoS Med."	Somatic	ENST00000275493.2	missense_variant
EGFR A289V	EGFR	A289V	High Grade Glioma	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55154129	55154129	C	T	"In an in vitro study, a Ba/F3 cell line expressing EGFR A289V demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0?0 uM)."	"Lee et al., 2006, PLoS Med."	Somatic	ENST00000275493.2	missense_variant
EGFR V441F	EGFR	V441F	Colorectal Cancer	"Panitumumab,Cetuximab"	Predictive	Supports	E	Resistance	chr7	55160161	55160161	G	T	"Next-generation sequencing data of cfDNA from 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD). EGFR V441G/D/F mutations were found in 19% (n=8) of patients with EGFR ECD domain III (location of cetuximab and panitumumab binding epitope) mutations. V441D and V441G were more common than V441F. Resistance of V441G to cetuximab was modeled in silico, and authors predicted that it destroys a critical hydrophobic node. In vitro, V441G/D transduced NIH3T3 cells had significantly reduced binding to panitumumab and cetuximab compared to EGFR wt NH3T3 cells (p<0.01 for all comparisons to wt). Authors inferred that EGFR domain III (ECD) mutations, including V441F, may be responsible for secondary resistance to EGFR blockade."	"Strickler et al., 2018, Cancer Discov"	Somatic	ENST00000275493.2	missense_variant
EGFR R451C	EGFR	R451C	Colorectal Cancer	"Cetuximab,Panitumumab,Futuximab/Modotuximab Mixture"	Predictive	Supports	D	Sensitivity/Response	chr7	55160191	55160191	C	T	"In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The R451C mutation showed moderate drug-receptor binding with sym004, cetuximab and panitumumab treatment and inhibition of EGFR phosphorylation."	"Snchez-Martn et al., 2016, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR G465R	EGFR	G465R	Colorectal Cancer	Futuximab/Modotuximab Mixture	Predictive	Supports	C	Sensitivity/Response	chr7	55160233	55160233	G	A	"An EGFR G465R mutation (22% of mutant alleles) was detected in a biopsy from one patient which had been previously treated with cetuximab in the analysis of 15 patients with refractory, metastatic CRC after cetuximab/panitumumab, prior to Sym004 (Futuximab/Modotuximab mixture) treatment. Subsequent treatment of this patient with Sym004 yielded disease stabilization lasting 15 weeks. In vitro analysis in colorectal cancer cell line NIH3T3 with EGFR mutations S492R, R451C, K467T, and G465R showed that antibody mixture Sym004 effectively bound to all mutants, whereas cetuximab and panitumumab did not effectively bind to all mutants. In-vitro, Sym004 inhibited growth of S492R and G465R EGFR mutant cell lines. In-vivo analysis of S492R and G465R mutant cell lines showed regression of S492R and tumor growth delay of G465R mutant cell lines."	"Snchez-Martn et al., 2016, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR G465R	EGFR	G465R	Colorectal Cancer	"Cetuximab,Panitumumab"	Predictive	Supports	C	Resistance	chr7	55160233	55160233	G	A	"An EGFR G465R mutation (22% of mutant alleles) was detected in a biopsy from one patient which had been previously treated with cetuximab in the analysis of 15 patients with refractory, metastatic CRC after cetuximab/panitumumab, prior to Sym004 treatment. Treatment of this patient with Sym004 yielded disease stabilization lasting 15 weeks. Sym004 is a 1:1 mixture of two non-overlapping anti-EGFR monoclonal antibodies. In vitro analysis in the murine fibroblast cell line NIH3T3 with ectopic expression of EGFR mutations S492R, R451C, K467T, and G465R showed that Sym004 effectively bound to all mutants, whereas cetuximab and panitumumab did not effectively bind to all mutants. In-vitro, Sym004 inhibited growth of S492R and G465R EGFR mutant cell lines. In-vivo analysis of S492R and G465R mutant cell lines showed regression of S492R and tumor growth delay of G465R mutant cell lines. G465R mutant cell lines were resistant to treatment with panitumumab or cetuximab in-vitro."	"Snchez-Martn et al., 2016, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR K467T	EGFR	K467T	Colorectal Cancer	"Panitumumab,Futuximab/Modotuximab Mixture"	Predictive	Supports	D	Sensitivity/Response	chr7	55160240	55160240	A	C	"In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. In NIH3T3 cells expressing EGFR with a K467T mutation, Sym004 and panitumumab bound the mutated receptor and inhibited EGFR phosphorylation in the presence of ligand while cetuximab neither bound to nor inhibited EGFR phosphorylation of the mutated receptor."	"Snchez-Martn et al., 2016, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR K467T	EGFR	K467T	Colorectal Cancer	Cetuximab	Predictive	Supports	D	Resistance	chr7	55160240	55160240	A	C	"In this preclinical study on the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. In NIH3T3 cells expressing EGFR with a K467T mutation, Sym004 and panitumumab bound the mutated receptor and inhibited EGFR phosphorylation in the presence of ligand while cetuximab neither bound to nor inhibited EGFR phosphorylation of the mutated receptor."	"Snchez-Martn et al., 2016, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR S492R	EGFR	S492R	Colorectal Cancer	Cetuximab	Predictive	Supports	C	Resistance	chr7	55160316	55160316	C	A	In-vitro studies found this mutation to confer resistance to cetuximab. 2 of 10 patients studied also harbored EGFR S492R and were resistant to cetuximab therapy. Panitumumab was still active in-vitro and in one patient.	"Montagut et al., 2012, Nat. Med."	Somatic	ENST00000275493.2	missense_variant
EGFR S492R	EGFR	S492R	Colorectal Cancer	Panitumumab	Predictive	Supports	C	Sensitivity/Response	chr7	55160316	55160316	C	A	"Tumor sequencing in pre- and post-therapy specimens from ten individuals with mCRC who experienced disease progression after a prior response to cetuximab with chemotherapy was performed. The S492R mutation was identified in two persons. One of them had already died, the other received treatment with panitumumab and had a partial response (50% tumor reduction in all liver lesions) for 5 months."	"Montagut et al., 2012, Nat. Med."	Somatic	ENST00000275493.2	missense_variant
EGFR S492R	EGFR	S492R	Colorectal Cancer	"Panitumumab,Futuximab/Modotuximab Mixture"	Predictive	Supports	D	Sensitivity/Response	chr7	55160316	55160316	C	A	"In this preclinical study of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The S492R mutation was sensitive to Sym004 and panitumumab treatment but resistant to cetuximab. Experiments include flow cytometry binding assay, kinase phosphorylation, cell viability, downstream signalling."	"Snchez-Martn et al., 2016, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR S492R	EGFR	S492R	Colorectal Cancer	Cetuximab	Predictive	Supports	D	Resistance	chr7	55160316	55160316	C	A	"In this preclinical study of the effects of cetuximab, panitumumab or sym004 on various EGFR mutations in colorectal cancer. The S492R mutation was sensitive to Sym004 and panitumumab treatment but resistant to cetuximab. Experiments include flow cytometry binding assay, kinase phosphorylation, cell viability, downstream signalling."	"Snchez-Martn et al., 2016, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR G598V	EGFR	G598V	Cancer	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55165350	55165350	G	T	"In an in vitro study, a Ba/F3 cell line expressing EGFR G598V demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0?0 uM)."	"Lee et al., 2006, PLoS Med."	Somatic	ENST00000275493.2	missense_variant
EGFR Exon 18 Overexpression	EGFR	Exon 18 Overexpression	Lung Non-small Cell Carcinoma	"Bevacizumab,Erlotinib"	Predictive	Supports	B	Sensitivity/Response	chr7	55170306	55171042			"Overexpression of EGFR exon 18 (Affymetrix Human Exon 1.0 ST) in tumor or blood samples was associated with tumor shrinkage, independently of EGFR mutational status in NSCLC treated with bevacizumab and erlotinib. 76 patients were analyzed for this study."	"Baty et al., 2013, PLoS ONE"	N/A	ENST00000344576.2	exon_variant
EGFR R705K	EGFR	R705K	Lung Non-small Cell Carcinoma	"Erlotinib,Gefitinib"	Predictive	Does Not Support	C	Sensitivity/Response	chr7	55173973	55173973	G	A	"In a large retrospective study, EGFR exons 18-21 were assessed using direct sequencing in 753 French NSCLC cases. Clinical details and patient outcomes were taken, including whether the first generation TKIs erlotinib or gefitinib were administered. One patient was found to have a R705K mutation, was administered a TKI, and an NSCLC progression was observed."	"Locatelli-Sanchez et al., 2013, Lung"	Somatic	ENST00000275493.2	missense_variant
EGFR G719S	EGFR	G719S	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	D	Sensitivity/Response	chr7	55174014	55174014	G	A	Gefinitib has been shown to be effective in treating cell lines with G719S missense mutations.	"Paez et al., 2004, Science"	Somatic	ENST00000275493.2	missense_variant
EGFR G719S	EGFR	G719S	Colorectal Cancer	Cetuximab	Predictive	Supports	D	Sensitivity/Response	chr7	55174014	55174014	G	A	"Whole genome sequencing of a case of colon carcinoma revealed a G724S mutation in the EGFR gene. In-vitro, this mutation was shown to be oncogenic and sensitive to Cetuximab, yet relatively insensitive towards small molecules. The same in-vitro results could be reproduced for the G719S mutation."	"Cho et al., 2014, Mol. Cancer"	Somatic	ENST00000275493.2	missense_variant
EGFR G719S	EGFR	G719S	Lung Non-small Cell Carcinoma	"Gefitinib,Erlotinib"	Predictive	Supports	B	Sensitivity/Response	chr7	55174014	55174014	G	A	"This small clinical (n=56) study suggests that patients with minor mutations of EGFR, like G719S, are likely to have a moderate response to Tyrosine kinase inhibitors like Gefitinib and Erlotinib. In this study 44 of 56 patients were treated with either gefitinib or erlotinib. 35 patients had a G719 mutation but the majority of these were G719S (20 with G719S, 9 with G719A, 3 with G719C)."	"Otsuka et al., 2015, Anticancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR G719	EGFR	G719	Lung Adenocarcinoma	Erlotinib	Predictive	Supports	B	Sensitivity/Response	chr7	55174014	55174015			"In a meta-analysis of 7 clinical trials of erlotinib (some vs placebo or other treatment), 10/24 patients with Exon 18 mutations harbored a G719 variant. These variants were associated with improved progression-free and overall survival. No statistical analysis was reported for this variant and PFS or OS, citing small sample size across the studies."	"Klughammer et al., 2016, J Thorac Oncol"	Somatic	ENST00000275493.2	protein_altering_variant
EGFR G719	EGFR	G719	Lung Non-small Cell Carcinoma	"Gefitinib,Erlotinib"	Predictive	Supports	B	Sensitivity/Response	chr7	55174014	55174015			"EGFR G719 mutations have been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In a study of patients treated with erlotinib or gefitinib, a subset of patients with EGFR mutation at codons G719 or L861 (n=30) was associated with improved response rate (47.5% vs 16.5%, P<0.001) median progression free survival (5.0 vs 2.0 months, P<0.001), and overall survival (15.0 vs. 10.4 months, P =0.030), compared to patients with wild-type EGFR (n=272). For the subset of patients with G719, the response rate was 53.3% (8 of 15), median PFS was 8.1 months, and median overall survival was 16.4 months."	"Wu et al., 2011, Clin. Cancer Res."	Somatic	ENST00000275493.2	protein_altering_variant
EGFR G719S	EGFR	G719S	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55174014	55174014	G	A	"In an in vitro study, a Ba/F3 cell line expressing EGFR G719S demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR G719S and EGFR L858R expressing cells were 16 nmol/L and 6 nmol/L, respectively."	"Kancha et al., 2009, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR G719A	EGFR	G719A	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	C	Sensitivity/Response	chr7	55174015	55174015	G	C	"In a study of 297 non-small cell lung cancer patients, 15% of the analyzed tumors had  EGFR mutations including deletions in exon 19 (n=22), L858R (n=16) and G719A (n=2). Patients with EGFR mutations treated with gefitinib were associated with improved response rates (42.1% vs. 6.6%, P=0.04) compared to wildtype EGFR patients."	"Douillard et al., 2010, J. Clin. Oncol."	Somatic	ENST00000275493.2	missense_variant
EGFR G719D	EGFR	G719D	Lung Non-small Cell Carcinoma	"Gefitinib,Erlotinib"	Predictive	Supports	C	Sensitivity/Response	chr7	55174015	55174015	G	A	"In a study, 2 participants with stage IV lung adenocarcinoma were sequenced at EGFR exons 18 to 21. Both patients were found to have G719D mutation and were treated with the 1st generation TKIs gefitinib or erlotinib. The first patient (M, 81, smoker) was treated with gefitinib and had a partial response, progression free survival (PFS) of 21.7 months, overall survival (OS) of 22.5 months and was alive at study end. The second patient (M, 76, smoker) was treated with erlotinib and had stable disease as response, PFS of 2.6 months, OS of 2.6 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type."	"Wu et al., 2011, Clin. Cancer Res."	Somatic		missense_variant
EGFR G719A	EGFR	G719A	Lung Non-small Cell Carcinoma	"Erlotinib,Gefitinib"	Predictive	Does Not Support	C	Sensitivity/Response	chr7	55174015	55174015	G	C	"In a large retrospective study, EGFR exons 18-21 were assessed using direct sequencing in 753 French NSCLC cases. Clinical details and patient outcomes were taken, including whether the first generation TKIs erlotinib or gefitinib were administered. One patient was found to have a G719A mutation, was administered a TKI, and an NSCLC progression was observed."	"Locatelli-Sanchez et al., 2013, Lung"	Somatic	ENST00000275493.2	missense_variant
EGFR S720	EGFR	S720	Lung Adenocarcinoma	Erlotinib	Predictive	Supports	C	Resistance	chr7	55174017	55174018			"Efficacy of erlotinib treatment was evaluated by meta-analysis of results from seven trials and literature review. Two patients with p.S270P, and one patient with p.S720F were observed to have poor survival outcomes."	"Klughammer et al., 2016, J Thorac Oncol"	Somatic	ENST00000275493.2	protein_altering_variant
EGFR G724S	EGFR	G724S	Colorectal Cancer	Cetuximab	Predictive	Supports	D	Sensitivity/Response	chr7	55174029	55174029	G	A	"Whole genome sequencing of a case of colon carcinoma revealed a G724S mutation in the EGFR gene. In-vitro, this mutation was shown to be oncogenic and sensitive to Cetuximab, yet relatively insensitive towards small molecules."	"Cho et al., 2014, Mol. Cancer"	Somatic	ENST00000275493.2	missense_variant
EGFR Exon 19 Deletion	EGFR	Exon 19 Deletion	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	D	Sensitivity/Response	chr7	55174722	55174820			Exon 19 deletion has been shown to be correlated with gefitinib response.	"Ji et al., 2006, Cancer Cell"	Somatic	ENST00000275493.2	inframe_deletion
EGFR Exon 19 Deletion	EGFR	Exon 19 Deletion	Lung Non-small Cell Carcinoma	"Gefitinib,Erlotinib"	Predictive	Supports	B	Sensitivity/Response	chr7	55174722	55174820			NSCLC patients with exon 19 deletions in EGFR had longer overall survival than patients with an L858R mutation when treated with gefitinib or erlotinib (38 versus 17 months; P = 0.04).	"Jackman et al., 2006, Clin. Cancer Res."	Somatic	ENST00000275493.2	inframe_deletion
EGFR Exon 19 Deletion	EGFR	Exon 19 Deletion	Lung Adenocarcinoma	Afatinib	Predictive	Supports	B	Sensitivity/Response	chr7	55174722	55174820			"A phase III clinical trial (NCT00949650) found that median progression free survival among patients with EGFR exon 19 deletion was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = .001). 308 patients had either exon 19 or L858 mutations."	"Sequist et al., 2013, J. Clin. Oncol."	Somatic	ENST00000275493.2	inframe_deletion
EGFR Exon 19 Deletion	EGFR	Exon 19 Deletion	Lung Non-small Cell Carcinoma	Afatinib	Predictive	Supports	D	Sensitivity/Response	chr7	55174722	55174820			Stable HEK293 cell lines expressing mutant EGFR cDNAs were created (using a pQCLIN retroviral vector) and their drug sensitivities to afatinib were examined by MTT assay. Phorphorylation of EGFR was assayed by Western blot. The 50% inhibitory concentration (IC50) of afatinib was significantly lower in cells harboring EGFR exon 19 deletion than in cells harboring EGFR L858R.	"Banno et al., 2015, Anticancer Res."	Somatic	ENST00000275493.2	inframe_deletion
EGFR Exon 19 Deletion	EGFR	Exon 19 Deletion	Lung Adenocarcinoma	Afatinib	Predictive	Supports	B	Sensitivity/Response	chr7	55174722	55174820			"In a phase 2 study (NCT00525148), patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib, were assessed by objective response. In total, 129 patients were treated with afatinib. 66% of the 106 patients with two common activating EGFR mutations (exon 19 deletion or L858R) had an objective response compared to 39% of 23 patients with less common EGFR mutations."	"Yang et al., 2012, Lancet Oncol."	Somatic	ENST00000275493.2	inframe_deletion
EGFR Exon 19 Deletion	EGFR	Exon 19 Deletion	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	B	Sensitivity/Response	chr7	55174722	55174820			"A randomized phase 3 trial involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease. Patients were randomly allocated (1:1) to receive either erlotinib or standard chemotherapy. The primary endpoint was progression-free survival (PFS). Median PFS was 9.7 months in the erlotinib group, compared with 5.2 months in the standard chemotherapy group."	"Rosell et al., 2012, Lancet Oncol."	Somatic	ENST00000275493.2	inframe_deletion
EGFR Exon 19 Deletion	EGFR	Exon 19 Deletion	Lung Non-small Cell Carcinoma	Afatinib	Predictive	Supports	D	Sensitivity/Response	chr7	55174722	55174820			Cells harboring an exon 19 deletion were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.	"Hirano et al., 2015, Oncotarget"	Somatic	ENST00000275493.2	inframe_deletion
EGFR Exon 19 Deletion	EGFR	Exon 19 Deletion	Lung Adenocarcinoma	Afatinib	Predictive	Supports	B	Sensitivity/Response	chr7	55174722	55174820			Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364 eligible patients with EGFR mutations were assigned to afatinib (n=242) or gemcitabine and cisplatin (n=122) treatment. The trial observed significantly longer median progression-free survival with afatinib vs. gemcitabine and cisplatin treatment (11.0 vs. 5.6 months). Afatinib/Chemotherapy group compositions: 51.2/50.8 % del 19; 38/37.7 % Leu858Arg; 10.8/11.5 % Uncommon.	"Wu et al., 2014, Lancet Oncol."	Somatic	ENST00000275493.2	inframe_deletion
EGFR Exon 19 Deletion	EGFR	Exon 19 Deletion	Lung Adenocarcinoma	Afatinib	Predictive	Supports	B	Sensitivity/Response	chr7	55174722	55174820			"In analysis of LUX-Lung 3 and LUX-Lung 6 trials (NCT00949650 and NCT01121393), of EGFR mutant NSCLC, median overall survival with afatinib treatment was seen to be significantly improved over chemotherapy (33.3 vs 21.1 and 31.4 vs 18.4 months in LUX-Lung 3 and LUX-Lung 6 respectively).  This effect was observed in the EGFR exon 19 deletion subgroup, but not in the L858R mutant subgroup."	"Yang et al., 2015, Lancet Oncol."	Somatic	ENST00000275493.2	inframe_deletion
EGFR Exon 19 Deletion	EGFR	Exon 19 Deletion	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	B	Sensitivity/Response	chr7	55174722	55174820			"90 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were treated with gefitinib, and exon 19 deletion of EGFR was associated with longer time to treatment failure than those with wild-type EGFR (median 8.9 versus 2.1). In multivariate analysis, exon 19 deletion was a significant predictive factor for TTF (HR = 0.0320; P < .0001)."	"Yang et al., 2008, J. Clin. Oncol."	Somatic	ENST00000275493.2	inframe_deletion
EGFR Exon 19 Deletion	EGFR	Exon 19 Deletion	Lung Adenocarcinoma	Gefitinib	Predictive	Supports	B	Sensitivity/Response	chr7	55174722	55174820			"In a phase 3 clinical trial of Korean, never-smoker, lung adenocarcinoma patients, a subset of patients with EGFR mutations (n=42) treated with gefitinib were associated with improved overall response rate compared to gemcitabine plus cisplatin treatment (84.6%, 22/26, vs. 37.5%, 6/16, P=0.002). By contrast, in EGFR mutation negative cases, the response rate was much lower (25.9%, 7/27). The frequency of mutation in exon 19 deletion and L858R was 64.3% (27/42) and 36.4% (16/42), respectively. Exon 19 and L858R mutations were mutually exclusive in this cohort."	"Han et al., 2012, J. Clin. Oncol."	Somatic	ENST00000275493.2	inframe_deletion
EGFR Exon 19 Deletion	EGFR	Exon 19 Deletion	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	A	Sensitivity/Response	chr7	55174722	55174820			"On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations."	"Khozin et al., 2014, Oncologist"	Somatic	ENST00000275493.2	inframe_deletion
EGFR Exon 19 Deletion	EGFR	Exon 19 Deletion	Lung Non-small Cell Carcinoma	Afatinib	Predictive	Supports	A	Sensitivity/Response	chr7	55174722	55174820			"Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test"	"Dungo et al., 2013, Drugs"	Somatic	ENST00000275493.2	inframe_deletion
EGFR Exon 19 Deletion	EGFR	Exon 19 Deletion	Lung Adenocarcinoma	Erlotinib	Predictive	Supports	C	Sensitivity/Response	chr7	55174722	55174820			"In a stage IV lung adenocarcinoma patient harboring EGFR exon 19 deletion, EGFR exon 19 deletion was associated with sensitivity to erlotinib monotherapy. Prior to identification of the EGFR exon 19 deletion, the patient was underwent complex treatments with standard chemotherapy and experienced disease progression; upon identification of EGFR exon 19 deletion and treatment with erlotinib, the patient achieved a clinical response."	"Kanemaru et al., 2016, Respir Investig"	Somatic	ENST00000275493.2	inframe_deletion
EGFR Exon 19 Deletion	EGFR	Exon 19 Deletion	Lung Non-small Cell Carcinoma	"Dacomitinib,Erlotinib"	Predictive	Supports	B	Sensitivity/Response	chr7	55174722	55174820			"Non-small cell cancer patients from two studies [The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)] with exon 19 deletion and L858R EGFR (Exon 21) mutations were pooled to compare the efficacy of dacomitinib to erlotinib. 121 patients with any EGFR mutation were enrolled, 101 had activating mutations in exon 19 or 21. Median progression-free survival and median survival were better following dacomitinib treatment (14.6 and 26.6 months, N=53) than erlotinib (9.6 and 23.2, P = 0.146 and P = 0.265, N=48). In exon 19 mutated patients (N=32 and 36) PFS was better for dacomitinib treated patients (HR of 0.585 [95% CI 0.335?.024], two-sided log-rank, P = 0.058) but did not reach significance."	"Ramalingam et al., 2016, Ann. Oncol."	Somatic	ENST00000275493.2	inframe_deletion
EGFR Exon 19 Deletion	EGFR	Exon 19 Deletion	Lung Adenocarcinoma	Gefitinib	Predictive	Supports	B	Sensitivity/Response	chr7	55174722	55174820			"A Japanese Phase III clinical study assessed the noninferiority of gefitinib in comparison to erlotinib in 561 patients with postoperative or recurrent stage IIIB/IV lung adenocarcinoma. Patients were pretreated with at least one chemotherapy regimen, but no tyrosine kinase inhibitors. In the subgroup of 156 patients with exon 19 deletions as their sole EGFR mutation, 83 and 78 were treated with erlotinib and gefitinib, respectively. Objective response (defined as complete + partial response) was approximately 65 percent for both erlotinib gefitinib and non significantly different  (p= .965). Disease control rate (defined as complete response + partial response + stable disease) was 91.6 and 83.3 percent for erlotinib and gefitinib, respectively (p=.113). The study was unable to demonstrate statistical noninferiority via the planned end point; however, the lack of statistically significant differences between erlotinib and gefitinib responses, and the milder adverse effects experienced by gefitinib treated patients, led the authors to conclude that gefitinib is a feasible alternative to erlotinib in treating patients with ex19del EGFR positive, advanced lung adenocarcinoma."	"Urata et al., 2016, J. Clin. Oncol."	Somatic	ENST00000275493.2	inframe_deletion
EGFR Exon 19 Deletion	EGFR	Exon 19 Deletion	Lung Non-small Cell Carcinoma	Anti-PD1 Monoclonal Antibody	Predictive	Supports	B	Resistance	chr7	55174722	55174820			"In a multicenter retrospective study, the relationship between EGFR status in 171 patients with non-small cell lung carcinoma and response to immune checkpoint blockade was examined. Immune checkpoint inhibitor included PD-1 inhibitor alone, PD-L1 inhibitor alone or PD-(L)1 inhibitor / CTLA-4 inhibitor combination. These patients were compared to 212 previously published EGFR wild type patient outcomes. The response rate in patients with EGFR wild type, EGFR L858R mutation, and EGFR exon 19 deletions were 22, 16, and 7% respectively."	"Hastings et al., 2019, Ann. Oncol."	Somatic	ENST00000275493.2	inframe_deletion
EGFR Exon 19 Deletion	EGFR	Exon 19 Deletion	Lung Non-small Cell Carcinoma	Anti-PD-L1 Monoclonal Antibody	Predictive	Supports	B	Resistance	chr7	55174722	55174820			"In a multicenter retrospective study, the relationship between EGFR status in 171 patients with non-small cell lung carcinoma and response to immune checkpoint blockade was examined. Immune checkpoint inhibitor included PD-1 inhibitor alone, PD-L1 inhibitor alone or PD-(L)1 inhibitor / CTLA-4 inhibitor combination. These patients were compared to 212 previously published EGFR wild type patient outcomes. The response rate in patients with EGFR wild type, EGFR L858R mutation, and EGFR exon 19 deletions were 22, 16, and 7% respectively."	"Hastings et al., 2019, Ann. Oncol."	Somatic	ENST00000275493.2	inframe_deletion
EGFR W731L	EGFR	W731L	Cancer	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55174729	55174729	G	T	"In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR W731L demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation."	"Foster et al., 2010, World J Surg Oncol"	Somatic	ENST00000275493.2	missense_variant
EGFR E734Q	EGFR	E734Q	Cancer	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55174737	55174737	G	C	"In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR E734Q demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation."	"Foster et al., 2010, World J Surg Oncol"	Somatic	ENST00000	missense_variant
EGFR V742A	EGFR	V742A	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55174762	55174762	T	C	"In an in vitro study, a Ba/F3 cell line expressing EGFR V742A demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR V742A and EGFR L858R expressing cells were 21 nmol/L and 6 nmol/L, respectively."	"Kancha et al., 2009, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR E746_A750del	EGFR	E746_A750del	Bronchiolo-alveolar Adenocarcinoma	Erlotinib	Predictive	Supports	C	Sensitivity/Response	chr7	55174772	55174786	GGAATTAAGAGAAGC		"EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib in a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma). One patient (Patient E2) had the E746_A750del mutation. The patient was a male never smoker, and demonstrated response for 8.5 months. Overall survival was 21+ months as the patient was alive at study end."	"Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000275493.2	inframe_deletion
EGFR E746_A750del	EGFR	E746_A750del	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	D	Sensitivity/Response	chr7	55174772	55174786	GGAATTAAGAGAAGC		"In an in vitro study using PC9 cells (EGFR exon 19 deletion), inhibition of cell viability was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an increased sensitivity to gefitinib (IC50: 23.0 nmol/L vs 200.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type)."	"Cross et al., 2014, Cancer Discov"	Somatic	ENST00000275493.2	inframe_deletion
EGFR E746_A750del	EGFR	E746_A750del	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	C	Sensitivity/Response	chr7	55174772	55174786	GGAATTAAGAGAAGC		"Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical improvement in response to gefitinib. Of 7 tumors with EGFR mutations, 4 were del E746-A750. 3 had adenocarcinoma with bronchioloalveolar carcinoma (BAC) features, with response duration and overall survival of 8 and 15 months, 5+ and 5+ months (treatment ongoing at study end) and 28 and 30+ months (alive at study end), and one former smoker with adenocarcinoma with BAC features, who had response duration of 5+ months with treatment ongoing at study end."	"Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000275493.2	inframe_deletion
EGFR E746G	EGFR	E746G	Lung Adenocarcinoma	Erlotinib	Predictive	Supports	C	Sensitivity/Response	chr7	55174774	55174774	A	G	"In a meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, one patient was described with the exon 19 mutation E746G from the BeTa study. Progression-free (415 days) and overall (462 days) survival suggested sensitivity in this patient. No statistical analysis was reported for this variant and PFS or OS, citing small sample size across the studies."	"Klughammer et al., 2016, J Thorac Oncol"	Somatic	ENST00000275493.2	missense_variant
EGFR L747P	EGFR	L747P	Lung Non-small Cell Carcinoma	"Erlotinib,Gefitinib"	Predictive	Does Not Support	C	Sensitivity/Response	chr7	55174776	55174777	TT	CC	"In a study, 2 participants with stage IV adenocarcinoma were sequenced at EGFR exons 18 to 21.  Both patients were found to have L747P mutation and were treated with the 1st generation TKIs gefitinib or erlotinib. The first patient (M, 62, nonsmoker) was treated with gefitinib and had progressive disease, progression free survival (PFS) of 1.0 months, overall survival (OS) of 7.7 months and was not alive at study end. The second patient (M, 39, nonsmoker) was treated with erlotinib and had progressive disease as response, PFS of 2.3 months, OS of 7.2 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type."	"Wu et al., 2011, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR L747_S752delinsQ	EGFR	L747_S752delinsQ	Lung Adenocarcinoma	Erlotinib	Predictive	Supports	C	Sensitivity/Response	chr7	55174776	55174793	TTAAGAGAAGCAACATCT	CAA	"EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib in a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma). One patient (Patient E1) had the del L747-S752 insQ mutation. The patient was a male never smoker and demonstrated response for 8 months. He continued to show response and remain on the drug when the manuscript was written."	"Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A."	Somatic		"inframe_insertion,inframe_deletion,delins"
EGFR L747_P753delinsS	EGFR	L747_P753delinsS	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55174777	55174794	TAAGAGAAGCAACATCTC		"In an in vitro study, a Ba/F3 cell line expressing EGFR L747_P753>S demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR L747_P753>S and EGFR L858R expressing cells were 5 nmol/L and 6 nmol/L, respectively."	"Kancha et al., 2009, Clin. Cancer Res."	Somatic	ENST00000275493.2	inframe_deletion
EGFR L747_P753delinsS	EGFR	L747_P753delinsS	Pancreatic Adenocarcinoma	Erlotinib	Predictive	Supports	C	Sensitivity/Response	chr7	55174777	55174794	TAAGAGAAGCAACATCTC		"Patients with recurrent pancreatic adenocarcinoma was treated with gemcitabine + nab-paclitaxel, FOLFIRINOX and docetaxel + irinotecan. After failure of these treatment, a tumor specimen from the pancreaticoduodenectomy was analyzed, which revealed an activating mutation in exon 19 (L747_P753>S) of EGFR. Mutations were also detected in CDKN2A, TP53, and amplifications of PRKCI and TERC. He began erlotinib at 150mg daily. CT imaging revealed a partial response by RECIST at 8, 24 and 32 weeks after starting erlotinib. At 40 weeks CT imaging revealed unequivocal disease progression. After disease progression to erlotinib, a repeat liver biopsy revealed an EGFR T790M mutation. He began treatment with osimertinib at 80mg daily. After 8 weeks of this treatment CT imaging revealed unequivocal disease progression."	"Cecchini et al., 2017, J Natl Compr Canc Netw"	Somatic	ENST00000275493.2	inframe_deletion
EGFR P753S	EGFR	P753S	Skin Squamous Cell Carcinoma	"Sirolimus,Cetuximab"	Predictive	Supports	C	Sensitivity/Response	chr7	55174794	55174794	C	T	72-year old male patient presents with SCC with a mutation profile consistent with UV exposure. Sequencing revealed a number of abnormalities including P753S mutation in EGFR. Patient began therapy with cetuximab and sirolimus and continued for 9 months. Disease burden was not measurable by Response Evaluation Criteria in Solid Tumors.	"Ganesan et al., 2016, J. Clin. Oncol."	Somatic	ENST00000275493.2	missense_variant
EGFR K757R	EGFR	K757R	Lung Adenocarcinoma	Erlotinib	Predictive	Supports	C	Sensitivity/Response	chr7	55174807	55174807	A	G	"In a meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, one patient was described with the exon 19 mutation K757R from the MERIT study. Progression-free (250 days) and overall (435 days) survival suggested sensitivity in this patient. Literature analysis did not identify additional reports of patients harboring this mutation."	"Klughammer et al., 2016, J Thorac Oncol"	Somatic	ENST00000275493.2	missense_variant
EGFR D761Y	EGFR	D761Y	Lung Non-small Cell Carcinoma	"Gefitinib,Erlotinib"	Predictive	Supports	C	Resistance	chr7	55174818	55174818	G	T	D761Y as a secondary mutation was reported to be associated with resistance to gefitinib and erlotinib in NSCLC cells that contain the L858R-EGFR mutation. This mutation combination was observed in a single patient with lung cancer and specifically in a metastatic brain lesion following gefitinib treatment. Functional validation of its role in drug sensitivity was examined in cell lines (293T and Ba/F3 cells).	"Balak et al., 2006, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR Exon 20 Insertion	EGFR	Exon 20 Insertion	Lung Adenocarcinoma	Afatinib	Predictive	Supports	B	Resistance	chr7	55181298	55181329			"In retrospective analysis of trials, afatinib conferred limited clinical benefit to patients with EGFR exon 20 insertion mutations (N=23). Only 2 patients had objective responses."	"Yang et al., 2015, Lancet Oncol."	Somatic	ENST00000275493.2	inframe_insertion
EGFR Exon 20 Insertion	EGFR	Exon 20 Insertion	Lung Adenocarcinoma	Erlotinib	Predictive	Supports	C	Resistance	chr7	55181298	55181329			"In stage IV lung adenocarcinoma patients (n=2) harboring EGFR inframe exon 20 insertion mutation, EGFR exon 20 insertion was associated with progressive disease after 1 and 3 months of erlotinib monotherapy, respectively; both patients were previously treated with standard chemotherapy."	"Lund-Iversen et al., 2012, J Thorac Oncol"	Somatic	ENST00000275493.2	inframe_insertion
EGFR Exon 20 Insertion	EGFR	Exon 20 Insertion	Lung Non-small Cell Carcinoma	Osimertinib	Predictive	Supports	B	Sensitivity/Response	chr7	55181298	55181329			Retrospective study of six Chinese patients with EGFR exon 20 insertion mutant stage IV non-small cell lung carcinoma treated with osimertinib. Four of the patients experienced partial response (67.7%) and two had stable disease during treatment. Two patients had sustained disease control and remained on treatment. The median progression-free survival was 6.2 months (95% CI 5.0-12.9 months).	"Fang et al., 2019, BMC Cancer"	Somatic	ENST00000275493.2	inframe_insertion
EGFR A763_Y764insFQEA	EGFR	A763_Y764insFQEA	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55181299	55181300		TCCAGGAAGCCT	"In an in vitro study, Ba/F3 and BID007 cell lines expressing EGFR A763_Y764insFQEA demonstrated increased sensitivity to erlotinib treatment (IC50=0.048M and 0.082M, respectively), comparable to Ba/F3 and NCI-H3255 cells expressing EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitors; IC50=0.006M and 0.068M, respectively). Sensitivity was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation, levels of BIM (a marker of EGFR TKI-induced cell killing) and cell viability."	"Yasuda et al., 2013, Sci Transl Med"	Somatic	ENST00000275493.2	inframe_insertion
EGFR A763_Y764insFQEA	EGFR	A763_Y764insFQEA	Lung Non-small Cell Carcinoma	Osimertinib	Predictive	Supports	C	Sensitivity/Response	chr7	55181299	55181300		TCCAGGAAGCCT	"In a retrospective study of 2316 Chinese patients with stage IV non-small cell lung carcinoma, a 65 year old female with the EGFR exon 20 insertion A763_Y764insFQEA received osimertinib as second-line treatment. The patient achieved a partial response with greater than 50% reduction in tumour size, and progression-free survival of 5.1 months. The patient had previously achieved partial response on gefinitib, but experienced disease progression after 9.0 months at which point a rebiopsy was found to harbor a T790M mutation."	"Fang et al., 2019, BMC Cancer"	Somatic	ENST00000275493.2	inframe_insertion
EGFR Y764_V765insHH	EGFR	Y764_V765insHH	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	D	Resistance	chr7	55181301	55181302		CACCAC	"In an in vitro study, a Ba/F3 cell line expressing EGFR Y764_V765insHH demonstrated reduced sensitivity to erlotinib treatment (IC50=3.845M), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generations EGFR tyrosine kinase inhibitors; IC50=4.155M). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation."	"Yasuda et al., 2013, Sci Transl Med"	Somatic	ENST00000275493.2	inframe_insertion
EGFR A767_V769dupASV	EGFR	A767_V769dupASV	Lung Adenocarcinoma	Erlotinib	Predictive	Supports	C	Resistance	chr7	55181307	55181308		GCCAGCGTG	"In a study of 19 non-small cell lung carcinoma patients with EGFR exon 20 insertion mutations and treated with erlotinib monotherapy, patients with EGFR A767_V769dupASV mutation (n=3) experienced progressive disease."	"Yasuda et al., 2013, Sci Transl Med"	Somatic	ENST00000275493.2	inframe_insertion
EGFR M766_A767insAI	EGFR	M766_A767insAI	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	D	Resistance	chr7	55181307	55181308		GCCATA	"In an in vitro study, a Ba/F3 cell line expressing EGFR M766_A767insAI demonstrated reduced sensitivity to erlotinib treatment (IC50=3.403M), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generation EGFR tyrosine kinase inhibitors; IC50=4.155M). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation."	"Yasuda et al., 2013, Sci Transl Med"	Somatic	ENST00000275493.2	inframe_insertion
EGFR A767_V769dupASV	EGFR	A767_V769dupASV	Lung Non-small Cell Carcinoma	Osimertinib	Predictive	Supports	C	Sensitivity/Response	chr7	55181307	55181308		GCCAGCGTG	"In a retrospective study of 2316 Chinese patients with stage IV non-small cell lung carcinoma, a 63 year old female with the EGFR exon 20 insertion A767_V769dupASV received osimertinib as first-line treatment. The patient achieved a partial response with greater than 30% reduction in tumour size, and progression-free survival of 6.0 months."	"Fang et al., 2019, BMC Cancer"	Somatic	ENST00000275493.2	inframe_insertion
EGFR S768I	EGFR	S768I	Lung Adenocarcinoma	Erlotinib	Predictive	Supports	C	Sensitivity/Response	chr7	55181312	55181312	G	T	A patient with metastatic lung adenocarcinoma was found to harbor EGFR T790M and S768I mutations when acquired resistance developed after 8 years of erlotinib treatment. Analysis of original tumor samples from 2001 and 2003 were found to also harbor the S768I (but not T790M) mutation. Three-dimensional visualization showed the 768 position to be outside of the erlotinib binding position.	"Hellmann et al., 2014, J Thorac Oncol"	Somatic	ENST00000275493.2	missense_variant
EGFR S768I	EGFR	S768I	Lung Adenocarcinoma	Gefitinib	Predictive	Supports	C	Sensitivity/Response	chr7	55181312	55181312	G	T	Case report of an 81-year old man with lung adenocarcinoma and EGFR S768I mutation. The patient then received chemotheraoy (vinorelbine) and showed stable disease. Gefitinib was administered when disease progression was noted 4 months later and the patient was followed-up without signs of disease progression for 461 days.	"Masago et al., 2010, Jpn. J. Clin. Oncol."	Somatic	ENST00000275493.2	missense_variant
EGFR S768I	EGFR	S768I	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Does Not Support	C	Sensitivity/Response	chr7	55181312	55181312	G	T	"S768I mutations in exon 20 of the EGFR gene are rare and are typically seen in conjunction with sensitizing EGFR mutations. Because of this mutation's rarity and the variability of responses of treated cases, its exact prognostic and predictive role is not fully understood. In our experience, S768I mutations in isolation do not necessarily confer sensitivity to erlotinib, but in conjunction with sensitizing EGFR mutations, S768I mutations do not restrict efficacy."	"Leventakos et al., 2016, J Thorac Oncol"	Somatic	ENST00000275493.2	missense_variant
EGFR S768I	EGFR	S768I	Lung Adenocarcinoma	Erlotinib	Predictive	Supports	C	Resistance	chr7	55181312	55181312	G	T	"In stage IV lung adenocarcinoma patients (n=2) harboring EGFR S768I mutation, EGFR S768I was associated with progressive disease after 1 month of erlotinib monotherapy; the patient was previously treated with standard chemotherapy."	"Lund-Iversen et al., 2012, J Thorac Oncol"	Somatic	ENST00000275493.2	missense_variant
EGFR S768I	EGFR	S768I	Cancer	"Gefitinib,Erlotinib"	Predictive	Does Not Support	D	Sensitivity/Response	chr7	55181312	55181312	G	T	"In an in vitro study, a Ba/F3 cell line expressing EGFR S768I demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR S768I and EGFR L858R expressing cells were 250 nmol/L and 6 nmol/L, respectively. Gefitinib was similarly tested and IC50 of 315 nanomolar was obtained, indicating non-response and potential resistance"	"Kancha et al., 2009, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR V769_D770insASV	EGFR	V769_D770insASV	Lung Adenocarcinoma	Erlotinib	Predictive	Supports	C	Sensitivity/Response	chr7	55181316	55181317		GCCAGCGTG	"In this meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, 1 patient with V769_770insASV had overall and progression-free survival of 642 days. From this and literature review it was concluded that although EGFR exon 20 insertions may confer reduced sensitivity to erlotinib, patients with this particular mutation appeared to benefit from therapy."	"Klughammer et al., 2016, J Thorac Oncol"	Somatic	ENST00000275493.2	direct_tandem_duplication
EGFR H773_V774insNPH	EGFR	H773_V774insNPH	Lung Adenocarcinoma	Erlotinib	Predictive	Supports	C	Resistance	chr7	55181319	55181320		AACCCCCAC	"A 61 year old male never smoker with EGFR H773_V774insNPH mutant lung adenocarcinoma was treated with fourth line erlotinib and had progressive disease as best response, progression free survival of 1.6 months, and overall survival of 4.4 months."	"Yasuda et al., 2013, Sci Transl Med"	Somatic	ENST00000275493.2	inframe_insertion
EGFR D770_N771insGL	EGFR	D770_N771insGL	Lung Adenocarcinoma	Erlotinib	Predictive	Supports	C	Resistance	chr7	55181319	55181320		GGGTTA	"2 patients with EGFR D770_N771insGL mutant lung adenocarcinoma were treated with first line erlotinib.  A 45 year old male never smoker had progressive disease as best response with +24% change to target lesions, progression free survival of 3.8 months, and still alive at study end after 39.3 months.   A 79 year old female never smoker had progressive disease as best response with +13% change to target lesions, progression free survival of 6 months and overall survival of 14 months."	"Yasuda et al., 2013, Sci Transl Med"	Somatic	ENST00000275493.2	inframe_insertion
EGFR D770_N771insGT	EGFR	D770_N771insGT	Lung Adenocarcinoma	Erlotinib	Predictive	Supports	C	Resistance	chr7	55181319	55181320		GGCACA	"In a lung adenocarcinoma patient harboring EGFR D770_N771insGT mutation, EGFR D770_N771insGT was associated with lack of response to treatment with erlotinib monotherapy."	"Arcila et al., 2013, Mol. Cancer Ther."	Somatic	ENST00000275493.2	inframe_insertion
EGFR D770_N771insNPG	EGFR	D770_N771insNPG	Lung Non-small Cell Carcinoma	"Afatinib,Gefitinib"	Predictive	Does Not Support	D	Sensitivity/Response	chr7	55181319	55181320		AACCCCGGC	"Ba/F3 cells transduced with EGFR D770_N771insNPG were IL3 growth independent, suggesting a driver mutation.  Gefitinib growth inhibition IC50 in D770_N771insNPG transduced Ba/F3 cells was 3.356 micro molar, which was higher than cells transduced with resistance mutation T790M (IC50=2.752). Similarly, afatinib growth inhibition IC50 was 0.0724 micro molar, which was higher than cells transduced with resistance mutation T790M (IC50=0.0629)."	"Yasuda et al., 2013, Sci Transl Med"	Somatic		inframe_insertion
EGFR D770_N771insG	EGFR	D770_N771insG	Lung Non-small Cell Carcinoma	Osimertinib	Predictive	Supports	C	Sensitivity/Response	chr7	55181319	55181320		GGT	"In a retrospective study of 2316 Chinese patients with stage IV non-small cell lung carcinoma, a 63 year old female with the EGFR exon 20 insertion D770_N771insG received osimertinib as second-line treatment. The patient had clinical improvement and achieved partial response with nearly 50% reduction in tumour size. Progression-free survival was 6.4 months."	"Fang et al., 2019, BMC Cancer"	Somatic	ENST00000275493.2	inframe_insertion
EGFR D770_N771insSVD	EGFR	D770_N771insSVD	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	D	Resistance	chr7	55181320	55181321		GCGTGGACA	"In an in vitro study, a Ba/F3 cell line expressing EGFR D770_N771insSVD demonstrated reduced sensitivity to erlotinib treatment (IC50=3.187M), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generation EGFR tyrosine kinase inhibitors; IC50=4.155M). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation."	"Yasuda et al., 2013, Sci Transl Med"	Somatic	ENST00000275493.2	
EGFR P772_H773insYNP	EGFR	P772_H773insYNP	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	C	Resistance	chr7	55181325	55181326		TATAATCCC	"A 79 year old Asian male never smoker with not otherwise specified NSCLC harboring EGFR P772_H773insYNP mutation was given erlotinib as first line treatment, and had progressive disease as best response with +2.3% change to target lesions, progression free survival of 2.1 months and overall survival of 16.5 months."	"Yasuda et al., 2013, Sci Transl Med"	Somatic		inframe_insertion
EGFR H773_V774insH	EGFR	H773_V774insH	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	D	Resistance	chr7	55181328	55181329		CAC	"In an in vitro study, a Ba/F3 cell line expressing EGFR H773_V774insH demonstrated reduced sensitivity to erlotinib treatment (IC50=3.902M), comparable to Ba/F3 cells expressing EGFR L858R and T790M co-mutation (T790M is a known resistant mutation to 1st and 2nd generation EGFR tyrosine kinase inhibitors; IC50=4.155M). Resistance was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation."	"Yasuda et al., 2013, Sci Transl Med"	Somatic	ENST00000275493.2	
EGFR V774M	EGFR	V774M	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Does Not Support	C	Sensitivity/Response	chr7	55181329	55181329	G	A	"In a study, 1 participant with stage IV squamous cell lung carcinoma was sequenced at EGFR exons 18 to 21 and was found to have V774M mutation, and was treated with the 1st generation TKI erlotinib. The patient (M, 80, smoker) had progressive disease as response, progression free survival (PFS) of 1.6 months, overall survival (OS) of 6.7 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type."	"Wu et al., 2011, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR V774A	EGFR	V774A	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	C	Sensitivity/Response	chr7	55181330	55181330	T	C	"In a study, 1 participant with stage IV adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V774A mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 51, nonsmoker) had a partial response, progression free survival (PFS) of 6.9 months, overall survival (OS) of 29.7 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type."	"Wu et al., 2011, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR R776C	EGFR	R776C	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55181335	55181335	C	T	"In an in vitro study, a Ba/F3 cell line expressing EGFR R776C demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR V742A and EGFR L858R expressing cells were 47 nmol/L and 6 nmol/L, respectively."	"Kancha et al., 2009, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR T785A	EGFR	T785A	Cancer	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55181362	55181362	A	G	"In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR T785A demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation."	"Foster et al., 2010, World J Surg Oncol"	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	A	Resistance	chr7	55181378	55181378	C	T	"The T790M mutation in EGFR has been shown to confer resistance to the tyrosine kinase inhibitor erlotinib, and patients harboring this mutation that are placed on the drug are likely to relapse."	"Denis et al., 2015, Clin. Chim. Acta"	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	B	Resistance	chr7	55181378	55181378	C	T	"In non-small cell lung cancer, the appearance of T790M mutation leads to resistance to gefitinib."	"Kobayashi et al., 2005, N. Engl. J. Med."	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma	Dacomitinib	Predictive	Supports	B	Resistance	chr7	55181378	55181378	C	T	"In Lung Cancer patients with acquired resistance to Dacomitinib (PF00299804), MET amplification and EGFR T790M were found to be the primary drivers of resistance."	"Sequist et al., 2011, Sci Transl Med"	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma	"Pemetrexed,Erlotinib"	Predictive	Supports	C	Sensitivity/Response	chr7	55181378	55181378	C	T	"In an NSCLC patient initially with L858R mutation, pemetrexed and cisplatin combination treatment was followed by erlotinib treatment. A slow progression developed which was found to be positive for L858R as well as T790M mutation which confers resistance to tyrosine kinase inhibitors. Due to slow tumor growth erlotinib was continued despite T790M, with re-addition of premetrexed, and this reduced tumor size and resulted in stable disease."	"Li et al., 2014, Lung Cancer"	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma	Staurosporine	Predictive	Supports	E	Sensitivity/Response	chr7	55181378	55181378	C	T	"In NSCLC containing a T790M mutation, staurosporine may be inhibitive of EGFR, especially when an L858R mutation is also present."	"Ai et al., 2014, Amino Acids"	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr7	55181378	55181378	C	T	"In NSCLC patients with T790M and another activating mutations, their progression free survival is shorter compared to those who do not possess T790M mutation."	"Ding et al., 2014, Onco Targets Ther"	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr7	55181378	55181378	C	T	Patients with NSCLC harboring EGFR T790M mutation have statistically worse overall survival compared to patients with L858R or other exon 19 activating mutations.	"Li et al., 2014, Onco Targets Ther"	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Cancer	"Gefitinib,Multikinase Inhibitor AEE788"	Predictive	Supports	D	Resistance	chr7	55181378	55181378	C	T	"Lung cancers can accumulate activating mutations in oncogenes such as EGFR. The common L858R EGFR mutation has been shown previously to be sensitive to small molecular tyrosine kinase inhibitors (ie. erlotinib). In response, tumors may accumulate an additional 'gatekeeper' mutation in EGFR, T790M. Authors show that T790M retain low affinity for gefitinib and that introduction of T790M in the presence of L858R mutant increases the ATP affinity of L858R and activates wild-type EGFR, thus showing that increased ATP affinity is the primary mode of resistance in tumors with T790M, though irreversible ATP inhibitors (ie. HKI-272) are able to overcome this resistance via covalent bonding."	"Yun et al., 2008, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma	Rociletinib	Predictive	Supports	B	Sensitivity/Response	chr7	55181378	55181378	C	T	"In a phase1-2 study, patients with the T790M mutation were more sensitive to rocelitinib in comparison to patients with T790M-negative NSCLC."	"Sequist et al., 2015, N. Engl. J. Med."	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma	Rociletinib	Predictive	Supports	D	Sensitivity/Response	chr7	55181378	55181378	C	T	CO-1686 (Rociletinib) more effectively induced apoptosis in EGFR mutated (T790M and others) NSCLC cell lines than those harboring wildtype EGFR. CO-1686 also more effectively reduced tumor volume of mouse xenografts harboring the T790M than those with wildtype EGFR.	"Walter et al., 2013, Cancer Discov"	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma	Osimertinib	Predictive	Supports	D	Sensitivity/Response	chr7	55181378	55181378	C	T	"Cell line, xenograft, and transgenic models were used to establish Osimertinib as an inhibitor of both EGFR mutation sensitizing (L858M, del exon 19) and T790M resistance mutants. Preclinically, the drug inhibits signaling pathways and cellular growth in both EGFRm(+) and EGFRm(+)/T790M(+) mutant cell lines in vitro, with lower activity against wild-type EGFR lines. Sustained tumor regression was observed in EGFR-mutant tumor xenograft and transgenic models. Treatment of 2 patients with advanced EGFRm(+) T790M(+) NSCLC was reported as proof of principle."	"Cross et al., 2014, Cancer Discov"	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma	Osimertinib	Predictive	Supports	B	Sensitivity/Response	chr7	55181378	55181378	C	T	"This phase I/II trial (NCT01802632) involved 253 non-small cell lung cancer patients with activating EGFR mutations, who had progressed on first generation tyrosine kinase inhibitor treatment, and were subsequently treated with Osimertinib (AZD9291). The overall objective tumor response rate was 51%. Among 127 patients with EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70). In contrast, among 61 patients without EGFR T790M, the response rate was 21% (95% CI, 12 to 34). The median progression-free survival was 9.6 months in EGFR T790M-positive patients and 2.8 months in EGFR T790M-negative patients."	"Jnne et al., 2015, N. Engl. J. Med."	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma	Osimertinib	Predictive	Supports	B	Sensitivity/Response	chr7	55181378	55181378	C	T	"This study summarized 9 EGFR-mutant patients from two clinical trials involving rociletinib (NCT01526928) and subsequent osimertinib (NCT01802632). 8 were T790M-positive prior to treatment with osimertinib. 6 transitioned directly from rociletinib to osimertinib. 3 patients achieved PR and 4 achieved SD. The median PFS was 208 days (95% CI, 41-208 days). Among 6 patients who transitioned directly from rociletinib to osimertinib all derived clinical benefit from osimertinib with either prolonged SD or PR."	"Sequist et al., 2016, JAMA Oncol"	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma	"Osimertinib,Rociletinib"	Predictive	Supports	D	Sensitivity/Response	chr7	55181378	55181378	C	T	"For cell harboring EGFR T790M mutation, osimertinib and rociletinib showed potent inhibition compared to erlotinib or afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay."	"Hirano et al., 2015, Oncotarget"	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Adenocarcinoma	"Erlotinib,Gefitinib"	Predictive	Supports	B	Resistance	chr7	55181378	55181378	C	T	"155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib). 98 patients were found to have developed EGFR T790M mutations."	"Yu et al., 2013, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Adenocarcinoma	Osimertinib	Predictive	Supports	C	Sensitivity/Response	chr7	55181378	55181378	C	T	"Case report of a patient with stage IV lung adenocarcinoma and a 15base pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After further progression, rebiopsy additionally identified the EGFR T790M mutation and the patient received several cycles of chemotherapy and targeted therapy including afatinib, cetuximab, erlotinib, AZD9291. She was treated with AZD9291 for 9 months until disease progression."	"Yu et al., 2015, JAMA Oncol"	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma	Osimertinib	Predictive	Supports	A	Sensitivity/Response	chr7	55181378	55181378	C	T	Osimertinib has been approved for the treatment of EGFR T790M mutant NSCLC.	"Greig, 2016, Drugs"	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma	"Erlotinib,Gefitinib"	Predictive	Supports	B	Resistance	chr7	55181378	55181378	C	T	"48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosine kinase inhibition by gefitinib (n=1) or erlotinib (n=40) underwent next generation sequencing (NGS failed in 5 samples leading to a remaining 43 specimens from 39 patients). The prevalence of various mutations post-treatment was analyzed. 79%, or 31 out of the 39 patients, had the T790M EGFR mutation present, indicating its importance in the development of resistance."	"Belchis et al., 2016, Oncotarget"	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma	Afatinib	Predictive	Supports	B	Resistance	chr7	55181378	55181378	C	T	"Patients with advanced NSCLC and acquired resistance to EGFR TKI (gefitinib or erlotinib) were analyzed for T790M mutations.  Of the 70 patients analyzed, 36 (51%) had the T790M mutation and 34 (49%) were T790M-negative.  There was no significant difference in the median post-progression or overall survival between patients with T790M mutation and without T790M mutation for initial TKI treatment.  However, subsequent treatment with afatinib showed partial response in six patients where 1/21(5%) were in the T790M-positive group and 5/13 (38%) were in the T790M-negative group (P=0.01)."	"Sun et al., 2013, Lung Cancer"	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma	Osimertinib	Predictive	Supports	A	Sensitivity/Response	chr7	55181378	55181378	C	T	"Randomized, international, open-label, phase 3 trial (NCT02151981) in 419 patients with T790M-positive advanced NSCLC and disease progression after first-line EGFR-TKI therapy. Patients were randomized, in a 2:1 ratio, to oral osimertinib or chemotherapy (pemetrexed plus either carboplatin or cisplatin every 3 weeks for up to six cycles, maintenance pemetrexed was allowed). Primary end point was PFS, which was significantly longer with osimertinib than with chemotherapy (10.1 months vs. 4.4 months; HR 0.30; 95% CI: 0.23 to 0.41; P<0.001). Objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with chemotherapy (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P<0.001)."	"Mok et al., 2016, N. Engl. J. Med."	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Adenocarcinoma	Osimertinib	Predictive	Supports	C	Sensitivity/Response	chr7	55181378	55181378	C	T	"In a lung adenocarcinoma patient harboring an EGFR E746_A750 mutation and an acquired EGFR T790M co-mutation, EGFR T790M was associated with sensitivity to osimertinib monotherapy. Prior to the development of the EGFR T790M mutation, the patient was treated with gefitinib and achieved a partial response, but subsequently tumor progression occurred; however, osimertinib treatment resulted a favorable tumor response with the extinguishment of the EGFR T790M mutation. In a stage IV lung adenocarcinoma patient harboring an EGFR L858R mutation and an acquired EGFR T790M co-mutation, EGFR T790M was associated with sensitivity to osimertinib monotherapy. Prior to the development of the EGFR T790M mutation, the patient was treated with erlotinib, followed by gefitinib for 12 months and achieved stable disease, but subsequently metastasis occurred; the EGFR T790M was then identified and subsequent 10 month treatment with osimertinib monotherapy resulted in a 45% disease regression."	"Planchard et al., 2015, Ann. Oncol."	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma	"Erlotinib,Gefitinib"	Predictive	Supports	C	Resistance	chr7	55181378	55181378	C	T	"In a study of 6 patients with progressive non-small cell lung cancer during gefitinib or erlotinib therapy, comparison of DNA sequences from the original diagnostic biopsy specimen and a post-treatment biopsy specimen demonstrated that 3 patients acquired a new EGFR-T790M mutation. Analysis of EGFR sequence from 155 NSCLC samples prior to treatment with an EGFR inhibitor showed no T790M mutations, suggesting that T790M is associated with progression on gefitinib or erlotinib. In vitro experiments showed that the addition of T790M drastically reduced sensitivity to gefitinib or erlotinib in cells containing the sensitizing EGFR mutation L858R."	"Pao et al., 2005, PLoS Med."	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	B	Resistance	chr7	55181378	55181378	C	T	"In a study of 14 patients with progressive non-small cell lung cancer during gefitinib treatment, comparison of DNA sequences from the original diagnostic biopsy specimen and the post-treatment biopsy specimen demonstrated that 7 patients acquired a new EGFR-T790M mutation. In addition, 52 pre-treatment tumours were examined with a sensitive real-time PCR assay and found no evidence of low frequency T790M mutation prior to gefitinib treatment."	"Kosaka et al., 2006, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma	Lapatinib	Predictive	Supports	D	Resistance	chr7	55181378	55181378	C	T	"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R/T790M mutation demonstrated a reduced response to lapatinib (IC50: >4000nM vs. 534nM) compared to wildtype EGFR cells. Similarly, NIH-3T3 ectopically expression EGFR-L858R/T790M showed reduced sensistivity to lapatinib compared to EGFR wt or L585R mutant cells. These results were further confirmed in a Ba/F3 cell line model"	"Li et al., 2008, Oncogene"	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma	Dacomitinib	Predictive	Supports	D	Sensitivity/Response	chr7	55181378	55181378	C	T	"In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. PF00299804 inhibited the growth of Ba/F3 cell lines containing the EFGR T790M resistance mutation as well as H1975 and H3255 cell lines that contain both EGFR L858R and T790M mutations and H820 containing an EGFR exon 19 deletion (Del 747_L751, Ins S) and a T790M mutation. All three cell lines were resistant to gefitinib in vitro, but sensitive to PF00299804 (IC50 <1 mol/L for all three cell lines)."	"Engelman et al., 2007, Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma	Neratinib	Predictive	Supports	D	Sensitivity/Response	chr7	55181378	55181378	C	T	"The NSCLC cell line NCI-H1975 carrying the EGFR T790M mutation was resistant to erlotinib but showed increased sensitivity to HKI-272 (neratinib, IC50: 0.29 mol/L). In an in vitro study Ba/F3 cells transfected with either EGFR-L858R or EGFR-L858R/T790M were used to assay cell growth. Ba/F3 cells require IL-3 in order to proliferate, but cells transfected with an activated oncogene are IL-3 independent. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to neratinib (IC50: 0.185umol/L vs. >10umol/L) compared to the same cells treated with erlotinib."	"Shimamura et al., 2006, Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma	Afatinib	Predictive	Supports	D	Sensitivity/Response	chr7	55181378	55181378	C	T	"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (IC50: 99nM vs. >4000nM) compared to the same cells treated with erlotinib. In an in vivo mouse xenograft study, the growth of cells with an EGFR-L858R/T790M mutation were more sensitive to treatment of afatinib (concentration: 15-20mg/kg) (median tumor volume = 75-150mm^3 vs. 1000mm^3), compared to reversible TKI lapatinib-treated xenografts. However, no complete responses were observed with afatinib alone."	"Li et al., 2008, Oncogene"	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma	Afatinib	Predictive	Supports	D	Sensitivity/Response	chr7	55181378	55181378	C	T	"In an in vitro study using purified EGFR protein, kinase activity was assayed and compared for wildtype EGFR, EGFR-T790M and EGFR-T790M/L858R using both reversible and irreversible TKI drugs. EFGR proteins with T790M or T790M/L858R mutations were more sensitive to afatinib treatment (IC50: 9.8nM and 24nM, respectively vs. IC50: >1000nM and >1000nM, respectively) compared to treatment with erlotinib or lapatinib treatment. In an in vitro study using NCI-H358 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (GI50: 42.0nM vs. >1000nM) compared to the same cells treated with erlotinib. However, IC50s were intermediate compared to a more potent pan-HER inhibitor."	"Cha et al., 2012, Int. J. Cancer"	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Lung Non-small Cell Carcinoma	Canertinib	Predictive	Supports	D	Sensitivity/Response	chr7	55181378	55181378	C	T	"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to canertinib (IC50: 101nM vs. >4000nM) compared to the same cells treated with erlotinib. IC50 values of canertinib were comparable to afatinib."	"Li et al., 2008, Oncogene"	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Cancer	"Gefitinib,Multikinase Inhibitor AEE788,Erlotinib"	Predictive	Supports	D	Resistance	chr7	55181378	55181378	C	T	"Experimental - EGFR T790M mutation has been associated with resistance to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In an in vitro study, Ba/F3 cells stably expressing EGFR T790M demonstrated resistance to gefitinib and erlotinib and the tool construct AEE788. These cells had very high IC50 nmol/L values for all three inhibitors in comparison to other constructs (Gefitinib>2000, Erlotinib>2000, AEE788>2000), indicating resitance to all three inhibitors."	"Kancha et al., 2009, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR T790M	EGFR	T790M	Pancreatic Adenocarcinoma	Osimertinib	Predictive	Does Not Support	C	Sensitivity/Response	chr7	55181378	55181378	C	T	"Patients with recurrent pancreatic adenocarcinoma was treated with gemcitabine + nab-paclitaxel, FOLFIRINOX and docetaxel + irinotecan. After failure of these treatment, a tumor specimen from the pancreaticoduodenectomy was analysed, which revealed an activating mutation in exon 19 (L747_P753>S) of EGFR. Mutations were also detected in CDKN2A, TP53, and amplifications of PRKCI and TERC. He began erlotinib at 150mg daily. CT imaging  revealed a partial response by RECIST at 8, 24 and 32 weeks after starting erlotinib. At 40 weeks CT imaging revealed unequivocal disease progression. After disease progression to erlotinib, a repeat liver biopsy revealed an EGFR T790M mutation. He began treatment with osimertinib at 80mg daily. After 8 weeks of this treatment CT imaging revealed unequivocal disease progression."	"Cecchini et al., 2017, J Natl Compr Canc Netw"	Somatic	ENST00000275493.2	missense_variant
EGFR C797S	EGFR	C797S	Lung Non-small Cell Carcinoma	Osimertinib	Predictive	Supports	B	Resistance	chr7	55181398	55181398	T	A	"An EGFR resistance mutation, C797S, was discovered by deep sequencing of cell-free plasma DNA (cfDNA) from patients with advanced lung cancer whose tumors had developed resistance to osimertinib. Expression of this mutant EGFR construct in a cell line rendered it resistant to osimertinib. ddPCR on serial cfDNA specimens collected from 15 osimertinib-treated subjects (all positive for T790M before treatment) revealed 6 cases with acquired C797S mutation."	"Thress et al., 2015, Nat. Med."	Somatic	ENST00000275493.2	missense_variant
EGFR C797S	EGFR	C797S	Lung Adenocarcinoma	Osimertinib	Predictive	Supports	C	Resistance	chr7	55181398	55181398	T	A	"Case report of a patient with stage IV lung adenocarcinoma and a 15base pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After further progression, rebiopsy additionally identified the EGFR T790M mutation and the patient received several cycles of chemotherapy and targeted therapy including afatinib, cetuximab, erlotinib, AZD9291. She was treated with AZD9291 for 9 months until disease progression. Repeat biopsy detected EGFRC797S mutation additionally to both aforementioned EGFR aberrations. In addition, PTEN Y27C and CTNNB1 S37F mutations were present in all 3 samples, and a TSC2 N486I was seen in the third biopsy sample only"	"Yu et al., 2015, JAMA Oncol"	Somatic	ENST00000275493.2	missense_variant
EGFR C797Y	EGFR	C797Y	Cancer	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55181399	55181399	G	A	"In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR C797Y demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation."	"Foster et al., 2010, World J Surg Oncol"	Somatic	ENST00000275493.2	missense_variant
EGFR Y801H	EGFR	Y801H	Cancer	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55181410	55181410	T	C	"In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR Y801H demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation."	"Foster et al., 2010, World J Surg Oncol"	Somatic	ENST00000275493.2	missense_variant
EGFR K806E	EGFR	K806E	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Does Not Support	C	Sensitivity/Response	chr7	55181425	55181425	A	G	"In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have K806E mutation, and was treated with the 1st generation TKI gefitinib. The patient (M, 77, nonsmoker) had progressive disease as response, progression free survival (PFS) of 1.6 months, overall survival (OS) of 28.1 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type."	"Wu et al., 2011, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR N826Y	EGFR	N826Y	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Does Not Support	C	Sensitivity/Response	chr7	55191725	55191725	A	T	"In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have N826Y mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 46, nonsmoker) had progressive disease as response, progression free survival (PFS) of 3.3 months, overall survival (OS) of 13.9 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type."	"Wu et al., 2011, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR N826S	EGFR	N826S	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	D	Resistance	chr7	55191726	55191726	A	G	"In an in vitro study, a Ba/F3 cell line expressing EGFR N826S demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR N826S and EGFR L858R expressing cells were 505 nmol/L and 6 nmol/L, respectively."	"Kancha et al., 2009, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR R831H	EGFR	R831H	Cancer	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55191741	55191741	G	A	"In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR R831H demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation."	"Foster et al., 2010, World J Surg Oncol"	Somatic	ENST00000275493.2	missense_variant
EGFR L838V	EGFR	L838V	Cancer	"Gefitinib,Erlotinib"	Predictive	Supports	D	Resistance	chr7	55191761	55191761	C	G	"In an in vitro study, a Ba/F3 cell line expressing EGFR L838V demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR L838V and EGFR L858R expressing cells were 160 nmol/L and 6 nmol/L, respectively. Similarly, gefitinib was tested and 187 nanomolar IC50 was seen, suggesting lack of sensitivity and potential resistance."	"Kancha et al., 2009, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR L838P	EGFR	L838P	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	C	Sensitivity/Response	chr7	55191762	55191762	T	C	"In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have L838P mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 66, nonsmoker) had a partial response, progression free survival (PFS) of 15.2 months, overall survival (OS) of 29.3 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type."	"Wu et al., 2011, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR N842S	EGFR	N842S	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Does Not Support	C	Sensitivity/Response	chr7	55191774	55191774	A	G	"In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have N842S mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 73, nonsmoker) progressive disease as response, progression free survival (PFS) of 0.9 months, overall survival (OS) of 9.7 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type."	"Wu et al., 2011, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR T847I	EGFR	T847I	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Does Not Support	C	Sensitivity/Response	chr7	55191789	55191789	C	T	"In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have T847I mutation, and was treated with the 1st generation TKI gefitinib. The patient (M, 77, smoker) progressive disease as response, progression free survival (PFS) of 1.1 months, overall survival (OS) of 1.1 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type."	"Wu et al., 2011, Clin. Cancer Res."	Somatic		missense_variant
EGFR V851I	EGFR	V851I	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Does Not Support	C	Sensitivity/Response	chr7	55191800	55191800	G	A	"In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V851I mutation, and was treated with the 1st generation TKI gefitinib. The patient (F, 69, nonsmoker) progressive disease as response, progression free survival (PFS) of 0.7 months, overall survival (OS) of 1.6 months and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common mutations (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type."	"Wu et al., 2011, Clin. Cancer Res."	Somatic		missense_variant
EGFR L858R	EGFR	L858R	Lung Non-small Cell Carcinoma	"Gefitinib,Erlotinib"	Predictive	Supports	B	Sensitivity/Response	chr7	55191822	55191822	T	G	There is no statistical difference in progression free survival between lung cancer patients treated with gefitinib or erlotinib with EGFR L858R mutations (N=72/242; univariate: P=0.283; multivariate: P=0.250) compared to patients with Exon 19 mutations (N=170).	"Lim et al., 2014, J Thorac Oncol"	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Non-small Cell Carcinoma	"Erlotinib,Gefitinib"	Predictive	Supports	B	Sensitivity/Response	chr7	55191822	55191822	T	G	"In NSCLC patients treated with EGFR tyrosine kinase inhibitors, the presence of L858R mutation is prognostic for better progression free survival."	"Fukihara et al., 2014, Oncology"	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	D	Sensitivity/Response	chr7	55191822	55191822	T	G	Gefinitib has been shown to be effective in treating cell lines with L858R missense mutations.	"Paez et al., 2004, Science"	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Non-small Cell Carcinoma		Prognostic	Supports	B	Better Outcome	chr7	55191822	55191822	T	G	Median survival of patients with EGFR L858R mutation is better than those with wild type EGFR.	"Douillard et al., 2014, J Thorac Oncol"	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Adenocarcinoma	Afatinib	Predictive	Supports	B	Sensitivity/Response	chr7	55191822	55191822	T	G	"A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = 0.001)."	"Sequist et al., 2013, J. Clin. Oncol."	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Adenocarcinoma	Afatinib	Predictive	Supports	B	Sensitivity/Response	chr7	55191822	55191822	T	G	"In a phase 2 study of patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib were assessed by objective response. 129 patients were treated with afatinib. 66% of the 106 patients with two common activating EGFR mutations (deletion 19 or L858R) had an objective response compared to 39% of 23 patients with less common mutations."	"Yang et al., 2012, Lancet Oncol."	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	B	Sensitivity/Response	chr7	55191822	55191822	T	G	"A randomized phase 3 trial (NCT00446225) involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease. Patients were randomly allocated (1:1) to receive either erlotinib or standard chemotherapy. The primary endpoint was progression-free survival (PFS). Median PFS was 9.7 months in the erlotinib group, compared with 5.2 months in the standard chemotherapy group."	"Rosell et al., 2012, Lancet Oncol."	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Non-small Cell Carcinoma	Afatinib	Predictive	Supports	D	Sensitivity/Response	chr7	55191822	55191822	T	G	Cells harboring L858R were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.	"Hirano et al., 2015, Oncotarget"	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Adenocarcinoma	Afatinib	Predictive	Supports	B	Sensitivity/Response	chr7	55191822	55191822	T	G	Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364 eligible patients with EGFR mutations were assigned to afatinib (n=242) or gemcitabine and cisplatin (n=122) treatment. The trial observed significantly longer median progression-free survival with afatinib vs. gemcitabine and cisplatin treatment (11.0 vs. 5.6 months). Afatinib/Chemotherapy group compositions: 51.2/50.8 % del 19; 38/37.7 % Leu858Arg; 10.8/11.5 % Uncommon.	"Wu et al., 2014, Lancet Oncol."	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	B	Sensitivity/Response	chr7	55191822	55191822	T	G	"90 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were treated with gefitinib, and the L858R EGFR mutation was associated with longer time to treatment failure than those with wild-type EGFR (median 9.1 versus 2.1). In multivariate analysis, L858R mutations plus adenocarcinoma was a significant predictive factor for time to treatment failure (HR = 0.1030; P = .0004)."	"Yang et al., 2008, J. Clin. Oncol."	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	B	Sensitivity/Response	chr7	55191822	55191822	T	G	"In a phase 3 clinical trial of non-small cell lung cancer (NSCLC) patients, a subset of patients with EGFR mutations (n=44) treated with gefitinib were associated with improved progression free survival (HR: 0.16, 95% CI: 0.05-0.49, P=0.001), and a higher objective response rate (ORR: 42.1% vs 21.1%, p=0.04) compared to patients treated with docetaxel. Of the 44 patients, 22 had an exon 19 deletion, 16 had an L858R mutation, one patient had an exon 20 T790M mutation, two had an exon G719A mutation and four had other mutations."	"Douillard et al., 2010, J. Clin. Oncol."	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Adenocarcinoma	Gefitinib	Predictive	Supports	C	Sensitivity/Response	chr7	55191822	55191822	T	G	"Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical improvement in response to gefitinib. Of 7 tumors with EGFR mutations, 1 was L858R. The patient was a female former smoker who had lung adenocarcinoma histology, and demonstrated response for 5 months, with overall survival 8 months."	"Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Non-small Cell Carcinoma	Lapatinib	Predictive	Supports	D	Sensitivity/Response	chr7	55191822	55191822	T	G	"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to lapatinib (IC50: 63nM vs. 534nM) compared to wildtype EGFR cells."	"Li et al., 2008, Oncogene"	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Non-small Cell Carcinoma	Dacomitinib	Predictive	Supports	D	Sensitivity/Response	chr7	55191822	55191822	T	G	"In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to Dacomitinib (IC50: 0.007umol/L vs. >10umol/L) compared to wildtype EGFR cells or compared to reversible TKI drug gefitinib (IC50: 0.075umol/L vs. wild-type >10umol/L)."	"Engelman et al., 2007, Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Non-small Cell Carcinoma	Neratinib	Predictive	Supports	D	Sensitivity/Response	chr7	55191822	55191822	T	G	"In an in vitro study using NCI-H3255 cells (EGFR L858R), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated sensitivity to neratinib (IC50: 0.0049 mol/L) compared to EGFRwt A549 cells (IC50 > 1 mol/L)."	"Shimamura et al., 2006, Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Non-small Cell Carcinoma	Afatinib	Predictive	Supports	D	Sensitivity/Response	chr7	55191822	55191822	T	G	"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to afatinib (IC50: 0.7nM vs. 60nM) compared to wildtype EGFR cells."	"Li et al., 2008, Oncogene"	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Non-small Cell Carcinoma	Canertinib	Predictive	Supports	D	Sensitivity/Response	chr7	55191822	55191822	T	G	"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to canertinib (IC50: 1nM vs. 198nM) compared to wildtype EGFR cells."	"Li et al., 2008, Oncogene"	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	C	Sensitivity/Response	chr7	55191822	55191822	T	G	"In a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma), EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib. Two patients had the del L858R mutation. One patient was a male former smoker who demonstrated response for 3 months with overall survival of 3.5 months, and the other patient was a female never smoker who had response for 6 months and overall survival of 17+ months as the patient was alive at study end."	"Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Adenocarcinoma	Gefitinib	Predictive	Supports	B	Sensitivity/Response	chr7	55191822	55191822	T	G	"In a phase 3 clinical trial of Korean, never-smoker, lung adenocarcinoma patients, a subset of patients with EGFR mutations (n=42) treated with gefitinib were associated with improved overall response rate compared to gemcitabine plus cisplatin treatment (84.6%, 22/26, vs. 37.5%, 6/16, P=0.002). By contrast, in EGFR mutation negative cases, the response rate was much lower (25.9%, 7/27). The frequency of mutation in exon 19 deletion and L858R was 64.3% (27/42) and 36.4% (16/42), respectively. Exon 19 and L858R mutations were mutually exclusive in this cohort."	"Han et al., 2012, J. Clin. Oncol."	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	A	Sensitivity/Response	chr7	55191822	55191822	T	G	"On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations."	"Khozin et al., 2014, Oncologist"	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Non-small Cell Carcinoma	Afatinib	Predictive	Supports	A	Sensitivity/Response	chr7	55191822	55191822	T	G	"Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test"	"Dungo et al., 2013, Drugs"	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Cancer	"Multikinase Inhibitor AEE788,Gefitinib,Erlotinib"	Predictive	Supports	D	Sensitivity/Response	chr7	55191822	55191822	T	G	"EGFR L858R was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors Gefitinib, Erlotinib, or the the tool compound AEE788, and IC50 values were measured. L858R EGFR cells had very low IC50 nmol/L values for all three inhibitors in comparison to other constructs (Gefitinib=12, Erlotinib=6, AEE788=6), indicating sensitivity to all three constructs."	"Kancha et al., 2009, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Cancer	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55191822	55191822	T	G	"MCF-7 cells were transduced with YFP tagged EGFR with E746_A750delELREA mutation, or YFP EGFR wildtype, and stained for ectopic YFP EGFR and phospho-Akt as a readout for EGFR pathway activity. Increased p-Akt stain was seen with ectopic mutant EGFR over wildtype cells. Parallel erlotinib incubations of cells with wildtype EGFR induced recompartmentalization of ectopic EGFR protien only at high concentration (10uM). Addition of erlotinib to mutant EGFR cell incubations reduced p-Akt signal and induced recompartmentalization of ectopic EGFR protien at considerably lower conecntration (100 nM) erlotinib.  These results indicate the EGFR L858R variant as a growth pathway driver targetable by erlotinib."	"de Gunst et al., 2007, Mol. Cancer"	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55191822	55191822	T	G	"In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to erlotinib (IC50: 40nM vs. 110nM) compared to EGFR wild type cells."	"Li et al., 2008, Oncogene"	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Cancer	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55191822	55191822	T	G	"In an in vitro study, a MCF-7 cell line expressing EGFR L858R mutation demonstrated sensitivity to erlotinib treatment, compared to MCF-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing YFP signal-EGFR relocation."	"Harada et al., 2011, Oncogene"	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55191822	55191822	T	G	"In an in vitro study, Ba/F3 and NCI-H3255 cell lines expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment (IC50=0.006 and 0.068 M). Sensitivity was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation, levels of BIM (a marker of EGFR TKI-induced cell killing) and cell viability."	"Yasuda et al., 2013, Sci Transl Med"	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55191822	55191822	T	G	"In an in vitro study, CHO and NCI-H3255 cells expressing EGFR L858R mutation were associated with sensitivity to erlotinib treatment. Sensitivity was determined by assessing cell density."	"Ray et al., 2016, Oncotarget"	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	C	Resistance	chr7	55191822	55191822	T	G	"This study analyzed patients with non small cell lung cancer (NSCLC) who were positive for EML4-ALK fusions (ALK+) and progressed on crizotinib monotherapy. One patient was biopsied twice following crizotinib progression and once pre-treatment. This patient was a 27 year old female with one pack year who experienced partial response on crizotinib as 4th line therapy. The patient's pre-crizotinib biopsy was ALK+ and lacked the EGFR mutation. A biopsy taken after 63 days on crizotinib showed EGFR L858R mutation and lacked ALK gene rearrangement by FISH (ALK Loss). Of note, a second post-treatment biopsy (after 113 on crizotinib) showed ALK rearrangement but lacked EGFR mutation. The authors interpreted the emergence of an ALK negative tumor (first post-critozitinib biopsy) as evidence of a separate oncogenic driver (EGFR L858R)."	"Doebele et al., 2012, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Adenocarcinoma	Erlotinib	Predictive	Supports	B	Sensitivity/Response	chr7	55191822	55191822	T	G	"In a prospective study of 46 Caucasian, advanced lung adenocarcinoma patients harboring EGFR mutations, first-line erlotinib treatment was assessed. Average PFS and OS for these 46 patients was 11 months (95% CI: 9.7-12.3 months) and 23 months (95% CI: 21.3-28.6+ months), respectively. A PFS rate of 81% at three months met the primary endpoint of presumed superiority over chemotherapy. Clinical benefit (CR+PR+SD) rate was 81%. Fifteen patients harbored EGFR L858R mutations, which was the only mutation found in exon 21. The authors note similar response profiles for exon 19 (27/46) and exon 21 mutations (15/46) to the overall population."	"De Grve et al., 2016, PLoS ONE"	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Adenocarcinoma	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55191822	55191822	T	G	"In an in vitro study, Ba/F3 cell line expressing EGFR L858R was associated with sensitivity to erlotinib treatment (IC50 26.9  12.4). Sensitivity was determined by assessing cell viability, AKT and ERK phosphorylation, and EGFR auto-phosphorylation."	"Konduri et al., 2016, Cancer Discov"	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Adenocarcinoma	Cetuximab	Predictive	Does Not Support	D	Sensitivity/Response	chr7	55191822	55191822	T	G	"In an in vitro study, Ba/F3 cell line expressing EGFR L858R did not show sensitivity to cetuximab treatment, while cells expressing EGFR-RAD51 fusion were sensitive. Sensitivity was determined by assessing cell viability, AKT and ERK phosphorylation and EGFR auto-phosphorylation."	"Konduri et al., 2016, Cancer Discov"	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Small Cell Carcinoma	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55191822	55191822	T	G	"In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells demonstrated increased sensitivity to erlotinib (IC50: 8 and 11 nM) compared to EGFRwt NCI-H2073 cells (IC50: 108 nM; 95%CI 52-223 nM)."	"Cross et al., 2014, Cancer Discov"	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Non-small Cell Carcinoma	Osimertinib	Predictive	Supports	D	Sensitivity/Response	chr7	55191822	55191822	T	G	"In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells demonstrated increased sensitivity to AZD9291 (IC50: 60 and 49 nM) compared to EGFRwt NCI-H2073 cells (IC50: 1865 nM; 95%CI 872-3988 nM). In vivo experiments with NCI-H3255 xenograft models showed drastic tumour volume reduction upon treatment with 5mg/kg/day AZD9291."	"Cross et al., 2014, Cancer Discov"	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	High Grade Glioma	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55191822	55191822	T	G	"In an in vitro study, a Ba/F3 cell line expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0?0 uM)."	"Lee et al., 2006, PLoS Med."	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Non-small Cell Carcinoma	Dacomitinib	Predictive	Supports	B	Sensitivity/Response	chr7	55191822	55191822	T	G	"The authors pooled patients with exon 19 deletion and L858R EGFR (Exon 21) mutations from both studies (The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)) to compare the efficacy of dacomitinib to erlotinib. 121 patients with any EGFR mutation were enrolled, 101 had activating mutations in exon 19 or 21. For those (exon19/21), the median PFS was 14.6 months with dacomitinib and 9.6 months with erlotinib The median survival was 26.6 months with dacomitinib versus 23.2 months with erlotinib."	"Ramalingam et al., 2016, Ann. Oncol."	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Cancer	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55191822	55191822	T	G	"In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR L858R demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR   expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation."	"Foster et al., 2010, World J Surg Oncol"	Somatic	ENST00000275493.2	missense_variant
EGFR L858R	EGFR	L858R	Lung Adenocarcinoma	Gefitinib	Predictive	Supports	B	Sensitivity/Response	chr7	55191822	55191822	T	G	"In a Japanese Phase III clinical trial, noninferiority of Gefitinib as compared to Erlotinib was assessed in 561 postoperative recurrent or stage IIIb/VI patients who had undergone prior chemotherapy treatment but no tyrosine kinase inhibitor therapy. In a subset of patients with sole EGFR L858R, there was an insignificant difference between the objective response and disease control rates for patients treated with erlotinib (N=67) and gefitinib (N=78). Progression free survival was also not significantly different and did not meet the noninferiority endpoint with Gefitinib and Erlotinib arms at 8.1 and 8.5 months, respectively (HR, 0.938; 95% CI, 0.675 to 1.304; P = .704)."	"Urata et al., 2016, J. Clin. Oncol."	Somatic	ENST00000275493.2	missense_variant
EGFR L861Q	EGFR	L861Q	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	C	Sensitivity/Response	chr7	55191831	55191831	T	A	"In a study, a group of 6 participants, 5 with stage IV and one with stage IIIB lung adenocarcinoma, were sequenced at EGFR exons 18 to 21. All patients had L861Q mutation and were treated with the 1st generation TKI gefitinib. 4 patients had partial response with progression free survival (PFS) of 4.3, 19.3, 10.0, 8.7 months; overall survival (OS) of 4.3, 34.9, 15.7, 15.7 months; and all 4 were alive at study end. One patient had stable disease, PFS 6.5 months, OS 15.2 months, and was not alive at study end. One patient had progressive disease as response, with PFS of 2.8 months, OS of 10.7 months, and was not alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type."	"Wu et al., 2011, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR L861Q	EGFR	L861Q	High Grade Glioma	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55191831	55191831	T	A	"In an in vitro study, a Ba/F3 cell line expressing EGFR L861Q demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0?0 uM)."	"Lee et al., 2006, PLoS Med."	Somatic	ENST00000275493.2	missense_variant
EGFR L861R	EGFR	L861R	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	C	Sensitivity/Response	chr7	55191831	55191831	T	G	"In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have L861R mutation, and was treated with the 1st generation TKI gefitinib. The patient (M, 83, nonsmoker) had a partial response, progression free survival (PFS) of 37.5 months, overall survival (OS) of 53.3 months and was alive at study end. As a whole, patients with uncommon EGFR mutations had a response rate of 47.5%, which was between common (del19 and L858R) at 74.1%, and wild type EGFR at 16.5%. Median PFS and OS (months) for the three groups: 5.0 and 15.0 uncommon, 8.5 and 19.6 common, 2.0 and 10.4 wild type."	"Wu et al., 2011, Clin. Cancer Res."	Somatic	ENST00000	missense_variant
EGFR A864T	EGFR	A864T	Lung Non-small Cell Carcinoma	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55191839	55191839	G	A	"In an in vitro study, a Ba/F3 cell line expressing EGFR A864T demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR A864T and EGFR L858R expressing cells were 49 nmol/L and 6 nmol/L, respectively."	"Kancha et al., 2009, Clin. Cancer Res."	Somatic	ENST00000275493.2	missense_variant
EGFR E868G	EGFR	E868G	Cancer	Erlotinib	Predictive	Supports	D	Sensitivity/Response	chr7	55191852	55191852	A	G	"In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR E868G demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation."	"Foster et al., 2010, World J Surg Oncol"	Somatic	ENST00000275493.2	missense_variant
EGFR Y1092 PHOSPHORYLATION	EGFR	Y1092 PHOSPHORYLATION	Lung Non-small Cell Carcinoma	"Gefitinib,Erlotinib"	Predictive	Supports	B	Sensitivity/Response	chr7	55205258	55205260			"While EGFR mutation is a strong predictive factor for EGFR inhibition, some patients with EGFR wild-type also respond.  The authors investigated whether phosphorylated EGFR could be a potential predictive biomarker in patients with wild-type EGFR. Phosphorylation of Y1068 (assessed by IHC) was associated with improved progression free survival (PFS) in 205 patients with stage IIb and IV NSCLC treated with EGFR tyrosine kinase inhibitors (gefitinib or erlotinib) compared to phospho-Y1068 negative patients (median PFS 7.0 months vs. 1.2 months, P??.001). In this group, 92 (44.9%) were EGFR mutant. In a subgroup of patients with wild-type EGFR, phospho-Y1068 expression positive patients had a significantly prolonged PFS (4.2months vs.1.2months P??.001) compared with those without phospho-Y1068 expression."	"Wang et al., 2012, J. Exp. Clin. Cancer Res."	N/A	ENST00000275493.2	N/A
HSPB1 EXPRESSION	HSPB1	EXPRESSION	Pancreatic Ductal Adenocarcinoma	Gemcitabine	Predictive	Supports	D	Sensitivity/Response	chr7	76302544	76304295			HSP27 (HSPB1) expression in pancreatic adenocarcinoma cell lines was associated with sensitivity to treatment with gemcitabine.	"Schfer et al., 2012, J. Cell. Mol. Med."	N/A	ENST00000248553.6	N/A
HGF EXPRESSION	HGF	EXPRESSION	Glioblastoma	MET Tyrosine Kinase Inhibitor SGX523	Predictive	Supports	D	Sensitivity/Response	chr7	81699006	81770198			Three metastatic glioblastoma cell lines were compared with their parental cell lines with regard to differential gene expression. HGF signalling was among the top pathways identified. Exogenous HFG led to an increase in MET activity (except in one cell line with high endogenous HGF levels) which was abrogated by MET inhibitor SGX523. Three HGF autocrine cell lines were grown in mice and showed significantly increased sensitivity to SGX523 than three non-HGF autocrine cell lines (P<0.05).	"Xie et al., 2012, Proc. Natl. Acad. Sci. U.S.A."	N/A	ENST00000222390.5	N/A
BRAF AKAP9::BRAF	BRAF	AKAP9::BRAF	Thyroid Gland Papillary Carcinoma		Diagnostic	Supports	B	Positive	chr7	91940867	91995800			"The AKAP9-BRAF fusion gene was found in 3/28 tumor samples of radiation-associated papillary thyroid carcinoma, and no samples of non-radiation associated papillary thyroid carcinoma. This fusion was associated with elevated BRAF kinase activity, similar to the V600E variant."	"Ciampi et al., 2005, J. Clin. Invest."	Somatic	ENST00000356239.3	transcript_fusion
CDK6 Overexpression	CDK6	Overexpression	Estrogen-receptor Positive Breast Cancer	Fulvestrant	Predictive	Supports	B	Resistance	chr7	92604921	92833917			"In two cohorts (n=45 and n=46) of ER+ breast cancer patients who had received fulvestrant, CDK6 overexpression correlated with shorter median time to progression in both cohorts (2.5 vs. 8.2 months and 3.4 vs. 8.9 months for CDK6 overexpression vs. normal expression). CDK6 expression did not correlate with other lines of treatment (N=68, tamoxifen or endocrine therapy). Four fulvestrant-resistant cell lines were derived from estrogen responsive and fulvestrant sensitive parental breast cancer cell line MCF-7/SO.5. Gene expression profiling showed upregulation of CDK6 in the fulvestrant resistant derivatives. Knockdown of CDK6 in these derivative cells resulted in fulvestrant sensitivity."	"Alves et al., 2016, Clin. Cancer Res."	N/A	ENST00000265734.4	N/A
CDK6 Overexpression	CDK6	Overexpression	Estrogen-receptor Positive Breast Cancer	"Fulvestrant,Palbociclib"	Predictive	Supports	D	Sensitivity/Response	chr7	92604921	92833917			"Four fulvestrant (estrogen receptor degrader) resistant cell lines were derived from parent fulvestrant sensitive ER+ MCF-7/SO.5 breast cancer cell line. Derivative cell lines showed some sensitivity to CDK4/6 inhibitor palbociclib, and increased growth inhibition when treated with fulvestrant and palbociclib together."	"Alves et al., 2016, Clin. Cancer Res."	Somatic	ENST00000265734.4	N/A
CDK6 Overexpression	CDK6	Overexpression	Glioblastoma Proneural Subtype	Palbociclib	Predictive	Supports	D	Sensitivity/Response	chr7	92604921	92833917			"In this study twelve GBM cell lines and normal human astrocytes (NHA) were treated with the CDK4/6 inhibitor palbociclib. NHA and several GBM cell lines were resistant to palbociclib with IC50 values greater than 1000 nM, while six of seven proneural subtype GBM lines were highly sensitive (IC50 9-210 nM). Palbociclib treatment induced cell accumulation in G1 phase in 3 sensitive proneural lines, but not in 3 resistant lines. Treatment with vehicle versus oral palbociclib (150 mg/kg/day) was compared in mice with intracranial implantation of proneural GBM stem cell-like G448 cells, which are shown to have higher than normal expression of CDK6. Mice receiving palbociclib had significantly longer survival time (p=0.038)."	"Li et al., 2017, Oncotarget"	N/A	ENST00000265734.4	N/A
ASNS Amplification	ASNS	Amplification	Ovarian Cancer	Asparaginase	Predictive	Supports	D	Resistance	chr7	97852118	97872542			ASNS amplification and expression was associated with resistance to L-asparaginase in ovarian cancer and leukemia cell lines. ASNS silencing increased sensitivity to l-ASP in 2/3 of ovarian cancer cell lines.	"Lorenzi et al., 2006, Mol. Cancer Ther."	Somatic	ENST00000175506.4	transcript_amplification
BRAF ZKSCAN1::BRAF	BRAF	ZKSCAN1::BRAF	Melanoma	Trametinib	Predictive	Supports	C	Sensitivity/Response	chr7	100015599	100029952			"Analysis of BRAF fusions in 20,573 tumors, across 12 distinct tumor types. BRAF fusions were identified in 55 (0.3%) patients and enriched in spitzoid melanoma, pilocytic astrocytomas, pancreatic acinar and papillary thyroid cancers. Clinical data were available for two patients. Among them one 46-year old woman with spitzoid melanoma that  harbored  a ZKSCAN1-BRAF fusion responded to treatment with the MEK inhibitor trametinib. Subcutaneous  tumor  nodules  exhibited  clinical responses within 14 days of therapy, and her dominant bulky right lung metastases showed significant response by Day 45. Subsequent robotic-assisted lobectomy was able to remove the previously unresectable tumor with clean surgical margins."	"Ross et al., 2016, Int. J. Cancer"	Somatic	ENST00000426572.1	transcript_fusion
STAG3 Underexpression	STAG3	Underexpression	Melanoma	Vemurafenib	Predictive	Supports	D	Resistance	chr7	100177563	100214380			A375 melanoma cells containing an inducible shRNA for STAG3 were grown as xenograft tumors in nude mice. The mice in which STAG3 was silenced had tumors that were less sensitive to vemurafenib-induced tumor shrinkage than the tumors of the control mice (P < .01).	"Shen et al., 2016, Nat. Med."	N/A	ENST00000426455.1	N/A
EPHB4 EXPRESSION	EPHB4	EXPRESSION	Colorectal Cancer	Bevacizumab	Predictive	Supports	B	Resistance	chr7	100802565	100827499			"EPHB4 expression, as assessed by quantitative RT-PCR in 13 colorectal cancer patients treated with bevacizumab, was higher in non-responders (p = 0.048). No difference was observed in a control group without bevacizumab treatment. qRT-PCR results were also shown to correlate with protein expression measured by IHC."	"Guijarro-Muoz et al., 2013, Med. Oncol."	N/A	ENST00000358173.3	N/A
MET Amplification	MET	Amplification	Gastric Adenocarcinoma	Onartuzumab	Predictive	Supports	C	Sensitivity/Response	chr7	116672405	116796342			"A case-study describing a patient with MET polysomy, MET over-expression and evidence of autocrine HGF-production (the growth factor ligand of MET). The patient initially achieved a complete response on MET-Inhibitor MetMAb (Onartuzumab) for 2 years and mixed response after recurrence with resistance in some of the newly developing metastases."	"Catenacci et al., 2011, Cancer Discov"	Somatic	ENST00000318493.6	transcript_amplification
MET Amplification	MET	Amplification	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	D	Resistance	chr7	116672405	116796342			"In this study a gefitinib-sensitive cell-line (HCC827), acquired gefitinib resistance (HCC827 GR) by a focal amplification of MET.  Resistance was conferred by the MET amplification driving ERBB3 (HER3)-dependent activation of PI3K."	"Engelman et al., 2007, Science"	Somatic	ENST00000318493.6	transcript_amplification
MET Amplification	MET	Amplification	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr7	116672405	116796342			A case-study of an ALK-negative patient with MET amplification (MET/CEP7 ratio >5.0) who achieved a durable partial response to MET/ALK-inhibitor crizotinib.	"Ou et al., 2011, J Thorac Oncol"	Somatic	ENST00000318493.6	transcript_amplification
MET Amplification	MET	Amplification	Lung Adenocarcinoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr7	116672405	116796342			"Case report of a patient with MET amplification without high-level MET/CEP7 ratio, MET exon 14 mutation or overexpression who achieved rapid response to crizotinib."	"Zhang et al., 2016, J Thorac Oncol"	Somatic	ENST00000318493.6	transcript_amplification
MET Amplification	MET	Amplification	Lung Squamous Cell Carcinoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr7	116672405	116796342			"Case report of a 73 year old patient with advanced squamous cell carcinoma of the lung that tested negative for EGFR, KRAS and PIK3CA mutations and ALK and ROS1 rearrangements. c-MET amplification was detected by FISH. Crizotinib led to a partial response."	"Schwab et al., 2014, Lung Cancer"	Somatic	ENST00000318493.6	transcript_amplification
MET Amplification	MET	Amplification	Lung Adenocarcinoma	"Erlotinib,Gefitinib"	Predictive	Supports	C	Resistance	chr7	116672405	116796342			"155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib). MET amplification was seen in 4 of 75 patients tested (no baseline samples available). One patient had small cell transformation and MET amplification, two patients had EGFR T790M mutation and MET amplification."	"Yu et al., 2013, Clin. Cancer Res."	N/A	ENST00000318493.6	transcript_amplification
MET Amplification	MET	Amplification	Glioblastoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr7	116672405	116796342			"A 62 year old female was diagnosed with glioblastoma (GBM) WHO grade 4. Treatment included radiation, temozolomide and cediranib. MET amplification was found by FISH, and ALK and MET inhibitor crizotinib treatment was started. A 40% reduction in size of contrast enhancing lesion was seen. After 6 months, progressive disease was seen and crizotinib withdrawn. The authors state this is a first report of response to prospective MET targeted therapy in GBM."	"Chi et al., 2012, J. Clin. Oncol."	Somatic	ENST00000318493.6	transcript_amplification
MET Amplification	MET	Amplification	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	D	Sensitivity/Response	chr7	116672405	116796342			"2 MET amplified NSCLC cell lines (EBC-1 and H1993), as well as 2 EGFR mutant and 2 MET and EGFR wild type cell lines were treated with ALK and MET inhibitor crizotinib, and the MET amplified cells had IC50 100 fold lower than the non MET amplified cell lines. Both crizotinib treatment and siRNA against MET increased apoptotic markers in MET amplified cells but not controls, indicating that crizotinib targeting of amplified MET was inducing the apoptotic effects. Tumors caused by MET amplified EBC-1 cells injected into mice were significantly inhibited with crizotinib treatment, while tumors from non-MET amplified cells showed no substantial effect."	"Tanizaki et al., 2011, J Thorac Oncol"	Somatic	ENST00000318493.6	transcript_amplification
MET Overexpression	MET	Overexpression	Skin Melanoma	Vemurafenib	Predictive	Supports	B	Resistance	chr7	116672405	116796342			"Whole exome sequencing, transcriptome and methylome alterations in 48 melanoma samples with acquired resistance to BRAFi +/- MEKi therapy compared to patient-matched baseline melanoma tissues were analyzed. 39% of resistant melanomas were not accounted for by any validated mutational mechanism. c-MET was overexpressed in 21 of 48 (44%) resistant samples. Methylome analysis revealed three CpG clusters (C1?) with differential methylation to be negatively correlated with differential c-MET mRNA expression. In nearly all (90%) pairwise comparisons of tumors and cell lines, differential c-MET mRNA expression could be accounted for by at least one differential CpG cluster methylation ( ?10% and FDR adjusted p ?0.05). In contrast, only 48% displayed a concordant differential expression pattern of at least one c-MET transcription factor. In an independent study, c-MET was overexpressed in 8 of 35 (23%) MAPKi-resistant tumors from 7 of 26 (27%) patients. In two human BRAF V600E mutant cell lines, BRAFi treatment led to progressive methylation-expression changes akin to observations across MAPKi-sensitive versus resistant tumors."	"Hugo et al., 2015, Cell"	N/A	ENST00000318493.6	N/A
MET Overexpression	MET	Overexpression	Uveal Melanoma	Crizotinib	Predictive	Supports	D	Sensitivity/Response	chr7	116672405	116796342			"c-MET and ligand HGF were expressed by 6 uveal melanoma cell lines in-vitro. GNA-mutant cell lines (n=3) showed stronger expression of ligand and receptor as well as more receptor phosphorylation. SiRNA mediated MET-knockdown reduced cell migration but not cell growth. Crizotinib treatment led to a decrease in cell growth and migration. At 25 nmol/L of crizotinib, only the migration of G-protein mutant cells lines and not G-protein wild type cell lines was decreased. Crizotinib did not lead to a reduction in tumor volume of two cell lines in vivo but reduced the formation of macrometastases (luciferase activity, p=0.03)."	"Surriga et al., 2013, Mol. Cancer Ther."	N/A	ENST00000318493.6	N/A
MET Overexpression	MET	Overexpression	Skin Melanoma	Vemurafenib	Predictive	Does Not Support	B	Resistance	chr7	116672405	116796342			"FFPE tumours from patients enrolled in the BRIM2 (n = 59) and BRIM3 (n = 150) trials of vemurafenib in advanced BRAF mutant (V600E/K) melanoma were analyzed for MET expression (IHC). Pretreatment MET expression was frequent at the ? + cutoff (BRIM3, 31%; BRIM2, 49%), but relatively infrequent at the ? + cutoff (BRIM3, 9%; BRIM2, 19%). Retrospective subset analyses showed that, irrespective of the cutoff used or the treatment arm, MET expression did not show prognostic significance, in terms of objective response rate, progression-free survival, or overall survival."	"Jubb et al., 2013, Histopathology"	N/A	ENST00000318493.6	N/A
MET Amplification	MET	Amplification	Colorectal Cancer	"Vemurafenib,Crizotinib"	Predictive	Supports	C	Sensitivity/Response	chr7	116672405	116796342			"Case report of a patient with BRAF V600E mutant metastatic colorectal cancer. Combined EGFR and BRAF inhibition (panitumumab and vemurafenib) showed an initial partial response for 4 months. Re-biopsy at the time of progression showed a MET amplification and overexpression (IHC, ISH) but no secondary mutations in candidate resistance genes (EGFR, KRAS, NRAS, MAP2K1). MET amplification was also present in a subset of tumor cells in the pretreatment sample. MET amplification was also identified in 3/17 (18%) chemonaive BRAF V600E colorectal cancer tumor tissues. Overexpression of MET in a BRAF mutant CRC cell line (WiDr) confered resistance to combined vemurafenib and panitumumab. The addition of crizotinib to this combination restored sensitivity in vitro. The patient was started on combined vemurafenib and crizotinib in January 2016 and had a metabolic, clinical and tumor marker response that was ongoing at the time of publication (06/16) without significant toxicity."	"Pietrantonio et al., 2016, Cancer Discov"	N/A	ENST00000318493.6	transcript_amplification
MET Amplification	MET	Amplification	Lung Adenocarcinoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr7	116672405	116796342			"In an evaluation of a patient with crizotinib-sensitive lung adenocarcinoma, an MET-Amplification was identified using CGP.  The patient attained a reduction in the target lesions by 38.7%, and the patient maintained response for at least 5 months post-treatment."	"Le et al., 2015, Clin Lung Cancer"	Somatic	ENST00000318493.6	transcript_amplification
MET Amplification	MET	Amplification	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr7	116672405	116796342			Case report of two patients with MET amplification (MET:CEP7 ratio ?) and no concomitant MET exon 14 deletion. A response to crizotinib was observed in both cases suggesting that MET amplification may predict response to this drug even in the absence of MET exon 14 mutations.	"Caparica et al., 2017, J Thorac Oncol"	N/A	ENST00000318493.6	transcript_amplification
MET Amplification	MET	Amplification	Cancer	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr7	116672405	116796342			"Case report of a 59-year-old white female patient (60 pack-years) with a CUP-syndrome. Molecular profiling identified both MET amplification (16 copies) and a KRAS G12V mutation. The patient was treated with crizotinib and experienced a complete normalization of tumor metabolic activity for more than 19 months. Other identified aberrations include CCND1 amplification (8 copies), MYC amplification (9 copies) as well as KRAS G12V, TP53 R273L and CARD11 N184S."	"Palma et al., 2014, Case Rep Oncol"	N/A	ENST00000318493.6	transcript_amplification
MET Amplification	MET	Amplification	Colorectal Cancer	Anti-EGFR Monoclonal Antibody	Predictive	Supports	D	Resistance	chr7	116672405	116796342			"Functional studies show that MET activation confers resistance to anti-EGFR therapy both in vitro and in vivo. Notably, in patient-derived colorectal cancer xenografts, MET amplification correlated with resistance to EGFR blockade, which could be overcome by MET kinase inhibitors."	"Bardelli et al., 2013, Cancer Discov"	Somatic	ENST00000318493.6	transcript_amplification
MET Amplification	MET	Amplification	Colorectal Cancer	"Crizotinib,Cetuximab"	Predictive	Supports	D	Sensitivity/Response	chr7	116672405	116796342			"Functional studies show that MET activation confers resistance to anti-EGFR therapy both in vitro and in vivo. Notably, in patient-derived colorectal cancer xenografts, MET amplification correlated with resistance to EGFR blockade, which could be overcome by MET kinase inhibitors."	"Bardelli et al., 2013, Cancer Discov"	Somatic	ENST00000318493.6	transcript_amplification
MET Overexpression	MET	Overexpression	Uveal Melanoma	"Selumetinib,Trametinib"	Predictive	Supports	D	Resistance	chr7	116672405	116796342			"In this study the authors screened for growth factors that elicited resistance in newly characterized metastatic uveal melanoma cell lines to clinical-grade MEK inhibitors, trametinib and selumetinib, showing that neuregulin 1 (NRG1) and hepatocyte growth factor (HGF) provide resistance to MEK inhibition. Trametinib enhances the responsiveness to NRG1 and sustained HGF-mediated activation of AKT. Targeting ERBB3 and cMET could overcome resistance to trametinib."	"Cheng et al., 2015, Cancer Res."	N/A	ENST00000318493.6	N/A
MET Overexpression	MET	Overexpression	Stomach Carcinoma	Rilotumumab	Predictive	Does Not Support	B	Sensitivity/Response	chr7	116672405	116796342			"In this randomised, double-blind, placebo-controlled phase 3 trial, 609 patients with MET+ (expression of at least 1+ intensity on 25% or more tumor cells) gastric cancer or gastroesophageal adenocarcinoma were randomized to chemotherapy (epirubicin, cisplatin, capecitabine) with placebo or MET inhibitor rilotumumab. Study treatment was stopped early because of a higher number of deaths in the rilotumumab arm. Median overall survival was 88 months (95% CI 77-102) in the rilotumumab group compared with 107 months (96-124) in the placebo group (stratified hazard ratio 134, 95% CI 110-163; p=0003)."	"Catenacci et al., 2017, Lancet Oncol."	N/A	ENST00000318493.6	N/A
MET Exon 14 Skipping Mutation	MET	Exon 14 Skipping Mutation	Cancer	Crizotinib	Predictive	Supports	D	Sensitivity/Response	chr7	116771849	116771989			The creation of a cell line model (HEK293) with MET exon 14 deletion (using the CRISPR/Cas9 system) led to enhanced cellular growth and sensitivity to the MET inhibitor crizotinib. MET exon 14 deletion results in an in-frame deletion in the MET protein. Recurrent splice site mutations that result in exon 14 skipping have been observed in ~3% of all lung cancers.	"Togashi et al., 2015, Lung Cancer"	Somatic	ENST00000318493.6	exon_loss_variant
MET Exon 14 Skipping Mutation	MET	Exon 14 Skipping Mutation	Lung Adenocarcinoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr7	116771849	116771989			We now report responses to the MET inhibitors crizotinib and cabozantinib in four patients with stage IV lung adenocarcinomas harboring mutations leading to MET exon 14 skipping.	"Paik et al., 2015, Cancer Discov"	Somatic	ENST00000318493.6	exon_loss_variant
MET Exon 14 Skipping Mutation	MET	Exon 14 Skipping Mutation	Lung Adenocarcinoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr7	116771849	116771989			A single patient with a MET c.3028G>A (splice donor site of exon 14) mutation exhibited clinical sensitivity to the c-Met inhibitor crizotinib. Exon 14 skipping was detected using qRT-PCR. Response to the therapy was demonstrated by comparing CAT scans obtained before treatment to those obtained during treatment (at 2 months of crizotinib therapy).	"Awad et al., 2016, J. Clin. Oncol."	Somatic	ENST00000318493.6	exon_loss_variant
MET Exon 14 Skipping Mutation	MET	Exon 14 Skipping Mutation	Lung Adenocarcinoma	Capmatinib	Predictive	Supports	C	Sensitivity/Response	chr7	116771849	116771989			"A patient with MET c.3028+1G>T mutation (METex14) had partial response (tumor reduction of 61%) after 13 months capmatinib. MET gene copy number was four, MET FISH 13.8 copy number, and IHC 3+."	"Frampton et al., 2015, Cancer Discov"	Somatic	ENST00000318493.6	exon_loss_variant
MET Exon 14 Skipping Mutation	MET	Exon 14 Skipping Mutation	Lung Adenocarcinoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr7	116771849	116771989			Case report of a patient with lung adenocarcinoma harboring a MET exon 14 skipping mutation and major response to crizotinib.	"Shea et al., 2016, J Thorac Oncol"	Somatic	ENST00000318493.6	exon_loss_variant
MET Exon 14 Skipping Mutation	MET	Exon 14 Skipping Mutation	Lung Adenocarcinoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr7	116771849	116771989			"In a never-smoking metastatic lung adenocarcinoma patient harboring a MET splice site mutation (c.2887-18_2887-7del12)  treated with crizotinib monotherapy, was  associated with a response as evident by the reduced size of tumors. Prior to identification of the MET splice site mutation, the patient was treated with stereotactic radiotherapy, palliative radiation, and a single cycle of pemetrexed; subsequently, the patient was treated with crizotinib, but progressed at 8 weeks of treatment."	"Jenkins et al., 2015, Clin Lung Cancer"	Somatic	ENST00000318493.6	exon_loss_variant
MET Exon 14 Skipping Mutation	MET	Exon 14 Skipping Mutation	Lung Non-small Cell Carcinoma	Tepotinib	Predictive	Supports	B	Sensitivity/Response	chr7	116771849	116771989			"In a interim analysis of Phase II trial for MET exon 14 skipping NSCLC, 34 patients received MEK selective inhibitor tepotinib. 9/15 (60.0%) evaluable patients had a confirmed PR and 3 (20.0%) had SD."	"Enriqueta Felip, 2018, ASCO Annual Meeting, Abstract 9016"	Somatic	ENST00000318493.6	exon_loss_variant
MET Exon 14 Skipping Mutation	MET	Exon 14 Skipping Mutation	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	B	Sensitivity/Response	chr7	116771849	116771989			"Pts with MET exon 14-altered NSCLC were enrolled into an expansion cohort of the phase I PROFILE 1001 study (NCT00585195) and received crizotinib. Responses were assessed. By data-cut off 18 pts with MET exon 14-altered NSCLC had enrolled and 17 received treatment (15 response-evaluable). Antitumor activity per RECIST was documented in 10/15 pts: 5 with confirmed PRs and 5 with unconfirmed PRs. Median PFS could not be calculated, with no deaths or PD by the data cut-off. Treatment-related AEs were generally tolerable, and were most commonly edema, nausea, vision disorder, bradycardia, and vomiting. AEs were mostly grade 1 or 2, with one grade 3 edema, and no grade 4/5 AEs."	"Alexander E. Drilon, 2016, ASCO Annual Meeting, Abstract 108"	Somatic	ENST00000318493.6	exon_loss_variant
MET Exon 14 Skipping Mutation	MET	Exon 14 Skipping Mutation	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr7	116771849	116771989			"In this case Report, a 67-year old female patient with a lung adenocarcinoma displaying a MET exon 14 donor splice site mutation (D1028N) detected using next generation sequencing. Within 5 weeks of crizotinib therapy, a partial response was observed."	"Mahjoubi et al., 2016, Invest New Drugs"	Somatic	ENST00000318493.6	exon_loss_variant
MET Exon 14 Skipping Mutation	MET	Exon 14 Skipping Mutation	Histiocytic And Dendritic Cell Cancer	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr7	116771849	116771989			"An 84 year old never-smoker with an upper chest mass was found to have stage 3 histiocytic sarcoma. Genomic profiling discovered a MET exon 14 variant c.2888-5_2944del62, as well as TP53 p.R175H and ZMYM3 c.3008-1G>A. After four months of crizotinib treatment tumour volume had decreased by >60%, however the patient showed progression at 11 months."	"Frampton et al., 2015, Cancer Discov"	Somatic	ENST00000318493.6	exon_loss_variant
MET Exon 14 Skipping Mutation	MET	Exon 14 Skipping Mutation	Cancer	Capmatinib	Predictive	Supports	D	Sensitivity/Response	chr7	116771849	116771989			"MET exon 14 skipping was modelled in vitro by expressing human MET cDNA with exon 14 deletion in HEK293 cells and mouse MET with homologous exon 15 deletion in NIH3T3 cells. NIH3T3 cells expressing MET with exon 15 deletion showed dose dependent inhibition of cell proliferation upon treatment with capmatinib, with significantly lower cell survival compared to control cells. In addition, HEK293 cells expressing MET with exon 14 deletion had increased ERK phosphorylation, while NIH3T3 cells expressing mouse MET with exon 15 deletion had increased MET phosphorylation and increased anchorage-independent colony formation compared to wt MET."	"Frampton et al., 2015, Cancer Discov"	Somatic	ENST00000318493.6	exon_loss_variant
MET Exon 14 Skipping Mutation	MET	Exon 14 Skipping Mutation	Lung Non-small Cell Carcinoma	Capmatinib	Predictive	Supports	A	Sensitivity/Response	chr7	116771849	116771989			"In a phase 2 trial, a total of 364 patients with non-small cell lung cancer and MET alterations were assigned to cohorts based on prior treatment and type of MET alteration. A total of 97 patients, from cohorts 4 (pretreated) and 5b (no previous treatment), had MET exon 14 skipping mutations. Among pretreated (1-2 lines of therapy) patients with NSCLC with a MET exon 14 skipping mutation, overall response was observed in 41% (95% confidence interval [CI], 29 to 53) of 69 patients. Overall response rate was 68% (95% CI, 48 to 84) of 28 patients who had not received treatment previously. The median duration of response was 9.7 months (95% CI, 5.6 to 13.0) for cohort 4 and 12.6 months (95% CI, 5.6 to could not be estimated) for cohort 5b."	"Wolf et al., 2020, N Engl J Med"	Somatic	ENST00000318493.6	exon_loss_variant
MET R1004G	MET	R1004G	Head And Neck Cancer	Crizotinib	Predictive	Supports	C	Sensitivity/Response	chr7	116771971	116771971	C	G	A patient with platinum-refractory oral cavity head and neck squamous carcinoma underwent comprehensive genomic profiling that identified an activating MET R1004G mutation. The patient showed a rapid response to the treatment of crizotinib.	"Chu et al., 2019, Oncologist"	Somatic	ENST00000397752.8	missense_variant
MET D1228N	MET	D1228N	Lung Non-small Cell Carcinoma	Crizotinib	Predictive	Supports	C	Resistance	chr7	116783353	116783353	G	A	Case report of a patient with NSCLC harboring a MET exon 14 skipping mutation and initial response to crizotinib. A second biopsy at the time of progression revealed an acquired MET D1228N mutation.	"Heist et al., 2016, J Thorac Oncol"	Somatic	ENST00000397752.3	missense_variant
MET D1228V	MET	D1228V	Lung Non-small Cell Carcinoma	Cabozantinib	Predictive	Supports	C	Sensitivity/Response	chr7	116783354	116783354	A	T	"Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined type I MET (savolitinib) and EGFR (osimertinib) inhibition and responded. When resistance developed, a new MET kinase domain mutation, D1228V, was detected. Drug binding predictions and in vitro studies demonstrated that the D1228V mutation induces resistance to type I but not type II MET TKIs. The patient was treated with erlotinib (EGFR TKI) combined with cabozantinib, a type II MET inhibitor, and had a response which continued at the time of report (5 months)."	"Bahcall et al., 2016, Cancer Discov"	Somatic	ENST00000397752.3	missense_variant
MET D1228V	MET	D1228V	Lung Non-small Cell Carcinoma	Savolitinib	Predictive	Supports	C	Resistance	chr7	116783354	116783354	A	T	"Case report of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET. After progression on erlotinib the patient was treated with combined type I MET (savolitinib) and EGFR (osimertinib) inhibition and responded. When resistance developed, a new MET kinase domain mutation, D1228V, was detected. Drug binding predictions and in vitro studies demonstrated that the D1228V mutation induces resistance to type I but not type II MET TKIs. The patient was treated with erlotinib (EGFR TKI) combined with cabozantinib, a type II MET inhibitor, and had a response which continued at the time of report (5 months)."	"Bahcall et al., 2016, Cancer Discov"	Somatic	ENST00000397752.3	missense_variant
POT1 MUTATION	POT1	MUTATION	Chronic Lymphocytic Leukemia		Prognostic	Supports	B	Poor Outcome	chr7	124822386	124929981			"In previously untreated patients with chronic lymphocytic leukemia, POT1 mutations (N=13) were associated with shorter overall survival than wildtype POT1 (N=148) in univariate and multivariate analysis (HR, 4.0; 95% CI, 1.6-10.1; P = .003) independent of IGHV mutation status, Binet stage, and serum beta-2-microglobulin."	"Herling et al., 2016, Blood"	Somatic	ENST00000357628.3	"protein_altering_variant,loss_of_function_variant"
SMO Mutation	SMO	Mutation	Basal Cell Carcinoma	Vismodegib	Predictive	Supports	B	Resistance	chr7	129188872	129213545			"In basal cell carcinoma, H231R, D473G, W281C and Q477E mutations conferred resistance to SMO-inhibitor vismodegib. SMO mutations were identified in 22 of 44 resistant basal cell carcinomas in 15 patients."	"Atwood et al., 2015, Cancer Cell"	Somatic	ENST00000249373.3	coding_transcript_variant
SMO Mutation	SMO	Mutation	Basal Cell Carcinoma	"Arsenic Trioxide,PSI"	Predictive	Supports	D	Sensitivity/Response	chr7	129188872	129213545			Basal cell carcinomas with ligand-binding pocket or constitutively active mutations in the SMO gene were sensitive to inhibition of downstream hedgehog signaling with PSI (aPKC-//GLI inhibitor) or arsenic trioxide.	"Atwood et al., 2015, Cancer Cell"	Somatic	ENST00000249373.3	coding_transcript_variant
SMO Mutation	SMO	Mutation	Basal Cell Carcinoma	"Vismodegib,Sonidegib"	Predictive	Supports	B	Resistance	chr7	129188872	129213545			"Study explored the response to the SMO inhibitor sonidegib (LDE225) in a cohort of 9 patients with advanced basal cell carcinoma  that exhibited treatment resistance with vismodegib (GDC0449). Sequencing revealed that 5 of these patients harbored SMO mutations known to confer resistance to the Smoothened inhibitors (D473G, D473H, Q477E, S533N, W535L) an additional patient harbored a SMO mutation of unknown consequence (R168H). Of these patients, 4 with a SMO mutation displayed progressive disease and 1 stable disease for 58 weeks according to RECIST v1.1 criteria."	"Danial et al., 2016, Clin. Cancer Res."	Somatic	ENST00000249373.3	coding_transcript_variant
SMO Mutation	SMO	Mutation	Cancer	Vismodegib	Predictive	Does Not Support	B	Sensitivity/Response	chr7	129188872	129213545			"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Twenty-one patients had mutations in the Hedgehog pathway (PTCH-1, n = 18; SMO, n = 3). None of the patients with SMO mutations responded to SHH-inhibition with vismodegib."	"Hainsworth et al., 2018, J. Clin. Oncol."	Somatic	ENST00000249373.3	coding_transcript_variant
SMO L412F	SMO	L412F	Basal Cell Carcinoma	Vismodegib	Predictive	Supports	D	Resistance	chr7	129206557	129206557	C	T	"In an in vitro study, mouse embryonic fibroblasts (MEFs), null for the Smo mouse gene expressing SMO L412F mutation, demonstrated resistance to vismodegib treatment (IC50: >320 nmol/L vs. 8.23 nmol/L) compared to MEFs expressing wild-type SMO. Resistance was determined by assessing GLI1 mRNA expression levels."	"Atwood et al., 2015, Cancer Cell"	Somatic	ENST00000249373.3	missense_variant
SMO L412F	SMO	L412F	Basal Cell Carcinoma	Vismodegib	Predictive	Supports	C	Resistance	chr7	129206557	129206557	C	T	"An Arab basal cell carcinoma patient harboring SMO L412F mutation was associated with response to vismodegib monotherapy. Prior to the identification of the mutation, the patient was treated with acitretin, but did not achieve any response."	"Khamaysi et al., 2016, Br. J. Dermatol."	Somatic	ENST00000249373.3	missense_variant
SMO D473H	SMO	D473H	Medulloblastoma	Vismodegib	Predictive	Supports	C	Resistance	chr7	129209348	129209348	G	C	"In this case report, the D473H mutation was reported as an acquired mechanism of resistance to the hedgehog pathway inhibitor GDC-0449 (vismodegib)."	"Yauch et al., 2009, Science"	Somatic	ENST00000249373.3	missense_variant
SMO D473H	SMO	D473H	Basal Cell Carcinoma	Vismodegib	Predictive	Supports	D	Resistance	chr7	129209348	129209348	G	C	"D473 mutations were identified in 5/30 resistant basal cell carcinomas. Crystal structure indicated this mutation interacts with a water molecule in the ligand binding pocket, putatively altering its interaction with the SMO inhibitor vismodegib. SMO-/- mouse embryonic fibroblasts expressing the SMO D473G mutant maintained hedgehog signaling in the presence of the drug and had IC50 values >40 fold higher than cells expressing wildtype SMO."	"Atwood et al., 2015, Cancer Cell"	Somatic	ENST00000249373.3	missense_variant
SMO D473H	SMO	D473H	Medulloblastoma	Patidegib	Predictive	Supports	D	Sensitivity/Response	chr7	129209348	129209348	G	C	"Saridegib treatment induced tumor reduction and significantly prolonged survival in a Shh-driven mouse medulloblastoma model, and was found to be active in cells with the D473H point mutation."	"Lee et al., 2012, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000249373.3	missense_variant
BRAF TRIM24::BRAF	BRAF	TRIM24::BRAF	Melanoma	Trametinib	Predictive	Supports	D	Sensitivity/Response	chr7	138460334	138554966			"A TRIM24-BRAF fusion was identified in a single patient with metastatic melanoma that was ""pan-negative"" for driver mutations. A cell-line (293H) ectopically expressing the TRIM24-BRAF fusion was found to be sensitive to the MEK-inhibitor Trametinib."	"Hutchinson et al., 2013, Clin. Cancer Res."	Somatic	ENST00000343526.4	transcript_fusion
BRAF TRIM24::BRAF	BRAF	TRIM24::BRAF	Skin Melanoma	Vemurafenib	Predictive	Supports	D	Resistance	chr7	138460334	138554966			Foundation One NGS assay and targeted RNAseq identified PAPSS1-BRAF fusion in a melanoma sample. Further BRAF fusions (TRIM24-BRAF) were identified in TCGA and additional samples. Ectopic expression of engineered cDNA in 293H cells showed that trametinib led to reduced ERK1/2 phosphorylation in fusion positive cells whereas vemurafenib was not effective.	"Hutchinson et al., 2013, Clin. Cancer Res."	Somatic	ENST00000343526.4	transcript_fusion
BRAF KIAA1549::BRAF	BRAF	KIAA1549::BRAF	Skin Melanoma	Trametinib	Predictive	Supports	C	Sensitivity/Response	chr7	138861139	138981318			"A 65 yr old male patient with metastatic acral lentiginous melanoma (BRAF, NRAS, KIT negative) was found to harbor a KIAA1549-BRAF (intron 15-intron 8) fusion in a subcutaneous metastasis sample after disease progression. Trametinib was started and fatigue and ECOG status improved but imaging revealed slight disease progression after 2 weeks (15 sites measurable, 9 stable, 6 progressive). No new metastases were identified. The patient was switched to pembrolizumab and major disease progression was noted."	"Menzies et al., 2015, Pigment Cell Melanoma Res"	Somatic	ENST00000440172.1	transcript_fusion
BRAF KIAA1549::BRAF	BRAF	KIAA1549::BRAF	Spindle Cell Sarcoma	"Bevacizumab,Temsirolimus,Sorafenib"	Predictive	Supports	C	Sensitivity/Response	chr7	138861139	138981318			"A patient with a malignant spindle cell tumor of the chest wall treated as a soft tissue sarcoma was identified to harbor a KIAA1549-BRAF fusion. This patient responded to treatment with the pan-kinase inhibitor sorafenib in combination with bevacizumab and temsirolimus, achieving stable disease after 2 cycles extending into 11 cycles at which time she expired due to co-morbidities (acute myocardial infarction, hypotension). Of note, sequencing of 236 cancer-related genes identified CDKN2A A68fs*51, SUFU E283fs*3, MAP3K1 N325fs*3 and homozygous deletion of PTEN as well."	"Subbiah et al., 2014, J Hematol Oncol"	Somatic	ENST00000440172.1	transcript_fusion
BRAF KIAA1549::BRAF	BRAF	KIAA1549::BRAF	Pilocytic Astrocytoma		Diagnostic	Supports	B	Positive	chr7	138861139	138981318			"Genetic alterations in pilocytic astrocytoma (PA) were evaluated. Whole-genome sequencing of normal (blood) and tumor samples (n=96) was performed along with corresponding RNA-Seq (n=73) and mate-pair (MP) sequencing (n=68).  Several known events activating the MAPK pathway were identified with KIAA1549-BRAF fusion being the most frequent variants (70 of 96 cases, 73%). Importantly, all but one of the cerebellar PA harbored a BRAF fusion (47 of 48 samples, 98%) with this one exception having a KRAS alteration."	"Jones et al., 2013, Nat. Genet."	Somatic	ENST00000440172.1	transcript_fusion
BRAF KIAA1549::BRAF	BRAF	KIAA1549::BRAF	Childhood Low-grade Glioma		Prognostic	Supports	B	Better Outcome	chr7	138861139	138981318			KIAA1549-BRAF fusion was identified in 87 of 272 patients with PLGGs using Fluorescence In situ hybridization (FISH) analysis. This mutation was strongly associated with a greater progression-free survival (p=0.0017) and overall survival (p=0.0029) [fusion-positive (n=64) vs fusion-negative (n=141)].	"Yang et al., 2018, Acta Neuropathol."	Somatic	ENST00000440172.1	transcript_fusion
BRAF KIAA1549::BRAF	BRAF	KIAA1549::BRAF	Childhood Low-grade Glioma	"Everolimus,Trametinib"	Predictive	Supports	D	Sensitivity/Response	chr7	138861139	138981318			"This preclinical study proposed to use a combination therapy of an MEK inhibitor (e.g. trametinib) and an mTOR inhibitor (e.g. everolimus) for the treatment of pediatric low-grade gliomas (PLGGs) with BRAF fusions to evade acquired resistance to MEK targeted therapy. The PI3K/Akt/mTOR pathway was identified as a resistance mechanism to MEKi treatment based on RNASeq and GSEA analysis. Using flank xenograft model, mice were injected with NIH3T3 cells expressing KIAA1549-BRAF fusions and treated daily with trametinib, everolimus either alone or combined with each other (n=~10 for each treatment arm). Combination therapy (Trametinib 1mg/kg+ Everolimus 10mg/kg) resulted in better suppression in tumor growth than single-agent treatment. Similarly, combination treatment strongly reduced colony formation as well as pERK and pS6 levels, showing on target effects."	"Jain et al., 2017, Oncotarget"	Somatic	ENST00000440172.1	transcript_fusion
BRAF KIAA1549::BRAF	BRAF	KIAA1549::BRAF	Childhood Low-grade Glioma		Prognostic	Supports	B	Better Outcome	chr7	138861139	138981318			"Hawkins et al. (2011) retrospectively studied 70 consecutive patient with incompletely resected pediatric low-grade astrocytomas (PLGA). KIAA1549-BRAF fusion was identified in 60% of cases in this cohort. Multi-variant analysis suggested that KIAA1549-BRAF fusion was the most significant favorable prognosis factor in incompletely resected PLGA and was independent of location, pathology, and age. Five-year PFS of fusion positive and fusion negative patients were 61% +/- 8% and 18% +/- 8% (P=0.0004), respectively. These results suggested that KIAA1549-BRAF fusion confers a less aggressive clinical phenotype on PLGA and may explain their tendency to growth arrest."	"Hawkins et al., 2011, Clin. Cancer Res."	Somatic	ENST00000440172.1	transcript_fusion
BRAF KIAA1549::BRAF	BRAF	KIAA1549::BRAF	Spindle Cell Sarcoma	"Bevacizumab,Temsirolimus,Sorafenib"	Predictive	Supports	C	Sensitivity/Response	chr7	138861139	138981318			A patients with malignant spindle cell tumor treated as as soft tissue sarcoma harboring KIAA1549-BRAF fusion were treated with sorafenib in combination with bevacizumab and temsirolimus.  Tumor of the chest wall showed good response.	"Ross et al., 2016, Int. J. Cancer"	Somatic	ENST00000440172.1	transcript_fusion
BRAF KIAA1549::BRAF	BRAF	KIAA1549::BRAF	Pilocytic Astrocytoma		Diagnostic	Supports	B	Positive	chr7	138861139	138981318			"This study identified a novel rearrangement event between the uncharacterized gene KIAA-1549 and BRAF in 66% (29 of 44) of pilocytic astrocytoma but not in 244 higher-grade astrocytomas that were evaluated. An in vitro study further showed that this fusion gene lacks the N-terminal BRAF auto-regulatory domain, leading to constitutive activation of BRAF."	"Jones et al., 2008, Cancer Res."	Somatic	ENST00000440172.1	transcript_fusion
BRAF KIAA1549::BRAF	BRAF	KIAA1549::BRAF	Pilocytic Astrocytoma		Oncogenic	Supports	D	Oncogenicity	chr7	138861139	138981318			"This study identified a novel rearrangement event between the uncharacterized gene KIAA-1549 and BRAF in 66% (29 of 44) of pilocytic astrocytomas. The fusion gene was shown to delete the N-terminal BRAF auto-regulatory domain which in vitro assays indicated leads to constitutive activation of BRAF. Cos7 cells were transfected with two isoforms of KIAA1549-BRAF (both exon 16:exon 9), BRAF V600E, or wildtype BRAF and evaluated activity via BRAF kinase assay. Both fusion isoforms showed similar or higher kinase activity than V600E transfected cells. NIH3T3 cells transfected with V600E or the short fusion isoform also demonstrated anchorage-independent growth in soft agarose."	"Jones et al., 2008, Cancer Res."	Somatic	ENST00000440172.1	transcript_fusion
BRAF KIAA1549::BRAF	BRAF	KIAA1549::BRAF	Childhood Pilocytic Astrocytoma	"Vemurafenib,Sorafenib"	Predictive	Supports	D	Resistance	chr7	138861139	138981318			A pilocytic astrocytoma (PA) cell line named DKFZ-BT66 was generated from a 2-year old patient with the disease. Expression of KIAA1549-BRAF fusion in this cell line was identified. Treatment with sorafenib or vemurafenib resulted in paradoxical activation of MAPK/ERK as seen by increased pERK in western blots. Authors note that their observation aligns with results from a phase II clinical trial wherein PA patients experienced tumor growth under sorafenib treatment induced by paradoxical MAPK activation.	"Selt et al., 2017, Oncotarget"	Somatic	ENST00000440172.1	transcript_fusion
BRAF KIAA1549::BRAF	BRAF	KIAA1549::BRAF	Childhood Pilocytic Astrocytoma	Selumetinib	Predictive	Supports	D	Sensitivity/Response	chr7	138861139	138981318			"In this preclinical experiment, a pediatric pilocytic astrocytoma cell line (DKFZ-BT66) harboring KIAA1549:BRAF fusion was generated from a two year old patient. Treatment with selumetinib resulted in a significant decrease in viable cell count at concentrations of 10M. Treatment with selumetinib fully abrogated ERK activation at concentrations of 0.1M for as long as 120 hours. Authors note that inhibitory effects were more pronounced in cells treated with trametinib than cells treated with selumetinib."	"Selt et al., 2017, Oncotarget"	Somatic	ENST00000440172.1	transcript_fusion
BRAF KIAA1549::BRAF	BRAF	KIAA1549::BRAF	Childhood Pilocytic Astrocytoma	Trametinib	Predictive	Supports	D	Sensitivity/Response	chr7	138861139	138981318			"In this preclinical experiment, a pediatric pilocytic astrocytoma cell line (DKFZ-BT66) harboring KIAA1549:BRAF fusion was generated from a two year old patient. Treatment with trametinib resulted in a significant decrease in viable cell count at concentrations of 100nM and above. Trametinib also fully abrogated ERK activation at concentrations of 0.1M for as long as 120 hours. Authors note that inhibitory effects were more pronounced in cells treated with trametinib than cells treated with selumetinib."	"Selt et al., 2017, Oncotarget"	Somatic	ENST00000440172.1	transcript_fusion
BRAF AKAP9::BRAF	BRAF	AKAP9::BRAF	Thyroid Gland Papillary Carcinoma		Diagnostic	Supports	B	Positive	chr7	140734479	140787584			"The AKAP9-BRAF fusion gene was found in 3/28 tumor samples of radiation-associated papillary thyroid carcinoma, and no samples of non-radiation associated papillary thyroid carcinoma. This fusion was associated with elevated BRAF kinase activity, similar to the V600E variant."	"Ciampi et al., 2005, J. Clin. Invest."	Somatic	ENST00000356239.3	transcript_fusion
BRAF AGK::BRAF	BRAF	AGK::BRAF	Melanoma	Sorafenib	Predictive	Supports	C	Sensitivity/Response	chr7	140734479	140794467			BRAF fusion AGK-BRAF was associated with decreased sensitivity to vemurafenib and increased sensitivity to sorafenib in-vitro. A single patient with this fusion showed durable response to sorafenib.	"Botton et al., 2013, Pigment Cell Melanoma Res"	Somatic	ENST00000355413.4	transcript_fusion
BRAF AGK::BRAF	BRAF	AGK::BRAF	Melanoma	Vemurafenib	Predictive	Supports	D	Resistance	chr7	140734479	140794467			A melanoma cell line with AGK-BRAF in-frame fusion showed decreased sensitivity towards Vemurafenib in comparison with BRAF mutated (V600E) cell lines.	"Botton et al., 2013, Pigment Cell Melanoma Res"	Somatic	ENST00000355413.4	transcript_fusion
BRAF PAPSS1::BRAF	BRAF	PAPSS1::BRAF	Melanoma	Vemurafenib	Predictive	Supports	D	Resistance	chr7	140734479	140787584			"BRAF-fusion in ""pan-negative"" melanomas were identified in TCGA data. Cell-lines with PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib."	"Hutchinson et al., 2013, Clin. Cancer Res."	Somatic	ENST00000265174.4	"gene_fusion,transcript_fusion"
BRAF PAPSS1::BRAF	BRAF	PAPSS1::BRAF	Melanoma	Trametinib	Predictive	Supports	D	Sensitivity/Response	chr7	140734479	140787584			"BRAF-fusion in ""pan-negative"" melanomas were identified in TCGA data. Cell-lines with a PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib but sensitive to treatment with Trametinib. This fusion is believed to activate MAPK pathway signaling."	"Hutchinson et al., 2013, Clin. Cancer Res."	Somatic	ENST00000265174.4	"gene_fusion,transcript_fusion"
BRAF TRIM24::BRAF	BRAF	TRIM24::BRAF	Melanoma	Trametinib	Predictive	Supports	D	Sensitivity/Response	chr7	140734479	140787584			"A TRIM24-BRAF fusion was identified in a single patient with metastatic melanoma that was ""pan-negative"" for driver mutations. A cell-line (293H) ectopically expressing the TRIM24-BRAF fusion was found to be sensitive to the MEK-inhibitor Trametinib."	"Hutchinson et al., 2013, Clin. Cancer Res."	Somatic	ENST00000343526.4	transcript_fusion
BRAF WILD TYPE	BRAF	WILD TYPE	Melanoma	MEK Inhibitor RO4987655	Predictive	Does Not Support	B	Resistance	chr7	140734479	140924764			"Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655. Among 12 patients with melanoma BRAF wild type and non-NRAS or NRAS unknown status, seven patients experienced partial response (n=3) or stable disease (n=4). Authors conclude that RO4987655 has clinical activity in BRAF V600-wt (and BRAF V600E) melanoma. They suggest that other drugs such as immune check point inhibitors are preferred in BRAF wt melanoma, so the role of RO4987655 as a single agent is limited for BRAF WT patients with the possible exception of a small window of opportunity for combinations with MEK inhibitors after immunotherapy progression."	"Zimmer et al., 2014, Clin. Cancer Res."	N/A	ENST00000288602.6	wild_type
BRAF TRIM24::BRAF	BRAF	TRIM24::BRAF	Skin Melanoma	Vemurafenib	Predictive	Supports	D	Resistance	chr7	140734479	140787584			Foundation One NGS assay and targeted RNAseq identified PAPSS1-BRAF fusion in a melanoma sample. Further BRAF fusions (TRIM24-BRAF) were identified in TCGA and additional samples. Ectopic expression of engineered cDNA in 293H cells showed that trametinib led to reduced ERK1/2 phosphorylation in fusion positive cells whereas vemurafenib was not effective.	"Hutchinson et al., 2013, Clin. Cancer Res."	Somatic	ENST00000343526.4	transcript_fusion
BRAF PPFIBP2::BRAF	BRAF	PPFIBP2::BRAF	Skin Melanoma	Trametinib	Predictive	Supports	C	Sensitivity/Response	chr7	140734479	140781693			"Case report of a 47year old female patient with metastatic melanoma (BRAF, NRAS, KIT negative). A PPFIBP2-BRAF fusion was identified from DNA from a brain metastasis (inton 3 of PPFIBP2 fused to intron 10 of BRAF). Trametinib was introduced and anemia and ECOG status improved. Imaging revealed a 90% decrease in extracranial and 19% decrease in intracranial metastases with no new metastases and no progressing sites at 6 weeks. Trametinib was stopped and pembrolizumab introduced at this time. Progressive disease was noted after 5 cycles of pembrolizumab but re-introduction of trametinib did not show an effect."	"Menzies et al., 2015, Pigment Cell Melanoma Res"	Somatic	ENST00000299492.4	transcript_fusion
BRAF KIAA1549::BRAF	BRAF	KIAA1549::BRAF	Skin Melanoma	Trametinib	Predictive	Supports	C	Sensitivity/Response	chr7	140734479	140787584			"A 65 yr old male patient with metastatic acral lentiginous melanoma (BRAF, NRAS, KIT negative) was found to harbor a KIAA1549-BRAF (intron 15-intron 8) fusion in a subcutaneous metastasis sample after disease progression. Trametinib was started and fatigue and ECOG status improved but imaging revealed slight disease progression after 2 weeks (15 sites measurable, 9 stable, 6 progressive). No new metastases were identified. The patient was switched to pembrolizumab and major disease progression was noted."	"Menzies et al., 2015, Pigment Cell Melanoma Res"	Somatic	ENST00000440172.1	transcript_fusion
BRAF BRAF::CUL1	BRAF	BRAF::CUL1	Ovarian Serous Carcinoma	Mitogen-Activated Protein Kinase Kinase Inhibitor	Predictive	Supports	C	Sensitivity/Response	chr7	140734479	140787584			"One patient with low-grade serous ovarian cancer had an in-frame fusion between the BRAF kinase domain and CUL1 identified by panel sequencing (MSK-IMPACT), with expression confirmed by whole-transcriptome sequencing. This patient with metastatic disease after treatment with carboplatin and paclitaxel, was enrolled onto a study of paclitaxel in combination with an oral MEK inhibitor and achieved a CR. She continued to receive therapy for 7 months, until discontinuation because of the development of pneumonitis. At publication, sustained CR had lasted > 18 months."	"Grisham et al., 2015, J. Clin. Oncol."	Somatic	ENST00000288602.6	transcript_fusion
BRAF ZKSCAN1::BRAF	BRAF	ZKSCAN1::BRAF	Melanoma	Trametinib	Predictive	Supports	C	Sensitivity/Response	chr7	140734479	140783157			"Analysis of BRAF fusions in 20,573 tumors, across 12 distinct tumor types. BRAF fusions were identified in 55 (0.3%) patients and enriched in spitzoid melanoma, pilocytic astrocytomas, pancreatic acinar and papillary thyroid cancers. Clinical data were available for two patients. Among them one 46-year old woman with spitzoid melanoma that  harbored  a ZKSCAN1-BRAF fusion responded to treatment with the MEK inhibitor trametinib. Subcutaneous  tumor  nodules  exhibited  clinical responses within 14 days of therapy, and her dominant bulky right lung metastases showed significant response by Day 45. Subsequent robotic-assisted lobectomy was able to remove the previously unresectable tumor with clean surgical margins."	"Ross et al., 2016, Int. J. Cancer"	Somatic	ENST00000426572.1	transcript_fusion
BRAF KIAA1549::BRAF	BRAF	KIAA1549::BRAF	Spindle Cell Sarcoma	"Bevacizumab,Temsirolimus,Sorafenib"	Predictive	Supports	C	Sensitivity/Response	chr7	140734479	140787584			"A patient with a malignant spindle cell tumor of the chest wall treated as a soft tissue sarcoma was identified to harbor a KIAA1549-BRAF fusion. This patient responded to treatment with the pan-kinase inhibitor sorafenib in combination with bevacizumab and temsirolimus, achieving stable disease after 2 cycles extending into 11 cycles at which time she expired due to co-morbidities (acute myocardial infarction, hypotension). Of note, sequencing of 236 cancer-related genes identified CDKN2A A68fs*51, SUFU E283fs*3, MAP3K1 N325fs*3 and homozygous deletion of PTEN as well."	"Subbiah et al., 2014, J Hematol Oncol"	Somatic	ENST00000440172.1	transcript_fusion
BRAF Amplification	BRAF	Amplification	Colorectal Cancer	"Panitumumab,Dabrafenib"	Predictive	Supports	C	Resistance	chr7	140734479	140924764			"Paired pre-treatment and post-progression tumor biopsies from BRAF-mutant CRC patients treated with RAF inhibitor combinations were analyzed. Alterations in MAPK pathway genes were found in resistant tumors not present in matched pre-treatment tumors, including KRAS amplification, BRAF amplification, and a MEK1 mutation."	"Ahronian et al., 2015, Cancer Discov"	Somatic	ENST00000288602.6	transcript_amplification
BRAF KIAA1549::BRAF	BRAF	KIAA1549::BRAF	Pilocytic Astrocytoma		Diagnostic	Supports	B	Positive	chr7	140734479	140787584			"Genetic alterations in pilocytic astrocytoma (PA) were evaluated. Whole-genome sequencing of normal (blood) and tumor samples (n=96) was performed along with corresponding RNA-Seq (n=73) and mate-pair (MP) sequencing (n=68).  Several known events activating the MAPK pathway were identified with KIAA1549-BRAF fusion being the most frequent variants (70 of 96 cases, 73%). Importantly, all but one of the cerebellar PA harbored a BRAF fusion (47 of 48 samples, 98%) with this one exception having a KRAS alteration."	"Jones et al., 2013, Nat. Genet."	Somatic	ENST00000440172.1	transcript_fusion
BRAF KIAA1549::BRAF	BRAF	KIAA1549::BRAF	Childhood Low-grade Glioma		Prognostic	Supports	B	Better Outcome	chr7	140734479	140787584			KIAA1549-BRAF fusion was identified in 87 of 272 patients with PLGGs using Fluorescence In situ hybridization (FISH) analysis. This mutation was strongly associated with a greater progression-free survival (p=0.0017) and overall survival (p=0.0029) [fusion-positive (n=64) vs fusion-negative (n=141)].	"Yang et al., 2018, Acta Neuropathol."	Somatic	ENST00000440172.1	transcript_fusion
BRAF KIAA1549::BRAF	BRAF	KIAA1549::BRAF	Childhood Low-grade Glioma	"Everolimus,Trametinib"	Predictive	Supports	D	Sensitivity/Response	chr7	140734479	140787584			"This preclinical study proposed to use a combination therapy of an MEK inhibitor (e.g. trametinib) and an mTOR inhibitor (e.g. everolimus) for the treatment of pediatric low-grade gliomas (PLGGs) with BRAF fusions to evade acquired resistance to MEK targeted therapy. The PI3K/Akt/mTOR pathway was identified as a resistance mechanism to MEKi treatment based on RNASeq and GSEA analysis. Using flank xenograft model, mice were injected with NIH3T3 cells expressing KIAA1549-BRAF fusions and treated daily with trametinib, everolimus either alone or combined with each other (n=~10 for each treatment arm). Combination therapy (Trametinib 1mg/kg+ Everolimus 10mg/kg) resulted in better suppression in tumor growth than single-agent treatment. Similarly, combination treatment strongly reduced colony formation as well as pERK and pS6 levels, showing on target effects."	"Jain et al., 2017, Oncotarget"	Somatic	ENST00000440172.1	transcript_fusion
BRAF KIAA1549::BRAF	BRAF	KIAA1549::BRAF	Childhood Low-grade Glioma		Prognostic	Supports	B	Better Outcome	chr7	140734479	140787584			"Hawkins et al. (2011) retrospectively studied 70 consecutive patient with incompletely resected pediatric low-grade astrocytomas (PLGA). KIAA1549-BRAF fusion was identified in 60% of cases in this cohort. Multi-variant analysis suggested that KIAA1549-BRAF fusion was the most significant favorable prognosis factor in incompletely resected PLGA and was independent of location, pathology, and age. Five-year PFS of fusion positive and fusion negative patients were 61% +/- 8% and 18% +/- 8% (P=0.0004), respectively. These results suggested that KIAA1549-BRAF fusion confers a less aggressive clinical phenotype on PLGA and may explain their tendency to growth arrest."	"Hawkins et al., 2011, Clin. Cancer Res."	Somatic	ENST00000440172.1	transcript_fusion
BRAF KIAA1549::BRAF	BRAF	KIAA1549::BRAF	Spindle Cell Sarcoma	"Bevacizumab,Temsirolimus,Sorafenib"	Predictive	Supports	C	Sensitivity/Response	chr7	140734479	140787584			A patients with malignant spindle cell tumor treated as as soft tissue sarcoma harboring KIAA1549-BRAF fusion were treated with sorafenib in combination with bevacizumab and temsirolimus.  Tumor of the chest wall showed good response.	"Ross et al., 2016, Int. J. Cancer"	Somatic	ENST00000440172.1	transcript_fusion
BRAF KIAA1549::BRAF	BRAF	KIAA1549::BRAF	Pilocytic Astrocytoma		Diagnostic	Supports	B	Positive	chr7	140734479	140787584			"This study identified a novel rearrangement event between the uncharacterized gene KIAA-1549 and BRAF in 66% (29 of 44) of pilocytic astrocytoma but not in 244 higher-grade astrocytomas that were evaluated. An in vitro study further showed that this fusion gene lacks the N-terminal BRAF auto-regulatory domain, leading to constitutive activation of BRAF."	"Jones et al., 2008, Cancer Res."	Somatic	ENST00000440172.1	transcript_fusion
BRAF KIAA1549::BRAF	BRAF	KIAA1549::BRAF	Pilocytic Astrocytoma		Oncogenic	Supports	D	Oncogenicity	chr7	140734479	140787584			"This study identified a novel rearrangement event between the uncharacterized gene KIAA-1549 and BRAF in 66% (29 of 44) of pilocytic astrocytomas. The fusion gene was shown to delete the N-terminal BRAF auto-regulatory domain which in vitro assays indicated leads to constitutive activation of BRAF. Cos7 cells were transfected with two isoforms of KIAA1549-BRAF (both exon 16:exon 9), BRAF V600E, or wildtype BRAF and evaluated activity via BRAF kinase assay. Both fusion isoforms showed similar or higher kinase activity than V600E transfected cells. NIH3T3 cells transfected with V600E or the short fusion isoform also demonstrated anchorage-independent growth in soft agarose."	"Jones et al., 2008, Cancer Res."	Somatic	ENST00000440172.1	transcript_fusion
BRAF KIAA1549::BRAF	BRAF	KIAA1549::BRAF	Childhood Pilocytic Astrocytoma	"Vemurafenib,Sorafenib"	Predictive	Supports	D	Resistance	chr7	140734479	140787584			A pilocytic astrocytoma (PA) cell line named DKFZ-BT66 was generated from a 2-year old patient with the disease. Expression of KIAA1549-BRAF fusion in this cell line was identified. Treatment with sorafenib or vemurafenib resulted in paradoxical activation of MAPK/ERK as seen by increased pERK in western blots. Authors note that their observation aligns with results from a phase II clinical trial wherein PA patients experienced tumor growth under sorafenib treatment induced by paradoxical MAPK activation.	"Selt et al., 2017, Oncotarget"	Somatic	ENST00000440172.1	transcript_fusion
BRAF Amplification	BRAF	Amplification	Melanoma	"Trametinib,Dabrafenib"	Predictive	Supports	C	Resistance	chr7	140734479	140924764			"In a retrospective study, authors analyzed BRAF V600 mutated melanoma metastases derived from 10 patients treated with the combination of dabrafenib and trametinib for resistance mechanisms and genetic correlates of response. An acquired resistance mechanism activating the MAPK pathway was identified in 9 tumors; BRAF amplification (n=4), MEK1/2 mutation (n=3), NRAS mutations (n=3). Among them, mutual exclusive alterations were BRAF amplification (n=4), MEK2 C125S (n=1), and NRAS Q61K (n=2)."	"Long et al., 2014, Nat Commun"	Somatic	ENST00000288602.6	transcript_amplification
BRAF KIAA1549::BRAF	BRAF	KIAA1549::BRAF	Childhood Pilocytic Astrocytoma	Selumetinib	Predictive	Supports	D	Sensitivity/Response	chr7	140734479	140787584			"In this preclinical experiment, a pediatric pilocytic astrocytoma cell line (DKFZ-BT66) harboring KIAA1549:BRAF fusion was generated from a two year old patient. Treatment with selumetinib resulted in a significant decrease in viable cell count at concentrations of 10M. Treatment with selumetinib fully abrogated ERK activation at concentrations of 0.1M for as long as 120 hours. Authors note that inhibitory effects were more pronounced in cells treated with trametinib than cells treated with selumetinib."	"Selt et al., 2017, Oncotarget"	Somatic	ENST00000440172.1	transcript_fusion
BRAF KIAA1549::BRAF	BRAF	KIAA1549::BRAF	Childhood Pilocytic Astrocytoma	Trametinib	Predictive	Supports	D	Sensitivity/Response	chr7	140734479	140787584			"In this preclinical experiment, a pediatric pilocytic astrocytoma cell line (DKFZ-BT66) harboring KIAA1549:BRAF fusion was generated from a two year old patient. Treatment with trametinib resulted in a significant decrease in viable cell count at concentrations of 100nM and above. Trametinib also fully abrogated ERK activation at concentrations of 0.1M for as long as 120 hours. Authors note that inhibitory effects were more pronounced in cells treated with trametinib than cells treated with selumetinib."	"Selt et al., 2017, Oncotarget"	Somatic	ENST00000440172.1	transcript_fusion
BRAF P731T	BRAF	P731T	Cancer	Vemurafenib	Predictive	Does Not Support	C	Sensitivity/Response	chr7	140734707	140734707	G	T	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion."	"Hainsworth et al., 2018, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF A728V	BRAF	A728V			Functional	Supports	D	Gain of Function	chr7	140734715	140734715	G	A	"The BRAF mutation A728V (also known as A727V) resulted in elevated kinase activity relative to wild-type BRAF in vitro, as well as increased phosphorylation of ERK1/2 in COS cells. B-RAF activity was determined using kinase dead MEK as a substrate. A727V activity was 14 times higher than basal WT BRAF. The authors classified A727V activity as intermediate, since its kinase activity was between basal WT BRAF and G12V RAS-activated WT B-RAF cells. In comparison, some BRAF variants displayed high kinase activity above the G12V RAS-activated WT BRAF cells."	"Wan et al., 2004, Cell"	Unknown		missense_variant
BRAF G606E	BRAF	G606E	Cancer	Vemurafenib	Predictive	Does Not Support	C	Sensitivity/Response	chr7	140753318	140753318	C	T	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion."	"Hainsworth et al., 2018, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF K601E	BRAF	K601E	Skin Melanoma	"Trametinib,Vemurafenib"	Predictive	Supports	D	Sensitivity/Response	chr7	140753334	140753334	T	C	"Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutantexpressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling."	"Dahlman et al., 2012, Cancer Discov"	Somatic	ENST00000288602.6	missense_variant
BRAF V600D	BRAF	V600D	Melanoma	Dabrafenib	Predictive	Supports	B	Sensitivity/Response	chr7	140753335	140753336	CA	AT	Patients with other BRAF V600 mutations also respond well to the V600E drug dabrafenib.	"Ponti et al., 2013, J. Clin. Pathol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600D	BRAF	V600D	Melanoma	Vemurafenib	Predictive	Supports	D	Sensitivity/Response	chr7	140753335	140753336	CA	AT	"In an in vitro study, WM2664, a BRAF V600D expressing cell line, demonstrated improved sensitivity to vemurafenib treatment, compared to BRAF wild-type expressing cells. Sensitivity was determined by assessing cell proliferation (WM2664, GI50: 1.5uM; vs. BRAF expressing cells (n=9) GI50: 10-41uM)."	"Tsai et al., 2008, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000288602.6	missense_variant
BRAF V600D	BRAF	V600D	Melanoma	Vemurafenib	Predictive	Supports	D	Sensitivity/Response	chr7	140753335	140753336	CA	AT	"In an in vitro study, the WM2664 and WM239A cell lines expressing BRAF V600D were associated with increased sensitivity to vemurafenib treatment, as compared to cell lines expressing BRAF wild-type. Sensitivity was determined by proliferation assay. In addition, vemurafenib treatment strongly inhibited MEK and ERK phosphorylation in WM2664 cells."	"Yang et al., 2010, Cancer Res."	Somatic	ENST00000288602.6	missense_variant
BRAF V600D	BRAF	V600D	Melanoma	BRAF Inhibitor	Predictive	Supports	C	Sensitivity/Response	chr7	140753335	140753336	CA	AT	"In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated with BRAF inhibitor monotherapy, response rate were 27%(4/15) for V600R, 100%(2/2) for V600D, 0% (0/2) for V600_K601>E, 0% (0/1) for V600G, 0% (0/1) for V600L, 0% (0/9) for V600_S602>DT, 0% (0/5) for L597, 0% (0/6) for K601E, 0% (0/2) for G469, 0% (0/1) for G593D,and 0% (0/1) for T599_V600insT Treated with MEK inhibitor monotherapy, response rate were 100% (1/1) for L597, and 0% (0/1) for K601E. Treated with BRAF inhibitor and MEK inhibitor combination thearpy, response rate were 55% (16/29) for V600R, 67% (2/3) for V600D, 50% (1/2) for V600_K601>E, 50% (1/2) for V600M, 22% (2/9) for L597,25% (1/4) for K601E, 67% (2/3) for G469, and 0% (0/1) for A598V."	"Menzer et al., 2019, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600D	BRAF	V600D	Melanoma	"BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor"	Predictive	Supports	C	Sensitivity/Response	chr7	140753335	140753336	CA	AT	"In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated with BRAF inhibitor monotherapy, response rate were 27%(4/15) for V600R, 100%(2/2) for V600D, 0% (0/2) for V600_K601>E, 0% (0/1) for V600G, 0% (0/1) for V600L, 0% (0/1) for V600_S602>DT, 0% (0/5) for L597, 0% (0/6) for K601E, 0% (0/2) for G469, 0% (0/1) for G593D,and 0% (0/1) for T599_V600insT Treated with MEK inhibitor monotherapy, response rate were 100% (1/1) for L597, and 0% (0/1) for K601E. Treated with BRAF inhibitor and MEK inhibitor combination thearpy, response rate were 55% (16/29) for V600R, 67% (2/3) for V600D, 50% (1/2) for V600_K601>E, 50% (1/2) for V600M, 22% (2/9) for L597,25% (1/4) for K601E, 67% (2/3) for G469, and 0% (0/1) for A598V."	"Menzer et al., 2019, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600	BRAF	V600	Melanoma		Diagnostic	Supports	B	Positive	chr7	140753336	140753337			BRAF mutations are associated with melanoma arising in non-chronic sun damaged skin and with superficial spreading melanoma.	"Lee et al., 2011, Br. J. Dermatol."	Somatic	ENST00000288602.6	protein_altering_variant
BRAF V600E	BRAF	V600E	Thyroid Gland Cancer		Diagnostic	Supports	B	Positive	chr7	140753336	140753336	A	T	BRAF V600E is shown to be associated with the tall-cell variant of papillary thyroid cancer.	"Howell et al., 2011, Ann. Surg. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Thyroid Gland Papillary Carcinoma		Diagnostic	Supports	B	Positive	chr7	140753336	140753336	A	T	Thyroid nodule with BRAF V600E mutation is highly correlated with papillary thyroid cancer.	"Crescenzi et al., 2014, Horm. Metab. Res."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Melanoma		Prognostic	Does Not Support	B	Poor Outcome	chr7	140753336	140753336	A	T	BRAF status does not predict outcome in patients treated with dacarbazine or temozolomide.	"Meckbach et al., 2014, PLoS ONE"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Melanoma	"Trametinib,Mirdametinib"	Predictive	Does Not Support	D	Resistance	chr7	140753336	140753336	A	T	"In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP but does not show resistance to MEK inhibitors."	"Nissan et al., 2014, Cancer Res."	Somatic	ENST00000288602.6	missense_variant
BRAF V600	BRAF	V600	Colorectal Cancer	Panitumumab	Predictive	Supports	B	Resistance	chr7	140753336	140753337			"In metastatic colorectal cancer patients with wildtype KRAS, BRAF mutations were associated with poor progression free survival regardless of treatment (panitumumab with best supportive care or best supportive care alone)."	"Peeters et al., 2013, Clin. Cancer Res."	Somatic	ENST00000288602.6	protein_altering_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	"Sorafenib,Panitumumab"	Predictive	Supports	D	Sensitivity/Response	chr7	140753336	140753336	A	T	Cetuximab or panitumumab may be ineffective in patients with BRAF mutation unless BRAF inhibitor such as Sorafenib is introduced.	"Di Nicolantonio et al., 2008, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Melanoma	Vemurafenib	Predictive	Supports	D	Resistance	chr7	140753336	140753336	A	T	"In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP and resistance to RAF inhibitors."	"Nissan et al., 2014, Cancer Res."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Lung Non-small Cell Carcinoma	Dabrafenib	Predictive	Supports	C	Resistance	chr7	140753336	140753336	A	T	"In a patient with V600E-positive NSCLC, KRAS G12D seemed to confer resistance to dabrafenib."	"Rudin et al., 2013, J Thorac Oncol"	Somatic	ENST00000288602.6	missense_variant
BRAF V600	BRAF	V600	Melanoma	"Trametinib,Dabrafenib"	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753337			"This was a Phase I and II study (NCT01072175) of dabrafenib and trametinib combination therapy vs. dabrafenib monotherapy in patients with metastatic melanoma.    Cutaneous squamous-cell carcinoma was seen in 7% of patients receiving combination therapy in contrast to 19% in those receiving monotherapy (P = 0.09).  Of 162 patients with V600E or V600K mutation, 108 were given combination therapy and 54 monotherapy.  After 1 year, 41% of patients in the combination group were alive and progression free whereas this was 9% in the monotherapy group (P<0.001).   Median progression-free survival was 9.4 months with combination and 5.8 months with monotherapy. Hazard ratio for progression or death was 0.39 (95% CI, 0.25 to 0.62; P<0.001)."	"Flaherty et al., 2012, N. Engl. J. Med."	Somatic	ENST00000288602.6	protein_altering_variant
BRAF V600E	BRAF	V600E	Melanoma	"Trametinib,Dabrafenib"	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	Dabrafenib with trametinib provides higher response rate and lower toxicity (as compared to chemotherapy) in patients with melanoma.	"Menzies et al., 2014, Clin. Cancer Res."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	"PLX4720,Pictilisib Bismesylate"	Predictive	Supports	D	Sensitivity/Response	chr7	140753336	140753336	A	T	Combined PI3K inhibitor GDC0941 and BRAF inhibitor PLX4720 administration to NSG mice subcutanousely injected with colorectal cell lines with a BRAF V600E mutation effectively inhibited tumor growth and reduced cellular proliferation.	"Rad et al., 2013, Cancer Cell"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	"PLX4720,Nutlin-3"	Predictive	Supports	D	Sensitivity/Response	chr7	140753336	140753336	A	T	Combined nutlin-3 and PLX4720 administration to athymic nude mice subcutanousely injected with the A357 colorectal cell line with a BRAF V600E mutation effectively inhibited tumor growth significantly more than single agent therapy.	"Ji et al., 2013, Clin. Cancer Res."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	"Bevacizumab,Vemurafenib,Capecitabine"	Predictive	Supports	D	Sensitivity/Response	chr7	140753336	140753336	A	T	"This in vivo study examined the efficacy of various treatments on athymic nude mice xenografted with colorectal cancer HT29 cells, which harbor BRAF V600E. The authors sought to understand whether the addition of vemurafenib (a BRAF V600E inhibitor) to agents approved for the treatment of metastatic colorectal cancer increased therapeutic efficacy, and which combinations worked best. Capecitabine, bevacizumab and vemurafenib combination therapy resulted in 100% tumor growth inhibition (TGI) and 190% increased lifespan (ILS) compared to vehicle treated controls. Seven mice experienced partial response and two experienced complete response. Triplet therapy resulted in better TGI and ILS compared to any agent in isolation or capecitabine + vemurafenib doublet therapy (p <0.05, p <0.0001, for all comparisons)."	"Yang et al., 2012, Cancer Res."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	Vemurafenib	Predictive	Supports	D	Sensitivity/Response	chr7	140753336	140753336	A	T	"This preclinical study examined vemurafenib efficacy on various colorectal cancer cell lines and in mouse xenograft experiments. Of the cell lines tested, six harbored BRAF V600E (and WT KRAS) and three harbored BRAF WT (but mutant KRAS). Of the six BRAF V600E expressing cell lines, four were sensitive to vemurafenib (IC50 ranging between 0.025 and 0.35 uM; HT29, Colo205, Colo741, LS411N). Cell lines expressing the BRAF V600E mutation responded better to vemurafenib treatment than cells wildtype for BRAF as measured by reduced cellular proliferation and inhibition of MET and ERK phosphorylation (none of the three BRAF wt cell lines had IC50s less than 10uM). Authors note that one of the vemurafenib-resistant cell lines harboring BRAF V600E (RKO) harbored a concurrent activating PIK3CA H1047R mutation. Nude, athymic mice with HT29 xenografts treated with vemurafenib experienced substantial tumor inhibition and increased lifespan at every dose tested, though authors found 75 mg/kg twice daily to be optimal (95% tumor growth inhibition, 90% increased lifespan compared to vehicle treated controls)."	"Yang et al., 2012, Cancer Res."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Thyroid Gland Papillary Carcinoma		Prognostic	Does Not Support	B	Poor Outcome	chr7	140753336	140753336	A	T	"Unlike other studies that suggest a poorer outcome, BRAF mutation in this study was not correlated with poorer prognosis in papillary thyroid cancer."	"Walczyk et al., 2014, Clin. Endocrinol. (Oxf)"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer		Prognostic	Supports	B	Poor Outcome	chr7	140753336	140753336	A	T	V600E is associated with adverse pathological features of colorectal cancer. This can be concluded as a marker of poor prognosis.	"Chen et al., 2014, PLoS ONE"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Melanoma		Prognostic	Supports	B	Poor Outcome	chr7	140753336	140753336	A	T	BRAF V600E is correlated with shorter disease-free and overall Survival in a Spanish cohort of melanoma patients.	"Nagore et al., 2014, J. Am. Acad. Dermatol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Thyroid Gland Papillary Carcinoma		Prognostic	Supports	B	Poor Outcome	chr7	140753336	140753336	A	T	BRAF mutation correlated with poor prognosis in papillary thyroid cancer in both older (>65 yo) and younger (<65 yo) cohorts.	"Howell et al., 2011, Ann. Surg. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Thyroid Gland Papillary Carcinoma		Prognostic	Supports	B	Poor Outcome	chr7	140753336	140753336	A	T	BRAF V600E is correlated with poor prognosis in papillary thyroid cancer in a study of 187 patients with PTC and other thyroid diseases.	"He et al., 2014, Oncol Lett"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Thyroid Gland Papillary Carcinoma		Prognostic	Supports	B	Poor Outcome	chr7	140753336	140753336	A	T	V600E is correlated with disease recurrence in both age cohorts (>65 and <65 yo).	"Howell et al., 2011, Ann. Surg. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Resistance	chr7	140753336	140753336	A	T	"This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 30 patients harbored BRAF V600E, were KRAS, NRAS and PIK3CA wt, and had individual response data. One patient (who harbored BRAF V600E in low copy number) responded, 11 had stable disease, and 18 progressed. Treatments included cetuximab + irinotecan (n=20), cetuximab monotherapy (n=5), cetuximab + FOLFIRI (n=4), and cetuximab + oxaliplatin + 5FU (n=1). Median PFS was 8 weeks (2-32 weeks), median OS was 25 weeks (4-237 weeks), and median number of previous chemotherapy lines was 2 (0-4). Median age was 61 years old (42-78) and there were 16 males and 14 females. Authors concluded that BRAF mutation (23/24 of mutants were BRAF V600E) was strongly associated with poor response to cetuximab and suggested that mutation status of BRAF is more informative than those of NRAS and PIK3CA exon 20 for predicting cetuximab response (second only to KRAS)."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Multiple Myeloma		Prognostic	Supports	B	Poor Outcome	chr7	140753336	140753336	A	T	"In patients with multiple myeloma, those with BRAF V600E had shorter overall survival than wild-type."	"Andrulis et al., 2013, Cancer Discov"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Thyroid Gland Papillary Carcinoma		Prognostic	Supports	B	Poor Outcome	chr7	140753336	140753336	A	T	"In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T (N=35), recurrence-free survival is worse than in patients harboring one of these mutations (N=159 BRAF, N=26 TERT promoter mutated) or no mutations in either gene (N=287)(P<0.001)."	"Xing et al., 2014, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Melanoma	Pictilisib	Predictive	Supports	C	Sensitivity/Response	chr7	140753336	140753336	A	T	"One patient with BRAF V600E mutated melanoma (with no detected PI3K pathway deregulation) had a partial response on treatment with pictilisib, a PI3K inhibitor, for 9.5 months. Study was a phase-1 with 60 patients enrolled."	"Sarker et al., 2015, Clin. Cancer Res."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	"Cetuximab,Panitumumab"	Predictive	Does Not Support	B	Resistance	chr7	140753336	140753336	A	T	"This meta-analysis of 7 randomized control trials evaluating overall survival (OS) (8 for progression free survival) could not definitely state that survival benefit of anti-EGFR monoclonal antibodies is limited to patients with wild type BRAF. In other words, the authors believe that there is insufficient data to justify the exclusion of anti-EGFR monoclonal antibody therapy for patients with mutant BRAF. In these studies, mutant BRAF specifically meant the V600E mutation."	"Rowland et al., 2015, Br. J. Cancer"	Somatic	ENST00000288602.6	missense_variant
BRAF Mutation	BRAF	Mutation	Cancer	Trametinib	Predictive	Supports	D	Sensitivity/Response	chr7	140753336	140781603			"In this screen of 218 solid cancer cell lines, BRAF mutations were predictive of response to the MEK inhibitor GSK1120212. 26 of these cell lines had the BRAF V600E mutation, one cell line had a G469A mutation, one had G596R mutation and one had an unspecified mutation. Also of note, in RAF/RAS mutant colon cancer cell lines, co-occurring PIK3CA/PTEN mutations led to a cytostatic response rather than a cytotoxic response."	"Jing et al., 2012, Mol. Cancer Ther."	Somatic	ENST00000288602.6	"gene_variant,gain_of_function_variant"
BRAF V600E	BRAF	V600E	Melanoma	MEK Inhibitor RO4987655	Predictive	Does Not Support	B	Resistance	chr7	140753336	140753336	A	T	"This was a phase I expansion and pharmacodynamic study of oral MEK inhibitor RO4987655 on advanced cancer. Of 17 patients with BRAF V600E melanoma, 4 achieved partial response, 5 experienced stable disease lasting longer than 16 weeks, and 8 experienced disease progression (including 2 with prior vemurafenib treatment). One of the partial responders had a concomitant EGFR mutation, and two of the stable disease patients had other concomitant mutations (in RET or MET). The median days on treatment was 113 (18-366) for BRAF V600E melanoma patients and 107 (17-323) for BRAF V600 wildtype patients (n=23). Patients with BRAF V600E mutant melanoma experienced similar response rates (24% vs 20%) and rates of metabolic response measured by decrease in FDG uptake assessed by FDG-PET (86% vs 75%) compared to non-BRAF mutant patients. Patients with melanoma, either BRAF wt or V600E, experienced significant decreases in Ki67 expression by day 15 of MEK inhibitor treatment (P<0.02). The authors conclude that RO4987655 has clinical activity in BRAF V600E and BRAF wt melanoma."	"Zimmer et al., 2014, Clin. Cancer Res."	Somatic	ENST00000288602.6	missense_variant
BRAF V600	BRAF	V600	Melanoma	Refametinib	Predictive	Supports	C	Resistance	chr7	140753336	140753337			Phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766. 2 of 2 patients with BRAF mutant melanoma had moderate progressive disease (despite receiving the highest doses administered in the study).	"Weekes et al., 2013, Clin. Cancer Res."	Somatic	ENST00000288602.6	protein_altering_variant
BRAF V600E	BRAF	V600E	Melanoma	"Dactolisib,Selumetinib"	Predictive	Supports	D	Sensitivity/Response	chr7	140753336	140753336	A	T	"49 BRAF-mutant melanoma cell lines from patients not previously treated with BRAF inhibition were analyzed. 21 exhibited primary resistance to BRAF inhibition using PLX4720. Inhibition of MEK1/2 (AZD6244 [selumetinib]) and PI3K/mTOR (BEZ235 [dactolisib]) was the most effective approach to counteract resistance in comparison to inhibition with the PLX4720 (progenitor of vemurafenib)-BEZ235 (where response was assessed by apoptosis, viability, p-ERK, p-Akt inhibition)."	"Penna et al., 2016, Oncotarget"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Hairy Cell Leukemia		Diagnostic	Supports	B	Positive	chr7	140753336	140753336	A	T	"In 47 patients with Hairy Cell Leukemia, sequencing discovered a V600E mutation in all 47 of the sequenced patients."	"Tiacci et al., 2011, N. Engl. J. Med."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Cancer	Cobimetinib	Predictive	Supports	D	Sensitivity/Response	chr7	140753336	140753336	A	T	"Preclinical study analyzing the differential response to MEK inhibitors in KRAS and BRAF mutant cancer cell lines and mouse xenografts. Inhibition of active, phosphorylated MEK by GDC-0973 (cobimetinib) is required for strong inhibition of the MAPK pathway in BRAF-mutant tumours. This study provides mechanistic rationale for improved efficacy of cobimetinib in BRAF-mutant models compared to MEK inhibitors acting through an alternative mechanism (GDC-0623 and G-573)."	"Hatzivassiliou et al., 2013, Nature"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Melanoma	Vemurafenib	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	The BRIM-3 Phase III trial NCT01006980 assessed BRAF inhibitor vemurafenib versus dacarbazine in 598 patients with treatment naive metastatic melanoma and confirmed V600E mutation. Significant differences were seen in overall survival (13.3 months with vemurafenib vs. 10.0 months with dacarbazine) and median progression free survival (6.9 months  with vemurafenib vs. 1.6 months with dacarbazine)	"McArthur et al., 2014, Lancet Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600K	BRAF	V600K	Melanoma	Vemurafenib	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753337	AC	TT	"In the Phase III study of vemurafenib versus dacarbazine BRIM-3 (NCT01006980) in metastatic melanoma, 57 patients were confirmed to have V600K mutation. In this subgroup of treatment-naive patients, significant differences were seen in overall survival (14.5 months with vemurafenib vs. 7.6 months with dacarbazine), as well as median progression free survival (5.9 months with vemurafenib vs. 1.7 months with dacarbazine)."	"McArthur et al., 2014, Lancet Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600K	BRAF	V600K	Melanoma	Vemurafenib	Predictive	Supports	C	Sensitivity/Response	chr7	140753336	140753337	AC	TT	"A 53 year old male presented with a scalp lesion which was incompletely excised. Metastases were seen in lymph node biopsy and subsequently in CT. BRAF inhibitor vemurafenib was then administered at 960 mg twice daily and later at 720 mg twice daily and reduction in metastases was observed. After 2 years complete radiological response was seen, while treatment was discontinued due to cardiomyopathy. 12 months after stopping vemurafenib patient did not show evidence of metastatic melanoma."	"Sahadudheen et al., 2016, Case Rep Oncol Med"	Somatic	ENST00000288602.6	missense_variant
BRAF Mutation	BRAF	Mutation	Colorectal Cancer	"Panitumumab,Cetuximab"	Predictive	Does Not Support	B	Sensitivity/Response	chr7	140753336	140781603			"A quantitative synthesis was performed on nine studies comparing treatment of metastatic colorectal cancer with cetuximab or panitumumab and chemotherapy, versus chemotherapy alone, or with other targeted inhibitors. It was found that in the patient subgroup with BRAF mutation (V600E in the majority of cases), there were no benefits to overall survival, progression free survival, or overall response rate with addition of cetuximab or panitumumab to treatment. This conclusion held in the first line treatment as well as general treatment setting."	"Pietrantonio et al., 2015, Eur. J. Cancer"	Somatic	ENST00000288602.6	"gene_variant,gain_of_function_variant"
BRAF V600E	BRAF	V600E	Colorectal Cancer	Vemurafenib	Predictive	Does Not Support	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"In this Phase II pilot study (NCT00405587) of BRAF V600 inhibitor vemurafenib in 21 metastatic colorectal cancer (CRC) patients with BRAF V600E, one patient had a durable 21 week partial response, and seven patients had 8 week stable disease as best response. Median progression free survival was 2.1 months and median overall survival was 7.7 months. The authors conclude that single agent vemurafenib did not show meaningful activity in V600E CRC, in contrast to the significant vemurafenib activity against V600 in melanoma."	"Kopetz et al., 2015, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	Dabrafenib	Predictive	Does Not Support	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"In trial NCT00880321, dabrafenib was tested in various solid tumor types harboring mutant BRAF after establishing dosage of 150 mg twice daily. In nine colorectal cancer patients with established V600E mutation, 1 confirmed response, 7 instances of stable disease, and 1 case of progressive disease was seen, which contrasted strongly with a 56% confirmed response rate seen in metastatic V600E melanoma patients similarly treated in the same study."	"Falchook et al., 2012, Lancet"	Somatic	ENST00000288602.6	missense_variant
BRAF V600	BRAF	V600	Melanoma	Dabrafenib	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753337			"In the NCT00880321 trial using mutant BRAF inhibitor dabrafenib in solid tumors, 10 cases of melanoma brain metastases were assessed for dabrafenib response. In nine patients a decrease in size of metastases was seen, and in four cases a complete resolution of brain lesions was observed. This subset of patients had median progression free survival of 4.2 months."	"Falchook et al., 2012, Lancet"	Somatic	ENST00000288602.6	protein_altering_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	"Cetuximab,Gefitinib,Vemurafenib"	Predictive	Supports	D	Sensitivity/Response	chr7	140753336	140753336	A	T	"5 of 7 colorectal cancer (CRC) cell lines with BRAF V600E mutation were resistant to treatment with the BRAF inhibitor vemurafenib. An RNAi screen in the WiDr cell line (a V600E CRC line) identified EGFR as an enhancer for survival when exposed to vemurafenib.  Treatment with vemurafenib and EGFR inhibitor (cetuximab or gefitinib) in V600E CRC cells (WiDr, VACO432 and KM20) showed inhibited growth as well as induction of the cleaved PARP apoptotic marker. WiDr and VACO432 cells were injected into immunodeficient mice. Modest response was seen with vemurafenib treatment, while combination treatment showed considerable tumor growth inhibition as compared to control."	"Prahallad et al., 2012, Nature"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Skin Melanoma	Vemurafenib	Predictive	Supports	A	Sensitivity/Response	chr7	140753336	140753336	A	T	"Phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation. At 6 months, overall survival was 84% (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group. A relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression was observed with vemurafenib as compared with dacarbazine (P<0.001 for both comparisons)."	"Chapman et al., 2011, N. Engl. J. Med."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Skin Melanoma	Vemurafenib	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"Phase 2 trial in 132 patients with previously treated metastatic melanoma with BRAF V600E mutation.  Confirmed overall response rate was 53% (95% confidence interval [CI], 44 to 62; 6% with a complete response and 47% with a partial response), median duration of response was 6.7 months (95% CI, 5.6 to 8.6), and median progression-free survival was 6.8 months (95% CI, 5.6 to 8.1). Median overall survival was 15.9 months (95% CI, 11.6 to 18.3)."	"Sosman et al., 2012, N. Engl. J. Med."	Somatic	ENST00000288602.6	missense_variant
BRAF V600	BRAF	V600	Skin Melanoma	"Trametinib,Dabrafenib"	Predictive	Supports	A	Sensitivity/Response	chr7	140753336	140753337			"The Combi-v (NCT01597908) open-label, randomized phase 3 trial had 704 patients with metastatic melanoma with a BRAF V600 mutation. Patients were randomized to receive either a combination of dabrafenib and trametinib or vemurafenib orally as first-line therapy. At preplanned interim analysis the overall survival rate at 12 months was 72% (95% confidence interval [CI], 67 to 77) in the combination-therapy group and 65% (95% CI, 59 to 70) in the vemurafenib group (hazard ratio for death in the combination-therapy group, 0.69; 95% CI, 0.53 to 0.89; P=0.005). Median progression-free survival was 11.4 months in the combination-therapy group and 7.3 months in the vemurafenib group (hazard ratio, 0.56; 95% CI, 0.46 to 0.69; P<0.001). Cutaneous squamous-cell carcinoma and keratoacanthoma occurred at 1% with combination-therapy and 18% in the vemurafenib group."	"Robert et al., 2015, N. Engl. J. Med."	Somatic	ENST00000288602.6	protein_altering_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	"Panitumumab,Vemurafenib"	Predictive	Does Not Support	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"Treatment response to mutant BRAF inhibitor vemurafenib and EGFR inhibitor panitumumab was assayed in 12 patients with metastatic colorectal cancer (CRC) who had progressed on chemotherapy. Two patients had confirmed partial responses, and 2 showed stable disease over 6 months. The authors conclude that although some efficacy is seen, only a small subset of patients respond to this treatment and the responses are not durable."	"Yaeger et al., 2015, Clin. Cancer Res."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Thyroid Gland Papillary Carcinoma	Vemurafenib	Predictive	Supports	C	Sensitivity/Response	chr7	140753336	140753336	A	T	"A 73 year old patient with prior history of breast cancer presented with metastatic papillary thyroid carcinoma. After two treatments of I-131 a comprehensive tumor profile revealed BRAF V600E as the only genetic alteration on a near diploid genome with trisomy 1q. Vemurafenib treatment resulted in improvement of symptoms and considerable reductions in tumor mass, and after 23 months the patient remained on therapy with well controlled disease."	"Ali et al., 2014, Case Rep Oncol"	Somatic	ENST00000288602.6	missense_variant
BRAF V600	BRAF	V600	Colorectal Cancer	"Trametinib,Dabrafenib"	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753337			"In clinical trial NCT01072175, 43 patients with BRAF V600 metastatic colorectal cancer (CRC) received mutant BRAF inhibitor dabrafenib and MEK inhibitor trametinib. Only 12% of patients showed  partial response or better, with one complete response lasting 36 months and ongoing after data cutoff. 56% of patients achieved stable disease. The median progression free survival (PFS) was 3.5 months, longer than the median PFS (2.5 months) reported for metastatic CRC treated with standard chemotherapy. The authors conclude that MAPK targeting in CRC is a valid approach that can produce meaningful responses but additional work is required to more effectively inhibit the pathway."	"Corcoran et al., 2015, J. Clin. Oncol."	Somatic	ENST00000288602.6	protein_altering_variant
BRAF V600E	BRAF	V600E	Melanoma	"Vemurafenib,Cobimetinib"	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"In this Phase III trial (coBRIM, NCT01689519) of 495 V600 mutant melanoma patients, 344 had V600E mutation. 174 patients were treated with vemurafenib and placebo, and 170 were treated with vemurafenib and cobimetinib and tested for progression free survival. 88 of 174 monotherapy group patients had an event with median progression free survival of 6.5 months. In the combination group 58 of 174 patients had an event with median progression-free survival not met, however, when in combination with other V600 mutations median progression-free survival was 9.9 months with combination treatment. Median time to followup for the whole cohort was 7.3 months. Hazard Ratio for progression or death was 0.57 (0.41-0.80)."	"Larkin et al., 2014, N. Engl. J. Med."	Somatic	ENST00000288602.6	missense_variant
BRAF V600	BRAF	V600	Melanoma	"Cobimetinib,Vemurafenib"	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753337			"In a randomized phase 3 study, previously untreated advanced or metastatic BRAF V600 mutation-positive melanoma patients treated with combination vemurafenib and cobimetinib showed improved progression free survival (9.9 vs 6.2 months), increased rate of complete or partial response (68% vs 45%), and improved overall survival at 9 months ( 81% vs 73%) compared to the vemurafenib and placebo control group."	"Larkin et al., 2014, N. Engl. J. Med."	Somatic	ENST00000288602.6	protein_altering_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	"Dactolisib,GDC-0879"	Predictive	Supports	D	Sensitivity/Response	chr7	140753336	140753336	A	T	"In a mouse model of BRAF V600E colorectal cancer, western blots from tumors in mice treated with BRAF inhibitor GDC-0879 and PI3K/mTOR inhibitor BEZ235 showed stronger reduction in phospho-Akt and phospho-S6 than PI3K/mTOR inhibitor alone, and combination inhibition also resulted in stronger phospho-ERK inhibition in tumors than did BRAF inhibition alone. Increased apoptosis in tumors was seen in dual treatment conditions with increased TUNEL-positive cells. In vehicle treated mice, area of colon covered by tumor increased, while treatment with single agent inhibitors caused growth inhibition resulting in no change in colon area covered by tumors. Administration of dual inhibitors induced tumor regression apparent in a decrease of colonic area covered by tumors over the course of treatment."	"Coffee et al., 2013, Clin. Cancer Res."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Gastrointestinal Neuroendocrine Tumor	"Trametinib,Vemurafenib,Dabrafenib"	Predictive	Supports	C	Sensitivity/Response	chr7	140753336	140753336	A	T	"BRAF mutations were identified in 9% of 108 cases of high-grade colorectal neuroendocrine tumors (80% V600E). Two patients were treated with a combination of BRAF and MEK inhibition and exhibited durable response (beyond 7 and 9 months, respectively). Urinary BRAF V600E tumor DNA correlated with disease response in one of the patients. BRAF and MEK inhibition was either dabrafenib+trametinib (case 1) or vemurafenib+trametinib (case 2)."	"Klempner et al., 2016, Cancer Discov"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer		Prognostic	Supports	B	Poor Outcome	chr7	140753336	140753336	A	T	"In a study of 908 patients with colorectal cancer, 45 patients had BRAF V600E mutations and 589 patients were BRAF wild type.  BRAF V600E mutations were more likely to be proximal tumors (68.9%, 20.7%; p<0.0001), they were more likely to be poorly differentiated (17.7%, 1.9%; p<0.0001), they were more likely to be mucinous carcinoma type (20.0%, 4.2%; p=0.0003), they were more likely to have lymphatic invasion (77.6%, 49.9%; p=0.0003), and they had a shorter survival time (31.1 mo, 41.6 mo; p=0.001).  The 3-year survival rate was significantly poorer in the V600E group when compared to the wild type group (63.8%, 87.9%; p<0.0001)."	"Amaki-Takao et al., 2016, Oncology"	Somatic	ENST00000288602.6	missense_variant
BRAF V600	BRAF	V600	Lung Non-small Cell Carcinoma	Vemurafenib	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753337			"Patients with BRAF-V600 mutated cancers were identified (n=122) and clinical response to vemurafenib was evaluated. Of the 20 patients with non-small-cell-lung cancer (17 with BRAF V600E, one with BRAF V600G and one with BRAF V600 unknown status), 19 were evaluable and the response rate to vemurafenib was 42%, tumor regression was observed in 14/19 patients, progression-free survival was 7.3 months, and 12-month overall survival was 66%."	"Hyman et al., 2015, N. Engl. J. Med."	Somatic	ENST00000288602.6	protein_altering_variant
BRAF V600	BRAF	V600	Langerhans-cell Histiocytosis	Vemurafenib	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753337			"Patients with BRAF-V600 mutated cancers were identified (n=122) and clinical response to vemurafenib was evaluated.  Of the 14 patients with Langerhans?cell histiocytosis, 43% of patients had a response to vemurafenib (1 complete and 5 partial responses), disease regression was observed in 12/14 patients, all patients detailed improvement in disease-related symptoms, 0 patients had progressive disease during treatment, 12-month progression free survival was 91%, and overall survival rate was 100%. Among all 18 patients with Erdheim-Chester disease or Langerhans histiocytosis, 94% had BRAF V600E mutations and the remaining 6 percent (1 patient) had an unknown V600 mutation."	"Hyman et al., 2015, N. Engl. J. Med."	Somatic	ENST00000288602.6	protein_altering_variant
BRAF V600	BRAF	V600	Colorectal Cancer	Vemurafenib	Predictive	Supports	B	Resistance	chr7	140753336	140753337			"Patients with BRAF-V600 mutated cancers were identified (n=122) and clinical response to vemurafenib was evaluated.  Of the 10 patients with colorectal cancer (80% BRAF V600E, 20% V600 unknown status), no responses were observed and overall survival was 9.3 months with a median progression-free survival of 4.5 months."	"Hyman et al., 2015, N. Engl. J. Med."	Somatic	ENST00000288602.6	protein_altering_variant
BRAF V600E	BRAF	V600E	Hairy Cell Leukemia	Vemurafenib	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"Two clinical trials evaluated the effects of vemurafenib in 54 patients with BRAF (V600E) positive hairy-cell leukemia.  The overall response rate was 98% with 19/54 having a complete response and 34/54 having a partial response.  In the Italian study (n=25), the median relapse-free survival was 9 months and in the U.S. study (n=24), rate of progression-free survival was 73% with overall survival rate of 91%."	"Tiacci et al., 2015, N. Engl. J. Med."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	"Vemurafenib,Panitumumab"	Predictive	Supports	C	Sensitivity/Response	chr7	140753336	140753336	A	T	Case report of a patient with BRAF V600E mutant metastatic colorectal cancer. Combined EGFR and BRAF inhibition (panitumumab and vemurafenib) showed an initial partial response for 4 months with subsequent disease progression.	"Pietrantonio et al., 2016, Cancer Discov"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Thyroid Gland Papillary Carcinoma	Vemurafenib	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"Open-label non-randomised phase 2 trial in patients with recurrent or metastatic BRAF V600E mutant papillary thyroid cancer refractory to radioactive iodine. Patients had (cohort 2) or had not (cohort 1) previously been treated with VEGFR inhibitors. 51 patients were enrolled (26 cohort 1, 25 cohort 2). In cohort 1, partial response was achieved in ten (38.5%) patients. Nine patients achieved stable disease for at least 6 months (35%). Median PFS was 18.2 months and median OS not reached after a median follow-up pf 18.8 months. In cohort 2, six patients (27.3%) achieved a partial response and another six patients achieved stable disease for at least six months. Median PFS was 8.9 months and median OS was 14.4. months."	"Brose et al., 2016, Lancet Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600	BRAF	V600	Colorectal Cancer	"Cetuximab,Vemurafenib"	Predictive	Does Not Support	B	Sensitivity/Response	chr7	140753336	140753337			"Patients with BRAF-V600 mutated cancers were identified (n=122) and subsequently underwent targeted therapy. 27 patients with colorectal cancer were treated with vemurafenib and cetuximab (N=24 with BRAF V600E mutation, N=3 with V600 unknown status). One response was observed; however, approximately half the patients had tumor regression that did not meet the standard criteria for a partial response. Median progression-free survival and overall survival for patients receiving combination therapy were 3.7 months (95% CI, 1.8 to 5.1) and 7.1 months (95% CI, 4.4 to not reached), respectively. Patients were heavily pretreated, with a median of two lines of previous therapy (range, one to six)."	"Hyman et al., 2015, N. Engl. J. Med."	Somatic	ENST00000288602.6	protein_altering_variant
BRAF V600E	BRAF	V600E	Multiple Myeloma	Vemurafenib	Predictive	Supports	C	Sensitivity/Response	chr7	140753336	140753336	A	T	"A 65-year-old man presented with stage II myeloma.  He was initially treated with chemotherapy and he received an autologous stem cell transplant. Sequencing of the recurrent tumor harbored BRAF V600E mutation and he was treated with vemurafenib.  After 7 weeks of treatment, the patient relapsed and died."	"Sharman et al., 2014, Clin Lymphoma Myeloma Leuk"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Multiple Myeloma	Vemurafenib	Predictive	Supports	C	Sensitivity/Response	chr7	140753336	140753336	A	T	A 54-year-old man presented with stage II myeloma.  He was initially treated with chemotherapy and received an autologous stem cell transplant.  Genomic profiling of the bone biopsy revealed BRAF V600E activating mutation and the patient was treated with vemurafenib.  At 4-months post treatment (time of case study report) the patient maintains near-resolution of hypermetabolic lesions.	"Sharman et al., 2014, Clin Lymphoma Myeloma Leuk"	Somatic	ENST00000288602.6	missense_variant
BRAF Mutation	BRAF	Mutation	Colorectal Cancer	Cetuximab	Predictive	Supports	D	Resistance	chr7	140753336	140781603			"A cohort of patient-derived xenografts (PDX) from 85 patients with metastatic colorectal cancer was created. PDX were treated with cetuximab and mechanisms of resistance investigated. None of the xenografts harboring KRAS (N=18), NRAS (N=7) or BRAF (N=3) mutations showed a response to cetuximab whereas 1 out of 4 xenografts with a PIK3CA mutation responded to cetuximab."	"Bertotti et al., 2011, Cancer Discov"	Somatic	ENST00000288602.6	"gene_variant,gain_of_function_variant"
BRAF V600E	BRAF	V600E	Melanoma	Vemurafenib	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"Multicenter, phase 1, dose-escalation trial of PLX4032 (Vemurafenib). Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients (N=37/48). Patients without the V600E mutation had evidence of tumor regression."	"Flaherty et al., 2010, N. Engl. J. Med."	Somatic	ENST00000288602.6	missense_variant
BRAF V600	BRAF	V600	Melanoma	Trametinib	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753337			"Patients who had histologically confirmed, unresectable stage IIIC or IV cutaneous melanoma with a V600E or V600K BRAF mutation were eligible for the study. 322 eligible patients (281 with the V600E mutation, 40 with the V600K mutation, and 1 with both mutations) in a 2:1 ratio to receive oral trametinib (2 mg once daily) or intravenous chemotherapy consisting of either dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square meter), at the discretion of the investigator, every 3 weeks. The primary end point was progression-free survival; secondary end points included overall survival, overall response rate, duration of response, and safety. Treatment continued until disease progression, death, or withdrawal from the study. In the intention-to-treat population, the median duration of progression-free survival was 4.8 months in the trametinib group as compared with 1.5 months in the chemotherapy group (hazard ratio for progression, 0.45; 95% confidence interval [CI], 0.33 to 0.63; P<0.001).  The 6-month overall survival rate in the intention-to-treat population was 81% in the trametinib group and 67% in the chemotherapy group."	"Flaherty et al., 2012, N. Engl. J. Med."	Somatic	ENST00000288602.6	protein_altering_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	"Vemurafenib,Cetuximab,Irinotecan"	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 patients with colorectal cancer (1 with appendiceal cancer). Six of 17 evaluable patients achieved an objective response, 15 patients total had either stable disease or radiographic response (the patient with appendiceal cancer had disease progression). Estimated median PFS was 7.7 months. Effect of the combined treatment was also observed in xenograft and cell line studies."	"Hong et al., 2016, Cancer Discov"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer		Prognostic	Supports	B	Poor Outcome	chr7	140753336	140753336	A	T	"In a study of 468 colorectal cancer samples, 61 patients had micro-satellite instability and there was a statistically significantly better prognosis for BRAF WT patients relative to BRAF (V600E)-mutated patients (Log-rank P=0.0903)."	"Schell et al., 2016, Nat Commun"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	"Cetuximab,Panitumumab"	Predictive	Supports	B	Resistance	chr7	140753336	140753336	A	T	"In metastatic colorectal cancer patients with wildtype KRAS status, those with a BRAF V600E mutation were less likely to respond to treatment with cetuximab or panitumumab than  those with wildtype BRAF (0%  vs. 32% , P=0.029). Regardless of KRAS status, patients with BRAF mutations had reduced progression-free and overall survival (P=0.0107 and P <0.0001, respectively). Transfection of the colorectal cancer cell line DiFi with a BRAF V600E expression vector conferred decreased sensitivity to cetuximab and panitumumab in comparison to cells transfected with empty vector."	"Di Nicolantonio et al., 2008, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer		Predictive	Supports	B	Resistance	chr7	140753336	140753336	A	T	"In a study of metastatic colorectal cancer patients who received 5-FU-based first-line chemotherapy, those with BRAF V600E mutations had reduced progression-free survival (4.3mo vs. 12.5mo, HR:4.9, 95%CI:2.7-9.0, P<0.0001, univariate analysis; HR:4.0, 95%CI:2.2-7.4, P<0.0001, multivariate analysis) and reduced overall survival (10.9mo vs. 40.5mo, HR:4.5, 95%CI:2.4-8.4, P<0.0001, univariate analysis; HR:4.1, 95%CI:2.1-8.0, P<0.0001, multivariate analysis) compared to those with wildtype BRAF."	"Souglakos et al., 2009, Br. J. Cancer"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	Oxaliplatin	Predictive	Supports	B	Resistance	chr7	140753336	140753336	A	T	"Of 100 metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, the 6 patients with either BRAF V600E or D594K had reduced progression-free survival compared to 94 patients with wildtype BRAF (5.0mo vs. 11.7mo, HR:6.4, 95%CI:2.6-15.6, P<0.0001)."	"Souglakos et al., 2009, Br. J. Cancer"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	Irinotecan	Predictive	Supports	B	Resistance	chr7	140753336	140753336	A	T	"The presence of BRAF V600E or D594K was associated with reduced progression-free survival in 5 patients with metastatic colorectal cancer treated with irinotecan-based first line therapy (3.5mo vs. 12.8mo, HR:4.1, 95%CI:1.5-11.3, P=0.006) when compared to 39 patients with wildtype BRAF."	"Souglakos et al., 2009, Br. J. Cancer"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	"Oxaliplatin,Capecitabine,Bevacizumab"	Predictive	Supports	B	Resistance	chr7	140753336	140753336	A	T	"In a study of metastatic colorectal cancer patients treated with capecitabine, oxaliplatin, and bevacizumab, those with BRAF V600E mutations had reduced progression-free survival (5.9mo vs. 12.2mo, P=0.003) and reduced overall survival (15.0mo vs. 24.6mo, P=0.002) compared to those with wildtype BRAF."	"Tol et al., 2009, N. Engl. J. Med."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Melanoma	Trametinib	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"In a study of 322 advanced melanoma patients with BRAF-V600E (N=281), BRAF-V600K (N=40), or both mutations (N=1), treatment with trametinib was associated with improved progression-free survival (4.8mo vs. 1.5mo; HR: 0.45, 95% CI: 0.33-0.63, P<0.001) compared to chemotherapy control group. Additionally, treatment with trametinib was associated with increased 6-month overall survival (HR: 0.54, 95% CI: 0.32-0.92, P=0.01). The authors note similar outcomes for the primary efficacy population (V600E only) and the intention-to-treat population."	"Flaherty et al., 2012, N. Engl. J. Med."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Thyroid Gland Papillary Carcinoma		Prognostic	Supports	B	Poor Outcome	chr7	140753336	140753336	A	T	"In a study of 102 papillary thyroid cancer patients with a 15 year median follow-up time, those with BRAF V600E mutations had reduced overall survival compared to those with wildtype BRAF (P=0.015, log-rank test). The presence of BRAF V600E was associated with poorer outcome as defined by persistent disease or death (Odds ratio:14.63, 95%CI:1.28-167.29, P=0.03, multivariate analysis."	"Elisei et al., 2008, J. Clin. Endocrinol. Metab."	Somatic	ENST00000288602.6	missense_variant
BRAF Mutation	BRAF	Mutation	Colorectal Cancer	"Chemotherapy,Cetuximab"	Predictive	Supports	B	Resistance	chr7	140753336	140781603			"This was a retrospective study of 350 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy who had individual response data and whose tumors were KRAS wildtype and BRAF assessable. Patients harboring BRAF mutations (total n=24, V600E n=23, D594G n=1) had a lower response rate than did patients with wildtype BRAF (n=326; 2/24 [4.3%] vs 124/326 [38%], OR: 0.15, p=0.0012). BRAF mutant patients also experienced significantly lower disease control rate, PFS, and OS (median 26 vs 54 weeks, HR: 3.03 p<0.0001) in response to cetuximab treatment. In multivariate analysis, the significant associations between BRAF mutations and poor outcome were confirmed. The authors noted that two responders had the following genotypes: V600E mutation in low copy number, and BRAF D594G, and suggested that mutation status of BRAF is more informative than those of NRAS and PIK3CA exon 20 for predicting cetuximab response (second only to KRAS)."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000288602.6	"gene_variant,gain_of_function_variant"
BRAF V600E	BRAF	V600E	Colorectal Cancer		Prognostic	Does Not Support	C	Poor Outcome	chr7	140753336	140753336	A	T	This study examined outcomes of 240 rectum cancer patients treated with total mesorectal excision therapy. Tumor samples were obtained at the time of surgery and genotyped for BRAF exon 15 mutations. BRAF V600E was identified in 5 cases. The authors reported that no differences were found in overall survival between patients with and without BRAF mutations (P > 0.1).	"He et al., 2009, Clin. Cancer Res."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Thyroid Gland Papillary Carcinoma		Prognostic	Supports	B	Poor Outcome	chr7	140753336	140753336	A	T	"In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5%  vs. 12.8% ,  Risk ratio:2.14, 95%CI:1.67-2.74, P<0.00001)."	"Kim et al., 2012, Cancer"	Somatic	ENST00000288602.6	missense_variant
BRAF V600K	BRAF	V600K	Melanoma	Dabrafenib	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753337	AC	TT	"Patients were treated with a specific RAF inhibitor (dabrafenib), which improved overall survival of patients with BRAF mutations (P<0.003), compared to non-treated patients with BRAF mutations. Patients having BRAF mutations were associated with reduced overall survival (11.1 mo vs. 46.1 mo for wild-type, P=0.006). BRAF mutations were more frequent in tumors with superficially spreading histological sub-type (43%  vs. 19% , P<0.001) compared to BRAF wild-type tumors."	"Long et al., 2011, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600K	BRAF	V600K	Melanoma	Trametinib	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753337	AC	TT	"In a study of 322 advanced melanoma patients with BRAF-V600E (N=281), BRAF-V600K (N=40), or both mutations (N=1), treatment with trametinib was associated with improved progression-free survival (4.8mo vs. 1.5mo; HR: 0.45, 95% CI: 0.33-0.63, P<0.001) compared to chemotherapy control group. Additionally, treatment with trametinib was associated with increased 6-month overall survival (HR: 0.54, 95% CI: 0.32-0.92, P=0.01). The authors note similar outcomes for the primary efficacy population (V600E only) and the intention-to-treat population, however, sub-group analysis for patients with V600K did not show significant improvement in PFS (HR: 0.50, 95% CI:0.18-1.35)."	"Flaherty et al., 2012, N. Engl. J. Med."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Lung Non-small Cell Carcinoma	"Dabrafenib,Trametinib"	Predictive	Supports	A	Sensitivity/Response	chr7	140753336	140753336	A	T	"Patients with BRAF V600E-mutant NSCLC (n=57) were enrolled into a phase 2, multicentre, non-randomised, open-label study, administering dabrafenib plus trametinib. The overall response rate was 36/57 (63.2%, [95% CI 49.3-75.6]) and the median progression-free survival was 9.7 months (95% CI 6.9-19.6). At data cutoff (11.6 months of follow-up), 18/36  (50%) confirmed responses were ongoing and 23/57 (40%) of patients had died."	"Planchard et al., 2016, Lancet Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	"FOLFOX-4 Regimen,Cetuximab"	Predictive	Supports	B	Resistance	chr7	140753336	140753336	A	T	"In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with BRAF V600E and wildtype NRAS/KRAS (n=14) mutation treated with FOLFOX4 plus cetuximab were associated with a decreased progression free survival (7.2mo vs. 9.7mo, HR:0.39, 95% CI:0.21-0.72, P=0.0017), and decreased overall survival (11.7mo vs. 28.5mo, HR:0.23, 95% CI:0.12-0.41, P<0.0001), as compared to patients with wildtype BRAF, NRAS and KRAS."	"Kaczirek et al., 2015, Clin Colorectal Cancer"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Melanoma	Vemurafenib	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"In a phase 2 clinical trial (NCT00949702) of 132 BRAF mutation positive metastatic melanoma patients treated with vemurafenib monotherapy, patients harboring BRAF V600E (n=123) or V600K (n=9) mutations were associated with a favorable objective response rate (53% per RECIST v1.1 criteria, 70/132), with 6% (8/132) and 47% (62/132) of patients achieving complete response and partial response, respectively."	"Trunzer et al., 2013, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Melanoma	Vemurafenib	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"In a clinical study (NCT01307397) of Polish, stage IIIC/IV, melanoma patients with metastases (n=75) harboring BRAF V600 mutation (as detected by cobas 4800 BRAF V600 Mutation Test), median overall survival was 61.9% (95% CI: 50.1-73.6) and median progression free survival was 7.4 months (95% CI: 5.5-9.2). Median duration of response was 7.4 months (95% CI: 5.7-9.2), with 3% (2/75) and 43% (29/75) of patients achieving a complete and partial response, respectively."	"Rutkowski et al., 2015, Contemp Oncol (Pozn)"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Melanoma	Vemurafenib	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"In a retrospective study of 300 stage IV melanoma patients, patients with BRAF V600E mutation (n=175) were associated with a 4.8% (8/167) complete response, a 58.1% (97/167) partial response and stable disease in 22.2% (37/167) of cases, while 15% (25/167) of patients harboring BRAF V600E experienced progressive disease."	"Ugurel et al., 2015, Ann. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Skin Melanoma	"Dabrafenib,Trametinib"	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"In a clinical trial (NCT01597908) of 704 metastatic melanoma patients, patients harboring a BRAF V600E mutation and treated with vemurafenib (n=317) were associated with a 51% response rate, as compared to a 64% response rate (p<0.001) in V600E mutation positive patients treated with dabrafenib and trametinib combination therapy (n=312). Median progression-free survival was 11.4 months in the combination-therapy group and 7.3 months in the vemurafenib group (hazard ratio, 0.56; 95% CI, 0.46 to 0.69; P<0.001)."	"Robert et al., 2015, N. Engl. J. Med."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Childhood Pilocytic Astrocytoma	Vemurafenib	Predictive	Supports	C	Sensitivity/Response	chr7	140753336	140753336	A	T	"In a case report, a 28 month old patient with a cervicomedullary low grade glioma compatible with pilocytic astrocytoma which was resected had a second lesion consistent with a ganglioglioma 3 years later. This mass progressed under treatment at which point PCR amplification of BRAF exon 15 and subsequent Sanger sequencing the initial biopsy revealed the tumor harbored a BRAF V600E mutation. Based on these results, vemurafenib monotherapy was started and radiological and clinical response was noted after 3 months of treatment, which was sustained after 6 months of therapy. Prior to vemurafenib treatment, the patient had undergone tracheotomy, was treated with standard chemotherapy and underwent another surgery, but had developed progressive disease."	"del Bufalo et al., 2014, J Transl Med"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Ovarian Serous Carcinoma	Vemurafenib	Predictive	Supports	C	Sensitivity/Response	chr7	140753336	140753336	A	T	"A stage 4B, low-grade papillary serous ovarian adenocarcinoma patient, harboring a BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was treated with standard chemotherapy, hormone therapy and bevacizumab prior to the identification of the BRAF V600E mutation; next, the patient was treated with paclitaxel and an anti-HER3 antibody and finally with vemurafenib, obtaining a partial response of greater than 1 year."	"Combe et al., 2015, Invest New Drugs"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	Panitumumab	Predictive	Supports	C	Resistance	chr7	140753336	140753336	A	T	"One patient participating in a large retrospective study of EGFR monoclonal antibodies in metastatic colorectal cancer had a tumor which harbored BRAF V600E, was wildtype for NRAS, KRAS and PIK3CA, and had individual response data. This patient was was a male treated with panitumumab monotherapy as 1st line therapy who experienced progressive disease (PFS: 7 weeks; OS: 10 weeks)."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600K	BRAF	V600K	Melanoma	Vemurafenib	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753337	AC	TT	"In a retrospective study of 300 stage IV melanoma patients, patients with BRAF V600K mutation (n=18) were associated with a 5.6% (1/18) complete response, a 22.2% (4/18) partial response and stable disease in 44.4% (8/18) of cases; however, 27.8% (5/18) of patients harboring BRAF V600K experienced progressive disease and patients with BRAF V600E mutation achieved a more impressive clinical benefit, as compared to patients with BRAF V600K mutation (P=0.016)."	"Ugurel et al., 2015, Ann. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600K	BRAF	V600K	Skin Melanoma	"Trametinib,Dabrafenib"	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753337	AC	TT	"In a clinical trial (NCT01597908) of 704 metastatic melanoma patients, patients harboring a BRAF V600K mutation and treated with vemurafenib (n=34) were associated with a 44% response rate, as compared to a 65% response rate in V600E mutation positive patients treated with dabrafenib and trametinib combination therapy (n=34)."	"Robert et al., 2015, N. Engl. J. Med."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Cholangiocarcinoma	"Trametinib,Dabrafenib"	Predictive	Supports	C	Sensitivity/Response	chr7	140753336	140753336	A	T	"Chemotherapy-refractory, metastatic cholangiocarcinoma with CNS involvement and a BRAF V600E mutation had a partial response at 8 weeks to dabrafenib and trametinib combination with complete radiologic regression at 12 weeks. At 6 months the patient was still on treatment."	"Kocsis et al., 2017, J Gastrointest Oncol"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Intrahepatic Cholangiocarcinoma	"Dabrafenib,Trametinib"	Predictive	Supports	C	Sensitivity/Response	chr7	140753336	140753336	A	T	"Two cases of patients with BRAF V600E positive, refractory intrahepatic cholangiocarcinoma showed excellent clinical and radiographic response to combination dabrafenib and trametinib treatment. One patient achieved complete remission at 6 months with progression at 9 months and the other partial remission at 2 months and no progression as of 5 months."	"Lavingia et al., 2016, J Gastrointest Oncol"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Intrahepatic Cholangiocarcinoma	"Trametinib,Dabrafenib"	Predictive	Supports	C	Sensitivity/Response	chr7	140753336	140753336	A	T	"Dabrafenib and trametinib combination showed durable response for a patient with standard chemotherapy and radiation refractory, poorly differentiated, intrahepatic cholangiocarcinoma harboring BRAF V600E. At time of publication, 8.5 months, the patient was still on treatment."	"Loaiza-Bonilla et al., 2014, Ecancermedicalscience"	Somatic	ENST00000288602.6	missense_variant
BRAF V600	BRAF	V600	Cholangiocarcinoma	Vemurafenib	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753337			"Eight patients with BRAF V600 (7 with V600E, 1 with V600 unknown) mutated cholangiocarcinoma received vemurafenib. Only one patients showed partial response and duration of response of this patient was longer than 12 months."	"Hyman et al., 2015, N. Engl. J. Med."	Somatic	ENST00000288602.6	protein_altering_variant
BRAF V600E	BRAF	V600E	Cholangiocarcinoma	"Panitumumab,Vemurafenib,Irinotecan"	Predictive	Supports	C	Sensitivity/Response	chr7	140753336	140753336	A	T	"A 31 year old patient with metastatic cholangiocarcinoma with BRAF V600E was treated with vemurafenib, panitumumab and irinotecan triplet therapy. By 2 months, 50% reduction of tumor volume was noted, including multiple lung metastases, complete clinical response was noted by CT 6 months post therapy and this treatment was continued."	"Silkin et al., 2016, J Gastrointest Cancer"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Lung Non-small Cell Carcinoma	Vemurafenib	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Within the BRAF mutant group, fourteen patients had refractory BRAF V600E-mutated NSCLC (adenocarcinoma, n = 13; sarcomatoid, n = 1). Six patients (43%; 95% CI, 18% to 71%) had objective responses (one CR, five PR), and two additional patients had SD > 120 days. The median DOR was 5 months (range, 4 to 14 months)."	"Hainsworth et al., 2018, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Ovarian Cancer	Vemurafenib	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among 4 patients with BRAF V600E mutant ovarian cancer, 2 had a partial response and one had stable disease > 120days."	"Hainsworth et al., 2018, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	Vemurafenib	Predictive	Supports	C	Sensitivity/Response	chr7	140753336	140753336	A	T	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among 2 patients with BRAF V600E mutant colorectal cancer, 1 had a partial response."	"Hainsworth et al., 2018, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Thyroid Gland Anaplastic Carcinoma	"Pertuzumab,Vemurafenib"	Predictive	Supports	C	Sensitivity/Response	chr7	140753336	140753336	A	T	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient with BRAF V600E mutant anaplastic thyroid cancer had a complete response."	"Hainsworth et al., 2018, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Laryngeal Squamous Cell Carcinoma	Vemurafenib	Predictive	Supports	C	Sensitivity/Response	chr7	140753336	140753336	A	T	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient with BRAF V600E mutant laryngeal cancer had a partial response with vemurafenib."	"Hainsworth et al., 2018, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600	BRAF	V600	Melanoma	"Cobimetinib,Vemurafenib"	Predictive	Supports	A	Sensitivity/Response	chr7	140753336	140753337			"In this double-blind, randomized, placebo-controlled, multicentre study, adult patients with histologically confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma were randomly assigned (1:1) to receive cobimetinib or placebo, in combination with oral vemurafenib. Progression-free survival was the primary endpoint. Between Jan 8, 2013, and Jan 31, 2014, 495 eligible adult patients were enrolled and randomly assigned to the cobimetinib plus vemurafenib group (n=247) or placebo plus vemurafenib group (n=248). Investigator-assessed median progression-free survival was 12.3 months for cobimetinib and vemurafenib versus 7.2 months for placebo and vemurafenib (HR 0.58 [95% CI 0.46-0.72], p<0.0001). Median overall survival was 22.3 months for cobimetinib and vemurafenib versus 17.4 months for placebo and vemurafenib (HR 0.70, 95% CI 0.55-0.90; p=0.005). The safety profile for cobimetinib and vemurafenib was tolerable and manageable, and no new safety signals were observed with longer follow-up."	"Ascierto et al., 2016, Lancet Oncol."	Somatic	ENST00000288602.6	protein_altering_variant
BRAF V600E	BRAF	V600E	Thyroid Gland Anaplastic Carcinoma	Vemurafenib	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"In a phase 2 basket?study of vemurafenib in BRAF V600-positive non-melanoma cancers, seven patients with anaplastic thyroid cancer were enrolled. All 7 patients had V600E mutations. One complete response and one partial response was observed, for a response rate of 29%."	"Hyman et al., 2015, N. Engl. J. Med."	Somatic	ENST00000288602.6	missense_variant
BRAF V600	BRAF	V600	Colorectal Cancer	"Encorafenib,Cetuximab"	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753337			"In a Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab, Twenty-six patients with refractory BRAF V600 mutant metastatic CRC (mCRC) were treated with a selective RAF kinase inhibitor (encorafenib) plus a monoclonal antibody targeting EGFR (cetuximab).  Confirmed overall response rates of 19% were observed and median progression-free survival was 3.7 months."	"van Geel et al., 2017, Cancer Discov"	Somatic	ENST00000288602.6	protein_altering_variant
BRAF V600	BRAF	V600	Colorectal Cancer	"Encorafenib,Cetuximab,Alpelisib"	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753337			"In a phase Ib dose-escalation study of encorafenib, cetuximab and alpelisib, twenty-eight patients with refractory BRAF V600-mutant metastatic CRC (mCRC) were treated with a selective RAF kinase inhibitor (encorafenib) plus a monoclonal antibody targeting EGFR (cetuximab) with a PI3K inhibitor (alpelisib).  Confirmed overall response rates of 18% were observed and median progression-free survival was 4.2 months"	"van Geel et al., 2017, Cancer Discov"	Somatic	ENST00000288602.6	protein_altering_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	"Dabrafenib,Trametinib,Panitumumab"	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"In this trial, 142 patients with metastatic, BRAF V600E mutant colorectal cancer were randomized to receive either BRAF inhibitor dabrafenib (D) + EGFR inhibitor panitumumab (P); or a triple therapy of D + P and MEK inhibition with trametinib (T) or T + P. Confirmed response rates for D+P (n=20), D+T+P (n=91), and T+P (n=31) were 10%, 21%, and 0%, respectively."	"Corcoran et al., 2018, Cancer Discov"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Adenocarcinoma	"Trametinib,Panitumumab"	Predictive	Does Not Support	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"In this trial, 142 patients with metastatic, BRAF V600E mutant colorectal cancer were randomized to receive either BRAF inhibitor dabrafenib (D) + EGFR inhibitor panitumumab (P); or a triple therapy of D + P and MEK inhibition with trametinib (T) or T + P. Confirmed response rates for D+P (n=20), D+T+P (n=91), and T+P (n=31) were 10%, 21%, and 0%, respectively."	"Corcoran et al., 2018, Cancer Discov"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Melanoma	"Dabrafenib,Trametinib"	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"Adjuvant dual treatment with BRAF inhibitor dabrafenib and MEK inhibitor trametinib was administered to patients with stage III resected melenoma with V600E or V600K mutation in this stage III trial (COMBO-AD, NCT01682083). 792 (91%) patients had V600E, and were administered dabrafenib and trametinib or placebo for 12 months. In subsequent analysis, relapse or death occurred in 150/397 patients (38%) in the treatment group and 229/395 patients (58%) in the placebo group for a 95% CI Hazard Ratio of 0.48 (0.39-0.58)."	"Long et al., 2017, N. Engl. J. Med."	Somatic	ENST00000288602.6	missense_variant
BRAF V600K	BRAF	V600K	Melanoma	"Dabrafenib,Trametinib"	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753337	AC	TT	"Adjuvant dual treatment with BRAF inhibitor dabrafenib and MEK inhibitor trametinib was administered to patients with stage III resected melenoma with V600E or V600K mutation in this stage III trial (COMBO-AD, NCT01682083). 78 (9%) patients had V600K, and were administered dabrafenib and trametinib or placebo for 12 months. In subsequent analysis, relapse or death occurred in 16/41 patients (39%) in the treatment group and 19/37 patients (51%) in the placebo group for a 95% CI Hazard Ratio of 0.54 (0.27-1.06)."	"Long et al., 2017, N. Engl. J. Med."	Somatic	ENST00000288602.6	missense_variant
BRAF V600	BRAF	V600	Melanoma	"Trametinib,Dabrafenib"	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753337			"Combination Dabrafenib and Trametinib treatment was assessed for adjuvant treatment of stage III resected BRAF V600 mutant melanoma in the COMBI-AD trial NCT01682083. Patients were treated with combination therapy or placebo for 12 months. The estimated 3-year rate of relapse-free survival was 58% in the treated group and 39% in the placebo group  with hazard ratio for relapse or death of 0.47 (95% CI, 0.39 to 0.58; P<0.001). 3-year overall survival rate for treated group was 86%, and 77% in the placebo group (hazard ratio for death, 0.57; 95% CI, 0.42-0.79; P=0.0006). The level of improvement observed did not cross the prespecified interim analysis boundary of P=0.000019. Distant metastasis-free survival and freedom from relapse was higher in the combination-treated group."	"Long et al., 2017, N. Engl. J. Med."	Somatic	ENST00000288602.6	protein_altering_variant
BRAF Mutation	BRAF	Mutation	Colorectal Cancer		Prognostic	Supports	B	Poor Outcome	chr7	140753336	140781603			"This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (made up of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan) alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between BRAF mutation status in primary tumors and post treatment PFS. Of 168 patients, 155 had wildtype BRAF and 13 had mutations in BRAFincluding V600E and D594K. The study found that patients harboring a BRAF mutation had a significantly worse outcome than patients expressing wildtype BRAF, regardless of first line chemotherapy regimen or use of monoclonal antibody treatment (Median PFS: 4.3 and 12.5 months, respectively; p <.0001)."	"Souglakos et al., 2009, Br. J. Cancer"	Somatic	ENST00000288602.6	"gene_variant,gain_of_function_variant"
BRAF Mutation	BRAF	Mutation	Colorectal Cancer	Oxaliplatin	Predictive	Supports	B	Resistance	chr7	140753336	140781603			"This was a retrospective clinical study of 100 metastatic colorectal cancer patients who received FOLFOX (oxaliplatin + 5-fluorouracil + folinic acid) first-line therapy alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between BRAF mutation status in primary tumors and response to oxaliplatin-based first-line therapy, as measured by post treatment PFS. Of 100 patients, 94 had wildtype BRAF and 6 had mutations in BRAFincluding V600E and D594K. The study found that patients harboring a BRAF mutation were significantly more resistant to oxaliplatin-based first-line therapy than patients with wildtype BRAF (Median PFS: 5.0 and 11. 7 months, respectively; p < .0001)."	"Souglakos et al., 2009, Br. J. Cancer"	Somatic	ENST00000288602.6	"gene_variant,gain_of_function_variant"
BRAF Mutation	BRAF	Mutation	Colorectal Cancer	Irinotecan	Predictive	Supports	B	Resistance	chr7	140753336	140781603			"This was a retrospective clinical study of 44 metastatic colorectal cancer patients who received FOLFIRI (5-Fluorouacil + Folinic acid + irinotecan) first-line therapy alone or with bevacizumab. It assessed the relationship between BRAF mutation status in primary tumors and response to irinotecan-based first line therapy, as measured by PFS. Of the 44 patients, 39 had wildtype BRAF and 5 had mutations in BRAFincluding V600E and D594K. The study found that patients harboring a BRAF mutation were significantly more resistant to irinotecan-based first-line therapy than patients with wildtype BRAF (Median PFS: 3.5 and 12.8 months, respectively; p = .006)."	"Souglakos et al., 2009, Br. J. Cancer"	Somatic	ENST00000288602.6	"gene_variant,gain_of_function_variant"
BRAF Mutation	BRAF	Mutation	Colorectal Cancer	Bevacizumab	Predictive	Supports	B	Resistance	chr7	140753336	140781603			"This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan). It assessed the relationship between BRAF mutation status in primary tumors and response to bevacizumab-containing first line chemotherapy, as measured by PFS. Of the 97 patients,89 had wildtype BRAF and 8 had mutations in BRAFincluding V600E and D594K. The study found that patients harboring a BRAF mutation were significantly more resistant to bevacizumab-containing first-line chemotherapy than patients with wildtype BRAF (Median PFS: 4.2 and 12.5 months, respectively; p < .0001)."	"Souglakos et al., 2009, Br. J. Cancer"	Somatic	ENST00000288602.6	"gene_variant,gain_of_function_variant"
BRAF Mutation	BRAF	Mutation	Colorectal Cancer	Cetuximab	Predictive	Supports	B	Resistance	chr7	140753336	140781603			"This was a retrospective clinical study of 92 metastatic colorectal cancer patients who received cetuximab in conjunction with salvage chemotherapy (refractory to at least one line of treatment). Salvage chemotherapy was composed of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan. The study assessed the relationship between BRAF mutation status in primary tumors and response to cetuximab-containing salvage chemotherapy, as measured by PFS. Of the 92 patients, 83 had wildtype BRAF and 9 had mutations in BRAFincluding V600E and D594K. The study found that patients harboring a BRAF mutation were significantly more resistant to cetuximab-containing salvage chemotherapy than patients with wildtype BRAF (Median PFS: 2.0 and 3.9, respectively; p = .0005)."	"Souglakos et al., 2009, Br. J. Cancer"	Somatic	ENST00000288602.6	"gene_variant,gain_of_function_variant"
BRAF Mutation	BRAF	Mutation	Colorectal Cancer		Prognostic	Supports	B	Poor Outcome	chr7	140753336	140781603			"This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (made up of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan, or 5-FU + oxaliplatin + irinotecan) alone or with monoclonal antibodies (bevacizumab or cetuximab). It assessed the relationship between BRAF mutation status in primary tumors and post treatment OS. Of 168 patients, 155 had wildtype BRAF and 13 had mutations in BRAFincluding V600E and D594K. The study found that patients harboring a BRAF mutation had a significantly worse outcome than patients expressing wildtype BRAF, regardless of first line chemotherapy regimen or use of monoclonal antibody treatment (Median OS: 10.9 and 40.5 months, respectively; p <.0001)."	"Souglakos et al., 2009, Br. J. Cancer"	Somatic	ENST00000288602.6	"gene_variant,gain_of_function_variant"
BRAF V600	BRAF	V600	Melanoma	"Trametinib,Dabrafenib"	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753337			"In this Phase III trial (NCT01584648 COMBI-d), 423 previously untreated patients with unresectable stage IIIC or IV BRAF V600E or V600K mutant melanoma received dabrafenib and trametinib or dabrafenib alone with primary endpoint of progression free survival with secondary endpoints including disease response. The hazard ratio for progression or death in the dabrafenibtrametinib group was 0.75 (95% confidence interval, 0.57 to 0.99; P=0.03). Of 210 patients in the dabrafenib + trametinib group, 67% of patients had a response, which was 16 percentage points higher than in the dabrafenib-alone group (95% CI, 6 to 25; P=0.002)."	"Long et al., 2014, N. Engl. J. Med."	Somatic	ENST00000288602.6	protein_altering_variant
BRAF V600E	BRAF	V600E	Melanoma	"Trametinib,Dabrafenib"	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"In this Phase III trial (NCT01584648 COMBI-d), previously untreated patients with unresectable stage IIIC or IV melanoma with BRAF V600E (359 patients) or V600K (61 patients) received dabrafenib and trametinib or dabrafenib alone with primary endpoint of progression free survival and secondary endpoints including disease response. The hazard ratio for progression or death in the V600E group was 0.81 for dabrafenib-trametinib vs dabrafenib-alone. Of 179 V600E patients in the dabrafenib-trametinib group, 68% of patients had a response, which was 15 percentage points higher than in the dabrafenib-alone group (95% CI, 4 to 24; P=0.006)."	"Long et al., 2014, N. Engl. J. Med."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Melanoma	"Dabrafenib,Trametinib"	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"In this Phase I and II study (NCT01072175) patients with metastatic melanoma were given dabrafenib and trametinib combination therapy vs. dabrafenib monotherapy. From V600E patients, 45 received monotherapy and 92 received combination therapy. Hazard ratio for progression or death was 0.43 (95% CI, 0.27-0.71). Both patients with the BRAF V600E and V600K mutation showed significant improvement in progression-free survival."	"Flaherty et al., 2012, N. Engl. J. Med."	Somatic	ENST00000288602.6	missense_variant
BRAF V600K	BRAF	V600K	Melanoma	"Trametinib,Dabrafenib"	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753337	AC	TT	"In this Phase III trial (coBRIM, NCT01689519) of 495 V600 mutant melanoma patients, 56 had V600K mutation. 32 patients were treated with vemurafenib and placebo, and 24 were treated with vemurafenib and cobimetinib and tested for progression free survival. 17 of 32 monotherapy group patients had an event with median progression free survival of 5.3 months. In the combination group 4 of 24 patients had an event with median progression-free survival not met, however, when in combination with other V600 mutations median progression-free survival was 9.9 months with combination treatment. Median time to followup for the whole cohort was 7.3 months. Hazard Ratio for progression or death was 0.27 (0.09-0.81)."	"Larkin et al., 2014, N. Engl. J. Med."	Somatic	ENST00000288602.6	missense_variant
BRAF V600	BRAF	V600	Melanoma	"Vemurafenib,Cobimetinib"	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753337			"In this Phase 1b study, 129 patients with unresectable or metastatic melanoma were verified for BRAF V600 mutation using the cobas 4800 mutation test were selected who had progressed on vemurafenib (66 patients) or never received BRAF inhibitor (63 patients). The combination of vemurafenib and cobimetinib was deemed safe and tolerable. Confirmed objective responses were seen in 15% of vemurafenib progressed patients and median progression-free survival was 2.8 months (95% CI 26?4). Confirmed objective responses were seen in 87% of patients who had never received BRAF inhibitor, including 10% with complete response. Median progression-free survival was 13.7 months (95% CI 101?75). The majority of patients had BRAF V600E mutation. Post-hoc sequencing of 94 tumor samples indicated seven tumors with a mutation other than BRAF V600E."	"Ribas et al., 2014, Lancet Oncol."	Somatic	ENST00000288602.6	protein_altering_variant
BRAF V600E	BRAF	V600E	Thyroid Gland Anaplastic Carcinoma	"Trametinib,Dabrafenib"	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"Interim analysis of a basket trial evaluating the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in previously treated V600E-mutated patients showed 11/16 patients with anaplastic thyroid carcinoma responded to treatment (overall response rate 69%; 95% CI, 41% to 89%). Seven patients had ongoing responses. Median duration of response, progression-free survival, and overall survival were not reached after 120 weeks."	"Subbiah et al., 2018, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer		Prognostic	Supports	B	Poor Outcome	chr7	140753336	140753336	A	T	"Patients with completely resected colorectal adenocarcinoma (Stage II-III) were treated with fluorouracil and leucovorin +/- ironotecan. Of the 1,307 FFPE samples tested, V600E was observed in 31 Stage II samples (7.6%) and 72 Stage III samples (7.9%). V600E was prognostic for overall survival, but not for relapse-free survival, in patients with stages II and III combined, and in stage III alone. For all MSI low and stable tumors, BRAF V600E positive samples had a hazard ratio (HR) of 2.19 (95% CI, 1.43 to 3.37, P=0.00034). For all samples in the cohort (MSI-H and MSI-L) BRAF V600E positive samples had a 1.66 HR (95% CI, 1.15 to 2.40, P=0.0069). The authors note prognostic value for BRAF V600E, especially in non-MSI high tumors."	"Roth et al., 2010, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer		Prognostic	Supports	B	Poor Outcome	chr7	140753336	140753336	A	T	"The CRYSTAL Phase III Trial evaluated efficacy of irinotecan, fluorouracil, and leucovorin (FOLFIRI) with or without Cetuximab for colorectal cancer patients who presented with unresectable metastatic disease. BRAF mutation status (V600E) was analyzed via LightMix BRAF V600E Kit. V600E mutations were detected in 60/999 tumor samples (6%), 59 of which were wild-type for KRAS. When comparing patients with wildtype KRAS (n=625), BRAF V600E tumors had worse outcomes relative to BRAF wildtype. For patients with BRAF V600E tumors (n=566), median overall survival (OS) was 25.1 months with cetuximab and 21.6 months without cetuximab. For patients with wildtype BRAF (n=59), median OS was 14.1 months with cetuximab and 10.3 months without cetuximab."	"Van Cutsem et al., 2011, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF Mutation	BRAF	Mutation	Colorectal Cancer		Prognostic	Supports	B	Poor Outcome	chr7	140753336	140781603			"In the Medical Research Council (MRC) COIN trial, ISRCTN27286448, patients who presented with advanced colorectal cancer were randomly assigned to chemotherapy (oxaliplatin and fluoropyrimidine; arm A), or chemotherapy plus cetuximab (arm B). Median overall survival was found to differ by mutation, regardless of treatment. Median overall survival was 8.8 months (IQR 4.5-27) for patients with BRAF variants, 14.4 months (IQR 8.5-24.0) for patients with KRAS variants, and 20.1 months (IQR 11.5-31.7) for wildtype patients. BRAF mutations were found in 102/1291 samples (7.90%), and of these, 12 were D594G and 90 V600E."	"Maughan et al., 2011, Lancet"	Somatic	ENST00000288602.6	"gene_variant,gain_of_function_variant"
BRAF Mutation	BRAF	Mutation	Colorectal Cancer		Prognostic	Supports	B	Poor Outcome	chr7	140753336	140781603			"A meta analysis was performed using data from 21 published studies (n = 9885 patients) to assess prognostic value of BRAF mutations in colorectal cancer. When evaluating 14 studies (n = 7778 patients), the odds ratio (OR) of a proximal lesion, which is associated with greater mortality in colon cancer, was increased for patients with BRAF mutations (OR 5.222, 95% CI 3.801?.174, P < 0.001). When evaluating 4 studies (n = 1526 patients), the odds ratio of T4 tumors, which indicates tumor growth past bowel lining, was increased for patients with BRAF mutations (OR 1.761, 95% CI 1.164?.663, P = 0.007). When evaluating 8 studies (n = 2786 patients), the odds ratio of poor tumor differentiation was increased in patients with BRAF mutations (OR 3.816, 95% CI 2.714?.365, P < 0.001). These results support that BRAF mutations indicate poor prognosis for patients with colorectal cancer."	"Clancy et al., 2013, Colorectal Dis"	Somatic	ENST00000288602.6	"gene_variant,gain_of_function_variant"
BRAF V600E	BRAF	V600E	Childhood Low-grade Glioma		Prognostic	Supports	B	Poor Outcome	chr7	140753336	140753336	A	T	"Using Sanger sequencing, BRAFV600E mutations were identified in 21 of 285 patients with PLGGs (7.4%). This mutation was enriched in hemispheric tumors (p<0.007) and was associated with shorter progression-free survival (p=0.011) and overall survival (p=0.032) [mt (n=18) vs wt (n=166)]."	"Yang et al., 2018, Acta Neuropathol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	"Cetuximab,Binimetinib,Encorafenib"	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"In a phase III trial, patients with BRAF V600E mutated metastatic colorectal cancer received triplet combination with encorafenib + binimetinib + cetuximab in a second or third-line setting. In the safety-lead in part of this trial, 30 patients were given triplet therapy, of which 29 with V600E mutation were included in the efficacy analysis. The objective response rate was 48% [95%CI: 29.4 - 67.5], median PFS was 8.0 mo [95%CI: 5.6 - 9.3], and median OS was 15.3 mo [95%CI: 9.6 - not reached]. The author concluded that triplet therapy was well tolerated and PFS and OS were substantially improved over historical standard of care."	"Scott Kopetz, 2019, Gastrointestinal Cancers Symposium, Abstract 688"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Biliary Tract Cancer	"Trametinib,Dabrafenib"	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"In a phase II trial, 33 patients with advanced or metastatic biliary tract cancer (BTC) received dabrafenib (D) and trametinib (T) in a second or higher line therapeutic context. Of the 33 patients, 30 had BRAF V600E mutated tumors, and 32 were evaluable. Objective response rate was 41% (13/32; 95% CI, 24 - 59%). Median PFS was 7.2 months (95% CI, 4.6 - 10.1 months), and median OS was 11.3 months (95% CI, 7.3 - 17.6 months). The author concluded that D+T therapy should be considered for patients with BRAF V600E mutated BTC."	"Zev A. Wainberg, 2019, Gastrointestinal Cancers Symposium, Abstract 187"	Somatic	ENST00000288602.6	missense_variant
BRAF V600	BRAF	V600	Melanoma	"Binimetinib,Encorafenib"	Predictive	Supports	A	Sensitivity/Response	chr7	140753336	140753337			"In a phase 3 trial, patients with melanoma with BRAF V600E or V600K mutation were randomly assigned to encorafenib plus binimetinib or vemurafenib or encorafenib. mPFS was 149 months (95% CI 110-185) in the encorafenib plus binimetinib group and 73 months (56-82) in the vemurafenib group (hazard ratio [HR] 054, 95% CI 041-071; two-sided p<00001)"	"Dummer et al., 2018, Lancet Oncol."	Somatic	ENST00000288602.6	protein_altering_variant
BRAF V600	BRAF	V600	Colorectal Cancer	"Vemurafenib,Cetuximab,Irinotecan"	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753337			"A randomized clinical trial was done with metastatic colorectal cancer (mCRC) patients (50 in the control group, 49 in the experimental group) with BRAF V600 mutations and RAS wild type that were enrolled from December 2014 to April 2016. The patients were randomized into groups with irinotecan and cetuximab with vemurafenib (VIC group) or without (IC group). The VIC group showed an improvement of progression of free survival (HR 0.42, 95% CI: 0.26 to 0.66, p < 0.001) with a median value of 4.4 months compared to 2.0 months for the IC group. In addition, for the VIC group, there was a 16% drug response rate while the IC group had a 4% drug response rate (p-value = 0.08). Some grade 3/4 adverse events were higher in the experimental arm, and skin toxicity and fatigue showed no increase."	"Scott Kopetz, 2017, ASCO Annual Meeting, Abstract 3505"	Somatic	ENST00000288602.6	protein_altering_variant
BRAF V600E	BRAF	V600E	Langerhans Cell Sarcoma	Vemurafenib	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"Off-label use of vemurafenib to treat BRAF V600E mutation-positive, refractory, childhood Langerhans cell histiocytosis (LCH) was evaluated. Fifty-four patients from 12 countries were treated with vemurafenib 20 mg/kg/day. Because LCH is a heterogeneous systemic disease, the quantitative Disease Activity Score (DAS), which reflects overall LCH extension, was used as an evaluation criterion. At 8 weeks, 38 patients had CRs (non-active disease) and 16 had PRs (active disease better). DAS decreased from a median value of 7 to 0 between VMF initiation and day 60 (P < 0.001)."	"Donadieu et al., 2019, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	"Cetuximab,Binimetinib,Encorafenib"	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"665 patients with BRAF V600E-mutated metastatic CRC were enrolled In this open-label, phase 3 trial. Patients were randomly assigned in a 1:1:1 ratio to receive encorafenib, binimetinib, and cetuximab (triplet-therapy group); encorafenib and cetuximab (doublet-therapy group); or the investigators?choice of either cetuximab and irinotecan or cetuximab and FOLFIRI. The median overall survival was 9.0 months in the triplet-therapy group and 5.4 months in the control group (hazard ratio for death, 0.52; 95% confidence interval [CI], 0.39 to 0.70; P<0.001). The confirmed response rate was 26% (95% CI, 18 to 35) in the triplet-therapy group and 2% (95% CI, 0 to 7) in the control group (triplet group vs. control P<0.001). The median progression-free survival in the triplet-therapy group was 4.3 months (95% CI, 4.1 to 5.2) and 1.5 months (95% CI, 1.5 to 1.7) in the control group (hazard ratio for disease progression or death, 0.38; 95% CI, 0.29 to 0.49; P<0.001)."	"Kopetz et al., 2019, N. Engl. J. Med."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	"Vemurafenib,Cetuximab,Irinotecan"	Predictive	Supports	D	Sensitivity/Response	chr7	140753336	140753336	A	T	"This in vivo study examined the efficacy of various treatments on athymic nude mice xenografted with colorectal cancer HT29 cells, which harbor BRAF V600E. The authors sought to understand whether the addition of vemurafenib (a BRAF V600E inhibitor) to agents approved for the treatment of metastatic colorectal cancer increased therapeutic efficacy, and which combinations worked best. Irinotecan, cetuximab and vemurafenib combination therapy resulted in >100% tumor growth inhibition (TGI) and 250% increased lifespan (ILS) compared to vehicle treated controls. Of the ten treated mice, nine experienced partial response and one experienced a complete response. Compared to all doublet and single agent combinations of vemurafenib, irinotecan, and cetuximab, triplet therapy produced the best TGI and ILS (p<0.05, p <0.0001 for all comparisons)."	"Yang et al., 2012, Cancer Res."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	"Erlotinib,Vemurafenib"	Predictive	Supports	D	Sensitivity/Response	chr7	140753336	140753336	A	T	"This in vivo study examined the efficacy of various treatments on athymic nude mice xenografted with colorectal cancer HT29 cells, which harbor BRAF V600E. The authors sought to understand whether the addition of vemurafenib (a BRAF V600E inhibitor) to agents approved for the treatment of metastatic colorectal cancer increased therapeutic efficacy, and which combinations worked best. Erlotinib and vemurafenib combination therapy resulted in >100% tumor growth inhibition (TGI) and 142% increased lifespan (ILS) compared to vehicle treated controls. Of ten treated mice, 9 experienced partial response. Doublet therapy produced a greater increase in TGI and ILS than either agent in isolation."	"Yang et al., 2012, Cancer Res."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Thyroid Gland Papillary Carcinoma	Vemurafenib	Predictive	Supports	B	Sensitivity/Response	chr7	140753336	140753336	A	T	"Open label phase 2 (Clinical Level B) trial including patients from across the globe (USA, Italy, and the Netherlands) investigating sensitivity to Vemurafenib in patients that have BRAF V600E-positive papillary thyroid cancer that have become resistant to radioactive iodine (the standard treatment). There were 116 patients identified for this trial, 51 of which met the conditions to be included. These 51 patients were split into two cohorts: 1) patients that had never been treated with a multikinase inhibitor targeting VEGFR and 2) patients that have previously been treated with a VEGFR multikinase inhibitor. In cohort 1, ten of 26 patients had best overall response. Best overall response was defined as the proportion of patients with a complete or partial response, however these ten patients were all partial response. In the same cohort 1, nine had achieved stable disease control for at least six months; therefore, 19 patients achieved disease control (73% of total cohort 1, 95% CI 52-88). In cohort 2, of 23 eligible patients, six had a partial response as best overall response and six had stable disease control for at least six months; therefore, 12 patients achieved disease control. (55% of total cohort 2, 95% CI 32-76). The authors conclude that vemurafenib is a potential treatment option for late-stage BRAF V600E-positive papillary thyroid cancer for treatment in patients nave to a multikinase inhibitor (Cohort 1) and to patients that have been previously treated with a multikinase inhibitor (Cohort 2)."	"Brose et al., 2016, Lancet Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Thyroid Gland Papillary Carcinoma		Prognostic	Supports	B	Poor Outcome	chr7	140753336	140753336	A	T	"Clinical study including 219 patients with papillary thyroid cancer (PTC) to determine a correlation between the BRAF V600E mutation and poor oncological outcome. This study found that 107 of the 219 (49%) patients had this mutation signifying that the BRAF V600E mutation is one of the most commonly occurring among PTC patients. This cohort was split into two groupsBRAF+ and BRAF-. Of the 107 patients that were BRAF+, 25% had tumor reoccurrence compared with 9% in the BRAF- group (P=0.004). Multivariate analysis was performed to assess BRAF correlation independent of known contributing factors to cancer such as age, gender, and multifocality. The results showed that the BRAF mutation is indicative/contributes to lymph node metastasis, associated with tumor reoccurrence, stage, and that recurrent disease was more extensive and required more aggressive treatments in BRAF+ patients compared with BRAF- patients. The authors conclude that PTC patients with the BRAF V600E mutation have worse clinicopathological outcomes, and that the BRAF mutation can be used to assess risk stratification in patients with PTC."	"Xing et al., 2005, J Clin Endocrinol Metab"	Somatic	ENST00000288602.6	missense_variant
BRAF V600E	BRAF	V600E	Colorectal Cancer	"Encorafenib,Cetuximab"	Predictive	Supports	A	Sensitivity/Response	chr7	140753336	140753336	A	T	"The open-label phase 3 BEACON CRC trial included 665 patients with BRAF V600E-mutated metastatic CRC. Patients were randomly assigned in a 1:1:1 ratio to receive encorafenib, binimetinib, and cetuximab (triplet-therapy group); encorafenib and cetuximab (doublet-therapy group); or the investigators?choice of either cetuximab and irinotecan or cetuximab and FOLFIRI. The median overall survival was 8.4 months (95% CI, 7.5 to 11.0) in the doublet-therapy group and 5.4 months (95% CI, 4.8 to 6.6) in the control group, with a significantly lower risk of death compared to the control group (hazard ratio for death doublet-group vs. control, 0.60; 95% CI, 0.45 to 0.79; P<0.001). The confirmed response rate was 26% (95% CI, 18 to 35) in the triplet-therapy group, 20% in the doublet-therapy group (95% CI 13 to 29) and 2% (95% CI, 0 to 7) in the control group (doublet group vs. control P<0.001). Median PFS was 4.2 months (95% CI, 3.7 to 5.4) in the doublet-therapy group, and 1.5 months (95% CI, 1.5 to 1.7) in the control group (hazard ratio for disease progression doublet-group vs control, 0.40; 95% CI, 0.31 to 0.52, P<0.001)."	"Kopetz et al., 2019, N. Engl. J. Med."	Somatic	ENST00000288602.6	missense_variant
BRAF A598V	BRAF	A598V	Melanoma	"BRAF Inhibitor,Mitogen-Activated Protein Kinase Kinase Inhibitor"	Predictive	Does Not Support	C	Sensitivity/Response	chr7	140753342	140753342	G	A	"In a retrospective study from 20 institutes in 4 countries, the efficacy of BRAF inhibitor and/or MEK inhibitor in patients with melanoma harboring BRAF nonV600E/K mutations were evaluated. Treated with BRAF inhibitor monotherapy, response rate were 27%(4/15) for V600R, 100%(2/2) for V600D, 0% (0/2) for V600_K601>E, 0% (0/1) for V600G, 0% (0/1) for V600L, 0% (0/1) for V600_S602>DT, 0% (0/5) for L597, 0% (0/6) for K601E, 0% (0/2) for G469, 0% (0/1) for G593D,and 0% (0/1) for T599_V600insT Treated with MEK inhibitor monotherapy, response rate were 100% (1/1) for L597, and 0% (0/1) for K601E. Treated with BRAF inhibitor and MEK inhibitor combination thearpy, response rate were 55% (16/29) for V600R, 67% (2/3) for V600D, 50% (1/2) for V600_K601>E, 50% (1/2) for V600M, 22% (2/9) for L597,25% (1/4) for K601E, 67% (2/3) for G469, and 0% (0/1) for A598V."	"Menzer et al., 2019, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF L597R	BRAF	L597R	Melanoma	Vemurafenib	Predictive	Supports	C	Sensitivity/Response	chr7	140753345	140753345	A	C	A case report of a patient with BRAF L597R mutation and clinical response to BRAF-inhibition (Vemurafenib) that correlated to in-vitro models.	"Bahadoran et al., 2013, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF L597R	BRAF	L597R	Skin Melanoma	"Trametinib,Vemurafenib"	Predictive	Supports	D	Sensitivity/Response	chr7	140753345	140753345	A	C	"Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutantexpressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling."	"Dahlman et al., 2012, Cancer Discov"	Somatic	ENST00000288602.6	missense_variant
BRAF L597S	BRAF	L597S	Skin Melanoma	"Vemurafenib,Trametinib"	Predictive	Supports	D	Sensitivity/Response	chr7	140753345	140753346	AG	GA	"Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutantexpressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling."	"Dahlman et al., 2012, Cancer Discov"	Somatic	ENST00000288602.6	missense_variant
BRAF L597S	BRAF	L597S	Skin Melanoma	MEK Inhibitor TAK-733	Predictive	Supports	C	Sensitivity/Response	chr7	140753345	140753346	AG	GA	Case report of a 69 year old patient with metastatic melanoma treated with MEK inhibitor TAK-733 in a clinical trial. A partial radiographic response with a decrease of 31% in the sum of maximum diameters of target metastatic lesions in the liver and spleen was noted after 2 cycles of therapy and remained progression free at more than 24 weeks. Follow-up sequencing analysis of DNA from the patient's tumor revealed a somatic BRAF L597S mutation.	"Dahlman et al., 2012, Cancer Discov"	Somatic	ENST00000288602.6	missense_variant
BRAF L597Q	BRAF	L597Q	Skin Melanoma	"Vemurafenib,Trametinib"	Predictive	Supports	D	Sensitivity/Response	chr7	140753345	140753345	A	T	"Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutantexpressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling."	"Dahlman et al., 2012, Cancer Discov"	Somatic	ENST00000288602.6	missense_variant
BRAF L597Q	BRAF	L597Q	Skin Melanoma	Trametinib	Predictive	Supports	C	Sensitivity/Response	chr7	140753345	140753345	A	T	Case study report including one patient with L597Q mutation-positive metastatic melanoma (M1b disease) treated with the MEK inhibitor trametinib. The L597Q patient achieved a RECIST partial response and showed maximum tumor shrinkage of 33% with trametinib as the first-line treatment and had a partial response for 6.2 months.	"Bowyer et al., 2014, Melanoma Res."	Somatic	ENST00000288602.6	missense_variant
BRAF L597Q	BRAF	L597Q	Cancer	Vemurafenib	Predictive	Does Not Support	C	Sensitivity/Response	chr7	140753345	140753345	A	T	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion."	"Hainsworth et al., 2018, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF L597V	BRAF	L597V	Skin Melanoma	Trametinib	Predictive	Supports	C	Sensitivity/Response	chr7	140753346	140753346	G	C	Case report of a phase 1 study in advanced melanoma patients. 97 patients with melanoma were enrolled and treated with trametinib. One patient with a BRAF Leu597Val had a confirmed partial response with 60% tumour reduction and received study treatment for more than 2 years.	"Falchook et al., 2012, Lancet Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF G596C	BRAF	G596C	Lung Non-small Cell Carcinoma	"Trametinib,Dabrafenib"	Predictive	Supports	D	Sensitivity/Response	chr7	140753349	140753349	C	A	"non-V600 BRAF mutations can be sensitive to clinically relevant doses of Dabrafenib and Trametinib in HEK293T cells, in lung epithelial cellular model (BEAS-2B) and in human cancer cell lines harboring non-V600 BRAF mutations"	"Noeparast et al., 2016, Oncotarget"	Somatic	ENST00000288602.6	missense_variant
BRAF G596R	BRAF	G596R	Colorectal Cancer	Vemurafenib	Predictive	Does Not Support	D	Sensitivity/Response	chr7	140753349	140753349	C	G	"In an in vitro study, an NCI-H508 cell line expressing BRAF G596R demonstrated insensitivity to vemurafenib treatment compared to HT29 cells expressing BRAF V600E (a known vemurafenib sensitizing mutation; IC50 9.89 uM vs 0.025-0.35uM for BRAF V600E expressing cell lines). Note that NCI-H508 also expresses PIK3CA E545K."	"Yang et al., 2012, Cancer Res."	Somatic	ENST00000288602.6	missense_variant
BRAF G596R	BRAF	G596R	Cancer	Vemurafenib	Predictive	Does Not Support	C	Sensitivity/Response	chr7	140753349	140753349	C	G	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion."	"Hainsworth et al., 2018, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF D594A	BRAF	D594A	Skin Melanoma	"Sorafenib,Mitogen-Activated Protein Kinase Kinase Inhibitor"	Predictive	Supports	E	Sensitivity/Response	chr7	140753354	140753354	T	G	"Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF binding in NRAS mutant D04 cells. Either pan-RAF (e.g. sorafenib in the abscence of CRAF T421N gatekeeper mutation) or MEK inhibitors (e.g., trametinib) could instead block ERK pathway hyperactivation in RAS mutated cancers."	"Heidorn et al., 2010, Cell"	Somatic	ENST00000288602.6	missense_variant
BRAF D594V	BRAF	D594V	Skin Melanoma	"Trametinib,Sorafenib"	Predictive	Supports	E	Sensitivity/Response	chr7	140753354	140753354	T	A	"Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF binding in NRAS mutant D04 cells. Either pan-RAF (e.g. sorafenib in the abscence of CRAF T421N gatekeeper mutation) or MEK inhibitors could instead block ERK pathway hyperactivation in RAS mutated cancers."	"Heidorn et al., 2010, Cell"	Somatic	ENST00000288602.6	missense_variant
BRAF D594G	BRAF	D594G	Colorectal Cancer		Prognostic	Supports	B	Poor Outcome	chr7	140753354	140753354	T	C	"In a study of 908 patients with colorectal cancer, 7 patients had BRAF (D594G) mutations and 45 patients had BRAF (V600E) mutations. Overall clinicopathological implications of BRAF V600E and D594G mutant tumors were similar but BRAF D594G mutations were more likely to be left-sided tumors (85.7% vs. 31.1%; p<0.0098) and they were more likely to present as metastatic tumors (71.4% vs. 28.9%; p<0.04) than BRAF V600E mutant tumors. The overall log-rank was p < 0.001 when all three groups were calculated simultaneously; p < 0.0001 comparing BRAF wild-type and BRAF V600E survival, p = 0.015 comparing BRAF wild-type and BRAF D594G survival, and p = 0.98 comparing BRAF V600E and BRAF D594G.  There was no statistically significant difference in OS between BRAF D594G and BRAF wt but BRAF V600E mutant patients had significantly worse survival when only stage IV patients (BRAF D594G N=5) were analyzed."	"Amaki-Takao et al., 2016, Oncology"	Somatic	ENST00000288602.6	missense_variant
BRAF D594G	BRAF	D594G	Colorectal Cancer		Prognostic	Supports	B	Poor Outcome	chr7	140753354	140753354	T	C	"In a study of 908 patients with colorectal cancer (CRC), 7 patients had BRAF D595G mutations and 589 patients were BRAF wild type. The survival rate of CRC patients at 3 years was significantly poorer in the BRAF D595G mutations when compared to the wild type group (50%, 87.9%; p<0.00152)."	"Amaki-Takao et al., 2016, Oncology"	Somatic	ENST00000288602.6	missense_variant
BRAF D594G	BRAF	D594G	Colorectal Cancer	"Cetuximab,Panitumumab"	Predictive	Does Not Support	C	Resistance	chr7	140753354	140753354	T	C	Two patients with stage IV BRAF (D594G) mutations received anti-EGFR antibody therapy (cetuximab and panitumumab). The first patient was on FOLFOX plus bevacizumab and showed no signs of progression for 10 months. No response was observed after cetuximab was given as a third line therapy. The second patient received panitumumab with FOLFOX and showed no signs of progression for 8 months with reduction of the size of metastases.	"Amaki-Takao et al., 2016, Oncology"	Somatic	ENST00000288602.6	missense_variant
BRAF D594G	BRAF	D594G	Colorectal Cancer	"Cetuximab,Irinotecan"	Predictive	Does Not Support	C	Resistance	chr7	140753354	140753354	T	C	"One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored BRAF D594G and was wildtype for KRAS, NRAS and PIK3CA. This patient was a 63 year old female treated with cetuximab and irinotecan (3rd line) who was one of two patients harboring a BRAF mutant tumor to experience a partial response. Progression free survival was 36 weeks and overall survival was 42 weeks from time of cetuximab administration. Authors note that cetuximab response is in accordance with cell line data suggesting that D594G cannot directly activate MAPK signaling, and that D594G mutants have low levels of p-MEK and are resistant to MEK inhibition."	"De Roock et al., 2010, Lancet Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF D594G	BRAF	D594G	Colorectal Cancer	"Cetuximab,Irinotecan"	Predictive	Supports	C	Resistance	chr7	140753354	140753354	T	C	"In a retrospective study of 53, KRAS exon 2 wild-type, metastatic colorectal cancer patients, patients harboring BRAF G466A (n=1), G469A (n=2), D594G (n=1), or V600E (n=2) mutations were reported to be non-responders to cetuximab in combination with irinotecan, (BRAF mutation positive: responders vs. non-responders = 0 vs. 6; BRAF wild-type: responders vs. non-responders 30 vs. 17; P=0.004), as compared to patients with wild-type BRAF."	"Hsu et al., 2016, Oncotarget"	Somatic	ENST00000288602.6	missense_variant
BRAF D594G	BRAF	D594G	Skin Melanoma	Sorafenib	Predictive	Supports	D	Sensitivity/Response	chr7	140753354	140753354	T	C	"In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRNA-mediated CRAF knowdown or Treatment with the pan-RAF Inhibitor sorafenib."	"Smalley et al., 2009, Oncogene"	Somatic	ENST00000288602.6	missense_variant
BRAF D594G	BRAF	D594G	Skin Melanoma	U0126	Predictive	Supports	D	Resistance	chr7	140753354	140753354	T	C	"In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRNA-mediated CRAF knowdown or Treatment with the pan-RAF Inhibitor sorafenib."	"Smalley et al., 2009, Oncogene"	Somatic	ENST00000288602.6	missense_variant
BRAF D594G	BRAF	D594G	Cancer	Vemurafenib	Predictive	Does Not Support	D	Sensitivity/Response	chr7	140753354	140753354	T	C	"RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R)."	"Yao et al., 2017, Nature"	Somatic	ENST00000288602.6	missense_variant
BRAF D594G	BRAF	D594G	Cancer	Trametinib	Predictive	Supports	D	Sensitivity/Response	chr7	140753354	140753354	T	C	"In a BRAF-mutation inducible model in the NIH3T3 cell line, class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R) were resistant to vemurafenib but sensitive to MEK-inhibitor trametinib."	"Yao et al., 2017, Nature"	Somatic	ENST00000288602.6	missense_variant
BRAF N581S	BRAF	N581S	Cancer	Vemurafenib	Predictive	Does Not Support	C	Sensitivity/Response	chr7	140753393	140753393	T	C	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion."	"Hainsworth et al., 2018, J. Clin. Oncol."	Somatic		missense_variant
BRAF L505H	BRAF	L505H	Melanoma	Vemurafenib	Predictive	Supports	D	Resistance	chr7	140777994	140777994	A	T	"Using a mutation screen in the BRAFV600E melanoma cell line A375, the L505H variant was identified as conferring resistance to vemurafenib. Analysis of the mutation in T293 cell lines found that the L505H mutant alone or with V600e had greater kinase activity and increased the levels of phospho-MEK. Finally, transduction of Ba/F3 cells with BRAF V600E/L505H IL3 independent proliferation."	"Wagenaar et al., 2014, Pigment Cell Melanoma Res"	Somatic	ENST00000288602.6	missense_variant
BRAF L505H	BRAF	L505H	Melanoma	Vemurafenib	Predictive	Supports	B	Resistance	chr7	140777994	140777994	A	T	"In this study, the investigators followed 10 patients treated with vemurafenib, and then they collected biopsies of lesions that progressed. In one of these patients, they identified the L505H mutation."	"Hoogstraat et al., 2015, Pigment Cell Melanoma Res"	Somatic	ENST00000288602.6	missense_variant
BRAF DEL 485-490	BRAF	DEL 485-490	Cancer	Pan-RAF Inhibitor LY3009120	Predictive	Supports	D	Sensitivity/Response	chr7	140778038	140778055	AGGTGCTGTCACATTCAA		"Cells harboring in-frame deletions in BRAF in the L485-P490 amino acid region were found to be sensitive to the RAF dimer inhibitor LY3009120, but not sensitive to the BRAF-selective inhibitors vemurafenib or dabrafenib. These deletions were observed in KRAS wildtype pancreatic, ovarian, NSCLC, and thyroid cancers. In three cell lines H2405 (NSCLC with L485-P490>Y), BxPC-3 (pancreatic with V487-P492>A), and OV-90 (ovarian with N486-P490del), BRAF deletionmediated MAPK activation was found to be sensitive to LY3009120 as evidenced by dose-dependent inhibition of phospho-MEK and ERK and cell growth inhibition with IC50 values of 0.04, 0.087, and 0.007 mol/L in these three cell lines. LY3009120, but not vemurafenib, also inhibited tumor growth of both H2405 and BxPC-3 cells xenografted into mice."	"Chen et al., 2016, Cancer Discov"	Somatic	ENST00000288602.6	inframe_deletion
BRAF K483M	BRAF	K483M	Skin Melanoma	"Sorafenib,Mitogen-Activated Protein Kinase Kinase Inhibitor"	Predictive	Supports	E	Sensitivity/Response	chr7	140778059	140778060	TT	CA	"Preclinical study in melanoma cell lines. Inactivity of BRAF as mediated by specific mutation (D594A, D594V or K483M) or selective pharmacological inhibition leads to MEK hyperactivation through CRAF binding in NRAS mutant D04 cells. Either pan-RAF (e.g. sorafenib in the abscence of CRAF T421N gatekeeper mutation) or MEK inhibitors (e.g., trametinib) could instead block ERK pathway hyperactivation in RAS mutated cancers."	"Heidorn et al., 2010, Cell"	Somatic	ENST00000288602.6	"missense_variant,loss_of_function_variant"
BRAF G469A	BRAF	G469A	Cancer	Vemurafenib	Predictive	Does Not Support	C	Sensitivity/Response	chr7	140781602	140781602	C	G	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion."	"Hainsworth et al., 2018, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF G469E	BRAF	G469E	Skin Melanoma	Sorafenib	Predictive	Supports	D	Sensitivity/Response	chr7	140781602	140781602	C	T	"In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition but underwent apoptosis after shRNA-mediated CRAF knowdown or Treatment with the pan-RAF Inhibitor sorafenib."	"Smalley et al., 2009, Oncogene"	Somatic		missense_variant
BRAF G469E	BRAF	G469E	Skin Melanoma	U0126	Predictive	Supports	D	Resistance	chr7	140781602	140781602	C	T	"In this preclinical study, melanoma cell lines harboring the kinase-dead G469E- and D594G mutations were identified. These cell lines were resitant to MEK-Inhibition (U0126) but underwent apoptosis after shRNA-mediated CRAF knowdown or treatment with the pan-RAF inhibitor sorafenib."	"Smalley et al., 2009, Oncogene"	Somatic		missense_variant
BRAF G466V	BRAF	G466V	Cancer	Vemurafenib	Predictive	Does Not Support	C	Sensitivity/Response	chr7	140781611	140781611	C	A	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion."	"Hainsworth et al., 2018, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF G466V	BRAF	G466V	Colorectal Cancer	"Panitumumab,Irinotecan"	Predictive	Supports	D	Sensitivity/Response	chr7	140781611	140781611	C	A	"In the study with a tumor from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treament with Panitumumab and irinotecan cause tumor regression. And in tumor cells of patient-derived xenograft generated from this patient, ERK signaling was sensitive to cetuximab and resistant to vemurafenib."	"Yao et al., 2017, Nature"	Somatic	ENST00000288602.6	missense_variant
BRAF G466V	BRAF	G466V	Colorectal Cancer	Vemurafenib	Predictive	Does Not Support	D	Sensitivity/Response	chr7	140781611	140781611	C	A	"In the study with a tumor from a patient with metastatic colorectal cancer BRAF (G466V) and wild-type RAS and NF1. Treatment with Panitumumab and irinotecan cause tumor regression. And in tumor cells of patient-derived xenograft generated from this patient, ERK signaling was sensitive to cetuximab and resistant to vemurafenib."	"Yao et al., 2017, Nature"	Somatic	ENST00000288602.6	missense_variant
BRAF G466V	BRAF	G466V	Solid Tumor	Vemurafenib	Predictive	Does Not Support	D	Sensitivity/Response	chr7	140781611	140781611	C	A	"RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E,  D594G, D594N, and G596R)."	"Yao et al., 2017, Nature"	Somatic	ENST00000288602.6	missense_variant
BRAF G464V	BRAF	G464V	Cancer	Vemurafenib	Predictive	Does Not Support	C	Sensitivity/Response	chr7	140781617	140781617	C	A	"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion."	"Hainsworth et al., 2018, J. Clin. Oncol."	Somatic	ENST00000288602.6	missense_variant
BRAF AGK::BRAF	BRAF	AGK::BRAF	Melanoma	Sorafenib	Predictive	Supports	C	Sensitivity/Response	chr7	141551189	141555567			BRAF fusion AGK-BRAF was associated with decreased sensitivity to vemurafenib and increased sensitivity to sorafenib in-vitro. A single patient with this fusion showed durable response to sorafenib.	"Botton et al., 2013, Pigment Cell Melanoma Res"	Somatic	ENST00000355413.4	transcript_fusion
BRAF AGK::BRAF	BRAF	AGK::BRAF	Melanoma	Vemurafenib	Predictive	Supports	D	Resistance	chr7	141551189	141555567			A melanoma cell line with AGK-BRAF in-frame fusion showed decreased sensitivity towards Vemurafenib in comparison with BRAF mutated (V600E) cell lines.	"Botton et al., 2013, Pigment Cell Melanoma Res"	Somatic	ENST00000355413.4	transcript_fusion
BRAF BRAF::CUL1	BRAF	BRAF::CUL1	Ovarian Serous Carcinoma	Mitogen-Activated Protein Kinase Kinase Inhibitor	Predictive	Supports	C	Sensitivity/Response	chr7	148698645	148760496			"One patient with low-grade serous ovarian cancer had an in-frame fusion between the BRAF kinase domain and CUL1 identified by panel sequencing (MSK-IMPACT), with expression confirmed by whole-transcriptome sequencing. This patient with metastatic disease after treatment with carboplatin and paclitaxel, was enrolled onto a study of paclitaxel in combination with an oral MEK inhibitor and achieved a CR. She continued to receive therapy for 7 months, until discontinuation because of the development of pneumonitis. At publication, sustained CR had lasted > 18 months."	"Grisham et al., 2015, J. Clin. Oncol."	Somatic	ENST00000288602.6	transcript_fusion
EZH2 Mutation	EZH2	Mutation	Myelodysplastic Syndrome		Prognostic	Supports	B	Poor Outcome	chr7	148807385	148884278			"In myelodysplastic syndrome, patients with point mutations in EZH2 have worse overall survival that their wild-type counterparts."	"Nikoloski et al., 2010, Nat. Genet."	Somatic	ENST00000320356.2	protein_altering_variant
EZH2 Overexpression	EZH2	Overexpression	Cancer		Prognostic	Supports	B	Poor Outcome	chr7	148807385	148884278			High expression of EZH2 was associated with poorer outcome in a meta-analysis encompassing 51 studies and 9444 patients.	"Jiang et al., 2016, Oncotarget"	N/A	ENST00000320356.2	N/A
EZH2 Mutation	EZH2	Mutation	Follicular Lymphoma		Prognostic	Supports	B	Better Outcome	chr7	148807385	148884278			"In advanced stage follicular lymphoma patients receiving rituximab + chemotherapy (R-CHOP or R-CVP), EZH2 mutations were associated with better failure free survival in patients with high-risk FLIPI scores compared to patients that were EZH2 wildtype with high-risk FLIPI scores."	"Pastore et al., 2015, Lancet Oncol."	Somatic	ENST00000320356.2	protein_altering_variant
EZH2 Y646	EZH2	Y646	Diffuse Large B-cell Lymphoma		Diagnostic	Supports	B	Positive	chr7	148811634	148811636			"Heterozygous mutations in EZH2 at Y641 were the second most frequent genetic event (after BCL2 t(14;18)) associated with a diagnosis of GCB-DLBCL in 35 / 320 patient samples. In contrast, mutations in EZH2 Y641 are not observed in centroblast samples from healthy controls."	"Morin et al., 2010, Nat. Genet."	Somatic	ENST00000320356.2	protein_altering_variant
EZH2 Y646	EZH2	Y646	Follicular Lymphoma		Diagnostic	Supports	B	Positive	chr7	148811634	148811636			"Heterozygous mutations in EZH2 at Y641 were the second most frequent genetic event (after BCL2 t(14;18)) associated with a diagnosis of Follicular non-Hodgkin Lymphoma in 18 / 251 patient samples. In contrast, mutations in EZH2 Y641 are not observed in centroblast samples from healthy controls."	"Morin et al., 2010, Nat. Genet."	Somatic	ENST00000320356.2	protein_altering_variant
EZH2 Y646	EZH2	Y646	Skin Melanoma	GSK126	Predictive	Supports	D	Sensitivity/Response	chr7	148811634	148811636			Preclinical study in melanoma cell lines. EZH2 expression was higher in EZH2 mutant (N=3) and wild-type melanoma cell lines (N=12) than untransformed cells (human epithelial melanocytes and human dermal fibroblasts). EZH2 mutant cell lines were the most sensitive to GSK126 compared to wild-type and untransformed.	"Tiffen et al., 2015, Oncotarget"	Somatic	ENST00000320356.2	protein_altering_variant
EZH2 Y646	EZH2	Y646			Functional	Supports	D	Gain of Function	chr7	148811634	148811636			"Using a baculovirus expression system, wild-type EZH2 or Y641 (Y641F, Y641H, Y641N, Y641S) mutants were coexpressed with the PRC2 complex in Spodoptera frugiperda cells. Methyltransferase activity assays showed that the Y641 mutants were more effective than the wildtype in catalyzing dimethyl to trimethyl reactions. In comparison to the wildtype, the enzyme turnover and catalytic efficiency for the mutants was lower for the non methylated and monomethylated substrates, and higher for dimethylated substrates. Western blots of patient derived lymphoma cell lines (one homozygous wildtype and four heterozygous Y641 mutant lines) supported steady state enzyme kinetic predictions where the homozygous wildtype line demonstrated increased me1 and me2, but decreased 3me at H3K27. Alternatively, the heterozygous lines displayed increased 3me but decreased me1 and me2 at H3K27. These results suggest both the wildtype and Y641 mutants contribute to trimethylation and therefore the altered expression signature."	"Sneeringer et al., 2010, Proc Natl Acad Sci U S A"	Somatic	ENST00000320356.2	protein_altering_variant
EZH2 Y646F	EZH2	Y646F	Skin Melanoma	JQEZ5	Predictive	Supports	D	Sensitivity/Response	chr7	148811635	148811635	T	A	Experiment with immunodeficient mice transplanted with melanoma cell lines indicates EZH2 inhibitor JQEZ5 might be effective in combination with a B-RAF inhibitor in RAF-mutant melanoma.	"Souroullas et al., 2016, Nat. Med."	Somatic	ENST00000320356.7	missense_variant
EZH2 Y646F	EZH2	Y646F			Functional	Supports	D	Gain of Function	chr7	148811635	148811635	T	A	"H3K27me3 (histone H3 Lys-27specific trimethylation) level was higher in EZH2 (Y641F) bearing germinal center B-cell type DLBCL derived lymphoma cell lines and tumors than in wild-type cells. There was no difference of H3K27Me2 and H3K9Me3 levels between Y641F/N and WT, indicating specificity in a gain of function of Y641F/N. Expression of Y641F mutation in HEK293T cells with wild-type EZH2 led to an increase in H3K27me3. Primary murine B-cell lines with Y641F mutation also showed an increase of H3K27me3. Structural modeling indicated that Y641F/N helped push the equilibrium to favor trimethylated products. A 3H methyl incorporation assay was used to study the activity of the PRC2 complex containing Y641F mutation in vitro. PRC2 complexes containing Y641F showed nearly two times higher activity with H3K27me2 substrates than PRC complexes with wild-type EZH2. This study indicates that EZH2 (Y641F) increases H3K27 trimethylation."	"Yap et al., 2011, Blood"	Somatic	ENST00000320356.7	missense_variant
EZH2 Y646F	EZH2	Y646F			Functional	Supports	D	Loss of Function	chr7	148811635	148811635	T	A	A 3H methyl incorporation assay tested the function of EZH2 Y641F containing PRC2 complexes in vitro. It showed that Y641F/N PRC2 complexes had significantly decreased enzyme activity on unmethylated and monomethylated H3 mimicking peptide substrates compared with wild-type.	"Yap et al., 2011, Blood"	Somatic	ENST00000320356.7	missense_variant
EZH2 Y646S	EZH2	Y646S			Functional	Supports	D	Gain of Function	chr7	148811635	148811635	T	G	Whole-cell lysates from frozen GCB-derived lymphoma sections with EZH2 Y641H showed a higher level of H3K27me3 (histone H3 Lys-27specific trimethylation) compared with those from tumor with wild-type EZH2 in western blots using an antibody specific for H3K27me3 (sample number 353).	"Yap et al., 2011, Blood"	Somatic	ENST00000320356.7	missense_variant
EZH2 Y646C	EZH2	Y646C			Functional	Supports	D	Loss of Function	chr7	148811635	148811635	T	C	"EZH2 mutations were identified in a screen of 614 patients with myeloid malignancies. Several mutations in the highly conserved CXC-SET domains were expressed in Sf9 insect cells along with polycomb repressive complex 2 components EED and SUZ12. Complexes were immunoprecipitated and assayed in vitro for H3K27M methyltransferase activity. EZH2 Y646C resulted in reduced methyltransferase activity, similar to the negative control (SET domain deletion). In addition, the SKM-1 cell line expressing EZH2 Y646C showed reduced H3K27M methyltransferase activity compared to EZH2-unmutated SKK-1 and MOLM-13 cell lines."	"Ernst et al., 2010, Nat Genet"	Unknown	ENST00000320356.7	missense_variant
EZH2 Y646F	EZH2	Y646F	B-cell Lymphoma		Oncogenic	Supports	D	Oncogenicity	chr7	148811635	148811635	T	A	"Ezh2 Y641F (EZH2 Y641F) was conditionally expressed in mouse B-cells and caused high-penetrance lymphoma that was further accelerated by Bcl2 overexpression or p53 loss (but not c-Myc overexpression). Expression of Ezh2 Y641F increased global abundance of H3K27 trimethylation (H3K27me3) and also caused widespread redistribution of H3K27me3 leading to widespread transciptional changes. Overall, these results suggest that Ezh2 Y641F induces B-cell lymphoma through widespread reorganization of chromatin structure."	"Souroullas et al., 2016, Nat. Med."	Somatic	ENST00000320356.7	missense_variant
EZH2 Y646H	EZH2	Y646H	Diffuse Large B-cell Lymphoma	Tazemetostat	Predictive	Supports	C	Sensitivity/Response	chr7	148811636	148811636	A	G	"A phase I safety and dose-escalation study (NCT01897571) was completed for tazemetostat in relapsed or refractory B-cell non-Hodgkin lymphoma or advanced solid tumors. Durable objective responses, including complete responses, were observed in eight (38%) of 21 patients with B-cell non-Hodgkin lymphoma and two (5%) of 43 patients with solid tumours. EZH2 mutation status was assessed retrospectively. Two DLBCL patients had mutations. One of these (with a Y646H mutation) had a durable partial response before disease progression after 16 months on study. The variant in the second patient was not reported and the duration of therapy for this patient that did not respond was among the shortest in the trial."	"Italiano et al., 2018, Lancet Oncol."	Somatic	ENST00000320356.7	missense_variant
EZH2 Y646N	EZH2	Y646N			Functional	Supports	D	Gain of Function	chr7	148811636	148811636	A	T	"H3K27me3 (histone H3 Lys-27specific trimethylation) level was higher in EZH2 (Y641N) bearing germinal center B-cell type DLBCL derived lymphoma cell lines and tumors than in wild-type cells. There was no difference of H3K27Me2 and H3K9Me3 levels between Y641F/N and WT, indicating specificity in a gain of function of Y641F/N. Expression of Y641N mutation in HEK293T cells with wild-type EZH2 led to an increase in H3K27me3. Structural modeling indicated that Y641F/N helped push the equilibrium to favor trimethylated products. A 3H methyl incorporation assay was used to study the activity of the PRC2 complex containing Y641N mutation in vitro. PRC2 complexes containing Y641N showed nearly two times higher activity with H3K27me2 substrates than PRC complexes with wild-type EZH2. This study indicates that EZH2 (Y641N) increases H3K27 trimethylation."	"Yap et al., 2011, Blood"	Somatic	ENST00000320356.7	missense_variant
EZH2 Y646N	EZH2	Y646N			Functional	Supports	D	Loss of Function	chr7	148811636	148811636	A	T	A 3H methyl incorporation assay tested the function of EZH2 Y641N containing PRC2 complexes in vitro. It showed that Y641F/N PRC2 complexes had significantly decreased enzyme activity on unmethylated and monomethylated H3 mimicking peptide substrates compared with wild-type.	"Yap et al., 2011, Blood"	Somatic	ENST00000320356.7	missense_variant
EZH2 Y646H	EZH2	Y646H			Functional	Supports	D	Gain of Function	chr7	148811636	148811636	A	G	Whole-cell lysates from frozen GCB-derived lymphoma sections with EZH2 Y641H showed a higher level of H3K27me3 (histone H3 Lys-27specific trimethylation) compared with those from tumor with wild-type EZH2 in western blots using an antibody specific for H3K27me3 (sample number 178).	"Yap et al., 2011, Blood"	Somatic	ENST00000320356.7	missense_variant
KMT2C MUTATION	KMT2C	MUTATION	Skin Squamous Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr7	152134925	152436005			Evaluation of 39 aggressive cutaneous squamous cell carcinomas revealed that tumors with a KMT2C mutation were 5x more likely to invade the bone (53% versus 10%; p=0.008).  Patients with KMT2C mutations also had significantly shorter recurrent free survival (21.6 versus 167.5; p=0.003) and an increased hazards ratio for death (HR=5.16; 95%CI:1.55 to 17.18).  This worse prognosis did not appear to be correlated with bone invasion (p=0.98).	"Pickering et al., 2014, Clin. Cancer Res."	Somatic	ENST00000262189.6	"transcription_variant,loss_of_function_variant"
DEFA1 EXPRESSION	DEFA1	EXPRESSION	Prostate Cancer	Docetaxel	Predictive	Supports	B	Sensitivity/Response	chr8	6977650	6980080			"Blood mRNA levels of DEFA1, DEFA1B and DEFA3 were associated with response to docetaxel treatment in castration resistant prostate cancer. The discovery cohort consisted of 6 patients, results were validated in 10 patients."	"Kohli et al., 2015, Onco Targets Ther"	N/A	ENST00000382692.2	N/A
VPS37A Underexpression	VPS37A	Underexpression	Ovarian Cancer	Cetuximab	Predictive	Supports	D	Resistance	chr8	17246571	17298024			Vps37A-deficient ovarian cancer cells become irresponsive to inhibition by the therapeutic antibody cetuximab in-vitro.	"Wittinger et al., 2011, Clin. Cancer Res."	Somatic	ENST00000324849.4	N/A
PBK OVEREXPRESSION	PBK	OVEREXPRESSION	Lung Non-small Cell Carcinoma	Gefitinib	Predictive	Supports	D	Resistance	chr8	27809620	27838095			TOPK (PBK) silencing sensitized lung cancer cells to gefitinib in preclinical xenograft models. Over-expression was also associated with resistance in various lung cancer cell lines.	"Li et al., 2016, Oncotarget"	Somatic	ENST00000301905.4	N/A
PBK NUCLEAR EXPRESSION	PBK	NUCLEAR EXPRESSION	Gastric Adenocarcinoma		Prognostic	Supports	B	Poor Outcome	chr8	27809620	27838095			"Microarray expression data from 48 patients with gastric adenocarcinoma were analyzed for genes differentially expressed with regard to overall survival. Upregulation of proteasome subunit beta type 8 (PSMB8) and PDZ binding kinase (PBK) was confirmed by real-time reverse transcription-PCR Analysis. IHC in 385 gastric cancer patients showed that increased nuclear expression of PSMB8 and PBK was correlated with depth of invasion, lymph node metastasis, and lower survival rates (survival duration, months according to nuclear PBK Expression: -, 72.3  1.2; +, 66.2  3.4; ++, 53.1  9.2; P = 0.002). Cytoplasmic staining of PSMB8 and PBK were not statistically significant. In multivariate analysis, nuclear expression of PSMB8 and PBK were not significant predictors of overall survival (P = 0.085, P = 0.083, respectively)."	"Kwon et al., 2016, Oncotarget"	N/A	ENST00000301905.4	N/A
NRG1 Expression	NRG1	Expression	Head And Neck Squamous Cell Carcinoma	Lapatinib	Predictive	Supports	D	Sensitivity/Response	chr8	31640426	32764776			"In non-HER2 amplified cell lines, sensitivity to HER2 kinase inhibitor lapatinib was found mainly in cell-lines with elevated NRG1 expression and HER3 activation. This aberration was mainly identified in head and neck cancer cell lines."	"Wilson et al., 2011, Cancer Cell"	N/A	ENST00000523534.1	N/A
NRG1 Expression	NRG1	Expression	Colorectal Cancer	Cetuximab	Predictive	Supports	D	Resistance	chr8	31640426	32764776			NRG1 upregulation or ERBB2 amplification were the main causes of resistance to cetuximab in-vivo and in-vitro in this study. Inhibition of ERBB2/ERBB3 signaling restored cetuximab sensitivity.	"Yonesaka et al., 2011, Sci Transl Med"	N/A	ENST00000523534.1	N/A
NRG1 Expression	NRG1	Expression	Ovarian Cancer	Seribantumab	Predictive	Supports	D	Sensitivity/Response	chr8	31640426	32764776			An NRG1-ERBB3 autocrine signal-transducing loop was identified in a subset of ovarian cancers and cell lines. Disruption of this loop led to decreased cell-growth in-vitro and prolonged survival in-vivo. An ERBB3 directed antibody (MM-121) inhibited tumor-growth in-vivo.	"Sheng et al., 2010, Cancer Cell"	N/A	ENST00000523534.1	N/A
NRG1 Expression	NRG1	Expression	Lung Non-small Cell Carcinoma	"Carboplatin,Paclitaxel,Cisplatin,Gemcitabine"	Predictive	Supports	D	Sensitivity/Response	chr8	31640426	32764776			In-vivo studies of residual NSCLC tumors (xenografts of 5 cell lines) after chemotherapy found increased EGFR-family signaling and NRG1 expression. NRG1 inhibition (YW538.24.71 antibody) led to decreased tumor growth and enhanced magnitude and response to chemotherapy.	"Hegde et al., 2013, Sci Transl Med"	N/A	ENST00000523534.1	N/A
NRG1 Expression	NRG1	Expression	Lung Non-small Cell Carcinoma	Patritumab	Predictive	Supports	B	Sensitivity/Response	chr8	31640426	32764776			"In this phase-2 study, 215 patients were randomized to either erlotinib and placebo or erlotinib and HER3 monoclonal antibody patritumab. HRG (NRG1) expression was retrospectively defined as predictive biomarker but prospectively assessed in 102 patients before unblinding. NRG1-high groups demonstrated clinical benefit from additional patritumab with hazard ratios of 0.37 (P = 0.0283) and 0.29 (P = 0.0027) in the high- and low-dose patritumab arms, respectively."	"Mendell et al., 2015, EBioMedicine"	N/A	ENST00000523534.1	N/A
NRG1 Expression	NRG1	Expression	Cancer	Anti-ErbB3 Monoclonal Antibody AV-203	Predictive	Supports	D	Sensitivity/Response	chr8	31640426	32764776			This screening study in various tumor xenografts identified NRG1 expression to correlate with sensivity to ERBB3 inhibitory antibody AV-203. ERBB3 expression was not predictive of response.	"Meetze et al., 2015, Clin. Cancer Res."	N/A	ENST00000523534.1	N/A
EIF4EBP1 PHOSPHORYLATION	EIF4EBP1	PHOSPHORYLATION	Gastric Adenocarcinoma	Everolimus	Predictive	Supports	D	Sensitivity/Response	chr8	38030682	38057145			"8 gastric cancer cell lines were treated with the MTOR inhibitor everolimus. Cell proliferation was effectively inhibited in 3 cell lines by everolimus. Phosphorylated EIF4EBP1 (T37/46, T70) levels were higher in cell lines and xenografts sensitive to everolimus."	"Nishi et al., 2013, Cancer Lett."	N/A	ENST00000338825.4	N/A
EIF4EBP1 PHOSPHORYLATION	EIF4EBP1	PHOSPHORYLATION	Colorectal Cancer	"WYE354,MTOR Kinase Inhibitor PP242,Dactolisib"	Predictive	Supports	D	Resistance	chr8	38030682	38057145			"12 CRC cell lines were evaluated. 40% of these were intrinsically resistant to mTOR inhibition with  BEZ235, PP242 or WYE354. mTOR independent phosphorylation of EIF4EBP1 (T37/46) was associated with resistance to mTOR inhibitors in one analyzed cell line (SW620)."	"Zhang et al., 2012, Cell Cycle"	N/A	ENST00000338825.4	N/A
FGFR1 Amplification	FGFR1	Amplification	Lung Squamous Cell Carcinoma	PD173074	Predictive	Supports	D	Sensitivity/Response	chr8	38411138	38467845			"Preclinical (in-vitro, in-vivo) evidence suggests predictive value of FGFR1 amplification for treatment with FGFR1-inhibitors. 4 of 83 cell lines exhibited FGFR1 amplification, and 3 of these were highly sensitive to PD173074. This sensitivity was confirmed in a mouse xenograft. Clinical trials are currently ongoing."	"Weiss et al., 2010, Sci Transl Med"	Somatic	ENST00000425967.3	transcript_amplification
FGFR1 Expression	FGFR1	Expression	Lung Cancer	Ponatinib	Predictive	Supports	D	Sensitivity/Response	chr8	38411138	38467845			"Preclinical evidence (in-vitro) for predictive value of FGFR1 mRNA and protein expression as well as mRNA expression of FGF2 and FGF9 for sensitivity to FGFR1 inhibition. The authors suggested that FGFR1 expression is a better predictive marker than FGFR1 amplification and proposes a connection between KRAS and PIK3CA mutations. This study used 58 cell lines, of which 14 exhibited ponatinib sensitivity. This sensitivity was correlated with FGFR1 mRNA and protein expression."	"Wynes et al., 2014, Clin. Cancer Res."	N/A	ENST00000425967.3	N/A
FGFR1 Amplification	FGFR1	Amplification	Lung Squamous Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr8	38411138	38467845			"In this study in surgically resected squamous cell lung cancer, FGFR1 amplification has been shown as an independent negative prognostic factor in Asian patients. FGFR1 amplification also correlates with cigarette smoking."	"Kim et al., 2013, J. Clin. Oncol."	Somatic	ENST00000425967.3	transcript_amplification
FGFR1 Amplification	FGFR1	Amplification	Lung Squamous Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr8	38411138	38467845			"This study shows an association of FGFR1 amplification with shorter overall and disease-free survival. However, no statistically significant association is seen on multivariate analysis."	"Seo et al., 2014, Virchows Arch."	Somatic	ENST00000425967.3	transcript_amplification
FGFR1 Amplification	FGFR1	Amplification	Lung Non-small Cell Carcinoma		Prognostic	Supports	B	Better Outcome	chr8	38411138	38467845			This study shows a reduction in the risk of death for patients with FGFR1 copy-number between 4 and 6. No difference in survival is seen between amplified and non-amplified patients in general.	"Tran et al., 2013, Lung Cancer"	Somatic	ENST00000425967.3	transcript_amplification
FGFR1 Amplification	FGFR1	Amplification	Cancer		Prognostic	Supports	B	Poor Outcome	chr8	38411138	38467845			"Meta-Analysis on prognostic value of FGFR1 amplification in different types of cancer shows significantly worse overall survival for patients with FGFR1 and FGFR2 amplification. However, larger studies are warranted for confirmation."	"Chang et al., 2014, PLoS ONE"	Somatic	ENST00000425967.3	transcript_amplification
FGFR1 Amplification	FGFR1	Amplification	Lung Non-small Cell Carcinoma	PD173074	Predictive	Supports	D	Sensitivity/Response	chr8	38411138	38467845			Preclinical study showing FGFR1 amplification in NSCLC and efficacy of FGFR-1 inhibition in one amplified cell line.	"Dutt et al., 2011, PLoS ONE"	Somatic	ENST00000425967.3	transcript_amplification
FGFR1 Amplification	FGFR1	Amplification	Lung Squamous Cell Carcinoma		Prognostic	Does Not Support	B	Poor Outcome	chr8	38411138	38467845			"Effect of FGFR1 amplification on survival unclear, no significant correlation with PFS and OS seen in this meta-analysis. However, FGFR1 amplification is significantly correlated with lymph node metastasis."	"Jiang et al., 2015, Lung Cancer"	Somatic	ENST00000425967.3	transcript_amplification
FGFR1 Expression	FGFR1	Expression	Breast Cancer		Prognostic	Supports	B	Poor Outcome	chr8	38411138	38467845			"FGFR1 expression, was assessed by IHC in 1,086 invasive breast cancers. FGFR1 expression was mainly associated with luminal cancer subtypes. Multivariate Cox regression analysis showed FGFR1 to be an independent poor prognostic marker in luminal A cancers for disease free survival (hazard ratio = 3.341, p = 0.008). In luminal A cancers, FGFR1 expression was also significantly associated with higher pN (lymph node metastases; p = 0.023) and pT (unfavorable tumor characteristics; p = 0.003) stages and lymphovascular invasion (p = 0.010)."	"Shi et al., 2016, Oncotarget"	N/A	ENST00000425967.3	N/A
FGFR1 Expression	FGFR1	Expression	Head And Neck Squamous Cell Carcinoma		Prognostic	Does Not Support	B	Poor Outcome	chr8	38411138	38467845			"This review identified 12 studies that addressed the prognostic role of FGFRs in HNSSC. Evidence was found for the expression of FGFR1 in cancer-associated fibroblasts, other results were conflicting. Significant risk of bias was reported for the included studies."	"Ipenburg et al., 2016, Target Oncol"	N/A	ENST00000425967.3	N/A
FGFR1 Expression	FGFR1	Expression	Head And Neck Squamous Cell Carcinoma	Infigratinib	Predictive	Supports	D	Sensitivity/Response	chr8	38411138	38467845			"FGFR1 mRNA expression, rather than copy number alterations, were predictive of response to FGFR inhibitor BGJ398 in cell lines and patient derived xenografts."	"Gke et al., 2015, Clin. Cancer Res."	N/A	ENST00000425967.3	N/A
FGFR1 Expression	FGFR1	Expression	Gastric Adenocarcinoma	Infigratinib	Predictive	Supports	D	Sensitivity/Response	chr8	38411138	38467845			FGFR inhibitor BGJ398 was most effective in a gastric cancer cell line model with high expression of FGFR1 and FGFR2IIIc.	"Schmidt et al., 2015, Anticancer Res."	N/A	ENST00000425967.3	N/A
FGFR1 Expression	FGFR1	Expression	Bladder Carcinoma	"PD173074,Dovitinib"	Predictive	Supports	D	Sensitivity/Response	chr8	38411138	38467845			"One urothelial cell line (JMSU1) with high expression of FGFR1 was sensitive to treatment with FGFR inhibitors  (SU5402, TKI258 or PD173074). IC50 values for PD173074 and TKI-258 (Dovitinib) were in nanomolar range compared with micromolar concentration for SU5402."	"Lamont et al., 2011, Br. J. Cancer"	N/A	ENST00000425967.3	N/A
FGFR1 Expression	FGFR1	Expression	Colorectal Cancer	Infigratinib	Predictive	Supports	D	Sensitivity/Response	chr8	38411138	38467845			"In vitro studies showed efficacy of FGFR inhibitor NVP-BGJ398 in cell lines exhibiting high FGFR1 protein. Three cell lines (SNU-C1, HDC9, HCT116) were analyzed. FGFR1 amplification (24/454, assessed by FISH) and/or activated pFGFR1 protein (18/99, assessed by mRNA in situ hybridization) was identified in primary CRC tissue samples."	"Gke et al., 2013, Digestion"	N/A	ENST00000425967.3	N/A
FGFR1 Expression	FGFR1	Expression	Head And Neck Squamous Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr8	38411138	38467845			"Expression of bFGF and FGFR1 were evaluated in 61 biopsy specimens of primary OSCC (IHC). Expression was evaluated in both the cancer cells and fibroblasts at the invasive front of each tumor. bFGF and FGFR1 were expressed in all tumor specimens, whereas expression of these proteins in cancer-associated fibroblasts was associated with lymph node metastasis (P < 0.05) and worse patient survival."	"Hase et al., 2006, J. Oral Pathol. Med."	N/A	ENST00000425967.3	N/A
FGFR1 Amplification	FGFR1	Amplification	Breast Cancer	Afimoxifene	Predictive	Supports	D	Resistance	chr8	38411138	38467845			"FGFR1-amplified breast cancer cell lines show resistance to 4-hydroxytamoxifen, which is reversed by small interfering RNA silencing of FGFR1."	"Turner et al., 2010, Cancer Res."	Somatic	ENST00000425967.3	transcript_amplification
FGFR1 Amplification	FGFR1	Amplification	Ewing Sarcoma Of Bone	Ponatinib	Predictive	Supports	D	Sensitivity/Response	chr8	38411138	38467845			"116 Ewing's sarcoma tumor samples were analyzed in this study. 2 patient's samples underwent whole genome sequencing, tumor samples from 51 patients underwent exome sequencing and expression analysis, 63 samples underwent FGFR1 copy number analysis, mRNA analysis and IHC. A FGFR1 N546K mutation was detected in one patient. Gain of the FGFR1 locus (qPCR) was observed in 13 of 41 patients (31.7%) and Ewing sarcoma cell lines (A673, CADO, SK-NMC, SK-ES, and VH-64). FGFR1 was also highly expressed in Ewing sarcoma (mRNA and IHC) and correlated with copy number. Retroviral transduction of FGFR1 wild-type or the FGFR1 N546K mutant into NIH3T3 cells led to enhanced proliferation especially for cells harboring the FGFR1 mutation. ShRNA mediated knockdown of FGFR1 inhibited growth of Ewing sarcoma and other cancer cells (A549 lung carcinoma cell line or leukemia cell lines HL60 and Kasumi) with almost complete growth suppression only in the Ewing sarcoma cell lines and knockdown of FGFR1 abrogated growth of cell lines in xenograft. Ponatinib treatment inhibited growth of Ewing sarcoma cell lines."	"Agelopoulos et al., 2015, Clin. Cancer Res."	N/A	ENST00000425967.3	transcript_amplification
FGFR1 Fusion	FGFR1	Fusion	Chronic Myelomonocytic Leukemia		Diagnostic	Supports	A	Negative	chr8	38411138	38467845			"The 2016 World Health Organization guidelines for the classification of myeloid malignancies uses the detection of PCM1-JAK2 or rearrangements involving PDGFRA, PDGFRB, or FGFR1 as recommended exclusion criteria for a diagnosis of chronic myelomonocytic leukemia, particularly in patients with evidence of eosinophilia."	"Arber et al., 2016, Blood"	Somatic	ENST00000425967.3	transcript_fusion
FGFR1 Fusion	FGFR1	Fusion	Hematologic Cancer		Diagnostic	Supports	A	Positive	chr8	38411138	38467845			"The 2016 World Health Organization guidelines for the classification of myeloid malignancies and acute leukemia describes a new class of disease defined by myeloid or lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2."	"Arber et al., 2016, Blood"	Somatic	ENST00000425967.3	transcript_fusion
FGFR1 Amplification	FGFR1	Amplification	Breast Cancer	Dovitinib	Predictive	Supports	B	Sensitivity/Response	chr8	38411138	38467845			"Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study. Dovitinib inhibited proliferation in one FGFR1- and one FGFR2-amplified breast cancer cell lines at higher IC50 values than in 11 nonamplified cell lines. Dovitinib inhibited tumor growth and caused regression in both a FGFR1- and FGFR2-amplified xenograft model. 81 patients were enrolled in the trial and treated with dovitinib. Unconfirmed response or stable disease >6 months was observed in 25% of FGFR1-amplified/HR-positive vs. 3% FGFR1-nonamplified/HR-positive breast cancer patientes. When FGF3 and FGFR2 amplifications were also assessed, a combined FGF-pathway amplified patient group had a higher mean reduction in target lesion size than patients with FGF-non-amplified tumors."	"Andr et al., 2013, Clin. Cancer Res."	N/A	ENST00000425967.3	transcript_amplification
FGFR1 Amplification	FGFR1	Amplification	Estrogen-receptor Positive Breast Cancer	Ponatinib	Predictive	Supports	D	Sensitivity/Response	chr8	38411138	38467845			In MDA-MB-134 cells (ER-positive breast cancer cells with amplified FGFR1) ponatinib potently inhibited cell growth with a GI50 value of 23 nmol/L and inhibited FGFR1 phosphorylation with an IC50 value of 7 nmol/L.	"Gozgit et al., 2012, Mol. Cancer Ther."	Somatic	ENST00000425967.3	transcript_amplification
FGFR1 Amplification	FGFR1	Amplification	Lung Squamous Cell Carcinoma	Infigratinib	Predictive	Supports	B	Sensitivity/Response	chr8	38411138	38467845			"Phase 1 study of FGFR-inhibitor BGJ398 (infigratinib) in advanced cancer with FGFR-aberrations (n=132). In the subgroup of FGFR1-amplified squamous NSCLC (as classified by FISH), 36 patients were treated at doses >100mg continuously and disease control was achieved in 50% of patients (4 PR and 14 SD) with 6 patients receiving treatment after 16 weeks. Of the 27 patients who had evaluable pre- and post- treatment target lesion assessments, 11 had reduced tumor burden."	"Nogova et al., 2017, J. Clin. Oncol."	Somatic	ENST00000425967.3	transcript_amplification
FGFR1 Amplification	FGFR1	Amplification	Breast Cancer	Infigratinib	Predictive	Does Not Support	B	Resistance	chr8	38411138	38467845			"Phase 1 study of FGFR-inhibitor BGJ398 (infigratinib) in advanced cancer with FGFR-aberrations (n=132). Among the 21 continuously treated (>100mg) patients with breast cancer and FGFR1 amplification (as classified by FISH), 9 had a best response of SD, three of which experienced reductions in tumor burden."	"Nogova et al., 2017, J. Clin. Oncol."	Somatic	ENST00000425967.3	transcript_amplification
FGFR1 Amplification	FGFR1	Amplification	Bladder Carcinoma	Infigratinib	Predictive	Does Not Support	C	Sensitivity/Response	chr8	38411138	38467845			"Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. Of the eight patients with FGFR3-mutated bladder/urothelial cancer, one patient with FGFR1 amplification was treated with 125 mg and progressed rapidly in cycle 1 after 11 days of treatment."	"Nogova et al., 2017, J. Clin. Oncol."	N/A	ENST00000425967.3	transcript_amplification
FGFR1 Amplification	FGFR1	Amplification	Breast Cancer	FGFR Inhibitor AZD4547	Predictive	Supports	C	Sensitivity/Response	chr8	38411138	38467845			"Activity of the FGFR-selective inhibitor AZD4547 in FGFR1-amplified breast cancer and FGFR2-amplified gastroesophageal cancer was analyzed in this study. 341 patients with advanced cancer were screened by FISH, identifying FGFR1 amplification in 18% of advanced HER2-negative breast cancers and FGFR2 amplification in 9% of advanced gastroesophageal cancer. 1 patient had a confirmed response among 8 patients treated with FGFR1-amplified breast cancer. In a preclinical model, FGFR1 amplification in breast cancer cell lines was less pronounced than FGFR2-amplifications in gastroesophageal cancers, which also had a higher response rate in the trial, indicating that high level amplification is associated with response and less common in FGFR1-amplified breast cancer."	"Pearson et al., 2016, Cancer Discov"	N/A	ENST00000425967.3	transcript_amplification
FGFR1 Expression	FGFR1	Expression	Sarcoma	"Infigratinib,FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074,FGFR Inhibitor AZD4547"	Predictive	Supports	D	Sensitivity/Response	chr8	38411138	38467845			"Targeting of FGFR1 by RNA interference and small-molecule inhibitors (PD173074, AZD4547, BGJ398) revealed that the requirement for FGFR1 signaling in STS cells is dictated by FGFR1 expression levels, and identified the MAPK-ERK1/2 axis as critical FGFR1 effector pathway."	"Chudasama et al., 2017, Clin. Cancer Res."	Somatic	ENST00000425967.3	N/A
FGFR1 Amplification	FGFR1	Amplification	Lung Non-small Cell Carcinoma	Dovitinib	Predictive	Supports	B	Sensitivity/Response	chr8	38411138	38467845			"Clinical trial studied the efficacy of Dovitinib on 26 patients with FGFR1 amplifications. Objective response for the cohort was 11.5%, disease control rate was 50%. 11.5% of patients exhibited partial response, 38.5% exhibited stable disease. Median PFS was 2.9 months, median OS was 5 months, this trend was worse with increases in FGFR1 amplification above average."	"Lim et al., 2016, Cancer"	Somatic	ENST00000425967.3	transcript_amplification
FGFR1 Amplification	FGFR1	Amplification	Breast Cancer	Pazopanib	Predictive	Supports	C	Sensitivity/Response	chr8	38411138	38467845			"Case report in a HR positive, Her2/neu negative breast cancer patient harboring an FGFR1 amplification. The patient responded to treatment to Pazopanib - including a near CR of brain metastases. Duration of Treatment or median PFS was not reported at the time of publication."	"Cheng et al., 2017, J Natl Compr Canc Netw"	Somatic	ENST00000425967.3	transcript_amplification
FGFR1 Fusion	FGFR1	Fusion	Acute Myeloid Leukemia	"Sorafenib,Sunitinib"	Predictive	Does Not Support	D	Sensitivity/Response	chr8	38411138	38467845			"In a preclinical trial, the AML cell line KG1 with the FGFR1OP2-FGFR1 fusion mutation was treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was much more effective in the growth inhibition of cells harboring the fusion mutation (IC50=17 nmol/L) compared to sorafenib (IC50>100 nmol/L) and sunitinib (IC50>100 nmol/L)."	"Gozgit et al., 2011, Mol. Cancer Ther."	Somatic	ENST00000425967.3	transcript_fusion
FGFR1 Amplification	FGFR1	Amplification	Breast Cancer	Lucitanib	Predictive	Supports	B	Sensitivity/Response	chr8	38411138	38467845			"In a phase 1 trial, patients with advanced solid tumors were treated with FGFR1/2, VEGFR1/2/3, and PDGFR inhibitor lucitanib. Among 12 patients with breast cancer harboring FGFR alterations (8 FGFR1 amplification, 4 11q amplification), 6 patients showed tumor response. The response rate was 50% and the duration of response was 48.7 weeks. Among the 8 patients with FGFR1 amplification, 4 showed a partial response and 4 achieved stable disease."	"Soria et al., 2014, Ann. Oncol."	Somatic	ENST00000425967.3	transcript_amplification
FGFR1 Amplification	FGFR1	Amplification	Adenosquamous Lung Carcinoma	Pazopanib	Predictive	Supports	C	Sensitivity/Response	chr8	38411138	38467845			"Patient diagnosed with metastatic squamous cell lung cancer had high-level amplification of FGFR1 and high expression of MYC.  Patient was treated with 400 mg pazopanib twice a day.  CT taken four and eight weeks after start of pazopanib showed tumor regression and cavitation.   Due to side effects, patient stopped taking pazopanib after 6 months.  No clinical or radiologic signs of tumor progression were present at that time."	"Malchers et al., 2014, Cancer Discov"	Somatic	ENST00000425967.3	transcript_amplification
FGFR1 N546K	FGFR1	N546K	Ewing Sarcoma Of Bone	Ponatinib	Predictive	Supports	E	Sensitivity/Response	chr8	38417331	38417331	G	T	"116 Ewing's sarcoma tumor samples were analyzed in this study. 2 patient's samples underwent whole genome sequencing, tumor samples from 51 patients underwent exome sequencing and expression analysis, 63 samples underwent FGFR1 copy number analysis, mRNA analysis and IHC. A FGFR1 N546K mutation was detected in one patient. Gain of the FGFR1 locus (qPCR) was observed in 13 of 41 patients (31.7%) and Ewing sarcoma cell lines (A673, CADO, SK-NMC, SK-ES, and VH-64). FGFR1 was also highly expressed in Ewing sarcoma (mRNA and IHC) and correlated with copy number. Retroviral transduction of FGFR1 wild-type or the FGFR1 N546K mutant into NIH3T3 cells led to enhanced proliferation especially for cells harboring the FGFR1 mutation. ShRNA mediated knockdown of FGFR1 inhibited growth of Ewing sarcoma and other cancer cells (A549 lung carcinoma cell line or leukemia cell lines HL60 and Kasumi) with almost complete growth suppression only in the Ewing sarcoma cell lines and knockdown of FGFR1 abrogated growth of cell lines in xenograft. Ponatinib treatment inhibited growth of Ewing sarcoma cell lines."	"Agelopoulos et al., 2015, Clin. Cancer Res."	Somatic	ENST00000341462.5	missense_variant
FGFR1 N546K	FGFR1	N546K	Pilocytic Astrocytoma	Pemigatinib	Predictive	Supports	C	Sensitivity/Response	chr8	38417331	38417331	G	T	Case report of a 32-year old male patient with pilocytic astrocytoma. Genomic profiling (FoundationOne) revealed a FGFR1 N546K mutation. The patient was enrolled in a phase I/II trial of pemigatinib and achieved a partial response lasting 18 months.	"Capone et al., 2022, JCO Precis Oncol"	Somatic	ENST00000341462.5	missense_variant
PREX2 R172I	PREX2	R172I	Melanoma	Vemurafenib	Predictive	Supports	C	Resistance	chr8	68027295	68027295	G	T	"In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E/K (known BRAF inhibitor sensitizing mutations), PREX2 R172I was associated with a case of acquired resistance to BRAF inhibitor (vemurafenib) monotherapy in one patient. This patient was an 83 year old male with stage IV M1c melanoma who took vemurafenib (960mg twice daily). The best overall response was a 5% increase in sum of target lesions, and progression free survival lasted 132 days. Prior to vemurafenib monotherapy, this patient harbored BRAF V600K and no other somatic genetic alterations noted in the baseline tumor. Following relapse, the patient gained PREX2 R172I in one of two disease progressive tumors. Whole exome sequencing and Sanger re-sequencing were used for all tumors. The authors indicated that the biology behind this potential resistance mutation was unknown."	"Shi et al., 2014, Cancer Discov"	Somatic	ENST00000288368.4	missense_variant
PTP4A3 OVEREXPRESSION	PTP4A3	OVEREXPRESSION	Colorectal Cancer	Cetuximab	Predictive	Supports	D	Sensitivity/Response	chr8	141391993	141431294			"In-vitro studies linked PRL-3 (PP4A3) expression to hyperactivation and dependence on EGFR signaling (through downregulation of PTP1B, an inhibitory phosphatase of EGFR). Retrospective analysis of 68 patients showed improved clinical response to the EGFR inhibitor cetuximab in tumors expressing PRL-3."	"Al-Aidaroos et al., 2013, J. Clin. Invest."	Somatic	ENST00000521578.1	N/A
JAK2 c.1641+1dup	JAK2	c.1641+1dup	Skin Melanoma	Pembrolizumab	Predictive	Supports	C	Resistance	chr9	5070053	5070054		G	Paired tumor samples were analyzed from four patients with metastatic melanoma and initial response with a subsequent relapse under pembrolizumab (PD-1 checkpoint inhibitor) therapy. Baseline biopsies were obtained before therapy initiation with pembrolizumab. A JAK2 F547 splice site mutation was observed at the time of relapse in patient 2. RNA sequencing revealed an in-frame stop codon after exon 12. The JAK2 mutation was the only homozygous mutation (allele frequency >85%) of 76 new nonsynonymous mutations in patient 2. Cell line modelling of baseline and relapse JAK2 mutational status revealed a loss of response to interferon gamma and  loss of JAK2 protein. This loss of response was also modeled in another cell line.	"Zaretsky et al., 2016, N. Engl. J. Med."	Somatic	ENST00000381652.3	
JAK2 Splice Site (c.1641+2T>G)	JAK2	Splice Site (c.1641+2T>G)	Melanoma	Pembrolizumab	Predictive	Supports	C	Resistance	chr9	5070054	5070054	T	G	"In a retrospective study of four relapsed, malignant melanoma patients, JAK2 (c.1641+2T>G) F547 splice site mutation was associated with acquired resistance to pembrolizumab monotherapy in one patient."	"Zaretsky et al., 2016, N. Engl. J. Med."	Somatic		splice_donor_variant
JAK2 V617F	JAK2	V617F	Lymphoid Leukemia		Diagnostic	Supports	B	Negative	chr9	5073770	5073770	G	T	"JAK2 V617F is not associated with lymphoid leukemia (B-lineage ALL, T-ALL or CLL)."	"Levine et al., 2005, Blood"	Somatic	ENST00000381652.3	"missense_variant,gain_of_function_variant"
JAK2 V617F	JAK2	V617F	Chronic Myeloid Leukemia		Diagnostic	Supports	B	Positive	chr9	5073770	5073770	G	T	"JAK2 V617F is associated with myeloid malignanices (AML, MDS, CMML/atypical CML)."	"Levine et al., 2005, Blood"	Somatic	ENST00000381652.3	"missense_variant,gain_of_function_variant"
JAK2 V617F	JAK2	V617F	Chronic Myeloid Leukemia		Diagnostic	Supports	B	Positive	chr9	5073770	5073770	G	T	"JAK2 V617F is associated with myeloid neoplasms (AML, MDS, CMML/aCML)."	"Levine et al., 2005, Blood"	Somatic	ENST00000381652.3	"missense_variant,gain_of_function_variant"
JAK2 V617F	JAK2	V617F	Bone Marrow Cancer		Diagnostic	Supports	B	Positive	chr9	5073770	5073770	G	T	The SNP rs10974944 in the Jak2 locus is associated with increased predisposition for JAK2 V617F mutation and its associated cancer.	"Kilpivaara et al., 2009, Nat. Genet."	Somatic	ENST00000381652.3	"missense_variant,gain_of_function_variant"
JAK2 V617F	JAK2	V617F	Polycythemia Vera	Peginterferon Alfa-2b	Predictive	Supports	B	Sensitivity/Response	chr9	5073770	5073770	G	T	"In patients with JAK2 V617F, the use of pegylated IFN-alpha-2a leads to reduction in the percentage of cells harboring JAK2 V617F."	"Kiladjian et al., 2006, Blood"	Somatic	ENST00000381652.3	"missense_variant,gain_of_function_variant"
JAK2 V617F	JAK2	V617F	Polycythemia Vera	Fedratinib	Predictive	Supports	D	Sensitivity/Response	chr9	5073770	5073770	G	T	TG101348 effectively inhibits STAT5 signaling in JAK2 V617F cells.	"Wernig et al., 2008, Cancer Cell"	Somatic	ENST00000381652.3	"missense_variant,gain_of_function_variant"
CD274 Expression	CD274	Expression	Lung Non-small Cell Carcinoma		Prognostic	Does Not Support	B	Poor Outcome	chr9	5450525	5470547			This meta-analysis did not find a significant connection between expression of PD-L1 and overall survival in patients with NSCLC.	"Zhong et al., 2015, Onco Targets Ther"	N/A	ENST00000381577.3	N/A
CD274 Expression	CD274	Expression	Lung Squamous Cell Carcinoma		Prognostic	Supports	B	Better Outcome	chr9	5450525	5470547			"In this study, PD-L1 expression (measured by IHC) was associated with better overall survival in the subgroup of Lung Squamous Cell Carcinomas (149 of 321 patients in the study)."	"Schmidt et al., 2015, PLoS ONE"	N/A	ENST00000381577.3	N/A
CD274 Expression	CD274	Expression	Ovarian Serous Carcinoma		Prognostic	Supports	B	Better Outcome	chr9	5450525	5470547			High expression of PD-L1 and PD-1 were associated with a favorable prognosis in patients with high grade serous ovarian carcinoma (n = 215 cases).	"Darb-Esfahani et al., 2016, Oncotarget"	N/A	ENST00000381577.3	N/A
CD274 Expression	CD274	Expression	Melanoma	"Pembrolizumab,Nivolumab"	Predictive	Supports	B	Sensitivity/Response	chr9	5450525	5470547			"Based on a meta-analysis of 20 trials (1475 patients), of which 7 studies (636 patients) included melanoma, PD-L1 expression was associated with a higher ORR rate in patients with melanoma. Active drugs were Nivolumab and Pembrolizumab, PD-1 receptor targeting antibodies."	"Carbognin et al., 2015, PLoS ONE"	N/A	ENST00000381577.3	N/A
CD274 Expression	CD274	Expression	Lung Non-small Cell Carcinoma	"Nivolumab,Pembrolizumab"	Predictive	Supports	B	Sensitivity/Response	chr9	5450525	5470547			"Based on a meta-analysis of 20 trials (1475 patients), PD-L1 expression was associated with a higher ORR rate in patients with NSCLC. Active drugs were Nivolumab and Pembrolizumab, PD-1 receptor targeting antibodies."	"Carbognin et al., 2015, PLoS ONE"	N/A	ENST00000381577.3	N/A
CD274 Expression	CD274	Expression	Lung Non-small Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr9	5450525	5470547			"74 patients with stage III NSCLC treated with concurrent chemoradiotherapy were retrospectively analyzed for PD-L1 expression and CD8+ tumour-infiltrating lymphocytes (TILs) density (IHC). CD8+ TIL density was an independent predictor of progression free survival (PFS) and overall survival (OS). Only when both TIL density and PD-L1 expression were both considered, was PD-L1 expression associated with survival. The subgroup, PD-L1+/CD8 low tumors had the shortest PFS (8.6 months, p = 0.02) and shortest, but not significantly different, OS (13.9 months, p = 0.11)."	"Tokito et al., 2016, Eur. J. Cancer"	N/A	ENST00000381577.3	N/A
CD274 Expression	CD274	Expression	Lung Non-small Cell Carcinoma	"Pembrolizumab,Atezolizumab,Avelumab,Nivolumab"	Predictive	Supports	B	Sensitivity/Response	chr9	5450525	5470547			"Meta-Analysis of PD-L1 (CD274) Expression Status in 914 patients (7 studies) and response to PD-1/PD-L1 monoclonal antibodies. Patients with PD-L1 positive tumors (PD-L1 tumor cell staining ?%), had a significantly higher ORR, compared to patients with PD-L1 negative tumors (OR: 2.44; 95% CIs: 1.61-3.68)."	"Passiglia et al., 2016, Oncotarget"	N/A	ENST00000381577.3	N/A
CD274 Expression	CD274	Expression	Lung Non-small Cell Carcinoma	Atezolizumab	Predictive	Supports	B	Sensitivity/Response	chr9	5450525	5470547			"Exploratory biomarker analysis from a phase-II randomized trial comparing atezolizumab (PD-L1) and docetaxel in previously treated, advanced or metastatic non-small cell lung cancer. Baseline PD-L1 expression (IHC) was assessed in tumour cells (as percentage of PD-L1-expressing tumour cells TC3?0%, TC2?% and <50%, TC1?% and <5%, and TC0<1%) and tumour-infiltrating immune cells (as percentage of tumour area: IC3?0%, IC2?% and <10%, IC1?% and <5%, and IC0<1%). Increasing PD-L1 Expression was associated with improved overall survival (TC3 or IC3 HR 049 [022-107; p=0068], TC2/3 or IC2/3 HR 054 [033-089; p=0014], TC1/2/3 or IC1/2/3 HR 059 [040-085; p=0005], TC0 and IC0 HR 104 [062-175; p=0871]) but not progression free survival or overall response rate."	"Fehrenbacher et al., 2016, Lancet"	N/A	ENST00000381577.3	N/A
CD274 Expression	CD274	Expression	Thyroid Gland Papillary Carcinoma		Prognostic	Supports	B	Poor Outcome	chr9	5450525	5470547			"Immunohistochemical analyses of PD-L1 protein was retrospectively performed on 251 archived FFPE surgical tissues (66 benign thyroid nodules and 185 papillary thyroid carcinomas PTC, E1L3N antibody). Patients with increased PD-L1 protein had significantly shorter median DFS (36 months [membranous staining] and 49 months [cytoplasmic staining] vs. 186 months [negative], p < 0.001 and p < 0.01, respectively)."	"Chowdhury et al., 2016, Oncotarget"	N/A	ENST00000381577.3	N/A
CD274 Expression	CD274	Expression	Stomach Carcinoma		Prognostic	Supports	B	Better Outcome	chr9	5450525	5470547			"465 gastric cancer samples and 15 corresponding liver metastases underwent IHC for PD1/PD-L1 protein expression. PD-L1 positivity in tumor cells was defined by at least 2% tumor cells with membranous positivity, PD-L1 positivity in immune cells by at least 10% PD-L1 positive immune cells. Patients with PD-L1 positive tumor cells had a significant better overall (p=0.028) and tumor specific survival (p=0.018). The same applied for patients with PD-L1 positive immune cells (p<0.001 each)."	"Bger et al., 2016, Oncotarget"	N/A	ENST00000381577.3	N/A
CD274 Expression	CD274	Expression	Cancer	Nivolumab	Predictive	Supports	B	Sensitivity/Response	chr9	5450525	5470547			"Trial NCT00730639 tested monoclonal antibody nivolumab against the PD-1 immune checkpoint receptor in pretreated patients with various cancer types. PD-L1 expression was tested in 42 patients by ICH from tumor FFPE biopsies. (18 melanoma, 10 NSCLC, 7 colorectal cancer, 5 renal cell cancer, 2 prostate cancer). 9 of 25 PD-L1 expressing patients showed objective response, and zero of 17 PD-L1 negative patients showed objective response (p=0.006). Biopsies were optional, and therefore not fully randomized."	"Topalian et al., 2012, N. Engl. J. Med."	N/A	ENST00000381577.3	N/A
CD274 Expression	CD274	Expression	Merkel Cell Carcinoma	Pembrolizumab	Predictive	Does Not Support	B	Sensitivity/Response	chr9	5450525	5470547			"Patients with Merkel Cell Carcinoma (n=26) were enrolled to receive pembrolizumab. Of these patients, 25 were evaluated for response rate to pembrolizumab and PD-L1 (CD274) expression. The response rate to pembrolizumab was 56% (95%CI: 35-76%), however, there was no correlation between PD-L1 expression (cutoff >1%) on tumor cells or on infiltrating immune cells and clinical response to pembrolizumab (P=0.61)."	"Nghiem et al., 2016, N. Engl. J. Med."	N/A	ENST00000381577.3	N/A
CD274 Expression	CD274	Expression	Melanoma	"Nivolumab,Ipilimumab"	Predictive	Does Not Support	B	Sensitivity/Response	chr9	5450525	5470547			"A clinical trial of 86 patients evaluated concurrent (n=53) or sequential (n=33) treatment of ipilimumab (anti-CTLA4) and nivolumab (anti-PD1). In the concurrent regimen cohort, 65% of patients showed clinical activity with no correlation between PD-L1 expression and response (6 of 13 patients were PD-L1 positive versus 9 of 22 patients were PD-L1 negative). In the sequential regimen cohort, 20% of patients had an objective response with a potential correlation between PD-L1 expression and response (4 of 8 patients were PD-L1 positive versus 1 of 13 patients were PD-L1 negative)."	"Wolchok et al., 2013, N. Engl. J. Med."	N/A	ENST00000381577.3	N/A
CD274 Expression	CD274	Expression	Lung Non-small Cell Carcinoma	Pembrolizumab	Predictive	Supports	B	Sensitivity/Response	chr9	5450525	5470547			"This open-label, randomized, phase-3 clinical trial compared pembrolizumab to chemotherapy in treating NSCLC patients with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of EGFR or translocation of ALK. Patients in the pembrolizumab group exhibited significantly better progression-free survival and overall survival compared to patients in the chemotherapy group."	"Reck et al., 2016, N. Engl. J. Med."	N/A	ENST00000381577.3	N/A
CD274 Expression	CD274	Expression	Head And Neck Squamous Cell Carcinoma	Radiation Therapy	Predictive	Supports	B	Resistance	chr9	5450525	5470547			"Radiation-resistant cell lines exhibited upregulation and increased activation of Axl, PI3 kinase signalling as well as increased expression of PD-L1. In 3 cohorts of HPV-negative head and neck squamous cell carcinoma patient samples evaluated with different methods [reverse phase protein array (N=68), mRNA expression array (N=97) or immunohistochemistry (N=114), respectively], increased expression of PD-L1 was also correlated with local failure following radiotherapy as compared to the PD-L1low expression group (P = 0.01, 1.9  10?, and 9  10?, respectively)."	"Skinner et al., 2017, Clin. Cancer Res."	N/A	ENST00000381577.3	N/A
CD274 Expression	CD274	Expression	Breast Cancer		Prognostic	Supports	B	Poor Outcome	chr9	5450525	5470547			"A meta-analysis of the role of PD-L1 expression in breast cancer found nine relevant studies with a total 8583 patients. PD-L1 expression was found to be associated with several poor prognostic indicators, such as ductal cancer, high tumor grade, ER negativity, PR negativity, HER2 positivity and aggressive molecular subtypes. PD-L1 overexpression had no significant impact on metastasis-free survival (HR 0.924, 95% CI = 0.747-1.141, p = 0.462), disease-free survival (HR 1.122, 95% CI = 0.878-1.434, p = 0.357) and overall specific survival (HR 0.837, 95% CI = 0.640-1.093, p = 0.191), but significantly correlated with shortened overall survival (HR 1.573, 95% CI = 1.010-2.451, p = 0.045)."	"Wang et al., 2017, Breast J"	N/A	ENST00000381577.3	N/A
CD274 Expression	CD274	Expression	Breast Cancer		Prognostic	Supports	B	Poor Outcome	chr9	5450525	5470547			"In this meta-analysis, 5 studies totalling 2,546 cases were combined to assess the prognostic association of PD-L1 expression in breast cancer. The combined hazard ratio (HR) for PD-L1 overexpression was 1.76 (OS). The pooled odds ratios (ORs) indicated that PD-L1 expression was associated with positive lymph node metastasis, higher histological grades, estrogen receptor (ER)-negativity, and triple-negative breast cancer (TNBC)."	"Zhang et al., 2017, Oncotarget"	N/A	ENST00000381577.3	N/A
CD274 Expression	CD274	Expression	Cancer		Prognostic	Supports	B	Better Outcome	chr9	5450525	5470547			"PD-L1 is not only expressed in tumor cells (TCs) but also upregulated in tumor-infiltrating immune cells (TIICs). This meta-analysis evaluated the prognostic value of PD-L1 expression in TIICs in different types of cancers. 18 studies involving 3674 patients were included. PD-L1 positivity in TIICs related to a lower risk of death (HR = 0.784, p=0.047), and TIICs indicated a better prognosis especially in breast cancer patients (HR = 0.359, p=0.002)."	"Zhao et al., 2017, PLoS ONE"	N/A	ENST00000381577.3	N/A
CD274 Expression	CD274	Expression	Lung Non-small Cell Carcinoma	"Nivolumab,Atezolizumab,Avelumab,Pembrolizumab,Durvalumab"	Predictive	Supports	B	Sensitivity/Response	chr9	5450525	5470547			"In this meta-analysis of 14 studies with 2857 patients, the immunotherapy response rate was higher among PD-L1-positive patients (RR: 2.19, 95% CI: 1.63-2.94). PD-L1 expression was also related to better progression-free survival (HR: 0.69, 95% CI: 0.57-0.85) and better overall survival (HR: 0.77, 95% CI: 0.67-0.89)."	"Aguiar et al., 2017, Immunotherapy"	N/A	ENST00000381577.3	N/A
CD274 Expression	CD274	Expression	Cancer		Prognostic	Supports	B	Poor Outcome	chr9	5450525	5470547			"A meta analysis of 60 research studies involving 10,310 solid tumors indicated that CD274 over expression results in poor overall survival (HR??.58, P?.001) and poor disease free/progression free survival (DFS/PFS) (HR??.72, P?0?001). When split into sub groups by cancer type overall survival  was poor for breast (HR??.98, P?0?014), urothelial (HR??.24, P?0.001), renal (HR??.30,  P?0.001), and gastric cancers (HR??.56, P?0?040). DFS/PFS was poor in patients with hepatocellular carcinoma (HR??.72,  P??.003), melanoma (HR??.39,  P?0.001), and renal carcinoma, (HR??.04,  P?0.001)."	"Wang et al., 2017, Medicine (Baltimore)"	N/A	ENST00000381577.3	N/A
CD274 Expression	CD274	Expression	Lung Non-small Cell Carcinoma	Pembrolizumab	Predictive	Supports	B	Sensitivity/Response	chr9	5450525	5470547			PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab.	"Garon et al., 2015, N. Engl. J. Med."	N/A	ENST00000381577.3	N/A
PTPRD Mutation	PTPRD	Mutation	Head And Neck Carcinoma	JSI-124	Predictive	Supports	D	Sensitivity/Response	chr9	8314246	10033790			"In this preclinical study, loss-of-function of PTPRD was mainly caused by mutation in head and neck cancer, as identified in TCGA data. PTPRD mutated cell-lines were more sensitive to STAT3 inhibition (JSI-124) than wild-type cells. The authors generated several representative HNSCC-derived PTPRD mutants by site-directed mutagenesis (S384R, K1502M, T1100M and L1147F)."	"Peyser et al., 2015, PLoS ONE"	Somatic	ENST00000381196.4	"transcript_variant,loss_of_function_variant"
RPS6 PHOSPHORYLATION	RPS6	PHOSPHORYLATION	Gastric Adenocarcinoma	Everolimus	Predictive	Supports	D	Sensitivity/Response	chr9	19376311	19376325			"54 patients with advanced gastric cancer were treated with everolimus. Two patient responsed and potential biomarkers were explored. High pre-treatment expression of phosphorylated RPS6 (pS6; at Ser240/4) was associated with higher disease control rate and progression free survival (P=0.043, P=0.001 respectively; N=28)."	"Yoon et al., 2012, Br. J. Cancer"	N/A	ENST00000380394.4	N/A
CDKN2A Loss	CDKN2A	Loss	Skin Melanoma	Alvocidib	Predictive	Supports	D	Sensitivity/Response	chr9	21967753	21994624			"Preclinical study in 9 melanoma cell lines. Three cell lines did not have CDKN2A (p16) mutations and showed expression of the protein on western blot analysis. Two of the other six cell lines had stop codons leading to a truncated protein, and three had missense mutations with evidence of protein expression on western blot (two cell lines with a P114L mutation and one with an E88K mutation). Mean IC50s of flavopiridol were significantly lower in cell lines with a mutated or non-expressed p16 (p16-) (mean 50% inhibitory concentration [IC(50)] = 12.5 nM), than in cell lines with intact p16 (p16+) (mean IC(50) = 25 nM)."	"Robinson et al., 2003, Melanoma Res."	Somatic	ENST00000579755.1	loss_of_function_variant
CDKN2A Loss	CDKN2A	Loss	Renal Cell Carcinoma	Palbociclib	Predictive	Supports	D	Sensitivity/Response	chr9	21967753	21994624			"Preclinical study of CDK4/6 inhibitor PD-0332991 in 28 renal carcinoma cell lines (25 malignant RCC and three non-malignant, transformed cell lines derived from kidney epithelium). Both p15 and p16 loss (CGH) were tested for association with response to PD-0332991 using Fisher's exact test. Cell lines with p16 and p15 losses were significantly more likely to be classified as responders (defined by pharmacokinetic data-based concentration of <=400nM) to PD-0332991 (p=0.027, relative risk (RR)=2.06 and p=0.047, RR=1.71, respectively). Four cell lines had homozygous deletions of CDKN2A but not CDKN2B, and three of these lines were classified as being sensitive to PD-0332991. There were no cell lines with only CDKN2B deletion."	"Logan et al., 2013, Anticancer Res."	Somatic	ENST00000579755.1	loss_of_function_variant
CDKN2A Loss	CDKN2A	Loss	Skin Melanoma	Palbociclib	Predictive	Supports	D	Sensitivity/Response	chr9	21967753	21994624			"In a cohort of 143 patients with primary invasive melanoma hemizygous or homozygous loss of CDKN2A was observed (FISH) in 56% of cases. PD0332991 efficacy (proliferation assay) was assessed in a panel of 47 melanoma cell lines. Loss of functional p16INK4A (CDKN2A) due to gene deletion (49% of cells), methylation (4% of cells), or mutation (19% of cells) was the most prevalent alteration occurring in 71% of cell lines, and significantly correlated with PD0332991 sensitivity (Fisher's exact test P < 0.02)."	"Young et al., 2014, Pigment Cell Melanoma Res"	Somatic	ENST00000579755.1	loss_of_function_variant
CDKN2A Loss	CDKN2A	Loss	Ovarian Cancer	Palbociclib	Predictive	Supports	D	Sensitivity/Response	chr9	21967753	21994624			"Preclinical study of the effects of PD-0332991 on proliferation, cell-cycle, apoptosis, and Rb phosphorylation in a panel of 40 human ovarian cancer cell lines. Concentration-dependent antiproliferative effects of PD-0332991 were seen in all ovarian cancer cell lines, but varied significantly between individual lines. Rb-proficient cell lines with low p16 expression were significantly more sensitive to PD-0332991 (as defined by IC50 < mean) in mRNA expression (Agilent), protein level (Western Blot) and copy number (Array CGH) analyses."	"Konecny et al., 2011, Clin. Cancer Res."	Somatic	ENST00000579755.1	loss_of_function_variant
CDKN2A Loss	CDKN2A	Loss	Her2-receptor Negative Breast Cancer	"Letrozole,Palbociclib"	Predictive	Supports	C	Sensitivity/Response	chr9	21967753	21994624			"A patient with metastatic ER-positive, her2-negative breast cancer with CDKN2A loss experienced a short-lived (~3-month) clinical response to palbociclib when given in combination with letrozole."	"Gao et al., 2015, Curr Oncol"	Somatic	ENST00000579755.1	loss_of_function_variant
CDKN2A Loss	CDKN2A	Loss	Ewing Sarcoma	"Linsitinib,Palbociclib"	Predictive	Supports	D	Sensitivity/Response	chr9	21967753	21994624			"A patient-derived xenograft (PDX) from a patient with cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss and FUS-ERG fusion positive Ewing's sarcoma was created. The PDX was treated in four cohorts (each N=6) with control, doxorubicin, CDK4/6 inhibitor palbociclib or IGF-1R inhibitor linsitinib. Both linsitinib and palbociclib cohorts were significantly more effective than control and doxorubicin. Doxorubicin was part of the patient's treatment (Neoadjuvant chemotherapy with DOX, vincristine, and cyclophosphamide) and was noted by authors as failing to control tumor growth."	"Murakami et al., 2016, Oncotarget"	Somatic	ENST00000579755.1	loss_of_function_variant
CDKN2A Loss	CDKN2A	Loss	Dermatofibrosarcoma Protuberans	Palbociclib	Predictive	Supports	D	Sensitivity/Response	chr9	21967753	21994624			"An imatinib-resistant cell line, DFSP105, was established from a dermatofibrosarcoma protuberans which had progressed to a high-grade fibrosarcomatous DFSP. The disease-associated COL1A1-PDGFB fusion was consistent with the most common form, a supernumerary ring chromosome. Genetic characterization of the cell line with a SNP array identified a homozygous CDKN2A/B deletion. Treatment of this cell line with CDK4/6 inhibitor palbociclib led to growth inhibition and reduced RB1 phosphorylation in vitro and in-vivo."	"Eilers et al., 2015, Mol. Cancer Ther."	Unknown	ENST00000579755.1	loss_of_function_variant
CDKN2A Loss	CDKN2A	Loss	Lung Non-small Cell Carcinoma	Palbociclib	Predictive	Does Not Support	B	Resistance	chr9	21967753	21994624			"TAPUR, a phase II basket trial, included a cohort of patients with advanced non-small lung cell carcinoma (NSCLC) harboring with CDKN2A loss or mutation and no RB mutations. Twenty-nine patients were treated with CDK4/6 inhibitor palbociclib; one experienced a partial response and 6 experienced stable disease lasting longer than 16 weeks (disease control rate: 29%). Median PFS was 7.9 weeks and median OS was 20.6 weeks. Authors concluded that palbociclib is worthy of further study in advanced NSCLC when standard treatment options aren't available."	"Eugene R Ahn, 2019, ASCO Annual Meeting, Abstract 9041"	Somatic	ENST00000579755.1	loss_of_function_variant
CDKN2A Loss	CDKN2A	Loss	Acute Lymphoblastic Leukemia		Prognostic	Supports	B	Poor Outcome	chr9	21967753	21994624			"A total of thirteen studies including 2857 patients were combined in a meta-analysis. Combined HRs suggested that CDKN2A/B deletions were poor prognostic factors for both overall survival (OS) (HR = 2.15, 95% CI 1.82-2.54) and event-free survival (EFS)/disease-free survival (DFS)/relapse-free survival (RFS) (HR = 2.16, 95% CI 1.73-2.69)."	"Zhang et al., 2019, Ann. Med."	Somatic	ENST00000579755.1	loss_of_function_variant
CDKN2A p16 Expression	CDKN2A	p16 Expression	Head And Neck Squamous Cell Carcinoma	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Predictive	Does Not Support	B	Resistance	chr9	21968056	21974866			"In this retrospective analysis of the SPECTRUM trial, p16 (CDKN2A) expression (and HPV-infection) was not predictive of response to EGFR-targeted therapy in combination with chemotherapy (n = 416 patient tumors)."	"Vermorken et al., 2014, Ann. Oncol."	N/A	ENST00000498124.1	N/A
CDKN2A p16 Expression	CDKN2A	p16 Expression	Head And Neck Squamous Cell Carcinoma		Prognostic	Supports	B	Better Outcome	chr9	21968056	21974866			"p16 positivity, as a surrogate marker for HPV-associated HNSSC was a favorable prognostic marker in recurrent or metastatic carcinoma."	"Argiris et al., 2014, Ann. Oncol."	N/A	ENST00000498124.1	N/A
CDKN2A p16 Expression	CDKN2A	p16 Expression	Head And Neck Squamous Cell Carcinoma	Panitumumab	Predictive	Supports	B	Resistance	chr9	21968056	21974866			"In this retrospective analysis of p16 status as surrogate marker for HPV in the SPECTRUM trial, p16 (CDKN2A) expression was not associated with improved response to EGFR-directed therapy (Panitumumab) in combination with chemotherapy compared to chemotherapy alone."	"Vermorken et al., 2013, Lancet Oncol."	N/A	ENST00000498124.1	N/A
CDKN2A p16 Expression	CDKN2A	p16 Expression	Head And Neck Squamous Cell Carcinoma	Cetuximab	Predictive	Does Not Support	B	Resistance	chr9	21968056	21974866			"In this study response to EGFR-inhibition by cetuximab was independent of HPV-status, represented by expression of p16 (CDKN2A, an established biomarker of HPV infection). Expression of p16 was assayed in 69 HNSCC patients by IHC."	"Pogorzelski et al., 2014, Cell Death Dis"	N/A	ENST00000498124.1	N/A
CDKN2A p16 Expression	CDKN2A	p16 Expression	Head And Neck Squamous Cell Carcinoma	Panitumumab	Predictive	Supports	B	Sensitivity/Response	chr9	21968056	21974866			p16-negative patients (HPV negative) have a longer overall survival under panitumumab/chemotherapy in comparison to chemotherapy alone.	"Vermorken et al., 2013, Lancet Oncol."	Somatic	ENST00000498124.1	N/A
CDKN2A p16 Expression	CDKN2A	p16 Expression	Oropharynx Cancer		Prognostic	Supports	A	Better Outcome	chr9	21968056	21974866			720 patients with stage III/IV oropharyngeal cancer were retrospectively analyzed for p16 and HPV status. p16 and HPV-positivity correlated well and both showed improved overall-survival compared to patients with HPV-negative/p16 negative tumors. HPV/p16 status was shown to be a strong and independent risk factor in oropharyngeal carcinoma.	"Ang et al., 2010, N. Engl. J. Med."	N/A	ENST00000498124.1	N/A
CDKN2A p16 Expression	CDKN2A	p16 Expression	Oropharynx Cancer	Cetuximab	Predictive	Does Not Support	B	Resistance	chr9	21968056	21974866			This study shows that benefit of EGFR inhibition in addition to radiotherapy was independent of p16/HPV status. 182 patients were evaluated.	"Rosenthal et al., 2016, J. Clin. Oncol."	N/A	ENST00000498124.1	N/A
CDKN2A p16 Expression	CDKN2A	p16 Expression	Head And Neck Squamous Cell Carcinoma		Prognostic	Supports	B	Better Outcome	chr9	21968056	21974866			"Patients from three studies (RTOG 0129, 0234, and 0522; 85, 95 and 142 patients, respectively) were retrospectively analyzed for p16 (CDKN2A) expression (IHC) and HPV-high risk status (ISH). p16 expression in non-oropharyngeal HNSSC was also prognostic and associated with a better outcome. However, p16-positive oropharyngeal HNSSC still had better PFS and OS than p16-positive non-oropharyngeal HNSSC."	"Chung et al., 2014, J. Clin. Oncol."	N/A	ENST00000498124.1	N/A
CDKN2A p16 Expression	CDKN2A	p16 Expression	Head And Neck Squamous Cell Carcinoma	Afatinib	Predictive	Supports	B	Resistance	chr9	21968056	21974866			"Phase III trial to compare afatinib or metothrexate in recurrent or metastatic head and neck squamous cell carcinoma. 483 patients were randomized to either afatinib (n=322) or methotrexate (n=161). 285 patients were assessed for p16 Status (IHC). In the post-hoc analysis, benefit of afatinib compared with methotrexate was more pronounced in p16-negative disease (HR 069 [95% CI 050?96], p=0.022) than in p16-positive disease (HR 095 [CI 051?75], p=0.67, interaction test p=032)."	"Machiels et al., 2015, Lancet Oncol."	N/A	ENST00000498124.1	N/A
CDKN2A p16 Expression	CDKN2A	p16 Expression	Lung Non-small Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr9	21968056	21974866			In a cohort of 73 patients with stage I or stage II NSCLC it was discovered that the CDKN2A protein (p16-INK4A) retrospectively evaluated via IHC was associated with adverse outcomes (p=0.004).	"Zhao et al., 2012, J Oncol"	Somatic	ENST00000498124.1	N/A
CDKN2A Mutation	CDKN2A	Mutation	Pancreatic Cancer	Palbociclib	Predictive	Does Not Support	B	Sensitivity/Response	chr9	21968056	21974866			"In a phase 2 trial, patients with pancreatic cancer with CDKN2A loss or mutation were received palbociclib. Among 12 patients no overall response or stable disease at 16 weeks were observed."	"Tareq Al Baghdadi, 2018, ASCO Annual Meeting, Abstract 2532"	Somatic	ENST00000498124.1	
CDKN2A Mutation	CDKN2A	Mutation	Cholangiocarcinoma	Palbociclib	Predictive	Does Not Support	B	Sensitivity/Response	chr9	21968056	21974866			"In a phase 2 trial, patients with gallbladder cancer or bile duct cancer with CDKN2A loss or mutation were received palbociclib. Among 10 patients, no overall response or stable disease at 16 weeks were observed."	"Tareq Al Baghdadi, 2018, ASCO Annual Meeting, Abstract 2532"	Somatic	ENST00000498124.1	
CDKN2A Promoter Hypermethylation	CDKN2A	Promoter Hypermethylation	Lung Non-small Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr9	21974828	21994592			"In NSCLC patients younger than 60 years at age of diagnosis, p16 (CDKN2A) promoter hypermethylation is associated with shorter time to recurrence and shorter overall survival."	"Bradly et al., 2012, Diagn. Mol. Pathol."	Somatic	ENST00000498124.1	N/A
CDKN2A Promoter Hypermethylation	CDKN2A	Promoter Hypermethylation	Lung Non-small Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr9	21974828	21994592			"In NSCLC patients younger than 60 years at age of diagnosis, p16 (CDKN2A) promoter hypermethylation is associated with shorter time to recurrence."	"Bradly et al., 2012, Diagn. Mol. Pathol."	Somatic	ENST00000498124.1	N/A
CDKN2A RS3814960	CDKN2A	RS3814960	Esophagus Squamous Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr9	21975018	21975018	C	T	"124 esophageal squamous cell carcinoma patients with radical resection were genotyped using MassArray.  The TC/CC genotype of p14ARF at rs3814960 had decreased overall survival (HR = 2.77, 95% CI: 1.33?.75, P = 0.006, Pc = 0.030) and decreased disease-free survival (DFS) (HR = 2.45, 95% CI: 1.30?.61, P = 0.005) compared to patients without this mutation."	"Li et al., 2016, PLoS ONE"	Somatic	ENST00000498124.1	5_prime_UTR_exon_variant
CDKN2B Loss	CDKN2B	Loss	Renal Cell Carcinoma	Palbociclib	Predictive	Supports	D	Sensitivity/Response	chr9	22002903	22009363			"Preclinical study of CDK4/6 inhibitor PD-0332991 in 28 renal carcinoma cell lines (25 malignant RCC and three non-malignant, transformed cell lines derived from kidney epithelium). Both p15 and p16 loss (CGH) were tested for association with response to PD-0332991 using Fisher's exact test. Cell lines with p16 and p15 losses were significantly more likely to be classified as responders (defined by pharmacokinetic data-based concentration of <=400nM) to PD-0332991 (p=0.027, relative risk (RR)=2.06 and p=0.047, RR=1.71, respectively). Four cell lines had homozygous deletions of CDKN2A but not CDKN2B, and three of these lines were classified as being sensitive to PD-0332991. There were no cell lines with only CDKN2B deletion."	"Logan et al., 2013, Anticancer Res."	Somatic	ENST00000276925.6	transcript_ablation
CDKN2B Loss	CDKN2B	Loss	Ewing Sarcoma	"Linsitinib,Palbociclib"	Predictive	Supports	D	Sensitivity/Response	chr9	22002903	22009363			"A patient-derived xenograft (PDX) from a patient with cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss and FUS-ERG fusion positive Ewing's sarcoma was created. The PDX was treated in four cohorts (each N=6) with control, doxorubicin, CDK4/6 inhibitor palbociclib or IGF-1R inhibitor linsitinib. Both linsitinib and palbociclib cohorts were significantly more effective than control and doxorubicin. Doxorubicin was part of the patient's treatment (Neoadjuvant chemotherapy with DOX, vincristine, and cyclophosphamide) and was noted by authors as failing to control tumor growth."	"Murakami et al., 2016, Oncotarget"	Somatic	ENST00000276925.6	transcript_ablation
CDKN2B METHYLATION	CDKN2B	METHYLATION	Acute Promyelocytic Leukemia		Prognostic	Supports	B	Poor Outcome	chr9	22009122	22009173			"This study analyses 45 new acute promyelocytic leukemia patients (22 male and 23 female). CDKN2B was found to be a negative prognostic biomarker for disease free survival (DFS). The 5-year DFS was 9.6% in methylated and 62.5% in unmethylated samples. While methylation also associated with young age, a multivariate analysis found CDKN2B methylation to be the only independent marker with significance (P=0.008) for DFS."	"Chim et al., 2006, Leukemia"	Somatic	ENST00000276925.6	N/A
B4GALT1 Overexpression	B4GALT1	Overexpression	Renal Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr9	33110637	33167356			438 patients with non-metastatic clear-cell renal carcinoma were were retrospectively analysed for B4GALT1 expression via IHC. High B4GALT1 expression was associated with poor overall survival (P<0.001 and P<0.001 in training and validation cohort) and identified as an independent adverse prognostic factor for survival (P=0.007 and P=0.002).	"Xie et al., 2016, Oncotarget"	N/A	ENST00000379731.4	N/A
GNAQ Mutation	GNAQ	Mutation	Uveal Melanoma	JQ1	Predictive	Supports	D	Sensitivity/Response	chr9	77716087	78031458			"Preclinical study in uveal melanoma cell lines. Cell lines (n=4) with GNAQ mutation (92.1, Omm1.3, Mel270, Mel202) were more sensitive to BRD4 inhibition with JQ1 than GNAQ/GNA11 wild type (n=3) cell line. JQ1 also inhibited growth of a GNAQ mutant cell line (92.1) in a mouse xenograft model compared to vehicle (N=5 mice/group)."	"Ambrosini et al., 2015, Oncotarget"	Somatic	ENST00000286548.4	
GNAQ Mutation	GNAQ	Mutation	Uveal Melanoma	Trametinib	Predictive	Supports	B	Sensitivity/Response	chr9	77716087	78031458			"Phase 1 study of trametinib in 97 patients with melanoma (16 with uveal melanoma). Analysis in patients with uveal melanoma identified GNAQ and GNA11 mutations in six patients, in which three SD and three PD were the best responses. One patient with a GNA11 mutation identified by Illumina genotyping stayed on study treatment for >40 weeks."	"Falchook et al., 2012, Lancet Oncol."	Somatic	ENST00000286548.4	
GNAQ Mutation	GNAQ	Mutation	Uveal Melanoma	"Sotrastaurin Acetate,Mirdametinib"	Predictive	Supports	D	Sensitivity/Response	chr9	77716087	78031458			Preclinical study in uveal melanoma. Increased PKC activity was found in uveal melanoma cell lines with GNA11 or GNAQ mutations (n=6) compared to GNA wt cell lines (n=4) and could be induced by introducing these mutations into wt cell lines. Cell lines carrying GNA mutations were more sensitive to PKC inhibition with AEB071 and AHT956 in vitro and in vivo. Combined inhibition of MEK and PKC with AEB071 and PD0325901led to sustained MAPK-signalling blockade and induced apoptosis.	"Chen et al., 2014, Oncogene"	Somatic	ENST00000286548.4	
GNAQ Mutation	GNAQ	Mutation	Uveal Melanoma	Cabozantinib	Predictive	Supports	B	Sensitivity/Response	chr9	77716087	78031458			"Patients with metastatic melanoma (n=77; 48 cutaneous, 23 uveal, 6 mucosal) were enrolled in a phase II randomised discontinuation trial assessing cabozantinib. Patients received 100 mg cabozantinib daily for 12 weeks. Patients with stable disease (SD; RECIST; n=26) were randomly assigned to cabozantinib (n=13) or placebo (n=13). In the uveal melanoma cohort, 61% of patients (14/23, 61%) had SD at week 12. 9 patients had either a GNAQ (n=5) or GNA11 (n=4) mutation; only 10 patients were analyzed. Patients with GNAQ mutations remained on the study treatment from 1.4-10.3 months. The median PFS for the 23 patients with uveal melanoma was 4.8 months (41% PFS at 6 months) and median OS was 12.6 months. In the entire cohort, median overall PFS was 3.8 months (33% PFS at 6 months). After randomisation, median PFS for cabozantinib patients was 4.1 months and 2.8 months for placebo (HR 0.59, p=0.284)."	"Daud et al., 2017, Br. J. Cancer"	Somatic	ENST00000286548.4	
GNAQ Q209	GNAQ	Q209	Uveal Melanoma	Selumetinib	Predictive	Does Not Support	B	Sensitivity/Response	chr9	77794571	77794573			"101 patients with metastatic uveal melanoma were randomized 1:1 to receive selumetinib or chemotherapy. Median PFS among patients randomized to chemotherapy was 7 weeks (95% CI, 4.3-8.4 weeks; median treatment duration, 8 weeks; interquartile range [IQR], 4.3-16 weeks) vs. 15.9 weeks with selumetinib (95% CI, 8.4-21.1 weeks; median treatment duration, 16.1 weeks; IQR, 8.1-25.3 weeks) (hazard ratio, 0.46; 95% CI, 0.30-0.71; P??.001). Most patients (80/96 evaluable harbored a mutation in exon 5 of GNAQ or GNA11) but PFS benefit from Selumetinib compared to chemotherapy was greater in the GNAQ and GNA11 wild-type population (25.9 weeks [range, 3.7-40.4 weeks] vs 15.4 weeks [range, 8.1-16.9 weeks]). However, PFS was still better with Selumetinib than chemotherapy in the GNA mutant population (hazard ratio 0.55, 95% CI, 0.34-0.87; P??.01). The difference was explained by potential GNAQ or GNA11 mutations outside of exon 5 in the GNA wild-type population. Another three mutations in exon 4 were retrospectively identified in the wild-type population and one had a major response."	"Carvajal et al., 2014, JAMA"	Somatic	ENST00000286548.4	protein_altering_variant
GNAQ Q209	GNAQ	Q209	Uveal Melanoma	Refametinib	Predictive	Supports	C	Sensitivity/Response	chr9	77794571	77794573			"Phase 1 study of MAPK1/2 inhibitor BAY 86-9766. 53 patients were evaluated for efficacy, one patients achieved a PR and 11 patients had stable disease. One ocular melanoma patient with prolonged stable disease, who later went on to complete 28 courses, was positive for GNAQ Q209L and PTEN R173S mutations. The PTEN mutation was identified only in the postdose biopsy and not in the predose biopsy."	"Weekes et al., 2013, Clin. Cancer Res."	Somatic	ENST00000286548.4	protein_altering_variant
GNAQ Q209P	GNAQ	Q209P	Skin Melanoma	Vemurafenib	Predictive	Supports	C	Resistance	chr9	77794572	77794572	T	G	A 26-year old patient presented with vemurafenib resistant BRAF-mutated (V600E) cutaneous melanoma. Five of his metastases were evaluated using whole genome sequencing. A GNAQ (Q209P) mutation was identified as unanimously present in all five tumors.	"Turajlic et al., 2014, Ann. Oncol."	Somatic	ENST00000286548.4	missense_variant
GNAQ Q209P	GNAQ	Q209P	Skin Melanoma	PLX4720	Predictive	Supports	D	Resistance	chr9	77794572	77794572	T	G	"Cells were derived from a 26-year old patient with vemurafenib resistant BRAF-mutated (V600E) cutaneous melanoma (designated 20 092 cells). Five of his metastases evaluated using whole genome sequencing contained a GNAQ (Q209P) mutation. 20 092 cells were insensitive to BRAF inhibition (PLX4720) in both proliferation assays and evaluation of pERK compared to BRAF V600E mutated, GNAQ wild-type A375P cells. Using GNAQ (Q209P) siRNA in 22 092 cells, ERK activity was suppressed and cell sensitivity to PLX4720 was increased."	"Turajlic et al., 2014, Ann. Oncol."	Somatic	ENST00000286548.4	missense_variant
SYK OVEREXPRESSION	SYK	OVEREXPRESSION	Ovarian Cancer	Paclitaxel	Predictive	Supports	D	Resistance	chr9	90801787	90898549			Overexpression and high p-SYK/SYK ratio were associated with resistance to paclitaxel. Inhibition of SYK with R406 resensitized cell lines to paclitaxel.	"Yu et al., 2015, Cancer Cell"	Somatic	ENST00000375754.4	N/A
FANCC Loss-of-function	FANCC	Loss-of-function	Pancreatic Cancer	"Chlorambucil,Gemcitabine,Cisplatin,Melphalan,Mitomycin"	Predictive	Supports	D	Sensitivity/Response	chr9	95099054	95317702			"In the pancreatic cell lines PL11 (FANCC homozygous deletion) and Hs766T (FANCG-mutated), sensitivity to DNA cross-linking agents was observed. PL11 cells (empty vector transduced) were more sensitive to mitomycin C (MMC), cisplatin, chlorambucil, and melphalan than PL11 cells transduced with a vector wildtype FANCC. Similarly, mouse xenografts of PL11 cells (empty vector) were more sensitive to MMC or gemcitabine than PL11 cells expressing a wildtype FANCC."	"van der Heijden et al., 2005, Clin. Cancer Res."	Unknown	ENST00000289081.3	loss_of_function_variant
PTCH1 Mutation	PTCH1	Mutation	Medulloblastoma	Sonidegib	Predictive	Supports	B	Sensitivity/Response	chr9	95442980	95508661			"133 sonic-hedghog driven medulloblastomas were sequenced for alterations (WGS or WES). 60 cases exhibited PTCH1 mutations, most of which were likely loss-of-function (spread across the gene and of types including: stop gain, splice site, frameshift, etc.). Functional models also showed PTCH1 mutant xenografts to be sensitive to SHH inhibition with sonidegib."	"Kool et al., 2014, Cancer Cell"	Somatic	ENST00000331920.6	"gene_variant,loss_of_function_variant"
PTCH1 LOH	PTCH1	LOH	Medulloblastoma	Vismodegib	Predictive	Supports	B	Sensitivity/Response	chr9	95442980	95508661			"Loss-of-heterozygosity in SHH-driven medulloblastoma was associated with increased PFS under therapy with vismodegib (AKA HhAntag691, GDC0449, GDC-0449). 43 patients total were enrolled for this study."	"Robinson et al., 2015, J. Clin. Oncol."	Somatic	ENST00000331920.6	loss_of_heterozygosity
PTCH1 Mutation	PTCH1	Mutation	Cancer	Vismodegib	Predictive	Supports	B	Sensitivity/Response	chr9	95442980	95508661			"The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Twenty-one patients had mutations in the Hedgehog pathway (PTCH-1, n = 18; SMO, n = 3). Three patients with PTCH1 mutations had PRs to vismodegib (17%; unknown primary cancer, n = 1; squamous skin cancer, n = 1; salivary gland cancer, n = 1)."	"Hainsworth et al., 2018, J. Clin. Oncol."	Somatic	ENST00000331920.6	"gene_variant,loss_of_function_variant"
RAD23B EXPRESSION	RAD23B	EXPRESSION	Sarcoma	Vorinostat	Predictive	Supports	D	Sensitivity/Response	chr9	107283279	107332194			"Western blot analyses were performed for HR23b (RAD23B) expression sarcoma cell lines after treatment with vorinostat, belinostat, mocetinostat and entinostat. All HDACi were able to regulate proliferation and apoptosis in vitro. Sensitivity to vorinostat correlated significantly with HR23b protein expression. IHC in 523 patient samples revealed high HR23b expression in 12.5% of sarcomas (among them malignant peripheral nerve sheath tumours, pleomorphic liposarcomas, leiomyosarcomas, dedifferentiated liposarcomas, synovial sarcomas and angiosarcomas) and 23.2% of GIST."	"Angelika Ihle et al., 2016, J Pathol Clin Res"	N/A	ENST00000358015.3	N/A
HSPA5 EXPRESSION	HSPA5	EXPRESSION	Colorectal Cancer	Fluorouracil	Predictive	Supports	B	Sensitivity/Response	chr9	125234853	125241330			"Expression of GRP78 (HSPA5) in colorectal cancer patients (n=396, by IHC) showed improved benefit from adjuvant chemotherapy in stage III patients (52% vs. 28%; p = 0.026). In vitro, GRP78 inhibition reduced response to 5-FU."	"Thornton et al., 2013, Int. J. Cancer"	N/A	ENST00000324460.6	N/A
ABL1 BCR::ABL	ABL1	BCR::ABL	Chronic Myeloid Leukemia		Diagnostic	Does Not Support	C	Positive	chr9	130854064	130887676			"Data from deep sequencing of a Ph-negative clone of a Ph-positive CML patient has found a driving mutation in DNMT3A that preceeded the BCR-ABL fusion, and may imply the possibility that BCR-ABL is not universally the initiating event in CML."	"Schmidt et al., 2014, Leukemia"	Somatic	ENST00000305877.8	transcript_fusion
ABL1 BCR::ABL	ABL1	BCR::ABL	Chronic Myeloid Leukemia		Diagnostic	Supports	A	Positive	chr9	130854064	130887676			"The presence of BCR-ABL fusion is considered the characterizing feature of chronic myeloid leukemia, and has been widely thought of as the initiating event in the disease."	"An et al., 2010, Leuk. Res."	Somatic	ENST00000305877.8	transcript_fusion
ABL1 BCR::ABL	ABL1	BCR::ABL	Acute Myeloid Leukemia	Imatinib	Predictive	Supports	D	Resistance	chr9	130854064	130887676			BCR-ABL fusions have been found to contribute to imatinib resistance in AML cell lines.	"Nimmanapalli et al., 2002, Oncogene"	Somatic	ENST00000305877.8	transcript_fusion
ABL1 BCR::ABL	ABL1	BCR::ABL	Acute Myeloid Leukemia	Imatinib	Predictive	Supports	A	Sensitivity/Response	chr9	130854064	130887676			Treatment of Philadelphia chromosome positive leukemias with imatinib results in high rates of complete remission in patients with CML.	"Nimmanapalli et al., 2002, Oncogene"	Somatic	ENST00000305877.8	transcript_fusion
ABL1 BCR::ABL	ABL1	BCR::ABL	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	A	Sensitivity/Response	chr9	130854064	130887676			The clinical use of imatinib in patients with BCR-ABL fusion has resulted in drastic prognostic improvements in patients with CML.	"An et al., 2010, Leuk. Res."	Somatic	ENST00000305877.8	transcript_fusion
ABL1 BCR::ABL	ABL1	BCR::ABL	Chronic Myeloid Leukemia	"Dasatinib,Nilotinib"	Predictive	Supports	A	Sensitivity/Response	chr9	130854064	130887676			"The use of nilotinib and dasatinib, second-generation BCR-ABL targeted therapies, has been effective in patients resistant to imatinib, leading to their FDA-approval."	"An et al., 2010, Leuk. Res."	Somatic	ENST00000305877.8	transcript_fusion
ABL1 BCR::ABL	ABL1	BCR::ABL	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	A	Sensitivity/Response	chr9	130854064	130887676			"BCR-ABL inhibitors such as imatinib have lead to significantly improved prognosis, response rate, overall survival, and patient outcome in CML patients compared to previous therapeutic regimens."	"An et al., 2010, Leuk. Res."	Somatic	ENST00000305877.8	transcript_fusion
ABL1 BCR::ABL	ABL1	BCR::ABL	Acute Lymphoblastic Leukemia	Dasatinib	Predictive	Supports	C	Sensitivity/Response	chr9	130854064	130887676			"Prior to dasatinib treatment, one imatinib-resistant patient with acute lymphoblastic leukemia had the BCR-ABL1 fusion with no secondary variants in at least ten bacterial clones generated using peripheral blood RNA. They had NEL (no evidence of leukemia) best hematologic and minor best cytogenetic responses to dasatinib."	"Talpaz et al., 2006, N. Engl. J. Med."	Somatic	ENST00000305877.8	transcript_fusion
ABL1 BCR::ABL	ABL1	BCR::ABL	Chronic Myeloid Leukemia	Dasatinib	Predictive	Supports	C	Sensitivity/Response	chr9	130854064	130887676			"Prior to dasatanib treatment, fifteen imatinib-resistant patients with chronic myeloid leukemia in various phases had the BCR-ABL1 fusion with no secondary variants in at least ten clones generated using peripheral blood RNA. They had no evidence of leukemia (n = 3), complete (9), minor (2), and no (1) best hematologic responses to dasatinib and complete (3), partial (3), minor (2), minimal (2), and no (5) best cytogenetic responses to dasatinib."	"Talpaz et al., 2006, N. Engl. J. Med."	Somatic	ENST00000305877.8	transcript_fusion
ABL1 BCR::ABL	ABL1	BCR::ABL	Chronic Myeloid Leukemia	"Dasatinib,Bafetinib,Nilotinib"	Predictive	Supports	D	Sensitivity/Response	chr9	130854064	130887676			"In an in vitro study, six CML cell lines expressing the BCR-ABL1 fusion protein showed sensitivity to nilotinib (IC50: 24.3-84.5 nM), dasatinib (IC50: 1.5-10.9 nM), and bafetinib (IC50: 11.8-87.7 nM). When comparing potency of these treatments against the 6 CML cell lines, dasatinib, nilotinib and bafetinib were on average 98.6, 9.85 and 16.4 times more potent than imatinib. Sensitivity was determined by assessing cell proliferation using the MTT assay."	"Deguchi et al., 2008, Leuk. Res."	Somatic	ENST00000305877.8	transcript_fusion
ABL1 RANBP2::ABL1	ABL1	RANBP2::ABL1	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"		Diagnostic	Supports	C	Positive	chr9	130854064	130887675			"This study included 1389 cases of high-risk pediatric B-ALL, of which 284 were identified by TaqMan Low Density Array to have a Ph-like gene expression signature. RT-PCR or RNAseq performed on Ph-like, CRLF2 negative patients revealed 17 cases with ABL1 fusions with 8 different partner genes. There were three cases with the RANBP2-ABL1 fusion. Considering the previously confirmed Ph-like expression signature in the tested cases, the results suggest that the presence of the RANBP2-ABL1 fusion in B-ALL indicates the BCR-ABL1-like (Ph-like) subtype of the disease."	"Reshmi et al., 2017, Blood"	Somatic	ENST00000283195	transcript_fusion
ABL1 ZMIZ1::ABL1	ABL1	ZMIZ1::ABL1	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"		Diagnostic	Supports	C	Positive	chr9	130854064	130887675			"This study included 1389 cases of high-risk pediatric B-ALL, of which 284 were identified by TaqMan Low Density Array to have a BCR-ABL1-like (Ph-like) gene expression signature. RT-PCR or RNAseq performed on Ph-like, CRLF2 negative patients revealed 17 cases with ABL1 fusions with 8 different partner genes. There were three cases with the ZMIZ1-ABL1 fusion. Considering the previously confirmed Ph-like expression signature in the tested cases, the results suggest that the presence of the ZMIZ1-ABL1 fusion in B-ALL indicates the BCR-ABL1-like (Ph-like) subtype of the disease."	"Reshmi et al., 2017, Blood"	Somatic	ENST00000334512.5	transcript_fusion
ABL1 ZMIZ1::ABL1	ABL1	ZMIZ1::ABL1	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"		Prognostic	Supports	B	Better Outcome	chr9	130854064	130887675			"A multicenter, retrospective, cohort study that included 122 paediatric patients (aged 1-18 years) with newly diagnosed ABL-class fusion B-cell acute lymphocytic leukemia who had not received tyrosine-kinase inhibitor treatment as a first-line therapy. ABL-class genes included ABL1, ABL2, CSF1R and PDGFRB. There were 33% of patients (40/122) that harbored an ABL1 fusion, including 16 with a ZMIZ1-ABL1 fusion. For patients that were ABL1 fusion positive the 5-year event-free survival was 68.6% (54.5-86.3), the 5-year overall survival was 82.9% (71.2-96.4) and the 5-year cumulative incidence of relapse was 29.6% (15.0-45.9). Additionally ABL1 fusion positive patients had the lowest levels of MRD at the end of induction therapy. Patients with ZMIZ1-ABL1 had a median MRD between 10^-3 and <10^4 at the end of induction, but between fusion parters, MRD did not differ significantly."	"den Boer et al., 2021, Lancet Haematol"	Somatic	ENST00000334512.5	transcript_fusion
ABL1 ZMIZ1::ABL1	ABL1	ZMIZ1::ABL1	B-lymphoblastic Leukemia/lymphoma		Oncogenic	Supports	C	Oncogenicity	chr9	130854064	130887675			"A 18-month-old female with B-cell acute lymphoblastic leukemia. Chromosome and FISH analysis using a BCR-ABL1 probe confirmed the involvement of ABL1 in a t(9;10)(q34;q22.3) translocation. Follow-up molecular analysis using RT-PCR confirmed the presence of a ZMIZ1-ABL1 fusion transcript (ZMIZ1 exon 14 and ABL1 exon 2). Patient was treated according to standard risk protocol without kinase inhibitors and is in first complete remission. Authors note that The ZMIZ1-ABL1 fusion transcript predicts the the synthesis of ZMIZ1-ABL fusion protein, which contains one of the proline-rich domains of ZMIZ1 and ABL tyrosine kinase domain. Similar to other oncogenic fusion proteins, the proline-rich domain of ZMIZ1 is involved in protein-protein interactions, and therefore the fusion may encode a constitutively activated tyrosine kinase that promotes cellular transformation. The authors further note that patients with t(9;10) would be eligible for imatinib treatment."	"Soler et al., 2008, Leukemia"	Somatic	ENST00000334512.5	transcript_fusion
ABL1 ZMIZ1::ABL1	ABL1	ZMIZ1::ABL1	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"		Diagnostic	Supports	C	Positive	chr9	130854064	130887675			"Study comprised 574 children with newly diagnosed B-cell precursor acute lymphoblastic leukemia (BCP-ALL) and focused on B-other/BCR-ABL-like which were identified by hierarchical clustering of gene expression data. RT-PCR followed by Sanger sequencing for detection of tyrosine kinase fusions was performed for 153 cases. There were 14 fusions found among the BCR-ABL-like cases (14/77=18%), which included one case with a ZMIZ1-ABL1 (exon 18 and exon 2). ZMIZ1-AML1 fusion was among a group of nine fusions found, and characterized by the authors as predictive for activated ABL signaling. The 8-year cumulative incidence of relapse for the fusion-positive BCR-ABL1-like group (35%) was comparable to the fusion-negative BCR-ABL1-like group (35%), and worse than non-BCR-ABL1-like B-other group (17%, p=0.07)."	"Boer et al., 2017, Oncotarget"	Somatic	ENST00000334512.5	transcript_fusion
ABL1 RANBP2::ABL1	ABL1	RANBP2::ABL1	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	Dasatinib	Predictive	Supports	C	Sensitivity/Response	chr9	130854064	130887675			"This retrospective study reported the outcome of 24 patients with Ph-like acute lymphoblastic leukemia (Ph-like ALL) harboring ABL-class fusions, who were treated with a combination of tyrosine kinase inhibitors (TKIs) and chemotherapy. Of the 24 patients reported, 12 had fusions involving ABL1; in 7/12 patients the ABL1 fusion was detected at diagnosis, and in 5/12 it was identified at relapse. One relapse patient was found to have a RANBP2-ABL1 fusion. This patient was a 20 year old female. An IKZF1 intragenic deletion was detected in her leukemia in addition to the RANBP2-ABL1 fusion. She had good initial prednisone response and reached complete remission (CR) after treatment on the GRAALL2005R trial. However, she relapsed with refractory disease. The RANBP2-ABL1 fusion was detected at relapse, and dasatinib (140 mg daily) was added to chemotherapy; this resulted in a brief response even though her leukemia was previously refractory to several lines of salvage treatment (best MRD level 8x10-3). However, the patient experienced another relapse and died of progressive disease. The case illustrates partial response to TKIs in combination with chemotherapy in a relapsed Ph-like B-ALL with RANBP2-ABL1 fusion."	"Tanasi et al., 2019, Blood"	Somatic	ENST00000283195	transcript_fusion
ABL1 NUP214::ABL1	ABL1	NUP214::ABL1	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	"Vincristine,Dexamethasone,Dasatinib"	Predictive	Supports	C	Sensitivity/Response	chr9	130854801	130887675			"A 15-year-old girl with B-cell precursor ALL was placed into the very high risk group after showing corticoid resistance on treatment day 8, and induction failure on day 35 (MRD >0.01). The patient received a successful bone marrow transplant and at day 100 showed a complete remission (CR). The patient relapsed 6 months later, and second line therapy was unsuccessful. During this relapse, SNP microarray was performed on the diagnostic sample and identified amplification of 9q34 flanked by the NUP214 and ABL1 genes. Follow-up molecular studies confirmed a NUP214-ABL1 fusion gene. The patient was then started on dasatinib in combination with vincristine and dexamethasone. The patient achieved a second CR, and continued on dasatinib until her disease relapsed 2 months later."	"Duployez et al., 2016, Haematologica"	Somatic	ENST00000359428.5	transcript_fusion
ABL1 NUP214::ABL1	ABL1	NUP214::ABL1	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"		Diagnostic	Supports	C	Positive	chr9	130854801	130887675			"Transcriptome and whole genome sequencing were performed on 15 cases of B-lymphoblastic leukemia/lymphoma (B-ALL) that were previously shown to have a BCR-ABL1-like (Ph-like) expression signature. Two cases were positive for the NUP214-ABL1 fusion, identified by RNA-seq analysis. In both cases the fusion was generated by a small copy number gain (duplication) in 9q34, with the breakpoints in the two partner genes. Considering the previously shown Ph-like expression signature in the studied cases, the results suggest association of the NUP214-ABL1 fusion in B-ALL with the Ph-like genetic subtype of the disease."	"Roberts et al., 2012, Cancer Cell"	Somatic	ENST00000359428.5	transcript_fusion
ABL1 NUP214::ABL1	ABL1	NUP214::ABL1	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"		Prognostic	Supports	B	Better Outcome	chr9	130854801	130887675			"A multicenter, retrospective, cohort study that included 122 pediatric patients (aged 1-18 years) with newly diagnosed ABL-class fusion B-cell acute lymphocytic leukemia who had not received tyrosine-kinase inhibitor treatment as a first-line therapy. ABL-class genes included ABL1, ABL2, CSF1R and PDGFRB. There were 33% of patients (40/122) that harbored an ABL1 fusion, including 7 with a NUP214-ABL1 fusion. For patients that were ABL1 fusion positive the 5-year event-free survival was 68.6% (54.5-86.3), the 5-year overall survival was 82.9% (71.2-96.4) and the 5-year cumulative incidence of relapse was 29.6% (15.0-45.9). Additionally ABL1 fusion positive patients had the lowest levels of MRD at the end of induction therapy (20/29 evaluable patients had less than 10^-2). Of patients with NUP214-ABL1, 4/7 had MRD <10^-2 at the end of induction."	"den Boer et al., 2021, Lancet Haematol"	Somatic	ENST00000359428.5	transcript_fusion
ABL1 NUP214::ABL1	ABL1	NUP214::ABL1	B-lymphoblastic Leukemia/lymphoma	"Nilotinib,Dasatinib,Imatinib,Ponatinib"	Predictive	Does Not Support	D	Sensitivity/Response	chr9	130854801	130887675			"A 22-year-old male with B-cell acute lymphoblastic leukemia was treated with induction therapy. FISH using a BCR-ABL1 probe demonstrated 50-80 extrachromosomal copies of ABL1; FISH using probes to the 3' regions of ABL1 and NUP214 confirmed NUP214-ABL1 amplification in ~99% of cells. The NUP214-ABL1 amplification was also confirmed by MLPA and SNP6.0 analysis. Additionally, this patient harbored a focal deletion of IKZF1 (exons 2-7) and CDKN2A/B (exons 1-2). Day 29 marrow showed complete morphological remission; however PCR-based IgVH MRD rearrangement studies revealed clonal IgVH rearrangement (1 in 10^4 cells). Patient underwent sibling donor allogenic stem cell transplant, and at 4 months is in complete remission. NUP214-ABL1 positive patient primary cells were cultured with various tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, and ponatinib). After 72-hour culture there was no significant reduction in viable cell numbers or increase in apoptosis, when compared to the no drug control. The in vitro sensitivity to TKIs may be attributed to variable NUP214-ABL1 copy number and/or focal deletions of IKZF1 and CDKN2A/B."	"Eyre et al., 2012, Blood"	Somatic	ENST00000359428.5	transcript_fusion
ABL1 SNX2::ABL1	ABL1	SNX2::ABL1	B-lymphoblastic Leukemia/lymphoma	Dasatinib	Predictive	Supports	C	Resistance	chr9	130862763	130887675			"A 7-yr-old boy with B-cell precursor acute lymphoblastic leukemia was found to harbor the SNX2-ABL1 fusion gene. Gene expression analysis showed enrichment for BCR-ABL1+ ALL using GSEA. After first relapse (15 months after diagnosis) the patient was given imatinib at a dose of 240 mg/m2/d once daily and his disease stabilized for 2 months. The patient received dasatinib (80 mg/m2/d once daily) after an umbilical cord blood transplant and did not respond to treatment. Patient was put back on imatinib at a dose of 600 mg/m2/d once daily which rapidly decreased the number of blast cells. However, 6 months after transplant he had bone marrow relapse and did not again achieve remission by the time of reporting."	"Masuzawa et al., 2014, Eur. J. Haematol."	Somatic	ENST00000379516.2	transcript_fusion
ABL1 SNX2::ABL1	ABL1	SNX2::ABL1	B-lymphoblastic Leukemia/lymphoma	Imatinib	Predictive	Supports	C	Reduced Sensitivity	chr9	130862763	130887675			"In a 29-year-old man with pre B-cell ALL, the t(5;9)(q23;q34) [SNX2-ABL1] was identified. The SNX2-ABL1 fusion, which joins the N-terminal domain of SNX2 without the PX domain to ABL1 exon 4, was detected by RACE PCR and confirmed by RT-PCR and Sanger sequencing. The patient responded to initial chemotherapy, but relapsed early. He then demonstrated a response to hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-C-VAD), but relapsed again. The patient next received imatinib and supportive measures, including hydroxycarbamide, but unfortunately succumbed to his disease approximately one year after diagnosis."	"Ernst et al., 2011, Br. J. Haematol."	Somatic	ENST00000379516.2	transcript_fusion
ABL1 SNX2::ABL1	ABL1	SNX2::ABL1	B-lymphoblastic Leukemia/lymphoma	"Imatinib,Dasatinib"	Predictive	Supports	D	Resistance	chr9	130862763	130887675			"SNX2-ABL1 protein (SNX2 exon 3 to ABL1 exon 4) was transfected in murine Ba/F3 cells and proliferation rates in the presence of IL-3, and tyrosine kinase inhibitors, imatinib and dasatinib was compared to BCR-ABL1 p190 and p210 transfected Ba/F3 cells. Cell proliferation assays showed that SNX2-ABL1 transfected cells had over 20% and 50% of cell survival after 24-hr incubation with imatinib (2M) and dasatinib (10nM). SNX2-ABL1 transfected cells continued to proliferate again 48 hr after treatment with dasatinib (10nM). This data was further supported by apoptosis (annexin V-propidium iodide) studies. In addition, newer tyrosine kinase inhibitors including nilotinib (500nM), bafetinib (500nM), rebastinib (500nM), and ponatinib (100nM), were examined and SNX2-ABL1 cells showed a better response, but still some resistance to these compounds. Further examination of downstream phosphorylation of SNX2-ABL1 cells showed only partial inhibition with imatinib and dasatinib."	"Tomita et al., 2014, Leuk. Res."	Somatic	ENST00000379516.2	transcript_fusion
ABL1 SNX2::ABL1	ABL1	SNX2::ABL1	B-lymphoblastic Leukemia/lymphoma		Prognostic	Supports	C	Poor Outcome	chr9	130862763	130887675			"A 16 yr-old male with precursor B-ALL was found to have the t(5;9)(q23;q34) in his peripheral blasts. Fluorescence in situ hybridization (FISH), RT-PCR, and sequencing of the product confirmed a SNX2-ABL1 fusion gene (SNX2 exon 3 fused in frame to ABL1 exon 4) was present. The patient also was found to carry an IKZF1 deletion (exons 2-8) and amplification of PAX5. The patient was treated with vindesine, idarubicin, and dexamethasone (VDP) and VDCP (plus cyclophosphamide) regimens. He received two bone marrow transplants, but eventually died of disease. The patient did not receive tyrosine-kinase inhibitors."	"Mu et al., 2017, Leuk. Lymphoma"	Somatic	ENST00000379516.2	transcript_fusion
ABL1 SNX2::ABL1	ABL1	SNX2::ABL1	B-lymphoblastic Leukemia/lymphoma		Prognostic	Supports	C	Poor Outcome	chr9	130862763	130887675			"This case report describes a 7-year old boy with B-ALL who presented with high white blood count (115.4x109 /L). Karyotype analysis showed a t(5;9)(q22;q34), resulting in a SNX2-ABL1 fusion. The patient was treated based on the ALL-BFM95 regimen; although he received remission, he relapsed during maintenance, 15 months after the initial diagnosis. He could not achieve the second remission using chemotherapy, but was treated at this time with imatinib (dose of 240 mg/m2 /d once daily); this allowed to achieve disease control and proceed with an umbilical cord blood transplant. However, at 6 months from transplantation, the patient developed bone marrow relapse again. He never achieved a remission after the second relapse (despite salvage chemotherapies and therapy with both imatinib and dasatinib). The patient died of progressive disease."	"Masuzawa et al., 2014, Eur. J. Haematol."	Somatic	ENST00000379516.2	transcript_fusion
ABL1 SNX2::ABL1	ABL1	SNX2::ABL1	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"		Diagnostic	Supports	C	Positive	chr9	130862763	130887675			"This retrospective study intended to clarify clinical characteristics of patients with B-lymphoblastic leukemia/lymphoma (B-ALL) and kinase fusions that are not well described (excluding ETV6-RUNX1, E2A-PBX1, MLL rearrangements and BCR-ABL). The SNX2-ABL1 fusion is rare; in this study investigating 373 high risk pediatric B-ALL patients of which 29 demonstrated uncommon kinase gene fusions, only one case with SNX2-ABL1 (exon 3-exon 4) was observed. Gene expression profiles were compared to Ph-positive B-ALL and reportedly all fusion-containing samples (except P2RY8-CRLF2) were similar to BCR-ABL1-positive patients. This patient did not respond to tyrosine kinase inhibitors administered in combination with chemotherapy at the first or second relapses."	"Imamura et al., 2016, Blood Cancer J"	Somatic	ENST00000379516.2	transcript_fusion
ABL1 SNX2::ABL1	ABL1	SNX2::ABL1	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"		Diagnostic	Supports	C	Positive	chr9	130862763	130887675			"In the study involving 1725 B-ALL patients, 264 were identified by microarray-based algorithm to have a Ph-like expression signature. Next generation sequencing (RNAseq, WGS, and/or WES) performed on 154 Ph-like patients revealed 91% possessed genomic alterations activating kinase signaling with 96 (62%) involving rearrangements. In one adolescent male, an in-frame SNX2-ABL1 fusion (exon 3 and exon 4) with the ABL1 tyrosine kinase domain intact was identified and confirmed by RT-PCR and Sanger. This patient, evaluated by WES and RNA-seq, also harbored IKZF1, EBF1, and VPREB deletions, and was designated Ph-like non CRLF2."	"Roberts et al., 2014, N. Engl. J. Med."	Somatic	ENST00000379516.2	transcript_fusion
ABL1 BCR::ABL M244V	ABL1	BCR::ABL M244V	Chronic Myeloid Leukemia	Imatinib	Predictive	Does Not Support	C	Resistance	chr9	130862943	130862943	A	G	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase patient had only a partial hematologic response which improved to a major cytogenetic response after dose escalation 18 months after therapy initiation. At months 7 and 8, the M244V was present in 100% of transcripts. No further testing for secondary variants was performed. At 18 months, 25% of cells were Ph-positive, but this did not meet the authors' threshold for loss of MCR which is >65% Ph-positive cells or an increase of 30%."	"Branford et al., 2003, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M244V	ABL1	BCR::ABL M244V	Cancer	Imatinib	Predictive	Supports	D	Sensitivity/Response	chr9	130862943	130862943	A	G	"A panel of 16 mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and evaluated for antiproliferative activity and substrate or auto-phosphorylation assays. The authors considered the M244V mutation sensitive to imatinib (IC50: 2000 vs. 260 nmol/L, 8x fold change, in a proliferative assay compared to Ba/F3 cells with unmutated BCR-ABL fusions)."	"O'Hare et al., 2005, Cancer Res."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M244V	ABL1	BCR::ABL M244V	Cancer	"Dasatinib,Nilotinib"	Predictive	Does Not Support	D	Resistance	chr9	130862943	130862943	A	G	"In an in vitro study, a Ba/F3 cell line stably expressing the M244V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to dasatinib and nilotinib treatment (IC50: 93.1 nM and 891.4 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 87.6 nM and 642.3 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	"Deguchi et al., 2008, Leuk. Res."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M244V	ABL1	BCR::ABL M244V	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	B	Resistance	chr9	130862943	130862943	A	G	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation  had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 46 patients with M244V mutations,  20, 27, and 45 achieved a CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	"Mller et al., 2009, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M244V	ABL1	BCR::ABL M244V	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130862943	130862943	A	G	"In this phase II multinational study, 60 imatinib-resistant patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with M244V, 4/5 had MaHRs which was higher than response rates among wild type patients, and 2/5 had MCyRs which was comparable to response rates among wild type patients."	"Guilhot et al., 2007, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M244V	ABL1	BCR::ABL M244V	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130862943	130862943	A	G	"Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the M244V secondary variant in 12/12 bacterial clones generated using peripheral blood RNA. They had complete best hematologic and no cytogenetic responses to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1."	"Talpaz et al., 2006, N. Engl. J. Med."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M244V	ABL1	BCR::ABL M244V	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130862943	130862943	A	G	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with M244V evaluated, 2/2 had complete hematologic responses and 2/3 had major cytogenetic responses."	"Cortes et al., 2011, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M244V	ABL1	BCR::ABL M244V	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130862943	130862943	A	G	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with M244V evaluated, 3/3 had CHR and 2/3 had MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M244V	ABL1	BCR::ABL M244V	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	D	Resistance	chr9	130862943	130862943	A	G	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The M244V mutation was associated with resistance in 2 M imatinib (1 clone recovered, 0.71%). In a review of 20 publications, this mutation was described in imatinib resistant patients."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M244V	ABL1	BCR::ABL M244V	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	C	Resistance	chr9	130862943	130862943	A	G	"In a study of 39 chronic phase CML patients with BCR-ABL variants, M244V was seen in 3 imatinib-resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M244V	ABL1	BCR::ABL M244V	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	C	Resistance	chr9	130862943	130862943	A	G	"In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 5 had M244V mutations"	"Guilhot et al., 2007, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M244V	ABL1	BCR::ABL M244V	Chronic Myeloid Leukemia	Axitinib	Predictive	Does Not Support	D	Resistance	chr9	130862943	130862943	A	G	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the M244V variant of ABL1 compared to those with wildtype ABL1 (IC50 of 690nM vs. 823 nM), indicating that the M244V variant does not induce resistance."	"Pemovska et al., 2015, Nature"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M244V	ABL1	BCR::ABL M244V	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	C	Resistance	chr9	130862943	130862943	A	G	One chronic myeloid leukemia patient in chronic phase had no response to imatinib. Bacterial clones generated using peripheral blood RNA later revealed the BCR-ABL1 fusion with the M244V secondary variant in 12/12 clones.	"Talpaz et al., 2006, N. Engl. J. Med."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M244V	ABL1	BCR::ABL M244V	Cancer	"Imatinib,Bafetinib"	Predictive	Supports	D	Resistance	chr9	130862943	130862943	A	G	"In an in vitro study, a Ba/F3 cell line stably expressing the M244V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib and bafetinib (INNO-406) treatment (IC50: > 2000.0 nM and 874.2 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 1712 nM and 152.9 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	"Deguchi et al., 2008, Leuk. Res."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL L248V	ABL1	BCR::ABL L248V	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	D	Resistance	chr9	130862955	130862955	C	G	"A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The L248V mutation was moderately resistant to imatinib."	"Redaelli et al., 2009, J. Clin. Oncol."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL L248V	ABL1	BCR::ABL L248V	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	C	Resistance	chr9	130862955	130862955	C	G	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase (CP) patient had a complete hematologic response but acquired resistance after 7 months of therapy and discontinued imatinib 3 months later. At month 11, the L248V, G250E, S417Y, E459K variants were present in approximately 25, 25, 25, and 50% of transcripts, respectively. The patient died in myeloid blast crisis at month 14 after a bone marrow transplant."	"Branford et al., 2003, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL L248V	ABL1	BCR::ABL L248V	Chronic Myeloid Leukemia	"Dasatinib,Nilotinib,Imatinib Mesylate"	Predictive	Supports	D	Resistance	chr9	130862955	130862955	C	G	"In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The L248V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to 2 M imatinib (3 clones recovered, ~2% of viable clones in this treatment), 50nM nilotinib (1 clone, ~2%), and 5nM dasatinib (3 clones, ~9%). In a review of 20 publications, this mutation was described in imatinib resistant patients."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL L248V	ABL1	BCR::ABL L248V	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130862955	130862955	C	G	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with L248V evaluated, 3/3 had complete hematologic responses and 2/3 had major cytogenetic responses."	"Cortes et al., 2011, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL L248V	ABL1	BCR::ABL L248V	Chronic Myeloid Leukemia	Axitinib	Predictive	Supports	D	Resistance	chr9	130862955	130862955	C	G	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed decreased incorporation when harboring fusions with the L248V variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1393nM vs. 823 nM), indicating resistance."	"Pemovska et al., 2015, Nature"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL L248V	ABL1	BCR::ABL L248V	Chronic Myeloid Leukemia	"Imatinib Mesylate,Nilotinib"	Predictive	Supports	D	Resistance	chr9	130862955	130862955	C	G	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. 61 clones grew in a combination of 400 nM imatinib and 50 nM nilotinib. Of these, 19 were sequenced and 2 (~11%) were found to have L248V mutations."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL L248V	ABL1	BCR::ABL L248V	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	B	Resistance	chr9	130862955	130862955	C	G	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 15 patients with L248V mutations, 6, 10, and 15 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	"Mller et al., 2009, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL L248V	ABL1	BCR::ABL L248V	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130862955	130862955	C	G	"In this phase II multinational study, 60 imatinib-resistantpatients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with L248V, 3/3 had MaHRs and 1/3 had MCyRs which were comparable to response rates among wild type patients."	"Guilhot et al., 2007, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL L248V	ABL1	BCR::ABL L248V	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	C	Resistance	chr9	130862955	130862955	C	G	"In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 3 had L248V mutations"	"Guilhot et al., 2007, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL L248R	ABL1	BCR::ABL L248R	Chronic Myeloid Leukemia	"Dasatinib,Imatinib Mesylate"	Predictive	Supports	D	Resistance	chr9	130862956	130862956	T	G	"In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using ?0 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 1 of these clones had an L248R mutation. To validate resistance to dasatinib, a Ba/F3 cell line stably expressing the L248R mutation in the ABL1 region of the BCR-ABL fusion was generated. The L248R variants was associated with higher dasatinib IC50 of 16 nM vs 1.34 nM in wildtype and higher imatinib IC50 of >10,000 nM vs 323 nM in wildtype as determined by dose response curves."	"Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL L248R	ABL1	BCR::ABL L248R	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	D	Resistance	chr9	130862956	130862956	T	G	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The L248R mutation was associated with resistance in 2 M imatinib (1 clone recovered, ~1%) and 8 M imatinib (1 clone, ~2%). In a review of 20 publications, this mutation had not been described in imatinib resistant patients."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL L248R	ABL1	BCR::ABL L248R	Chronic Myeloid Leukemia	Axitinib	Predictive	Supports	D	Resistance	chr9	130862956	130862956	T	G	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with the L248R variant of ABL1 compared to those with wildtype ABL1 (IC50 of 1399nM vs. 823 nM), indicating resistance."	"Pemovska et al., 2015, Nature"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL G250E	ABL1	BCR::ABL G250E	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	D	Resistance	chr9	130862962	130862962	G	A	"A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The G250E mutation was resistant to imatinib."	"Redaelli et al., 2009, J. Clin. Oncol."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL G250E	ABL1	BCR::ABL G250E	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	C	Resistance	chr9	130862962	130862962	G	A	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase (CP) patient had a complete hematologic response (CHR) but acquired resistance 7 months after therapy initiation. At month 11, the L248V, G250E, S417Y, E459K variants were present in approximately 25, 25, 25, and 50% of transcripts, respectively. The patient died in accelerated phase at month 14. An accelerated-phase patient had a CHR but progressed to partial hematologic response concurrent with the appearance of the G250E variant in ~25% of transcripts and the M351T variant in ~50% of transcripts. The patient died at 12 months."	"Branford et al., 2003, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL G250E	ABL1	BCR::ABL G250E	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	C	Resistance	chr9	130862962	130862962	G	A	"In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The G250E mutation was  resistant to imatinib ."	"O'Hare et al., 2005, Cancer Res."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL G250E	ABL1	BCR::ABL G250E	Chronic Myeloid Leukemia	Nilotinib	Predictive	Supports	D	Resistance	chr9	130862962	130862962	G	A	"In an in vitro study, a Ba/F3 cell line stably expressing the G250E mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 4.56-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation."	"Redaelli et al., 2009, J. Clin. Oncol."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL G250E	ABL1	BCR::ABL G250E	Cancer	Nilotinib	Predictive	Does Not Support	D	Resistance	chr9	130862962	130862962	G	A	"In an in vitro study, a Ba/F3 cell line stably expressing the G250E mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib treatment (IC50: 866 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 642.3 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	"Deguchi et al., 2008, Leuk. Res."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL G250E	ABL1	BCR::ABL G250E	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130862962	130862962	G	A	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with G250E evaluated, 1/1 had a complete hematologic response and 2/2 had major cytogenetic responses."	"Cortes et al., 2011, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL G250E	ABL1	BCR::ABL G250E	Chronic Myeloid Leukemia	Bosutinib	Predictive	Supports	C	Reduced Sensitivity	chr9	130862962	130862962	G	A	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with G250E, 3/6 had a CHR and 0/5 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL G250E	ABL1	BCR::ABL G250E	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	B	Resistance	chr9	130862962	130862962	G	A	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation  had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Of 60 patients with G250E mutations, 20, 29, and 56 achieved a CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	"Mller et al., 2009, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL G250E	ABL1	BCR::ABL G250E	Chronic Myeloid Leukemia	Dasatinib	Predictive	Supports	C	Reduced Sensitivity	chr9	130862962	130862962	G	A	"In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with G250E, 6/9 had MaHRs which was comparable to response rates among wild type patients, and 1/9 had MCyRs which was lower than response rates among wild type patients."	"Guilhot et al., 2007, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL G250E	ABL1	BCR::ABL G250E	Chronic Myeloid Leukemia	Axitinib	Predictive	Supports	D	Resistance	chr9	130862962	130862962	G	A	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed higher incorporation when harboring fusions with the G250E variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1295nM vs. 823 nM), indicating resistance."	"Pemovska et al., 2015, Nature"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL G250E	ABL1	BCR::ABL G250E	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	D	Resistance	chr9	130862962	130862962	G	A	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The G250E mutation was associated with resistance in 2 M imatinib (3 clone recovered, ~2%), 4 M imatinib (1 clone recovered, ~0.74%), and 50 nM nilotinib (5 clone, ~11%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL G250E	ABL1	BCR::ABL G250E	Chronic Myeloid Leukemia	Nilotinib	Predictive	Supports	D	Resistance	chr9	130862962	130862962	G	A	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The G250E mutation was associated with resistance in 2 M imatinib (3 clone recovered, ~2%), 4 M imatinib (1 clone recovered, ~0.74%), and 50 nM nilotinib (5 clone, ~11%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL G250E	ABL1	BCR::ABL G250E	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	C	Resistance	chr9	130862962	130862962	G	A	"In a study of 39 chronic phase CML patients with BCR-ABL variants, G250E was seen in 6 imatinib-resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL G250E	ABL1	BCR::ABL G250E	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	B	Resistance	chr9	130862962	130862962	G	A	"In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 9 had G250E mutations"	"Guilhot et al., 2007, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL G250E	ABL1	BCR::ABL G250E	Cancer	"Imatinib,Bafetinib"	Predictive	Supports	D	Resistance	chr9	130862962	130862962	G	A	"In an in vitro study, a Ba/F3 cell line stably expressing the G250E mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib and bafetinib (INNO-406) treatment (IC50: > 2000.0 nM and 852 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 1712 nM and 152.9 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	"Deguchi et al., 2008, Leuk. Res."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL G250E	ABL1	BCR::ABL G250E	Cancer	Dasatinib	Predictive	Supports	D	Sensitivity/Response	chr9	130862962	130862962	G	A	"In an in vitro study, a Ba/F3 cell line stably expressing the G250E mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with increased sensitivity to dasatinib treatment (IC50: 27.2 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 87.6 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	"Deguchi et al., 2008, Leuk. Res."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Q252H	ABL1	BCR::ABL Q252H	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	D	Sensitivity/Response	chr9	130862969	130862969	G	C	"A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The Q252H mutation was sensitive to imatinib."	"Redaelli et al., 2009, J. Clin. Oncol."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Q252H	ABL1	BCR::ABL Q252H	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	C	Resistance	chr9	130862969	130862969	G	C	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A chronic-phase (CP) patient achieved a complete hematologic response (CHR). The Q252H variant was detected but was absent when the patient progressed to myeloid blast crisis (MBC) with a double Philadelphia chromosome and died. A second CP patient had a partial hematologic response (PHR) with the Q252H and M351T variants. They progressed to MBC and the double Ph-chromosome was later detected without any secondary variants prior to death. The third CP patient had a PHR but became resistant. The Q252H variant was later detected and the patient died in MBC. An accelerated-phase (AP) patient had a CHR but progressed to MBC with the appearance of the Q252H variant. The patient died in MBC after a bone marrow transplant."	"Branford et al., 2003, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Q252H	ABL1	BCR::ABL Q252H	Cancer	"Dasatinib,Nilotinib"	Predictive	Does Not Support	D	Resistance	chr9	130862969	130862969	G	C	"In an in vitro study, a Ba/F3 cell line stably expressing the Q252H mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to dasatinib and nilotinib treatment (IC50: 62.3 nM and 895.5 nM) as compared to wild-type expressing Ba/F3 cells (IC50: 87.6 nM and 642.3 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	"Deguchi et al., 2008, Leuk. Res."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Q252H	ABL1	BCR::ABL Q252H	Chronic Myeloid Leukemia	Axitinib	Predictive	Supports	D	Resistance	chr9	130862969	130862969	G	C	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with the Q252H variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1155nM vs. 823 nM), indicating resistance."	"Pemovska et al., 2015, Nature"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Q252H	ABL1	BCR::ABL Q252H	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130862969	130862969	G	C	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation  had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Of 6 patients with  Q252H mutations, 1, 1, and 3 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations. The authors identify Q252H as one of 4 variants with a low CCyR but advise caution when interpreting these results due to low sample size."	"Mller et al., 2009, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Q252H	ABL1	BCR::ABL Q252H	Chronic Myeloid Leukemia	Dasatinib	Predictive	Supports	D	Resistance	chr9	130862969	130862969	G	C	"In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using ?0 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 1 of these clones had an Q252H mutation."	"Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Q252H	ABL1	BCR::ABL Q252H	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	D	Resistance	chr9	130862969	130862969	G	C	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The Q252H mutation was associated with resistance to 4 M and 16 M imatinib (4 clones [~3%] and 1 clone [~3%] recovered, respectively) as well as 10 nM dasatinib (1 clone [~2%]). No clones recovered at 2 M/8 M imatinib or 5 nM dasatinib. In a review of 20 publications, this mutation was previously described in imatinib resistant patients."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Q252H	ABL1	BCR::ABL Q252H	Chronic Myeloid Leukemia	Dasatinib	Predictive	Supports	D	Resistance	chr9	130862969	130862969	G	C	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The Q252H mutation was associated with resistance to 4 M and 16 M imatinib (4 clones [~3%] and 1 clone [~3%] recovered, respectively) as well as 10 nM dasatinib (1 clone [~2%]). No clones recovered at 2 M/8 M imatinib or 5 nM dasatinib. In a review of 20 publications, this mutation was previously described in imatinib resistant patients."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Q252H	ABL1	BCR::ABL Q252H	Cancer	"Bafetinib,Imatinib"	Predictive	Supports	D	Resistance	chr9	130862969	130862969	G	C	"In an in vitro study, a Ba/F3 cell line stably expressing the Q252H mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib and bafetinib (INNO-406) treatment (IC50: > 2000.0 nM and 888.1 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 1712 nM and 152.9 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	"Deguchi et al., 2008, Leuk. Res."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Y253H	ABL1	BCR::ABL Y253H	Chronic Myeloid Leukemia	"Nilotinib,Imatinib Mesylate"	Predictive	Supports	D	Resistance	chr9	130862970	130862970	T	C	"In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The Y253H mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to 50nM nilotinib (14 clones recovered, ~30% of viable clones in this treatment), 500nM nilotinib (50 clones, ~63%), and 16 nM imatinib (16 clones; ~48%). Resistant clones were also found at 2, 4, and 8 M imatinib. In a review of 20 publications, this mutation was described in imatinib resistant patients."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Y253H	ABL1	BCR::ABL Y253H	Chronic Myeloid Leukemia	Axitinib	Predictive	Does Not Support	D	Resistance	chr9	130862970	130862970	T	C	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the Y253H variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 867nM vs. 823 nM), indicating that the variant does not induce resistance."	"Pemovska et al., 2015, Nature"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Y253H	ABL1	BCR::ABL Y253H	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130862970	130862970	T	C	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with Y253H evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response."	"Cortes et al., 2011, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Y253H	ABL1	BCR::ABL Y253H	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130862970	130862970	T	C	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with Y253H evaluated, 5/6 had CHR and 4/6 had MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Y253H	ABL1	BCR::ABL Y253H	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130862970	130862970	T	C	"In this phase II multinational study, 60 imatinib-resistant patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with Y253H, 5/6 had MaHRs which was higher than response rates among wild type patients and 2/6 had MCyRs which was comparable to response rates among wild type patients."	"Guilhot et al., 2007, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Y253H	ABL1	BCR::ABL Y253H	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	B	Resistance	chr9	130862970	130862970	T	C	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation  had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 23 patients with the Y253H mutation, 14, 15, and 20 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	"Mller et al., 2009, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Y253H	ABL1	BCR::ABL Y253H	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130862970	130862970	T	C	"Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the Y253H secondary variant in 11/11 bacterial clones generated using peripheral blood RNA. They had complete response as best hematologic response and complete response as best cytogenetic response to dasatinib which were improved compared to responses in patients with unmutated BCR-ABL1."	"Talpaz et al., 2006, N. Engl. J. Med."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Y253H	ABL1	BCR::ABL Y253H	Chronic Myeloid Leukemia	"Nilotinib,Imatinib Mesylate"	Predictive	Supports	C	Resistance	chr9	130862970	130862970	T	C	"In this open-label, phase II registration trial, patients that were imatinib resistant or intolerant underwent nilotinib monotherapy. Within 12 months of nilotinib therapy, there was no significant difference in response to nilotinib treatment between patients with mutations in the Abl1 kinase domain versus without. However, the authors identify Y253H, E255K/V, and F359C/V variants as resistant as they had an IC50 of >150 nM. In patients with Y253H mutations prior to nilotinib treatment, complete hematologic response was achieved in 0 of 6 patients, major cytogenetic response in 1 of 8 patients, complete cytogenetic response in 0 of 8 patients, and major molecular response in 0 of 7 patients. After median follow-up of 15.5 months, 3 of 8 patients with this mutation progressed or died. The Y253H mutation was present in two patients at baseline and newly emerged in two patients at progression."	"Hughes et al., 2009, J. Clin. Oncol."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Y253H	ABL1	BCR::ABL Y253H	Chronic Myeloid Leukemia	"Nilotinib,Imatinib Mesylate"	Predictive	Supports	D	Resistance	chr9	130862970	130862970	T	C	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. 61 clones grew in a combination of 400 nM imatinib and 50 nM nilotinib. Of these, 19 were sequenced and 5 (~26%) were found to have Y253H mutations."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Y253H	ABL1	BCR::ABL Y253H	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	C	Resistance	chr9	130862970	130862970	T	C	"In a study of 39 chronic phase CML patients with BCR-ABL variants, Y253H was seen in 6 imatinib-resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Y253H	ABL1	BCR::ABL Y253H	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	B	Resistance	chr9	130862970	130862970	T	C	"In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 6 had Y253H mutations"	"Guilhot et al., 2007, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Y253H	ABL1	BCR::ABL Y253H	Acute Lymphoblastic Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130862970	130862970	T	C	"Prior to dasatinib treatment, one imatinib-resistant patient with acute lymphoblastic leukemia had the BCR-ABL1 fusion with Y253H and Y253H/Q252R variants in 9/10 and 1/10 clones, respectively. Clones were generated using peripheral blood RNA. The patient had complete response as best cytogenetic response and complete response as best hematologic response to dasatinib which were improved compared to responses in a patient with unmutated BCR-ABL1."	"Talpaz et al., 2006, N. Engl. J. Med."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Y253H	ABL1	BCR::ABL Y253H	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130862970	130862970	T	C	"Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with Y253H, M388L, and M388L/M244V variants in 4/10, 5/10, and 1/10 clones, respectively. Clones were generated using peripheral blood RNA. The patient had no response as best cytogenetic response and complete response as best hematologic response to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1."	"Talpaz et al., 2006, N. Engl. J. Med."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Y253F	ABL1	BCR::ABL Y253F	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	D	Resistance	chr9	130862971	130862971	A	T	"A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The Y253F mutation was moderately resistant to imatinib."	"Redaelli et al., 2009, J. Clin. Oncol."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Y253F	ABL1	BCR::ABL Y253F	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	C	Resistance	chr9	130862971	130862971	A	T	"In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The Y253F mutation was  moderately resistant to imatinib ."	"O'Hare et al., 2005, Cancer Res."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Y253F	ABL1	BCR::ABL Y253F	Cancer	"Nilotinib,Dasatinib,Bafetinib"	Predictive	Does Not Support	D	Resistance	chr9	130862971	130862971	A	T	"In an in vitro study, a Ba/F3 cell line stably expressing the Y253F mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib, dasatinib, and bafetinib (INNO-406) treatment (IC50: 975.3 nM, 16.8 nM, and 490.8 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 642.3 nM, 87.6 nM, and 152.9 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	"Deguchi et al., 2008, Leuk. Res."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Y253F	ABL1	BCR::ABL Y253F	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130862971	130862971	A	T	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with Y253F evaluated, 1/1 had a complete hematologic response and 0/1 had a major cytogenetic response."	"Cortes et al., 2011, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Y253F	ABL1	BCR::ABL Y253F	Chronic Myeloid Leukemia	Axitinib	Predictive	Supports	D	Resistance	chr9	130862971	130862971	A	T	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with the Y253F variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1275nM vs. 823 nM), indicating resistance."	"Pemovska et al., 2015, Nature"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Y253F	ABL1	BCR::ABL Y253F	Cancer	Imatinib	Predictive	Supports	D	Resistance	chr9	130862971	130862971	A	T	"In an in vitro study, a Ba/F3 cell line stably expressing the Y253F mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib treatment (IC50: > 2000.0 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 1712 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	"Deguchi et al., 2008, Leuk. Res."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Y253F	ABL1	BCR::ABL Y253F	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	C	Resistance	chr9	130862971	130862971	A	T	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An AP patient had a complete hematologic response. After 9 months of therapy, the patient progressed returning to chronic phase. Concurrently, the Y253F and E255V variants were found in ~50% and ~50% of BCR-ABL1 transcripts, respectively. Imatinib was withdrawn at 10 months and the patient died 14 months after treatment initiation."	"Branford et al., 2003, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E255V	ABL1	BCR::ABL E255V	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	C	Resistance	chr9	130862977	130862977	A	T	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An AP patient had a complete hematologic response. After 9 months of therapy, the patient progressed returning to chronic phase. Concurrently, the Y253F and E255V variants were found in ~50% and ~50% of BCR-ABL1 transcripts, respectively. Imatinib was withdrawn at 10 months and the patient died 14 months after treatment initiation."	"Branford et al., 2003, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E255V	ABL1	BCR::ABL E255V	Chronic Myeloid Leukemia	Nilotinib	Predictive	Supports	D	Resistance	chr9	130862977	130862977	A	T	"In an in vitro study, a Ba/F3  cell line stably expressing the E255V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 10.31-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein. Sensitivity was determined by assessing cell proliferation."	"Redaelli et al., 2009, J. Clin. Oncol."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E255V	ABL1	BCR::ABL E255V	Chronic Myeloid Leukemia	"Nilotinib,Imatinib Mesylate"	Predictive	Supports	D	Resistance	chr9	130862977	130862977	A	T	"In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The E255V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was identified and associated with resistance to imatinib (1 clone, 0.43% of viable clones in this treatment, recovered in 4 M but none at 2, 8, or 16 M) and nilotinib (1 clone, 1.25%, recovered at 500nM but none at 50, 2000 or 5000nM). In a review of 20 publications, this mutation was described in imatinib resistant patients."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E255V	ABL1	BCR::ABL E255V	Chronic Myeloid Leukemia	Axitinib	Predictive	Supports	D	Resistance	chr9	130862977	130862977	A	T	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with the E255V variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1350nM vs. 823 nM), indicating resistance."	"Pemovska et al., 2015, Nature"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E255V	ABL1	BCR::ABL E255V	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130862977	130862977	A	T	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with E255V evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response."	"Cortes et al., 2011, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E255V	ABL1	BCR::ABL E255V	Chronic Myeloid Leukemia	Bosutinib	Predictive	Supports	C	Reduced Sensitivity	chr9	130862977	130862977	A	T	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with E255V, 1/1 had a CHR and 0/1 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E255V	ABL1	BCR::ABL E255V	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	B	Resistance	chr9	130862977	130862977	A	T	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 11 patients with E255V mutations, 4, 4, and 9 achieved a CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	"Mller et al., 2009, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E255V	ABL1	BCR::ABL E255V	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130862977	130862977	A	T	"Three chronic myeloid leukemia patients had the BCR-ABL1 fusion with the E255V secondary variant in one or more bacterial clones generated using peripheral blood RNA. They had no best cytogenetic responses but had complete (n = 2) or minor best hematologic responses to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1. The first patient, in chronic phase, had E255V, E255V/Q447R, E255V/T345A, and E255V/T345A/H396R variants in 6/10, 2/10, 1/10, and 1/10 clones, respectively. The second patient, in chronic phase, had E255V and E255K variants in 10/11 and 1/11 clones, respectively. The third patient, in myeloid blast crisis, had E255V and E292V variants in 10/12 and 2/12 clones, respectively."	"Talpaz et al., 2006, N. Engl. J. Med."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E255V	ABL1	BCR::ABL E255V	Chronic Myeloid Leukemia	"Nilotinib,Imatinib Mesylate"	Predictive	Supports	C	Resistance	chr9	130862977	130862977	A	T	"In this open-label, phase II registration trial, patients that were imatinib resistant or intolerant underwent nilotinib monotherapy. Within 12 months of nilotinib therapy, there was no significant difference in response to nilotinib treatment between patients with mutations in the Abl1 kinase domain versus without. However, the authors identify Y253H, E255K/V, and F359C/V variants as resistant as they had an IC50 greater than 150 nM. In patients with E255K and/or E255V mutations prior to nilotinib treatment, complete hematological responses were achieved in 5 of 7 patients, major cytogenetic responses in 3 of 7 patients, complete cytogenetic responses in 0 of 7 patients, and a major molecular response in 1 of 7 patients. After a median follow-up of 15.5 months, 6 of 7 patients with this mutation progressed or died. The E255K mutation was present in 6 patients at baseline and newly emerged in 4 patients at progression. The E255V mutation was present in 0 patients at baseline and newly emerged in 3 patients at progression."	"Hughes et al., 2009, J. Clin. Oncol."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E255V	ABL1	BCR::ABL E255V	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	C	Resistance	chr9	130862977	130862977	A	T	"In a study of 39 chronic phase CML patients with BCR-ABL variants, E255V was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL D276G	ABL1	BCR::ABL D276G	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	D	Resistance	chr9	130872133	130872133	A	G	"A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The D276G mutation was moderately resistant to imatinib."	"Redaelli et al., 2009, J. Clin. Oncol."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL D276G	ABL1	BCR::ABL D276G	Chronic Myeloid Leukemia	Nilotinib	Predictive	Supports	D	Sensitivity/Response	chr9	130872133	130872133	A	G	"In an in vitro study, a Ba/F3  cell line stably expressing the D276G mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to nilotinib treatment (IC50: 2.00-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation."	"Redaelli et al., 2009, J. Clin. Oncol."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL D276G	ABL1	BCR::ABL D276G	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130872133	130872133	A	G	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with D276G evaluated, 1/1 had a complete hematologic responses and 0/1 had a major cytogenetic response."	"Cortes et al., 2011, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL D276G	ABL1	BCR::ABL D276G	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130872133	130872133	A	G	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 8 patients with D276G mutations, 3, 4, and 7 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	"Mller et al., 2009, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL D276G	ABL1	BCR::ABL D276G	Chronic Myeloid Leukemia	Axitinib	Predictive	Supports	D	Resistance	chr9	130872133	130872133	A	G	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporations when harboring fusions with the D276G variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1105nM vs. 823 nM), indicating resistance."	"Pemovska et al., 2015, Nature"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL D276G	ABL1	BCR::ABL D276G	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	D	Resistance	chr9	130872133	130872133	A	G	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The D276G mutation was associated with resistance in 2 M imatinib (1 clone recovered, ~0.71%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E279K	ABL1	BCR::ABL E279K	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130872141	130872141	G	A	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 8 patients with E279K mutations, 5, 5, and 8 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	"Mller et al., 2009, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E279K	ABL1	BCR::ABL E279K	Chronic Myeloid Leukemia	Axitinib	Predictive	Supports	D	Sensitivity/Response	chr9	130872141	130872141	G	A	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the E279K variant of ABL1 compared to those with wildtype ABL1 (IC50 of 778nM vs. 823 nM), indicating that the E279K variant does not induce resistance."	"Pemovska et al., 2015, Nature"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E292V	ABL1	BCR::ABL E292V	Chronic Myeloid Leukemia	Nilotinib	Predictive	Supports	D	Resistance	chr9	130872181	130872181	A	T	"In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib. The E292V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was identified and associated with resistance to nilotinib treatment (1 clone recovered at 50nM). In a review of 20 publications, this mutation was not previously described in imatinib resistant patients."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 L298V	ABL1	L298V	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130872198	130872198	C	G	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with L298V evaluated, 1/1 had a complete hematologic response and 0/1 had a major cytogenetic response."	"Cortes et al., 2011, Blood"	Somatic	ENST00000318560.5	missense_variant
ABL1 BCR::ABL V299L	ABL1	BCR::ABL V299L	Chronic Myeloid Leukemia	Nilotinib	Predictive	Supports	D	Sensitivity/Response	chr9	130872201	130872201	G	C	"In an in vitro study, a Ba/F3 cell line stably expressing the V299L mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to nilotinib treatment (IC50: 1.34-fold), comparable to Ba/F3 cells expressing BCR-ABL1 fusion protein. Sensitivity was determined by assessing cell proliferation."	"Redaelli et al., 2009, J. Clin. Oncol."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL V299L	ABL1	BCR::ABL V299L	Chronic Myeloid Leukemia	Bosutinib	Predictive	Supports	C	Reduced Sensitivity	chr9	130872201	130872201	G	C	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with V299L, 1/2 had a CHR and 0/2 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL V299L	ABL1	BCR::ABL V299L	Chronic Myeloid Leukemia	Dasatinib	Predictive	Supports	C	Resistance	chr9	130872201	130872201	G	C	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response, major cytogenetic response, complete cytogenetic response (CCyR), and major molecular response. There was 1 patient with a V299L mutation who did not achieved CCyR with dasatinib monotherapy. Analyses by variant included patients with multiple kinase domain mutations. Of the 63 variants considered, the authors associate T315I, F317L, and V299L with resistance to dasatinib or lower levels of response due to clinical resistance and low in vitro sensitivity. They suggest considering alternative treatment options for patients with these variants."	"Mller et al., 2009, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL V299L	ABL1	BCR::ABL V299L	Chronic Myeloid Leukemia	Dasatinib	Predictive	Supports	D	Resistance	chr9	130872201	130872201	G	C	"In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using ?0 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 1 of these clones had an V299L mutation. To validate resistance to dasatinib, a Ba/F3 cell line stably expressing the V299L mutation in the ABL1 region of the BCR-ABL fusion was generated and associated with higher dasatinib IC50 of 18 nM vs 1.34 nM in wildtype as determined by dose response curves."	"Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL V299L	ABL1	BCR::ABL V299L	Chronic Myeloid Leukemia	"Imatinib Mesylate,Dasatinib"	Predictive	Supports	D	Resistance	chr9	130872201	130872201	G	C	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. Of the 11 clones that grew in a combination of 400 nM imatinib and 10 nM dasatinib, 1 (9%) was found to have a V299L mutation."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL V299L	ABL1	BCR::ABL V299L	Chronic Myeloid Leukemia	Dasatinib	Predictive	Supports	D	Resistance	chr9	130872201	130872201	G	C	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The V299L mutation was associated with resistance in 10 nM dasatinib (3 clone recovered, ~5%). No clones were recovered in 5 nM dasatinib. In a review of 20 publications, this mutation was described in imatinib resistant patients."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL V299L	ABL1	BCR::ABL V299L	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	B	Resistance	chr9	130872201	130872201	G	C	"In a study of 39 chronic phase CML patients with BCR-ABL variants, V299L was seen in two imatinib-resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL V299L	ABL1	BCR::ABL V299L	Chronic Myeloid Leukemia	Axitinib	Predictive	Supports	D	Sensitivity/Response	chr9	130872201	130872201	G	C	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed decreased incorporation when harboring fusions with the V299L variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 188nM vs. 823 nM), indicating V299L induces sensitivity compared to BCR-ABL1 without secondary variants."	"Pemovska et al., 2015, Nature"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Q300R	ABL1	BCR::ABL Q300R	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130872205	130872205	A	G	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with Q300R, 1/1 had a CHR and 1/1 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL Q300R	ABL1	BCR::ABL Q300R	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	C	Resistance	chr9	130872205	130872205	A	G	"In a study of 39 chronic phase CML patients with BCR-ABL variants, Q300R was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F311L	ABL1	BCR::ABL F311L	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130872883	130872883	T	C	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with F311L evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response."	"Cortes et al., 2011, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F311L	ABL1	BCR::ABL F311L	Chronic Myeloid Leukemia	"Nilotinib,Imatinib Mesylate"	Predictive	Supports	D	Resistance	chr9	130872883	130872883	T	C	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. 61 clones grew in a combination of 400 nM imatinib and 50 nM nilotinib. Of these, 19 were sequenced and 1 (~5%) was found to have an F311L mutation."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL T315A	ABL1	BCR::ABL T315A	Chronic Myeloid Leukemia	Dasatinib	Predictive	Supports	D	Resistance	chr9	130872895	130872895	A	G	"In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using ?0 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 60 of these clones had T315A mutations. To validate resistance to dasatinib, Ba/F3 cell lines stably expressing a T315A mutation in the ABL1 region of the BCR-ABL fusion were generated. T315A was associated with higher dasatinib IC50 of 125 nM vs 1.34 nM in wildtype as determined by dose response curves."	"Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL T315A	ABL1	BCR::ABL T315A	Chronic Myeloid Leukemia	Axitinib	Predictive	Supports	D	Sensitivity/Response	chr9	130872895	130872895	A	G	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed decreased incorporation when harboring fusions with the T315A variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 389nM vs. 823 nM), indicating T315A induces sensitivity compared to BCR-ABL1 without secondary variants."	"Pemovska et al., 2015, Nature"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL T315A	ABL1	BCR::ABL T315A	Cancer	"Nilotinib,Bafetinib"	Predictive	Does Not Support	D	Resistance	chr9	130872895	130872895	A	G	"In an in vitro study, a Ba/F3 cell line stably expressing the dasatinib-resistance variant T315A in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib and bafetinib (INNO-406) treatment (IC50: 949.2 nM, 422.5 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 642.3 nM and 152.9 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	"Deguchi et al., 2008, Leuk. Res."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL T315A	ABL1	BCR::ABL T315A	Cancer	"Dasatinib,Imatinib"	Predictive	Supports	D	Resistance	chr9	130872895	130872895	A	G	"In an in vitro study, a Ba/F3 cell line stably expressing T315A in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib and dasatinib treatment (IC50: >2000.0 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 1712 nM and 87.6 nM). Sensitivity was determined by assessing cell proliferation. The authors examined X-ray crystal structure of dasatinib/ABL to determine why dasatinib was ineffective against mutations at amino acid 315, and found that T315A causes decreased steric and hydrogen-bonding interactions with dasatinib."	"Deguchi et al., 2008, Leuk. Res."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F317I	ABL1	BCR::ABL F317I	Chronic Myeloid Leukemia	Dasatinib	Predictive	Supports	D	Resistance	chr9	130872901	130872901	T	A	"In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using ?0 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 1 of these clones had an F317I mutation."	"Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F317I	ABL1	BCR::ABL F317I	Chronic Myeloid Leukemia	Dasatinib	Predictive	Supports	D	Resistance	chr9	130872901	130872901	T	A	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The F317I mutation was associated with resistance in 5 nM dasatinib (2 clone recovered, ~ 6%) and 10 nM dasatinib (10 clones, ~18%)."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F317S	ABL1	BCR::ABL F317S	Chronic Myeloid Leukemia	Dasatinib	Predictive	Supports	D	Resistance	chr9	130872902	130872902	T	C	"In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasatinib resistant subclones were identified using ?0 nM dasatinib in liquid culture. 201 individual clones were identified representing 10 different mutations at 6 different residues. 1 of these clones had an F317S mutation."	"Burgess et al., 2005, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F317C	ABL1	BCR::ABL F317C	Chronic Myeloid Leukemia	Dasatinib	Predictive	Supports	D	Resistance	chr9	130872902	130872902	T	G	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The F317C mutation was associated with resistance in 5 nM dasatinib (1 clone recovered, ~ 3%) and 10 nM dasatinib (6 clones, ~11%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 G340L	ABL1	G340L	Lung Non-small Cell Carcinoma	"Dasatinib,Imatinib Mesylate"	Predictive	Supports	D	Sensitivity/Response	chr9	130872913	130872914	GG	CT	"In this in vitro study, the H2110 non-small cell lung cancer cell line (heterozygous for a G340L mutation) was shown to be susceptible to imatinib and dasatinib monotherapies. This line showed a significant reduction in colony formation (P = 0.0001) and MTT assay, which tests for NADH activity (P < 0.001), with imatinib vs vehicle treatment. A significant reduction in colony formation (P < 0.001) with dasatinib treatment vs vehicle was also observed. There was no significant difference in a lung cancer cell line without a known driver (H2126) nor in an immortalized bronchial epithelial line (Beas-2B) with either drug treatment in colony forming and MTT assays. Moreover, a significant increase in cytotoxicity was noted with siRNA facilitated depletion of ABL1 (P < 0.001) with no significant change in H2126 or Beas-2B lines supporting ABL1 as the primary drug target."	"Testoni et al., 2016, EMBO Mol Med"	Somatic	ENST00000372348.2	coding_sequence_variant
ABL1 BCR::ABL N331S	ABL1	BCR::ABL N331S	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130872944	130872944	A	G	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with N331S evaluated, 1/1 had a major cytogenetic response."	"Cortes et al., 2011, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 R351W	ABL1	R351W	Lung Non-small Cell Carcinoma	Dasatinib	Predictive	Supports	D	Sensitivity/Response	chr9	130872946	130872946	C	T	"In this in vitro study, the H1915 non-small cell lung cancer cell line (homozygous for a R351W mutation) was shown to be susceptible to dasatinib. This line showed a significant reduction in colony formation (P < 0.001) and MTT assay, which tests for NADH activity (P = 1.09 x 10^5), with dasatinib vs vehicle treatment. There was no significant difference in a lung cancer cell line without a known driver (H2126) nor in an immortalized bronchial epithelial line (Beas-2B) with either drug treatment in colony forming and MTT assays. Additionally, reduction in cell viability upon kinase inhibitor treatment could be rescued with tetracycline-induced overexpression of resistant ABL1-T315I (P < 0.001) confirming the genetic dependency of this cell line on ABL1. Moreover, a significant increased in cytotoxicity was noted with siRNA facilitated depletion of ABL1 (P < 0.005) with no significant change in H2126 or Beas-2B lines supporting ABL1 as the primary drug target."	"Testoni et al., 2016, EMBO Mol Med"	Somatic	ENST00000372348.2	missense_variant
ABL1 R351W	ABL1	R351W	Lung Non-small Cell Carcinoma	Imatinib	Predictive	Supports	D	Sensitivity/Response	chr9	130872946	130872946	C	T	"In this in vitro study, the H1915 non-small cell lung cancer cell line (homozygous for a R351W mutation) was shown to be susceptible to imatinib. This line showed a significant reduction in colony formation (P = 0.0004) and MTT assay, which tests for NADH activity (P < 0.001), with imatinib vs vehicle treatment. There was no significant difference in a lung cancer cell line without a known driver (H2126) nor in an immortalized bronchial epithelial line (Beas-2B) with either drug treatment in colony forming and MTT assays. Additionally, reduction in cell viability upon kinase inhibitor treatment was rescued with tetracycline-induced overexpression of resistant ABL1-T315I (P < 0.001) confirming the genetic dependency of this cell line on ABL1. Moreover, siRNA facilitated depletion of ABL1 expression resulted in significantly increased cytotoxicity (P < 0.004) with no significant change in H2126 or Beas-2B lines for 2/3 siRNAs supporting ABL1 as the primary drug target. Significant tumor reduction was observed in murine NSCLC xenografts of the H1915 cell line treated with imatinib compared to vehicle treatment (P = 0.0016). No change in tumor growth was observed in xenografts of the H650 cell line containing a wildtype ABL1 locus. In both in vitro and in vivo experiments, doxycycline-inducible expression of drug-resistant ABL1-T315I rescued imatinib-mediated inhibitory effects supporting the specificity of drug responses."	"Testoni et al., 2016, EMBO Mol Med"	Somatic	ENST00000372348.2	missense_variant
ABL1 BCR::ABL N336S	ABL1	BCR::ABL N336S	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130872959	130872959	A	G	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with N336S, 1/1 had a CHR and 0/1 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL N336S	ABL1	BCR::ABL N336S	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	C	Resistance	chr9	130872959	130872959	A	G	"In a study of 39 chronic phase CML patients with BCR-ABL variants, N336S was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M343T	ABL1	BCR::ABL M343T	Chronic Myeloid Leukemia	Axitinib	Predictive	Supports	D	Resistance	chr9	130872980	130872980	T	C	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with the M343T variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1175nM vs. 823 nM), indicating resistance."	"Pemovska et al., 2015, Nature"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M351T	ABL1	BCR::ABL M351T	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	D	Sensitivity/Response	chr9	130873004	130873004	T	C	"A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The M351T mutation was sensitive to imatinib."	"Redaelli et al., 2009, J. Clin. Oncol."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M351T	ABL1	BCR::ABL M351T	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	C	Resistance	chr9	130873004	130873004	T	C	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. Three CP patients, with the M351T variants detected prior to resistance, had hematologic responses prior to progression. One patient became resistant after the appearance of the M351T variant but responded to dose escalation. The last patient, who also had the Q252H variant, progressed to myeloid blast crisis (MBC) after which there was cytogenetic evidence of a double Ph-chromosome and no detectable secondary variants. Three accelerated-phase (AP) patients returned to CP and had M351T variants. One of these patients also had E255K and F359V variants and progressed to AP. The remaining two, one of whom also had H396R variant, progressed to MBC and died. Two additional AP patients also had M351T variants but initially had CHRs. One who also had the G250E variant died from disease progression. The other also had the F359V variant progressed to MBC with cytogenetic evidence of the double Ph-chromosome and no detectable secondary variants at progression."	"Branford et al., 2003, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M351T	ABL1	BCR::ABL M351T	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	C	Sensitivity/Response	chr9	130873004	130873004	T	C	"In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The M351T mutation was  sensitive to imatinib ."	"O'Hare et al., 2005, Cancer Res."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M351T	ABL1	BCR::ABL M351T	Chronic Myeloid Leukemia	Nilotinib	Predictive	Supports	D	Sensitivity/Response	chr9	130873004	130873004	T	C	"In an in vitro study, Ba/F3 cell line stably expressing the M351T mutation in the ABL1 portion of the BCR-ABL1 gene fusion was associated with sensitivity to nilotinib treatment (IC50: 0.44-fold), comparable to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation."	"Redaelli et al., 2009, J. Clin. Oncol."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M351T	ABL1	BCR::ABL M351T	Cancer	"Dasatinib,Bafetinib,Nilotinib"	Predictive	Does Not Support	D	Resistance	chr9	130873004	130873004	T	C	"In an in vitro study, a Ba/F3 cell line stably expressing the M351T mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib, dasatinib, and bafetinib treatment (IC50: 580.4 nM, 88 nM, 582.9 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 642.3 nM, 87.6 nM, 152.9 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	"Deguchi et al., 2008, Leuk. Res."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M351T	ABL1	BCR::ABL M351T	Chronic Myeloid Leukemia	Bosutinib	Predictive	Supports	C	Reduced Sensitivity	chr9	130873004	130873004	T	C	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with M351T, 1/1 had a CHR and 0/1 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M351T	ABL1	BCR::ABL M351T	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	B	Resistance	chr9	130873004	130873004	T	C	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 54 patients with M351T mutations, 25, 28, and 51 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	"Mller et al., 2009, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M351T	ABL1	BCR::ABL M351T	Chronic Myeloid Leukemia	Dasatinib	Predictive	Supports	C	Reduced Sensitivity	chr9	130873004	130873004	T	C	"In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with M351T, 3/6 had MaHRs which was comparable to response rates among wild type patients, and 1/6 had MCyRs which was lower than response rates among wild type patients."	"Guilhot et al., 2007, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M351T	ABL1	BCR::ABL M351T	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130873004	130873004	T	C	"Prior to dasatinib treatment, four imatinib-resistant patients with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the M351T and M351S; M351T; M351T; and M351T secondary variants in 8/9 and 1/9; 4/10; 10/10; and 11/11 bacterial clones, respectively. Clones were generated using peripheral blood RNA. They had complete response as best hematologic response and complete (n = 3) or partial (n = 1) responses as best cytogenetic response to dasatinib. An additional patient, in myeloid blast crisis, had the M351T variant in 10/10 clones with complete response as best hematologic response and complete response as best cytogenetic response to dasatinib. An additional patient in accelerated phase had the M351T and M351A variants in 6/10 and 1/10 clones, respectively, with complete response as best hematologic response and none as best cytogenetic response to dasatinib. Overall, responses among these patients were comparable to those among patients with unmutated BCR-ABL1."	"Talpaz et al., 2006, N. Engl. J. Med."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M351T	ABL1	BCR::ABL M351T	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	D	Resistance	chr9	130873004	130873004	T	C	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The M351T mutation was associated with resistance in 2 M imatinib (1 clone recovered, ~0.71%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M351T	ABL1	BCR::ABL M351T	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	C	Resistance	chr9	130873004	130873004	T	C	"In a study of 39 chronic phase CML patients with BCR-ABL variants, M351T was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M351T	ABL1	BCR::ABL M351T	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	C	Resistance	chr9	130873004	130873004	T	C	"In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 6 had M351T mutations"	"Guilhot et al., 2007, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M351T	ABL1	BCR::ABL M351T	Chronic Myeloid Leukemia	Axitinib	Predictive	Does Not Support	D	Resistance	chr9	130873004	130873004	T	C	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed decreased incorporation when harboring fusions with the M351T variant of ABL1 compared to those with wildtype ABL1 (IC50 of 553nM vs. 823 nM), indicating the M351T variant induces sensitivity compared to BCR-ABL1 without secondary variants."	"Pemovska et al., 2015, Nature"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL M351T	ABL1	BCR::ABL M351T	Cancer	Imatinib	Predictive	Supports	D	Resistance	chr9	130873004	130873004	T	C	"In an in vitro study, a Ba/F3 cell line stably expressing the M351T mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib treatment (IC50: >2000.0 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 1712 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	"Deguchi et al., 2008, Leuk. Res."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E355G	ABL1	BCR::ABL E355G	Chronic Myeloid Leukemia	Imatinib	Predictive	Does Not Support	C	Resistance	chr9	130873016	130873016	A	G	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A CP patient had complete cytogenetic response until progressing to accelerated phase with concurrent detection of the E355G variant. After dose escalation, this patient achieved a major cytogenetic response with continued presence of E355G. Another CP patient had a major cytogenetic response to imatinib which was maintained after the detection of the E355G variant."	"Branford et al., 2003, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E355G	ABL1	BCR::ABL E355G	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130873016	130873016	A	G	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with E355G evaluated, 2/2 had complete hematologic responses and 1/2 had major cytogenetic responses."	"Cortes et al., 2011, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E355G	ABL1	BCR::ABL E355G	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130873016	130873016	A	G	"In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with E355G, 2/4 had MaHRs and 2/4 had MCyRs which were comparable to response rates among wild type."	"Guilhot et al., 2007, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E355G	ABL1	BCR::ABL E355G	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	B	Resistance	chr9	130873016	130873016	A	G	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 19 patients with E355G mutations, 4, 9, and 17 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	"Mller et al., 2009, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E355G	ABL1	BCR::ABL E355G	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130873016	130873016	A	G	"Prior to dasatinib treatment, three imatinib-resistant patients with chronic myeloid leukemia had the BCR-ABL1 fusion with the E355G secondary variant in one or more bacterial clones. Clones were generated using peripheral blood RNA. The first two, in chronic and accelerated phases, had minimal or no best cytogenetic responses but had complete or no evidence of leukemia best hematologic responses, respectively. Of these, the first had E355G and E355G/Q252R variants in 8/10 and 1/10 clones, respectively, and the second had E355G, E355G/L324Q, and L324Q variants in 6/10, 1/10, and 3/10 clones, respectively. The third patient, in lymphoid blast crisis with the E355G variant in 10/10 clones, had complete best hematologic and partial best cytogenetic responses to dasatinib. All responses were comparable to responses in patients with unmutated BCR-ABL1."	"Talpaz et al., 2006, N. Engl. J. Med."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E355G	ABL1	BCR::ABL E355G	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	D	Resistance	chr9	130873016	130873016	A	G	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The E355G mutation was associated with resistance in 2 M imatinib (1 clone recovered, ~0.71%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E355G	ABL1	BCR::ABL E355G	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	C	Resistance	chr9	130873016	130873016	A	G	"In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 4 had E355G mutations"	"Guilhot et al., 2007, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E355G	ABL1	BCR::ABL E355G	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	C	Resistance	chr9	130873016	130873016	A	G	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An acute-phase patient achieved complete hematologic response but progressed to chronic phase with detection of the E355G mutation and then to accelerated phase. After allograft, this patient relapsed into chronic phase and the E355G mutation was again detected in 100% of transcripts."	"Branford et al., 2003, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359V	ABL1	BCR::ABL F359V	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	D	Resistance	chr9	130873027	130873027	T	G	"A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The F359V mutation was moderately resistant to imatinib."	"Redaelli et al., 2009, J. Clin. Oncol."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359V	ABL1	BCR::ABL F359V	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	C	Resistance	chr9	130873027	130873027	T	G	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An accelerated-phase (AP) patient improved to chronic phase. M351T, E255K, and F359V variants were each present in ~25% of transcripts beginning at 6, 11, and 14 months, respectively. At 20 months, the patient returned to accelerated phase with an increase in the proportion of E255K variants to ~75% of transcripts. Another AP patient had a complete hematologic response with the M351T variant present in ~25 to ~75% of transcripts and the F359V variant present in ~25% to ~50% of transcripts between 8 and 16 months after therapy initiation but prior to resistance. At 17 months, the patient progressed to myeloid blast crisis and there was cytogenetic evidence of a double Ph-chromosome. At that time, no secondary variants could be detected."	"Branford et al., 2003, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359V	ABL1	BCR::ABL F359V	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	C	Resistance	chr9	130873027	130873027	T	G	"In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The F359V mutation was  moderately resistant to imatinib ."	"O'Hare et al., 2005, Cancer Res."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359V	ABL1	BCR::ABL F359V	Chronic Myeloid Leukemia	Nilotinib	Predictive	Supports	D	Resistance	chr9	130873027	130873027	T	G	"In an in vitro study, a Ba/F3  cell line stably expressing the F359V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 5.16-fold), as compared to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation."	"Redaelli et al., 2009, J. Clin. Oncol."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359V	ABL1	BCR::ABL F359V	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130873027	130873027	T	G	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with F359V evaluated, 6/6 had complete hematologic responses and 4/7 had major cytogenetic responses."	"Cortes et al., 2011, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359V	ABL1	BCR::ABL F359V	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130873027	130873027	T	G	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with F359V, 0/2 had a CHR and 1/2 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359V	ABL1	BCR::ABL F359V	Chronic Myeloid Leukemia	Dasatinib	Predictive	Supports	C	Reduced Sensitivity	chr9	130873027	130873027	T	G	"In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with F359V, 5/7 had MaHRs which was comparable to response rates among wild type patients, and 1/7 had MCyRs which which was lower than response rates among wild type patients."	"Guilhot et al., 2007, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359V	ABL1	BCR::ABL F359V	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	B	Resistance	chr9	130873027	130873027	T	G	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase) patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Of the 27 with F359V mutations, 14, 17, and 25 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	"Mller et al., 2009, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359V	ABL1	BCR::ABL F359V	Chronic Myeloid Leukemia	Dasatinib	Predictive	Supports	C	Resistance	chr9	130873027	130873027	T	G	"Prior to dasatinib treatment, two imatinib-resistant patients with chronic myeloid leukemia (CML) in chronic phase had the BCR-ABL1 fusion, one with the T315I, F359V, M244V, and G250E variants in 2/10, 6/10, 1/10, and 1/10 clones, respectively, and the other with F359V, F359V/F486S, F359V/L273M, and L273M variants in 6/10, 1/10, 2/10, and 1/10 clones, respectively. Clones were generated using peripheral blood RNA. The patients had no best cytogenetic responses and no or complete best hematologic responses to dasatinib. Two additional patients with CML, in myeloid blast crisis,  had F359V in 1/10 and 9/10 clones. They had no hematologic and no cytogenetic responses. Overall, responses were poor compared to responses in patients with unmutated BCR-ABL1."	"Talpaz et al., 2006, N. Engl. J. Med."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359V	ABL1	BCR::ABL F359V	Chronic Myeloid Leukemia	Axitinib	Predictive	Does Not Support	D	Resistance	chr9	130873027	130873027	T	G	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the F359V variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 933nM vs. 823 nM), indicating that the variant does not induce resistance."	"Pemovska et al., 2015, Nature"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359I	ABL1	BCR::ABL F359I	Chronic Myeloid Leukemia	Axitinib	Predictive	Does Not Support	D	Resistance	chr9	130873027	130873027	T	A	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the F359I variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 975nM vs. 823 nM), indicating that the variant does not induce resistance."	"Pemovska et al., 2015, Nature"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359I	ABL1	BCR::ABL F359I	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130873027	130873027	T	A	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with F359I evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response."	"Cortes et al., 2011, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359I	ABL1	BCR::ABL F359I	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130873027	130873027	T	A	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with F359I evaluated, 2/2 had CHR and 2/2 had MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were occurring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359I	ABL1	BCR::ABL F359I	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	B	Resistance	chr9	130873027	130873027	T	A	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 12 patients with F359I mutations, 7, 10, and 12 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	"Mller et al., 2009, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359I	ABL1	BCR::ABL F359I	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130873027	130873027	T	A	"Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the F359I secondary variant in 9/9 bacterial clones generated using peripheral blood RNA. They had complete best hematologic and no cytogenetic responses to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1."	"Talpaz et al., 2006, N. Engl. J. Med."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359V	ABL1	BCR::ABL F359V	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	D	Resistance	chr9	130873027	130873027	T	G	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The F359V mutation was associated with resistance in 2 M imatinib (3 clones recovered, ~2%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359V	ABL1	BCR::ABL F359V	Chronic Myeloid Leukemia	"Nilotinib,Imatinib Mesylate"	Predictive	Supports	C	Resistance	chr9	130873027	130873027	T	G	"In this open-label, phase II registration trial, patients that were imatinib-resistant or intolerant underwent nilotinib monotherapy. Within 12 months of nilotinib therapy, there was no significant difference in response to nilotinib treatment between patients with mutations in the Abl1 kinase domain versus without. However, the authors identify Y253H, E255K/V, and F359C/V variants as resistant as they had an IC50 of >150nM. In patients with F359C and/or F359V mutations prior to nilotinib treatment, complete hematological responses were achieved in 3 of 10 patients, a major cytogenetic response in 1 of 11 patients, a complete cytogenetic response in 0 of 11 patients, and major molecular response in 0 of 10 patients. After a median follow-up of 15.5 months, 9 of 11 patients with this mutation progressed or died. The F359C mutation was present in 1 patient at baseline and newly emerged in 1 patient at progression. The F359V mutation was present in 4 patients at baseline and newly emerged in 1 patient at progression."	"Hughes et al., 2009, J. Clin. Oncol."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359I	ABL1	BCR::ABL F359I	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	C	Resistance	chr9	130873027	130873027	T	A	"In a study of 39 chronic phase CML patients with BCR-ABL variants, F359I was seen in two imatinib-resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359V	ABL1	BCR::ABL F359V	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	C	Resistance	chr9	130873027	130873027	T	G	"In a study of 39 chronic phase CML patients with BCR-ABL variants, C475V was seen in one imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359V	ABL1	BCR::ABL F359V	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	C	Resistance	chr9	130873027	130873027	T	G	"In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 7 had F359V mutations"	"Guilhot et al., 2007, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359V	ABL1	BCR::ABL F359V	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130873027	130873027	T	G	"Prior to dasatinib treatment, one imatinib-resistant patients with chronic myeloid leukemia (CML) in myeloid blast crisis had the BCR-ABL1 fusion with F359V, F359V/Q252R, and L273M secondary variants in 9/12, 1/12, and 2/12 clones, respectively. Clones were generated using peripheral blood RNA. The patient had complete best cytogenetic and no evidence of leukemia best hematologic responses to dasatinib which were better outcomes in comparison to those seen in patients with unmutated BCR-ABL in this phase."	"Talpaz et al., 2006, N. Engl. J. Med."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359C	ABL1	BCR::ABL F359C	Chronic Myeloid Leukemia	"Nilotinib,Imatinib Mesylate"	Predictive	Supports	D	Resistance	chr9	130873028	130873028	T	G	"In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The F359C mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to 50nM nilotinib (6 clones recovered, ~13% of viable clones in this treatment) and 2 M imatinib (6 clones, ~4%). In a review of 20 publications, this mutation was described in imatinib resistant patients."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359C	ABL1	BCR::ABL F359C	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130873028	130873028	T	G	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with F359C, 2/2 had a CHR and 1/2 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359C	ABL1	BCR::ABL F359C	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130873028	130873028	T	G	"In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with F359C, 2/2 had MaHRs and 2/2 had MCyRs which were comparable to response rates among wild type patients."	"Guilhot et al., 2007, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359C	ABL1	BCR::ABL F359C	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130873028	130873028	T	G	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 5 patients with F359C mutations, 3, 3, and 4 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	"Mller et al., 2009, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359C	ABL1	BCR::ABL F359C	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130873028	130873028	T	G	"Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with G250E and F359C variants in 3/10 and 5/10 clones, respectively. Clones were generated using peripheral blood RNA. The patient had complete best cytogenetic and complete best hematologic responses to dasatinib which were improved compared to responses in patients with unmutated BCR-ABL1."	"Talpaz et al., 2006, N. Engl. J. Med."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359C	ABL1	BCR::ABL F359C	Chronic Myeloid Leukemia	"Nilotinib,Imatinib Mesylate"	Predictive	Supports	C	Resistance	chr9	130873028	130873028	T	G	"In this open-label, phase II registration trial, patients that were imatinib resistant or intolerant underwent nilotinib monotherapy. Within 12 months of nilotinib therapy, there was no significant difference in response to nilotinib treatment between patients with mutations in the Abl1 kinase domain versus without. However, the authors identify Y253H, E255K/V, and F359C/V variants as resistant as they had an IC50 of >150nM. In patients with F359C and/or F359V mutations prior to nilotinib treatment, complete hematological responses were achieved in 3 of 10 patients, a major cytogenetic response in 1 of 11 patients, a complete cytogenetic response in 0 of 11 patients, and major molecular response in 0 of 10 patients. After a median follow-up of 15.5 months, 9 of 11 patients with this mutation progressed or died. The F359C mutation was present in 1 patient at baseline and newly emerged in 1 patient at progression. The F359V mutation was present in 4 patients at baseline and newly emerged in 1 patient at progression."	"Hughes et al., 2009, J. Clin. Oncol."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359C	ABL1	BCR::ABL F359C	Chronic Myeloid Leukemia	"Imatinib Mesylate,Nilotinib"	Predictive	Supports	D	Resistance	chr9	130873028	130873028	T	G	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. 61 clones grew in a combination of 400 nM imatinib and 50 nM nilotinib. Of these, 19 were sequenced and 7 (~37%) were found to have F359C mutations."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359C	ABL1	BCR::ABL F359C	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	C	Resistance	chr9	130873028	130873028	T	G	"In a study of 39 chronic phase CML patients with BCR-ABL variants, F359C was seen in two imatinib-resistant patients that were also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F359C	ABL1	BCR::ABL F359C	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	C	Resistance	chr9	130873028	130873028	T	G	"In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 2 had F359C mutations"	"Guilhot et al., 2007, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL L364P	ABL1	BCR::ABL L364P	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130874873	130874873	T	C	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with L364P evaluated, 1/1 had a major cytogenetic response."	"Cortes et al., 2011, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL V379I	ABL1	BCR::ABL V379I	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130874917	130874917	G	A	"Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in accelerated phase had the BCR-ABL1 fusion with E279K, V379I, and V379I/F317L/M351T variants in 3/11, 5/11, and 1/11 clones, respectively. Clones were generated using peripheral blood RNA. The patient had complete response as best cytogenetic response and no evidence of leukemia as best hematologic response to dasatinib which were improved compared to responses in patients with unmutated BCR-ABL1. An additional patient, in myeloid blast crisis, had V379I in 9/10 bacterial clones generated using peripheral blood RNA. They had complete response as best hematologic response and none as best cytogenetic response to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1."	"Talpaz et al., 2006, N. Engl. J. Med."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL V379I	ABL1	BCR::ABL V379I	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130874917	130874917	G	A	"In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with V379I, 3/4 had MaHRs and 2/4 had MCyRs which were comparable to response rates among wild type patients."	"Guilhot et al., 2007, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL V379I	ABL1	BCR::ABL V379I	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	D	Resistance	chr9	130874917	130874917	G	A	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The V379I mutation was associated with resistance in 2 M imatinib (2 clones recovered, ~1%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL V379I	ABL1	BCR::ABL V379I	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	C	Resistance	chr9	130874917	130874917	G	A	"In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 4 had V379I mutations"	"Guilhot et al., 2007, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL L384M	ABL1	BCR::ABL L384M	Chronic Myeloid Leukemia	"Nilotinib,Imatinib Mesylate"	Predictive	Supports	D	Resistance	chr9	130874932	130874932	C	A	"In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The L384M mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance in 50nM nilotinib (1 clone recovered, ~2% of viable clones in this treatment) and 2 M imatinib (1 clone, ~0.7%). L384M was one of 3 novel mutations that were not identified in imatinib resistant patients from a review of 20 publications."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL L384M	ABL1	BCR::ABL L384M	Chronic Myeloid Leukemia	Axitinib	Predictive	Does Not Support	D	Resistance	chr9	130874932	130874932	C	A	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the L384M variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 916nM vs. 823 nM), indicating baseline sensitivity."	"Pemovska et al., 2015, Nature"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL L384M	ABL1	BCR::ABL L384M	Chronic Myeloid Leukemia	Dasatinib	Predictive	Supports	C	Resistance	chr9	130874932	130874932	C	A	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, a majority of patients with and without ABL1 mutation had comparable complete hematologic response, major cytogenetic response, complete cytogenetic response (CCyR), and major molecular response. However, out of 2 patients with the L384M mutation, 0 achieved CCyR with dasatinib monotherapy. Analyses by variant included patients with multiple kinase domain mutations."	"Mller et al., 2009, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL L387M	ABL1	BCR::ABL L387M	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130874941	130874941	T	A	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 5 patients with L387M mutations, 4, 4, and 5 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	"Mller et al., 2009, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL L387M	ABL1	BCR::ABL L387M	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130874941	130874941	T	A	"Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with L387M, L387M/F192L, and E450G variants in 7/10, 2/10, and 1/10 clones, respectively. Clones were generated using peripheral blood RNA. The patient had minimal best cytogenetic and complete best hematologic responses to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1."	"Talpaz et al., 2006, N. Engl. J. Med."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL L387F	ABL1	BCR::ABL L387F	Chronic Myeloid Leukemia	Nilotinib	Predictive	Supports	D	Resistance	chr9	130874943	130874943	G	C	"In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib. The L387F mutation in the ABL1 portion of the BCR-ABL1 fusion protein was identified and associated with resistance to nilotinib treatment (1 clone recovered at 50nM)."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL L387F	ABL1	BCR::ABL L387F	Chronic Myeloid Leukemia	Bosutinib	Predictive	Supports	C	Resistance	chr9	130874943	130874943	G	C	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with L387F, 1/1 had a CHR and 0/1 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL L387F	ABL1	BCR::ABL L387F	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	C	Resistance	chr9	130874943	130874943	G	C	"In a study of 39 chronic phase CML patients with BCR-ABL variants, L387F was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL H396R	ABL1	BCR::ABL H396R	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	D	Resistance	chr9	130874969	130874969	A	G	"A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The H396R mutation was resistant to imatinib."	"Redaelli et al., 2009, J. Clin. Oncol."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL H396R	ABL1	BCR::ABL H396R	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	C	Resistance	chr9	130874969	130874969	A	G	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An accelerated-phase patient had a return to chronic phase but progressed to myeloid blast crisis after 5 months of therapy. At that time, the M351T and H396R variants were detected in ~50% and ~25% of transcripts, respectively. At 10 months, the patient died."	"Branford et al., 2003, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL H396R	ABL1	BCR::ABL H396R	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	C	Resistance	chr9	130874969	130874969	A	G	"In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL protein and were grouped according to their anti-proliferative activity. Mutant cell lines that exhibited a greater than 4-fold increase in IC50 value were considered resistant to drug, 2-4 fold increase in IC50 were moderately resistant and less than 2-fold change in IC50 was sensitive to drug treatment. The H396R mutation was  resistant to imatinib ."	"O'Hare et al., 2005, Cancer Res."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL H396R	ABL1	BCR::ABL H396R	Chronic Myeloid Leukemia	Bosutinib	Predictive	Supports	C	Resistance	chr9	130874969	130874969	A	G	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with H396R, 0/1 had a CHR and 0/1 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL H396R	ABL1	BCR::ABL H396R	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130874969	130874969	A	G	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with H396R evaluated, 1/1 had a complete hematologic response."	"Cortes et al., 2011, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL H396R	ABL1	BCR::ABL H396R	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	B	Resistance	chr9	130874969	130874969	A	G	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 33 patients with H396R mutations, 13, 17, and 30 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	"Mller et al., 2009, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL H396R	ABL1	BCR::ABL H396R	Chronic Myeloid Leukemia	Axitinib	Predictive	Supports	D	Resistance	chr9	130874969	130874969	A	G	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with the H396R variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 1247nM vs. 823 nM), indicating resistance."	"Pemovska et al., 2015, Nature"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL H396P	ABL1	BCR::ABL H396P	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130874969	130874969	A	C	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with H396P evaluated, 1/1 had a complete hematologic response and 2/2 had major cytogenetic responses."	"Cortes et al., 2011, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL H396P	ABL1	BCR::ABL H396P	Chronic Myeloid Leukemia	"Imatinib Mesylate,Nilotinib"	Predictive	Supports	D	Resistance	chr9	130874969	130874969	A	C	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. 61 clones grew in a combination of 400 nM imatinib and 50 nM nilotinib. Of these, 19 were sequenced and 1 (~5%) was found to have an H396P mutation."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL H396R	ABL1	BCR::ABL H396R	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	D	Resistance	chr9	130874969	130874969	A	G	"In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were grown in a range of tyrosine kinase inhibitor concentrations to identify resistance mutations. The H396R mutation was associated with resistance in 2 M imatinib (1 clone recovered, ~0.71%) and 4 M imatinib (1 clone, ~0.74%). In a review of 20 publications, this mutation was previously described in imatinib resistant patients."	"Bradeen et al., 2006, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL H396R	ABL1	BCR::ABL H396R	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	C	Resistance	chr9	130874969	130874969	A	G	"In a study of 39 chronic phase CML patients with BCR-ABL variants, H396R was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL H396P	ABL1	BCR::ABL H396P	Chronic Myeloid Leukemia	Axitinib	Predictive	Does Not Support	D	Resistance	chr9	130874969	130874969	A	C	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed lower incorporation when harboring fusions with the H396P variant of ABL1 compared to those with wildtype ABL1 (IC50 of 683nM vs. 823 nM), indicating the H396P variant induces sensitivity compared to BCR-ABL1 without secondary variants."	"Pemovska et al., 2015, Nature"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL H396R	ABL1	BCR::ABL H396R	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130874969	130874969	A	G	"Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with H396R and E355G variants in 9/11 and 1/11 clones, respectively. Clones were generated using peripheral blood RNA. The patient had no best cytogenetic and complete best hematologic responses to dasatinib which were comparable to responses in patients with unmutated BCR-ABL1."	"Talpaz et al., 2006, N. Engl. J. Med."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL H396P	ABL1	BCR::ABL H396P	Cancer	"Nilotinib,Bafetinib"	Predictive	Does Not Support	D	Resistance	chr9	130874969	130874969	A	C	"In an in vitro study, a Ba/F3 cell line stably expressing H396P in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib and bafetinib (INNO-406) treatment (IC50: 986.9 nM and 280.1 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 642.3 nM and 152.9 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	"Deguchi et al., 2008, Leuk. Res."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL H396P	ABL1	BCR::ABL H396P	Cancer	Imatinib	Predictive	Supports	D	Resistance	chr9	130874969	130874969	A	C	"In an in vitro study, a Ba/F3 cell line stably expressing H396P in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib treatment (IC50: >2000.0 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 1712 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	"Deguchi et al., 2008, Leuk. Res."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL H396P	ABL1	BCR::ABL H396P	Cancer	Dasatinib	Predictive	Supports	D	Sensitivity/Response	chr9	130874969	130874969	A	C	"In an in vitro study, a Ba/F3 cell line stably expressing H396P in the ABL1 portion of the BCR-ABL1 fusion protein was associated with increased sensitivity to dasatinib treatment (IC50: 8.9 nM) as compared to wild-type BCR-ABL1 expressing Ba/F3 cells (IC50: 87.6 nM). Sensitivity was determined by assessing cell proliferation using the MTT assay."	"Deguchi et al., 2008, Leuk. Res."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL A397P	ABL1	BCR::ABL A397P	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130874971	130874971	G	C	"In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with A397P,  2/2 had MaHRs and 1/2 had MCyRs which were comparable to response rates among wild type patients."	"Guilhot et al., 2007, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL A397P	ABL1	BCR::ABL A397P	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	C	Resistance	chr9	130874971	130874971	G	C	"In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 2 had A397P mutations. Both patients with A397P mutation achieved major hematologic response, and one also had major cytogenetic response."	"Guilhot et al., 2007, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL G398R	ABL1	BCR::ABL G398R	Chronic Myeloid Leukemia	Nilotinib	Predictive	Supports	D	Sensitivity/Response	chr9	130874974	130874974	G	C	"In an in vitro study, a Ba/F3 cell line stably expressing the G398R mutation in the ABL1 portion of the BCR-ABL1 gene fusion was associated with sensitivity to nilotinib treatment (IC50: 0.49-fold), comparable to Ba/F3 cells expressing BCR-ABL1 fusion protein (reported to be sensitizing to nilotinib). Sensitivity was determined by assessing cell proliferation."	"Redaelli et al., 2009, J. Clin. Oncol."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL G398R	ABL1	BCR::ABL G398R	Chronic Myeloid Leukemia	Dasatinib	Predictive	Supports	D	Sensitivity/Response	chr9	130874974	130874974	G	C	"In an in vitro study, a Ba/F3  cell line stably expressing the G398R mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (IC50: 1.27nM vs. IC50: 1.83nM), comparable to Ba/F3 cells expressing BCR-ABL1 fusion protein. Sensitivity was determined by assessing cell proliferation."	"Redaelli et al., 2009, J. Clin. Oncol."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL S417Y	ABL1	BCR::ABL S417Y	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	C	Resistance	chr9	130875032	130875032	C	A	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase (CP) patient had a complete hematologic response but acquired resistance 7 months after therapy initiation. At month 11, the L248V, G250E, S417Y, E459K variants were present in approximately 25, 25, 25, and 50% of transcripts, respectively. The patient died in accelerated phase at month 14."	"Branford et al., 2003, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL D421G	ABL1	BCR::ABL D421G	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130875044	130875044	A	G	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with D421G evaluated, 1/1 had a complete hematologic response and 0/1 had a major cytogenetic response."	"Cortes et al., 2011, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E450V	ABL1	BCR::ABL E450V	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130878493	130878493	A	T	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with E450V evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response."	"Cortes et al., 2011, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E453Q	ABL1	BCR::ABL E453Q	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130878501	130878501	G	C	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with E453Q evaluated, 1/1 had a complete hematologic response and 1/1 had a major cytogenetic response."	"Cortes et al., 2011, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E453K	ABL1	BCR::ABL E453K	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130878501	130878501	G	A	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with E453K evaluated, 1/1 had a major cytogenetic response."	"Cortes et al., 2011, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E453A	ABL1	BCR::ABL E453A	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130878502	130878502	A	C	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with E453A, 1/1 had a CHR and 0/0 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E453A	ABL1	BCR::ABL E453A	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	C	Resistance	chr9	130878502	130878502	A	C	"In a study of 39 chronic phase CML patients with BCR-ABL variants, E453A was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E459K	ABL1	BCR::ABL E459K	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	B	Resistance	chr9	130878519	130878519	G	A	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 12 patients with the E459K mutations, 4, 6, and 11 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	"Mller et al., 2009, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E459K	ABL1	BCR::ABL E459K	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	C	Resistance	chr9	130878519	130878519	G	A	"In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL mutations did not differ from the rate of the total population of 100 imatinib-resistant or -intolerant patients. 44 (73%) of 60 BCR-ABL mutant patients achieved major hematologic responses (MaHRs) and 18 (30%) of 60 achieved major cytogenetic responses (MCyRs). Of patients with E459K, 1/3 had MaHRs which was lower than response rates among wild type patients, and 3/3 had MCyRs which was higher than response rates among wild type patients."	"Guilhot et al., 2007, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E459K	ABL1	BCR::ABL E459K	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	C	Resistance	chr9	130878519	130878519	G	A	"In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 3 had E459K mutations"	"Guilhot et al., 2007, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL E459K	ABL1	BCR::ABL E459K	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	C	Resistance	chr9	130878519	130878519	G	A	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase (CP) patient had a complete hematologic response but acquired resistance 7 months after treatment initiation. At month 11, the L248V, G250E, S417Y, and E459K variants were present in approximately 25, 25, 25, and 50% of transcripts, respectively. The patient died in accelerated phase at month 14."	"Branford et al., 2003, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL P480A	ABL1	BCR::ABL P480A	Chronic Myeloid Leukemia	Bosutinib	Predictive	Does Not Support	C	Resistance	chr9	130880082	130880082	C	G	"In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. The authors conclude that bosutanib is effective across all BCR-ABL mutations observed except T315I. Of patients with P480A evaluated, 1/1 had a major cytogenetic response."	"Cortes et al., 2011, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F486S	ABL1	BCR::ABL F486S	Chronic Myeloid Leukemia	Nilotinib	Predictive	Supports	D	Sensitivity/Response	chr9	130880101	130880101	T	C	"In an in vitro study, a Ba/F3 cell line stably expressing the F486S mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to nilotinib treatment (IC50: 1.85-fold), comparable to Ba/F3 cells expressing BCR-ABL fusion protein. Sensitivity was determined by assessing cell proliferation."	"Redaelli et al., 2009, J. Clin. Oncol."	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F486S	ABL1	BCR::ABL F486S	Chronic Myeloid Leukemia	Axitinib	Predictive	Does Not Support	D	Resistance	chr9	130880101	130880101	T	C	"In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the F486S variant of ABL1 compared to fusions with wildtype ABL1 (IC50 of 897nM vs. 823 nM), indicating baseline sensitivity."	"Pemovska et al., 2015, Nature"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F486S	ABL1	BCR::ABL F486S	Chronic Myeloid Leukemia	Bosutinib	Predictive	Supports	C	Resistance	chr9	130880101	130880101	T	C	"This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chronic phase CML and BCR-ABL fusions. Complete hematologic response (CHR) and major cytogenetic response (MCyR) were comparable for patients with Abl1 mutation versus without. Of patients with F486S, 0/1 had a CHR and 0/1 had a MCyR. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occuring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F486S	ABL1	BCR::ABL F486S	Chronic Myeloid Leukemia	Dasatinib	Predictive	Does Not Support	B	Resistance	chr9	130880101	130880101	T	C	"This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from the START-C, START-R, and CA180-034 trials. With dasatinib monotherapy, patients with and without ABL1 mutation had comparable complete hematologic response (CHR), major cytogenetic response (MCyR), complete cytogenetic response (CCyR), and major molecular response (MMR). Out of 13 patients with F486S mutations, 5, 6, and 12 achieved CCyR, MCyR, and CHR with dasatinib monotherapy, respectively. Analyses by variant included patients with multiple kinase domain mutations."	"Mller et al., 2009, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F486S	ABL1	BCR::ABL F486S	Chronic Myeloid Leukemia	Imatinib Mesylate	Predictive	Supports	C	Resistance	chr9	130880101	130880101	T	C	"In a study of 39 chronic phase CML patients with BCR-ABL variants, F486S was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. Nine patients in this study had multiple kinase domain mutations, but it was not indicated when mutations were co-occurring."	"Khoury et al., 2012, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 BCR::ABL F486S	ABL1	BCR::ABL F486S	Chronic Myeloid Leukemia	Imatinib	Predictive	Supports	C	Resistance	chr9	130880101	130880101	T	C	"In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An accelerate-phase patient had a complete cytogenetic response until progressing to major cytogenetic response (MCyR) at month 17 and then losing MCyR at month 24 despite dose escalation. At month 9, the F486S variant was found in ~25% of transcripts increasing to ~50% at month 16 and then remaining at a stable proportion."	"Branford et al., 2003, Blood"	Somatic	ENST00000318560.5	"missense_variant,transcript_fusion"
ABL1 NUP214::ABL1	ABL1	NUP214::ABL1	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"	"Vincristine,Dexamethasone,Dasatinib"	Predictive	Supports	C	Sensitivity/Response	chr9	131125561	131230769			"A 15-year-old girl with B-cell precursor ALL was placed into the very high risk group after showing corticoid resistance on treatment day 8, and induction failure on day 35 (MRD >0.01). The patient received a successful bone marrow transplant and at day 100 showed a complete remission (CR). The patient relapsed 6 months later, and second line therapy was unsuccessful. During this relapse, SNP microarray was performed on the diagnostic sample and identified amplification of 9q34 flanked by the NUP214 and ABL1 genes. Follow-up molecular studies confirmed a NUP214-ABL1 fusion gene. The patient was then started on dasatinib in combination with vincristine and dexamethasone. The patient achieved a second CR, and continued on dasatinib until her disease relapsed 2 months later."	"Duployez et al., 2016, Haematologica"	Somatic	ENST00000359428.5	transcript_fusion
ABL1 NUP214::ABL1	ABL1	NUP214::ABL1	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"		Diagnostic	Supports	C	Positive	chr9	131125561	131230769			"Transcriptome and whole genome sequencing were performed on 15 cases of B-lymphoblastic leukemia/lymphoma (B-ALL) that were previously shown to have a BCR-ABL1-like (Ph-like) expression signature. Two cases were positive for the NUP214-ABL1 fusion, identified by RNA-seq analysis. In both cases the fusion was generated by a small copy number gain (duplication) in 9q34, with the breakpoints in the two partner genes. Considering the previously shown Ph-like expression signature in the studied cases, the results suggest association of the NUP214-ABL1 fusion in B-ALL with the Ph-like genetic subtype of the disease."	"Roberts et al., 2012, Cancer Cell"	Somatic	ENST00000359428.5	transcript_fusion
ABL1 NUP214::ABL1	ABL1	NUP214::ABL1	"B-lymphoblastic Leukemia/lymphoma, BCR-ABL1like"		Prognostic	Supports	B	Better Outcome	chr9	131125561	131230769			"A multicenter, retrospective, cohort study that included 122 pediatric patients (aged 1-18 years) with newly diagnosed ABL-class fusion B-cell acute lymphocytic leukemia who had not received tyrosine-kinase inhibitor treatment as a first-line therapy. ABL-class genes included ABL1, ABL2, CSF1R and PDGFRB. There were 33% of patients (40/122) that harbored an ABL1 fusion, including 7 with a NUP214-ABL1 fusion. For patients that were ABL1 fusion positive the 5-year event-free survival was 68.6% (54.5-86.3), the 5-year overall survival was 82.9% (71.2-96.4) and the 5-year cumulative incidence of relapse was 29.6% (15.0-45.9). Additionally ABL1 fusion positive patients had the lowest levels of MRD at the end of induction therapy (20/29 evaluable patients had less than 10^-2). Of patients with NUP214-ABL1, 4/7 had MRD <10^-2 at the end of induction."	"den Boer et al., 2021, Lancet Haematol"	Somatic	ENST00000359428.5	transcript_fusion
ABL1 NUP214::ABL1	ABL1	NUP214::ABL1	B-lymphoblastic Leukemia/lymphoma	"Nilotinib,Dasatinib,Imatinib,Ponatinib"	Predictive	Does Not Support	D	Sensitivity/Response	chr9	131125561	131230769			"A 22-year-old male with B-cell acute lymphoblastic leukemia was treated with induction therapy. FISH using a BCR-ABL1 probe demonstrated 50-80 extrachromosomal copies of ABL1; FISH using probes to the 3' regions of ABL1 and NUP214 confirmed NUP214-ABL1 amplification in ~99% of cells. The NUP214-ABL1 amplification was also confirmed by MLPA and SNP6.0 analysis. Additionally, this patient harbored a focal deletion of IKZF1 (exons 2-7) and CDKN2A/B (exons 1-2). Day 29 marrow showed complete morphological remission; however PCR-based IgVH MRD rearrangement studies revealed clonal IgVH rearrangement (1 in 10^4 cells). Patient underwent sibling donor allogenic stem cell transplant, and at 4 months is in complete remission. NUP214-ABL1 positive patient primary cells were cultured with various tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, and ponatinib). After 72-hour culture there was no significant reduction in viable cell numbers or increase in apoptosis, when compared to the no drug control. The in vitro sensitivity to TKIs may be attributed to variable NUP214-ABL1 copy number and/or focal deletions of IKZF1 and CDKN2A/B."	"Eyre et al., 2012, Blood"	Somatic	ENST00000359428.5	transcript_fusion
TTF1 AMPLIFICATION	TTF1	AMPLIFICATION	Lung Adenocarcinoma		Prognostic	Does Not Support	B	N/A	chr9	132375621	132406822			6 of 89 patients with lung adenocarcinoma had amplification of TTF1. There was no statistical difference in overall survival between patients with and without gene amplification.	"Barletta et al., 2009, J. Cell. Mol. Med."	Somatic	ENST00000334270.2	transcript_amplification
TSC1 Frameshift Truncation	TSC1	Frameshift Truncation	Lung Non-small Cell Carcinoma	Sirolimus	Predictive	Supports	D	Sensitivity/Response	chr9	132891348	132944621			"Following rapamycin treatment of mice with KrasG12D-induced lung tumors, mice with Tsc1 deletion (exon17/18 deletion resulting in frameshift) in the lung exhibit increased overall survival, increased apoptosis, reduced proliferation and reduced tumor burden compared to Tsc1 wildtype mice."	"Liang et al., 2010, Oncogene"	Somatic	ENST00000298552.3	frameshift_truncation
TSC1 Loss-of-function	TSC1	Loss-of-function	Bladder Carcinoma	Everolimus	Predictive	Supports	B	Sensitivity/Response	chr9	132891348	132944621			Tumors expressing TSC1 or TSC2 mutations show notably more sensitivity to everolimus than their wild-type counterparts.	"Iyer et al., 2012, Science"	Somatic	ENST00000298552.3	loss_of_function_variant
TSC1 Frameshift Truncation	TSC1	Frameshift Truncation	Invasive Bladder Transitional Cell Carcinoma	Everolimus	Predictive	Supports	B	Sensitivity/Response	chr9	132891348	132944621			"A patient with metastatic bladder cancer that responded well to the mTOR inhibitor everolimus was shown to harbor a TSC1 frameshift truncation mutation (c.1907_1908del, p.Glu636fs) and a nonsense NF2 mutation. 2/3 additional patients with TSC1 mutations also had mild responses to everolimus."	"Iyer et al., 2012, Science"	Somatic	ENST00000298552.3	frameshift_truncation
NOTCH1 Mutation	NOTCH1	Mutation	Mantle Cell Lymphoma		Prognostic	Supports	B	Poor Outcome	chr9	136494444	136545862			"14 out of 121 patient samples contained mutations in NOTCH1. Those with mutations had worse overall survival than wild-type (median OS, 1.43 years vs. 3.86 years)."	"Kridel et al., 2012, Blood"	Somatic	ENST00000277541.6	protein_altering_variant
NOTCH1 Amplification	NOTCH1	Amplification	Colorectal Cancer	NOTCH1 Antibody (PF-06293622)	Predictive	Supports	D	Sensitivity/Response	chr9	136494444	136545862			"NOTCH1 copy-number gain in a patient-derived tumor xenograft model of colorectal cancer, was associated with increased NOTCH1 and JAG1 activity and response to a NOTCH1-targeting antibody (PF-06293622)."	"Arcaroli et al., 2016, Int. J. Cancer"	Somatic	ENST00000277541.6	transcript_amplification
NOTCH1 Amplification	NOTCH1	Amplification	Colorectal Cancer		Prognostic	Supports	B	Poor Outcome	chr9	136494444	136545862			NOTCH1 amplifications (as determined by FISH) were significantly (log-rank p??.025) associated with worse survival in a cohort of 116 patients with colorectal cancer.	"Arcaroli et al., 2016, Int. J. Cancer"	Somatic	ENST00000277541.6	transcript_amplification
NOTCH1 Mutation	NOTCH1	Mutation	Chronic Lymphocytic Leukemia		Prognostic	Supports	B	Poor Outcome	chr9	136494444	136545862			"In the randomized UK LRF CCL4 phase 3 trial comparing first-line treatment with chlorambucil, fludarabine, or fludarabine plus cyclophosphamide, univariate analysis of patients with NOTCH1 mutations (within amino acids 2405-2525, a 399bp region of the PEST domain) demonstrated poorer overall survival (54.8 vs 74.6 months, P=0.02) and progression free survival (22 vs 26.4 months, P=0.02) compared to patients with wild-type NOTCH1. Progression-free survival was not significant (P = 0.21), however, overall survival remained significant (P = 0.03) under multivariate analysis."	"Oscier et al., 2013, Blood"	Unknown	ENST00000277541.6	protein_altering_variant
NOTCH1 Mutation	NOTCH1	Mutation	Chronic Lymphocytic Leukemia		Prognostic	Does Not Support	B	Poor Outcome	chr9	136494444	136545862			"In a multivariate analysis of 774 CLL patients, NOTCH1 mutations were not significantly correlated with shorter time to first treatment (HR=1.305; 95% CI=0.923-1.847)."	"Baliakas et al., 2015, Leukemia"	Somatic	ENST00000277541.6	protein_altering_variant
NOTCH1 Loss-of-function	NOTCH1	Loss-of-function	Head And Neck Squamous Cell Carcinoma	Porcupine Inhibitor WNT974	Predictive	Supports	D	Sensitivity/Response	chr9	136494444	136545862			"In an evaluation of 96 head and neck squamous cell carcinoma (HNSCC) cell lines, 31 were responsive to LGK974 (PORCN inhibitor). Of 40 cell lines (25 responsive, 15 non-responsive) that were exome sequenced, 6 cell lines had NOTCH1 loss-of-function mutations (N-terminal frameshift/nonsense) and 5/6 cell lines that had NOTCH1 mutations were susceptible to LGK974 (PORCN inhibitor)."	"Liu et al., 2013, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000277541.6	loss_of_function_variant
NOTCH1 Mutation	NOTCH1	Mutation	Chronic Lymphocytic Leukemia		Prognostic	Supports	A	Poor Outcome	chr9	136494444	136545862			"In a study of 406 previously untreated CLL cases, a multivariate analysis indicated clonal NOTCH1 mutations (N=55) were significantly associated with reduced overall survival (HR: 1.5; 95%CI: 1.13-1.99; P = 0.0049). Subclonal mutations (VAF <12%) were not associated with reduced OS (N=29, P=0.94, univariate analysis)."	"Nadeu et al., 2016, Blood"	Somatic	ENST00000277541.6	protein_altering_variant
NOTCH1 P2514FS	NOTCH1	P2514FS	Chronic Lymphocytic Leukemia		Prognostic	Supports	B	Poor Outcome	chr9	136496197	136496198			"In a cohort of 120 patients with chronic lymphoytic leukemia, those with P2515 frameshift deletions in NOTCH1 at diagnosis had worse overall and treatment free survival. NOTCH1 mutations were also found to be an independent poor predictor of survival regardless of TP53 and IGHV status."	"Fabbri et al., 2011, J. Exp. Med."	Somatic	ENST00000277541.6	frameshift_truncation
NOTCH1 P2514FS	NOTCH1	P2514FS	Chronic Lymphocytic Leukemia		Prognostic	Supports	B	Poor Outcome	chr9	136496197	136496198			"NOTCH1 mutations were found to be associated with worse overall survival (3.77-fold increase in the hazard of death, P < .001) in a series of 309 newly diagnosed CLL and confirmed in an additional set of 230 patients. NOTCH1 mutations were mostly represented (26/34, 76.5%) by a recurrent 2-bp frameshift deletion (c.7544_7545delCT), with the remaining being other frameshift deletions or insertions."	"Rossi et al., 2012, Blood"	Somatic	ENST00000277541.6	frameshift_truncation
NOTCH1 V2444FS	NOTCH1	V2444FS	Lung Non-small Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr9	136496409	136496409	G	TGT	"NOTCH1 gain-of-function mutations, including V2444fs, have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context."	"Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000277541.6	frameshift_variant
NOTCH1 R2327W	NOTCH1	R2327W	Lung Non-small Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr9	136496760	136496760	G	A	"NOTCH1 gain-of-function mutations, including R2327W (called R2328W in publication), have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context."	"Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000277541.6	missense_variant
NOTCH1 S2275FS	NOTCH1	S2275FS	Lung Non-small Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr9	136496917	136496918		A	"NOTCH1 gain-of-function mutations, including S2275fs, have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context."	"Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000277541.6	plus_1_frameshift_variant
NOTCH1 D1642H	NOTCH1	D1642H	Lung Non-small Cell Carcinoma		Prognostic	Supports	B	Poor Outcome	chr9	136504767	136504767	C	G	"NOTCH1 gain-of-function mutations, including D1642H (called D1643H in publication), have shown to be correlated with poor prognosis in lung cancer. This is in a TP53 wild-type context."	"Westhoff et al., 2009, Proc. Natl. Acad. Sci. U.S.A."	Somatic	ENST00000277541.6	missense_variant
EIF1AX MUTATION	EIF1AX	MUTATION	Uveal Melanoma		Prognostic	Supports	C	Better Outcome	chrX	20138595	20141636			"EIF1AX was identified as a uveal melanoma (UM) driver gene by whole-exome sequencing. Approximately 14%?0% of UM carry a mutation in EIF1AX, with most mutations found in exons 1 and 2. EIF1AX mutations are associated with a good prognosis, and are inversely associated with metastasis. This assertion is based on observed survival for 19 EIF1AX mutant UM cases compared to 69 EIF1AX wildtype cases."	"Martin et al., 2013, Nat. Genet."	Somatic	ENST00000379607.5	transcript_variant
BCOR Mutation	BCOR	Mutation	Stomach Cancer		Prognostic	Supports	B	Better Outcome	chrX	40051248	40177329			"46 patients with poorly cohesive, signet-cell ring, gastric carcinoma were evaluated for genetic mutations.  Overall survival rate of BCOR positive cases were significantly better than BCOR negative cases cases (p=0.038)."	"Rokutan et al., 2016, J. Pathol."	Somatic	ENST00000342274.4	transcript_variant
ARAF S214C	ARAF	S214C	Lung Non-small Cell Carcinoma	Sorafenib	Predictive	Supports	C	Sensitivity/Response	chrX	47566722	47566722	C	G	"In one patient with S214C mutation, the use of sorafenib has led to more than 5 years of survival and near remission."	"Imielinski et al., 2014, J. Clin. Invest."	Somatic	ENST00000377045.4	missense_variant
ARAF S214C	ARAF	S214C	Lung Non-small Cell Carcinoma	Sorafenib	Predictive	Supports	D	Sensitivity/Response	chrX	47566722	47566722	C	G	Sorafenib can inhibit ARF-mediated MEK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.	"Imielinski et al., 2014, J. Clin. Invest."	Somatic	ENST00000377045.4	missense_variant
ARAF S214C	ARAF	S214C	Lung Non-small Cell Carcinoma	Trametinib	Predictive	Supports	D	Sensitivity/Response	chrX	47566722	47566722	C	G	Trametinib can inhibit ARF-mediated ERK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.	"Imielinski et al., 2014, J. Clin. Invest."	Somatic	ENST00000377045.4	missense_variant
ARAF S214C	ARAF	S214C	Lung Cancer		Oncogenic	Supports	D	Oncogenicity	chrX	47566722	47566722	C	G	"194 somatic mutations seen in primary lung cancers were functionally evaluated using three approaches: (1) differences in pattern or extent of changes in gene expression in A549 cells induced by transduction of lentiviral vectors containing mutant vs. wild-type genes; (2) xenograft assay based on human lung epithelial cells harbouring the variant introduced in mice and subsequent measurement of tumour size; (3) evaluation of resistance to erlotinib, afatinib, lapatinib, sofarenib and trametinib in PC9 isogenic lines expressing mutant alleles. ARAF S214C mutations showed differences in gene expression from wild-type, induced tumour formation, and in the presence of erlotinib rescued cell viability."	"Berger et al., 2016, Cancer Cell"	Somatic	ENST00000377045.4	missense_variant
ARAF S490T	ARAF	S490T	Colorectal Cancer	"Vemurafenib,Cetuximab,Irinotecan"	Predictive	Supports	C	Resistance	chrX	47569941	47569941	T	A	"Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient had an acquired ARAF S490T mutation that was not identified before treatment initiation."	"Hong et al., 2016, Cancer Discov"	Somatic	ENST00000377045.4	missense_variant
TIMP1 Overexpression	TIMP1	Overexpression	Breast Cancer	Fulvestrant	Predictive	Supports	D	Resistance	chrX	47582313	47586789			TIMP1 overexpression was associated with resistance to fulvestrant in breast cancer cell lines.	"Bjerre et al., 2013, Tumour Biol."	N/A	ENST00000218388.4	N/A
TIMP1 Overexpression	TIMP1	Overexpression	Breast Cancer	Paclitaxel	Predictive	Supports	B	Resistance	chrX	47582313	47586789			High expression of TIMP-1 was assessed by IHC in 99 primary breast cancers that had not spread beyond the breast after 6 postoperative courses of paclitaxel-based chemotherapy. High TIMP1 levels were associated with worse 5-year disease free survival (71.1%) than low levels (88.5 %; P = 0.020). High TIMP-1 levels were also associated with worse 5-year overall survival (78.9 %) than low levels (96.7 %; P = 0.004).	"Zhu et al., 2012, Med. Oncol."	N/A	ENST00000218388.4	N/A
SSX4 SS18::SSX4	SSX4	SS18::SSX4	Synovial Sarcoma		Diagnostic	Supports	C	Positive	chrX	48402082	48406079			"Three synovial sarcomas were assayed for SYT-SSX fusion messenger RNA by nested RT-PCR. In a single case an SYT-SSX4 (SS18-SSX4) fusion was detected. The majority of synovial sarcomas are characterized by SS18-SSX1 or SS18-SSX2, but other rare events such as this SS18-SSX4 may explain some or all of the synovial sarcomas that are negative for the most common fusions."	"Skytting et al., 1999, J. Natl. Cancer Inst."	Somatic	ENST00000415083.2	transcript_fusion
FOXP3 EXPRESSION	FOXP3	EXPRESSION	Breast Cancer	Epirubicin	Predictive	Supports	B	Sensitivity/Response	chrX	49250436	49264826			"1,097 patients with breast cancer were evaluated for FOXP3 expression by IHC. FOXP3 expression was found in 405 tumor samples and associated with improved OS in patients treated with anthracycline-based adjuvant chemotherapy (6 cycles of 'FEC100' aka epirubicin + cyclophosphamide + 5-fluorouracil) but not in patients treated with sequential anthracycline->taxane (3 cycles of FEC100 followed by 3 cycles of docetaxel). In-vitro experiments confirmed that FOXP3 expression enhance anthracycline efficacy. The in vitro data consisted of testing the sensitivity of various breast cancer cell lines to anthracyclines after treatment with valproic acid (which increases FOXP3 expression). The authors observed that, while valproic acid has no intrinsic cytotoxic effect on tumor cells, it enhanced the cytotoxic effect of epirubicin specifically in cell lines where FOXP3 expression was increased."	"Ladoire et al., 2012, Ann. Oncol."	N/A	ENST00000376207.4	N/A
MAGEH1 EXPRESSION	MAGEH1	EXPRESSION	Bile Duct Adenocarcinoma	Gemcitabine	Predictive	Supports	D	Resistance	chrX	55452105	55453565			"10 biliary tract carcinoma cell lines were sorted based on their gemcitabine sensitivity. MAGEH1 protein expression was negatively correlated with sensitivity. In a clinical validation cohort, MAGEH protein expression was found in 4/4 ""non-effective"" cases and 2/5 effective cases based on RECIST criteria after gemcitabine treatment."	"Ojima et al., 2010, Cancer Sci."	N/A	ENST00000342972.1	N/A
AR OVEREXPRESSION	AR	OVEREXPRESSION	Breast Cancer	Dactolisib	Predictive	Supports	D	Sensitivity/Response	chrX	67544623	67730619			In-vitro and xenograft studies of response of breast cancer cell lines to PI3K/mTOR inhibitor NVP-BEZ235 showed that sensitivity correlated with expression of the androgen receptor (AR). Reintroduction of AR expression resensitized nonresponsive AR-negative cells to NVP-BEZ235. A dihydrotestosterone (DHT) and NVP-BEZ235 combination achieved tumor regression and complete response in AR/ER expressing tumors (xenografts).	"Wang et al., 2014, Mol. Cancer Ther."	Somatic	ENST00000374690.3	N/A
AR Mutation	AR	Mutation	Prostate Cancer	"Bicalutamide,Flutamide,Cyproterone Acetate,Nilutamide"	Predictive	Supports	B	Resistance	chrX	67544623	67730619			"In a study of 150 patients with metastatic castration resistant prostate cancer (mCRPC), 71.3% of cases (n=107) harbored androgen receptor (AR) pathway aberrations.   Within the AR mutation cohort, 78 patients had AR amplification mutations, 16 patients had AR missense mutations, and 13 patients had mutations in ZBTB16, NCOR1, FOXA1, and SPOP, which are all AR regulators or downstream effectors.  All AR mutations were exclusive to mCRPC neoplasms and were not found in primary prostate cancer."	"Robinson et al., 2015, Cell"	Somatic	ENST00000374690.3	transcript_variant
AR V7 EXPRESSION	AR	V7 EXPRESSION	Prostate Cancer	"Enzalutamide,Abiraterone"	Predictive	Supports	B	Resistance	chrX	67544820	67696075			"Detection of AR-V7 in circulating tumor cells of 62 patients treated with either enzalitamide (n=31) or arbiraterone (n=31), was correlated with lower PSA response rates and PSA PFS in men receiving enzalutamide or abiraterone."	"Antonarakis et al., 2014, N. Engl. J. Med."	N/A	ENST00000504326.1	
AR W742	AR	W742	Prostate Carcinoma	Bicalutamide	Predictive	Supports	D	Resistance	chrX	67717528	67717530			"LNCaP-FGC cells with mutations at codon 741 (W741C, W741L) were able to use bicalutamide as an AR agonist, promoting cell growth and increased prostate-specific antigen secretion."	"Hara et al., 2003, Cancer Res."	Somatic	ENST00000374690.3	missense_variant
AR F877L	AR	F877L	Prostate Cancer	"Apalutamide,Enzalutamide"	Predictive	Supports	D	Resistance	chrX	67723707	67723707	T	C	"Mutations F876L in the ligand binding domain of the androgen receptor confered resistance to enzalutamide and ARN-509, causing these compounds to function as partial agonists in two prostate cancer cell lines."	"Joseph et al., 2013, Cancer Discov"	Somatic	ENST00000374690.3	missense_variant
ATRX Underexpression	ATRX	Underexpression	Malignant Astrocytoma	"PCV Regimen,Temozolomide"	Predictive	Supports	B	Sensitivity/Response	chrX	77504878	77786216			"A retrospective tumor sample study found that the loss of ATRX expression (less than 10% of nuclei) in IDH-mutant astrocytomas treated with temozolomide or a combination of procarbazine, lomustine and vincristine (PCV) was associated with better outcomes. Patients with IDH-mutant tumors and ATRX expression loss (n=40) experienced greater time to treatment failure (55.6 months vs. 31.8 months; P = 0.0168) and a greater progression-free survival (37.1 months vs. 18.1 months; P = 0.038) compared to patients with IDH-mutant tumors with ATRX expression (n=9)."	"Wiestler et al., 2013, Acta Neuropathol."	N/A	ENST00000373344.5	N/A
ATRX Underexpression	ATRX	Underexpression	Glioblastoma		Prognostic	Supports	D	Poor Outcome	chrX	77504878	77786216			"In a glioblastoma mouse model induced by NRAS and p53 knockdown, ATRX loss was associated with a decreased median survival (69 days vs. 84 days; P = .0032). Also, the tumors grew to a larger size at earlier time points. ATRX loss was also associated with greater microsatellite instability."	"Koschmann et al., 2016, Sci Transl Med"	N/A	ENST00000373344.5	N/A
ATRX Underexpression	ATRX	Underexpression	Childhood Low-grade Glioma		Prognostic	Supports	B	Poor Outcome	chrX	77504878	77786216			"Loss of ATRX was identified in 12 of 247 patients with PLGGs using immunohistochemistry. Survival analysis showed that ATRX loss was associated with adverse overall survival (p<0.0001) and progression-free survival (p=0.0002) [mt (n=10) vs wt (n=175)]. In a multivariate analysis taking into account age, grade, histology, tumour location, and extent of resection, ATRX was still an independent prognosticator of PFS [HR 3.85 (95% CI 1.27?1.65); p = 0.017], and OS [HR 3.53 (95% CI 1.02?2.24); p = 0.047]."	"Yang et al., 2018, Acta Neuropathol."	Somatic	ENST00000373344.5	N/A
ATRX Mutation	ATRX	Mutation	Malignant Astrocytoma		Diagnostic	Supports	B	Positive	chrX	77504878	77786216			"Whole exome sequencing of 4 low grade gliomas (LGGs) and targeted sequencing of 28 LGGs revealed ATRX variants are found exclusively in a subset of IDH1-mutant, 1p/19q intact LGGs. Paired blood samples were sequenced in all cases and mutations were confirmed by Sanger. IDH1mutation was found in 28/32 LGGs and of these 12 possessed an ATRX mutation (~43%). In all 12 ATRX mutated cases 1p/19q was intact (correlation p=0.0003), and ATRX variants were not observed in the 12 1p/19q codeleted cases. Additionally, multiplex mRNA profiling of 28 astrocytic tumors with subclasses assigned based on 75 gene signatures demonstrated ATRX mutations were associated (p=.0044) with the early progenitor-like subclass (EPL) (11/13 EPL cases harbored ATRX mutants)."	"Kannan et al., 2012, Oncotarget"	Somatic	ENST00000373344.5	
ATRX Deletion	ATRX	Deletion	Cancer	"Fluorouracil,Cisplatin"	Predictive	Supports	D	Sensitivity/Response	chrX	77504878	77786216			"Transgenic mice were generated with conditional knockouts affecting exon 18 of the mouse ATRX gene, previously shown to be an equivalent of a loss of function. Macrophages derived from the knockout mice were significantly more sensitive to 5-FU (P<0.05) compared to macrophages derived from wild-type mice, as demonstrated by reduced survival by TUNEL assays. Re-introduction of ATRX rescued cells from 5-FU treatment. Similar significant (P<0.05) increases in TUNEL-positive cells were seen for ATRX-deficient neurons treated with 5-FU, as well as myoblasts and embryonic fibroblasts treated with 5-FU or cisplatin. The authors conclude that ATRX loss leads to sensitivity to DNA damaging agents."	"Conte et al., 2012, PLoS One"	N/A	ENST00000373344.5	deletion
BTK C481S	BTK	C481S	Chronic Lymphocytic Leukemia	Ibrutinib	Predictive	Supports	B	Resistance	chrX	101356177	101356177	A	T	Whole exome sequencing of 6 chronic lymphocytic leukemia patients with acquired resistance to ibrutinib determined 5/6 patients harbored a C481S mutation in BTK.	"Woyach et al., 2014, N. Engl. J. Med."	Somatic	ENST00000308731.7	missense_variant
BTK C481S	BTK	C481S	Chronic Lymphocytic Leukemia	Ibrutinib	Predictive	Supports	B	Resistance	chrX	101356177	101356177	A	T	"In a trial of 308 patients with chronic lymphocytic leukemia treated with ibrutinib, 31 discontinued treatment due to disease progression (13 CLL progression, 18 Richters transformation). 11/13 patients were deep sequenced for BTK and PLCG2. 9 patients were identified with BTK mutations (C481S in 8 patients). In 5 patients, C481S was the sole abnormality."	"Maddocks et al., 2015, JAMA Oncol"	Somatic	ENST00000308731.7	missense_variant
BTK T316A	BTK	T316A	Chronic Lymphocytic Leukemia	Ibrutinib	Predictive	Supports	C	Resistance	chrX	101358645	101358645	T	C	"Case report of a patient with CLL and Richter-transformed relapse under ibrutinib (after an initial partial response for 10 months). Sequencing of sequential samples of this patient revealed a novel BTK T316 mutation at relapse (allele frequency of 75%). Characterization of this mutation showed that is was located on the SH2 domain, not associated with Ibrutinib binding. Introduction of this mutation in an Ibrutinib-sensitive lymphoma cell line showed resistance comparable to the known C481 resistance mutations, which was also confirmed by absence of downstream signaling."	"Sharma et al., 2016, Oncotarget"	Somatic	ENST00000308731.7	missense_variant
STAG2 Underexpression	STAG2	Underexpression	Bladder Carcinoma		Prognostic	Supports	B	Better Outcome	chrX	123961718	124102656			Tumor samples from 125 patients with bladder cancer were assessed by IHC for STAG2 expression. STAG2-negativity was associated with lower histological grade (p??.009). Complete loss of STAG2 expression was associated with a lower risk of recurrence (P??.023) and diminished risk of death (P??.034) in log-rank analysis and was a beneficial factor in uni- and multivariate analysis.	"Qiao et al., 2016, Tumour Biol."	N/A	ENST00000371157.3	N/A
STAG2 Underexpression	STAG2	Underexpression	Melanoma	Vemurafenib	Predictive	Supports	D	Resistance	chrX	123961718	124102656			A375 melanoma cells containing an inducible shRNA for STAG2 were grown as xenograft tumors in nude mice. The mice in which STAG2 was silenced had tumors that were less sensitive to vemurafenib-induced tumor shrinkage than the tumors of the control mice (P < .01).	"Shen et al., 2016, Nat. Med."	N/A	ENST00000371157.3	N/A
STAG2 MUTATION	STAG2	MUTATION	Ewing Sarcoma Of Bone		Prognostic	Supports	B	Poor Outcome	chrX	124042568	124083458			"In a study of 96 Ewing sarcoma tumors, 15% showed heterogenous loss of STAG2 expression in IHC analysis.  Of those with STAG2 expression loss, 88% presented with metastatic disease compared to only 27% of patients who expressed STAG2 on IHC (P=0.002)."	"Crompton et al., 2014, Cancer Discov"	N/A	ENST00000218089.9	protein_altering_variant
STAG2 MUTATION	STAG2	MUTATION	Acute Myeloid Leukemia		Prognostic	Does Not Support	B	Poor Outcome	chrX	124042568	124083458			"In a retrospective cohort study of 389 uniformly treated acute myeloid leukemia (AML) patients, 23 patients harbored mutations in genes of the cohesin complex including 5 who harbored mutations in STAG2. Mutation in the cohesin complex was not associated with worse overall survival (OS) or relapse free survival (RFS) compared to wildtype patients. The presence of STAG2 mutations had no influence on OS or RFS compared to wildtype (OS HR: 1.53, p = 0.4; RFS HR: 1.26, P = 0.7), though the authors note that the analysis was limited by the small number of patients. Authors speculate that co-occurring mutations in NPM1 may mask prognostic effects of STAG2 mutations."	"Thol et al., 2014, Blood"	Somatic	ENST00000218089.9	protein_altering_variant
FGF13 CYTOPLASMIC EXPRESSION	FGF13	CYTOPLASMIC EXPRESSION	Prostate Cancer		Prognostic	Supports	B	Poor Outcome	chrX	138632850	139204107			"243 primary PCa, 37 metastatic PCa, and  20  castration-resistant  PCa  (CRPC) specimens underwent IHC and microarray analysis. Immunohistochemistry (IHC) showed that FGF13 was detectable in the majority of human PCa samples, and FGF13 IHC scores were higher in high-grade prostatic intraepithelial neoplasia, in primary PCa, and in metastatic PCa than in benign prostatic tissue. There was a significant association between high cytoplasmic FGF13 staining and a risk of biochemical recurrence (BCR) after radical prostatectomy. Multivariate regression analysis indicated that high cytoplasmic FGF13 staining was associated with BCR. Results were recapitulated in cell lines and public databases."	"Yu et al., 2016, Int. J. Cancer"	N/A	ENST00000370603.3	N/A
CTAG1B Overexpression	CTAG1B	Overexpression	Multiple Myeloma	Letetresgene Autoleucel	Predictive	Supports	B	Sensitivity/Response	chrX	154617609	154619271			Clinical responses to NY-ESO-1/LAGE-1 TCR-engineered T-cells were observed in 16 of 20 patients (80%) with advanced multiple myeloma expressing NY-ESO-1 and/or LAGE-1 in this Phase 1/2a trial showing a median progression free survival of 19.1 months.	"Rapoport et al., 2015, Nat. Med."	N/A	ENST00000328435.2	N/A
CTAG2 Overexpression	CTAG2	Overexpression	Multiple Myeloma	Letetresgene Autoleucel	Predictive	Supports	B	Sensitivity/Response	chrX	154651972	154653579			Clinical responses to NY-ESO-1/LAGE-1 TCR-engineered T-cells were observed in 16 of 20 patients (80%) with advanced multiple myeloma expressing NY-ESO-1 and/or LAGE-1 in this Phase 1/2a trial showing a median progression free survival of 19.1 months.	"Rapoport et al., 2015, Nat. Med."	N/A	ENST00000247306.4	N/A
